0001144204-13-054919.txt : 20131011 0001144204-13-054919.hdr.sgml : 20131011 20131011144652 ACCESSION NUMBER: 0001144204-13-054919 CONFORMED SUBMISSION TYPE: 10-K/A PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20120930 FILED AS OF DATE: 20131011 DATE AS OF CHANGE: 20131011 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOANALYTICAL SYSTEMS INC CENTRAL INDEX KEY: 0000720154 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 351345024 STATE OF INCORPORATION: IN FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 10-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 000-23357 FILM NUMBER: 131147792 BUSINESS ADDRESS: STREET 1: 2701 KENT AVE CITY: WEST LAFAYETT STATE: IN ZIP: 47906-1382 BUSINESS PHONE: 3174634527 MAIL ADDRESS: STREET 1: 2701 KENT AVENUE CITY: WEST LAFAYETTE STATE: IN ZIP: 47906-1382 10-K/A 1 v355517_10ka.htm 10-K/A

  

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-K/A

 

(Mark One)

x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the fiscal year ended September 30, 2012.
     OR 
o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from ___________ to _____________.

 

Commission File Number 000-23357

 

BIOANALYTICAL SYSTEMS, INC.

 

(Exact name of the registrant as specified in its charter)

 

INDIANA
(State or other jurisdiction of incorporation or organization)		   35-1345024
(I.R.S. Employer Identification No.)
     
2701 KENT AVENUE
WEST LAFAYETTE, INDIANA
(Address of principal executive offices)		   47906
(Zip code)

 

(765) 463-4527
(Registrant's telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act: None

 

Securities registered pursuant to section 12(g) of the Act: Common Shares

 

Indicate by checkmark if the registrant is a well-known seasoned issuer, as defined by Rule 405 of the Securities Act. YES o NO x

 

Indicate by checkmark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. YES o NO x

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES x        NO o

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate website, if any, every Interactive Data File to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). YES x NO o

 

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. x

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer o Accelerated filer o Non-accelerated filer o Smaller Reporting Company x

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). YES o NO x

 

Based on the closing price on the NASDAQ Capital Market on March 31, 2012, the aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant was $7,402,000. As of December 28, 2012, 7,638,738 of registrant's common shares were outstanding.

 

Documents Incorporated by Reference 

Portions of the registrant’s definitive proxy statement for its 2013 Annual Meeting of Shareholders are incorporated by reference into Part III hereof.

 

 
 

 

TABLE OF CONTENTS

 

    Page
     
  Explanatory Note 1
     
PART I    
     
Item 1. Business 2
Item 1A. Risk Factors 13
Item 1B. Unresolved Staff Comments 20
Item 2. Properties 20
Item 3. Legal Proceedings 20
Item 4. Mine Safety Disclosures 20
     
PART II    
     
Item 5. Market for Registrant's Common Equity and Related Stockholder Matters 21
Item 6. Selected Financial Data 22
Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations 23
Item 7A. Quantitative and Qualitative Disclosures about Market Risk 38
Item 8. Financial Statements and Supplementary Data 39
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 65
Item 9A. Controls and Procedures 65
Item 9B. Other Information 66
     
PART III    
     
Item 10. Directors and Executive Officers of the Registrant 66
Item 11. Executive Compensation 68
Item 12. Security Ownership of Certain Beneficial Owners and Management 68
Item 13. Certain Relationships and Related Transactions 68
Item 14. Principal Accounting Fees and Services 68
     
PART IV    
     
Item 15. Exhibits and Financial Statement Schedules 69

 

 
 

 

Explanatory Note

 

Bioanalytical Systems Inc. (“we”, “us”, “our”, or the “Company”) is filing this Amendment on Form 10-K/A (this “Amendment”) to amend our Annual Report on Form 10-K for the fiscal year ended September 30, 2012, originally filed with the Securities and Exchange Commission (the “SEC”) on December 31, 2012 (the “Original Filing”). The Amendment restates our consolidated financial statements and related dosclosures for the fiscal years ended September 30, 2012 and 2011. This Amendment also amends certain other Items in the Original Filing, as listed in “Items Amended in this Amendment” below, as a result of the restatements. Details of the impact of these restatements are discussed below and in Note 3 to the accompanying consolidated financial statements and in Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

Restatement Background

 

In August 2013, we announced a delay in filing our Form 10-Q for the three and nine months ended June 30, 2013 until management resolved a complex accounting issue related to the accounting treatment for our outstanding warrants. In the same month, we announced that investors should no longer rely upon our previously issued consolidated financial statements and the related independent auditors’ reports for the fiscal years ended September 30, 2012 and 2011, or the quarterly financial statements for the first two quarters of fiscal 2013, or any earnings releases relating to these periods, because of errors in such financial statements.

 

As a result of the identification of such errors, we have undertaken a comprehensive review of our previously filed consolidated financial statements. We concluded that the warrants issued in connection with our public offering in May 2011 were incorrectly accounted for as equity and the fair value of those warrants should have been recorded as a liability. As a result, we have restated our previously reported consolidated financial statements for the years ended September 30, 2012 and 2011, as well as the condensed consolidated financial statements for the three and six months ended December 31, 2012 and March 31, 2013.

 

Internal Control Consideration

 

Our management has determined that there was a control deficiency in our internal control over financial reporting that constitutes a material weakness, as discussed in Part II – Item 9A of this Amendment. A material weakness is a control deficiency, or combination of control deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the annual or interim condensed consolidated financial statements will not be prevented or detected on a timely basis. For a discussion of management’s consideration of our disclosure controls and procedures, internal control over financial reporting and the material weakness identified, see Part II – Item 9A included in this Amendment.

 

Items Amended in This Amendment

 

For the convenience of the reader, this Amendment sets forth the Original Filing, in its entirety, as modified and superseded where necessary to reflect the restatement. The following items in the Original Filing have been amended as a result of, and to reflect, the restatement:

 

·Part I – Item 1A. Risk Factors;
·Part II – Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations;
·Part II – Item 8. Financial Statements and Supplementary Data; and
·Part II – Item 9A. Controls and Procedures.

 

In accordance with applicable SEC rules, this Amendment includes new certifications required by Rule 13a-14 under the Securities and Exchange Act of 1934, as amended (“Exchange Act”), dated as of the filing date of this Amendment.

 

We have not updated items in this Amendment to reflect events occurring after the Original Filing date, other than those associated with the restatement of our consolidated financial statements.

 

1
 

 

PART I

 

This Report may contain "forward-looking statements," within the meaning of Section 27A of the Securities Act of 1933, as amended, and/or Section 21E of the Securities Exchange Act of 1934, as amended. Those statements may include, but are not limited to, discussions regarding our intent, belief or current expectations with respect to (i) our strategic plans; (ii) our future profitability, liquidity and capital resources; (iii) our capital requirements; (iv) industry trends affecting our financial condition or results of operations; (v) our sales or marketing plans; or (vi) our growth strategy. Investors in our common shares are cautioned that reliance on any forward-looking statement involves risks and uncertainties, including the risk factors contained beginning on page 13 of the Report. Although we believe that the assumptions on which the forward-looking statements contained herein are based are reasonable, any of those assumptions could fail to project actual events and, as a result, the forward-looking statements based upon those assumptions could prove to be significantly different from actual results. In light of the uncertainties inherent in any forward-looking statement, the inclusion of a forward-looking statement herein should not be regarded as a representation by us that our plans and objectives will be achieved. We do not undertake any obligation to update any forward-looking statement.

 

(Dollar amounts in thousands, except per share data, unless noted otherwise.)

 

ITEM 1 - BUSINESS

 

General

 

We are an international contract research organization providing drug discovery and development services. Our clients and partners include pharmaceutical, biotechnology, academic and government organizations. We apply innovative technologies and products and a commitment to quality to help clients and partners accelerate the development of safe and effective therapeutics and maximize the returns on their research and development investments. We offer an efficient, variable-cost alternative to our clients' internal product development programs. Outsourcing development work to reduce overhead and speed drug approvals through the Food and Drug Administration ("FDA") is an established alternative to in-house development among pharmaceutical companies. We derive our revenues from sales of our research services and drug development tools, both of which are focused on determining drug safety and efficacy. The Company has been involved in the research of drugs to treat numerous therapeutic areas for over 35 years since its formation as a corporation organized in Indiana in 1974.

 

We support the preclinical and clinical development needs of researchers and clinicians for small molecule and large biomolecule drug candidates. We believe our scientists have the skills in analytical instrumentation development, chemistry, computer software development, physiology, medicine, analytical chemistry and toxicology to make the services and products we provide increasingly valuable to our current and potential clients. Our principal clients are scientists engaged in analytical chemistry, drug safety evaluation, clinical trials, drug metabolism studies, pharmacokinetics and basic research from small start-up biotechnology companies to many of the largest global pharmaceutical companies. We are committed to bringing scientific expertise, quality and speed to every drug discovery and development program to help our clients develop safe and effective products.

 

In fiscal 2012, to reduce operating costs, strengthen our ability to meet clients’ needs by improving laboratory utilization and better position the Company for growth, we announced plans to restructure our bioanalytical operations. We consolidated our laboratory in McMinnville, Oregon into our headquarters facility in West Lafayette, Indiana and closed our facility and laboratory in Warwickshire, United Kingdom. In total, 74 employees were terminated as part of these restructuring activities. These activities are discussed further in Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations and in Note 14 to our Consolidated Financial Statements.

 

Industry Overview

 

Drug discovery and development is the process of creating drugs for the treatment of human disease. The drug discovery process aims to identify potential drug candidates, while the drug development process involves the testing of these drug candidates in animals and humans to meet regulatory requirements. Discovering and developing new drugs is an extremely expensive, complex, high-risk and time-consuming process. Multiple industry sources estimate the fully capitalized cost of developing and commercializing a new pharmaceutical product ranges from $800 million to over $1 billion. In addition, it generally takes between 10 and 15 years to develop a new prescription drug and obtain approval to market it in the United States.

 

The drug development services industry provides independent product development services to pharmaceutical companies, biotechnology companies, and government organizations. This industry has evolved from providing limited clinical trial services in the 1970s to a full-service industry today characterized by broader relationships with clients and by service offerings that encompass the entire drug development process, including preclinical evaluations, study design, clinical trial management, data collection, biostatistical analyses, regulatory consulting, clinical laboratory and diagnostic services, pre- and post-approval safety analysis, product registration and post-approval support.

 

2
 

 

Over the past 25 years, technological advances, as well as the emergence of the biotechnology industry, have dramatically changed the drug discovery process. New and improved technologies have evolved such as ultra high-throughput screening, new in vitro and in vivo preclinical profiling techniques and the gene-based drug research commonly referred to as genomics. The objective of these innovations is to find more drug targets and to screen chemical compounds against targets much more quickly, with literally millions of compounds possible. This process is expected to produce many more molecules having the ability to affect biological activity. These molecules then need to be tested quickly and economically to determine their viability as potentially safe and effective drug candidates.

 

Trends Affecting the Drug Discovery and Development Industry

 

Our services and products are marketed globally to pharmaceutical, medical research and biotechnology companies and institutions engaged in drug research and development. The research services industry is highly fragmented among many niche vendors led by a small number of larger companies; the latter offer an ever-growing portfolio of start-to-finish pharmaceutical development services. Our products are also marketed to academic and governmental institutions. Our services and products may have distinctly different clients (often separate divisions in a single large pharmaceutical company) and requirements. We believe that all clients are facing increased pressure to outsource facets of their research and development activities and that the following factors will increase client outsourcing:

 

Accelerated Drug Development

 

Clients continue to demand faster, more efficient, more selective development of an increasing pool of drug candidates. Consequently, our clients require fast, high-quality service in order to make well-informed decisions to quickly exclude poor candidates and speed development of successful ones. The need for additional development capacity to exploit more opportunities, accelerate development, extend market exclusivity and increase profitability drives the demand for outsourced services.

 

Increase in Potential New Drug Candidates

 

While research and development spending and the number of drug candidates are increasing, the time and cost required to develop a new drug candidate also have increased. Many pharmaceutical and biotechnology companies do not have sufficient internal resources to pursue development of all of these new drug candidates on their own. Consequently, these companies are looking to the drug discovery and development services industry for cost-effective, innovative and rapid means of developing new drugs.

 

Cost Pressures of Introducing New Drugs

 

Market forces, healthcare reform and other governmental initiatives place significant pressures on pharmaceutical and biotechnology companies to reduce drug prices. In addition, increased competition as a result of patent expiration, market acceptance of generic drugs, and governmental and privately managed care organization efforts to reduce healthcare costs have added to drug pricing pressures. The industry is responding by consolidating, streamlining operations, decentralizing internal discovery and development processes, and minimizing fixed costs. In addition, increased pressures to differentiate products and justify drug pricing are resulting in an increased focus on healthcare economics, safety monitoring and commercialization services. Moreover, pharmaceutical and biotechnology companies are attempting to increase the speed and efficiency of internal new drug discovery and development processes.

 

Patent Expiration

 

As exclusivity ends with patent expiry, drug companies defend their proprietary positions against generic competition with various patent extension strategies. Both the drug company creating these extensions and the generic competitors should provide additional opportunities for us.

 

Alliances

 

Strategic alliances allow pharmaceutical companies to share research know-how and to develop and market new drugs faster in more diverse, global markets. We believe that such alliances will lead to a greater number of potential drugs in testing, many under study by small companies lacking broad technical resources. Those small companies can add shareholder value by further developing new products through outsourcing, reducing risk for potential allies.  Clients seek realistic business partnerships with their service provider in an effort to ensure that costs are controlled as their development programs progress. We have long-standing business relationships with many pharmaceutical companies and continue to offer flexible services and adapt to our client’s requirements.

 

3
 

 

Mergers and Acquisitions

 

Consolidation in the pharmaceutical industry is commonplace. As firms blend personnel, resources and business activities, we believe they will continue to streamline operations and minimize staffing, which may lead to more outsourcing. Consolidation may result in a disruption in the progress of drug development programs as merging companies rationalize their respective drug development pipelines.

 

Biotechnology Industry and Virtual Drug Company Growth

 

The U.S. biotechnology industry has grown rapidly over the last decade and has emerged as a key client segment for the drug discovery and development services industry. In recent years, this industry has generated significant numbers of new drug candidates that will require development and regulatory approval. Many biotechnology drug developers do not have in-house resources to conduct development. Many new companies choose only to carry a product to a developed stage sufficient to attract a partner who will manufacture and market the drug. Because of the time and cost involved, these companies rely heavily on CROs to conduct research for their drug candidates.

 

Unique Technical Expertise

 

The increasing complexity of new drugs requires highly specialized, innovative, solution-driven research not available in all client labs. We believe that this need for unique technical expertise will increasingly lead to outsourcing of research activity.

 

Data Management and Quality Expertise

 

Our clients and the FDA require more data, greater access to that data, consistent and auditable management of that data, and greater security and control of that data. We have made significant investments in software throughout our contract services groups to optimize efficiency and ensure compliance with FDA regulations and market expectations.

 

Changes in the Regulatory Environment

 

The drug discovery and development process is heavily regulated by the FDA and its Center for Drug Evaluation and Research. Recent product safety concerns, increases in drug and general healthcare costs and the emergence of importation issues have placed the FDA and other regulatory agencies under increased scrutiny. The war on terror, the risk of global vaccine shortages and the threat of new potential pandemics have elevated the FDA’s focus on research in the areas of bioterrorism and vaccine development. As a result of these and other events, drug safety, cost and availability are under intense monitoring and review by Congress, the FDA and other government agencies. In 2007, primarily in response to the FDA’s handling of postmarket data and recent drug safety concerns, the FDA Act was signed into law. In addition to reauthorizing and amending various provisions that were scheduled to expire, this Act provided the FDA with new regulatory authority to require drug sponsors to run post-approval studies and clinical trials and develop and implement risk evaluation and mitigation strategies. It is also likely that additional legislation will be passed that will impact the FDA and drug development and approval process in the United States. The FDA Act, continued drug safety issues and future legislation could have a lasting and pronounced impact on the drug discovery and development industry.

 

Globalization of the Marketplace

 

Foreign firms rely on independent development companies with experience in the U.S. to provide integrated services through all phases of product development and to assist in preparing complex regulatory submissions. Domestic drug firms are broadening product availability globally, demanding local regulatory approval. We believe that domestic service providers with global reach, established regulatory expertise, and a broad range of integrated development services will benefit from this trend.

 

4
 

 

Our Solution

 

We address the needs of the pharmaceutical and biotechnology industries, as well as academic, non-profit and government organizations, for drug discovery and development by providing integrated services to help our clients maximize the return on their research and development investments. Our application of innovative technologies and products and our commitment to quality throughout the drug discovery and development process offer our clients a way to identify and develop successful drugs and devices more quickly and cost-effectively. We have obtained significant drug development expertise from more than 35 years of operation.

 

The Company's Role in the Drug Development Process

 

After a new drug candidate is identified and carried through preliminary screening, the development process for new drugs has three distinct phases.

 

1) The preclinical phase includes safety testing to prepare an Investigational New Drug ("IND") application for submission to the FDA. The IND must be accepted by the FDA before the drug can be tested in humans. Once a pharmacologically active molecule is fully analyzed to confirm its integrity, the initial dosage form for clinical trials is created. An analytical chemistry method is developed to enable reliable quantification. Stability and purity of the formulation are also determined. 

 

Clients work with our preclinical services group to establish pharmacokinetics (PK), pharmacodynamics (PD) and safety testing of the new drug. These safety studies range from dose ranging studies, that involve acute safety monitoring of drugs and medical devices to chronic, multi-year oncogenicity and reproductive toxicity studies. Dose formulation analysis is provided by our pharmaceutical analysis group. Bioanalyses of blood sampled under these protocols by our bioanalytical services group provide pharmacokinetic and metabolism data that is used with the safety and toxicity information to determine the exposure required to demonstrate toxicity. A no effect level is then established for the drug and sets the basis for future dose levels in further safety testing and clinical phase I studies. Upon successful completion of preclinical safety studies, an IND submission is prepared and provided to the FDA for review prior to human clinical trials.

 

Many of our products are designed for use in discovery and preclinical development. The Culex® family of robotic automated dose delivery and blood and other biofluids sampling and physiological parameters measurement systems enable researchers to quickly and cost effectively determine PK/PD profiles of drugs in large and small animal models. The Culex system allows experiments on freely moving conscious animals from early research for therapeutic target validation to lead optimization of compounds. Using the Culex system, researchers are able to automatically dose and sample in-vivo to develop pharmacokinetic and pharmacodynamic profiles of drugs during early screening in rodents and other animals quickly and cost effectively. Our bioanalytical services group utilizes our depth of expertise in liquid chromatography with detection by mass spectrometry to support research, preclinical and clinical programs. We also offer bioanalytical services that utilize electrochemistry, spectrophotometric (UV/Vis or fluorescence) and Corona Discharge detection as options. We have invested heavily in robotics and mass spectrometry systems. Application of this technology allows us to rapidly develop and validate methods for new compounds and obtain information suitable for regulatory submission.

 

2) The clinical phase further explores the safety and efficacy of the drug candidate in humans. The sponsor conducts Phase I human clinical trials in a limited number of healthy individuals to determine safety and tolerability. Bioanalytical assays determine the availability and metabolism of the active ingredient following administration. Expertise in method development and validation is critical, particularly for new chemical entities.

 

Exhaustive safety, tolerability and dosing regimens are established in sick patients in Phase II trials. Phase III clinical trials verify efficacy and safety. After successful completion of Phase III trials, the sponsor of the new drug submits a New Drug Application ("NDA") or Product License Application ("PLA") to the FDA requesting that the product be approved for marketing. Early manufacturing demonstrates production of the substance in accordance with FDA Good Manufacturing Practices ("GMP") guidelines. Data are compiled in an NDA, or for biotechnology products a PLA, for submission to the FDA requesting approval to market the drug or product. The bioanalytical sample count per study grows rapidly from Phase I through Phase III. Phase II and III studies may take several years to complete, supported by well-proven, consistently applied analytical methods.

 

Our services include evaluation of bioequivalence and bioavailability to monitor the rate and extent to which a drug is available in the body and to demonstrate that the availability is consistent between formulations. We also offer in-vitro bioequivalence testing for non-absorbed oral drugs. We offer support and testing services in clinical sample development, release and stability.

 

5
 

 

3) The Post-approval phase follows FDA approval of the NDA or PLA. This includes production and continued analytical and clinical monitoring of the drug. The post-approval phase also includes development and regulatory approval of product modifications and line extensions, including improved dosage forms. The drug manufacturer must comply with quality assurance and quality control requirements throughout production and must continue analytical and stability studies of the drug during commercial production to continue to validate production processes and confirm product shelf life. Samples from each manufactured batch must be tested prior to release of the batch for distribution to the public. 

 

We also provide services in all areas during the post-approval phase, including bioequivalence studies of new formulations, line extensions, new disease indications and drug interaction studies. Our ability to offer GMP electrochemical detection services has provided increased business opportunities for release testing.

 

The increases in our services offerings have resulted in our ability to provide a broader range of services to our clients, often using combined services of several disciplines to address client needs. Our ability to solve client problems by combining our knowledge base, services and products has been a factor in our selection by major pharmaceutical companies to assist in several preclinical through the post-approval phases.

 

Company Services and Products

 

Overview

 

We focus on developing innovative services and products that increase efficiency and reduce costs associated with taking new drugs to market. We operate in two business segments – contract research services and research products, both of which address the bioanalytical, preclinical, and clinical research needs of drug developers. Both segments arose out of our expertise in a number of core technologies designed to quantify trace chemicals in complex matrices.

 

Services

 

The contract research services segment provides screening and pharmacological testing, preclinical safety testing, formulation development, regulatory compliance and quality control testing. Revenues from the services segment were $21.3 million for fiscal 2012. The following is a description of the services provided by our contract research services segment:

 

·Product Characterization, Method Development and Validation: Analytical methods, primarily performed in West Lafayette, Indiana, determine potency, purity, chemical composition, structure and physical properties of a compound. Methods are validated to ensure that data generated are accurate, precise, reproducible and reliable and are used consistently throughout the drug development process and in later product support.

 

·Bioanalytical Testing: We analyze specimens from preclinical and clinical trials to measure drug and metabolite concentrations in complex biological matrices. Bioanalysis is performed at our facilities in West Lafayette, Indiana.

 

·Stability Testing: We test stability of drug substances and formulated drug products and maintain secure storage facilities in West Lafayette, Indiana to establish and confirm product purity, potency and shelf life. We have multiple International Conference on Harmonization validated controlled-climate GMP (Good Manufacturing Practices) systems in place, and the testing capability to complete most stability programs.

 

·In Vivo Pharmacology: We provide preclinical in vivo sampling services for the continuous monitoring of chemical changes in life, in particular, how a drug enters, travels through, and is metabolized in living systems. Most services are performed in customized facilities in West Lafayette and Evansville, Indiana using our robotic Culex® APS (Automated Pharmacology System) system.

 

·Preclinical and Pathology Services: We provide pharmacokinetic and safety testing in studies ranging from acute safety monitoring of drugs and medical devices to chronic, multi-year oncogenicity studies in our Evansville, Indiana site. Depending on protocol, multiple tissues may be collected to monitor pathological changes. 

 

Research Products

 

We focus our products business on expediting preclinical screening of developmental drugs. We compete in small niches of the multibillion dollar analytical instrument industry. The products business targets unique niches in life science research. We design, develop, manufacture and market state-of-the-art:

 

·In vivo sampling systems and accessories (including disposables, training and systems qualification)

 

·Physiology monitoring tools

 

·Liquid chromatography and electrochemistry instruments platforms

 

6
 

 

Revenues for our products segment were $6.9 million for fiscal 2012. We offer three (3) principal product lines: Analytical Products, In vivo Sampling Products and Vetronics’ Products. The following is a brief description of the products offered:

 

·Analytical Products: The analytical products consist of our liquid chromatographic and electrochemical instruments with associated accessories. The critical component of these products is the Epsilon® electrochemical platform. This incorporates all the hardware capabilities needed for most electrochemical experiments but can be modified through software development. The market is principally academic institutions and industrial research companies.

 

·In vivo Sampling Products: The in vivo sampling products consist of the Culex® family of automated in vivo sampling and dosing instruments. These are used by pharmaceutical researchers to dose animals and collect biological samples (blood, bile, urine, microdialysate, feces or any bio-fluid) from the animals. Since dosing and sample collections are automated, animals are not manually handled, reducing stress on the animals and producing more representative pharmacological data. Behavior and other physiological parameters can also be monitored simultaneously. Compared to manual methods, the Culex® products offer significant reduction in test model use and comparable reduction in labor. The line also includes miniaturized in vivo sampling devices sold to drug developers and medical research centers to assist in the study of a number of medical conditions including stroke, depression, Alzheimer’s and Parkinson’s diseases, diabetes and osteoporosis.

 

·Vetronics’ Products: The Vetronics’ products consist of instruments and related software to monitor and diagnose cardiac function (electro-cardiogram) and measure other vital physiological parameters primarily in cats and dogs in veterinary clinics.

 

Clients

 

Over the past five years, we have regularly provided our services and/or products to most of the top 25 pharmaceutical companies in the world, as ranked by the number of research and development projects. Approximately 11% of our revenues are generated from customers outside of North America.

 

We balance our business development effort between large pharmaceutical developers and smaller drug development companies.

 

The Preferred Provider Agreement (“PPA”) with Pharmasset, Inc. expired under its own terms, though they remain a large client of the Company. Pharmasset, Inc., now known as Gilead Sciences, Inc. (‘Gilead’) via acquisition, accounted for approximately 7.3% and 14.5% of our total revenues in fiscal 2012 and 2011, respectively, and 7.4% and 6.3% of total trade accounts receivable at September 30, 2012 and 2011, respectively.

 

Pfizer, Inc. remains a large client, accounting for approximately 3.4% and 5.2% of our total revenues in fiscal 2012 and 2011, respectively. Pfizer, Inc. accounted for 8.4% and 4.2% of total trade accounts receivable at September 30, 2012 and 2011, respectively.

 

There can be no assurance that our business will not continue to be dependent on continued relationships with Gilead and Pfizer, Inc. or other clients, or that annual results will not be dependent on a few large projects. In addition, there can be no assurance that significant clients in any one period will continue to be significant clients in other periods. In any given year, there is a possibility that a single pharmaceutical company may account for 5% or more of our total revenue. Since we do not have long-term contracts with most of our clients, the importance of a single client may vary dramatically from year to year.

 

Sales and Marketing

 

With a primary focus on both large and small pharmaceutical and biotechnology companies, we promote our services through concentrated business development efforts, scientist-to-scientist communications and centralized corporate marketing programs. We recognize that our growth and customer satisfaction depend upon our ability to continually improve and create new client relationships.

 

7
 

 

Our sales and global marketing initiatives include integrated campaigns designed to help differentiate and promote our products and services. Through trade events, online and print advertising in trade publications, direct communication, newsletters, and our website, we provide our perspective on current industry challenges or developments to create an ongoing dialogue with our clients and to promote our industry expertise, quality, technology and innovation. We reinforce key messages and selling points through client presentations, corporate material, at trade events and industry conferences.

 

We encourage and sponsor the participation of our scientific and technical personnel in a variety of professional endeavors, including speaking and the presentation of papers at national and international professional trade meetings and the publication of scientific articles in medical and pharmaceutical journals. Through these presentations and publications, we seek to further our reputation for professional excellence.

 

We currently have 6 employees on our global sales and marketing staff. We have a network of 15 established distributors covering Japan, the Pacific Basin, South America, the Middle East, India, South Africa and Eastern Europe. All of our distributor relationships are managed from the corporate headquarters in West Lafayette, Indiana.

 

Contractual Arrangements

 

Our service contracts typically establish an estimated fee to be paid for identified services. In most cases, some percentage of the contract costs is paid in advance. While we are performing a contract, clients often adjust the scope of services to be provided based on interim project results. Fees are adjusted accordingly. Generally, our fee-for-service contracts are terminable by the client upon written notice of 30 days or less for a variety of reasons, including the client's decision to forego a particular study, the failure of product prototypes to satisfy safety requirements, and unexpected or undesired results of product testing. Cancellation or delay of ongoing contracts may result in fluctuations in our quarterly and annual results. We are generally able to recover at least our invested costs when contracts are terminated.

 

Our products business offers annual service and maintenance agreements on most product lines.

 

Backlog

 

The contracts pursuant to which we provide our services are terminable upon written notice of 30 days or less. We maintain projections based on bids and contracts to optimize asset utilization. We have increased the use of sales forecasts in manufacturing our products, with the result that we rarely have a significant backlog for Products. For Services, backlog generally includes work to be performed under signed agreements (i.e., contracts and letters of intent). Once work under a signed agreement begins, net revenues are recognized over the life of the project. Some of our studies and projects are performed over an extended period of time, which may exceed several years. We maintain an order backlog to track anticipated net revenues yet to be earned for work that has not been performed.

 

Although backlog can provide meaningful information to our management with respect to a particular study, we believe that our backlog for Services as of any date is not necessarily a meaningful indicator of our future results for a variety of reasons. Studies vary in duration; the scope of studies may change, which may either increase or decrease their value; and studies may be terminated, or delayed at any time by the client or regulatory authorities.

 

Competition

 

Services

 

We compete with in-house research, development, quality control and other support service departments of pharmaceutical and biotechnology companies. There are also full-service Contract Research Organizations ("CROs") that compete in this industry. Several of our competitors have significantly greater financial resources than we do. The largest CRO competitors offering similar research services include:

 

·Covance, Inc.;

 

·Pharmaceutical Product Development, Inc.;

 

·Charles River Laboratories, Inc.;

 

·Parexel; and

 

·MDS Health Group Ltd.

 

8
 

 

CROs generally compete on:

 

·regulatory compliance record;

 

·reputation for on-time quality performance

 

·quality system;

 

·previous experience;

 

·medical and scientific expertise in specific therapeutic areas;

 

·scientist-to-scientist relationships;

 

·quality of contract research;

 

·financial viability;

 

·database management;

 

·statistical and regulatory services;

 

·ability to recruit investigators;

 

·ability to integrate information technology with systems to optimize research efficiency;

 

·quality of facilities;

 

·an international presence with strategically located facilities; and

 

·price.

 

Products

 

Founded as a provider of instrumentation and products utilized in life and physical sciences research laboratories, we continue to serve these product niches today. Though many global analytical instruments competitors exist, we have an extensive, long standing network of customers who are repeat buyers and recommend our products. In contrast, there are few competitors for our in vivo sampling products. The primary market is large pharmaceutical research departments. Our differentiators are high quality, flexibility to meet customers’ specific needs and superior technical support and service. We provide equipment that enables our customers to attain premium scientific laboratory information on a reasonable operating investment. As customers’ needs constantly change, we continually invest in the refinement of our products and in new product opportunities that meet our operating objectives.

 

Government Regulation

 

We are subject to various regulatory requirements designed to ensure the quality and integrity of our data and products. These regulations are promulgated primarily under the Federal Food, Drug and Cosmetic Act, and include Good Laboratory Practice ("GLP"), Good Manufacturing Practice ("GMP"), and Good Clinical Practice ("GCP") guidelines administered by the FDA. The standards of GLP, GMP, and GCP are required by the FDA and by similar regulatory authorities around the world. These guidelines demand rigorous attention to employee training; detailed documentation; equipment validation; careful tracking of changes and routine auditing of compliance. Noncompliance with these standards could result in disqualification of project data collected by the Company. Material violation of GLP, GMP, or GCP guidelines could result in regulatory sanctions and, in severe cases, could also result in a discontinuance of selected operations. Since October 2004, we have been audited, on a routine basis, by the FDA and UK’s MHRA twenty times. The FDA has visited seven times in West Lafayette, three times each at the Oregon and Evansville locations and twice at the UK location. MHRA has visited the UK facility five times. Of the fifteen FDA audits, seven were without findings.  Where the FDA had findings, which have not been significant to our operations, we have taken actions to address the findings. The UK facility was found to be compliant with GLP and GCP. 

 

We have not experienced any significant problems to date in complying with the regulations of such agencies and do not believe that any existing or proposed regulations will require material capital expenditures or changes in our method of operation.

 

9
 

 

Analytical Services

 

Laboratories that provide information included in INDs, NDAs and PLAs must conform to regulatory requirements that are designed to ensure the quality and integrity of the testing process. Most of our contract research services are subject to government standards for laboratory practices that are embodied in guidelines for GLP. The FDA and other regulatory authorities require that test results submitted to such authorities be based on studies conducted in accordance with GLP. These guidelines are set out to help the researcher perform work in compliance with a pre-established plan and standardized procedures. These guidelines include but are not restricted to:

 

·Resources – organization, personnel, facilities and equipment

 

·Rules – protocols and written procedures

 

·Characterization – test items and test systems

 

·Documentation – raw data, final report and archives

 

·Quality assurance unit – formalized internal audit function

  

We must also maintain reports for each study for specified periods for auditing by the study sponsor and by the FDA or similar regulatory authorities in other parts of the world. Noncompliance with GLP can result in the disqualification of data collected during the preclinical trial.

 

Preclinical Services

 

Our animal research facilities are subject to a variety of federal and state laws and regulations, including The Animal Welfare Act and the rules and regulations enforced by the United States Department of Agriculture ("USDA") and the National Institutes of Health ("NIH"). These regulations establish the standards for the humane treatment, care and handling of animals by dealers and research facilities. Our animal research facilities maintain detailed standard operating procedures and other documentation necessary to comply with applicable regulations for the humane treatment of the animals in our custody. Besides being licensed by the USDA as a research facility, we are also accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International ("AAALAC") and have registered assurance with the NIH.

 

Quality Assurance and Information Technology

 

To assure compliance with applicable regulations, we have established quality assurance programs at our facilities that audit test data, train personnel and review procedures and regularly inspect facilities. In addition, FDA regulations and guidelines serve as a basis for our Standard Operating Procedures (“SOPs”) where applicable. On an ongoing basis, we endeavor to standardize SOPs across all relevant operations. In addition, we have both developed and purchased software to ensure compliant documentation, handling and reporting of laboratory-generated study data. In fiscal 2004, we purchased 21 CFR Part 11 (FDA guidelines on electronic records and electronic signatures that define the criteria under which electronic records and electronic signatures are considered to be trustworthy, reliable and equivalent to paper records) compliant software for our preclinical research group. At the end of fiscal 2012, our contract research operations were compliant with applicable US FDA regulations (including 21 CFR Part 11) in our analytical, bioanalytical, toxicology, lab information management, and document management systems. Systems compliant with 21 CFR Part 11 were formally validated and released for use in regulated studies.

 

We manage our business systems through the use of an Enterprise Resource Planning ("ERP") system. We are continually refining and adjusting our ERP system to improve efficiency, provide better management tools and address changes in our business. These changes are appropriately documented and tested before implementation. We also test these systems in connection with management’s annual review of our internal control systems. Management’s assessment and report on internal controls over financial reporting is included in Item 9A.

 

Controlled, Hazardous, and Environmentally Threatening Substances

 

Some of our development and testing activities are subject to the Controlled Substances Act administered by the Drug Enforcement Agency ("DEA"), which strictly regulates all narcotic and habit-forming substances. We maintain restricted-access facilities and heightened control procedures for projects involving such substances due to the level of security and other controls required by the DEA. In addition, we are subject to other federal and state regulations concerning such matters as occupational safety and health and protection of the environment.

 

Our laboratories are subject to licensing and regulation under federal, state and local laws relating to hazard communication and employee right-to-know regulations, the handling and disposal of medical specimens and hazardous waste, as well as the safety and health of laboratory employees. All of our laboratories are subject to applicable federal and state laws and regulations relating to the storage and disposal of all laboratory specimens, including the regulations of the Environmental Protection Agency, the Department of Transportation, the National Fire Protection Agency and the Resource Conservation and Recovery Act. Although we believe that we are currently in compliance in all material respects with such federal, state and local laws, failure to comply could subject us to denial of the right to conduct business, fines, criminal penalties and other enforcement actions.

 

10
 

 

The regulations of the U.S. Department of Transportation, the U.S. Public Health Service and the U.S. Postal Service apply to the surface and air transportation of laboratory specimens. Our laboratories also comply with the International Air Transport Association regulations which govern international shipments of laboratory specimens. Furthermore, when materials are sent to a foreign country, the transportation of such materials becomes subject to the laws, rules and regulations of such foreign country.

 

Safety

 

In addition to comprehensive regulation of safety in the workplace, the Occupational Safety and Health Administration has established extensive requirements relating to workplace safety for health care employers whose workers may be exposed to blood-borne pathogens such as HIV and the hepatitis B virus. These regulations, among other things, require work practice controls, protective clothing and equipment, training, medical follow-up, vaccinations and other measures designed to minimize exposure to chemicals, and transmission of blood-borne and airborne pathogens. Furthermore, relevant employees receive initial and periodic training focusing on compliance with applicable hazardous materials regulations and health and safety guidelines.

 

HIPAA

 

The U.S. Department of Health and Human Services has promulgated final regulations under the Health Insurance Portability and Accountability Act of 1996 ("HIPAA") that govern the disclosure of confidential medical information in the United States. We have had a global privacy policy in place since January 2001 and believe that we are in compliance with the current European Union and HIPAA requirements. We continue to monitor our compliance with these regulations, and we intend to take appropriate steps to ensure compliance as these and other privacy regulations are revised or come into effect.

 

Product Liability and Insurance

 

We maintain product liability and professional errors and omissions liability insurance, providing approximately $3.0 million in coverage on a claims-made basis. Additionally, in certain circumstances, we seek to manage our liability risk through contractual provisions to be indemnified by the client or covered by the client’s liability insurance policies. Also, in certain types of engagements, we seek to limit our contractual liability to clients to the amount of fees received. The contractual arrangements are subject to negotiation with clients, and the terms and scope of such indemnification, liability limitation and insurance coverage vary by client and project.

 

Research and Development

 

In fiscal 2012 and 2011, we spent $542 and $534, respectively, on research and development. Separate from our contract research services business, we maintain applications research and development to enhance our products business.

 

Expenditures cover hardware and software engineering costs, laboratory supplies, labor, prototype development and laboratory demonstrations of new products and applications for those products.

 

Intellectual Property

 

We believe that our patents, trademarks, copyrights and other proprietary rights are important to our business. Accordingly, we actively seek protection for those rights both in the United States and abroad. Where we deem it to be an appropriate course of action, we will vigorously prosecute patent infringements. We do not believe, however, that the loss of any one of our patents, trademarks, copyrights or other proprietary rights would be material to our consolidated revenues or earnings.

 

We currently hold three federally registered trademarks. We also have two pending patents, one on the Dried Blood Spot (DBS) sampling card for the Culex Automated Blood Sampling Instrumentation and the second for the No Blood Waste technology also for the Culex instrument. The former (DBS) reduces the cost of bio-sample collection, shipment and storage and the latter is important for the precise sampling of bio-fluids of very small volume from animals such as mice. We also generate client value through continuing client support, hardware and software upgrades, system reliability and accuracy. In addition to these formal intellectual property rights, we rely on trade secrets, unpatented know-how and continuing applications research which we seek to protect through means of reasonable business procedures, such as confidentiality agreements. We believe that the greatest value that we generate for our clients comes from these trade secrets, know-how and applications research.

 

11
 

 

Raw Materials

 

There are no specialized raw materials that are particularly essential to our business. We have a variety of alternative suppliers for our essential components.

 

Employees

 

At September 30, 2012, we had 160 full-time employees and 10 part-time employees. All employees enter into confidentiality agreements intended to protect our proprietary information. We believe that our relations with our employees are good. None of our employees are represented by a labor union. Our performance depends on our ability to attract and retain qualified professional, scientific and technical staff. The level of competition among employers for skilled personnel is high. We believe that our employee benefit plans enhance employee morale, professional commitment and work productivity and provide an incentive for employees to remain with the Company.

 

Executive Officers of the Registrant

 

The following table illustrates information concerning the person who served as our executive officer as of September 30, 2012. Except as indicated in the following paragraphs, the principal occupation of this person has not changed in the past three years. Officers are elected annually at the annual meeting of the board of directors.

 

Name Age Position
Jacqueline M. Lemke    50 Interim President and Chief Executive Officer,
    Chief Financial Officer, Vice President-Finance
Lori Payne, Ph.D. 52 Vice President, Bioanalytical Services
John P. Devine, Jr. 51 Vice President, Non-Clinical Services

 

Jacqueline M. Lemke, joined the Company as Vice President, Finance and Chief Financial Officer on April 9, 2012. She was named Interim President and Chief Executive Officer on July 5, 2012. Prior to joining the Company, Ms. Lemke, was Vice President of Finance and Global CFO of Remy, Inc., a division of Remy International, from 2007 – 2010 where she built a 44-person global finance team and created a financial system to support rapid decision making and clear lines of management accountability. From 2004 - 2005, she served as Vice President of Finance, Global CFO Connected Home Solutions at Motorola, Inc., and, prior to that, was Strategic Planning Director, Global Invista division at DuPont Company. Ms. Lemke is a Certified Public Accountant (CPA) and began her career as a tax consultant at Deloitte & Touche. She earned her bachelor’s degree in finance and accounting from Drexel University and her master’s degree in management from Northwestern University.

 

Lori Payne, Ph.D., joined the Company in 2001 and has been Vice President, Bioanalytical Services, since fiscal 2012. Prior to joining BASi, Dr. Payne was a group leader in the Pharmacokinetics and Drug Metabolism Department of a major pharmaceutical company. The group was in charge of the development, validation and use of bioanalytical methods for quantification of veterinary pharmaceuticals and their metabolites in biological matrices as well as the determination of the metabolic pathways of new drugs and their pharmacokinetics. Dr. Payne has written several publications and given numerous presentations at professional meetings. Her work has contributed to several successful FDA registrations of new drugs. Dr. Payne earned her bachelor’s degree in environmental biochemistry from the University of California-Davis and a Ph.D. in chemistry from Louisiana State University.

 

John P. Devine, Jr., joined the Company in 1989 and has been Vice President, Non-Clinical Services, since fiscal 2011. Mr. Devine is responsible for BASi’s in vivo discovery services and toxicology.  During his 20 plus tenure at BASi, he has helped develop a novel blood collection method in swine and authored more than 350 preclinical study reports. He earned his bachelor’s degree in biology from the University of Southern Indiana and is a regional and national member of the Society of Toxicology.

 

Investor Information

 

We file various reports with, or furnish them to, the Securities and Exchange Commission (the “SEC”), including our annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to such reports. These reports are available free of charge upon written request or by visiting www.BASinc.com/invest. Other media inquiries and requests for reports or investor’s kits should be directed to:

 

BASi Investor Relations, Corporate Center

2701 Kent Avenue, West Lafayette, IN 47906 USA

Phone 765-463-4527, Fax 765-497-1102, basi@BASinc.com

 

12
 

 

Inquiries from shareholders, security analysts, portfolio managers, registered representatives and other interested parties should be directed to:

 

Neil G. Berkman Associates

11835 West Olympic Blvd., Suite 405E, Los Angeles, CA 90064

Phone 310-477-3118, nberkman@berkmanassociates.com

 

ITEM 1A - RISK FACTORS

 

Risks Related to Our Business

 

Our business is subject to many risks and uncertainties, which may affect our future financial performance. If any of the events or circumstances described below occurs, our business and financial performance could be adversely affected, our actual results could differ materially from our expectations and the market value of our stock could decline. The risks and uncertainties discussed below are not the only ones we face. There may be additional risks and uncertainties not currently known to us or that we currently do not believe are material that may adversely affect our business and financial performance.

 

If we fail to meet our current debt covenants, refinance our existing indebtedness or extend the maturity date of our loans with Regions Bank, our business and financial condition could be materially and adversely affected.

 

We have notes payable to Regions Bank (“Regions”) that are secured by mortgages on our facilities in West Lafayette and Evansville, Indiana. We also have a line of credit with Entrepreneur Growth Capital LLC ("EGC" and together with Regions, the "Lenders"). Borrowings under the EGC credit agreement are secured by a blanket lien on our personal property, including certain eligible accounts receivable, inventory, and intellectual property assets, a second mortgage on our West Lafayette and Evansville, Indiana real estate, and all common stock of our U.S. subsidiaries and 65% of the common stock of our non-United States subsidiary. The Regions loans contain cross-default provisions with each other and with the revolving line of credit with EGC. The EGC credit agreement also contains cross-default provisions with the Regions loans and any future EGC loans.

 

The agreements governing the Regions and EGC indebtedness include certain financial covenants with which we must comply each quarter, including a fixed charge coverage and a tangible net worth covenant. A breach of any of these covenants or our inability to comply with any required financial ratios could result in a default under one or more credit agreements, unless we are able to obtain the necessary waivers or amendments to the credit agreements. Upon the occurrence of an event of default that is not waived, and subject to any appropriate cure periods, the lenders under the affected credit agreements could elect to exercise any of their available remedies, which may include the right to not lend any additional amounts to us or, in certain instances, to declare all outstanding borrowings, together with accrued interest and other fees, to be immediately due and payable. If we are unable to repay the borrowings with respect to such credit facility when due, the lenders would be permitted to proceed against their collateral. In addition, EGC could refuse to make further advances to us under our line of credit. If the Lenders take any or all of these steps, our operating results and financial condition will be materially adversely affected and we may be unable to continue to fund our operations.

 

The Regions loans originally matured on November 1, 2012. We secured an extension of that maturity date to October 31, 2013. All amounts due under this credit facility are due and payable on the maturity date. We are pursuing alternatives to refinance the Regions indebtedness, including borrowing from another lending institution and a sale and leaseback of our West Lafayette, Indiana building. In the event we are unable to refinance or extend the maturity of our existing indebtedness, our Lenders would be entitled to exercise remedies against us, including their right to foreclose or otherwise enforce their mortgage liens and security interests in our assets. If the Lender takes any or all of these steps, our operating results and financial condition will be materially adversely affected and we may be unable to continue to fund our operations.

 

The decline in our revenues has reduced the amount of cash provided by our operating activities and we have limited ability to raise additional cash.

 

We depend on cash generated by our operations and borrowings on our line of credit to fund our business operations. The decline in our revenue during fiscal 2012 contributed to a decrease in our cash flow fron operations and a reduction in our borrowing capacity under our revolving line of credit, reducing liquidity. Substantially all of our assets are encumbered as security for our existing indebtedness. It could be difficult to raise additional debt without additional collateral for security. There is also a limited market for our common shares, which could make it difficult to issue additional equity. It could therefore be difficult to raise additional cash if our revolving line of credit and operations do not generate sufficient cash to fund our operations.

 

We have experienced periods of losses on our operating activities.

 

Our overall strategy includes increasing revenue and reducing/controlling operating expenses. We have concentrated our efforts in ongoing, Company-wide efficiency activities intended to increase productivity and reduce costs including personnel reductions, reduction or elimination of non-personnel expenses and realigning and streamlining operations. We cannot assure that our efforts will result in any increased profitability, or if our efforts result in profit, that profits will continue, for any meaningful period of time.

 

If we are unable to maintain effective internal control over financial reporting or disclosure controls and procedures, the accuracy and timeliness of our financial reporting may be adversely affected.

 

Maintaining effective internal controls over financial reporting is necessary for us to produce reliable financial statements. Moreover, we must maintain effective disclosure controls and procedures in order to provide reasonable assurance that the information required to be reported in our periodic reports filed with the SEC is recorded, processed, summarized and reported within the time periods specified by the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. As a result of the issues that led to the restatement of our consolidated financial statements in this Form 10-K/A as discussed in Note 3 to the consolidated financial statements, our Chief Executive Officer and Chief Financial Officer reassessed the effectiveness of our internal control over financial reporting and our disclosure controls and procedures as of September 30, 2012 as described in Item 9A of this report and have concluded that our internal control over financial reporting and our disclosure controls and procedures were not effective as of September 30, 2012. The internal control deficiency resulted in the misstatement of our financial statements and financial disclosures for the years ended September 30, 2011 and 2012 and the quarters ended June 30 and December 31, 2011, March 31, June 30, and December 31, 2012, and March 31, 2013. If we are unable to effectively remediate this material weakness or we are otherwise unable to maintain effective internal controls over financial reporting or disclosure controls and procedures, it could result in another material misstatement of our consolidated financial statements that would require a restatement, investor confidence in the accuracy and timeliness of our financial reports may be adversely impacted, and the market price of our common shares could be negatively impacted.

 

We rely on a limited number of key customers and a loss of one or more of these key customers will adversely affect our operating results.

 

Two customers account for approximately 19.7% of our total revenue in fiscal 2011 and 10.7% of our total revenues in fiscal 2012. Our agreement with one of those large customers that required the customer to use us as their preferred provider for toxicology services expired on July 29, 2012. Although the parties continue to operate under substantially the same economic terms and conditions as are set forth in the preferred provider agreement, neither we nor our customer are obliged to do so. The loss of a significant amount of business from one of our major customers would materially and adversely affect our results of operations until such time, if ever, as we are able to replace the lost business. Dependence on a small number of customers could make it difficult for us to negotiate attractive prices for our products. Moreover, to the extent that we are dependent on any single customer, we are subject to the risks faced by that customer to the extent that such risks impede the customer's ability to stay in business and make timely payments to us.

 

13
 

 

The majority of our customers’ contracts can be terminated upon short notice.

 

Most of our contracts for CRO services are terminable by the client upon 30 days’ notice. Clients terminate or delay their contracts for a variety of reasons, including but not limited to:

 

•products being tested fail to satisfy safety requirements;

 

•products have undesired clinical results;

 

•the client decides to forego a particular study;

 

•inability to enroll enough patients in the study;

 

•inability to recruit enough investigators;

 

•production problems cause shortages of the drug; and

 

•actions by regulatory authorities.

 

The loss, reduction in scope or delay of a large contract or the loss or delay of multiple contracts could materially adversely affect our business, although our contracts frequently entitle us to receive the costs of winding down the terminated projects, as well as all fees earned by us up to the time of termination. Some contracts also entitle us to a termination fee.

 

We may bear financial risk if we underprice our contracts or overrun cost estimates.

 

Since some of our contracts are structured as fixed price or fee-for-service, we bear the financial risk if we initially underprice our contracts or otherwise overrun our cost estimates. Such underpricing or significant cost overruns could have a material adverse effect on our business, results of operations, financial condition, and cash flows.

 

A reduction in research and development budgets at pharmaceutical and biotechnology companies may adversely affect our business.

 

Our customers include researchers at pharmaceutical and biotechnology companies. Our ability to continue to grow and win new business is dependent in large part upon the ability and willingness of the pharmaceutical and biotechnology industries to continue to spend on research and development and to outsource the products and services we provide. Fluctuations in the research and development budgets of these researchers and their organizations could have a significant effect on the demand for our products and services. Research and development budgets fluctuate due to changes in available resources, mergers of pharmaceutical and biotechnology companies, spending priorities and institutional budgetary policies. Our business could be adversely affected by any significant decrease in life sciences research and development expenditures by pharmaceutical and biotechnology companies. Similarly, economic factors and industry trends that affect our clients in these industries also affect our business.

 

In recent years, we have seen evidence that suggests that many customers have reduced their research and development budgets. We believe that this is in connection with the general economic slowdown and consolidation in our target industry. While this condition continues, our revenues may be negatively impacted.

 

Our future success depends on our ability to keep pace with rapid technological changes that could make our services and products less competitive or obsolete.

 

The biotechnology, pharmaceutical and medical device industries generally, and contract research services more specifically, are subject to increasingly rapid technological changes. Our competitors or others might develop technologies, services or products that are more effective or commercially attractive than our current or future technologies, services or products, or that render our technologies, services or products less competitive or obsolete. If competitors introduce superior technologies, services or products and we cannot make enhancements to ours to remain competitive, our competitive position, and in turn our business, revenues and financial condition, would be materially and adversely affected.

 

Hardware or software failures, delays in the operations of our computer and communications systems or the failure to implement system enhancements could harm our business.

 

Our success depends on the efficient and uninterrupted operation of our computer and communications systems. A failure of our network or data gathering procedures could impede the processing of data, delivery of databases and services, client orders and day-to-day management of our business and could result in the corruption or loss of data. While some of our operations have disaster recovery plans in place, they might not adequately protect us. Despite any precautions we take, damage from fire, floods, hurricanes, power loss, telecommunications failures, computer viruses, break-ins and similar events at our computer facilities could result in interruptions in the flow of data to our servers and from our servers to our clients. In addition, any failure by our computer environment to provide our required data communications capacity could result in interruptions in our service. In the event of a delay in the delivery of data, we could be required to transfer our data collection operations to an alternative provider of server hosting services. Such a transfer could result in delays in our ability to deliver our products and services to our clients. Additionally, significant delays in the planned delivery of system enhancements, improvements and inadequate performance of the systems once they are completed could damage our reputation and harm our business. Finally, long-term disruptions in the infrastructure caused by events such as natural disasters, the outbreak of war, the escalation of hostilities and acts of terrorism, particularly involving cities in which we have offices, could adversely affect our businesses. Although we carry property and business interruption insurance, our coverage might not be adequate to compensate us for all losses that may occur.

 

We operate in a highly competitive industry.

 

The CRO services industry is highly competitive. We often compete for business not only with other, often larger and better capitalized, CRO companies, but also with internal discovery and development departments within our clients, some of which are large pharmaceutical and biotechnology companies with greater resources than we have. If we do not compete successfully, our business will suffer. The industry is highly fragmented, with numerous smaller specialized companies and a handful of full-service companies with global capabilities much larger than ours. Increased competition might lead to price and other forms of competition that might adversely affect our operating results. As a result of competitive pressures, our industry experienced consolidation in recent years. This trend is likely to produce more competition among the larger companies for both clients and acquisition candidates.

 

14
 

 

The loss of our key personnel could adversely affect our business.

 

Our success depends to a significant extent upon the efforts of our senior management team and other key personnel. The loss of the services of such personnel could adversely affect our business. Also, because of the nature of our business, our success is dependent upon our ability to attract, train, manage and retain technologically qualified personnel. There is substantial competition for qualified personnel, and an inability to recruit or retain qualified personnel may impact our ability to grow our business and compete effectively in our industry.

 

In particular, during fiscal 2012, we experienced substantial turnover throughout our organization due to our restructuring efforts. Our Chief Executive Officer and Vice President of Business Development and Marketing resigned and the Senior Vice Presidents of the Instruments Division and Human Resources retired during the current fiscal year. We also replaced our Chief Financial Officer earlier in the year. We are currently evaluating and rebuilding our organization. There is no assurance that our efforts will be successful.

 

Any failure by us to comply with existing regulations could harm our reputation and operating results.

 

Any failure on our part to comply with existing regulations could result in the termination of ongoing research or the disqualification of data for submission to regulatory authorities. For example, if we were to fail to properly monitor compliance with study protocols, the data collected could be disqualified. If this were to happen, we may be contractually required to repeat a study at no further cost to the customer, but at substantial cost to us. This would harm our reputation, our prospects for future work and our operating results. Furthermore, the issuance of a notice from the FDA based on a finding of a material violation by us of good clinical practice, good laboratory practice or good manufacturing practice requirements could materially and adversely affect our business and financial performance.

 

Our business uses biological and hazardous materials, which could injure people or violate laws, resulting in liability that could adversely impact our financial condition and business.

 

Our activities involve the controlled use of potentially harmful biological materials, as well as hazardous materials, chemicals and various radioactive compounds. We cannot completely eliminate the risk of accidental contamination or injury from the use, storage, handling or disposal of these materials. In the event of contamination or injury, we could be held liable for damages that result, and any liability could exceed our insurance coverage and ability to pay. Any contamination or injury could also damage our reputation, which is critical to getting new business. In addition, we are subject to federal, state and local laws and regulations governing the use, storage, handling and disposal of these materials and specified waste products. The cost of compliance with these laws and regulations is significant and if changes are made to impose additional requirements, these costs could increase and have an adverse impact on our financial condition and results of operations.

 

15
 

 

 

Our products business depends on our intellectual property.

 

Our products business is dependent, in part, on our ability to obtain patents in various jurisdictions on our current and future technologies and products, to defend our patents and protect our trade secrets and to operate without infringing on the proprietary rights of others. There can be no assurance that our patents will not be challenged by third parties or that, if challenged, those patents will be held valid. In addition, there can be no assurance that any technologies or products developed by us will not be challenged by third parties owning patent rights and, if challenged, will be held not to infringe on those patent rights. The expense involved in any patent litigation can be significant. We also rely on unpatented proprietary technology, and there can be no assurance that others will not independently develop or obtain similar products or technologies.

 

We might incur substantial expense to develop products that are never successfully commercialized.

 

We have incurred and expect to continue to incur substantial research and development and other expenses in connection with our products business. The potential products to which we devote resources might never be successfully developed or commercialized by us for numerous reasons, including:

 

  •   inability to develop products that address our customers’ needs;

 

  •   competitive products with superior performance;

 

  •   patent conflicts or unenforceable intellectual property rights;

 

  •   demand for the particular product; and

 

  •   other factors that could make the product uneconomical.

 

Incurring significant expenses for a potential product that is not successfully developed and/or commercialized could have a material adverse effect on our business, financial condition, prospects and stock price.

 

Providing CRO services creates a risk of liability.

 

In certain circumstances, we seek to manage our liability risk through contractual provisions with clients requiring us to be indemnified by the clients or covered by the clients’ product liability insurance policies. Although most of our clients are large, well-capitalized companies, the financial performance of these indemnities is not secured. Therefore, we bear the risk that the indemnifying party may not have the financial ability to fulfill its indemnification obligations or the liability would exceed the amount of applicable insurance. Furthermore, we could be held liable for errors and omissions in connection with the services we perform. There can be no assurance that our insurance coverage will be adequate, or that insurance coverage will continue to be available on acceptable terms, or that we can obtain indemnification arrangements or otherwise be able to limit our liability risk.

 

16
 

 

We may expand our business through acquisitions.

 

We occasionally review acquisition candidates and acquisitions which we have already made. Factors which may affect our ability to grow successfully through acquisitions include:

 

·inability to obtain financing;
·difficulties and expenses in connection with integrating the acquired companies and achieving the expected benefits;
·diversion of management’s attention from current operations;
·the possibility that we may be adversely affected by risk factors facing the acquired companies;
·acquisitions could be dilutive to earnings, or in the event of acquisitions made through the issuance of our common stock to the shareholders of the acquired company, dilutive to the percentage of ownership of our existing stockholders;
·potential losses resulting from undiscovered liabilities of acquired companies not covered by the indemnification we may obtain from the seller; and
·loss of key employees of the acquired companies.

 

Changes in government regulation or in practices relating to the pharmaceutical industry could change the need for the services we provide.

 

Governmental agencies throughout the world, but particularly in the United States, strictly regulate the drug development process. Our business involves helping pharmaceutical and biotechnology companies comply with the regulatory drug approval process. Changes in regulation, such as a relaxation in regulatory requirements or the introduction of simplified drug approval procedures, or an increase in regulatory requirements that we have difficulty satisfying, or that make our services less competitive, could substantially change the demand for our services. Also, if the government increases efforts to contain drug costs and pharmaceutical and biotechnology company profits from new drugs, our customers may spend less, or reduce their growth in spending on research and development.

 

Privacy regulations could increase our costs or limit our services.

 

The US Department of Health and Human Services has issued regulations under the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”). These regulations demand greater patient privacy and confidentiality. Some state governments are considering more stringent regulations. These regulations might require us to increase our investment in security or limit the services we offer. We could be found legally liable if we fail to meet existing or proposed regulation on privacy and security of health information.

 

We may be affected by health care reform.

 

In March 2010, the United States Congress enacted health care reform legislation intended over time to expand health insurance coverage and impose health industry cost containment measures.  This legislation may significantly impact the pharmaceutical and biotechnology industries.  In addition, the U.S. Congress, various state legislatures and European and Asian governments may consider various types of health care reform in order to control growing health care costs. We are presently uncertain as to the effects of the recently enacted legislation on our business and are unable to predict what legislative proposals will be adopted in the future, if any.

 

Implementation of health care reform legislation may have certain benefits but also may contain costs that could limit the profits that can be made from the development of new drugs. This could adversely affect research and development expenditures by pharmaceutical and biotechnology companies, which could in turn decrease the business opportunities available to us both in the United States and abroad. In addition, new laws or regulations may create a risk of liability, increase our costs or limit our service offerings.

 

We rely on air transportation to serve our customers.

 

Our laboratories and certain of our other businesses are heavily reliant on air travel for transport of samples and other material, products and people. A significant disruption to the air travel system, or our access to it, could have a material adverse effect on our business.

 

17
 

 

We depend on the pharmaceutical and biotechnology industries.

 

Over the past several years, some areas of our businesses have grown significantly as a result of the increase in pharmaceutical and biotechnology companies outsourcing their preclinical and clinical research support activities. We believe that due to the significant investment in facilities and personnel required to support drug development, pharmaceutical and biotechnology companies look to outsource some or all of those services. By doing so, they can focus their resources on their core competency of drug discovery, while obtaining the outsourced services from a full-service provider like us. Our revenues depend greatly on the expenditures made by these pharmaceutical and biotechnology companies in research and development. In some instances, companies in these industries are reliant on their ability to raise capital in order to fund their research and development projects. Accordingly, economic factors and industry trends that affect our clients in these industries also affect our business. If companies in these industries were to reduce the number of research and development projects they conduct or outsource, our business could be materially adversely affected.

 

Unfavorable general economic conditions may materially adversely affect our business.

 

Unfavorable global economic conditions, including the recent recession in the United States and the recent financial crisis affecting the banking system and financial markets, could negatively affect our business. While it is difficult for us to predict the impact of general economic conditions on our business, these conditions could reduce customer demand for some of our services, which could cause our revenue to decline. Also, our customers, particularly smaller biotechnology companies which are especially reliant on the credit and capital markets, may not be able to obtain adequate access to credit or equity funding, which could affect their ability to make timely payments to us. Moreover, we rely on credit facilities to provide working capital to support our operations. We regularly evaluate alternative financing sources. Further changes in the commercial credit market or in the financial stability of our creditors may impact the ability of our creditors to provide additional financing. In addition, the financial condition of our credit facility providers, which is beyond our control, may adversely change. Any decrease in our access to borrowings under our credit facility, tightening of lending standards and other changes to our sources of liquidity could adversely impact our ability to obtain the financing we need to continue operating the business in our current manner. For these reasons, among others, if the economic conditions stagnate or decline, our operating results and financial condition could be adversely affected.

 

18
 

 

Risks Related to Share Ownership

 

Our share price could be volatile and our trading volume may fluctuate substantially.

 

The market price of our common stock has historically experienced and might continue to experience volatility.

Many factors could have a significant impact on the future price of our common shares, including:

 

  · our failure to successfully implement our business objectives;

 

  · compliance with ongoing regulatory requirements;

 

  · market acceptance of our products;

 

  · technological innovations, new commercial products or drug discovery efforts and preclinical and clinical activities by us or our competitors;

 

  · changes in government regulations;

 

  · general economic conditions and other external factors;

 

  · actual or anticipated fluctuations in our quarterly financial and operating results;

 

  · the degree of trading liquidity in our common shares; and

 

  · our ability to meet the minimum standards required for remaining listed on the NASDAQ Capital Market.

 

These factors also include ones beyond our control, such as market conditions within our industry and changes in pharmaceutical and biotechnology industries. In addition, in recent years, the stock market has experienced significant price and volume fluctuations. The stock market, and in particular the market for pharmaceutical and biotechnology company stocks, has also experienced significant decreases in value in the past. This volatility and valuation decline have affected the market prices of securities issued by many companies, often for reasons unrelated to their operating performance, and might adversely affect the price of our common stock.

 

If we are unable to maintain listing of our securities on the NASDAQ Capital Market or any stock exchange, it may be more difficult for the Company's shareholders to sell their securities.

 

On August 15, 2013, the Company received a letter from the NASDAQ Listing Qualification Department stating that the Company no longer complies with the listing rules for continued listing of the Company's common shares on the NASDAQ Capital Market, because the Company did not timely file its Form 10-Q for the period ended June 30, 2013 with the Securities and Exchange Commission. This letter further states that, under the listing rules, the Company has until October 14, 2013 to submit a plan to regain compliance. If the Company’s plan is accepted, the Company may be granted an exception of up to 180 calendar days from the initial filing’s due date, or until February 10, 2014, to regain compliance. The Company intends to comply with the dates given above in order to regain compliance with the listing rules; however, if, for any reason, NASDAQ should delist the Company's securities from trading on its exchange and the Company is unable to obtain listing on another national securities exchange, a reduction in some or all of the following may occur, each of which could have a material adverse effect on our shareholders:

 

  •   the liquidity of our common stock;
       
  •   the market price of our common stock;
       
  •   our ability to obtain financing for the continuation of our operations;
       
  •   the number of institutional and general  investors that will consider investing in our common stock;
       
  •   the number of investors in general that will consider investing in our common stock;
       
  •   the number of market makers in our common stock;
       
  •   the availability of information concerning the trading prices and volume of our common stock; and
       
  •   the number of broker-dealers willing to execute trades in shares of our common stock.

 

19
 

 

ITEM 1B- UNRESOLVED STAFF COMMENTS

 

Not applicable.

 

ITEM 2-PROPERTIES

 

We operate in the following locations, all of which we own, except as otherwise indicated:

 

•              Our principal executive offices are located at 2701 Kent Avenue, West Lafayette, Indiana 47906, with approximately 117,000 square feet of operations, manufacturing, and administrative space. Both the services segment and the products segment conduct operations at this facility. The building has been financed by mortgages. On July 12, 2012, we listed the facility for sale with the intent to leaseback 80% of that square footage in which to continue our laboratory and manufacturing operations.

 

•               BAS Evansville Inc. is in Evansville, Indiana. We occupy 10 buildings with roughly 92,000 square feet of operating and administrative space on 52 acres. Most of this site is engaged in preclinical toxicology testing of developmental drugs in animal models. The services segment conducts operations at this facility.

 

•              Bioanalytical Systems, Ltd. was located in Warwickshire, UK. This leased facility was closed in our fourth fiscal quarter of 2012.

 

•              BASi Northwest Laboratory was located in McMinnville, Oregon, approximately 40 miles from Portland. This leased facility was closed in our third fiscal quarter of 2012.

 

We believe that our facilities are adequate for our operations and that suitable additional space will be available if and when needed. The terms of any mortgages and leases for the above properties are detailed in Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations, and Notes 7 and 8 to the Notes to Consolidated Financial Statements.

 

ITEM 3-LEGAL PROCEEDINGS

 

We currently do not have any material pending legal proceedings.

 

ITEM 4- MINE SAFETY DISCLOSURES

 

Not applicable.

 

[Remainder of page intentionally left blank.]

 

20
 

 

PART II

 

ITEM 5-MARKET FOR REGISTRANT’S COMMON EQUITY AND RELATED STOCKHOLDER MATTERS

 

Market Information

 

As of September 30, 2012, our common stock was traded on the NASDAQ Capital Market under the symbol “BASi”. The following table sets forth the quarterly high and low sales price per share of our common stock from October 1, 2010 through September 30, 2012.

 

   High   Low 
Fiscal Year Ended September 30, 2011          
First Quarter  $3.55   $0.84 
Second Quarter   2.60    1.84 
Third Quarter   2.75    1.83 
Fourth Quarter   2.00    1.19 
           
Fiscal Year Ended September 30, 2012          
First Quarter  $1.58   $1.22 
Second Quarter   1.39    1.12 
Third Quarter   1.45    0.82 
Fourth Quarter   1.40    0.86 

 

Holders

 

There were approximately 2,700 holders of record of our common stock as of December 28, 2012.

 

Dividends

 

We did not pay any cash dividends on our common shares in fiscal years 2011 or 2012 and do not anticipate paying cash dividends in the foreseeable future.

 

Equity Compensation Plan Information

 

We maintain a stock option plan that allows for the granting of common stock options to certain key employees and directors. The following table gives information about equity awards under our stock option plans as of September 30, 2012 (in thousands except per share amounts):

 

Plan Category   Number of Securities to be
Issued upon Exercise of
Outstanding Options		     Weighted Average
Exercise Price per share
of Outstanding Options		     Number of Securities
Remaining Available for Future
Issuance under the Equity
Compensation Plan
(Excluding Securities Reflected
in First Column)		  
Equity compensation plans approved by security holders     229     $ 2.33       339  
Equity compensation plans not approved by security holders (1)     125     $ 1.38       --  
                         
Total     354     $ 1.99       339  

 

(1)Refers to an option to purchase 125,000 shares at $1.38 granted to Jacqueline M. Lemke on April 9, 2012.

 

For additional information regarding our stock option plans approved by security holders, please see Note 10 to the Notes to Consolidated Financial Statements included in Item 8 of this report.

 

21
 

 

On August 17, 2012, the Company sold 101,500 common shares directly to our interim CEO and members of our Board of Directors at the closing price on the previous day on the NASDAQ Capital Market on of $1.26 per share.

 

ITEM 6 – SELECTED FINANCIAL DATA

 

Not applicable.

 

[Remainder of page intentionally left blank.]

 

22
 

 

ITEM 7-MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

This report contains statements that constitute forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Those statements appear in a number of places in this Report and may include statements regarding our intent, belief or current expectations with respect to, but are not limited to (i) our strategic plans; (ii) trends in the demand for our products and services; (iii) trends in the industries that consume our products and services; (iv) our ability to develop new products and services; (v) our ability to make capital expenditures and finance operations; (vi) global economic conditions, especially as they impact our markets; (vii) our cash position; and (viii) our ability to refinance our outstanding indebtedness. Readers are cautioned that any such forward looking statements are not guarantees of future performance and involve risks and uncertainties. Actual results may differ materially from those in the forward looking statements as a result of various factors, many of which are beyond our control.

 

In addition, we have based these forward-looking statements on our current expectations and projections about future events. Although we believe that the assumptions on which the forward-looking statements contained herein are based are reasonable, actual events may differ from those assumptions, and as a result, the forward-looking statements based upon those assumptions may not accurately project future events. The following discussion and analysis should be read in conjunction with the Consolidated Financial Statements and notes thereto included or incorporated by reference elsewhere in this Report. In addition to the historical information contained herein, the discussions in this Report may contain forward-looking statements that may be affected by risks and uncertainties, including those discussed in Item 1A, Risk Factors. Our actual results could differ materially from those discussed in the forward-looking statements.

 

The following amounts are in thousands unless otherwise indicated.

 

Restatement of Previously Issued Consolidated Financial Statements

 

This Amendment on Form 10-K/A (the “Amendment”) amends the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2012, originally filed with the Securities and Exchange Commission (the “SEC”) on December 31, 2012 (the “Original Filing”). Certain financial information presented in this Amendment reflects restated consolidated financial information for the years ended September 30, 2012 and 2011.

 

In August 2013, we announced the delay in filing our Form 10-Q for the three and nine months ended June 30, 2013 until management resolved a complex accounting issue related to the accounting treatment for our outstanding warrants. In the same month, we announced that investors should no longer rely upon our previously issued consolidated financial statements and the related independent auditors’ reports for the fiscal years ended September 30, 2012 and 2011, or the quarterly financial statements for the first two quarters of fiscal 2013, or any earnings releases relating to those periods because of errors in such consolidated financial statements. See Item 9A, Controls and Procedures.

 

We concluded that the warrants issued in connection with our public offering in May 2011 were incorrectly accounted for as equity. As a result, we have reclassified the fair value of the warrants from equity into a liability. Also, we have recalculated the fair value of the warrants at each quarterly reporting period subsequent to the offering with an entry to other income or expense and an offset to the liability. The restatement adjustments in total resulted in a cumulative net decrease to Total shareholders’ equity of $1,213 and $1,286 as of September 30, 2012 and 2011, respectively, a decrease to our previously reported net loss for the fiscal year ended September 30, 2012 of $73 and an increase to our previously reported net income for the fiscal year ended September 30, 2011 of $1,759. There was no net effect on the consolidated statements of cash flows for fiscal years 2012 and 2011 as the income from the change in the fair value of the warrants is a non-cash item. More detail can be found in Note 3, Restatement of Previously Issued Consolidated Financial Statements in the accompanying consolidated financial statements.

 

Business Overview

 

We are an international contract research organization providing drug discovery and development services. Our clients and partners include pharmaceutical, biotechnology, academic and governmental organizations. We apply innovative technologies and products and a commitment to quality to help clients and partners accelerate the development of safe and effective therapeutics and maximize the returns on their research and development investments. We offer an efficient, variable-cost alternative to our clients' internal product development programs. Outsourcing development work to reduce overhead and speed drug approvals through the Food and Drug Administration ("FDA") is an established alternative to in-house development among pharmaceutical companies. We derive our revenues from sales of our research services and drug development tools, both of which are focused on determining drug safety and efficacy. The Company has been involved in the research of drugs to treat numerous therapeutic areas for over 35 years.

 

We support the preclinical and clinical development needs of researchers and clinicians for small molecule and large biomolecule drug candidates. We believe our scientists have the skills in analytical instrumentation development, chemistry, computer software development, physiology, medicine, analytical chemistry and toxicology to make the services and products we provide increasingly valuable to our current and potential clients. Our principal clients are scientists engaged in analytical chemistry, drug safety evaluation, clinical trials, drug metabolism studies, pharmacokinetics and basic research at many of the small start-up biotechnology companies and the largest global pharmaceutical companies.

 

Our business is largely dependent on the level of pharmaceutical and biotechnology companies' efforts in new drug discovery and approval. Our services segment is a direct beneficiary of these efforts, through outsourcing by these companies of research work. Our products segment is an indirect beneficiary of these efforts, as increased drug development leads to capital expansion, providing opportunities to sell the equipment we produce and the consumable supplies we provide that support our products.

 

Research services are capital intensive. The investment in equipment and facilities to serve our markets is substantial and continuing. While our physical facilities are adequate to meet market needs for the near term, rapid changes in automation, precision, speed and technologies necessitate a constant investment in equipment and software to meet market demands. We are also impacted by the heightened regulatory environment and the need to improve our business infrastructure to support our operations, which will necessitate additional capital investment. Our ability to generate capital to reinvest in our capabilities, both through operations and financial transactions, is critical to our success. While we are currently committed to fully utilizing recent additions to capacity, sustained growth will require additional investment in future periods. Our financial position could limit our ability to make such investments.

 

23
 

 

Executive Overview

 

Our revenues are dependent on a relatively small number of industries and clients. As a result, we closely monitor the market for our services. For a discussion of the trends affecting the market for our services, see “Item 1. Business – Trends Affecting the Drug Discovery and Development Industry.” In fiscal 2012, we experienced decreased demand for our products and services as compared to fiscal 2011. We believe in the fundamentals of the market and that it will continue to slowly rebound in future periods. For fiscal 2013, we plan to focus on sales execution, operational excellence and building strategic partnerships with pharmaceutical and biotechnology companies, to differentiate our company and create value for our clients and shareholders.

 

We review various metrics to evaluate our financial performance, including revenue, margins and earnings. Revenues declined approximately 14.9% and gross margin declined 34.9% from fiscal 2011. In fiscal 2012, we consolidated our bioanlaytical laboratories into our headquarters in West Lafayette, Indiana, closing facilities in McMinnville, Oregon and the UK to reduce operating costs and strengthen our ability to meet clients’ needs by improving laboratory utilization. We also implemented personnel reductions and other cost cutting measures in Selling, R&D and General and Administrative functions. The cost of these restructuring activities totaled $3,195 in the current year. As a result, we reported a net loss of $6,317 in fiscal 2012 as compared to net income of $2,302 in fiscal 2011.

 

The majority of the restructuring activities, though, occurred in the second half of the fiscal year. Due to these activities, gross margin improved 60.5% in the second half of fiscal 2012. Operating expenses declined 32.5% in the same time period. As a result, we had operating income of $452 before restructuring charges in the second half of fiscal 2012 compared to an operating loss of $2,943 in the first half. We will continue initiatives to control costs and improve productivity to achieve our financial objectives. For a detailed discussion of our revenue, margins, earnings and other financial results for the fiscal year ended September 30, 2012, see “Results of Operations – 2012 Compared to 2011” below.

 

As of September 30, 2012, we had $721 of cash and cash equivalents as compared to $2,963 of cash and cash equivalents at the end of fiscal 2011. In fiscal 2012, we used $200 in cash from operations primarily from the net loss we reported versus net income in fiscal 2011. Total capital expenditures declined 7.2% in fiscal 2012, particularly in the second half, as we limited spending to only necessary expenditures. We negotiated an amendment on our loans with Regions Bank, extending the maturity date to October 2013. Our line of credit with Entrepreneur Growth Capital LLC was automatically renewed for another year. We listed for sale our headquarters facility in West Lafayette, Indiana with the intent to leaseback 80% of that square footage in which to continue our laboratory and manufacturing operations. Further, we announced the launch of Culex® NxT, the latest generation of the Company’s proprietary in vivo automated sampling system, which we expect to begin shipping in our second quarter of fiscal 2013. We are poised for increased capacity utilization and potential strategic growth in fiscal 2013.

 

We believe that the development of innovative new drugs is going through an evolution, evidenced by the significant reduction of expenditures on research and development at several major international pharmaceutical companies, accompanied by increases in outsourcing and investments in smaller start-up companies that are performing the early development work on new compounds. Many of these companies are funded by either venture capital or pharmaceutical investment, or both, and generally do not build internal staffs that possess the extensive scientific and regulatory capabilities to perform the various activities necessary to progress a drug candidate to the filing of an Investigative New Drug (“IND”) application with the FDA.

 

While continuing to maintain and develop our relationships with large pharmaceutical companies, we intend to aggressively promote our services to developing businesses, which will require us to expand our existing capabilities to provide services early in the drug development process, and to consult with clients on regulatory strategy and compliance leading to their FDA filings. We have launched our Enhanced Drug Discovery services as part of this strategy, utilizing our proprietary Culex® technology to provide early experiments in our laboratories that previously would have been conducted in the sponsor’s facilities. As we move forward, we must balance the demands of the large pharmaceutical companies with the personal touch needed by smaller biotechnology companies to develop a competitive advantage. We intend to accomplish this through the use of and expanding upon our existing project management skills, strategic partnerships and progressive relationship management.

 

We are focused on improving our cash flow from operations in fiscal 2013 to reduce our reliance on our line of credit. If we are unable to increase cash flow from operations in fiscal 2013, we may not have sufficient liquidity to continue our business.

 

Patient Protection and Affordable Care Act

 

In March 2010, the Patient Protection and Affordable Care Act (the “Act”) was enacted by the U.S. Congress and signed into law by the President. The purpose of the legislation is to extend medical insurance coverage to a higher percentage of U.S. citizens. Many of the provisions in the Act have delayed effective dates over the next decade, and will require extensive regulatory guidance. Companies in our principal client industry, pharmaceuticals, will be required under the Act to provide additional discounts on medicines provided under Medicare and Medicaid to assist in the funding of the program; however, government estimates are that over 31 million additional citizens will eventually be covered by medical insurance as a result of the Act, which should expand the markets for their products. It is premature to accurately predict the impacts these and other competing forces will have on our basic client market, drug development. Additionally, the Act does not directly impact spiraling health care costs in the U.S., which could lead to additional legislation impacting our target markets in the future.

  

We maintain an optional health benefits package for all of our full-time employees, which is largely paid by our contributions with employees paying a portion of the cost, generally less than 20% of the total. Based on our current understanding of the Act, we do not anticipate significant changes to our programs or of their costs to the Company or our employees as a result of the Act.

 

We have experienced increases in the costs of our health benefit programs in excess of inflation rates, and expect those trends to continue. We are exploring options in plan funding, delivery of benefits and employee wellness in our continuing effort to obtain maximum benefit for our health care expenditures, while maintaining quality programs for our employees. We do not expect these efforts to have a material financial impact on the Company.

 

24
 

 

Results of Operations

 

The following table summarizes the consolidated statement of operations as a percentage of total revenues:

 

   Year Ended September 30, 
   2012   2011 
   (Restated)   (Restated) 
         
Service revenue   75.6%   77.3%
Product revenue   24.4    22.7 
Total revenue   100.0%   100.0%
           
           
Cost of service revenue (a)   86.7    76.8 
Cost of product revenue (a)   42.0    39.3 
Total cost of revenue   75.8    68.3 
           
Gross profit   24.2    31.7 
           
Operating expenses   33.1    27.8 
Restructuring charges   11.3    — 
Operating income (loss)   (20.2)   3.9 
           
Other (income) expense   2.2    (3.2)
           
Income (loss) before income taxes   (22.4)   7.1 
           
Income tax expense   0.0    0.2 
           
Net income (loss)   (22.4)%   6.9%

 

(a) Percentage of service and product revenues, respectively.

 

25
 

 

2012 Compared to 2011

 

Service and Product Revenues

 

Revenues for the year ended September 30, 2012 decreased 14.9% to $28,208 compared to $33,144 for the year ended September 30, 2011.

 

Our Services revenue decreased 16.8% to $21,312 compared to $25,613 for the prior fiscal year primarily as a result of lower bioanalytical analysis and toxicology revenues. Study delays by clients, lower new bookings in the current fiscal year and price declines contributed to the decline in bioanalytical analysis revenues as did the closure of our McMinnville, Oregon laboratory as part of our restructuring activities described in Note 14 to our Consolidated Financial Statements. The decline in toxicology revenues stems mainly from the residual effect of two significant customers merging their operations which led to a cancellation of a large contract expected to earn revenues in the current fiscal year. This decline was slightly offset by higher pharmaceutical analysis and discovery services revenues, included in Other laboratory services in the table below, as new bookings and volumes of studies have increased from the prior year. Our Enhanced Drug Discovery services were launched in fiscal 2011. The following table shows more detail for our Service revenue.

 

 

   Fiscal Year Ended
September 30,		         
   2012   2011   Change   % 
Bioanalytical analysis  $10,983   $13,634   $(2,651)   -19.4%
Toxicology   7,449    9,952    (2,503)   -25.2%
Other laboratory services   2,880    2,027    853    42.1%

 

 

Sales in our Products segment decreased 8.4% from $7,531 to $6,896 when compared to the prior fiscal year. The majority of the decrease stems both from lower sales of our Culex automated in vivo sampling systems over prior fiscal year with the release of the Culex Nxt system in fiscal 2013 believed to have caused a slowdown in fiscal 2012 orders and from lower analytical instruments sales due to customer spending slowdown. The following table shows more detail for our Product revenue.

 

   Fiscal Year Ended
September 30,		         
   2012   2011   Change   % 
Culex, in-vivo sampling systems  $3,693   $4,028   $(335)   -8.3%
Analytical instruments   2,554    2,971    (417)   -14.0%
Other instruments   649    532    117    22.0%

 

Cost of Revenue

 

Cost of revenue for the year ended September 30, 2012 was $21,370 or 75.8% of revenue compared to $22,638, or 68.3% of revenue for the comparable prior period.

 

Cost of Service revenue as a percentage of Service revenue increased to 86.7% in the current fiscal year from 76.8% in the prior year. The principal cause of this increase was the revenue decline which led to lower absorption of the fixed costs in our Service segment. A significant portion of our costs of productive capacity in the Service segment are fixed. Thus, decreases in revenues lead to increases in costs as a percentage of revenue.

 

Cost of Product revenue as a percentage of Product revenue in the current fiscal year increased to 42.0% from 39.3% in the prior fiscal year. This increase is mainly due to a change in the mix of products sold in fiscal 2012.

 

26
 

 

Operating Expenses

 

Selling expenses for the year ended September 30, 2012 increased by 4.5% to $3,263 from $3,121 for the year ended September 30, 2011. This increase was primarily driven by an increase in the number of sales personnel and higher spending for marketing, advertising and consulting services as we implemented our new sales and marketing strategy in the first half of the fiscal year. In the second half of fiscal 2012, we reduced selling expenses 36.4% due to restructuring activities at our West Lafayette, Indiana and UK locations.

 

Research and development expenses for the year ended September 30, 2012 increased 1.5% to $542 from $534 for the year ended September 30, 2011. In the second half of fiscal 2012, we reduced research and development expenses 40.6% due to personnel reductions as part of restructuring activities.

 

General and administrative expenses for the current fiscal year decreased 0.7% to $5,524 from $5,564 for the prior year. More specifically, general and administrative expenses for the second half of fiscal 2012 were 29.2% lower than the first half of fiscal 2012 due to restructuring activities at our West Lafayette and Evansville, Indiana locations as well as our UK location. This decrease occurred despite recording severance expenses for our former CEO and CFO, higher consulting and accounting fees and increased product liability insurance and software maintenance.

 

Other Income/Expense (Restated)

 

Other income (expense), net, was $(629) for the year ended September 30, 2012 as compared to $1,065 for the year ended September 30, 2011. The primary reason for the change is due to the change in fair value of the warrant liability. In fiscal 2012, Class B Warrants expired which reduced the fair value to zero.

 

Income Taxes

 

Our effective tax rate for continuing operations for the year ended September, 30, 2012 was (0.1%) compared to 2.1% for the prior fiscal year. The current year expense primarily relates to state franchise taxes. The expense in fiscal 2011 relates to cash tax expense for U.S. corporate alternative minimum tax. No net benefits have been provided on taxable losses in the current fiscal year.

 

Restructuring Activities

 

In March 2012, we announced a plan to restructure our bioanalytical laboratory operations. We consolidated our laboratory in McMinnville, Oregon into our 120,000 square foot headquarters facility in West Lafayette, Indiana. This plan was implemented to reduce operating costs and strengthen our ability to meet clients’ needs by improving laboratory utilization. In the fourth quarter of fiscal 2012, we decided to initiate closure of our facility and bioanalytical laboratory in Warwickshire, United Kingdom after careful evaluation of its financial performance and analysis of our strategic alternatives. We will continue to sell our products globally while further consolidating delivery of our CRO services into our Indiana locations. As part of the overall evaluation of our business, personnel reductions in the Selling, R&D and General and Administrative functions were also implemented at both of our Indiana locations during the second half of fiscal 2012. In total, 74 employees were terminated as part of the restructuring activities this fiscal year.

 

The following table sets forth the costs incurred in connection with these restructuring activities during the year ended September 30, 2012.

 

Description  Amount 
One-time termination benefits  $1,454 
Lease related costs   861 
Equipment moving costs and method transfers   153 
Travel and relocation costs   47 
Loss on sale of equipment   446 
Other costs   234 
Total  $3,195 

 

27
 

 

We have reserved for lease payments at the cease use date and have considered free rent, sublease rentals and the number of days it would take to restore the space to its original condition prior to our improvements. Based on this, we have reserved $861 for lease related costs.

 

Restructuring related costs incurred during fiscal 2012 totaled $1,360 in our Services segment, $0 in our Products segment and $1,835 in corporate expenses.

 

The following table sets forth the rollforward of the restructuring activity for the year ended September 30, 2012.

 

   Balance,
September 30,
2011		   Total
Charges		   Cash
Payments		   Other   Balance,
September 30,
2012		 
One-time termination benefits  $-   $1,454   $(1,006)  $-   $448 
Lease related costs   -    861    (61)   -    800 
Equipment moving costs and method transfers   -    153    (104)   -    49 
Travel and relocation costs   -    47    (43)   -    4 
Loss on sale of equipment   -    446    -    (539)   (93)
Other costs   -    234    (37)   -    197 
Total  $-   $3,195   $(1,251)  $(539)  $1,405 

 

Other costs include legal and professional fees and other costs incurred in connection with transitioning services from sites being closed as well as costs incurred to remove improvements previously made to the UK facility. Other activity in the reserve rollforward primarily reflects a receivable for settlement of the capital lease in the UK.

 

Liquidity and Capital Resources

 

Comparative Cash Flow Analysis

 

At September 30, 2012, we had cash and cash equivalents of $721 compared to $2,963 at September 30, 2011.

 

Net cash used by operating activities was $200 for the year ended September 30, 2012, compared to $1,088 provided for the year ended September 30, 2011. The decrease in cash provided by operating activities in the current fiscal year partially results from our current operating loss versus operating income in the prior year period as well as cash paid during the current year for restructuring activities of $1,251. Other contributing factors to our cash from operations were an increase in accounts payable of $2,375, partially due to the restructuring liabilities of $1,405, and noncash charges of $2,278 of depreciation and amortization. Included in operating activities for fiscal 2011 are non-cash charges of $2,134 and $1,759 for depreciation and amortization and the change in fair value of the warrant liability offset by a decrease in customer advances of $1,010. The impact on operating cash flow of other changes in working capital was not material.

 

We have seen significant reductions in expenses in the second half of fiscal 2012 as compared to the first half. Operating expenses declined approximately 32.5% in the second half of fiscal 2012 primarily due to restructuring efforts and cost containment initiatives.

 

Investing activities used $860 in fiscal 2012 for capital expenditures. Our principal investments included a waste-water treatment facility at one of our sites, renovation costs associated with a health care clinic at our corporate headquarters, new laboratory equipment, replacements and upgrades in all of our facilities, as well as general building and information technology infrastructure expenditures at all sites. The proceeds from sale of equipment relate to the closure of our UK facility. The decrease in capital spending from fiscal 2011 is a result of cost containment initiatives during the year.

 

Financing activities used $1,164 in the current fiscal year as compared to $1,660 provided in fiscal 2011. The main use of cash in fiscal 2012 was for long-term debt and capital lease payments of $1,390. These were slightly offset by net borrowings on our line of credit of $98 and a direct common share purchase by Company executives and directors, which provided $128. The main source of cash in fiscal 2011 was the completion of our May 2011 equity offering, which netted $4,606, as well as net borrowings on our line of credit of $151, offset by long-term debt and capital lease payments of $3,097, including the two $500 individual principal payments on one mortgage and one note payable and the down payments of $618 for the new capital leases for laboratory equipment.

 

28
 

 

Capital Resources

 

Property and equipment spending totaled $1,090 and $1,174 in fiscal 2012 and 2011, respectively. The decrease in spending in fiscal 2012 is the result of cost containment initiatives during the year.

 

We have notes payable to Regions Bank (“Regions”) aggregating approximately $5,800. Regions notes payable currently include two outstanding mortgages on our facilities in West Lafayette and Evansville, Indiana, which total $4,768. The mortgage loans initially matured in November 2012 with an interest rate fixed at 4.1% and monthly principal payments of approximately $38 plus interest.

 

On November 29, 2010, we executed amendments on two loans with Regions. Regions agreed to accept a $500 principal payment on the note payable maturing on December 18, 2010 and a $500 principal payment on one mortgage maturing on February 11, 2011. The principal payments were made on December 17, 2010 and February 11, 2011, respectively. Upon receipt of these two payments, Regions incorporated the two loans into a replacement note payable for $1,341 maturing on November 1, 2012. The replacement note payable bears interest at a per annum rate equal to the 30-day LIBOR plus 300 basis points (minimum of 4.5%) with monthly principal payments of approximately $14 plus interest. The replacement note payable is secured by real estate at our West Lafayette and Evansville, Indiana locations. At September 30, 2012, the replacement note payable had a balance of $1,074.

 

As part of the amendment, Regions also agreed to amend the loan covenants for the related debt to be more favorable to us. Regions requires us to maintain certain ratios including a fixed charge coverage ratio and total liabilities to tangible net worth ratio. The fixed charge coverage ratio calculation currently requires a ratio of not less than 1.25 to 1.00. We are also required to maintain a ratio of our total liabilities to tangible net worth of not greater than 2.10 to 1.00. If we fail to comply with these covenants, the loan agreement restricts our ability to purchase fixed assets.

 

On November 9, 2012, we executed a sixth amendment with Regions. On December 21, 2012, we executed an amended and restated sixth amendment with Regions. Regions agreed to extend the term loan and mortgage loan maturity dates to October 31, 2013. The unpaid principal on the notes was incorporated into a replacement note payable for $5,786 bearing interest at LIBOR plus 400 basis points (minimum of 6.0%) with monthly principal payments of approximately $47 plus interest. The replacement note payable is secured by real estate at our West Lafayette and Evansville, Indiana locations.

 

At September 30, 2012, we were not in compliance with the fixed charge coverage and the total liabilities to tangible net worth ratios in the Regions agreements, mainly due to the net losses in the first nine months of fiscal 2012, restructuring charges incurred in current fiscal year and the treatment of our warrants as a liability instead of as equity. On November 6, 2012, Regions waived compliance with the fixed charge coverage ratio. On December 21, 2012, Regions waived compliance with the total liabilities to tangible net worth ratio. Based on projections for fiscal 2013, we expect to be in compliance with the fixed charge coverage covenants for fiscal 2013 and in breach of the total liabilities to tangible net worth ratio covenant for the first two fiscal quarters of 2013, primarily due to the treatment of our warrants as a liability. On September 10, 2013, Regions waived our expected breach. Failure to comply with those covenants in future quarters would be a default under the Regions loans, requiring us to negotiate with Regions regarding loan modifications or waivers. If we are unable to obtain such modifications or waivers, Regions could accelerate the maturity of the loans and cause a cross default with our other lender.

 

Borrowings under our credit agreements are collateralized by substantially all assets related to our operations and all common stock of our U.S. subsidiaries and 65% of the common stock of our non-United States subsidiaries. Under the terms of our credit agreements, we have agreed to restrict advances to subsidiaries and limit additional indebtedness. The Regions loan agreements both contain cross-default provisions with each other and with the revolving line of credit with Entrepreneur Growth Capital LLC (“EGC”) described below.

 

The replacement note payable with Regions matures in the first quarter of fiscal 2014. We intend to refinance the amounts in lieu of making balloon payments for the remaining principal balances or sell the building in West Lafayette, Indiana. On July 12, 2012, we listed for sale our 7.25 acres and 120,000 square foot facility at 2701 Kent Avenue, West Lafayette, Indiana with the intent to leaseback approximately 80% of that square footage in which to continue our laboratory and manufacturing operations. The asking price was $12,500. We performed an impairment analysis on the building when we listed it for sale, but noted no impairment. As of September 30, 2012 the net book value of the facility and land was $9,585.

 

We may be unsuccessful in renegotiating the terms of the debt or they may be unfavorable to us. For these reasons, if we are unsuccessful at refinancing our long-term debt, our operating results and financial condition could be adversely affected.

 

29
 

 

Revolving Line of Credit

 

On January 13, 2010, we entered into a new $3,000 revolving line of credit agreement (“Credit Agreement”) with EGC. The term of the Credit Agreement expires on January 31, 2014. If we terminate prior to the expiration of the term, then we are subject to an early termination fee equal to the minimum interest charges of $15 for each of the months remaining until expiration.

 

Borrowings under the Credit Agreement bear interest at an annual rate equal to Citibank’s Prime Rate plus five percent (5%), or 8.25% as of September 30, 2012, with minimum monthly interest of $15. Interest is paid monthly. The line of credit also carries an annual facilities fee of 2% and a 0.2% collateral monitoring fee. Borrowings under the Credit Agreement are secured by a blanket lien on our personal property, including certain eligible accounts receivable, inventory, and intellectual property assets, a second mortgage on our West Lafayette and Evansville real estate and all common stock of our U.S. subsidiaries and 65% of the common stock of our non-United States subsidiary. Borrowings are calculated based on 75% of eligible accounts receivable. Under the Credit Agreement, the Company has agreed to restrict advances to subsidiaries, limit additional indebtedness and capital expenditures and maintain a minimum tangible net worth of at least $8,500. Pursuant to the terms of the Credit Agreement, the line of credit will automatically renew on January 31, 2014 unless either party gives a 60-day notice of intent to terminate or withdraw. On December 21, 2012, we negotiated an amendment to this Credit Agreement. The amendment reduced the minimum tangible net worth covenant requirement from $8,500 to $8,000, effective on January 1, 2013, and waived all non-compliances with this covenant through December 31, 2012.

 

The Credit Agreement also contains cross-default provisions with the Regions loans and any future EGC loans. At September 30, 2012, we were not in compliance with the minimum tangible net worth covenant requirement. On December 21, 2012, EGC waived compliance with this covenant as part of the amendment. At September 30, 2012, we had available borrowing capacity of $1,927 on this line, of which $1,444 was outstanding and $721 of cash on hand. We had a decrease in our total borrowing capacity of $535, from $2,462 to $1,927, from the fiscal year ended September 30, 2011 primarily as a result of lower accounts receivable from lower revenues offset slightly by our success in collecting receivables.

 

Based on our current business activities and cash on hand, we expect to borrow on our revolving credit facility in fiscal 2013 to finance working capital. Based on projections for fiscal 2013, we expect to be in breach of the tangible net worth covenant for our first three quarters of fiscal 2013, but in compliance in our fourth fiscal quarter. EGC waived our projected breach for our first fiscal quarter of 2013 in the amendment to the Credit Agreement on December 21, 2012. EGC waived our expected breach for our second and third fiscal quarters of 2013 on October 9, 2013. Failure to comply with the minimum tangible net worth covenant or any other event of default under the Credit Agreement would allow EGC to stop rendering advances and to accelerate the maturity of the outstanding balance. To conserve cash, we instituted a freeze on non-essential capital expenditures and are monitoring all spending closely.

 

For fiscal 2013, we expect to see slow but continued improvement in the volume of new bookings with little improvement in pricing. We also expect improved gross profit margins due to cost controls implemented and restructuring activities. Based on our expected revenue, the availability on our line of credit, the impact of the cost reductions implemented and restructuring activities during fiscal 2012, we project that we will have the liquidity required to meet our fiscal 2013 operations and debt obligations. Should operations materially fail to meet our expectations for the coming fiscal year, we may not be able to comply with all of our debt covenants, requiring that we obtain a waiver at that time. If that situation arises, we will be required to negotiate with our lending bank again to obtain loan modifications or waivers as described above. We cannot predict whether our lenders will provide those waivers, if required, what the terms of any such waivers might be or what impact any such waivers will have on our liquidity, financial condition or results of operations.

 

We are focused on improving our cash flow from operations in fiscal 2013 to reduce our reliance on our line of credit. If we are unable to increase cash flow from operations in fiscal 2013, we may not have sufficient liquidity to continue our business.

 

30
 

 

The following table summarizes the cash payments under our contractual term debt and other obligations at September 30, 2012 and the effect such obligations are expected to have on our liquidity and cash flows in future fiscal periods (amounts in thousands). The table does not include our revolving line of credit. Additional information on the debt is described in Note 8, Debt Arrangements.

 

   2013   2014   2015   2016   2017   Total 
                               
Notes payable  $583   $5,259   $—   $—   $—   $5,842 
Capital lease obligations   388    307    281    214    4    1,194 
Operating leases   371    370    223    13    —    977 
                               
   $1,342   $5,936   $504   $227   $4   $8,013 

 

We anticipate spending approximately $0.8 million in fiscal 2013 on capital assets.

 

Equity Offering (amounts in this section not in thousands)(Restated)

 

On May 11, 2011, we completed a registered public offering of 5,506 units at a price of $1,000 per unit. Each unit consists of one 6% Series A convertible preferred share which is convertible into 500 common shares at a conversion price of $2.00 per share, one Class A Warrant to purchase 250 common shares at an exercise price of $2.00 per share, and one Class B Warrant to purchase 250 common shares at an exercise price of $2.00 per share.

 

The designation, rights, preferences and other terms and provisions of the Preferred Shares are set forth in the Certificate of Designation. Until May 11, 2014, the Series A preferred shares have a stated dividend rate of 6% per annum, payable quarterly in cash or, subject to certain conditions, in common shares or a combination of cash and common shares, at our election. After May 11, 2014, the Series A preferred shares will participate in any dividends payable upon our common shares on an "as converted" basis. If the preferred shares are converted prior to May 11, 2014, we must also pay to the converting holder in cash, or subject to certain conditions, in common shares or a combination thereof, $180 per $1,000 of the stated value of the preferred shares less any dividends paid prior to conversion (a “make-whole” payment). Class A Warrants are exercisable immediately and expire in May 2016. Class B Warrants expired in May 2012. The Class A and B Warrants are accounted for as a liability using the fair value for each on the issuance date and are marked to fair value at each reporting date. The net proceeds from the sale of the units, after deducting the fees and expenses of the placement agent and other expenses were $4.6 million. We used the proceeds for the purchase of laboratory equipment and for working capital and general corporate purposes. Because the preferred dividend or make-whole payment is triggered at the option of the preferred shareholder, we recorded the dividend liability at the time of the offering close and will not have any preferred dividends subsequent to the fiscal quarter ended June 30, 2011.

 

As of September 30, 2012, 4,171 preferred shares have been converted into 2,486,127 common shares and 135,793 common shares have been issued for quarterly preferred dividends for remaining outstanding, unconverted preferred shares. No warrants have been exercised as of September 30, 2012. At September 30, 2012, 1,335 preferred shares and 1,376,500 warrants remained outstanding.

 

Inflation

 

We do not believe that inflation has had a material adverse effect on our business, operations or financial condition.

 

Critical Accounting Policies

 

"Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Liquidity and Capital Resources" discusses the consolidated financial statements of the Company, which have been prepared in accordance with accounting principles generally accepted in the United States. Preparation of these financial statements requires management to make judgments and estimates that affect the reported amounts of assets, liabilities, revenues and expenses, and the disclosures of contingent assets and liabilities. Certain significant accounting policies applied in the preparation of the financial statements require management to make difficult, subjective or complex judgments, and are considered critical accounting policies. We have identified the following areas as critical accounting policies.

 

Revenue Recognition

 

The majority of our service contracts involve the processing of bioanalytical samples for pharmaceutical companies. These contracts generally provide for a fixed fee for each assay method developed or sample processed and revenue is recognized under the specific performance method of accounting. Under the specific performance method, revenue and related direct costs are recognized when services are performed. Other service contracts generally consist of preclinical studies for pharmaceutical companies. Service revenue is recognized based on the ratio of direct costs incurred to total estimated direct costs under the proportional performance method of accounting. Losses on contracts are provided in the period in which the loss becomes determinable. Revisions in profit estimates are reflected on a cumulative basis in the period in which such revisions become known. The establishment of contract prices and total contract costs involves estimates made by the Company at the inception of the contract period. These estimates could change during the term of the contract which could impact the revenue and costs reported in the consolidated financial statements. Projected losses on contracts are provided for in their entirety when known. Revisions to estimates have not been material. Service contract fees received upon acceptance are deferred and classified within customer advances, until earned. Unbilled revenues represent revenues earned under contracts in advance of billings.

 

31
 

 

Product revenue from sales of equipment not requiring installation, testing or training is recognized upon shipment to customers. One product includes internally developed software and requires installation, testing and training, which occur concurrently. Revenue from these sales is recognized upon completion of the installation, testing and training when the services are bundled with the equipment sale.

 

Long-Lived Assets, Including Goodwill

 

Long-lived assets, such as property and equipment, and purchased intangibles subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized of the amount by which the carrying amount of the asset exceeds the fair value of the asset.

 

We carry goodwill at cost. Other intangible assets with definite lives are stated at cost and are amortized on a straight-line basis over their estimated useful lives. All intangible assets acquired that are obtained through contractual or legal right, or are capable of being separately sold, transferred, licensed, rented, or exchanged, are recognized as an asset apart from goodwill. Goodwill is not amortized.

 

Goodwill is tested annually for impairment, and more frequently if events and circumstances indicate that the asset might be impaired. First, we can assess qualitative factors in determining whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. We elected to bypass the qualitative assessment aspect of this guidance due to the restructuring circumstances. Then, we followed a two-step quantitative process. In the first step, we compare the fair value of each reporting unit, as computed primarily by present value cash flow calculations, to its book carrying value, including goodwill. We do not believe that market value is indicative of the true fair value of the Company mainly due to average daily trading volumes of less than 1%. If the fair value exceeds the carrying value, no further work is required and no impairment loss is recognized. If the carrying value exceeds the fair value, the goodwill of the reporting unit is potentially impaired and we would then complete step 2 in order to measure the impairment loss. In step 2, the implied fair value is compared to the carrying amount of the goodwill. If the implied fair value of goodwill is less than the carrying value of goodwill, we would recognize an impairment loss equal to the difference. The implied fair value is calculated by allocating the fair value of the reporting unit (as determined in step 1) to all of its assets and liabilities (including unrecognized intangible assets) and any excess in fair value that is not assigned to the assets and liabilities is the implied fair value of goodwill.

 

The discount rate, gross margin and sales growth rates are the material assumptions utilized in our calculations of the present value cash flows used to estimate the fair value of the reporting units when performing the annual goodwill impairment test. Our reporting units with goodwill at September 30, 2012 are Vetronics, which is included in our Products segment, bioanalytical services and preclinical services located in Evansville, Indiana, which are both included in our Services segment, based on the discrete financial information available which is reviewed by management. We utilize a cash flow approach in estimating the fair value of the reporting units, where the discount rate reflects a weighted average cost of capital rate. The cash flow model used to derive fair value is sensitive to the discount rate and sales growth assumptions used.

 

Due to the closure of the McMinnville, Oregon site, we tested for impairment of the bioanalytical business at the end of our third fiscal quarter using the cash flow approach as explained above. This test resulted in no impairment to the goodwill valuation as currently recorded on the books.

 

We also performed our annual impairment test for all reporting units mentioned above at September 30, 2012. Using a discount rate of 14% and a revenue growth rate of 5% for the Bioanalytical services and 0% for both the preclinical services and Vetronics units, the fair values of the reporting units described above are greater than the carrying values by approximately $3.7 million.

 

32
 

 

Considerable management judgment is necessary to evaluate the impact of operating and macroeconomic changes and to estimate future cash flows. Assumptions used in our impairment evaluations, such as forecasted sales growth rates and our cost of capital or discount rate, are based on the best available market information. Changes in these estimates or a continued decline in general economic conditions could change our conclusion regarding an impairment of goodwill and potentially result in a non-cash impairment loss in a future period. The assumptions used in our impairment testing could be adversely affected by certain of the risks discussed in “Risk Factors” in Item 1A of this report. There have been no significant events since the timing of our impairment tests that would have triggered additional impairment testing.

 

At September 30, 2012, remaining recorded goodwill was $1,383, and the net balance of other intangible assets was $0.

 

Stock-Based Compensation

 

We recognize the cost resulting from all share-based payment transactions in our financial statements using a fair-value-based method. We measure compensation cost for all share-based awards based on estimated fair values and recognize compensation over the vesting period for awards. We recognized stock-based compensation related to stock options of $83 and $153 during the fiscal years ended September 30, 2012 and 2011, respectively.

 

We use the binomial option valuation model to determine the grant date fair value. The determination of fair value is affected by our common stock price as well as assumptions regarding subjective and complex variables such as expected employee exercise behavior and our expected stock price volatility over the term of the award. Generally, our assumptions are based on historical information and judgment is required to determine if historical trends may be indicators of future outcomes. We estimated the following key assumptions for the binomial valuation calculation:

 

     
  •  Risk-free interest rate. The risk-free interest rate is based on U.S. Treasury yields in effect at the time of grant for the expected term of the option.
     
  •  Expected volatility. We use our historical stock price volatility on our common stock for our expected volatility assumption.
     
  •  Expected term. The expected term represents the weighted-average period the stock options are expected to remain outstanding. The expected term is determined based on historical exercise behavior, post-vesting termination patterns, options outstanding and future expected exercise behavior.
     
  •  Expected dividends. We assumed that we will pay no dividends.

 

Employee stock-based compensation expense recognized in fiscal 2012 and 2011 was calculated based on awards ultimately expected to vest and has been reduced for estimated forfeitures. Forfeitures are revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates and an adjustment will be recognized at that time.

 

Changes to our underlying stock price, our assumptions used in the binomial option valuation calculation and our forfeiture rate as well as future grants of equity could significantly impact compensation expense recognized in future periods.

 

Income Tax Accounting

 

As described in Note 9 to the consolidated financial statements, we use the asset and liability method of accounting for income taxes. We recognize deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. We measure deferred tax assets and liabilities using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. We recognize the effect on deferred tax assets and liabilities of a change in tax rates in income in the period that includes the enactment date. We record valuation allowances based on a determination of the expected realization of tax assets.

 

33
 

 

We recognize the tax benefit from an uncertain tax position only if it is more likely than not to be sustained upon examination based on the technical merits of the position. We measure the amount of the accrual for which an exposure exists as the largest amount of benefit determined on a cumulative probability basis that we believe is more likely than not to be realized upon ultimate settlement of the position.

 

We record interest and penalties accrued in relation to uncertain income tax positions as a component of income tax expense. Any changes in the accrued liability for uncertain tax positions would impact our effective tax rate. Over the next twelve months we do not anticipate resolution to the carrying value of our reserve. Interest and penalties are included in the reserve.

 

As of September 30, 2012 and 2011, we had a $16 and $16 liability for uncertain income tax positions, respectively.

 

We file income tax returns in the U.S., several U.S. states, and the foreign jurisdiction of the United Kingdom. We remain subject to examination by taxing authorities in the jurisdictions in which we have filed returns for years after 2007.

 

We have an accumulated net deficit in our UK subsidiary. Consequently, United States deferred tax assets on such earnings have not been recorded. Also, a valuation allowance was established in fiscal 2009 against the U.S. deferred income tax balance. We had previously recorded a valuation allowance on the UK subsidiary deferred income tax balance.

 

Inventories

 

Inventories are stated at the lower of cost or market using the first-in, first-out (FIFO) cost method of accounting. We evaluate inventories on a regular basis to identify inventory on hand that may be obsolete or in excess of current and future projected market demand. For inventory deemed to be obsolete, we provide a reserve for this inventory. Inventory that is in excess of current and projected use is reduced by an allowance to a level that approximates the estimate of future demand.

 

New Accounting Pronouncements

 

In May 2011, the FASB issued updated fair value measurement and disclosure guidance that clarifies how to measure fair value and requires additional disclosures regarding Level 3 fair value measurements, as well as any transfers between Level 1 and Level 2 fair value measurements. The updated accounting guidance is effective for fiscal years and interim periods beginning on or after December 15, 2011 on a prospective basis. The Company adopted this guidance in the second fiscal quarter with no material impact on the consolidated financial statements.

 

In June 2011, the FASB amended the manner in which an entity presents the total of comprehensive income, the components of net income and the components of other comprehensive income either in a single, continuous statement of comprehensive income or in two separate but consecutive statements. The amendment eliminates the option to present the components of other comprehensive income as part of the statement of equity. The amendment is effective for fiscal years and interim periods beginning on or after December 15, 2011 on a retrospective basis. The adoption of this guidance will not change the previously reported amounts of comprehensive income. The Company has presented other comprehensive income on the face of the condensed consolidated statements of operations for all periods presented.

 

In September 2011, the FASB issued an accounting standards update that amends the two-step goodwill impairment test by permitting an entity to first assess qualitative factors in determining whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the entity determines that it is not more likely than not that the fair value of a reporting unit is less than its carrying amount, then performing the two-step goodwill impairment test is unnecessary. The amendment is effective for fiscal years and interim periods beginning on or after December 15, 2011 on a prospective basis, early adoption is permitted. The Company elected to bypass the qualitative assessment aspect of this guidance due to the restructuring circumstances and performed a quantitative analysis in the third and fourth fiscal quarters of 2012. The quantitative analysis resulted in no impairment to the goodwill valuation as currently recorded on the books.

 

2011 Quarterly Results (Unaudited)

 

Certain selected quarterly financial information for the fiscal year ended September 30, 2011 is presented below. The consolidated statements of operations and comprehensive income (loss) for the three month period ended June 30, 2011 has been restated from previously reported results. The consolidated balance sheet as of June 30, 2011 has also been restated from previously reported results. There was no net effect on the consolidated statements of cash flows for the third fiscal quarter of 2011 as the expense of the change in the warrant fair value is a non-cash item. For additional information and a detailed discussion of the accounts restated, see Note 3 to the accompanying consolidated financial statements.

  

[Remainder of page intentionally left blank.]

 

34
 

  

Consolidated Statement of Operations

 

   For the Three Months Ended   For the Nine Months Ended 
   June 30, 2011   June 30, 2011 
   As Reported   Restated   As Reported   Restated 
         -         - 
Operating income  $481   $481   $1,669   $1,669 
         -         - 
Interest expense   (70)   (70)   (473)   (473)
Change in fair value of warrant liability - (increase) decrease   -    (185)   -    (185)
Other income (expense)   7    7    15    15 
Income (loss) before income taxes   418    233    1,211    1,026 
                     
Income tax expense   -    -    -    - 
                     
Net income (loss)  $418   $233   $1,211   $1,026 
                     
Less:  Deemed dividend on Series A preferred shares   (3,277)   (5,506)   (3,277)   (5,506)
Less:  Preferred stock dividends   (991)   (991)   (991)   (991)
                     
Net loss attributable to common shareholders  $(3,850)  $(6,264)  $(3,057)  $(5,471)
                     
Basic net loss per share  $(0.65)  $(1.06)  $(0.58)  $(1.04)
Diluted net loss per share  $(0.65)  $(1.06)  $(0.58)  $(1.04)

 

Consolidated Balance Sheet

 

   As of June 30, 2011 
   As Reported   Restated 
         
Total assets  $34,310   $34,310 
           
Total other current liabilities   10,761    10,761 
Fair value of warrant liability   -    3,230 
Total current liabilities   10,761    13,991 
           
Other long-term debt   7,296    7,296 
           
Total liabilities   18,057    21,287 
           
Shareholders' equity:          
Preferred Shares   2,135    2,135 
Common Shares   1,690    1,690 
Additional paid-in capital   19,370    18,554 
Accumulated deficit   (7,038)   (9,452)
Accumulated other comprehensive income   96    96 
Total shareholders' equity   16,253    13,023 
           
Total liabilities and shareholders' equity  $34,310   $34,310 

 

Quarter ended June 30, 2011, Restated

 

Due to the error in recording the Class A and B Warrants as equity, we restated the total liabilities to include the warrant liability and adjusted the additional paid-in capital and accumulated deficit accordingly. For the quarter ended June 30, 2011, we recorded net income of $233. This restated income was lower due to the recording of the fair value adjustments for the Class A and B Warrants from the May 2011 public offering. In the third quarter of fiscal 2011, the fair value of the warrants increased from $3,045 to $3,230. The assumptions used to compute the fair value of the warrants at June 30, 2011 were as follows:

 

35
 

 

   Warrant A   Warrant B 
         
Risk-free interest rate   1.69%   0.17%
Dividend yield   0.00%   0.00%
Volatility of the Company's common stock   108.19%   116.48%
Expected life of the options (years)   4.9    0.9 
           
Fair value per unit  $1.536   $0.811 

 

Quarter ended September 30, 2011

 

For the quarter ended September 30, 2011, we recorded net income of $1,276. This restated income was higher due to the recording of the fair value adjustments for the Class A and B Warrants from the May 2011 public offering. In the fourth quarter of fiscal 2011, the fair value of the warrants decreased from $3,230 to $1,286.

 

2012 Quarterly Results (Unaudited)

 

Certain selected quarterly financial information for the fiscal year ended September 30, 2012 is presented below. The consolidated statements of operations and comprehensive income (loss) for the three month periods ended December 31, 2011, March 31, 2012 and June 30, 2012 have been restated from previously reported results. The consolidated balance sheets as of December 31, 2011, March 31, 2012 and June 30, 2012 have also been restated from previously reported results. There was no net effect on the consolidated statements of cash flows for the first three fiscal quarters of 2012 as the income (loss) from the change in the warrant fair value is a non-cash item. For additional information and a detailed discussion of the accounts restated, see Note 3 to the accompanying consolidated financial statements.

 

Consolidated Statements of Operations and Comprehensive Income (Loss)

 

   For the Three Months Ended   For the Six Months Ended 
   December 31, 2011   March 31, 2012   March 31, 2012 
   As Reported   Restated   As Reported   Restated   As Reported   Restated 
                         
Operating loss   (1,302)   (1,302)   (1,705)   (1,705)   (3,007)   (3,007)
                               
Interest expense   (189)   (189)   (179)   (179)   (368)   (368)
Change in fair value of warrant liability - (increase) decrease   -    (56)   -    56    -    - 
Other income   -    -    -    -    -    - 
Loss before income taxes   (1,491)   (1,547)   (1,884)   (1,828)   (3,375)   (3,375)
                               
Income tax expense   -    -    -    -    -    - 
                               
Net loss  $(1,491)  $(1,547)  $(1,884)  $(1,828)  $(3,375)  $(3,375)
                               
Other comprehensive income (loss):                              
Foreign currency translation adjustment   (1)   (1)   23    23    22    22 
                               
Comprehensive Loss  $(1,492)  $(1,548)  $(1,861)  $(1,805)  $(3,353)  $(3,353)
                               
Basic net loss per share  $(0.21)  $(0.22)  $(0.27)  $(0.26)  $(0.48)  $(0.48)
Diluted net loss per share  $(0.21)  $(0.22)  $(0.27)  $(0.26)  $(0.48)  $(0.48)

 

36
 

 

   For the Three Months Ended   For the Nine Months Ended 
   June 30, 2012   June 30, 2012 
   As Reported   Restated   As Reported   Restated 
                 
Operating loss   (540)   (540)   (3,547)   (3,547)
                     
Interest expense   (172)   (172)   (540)   (540)
Change in fair value of warrant liability - decrease   -    458    -    458 
Other income   8    8    8    8 
Loss before income taxes   (704)   (246)   (4,079)   (3,621)
                     
Income tax expense   -    -    -    - 
                     
Net loss  $(704)  $(246)  $(4,079)  $(3,621)
                     
Other comprehensive invome (loss):                    
Foreign currency translation adjustment   (17)   (17)   4    4 
                     
Comprehensive Loss  $(721)  $(263)  $(4,075)  $(3,617)
                     
Basic net loss per share  $(0.10)  $(0.03)  $(0.58)  $(0.51)
Diluted net loss per share  $(0.10)  $(0.03)  $(0.58)  $(0.51)

 

Consolidated Balance Sheet

 

   As of December 31, 2011   As of March 31, 2012   As of June 30, 2012 
   As Reported   Restated   As Reported   Restated   As Reported   Restated 
                         
Total assets  $31,685   $31,685   $29,678   $29,678   $28,781   $28,781 
                               
Total other current liabilities   16,394    16,394    16,232    16,232    15,968    15,968 
Fair value of warrant liability   -    1,342    -    1,286    -    828 
Total current liabilities   16,394    17,736    16,232    17,518    15,968    16,796 
                               
Other long-term debt   1,118    1,118    1,051    1,051    1,062    1,062 
                               
Total liabilities   17,512    18,854    17,283    18,569    17,030    17,858 
                               
Shareholders' equity:                              
Preferred Shares   2,135    2,135    1,935    1,935    1,685    1,685 
Common Shares   1,705    1,705    1,743    1,743    1,781    1,781 
Additional paid-in capital   19,480    18,664    19,725    18,909    20,015    19,199 
Accumulated deficit   (9,197)   (9,723)   (11,081)   (11,551)   (11,785)   (11,797)
Accumulated other comprehensive income   50    50    73    73    55    55 
Total shareholders' equity   14,173    12,831    12,395    11,109    11,751    10,923 
                               
Total liabilities and shareholders' equity  $31,685   $31,685   $29,678   $29,678   $28,781   $28,781 

  

Quarter ended December 31, 2011, Restated

 

Due to the error in recording the Class A and B Warrants as equity, we restated the total liabilities to include the warrant liability and adjusted the additional paid-in capital and accumulated deficit accordingly. For the quarter ended December 31, 2011, we recorded a net loss of $1,547. This restated loss was higher due to the recording of the fair value adjustments for the Class A and B Warrants. In the first quarter of fiscal 2012, the fair value of the warrants increased slightly from $1,286 to $1,342.

 

 

37
 

 

Quarter ended March 31, 2012, Restated

 

Due to the error in recording the Class A and B Warrants as equity, we restated the total liabilities to include the warrant liability and adjusted the additional paid-in capital and accumulated deficit accordingly. For the quarter ended March 31, 2012, we recorded a net loss of $1,828. This restated loss was lower due to the recording of the fair value adjustments for the Class A and B Warrants. In the second quarter of fiscal 2012, the fair value of the warrants decreased slightly from $1,342 to $1,286.

 

Quarter ended June 30, 2012, Restated

 

Due to the error in recording the Class A and B Warrants as equity, we restated the total liabilities to include the warrant liability and adjusted the additional paid-in capital and accumulated deficit accordingly. For the quarter ended June 30, 2012, we recorded a net loss of $246. This restated loss was lower due to the recording of the fair value adjustments for the Class A Warrants and the expiration of the Class B Warrants. In the second quarter of fiscal 2012, the fair value of the warrants decreased from $1,286 to $828.

 

The assumptions used to compute the fair value of the warrants for the first three fiscal quarters of 2012were as follows:

 

   December 31, 2011   March 31, 2012   June 30, 2012 
   Warrant A   Warrant B   Warrant A   Warrant B   Warrant A 
                     
Risk-free interest rate   0.68%   0.04%   0.81%   0.07%   0.55%
Dividend yield   0.00%   0.00%   0.00%   0.00%   0.00%
Volatility of the Company's common stock   115.75%   83.50%   118.87%   48.48%   121.75%
Expected life of the options (years)   4.4    0.4    4.1    0.1    3.9 
                          
Fair value per unit  $0.901   $0.074   $0.933   $0.001   $0.602 

 

Quarter ended September 30, 2012

 

For the quarter ended September 30, 2012, we recorded a net loss of $2,695. This restated loss was higher due to the recording of the fair value adjustments for the Class A Warrants. In the fourth quarter of fiscal 2012, the fair value of the warrants increased from $828 to $1,213.

 

ITEM 7A – QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Not applicable.

 

38
 

 

ITEM 8-FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

 

Index to Consolidated Financial Statements

 

    Page
     
Consolidated Financial Statements of Bioanalytical Systems, Inc.  
   
  Consolidated Balance Sheets as of September 30, 2012 and 2011 40
     
  Consolidated Statements of Operations and Comprehensive Income (Loss) for the Years Ended September 30, 2012 and 2011 41
     
  Consolidated Statements of Shareholders’ Equity for the Years Ended September 30, 2012 and 2011 42
     
  Consolidated Statements of Cash Flows for the Years Ended September 30, 2012 and 2011 43
     
  Notes to Consolidated Financial Statements 44
     
  Report of Independent Registered Public Accounting Firm 64
   
Financial Statement Schedules:  
   
Schedules are not required, are not applicable or the information is shown in the Notes to the Consolidated Financial Statements.  

 

39
 

 

BIOANALYTICAL SYSTEMS, INC.

CONSOLIDATED BALANCE SHEETS

(In thousands, except share amounts)

 

   As of September 30, 
   2012   2011 
   (Restated)  

(Restated)

 
Assets          
Current assets:          
Cash and cash equivalents  $721   $2,963 
Accounts receivable          
Trade   3,366    4,073 
Unbilled revenues and other   921    1,116 
Inventories   1,656    1,636 
Prepaid expenses   228    585 
Total current assets   6,892    10,373 
           
           
Property and equipment, net   18,628    20,399 
Goodwill   1,383    1,383 
Intangible assets, net   —    54 
Debt issue costs, net   18    75 
Other assets   54    62 
           
Total assets  $26,975   $32,346 
           
Liabilities and shareholders’ equity          
Current liabilities:          
Accounts payable  $3,934   $1,764 
Accrued expenses   2,067    1,762 
Customer advances   3,012    3,571 
Income tax accruals   17    56 
Revolving line of credit   1,444    1,346 

Fair value of warrant liability

   1,213    1,286 
Current portion of capital lease obligation   330    613 
Current portion of long-term debt   583    735 
Total current liabilities   12,600    11,133 
           
Capital lease obligation, less current portion   739    1,071 
Long-term debt, less current portion   5,259    5,842 
           
Shareholders’ equity:          
Preferred shares, authorized 1,000,000 shares, no par value:          
1,335 Series A shares at $1,000 stated value issued and outstanding at September 30, 2012 and
2,135 at September 30, 2011		   1,335    2,135 
Common shares, no par value:          
Authorized 19,000,000 shares; 7,638,738 issued and outstanding at September 30, 2012 and 6,945,631 at September 30, 2011   1,871    1,698 
Additional paid-in capital   19,635    18,592 
Accumulated deficit   (14,493)   (8,176)
Accumulated other comprehensive income   29    51 
           
Total shareholders’ equity   8,377    14,300 
           
Total liabilities and shareholders’ equity  $26,975   $32,346 

 

The accompanying notes are an integral part of the consolidated financial statements.

 

40
 

 

BIOANALYTICAL SYSTEMS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)
(In thousands, except per share amounts)

 

   For the Years Ended
September 30,		 
   2012   2011 
  

(Restated)

  

(Restated)

 
         
Service revenue  $21,312   $25,613 
Product revenue   6,896    7,531 
Total revenue   28,208    33,144 
           
Cost of service revenue   18,472    19,679 
Cost of product revenue   2,898    2,959 
Total cost of revenue   21,370    22,638 
           
Gross profit   6,838    10,506 
Operating expenses:          
Selling   3,263    3,121 
Research and development   542    534 
General and administrative   5,524    5,564 
Total operating expenses   9,329    9,219 
           
Restructuring charges   3,195    — 
           
Operating income (loss)   (5,686)   1,287 
           
Interest expense   (714)   (706)

Change in fair value of warrant liability - decrease

   73    1,759 
Other income   12    12 
Income (loss) before income taxes   (6,315)   2,352 
           
Income tax expense   2    50 
           
Net income (loss)  $(6,317)  $2,302 
           
Other comprehensive income (loss):          
Foreign currency translation adjustment   (22)   (49)
           
Comprehensive income (loss)  $(6,339)  $2,253 
           
           
Basic net loss per share:  $(0.88)  $(0.74)
Diluted net loss per share:  $(0.88)  $(0.74)
           
Weighted common shares outstanding:          
Basic   7,158    5,667 
Diluted   7,158    5,667 

 

The accompanying notes are an integral part of the consolidated financial statements.

 

41
 

 

BIOANALYTICAL SYSTEMS, INC.

CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY

(In thousands, except number of shares)

 

   Preferred Shares   Common Shares   Additional paid-   Accumulated   Accumulated other comprehensive   Total shareholders' 
   Number   Amount   Number   Amount   in capital   deficit   income (loss)   equity 
                                 
Balance at October 1, 2010   -   $-    4,915,318   $1,191   $13,357   $(3,981)  $100   $10,667 
                                         
Comprehensive income:                                        
         Net income                            2,302         2,302 
         Foreign currency translation adjustments                                 (49)   (49)
                                         
Stock based compensation expense                       153              153 
                                         
Issuance of preferred shares, net of issuance costs of $900,281   5,506    5,506              (900)             4,606 
                                         
Fair value attributed to warrants   -    (3,045)             -              (3,045)
                                         
Preferred stock - beneficial conversion feature        (2,461)             2,461              - 
                                         
Preferred stock - deemed dividend        5,506                   (5,506)        - 
                                         
Preferred stock - recognition of full dividend/make-whole                            (991)        (991)
                                         
Conversion of preferred shares to common shares   (3,371)   (3,371)   1,685,500    421    2,950              - 
                                         
Common shares issued for dividends/make-whole payment   -    -    344,813    86    571              657 
                                         
Balance at September 30, 2011 (Restated)   2,135   $2,135    6,945,631   $1,698   $18,592   $(8,176)  $51   $14,300 
                                         
Comprehensive loss:                                        
         Net loss                            (6,317)        (6,317)
         Foreign currency translation adjustments                                 (22)   (22)
                                         
Stock based compensation expense                       83              83 
                                         
Conversion of preferred shares to common shares   (800)   (800)   400,000    100    700              - 
                                         
Common shares issued for dividends/make-whole payment   -    -    191,607    48    157              205 
                                         
Direct common share purchase from Directors   -    -    101,500    25    103              128 
                                         
Balance at September 30, 2012 (Restated)   1,335   $1,335    7,638,738   $1,871   $19,635   $(14,493)  $29   $8,377 

 

The accompanying notes are an integral part of the consolidated financial statements.

 

42
 

 

BIOANALYTICAL SYSTEMS, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

 

   Years Ended September 30, 
   2012   2011 
  

(Restated)

  

(Restated)

 
Operating activities:          
Net income (loss)  $(6,317)  $2,302 
Adjustments to reconcile net income (loss) to net cash (used) provided by operating activities:          
Depreciation and amortization   2,278    2,134 
Employee stock compensation expense   83    153 

Change in fair value of warrant liability - decrease

   (73)   (1,759)
Provision for doubtful accounts   (15)   16 
Gain on interest rate swaps   —    (31)
(Gain) loss on sale of property and equipment   451    (9)
Deferred income taxes   —    (14)
Changes in operating assets and liabilities:          
Accounts receivable   917    (236)
Inventories   (20)   37 
Refundable income taxes   (39)   56 
Prepaid expenses and other assets   414    17 
Accounts payable   2,375    (482)
Accrued expenses   305    (86)
Customer advances   (559)   (1,010)
Net cash (used) provided by operating activities   (200)   1,088 
           
Investing activities:          
Capital expenditures   (1,090)   (1,174)
Proceeds from sale of equipment   230      
Net cash used by investing activities   (860)   (1,174)
           
Financing activities:          
Net proceeds from registered direct offering   —    4,606 
Direct common shares purchased by interim CEO and Board of Directors   128    — 
Payments of long-term debt   (735)   (1,756)
Payments on revolving line of credit   (27,695)   (30,917)
Borrowings on revolving line of credit   27,793    31,068 
Payments on capital lease obligations   (655)   (1,341)
Net cash (used) provided by financing activities   (1,164)   1,660 
           
           
Effect of exchange rate changes   (18)   (33)
           
Net (decrease) increase in cash and cash equivalents   (2,242)   1,541 
Cash and cash equivalents at beginning of year   2,963    1,422 
Cash and cash equivalents at end of year  $721   $2,963 
           
Supplemental disclosure of non-cash financing activities:          
Preferred stock dividends accrued, but not paid  $—   $991 
Preferred stock dividends paid in common shares  $(106)  $(657)
Equipment financed under capital leases  $356   $1,888 
Termination of capital lease obligation  $322   $— 

 

The accompanying notes are an integral part of the consolidated financial statements.

 

43
 

 

BIOANALYTICAL SYSTEMS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

(Amounts in thousands unless otherwise listed)

 

1. DESCRIPTION OF THE BUSINESS

 

Bioanalytical Systems, Inc. and its subsidiaries (the “Company” or “BASi” or “we”) engage in research services and other services related to pharmaceutical development. We also manufacture scientific instruments for medical research, which we sell with related software for use in industrial, governmental and academic laboratories. We conduct our businesses through our research and manufacturing facilities in Indiana. Our customers are located throughout the world.

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

(a)Principles of Consolidation

 

The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant inter-company accounts and transactions have been eliminated.

 

(b)Revenue Recognition

 

The majority of our Bioanalytical and analytical research service contracts involve the development of analytical methods and the processing of bioanalytical samples for pharmaceutical companies and generally provide for a fixed fee for each sample processed. Revenue is recognized under the specific performance method of accounting and the related direct costs are recognized when services are performed. Our preclinical research service contracts generally consist of preclinical studies, and revenue is recognized under the proportional performance method of accounting. Revisions in profit estimates, if any, are reflected on a cumulative basis in the period in which such revisions become known. The establishment of contract prices and total contract costs involves estimates we make at the inception of the contract. These estimates could change during the term of the contract and impact the revenue and costs reported in the consolidated financial statements. Revisions to estimates have generally not been material. Research service contract fees received upon acceptance are deferred until earned, and classified within customer advances. Unbilled revenues represent revenues earned under contracts in advance of billings.

 

Product revenue from sales of equipment not requiring installation, testing or training is recognized upon shipment to customers. One product includes internally developed software and requires installation, testing and training, which occur concurrently. Revenue from these sales is recognized upon completion of the installation, testing and training when the services are bundled with the equipment sale.

 

(c)Cash Equivalents

 

We consider all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents.

 

One or more of the financial institutions holding the Company’s cash accounts are participating in the FDIC’s Transaction Account Guarantee Program. Under that program, through December 31, 2010, all noninterest-bearing transaction accounts are fully guaranteed by the FDIC for the entire amount in the account. Pursuant to legislation enacted in 2010, the FDIC will fully insure all noninterest-bearing transaction accounts beginning December 31, 2010 through December 31, 2012, at all FDIC-insured institutions.

 

For financial institutions opting out of the FDIC’s Transaction Account Guarantee Program or interest-bearing cash accounts, the FDIC’s insurance limits were permanently increased to $250,000, effective July 21, 2010. At September 30, 2012, the Company did not have any cash accounts that exceeded federally insured limits.

 

44
 

 

(d)Accounts Receivable

 

We perform periodic credit evaluations of our customers’ financial conditions and generally do not require collateral on trade accounts receivable. We account for trade receivables based on the amounts billed to customers. Past due receivables are determined based on contractual terms. We do not accrue interest on any of our trade receivables. The allowance for doubtful accounts is determined by management based on our historical losses, specific customer circumstances, and general economic conditions. Periodically, management reviews accounts receivable and adjusts the allowance based on current circumstances and charges off uncollectible receivables when all attempts to collect have failed. Our allowance for doubtful accounts was $123 and $108 at September 30, 2012 and 2011, respectively.

 

A summary of activity in our allowance for doubtful accounts is as follows:

 

   2012   2011 
         
Opening balance  $108   $165 
Charged to expense   84    13 
Accounts recovered   15    (61)
Accounts written off   (84)   (9)
Ending balance  $123   $108 

 

(e)Inventories

 

Inventories are stated at the lower of cost or market using the first-in, first-out (FIFO) cost method of accounting. We evaluate inventories on a regular basis to identify inventory on hand that may be obsolete or in excess of current and future projected market demand. For inventory deemed to be obsolete, we provide a reserve for this inventory. Inventory that is in excess of current and projected use is reduced by an allowance to a level that approximates the estimate of future demand.

 

(f)Property and Equipment

 

We record property and equipment at cost, including interest capitalized during the period of construction of major facilities. We compute depreciation, including amortization on capital leases, using the straight-line method over the estimated useful lives of the assets, which we estimate to be: buildings and improvements, 34 to 40 years; machinery and equipment, 5 to 10 years, and office furniture and fixtures, 10 years. In our European operations, we depreciate leasehold improvements, using the straight-line method, over 7 years, corresponding to the terms of the operating lease for the European facility. Depreciation expense was $2,217 in fiscal 2012 and $2,085 in fiscal 2011. Expenditures for maintenance and repairs are expensed as incurred.

 

Property and equipment, net, as of September 30, 2012 and 2011 consisted of the following:

 

   2012   2011 
         
Land and improvements  $914   $527 
Buildings and improvements   21,278    21,433 
Machinery and equipment   19,496    22,361 
Office furniture and fixtures   701    949 
Construction in progress   35    493 
    42,424    45,763 
Less:  accumulated depreciation   (23,796)   (25,364)
Net property and equipment  $18,628   $20,399 

 

45
 

 

(g)Long-Lived Assets including Goodwill

 

Long-lived assets, such as property and equipment, and purchased intangibles subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized of the amount by which the carrying amount of the asset exceeds the fair value of the asset.

 

We carry goodwill at cost. Other intangible assets with definite lives are stated at cost and are amortized on a straight-line basis over their estimated useful lives. All intangible assets acquired that are obtained through contractual or legal right, or are capable of being separately sold, transferred, licensed, rented, or exchanged, are recognized as an asset apart from goodwill. Goodwill is not amortized.

 

Goodwill is tested annually for impairment, and more frequently if events and circumstances indicate that the asset might be impaired. First, we can assess qualitative factors in determining whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. We elected to bypass the qualitative assessment aspect of this guidance due to the restructuring circumstances. Then, we followed a two-step quantitative process. In the first step, we compare the fair value of each reporting unit, as computed primarily by present value cash flow calculations, to its book carrying value, including goodwill. We do not believe that market value is indicative of the true fair value of the Company mainly due to average daily trading volumes of less than 1%. If the fair value exceeds the carrying value, no further work is required and no impairment loss is recognized. If the carrying value exceeds the fair value, the goodwill of the reporting unit is potentially impaired and we would then complete step 2 in order to measure the impairment loss. In step 2, the implied fair value is compared to the carrying amount of the goodwill. If the implied fair value of goodwill is less than the carrying value of goodwill, we would recognize an impairment loss equal to the difference. The implied fair value is calculated by allocating the fair value of the reporting unit (as determined in step 1) to all of its assets and liabilities (including unrecognized intangible assets) and any excess in fair value that is not assigned to the assets and liabilities is the implied fair value of goodwill.

 

The discount rate, gross margin and sales growth rates are material assumptions utilized in our calculations of the present value cash flows used to estimate the fair value of the reporting units when performing the annual goodwill impairment test. Our reporting units with goodwill at September 30, 2012 are Vetronics, which is included in our Products segment, bioanalytical services and preclinical services, which are both included in our Services segment, based on the discrete financial information available which is reviewed by management. We utilize a cash flow approach in estimating the fair value of the reporting units, where the discount rate reflects a weighted average cost of capital rate. The cash flow model used to derive fair value is sensitive to the discount rate and sales growth assumptions used.

 

Due to the closure of the McMinnville, Oregon site, we tested for impairment of the bioanalytical business at the end of our third fiscal quarter using the cash flow approach as explained above. This test resulted in no impairment to the goodwill valuation as currently recorded on the books.

 

We also performed our annual impairment test for all reporting units mentioned above at September 30, 2012. Using a discount rate of 14% and a revenue growth rate of 5% for the Bioanalytical services and 0% for both the preclinical services and Vetronics units, the fair values of the reporting units described above are greater than the carrying values by approximately $3.7 million.

 

Considerable management judgment is necessary to evaluate the impact of operating and macroeconomic changes and to estimate future cash flows. Assumptions used in our impairment evaluations, such as forecasted sales growth rates and our cost of capital or discount rate, are based on the best available market information. Changes in these estimates or a continued decline in general economic conditions could change our conclusion regarding an impairment of goodwill and potentially result in a non-cash impairment loss in a future period. The assumptions used in our impairment testing could be adversely affected by certain risks. There have been no significant events since the timing of our impairment tests that would have triggered additional impairment testing.

 

46
 

 

At September 30, 2012 and 2011, remaining recorded goodwill was $1,383, and the net balance of other intangible assets was $0 and $54, respectively. The components of intangible assets subject to amortization are as follows:

 

       September 30, 2012 
   Weighted
average life
(years)		   Gross Carrying
Amount		   Accumulated
Amortization		 
                
FDA compliant facility   10   $302   $302 

 

       September 30, 2011 
   Weighted
average life
(years)		   Gross Carrying
Amount		   Accumulated
Amortization		 
                
FDA compliant facility   10   $302   $248 

 

Amortization expense for intangible assets for fiscal years ended September 30, 2012 and 2011 was $54 and $30, respectively. As of September 30, 2012, all intangible assets have been fully amortized.

 

(h)Advertising Expense

 

We expense advertising costs as incurred. Advertising expense was $203 and $229 for the years ended September 30, 2012 and 2011, respectively.

 

(i)Stock-Based Compensation

 

We have a stock-based employee compensation plan and a stock-based employee and outside director compensation plan, which are described more fully in Note 10. All options granted under these plans have an exercise price equal to the market value of the underlying common shares on the date of grant. We expense the estimated fair value of stock options over the vesting periods of the grants. Our policy is to recognize expense for awards subject to graded vesting using the straight-line attribution method, reduced for estimated forfeitures. Forfeitures are revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates and an adjustment is recognized at that time.

 

We use a binomial option-pricing model as our method of valuation for share-based awards, requiring us to make certain assumptions about the future, which are more fully described in Note 10. Stock-based compensation expense for employee stock options for the years ended September 30, 2012 and 2011 was $83 and $153, respectively.

 

(j)Income Taxes

 

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. We record valuation allowances based on a determination of the expected realization of tax assets.

 

We may recognize the tax benefit from an uncertain tax position only if it is more likely than not to be sustained upon examination based on the technical merits of the position. The amount of the accrual for which an exposure exists is measured as the largest amount of benefit determined on a cumulative probability basis that we believe is more likely than not to be realized upon settlement of the position.

 

We record interest and penalties accrued in relation to uncertain income tax positions as a component of income tax expense. Any changes in the liability for uncertain tax positions would impact our effective tax rate. We do not expect the total amount of unrecognized tax benefits to significantly change in the next twelve months.

 

47
 

 

(k)New Accounting Pronouncements

 

In May 2011, the FASB issued updated fair value measurement and disclosure guidance that clarifies how to measure fair value and requires additional disclosures regarding Level 3 fair value measurements, as well as any transfers between Level 1 and Level 2 fair value measurements. The updated accounting guidance is effective for fiscal years and interim periods beginning on or after December 15, 2011 on a prospective basis. The Company adopted this guidance in the second fiscal quarter with no material impact on the consolidated financial statements.

 

In June 2011, the FASB amended the manner in which an entity presents the total of comprehensive income, the components of net income and the components of other comprehensive income either in a single, continuous statement of comprehensive income or in two separate but consecutive statements. The amendment eliminates the option to present the components of other comprehensive income as part of the statement of equity. The amendment is effective for fiscal years and interim periods beginning on or after December 15, 2011 on a retrospective basis. The adoption of this guidance will not change the previously reported amounts of comprehensive income. The Company has presented other comprehensive income on the face of the condensed consolidated statements of operations for all periods presented.

 

In September 2011, the FASB issued an accounting standards update that amends the two-step goodwill impairment test by permitting an entity to first assess qualitative factors in determining whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the entity determines that it is not more likely than not that the fair value of a reporting unit is less than its carrying amount, then performing the two-step goodwill impairment test is unnecessary. The amendment is effective for fiscal years and interim periods beginning on or after December 15, 2011 on a prospective basis, early adoption is permitted. The Company elected to bypass the qualitative assessment aspect of this guidance due to the restructuring circumstances and performed a quantitative analysis in the third and fourth fiscal quarters of 2012. The quantitative analysis resulted in no impairment to the goodwill valuation as currently recorded on the books.

 

(l)Fair Value

 

The provisions of the Fair Value Measurements and Disclosure Topic defines fair value, establishes a consistent framework for measuring fair value and provides the disclosure requirements about fair value measurements. This Topic also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s judgment about the assumptions market participants would use in pricing the asset or liability based on the best information available in the circumstances. The hierarchy is broken down into three levels based on the inputs as follows:

 

  •   Level 1 – Valuations based on quoted prices for identical assets or liabilities in active markets that the Company has the ability to access.

 

  •   Level 2 – Valuations based on quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.

 

  •   Level 3 – Valuations based on inputs that are unobservable and significant to the overall fair value measurement.

 

We have Class A and B Warrants from the May 2011 offering that are measured at fair value on a recurring basis. We recorded these warrants as a liability determining the fair value at inception on May 11, 2011. Subsequent quarterly fair value measurements, using the Black Scholes model which is considered a level 2 measurement, are calculated with fair value changes charged to the statement of operations and comprehensive income (loss). Class B Warrants expired in May 2012 and the liability was reduced to zero. The assumptions used to compute the fair value of the warrants at September 30, 2012 and 2011 were as follows:

 

   September 30, 2012   September 30, 2011 
   Warrant A   Warrant A   Warrant B 
             
Risk-free interest rate   0.41%   0.86%   0.08%
Dividend yield   0.00%   0.00%   0.00%
Volatility of the Company's common stock   117.30%   111.44%   74.43%
Expected life of the options (years)   3.6    4.6    0.6 
                
Fair value per unit  $0.881   $0.844   $0.091 

 

The carrying amounts for cash and cash equivalents, accounts receivable, inventories, prepaid expenses and other assets, accounts payable and other accruals approximate their fair values because of their nature and respective duration. The fair value of the revolving credit facility and certain long-term debt is equal to their carrying values due to the variable nature of their interest rates. Our long-term fixed rate debt was initiated in February 2011 and renewed on November 1, 2012. Our interest rate swap expired under its terms in fiscal 2011.

 

48
 

  

(m)Use of Estimates

 

The preparation of financial statements in conformity with generally accepted accounting principles requires us to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Significant estimates as part of the issuance of these consolidated financial statements include but are not limited to the determination of fair values, allowance for doubtful accounts, inventory obsolescence, deferred tax valuations, depreciation, impairment charges and stock compensation. Our actual results could differ from those estimates.

 

(n)Research and Development

 

In fiscal 2012 and 2011, we spent $542 and $534, respectively, on research and development. Separate from our contract research services business, we maintain applications research and development to enhance our products business.

 

(o)Comprehensive Income (Loss)

 

We report comprehensive income (loss) on our Consolidated Statements of Operations. Other comprehensive income (loss) represents changes in shareholders’ equity and is comprised of foreign currency translation adjustments.

 

(p)Foreign Currency

 

For our subsidiary outside of the United States that operates in a local currency environment, income and expense items are translated to United States dollars at the monthly average rates of exchange prevailing during the year, assets and liabilities are translated at year-end exchange rates and equity accounts are translated at historical exchange rates. Translation adjustments are accumulated in a separate component of shareholders' equity in the consolidated balance sheets and are included in the determination of comprehensive income (loss) in the consolidated statements of shareholders' equity. Transaction gains and losses are included in the determination of net income (loss) in the consolidated statements of operations and comprehensive income (loss).

  

3. RESTATEMENT OF PREVIOUSLY ISSUED CONSOLIDATED FINANCIAL STATEMENTS

 

In August 2013, we announced a delay in filing our Form 10-Q for the three and nine months ended June 30, 2013 until management resolved a complex accounting issue related to the accounting treatment for our outstanding warrants. In the same month, we announced that investors should no longer rely on our previously issued consolidated financial statements and the related independent auditors’ reports for the fiscal years ended September 30, 2012 and 2011, or the quarterly financial statements for the first two quarters of fiscal 2013, or any earnings releases relating to these periods, because of errors in such financial statements.

 

As a result of the identification of such errors, we have undertaken a comprehensive review of our previously filed consolidated financial statements. We concluded that the warrants issued in connection with our public offering in May 2011 were incorrectly accounted for as equity and the fair value of the warrants should have been recorded as a liability. As a result, we have restated our previously reported consolidated financial statements for the years ended September 30, 2012 and 2011. The restatement adjustments resulted in a cumulative net decrease to Total shareholders’ equity of $1,213 and $1,286 as of September 30, 2012 and 2011, respectively, a decrease to our previously reported net loss for the fiscal year ended September 30, 2012 of $73 and an increase in previously reported net income of $1,759 for the fiscal year ended September 30, 2011. The decrease in our net loss and increase in net income was a result of the changes in the fair value of the warrant liability that is now correctly recorded in other income (expense) as the change in fair value of warrant liability- (increase) decrease. Except as otherwise specified, all information presented in the accompanying consolidated financial statements and the related notes are presented after inclusion of all such adjustments. There was no net effect on the consolidated statements of cash flows for fiscal years 2012 and 2011 as the change in the fair value of the warrant liability is a non-cash item.

 

The following table summarizes the effects of the restatement adjustments, previously discussed, on the consolidated statements of operations and comprehensive income (loss) items for the years ended September 30:

 

   2012   2011 
   As Reported   Adjustment   Restated   As Reported   Adjustment   Restated 
Total revenue  $28,208   $-   $28,208   $33,144        $33,144 
Total cost of revenue   21,370    -    21,370    22,638         22,638 
                               
Gross profit   6,838    -    6,838    10,506    -    10,506 
                               
Total operating expenses   9,329    -    9,329    9,219         9,219 
Restructuring charges   3,195    -    3,195    -         - 
                               
Operating income (loss)   (5,686)   -    (5,686)   1,287    -    1,287 
                               
Interest expense   (714)   -    (714)   (706)        (706)
Change in fair value of warrant liability - decrease   -    73    73    -    1,759    1,759 
Other income   12    -    12    12    -    12 
                               
Income (loss) before income taxes   (6,388)   73    (6,315)   593    1,759    2,352 
                               
Income tax expense   2    -    2    50         50 
                               
Net income (loss)   (6,390)   73    (6,317)   543    1,759    2,302 
                               
Other comprehensive income (loss):                              
    Foreign currency translation adjustment   (22)   -    (22)   (49)   -    (49)
Comprehensive income (loss)  $(6,412)  $73   $(6,339)  $494   $1,759   $2,253 
                               
Basic EPS  $(0.89)  $0.01   $(0.88)  $(0.66)  $(0.08)  $(0.74)
Diluted EPS  $(0.89)  $0.01   $(0.88)  $(0.66)  $(0.08)  $(0.74)

 

49
 

 

The following table summarizes the effects of the restatement adjustments, previously discussed, on the consolidated balance sheet items as of September 30:

 

   2012   2011 
   As Reported   Adjustment   Restated   As Reported   Adjustment   Restated 
                         
Total assets  $26,975   $-   $26,975   $32,346        $32,346 
                               
Total other current liabilities   11,387    -    11,387    9,847         9,847 
Fair value of warrant liability   -    1,213    1,213    -    1,286    1,286 
Total current liabilities   11,387    1,213    12,600    9,847    1,286    11,133 
                               
Other long-term debt   5,998    -    5,998    6,913         6,913 
                               
Total liabilities   17,385    1,213    18,598    16,760    1,286    18,046 
                               
Shareholders' equity:                              
Preferred Shares   1,335    -    1,335    2,135    -    2,135 
Common Shares   1,871    -    1,871    1,698    -    1,698 
Additional paid-in capital   20,451    (816)   19,635    19,408    (816)   18,592 
Accumulated deficit   (14,096)   (397)   (14,493)   (7,706)   (470)   (8,176)
Accumulated other comprehensive income   29    -    29    51         51 
Total shareholders' equity   9,590    (1,213)   8,377    15,586    (1,286)   14,300 
                               
Total liabilities and shareholders' equity  $26,975   $-   $26,975   $32,346   $-   $32,346 

 

4. SALE OF PREFERRED SHARES AND WARRANTS (not in thousands)

 

On May 11, 2011, we completed a registered public offering of 5,506 units at a price of $1,000 per unit. Each unit consisted of one 6% Series A convertible preferred share which is convertible into 500 common shares, one Class A Warrant to purchase 250 common shares at an exercise price of $2.00 per share, and one Class B Warrant to purchase 250 common shares at an exercise price of $2.00 per share.

 

The designation, rights, preferences and other terms and provisions of the Series A preferred shares are set forth in the Certificate of Designation. Until May 11, 2014, the Series A preferred shares have a stated dividend rate of 6% per annum, payable quarterly in cash or, subject to certain conditions, in common shares or a combination of cash and common shares, at our election. After May 11, 2014, the Series A preferred shares will participate in any dividends payable upon our common shares on an "as converted" basis. If the preferred shares are converted prior to May 11, 2014, we must also pay to the converting holder in cash, or subject to certain conditions, in common shares or a combination of cash and common shares, a “make-whole” payment of $180 per $1,000 of the stated value of the preferred shares less any dividends paid prior to conversion. Class A Warrants are exercisable immediately and expire in May 2016. Class B Warrants expired in May 2012. The net proceeds from the sale of the units, after deducting the fees and expenses of the placement agent and other expenses were $4.6 million. We used the proceeds for the purchase of laboratory equipment and for working capital and general corporate purposes.

 

The holders of the preferred shares are not entitled to vote together with common shareholders unless converted to common shares. The Series A preferred shares are considered to be an equity instrument. The warrants have been accounted for as a liability and valued using the Black Scholes pricing model. The total fair value of the Class A Warrants at issuance was $1.973 million and the total fair value of the Class B Warrants at issuance was $1.072 million for a total liability of $3.045 million. The assumptions used to compute the fair value of the warrants at the time of issuance were as follows:

 

   Warrant A   Warrant B 
         
Risk-free interest rate   1.87%   0.18%
Dividend yield   0.00%   0.00%
Volatility of the Company's common stock   106.91%   116.01%
Expected life of the options (years)   5.0    1.0 
           
Fair value per unit  $1.433   $0.779 

 

50
 

 

The Series A preferred shares were valued using the common shares available upon conversion of all preferred shares of 2,753,000 and the closing market price of our stock on May 11, 2011 of $1.86. Adding in the total possible dividend for the preferred shares of 18% over three years, or $991,080, the total calculated fair value of the preferred shares was $6.112 million. We then allocated the gross proceeds of the offering of $5.506 million to the preferred shares after deducting the fair value of the warrants described above.

 

We have also recognized a beneficial conversion feature related to the Series A preferred shares, to the extent that the conversion feature, based on the proceeds allocated to the Series A preferred shares, was in-the-money at the time they were issued. Such beneficial conversion feature amounted to approximately $2.461 million. Because the Series A preferred shares do not have a stated redemption date and may be converted by the holder at any time, the discount recognized by the allocation of proceeds to the beneficial conversion feature has been immediately charged through accumulated deficit as a deemed dividend to the holders of the Series A preferred shares in the amount of $5.506 million. This will be the only deemed distribution recorded for the Series A preferred shares included in this offering. Further, because the preferred dividends or make-whole payments are payable any time after the closing on May 11, 2011 at the option of the holder, we recognized the full value, $991,080, as a liability included in accounts payable and charged immediately through accumulated deficit. There will be no other dividends recorded for the Series A preferred shares included in this offering.

 

As of September 30, 2012, 4,171 preferred shares have been converted into 2,486,127 common shares and 135,793 common shares have been issued for quarterly preferred dividends for remaining outstanding, unconverted preferred shares. No warrants have been exercised as of September 30, 2012. At September 30, 2012, 1,335 preferred shares and 1,376,500 warrants remained outstanding. Also at September 30, 2012, $227,977 of the $991,080 in preferred dividends remains accrued in accounts payable for future preferred dividends.

 

5. LOSS PER SHARE

 

We compute basic loss per share using the weighted average number of common shares outstanding. The net loss applicable to common shareholders for fiscal 2011 is the net of the net income for the year less the deemed dividend for the Series A preferred shares from the May 2011 registered direct offering described in Note 4 and less the dividends earned on the outstanding Series A preferred shares.

 

The Company has three categories of dilutive potential common shares: the Series A preferred shares issued in May 2011 in connection with the registered direct offering, the Warrants issued in connection with the same offering in May 2011, and shares issuable upon exercise of options. We compute diluted earnings per share using the if-converted method for preferred stock and the treasury stock method for stock options and warrants. Shares issuable upon exercise of options were not considered in computing diluted earnings per share for the fiscal years ended September 30, 2012 and 2011 because they were anti-dilutive. Warrants for 1,376,500 and 2,753,000 common shares and 936,000 and 2,753,000 common shares issuable upon conversion of preferred shares were not considered in computing diluted earnings per share for fiscal 2012 and 2011, respectively, because they were also anti-dilutive.

 

51
 

 

The following table reconciles our computation of basic net loss per share to diluted net loss per share:

 

   Years Ended
September 30,		 
   2012   2011 
   (Restated)   (Restated) 
Basic net loss per share:          
Net income (loss)  $(6,317)  $2,302 
Less:  Deemed dividend for Series A Preferred Shares   —    (5,506)
Less:  Preferred dividend   —    (991)
Net loss applicable to common shareholders  $(6,317)  $(4,195)
Weighted average common shares outstanding   7,158    5,667 
Basic net loss per share  $(0.88)  $(0.74)
           
Diluted net loss per share:          
Net loss applicable to common shareholders  $(6,317)  $(4,195)
Weighted average common shares outstanding   7,158    5,667 
Diluted net loss per share  $(0.88)  $(0.74)

 

6. INVENTORIES

 

Inventories at September 30 consisted of the following:

 

   2012   2011 
Raw materials  $1,407   $1,352 
Work in progress   283    379 
Finished goods   276    309 
   $1,966   $2,040 
Obsolescence reserve   (310)   (404)
   $1,656   $1,636 

 

7. LEASE ARRANGEMENTS

 

The total amount of equipment capitalized under capital lease obligations as of September 30, 2012 and 2011 was $5,778 and $6,222, respectively. Accumulated amortization on capital leases at September 30, 2012 and 2011 was $4,775 and $4,086, respectively. Amortization of assets acquired through capital leases is included in depreciation expense.

 

52
 

 

During fiscal 2012, we added $356 in computer equipment through new capital lease arrangements. In fiscal 2011, we added $1,888 in equipment to our U.S. and U.K. bioanalytical laboratories through new capital lease arrangements. Due to restructuring activities outlined in Note 14, we terminated a capital lease for laboratory equipment in the UK. The activity resulted in a liability reduction of $322. Future minimum lease payments on capital leases at September 30, 2012 for the next five years are as follows:

 

   Principal   Interest   Total 
             
2013  $330   $58   $388 
2014   268    39    307 
2015   259    22    281 
2016   208    6    214 
2017   4    -    4 
                
   $1,069   $125   $1,194 

 

We lease office space and equipment under noncancelable operating leases that terminate at various dates through 2016. The UK building lease expires in 2023 but includes an opt out provision after 7 years, or in fiscal 2015. Certain of these leases contain renewal options. Total rental expense under these leases was $1,284 and $441 in fiscal 2012 and 2011, respectively. The increase in fiscal 2012 is due to the accrual in restructuring for the UK building lease through the opt out date.

 

Future minimum lease payments for the following fiscal years under operating leases at September 30, 2012 are as follows:

 

2013  $371 
2014   370 
2015   223 
2016   13 
   $977 

 

8. DEBT ARRANGEMENTS

 

Long-term debt consisted of the following at September 30:

 

   2012   2011 
         
Mortgage note payable to a bank, payable in monthly principal and interest installments of $40. Interest is fixed at 4.1%.  Collateralized by underlying property.  Due October, 2013. (b)  $3,236   $3,573 
           
Mortgage note payable to a bank, payable in monthly principal and interest installments of $17. Interest is fixed at 4.1%.  Collateralized by underlying property.  Due October, 2013. (b)   1,532    1,674 
           
Replacement note payable to a bank, payable in monthly principal installments of $14 plus interest.  The interest rate is 4.5%. Collateralized by West Lafayette and Evansville properties. Due October, 2013.  (a) (b)   1,074    1,245 
           
Note payable to Algo Holdings, payable in monthly installments of $10.  There is no interest on this note if paid within terms.  Termed May 1, 2012.  See Note 13.   —    85 
   $5,842   $6,577 
Less current portion   583    735 
  $5,259   $5,842 

 

53
 

 

Our principal payment obligation for the year ending September 30, 2013 is $583. Cash interest payments of $715 and $647 were made in 2012 and 2011, respectively.

 

Mortgages and note payable

 

We have notes payable to Regions Bank (“Regions”) aggregating approximately $5,800.

 

Regions notes payable currently include two outstanding mortgages on our facilities in West Lafayette and Evansville, Indiana, which total $4,768. The mortgages originally mature in November 2012 with an interest rate fixed at 4.1% and monthly principal payments of approximately $38 plus interest.

 

(a) On November 29, 2010, we executed amendments on two loans with Regions. Regions agreed to accept a $500 principal payment on the note payable maturing on December 18, 2010 and a $500 principal payment on one mortgage maturing on February 11, 2011. The principal payments were made on December 17, 2010 and February 11, 2011, respectively. Upon receipt of these two payments, Regions incorporated the two loans into a replacement note payable for $1,341 maturing on November 1, 2012. The replacement note payable bears interest at a per annum rate equal to the 30-day LIBOR plus 300 basis points (minimum of 4.5%) with monthly principal payments of approximately $14 plus interest. The replacement note payable is secured by real estate at our West Lafayette and Evansville, Indiana locations. At September 30, 2012, the replacement note payable had a balance of $1,074.

 

As part of the amendment, Regions also agreed to amend the loan covenants for the related debt to be more favorable to us. Regions requires us to maintain certain ratios including a fixed charge coverage ratio and total liabilities to tangible net worth ratio. The fixed charge coverage ratio calculation currently requires a ratio of not less than 1.25 to 1.00. We are also required to maintain a ratio of our total liabilities to tangible net worth ratio of not greater than 2.10 to 1.00. If we fail to comply with these covenants, the loan agreement restricts our ability to purchase fixed assets.

 

(b) On November 9, 2012, we executed a sixth amendment with Regions. On December 21, 2012, we executed an amended and restated sixth amendment with Regions. Regions agreed to extend the term loan and mortgage loan maturity dates to October 31, 2013. The unpaid principal on the notes was incorporated into a replacement note payable for $5,786 bearing interest at LIBOR plus 400 basis points (minimum of 6.0%) with monthly principal payments of approximately $47 plus interest. The replacement note payable is secured by real estate at our West Lafayette and Evansville, Indiana locations.

 

At September 30, 2012, we were not in compliance with the fixed charge coverage and the total liabilities to tangible net worth ratios in the Regions agreements, mainly due to the net losses in the first nine months of fiscal 2012, restructuring charges incurred in current fiscal year and the treatment of our warrants as a liability instead of as equity. On November 6, 2012, Regions waived compliance with the fixed charge coverage ratio. On December 21, 2012, Regions waived compliance with the total liabilities to tangible net worth ratio. Based on projections for fiscal 2013, we expect to be in compliance with the fixed charge coverage covenants for fiscal 2013 and in breach of the total liabilities to tangible net worth ratio covenant for the first two fiscal quarters of 2013, primarily due to the treatment of our warrants as a liability. On September 10, 2013, Regions waived our expected breach. Failure to comply with those covenants in future quarters would be a default under the Regions loans, requiring us to negotiate with Regions regarding loan modifications or waivers. If we are unable to obtain such modifications or waivers, Regions could accelerate the maturity of the loans and cause a cross default with our other lender.

 

The Regions loans contain both cross-default provisions with each other and with the revolving line of credit with Entrepreneur Growth Capital described below.

 

The mortgages and replacement note payable with Regions mature in the first quarter of fiscal 2014. We intend to refinance the amounts in lieu of making balloon payments for the remaining principal balances or sell the building in West Lafayette, Indiana. On July 12, 2012, we listed for sale our 7.25 acres and 120,000 square foot facility at 2701 Kent Avenue, West Lafayette, Indiana with the intent to leaseback 80% of that square footage in which to continue our laboratory and manufacturing operations. The asking price was $12,500. We performed an impairment analysis on the building when we listed it for sale, but noted no impairment necessary. As of September 30, 2012 the net book value of the facility and land was $9,585.

 

54
 

 

We may be unsuccessful in renegotiating the terms of the debt or those terms may be unfavorable to us. For these reasons, if we are unsuccessful at refinancing our long-term debt, our operating results and financial condition could be adversely affected.

 

Revolving Line of Credit

 

On January 13, 2010, we entered into a new $3,000 revolving line of credit agreement (“Credit Agreement”) with EGC. The term of the Credit Agreement expires on January 31, 2014. If we terminate prior to the expiration of the term, then we are subject to an early termination fee equal to the minimum interest charges of $15 for each of the months remaining until expiration.

 

Borrowings under the Credit Agreement bear interest at an annual rate equal to Citibank’s Prime Rate plus five percent (5%), or 8.25% as of September 30, 2012, with minimum monthly interest of $15. Interest is paid monthly. The line of credit also carries an annual facilities fee of 2% and a 0.2% collateral monitoring fee. Borrowings under the Credit Agreement are secured by a blanket lien on our personal property, including certain eligible accounts receivable, inventory, and intellectual property assets, a second mortgage on our West Lafayette and Evansville real estate and all common stock of our U.S. subsidiaries and 65% of the common stock of our non-United States subsidiary. Borrowings are calculated based on 75% of eligible accounts receivable. Under the Credit Agreement, the Company has agreed to restrict advances to subsidiaries, limit additional indebtedness and capital expenditures and maintain a minimum tangible net worth of at least $8,500. Pursuant to the terms of the Credit Agreement, the line of credit will automatically renew on January 31, 2014 unless either party gives a 60-day notice of intent to terminate or withdraw.

  

On December 21, 2012, we negotiated an amendment to this Credit Agreement. The amendment reduced the minimum tangible net worth covenant requirement from $8,500 to $8,000, effective on January 1, 2013, and waived all non-compliances with this covenant through December 31, 2012.

 

The Credit Agreement also contains cross-default provisions with the Regions loans and any future EGC loans. At September 30, 2012, we were not in compliance with the minimum tangible net worth covenant requirement. On December 21, 2012, EGC waived compliance with this covenant as part of the amendment. Based on projections for fiscal 2013, we expect to be in breach of the tangible net worth covenant for our first three quarters of fiscal 2013, but in compliance in our fourth fiscal quarter. EGC waived our projected breach for our first fiscal quarter of 2013 in the amendment to the Credit Agreement on December 21, 2012. EGC waived our expected breach for our second and third fiscal quarters of 2013 on October 9, 2013. At September 30, 2012, we had available borrowing capacity of $1,927 on this line, of which $1,444 was outstanding.

 

55
 

 

9. INCOME TAXES

 

Significant components of our deferred tax assets and liabilities as of September 30 are as follows:

 

   2012   2011 
   (Restated)   (Restated) 
Deferred tax assets - Current:          
Inventory  $202   $236 
Accrued compensation and vacation   255    271 
Accrued expenses and other   252    118 
Total current deferred tax assets   709    625 
           
Deferred tax liabilities – Current:          
Prepaid expenses   (74)   (116)
Total net current deferred tax assets   635    509 
           
Deferred tax assets - Noncurrent:          
Domestic net operating loss carryforwards   2,483    1,585 
Stock compensation expense   14    29 
Foreign net operating loss   2,334    1,326 
Foreign tax credit carryover   119    119 
AMT credit carryover   42    45 
Total noncurrent deferred tax assets   4,992    3,104 
           
Deferred tax liabilities - Noncurrent:          
Unrealized gain/loss - warrant liability   (296)   (685)
Basis difference for fixed assets   (459)   (562)
Basis difference for intangibles   -    (21)
    (755)   (1,268)
           
Total net noncurrent deferred tax assets   4,237    1,836 
           
Valuation allowance for net deferred tax assets   (4,872)   (2,345)
Net deferred tax  asset (liability)  $-   $- 

 

Significant components of the provision (benefit) for income taxes are as follows as of the year ended September 30:

 

   2012   2011 
Current:          
Federal  $(3)  $37 
State and local   5    13 
Foreign   -    - 
           
Deferred:          
Federal   -    - 
State and local   -    - 
Foreign   -    - 
Income tax expense  $2   $50 

 

56
 

 

The effective income tax rate on continuing operations varied from the statutory federal income tax rate as follows:

 

   2012   2011 
         
Statutory federal income tax rate   34.0%   34.0%
Increases (decreases):          
State and local income taxes, net of Federal tax benefit, if applicable   (0.1)   0.4 
Nondeductible expenses   (0.5)   2.9 
Valuation allowance changes   (33.5)   (35.4)
Other   ---    0.2 
           
Effective income tax rate   (0.1)%   2.1%

 

In fiscal 2012 and 2011, our foreign operations generated losses before income taxes of $3,636 and $745, respectively. We have foreign net operating loss carryforwards of $8,854 that have an indefinite life under current UK tax law. We have a valuation allowance for the deferred tax asset related to the foreign net operating losses.

 

Realization of deferred tax assets associated with the net operating loss carryforward and credit carryforward is dependent upon generating sufficient taxable income prior to their expiration. The valuation allowance in fiscal 2012 and 2011 was $2,538 and $1,021, respectively for our domestic operations. Payments made in fiscal 2012 and 2011 for income taxes amounted to $12 and $8, respectively.

 

At September 30, 2012, we had domestic net operating loss carryforwards of approximately $4,935 for federal and $9,469 for state, which expire from September 30, 2014 through 2029. Also, we have a foreign tax credit carryforward of approximately $119, which expires September 30, 2016. Further, we have an alternative minimum tax credit carryforward of approximately $42 available to offset future federal income taxes. This credit has an unlimited carryforward period.

 

We may recognize the tax benefit from an uncertain tax position only if it is more likely than not to be sustained upon regulatory examination based on the technical merits of the position. The amount of the benefit for which an exposure exists is measured as the largest amount of benefit determined on a cumulative probability basis that we believe is more likely than not to be realized upon ultimate settlement of the position. At September 30, 2012, a $16 liability remained for other uncertain income tax positions.

 

A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:

 

Change in unrecognized tax benefits:

 

   2012   2011 
Balance at beginning of the year  $16   $30 
Additions based on tax positions related to the current year   -    - 
Additions for tax positions of prior years   -    - 
Reductions for tax positions of prior years   -    (14)
Settlements   -    - 
Balance at end of the year  $16   $16 

 

As noted in the table above, there has been no change in our gross uncertain tax positions during fiscal 2012 based on a state tax position. For fiscal 2011, we had a reduction of $14 in our gross uncertain tax positions during fiscal 2011 based on correspondence with a state taxing authority.

 

We are no longer subject to U.S. federal tax examinations for years before 2008 or state and local for years before 2007, with limited exceptions. For federal purposes, the tax attributes carried forward could be adjusted through the examination process and are subject to examination 3 years from the date of utilization. Furthermore, we are no longer subject to income tax examinations in the United Kingdom for years prior to 2007.

 

57
 

 

10. STOCK-BASED COMPENSATION 

 

Summary of Stock Option Plans and Activity

 

In March 2008, our shareholders approved the 2008 Stock Option Plan (the “Plan”) to replace the 1997 Outside Director Stock Option Plan and the 1997 Employee Stock Option Plan. Future common shares will be granted from the 2008 Stock Option Plan. The purpose of the Plan is to promote our long-term interests by providing a means of attracting and retaining officers, directors and key employees. The Compensation Committee shall administer the Plan and approve the particular officers, directors or employees eligible for grants. Under the Plan, employees are granted the option to purchase our common shares at fair market value on the date of the grant. Generally, options granted vest and become exercisable in four equal installments commencing one year from date of grant and expire upon the earlier of the employee’s termination of employment with us, or ten years from the date of grant. This plan terminates in fiscal 2018. The Compensation Committee may also issue non-qualified stock option grants with vesting periods different from the 2008 Plan.

 

The maximum number of common shares that may be granted under the Plan is 500 shares. At September 30, 2012, 339 shares remain available for grants under the Plan.

 

The weighted-average assumptions used to compute the fair value of options granted for the fiscal years ended September 30 were as follows:

 

   2012  2011
Risk-free interest rate  1.39%  3.08%
Dividend yield  0.00%  0.00%
Volatility of the expected market price of the Company's common stock  93.00%- 97.00%  90.00%-91.00%
Expected life of the options (years)  7.0 - 8.0  8.0

 

58
 

 

A summary of our stock option activity for all options and related information for the years ended September 30, 2012 and 2011, respectively, is as follows (in thousands except for share prices):

 

   Options
(shares)		   Weighted-
Average
Exercise Price		   Weighted-
Average Grant
Date Fair Value		   Weighted-Average
Remaining
Contractual Life
(Years)		   Aggregate
Intrinsic
Value		 
                     
Outstanding - October 1, 2010   705   $2.66                
Exercised   -   $-                
Granted   27   $2.24   $1.84           
Terminated   (59)  $2.54                
Outstanding - September 30, 2011   673   $2.65   $1.83    7.2   $69 
                          
                          
Outstanding - October 1, 2011   673   $2.65                
Exercised   -   $-                
Granted   200   $1.30   $1.05           
Terminated   (519)  $2.58                
Outstanding - September 30, 2012   354   $1.99   $1.46    8.0   $42 
                          
Exercisable at September 30, 2012   94   $3.83   $2.59    5.3   $7 

 

A summary of non-vested options for the year ended September 30, 2012 is as follows:

 

   Number of
Shares		   Weighted-
Average Grant
Date Fair Value		 
         
Non-vested options at October 1, 2011   385   $1.14 
Granted   200   $1.05 
Vested   (128)  $1.25 
Forfeited   (197)  $1.09 
Non-vested options at September 30, 2012   260   $1.06 

 

No options were exercised in fiscal years 2012 and 2011. As of September 30, 2012, our total unrecognized compensation cost related to non-vested stock options was $217 and is expected to be recognized over a weighted-average service period of 1.24 years. As of September 30, 2012, there are 125 shares outstanding that were granted outside of the Plan.

 

The following table summarizes outstanding and exercisable options as of September 30, 2012 (in thousands except per share amounts):

 

Range of Exercise Prices  Shares
Outstanding		   Weighted-
Average
Remaining
Contractual
Life (Years)		   Weighted-
Average
Exercise Price		   Shares
Exercisable		   Weighted-
Average
Exercise Price		 
                     
$0.79 - 1.01   128    8.32   $0.97    24   $1.01 
$1.02 - 4.59   155    9.40   $1.38    7   $1.35 
$4.60 - 8.79   71    4.24   $5.19    62   $5.21 

 

59
 

 

11. RETIREMENT PLAN

 

We have a 401(k) Retirement Plan (the “Plan”) covering all employees over twenty-one years of age with at least one year of service. Under the terms of the Plan, we contribute 1% of each participant’s total wages to the Plan and match 22% of the first 10% of the employee contribution. The Plan also includes provisions for various contributions which may be instituted at the discretion of the Board of Directors. The contribution made by the participant may not exceed 30% of the participant’s annual wages. We made no discretionary contributions under the plan in 2012 and 2011. Similar to fiscal 2011, we suspended our match of the employee contribution as part of our cost reduction efforts. Contribution expense was $17 and $15 in fiscal 2012 and 2011, respectively. The amounts recorded in fiscal 2012 and 2011 relate to statutory contributions for our European location.

 

12. SEGMENT INFORMATION

 

We operate in two principal segments – contract research services and research products. Our Services segment provides research and development support on a contract basis directly to pharmaceutical companies. Our Products segment provides liquid chromatography, electrochemical and physiological monitoring products to pharmaceutical companies, universities, government research centers, and medical research institutions. We evaluate performance and allocate resources based on these segments. Certain of our assets are not directly attributable to the Services or Products segments. These assets are grouped into the Corporate segment and include cash and cash equivalents, deferred income taxes, refundable income taxes, debt issue costs and certain other assets. We do not allocate such items to the principal segments because they are not used to evaluate their financial position. The accounting policies of these segments are the same as those described in the summary of significant accounting policies.

 

(a)Operating Segments

 

   Years Ended
September 30,		 
   2012   2011 
   (Restated)   (Restated) 
Revenue:          
Service  $21,312   $25,613 
Product   6,896    7,531 
   $28,208   $33,144 
           
Operating income (loss):          
Service  $(3,863)  $745 
Product   12    542 
Corporate   (1,835)   — 
   $(5,686)  $1,287 
           
Interest Expense   (714)   (706)

Change in fair value of warrant liability- decrease

   

73

    1,759 
Other income   12    12 
           
Income (loss) before income taxes  $(6,315)  $2,352 

 

60
 

 

Restructuring costs of $1,360 and $1,835 are included in the operating losses for fiscal 2012 for the Service and Corporate segments, respectively.

 

   Years Ended
September 30,		 
   2012   2011 
Identifiable assets:          
Service  $15,864   $18,121 
Product   7,262    7,674 
Corporate   3,849    6,551 
   $26,975   $32,346 
           
Goodwill, net:          
Service  $1,009   $1,009 
Product   374    374 
   $1,383   $1,383 
           
Intangible assets, net:          
Service  $—   $54 
Product   —    — 
   $—   $54 
           
Depreciation and amortization:          
Service  $2,036   $1,899 
Product   242    235 
   $2,278   $2,134 
           
Capital Expenditures:          
Service  $864   $1,098 
Product   226    76 
   $1,090   $1,174 

 

(b)Geographic Information

 

   Years Ended
September 30,		 
   2012   2011 
Sales to External Customers:          
North America  $25,042   $29,451 
Pacific Rim   961    912 
Europe   1,858    2,542 
Other   347    239 
   $28,208   $33,144 
           
Long-lived Assets:          
North America  $20,083   $20,872 
Europe   —    1,101 
   $20,083   $21,973 

 

61
 

 

(c)Major Customers

 

The Preferred Provider Agreement (“PPA”) with Pharmasset, Inc., signed in the first quarter of fiscal 2011, expired under its own terms, though they remain a large client of the Company. Pharmasset, Inc., now known as Gilead Sciences, Inc. (‘Gilead’) via acquisition, accounted for approximately 7.3% and 14.5% of our total revenues in fiscal 2012 and 2011, respectively, and 7.4% and 6.3% of total trade accounts receivable at September 30, 2012 and 2011, respectively. Pfizer, Inc. remains a large client, accounting for approximately 3.4% and 5.2% of our total revenues in fiscal 2012 and 2011, respectively. Pfizer, Inc. accounted for 8.4% and 4.2% of total trade accounts receivable at September 30, 2012 and 2011, respectively.

 

 

13. SETTLEMENT OF CONTINGENT LIABILITY

 

In June of 2008 as part of selling our Baltimore Clinical Pharmacology Research Unit, we subleased the building space it occupied to the purchaser of the assets. We remained contingently liable for the rent payments of $800 per year through 2015 in the event the sublessor did not perform. In 2009, the purchaser ceased operations in Baltimore and sought to renegotiate the terms of its sublease. In March of 2010, a settlement was reached with the landlord of the building which canceled the sublessor’s and our obligations under the lease in exchange for a cash payment from the sublessor. We agreed to contribute $250 to the settlement, payable in twenty-five monthly installments of $10 without interest. We recorded the discounted liability of $216 in March 2010 and recognized the related expense in general and administrative expenses. In May 2012, we made the final payment and extinguished the liability.

 

 

14. RESTRUCTURING

 

In March 2012, we announced a plan to restructure our bioanalytical laboratory operations. We consolidated our laboratory in McMinnville, Oregon into our 120,000 square foot headquarters facility in West Lafayette, Indiana. This plan was implemented to reduce operating costs and strengthen our ability to meet clients’ needs by improving laboratory utilization. In the fourth fiscal quarter of 2012, we decided to initiate closure of our facility and bioanalytical laboratory in Warwickshire, United Kingdom after careful evaluation of its financial performance and analysis of our strategic alternatives. We will continue to sell our products globally while further consolidating delivery of our CRO services into our Indiana locations. As part of the overall evaluation of our business, personnel reductions in the Selling, R&D and General and Administrative functions were also implemented at both of our Indiana locations during the second half of fiscal 2012. In total, 74 employees were terminated as part of the restructuring activities this fiscal year.

 

The following table sets forth the costs incurred in connection with these restructuring activities during the year ended September 30, 2012.

 

Description  2012 
One-time termination benefits  $1,454 
Lease related costs   861 
Equipment moving costs and method transfers   153 
Travel and relocation costs   47 
Loss on sale of equipment   446 
Other costs   234 
Total  $3,195 

 

We have reserved for lease payments at the cease use date and have considered free rent, sublease rentals and the number of days it would take to restore the space to its original condition prior to our improvements. Based on this, we have reserved $861 for lease related costs.

 

Restructuring related costs incurred during fiscal 2012 totaled $1,360 in our Services segment, $0 in our Products segment and $1,835 in corporate expenses.

 

62
 

 

The following table sets forth the rollforward of the restructuring activity for the year ended September 30, 2012.

 

   Balance,
September 30,
2011		   Total
Charges		   Cash
Payments		   Other   Balance,
September 30,
2012		 
One-time termination benefits  $-   $1,454   $(1,006)  $-   $448 
Lease related costs   -    861    (61)   -    800 
Equipment moving costs and method transfers   -    153    (104)   -    49 
Travel and relocation costs   -    47    (43)   -    4 
Loss on sale of equipment   -    446    -    (539)   (93)
Other costs   -    234    (37)   -    197 
Total  $-   $3,195   $(1,251)  $(539)  $1,405 

 

Other costs include legal and professional fees and other costs incurred in connection with transitioning services from sites being closed as well as costs incurred to remove improvements previously made to the UK facility. Other activity in the reserve rollforward primarily reflects a receivable for settlement of the capital lease in the UK.

 

15. SELF-INSURANCE

 

The Company is self-insured for certain costs related its employee health plan.  Costs resulting from noninsured losses are charged to income when incurred.  The Company has purchased insurance which limits its exposure for individual claims to approximately $60 and has a minimum annual aggregate attachment point of $2,072 at September 30, 2012.  The Company’s expense related to the plan was $1,231 and $1,089 for the years ended September 30, 2012 and 2011.

 

16. MANAGEMENT’S PLAN

 

Our long-term strategic objective is to maximize the Company’s intrinsic value per share.   However, in response to our financial performance through the second quarter of fiscal 2012, we began to operate the business in a manner designed to place more emphasis on cash flow generation. Thus, our short-term tactical objective is to maximize free cash flow from operating activities.

 

Revenues declined approximately 14.9% and gross margin declined 34.9% from fiscal 2011. In fiscal 2012, we consolidated our bioanalytical laboratories into our headquarters in West Lafayette, Indiana, closing facilities in McMinnville, Oregon and the UK to reduce operating costs and strengthen our ability to meet clients’ needs by improving laboratory utilization. We also implemented personnel reductions and other cost cutting measures in Selling, R&D and General and Administrative functions. These restructuring activities totaled $3,195 in the current year. As a result, we reported a net loss of $6,317 in fiscal 2012 as compared to net income of $2,302 in fiscal 2011.

 

The majority of the restructuring activities, though, occurred in the second half of the fiscal year. Due to these activities, gross margin improved 60.5% in the second half of fiscal 2012. Operating expenses declined 32.5% in the same time period. As a result, we had operating income of $452 before restructuring charges in the second half of fiscal 2012 compared to an operating loss of $2,943 in the first half. The % and $ amounts in the preceding sentences in this paragraph are unaudited. We will continue initiatives to control costs and improve productivity to achieve our financial objectives. Total capital expenditures declined 7.2% in fiscal 2012, particularly in the second half, as we limited spending to only necessary expenditures.

 

We negotiated an amendment on our loans with Regions Bank, extending the maturity date to October 2013. Our line of credit with Entrepreneur Growth Capital LLC was renewed for another year. Further, we listed for sale our headquarters facility in West Lafayette, Indiana with the intent to leaseback 80% of that square footage in which to continue our laboratory and manufacturing operations.

 

In fiscal 2013, we will continue to assess the need for additional cost controls such as freezing non-essential capital expenditures, reducing non-essential expenses, and monitoring our operations for efficiencies to further reduce our break-even point. For fiscal 2013, we expect to see slow but continued improvement in the volume of new bookings with little improvement in pricing. We also expect improved gross profit margins due to cost controls implemented and restructuring activities. We have debt and lease obligations of approximately $1.3 million in fiscal 2013. Based on our expected revenue, the availability on our line of credit, the impact of the cost reductions implemented and restructuring activities during fiscal 2012, we project that we will have the liquidity required to meet our fiscal 2013 operations and debt obligations.

 

[Remainder of page intentionally left blank.]

 

63
 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

To the Board of Directors

Bioanalytical Systems Inc.

 

We have audited the consolidated balance sheets of Bioanalytical Systems, Inc. as of September 30, 2012 and 2011, and the related consolidated statements of operations and comprehensive income (loss), shareholders' equity and cash flows for the years then ended. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits.

 

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audit included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

 

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Bioanalytical Systems, Inc as of September 30, 2012 and 2011, and the results of its operations and its cash flows for the years then ended, in conformity with U.S. generally accepted accounting principles.

 

As discussed in Note 3 to the consolidated financial statements, the 2012 and 2011 consolidated financial statements have been restated to correct a misstatement.

 

/s/ Crowe Horwath LLP

Fort Wayne, Indiana

December 31, 2012, except for Note 3, as to which the date is October 11, 2013

 

64
 

 

ITEM 9-CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

 

None.

 

ITEM 9A-CONTROLS AND PROCEDURES

 

Disclosure Controls and Procedures

 

We maintain disclosure controls and procedures that are designed to provide reasonable assurance to our management and board of directors that information required to be disclosed in the reports we file or submit to the Securities and Exchange Commission, is recorded, processed, summarized and reported within the time periods specified by the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to our management, including our interim Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. Based on an evaluation conducted under the supervision and with the participation of the Company’s management, including our interim Chief Executive Officer and our Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of September 30, 2012, including those procedures described below, we, including our interim Chief Executive Officer and Chief Financial Officer, determined that those controls and procedures were not effective for the reasons discussed in the section below entitled, Management’s Report on Internal Control over Financial Reporting.

 

Management’s Report on Internal Control over Financial Reporting

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Under the supervision and with the participation of our management, including our interim Principal Executive Officer and Principal Financial Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission.

 

Management’s original assessment identified material weaknesses in the computations of the debt covenant compliance and other certain calculations. Following the filing of the Original Filing, management identified an additional material weakness in the Company’s internal controls over financial reporting due to the failure to properly account for the warrants issued in connection with the May 2011 public offering. Based on these material weaknesses, management determined that the Company’s internal control over financial reporting was not effective for the year ended September 30, 2012. A material weakness is a control deficiency, or combination of control deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis.

 

With respect to the computation of debt covenants, we miscalculated the projected covenant compliance for fiscal 2012. Our computation projected our compliance with the minimum tangible net worth covenant for the fourth fiscal quarter ended September 30, 2012. The corrected computation projected a breach of this covenant for which we obtained a waiver from EGC on December 21, 2012. With respect to the other certain calculations, these were caused by journal entries material to the consolidated financial statements found during the course of the annual audit. In our initial computations, we did not correctly compute values related to the restructuring and medical reserves.

 

In May 2011, we sold units of convertible preferred shares and warrants in a public offering which raised new capital for the Company. We erroneously recorded the warrants as equity instead of a liability. This error caused other calculations related to the offering, such as the beneficial conversion feature and deemed dividend, to be misstated. Further, other income from the change in the fair value of the warrant liability was misstated because we did not correctly record the fair value of the warrants at each reporting period. Based on the erroneous recording of the warrants as equity instead of a liability, we have restated our previously issued consolidated financial statements for the fiscal years ended September 30, 2012 and 2011 and the first two quarters of fiscal 2013.

 

As a corrective action, we have instituted an additional check balance on the covenant compliance calculations. Also, we intend to seek the counsel of other experts in accounting before discussions with our auditors on future unusual and non-recurring transactions.

 

65
 

 

Changes in Internal Controls

 

There were no changes in our internal control over financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, during fiscal 2012 that have materially affected or are reasonably likely to materially affect our internal control over financial reporting. The changes described above were implemented during fiscal 2013.

 

This annual report does not include an attestation report of the Company’s registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by the Company’s registered public accounting firm pursuant to rules of the Securities and Exchange Commission that permit the Company to provide only Management’s report in this report.

 

ITEM 9B-OTHER INFORMATION

 

None.

 

PART III

 

ITEM 10-DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT

 

The following information concerns the persons who served as the directors of the Company as of September 30, 2012. Except as indicated in the following paragraphs, the principal occupations of these persons have not changed in the past five years. Information concerning the executive officers of the Company may be found in “Executive Officers of the Registrant” under Item 1 of this report, which is incorporated herein by reference. Information required by Part III, Item 10 is incorporated herein by this reference from the Company’s Proxy Statement for the 2013 Annual Meeting.

 

Name Age Position
John B. Landis, Ph.D. 59 Chairman
Larry S. Boulet 66 Director
David W. Crabb, M.D. 59 Director
Richard A. Johnson 67 Director
David L. Omachinski 60 Director
A. Charlene Sullivan, Ph.D. 63 Director

 

John B. Landis, Ph.D. was elected as a director of the Company on November 12, 2009 and elected as the Chairman of the Board on February 11, 2010. Dr. Landis retired from his position as Senior Vice President, Pharmaceutical Sciences of Schering-Plough in October 2008 and is currently an Adjunct Professor at Purdue University's Department of Chemistry. Prior to joining Schering-Plough in 2003, Dr. Landis served in various management positions with Pharmacia Corporation and The Upjohn Company, including Director of Quality Control, Executive Director of Quality Control, Vice President of Quality Control, Vice President of Analytical Research, Vice President of CNS Psychiatry, and Senior Vice President of Preclinical Development. Dr. Landis received his Bachelor of Science in Chemistry from Kent State University, his Masters in Analytical Chemistry from Purdue University and his Ph.D. in Analytical Chemistry from Purdue University.

 

Larry S. Boulet has served as a director of the Company since May 2007. Mr. Boulet was a Senior Audit Partner with PricewaterhouseCoopers (PwC) and a National Financial Services Industry Specialist. For the last five years of his career with PwC, Mr. Boulet served as Partner-in-charge of the Indianapolis office’s Private Client Group. Prior to serving on our Board, he served on the Board of Directors of Century Realty Trust, an Indiana based, real estate investment trust. He also served as Audit Committee Chairman until the Trust’s sale and liquidation in 2007. Currently, Mr. Boulet also serves on the Indiana State University Foundation Board of Directors, where he is a past Chairman of the Board. He holds a Bachelor of Science degree in Accounting from Indiana State University.

 

David W. Crabb, M.D. has served as a director of the Company since February, 2004. He has been Chairman of the Indiana University Department of Medicine since 2001. He has been a member of the faculty of the Departments of Medicine and Biochemistry and Molecular Biology since 1983. He served as Vice Chairman for Research for the department and as an Assistant Dean for Research from 1993 to 2000. Dr. Crabb is the Director of the Indiana Alcohol Research Center, serves on several editorial boards and is a member of the Boards of Directors of Polymer Technology Sciences, Inc., The Regenstrief Institute, and the Health and Hospital Corporation of Marion County. He was a recipient of a NIH Merit award and numerous other research and teaching awards.

 

66
 

 

Richard A. Johnson, Ph.D. was elected as a director of the Company on May 9, 2012. Dr. Johnson is currently an executive scientific consultant. From 1990 to 2008, he served as Founder and President of AvTech Laboratories. Prior to founding AvTech Laboratories, he served in various positions with The Upjohn Company, including Senior Research Scientist, Manager of Product Control, Manager of Quality Assurance Product Support and Director of Strategic Planning. Dr. Johnson received his Bachelor of Science in Chemistry from the Illinois Institute of Technology and his Ph.D. in Chemical Physics from Michigan State University.

 

David L. Omachinski was elected as a director of the Company on October 8, 2009. Mr. Omachinski is currently an executive management consultant. From 1993 to 2005, he served in various executive management positions with Oshkosh B'Gosh, Inc., including President, Chief Operating Officer, Chief Financial Officer, Vice President of Finance and Treasurer. Mr. Omachinski also previously held various executive roles with Schumaker, Romenesko & Associates, S.C., a Wisconsin-based, full service, regional accounting firm. Mr. Omachinski also serves on the board of Anchor BanCorp Wisconsin, Inc. since 1999, the University of Wisconsin-Oshkosh Foundation since 2003, and Chamco, Inc. since 2002. Mr. Omachinski received his Bachelor of Business Administration from the University of Wisconsin-Oshkosh and is a certified public accountant. Mr. Omachinski is the Chairman of the Board of Directors and Chair of the Audit Committee of Anchor Bancorp.  On June 26, 2009, Anchor Bancorp and the Bank each consented to the issuance of an Order to Cease and Desist (together, the "Orders") by the Office of Thrift Supervision (the "OTS"). The Orders require Anchor Bancorp and its directors, officers and employees to cease and desist from engaging in any unsafe and unsound practices that resulted in the operation of Anchor Bancorp with insufficient liquidity and earnings and an inadequate level of capital for its risk profile or the Bank operating at a loss, with a large volume of adversely classified assets, or with an inadequate level of capital for the kind and quality of assets held.  The Orders require Anchor Bancorp and the Bank to notify, and in some cases receive permission from, the OTS prior to making certain payments, incurring indebtedness, entering into certain contractual arrangements or changing its management or directors.  Further, the Orders require each of Anchor Bancorp and the Bank to submit financial plans to the OTS within a prescribed period of time.  Finally, the Bank must meet and maintain certain core capital and total risk-based capital ratios.

 

A. Charlene Sullivan, Ph.D. was elected as a director of the Company in January 2010. Dr. Sullivan is an Associate Professor of Management at the School of Management and the Krannert Graduate School of Management at Purdue University since 1984 and has been a faculty member at Purdue since 1978.  Throughout her career at Purdue, Dr. Sullivan has taught undergraduate and graduate classes on corporate finance, financial institutions and markets and financial and managerial accounting and has received numerous awards and honors from the university.  Since 2000 Dr. Sullivan also has served as the Management Faculty Advisor for the Technical Assistance Program at Purdue, which consults with small businesses in Indiana.  In addition, Dr. Sullivan has served as a financial analyst for the Indiana Gaming Commission since 1995 and as a risk management consultant for Edgar Dunn & Company (a strategy and consulting firm) since 1994.  Dr. Sullivan has served on the boards of directors of several private financial institutions and not-for-profit organizations, including the Federal Reserve Bank of Chicago from 1990 until 1996 and the Purdue Employees Federal Credit Union from 1997 until April 2009.  She currently serves on the board of directors of the Greater Lafayette Community Foundation and on the Asset-Liability Committee for the Purdue Employees Federal Credit Union.  Dr. Sullivan earned a B.S. degree in Home Economics from the University of Kentucky and a M.S. and Ph.D. in Management from Purdue University.

 

The Board of Directors has established an Audit Committee. The Audit Committee is responsible for recommending independent auditors, reviewing, in connection with the independent auditors, the audit plan, the adequacy of internal controls, the audit report and management letter and undertaking such other incidental functions as the board may authorize. Larry S. Boulet, Richard A. Johnson, David Omachinski and A. Charlene Sullivan are the members of the Audit Committee. The Board of Directors has determined that each of Mr. Boulet and Mr. Omachinski is an audit committee financial expert (as defined by Item 401(h) of Regulation S-K). All of the members of the Audit Committee are “independent” (as defined by Item 7(d)(3)(iv) of Schedule 14A).

 

The Board of Directors has adopted a Code of Ethics (as defined by Item 406 of Regulation S-K) that applies to the Company’s Officers, Directors and employees, a copy of which is incorporated herein by reference to Exhibit 14 to Form 10-K for the fiscal year ended September 30, 2006.

 

The information contained under the caption “Section 16(a) Beneficial Ownership Reporting Compliance” in the Proxy Statement is incorporated herein by reference.

 

67
 

 

ITEM 11-EXECUTIVE COMPENSATION

 

The information included under the captions “Election of Directors – Non-employee Director Compensation and Benefits” and “Compensation of Executive Officers” in the Proxy Statement for the 2013 Annual Meeting is incorporated herein by reference in response to this item.

 

ITEM 12-SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

 

The information contained under the “Principal Shareholders Table” in the Proxy Statement for the 2013 Annual Meeting and Item 5 of this report is incorporated herein by reference in response to this item.

 

For additional information regarding our stock option plans, please see Note 10 in the Notes to Consolidated Financial Statements in this report.

 

ITEM 13-CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

 

The information included under the captions “Certain Relationships and Related Transactions” and “Election of Directors – Board Independence” in the Proxy Statement for the 2013 Annual Meeting is incorporated herein by reference in response to this item.

 

 

ITEM 14-PRINCIPAL ACCOUNTING FEES AND SERVICES

 

The information included under the caption “Selection of Independent Registered Public Accounting Firm” in the Proxy Statement for the 2013 Annual Meeting is incorporated herein by reference.

 

[Remainder of page intentionally left blank.]

 

68
 

 

PART IV

 

ITEM 15-EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

 

(a) Documents filed as part of this Report.

 

1.Financial Statements: See Index to Consolidated Financial Statements under Item 8 on Page 30 of this report.

 

2.Financial Statement Schedules: Schedules are not required, are not applicable or the information is shown in the Notes to the Consolidated Financial Statements.

 

3.Exhibits: The following exhibits are filed as part of, or incorporated by reference into, this report:

 

Number   Description of Exhibits

 

(3) 3.1 Second Amended and Restated Articles of Incorporation of Bioanalytical Systems, Inc. as amended through May 9, 2011 (incorporated by reference to Exhibit 3.1 to Form-10Q for the quarter ended June 30, 2011).

 

  3.2 Second Amended and Restated Bylaws of Bioanalytical Systems, Inc., as subsequently amended (incorporated by reference to Exhibit 3.2 to Form 10-K for the fiscal year ended September 30, 2009).

 

(4) 4.1 Specimen Certificate for Common Shares (incorporated by reference to Exhibit 4.1 to Registration Statement on form S-1, Registration No. 333-36429).

 

  4.2 Form of Warrant (incorporated by reference to Exhibit 4.2 to Registration Statement on Form S-1, Registration No. 333-172508).
     
  4.3 Certificate of Designation of Preferences, Rights, and Limitations of Convertible Preferred Shares (incorporated by reference to Exhibit 3.1 on Form 8-K, dated May 12, 2011).
     
  4.4 Specimen Certificate for 6% Series A Convertible Preferred Shares (incorporated by reference to Exhibit 4.3 to Registration Statement on Form S-1, Registration No. 333-172508).

 

(10) 10.1 Loan Agreement between Bioanalytical Systems, Inc. and Regions Bank dated December 18, 2007 (incorporated by reference to Exhibit 10.7 of Form 10-K for the fiscal year ended September 30, 2007).

 

  10.2

Agreement for Lease, by and among Bioanalytical Systems, Inc., Bioanalytical Systems Limited and Pettifer Estates Limited, dated October 11, 2007 (incorporated by reference to Exhibit 10.1 to Form 8-K filed October 17, 2007).

 

  10.3 Form of Lease, by and among Bioanalytical Systems, Inc., Bioanalytical Systems Limited and Pettifer Estates Limited (incorporated by reference to Exhibit 10.2 to Form 8-K filed October 17, 2007).

 

  10.4 Bioanalytical Systems, Inc. 2008 Director and Employee Stock Option Plan (*) (incorporated by reference to Appendix A to the Revised Definitive Proxy Statement filed February 5, 2008, SEC File No. 000-23357).
     
  10.5 Form of Bioanalytical Systems, Inc. 2008 Director and Employee Stock Option Plan (*) (incorporated by reference to Exhibit 10.31 to Form 10-K for the fiscal year ended September 30, 2008).
     
  10.6 Loan and Security Agreement by and between Bioanalytical Systems, Inc., and Entrepreneur Growth Capital LLC, executed January 13, 2010 (incorporated by reference to Exhibit 10.35 to Form 10-K for the fiscal year ended September 30, 2009).

 

69
 

 

Number   Description of Exhibits
     
  10.7 Promissory Note between Bioanalytical Systems, Inc. and Algorithme Holding Inc. dated April 30, 2010 (incorporated by reference to Exhibit 10.1 to Form 8-K filed April 30, 2010).
  10.8 Amendment to Loan Agreement between Bioanalytical Systems, Inc., and Entrepreneur Growth Capital LLC, dated May 13, 2010 (incorporated by reference to Exhibit 10.9 to Form 10-Q for the fiscal quarter ended March 31, 2010).
     
  10.9 Fourth Amendment to Loan Agreement between Bioanalytical Systems, Inc. and Regions Bank, executed November 29, 2010 (incorporated by reference to Exhibit 10.1 for Form 8-K filed December 2, 2010).
     
  10.10 Amendment to Loan Agreement between Bioanalytical Systems, Inc., and Entrepreneur Growth Capital LLC, dated December 23, 2010 (incorporated by reference to Exhibit 10.1 for Form 8-K filed December 30, 2010).
     
  10.11 Fourth Amendment to Loan Agreement between Bioanalytical Systems, Inc. and Regions Bank, as amended on December 29, 2010 (incorporated by reference to Exhibit 10.1 for Form 8-K filed January 5, 2011).
     
  10.12 Fifth Amendment to Loan Agreement between Bioanalytical Systems, Inc. and Regions Bank, executed February 22, 2011 and effective February 11, 2011 (incorporated by reference to Exhibit 10.1 for Form 8-K filed February 24, 2011).
     
  10.13 Form of Securities Purchase Agreement between Bioanalytical Systems, Inc. and certain purchasers, dated May 5, 2011 (incorporated by reference to Exhibit 10.27 to Registration Statement on Form S-1, Registration No. 333-172508).
     
  10.14 Placement Agency Agreement between Bioanalytical Systems, Inc. and Ladenburg Thalmann & Co. Inc, dated May 5, 2011 (incorporated by reference to Exhibit 10.1 on Form 8-K, dated May 9, 2011).
     
  10.15 Amendment No. 2 to Employment Agreement between Michael R. Cox and Bioanalytical Systems, Inc., dated September 30, 2011 (incorporated by reference to Exhibit 10.28 to Form 10-K for the year ended September 30, 2011).
     
  10.16 Severance Agreement between Michael R. Cox and Bioanalytical Systems Inc., dated March 31, 2012 (*) (incorporated by reference to Exhibit 10.2 for Form 8-K filed April 5, 2012).
     
  10.17 Employment Agreement between Jacqueline M. Lemke and Bioanalytical Systems Inc., effective April 9, 2012 (*) (incorporated by reference to Exhibit 10.1 for Form 8-K filed April 5, 2012).
     
  10.18 Employee Incentive Stock Option Agreement between Anthony S. Chilton and Bioanalytical Systems, Inc., dated April 9, 2012 (incorporated by reference to Exhibit 10.3 to Form 10-Q for the fiscal quarter ended March 31, 2012).
     
  10.19 Non-Qualified Employee Stock Option Agreement between Jacqueline M. Lemke and Bioanalytical Systems, Inc., dated April 9, 2012 (incorporated by reference to Exhibit 10.4 to Form 10-Q for the fiscal quarter ended March 31, 2012).
     
  10.20 Waiver letter, dated May 8, 2012, from Regions Bank (incorporated by reference to Exhibit 10.5 to Form 10-Q for fiscal quarter ended March 31, 2012).
     
  10.21

Severance Agreement between Anthony S. Chilton and Bioanalytical Systems, Inc., dated July 4, 2012 (*) (incorporated by reference to Exhibit 10.21 to Form 10-K for the year ended September 30, 2012).

     
  10.22 Severance Agreement between Alberto F. Hidalgo and Bioanalytical Systems, Inc., dated July 6, 2012 (*) (incorporated by reference to Exhibit 10.22 to Form 10-K for the year ended September 30, 2012).

 

70
 

 

Number   Description of Exhibits
     
  10.23 Addendum to Employment Agreement between Jacqueline M. Lemke and Bioanalytical Systems, Inc., effective October 15, 2012 (*) (incorporated by reference to Exhibit 10.1 for Form 8-K filed October 19, 2012).
     
  10.24 Sixth Amendment to Loan Agreement between Bioanalytical Systems, Inc. and Regions Bank, executed November 9, 2012 and effective November 1, 2012 (incorporated by reference to Exhibit 10.1 for Form 8-K filed November 9, 2012).
     
  10.25 Waiver letter, dated September 10, 2013, from Regions Bank (filed herewith).
     
  10.26 Waiver letter, dated October 9, 2013, from Entrepreneur Growth Capital LLC (filed herewith).
     
(14) 14.1 Code of Ethics (incorporated by reference to Exhibit 14 to Form 10-K for the fiscal year ended September 30, 2006).

 

(21) 21.1 Subsidiaries of the Registrant (incorporated by reference to Exhibit 21.1 to Form 10-K for the year ended September 30, 2012).

 

(23) 23.1 Consent of Independent Registered Public Accounting Firm Crowe Horwath LLP (filed herewith).

 

(31) 31.1 Certification of Chief Executive Officer (filed herewith).

 

(32) 32.1 Written Statement of Chief Executive Officer and Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350) (filed herewith)..
     
  101  XBRL data file (filed herewith).

 

* Management contract or compensatory plan or arrangement.

 

71
 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  BIOANALYTICAL SYSTEMS, INC.
  (Registrant)
   
   

Date:   October 11, 2013

 By:  /s/  Jacqueline M. Lemke
  Jacqueline M. Lemke
  President and Chief Executive Officer and
Vice President of Finance and Chief Financial Officer

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

 

Signature   Capacity   Date
         
/s/  Jacqueline M. Lemke   President and Chief Executive Officer, Vice President of Finance and  

October 11, 2013

Jacqueline M. Lemke   Chief Financial Officer (Principal Executive Officer and Principal Financial Officer)    
         
/s/  John B. Landis, Ph.D.   Chairman  

October 11, 2013

John B. Landis, Ph.D.        
         
/s/  Larry S. Boulet   Director  

October 11, 2013

Larry S. Boulet        
         
/s/  David W. Crabb   Director  

October 11, 2013

David W. Crabb        
         
/s/  Richard A. Johnson, Ph.D.   Director  

October 11, 2013

Richard A. Johnson, Ph.D.        
         
/s/  David L. Omachinski   Director  

October 11, 2013

David L. Omachinski        
         
/s/  A. Charlene Sullivan, Ph.D.   Director  

October 11, 2013

A. Charlene Sullivan, Ph.D.        

 

72
 

 

EXHIBIT INDEX

 

Number   Description of Exhibits

 

(3) 3.1 Second Amended and Restated Articles of Incorporation of Bioanalytical Systems, Inc. as amended through May 9, 2011 (incorporated by reference to Exhibit 3.1 to Form-10Q for the quarter ended June 30, 2011).

 

  3.2 Second Amended and Restated Bylaws of Bioanalytical Systems, Inc., as subsequently amended (incorporated by reference to Exhibit 3.2 to Form 10-K for the fiscal year ended September 30, 2009).

 

(4) 4.1 Specimen Certificate for Common Shares (incorporated by reference to Exhibit 4.1 to Registration Statement on form S-1, Registration No. 333-36429).

 

  4.2 Form of Warrant (incorporated by reference to Exhibit 4.2 to Registration Statement on Form S-1, Registration No. 333-172508).
     
  4.3 Certificate of Designation of Preferences, Rights, and Limitations of Convertible Preferred Shares (incorporated by reference to Exhibit 3.1 on Form 8-K, dated May 12, 2011).
     
  4.4 Specimen Certificate for 6% Series A Convertible Preferred Shares (incorporated by reference to Exhibit 4.3 to Registration Statement on Form S-1, Registration No. 333-172508).

 

(10) 10.1 Loan Agreement between Bioanalytical Systems, Inc. and Regions Bank dated December 18, 2007 (incorporated by reference to Exhibit 10.7 of Form 10-K for the fiscal year ended September 30, 2007).

 

  10.2

Agreement for Lease, by and among Bioanalytical Systems, Inc., Bioanalytical Systems Limited and Pettifer Estates Limited, dated October 11, 2007 (incorporated by reference to Exhibit 10.1 to Form 8-K filed October 17, 2007).

 

  10.3 Form of Lease, by and among Bioanalytical Systems, Inc., Bioanalytical Systems Limited and Pettifer Estates Limited (incorporated by reference to Exhibit 10.2 to Form 8-K filed October 17, 2007).

 

  10.4 Bioanalytical Systems, Inc. 2008 Director and Employee Stock Option Plan (*) (incorporated by reference to Appendix A to the Revised Definitive Proxy Statement filed February 5, 2008, SEC File No. 000-23357).
     
  10.5 Form of Bioanalytical Systems, Inc. 2008 Director and Employee Stock Option Plan (*) (incorporated by reference to Exhibit 10.31 to Form 10-K for the fiscal year ended September 30, 2008).
     
  10.6 Loan and Security Agreement by and between Bioanalytical Systems, Inc., and Entrepreneur Growth Capital LLC, executed January 13, 2010 (incorporated by reference to Exhibit 10.35 to Form 10-K for the fiscal year ended September 30, 2009).
     
  10.7 Promissory Note between Bioanalytical Systems, Inc. and Algorithme Holding Inc. dated April 30, 2010 (incorporated by reference to Exhibit 10.1 to Form 8-K filed April 30, 2010).
     
  10.8 Amendment to Loan Agreement between Bioanalytical Systems, Inc., and Entrepreneur Growth Capital LLC, dated May 13, 2010 (incorporated by reference to Exhibit 10.9 to Form 10-Q for the fiscal quarter ended March 31, 2010).
     
  10.9 Fourth Amendment to Loan Agreement between Bioanalytical Systems, Inc. and Regions Bank, executed November 29, 2010 (incorporated by reference to Exhibit 10.1 for Form 8-K filed December 2, 2010).

 

73
 

 

Number   Description of Exhibits
     
  10.10 Amendment to Loan Agreement between Bioanalytical Systems, Inc., and Entrepreneur Growth Capital LLC, dated December 23, 2010 (incorporated by reference to Exhibit 10.1 for Form 8-K filed December 30, 2010).
     
  10.11 Fourth Amendment to Loan Agreement between Bioanalytical Systems, Inc. and Regions Bank, as amended on December 29, 2010 (incorporated by reference to Exhibit 10.1 for Form 8-K filed January 5, 2011).
     
  10.12 Fifth Amendment to Loan Agreement between Bioanalytical Systems, Inc. and Regions Bank, executed February 22, 2011 and effective February 11, 2011 (incorporated by reference to Exhibit 10.1 for Form 8-K filed February 24, 2011).
     
  10.13 Form of Securities Purchase Agreement between Bioanalytical Systems, Inc. and certain purchasers, dated May 5, 2011 (incorporated by reference to Exhibit 10.27 to Registration Statement on Form S-1, Registration No. 333-172508).
     
  10.14 Placement Agency Agreement between Bioanalytical Systems, Inc. and Ladenburg Thalmann & Co. Inc, dated May 5, 2011 (incorporated by reference to Exhibit 10.1 on Form 8-K, dated May 9, 2011).
     
  10.15 Amendment No. 2 to Employment Agreement between Michael R. Cox and Bioanalytical Systems, Inc., dated September 30, 2011 (incorporated by reference to Exhibit 10.28 to Form 10-K for the year ended September 30, 2011).
     
  10.16 Severance Agreement between Michael R. Cox and Bioanalytical Systems Inc., dated March 31, 2012 (*) (incorporated by reference to Exhibit 10.2 for Form 8-K filed April 5, 2012).
     
  10.17 Employment Agreement between Jacqueline M. Lemke and Bioanalytical Systems Inc., effective April 9, 2012 (*) (incorporated by reference to Exhibit 10.1 for Form 8-K filed April 5, 2012).
     
  10.18 Employee Incentive Stock Option Agreement between Anthony S. Chilton and Bioanalytical Systems, Inc., dated April 9, 2012 (incorporated by reference to Exhibit 10.3 to Form 10-Q for the fiscal quarter ended March 31, 2012).
     
  10.19 Non-Qualified Employee Stock Option Agreement between Jacqueline M. Lemke and Bioanalytical Systems, Inc., dated April 9, 2012 (incorporated by reference to Exhibit 10.4 to Form 10-Q for the fiscal quarter ended March 31, 2012).
     
  10.20 Waiver letter, dated May 8, 2012, from Regions Bank (incorporated by reference to Exhibit 10.5 to Form 10-Q for fiscal quarter ended March 31, 2012).
     
  10.21 Severance Agreement between Anthony S. Chilton and Bioanalytical Systems, Inc., dated July 4, 2012 (*) (incorporated by reference to Exhibit 10.21 to Form 10-K for the year ended September 30, 2012).
     
  10.22 Severance Agreement between Alberto F. Hidalgo and Bioanalytical Systems, Inc., dated July 6, 2012 (*) (incorporated by reference to Exhibit 10.22to Form 10-K for the year ended September 30, 2012).
     
  10.23 Addendum to Employment Agreement between Jacqueline M. Lemke and Bioanalytical Systems, Inc., effective October 15, 2012 (*) (incorporated by reference to Exhibit 10.1 for Form 8-K filed October 19, 2012).
     
  10.24 Sixth Amendment to Loan Agreement between Bioanalytical Systems, Inc. and Regions Bank, executed November 9, 2012 and effective November 1, 2012 (incorporated by reference to Exhibit 10.1 for Form 8-K filed November 9, 2012).
     
  10.25 Waiver letter, dated September 10, 2013, from Regions Bank (filed herewith).
     
  10.26 Waiver letter, dated October 9, 2013, from Entrepreneur Growth Capital LLC (filed herewith).

 

74
 

 

Number   Description of Exhibits
     
(14) 14.1 Code of Ethics (incorporated by reference to Exhibit 14 to Form 10-K for the fiscal year ended September 30, 2006).

 

(21) 21.1 Subsidiaries of the Registrant (incorporated by reference to Exhibit 21.1 to Form 10-K for the year ended September 30, 2012).

 

(23) 23.1 Consent of Independent Registered Public Accounting Firm Crowe Horwath LLP (filed herewith).

 

(31) 31.1 Certification of Chief Executive Officer (filed herewith).

 

(32) 32.1 Written Statement of Chief Executive Officer and Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350) (filed herewith)..
     
  101  XBRL data file (filed herewith).

 

* Management contract or compensatory plan or arrangement.

 

75

 

 GRAPHIC 2 image_001.gif GRAPHIC begin 644 image_001.gif M1TE&.#=A"P%%`'<``"'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E`"P` M````"P%%`(<````8&!@9&1D("`@.#@X?'Q\4%!0%!04*"@H7%Q<6%A81$1$< M'!P)"0D&!@8:&AH='1T,#`P+"PL!`0$-#0T/#P\#`P,$!`0"`@(0$!`'!P<3 M$Q,2$A(5%14;&QL>'AXR,C(O+R\@("`D)"0Z.CHK*RLF)B8S,S,T-#0]/3T[ M.SLQ,3$^/CXJ*BHI*2DX.#@M+2T_/S\B(B(\/#PC(R,E)24N+BXP,#`W-S M7EY!04%$1$1,3$Q?7U]<7%Q'1T==75U+2TM&1D9-34U:6EI%145)24E#0T-8 M6%A24E)5555`0$!75U=(2$A.3DY"0D)04%!T='1Y>7EN;FY\?'QV=G9R'AM;6UZ>GIG9V=C8V-O;V]L;&QJ:FIB M8F)_?W]F9F9W=W=A86%@8&!D9&1^?GYH:&AK:VM[>WN;FYN6EI:&AH:0D)"- MC8V=G9V4E)2GIZ1D9&`@("/CX^:FIJ%A86!@8&)B8F'AX>8F)B,C(R# M@X.$A(25E96.CHZ7EY>3DY.?GY^*BHJ(B(B+BXN2DI*"@H*9F9FUM;6NKJZF MIJ:OKZ^TM+2GIZ>VMK:@H*"YN;FMK:V]O;VPL+"KJZNWM[>BHJ*IJ:FEI:6[ MN[NHJ*BDI*2CHZ.XN+BJJJJ_O[^\O+RRLK*SL[.^OKZAH:&ZNKJLK*RQL;'5 MU=7!P<';V]O-SWM['Q\?&QL;:VMK$Q,39V=G2TM+%Q<7WT]/3O[^_JZNKS\_/Z^OKL[.SBXN+@X.#R\O+N[N[EY>7P\/#AX>'D MY.3FYN;IZ>G___\(_P#_"1Q(L*#!@P@3*ES(L*'#AQ`C2CP(#IC"RQ_#&5L+K$P1,Z*0C$J2:)W`8WU?D@+`NK7KUZT%C!@AI-"XH)ASZTX8 M[@@)9&>4H%&T:`FCG>S:%4("F_4``M`)-!=08O/NZ]<5F2AU(DVR1F`&(?\I M8)VGFN:.U*E7=XB)`=@'UF"??UF9$#9G#J%PIPQ$FT>0-.$3,`C`5E9!XZ30 M'!OB@.3.._1%Z%$X*C@1B1M$0"+0$V_`,48(",Y0DT`Q'ZUC6$#`*E(@0,`O`IH`S2AECS#.1S`$$*L9`8Q,]:M:I MYDCUI&:/1.[8&0U!T$@3D3,-$C3-"X:P@<0R!KFI2",CN+.3.C"(>9`X##1' M1T'WU!%##$N$*NH24!`!1:E$F'JJJ%"DHA`U=L3_T!QK5!`23#W4W(''0-54 M8<6HHQ+!PHT(X:/*%3(T-T,8UB2$1!YZ'!$*%FI@D4TAZ4#WJ,#:#IH,,U`J6%#0VM0; M*5-$&FC4<4]"Z/0QB!:;'&$3I;!Q@A`YF<*634+(O%9!.`H=8L$!JQB$Y-_4 M(T3,$H<;I,\`KR6!$"V,LW:!D0>U@4%K(^AD4"WDOV:!+0Q-P5H%GQ.TB?K8 M.,@MI`,`W&E$"W6@0QS$\+N$`&,%92B#%(I1DW5$[36#N(@@$'BFA1'/F<$:#"*-YK$'A0NH!`#L01!6O20`^ M&K*.B57!(/)(PFM@89!JO.8$V4H(.*+@F@BDD"#W"%-S6O"\A#2#`P#P1$'^ MQYHT**00`!"#1IS!!2]48@]W:(@:KE")%_!@"AT1QIX0D@[7%0DA+H#-`GZ& MD&>@KC5Z5$@ZWL"-@<0CF*V9`"4>(HT$:.$@?GB-D@@R#U^V!AD-`43Z6%.$ M>F`R3%2HU&LXF1!["```?HC9/UC0FA=HS2#FR$`1-'+_B!C`X@U&D,,N&/(' M(7B"#Y;(@3)@0HP"&.@@;'M-`ZBBD'Y`,X^7?(@B7C,`?T#$"SHX"!Q^.1!Q M8&*=@V2(/W;6FM*Q+DQ7L,4Q7;."!AKD'3L`P!#JR`77?`(TT!&+40923@ MA"YZ"#\Z\)HAQ-`ARG!I0;+IFE@.A![OL@5L@>8<;T/`*4>BB$5\0@CX4THP'Z((29G`$+>P`3I?TPV^O MX8`4JE"$`V@5``?@P1HPQY!;_[R&`/A@1QT'PHM3%&04L/G7A(Y`4H$@8IRL M*4]"TN%!Z[U&=@(1[`/(08\T-`<-02J(-L[ZAX+(ZC4OI!T!($/-]A##ZS0A0)DP:8B`6'%FC.`0#QD&[>%1S4@2Q`'/*$@0.!H M-SYR#B*\YL`#60-LCL&03,$)=UC`@@TBCCOHX`1FH`0OP-`(,:S`#2))RS`( MZ!H]C&(4E^C!!9H#AA(G9!E5;$T%!&<06%A`/B<[8FLBL%F/J&-BKGG#TM39 M&AR4N?\A_;"=:ZS0X0\+)!Q:2%)!>E$@%`_$&R9LS@HRP>6)*(($'N7F*ZP@ M@CS8(^P(X#_T^QK_/OJUK%%$0[S!UM8@X!>AF`(NZ!`( M7B#B#(PC`T'JX5#75"#1'5D'%5ZC1(&PPP&O,0)$Z,%DUA`A+8*UD7CXH&P"T1]L>/!MA7!#HB[`P@=N0(479.%H MK`'X!V&S`9X/1!G]Z,4_CB&,=\3B'ZK0!S&:*9!U4-(UOUAXPP(DD8#)B@0I3`KPY`BT5<0H=`' MLZ(!!Z(0UK`$61`+-R!7"'$.73`,MJ`)_Z`/A480Z.`)+G`(6V`("P$/8W@0 MO8!W"!$+%/_X&@_`;@81#+>E@X!H97KP&A1@909Q#PSSA0`P1#>_D@P0A.J[1!HE1$$=W0I:H$+'P M&@=`1`NA,:YQ%YRB(*[!>0/A#+#1+`[A"*^A`9,F6`J0B`)!HH`0CI!",,`>4``IF<`9$0'8#D0Q6MQ`;>7D#,0^Z!QO'=A#2D)(8 MU1![(&S_<%*N80`$9A#DX),P:1#AP#FNL5@$`0JOH0-M61#Y`$JM80$.TV%* MD($$`0X.!AO2!@P`0`L+(0BN(0%A:1#I\`F)``6(,`EQ8`L"D`EG)`ZQZ`G; M(`AJ>1#O\`8XX`M1H`EM@`4A=P[Z&)$6`!N8H!"`,"LA.1#3H%458'`',0\, ML`G1Q8[J4U0)<1Z%61`C]QJ*.1#F0'VP_T5&`[$/?R@0"-<:0\`I8?(&W8@0 M^V!YKR%MRE`!($"-!S$.\@D`$9!=!L$.)M`%BZ`&1'`(46`+1O`)SR8,VY"* MGS`-W;`-`L$-\4`,P#<.B4`#LV`%IP`';U`)!'`Q!O$,L;!XV)!=^C!I!-$. M(O,:,:"/YC"7K\$`RSBAKW$!C+00YQ$V`J$/G\@:)=`/O$%@:RB.2 MP]<:7L!NU>!B`]$/(10;;D00\A`F!3"<`_$.:N0:TO8-ML.5"&&=+I"1\W`& M7Y`)BA`$C[`"C``'5\`$9Z`*D/`*5'`#3E`!SK8%L?`$P*`*>Z`%6Y`'6,`) MOQ`,6Z`%F-`'AO^@!D\@"6[@!7<`70/1#7>@"W4P#XN0!?\0##N`/UW&BB-# M$.+0=L`0Q#C\'&QI`G0*A#6A2 M$"_Y&@NP0__@DLT1`'^0"M0J$/Q@"P3H:0.!#6(V`41P?0^S=KLJ$/W_`&PV M2\`::X`9.0`A=@`EG8`:CD`:$L`=-\`93H`MW$`M[T`L]<`J; M``6;\`9FH`E\P`9QT`2%(`2)\`M]D`EH\`=:4`L$(0U*L`0A,@IXL`FJ$`>\ M-Z&9H`D?4#%F<`KR8Q#1P)%M

\\`RR<'84HP`^8`,^``.EQAH-\$,%`0QY M%AMV,`L_(PZC$`E>V!HD4!#9<`.HN@F+9Q#V(`2NP0.(\`MI@0N*\*,.4`<# M^0_1$$2L@00AXA"F\(C2=@V:Q)^!(*;=``GI_^.J"$$*3K`&:K`(CO`&HM`& MME`'8W`)F_`*>@"_AD`(?'`%W2`*W?`)U"`$B@`'G#`)=.`-7<`)?+`)O)`% MC-`&9'`'?$`*0M`&KC`07D()+Q`.B-`,`&`*K.!G?@E;KA7"(5R<`(`!K("` M`V$,(ER<,_6(J'-,+%S"H,;"$V`!O=:2I]`$.,L:"@`%6M"TK7$`1/"&V="B M%","-?H/Z+`*<5`FK;$#4#PZ>:"B`P$,:)9:[L@0M4"!84`0S6!",W4!.R`# M.D`YK&$$Y&<0V@`!1F`&7M`'0M`#1N`%&<`+6L`"(!`'6$``AB`%77`%1;`. MK]`*40`,JT`!@?`%6?^``ER@!@@@!EJ``D(@!%(P`VUP`BOP!"/P`EM`)><0 M!+;@#FFPAO[P!<[P"#A0#5YB#\[@5:[\RE[E#,Y`#/R`GP3QRM$0"K$\"L@@ M#@"T6'$,M0!D\@`21L M:@8P!VO0"KLT$*AP!GZP!N9\SN;,!G,@![8\:V/0!QGPB``P`"VP!H"@$O17G<+4=,0ZT-1'R\">% MG1?7@,\"P0Q0FA#:D,:/G=E+,@\FF`[OB1#FH*6:/=JD7=JF?=JH_2+@0)02 M(0ZBG=JP+1(NDUUL?14EQ0SFP),+<0_Q@";IX#+=2"6R65*Q7=PDP08A,`A, M4`?#@`570`28X!4'P08T$`F?#0:6$`:;(`SW-`M]_]`(?S`%]3`**-`(9T`) MLZ`DR&`A0O`(6D`*>[T/X1P2ZH#8F<-ST-!V\*"5#F$.8BH0Y;#8,4$.T)`6 MY'`-J@`%2&`#NT`/RX`'/F`$E?#9[*`">Y`$791B'P`$:V`&,JO$L1`"BO`Y MT0`+&<`(,%`)@C(/T>`!`K`)T3#8#0$/L3@/`RD/O9@0YE!TX0"=XZ#;"R$/ M<,T1X%#-2Y/C_T`/[QD.DM@0U&40Y_"\*H$.2C[56V`'9'"UM>`%+*`"Y$D0 M8)`$E>`!I4D0E``'??#=-[<%R/H/73`"E^`+`S$+21"8#X$,-Z4/]BT0WH#".X$.C_\)V^UP`UG20/A@!;M`!>5&JEOP"WKP!I+`DHL@ M!GX`!EH0!BY&#S"`G>>0`FF0`X@W"C,@X,9]$.3P#9]=W,Z`!')P!&2%"["D M!>9$$)A@(G#@!F)`03PD",L@!+&`!2TD$'B@E>@@!U8`!Q0F!B]P MZJ2]#U]P!=ND#:$N"PZQSA#$/P"VL0!U&P`DU0";=@ M1R?@4=J0!6U0!;8\"D@@$&'@`XZ@!;P'#R2`"GWG#$E`!E(`"2G0!Z`I\&:A M#?[_J1+K(-T;D0\O4`9'D`BG8`9R0`1!D`K=6`BJ^@AXH`01[?%Q,!"3\`>- M(`"XH`]`X.?A0`QDP`..,`--4`8K0*FQ7:HPWQ#V<`5W4`*L,P-]4`*B-A!E MH`4X``(XD`6-T`9<11"V<`-+X01@<`4@``Q;H'4#D0)&4`?"H`9LD`E00&'% M+0P;&_8*L0\],`A@0$SZ$`)K\`1>,0Y6P`:(4`>G`"YB``)U]`IVU7<_P*^\ MP`4020YP4`<@P((VH`9T<`5B[?AA7P\ST*;U7@M!D`A18/+_4`?F0Q!_L`E9 M`)'_$!@%X0Q&<`:>0`=S?0\W,`A;_X^7`$?B`$DY8- M2W`&,>`B\6``1/@/G;R$#1T^A!A1XD2*%2U>Q%@QVI)+1%JM^ZPCA@SS@IFHP-I2:&,_](=*YI4Z5*F39U6K,4A M@)0!!Q;,D`!A#:QSZ\0`R$`#6\%'*)2KA@0`#L_ ` end GRAPHIC 3 image_002.gif GRAPHIC begin 644 image_002.gif M1TE&.#EA/`&C`'<`,2'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E`"'Y M!`$`````+``````[`:,`AP``````````,P``9@``F0``S```_P`S```S,P`S M9@`SF0`SS``S_P!F``!F,P!F9@!FF0!FS`!F_P"9``"9,P"99@"9F0"9S`"9 M_P#,``#,,P#,9@#,F0#,S`#,_P#_``#_,P#_9@#_F0#_S`#__S,``#,`,S,` M9C,`F3,`S#,`_S,S`#,S,S,S9C,SF3,SS#,S_S-F`#-F,S-F9C-FF3-FS#-F M_S.9`#.9,S.99C.9F3.9S#.9_S/,`#/,,S/,9C/,F3/,S#/,_S/_`#/_,S/_ M9C/_F3/_S#/__V8``&8`,V8`9F8`F68`S&8`_V8S`&8S,V8S9F8SF68SS&8S M_V9F`&9F,V9F9F9FF69FS&9F_V:9`&:9,V:99F:9F6:9S&:9_V;,`&;,,V;, M9F;,F6;,S&;,_V;_`&;_,V;_9F;_F6;_S&;__YD``)D`,YD`9ID`F9D`S)D` M_YDS`)DS,YDS9IDSF9DSS)DS_YEF`)EF,YEF9IEFF9EFS)EF_YF9`)F9,YF9 M9IF9F9F9S)F9_YG,`)G,,YG,9IG,F9G,S)G,_YG_`)G_,YG_9IG_F9G_S)G_ M_\P``,P`,\P`9LP`F/($.*'$FRI,F3*%.J7,FRIE+(I*G4HU)-)6K5A<$9@4I*"H5<.*'0NQ MZ<"M!H%B!'M0;46W9!W"C7MR;D>M`YW6=&L7V]Z!614"IDNXL%!!`;HR#;"5 M16(68+\B7BBH:0!LCB%'92%9X.56`2YC%FVXM.F75Q([Q;QT,N:%HH]B9AJ5 M,=8K,P,L!(N4:=^JOT_['5PPN'#`H9WB1>SYMF"D3Z!G]D>W\[] M8\W47)>"_^:*6_O7@KJ;%V2K56GW]_`S"IHY'O-6YJQ=8Q/T=>;2`.(!.!AI M7RGVDG'Q\81@3]-1%]Y^HG$&VGW_;=7*5@)BUA5NLPT$F4+S)2CBB`,G74CTW-M]>UY1KTI;56ALMN:]NVE6)!S5*;DZJ>99A: M;&#!.A^_V/Q[UH<%>AB:ATX)F"-U`'XU+6U/0AQPAJ&Q9U:)I!'$V%C(1KHP MA&BEQE9L7=9',&*D];K8QP4OU1M71H:VEO%"-7!4G*](0=XP-8[*>[+"!!F%M$-'ZLCIR ML5!WF+33>=UKL\<"EA?:A3)G_":7>?O_&NN72656L,+.!:TSMUU"6FFMB1T% MX$S_XK58Q8A_-O?.C4%\;K^7YXS4X35.C1V$`(H-F==:D_IPVC"QS/)WMCTI MN)?\#2RWU'5?K;="_R;.]]O88=@E6)E9F5GG94],T,^LYX0KSHO)_"/!6,F* ML\!T[^;SW4_OYW+.`4YG,JPG[TQ:7%/8`Q8Z.FIQ8QVDA5'.IB&)/THSEZ"8S(41_:8"@H M$T%0/B]D8"#Y")].880YJ.-(%<^22"AI,26/)`I2SA,2_!A$2]+RL66J`B%R@TDG5G51J9G:"&E?\:W16' M([^,&^S6>9(;:D1B!#U.L)0&0&]2Y'">T0ZLN(//B]A*E%CC&H34XD"'5!1" M9?I*1PMC4(NRD)`E59[HN.4^AKSPHUQI)%TT6I%_F?.:,E14.06YFF-ZS)5M M*0@V\VBOO5G4(I*"#VF&JN6_@2B$^F=H2I#0]V-M"$^_9IVT(JFBL9U:*ICV>>.9S-VLN`U6(B6%4$,^5J#3Q:IQWJJCX0);+<8$%%`UW!-M M*G*X+BWR(J65HE!-%JO>I6A'*Z7*A#8HHE;_7:AQ<)G9%KLTU*\]=DM$8VQQ M/FFNU/$E,MOA3+L3R1YKE9S"!$L1+%^3QN?;:9B,20 M"[^T=B6VDVJ3Z_JBVXB@K5DPO^T%N'L/QVB%PK'E+K!:Z[3),>S M9-9M6L\4UV7E.2GBXGG?3JAN]K(XH1\M)SD\\@-ARK#RV[,08ZJ##$)$T"_")=.Z7.R6N*;$`3' MS;LRID@_T<:?Z!P$_Y=O<6=0POR_/G%O4H'<[V+AQD2PM8NV=R5EBF<`5L]?)2I`W7RE9`F6A0B^EI$I&0 M(9]=#&0362/_6A?$ETRU0X3,D`+US\-!PRY1ZQ2M2?5VR!4.]#+E6=G?%@<99W;'A]BLXSSK-"-%S6E05:B(F$YY:J6][Y(+LR28;2[IV M-[QD1,@-7*;VBLEZ@E?O(/.MVE6SUNW&5[3-)%)KA]PSR?_^ M];;+]&YOK&V48 MK:%-H'=YS-3F[T-U/UW.Z:G!?+I"%3FX M%6+SO&R\,=J>=<5:H]S@Z'M,4-T)F?4*U[.G^Y)?ZJVK3>[=@S_0Y$0?N9?[ M*L@2ET7L?_>JXL$T^`O>N=9K_SDT%=Q8@6YU897O^Q_UF>_!ODAG^B4MX,[N MH:Q'Z=%BM[;Z+PG4NXZV?E<K8M&??T##?PV"5!TT`1/3X)J.4)UCFGS_F%9,8R3=T4M*HHYX\`@D M)&%32.D7CV21-$(A?69([>]Y,3_6S/3C__U'TDU1@7]@!'_Y1SH9PTN;0X#^ MMTRZ,X#?XX#+9'Z:U56:98!!0H'#T4Q_X8"#P8$;J"3Y=X!#LH$$N'Z443`U M,DGC-DE:4A\-46U?UWI-I7C^=D%9UUZ"E!21UW>7A6S6EQ93]C-X@F'KAA*_ MDA4:!A%DAV@0@1];1VMR!11-N&N\,S5F1A&5=6YO082RYQ`.=81U<5VN]W6/ M=5=R`3`U9WI7=H5P-7-[07,LF"=O]D@2PU9.PU1U=B>$%1/-TAOM9WY!V&@Q MZ'H-=!4E\E:A%UF&E$T__\)"^/0781=-QY8<%H1W!V0DTA95,J%]P^$PX15+ MSH=J9SB*"/$WI3=N[B.%'N,?Y,9Y,4A[;W%<2G9(X@#92C(8X3(@CEY=TF=:#5=5=O:81.A@E5R4Z_8%&J&477]B+'#,7L&AT#U@V MBG5;<9=%,G0KCI<1,B:&)6%5*-8?AV16SYA@IR1TKY9I\;1`66@OOPA75886 MQM=.2[@=EF0V)6>+BY6/$H$VOH=J9G5,'X<>BD'VY&$NJ6$;*2U6&0Z(:.+A$YC[$> MF&9+8$<46<.YQ%%I15L-B;XY4@FFWB0\12#P) M$ARG%5OV>1W5(,(%CBT9D90V;F`CDZ2(B2*B9?LV1VZDECWD1C6REG"IEG(9 ME\O76G-YEW69%`,S27L9,2927'2)EX(9F'19+#^&A8.9F"*EF(Q)F(WYF(ZY MED^8;I6U2Y9IF39D69EYF9S9F9[YF:#YF0G8F2L6FJ9YFJ8YFO>UF:C)F:S9 MFK`9F[*)F@?WCVN())]#DT\8-&14+:TF('ID7$9OC*)Q82R,RG:F3$9C$%T>%BQ+_!R)FD95NMR!(%QU: M!D%XHYY,\11%YBYJM%6!E2[TP6_FZ6[8I-Q18C M)2-.F4\01$D7,A*6)&=E-C'5-HS=*6WO^&;-&1>.4T3[=22PQY'21&].YR'! MZ60QRFEW(B"G,Q'!=3%]%V#&EA6Z>1)-\4/0X3W\J)07Q%8,HQA*V3"QQD!` M.F33\QG=LE3=LI<)$QVW<9/N4FWB,G"8Z7>TC(E MHQM:%A7=@A9^YD.\Q%-/>-&B4/8X>"$;O<$A/.:- M"2IZGL>7Z:&IY!A+I$HS<`%.#[*IHKBEWO,@'"=%?--).T4EDT$E2N@O$'@S M2>%F^2&H,@,6%DHA&Z5I$3*E)F$=@KHBN]@83?1HN+I\Y1$='&*/!19*MX4> M;$@G31PC1/\A.4`RJO<1%>=22K!Q-B#&9BCD9=PZJ,H!.<0ZM!QI(_9A2;`!IMF4 M(>=!H"03,S:?N! M(5=3&QP"16%::@5C(++4%3'K94Q[,0HKLZ3VMF?A7>+1JQ;2L0YGJP[T,8PV M':N20^E!)9E*.9+C&@5[N'<[?Y);,DXRL@SJ62"E(;=E,M[% M<=2156*'M_SG/=5S&X3JN/1:N(?+&=%28+!8!1GMDAKS^&K^`!D@$WG*;A<1LH5F3_,CTXTG'J$B)Z ML:=;1B;F^2YB53LWTKX>)QF&^2VTTZ+@^U4#(R%NUQKPZ[WA2SL]M50WX;_I MNV6W1+_U"R+@BI4`[&6XP4,6`K]R5%OEA53162+<(A$A2Q*LF&UJ=K;::1,? M^F9&#"8:25A46(;>!L,A@<--3*/>*<0%FEZ)5L5] M*"5DB75:J,4?ZL5RH74TW%R#R&)6W,3)2L80D<9HYRYN?"4\O%N#:+(]4\>O MIXQQ9ILR/)Y\3")/C%1R7+?*-,AAW[E<*"'#'='!0;-+/<6]3['(BFR5(*R0 M!^5S;-+&">+'X8?$A0*=TU3*7!RXIMP=-+5CMU@TEXP2A_QXGLP=VE@J$[I% M=_S*PM03VXBDHR9YLZS+/M'+H`O*5]3"13EML8R2RRS,9DG*P)1=[P*Z6`R6 M662WU)3*31S&FF-A/+-9VP:R-E EX-10.25 4 v355517_ex10-25.htm EXHIBIT 10.25

 

 

Exhibit 10.25

 

 

 

 

 

 

September 10, 2013

 

 

 

 

Bioanalytical Systems, Inc.

2710 Kent Avenue

West Lafayette, Indiana 47906

Attn: Jacqueline M. Lemke, Interim President & CEO

 

 

 

Dear Ms. Lemke:

 

Incidental to that certain Loan Agreement entered into by and between Bioanalytical Systems, Inc. ("Borrower") and Regions Bank ("Bank") dated December 18, 2007 (such Loan Agreement, as amended, hereinafter referred to collectively as the "Loan Agreement"), and subject to further conditions set forth herein, Bank hereby waives Borrower's compliance with the Total Liabilities to Tangible Net Worth Ratio covenant as set forth in Section

8(c) for the period ending as of December 31, 2012 and March 31, 2013.

 

The waiver of Borrower's compliance with the financial covenant as set forth above constitutes a singular waiver and shall not be deemed to be or to imply Bank's waiver of Borrower's strict compliance with the terms and provisions of the Loan Agreement. The waiver contained herein is also subject to receipt by Bank of such additional documentation as may be required by Bank to modify the Loan Agreement and other related loan documents and to provide further security for the loans from Bank to Borrower.

 

The waiver granted herein shall not be deemed to create a course of conduct or obligation upon Bank to waive Borrower's future non-compliance with any of the terms or provisions as set forth in the Loan Agreement. No delay or omission of Bank to exercise any right or power under the Loan Agreement shall impair such right or power or be construed as a waiver of any default or as an acquiescence except as expressly set forth herein. All waivers of Borrower's noncompliance with the terms and provisions of the Loan Agreement shall not be valid unless in writing and signed by Bank, and then only to the extent specifically set forth in such writing.

 

 

 

 

 

 

 

  

 

 

 EX-10.26 5 v355517_ex10-26.htm EXHIBIT 10.26

 

Exhibit 10.26

 

 

 

October 9, 2013

 

Jacqueline M. Lemke Vice

President- Finance Chief

Financial Officer

Bioanalytical Systems Inc.

Purdue Research Park

2701 Kent Avenue

West Lafayette, IN 47906

 

Re:     Waiver- Net Worth Covenant

 

Dem Ms. Lemke:

 

We refer you to that ce1iain Loan and Security Agreement between Bioanalytical Systems, Inc. ("Borrower") and Entrepreneur Growth Capital, LLC ("Lender") dated on or about January 11, 2010 (the "Agreement"). All capitalized terms used herein and not otherwise defined shall have the meaning ascribed to them in the Agreement.

 

This letter shall serve to confirm that Lender hereby waives Borrower's compliance with the tangible net worth covenant set forth in Section 4.15 of the Loan Agreement for the periods ending March 31, 2013 and June 30, 2013. Borrower understands that the waiver set forth herein shall apply only for the stated periods.

 

Borrower agrees to pay Lender a fee in the amount of $2,000.00 as consideration tor the aforesaid waiver and documentation this letter agreement, which fee will be automatically charged to Borrower's revolving loan account.

 

Except as hereby or heretofore amended or supplemented, the Agreement shall remain in full force and effect in accordance with its original terms and conditions.

 

If the foregoing correctly sets forth your and our understanding, please execute the enclosed copy of this letter in the spaces provided below and return such fully executed copy to the undersigned as soon as possible.

 

Page 1 of 2
 

 

This Amendment may be executed in one or more counterparts, each of which when so executed shall be deemed to be an original, but all of which when taken together shall constitute one and the same instrument. An executed facsimile of this Amendment shall be deemed to be a valid and binding agreement between the parties hereto

 

    Very truly yours,
     
    ENTREPRENEUR GROWTH
    CAPITALLLC
    as Lender
       
    By: /s/ Charles L. Bert
    Name:  Charles L. Bert
    Title: Vice President
       
BIOANALYTICAL SYSTEMS,  INC.      
as Borrower      
       
By: /s/ Jacqueline M. Lemke      
Name:  Jacqueline M. Lemke      
Title: Vice President - Finance      
  Chief Financial Officer      

 

Page 2 of 2

 

 EX-23.1 6 v355517_ex23-1.htm EXHIBIT 23.1

 

Exhibit 23.1

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We consent to the incorporation by reference in the Registration Statements (Nos. 333-56123, 333-56127 and 333-153734) on Form S-8 of Bioanalytical Systems, Inc. of our report dated December 31, 2012, except for Note 3, as to which the date is October 11, 2013, relating to the financial statements appearing in this Annual Report on Form 10-K/A.

 

 

/s/ Crowe Horwath LLP

 

Fort Wayne, Indiana

October 11, 2013

 

 

 

 EX-31.1 7 v355517_ex31-1.htm EXHIBIT 31.1

 

Exhibit 31.1 

 

CERTIFICATIONS

 

I, Jacqueline M. Lemke, President and Chief Executive Officer and Vice President of Finance and Chief Financial Officer, certify that:

 

1.I have reviewed this report on Form 10-K/Aof Bioanalytical Systems, Inc.;

 

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting.

 

5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions);

 

a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 

b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

 

 

 

 

Date:  October 11, 2013

/s/ Jacqueline M. Lemke

Jacqueline M. Lemke
President and Chief Executive Officer and Vice President of Finance and Chief Financial Officer

 

 



 EX-32.1 8 v355517_ex32-1.htm EXHIBIT 32.1

 

Exhibit 32.1

 

Certifications of Chief Executive Officer and Chief Financial Officer

Pursuant to Section 906

Of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350)

 

The undersigned, the President and Chief Executive Officer and Vice President of Finance and Chief Financial Officer of Bioanalytical Systems Inc. (the “Company”), hereby certifies that, to the best of her knowledge:

 

(a)the Form 10-K/A Annual Report of the Company for the year ended September 30, 2012 filed with the Securities and Exchange Commission (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(b)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

 

By:  /s/  Jacqueline M. Lemke

Jacqueline M. Lemke
President and Chief Executive Officer and Vice President of Finance and Chief Financial Officer
Date:   October 11, 2013

 

 

 

 

 GRAPHIC 9 tlogo.jpg GRAPHIC begin 644 tlogo.jpg M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$" M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,# M`P,#`P,#`P,#_\``$0@`-P'X`P$1``(1`0,1`?_$`'<```$$`P$!`0`````` M```````%!@<(`P0)`@$*`0$`````````````````````$``!!0$``00!`P(# M!P,%```$`0(#!08'"``1$A,4(14),18B(Q=!4=:8&5D*83(E0E(S)A@1`0`` M``````````````````#_V@`,`P$``A$#$0`_`/VA=P\]_"/QFV0_//(CRU\= MN(;PNB"TXN.ZIU[#872D9RR+L`:^]AI='=5]A)4FFU1,44Z1K&^0>1J*JL=[ M!#O_`%??XK/^XMX6_P#,ARC_`(H]`?\`5]_BL_[BWA;_`,R'*/\`BCT!_P!7 MW^*S_N+>%O\`S([_:W`F>R&+R/>.;Z#3Z:] ML'_4#3T5)6:$FPL[(R3_``QPPQOD>[]$15]!>KT!Z`]`>@/0'H#T!Z#4/B)G M!,A#,=7ERC31C','B+>'.^-R1$M%F1T)#H7JCO@Y/B[V]E]!SMXKW[OG;>,] M*ZU83T?-#.=;?72Q9*##DW)!^?PU/*\_#W9&BO*6K?='F`M(FL*VS6(1QCPY M%BG&DAJ0388\X M[2S:JMR&M'#.L9FGUK:@^,V4`8V44B1'0Q%?5(KD:$X;6/?%V^6KL9>UF=!( M6ZGT%B?E3=-(J"#AK5B0+'8UE?7QD2S2K(Z:1))/@U(OZ/10IURCR5[STSE- MMUJAS_'MH%E.FK@=#ELA?I^18UF6V59D>B:*CUB["VI:BV#KHS;L6EMH!U@C M?"&0=_@<9($M>0_;-UQ_=<+IJ(+,'YOL^QGY;,3<;FL7_ M`"XRR9\OG=CG=?5"NF*E'SFUS&F%-"8Z8AT"K*-)*^8>7V".]YV_?4WD51<" MSU'F6P[#F5CN:C:GCZ>X?0&!WP67_$NZ`""LJC(E,L$-A:ZZKWE""%1-5DK( MEF":,#=;0XK:TVY?ETO:+01-J(LR%\X-G5X;N^^W6:SNCJ?'7N55QW?!8ZO)QMX36$;4+'WW M1*@#9[.VK&Y^B;<1GBC2V'[C/AK+B7)Y M]=9%6G4FGOFZ.M@A0EE-6@Y)DU[%97BR1P0$L'+8(Z7[9!Y6,#= M+YQSSHE=6PR=MQMIM^:V.9S6^#&K&T-/F#K3(;%^CJ8Y`KN5+4LJ`@V*E>D4 M+19`V%?J\/?E9W73>/F2R&OHJ`#3CZ3?YCFI%7,!=D&B6>ZM!*RHTT9E;(VM MAJ\S$PH@H4]X$%D[Z1F60,CVOD!X4E]URNZA29[8V_,+K$ZK+[*UII>,Z=C6Q3H/`$/]!\G]7S#RFY-P M31XA3,5UN(F:FZC7U6E97`6I$&G?78JSD<+/117@G]LK.^:$TF8@4G[90@!X M'EO"QV;EZ&W9Z>OT-AE;')BP?GTDU?66P&BBEM[>Q"C!BU8]9;7'+].9D;+1":"^H*LV&MM;:O)7XCB6PC48 MV.$N5T4LD@6!SDFDFS3ELS:X^^9)=CBG_LUI2AD-&L3AJ:>PJ3G,-BF<)%"I M:Q?"&:3YR#HV%\:(%"L!YLZB7C5]WOI>.C#Q6:[]>\2T%;G0#QKT2MIMV1RN MOZ!35%W,Q3*JWW9(\L[23HDBH6/*B1Q*?A/#H^QZ2,:]OO\`%[6O;\FN:OLY M$5/=KD1S5]E_HJ(J>@C'M'8,3P/F&PZ[T0PT/)8NM:?8I5U\]O=6)!)8];44 M=!3BHI5QH=!6/=S?&SC-SUX M:JHKH;.6^5@LJZ[L[2L0L&ZU%/3%C@25%/=F_GO#/E=&]H\_TN8DBPS-:YGH M-C%]V(-ZV?PK?TE/G^BMQ]3T2@;FK\C14U]B+)Y]=-9%2GT]"10W5=?U)`\M M=[&*^!T)$4\L;IOQP?'5.L47+!\6-81%6&EZ=N:WF/.*(46QG2^W-Q4W=X(- M9&5U?9NH<]6TFHX5O1LK4;VOPX'5 M\R/G+Z2SCO\`G=IKM!DWD_@G#!VXY>6.K083R98(!B2+)C1FJD4BH#/WO?\` M3XWR$YWP)V.23_5C,:S38[H0XEO:484^.DBBN,YJ*YD5<.!-"RSKYV%P6))$ MD9,BI7(.*07&#+\;_*_3^1M+C[4'GBXDB7;]`R/0`;!M[IH*D?"Q1H->U%_3 M5<%`-7ZX[WAKW6$\,)3%DE"E.:.OW!)FTZ7U_.\WN]+79'&$['^_\]A,IG2K MFPD"MG6O1`\(7<&%@)+)#!&,8ZT@@;_G?B0.0G\:1SV0!&KO)KI.DZSY#\%Y MUS[*6?5.,8@31T2Z.^T]7@M7?Z++4>AR^6)V8.3/#K+2&2Y@2U&5GY8=?8`G M-B?'.L;0<7D7Y,W'C]XTKY+VV+KRZ;.YS-:'>XR+45!=K7+IIJ2MBJ\WIABX M\KH#0+VY:(CVS-'.^37P2>RM:\-+:^3.CYYH_$O-7.9S]S8^4EA9X^O96FWU M9!2;4/#%].85))/4VMFN8CQN=M62HX%Q+#4'651Q?R9X`N+`LSH85)9%&0L4 M:SQP2OGACF5B+*R&:2$=\T3'^Z-S]B3F+^?9FDH"M=T?L M&OGPG.,R,75`PRVHF9O=?=Z._+M;*M:+DL?FLZ4?8N'_`"#7QQMA&@FGEC8H M;U+U$$+I-5Q3:6U;_JOH<)I^ITU/0TFACI)\%DM'ELA=F,T!TQK? MM&=)`0C3F_7%)'%),H?.Y=LR7`L0)N-@PL@.SW7-N=#Z]A7?)BNS MB2,U6M_M<7)UVLFR9]>7HA\-8B_W$)935LXUUP?KX'0CAJ$RB9@>P]-Y'(I+S)Q[DCFVD(SI%]6E%555& M0&?,.Y')`A$(Y,JCM5&C6QCK)S(1BYJ]A?S2%\L<8QA%N.I(\HNI MZ*X0>)#90/G9DRT<452.Y\$DS2"5B%>&Q2FRJ-_G>@^Q_P`,/_C;3!5QL6=\ MRO\`Y+)R:J(8G0=0KB!9(TF3^TK-;3-@C5>XD(&?`RK(DCG<1]_Y(CQ_O"W6?_\`&&_@UT(F6(AY]Y85!.LD=$+3:GHF\RMY3O\`MC0>+4U6 M@H*\G,&6(DK21!3$B,*'7Y11/=_A]!/_`(U?^/?_``S^,G;N.^3')X.NU6WY M1LQ>DZ-\;F_T1P?H%)[G@ M8*R&YB.E+J9-;!4RQODN;.K^9#C2W(]T:/@&^ER$20ND'; M."PSK&+D"@+:8:CYGC,?7RU9P]D.\CX*L4HA,,+GDQ,254@B62;XM=&KPD'T!Z`]`>@/0?%7V157W]D15_1%5?T_W(B*JK_Z)Z#C-_&=L[Z@ MYL-5AT9>C9NO+7R9RW3MP+1R9_*X.QR=O8'8G'UW/1(:2;+#W5*]D$=Q'7OK MK$\&8TR>4F[#(F#JETN"O3-TPI,B@"?WUS(<9PIS*AT$Z;W-LKHAITC#$]-[- MFM1+04'X6B2Q7&T=H3=/J(I+EL,\6=M`S!`@1V1SAV.]!S+_`(NY]#:\>[^W M5TFAKAT\Q?(JMHA=0%7CPEY2OO:RMK$IQ*W/T52ZC#0:0)5C0N20L4AQ1#S% M)9&"AYV?ER]F_CW&''L$B3RDE/),`LI:=Y'XO/-.*%G?W+\L<05]E96,)RME MCG4N&JE$8Q'$?8P%GPIL:K2]1\P]AJ70T'D'>=?J8^G[P7 MBGUW:_VSG+#!BZG]A,T]<'8-K*O9Z?+,N*S07-'7U8RM!!>5NAS<-IUG(TVAV-[;V> M'=F1L17Y^XENR%!J#JC\6O.6>>R/(LG,"^7FU46F-\`>PT>=K0[>VS7)ZVMJ MHKHA]\#7$U95(/#?&DZFY$=;"Y+Z?W'Y61CTF:&GY"S(KV/")J*DH]+Y.^(< M_222,Q1XO@=V!XVU%A5SU%EU7J9$.8O.@[6-U`T:DS465YECX&0TM@%4'%QW M]BY@SX1/\D'_`/R4T=7H^'B(%+O.Z@O-AANU)FI;=^MXSS M/F_D%SZ480*6LK=KSG7[>^C!EAKII[[13Z*DJ"19ZPL5!)(9F.%FB*7[QPFG MQ8Z#7]LJ0>X5]!7U$>[Y#R2.7MOVDS22P[NTBK MOP6:"^IN97[XRQ7`-!M2JVW@L;4(NOEDK(]"\4.D64,;@D,4>"3[!JZ"1H@DI(T,99`7'Y MT7'88RDLH6U[8;2,NU@6I*&.K98+.P+/@("+%H%C6HUK61-1J(C M4_PM3]/Z)^B?[/076END^G#R=2^#E-/JNN5\- MU:658?5J')?8L-8X2Y0X""6Q1,F_*>-#*'1#39>@V5-/G]/607%,236&3@$K M*V&0JFM`KNKF_NGNBA03^6$D0+P1Z\6;2B7PP]_ MQB4@"RAD(J&BL[CSA3S;J-LT$24X%?\`;*3).Y!8(F+*0K8&2/:&3,4V3Z-Y M]@]2UE99X+=\\\.!7J.T7X$`B=ST+SOY*_"W'65@ZMK0SNSI(;SH0$>@=B`B4L[32 ML&EF9!;6]>0,#&T6`>P!N4E#H[R[.3Y3G^7I##9;*P@KD+M+"<=!)SK:VFFM MK0J<9'R)#+,>=(KFHOLB_P"Q/Z(%#N'#DO\`Y,?-\E33W0#<^X+&E?-(3/60 MLLIF:3)*<22#751);*.OC/T MG&*Z2&0LT);F*R[;SP":@A)K"!K2$FV@)=%&\1S2XWJCQW1S-CEC".^Z;BPL M^U_QSCGT&UYZ+2=WNJ]MGL0,6AVKLSN-=+RU16U1$Y6GLEKM`"*<67.(97V, M$2A,*8YAJP.#JQZ#G!TO7$L_E!\9\C/"7/7C^-/:B@$:=`,*+:ZS141!EG^+ M+H:N>R6"OYDT66.`&T=&IT,LC1V,^[T'0PBFK"K6MNYQ&/MJ<>R$KCD?*R8< M2W_#6S%]XWL;*,8^N'>^-Z.8LD$;_;Y,:J!SE_DWJUU?!]L!#569[^1<[V'D M8\^G!H+VRJ#\"*VNK1P<[<_N8EO9Z'/6]_#"/9U95$0/"3^4Y/J:QX7BXQN& M=,Y%S#HC"PSTW&!R6J<=70J/7F27MRD@0_D&-C!GE(5T/QFG9]:HK9)&^ MSW!Q/W?2'X;R%_F6>_1C54YO%\^#BJ`"HANIK_INB\7L]4X&AJ(J@2+3[?HF MBL,?8*#F*ZQ"-1%F5HY4A#21`OK4YK7\A_C*T--THVWIMIDO$7AS"6ZY]T:LC6.N#^QT7Z0L5?CZ!S?QZ$R:[PDX?;VZ(0' MLL1+:Q@)$\<(2DNC#_Q:VM^/1.G2NI$!QTHP,RR!#A$EY;.D_ MEVS6:M&K/7.\%J^YS$$`!/V0W$?:MW_=!UA:#6WP_;X1:ZF9$.0!]7Y,B/:2 MDBI"\+Z[6ZI.1\[WNT#IW,#SU5J=N;7TU4:=/86BQ%W-A.VMJ1R322K.P:"?)5,.OJ?J_-J0BS MOZU`M'+,3&W39BP990OHZO\`$.7WBD*$F&6(-#^2E3I-IX!`U+,E):V'EZ!! M$S;5]4;2((/RSHEA--#.79YZZJ]`.>&*^H+J;!#@[9HQ+@+4:&>OG#J=Z`]! M!75N]<7X072B]+T-5E)].+=V=*QPS"B[./,`!NN2(JVM:3',99(YG1:D4:TFGB-M#LS?159MM`.^GM` M'22TZS6$M/64TC+(J**6O`&$@T<+)'GU2HX%28%7T#[I_-3PO:0:-5=EY ML(@\)9DY:3-"")C!!N=*4\4^46*"S>(*!:3R-A=*Z"00MCT9+'(WT%N@B:ZT M""L:^<.PKC1!S*XT22$D,H$J.(D0D,B)7PS"SQ?"2-[%5KF_%R+_`$7T&NX* MDKY$.<)5`R^Q(Z&.'$&D^-F3$29`A"L8[VL#(622M]_\V5K7.17(B^@2B[_% ME/J@S+7.FOORY(:460D`UUN=31S6CXZZ%'3*:36-$?-[1HYT3F>_Z.]O0>8- MED)V"$IQ57^CV.3^J*GH,_H#T! MZ`]!KEEC`"D&FSQ"B"0R$$D3/1D4$$+%?++(]WZ-8QC555_W>@YQ^'6^Q_,N M!Z$_HMJW-"";KK&\!SY"VUW%2YA^\O4_=:8!U4ZT!(M;%Q!90,;/>(R:9[(F M->Y7!X/YY+#7WV>DSYL@NHM:@U*^RR]\VU,J;<2KG=]X MLR_D#S1/3Y1/9[L"NGD;QV2;NW`?(FDJA7&9$]W.M[>I8,BMJK%:&W!LL\=4 M5!4#ZVT-@V$+`5EE61X@]M*YL7U.G('"\?H*,?Q[9XS+\%.K3:U]4X_J74=0 M&-['-'FK=-LK2Q'/%B/9#(%&>0LTCADA&;"]7?&%D;F?(&[YHUE7:=?\(B+4 MVQ0')=[+UDP(OSFJ!;$+%WJYO0:0*(MLA@U;90O8'$T>660F17LD';#+*T'E MS0(7.>77D[;S&6'U:[(\6TU)2P6AA++8*6L(S5KIJ'$"1^Y08YM:(.==-:4B MR^T*O';$]L@,_J%MC*OS]Y#H]091#187QLZY:RWEH%DY!<2.9?YV&UL;/2V> M?_?,A)9U\D,4#8+F!MA!^0BA31Q2D0!=++[[+[*XUM5F-!07ZXLZGJ+]:6UC MLIZJZMZ$#4PUMHP>)11)I5QL*)-(^2`QKW-8U6*\*A>%5;:5>E\KF&."; M467DETBSS,#3"#K-H4^HNY;9#R?S(Z65D5R3(D$=57C"B0.8.5.;;1V,R!*' MF>*)9^-'5*,A:22>[I!`:\&_LY*D"P._>JN>`9Q@\1!43D=%\T='%(K/C\E3 MXHOH*X=JR4FMV'\?.NAA)I69.[?`#<7.HTEO^T7=W0Y40:IBV2@V.>LMG<#5 M),`Q>FK'Q7@J&@PR`6U@'(@27YRU.=Z%QO$U!1@LL5CUWF-N)1V`4Y<^CJ@M M(,-HH4R!$7Y>BCK:*RF,>*\,Q(W0LE40I[&#RA8VO[/S2XOL7D\KML;?W>R` ML;JFIJ_3UD`K(9Y[`^I"+G%&=.R/Z&S$L:Z1JJB*&0']H=UG4 M6$EM6RE29#(9AH/[Q`LT$S+/86K@I:=U="J%%QD.D1_YA#GQQJWZ(49\Y@KK MXA<_9R'5^1?*AD$$H\AOJ2?#5(=#6U4`//-32S:;,_780'FVMVHQ5D;733%M M8KBJV:5GZS2-8#6VQ>0RG\@F;V=Y;#`C6/C-84MU+-&195E>1A-5HM56VFAD M_(.KL1)4TNNL'!GS"!/.B**B:?\`&)XDX7@S>TRNPET$67O:Z]7+WD^:O9:P MF,P>OOA!QR3:J4B%SX5-!84QL\:.5T4BJQ_LY%1`ISXGFYGCD/7^*Z:^IZ/8 MU7=NA;(;+61P-;:E4O,0$2UE#5PR2U]G!<"N(B#A M83\+(9&PEN^Y'*YZ(WW:?(B.F8WE6GK0+"QN.&][YCV08>D&()T M$E1161%%L&T20$M2*PBR&C-G^?XMA,D<#D&&<6H\D8?>YER]-U?B]3<]Z"?' M0:7IJ7VUEPVG.472\G"P6QT\H-K!33+56.7UU]G`:^28N5J?CSSM&^T&*5L2RM'.B%>K)FK&C9@<_=\6M#Y-^,7D.5I2*/)9Q-OR+=C*38 M0UI2]%`@_P!.CK-@*31RAB;,50W(2QHD=:U-?04]$VY'"B>2V"CY[;.LJQ2RAU*G5*^P&TO\`K]P2]@[%J1Z@8R@UV6SL_,-]CFW? MRL'+87MG3?B5*W$OYK@ZU^@YW\&#&$\]/,\V(L-7W]+R&Q8+!^+`D9]H$@Z$RRAD0C@X/Y+`OW#PYZ6)*XA MU8^ZY?-H`QAIB'VF9!ZGC+#15;U@,KGP0FTXDS7R?D1>S?T_Q^_U2`C>3D>: ML>J^#"W:#V"9GM%U^Y_F(.:0-/-Q70N0*RFEO@JJM=*VS%.)(-DG&>+"Z&+[ M3"0X2`Z$^@HOY!XV++>2?CYY,6@12X;%TN[P/2[JN=._^VJVZ`?;XW3:@)LR M-)R-/H8)V2E1(DE;.6UTD1$$[Y00M,WH%8=M,OE*.:.Y@OL]M=&3=5D:6E*& M/CKG.9R8">Z"+<(#;%W6@=F]M<#L.S=&%8ON*1C:C]O@J'A:'3V@TT@T\Q;26RHZ>-\;880KA_&:X:WQ5U M72Q@@:48W.GFRL)^,,!\,P"$5*+XE\1KJ1L<$=/BJNCL* M[\J8\REM::%M8716]B13T$]QD4T]+(X)1.P3EV`=8LEO!>#&$3'QK8LA%F'ER^PL"214@,'''0<4&>=QI[5KA!X)I)'PN1D\07[@U^<*TG]I!V]:;>L MJ"KLFO#LJX@L&O%.$K4F.!B+=8#L*+*5D3UA^ISH96JY'-1J@W>N]3RG$^<: M[J>WF(@RV)IB[Z[>'^&XU*X")Q!KPX#3`(BYQQ(WS?4V3[9&1N2-KW_%BA^1 MKK':MCWWJ)U#);2XWT!M?HES$/3LH2`5+F) MK'4`V='3W3X9BH\K+85,US&1[^UG(-.&O7CE6_PNXX+Q]T:;!(-,5H[HO90! M:FS.".T=@[,Q]"TU7&C+BOO!5'I,YFZX&&*M@?,:0"P@-F:LMCKH2:IJC@]C MT?)Z6AK)"\G69K-[>YLKNNN3[`BQSNB#$.6:@6UN;6MGJ&/+C=9&(& MC0ZA?Q^^%8O<[P/J?2LEG;+@.3M+"//4VD_?)-!T3=YO:?E2LTV9J=N9A<^' M@]?BZVP-!BCLPO[A86(COKCFA@#]&J(B(B(B(B)[(B?HB(G]$1/]B)Z"LW4M MB!HCR\.LD;@ZVXJ%+"%-SS[;1?![YY"*@<\DQ9JRBLP)@C4D&A5MBR-L4LTD M4P4H0Y1WX_Y.1($LM-'#H+.W=5RCQA_M%7=YDNP0BX-N\]:EEWF;.!SH/M/Q9+'Y#ZH6OAG>4(P:&00)_P"(/C]["%KQ$='5@$*)$T4,@*2RL+2P ML!B*Z.`N>-S;:>>1DBV)C91)AYOD]TSII0L'Z`]`>@/0'H#T!Z`]`>@/08E' M@=,TAT,+IV-^+)UC8LS&^ST^+9%;\VM]I'?HB_\`U+_O7T'S\<=2$+6"%2FP MN':3]3/R&CO>V1T"3?'[$A=(Q'*WW^*N1%]O=/0?%%%<]TCAH'2/5CGR+#&K MWNC=$Z-SGJWY.5CH&*BK_16-]OZ)Z#X.&()]OXHHXWW/;)-^/!%#]LC8V0M? M+];6_8]L4;6HJ^ZHUJ)_1$]!Z8./$]9(X(8WJU6*]D3&/5BR/E5JN:U%5JRR M.=[?T^3E7^JKZ#VZ*-[HWOC8]\+G/A>YC7.BK55/95:JI M_1?0>6P0-C9"V&)L,:LQCW-:KVLD^*R-:Y4]VMD^#?DB?HOLGO_3T&)@@L@SHQB/=(C&I(]K6O>C41[FL5RL:YWM\G-8KW>R M+_3W7_?Z`[7*QZM]T_7V54_V^@\1000 M?/Z88H?L=\W_`%1LC^;_`/[G_!$^3O\`U7]?0>)1!9I8IYAAYIH'(^":6&.2 M6%[?E\712/:KXW)\U]E147]5_P!_H,[FHY%:Y$@ MSB!B`#Q!@BC!"0,2.`42"(8>%C4]FLB@A:R.-C43]$1$1/0;/H$2KS.UDT7R7XO3V80P(R"(D0L4B-T1`Q(\S7PSCSQ/5KV/16N:JHJ*B^@U:ZGJ*= MLC*FJK:MDSE?*RN!%";*YTLY#G2-&BB1[EG)D>JK[K\Y'+_5RJH**HCD5KD1 MS7(J.:J(J*BI[*BHOZ*BIZ#`H@KI1YW##NG$9+&+,L,:RC1SHQLT8\BM^<+) MFQ-1R-5$@V/0),-!1#S1$04M3#/`68?#/#6AQS0G6!%@6>;%(R% MKXRSBK8J6:1%1\LA,KG*JR/50S6-35V\4<%M6U]I!#-^1%#8ACFQ13_5,/\` M?'&3'*QDWT$2,^2(CO@]R>_LJHH:Q6)(XYHWQ2L9+%*QTU6O M8]CD5KV/:JHJ*GLJ>@P!`@U@L(-:&+7A#HYL`80\(@L#7/=(YL(\#(XHT=(] M7*C43W557_;Z#0ILYGL[!&+GZ&FHAHA1P8AJ:K!K((PA)")10XX0H((V"C2F M2NCC1$8QTKU1$5SO<,%/E,OGWRR46=I*>6>0B6:6MJP@I99"S["T(624>&.1 MZ2V-L5,J*OM]A$CD_5[O<$RMYS@::T'NZC%YBKNA/R4'MZ^CK@[2*,QLC"!F MV`X\9:AR,E5/I5ZQ(B-1&I\&?$''9U-7=AOKKFMK[>ODF$(>#9ACGAO(KS(+ M`"=XQ4U4.-BK"$+%$U5]U2.-K?Z-3T&@1C,>7:E7Q64S1-X=$#`=%C6%OGZ:RL0OA^ M%8F5PD]B'];26,_$/?$I@J(PR9O^6]ONR:1O]'N10PW^*Q^K9/'ILMGM`TD/ M]OG6XIJ^Q?(#]BS(*LA8\LB0-FSOU]!JW7/<)I)8I]!C180?R(VN6)OLQRM3W143T&Q38G'YTV2RHUCE5L:_\`M1J*J>@3NA\ZRG4L MZW+;(#]QIV76>OVP>[$_^1S-T#>UWV-ECF@($E)!2(F"5CX2A9)(9&NCDG;T?;$T`(X53)GEK@L_8W)M(/6GYR3\`J%!_B M0.R-7>\L4IK]8PJVL&:&J['U@Z_IR[RZ(NW6@-G?;"S M.BL#K+YFS23)(A)LDLDGVK[*@:[/XTO%$:<4FNS&JJ)0*RQJ:]:S=:,7]OAL M1K`3[Z]4+7&Y/&\]SU/ M@L+1T>4S6<`8/39>A%&KP*JO?/.]/QJ\=&)%%.6LKW/]O>257N[)&.8Y$56JK7(K7(CFJCF^Z+_`%145/0,<;G&9%5ZQMM?9Y8YKHEN M[7\9Y`4HLH$A`32FA'2A(#`QDA$4Y:TU]B(CY*XT1OT,+FF5T#6M'?$3/"L:P3RQO"%.AUN0SPDV5!JPH30FMGJ%%B$)>%.JP3BO!X<:: M:V\NFSOCD#&RV=J0)X-&AH9,-;=ZPJ.6LSR6]@X2KB"MX(8+&2,=YT<2,8., M./`QP6&]`>@/0'H#T!Z`]`>@AC2=JJ*'I17)`<[>:C>1\ML^LA4-&?DH3K7. MU9UA320!C7^EI9T*)T,`=?'+(U@;2K*#[9XHTEDC"0L;K:7>93/;/.$.*H]- M4!7-9,]J,D<(=`R:-DS&N>V,B+Y*R1J. MYQO.K[^S2EPW-@/08"9E&&((;!.4Z""69!AFL>20L4;GI`.V22*-T\JM^+$DS8<0$CQ"Z7(O`BTI[CG.9"V. MEFN`6$(GR=&X\9%3_-;Z!=SNSH]59:VLI9"B)<3?-S%\1*',*+%?)6@VY%:- M(0V-Y;PZ^T&DDD8U8?\`/:C'N5'HT'7Z`]`>@/0,:UZ1C:7H&/Y;96SQ]SO: M'7Z;*TR5UG*RRH\'-G!]6?[U(A6%)&/\` MF@9Y.J9B6IYE?4<5UK*;K)M%#D[#,5)%C%^T:&B)T8.MMX9%&*J\G'60,63"U[45_Z!)/H#T!Z`]`>@/0'H#T!Z`]`>@/0'H#T!Z`]`>@/0:5E95] M/7'V]L<)6554$596=D>1$(#7UX,$A1IQA4[F0C""#1.DDD>Y&L8U5541/0?E M?\U?*RX\H.DNLHCSJ'A>2(T&4P&,*N(*ENSKSJ*E#ONFV=J#,(%"?UFHV96> MJ(7WE>H.*D.M@1],18+65X51L+NV%"N"CM%K1]';,IJ6BOHZR'-S!P7P]2=O MM[+86-=36?/-?F:HVXE`E*M*,*L&((&5A4<9`DX9X?W$V6%3KAH1E&ES3WM! M'O,=#$-GZBNKF70E3-/IJS"!U[^C4MO/E@"(^POCZO/C2Q=?LJJ5Q9>@+IPVV"MA/ M:E.[-A9#QPYY;^0ER?-9Z_6#\KA*4%"+F%X8=U5E M11Z>6IC/DL6VE54_);:VK7?O<'0[@3.#%S1Q2SRL4TM@\+Q94!,*N;QT=I,7 M2W9#YPK@P\>OUVH#@M*6UN);7=MJQBM->39^X,RDI1`%,P1;8HMXTL!E:'"U M!@W!;0N`/[VZ'67TF>RQ=FW3TIL\]9J9B$J*V[P\\8UT%6)HM-=OC_,()DK) M!?P_RQF!3&$FN"Q/+,=;Y\^_N;`R'\6T#J*6OJQA2!!A`4T.$EX3-Z`]`>@/0(.JDM(LOI):,AXEU%0W$E05'4OO MI!K1E>0ZO(91QD"27+X2T8Y!&RQ*2J?6CVJ[W0*L77;=%S;QPVNWT-[%T;IV M$3'XS05E75T.")'ZEI:SGU)6TKZRXL3:RE?H+S9!7$,)L_RC$MHHE1J(UJ`L M5/3=SI,5VNN"GL!=WSOLY_.AYL_DWZ*U`J3[G*VM+<+06/XPMN)'CM;&2Z:+ M[(X@V.PB\,;Z=<\CZ^DBDB?W3+1 M.+33&`3LD-^MKT@#EFBA_P`#W?U>Y[`Q.(L/!3PZQE));971:7"#C':NUME) MK*4VL31&=*\AMO65PWXQAZXOG2:C2CUT/U3FLK/IBC^Q[(5"7>\=TCYQC>.[ M/,D#VE5TSMW"<"/8,C"(K)\OU;7550;;R2&'UTL0L6?L)"89A_MF;,V)5B?% M]B>@:=MY";.O\5]7W4BBJP-%07&JA!"'S^DT=7;Y^AZS88VFNP\]%846CD_N MC(B0G1LDG':-,3\WO<,SY/"T=#8'VG[H62*0$$EE.+40E0`-D)`$]H66XY== M<6L)U9=.3\@5SVBSLA>C9(6N3]0@GR2=F]56XWAFIKH;.A[K2U$)M*-,K,M;W%Y8V'[G6GT@,O[A"`(!,2YGPM3!7,9.J+!(%?,-U;JE!_'$S?XVO MN+7JG'^::'.%0[1[]?IKXW@N@L\+L[8RMAU^JT%/B#C@Y%)B$L;">)5D2 M&3Y>@M)5]+L=)5;#49PBKMZ#-8$"RKBQ7L$`O-3:Y(+;,^Q2$-/K@(::Q`=$ MV3XR,8:_[8W_`!C=Z!#X3O>@=!HZ30Z:PSL<'^D?-DV]"*`<%K,;V\V@;H=U M5'U9`S&CU#JJ]KI1H9/G*CT7X^\;T50]\0ZAK>EU,U9=-K:3;.PDM?V4"[Q.JRWXQTE8-2;K+7-;?PLF2=\`Q_X>]CT^ZC[5 M0)G+D31\;[I6\@?-&,(LVBJ'4O-=(W1'#QOF2591V_%Z`]>) M=;O.KQYO0@UTI?/]AR7(=4K-*=6&410I'1C;&WS>/A#^@NKM":?(LB_'#8X[\$W(=5$G##+ M&CN26C\?.5`STNFWW;^K%9$(ZW MFERU?=7UC2;GMG5M1"(UEF0A,.;R]T4!5MD?(LGTQ+(D,8 MEU4T]=7;KQ3I]G8%55^:ZPI+J*KY,%US&7A3JA\%D-0Z6ELXH"&(C"1R!R6, M^Q(V/D!7X3W/0=S"N"1SZGA:'T%(_,W+;_4TU)9<;H(+_N' M),_L.V\;'M9Y?[8+Z'ACKZ+;:`G[RXYC*\>EQA,$+('R2N()A0N)SP=14W/![[M:FZ0VA6O%N@\G4: M+#<[N*XR]JGQP]&*LY1T,A/CE`F&C@?\9"4?$#IZWU7L>+Q`NYHN7%GB*G`802GQX%SHV9TTBYLW65@P0ET'TC-:UK7SS1!:,7\ MC\8?\QT+B_HB_*<.R2,=Q'UM^]T$@/0'H#T!Z`]`>@/050\X.>8_JGB[U;#=%Z!@^7GSM&P%'B M:N\K+;0R:N0C4XVK?2D@@NB(BL#XZPB)[H3&2C221/#D3+X.4%S9'JOG[XT5 M]F4=U6R8+DJD>J/K"+N<=-](*;%WN:TF``M0WS&5Y/W5]>2KFSQ30O)'("-` M/`C!@5-(Z@_D.\2EG;D!6TI\T5+94JO/R&P2AGI*8_M=I6)AEYWH*HL$9JRS M#U\3H*XL2G@IA:P'47X'8YZ;)H?GQXLD5))5'6!(4^V")H[3^[-8*6NB*I/) M(*ON]87A"C!J\XH9MD+HUGL4?*X9(G@GQ>`&<)]*RPAJ$@9 M?1[_`$NGZ%G#+O:;FEO.N:%MM0T9F4T[JG%QX%CQ]QN`PW/IZCF M^K`V=";NNEZ2SNJBUK;2G_OG4;_17W2*^I;4D%@TH5;OS[*%*IDLBU3V.$5? M>%40&B7SO,S>7E/U).HT(_0P^&VF.;R7\>A=HC^6DZT2SL=.DL M`:XZ,;\-CXVBK[22JY0\]_P>3V#R"^J:KG-/SRGYOTA`:[96.FSH[K*UREO3 M[2VV]A7=)R=!J.4B8$\C]UJ#`E^KV0UIPSX(WM"/-=R=K.+>->*V78>7E?V/ MU?Q\N*#:;L`^,36Z#%&TYV*H,1.G1ZHFPUVFTH$4%3*6;;DEAS?5-$>4KB90 M3M;Q:NT7BWU7E?..[Y'&U>GZKJ;O+==@;57<6+UUYY!S;N\IS)*B^S=49I*3 MHI)5&''^1%.,4R&$IA)$NTFINM-1_: M'E+ZGPF52"46[='8D4A.XLI'E7I`URR%U75I'*+7#S!1R21RS2,G:B`Q>,\] M-Q)_>;&]Z'0[.@W_`$_1Z^:C!2V=68(DD2.NNJ$LO1;#73#OFI0`)C0X75U< M,8I$D`0[2'(H:>(YI19#QJL>89#I`&JB#YW9YY.F:VQCNXB/R\=$-17>NL*2 MVK"C@JO*35R)(A\)4M7#"]2?DY)U!QZG.39F:OT@]*4;,3/8`6I M$,A,Z"QN8&?^Q,W!J.EV073<1'@]!U+(ZGI.?.K\M9GU?0:H/&U@>5(NB2TK M:$>^(I:5!GEEH-W5].YA3]F/X/C<7GLB^OB ML>G5'#@.ID7W0]/-4S;*`LJOO]"7'7U=DRLCK:RQBC<4VQ M^56,:U9)/C]DBM1$5[_@UC/F]4]U]D1/?^B)Z"AVJY)SJY\2,US;7=NYOGV, MW.>M<;V8$7$-R`W8:_L#M=CI,Y0ZJRL\S8&3;J!MZ!87 MJV7,O=/QJT"W^6R-KD]AH+:FIM%05UN[?79?.M=30Y^KE.N`3JIP=?8%V)#Z MZ.:Q<*(]K7Q0_>KP9O9^?9_;<7Q6*ZIU3-9#4?W?R8W)=.&!RU!$G8YSE=Z!Y>/6*Y_AN9UM?RS81;;G=G M8W-]BK*LMZ.VRE9E;:S*)SN6PKLM$/FQ\;DZ=T-<"HS7RDQC?D%S$FS$$R@B M>6N0+WWCAU_%AZ[$8+^YL;8TY>SZ/*;!B\U7&?"*PN+V:OMZ`N,4(57/3XFB M?)R(W[HO?[&@E]UPN1VEAXZF:';9'"=HQ'5HMCPF2TM*Y8M%T0;F>\J-UCZ& MGN)!;37C77&[G4-(@"8E@+7LDL&_!!'J@,K3<[HK#F'F93!;ODE7U3IP&M_U M?T!5H9+F\)!9\Q#RN*_O\9NC'O,R)3\J MP=N9H@B'PQXT?S1V(*YWV[AG3LVSD^8RG>'LL:BT>_379&=(J0 MIP'0Y,HG\FBKK:&:26.2WJ8)7"RS1+]9#(62JC7O>U`:)^0MB.SYW=NUD4-/ M5<^T65$PZ2W$3SB[J\I;6ZT\\":#]AL)J]M'6#"O6K0H*.@Y#;\OW/D#T3H6:;;.W^NT+DCI,SG;K.6-=H+VSG=9TS!!*NF)GF=.\J".#X?8]WQ:OH$#>8 M[!6U;PIMYH<_6VV)Z!G;WD3K'0*)6:'=!X#8Y\6L`CGL66&KFGPUS]I. MO.YSDZBZ#@O"A,MUY263QK@N8\;^\<[Q7*\> M'5B4FBLLI2=-I]8,P40/G=GF;*LUN8SA1-3:-6:")S31[.:6-7?XXD60%GR) MY;L-B#Q&&I[K@^3WV1TRR9DG>XA-^-I.MST3@@/0'H#T!Z`]!__V3\_ ` end EX-101.INS 10 basi-20120930.xml XBRL INSTANCE DOCUMENT 7.25 120000 2072000 12500000 -0.072 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>13. SETTLEMENT OF CONTINGENT LIABILITY</strong></p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>&nbsp;</strong></p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> In June of 2008 as part of selling our Baltimore Clinical Pharmacology Research Unit, we subleased the building space it occupied to the purchaser of the assets. We remained contingently liable for the rent payments of $800 per year through 2015 in the event the sublessor did not perform. In 2009, the purchaser ceased operations in Baltimore and sought to renegotiate the terms of its sublease. In March of 2010, a settlement was reached with the landlord of the building which canceled the sublessor&#39;s and our obligations under the lease in exchange for a cash payment from the sublessor. We agreed to contribute $250 to the settlement, payable in twenty-five monthly installments of $10 without interest. We recorded the discounted liability of $216 in March 2010 and recognized the related expense in general and administrative expenses<strong>.</strong> In May 2012, we made the final payment and extinguished the liability.</p> <!--EndFragment--></div> </div> 800000 216000 180000 500000 500000 0.1 0.01 3700000 128000 101500 103000 25000 128000 991000 0.063 0.074 0.042 0.084 -1759000 -73000 -1759000 -73000 1.25 -0.349 0.605 5506000 0.75 0.002 10000 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>16. MANAGEMENT&#39;S PLAN</strong></p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> Our long-term strategic objective is to maximize the Company&#39;s intrinsic value per share.&nbsp;&nbsp;&nbsp;However, in response to our financial performance through the second quarter of fiscal 2012, we began to operate the business in a manner designed to place more emphasis on cash flow generation. Thus, our short-term tactical objective is to maximize free cash flow from operating activities.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> Revenues declined approximately 14.9% and gross margin declined 34.9% from fiscal 2011. In fiscal 2012, we consolidated our bioanalytical laboratories into our headquarters in West Lafayette, Indiana, closing facilities in McMinnville, Oregon and the UK to reduce operating costs and strengthen our ability to meet clients&#39; needs by improving laboratory utilization. We also implemented personnel reductions and other cost cutting measures in Selling, R&amp;D and General and Administrative functions. These restructuring activities totaled $3,195 in the current year. As a result, we reported a net loss of $6,317 in fiscal 2012 as compared to net income of $2,302 in fiscal 2011.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The majority of the restructuring activities, though, occurred in the second half of the fiscal year. Due to these activities, gross margin improved 60.5% in the second half of fiscal 2012. Operating expenses declined 32.5% in the same time period. As a result, we had operating income of $452 before restructuring charges in the second half of fiscal 2012 compared to an operating loss of $2,943 in the first half. The % and $ amounts in the preceding sentences in this paragraph are unaudited. We will continue initiatives to control costs and improve productivity to achieve our financial objectives. Total capital expenditures declined 7.2% in fiscal 2012, particularly in the second half, as we limited spending to only necessary expenditures.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> We negotiated an amendment on our loans with Regions Bank, extending the maturity date to October 2013. Our line of credit with Entrepreneur Growth Capital LLC was renewed for another year. Further, we listed for sale our headquarters facility in West Lafayette, Indiana with the intent to leaseback 80% of that square footage in which to continue our laboratory and manufacturing operations.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> In fiscal 2013, we will continue to assess the need for additional cost controls such as freezing non-essential capital expenditures, reducing non-essential expenses, and monitoring our operations for efficiencies to further reduce our break-even point. For fiscal 2013, we expect to see slow but continued improvement in the volume of new bookings with little improvement in pricing. We also expect improved gross profit margins due to cost controls implemented and restructuring activities. We have debt and lease obligations of approximately $1.3 million in fiscal 2013. Based on our expected revenue, the availability on our line of credit, the impact of the cost reductions implemented and restructuring activities during fiscal 2012, we project that we will have the liquidity required to meet our fiscal 2013 operations and debt obligations.</p> <!--EndFragment--></div> </div> -0.325 P7Y -2461000 2461000 2461000 5506000 -5506000 5506000 6112000 0.18 -13000 -84000 -0.149 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The assumptions used to compute the fair value of the warrants at the time of issuance were as follows:</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 80%" cellspacing="0" cellpadding="0" align="center"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Warrant A</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Warrant B</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="2"> &nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="2"> &nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 72%">Risk-free interest rate</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> 1.87</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">%</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> 0.18</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">%</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">Dividend yield</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">0.00</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">%</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">0.00</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">%</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">Volatility of the Company&#39;s common stock</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">106.91</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">%</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">116.01</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">%</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">Expected life of the options (years)</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">5.0</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">1.0</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt">Fair value per unit</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">1.433</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">0.779</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> </table> <!--EndFragment--></div> </div> 60000 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>15. SELF-INSURANCE</strong></p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The Company is self-insured for certain costs related its employee health plan.&nbsp;&nbsp;Costs resulting from noninsured losses are charged to income when incurred.&nbsp;&nbsp;The Company has purchased insurance which limits its exposure for individual claims to approximately $60 and has a minimum annual aggregate attachment point of $2,072 at September 30, 2012.&nbsp;&nbsp;The Company&#39;s expense related to the plan was $1,231 and $1,089 for the years ended September 30, 2012 and 2011.</p> <!--EndFragment--></div> </div> 1089000 1231000 1.14 1.06 128 1.25 197 1.09 200 1.05 385 260 2.59 1.83 1.46 125000 120000 2.10 1116000 921000 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>Explanatory Note</strong></p> <p style="TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>&nbsp;</strong></p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> Bioanalytical Systems Inc. ("we", "us", "our", or the "Company") is filing this Amendment on Form 10-K/A (this "Amendment") to amend our Annual Report on Form 10-K for the fiscal year ended September 30, 2012, originally filed with the Securities and Exchange Commission (the "SEC") on December 31, 2012 (the "Original Filing"). The Amendment restates our consolidated financial statements and related dosclosures for the fiscal years ended September 30, 2012 and 2011. This Amendment also amends certain other Items in the Original Filing, as listed in "Items Amended in this Amendment" below, as a result of the restatements. Details of the impact of these restatements are discussed below and in Note 3 to the accompanying consolidated financial statements and in <em>Management&#39;s Discussion and Analysis of Financial Condition and Results of Operations</em>.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>Restatement Background</strong></p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>&nbsp;</strong></p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> In August 2013, we announced a delay in filing our Form 10-Q for the three and nine months ended June 30, 2013 until management resolved a complex accounting issue related to the accounting treatment for our outstanding warrants. In the same month, we announced that investors should no longer rely upon our previously issued consolidated financial statements and the related independent auditors&#39; reports for the fiscal years ended September 30, 2012 and 2011, or the quarterly financial statements for the first two quarters of fiscal 2013, or any earnings releases relating to these periods, because of errors in such financial statements.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> As a result of the identification of such errors, we have undertaken a comprehensive review of our previously filed consolidated financial statements. We concluded that the warrants issued in connection with our public offering in May 2011 were incorrectly accounted for as equity and the fair value of those warrants should have been recorded as a liability. As a result, we have restated our previously reported consolidated financial statements for the years ended September 30, 2012 and 2011, as well as the condensed consolidated financial statements for the three and six months ended December 31, 2012 and March 31, 2013.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>Internal Control Consideration</strong></p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> Our management has determined that there was a control deficiency in our internal control over financial reporting that constitutes a material weakness, as discussed in Part II - Item 9A of this Amendment. A material weakness is a control deficiency, or combination of control deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the annual or interim condensed consolidated financial statements will not be prevented or detected on a timely basis. For a discussion of management&#39;s consideration of our disclosure controls and procedures, internal control over financial reporting and the material weakness identified, see Part II - Item 9A included in this Amendment.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>Items Amended in This Amendment</strong></p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> For the convenience of the reader, this Amendment sets forth the Original Filing, in its entirety, as modified and superseded where necessary to reflect the restatement. The following items in the Original Filing have been amended as a result of, and to reflect, the restatement:</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 54.3pt">&nbsp;</td> <td style="FONT-FAMILY: Symbol; WIDTH: 18pt">&middot;</td> <td>Part I - Item 1A. Risk Factors;</td> </tr> </table> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 54.3pt">&nbsp;</td> <td style="FONT-FAMILY: Symbol; WIDTH: 18pt">&middot;</td> <td>Part II - Item 7. Management&#39;s Discussion and Analysis of Financial Condition and Results of Operations;</td> </tr> </table> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 54.3pt">&nbsp;</td> <td style="FONT-FAMILY: Symbol; WIDTH: 18pt">&middot;</td> <td>Part II - Item 8. Financial Statements and Supplementary Data; and</td> </tr> </table> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 54.3pt">&nbsp;</td> <td style="FONT-FAMILY: Symbol; WIDTH: 18pt">&middot;</td> <td>Part II - Item 9A. Controls and Procedures.</td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> In accordance with applicable SEC rules, this Amendment includes new certifications required by Rule 13a-14 under the Securities and Exchange Act of 1934, as amended ("Exchange Act"), dated as of the filing date of this Amendment.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> We have not updated items in this Amendment to reflect events occurring after the Original Filing date, other than those associated with the restatement of our consolidated financial statements.</p> <!--EndFragment--></div> </div> true --09-30 FY 2012 2012-09-30 10-K 0000720154 7638738 Yes Smaller Reporting Company 7402000 BIOANALYTICAL SYSTEMS INC No No BASI 2016-05-31 2012-05-31 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <font style="FONT-SIZE: 10pt"><strong>3</strong></font><strong>. <font style="FONT-SIZE: 10pt">RESTATEMENT OF PREVIOUSLY ISSUED CONSOLIDATED FINANCIAL STATEMENTS</font></strong></p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> In August 2013, we announced a delay in filing our Form 10-Q for the three and nine months ended June 30, 2013 until management resolved a complex accounting issue related to the accounting treatment for our outstanding warrants. In the same month, we announced that investors should no longer rely on our previously issued consolidated financial statements and the related independent auditors&#39; reports for the fiscal years ended September 30, 2012 and 2011, or the quarterly financial statements for the first two quarters of fiscal 2013, or any earnings releases relating to these periods, because of errors in such financial statements.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> As a result of the identification of such errors, we have undertaken a comprehensive review of our previously filed consolidated financial statements. We concluded that the warrants issued in connection with our public offering in May 2011 were incorrectly accounted for as equity and the fair value of the warrants should have been recorded as a liability. As a result, we have restated our previously reported consolidated financial statements for the years ended September 30, 2012 and 2011. The restatement adjustments resulted in a cumulative net decrease to Total shareholders&#39; equity of $1,213 and $1,286 as of September 30, 2012 and 2011, respectively, a decrease to our previously reported net loss for the fiscal year ended September 30, 2012 of $73 and an increase in previously reported net income of $1,759 for the fiscal year ended September 30, 2011. The decrease in our net loss and increase in net income was a result of the changes in the fair value of the warrant liability that is now correctly recorded in other income (expense) as the change in fair value of warrant liability- (increase) decrease. Except as otherwise specified, all information presented in the accompanying consolidated financial statements and the related notes are presented after inclusion of all such adjustments. There was no net effect on the consolidated statements of cash flows for fiscal years 2012 and 2011 as the change in the fair value of the warrant liability is a non-cash item.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The following table summarizes the effects of the restatement adjustments, previously discussed, on the consolidated statements of operations and comprehensive income (loss) items for the years ended September 30:</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 100%" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; COLOR: black; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif" colspan="10">2012</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; COLOR: black; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif" colspan="10">2011</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; COLOR: black; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif" colspan="2">As Reported</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; COLOR: black; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif" colspan="2">Adjustment</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; COLOR: black; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif" colspan="2">Restated</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; COLOR: black; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif" colspan="2">As Reported</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; COLOR: black; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif" colspan="2">Adjustment</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; COLOR: black; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif" colspan="2">Restated</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 34%"> Total revenue</td> <td style="FONT: 10pt Times New Roman, Times, Serif; WIDTH: 1%"> &nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 1%"> $</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 8%"> 28,208</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 1%"> &nbsp;</td> <td style="FONT: 10pt Times New Roman, Times, Serif; WIDTH: 1%"> &nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 1%"> $</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 8%"> -</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 1%"> &nbsp;</td> <td style="FONT: 10pt Times New Roman, Times, Serif; WIDTH: 1%"> &nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 1%"> $</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 8%"> 28,208</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 1%"> &nbsp;</td> <td style="FONT: 10pt Times New Roman, Times, Serif; WIDTH: 1%"> &nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 1%"> $</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 8%"> 33,144</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 8%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT: 10pt Times New Roman, Times, Serif; WIDTH: 1%"> &nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 1%"> $</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 8%"> 33,144</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 1%"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> Total cost of revenue</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 21,370</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> -</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 21,370</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 22,638</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 22,638</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> Gross profit</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 6,838</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> -</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 6,838</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 10,506</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> -</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 10,506</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> Total operating expenses</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 9,329</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> -</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 9,329</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 9,219</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 9,219</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> Restructuring charges</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 3,195</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> -</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 3,195</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> -</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> -</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> Operating income (loss)</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> (5,686</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> )</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> -</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> (5,686</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> )</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 1,287</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> -</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 1,287</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> Interest expense</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> (714</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> )</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> -</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> (714</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> )</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> (706</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> )</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> (706</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> )</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> Change in fair value of warrant liability - decrease</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> -</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 73</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 73</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> -</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 1,759</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 1,759</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> Other income</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 12</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> -</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 12</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 12</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> -</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 12</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> Income (loss) before income taxes</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> (6,388</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> )</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 73</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> (6,315</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> )</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 593</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 1,759</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 2,352</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> Income tax expense</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 2</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> -</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 2</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 50</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 50</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> Net income (loss)</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> (6,390</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> )</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 73</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> (6,317</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> )</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 543</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 1,759</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 2,302</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> Other comprehensive income (loss):</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;&nbsp;&nbsp;&nbsp;Foreign currency translation adjustment</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> (22</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> )</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> -</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> (22</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> )</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> (49</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> )</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> -</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> (49</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> )</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> Comprehensive income (loss)</td> <td style="PADDING-BOTTOM: 2.5pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> (6,412</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> )</td> <td style="PADDING-BOTTOM: 2.5pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 73</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> (6,339</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> )</td> <td style="PADDING-BOTTOM: 2.5pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 494</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 1,759</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 2,253</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> Basic EPS</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> $</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> (0.89</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> )</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> $</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 0.01</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> $</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> (0.88</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> )</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> $</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> (0.66</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> )</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> $</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> (0.08</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> )</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> $</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> (0.74</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> )</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> Diluted EPS</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> $</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> (0.89</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> )</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> $</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 0.01</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> $</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> (0.88</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> )</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> $</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> (0.66</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> )</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> $</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> (0.08</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> )</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> $</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> (0.74</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> )</td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The following table summarizes the effects of the restatement adjustments, previously discussed, on the consolidated balance sheet items as of September 30:</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 100%" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td>&nbsp;</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; COLOR: black; TEXT-ALIGN: center" colspan="10">2012</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; COLOR: black; TEXT-ALIGN: center" colspan="10">2011</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td nowrap="nowrap">&nbsp;</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; COLOR: black; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">As Reported</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; COLOR: black; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Adjustment</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; COLOR: black; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Restated</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; COLOR: black; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">As Reported</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; COLOR: black; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Adjustment</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; COLOR: black; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Restated</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td>&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td colspan="2">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td colspan="2">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td colspan="2">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td colspan="2">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td colspan="2">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td colspan="2">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; WIDTH: 34%"> Total assets</td> <td style="PADDING-BOTTOM: 2.5pt; WIDTH: 1%">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 8%"> 26,975</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt; WIDTH: 1%">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 8%"> -</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt; WIDTH: 1%">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 8%"> 26,975</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt; WIDTH: 1%">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 8%"> 32,346</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt; WIDTH: 1%">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 8%"> &nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt; WIDTH: 1%">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 8%"> 32,346</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="TEXT-ALIGN: left">Total other current liabilities</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">11,387</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">-</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">11,387</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">9,847</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">9,847</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">Fair value of warrant liability</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> -</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 1,213</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 1,213</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> -</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 1,286</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 1,286</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="TEXT-ALIGN: left; PADDING-LEFT: 9pt">Total current liabilities</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">11,387</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">1,213</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">12,600</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">9,847</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">1,286</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">11,133</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">Other long-term debt</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 5,998</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> -</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 5,998</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 6,913</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 6,913</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="TEXT-ALIGN: left; PADDING-LEFT: 9pt">Total liabilities</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">17,385</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">1,213</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">18,598</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">16,760</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">1,286</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">18,046</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="TEXT-ALIGN: left">Shareholders&#39; equity:</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="PADDING-LEFT: 9pt">Preferred Shares</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">1,335</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">-</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">1,335</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">2,135</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">-</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">2,135</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="PADDING-LEFT: 9pt">Common Shares</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">1,871</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">-</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">1,871</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">1,698</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">-</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">1,698</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="TEXT-ALIGN: left; PADDING-LEFT: 9pt">Additional paid-in capital</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">20,451</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">(816</td> <td style="TEXT-ALIGN: left">)</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">19,635</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">19,408</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">(816</td> <td style="TEXT-ALIGN: left">)</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">18,592</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="TEXT-ALIGN: left; PADDING-LEFT: 9pt">Accumulated deficit</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">(14,096</td> <td style="TEXT-ALIGN: left">)</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">(397</td> <td style="TEXT-ALIGN: left">)</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">(14,493</td> <td style="TEXT-ALIGN: left">)</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">(7,706</td> <td style="TEXT-ALIGN: left">)</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">(470</td> <td style="TEXT-ALIGN: left">)</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">(8,176</td> <td style="TEXT-ALIGN: left">)</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; PADDING-LEFT: 9pt"> Accumulated other comprehensive income</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 29</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> -</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 29</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 51</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 51</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; PADDING-LEFT: 0.25in"> Total shareholders&#39; equity</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 9,590</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> (1,213</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">)</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 8,377</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 15,586</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> (1,286</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">)</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 14,300</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; PADDING-LEFT: 0.25in"> Total liabilities and shareholders&#39; equity</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 26,975</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> -</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 26,975</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 32,346</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> -</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 32,346</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left">&nbsp;</td> </tr> </table> <!--EndFragment--></div> </div> 1764000 3934000 4073000 3366000 56000 17000 1762000 2067000 25364000 23796000 51000 29000 51000 29000 18592000 19635000 19408000 20451000 -816000 -816000 1174000 1090000 1098000 864000 76000 226000 153000 83000 153000 83000 900281 -3045000 -3045000 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 0.25in; TEXT-INDENT: 0px"> &nbsp;</td> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 0.5in; TEXT-INDENT: 0px"> <em>(h)</em></td> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> <em>Advertising Expense</em></td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> We expense advertising costs as incurred. Advertising expense was $203 and $229 for the years ended September 30, 2012 and 2011, respectively.</p> <!--EndFragment--></div> </div> 229000 203000 165000 108000 123000 -61000 15000 108000 123000 -9000 -84000 30000 54000 2753000 1376500 2753000 936000 32346000 26975000 18121000 15864000 7674000 7262000 6551000 3849000 32346000 26975000 10373000 6892000 21433000 21278000 6222000 5778000 613000 330000 1888000 356000 1888000 356000 1071000 739000 1069000 125000 1194000 330000 58000 388000 4000 4000 208000 6000 214000 259000 22000 281000 268000 39000 307000 4086000 4775000 1422000 2963000 721000 1541000 -2242000 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 0.25in; TEXT-INDENT: 0px"> &nbsp;</td> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 0.5in; TEXT-INDENT: 0px"> <em>(c)</em></td> <td style="PADDING-BOTTOM: 0px; TEXT-ALIGN: justify; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> <em>Cash Equivalents</em></td> </tr> </table> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> We consider all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> One or more of the financial institutions holding the Company&#39;s cash accounts are participating in the FDIC&#39;s Transaction Account Guarantee Program. Under that program, through December 31, 2010, all noninterest-bearing transaction accounts are fully guaranteed by the FDIC for the entire amount in the account. Pursuant to legislation enacted in 2010, the FDIC will fully insure all noninterest-bearing transaction accounts beginning December 31, 2010 through December 31, 2012, at all FDIC-insured institutions.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> For financial institutions opting out of the FDIC&#39;s Transaction Account Guarantee Program or interest-bearing cash accounts, the FDIC&#39;s insurance limits were permanently increased to $250,000, effective July 21, 2010. At September 30, 2012, the Company did not have any cash accounts that exceeded federally insured limits.</p> <!--EndFragment--></div> </div> 250000 2.00 2.00 250 250 1376500 344813 191607 135793 19000000 19000000 6945631 7638738 6945631 7638738 1698000 1871000 1698000 1871000 2253000 -6339000 494000 -6412000 1759000 73000 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 0.25in; TEXT-INDENT: 0px"> &nbsp;</td> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 0.5in; TEXT-INDENT: 0px"> <em>(o)</em></td> <td style="PADDING-BOTTOM: 0px; TEXT-ALIGN: justify; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> <em>Comprehensive Income (Loss)</em></td> </tr> </table> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> We report comprehensive income (loss) on our Consolidated Statements of Operations. Other comprehensive income (loss) represents changes in shareholders&#39; equity and is comprised of foreign currency translation adjustments.</p> <!--EndFragment--></div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 0.25in; TEXT-INDENT: 0px"> &nbsp;</td> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 0.5in; TEXT-INDENT: 0px"> <em>(a)</em></td> <td style="PADDING-BOTTOM: 0px; TEXT-ALIGN: justify; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> <em>Principles of Consolidation</em></td> </tr> </table> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant inter-company accounts and transactions have been eliminated.</p> <!--EndFragment--></div> </div> 493000 35000 4171 2486127 500 22638000 21370000 22638000 21370000 2959000 2898000 19679000 18472000 37000 -3000 13000 5000 3571000 3012000 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>8. DEBT ARRANGEMENTS</strong></p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> Long-term debt consisted of the following at September 30:</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 90%" cellspacing="0" cellpadding="0" align="center"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: center; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: center"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2">2012</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: center"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: center"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2">2011</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: center"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold" colspan="2"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold" colspan="2"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 72%; TEXT-INDENT: 0px"> Mortgage note payable to a bank, payable in monthly principal and interest installments of $40. Interest is fixed at 4.1%.&nbsp; Collateralized by underlying property.&nbsp; Due October, 2013. (b)</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> 3,236</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> 3,573</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: right"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: right"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> Mortgage note payable to a bank, payable in monthly principal and interest installments of $17. Interest is fixed at 4.1%.&nbsp; Collateralized by underlying property.&nbsp; Due October, 2013. (b)</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">1,532</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">1,674</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: right"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: right"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> Replacement note payable to a bank, payable in monthly principal installments of $14 plus interest.&nbsp; The interest rate is 4.5%. Collateralized by West Lafayette and Evansville properties. Due October, 2013. &nbsp;(a) (b)</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">1,074</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">1,245</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: right"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: right"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> Note payable to Algo Holdings, payable in monthly installments of $10.&nbsp; There is no interest on this note if paid within terms.&nbsp; Termed May 1, 2012.&nbsp; See Note 13.</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> -</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 85</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> &nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">5,842</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">6,577</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> Less current portion</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 583</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 735</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 5,259</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 5,842</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> Our principal payment obligation for the year ending September&nbsp;30, 2013 is $583. Cash interest payments of $715 and $647 were made in 2012 and 2011, respectively.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <em>&nbsp;</em></p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <em>Mortgages and note payable</em></p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <em>&nbsp;</em></p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> We have notes payable to Regions Bank ("Regions") aggregating approximately $5,800.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> Regions notes payable currently include two outstanding mortgages on our facilities in West Lafayette and Evansville, Indiana, which total $4,768. The mortgages originally mature in November 2012 with an interest rate fixed at 4.1% and monthly principal payments of approximately $38 plus interest.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> <font style="FONT-SIZE: 10pt">(a) On November 29, 2010, we executed amendments on two loans with Regions. Regions agreed to accept a $500 principal payment on the note payable maturing on December 18, 2010 and a $500 principal payment on one mortgage maturing on February 11, 2011. The principal payments were made on December 17, 2010 and February 11, 2011, respectively. Upon receipt of these two payments, Regions incorporated the two loans into a replacement note payable for $1,341 maturing on November 1, 2012.</font> <font style="FONT-SIZE: 10pt">The replacement note payable bears interest at a per annum rate equal to the 30-day LIBOR plus 300 basis points (minimum of 4.5%) with monthly principal payments of approximately $14 plus interest. The replacement note payable is secured by real estate at our West Lafayette and Evansville, Indiana locations. At September 30, 2012, the replacement note payable had a balance of $1,074.</font></p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> As part of the amendment, Regions also agreed to amend the loan covenants for the related debt to be more favorable to us. Regions requires us to maintain certain ratios including a fixed charge coverage ratio and total liabilities to tangible net worth ratio. The fixed charge coverage ratio calculation currently requires a ratio of not less than 1.25 to 1.00. We are also required to maintain a ratio of our total liabilities to tangible net worth ratio of not greater than 2.10 to 1.00. If we fail to comply with these covenants, the loan agreement restricts our ability to purchase fixed assets.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> (b) On November 9, 2012, we executed a sixth amendment with Regions. On December 21, 2012, we executed an amended and restated sixth amendment with Regions. Regions agreed to extend the term loan and mortgage loan maturity dates to October 31, 2013. The unpaid principal on the notes was incorporated into a replacement note payable for $5,786 bearing interest at LIBOR plus 400 basis points (minimum of 6.0%) with monthly principal payments of approximately $47 plus interest. The replacement note payable is secured by real estate at our West Lafayette and Evansville, Indiana locations.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> At September 30, 2012, we were not in compliance with the fixed charge coverage and the total liabilities to tangible net worth ratios in the Regions agreements, mainly due to the net losses in the first nine months of fiscal 2012, restructuring charges incurred in current fiscal year and the treatment of our warrants as a liability instead of as equity. On November 6, 2012, Regions waived compliance with the fixed charge coverage ratio. On December 21, 2012, Regions waived compliance with the total liabilities to tangible net worth ratio. Based on projections for fiscal 2013, we expect to be in compliance with the fixed charge coverage covenants for fiscal 2013 and in breach of the total liabilities to tangible net worth ratio covenant for the first two fiscal quarters of 2013, primarily due to the treatment of our warrants as a liability. On September 10, 2013, Regions waived our expected breach. Failure to comply with those covenants in future quarters would be a default under the Regions loans, requiring us to negotiate with Regions regarding loan modifications or waivers. If we are unable to obtain such modifications or waivers, Regions could accelerate the maturity of the loans and cause a cross default with our other lender.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The Regions loans contain both cross-default provisions with each other and with the revolving line of credit with Entrepreneur Growth Capital described below.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The mortgages and replacement note payable with Regions mature in the first quarter of fiscal 2014. We intend to refinance the amounts in lieu of making balloon payments for the remaining principal balances or sell the building in West Lafayette, Indiana. On July 12, 2012, we listed for sale our 7.25 acres and 120,000 square foot facility at 2701 Kent Avenue, West Lafayette, Indiana with the intent to leaseback 80% of that square footage in which to continue our laboratory and manufacturing operations. The asking price was $12,500. We performed an impairment analysis on the building when we listed it for sale, but noted no impairment necessary. As of September 30, 2012 the net book value of the facility and land was $9,585.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> We may be unsuccessful in renegotiating the terms of the debt or those terms may be unfavorable to us. For these reasons, if we are unsuccessful at refinancing our long-term debt, our operating results and financial condition could be adversely affected.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <em>Revolving Line of Credit</em></p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> On January 13, 2010, we entered into a new $3,000 revolving line of credit agreement ("Credit Agreement") with EGC. The term of the Credit Agreement expires on January 31, 2014. If we terminate prior to the expiration of the term, then we are subject to an early termination fee equal to the minimum interest charges of $15 for each of the months remaining until expiration.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> Borrowings under the Credit Agreement bear interest at an annual rate equal to Citibank&#39;s Prime Rate plus five percent (5%), or 8.25% as of September 30, 2012, with minimum monthly interest of $15. Interest is paid monthly. The line of credit also carries an annual facilities fee of 2% and a 0.2% collateral monitoring fee. Borrowings under the Credit Agreement are secured by a blanket lien on our personal property, including certain eligible accounts receivable, inventory, and intellectual property assets, a second mortgage on our West Lafayette and Evansville real estate and all common stock of our U.S. subsidiaries and 65% of the common stock of our non-United States subsidiary. Borrowings are calculated based on 75% of eligible accounts receivable. Under the Credit Agreement, the Company has agreed to restrict advances to subsidiaries, limit additional indebtedness and capital expenditures and maintain a minimum tangible net worth of at least $8,500. Pursuant to the terms of the Credit Agreement, the line of credit will automatically renew on January 31, 2014 unless either party gives a 60-day notice of intent to terminate or withdraw.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;&nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> On December 21, 2012, we negotiated an amendment to this Credit Agreement. The amendment reduced the minimum tangible net worth covenant requirement from $8,500 to $8,000, effective on January 1, 2013, and waived all non-compliances with this covenant through December 31, 2012.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The Credit Agreement also contains cross-default provisions with the Regions loans and any future EGC loans. At September 30, 2012, we were not in compliance with the minimum tangible net worth covenant requirement. On December 21, 2012, EGC waived compliance with this covenant as part of the amendment. Based on projections for fiscal 2013, we expect to be in breach of the tangible net worth covenant for our first three quarters of fiscal 2013, but in compliance in our fourth fiscal quarter. EGC waived our projected breach for our first fiscal quarter of 2013 in the amendment to the Credit Agreement on December 21, 2012. EGC waived our expected breach for our second and third fiscal quarters of 2013 on October 9, 2013. At September 30, 2012, we had available borrowing capacity of $1,927 on this line, of which $1,444 was outstanding.</p> <!--EndFragment--></div> </div> 0.03 0.05 0.04 30-day LIBOR Citibanks' Prime Rate LIBOR 1341000 monthly monthly monthly monthly monthly monthly 0.0825 0.045 0.06 0.071 0.041 0.071 0.041 0.075 0.041 2013-10-31 2013-10-31 2013-10-31 2013-05-31 2011-01-31 2013-01-31 2012-05-01 2013-10-31 40000 17000 14000 10000 38000 14000 47000 -14000 1268000 755000 625000 709000 3104000 4992000 236000 202000 509000 635000 1836000 4237000 1585000 2483000 1326000 2334000 45000 42000 119000 119000 271000 255000 29000 14000 118000 252000 2345000 4872000 685000 296000 21000 116000 74000 562000 459000 15000 17000 0.22 0.3 2085000 2217000 2134000 2278000 1899000 2036000 235000 242000 1286000 1213000 1286000 1213000 0 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>10. STOCK-BASED COMPENSATION</strong>&nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <em>Summary of Stock Option Plans and Activity</em></p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> In March 2008, our shareholders approved the 2008 Stock Option Plan (the "Plan") to replace the 1997 Outside Director Stock Option Plan and the 1997 Employee Stock Option Plan. Future common shares will be granted from the 2008 Stock Option Plan. The purpose of the Plan is to promote our long-term interests by providing a means of attracting and retaining officers, directors and key employees. The Compensation Committee shall administer the Plan and approve the particular officers, directors or employees eligible for grants. Under the Plan, employees are granted the option to purchase our common shares at fair market value on the date of the grant. Generally, options granted vest and become exercisable in four equal installments commencing one year from date of grant and expire upon the earlier of the employee&#39;s termination of employment with us, or ten years from the date of grant. This plan terminates in fiscal 2018. The Compensation Committee may also issue non-qualified stock option grants with vesting periods different from the 2008 Plan.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The maximum number of common shares that may be granted under the Plan is 500 shares. At September 30, 2012, 339 shares remain available for grants under the Plan.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The weighted-average assumptions used to compute the fair value of options granted for the fiscal years ended September 30 were as follows:</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.25in"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 80%" cellspacing="0" cellpadding="0" align="center"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" nowrap="nowrap">2012</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" nowrap="nowrap">2011</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 72%">Risk-free interest rate</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: center; WIDTH: 12%" nowrap="nowrap">1.39%</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: center; WIDTH: 12%" nowrap="nowrap">3.08%</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">Dividend yield</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: center" nowrap="nowrap"> 0.00%</td> <td style="FONT-SIZE: 10pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: center" nowrap="nowrap"> 0.00%</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> Volatility of the expected market price of the Company&#39;s common stock</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif" nowrap="nowrap">93.00%- 97.00%</td> <td style="FONT-SIZE: 10pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: center" nowrap="nowrap"> 90.00%-91.00%</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">Expected life of the options (years)</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: center" nowrap="nowrap">7.0 - 8.0</td> <td style="FONT-SIZE: 10pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: center" nowrap="nowrap"> 8.0</td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> A summary of our stock option activity for all options and related information for the years ended September 30, 2012 and 2011, respectively, is as follows (in thousands except for share prices):</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 100%" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Options<br /> (shares)</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Weighted-<br /> Average<br /> Exercise Price</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Weighted-<br /> Average Grant<br /> Date Fair Value</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Weighted-Average<br /> Remaining<br /> Contractual Life<br /> (Years)</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Aggregate<br /> Intrinsic<br /> Value</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="2"> &nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="2"> &nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="2"> &nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="2"> &nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="2"> &nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; WIDTH: 30%">Outstanding - October 1, 2010</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%">705</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> 2.66</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-LEFT: 0.125in">Exercised</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">-</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">-</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-LEFT: 0.125in">Granted</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">27</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">2.24</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">1.84</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; PADDING-LEFT: 0.125in"> Terminated</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> (59</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> )</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: right"> 2.54</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: right"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: right"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: right"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">Outstanding - September 30, 2011</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 673</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: right"> 2.65</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: right"> 1.83</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: right"> 7.2</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: right"> 69</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt">Outstanding - October 1, 2011</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">673</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">2.65</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-LEFT: 0.125in">Exercised</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">-</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">-</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-LEFT: 0.125in">Granted</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">200</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">1.30</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">1.05</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; PADDING-LEFT: 0.125in"> Terminated</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> (519</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> )</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: right"> 2.58</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: right"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: right"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: right"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">Outstanding - September 30, 2012</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 354</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: right"> 1.99</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: right"> 1.46</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: right"> 8.0</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: right"> 42</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">Exercisable at September 30, 2012</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 94</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: right"> 3.83</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: right"> 2.59</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: right"> 5.3</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: right"> 7</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.5in"> A summary of non-vested options for the year ended September 30, 2012 is as follows:</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.5in"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 70%" cellspacing="0" cellpadding="0" align="center"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Number of<br /> Shares</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Weighted-<br /> Average Grant<br /> Date Fair Value</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt" colspan="2">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt" colspan="2">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; WIDTH: 72%">Non-vested options at October 1, 2011</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%">385</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> 1.14</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-LEFT: 0.125in">Granted</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">200</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">1.05</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-LEFT: 0.125in">Vested</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">(128</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">)</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">1.25</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; PADDING-LEFT: 0.125in"> Forfeited</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> (197</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> )</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: right"> 1.09</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">Non-vested options at September 30, 2012</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 260</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: right"> 1.06</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.5in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> No options were exercised in fiscal years 2012 and 2011. <font style="COLOR: black">As of September 30, 2012, our total unrecognized compensation cost related to non-vested stock options was $217 and is expected to be recognized over a weighted-average service period of 1.24&nbsp;years. As of September 30, 2012, there are 125 shares outstanding that were granted outside of the Plan.</font></p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The following table summarizes outstanding and exercisable options as of September&nbsp;30, 2012 (in thousands except per share amounts):</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 100%" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: left"> Range of Exercise Prices</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2">Shares<br /> Outstanding</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2">Weighted-<br /> Average<br /> Remaining<br /> Contractual<br /> Life (Years)</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2">Weighted-<br /> Average<br /> Exercise Price</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2">Shares<br /> Exercisable</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2">Weighted-<br /> Average<br /> Exercise Price</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold" colspan="2"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold" colspan="2"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold" colspan="2"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold" colspan="2"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold" colspan="2"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; WIDTH: 30%">$0.79 - 1.01</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%">128</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> 8.32</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> 0.97</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%">24</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> 1.01</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt">$1.02 - 4.59</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">155</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">9.40</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">1.38</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">7</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">1.35</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt">$4.60 - 8.79</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">71</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">4.24</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">5.19</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">62</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">5.21</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> </table> <!--EndFragment--></div> </div> 227977000 -991000 -991000 991080000 -0.74 -0.88 -0.66 -0.89 -0.08 0.01 -0.74 -0.88 -0.66 -0.89 -0.08 0.01 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>5. LOSS PER SHARE</strong></p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> We compute basic loss per share using the weighted average number of common shares outstanding. The net loss applicable to common shareholders for fiscal 2011 is the net of the net income for the year less the deemed dividend for the Series A preferred shares from the May 2011 registered direct offering described in Note 4 and less the dividends earned on the outstanding Series A preferred shares.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The Company has three categories of dilutive potential common shares: the Series A preferred shares issued in May 2011 in connection with the registered direct offering, the Warrants issued in connection with the same offering in May 2011, and shares issuable upon exercise of options. We compute diluted earnings per share using the if-converted method for preferred stock and the treasury stock method for stock options and warrants. Shares issuable upon exercise of options were not considered in computing diluted earnings per share for the fiscal years ended September 30, 2012 and 2011 because they were anti-dilutive. Warrants for 1,376,500 and 2,753,000 common shares and 936,000 and 2,753,000 common shares issuable upon conversion of preferred shares were not considered in computing diluted earnings per share for fiscal 2012 and 2011, respectively, because they were also anti-dilutive.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The following table reconciles our computation of basic net loss per share to diluted net loss per share:</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 80%" cellspacing="0" cellpadding="0" align="center"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="6" nowrap="nowrap">Years Ended<br /> September 30,</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">2012</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">2011</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">(<font style="FONT: 10pt Times New Roman, Times, Serif">Restated<em>)</em></font></td> <td style="FONT-SIZE: 10pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">(<font style="FONT: 10pt Times New Roman, Times, Serif">Restated<em>)</em></font></td> <td style="FONT-SIZE: 10pt" nowrap="nowrap">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; FONT-STYLE: italic; TEXT-ALIGN: justify"> Basic net loss per share:</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0.125in; WIDTH: 72%"> Net income (loss)</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> (6,317</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">)</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> 2,302</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0.125in"> Less:&nbsp; Deemed dividend for Series A Preferred Shares</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">-</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">(5,506</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">)</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; PADDING-LEFT: 0.125in"> Less:&nbsp; Preferred dividend</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> -</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> (991</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> )</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0.25in">Net loss applicable to common shareholders</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">(6,317</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">)</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">(4,195</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">)</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; PADDING-LEFT: 0.125in"> Weighted average common shares outstanding</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 7,158</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 5,667</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 0.125in"> Basic net loss per share</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> (0.88</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> )</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> (0.74</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> )</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; FONT-STYLE: italic">Diluted net loss per share:</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0.125in"> Net loss applicable to common shareholders</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">(6,317</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">)</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">(4,195</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">)</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; PADDING-LEFT: 0.125in"> Weighted average common shares outstanding</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 7,158</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 5,667</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 0.125in"> Diluted net loss per share</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> (0.88</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> )</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> (0.74</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> )</td> </tr> </table> <!--EndFragment--></div> </div> 0.021 -0.001 0.34 0.34 -0.354 -0.335 0.029 -0.005 0.002 0.004 -0.001 -33000 -18000 P1Y2M27D 217000 0.145 0.073 0.052 0.034 1000 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The assumptions used to compute the fair value of the warrants at September 30, 2012 and 2011 were as follows:</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 80%" cellspacing="0" cellpadding="0" align="center"> <tr style="VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">September 30, 2012</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="6" nowrap="nowrap">September 30, 2011</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td nowrap="nowrap">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Warrant A</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Warrant A</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Warrant B</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: center" colspan="2">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: center" colspan="2">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: center" colspan="2">&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="TEXT-ALIGN: left; WIDTH: 46%">Risk-free interest rate</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: right; WIDTH: 15%">0.41</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">%</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: right; WIDTH: 15%">0.86</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">%</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: right; WIDTH: 15%">0.08</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">%</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="TEXT-ALIGN: left">Dividend yield</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">0.00</td> <td style="TEXT-ALIGN: left">%</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">0.00</td> <td style="TEXT-ALIGN: left">%</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">0.00</td> <td style="TEXT-ALIGN: left">%</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="TEXT-ALIGN: left">Volatility of the Company&#39;s common stock</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">117.30</td> <td style="TEXT-ALIGN: left">%</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">111.44</td> <td style="TEXT-ALIGN: left">%</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">74.43</td> <td style="TEXT-ALIGN: left">%</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="TEXT-ALIGN: left">Expected life of the options (years)</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">3.6</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">4.6</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">0.6</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td>Fair value per unit</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">0.881</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">0.844</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">0.091</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> </table> <!--EndFragment--></div> </div> 1.433 0.779 0 0 0 0 0 P5Y P1Y P4Y7M6D P3Y7M6D P7M6D 1.0691 1.1601 1.1144 1.173 0.7443 0.0187 0.0018 0.0086 0.0041 0.0008 0.14 0.05 0 0 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 0.25in; TEXT-INDENT: 0px"> &nbsp;</td> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 0.5in; TEXT-INDENT: 0px"> <em>(l)</em></td> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> <em>Fair Value</em> </td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The provisions of the Fair Value Measurements and Disclosure Topic defines fair value, establishes a consistent framework for measuring fair value and provides the disclosure requirements about fair value measurements. This Topic also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#39;s judgment about the assumptions market participants would use in pricing the asset or liability based on the best information available in the circumstances. The hierarchy is broken down into three levels based on the inputs as follows:</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 100%" cellspacing="0" cellpadding="0"> <tr> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 5%; TEXT-INDENT: 0px"> &nbsp;</td> <td style="VERTICAL-ALIGN: top; PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 2%; TEXT-INDENT: 0px"> &bull;</td> <td style="VERTICAL-ALIGN: top; PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 1%; TEXT-INDENT: 0px"> &nbsp;</td> <td style="VERTICAL-ALIGN: top; PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> Level 1 - Valuations based on quoted prices for identical assets or liabilities in active markets that the Company has the ability to access.</td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 100%" cellspacing="0" cellpadding="0"> <tr> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 5%; TEXT-INDENT: 0px"> &nbsp;</td> <td style="VERTICAL-ALIGN: top; PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 2%; TEXT-INDENT: 0px"> &bull;</td> <td style="VERTICAL-ALIGN: top; PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 1%; TEXT-INDENT: 0px"> &nbsp;</td> <td style="VERTICAL-ALIGN: top; PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> Level 2 - Valuations based on quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.</td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 100%" cellspacing="0" cellpadding="0"> <tr> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 5%; TEXT-INDENT: 0px"> &nbsp;</td> <td style="VERTICAL-ALIGN: top; PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 2%; TEXT-INDENT: 0px"> &bull;</td> <td style="VERTICAL-ALIGN: top; PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 1%; TEXT-INDENT: 0px"> &nbsp;</td> <td style="VERTICAL-ALIGN: top; PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> Level 3 - Valuations based on inputs that are unobservable and significant to the overall fair value measurement.</td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> We have Class A and B Warrants from the May 2011 offering that are measured at fair value on a recurring basis. We recorded these warrants as a liability determining the fair value at inception on May 11, 2011. Subsequent quarterly fair value measurements, using the Black Scholes model which is considered a level 2 measurement, are calculated with fair value changes charged to the statement of operations and comprehensive income (loss). Class B Warrants expired in May 2012 and the liability was reduced to zero. The assumptions used to compute the fair value of the warrants at September 30, 2012 and 2011 were as follows:</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 80%" cellspacing="0" cellpadding="0" align="center"> <tr style="VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">September 30, 2012</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="6" nowrap="nowrap">September 30, 2011</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td nowrap="nowrap">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Warrant A</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Warrant A</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Warrant B</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: center" colspan="2">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: center" colspan="2">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: center" colspan="2">&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="TEXT-ALIGN: left; WIDTH: 46%">Risk-free interest rate</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: right; WIDTH: 15%">0.41</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">%</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: right; WIDTH: 15%">0.86</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">%</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: right; WIDTH: 15%">0.08</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">%</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="TEXT-ALIGN: left">Dividend yield</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">0.00</td> <td style="TEXT-ALIGN: left">%</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">0.00</td> <td style="TEXT-ALIGN: left">%</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">0.00</td> <td style="TEXT-ALIGN: left">%</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="TEXT-ALIGN: left">Volatility of the Company&#39;s common stock</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">117.30</td> <td style="TEXT-ALIGN: left">%</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">111.44</td> <td style="TEXT-ALIGN: left">%</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">74.43</td> <td style="TEXT-ALIGN: left">%</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="TEXT-ALIGN: left">Expected life of the options (years)</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">3.6</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">4.6</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">0.6</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td>Fair value per unit</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">0.881</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">0.844</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">0.091</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The carrying amounts for cash and cash equivalents, accounts receivable, inventories, prepaid expenses and other assets, accounts payable and other accruals approximate their fair values because of their nature and respective duration. The fair value of the revolving credit facility and certain long-term debt is equal to their carrying values due to the variable nature of their interest rates. Our long-term fixed rate debt was initiated in February 2011 and renewed on November 1, 2012. Our interest rate swap expired under its terms in fiscal 2011.</p> <!--EndFragment--></div> </div> 248000 302000 302000 302000 P10Y P10Y <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 0.25in; TEXT-INDENT: 0px"> &nbsp;</td> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 0.5in; TEXT-INDENT: 0px"> <em>(p)</em></td> <td style="PADDING-BOTTOM: 0px; TEXT-ALIGN: justify; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> <em>Foreign Currency</em></td> </tr> </table> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.25in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> For our subsidiary outside of the United States that operates in a local currency environment, income and expense items are translated to United States dollars at the monthly average rates of exchange prevailing during the year, assets and liabilities are translated at year-end exchange rates and equity accounts are translated at historical exchange rates. Translation adjustments are accumulated in a separate component of shareholders&#39; equity in the consolidated balance sheets and are included in the determination of comprehensive income (loss) in the consolidated statements of shareholders&#39; equity. Transaction gains and losses are included in the determination of net income (loss) in the consolidated statements of operations and comprehensive income (loss).</p> <!--EndFragment--></div> </div> 949000 701000 322000 9000 -451000 5564000 5524000 1383000 1383000 1009000 1009000 374000 374000 10506000 6838000 10506000 6838000 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 0.25in; TEXT-INDENT: 0px"> &nbsp;</td> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 0.5in; TEXT-INDENT: 0px"> <em>(g)</em></td> <td style="PADDING-BOTTOM: 0px; TEXT-ALIGN: justify; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> <em>Long-Lived Assets including Goodwill</em></td> </tr> </table> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> Long-lived assets, such as property and equipment, and purchased intangibles subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized of the amount by which the carrying amount of the asset exceeds the fair value of the asset.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> We carry goodwill at cost. Other intangible assets with definite lives are stated at cost and are amortized on a straight-line basis over their estimated useful lives. All intangible assets acquired that are obtained through contractual or legal right, or are capable of being separately sold, transferred, licensed, rented, or exchanged, are recognized as an asset apart from goodwill. Goodwill is not amortized<font style="COLOR: red">.</font></p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> Goodwill is tested annually for impairment, and more frequently if events and circumstances indicate that the asset might be impaired. First, we can assess qualitative factors in determining whether&nbsp;it is more likely than not that the fair value of a reporting unit is less than its carrying amount.&nbsp;We elected to bypass the qualitative assessment aspect of this guidance due to the restructuring circumstances. Then, we followed a two-step quantitative process. In the first step, we compare the fair value of each reporting unit, as computed primarily by present value cash flow calculations, to its book carrying value, including goodwill. We do not believe that market value is indicative of the true fair value of the Company mainly due to average daily trading volumes of less than 1%. If the fair value exceeds the carrying value, no further work is required and no impairment loss is recognized. If the carrying value exceeds the fair value, the goodwill of the reporting unit is potentially impaired and we would then complete step 2 in order to measure the impairment loss. In step 2, the implied fair value is compared to the carrying amount of the goodwill. If the implied fair value of goodwill is less than the carrying value of goodwill, we would recognize an impairment loss equal to the difference. The implied fair value is calculated by allocating the fair value of the reporting unit (as determined in step 1) to all of its assets and liabilities (including unrecognized intangible assets) and any excess in fair value that is not assigned to the assets and liabilities is the implied fair value of goodwill.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The discount rate, gross margin and sales growth rates are material assumptions utilized in our calculations of the present value cash flows used to estimate the fair value of the reporting units when performing the annual goodwill impairment test. Our reporting units with goodwill at September 30, 2012 are Vetronics, which is included in our Products segment, bioanalytical services and preclinical services, which are both included in our Services segment, based on the discrete financial information available which is reviewed by management. We utilize a cash flow approach in estimating the fair value of the reporting units, where the discount rate reflects a weighted average cost of capital rate. The cash flow model used to derive fair value is sensitive to the discount rate and sales growth assumptions used.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> Due to the closure of the McMinnville, Oregon site, we tested for impairment of the bioanalytical business at the end of our third fiscal quarter using the cash flow approach as explained above. This test resulted in no impairment to the goodwill valuation as currently recorded on the books.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> We also performed our annual impairment test for all reporting units mentioned above at September 30, 2012. Using a discount rate of 14% and a revenue growth rate of 5% for the Bioanalytical services and 0% for both the preclinical services and Vetronics units, the fair values of the reporting units described above are greater than the carrying values by approximately $3.7 million.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> Considerable management judgment is necessary to evaluate the impact of operating and macroeconomic changes and to estimate future cash flows. Assumptions used in our impairment evaluations, such as forecasted sales growth rates and our cost of capital or discount rate, are based on the best available market information. Changes in these estimates or a continued decline in general economic conditions could change our conclusion regarding an impairment of goodwill and potentially result in a non-cash impairment loss in a future period. The assumptions used in our impairment testing could be adversely affected by certain risks. There have been no significant events since the timing of our impairment tests that would have triggered additional impairment testing.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> At September 30, 2012 and 2011, remaining recorded goodwill was $1,383, and the net balance of other intangible assets was $0 and $54, respectively. The components of intangible assets subject to amortization are as follows:</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 90%" cellspacing="0" cellpadding="0" align="center"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="6" nowrap="nowrap">September 30, 2012</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Weighted<br /> average life<br /> (years)</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Gross Carrying<br /> Amount</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Accumulated<br /> Amortization</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 58%; TEXT-INDENT: 0px"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> FDA compliant facility</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 10</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 302</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 302</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 90%" cellspacing="0" cellpadding="0" align="center"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right" colspan="2" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="6" nowrap="nowrap">September 30, 2011</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Weighted<br /> average life<br /> (years)</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Gross Carrying<br /> Amount</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Accumulated<br /> Amortization</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 58%; TEXT-INDENT: 0px"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> FDA compliant facility</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 10</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 302</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 248</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> Amortization expense for intangible assets for fiscal years ended September&nbsp;30, 2012 and 2011 was $54 and $30, respectively. As of September 30, 2012, all intangible assets have been fully amortized.</p> <!--EndFragment--></div> </div> -745000 -3636000 2352000 -6315000 593000 -6388000 1759000 73000 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>9. INCOME TAXES</strong></p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> Significant components of our deferred tax assets and liabilities as of September&nbsp;30 are as follows:</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 90%" cellspacing="0" cellpadding="0" align="center"> <tr style="VERTICAL-ALIGN: bottom"> <td nowrap="nowrap">&nbsp;</td> <td style="FONT-WEIGHT: bold; COLOR: black; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; COLOR: black; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">2012</td> <td style="FONT-WEIGHT: bold; COLOR: black; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-WEIGHT: bold; COLOR: black; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; COLOR: black; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">2011</td> <td style="FONT-WEIGHT: bold; COLOR: black; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td nowrap="nowrap">&nbsp;</td> <td style="COLOR: black" nowrap="nowrap">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">(Restated)</td> <td style="COLOR: black" nowrap="nowrap">&nbsp;</td> <td style="COLOR: black" nowrap="nowrap">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">(Restated)</td> <td style="COLOR: black" nowrap="nowrap">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="COLOR: black; TEXT-ALIGN: left">Deferred tax assets - Current:</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 36px; WIDTH: 72%"> Inventory</td> <td style="COLOR: black; WIDTH: 2%">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="COLOR: black; TEXT-ALIGN: right; WIDTH: 10%">202</td> <td style="COLOR: black; TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="COLOR: black; WIDTH: 2%">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="COLOR: black; TEXT-ALIGN: right; WIDTH: 10%">236</td> <td style="COLOR: black; TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 36px"> Accrued compensation and vacation</td> <td style="COLOR: black">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: left">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: right">255</td> <td style="COLOR: black; TEXT-ALIGN: left">&nbsp;</td> <td style="COLOR: black">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: left">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: right">271</td> <td style="COLOR: black; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 36px"> Accrued expenses and other</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; COLOR: black; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; COLOR: black; TEXT-ALIGN: right"> 252</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; COLOR: black; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; COLOR: black; TEXT-ALIGN: right"> 118</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="COLOR: black; TEXT-ALIGN: left">Total current deferred tax assets</td> <td style="COLOR: black">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: left">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: right">709</td> <td style="COLOR: black; TEXT-ALIGN: left">&nbsp;</td> <td style="COLOR: black">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: left">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: right">625</td> <td style="COLOR: black; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="TEXT-INDENT: 0.5in">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="COLOR: black; TEXT-ALIGN: left">Deferred tax liabilities - Current:</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 36px"> Prepaid expenses</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; COLOR: black; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; COLOR: black; TEXT-ALIGN: right"> (74</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> )</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; COLOR: black; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; COLOR: black; TEXT-ALIGN: right"> (116</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> )</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-WEIGHT: bold; COLOR: black; TEXT-ALIGN: left">Total net current deferred tax assets</td> <td style="FONT-WEIGHT: bold; COLOR: black">&nbsp;</td> <td style="FONT-WEIGHT: bold; COLOR: black; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-WEIGHT: bold; COLOR: black; TEXT-ALIGN: right"> 635</td> <td style="FONT-WEIGHT: bold; COLOR: black; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-WEIGHT: bold; COLOR: black">&nbsp;</td> <td style="FONT-WEIGHT: bold; COLOR: black; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-WEIGHT: bold; COLOR: black; TEXT-ALIGN: right"> 509</td> <td style="FONT-WEIGHT: bold; COLOR: black; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="COLOR: black; TEXT-ALIGN: left">Deferred tax assets - Noncurrent:</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 36px"> Domestic net operating loss carryforwards</td> <td style="COLOR: black">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: left">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: right">2,483</td> <td style="COLOR: black; TEXT-ALIGN: left">&nbsp;</td> <td style="COLOR: black">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: left">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: right">1,585</td> <td style="COLOR: black; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 36px"> Stock compensation expense</td> <td style="COLOR: black">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: left">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: right">14</td> <td style="COLOR: black; TEXT-ALIGN: left">&nbsp;</td> <td style="COLOR: black">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: left">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: right">29</td> <td style="COLOR: black; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 36px"> Foreign net operating loss</td> <td style="COLOR: black">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: left">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: right">2,334</td> <td style="COLOR: black; TEXT-ALIGN: left">&nbsp;</td> <td style="COLOR: black">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: left">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: right">1,326</td> <td style="COLOR: black; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 36px"> Foreign tax credit carryover</td> <td style="COLOR: black">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: left">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: right">119</td> <td style="COLOR: black; TEXT-ALIGN: left">&nbsp;</td> <td style="COLOR: black">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: left">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: right">119</td> <td style="COLOR: black; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 36px"> AMT credit carryover</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; COLOR: black; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; COLOR: black; TEXT-ALIGN: right"> 42</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; COLOR: black; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; COLOR: black; TEXT-ALIGN: right"> 45</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="COLOR: black; TEXT-ALIGN: left">Total noncurrent deferred tax assets</td> <td style="COLOR: black">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: left">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: right">4,992</td> <td style="COLOR: black; TEXT-ALIGN: left">&nbsp;</td> <td style="COLOR: black">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: left">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: right">3,104</td> <td style="COLOR: black; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="COLOR: black; TEXT-ALIGN: left">Deferred tax liabilities - Noncurrent:</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 36px"> Unrealized gain/loss - warrant liability</td> <td style="COLOR: black">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: left">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: right">(296</td> <td style="COLOR: black; TEXT-ALIGN: left">)</td> <td style="COLOR: black">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: left">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: right">(685</td> <td style="COLOR: black; TEXT-ALIGN: left">)</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 36px"> Basis difference for fixed assets</td> <td style="COLOR: black">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: left">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: right">(459</td> <td style="COLOR: black; TEXT-ALIGN: left">)</td> <td style="COLOR: black">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: left">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: right">(562</td> <td style="COLOR: black; TEXT-ALIGN: left">)</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 36px"> Basis difference for intangibles</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; COLOR: black; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; COLOR: black; TEXT-ALIGN: right"> -</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; COLOR: black; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; COLOR: black; TEXT-ALIGN: right"> (21</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> )</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td>&nbsp;</td> <td style="COLOR: black">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: left">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: right">(755</td> <td style="COLOR: black; TEXT-ALIGN: left">)</td> <td style="COLOR: black">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: left">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: right">(1,268</td> <td style="COLOR: black; TEXT-ALIGN: left">)</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-WEIGHT: bold; COLOR: black; TEXT-ALIGN: left">Total net noncurrent deferred tax assets</td> <td style="FONT-WEIGHT: bold; COLOR: black">&nbsp;</td> <td style="FONT-WEIGHT: bold; COLOR: black; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-WEIGHT: bold; COLOR: black; TEXT-ALIGN: right"> 4,237</td> <td style="FONT-WEIGHT: bold; COLOR: black; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-WEIGHT: bold; COLOR: black">&nbsp;</td> <td style="FONT-WEIGHT: bold; COLOR: black; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-WEIGHT: bold; COLOR: black; TEXT-ALIGN: right"> 1,836</td> <td style="FONT-WEIGHT: bold; COLOR: black; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="COLOR: black; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> Valuation allowance for net deferred tax assets</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; COLOR: black; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; COLOR: black; TEXT-ALIGN: right"> (4,872</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> )</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; COLOR: black; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; COLOR: black; TEXT-ALIGN: right"> (2,345</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> )</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-WEIGHT: bold; COLOR: black; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> Net deferred tax&nbsp;&nbsp;asset (liability)</td> <td style="COLOR: black; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; COLOR: black; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; COLOR: black; TEXT-ALIGN: right"> -</td> <td style="COLOR: black; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="COLOR: black; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; COLOR: black; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; COLOR: black; TEXT-ALIGN: right"> -</td> <td style="COLOR: black; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> Significant components of the provision (benefit) for income taxes are as follows as of the year ended September 30:</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 80%" cellspacing="0" cellpadding="0" align="center"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2">2012</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2">2011</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"> Current:</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 36px; WIDTH: 72%"> Federal</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%">(3</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">)</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%">37</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 36px"> State and local</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">5</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">13</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 36px"> Foreign</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">-</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">-</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 9px"> &nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"> Deferred:</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 36px"> Federal</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">-</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">-</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 36px"> State and local</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">-</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">-</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; PADDING-LEFT: 36px"> Foreign</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> -</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> -</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"> Income tax expense</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 2</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 50</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The effective income tax rate on continuing operations varied from the statutory federal income tax rate as follows:</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 80%" cellspacing="0" cellpadding="0" align="center"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2">2012</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2">2011</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold" colspan="2"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold" colspan="2"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 72%; TEXT-INDENT: 0px"> Statutory federal income tax rate</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> 34.0</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">%</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> 34.0</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">%</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> Increases (decreases):</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-TOP: 0px; PADDING-LEFT: 0.125in; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> State and local income taxes, net of Federal tax benefit, if applicable</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">(0.1</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">)</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">0.4</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-TOP: 0px; PADDING-LEFT: 0.125in; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> Nondeductible expenses</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">(0.5</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">)</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">2.9</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-TOP: 0px; PADDING-LEFT: 0.125in; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> Valuation allowance changes</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">(33.5</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">)</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">(35.4</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">)</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; PADDING-TOP: 0px; PADDING-LEFT: 0.125in; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> Other</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> ---</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 0.2</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> &nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> Effective income tax rate</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> (0.1</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> )%</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 2.1</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> %</td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> In fiscal 2012 and 2011, our foreign operations generated losses before income taxes of $3,636 and $745, respectively. We have foreign net operating loss carryforwards of $8,854 that have an indefinite life under current UK tax law. We have a valuation allowance for the deferred tax asset related to the foreign net operating losses.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> Realization of deferred tax assets associated with the net operating loss carryforward and credit carryforward is dependent upon generating sufficient taxable income prior to their expiration. The valuation allowance in fiscal 2012 and 2011 was $2,538 and $1,021, respectively for our domestic operations. Payments made in fiscal 2012 and 2011 for income taxes amounted to $12 and $8, respectively.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> At September 30, 2012, we had domestic net operating loss carryforwards of approximately $4,935 for federal and $9,469 for state, which expire from September 30, 2014 through 2029. Also, we have a foreign tax credit carryforward of approximately $119, which expires September 30, 2016. Further, we have an alternative minimum tax credit carryforward of approximately $42 available to offset future federal income taxes. This credit has an unlimited carryforward period.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> We may recognize the tax benefit from an uncertain tax position only if it is more likely than not to be sustained upon regulatory examination based on the technical merits of the position. The amount of the benefit for which an exposure exists is measured as the largest amount of benefit determined on a cumulative probability basis that we believe is more likely than not to be realized upon ultimate settlement of the position. At September 30, 2012, a $16 liability remained for other uncertain income tax positions.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.25in"> A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <p style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.75in; MARGIN-TOP: 0pt"> Change in unrecognized tax benefits:</p> <p style="MARGIN: 0px">&nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.75in; WIDTH: 80%" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">2012</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">2011</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 72%">Balance at beginning of the year</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%">16</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%">30</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">Additions based on tax positions related to the current year</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">-</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">-</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">Additions for tax positions of prior years</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">-</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">-</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">Reductions for tax positions of prior years</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">-</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">(14</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">)</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">Settlements</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> -</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> -</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> Balance at end of the year</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 16</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 16</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> As noted in the table above, there has been no change in our gross uncertain tax positions during fiscal 2012 based on a state tax position. For fiscal 2011, we had a reduction of $14 in our gross uncertain tax positions during fiscal 2011 based on correspondence with a state taxing authority.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> We are no longer subject to U.S. federal tax examinations for years before 2008 or state and local for years before 2007, with limited exceptions. For federal purposes, the tax attributes carried forward could be adjusted through the examination process and are subject to examination 3 years from the date of utilization. Furthermore, we are no longer subject to income tax examinations in the United Kingdom for years prior to 2007.</p> <!--EndFragment--></div> </div> 8000 12000 50000 2000 50000 2000 50000 2000 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 0.25in; TEXT-INDENT: 0px"> &nbsp;</td> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 0.5in; TEXT-INDENT: 0px"> <em>(j)</em></td> <td style="PADDING-BOTTOM: 0px; TEXT-ALIGN: justify; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> <em>Income Taxes</em></td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. We record valuation allowances based on a determination of the expected realization of tax assets.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> We may recognize the tax benefit from an uncertain tax position only if it is more likely than not to be sustained upon examination based on the technical merits of the position. The amount of the accrual for which an exposure exists is measured as the largest amount of benefit determined on a cumulative probability basis that we believe is more likely than not to be realized upon settlement of the position.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> We record interest and penalties accrued in relation to uncertain income tax positions as a component of income tax expense. Any changes in the liability for uncertain tax positions would impact our effective tax rate. We do not expect the total amount of unrecognized tax benefits to significantly change in the next twelve months.</p> <!--EndFragment--></div> </div> -482000 2375000 236000 -917000 -86000 305000 -1010000 -559000 -56000 39000 -37000 20000 -17000 -414000 54000 54000 706000 714000 706000 714000 647000 715000 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>6. INVENTORIES</strong></p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> Inventories at September&nbsp;30 consisted of the following:</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 70%" cellspacing="0" cellpadding="0" align="center"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: center" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">2012</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">2011</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 72%">Raw materials</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> 1,407</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> 1,352</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">Work in progress</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">283</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">379</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> Finished goods</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 276</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 309</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">1,966</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">2,040</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> Obsolescence reserve</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> (310</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> )</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> (404</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> )</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 1,656</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 1,636</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> </table> <!--EndFragment--></div> </div> 309000 276000 2040000 1966000 1636000 1656000 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 0.25in; TEXT-INDENT: 0px"> &nbsp;</td> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 0.5in; TEXT-INDENT: 0px"> <em>(e)</em></td> <td style="PADDING-BOTTOM: 0px; TEXT-ALIGN: justify; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> <em>Inventories</em></td> </tr> </table> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> Inventories are stated at the lower of cost or market using the first-in, first-out (FIFO) cost method of accounting. We evaluate inventories on a regular basis to identify inventory on hand that may be obsolete or in excess of current and future projected market demand. For inventory deemed to be obsolete, we provide a reserve for this inventory. Inventory that is in excess of current and projected use is reduced by an allowance to a level that approximates the estimate of future demand.</p> <!--EndFragment--></div> </div> 1352000 1407000 404000 310000 379000 283000 527000 914000 2023-12-31 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>7. LEASE ARRANGEMENTS</strong></p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The total amount of equipment capitalized under capital lease obligations as of September 30, 2012 and 2011 was $5,778 and $6,222, respectively. Accumulated amortization on capital leases at September 30, 2012 and 2011 was $4,775 and $4,086, respectively. Amortization of assets acquired through capital leases is included in depreciation expense.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> During fiscal 2012, we added $356 in computer equipment through new capital lease arrangements. In fiscal 2011, we added $1,888 in equipment to our U.S. and U.K. bioanalytical laboratories through new capital lease arrangements. Due to restructuring activities outlined in Note 14, we terminated a capital lease for laboratory equipment in the UK. The activity resulted in a liability reduction of $322. Future minimum lease payments on capital leases at September 30, 2012 for the next five years are as follows:</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 70%" cellspacing="0" cellpadding="0" align="center"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Principal</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Interest</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Total</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center" nowrap="nowrap">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> &nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt" colspan="2">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt" colspan="2">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt" colspan="2">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 58%; TEXT-INDENT: 0px"> 2013</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%">330</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%">58</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%">388</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> 2014</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">268</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">39</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">307</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> 2015</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">259</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">22</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">281</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> 2016</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">208</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">6</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">214</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> 2017</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">4</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">-</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">4</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 1,069</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 125</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 1,194</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> </table> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> We lease office space and equipment under noncancelable operating leases that terminate at various dates through 2016. The UK building lease expires in 2023 but includes an opt out provision after 7 years, or in fiscal 2015. Certain of these leases contain renewal options. Total rental expense under these leases was $1,284 and $441 in fiscal 2012 and 2011, respectively. The increase in fiscal 2012 is due to the accrual in restructuring for the UK building lease through the opt out date.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> Future minimum lease payments for the following fiscal years under operating leases at September 30, 2012 are as follows:</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 50%" cellspacing="0" cellpadding="0" align="center"> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 84%">2013</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 12%">371</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">2014</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">370</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">2015</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">223</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> 2016</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 13</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 977</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> </table> <!--EndFragment--></div> </div> 16760000 17385000 1286000 1213000 18046000 18598000 32346000 26975000 32346000 26975000 11133000 12600000 9847000 11387000 1286000 1213000 1444000 Borrowings under the Credit Agreement are secured by a blanket lien on our personal property, including certain eligible accounts receivable, inventory, and intellectual property assets, and a second mortgage on our West Lafayette and Evansville real estate and all common stock of our U.S. subsidiaries and 65% of the common stock of our non-United States subsidiary. 0.02 1927000 annually monthly 3000000 15000 1346000 1444000 3573000 3236000 1674000 1532000 1245000 1074000 6577000 5842000 5800000 4768000 85000 5786000 1300000 735000 583000 583000 5842000 5259000 250000 22361000 19496000 8500000 8000000 1660000 -1164000 -1174000 -860000 1088000 -200000 2302000 -6317000 2302000 -6317000 543000 -6390000 1759000 73000 -4195000 -6317000 -4195000 -6317000 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 0.25in; TEXT-INDENT: 0px"> &nbsp;</td> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 0.5in; TEXT-INDENT: 0px"> <em>(k)</em></td> <td style="PADDING-BOTTOM: 0px; TEXT-ALIGN: justify; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> <em>New Accounting Pronouncements</em></td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> In May 2011, the FASB issued updated fair value&nbsp;measurement and disclosure&nbsp;guidance that clarifies how&nbsp;to measure fair value&nbsp;and requires additional disclosures regarding Level 3 fair value measurements, as well as any transfers between Level 1 and Level 2 fair value measurements. The updated accounting guidance is effective for fiscal years and interim periods beginning on or after December&nbsp;15, 2011 on a prospective basis. The Company adopted this guidance in the second fiscal quarter with no material impact on&nbsp;the consolidated financial statements.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> In June 2011, the FASB amended the manner in which an entity presents the total of comprehensive income, the components of net income and the components of other comprehensive income either in a single, continuous statement of comprehensive income or in two separate but consecutive statements.&nbsp;The amendment&nbsp;eliminates the option to present the components of other comprehensive income as part of the statement of equity. The amendment&nbsp;is effective for fiscal years and interim periods beginning on or after December&nbsp;15, 2011 on a retrospective basis.&nbsp;The adoption of this guidance&nbsp;will not change the previously reported amounts of comprehensive income. The Company has presented other comprehensive income on the face of the condensed consolidated statements of operations for all periods presented.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> In September 2011, the FASB issued an&nbsp;accounting&nbsp;standards&nbsp;update&nbsp;that amends the two-step goodwill impairment test&nbsp;by permitting an entity to first assess qualitative factors in determining whether&nbsp;it is more likely than not that the fair value of a reporting unit is less than its carrying amount.&nbsp;If the entity determines that it is not more likely than not that the fair value of a reporting unit is less than its carrying amount, then performing the two-step goodwill impairment test&nbsp;is unnecessary. The amendment&nbsp;is effective for fiscal years and interim periods beginning on or after December&nbsp;15, 2011 on a&nbsp;prospective basis, early adoption is permitted. The Company elected to bypass the qualitative assessment aspect of this guidance due to the restructuring circumstances and performed a quantitative analysis in the third and fourth fiscal quarters of 2012. The quantitative analysis resulted in no impairment to the goodwill valuation as currently recorded on the books.</p> <!--EndFragment--></div> </div> 20872000 20083000 1101000 21973000 20083000 -694000 -702000 9219000 9329000 9219000 9329000 1287000 -2943000 -5686000 452000 745000 -3863000 542000 12000 -1835000 1287000 -5686000 977000 371000 13000 223000 370000 441000 1284000 8854000 4935000 9469000 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div> <p style="TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <!--StartFragment-->September 30, 2014 through 2029 <!--EndFragment--></p> </div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div> <p style="TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <!--StartFragment-->September 30, 2014 through 2029 <!--EndFragment--></p> </div> </div> 1021000 2538000 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>1. DESCRIPTION OF THE BUSINESS</strong></p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>&nbsp;</strong></p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> Bioanalytical Systems, Inc. and its subsidiaries (the "Company" or "BASi" or "we") engage in research services and other services related to pharmaceutical development. We also manufacture scientific instruments for medical research, which we sell with related software for use in industrial, governmental and academic laboratories. We conduct our businesses through our research and manufacturing facilities in Indiana. Our customers are located throughout the world.</p> <!--EndFragment--></div> </div> 62000 54000 -49000 -22000 -49000 -22000 -49000 -22000 9847000 11387000 9847000 11387000 6913000 5998000 6913000 5998000 12000 12000 12000 12000 1174000 1090000 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>11. RETIREMENT PLAN</strong></p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>&nbsp;</strong></p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> We have a&nbsp;401(k) Retirement Plan (the "Plan") covering all employees over twenty-one years of age with at least one year of service. Under the terms of the Plan, we contribute 1% of each participant&#39;s total wages to the Plan and match 22% of the first 10% of the employee contribution. The Plan also includes provisions for various contributions which may be instituted at the discretion of the Board of Directors. The contribution made by the participant may not exceed 30% of the participant&#39;s annual wages. We made no discretionary contributions under the plan in 2012 and 2011. Similar to fiscal 2011, we suspended our match of the employee contribution as part of our cost reduction efforts. Contribution expense was $17 and $15 in fiscal 2012 and 2011, respectively. The amounts recorded in fiscal 2012 and 2011 relate to statutory contributions for our European location.</p> <!--EndFragment--></div> </div> 0.06 991000 1000 1000 1000000 1000000 2135 1335 2753000 2135 1335 2135000 1335000 2135000 1335000 2135000 1335000 585000 228000 31068000 27793000 4600000 4606000 230000 45763000 42424000 20399000 18628000 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 0.25in; TEXT-INDENT: 0px"> &nbsp;</td> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 0.5in; TEXT-INDENT: 0px"> <em>(f)</em></td> <td style="PADDING-BOTTOM: 0px; TEXT-ALIGN: justify; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> <em>Property and Equipment</em></td> </tr> </table> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> We record property and equipment at cost, including interest capitalized during the period of construction of major facilities. We compute depreciation, including amortization on capital leases, using the straight-line method over the estimated useful lives of the assets, which we estimate to be: buildings and improvements, 34 to 40 years; machinery and equipment, 5 to 10 years, and office furniture and fixtures, 10 years. In our European operations, we depreciate leasehold improvements, using the straight-line method, over 7 years, corresponding to the terms of the operating lease for the European facility. Depreciation expense was $2,217 in fiscal 2012 and $2,085 in fiscal 2011. Expenditures for maintenance and repairs are expensed as incurred.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> Property and equipment, net, as of September 30, 2012 and 2011 consisted of the following:</p> <p style="TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 80%" cellspacing="0" cellpadding="0" align="center"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2">2012</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2">2011</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="2"> &nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="2"> &nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 72%">Land and improvements</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%">914</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%">527</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">Buildings and improvements</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">21,278</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">21,433</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">Machinery and equipment</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">19,496</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">22,361</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">Office furniture and fixtures</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">701</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">949</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> Construction in progress</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 35</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 493</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">42,424</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">45,763</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">Less:&nbsp; accumulated depreciation</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">(23,796</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">)</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">(25,364</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">)</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> Net property and equipment</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 18,628</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 20,399</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> </table> <!--EndFragment--></div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> Property and equipment, net, as of September 30, 2012 and 2011 consisted of the following:</p> <p style="TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 80%" cellspacing="0" cellpadding="0" align="center"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2">2012</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2">2011</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="2"> &nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="2"> &nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 72%">Land and improvements</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%">914</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%">527</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">Buildings and improvements</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">21,278</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">21,433</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">Machinery and equipment</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">19,496</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">22,361</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">Office furniture and fixtures</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">701</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">949</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> Construction in progress</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 35</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 493</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">42,424</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">45,763</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">Less:&nbsp; accumulated depreciation</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">(23,796</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">)</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">(25,364</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">)</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> Net property and equipment</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 18,628</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 20,399</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> </table> <!--EndFragment--></div> </div> P34Y P40Y P5Y P10Y P10Y P7Y 16000 -15000 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 0.25in; TEXT-INDENT: 0px"> &nbsp;</td> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 0.5in; TEXT-INDENT: 0px"> <em>(d)</em></td> <td style="PADDING-BOTTOM: 0px; TEXT-ALIGN: justify; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> <em>Accounts Receivable</em></td> </tr> </table> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> We perform periodic credit evaluations of our customers&#39; financial conditions and generally do not require collateral on trade accounts receivable. <font style="COLOR: black">We account for trade receivables based on the amounts billed to customers. Past due receivables are determined based on contractual terms. We do not accrue interest on any of our trade receivables. The allowance for doubtful accounts is determined by management based on our historical losses, specific customer circumstances, and general economic conditions. Periodically, management reviews accounts receivable and adjusts the allowance based on current circumstances and charges off uncollectible receivables when all attempts to collect have failed.</font> Our allowance for doubtful accounts was $123 and $108 at September 30, 2012 and 2011, respectively.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> A summary of activity in our allowance for doubtful accounts is as follows:</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 70%" cellspacing="0" cellpadding="0" align="center"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2">2012</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2">2011</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt" colspan="2">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt" colspan="2">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 72%">Opening balance</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%">108</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%">165</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">Charged to expense</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">84</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">13</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">Accounts recovered</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">15</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">(61</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">)</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> Accounts written off</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> (84</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> )</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> (9</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> )</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 0.25in"> Ending balance</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 123</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 108</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> </table> <!--EndFragment--></div> </div> 5506000 30917000 27695000 1341000 655000 1756000 735000 534000 542000 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 0.25in; TEXT-INDENT: 0px"> &nbsp;</td> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 0.5in; TEXT-INDENT: 0px"> <em>(n)</em></td> <td style="PADDING-BOTTOM: 0px; TEXT-ALIGN: justify; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> <em>Research and Development</em></td> </tr> </table> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> In fiscal 2012 and 2011, we spent $542 and $534, respectively, on research and development. Separate from our contract research services business, we maintain applications research and development to enhance our products business.</p> <!--EndFragment--></div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>14. RESTRUCTURING</strong></p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>&nbsp;</strong></p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> In March 2012, we announced a plan to restructure our bioanalytical laboratory operations. We consolidated our laboratory in McMinnville, Oregon into our 120,000 square foot headquarters facility in West Lafayette, Indiana. This plan was implemented to reduce operating costs and strengthen our ability to meet clients&#39; needs by improving laboratory utilization. In the fourth fiscal quarter of 2012, we decided to initiate closure of our facility and bioanalytical laboratory in Warwickshire, United Kingdom after careful evaluation of its financial performance and analysis of our strategic alternatives. We will continue to sell our products globally while further consolidating delivery of our CRO services into our Indiana locations. As part of the overall evaluation of our business, personnel reductions in the Selling, R&amp;D and General and Administrative functions were also implemented at both of our Indiana locations during the second half of fiscal 2012. In total, 74 employees were terminated as part of the restructuring activities this fiscal year.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The following table sets forth the costs incurred in connection with these restructuring activities during the year ended September 30, 2012.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 70%" cellspacing="0" cellpadding="0" align="center"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt" nowrap="nowrap"> <u>Description</u></td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">2012</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 84%">One-time termination benefits</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 12%"> 1,454</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">Lease related costs</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">861</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">Equipment moving costs and method transfers</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">153</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">Travel and relocation costs</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">47</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">Loss on sale of equipment</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">446</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> Other costs</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 234</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; PADDING-LEFT: 0.75in"> Total</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 3,195</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> We have reserved for lease payments at the cease use date and have considered free rent, sublease rentals and the number of days it would take to restore the space to its original condition prior to our improvements. Based on this, we have reserved $861 for lease related costs.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> Restructuring related costs incurred during fiscal 2012 totaled $1,360 in our Services segment, $0 in our Products segment and $1,835 in corporate expenses.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The following table sets forth the rollforward of the restructuring activity for the year ended September 30, 2012.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 100%" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Balance,<br /> September 30,<br /> 2011</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Total<br /> Charges</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Cash<br /> Payments</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Other</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Balance,<br /> September 30,<br /> 2012</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 30%">One-time termination benefits</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%">-</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> 1,454</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> (1,006</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">)</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%">-</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%">448</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">Lease related costs</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">-</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">861</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">(61</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">)</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">-</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">800</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">Equipment moving costs and method transfers</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">-</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">153</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">(104</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">)</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">-</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">49</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">Travel and relocation costs</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">-</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">47</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">(43</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">)</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">-</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">4</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">Loss on sale of equipment</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">-</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">446</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">-</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">(539</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">)</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">(93</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">)</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> Other costs</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> -</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 234</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> (37</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> )</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> -</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 197</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; PADDING-LEFT: 0.75in"> Total</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> -</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 3,195</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> (1,251</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> )</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> (539</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> )</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 1,405</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> Other costs include legal and professional fees and other costs incurred in connection with transitioning services from sites being closed as well as costs incurred to remove improvements previously made to the UK facility. Other activity in the reserve rollforward primarily reflects a receivable for settlement of the capital lease in the UK.</p> <!--EndFragment--></div> </div> 1360000 0 1835000 3195000 1454000 153000 47000 446000 234000 861000 1360000 1835000 3195000 448000 49000 4000 -93000 197000 1405000 800000 -539000 -539000 1006000 104000 43000 37000 1251000 61000 -8176000 -14493000 -7706000 -14096000 -470000 -397000 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 0.25in; TEXT-INDENT: 0px"> &nbsp;</td> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 0.5in; TEXT-INDENT: 0px"> <em>(b)</em></td> <td style="PADDING-BOTTOM: 0px; TEXT-ALIGN: justify; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> <em>Revenue Recognition</em></td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The majority of our Bioanalytical and analytical research service contracts involve the development of analytical methods and the processing of bioanalytical samples for pharmaceutical companies and generally provide for a fixed fee for each sample processed. Revenue is recognized under the specific performance method of accounting and the related direct costs are recognized when services are performed. Our preclinical research service contracts generally consist of preclinical studies, and revenue is recognized under the proportional performance method of accounting. Revisions in profit estimates, if any, are reflected on a cumulative basis in the period in which such revisions become known. The establishment of contract prices and total contract costs involves estimates we make at the inception of the contract. These estimates could change during the term of the contract and impact the revenue and costs reported in the consolidated financial statements. Revisions to estimates have generally not been material. Research service contract fees received upon acceptance are deferred until earned, and classified within customer advances. Unbilled revenues represent revenues earned under contracts in advance of billings.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> Product revenue from sales of equipment not requiring installation, testing or training is recognized upon shipment to customers. One product includes internally developed software and requires installation, testing and training, which occur concurrently. Revenue from these sales is recognized upon completion of the installation, testing and training when the services are bundled with the equipment sale.</p> <!--EndFragment--></div> </div> 33144000 28208000 25613000 21312000 7531000 6896000 29451000 25042000 912000 961000 2542000 1858000 239000 347000 9585000 1.86 7531000 6896000 33144000 28208000 33144000 28208000 25613000 21312000 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> Significant components of the provision (benefit) for income taxes are as follows as of the year ended September 30:</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 80%" cellspacing="0" cellpadding="0" align="center"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2">2012</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2">2011</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"> Current:</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 36px; WIDTH: 72%"> Federal</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%">(3</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">)</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%">37</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 36px"> State and local</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">5</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">13</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 36px"> Foreign</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">-</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">-</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 9px"> &nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"> Deferred:</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 36px"> Federal</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">-</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">-</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 36px"> State and local</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">-</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">-</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; PADDING-LEFT: 36px"> Foreign</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> -</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> -</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"> Income tax expense</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 2</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 50</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> </table> <!--EndFragment--></div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> A summary of activity in our allowance for doubtful accounts is as follows:</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 70%" cellspacing="0" cellpadding="0" align="center"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2">2012</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2">2011</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt" colspan="2">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt" colspan="2">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 72%">Opening balance</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%">108</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%">165</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">Charged to expense</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">84</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">13</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">Accounts recovered</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">15</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">(61</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">)</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> Accounts written off</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> (84</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> )</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> (9</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> )</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 0.25in"> Ending balance</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 123</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 108</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> </table> <!--EndFragment--></div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> Long-term debt consisted of the following at September 30:</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 90%" cellspacing="0" cellpadding="0" align="center"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: center; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: center"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2">2012</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: center"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: center"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2">2011</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: center"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold" colspan="2"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold" colspan="2"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 72%; TEXT-INDENT: 0px"> Mortgage note payable to a bank, payable in monthly principal and interest installments of $40. Interest is fixed at 4.1%.&nbsp; Collateralized by underlying property.&nbsp; Due October, 2013. (b)</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> 3,236</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> 3,573</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: right"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: right"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> Mortgage note payable to a bank, payable in monthly principal and interest installments of $17. Interest is fixed at 4.1%.&nbsp; Collateralized by underlying property.&nbsp; Due October, 2013. (b)</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">1,532</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">1,674</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: right"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: right"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> Replacement note payable to a bank, payable in monthly principal installments of $14 plus interest.&nbsp; The interest rate is 4.5%. Collateralized by West Lafayette and Evansville properties. Due October, 2013. &nbsp;(a) (b)</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">1,074</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">1,245</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: right"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: right"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> Note payable to Algo Holdings, payable in monthly installments of $10.&nbsp; There is no interest on this note if paid within terms.&nbsp; Termed May 1, 2012.&nbsp; See Note 13.</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> -</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 85</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> &nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">5,842</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">6,577</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> Less current portion</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 583</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 735</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 5,259</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 5,842</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> </table> <!--EndFragment--></div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> Significant components of our deferred tax assets and liabilities as of September&nbsp;30 are as follows:</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 90%" cellspacing="0" cellpadding="0" align="center"> <tr style="VERTICAL-ALIGN: bottom"> <td nowrap="nowrap">&nbsp;</td> <td style="FONT-WEIGHT: bold; COLOR: black; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; COLOR: black; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">2012</td> <td style="FONT-WEIGHT: bold; COLOR: black; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-WEIGHT: bold; COLOR: black; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; COLOR: black; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">2011</td> <td style="FONT-WEIGHT: bold; COLOR: black; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td nowrap="nowrap">&nbsp;</td> <td style="COLOR: black" nowrap="nowrap">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">(Restated)</td> <td style="COLOR: black" nowrap="nowrap">&nbsp;</td> <td style="COLOR: black" nowrap="nowrap">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">(Restated)</td> <td style="COLOR: black" nowrap="nowrap">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="COLOR: black; TEXT-ALIGN: left">Deferred tax assets - Current:</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 36px; WIDTH: 72%"> Inventory</td> <td style="COLOR: black; WIDTH: 2%">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="COLOR: black; TEXT-ALIGN: right; WIDTH: 10%">202</td> <td style="COLOR: black; TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="COLOR: black; WIDTH: 2%">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="COLOR: black; TEXT-ALIGN: right; WIDTH: 10%">236</td> <td style="COLOR: black; TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 36px"> Accrued compensation and vacation</td> <td style="COLOR: black">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: left">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: right">255</td> <td style="COLOR: black; TEXT-ALIGN: left">&nbsp;</td> <td style="COLOR: black">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: left">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: right">271</td> <td style="COLOR: black; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 36px"> Accrued expenses and other</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; COLOR: black; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; COLOR: black; TEXT-ALIGN: right"> 252</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; COLOR: black; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; COLOR: black; TEXT-ALIGN: right"> 118</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="COLOR: black; TEXT-ALIGN: left">Total current deferred tax assets</td> <td style="COLOR: black">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: left">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: right">709</td> <td style="COLOR: black; TEXT-ALIGN: left">&nbsp;</td> <td style="COLOR: black">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: left">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: right">625</td> <td style="COLOR: black; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="TEXT-INDENT: 0.5in">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="COLOR: black; TEXT-ALIGN: left">Deferred tax liabilities - Current:</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 36px"> Prepaid expenses</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; COLOR: black; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; COLOR: black; TEXT-ALIGN: right"> (74</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> )</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; COLOR: black; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; COLOR: black; TEXT-ALIGN: right"> (116</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> )</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-WEIGHT: bold; COLOR: black; TEXT-ALIGN: left">Total net current deferred tax assets</td> <td style="FONT-WEIGHT: bold; COLOR: black">&nbsp;</td> <td style="FONT-WEIGHT: bold; COLOR: black; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-WEIGHT: bold; COLOR: black; TEXT-ALIGN: right"> 635</td> <td style="FONT-WEIGHT: bold; COLOR: black; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-WEIGHT: bold; COLOR: black">&nbsp;</td> <td style="FONT-WEIGHT: bold; COLOR: black; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-WEIGHT: bold; COLOR: black; TEXT-ALIGN: right"> 509</td> <td style="FONT-WEIGHT: bold; COLOR: black; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="COLOR: black; TEXT-ALIGN: left">Deferred tax assets - Noncurrent:</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 36px"> Domestic net operating loss carryforwards</td> <td style="COLOR: black">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: left">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: right">2,483</td> <td style="COLOR: black; TEXT-ALIGN: left">&nbsp;</td> <td style="COLOR: black">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: left">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: right">1,585</td> <td style="COLOR: black; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 36px"> Stock compensation expense</td> <td style="COLOR: black">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: left">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: right">14</td> <td style="COLOR: black; TEXT-ALIGN: left">&nbsp;</td> <td style="COLOR: black">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: left">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: right">29</td> <td style="COLOR: black; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 36px"> Foreign net operating loss</td> <td style="COLOR: black">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: left">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: right">2,334</td> <td style="COLOR: black; TEXT-ALIGN: left">&nbsp;</td> <td style="COLOR: black">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: left">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: right">1,326</td> <td style="COLOR: black; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 36px"> Foreign tax credit carryover</td> <td style="COLOR: black">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: left">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: right">119</td> <td style="COLOR: black; TEXT-ALIGN: left">&nbsp;</td> <td style="COLOR: black">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: left">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: right">119</td> <td style="COLOR: black; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 36px"> AMT credit carryover</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; COLOR: black; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; COLOR: black; TEXT-ALIGN: right"> 42</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; COLOR: black; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; COLOR: black; TEXT-ALIGN: right"> 45</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="COLOR: black; TEXT-ALIGN: left">Total noncurrent deferred tax assets</td> <td style="COLOR: black">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: left">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: right">4,992</td> <td style="COLOR: black; TEXT-ALIGN: left">&nbsp;</td> <td style="COLOR: black">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: left">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: right">3,104</td> <td style="COLOR: black; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="COLOR: black; TEXT-ALIGN: left">Deferred tax liabilities - Noncurrent:</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 36px"> Unrealized gain/loss - warrant liability</td> <td style="COLOR: black">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: left">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: right">(296</td> <td style="COLOR: black; TEXT-ALIGN: left">)</td> <td style="COLOR: black">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: left">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: right">(685</td> <td style="COLOR: black; TEXT-ALIGN: left">)</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 36px"> Basis difference for fixed assets</td> <td style="COLOR: black">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: left">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: right">(459</td> <td style="COLOR: black; TEXT-ALIGN: left">)</td> <td style="COLOR: black">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: left">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: right">(562</td> <td style="COLOR: black; TEXT-ALIGN: left">)</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 36px"> Basis difference for intangibles</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; COLOR: black; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; COLOR: black; TEXT-ALIGN: right"> -</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; COLOR: black; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; COLOR: black; TEXT-ALIGN: right"> (21</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> )</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td>&nbsp;</td> <td style="COLOR: black">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: left">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: right">(755</td> <td style="COLOR: black; TEXT-ALIGN: left">)</td> <td style="COLOR: black">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: left">&nbsp;</td> <td style="COLOR: black; TEXT-ALIGN: right">(1,268</td> <td style="COLOR: black; TEXT-ALIGN: left">)</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-WEIGHT: bold; COLOR: black; TEXT-ALIGN: left">Total net noncurrent deferred tax assets</td> <td style="FONT-WEIGHT: bold; COLOR: black">&nbsp;</td> <td style="FONT-WEIGHT: bold; COLOR: black; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-WEIGHT: bold; COLOR: black; TEXT-ALIGN: right"> 4,237</td> <td style="FONT-WEIGHT: bold; COLOR: black; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-WEIGHT: bold; COLOR: black">&nbsp;</td> <td style="FONT-WEIGHT: bold; COLOR: black; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-WEIGHT: bold; COLOR: black; TEXT-ALIGN: right"> 1,836</td> <td style="FONT-WEIGHT: bold; COLOR: black; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="COLOR: black; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> Valuation allowance for net deferred tax assets</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; COLOR: black; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; COLOR: black; TEXT-ALIGN: right"> (4,872</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> )</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; COLOR: black; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; COLOR: black; TEXT-ALIGN: right"> (2,345</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> )</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-WEIGHT: bold; COLOR: black; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> Net deferred tax&nbsp;&nbsp;asset (liability)</td> <td style="COLOR: black; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; COLOR: black; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; COLOR: black; TEXT-ALIGN: right"> -</td> <td style="COLOR: black; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="COLOR: black; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; COLOR: black; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; COLOR: black; TEXT-ALIGN: right"> -</td> <td style="COLOR: black; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> </table> <!--EndFragment--></div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The following table reconciles our computation of basic net loss per share to diluted net loss per share:</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 80%" cellspacing="0" cellpadding="0" align="center"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="6" nowrap="nowrap">Years Ended<br /> September 30,</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">2012</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">2011</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">(<font style="FONT: 10pt Times New Roman, Times, Serif">Restated<em>)</em></font></td> <td style="FONT-SIZE: 10pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">(<font style="FONT: 10pt Times New Roman, Times, Serif">Restated<em>)</em></font></td> <td style="FONT-SIZE: 10pt" nowrap="nowrap">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; FONT-STYLE: italic; TEXT-ALIGN: justify"> Basic net loss per share:</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0.125in; WIDTH: 72%"> Net income (loss)</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> (6,317</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">)</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> 2,302</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0.125in"> Less:&nbsp; Deemed dividend for Series A Preferred Shares</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">-</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">(5,506</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">)</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; PADDING-LEFT: 0.125in"> Less:&nbsp; Preferred dividend</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> -</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> (991</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> )</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0.25in">Net loss applicable to common shareholders</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">(6,317</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">)</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">(4,195</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">)</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; PADDING-LEFT: 0.125in"> Weighted average common shares outstanding</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 7,158</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 5,667</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 0.125in"> Basic net loss per share</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> (0.88</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> )</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> (0.74</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> )</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; FONT-STYLE: italic">Diluted net loss per share:</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0.125in"> Net loss applicable to common shareholders</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">(6,317</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">)</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">(4,195</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">)</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; PADDING-LEFT: 0.125in"> Weighted average common shares outstanding</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 7,158</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 5,667</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 0.125in"> Diluted net loss per share</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> (0.88</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> )</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> (0.74</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> )</td> </tr> </table> <!--EndFragment--></div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The effective income tax rate on continuing operations varied from the statutory federal income tax rate as follows:</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 80%" cellspacing="0" cellpadding="0" align="center"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2">2012</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2">2011</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold" colspan="2"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold" colspan="2"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 72%; TEXT-INDENT: 0px"> Statutory federal income tax rate</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> 34.0</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">%</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> 34.0</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">%</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> Increases (decreases):</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-TOP: 0px; PADDING-LEFT: 0.125in; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> State and local income taxes, net of Federal tax benefit, if applicable</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">(0.1</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">)</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">0.4</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-TOP: 0px; PADDING-LEFT: 0.125in; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> Nondeductible expenses</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">(0.5</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">)</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">2.9</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-TOP: 0px; PADDING-LEFT: 0.125in; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> Valuation allowance changes</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">(33.5</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">)</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">(35.4</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">)</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; PADDING-TOP: 0px; PADDING-LEFT: 0.125in; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> Other</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> ---</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 0.2</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> &nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> Effective income tax rate</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> (0.1</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> )%</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 2.1</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> %</td> </tr> </table> <!--EndFragment--></div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The following table summarizes the effects of the restatement adjustments, previously discussed, on the consolidated statements of operations and comprehensive income (loss) items for the years ended September 30:</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 100%" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; COLOR: black; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif" colspan="10">2012</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; COLOR: black; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif" colspan="10">2011</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; COLOR: black; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif" colspan="2">As Reported</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; COLOR: black; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif" colspan="2">Adjustment</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; COLOR: black; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif" colspan="2">Restated</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; COLOR: black; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif" colspan="2">As Reported</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; COLOR: black; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif" colspan="2">Adjustment</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; COLOR: black; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif" colspan="2">Restated</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 34%"> Total revenue</td> <td style="FONT: 10pt Times New Roman, Times, Serif; WIDTH: 1%"> &nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 1%"> $</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 8%"> 28,208</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 1%"> &nbsp;</td> <td style="FONT: 10pt Times New Roman, Times, Serif; WIDTH: 1%"> &nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 1%"> $</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 8%"> -</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 1%"> &nbsp;</td> <td style="FONT: 10pt Times New Roman, Times, Serif; WIDTH: 1%"> &nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 1%"> $</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 8%"> 28,208</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 1%"> &nbsp;</td> <td style="FONT: 10pt Times New Roman, Times, Serif; WIDTH: 1%"> &nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 1%"> $</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 8%"> 33,144</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 8%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT: 10pt Times New Roman, Times, Serif; WIDTH: 1%"> &nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 1%"> $</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 8%"> 33,144</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 1%"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> Total cost of revenue</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 21,370</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> -</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 21,370</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 22,638</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 22,638</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> Gross profit</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 6,838</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> -</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 6,838</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 10,506</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> -</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 10,506</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> Total operating expenses</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 9,329</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> -</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 9,329</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 9,219</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 9,219</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> Restructuring charges</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 3,195</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> -</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 3,195</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> -</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> -</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> Operating income (loss)</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> (5,686</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> )</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> -</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> (5,686</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> )</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 1,287</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> -</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 1,287</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> Interest expense</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> (714</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> )</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> -</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> (714</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> )</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> (706</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> )</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> (706</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> )</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> Change in fair value of warrant liability - decrease</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> -</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 73</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 73</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> -</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 1,759</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 1,759</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> Other income</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 12</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> -</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 12</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 12</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> -</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 12</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> Income (loss) before income taxes</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> (6,388</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> )</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 73</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> (6,315</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> )</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 593</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 1,759</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 2,352</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> Income tax expense</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 2</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> -</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 2</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 50</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 50</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> Net income (loss)</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> (6,390</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> )</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 73</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> (6,317</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> )</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 543</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 1,759</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 2,302</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> Other comprehensive income (loss):</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;&nbsp;&nbsp;&nbsp;Foreign currency translation adjustment</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> (22</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> )</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> -</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> (22</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> )</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> (49</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> )</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> -</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> (49</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> )</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> Comprehensive income (loss)</td> <td style="PADDING-BOTTOM: 2.5pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> (6,412</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> )</td> <td style="PADDING-BOTTOM: 2.5pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 73</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> (6,339</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> )</td> <td style="PADDING-BOTTOM: 2.5pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 494</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 1,759</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 2,253</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> Basic EPS</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> $</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> (0.89</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> )</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> $</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 0.01</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> $</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> (0.88</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> )</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> $</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> (0.66</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> )</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> $</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> (0.08</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> )</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> $</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> (0.74</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> )</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> Diluted EPS</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> $</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> (0.89</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> )</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> $</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 0.01</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> $</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> (0.88</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> )</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> $</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> (0.66</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> )</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> $</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> (0.08</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> )</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> $</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> (0.74</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> )</td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The following table summarizes the effects of the restatement adjustments, previously discussed, on the consolidated balance sheet items as of September 30:</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 100%" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td>&nbsp;</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; COLOR: black; TEXT-ALIGN: center" colspan="10">2012</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; COLOR: black; TEXT-ALIGN: center" colspan="10">2011</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td nowrap="nowrap">&nbsp;</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; COLOR: black; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">As Reported</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; COLOR: black; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Adjustment</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; COLOR: black; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Restated</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; COLOR: black; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">As Reported</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; COLOR: black; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Adjustment</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; COLOR: black; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Restated</td> <td style="COLOR: black; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td>&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td colspan="2">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td colspan="2">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td colspan="2">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td colspan="2">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td colspan="2">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td colspan="2">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; WIDTH: 34%"> Total assets</td> <td style="PADDING-BOTTOM: 2.5pt; WIDTH: 1%">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 8%"> 26,975</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt; WIDTH: 1%">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 8%"> -</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt; WIDTH: 1%">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 8%"> 26,975</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt; WIDTH: 1%">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 8%"> 32,346</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt; WIDTH: 1%">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 8%"> &nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt; WIDTH: 1%">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 8%"> 32,346</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="TEXT-ALIGN: left">Total other current liabilities</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">11,387</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">-</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">11,387</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">9,847</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">9,847</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">Fair value of warrant liability</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> -</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 1,213</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 1,213</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> -</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 1,286</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 1,286</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="TEXT-ALIGN: left; PADDING-LEFT: 9pt">Total current liabilities</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">11,387</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">1,213</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">12,600</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">9,847</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">1,286</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">11,133</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">Other long-term debt</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 5,998</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> -</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 5,998</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 6,913</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 6,913</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="TEXT-ALIGN: left; PADDING-LEFT: 9pt">Total liabilities</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">17,385</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">1,213</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">18,598</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">16,760</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">1,286</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">18,046</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="TEXT-ALIGN: left">Shareholders&#39; equity:</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="PADDING-LEFT: 9pt">Preferred Shares</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">1,335</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">-</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">1,335</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">2,135</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">-</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">2,135</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="PADDING-LEFT: 9pt">Common Shares</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">1,871</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">-</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">1,871</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">1,698</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">-</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">1,698</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="TEXT-ALIGN: left; PADDING-LEFT: 9pt">Additional paid-in capital</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">20,451</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">(816</td> <td style="TEXT-ALIGN: left">)</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">19,635</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">19,408</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">(816</td> <td style="TEXT-ALIGN: left">)</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">18,592</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="TEXT-ALIGN: left; PADDING-LEFT: 9pt">Accumulated deficit</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">(14,096</td> <td style="TEXT-ALIGN: left">)</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">(397</td> <td style="TEXT-ALIGN: left">)</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">(14,493</td> <td style="TEXT-ALIGN: left">)</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">(7,706</td> <td style="TEXT-ALIGN: left">)</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">(470</td> <td style="TEXT-ALIGN: left">)</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">(8,176</td> <td style="TEXT-ALIGN: left">)</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; PADDING-LEFT: 9pt"> Accumulated other comprehensive income</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 29</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> -</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 29</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 51</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 51</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; PADDING-LEFT: 0.25in"> Total shareholders&#39; equity</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 9,590</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> (1,213</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">)</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 8,377</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 15,586</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> (1,286</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">)</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 14,300</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; PADDING-LEFT: 0.25in"> Total liabilities and shareholders&#39; equity</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 26,975</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> -</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 26,975</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 32,346</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> -</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 32,346</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left">&nbsp;</td> </tr> </table> <!--EndFragment--></div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> At September 30, 2012 and 2011, remaining recorded goodwill was $1,383, and the net balance of other intangible assets was $0 and $54, respectively. The components of intangible assets subject to amortization are as follows:</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 90%" cellspacing="0" cellpadding="0" align="center"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="6" nowrap="nowrap">September 30, 2012</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Weighted<br /> average life<br /> (years)</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Gross Carrying<br /> Amount</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Accumulated<br /> Amortization</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 58%; TEXT-INDENT: 0px"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> FDA compliant facility</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 10</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 302</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 302</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 90%" cellspacing="0" cellpadding="0" align="center"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right" colspan="2" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="6" nowrap="nowrap">September 30, 2011</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Weighted<br /> average life<br /> (years)</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Gross Carrying<br /> Amount</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Accumulated<br /> Amortization</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 58%; TEXT-INDENT: 0px"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> FDA compliant facility</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 10</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 302</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 248</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> </table> <!--EndFragment--></div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> Future minimum lease payments on capital leases at September 30, 2012 for the next five years are as follows:</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 70%" cellspacing="0" cellpadding="0" align="center"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Principal</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Interest</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Total</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center" nowrap="nowrap">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> &nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt" colspan="2">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt" colspan="2">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt" colspan="2">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 58%; TEXT-INDENT: 0px"> 2013</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%">330</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%">58</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%">388</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> 2014</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">268</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">39</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">307</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> 2015</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">259</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">22</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">281</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> 2016</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">208</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">6</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">214</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> 2017</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">4</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">-</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">4</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 1,069</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 125</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 1,194</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> </table> <!--EndFragment--></div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> Future minimum lease payments for the following fiscal years under operating leases at September 30, 2012 are as follows:</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 50%" cellspacing="0" cellpadding="0" align="center"> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 84%">2013</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 12%">371</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">2014</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">370</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">2015</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">223</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> 2016</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 13</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 977</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> </table> <!--EndFragment--></div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> Inventories at September&nbsp;30 consisted of the following:</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 70%" cellspacing="0" cellpadding="0" align="center"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: center" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">2012</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">2011</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 72%">Raw materials</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> 1,407</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> 1,352</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">Work in progress</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">283</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">379</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> Finished goods</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 276</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 309</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">1,966</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">2,040</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> Obsolescence reserve</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> (310</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> )</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> (404</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> )</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 1,656</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 1,636</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> </table> <!--EndFragment--></div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.5in"> A summary of non-vested options for the year ended September 30, 2012 is as follows:</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.5in"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 70%" cellspacing="0" cellpadding="0" align="center"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Number of<br /> Shares</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Weighted-<br /> Average Grant<br /> Date Fair Value</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt" colspan="2">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt" colspan="2">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; WIDTH: 72%">Non-vested options at October 1, 2011</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%">385</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> 1.14</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-LEFT: 0.125in">Granted</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">200</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">1.05</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-LEFT: 0.125in">Vested</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">(128</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">)</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">1.25</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; PADDING-LEFT: 0.125in"> Forfeited</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> (197</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> )</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: right"> 1.09</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">Non-vested options at September 30, 2012</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 260</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: right"> 1.06</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> </table> <!--EndFragment--></div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The following table sets forth the costs incurred in connection with these restructuring activities during the year ended September 30, 2012.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 70%" cellspacing="0" cellpadding="0" align="center"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt" nowrap="nowrap"> <u>Description</u></td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">2012</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 84%">One-time termination benefits</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 12%"> 1,454</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">Lease related costs</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">861</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">Equipment moving costs and method transfers</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">153</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">Travel and relocation costs</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">47</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">Loss on sale of equipment</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">446</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> Other costs</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 234</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; PADDING-LEFT: 0.75in"> Total</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 3,195</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> </table> <!--EndFragment--></div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The following table sets forth the rollforward of the restructuring activity for the year ended September 30, 2012.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 100%" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Balance,<br /> September 30,<br /> 2011</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Total<br /> Charges</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Cash<br /> Payments</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Other</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Balance,<br /> September 30,<br /> 2012</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 30%">One-time termination benefits</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%">-</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> 1,454</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> (1,006</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">)</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%">-</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%">448</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">Lease related costs</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">-</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">861</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">(61</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">)</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">-</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">800</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">Equipment moving costs and method transfers</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">-</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">153</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">(104</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">)</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">-</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">49</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">Travel and relocation costs</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">-</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">47</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">(43</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">)</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">-</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">4</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">Loss on sale of equipment</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">-</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">446</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">-</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">(539</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">)</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">(93</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">)</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> Other costs</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> -</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 234</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> (37</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> )</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> -</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 197</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; PADDING-LEFT: 0.75in"> Total</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> -</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 3,195</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> (1,251</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> )</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> (539</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> )</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 1,405</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> </table> <!--EndFragment--></div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 0.25in; TEXT-INDENT: 0px"> &nbsp;</td> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 0.5in; TEXT-INDENT: 0px"> <em>(b)</em></td> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> <em>Geographic Information</em></td> </tr> </table> <p style="TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 80%" cellspacing="0" cellpadding="0" align="center"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="6">Years Ended<br /> September 30,</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2">2012</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2">2011</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">Sales to External Customers:</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0.625in; WIDTH: 72%"> North America</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> 25,042</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> 29,451</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0.625in"> Pacific Rim</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">961</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">912</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-LEFT: 0.625in">Europe</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">1,858</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">2,542</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; PADDING-LEFT: 0.625in"> Other</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 347</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 239</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 28,208</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 33,144</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt">Long-lived Assets:</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0.625in"> North America</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">20,083</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">20,872</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; PADDING-LEFT: 0.625in"> Europe</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> -</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 1,101</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 20,083</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 21,973</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> </table> <!--EndFragment--></div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 0.25in; TEXT-INDENT: 0px"> &nbsp;</td> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 0.5in; TEXT-INDENT: 0px"> <em>(a)</em></td> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> <em>Operating Segments</em></td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 80%" cellspacing="0" cellpadding="0" align="center"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="6">Years Ended<br /> September 30,</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2">2012</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2">2011</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="2"> (Restated)</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="2"> (Restated)</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt">Revenue:</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-LEFT: 0.625in; WIDTH: 72%"> Service</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> 21,312</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> 25,613</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; PADDING-LEFT: 0.625in"> Product</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 6,896</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 7,531</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">28,208</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">33,144</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">Operating income (loss):</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-LEFT: 0.625in">Service</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">(3,863</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">)</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">745</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-LEFT: 0.625in">Product</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">12</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">542</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; PADDING-LEFT: 0.625in"> Corporate</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> (1,835</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> )</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> -</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">(5,686</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">)</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">1,287</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">Interest Expense</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">(714</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">)</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">(706</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">)</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"> <p style="MARGIN: 0pt 0px">Change in fair value of warrant liability- decrease</p> </td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"> <p style="MARGIN: 0pt 0px">73</p> </td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">1,759</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> Other income</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 12</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 12</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> Income (loss) before income taxes</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> (6,315</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> )</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 2,352</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> </table> <p style="TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> Restructuring costs of $1,360 and $1,835 are included in the operating losses for fiscal 2012 for the Service and Corporate segments, respectively.</p> <p style="TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 80%" cellspacing="0" cellpadding="0" align="center"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="6">Years Ended<br /> September 30,</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2">2012</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2">2011</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">Identifiable assets:</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-LEFT: 0.625in; WIDTH: 72%"> Service</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> 15,864</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> 18,121</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-LEFT: 0.625in">Product</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">7,262</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">7,674</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; PADDING-LEFT: 0.625in"> Corporate</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 3,849</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 6,551</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 26,975</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 32,346</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">Goodwill, net:</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-LEFT: 0.625in">Service</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">1,009</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">1,009</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; PADDING-LEFT: 0.625in"> Product</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 374</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 374</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 1,383</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 1,383</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">Intangible assets, net:</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-LEFT: 0.625in">Service</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">-</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">54</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; PADDING-LEFT: 0.625in"> Product</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> -</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> -</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> -</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 54</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">Depreciation and amortization:</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-LEFT: 0.625in">Service</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">2,036</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">1,899</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; PADDING-LEFT: 0.625in"> Product</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 242</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 235</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 2,278</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 2,134</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">Capital Expenditures:</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-LEFT: 0.625in">Service</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">864</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">1,098</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; PADDING-LEFT: 0.625in"> Product</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 226</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 76</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 1,090</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 1,174</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> </table> <!--EndFragment--></div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> A summary of our stock option activity for all options and related information for the years ended September 30, 2012 and 2011, respectively, is as follows (in thousands except for share prices):</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 100%" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Options<br /> (shares)</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Weighted-<br /> Average<br /> Exercise Price</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Weighted-<br /> Average Grant<br /> Date Fair Value</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Weighted-Average<br /> Remaining<br /> Contractual Life<br /> (Years)</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Aggregate<br /> Intrinsic<br /> Value</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="2"> &nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="2"> &nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="2"> &nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="2"> &nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="2"> &nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; WIDTH: 30%">Outstanding - October 1, 2010</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%">705</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> 2.66</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-LEFT: 0.125in">Exercised</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">-</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">-</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-LEFT: 0.125in">Granted</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">27</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">2.24</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">1.84</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; PADDING-LEFT: 0.125in"> Terminated</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> (59</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> )</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: right"> 2.54</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: right"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: right"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: right"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">Outstanding - September 30, 2011</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 673</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: right"> 2.65</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: right"> 1.83</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: right"> 7.2</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: right"> 69</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt">Outstanding - October 1, 2011</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">673</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">2.65</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-LEFT: 0.125in">Exercised</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">-</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">-</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-LEFT: 0.125in">Granted</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">200</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">1.30</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">1.05</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; PADDING-LEFT: 0.125in"> Terminated</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> (519</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> )</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: right"> 2.58</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: right"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: right"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: right"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">Outstanding - September 30, 2012</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 354</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: right"> 1.99</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: right"> 1.46</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: right"> 8.0</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: right"> 42</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">Exercisable at September 30, 2012</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 94</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: right"> 3.83</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: right"> 2.59</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: right"> 5.3</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: right"> 7</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> </table> <!--EndFragment--></div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The weighted-average assumptions used to compute the fair value of options granted for the fiscal years ended September 30 were as follows:</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.25in"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 80%" cellspacing="0" cellpadding="0" align="center"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" nowrap="nowrap">2012</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" nowrap="nowrap">2011</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 72%">Risk-free interest rate</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: center; WIDTH: 12%" nowrap="nowrap">1.39%</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: center; WIDTH: 12%" nowrap="nowrap">3.08%</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">Dividend yield</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: center" nowrap="nowrap"> 0.00%</td> <td style="FONT-SIZE: 10pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: center" nowrap="nowrap"> 0.00%</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> Volatility of the expected market price of the Company&#39;s common stock</td> <td style="FONT: 10pt Times New Roman, Times, Serif">&nbsp;</td> <td style="TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif" nowrap="nowrap">93.00%- 97.00%</td> <td style="FONT-SIZE: 10pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: center" nowrap="nowrap"> 90.00%-91.00%</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">Expected life of the options (years)</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: center" nowrap="nowrap">7.0 - 8.0</td> <td style="FONT-SIZE: 10pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: center" nowrap="nowrap"> 8.0</td> </tr> </table> <!--EndFragment--></div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.75in; MARGIN-TOP: 0pt"> Change in unrecognized tax benefits:</p> <p style="MARGIN: 0px">&nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.75in; WIDTH: 80%" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">2012</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">2011</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 72%">Balance at beginning of the year</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%">16</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%">30</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">Additions based on tax positions related to the current year</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">-</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">-</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">Additions for tax positions of prior years</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">-</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">-</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">Reductions for tax positions of prior years</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">-</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">(14</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">)</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">Settlements</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> -</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> -</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> Balance at end of the year</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 16</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 16</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> </table> <!--EndFragment--></div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>12. SEGMENT INFORMATION</strong></p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>&nbsp;</strong></p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> We operate in two principal segments - contract research services and research products. Our Services segment provides research and development support on a contract basis directly to pharmaceutical companies. Our Products segment provides liquid chromatography, electrochemical and physiological monitoring products to pharmaceutical companies, universities, government research centers, and medical research institutions. We evaluate performance and allocate resources based on these segments. Certain of our assets are not directly attributable to the Services or Products segments. These assets are grouped into the Corporate segment and include cash and cash equivalents, deferred income taxes, refundable income taxes, debt issue costs and certain other assets. We do not allocate such items to the principal segments because they are not used to evaluate their financial position. The accounting policies of these segments are the same as those described in the summary of significant accounting policies.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 0.25in; TEXT-INDENT: 0px"> &nbsp;</td> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 0.5in; TEXT-INDENT: 0px"> <em>(a)</em></td> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> <em>Operating Segments</em></td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 80%" cellspacing="0" cellpadding="0" align="center"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="6">Years Ended<br /> September 30,</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2">2012</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2">2011</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="2"> (Restated)</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="2"> (Restated)</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt">Revenue:</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-LEFT: 0.625in; WIDTH: 72%"> Service</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> 21,312</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> 25,613</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; PADDING-LEFT: 0.625in"> Product</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 6,896</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 7,531</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">28,208</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">33,144</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">Operating income (loss):</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-LEFT: 0.625in">Service</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">(3,863</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">)</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">745</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-LEFT: 0.625in">Product</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">12</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">542</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; PADDING-LEFT: 0.625in"> Corporate</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> (1,835</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> )</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> -</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">(5,686</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">)</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">1,287</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">Interest Expense</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">(714</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">)</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">(706</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">)</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"> <p style="MARGIN: 0pt 0px">Change in fair value of warrant liability- decrease</p> </td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"> <p style="MARGIN: 0pt 0px">73</p> </td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">1,759</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> Other income</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 12</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 12</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> Income (loss) before income taxes</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> (6,315</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> )</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 2,352</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> </table> <p style="TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> Restructuring costs of $1,360 and $1,835 are included in the operating losses for fiscal 2012 for the Service and Corporate segments, respectively.</p> <p style="TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 80%" cellspacing="0" cellpadding="0" align="center"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="6">Years Ended<br /> September 30,</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2">2012</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2">2011</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">Identifiable assets:</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-LEFT: 0.625in; WIDTH: 72%"> Service</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> 15,864</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> 18,121</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-LEFT: 0.625in">Product</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">7,262</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">7,674</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; PADDING-LEFT: 0.625in"> Corporate</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 3,849</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 6,551</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 26,975</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 32,346</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">Goodwill, net:</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-LEFT: 0.625in">Service</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">1,009</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">1,009</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; PADDING-LEFT: 0.625in"> Product</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 374</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 374</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 1,383</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 1,383</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">Intangible assets, net:</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-LEFT: 0.625in">Service</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">-</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">54</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; PADDING-LEFT: 0.625in"> Product</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> -</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> -</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> -</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 54</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">Depreciation and amortization:</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-LEFT: 0.625in">Service</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">2,036</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">1,899</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; PADDING-LEFT: 0.625in"> Product</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 242</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 235</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 2,278</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 2,134</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">Capital Expenditures:</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-LEFT: 0.625in">Service</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">864</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">1,098</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; PADDING-LEFT: 0.625in"> Product</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 226</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 76</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 1,090</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 1,174</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> </table> <p style="TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 0.25in; TEXT-INDENT: 0px"> &nbsp;</td> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 0.5in; TEXT-INDENT: 0px"> <em>(b)</em></td> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> <em>Geographic Information</em></td> </tr> </table> <p style="TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 80%" cellspacing="0" cellpadding="0" align="center"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="6">Years Ended<br /> September 30,</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2">2012</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2">2011</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">Sales to External Customers:</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0.625in; WIDTH: 72%"> North America</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> 25,042</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> 29,451</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0.625in"> Pacific Rim</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">961</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">912</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-LEFT: 0.625in">Europe</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">1,858</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">2,542</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; PADDING-LEFT: 0.625in"> Other</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 347</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 239</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 28,208</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 33,144</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt">Long-lived Assets:</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0.625in"> North America</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">20,083</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">20,872</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; PADDING-LEFT: 0.625in"> Europe</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> -</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 1,101</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 20,083</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 21,973</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> </table> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 0.25in; TEXT-INDENT: 0px"> &nbsp;</td> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 0.5in; TEXT-INDENT: 0px"> <em>(c)</em></td> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> <em>Major Customers</em></td> </tr> </table> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The Preferred Provider Agreement ("PPA") with Pharmasset, Inc., signed in the first quarter of fiscal 2011, expired under its own terms, though they remain a large client of the Company. Pharmasset, Inc., now known as Gilead Sciences, Inc. (&#39;Gilead&#39;) via acquisition, accounted for approximately 7.3% and 14.5% of our total revenues in fiscal 2012 and 2011, respectively, and 7.4% and 6.3% of total trade accounts receivable at September 30, 2012 and 2011, respectively. Pfizer, Inc. remains a large client, accounting for approximately 3.4% and 5.2% of our total revenues in fiscal 2012 and 2011, respectively. Pfizer, Inc. accounted for 8.4% and 4.2% of total trade accounts receivable at September 30, 2012 and 2011, respectively.</p> <!--EndFragment--></div> </div> 3121000 3263000 153000 83000 0.844 0.881 0.091 0 0 P8Y P7Y P8Y 0.91 0.97 0.9 0.93 0.0308 0.0139 500000 339000 7000 94 3.83 P5Y3M18D 59 519 27 200 1.84 1.05 69000 42000 705 673 354 2.66 2.65 1.99 P7Y2M12D P8Y <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The following table summarizes outstanding and exercisable options as of September&nbsp;30, 2012 (in thousands except per share amounts):</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 100%" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: left"> Range of Exercise Prices</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2">Shares<br /> Outstanding</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2">Weighted-<br /> Average<br /> Remaining<br /> Contractual<br /> Life (Years)</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2">Weighted-<br /> Average<br /> Exercise Price</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2">Shares<br /> Exercisable</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2">Weighted-<br /> Average<br /> Exercise Price</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold" colspan="2"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold" colspan="2"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold" colspan="2"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold" colspan="2"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold" colspan="2"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; WIDTH: 30%">$0.79 - 1.01</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%">128</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> 8.32</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> 0.97</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%">24</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> 1.01</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt">$1.02 - 4.59</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">155</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">9.40</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">1.38</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">7</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">1.35</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt">$4.60 - 8.79</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">71</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">4.24</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">5.19</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">62</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">5.21</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> </table> <!--EndFragment--></div> </div> 2.54 2.58 2.24 1.30 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 0.25in; TEXT-INDENT: 0px"> &nbsp;</td> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 0.5in; TEXT-INDENT: 0px"> <em>(i)</em></td> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> <em>Stock-Based Compensation</em></td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> We have a stock-based employee compensation plan and a stock-based employee and outside director compensation plan, which are described more fully in Note 10. All options granted under these plans have an exercise price equal to the market value of the underlying common shares on the date of grant. We expense the estimated fair value of stock options over the vesting periods of the grants. <font style="COLOR: black">Our policy is to recognize expense for awards subject to graded vesting using the straight-line attribution method,</font> reduced for estimated forfeitures. Forfeitures are revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates and an adjustment is recognized at that time.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> We use a binomial option-pricing model as our method of valuation for share-based awards, requiring us to make certain assumptions about the future, which are more fully described in Note 10. Stock-based compensation expense for employee stock options for the years ended September 30, 2012 and 2011 was $83 and $153, respectively.</p> <!--EndFragment--></div> </div> 1.01 1.35 5.21 0.79 1.02 4.60 24000 7000 62000 128000 155000 71000 0.97 1.38 5.19 P8Y3M26D P9Y4M24D P4Y2M27D 1.01 4.59 8.79 2135 1335 4915318 6945631 7638738 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>&nbsp;</strong></p> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 0.25in; TEXT-INDENT: 0px"> &nbsp;</td> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 0.5in; TEXT-INDENT: 0px"> <em>(a)</em></td> <td style="PADDING-BOTTOM: 0px; TEXT-ALIGN: justify; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> <em>Principles of Consolidation</em></td> </tr> </table> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant inter-company accounts and transactions have been eliminated.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 0.25in; TEXT-INDENT: 0px"> &nbsp;</td> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 0.5in; TEXT-INDENT: 0px"> <em>(b)</em></td> <td style="PADDING-BOTTOM: 0px; TEXT-ALIGN: justify; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> <em>Revenue Recognition</em></td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The majority of our Bioanalytical and analytical research service contracts involve the development of analytical methods and the processing of bioanalytical samples for pharmaceutical companies and generally provide for a fixed fee for each sample processed. Revenue is recognized under the specific performance method of accounting and the related direct costs are recognized when services are performed. Our preclinical research service contracts generally consist of preclinical studies, and revenue is recognized under the proportional performance method of accounting. Revisions in profit estimates, if any, are reflected on a cumulative basis in the period in which such revisions become known. The establishment of contract prices and total contract costs involves estimates we make at the inception of the contract. These estimates could change during the term of the contract and impact the revenue and costs reported in the consolidated financial statements. Revisions to estimates have generally not been material. Research service contract fees received upon acceptance are deferred until earned, and classified within customer advances. Unbilled revenues represent revenues earned under contracts in advance of billings.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> Product revenue from sales of equipment not requiring installation, testing or training is recognized upon shipment to customers. One product includes internally developed software and requires installation, testing and training, which occur concurrently. Revenue from these sales is recognized upon completion of the installation, testing and training when the services are bundled with the equipment sale.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 0.25in; TEXT-INDENT: 0px"> &nbsp;</td> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 0.5in; TEXT-INDENT: 0px"> <em>(c)</em></td> <td style="PADDING-BOTTOM: 0px; TEXT-ALIGN: justify; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> <em>Cash Equivalents</em></td> </tr> </table> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> We consider all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> One or more of the financial institutions holding the Company&#39;s cash accounts are participating in the FDIC&#39;s Transaction Account Guarantee Program. Under that program, through December 31, 2010, all noninterest-bearing transaction accounts are fully guaranteed by the FDIC for the entire amount in the account. Pursuant to legislation enacted in 2010, the FDIC will fully insure all noninterest-bearing transaction accounts beginning December 31, 2010 through December 31, 2012, at all FDIC-insured institutions.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> For financial institutions opting out of the FDIC&#39;s Transaction Account Guarantee Program or interest-bearing cash accounts, the FDIC&#39;s insurance limits were permanently increased to $250,000, effective July 21, 2010. At September 30, 2012, the Company did not have any cash accounts that exceeded federally insured limits.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 0.25in; TEXT-INDENT: 0px"> &nbsp;</td> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 0.5in; TEXT-INDENT: 0px"> <em>(d)</em></td> <td style="PADDING-BOTTOM: 0px; TEXT-ALIGN: justify; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> <em>Accounts Receivable</em></td> </tr> </table> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> We perform periodic credit evaluations of our customers&#39; financial conditions and generally do not require collateral on trade accounts receivable. <font style="COLOR: black">We account for trade receivables based on the amounts billed to customers. Past due receivables are determined based on contractual terms. We do not accrue interest on any of our trade receivables. The allowance for doubtful accounts is determined by management based on our historical losses, specific customer circumstances, and general economic conditions. Periodically, management reviews accounts receivable and adjusts the allowance based on current circumstances and charges off uncollectible receivables when all attempts to collect have failed.</font> Our allowance for doubtful accounts was $123 and $108 at September 30, 2012 and 2011, respectively.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> A summary of activity in our allowance for doubtful accounts is as follows:</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 70%" cellspacing="0" cellpadding="0" align="center"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2">2012</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2">2011</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt" colspan="2">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt" colspan="2">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 72%">Opening balance</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%">108</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%">165</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">Charged to expense</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">84</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">13</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">Accounts recovered</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">15</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">(61</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">)</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> Accounts written off</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> (84</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> )</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> (9</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> )</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 0.25in"> Ending balance</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 123</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 108</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> </table> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 0.25in; TEXT-INDENT: 0px"> &nbsp;</td> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 0.5in; TEXT-INDENT: 0px"> <em>(e)</em></td> <td style="PADDING-BOTTOM: 0px; TEXT-ALIGN: justify; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> <em>Inventories</em></td> </tr> </table> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> Inventories are stated at the lower of cost or market using the first-in, first-out (FIFO) cost method of accounting. We evaluate inventories on a regular basis to identify inventory on hand that may be obsolete or in excess of current and future projected market demand. For inventory deemed to be obsolete, we provide a reserve for this inventory. Inventory that is in excess of current and projected use is reduced by an allowance to a level that approximates the estimate of future demand.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 0.25in; TEXT-INDENT: 0px"> &nbsp;</td> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 0.5in; TEXT-INDENT: 0px"> <em>(f)</em></td> <td style="PADDING-BOTTOM: 0px; TEXT-ALIGN: justify; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> <em>Property and Equipment</em></td> </tr> </table> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> We record property and equipment at cost, including interest capitalized during the period of construction of major facilities. We compute depreciation, including amortization on capital leases, using the straight-line method over the estimated useful lives of the assets, which we estimate to be: buildings and improvements, 34 to 40 years; machinery and equipment, 5 to 10 years, and office furniture and fixtures, 10 years. In our European operations, we depreciate leasehold improvements, using the straight-line method, over 7 years, corresponding to the terms of the operating lease for the European facility. Depreciation expense was $2,217 in fiscal 2012 and $2,085 in fiscal 2011. Expenditures for maintenance and repairs are expensed as incurred.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> Property and equipment, net, as of September 30, 2012 and 2011 consisted of the following:</p> <p style="TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 80%" cellspacing="0" cellpadding="0" align="center"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2">2012</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2">2011</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="2"> &nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="2"> &nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 72%">Land and improvements</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%">914</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%">527</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">Buildings and improvements</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">21,278</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">21,433</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">Machinery and equipment</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">19,496</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">22,361</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">Office furniture and fixtures</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">701</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">949</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> Construction in progress</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 35</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 493</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">42,424</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">45,763</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">Less:&nbsp; accumulated depreciation</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">(23,796</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">)</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">(25,364</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">)</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> Net property and equipment</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 18,628</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 20,399</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> </table> <p style="TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 0.25in; TEXT-INDENT: 0px"> &nbsp;</td> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 0.5in; TEXT-INDENT: 0px"> <em>(g)</em></td> <td style="PADDING-BOTTOM: 0px; TEXT-ALIGN: justify; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> <em>Long-Lived Assets including Goodwill</em></td> </tr> </table> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> Long-lived assets, such as property and equipment, and purchased intangibles subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized of the amount by which the carrying amount of the asset exceeds the fair value of the asset.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> We carry goodwill at cost. Other intangible assets with definite lives are stated at cost and are amortized on a straight-line basis over their estimated useful lives. All intangible assets acquired that are obtained through contractual or legal right, or are capable of being separately sold, transferred, licensed, rented, or exchanged, are recognized as an asset apart from goodwill. Goodwill is not amortized<font style="COLOR: red">.</font></p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> Goodwill is tested annually for impairment, and more frequently if events and circumstances indicate that the asset might be impaired. First, we can assess qualitative factors in determining whether&nbsp;it is more likely than not that the fair value of a reporting unit is less than its carrying amount.&nbsp;We elected to bypass the qualitative assessment aspect of this guidance due to the restructuring circumstances. Then, we followed a two-step quantitative process. In the first step, we compare the fair value of each reporting unit, as computed primarily by present value cash flow calculations, to its book carrying value, including goodwill. We do not believe that market value is indicative of the true fair value of the Company mainly due to average daily trading volumes of less than 1%. If the fair value exceeds the carrying value, no further work is required and no impairment loss is recognized. If the carrying value exceeds the fair value, the goodwill of the reporting unit is potentially impaired and we would then complete step 2 in order to measure the impairment loss. In step 2, the implied fair value is compared to the carrying amount of the goodwill. If the implied fair value of goodwill is less than the carrying value of goodwill, we would recognize an impairment loss equal to the difference. The implied fair value is calculated by allocating the fair value of the reporting unit (as determined in step 1) to all of its assets and liabilities (including unrecognized intangible assets) and any excess in fair value that is not assigned to the assets and liabilities is the implied fair value of goodwill.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The discount rate, gross margin and sales growth rates are material assumptions utilized in our calculations of the present value cash flows used to estimate the fair value of the reporting units when performing the annual goodwill impairment test. Our reporting units with goodwill at September 30, 2012 are Vetronics, which is included in our Products segment, bioanalytical services and preclinical services, which are both included in our Services segment, based on the discrete financial information available which is reviewed by management. We utilize a cash flow approach in estimating the fair value of the reporting units, where the discount rate reflects a weighted average cost of capital rate. The cash flow model used to derive fair value is sensitive to the discount rate and sales growth assumptions used.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> Due to the closure of the McMinnville, Oregon site, we tested for impairment of the bioanalytical business at the end of our third fiscal quarter using the cash flow approach as explained above. This test resulted in no impairment to the goodwill valuation as currently recorded on the books.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> We also performed our annual impairment test for all reporting units mentioned above at September 30, 2012. Using a discount rate of 14% and a revenue growth rate of 5% for the Bioanalytical services and 0% for both the preclinical services and Vetronics units, the fair values of the reporting units described above are greater than the carrying values by approximately $3.7 million.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> Considerable management judgment is necessary to evaluate the impact of operating and macroeconomic changes and to estimate future cash flows. Assumptions used in our impairment evaluations, such as forecasted sales growth rates and our cost of capital or discount rate, are based on the best available market information. Changes in these estimates or a continued decline in general economic conditions could change our conclusion regarding an impairment of goodwill and potentially result in a non-cash impairment loss in a future period. The assumptions used in our impairment testing could be adversely affected by certain risks. There have been no significant events since the timing of our impairment tests that would have triggered additional impairment testing.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> At September 30, 2012 and 2011, remaining recorded goodwill was $1,383, and the net balance of other intangible assets was $0 and $54, respectively. The components of intangible assets subject to amortization are as follows:</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 90%" cellspacing="0" cellpadding="0" align="center"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="6" nowrap="nowrap">September 30, 2012</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Weighted<br /> average life<br /> (years)</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Gross Carrying<br /> Amount</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Accumulated<br /> Amortization</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 58%; TEXT-INDENT: 0px"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> FDA compliant facility</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 10</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 302</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 302</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 90%" cellspacing="0" cellpadding="0" align="center"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right" colspan="2" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="6" nowrap="nowrap">September 30, 2011</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Weighted<br /> average life<br /> (years)</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Gross Carrying<br /> Amount</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Accumulated<br /> Amortization</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 58%; TEXT-INDENT: 0px"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> FDA compliant facility</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 10</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 302</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 248</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> Amortization expense for intangible assets for fiscal years ended September&nbsp;30, 2012 and 2011 was $54 and $30, respectively. As of September 30, 2012, all intangible assets have been fully amortized.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 0.25in; TEXT-INDENT: 0px"> &nbsp;</td> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 0.5in; TEXT-INDENT: 0px"> <em>(h)</em></td> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> <em>Advertising Expense</em></td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> We expense advertising costs as incurred. Advertising expense was $203 and $229 for the years ended September 30, 2012 and 2011, respectively.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 0.25in; TEXT-INDENT: 0px"> &nbsp;</td> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 0.5in; TEXT-INDENT: 0px"> <em>(i)</em></td> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> <em>Stock-Based Compensation</em></td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> We have a stock-based employee compensation plan and a stock-based employee and outside director compensation plan, which are described more fully in Note 10. All options granted under these plans have an exercise price equal to the market value of the underlying common shares on the date of grant. We expense the estimated fair value of stock options over the vesting periods of the grants. <font style="COLOR: black">Our policy is to recognize expense for awards subject to graded vesting using the straight-line attribution method,</font> reduced for estimated forfeitures. Forfeitures are revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates and an adjustment is recognized at that time.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> We use a binomial option-pricing model as our method of valuation for share-based awards, requiring us to make certain assumptions about the future, which are more fully described in Note 10. Stock-based compensation expense for employee stock options for the years ended September 30, 2012 and 2011 was $83 and $153, respectively.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 0.25in; TEXT-INDENT: 0px"> &nbsp;</td> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 0.5in; TEXT-INDENT: 0px"> <em>(j)</em></td> <td style="PADDING-BOTTOM: 0px; TEXT-ALIGN: justify; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> <em>Income Taxes</em></td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. We record valuation allowances based on a determination of the expected realization of tax assets.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> We may recognize the tax benefit from an uncertain tax position only if it is more likely than not to be sustained upon examination based on the technical merits of the position. The amount of the accrual for which an exposure exists is measured as the largest amount of benefit determined on a cumulative probability basis that we believe is more likely than not to be realized upon settlement of the position.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> We record interest and penalties accrued in relation to uncertain income tax positions as a component of income tax expense. Any changes in the liability for uncertain tax positions would impact our effective tax rate. We do not expect the total amount of unrecognized tax benefits to significantly change in the next twelve months.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 0.25in; TEXT-INDENT: 0px"> &nbsp;</td> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 0.5in; TEXT-INDENT: 0px"> <em>(k)</em></td> <td style="PADDING-BOTTOM: 0px; TEXT-ALIGN: justify; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> <em>New Accounting Pronouncements</em></td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> In May 2011, the FASB issued updated fair value&nbsp;measurement and disclosure&nbsp;guidance that clarifies how&nbsp;to measure fair value&nbsp;and requires additional disclosures regarding Level 3 fair value measurements, as well as any transfers between Level 1 and Level 2 fair value measurements. The updated accounting guidance is effective for fiscal years and interim periods beginning on or after December&nbsp;15, 2011 on a prospective basis. The Company adopted this guidance in the second fiscal quarter with no material impact on&nbsp;the consolidated financial statements.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> In June 2011, the FASB amended the manner in which an entity presents the total of comprehensive income, the components of net income and the components of other comprehensive income either in a single, continuous statement of comprehensive income or in two separate but consecutive statements.&nbsp;The amendment&nbsp;eliminates the option to present the components of other comprehensive income as part of the statement of equity. The amendment&nbsp;is effective for fiscal years and interim periods beginning on or after December&nbsp;15, 2011 on a retrospective basis.&nbsp;The adoption of this guidance&nbsp;will not change the previously reported amounts of comprehensive income. The Company has presented other comprehensive income on the face of the condensed consolidated statements of operations for all periods presented.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> In September 2011, the FASB issued an&nbsp;accounting&nbsp;standards&nbsp;update&nbsp;that amends the two-step goodwill impairment test&nbsp;by permitting an entity to first assess qualitative factors in determining whether&nbsp;it is more likely than not that the fair value of a reporting unit is less than its carrying amount.&nbsp;If the entity determines that it is not more likely than not that the fair value of a reporting unit is less than its carrying amount, then performing the two-step goodwill impairment test&nbsp;is unnecessary. The amendment&nbsp;is effective for fiscal years and interim periods beginning on or after December&nbsp;15, 2011 on a&nbsp;prospective basis, early adoption is permitted. The Company elected to bypass the qualitative assessment aspect of this guidance due to the restructuring circumstances and performed a quantitative analysis in the third and fourth fiscal quarters of 2012. The quantitative analysis resulted in no impairment to the goodwill valuation as currently recorded on the books.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 0.25in; TEXT-INDENT: 0px"> &nbsp;</td> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 0.5in; TEXT-INDENT: 0px"> <em>(l)</em></td> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> <em>Fair Value</em> </td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The provisions of the Fair Value Measurements and Disclosure Topic defines fair value, establishes a consistent framework for measuring fair value and provides the disclosure requirements about fair value measurements. This Topic also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#39;s judgment about the assumptions market participants would use in pricing the asset or liability based on the best information available in the circumstances. The hierarchy is broken down into three levels based on the inputs as follows:</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 100%" cellspacing="0" cellpadding="0"> <tr> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 5%; TEXT-INDENT: 0px"> &nbsp;</td> <td style="VERTICAL-ALIGN: top; PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 2%; TEXT-INDENT: 0px"> &bull;</td> <td style="VERTICAL-ALIGN: top; PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 1%; TEXT-INDENT: 0px"> &nbsp;</td> <td style="VERTICAL-ALIGN: top; PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> Level 1 - Valuations based on quoted prices for identical assets or liabilities in active markets that the Company has the ability to access.</td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 100%" cellspacing="0" cellpadding="0"> <tr> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 5%; TEXT-INDENT: 0px"> &nbsp;</td> <td style="VERTICAL-ALIGN: top; PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 2%; TEXT-INDENT: 0px"> &bull;</td> <td style="VERTICAL-ALIGN: top; PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 1%; TEXT-INDENT: 0px"> &nbsp;</td> <td style="VERTICAL-ALIGN: top; PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> Level 2 - Valuations based on quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.</td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 100%" cellspacing="0" cellpadding="0"> <tr> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 5%; TEXT-INDENT: 0px"> &nbsp;</td> <td style="VERTICAL-ALIGN: top; PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 2%; TEXT-INDENT: 0px"> &bull;</td> <td style="VERTICAL-ALIGN: top; PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 1%; TEXT-INDENT: 0px"> &nbsp;</td> <td style="VERTICAL-ALIGN: top; PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> Level 3 - Valuations based on inputs that are unobservable and significant to the overall fair value measurement.</td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> We have Class A and B Warrants from the May 2011 offering that are measured at fair value on a recurring basis. We recorded these warrants as a liability determining the fair value at inception on May 11, 2011. Subsequent quarterly fair value measurements, using the Black Scholes model which is considered a level 2 measurement, are calculated with fair value changes charged to the statement of operations and comprehensive income (loss). Class B Warrants expired in May 2012 and the liability was reduced to zero. The assumptions used to compute the fair value of the warrants at September 30, 2012 and 2011 were as follows:</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 80%" cellspacing="0" cellpadding="0" align="center"> <tr style="VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">September 30, 2012</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="6" nowrap="nowrap">September 30, 2011</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td nowrap="nowrap">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Warrant A</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Warrant A</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Warrant B</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: center" colspan="2">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: center" colspan="2">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: center" colspan="2">&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="TEXT-ALIGN: left; WIDTH: 46%">Risk-free interest rate</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: right; WIDTH: 15%">0.41</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">%</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: right; WIDTH: 15%">0.86</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">%</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: right; WIDTH: 15%">0.08</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">%</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="TEXT-ALIGN: left">Dividend yield</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">0.00</td> <td style="TEXT-ALIGN: left">%</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">0.00</td> <td style="TEXT-ALIGN: left">%</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">0.00</td> <td style="TEXT-ALIGN: left">%</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="TEXT-ALIGN: left">Volatility of the Company&#39;s common stock</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">117.30</td> <td style="TEXT-ALIGN: left">%</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">111.44</td> <td style="TEXT-ALIGN: left">%</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">74.43</td> <td style="TEXT-ALIGN: left">%</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="TEXT-ALIGN: left">Expected life of the options (years)</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">3.6</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">4.6</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">0.6</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td>Fair value per unit</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">0.881</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">0.844</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">0.091</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The carrying amounts for cash and cash equivalents, accounts receivable, inventories, prepaid expenses and other assets, accounts payable and other accruals approximate their fair values because of their nature and respective duration. The fair value of the revolving credit facility and certain long-term debt is equal to their carrying values due to the variable nature of their interest rates. Our long-term fixed rate debt was initiated in February 2011 and renewed on November 1, 2012. Our interest rate swap expired under its terms in fiscal 2011.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 0.25in; TEXT-INDENT: 0px"> &nbsp;</td> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 0.5in; TEXT-INDENT: 0px"> <em>(m)</em></td> <td style="PADDING-BOTTOM: 0px; TEXT-ALIGN: justify; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> <em>Use of Estimates</em></td> </tr> </table> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The preparation of financial statements in conformity with generally accepted accounting principles requires us to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Significant estimates as part of the issuance of these consolidated financial statements include but are not limited to the determination of fair values, allowance for doubtful accounts, inventory obsolescence, deferred tax valuations, depreciation, impairment charges and stock compensation. Our actual results could differ from those estimates.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 0.25in; TEXT-INDENT: 0px"> &nbsp;</td> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 0.5in; TEXT-INDENT: 0px"> <em>(n)</em></td> <td style="PADDING-BOTTOM: 0px; TEXT-ALIGN: justify; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> <em>Research and Development</em></td> </tr> </table> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> In fiscal 2012 and 2011, we spent $542 and $534, respectively, on research and development. Separate from our contract research services business, we maintain applications research and development to enhance our products business.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 0.25in; TEXT-INDENT: 0px"> &nbsp;</td> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 0.5in; TEXT-INDENT: 0px"> <em>(o)</em></td> <td style="PADDING-BOTTOM: 0px; TEXT-ALIGN: justify; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> <em>Comprehensive Income (Loss)</em></td> </tr> </table> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> We report comprehensive income (loss) on our Consolidated Statements of Operations. Other comprehensive income (loss) represents changes in shareholders&#39; equity and is comprised of foreign currency translation adjustments.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 0.25in; TEXT-INDENT: 0px"> &nbsp;</td> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 0.5in; TEXT-INDENT: 0px"> <em>(p)</em></td> <td style="PADDING-BOTTOM: 0px; TEXT-ALIGN: justify; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> <em>Foreign Currency</em></td> </tr> </table> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.25in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> For our subsidiary outside of the United States that operates in a local currency environment, income and expense items are translated to United States dollars at the monthly average rates of exchange prevailing during the year, assets and liabilities are translated at year-end exchange rates and equity accounts are translated at historical exchange rates. Translation adjustments are accumulated in a separate component of shareholders&#39; equity in the consolidated balance sheets and are included in the determination of comprehensive income (loss) in the consolidated statements of shareholders&#39; equity. Transaction gains and losses are included in the determination of net income (loss) in the consolidated statements of operations and comprehensive income (loss).</p> <!--EndFragment--></div> </div> 10667000 14300000 8377000 2135000 1335000 1191000 1698000 1871000 13357000 18592000 19635000 -3981000 -8176000 -14493000 100000 51000 29000 15586000 9590000 -1286000 -1213000 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>4. SALE OF PREFERRED SHARES AND WARRANTS (not in thousands)</strong></p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> On May 11, 2011, we completed <font style="COLOR: black">a registered public offering of 5,506 units at a price of $1,000 per unit. Each unit consisted of one 6% Series A convertible preferred share which is convertible into 500 common shares, one Class A Warrant to purchase 250 common shares</font> at an exercise price of $2.00 per share<font style="COLOR: black">, and one Class B Warrant to purchase 250 common shares</font> at an exercise price of $2.00 per share<font style="COLOR: black">.</font></p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> <font style="FONT-SIZE: 10pt">The designation, rights, preferences and other terms and provisions of the Series A preferred shares are set forth in the Certificate of Designation. Until May 11, 2014, the Series A preferred shares have a stated dividend rate of 6% per annum, payable quarterly in cash or, subject to certain conditions, in common shares or a combination of cash and common shares, at our election. After May 11, 2014, the Series A preferred shares will participate in any dividends payable upon our common shares on an "as converted" basis.</font> <font style="FONT-SIZE: 10pt">If the preferred shares are converted prior to May 11, 2014, we must also pay to the converting holder in cash, or subject to certain conditions, in common shares or a combination of cash and common shares, a "make-whole" payment of $180 per $1,000 of the stated value of the preferred shares less any dividends paid prior to conversion. Class A Warrants are exercisable immediately and expire in May 2016. Class B Warrants expired in May 2012. The net proceeds from the sale of the units, after deducting the fees and expenses of the placement agent and other expenses were $4.6 million. We used the <font style="COLOR: black">proceeds for the purchase of laboratory equipment and for working capital and general corporate purposes.</font></font></p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The holders of the preferred shares are not entitled to vote together with common shareholders unless converted to common shares. The Series A preferred shares are considered to be an equity instrument. The warrants have been accounted for as a liability and valued using the Black Scholes pricing model. The total fair value of the Class A Warrants at issuance was $1.973 million and the total fair value of the Class B Warrants at issuance was $1.072 million for a total liability of $3.045 million. The assumptions used to compute the fair value of the warrants at the time of issuance were as follows:</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 80%" cellspacing="0" cellpadding="0" align="center"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Warrant A</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Warrant B</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="2"> &nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="2"> &nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 72%">Risk-free interest rate</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> 1.87</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">%</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> 0.18</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">%</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">Dividend yield</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">0.00</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">%</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">0.00</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">%</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">Volatility of the Company&#39;s common stock</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">106.91</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">%</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">116.01</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">%</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">Expected life of the options (years)</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">5.0</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">1.0</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt">Fair value per unit</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">1.433</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">0.779</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The Series A preferred shares were valued using the common shares available upon conversion of all preferred shares of 2,753,000 and the closing market price of our stock on May 11, 2011 of $1.86. Adding in the total possible dividend for the preferred shares of 18% over three years, or $991,080, the total calculated fair value of the preferred shares was $6.112 million. We then allocated the gross proceeds of the offering of $5.506 million to the preferred shares after deducting the fair value of the warrants described above.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> We have also recognized a beneficial conversion feature related to the Series A preferred shares, to the extent that the conversion feature, based on the proceeds allocated to the Series A preferred shares, was in-the-money at the time they were issued. Such beneficial conversion feature amounted to approximately $2.461 million. Because the Series A preferred shares do not have a stated redemption date and may be converted by the holder at any time, the discount recognized by the allocation of proceeds to the beneficial conversion feature has been immediately charged through accumulated deficit as a deemed dividend to the holders of the Series A preferred shares in the amount of $5.506 million. This will be the only deemed distribution recorded for the Series A preferred shares included in this offering. Further, because the preferred dividends or make-whole payments are payable any time after the closing on May 11, 2011 at the option of the holder, we recognized the full value, $991,080, as a liability included in accounts payable and charged immediately through accumulated deficit. There will be no other dividends recorded for the Series A preferred shares included in this offering.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> As of September 30, 2012, 4,171 preferred shares have been converted into 2,486,127 common shares and 135,793 common shares have been issued for quarterly preferred dividends for remaining outstanding, unconverted preferred shares. No warrants have been exercised as of September 30, 2012. At September 30, 2012, 1,335 preferred shares and 1,376,500 warrants remained outstanding. Also at September 30, 2012, $227,977 of the $991,080 in preferred dividends remains accrued in accounts payable for future preferred dividends.</p> <!--EndFragment--></div> </div> -657000 -106000 -3371 -800 1685500 400000 5506 5506 -3371000 -800000 421000 100000 2950000 700000 5506000 -900000 4606000 86000 48000 571000 157000 657000 205000 42000 119000 75000 18000 31000 30000 16000 16000 14000 14000 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 0.25in; TEXT-INDENT: 0px"> &nbsp;</td> <td style="PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; WIDTH: 0.5in; TEXT-INDENT: 0px"> <em>(m)</em></td> <td style="PADDING-BOTTOM: 0px; TEXT-ALIGN: justify; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; TEXT-INDENT: 0px"> <em>Use of Estimates</em></td> </tr> </table> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The preparation of financial statements in conformity with generally accepted accounting principles requires us to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Significant estimates as part of the issuance of these consolidated financial statements include but are not limited to the determination of fair values, allowance for doubtful accounts, inventory obsolescence, deferred tax valuations, depreciation, impairment charges and stock compensation. Our actual results could differ from those estimates.</p> <!--EndFragment--></div> </div> 1072000 3045000 5667000 7158000 5667000 7158000 utr:acre utr:sqft iso4217:USD xbrli:pure xbrli:shares iso4217:USD xbrli:shares iso4217:USD basi:warrants 0000720154 2012-04-01 2012-09-30 0000720154 us-gaap:CertificationMarksMember 2011-10-01 2012-09-30 0000720154 us-gaap:BuildingMember 2011-10-01 2012-09-30 0000720154 us-gaap:BuildingAndBuildingImprovementsMember us-gaap:MinimumMember 2011-10-01 2012-09-30 0000720154 us-gaap:BuildingAndBuildingImprovementsMember us-gaap:MaximumMember 2011-10-01 2012-09-30 0000720154 us-gaap:WarrantMember 2011-10-01 2012-09-30 0000720154 us-gaap:StockOptionsMember us-gaap:MinimumMember 2011-10-01 2012-09-30 0000720154 us-gaap:StockOptionsMember us-gaap:MaximumMember 2011-10-01 2012-09-30 0000720154 us-gaap:StockOptionsMember 2011-10-01 2012-09-30 0000720154 us-gaap:StateAndLocalJurisdictionMember 2011-10-01 2012-09-30 0000720154 us-gaap:SeriesAPreferredStockMember 2011-10-01 2012-09-30 0000720154 us-gaap:SegmentGeographicalGroupsOfCountriesGroupTwoMember 2011-10-01 2012-09-30 0000720154 us-gaap:SegmentGeographicalGroupsOfCountriesGroupOneMember 2011-10-01 2012-09-30 0000720154 us-gaap:AdditionalPaidInCapitalMember 2011-10-01 2012-09-30 0000720154 us-gaap:ScenarioAdjustmentMember 2011-10-01 2012-09-30 0000720154 us-gaap:ScenarioPreviouslyReportedMember 2011-10-01 2012-09-30 0000720154 us-gaap:RetainedEarningsMember 2011-10-01 2012-09-30 0000720154 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2011-10-01 2012-09-30 0000720154 us-gaap:PreferredStockMember 2011-10-01 2012-09-30 0000720154 us-gaap:OtherRestructuringMember 2011-10-01 2012-09-30 0000720154 basi:ServicesThreeMember 2011-10-01 2012-09-30 0000720154 basi:ServicesTwoMember 2011-10-01 2012-09-30 0000720154 basi:ServicesOneMember 2011-10-01 2012-09-30 0000720154 us-gaap:OneTimeTerminationBenefitsMember 2011-10-01 2012-09-30 0000720154 basi:NotePayableSixMember 2011-10-01 2012-09-30 0000720154 basi:LeaseRelatedCostsMember 2011-10-01 2012-09-30 0000720154 us-gaap:MachineryAndEquipmentMember us-gaap:MinimumMember 2011-10-01 2012-09-30 0000720154 us-gaap:MachineryAndEquipmentMember us-gaap:MaximumMember 2011-10-01 2012-09-30 0000720154 basi:NotePayableToAlgoHoldingsMember 2011-10-01 2012-09-30 0000720154 basi:MajorCustomerTwoMember 2011-10-01 2012-09-30 0000720154 basi:MajorCustomerOneMember 2011-10-01 2012-09-30 0000720154 basi:SegmentGeographicalGroupsOfCountriesOtherGroupMember 2011-10-01 2012-09-30 0000720154 basi:SegmentGeographicalGroupsOfCountriesGroupThreeMember 2011-10-01 2012-09-30 0000720154 basi:RangeThreeMember 2011-10-01 2012-09-30 0000720154 basi:RangeTwoMember 2011-10-01 2012-09-30 0000720154 basi:RangeOneMember 2011-10-01 2012-09-30 0000720154 us-gaap:LineOfCreditMember us-gaap:MinimumMember 2011-10-01 2012-09-30 0000720154 us-gaap:LineOfCreditMember 2011-10-01 2012-09-30 0000720154 basi:AmendedRevolvingLineOfCreditMember 2011-10-01 2012-09-30 0000720154 basi:MortgageNotesPayableOneAndTwoMember 2011-10-01 2012-09-30 0000720154 basi:ReplacementNotePayableMember 2011-10-01 2012-09-30 0000720154 basi:MortgageNotePayableTwoMember 2011-10-01 2012-09-30 0000720154 basi:MortgageNotePayableOneMember 2011-10-01 2012-09-30 0000720154 basi:UnitMember 2011-10-01 2012-09-30 0000720154 basi:ClassBWarrantMember 2011-10-01 2012-09-30 0000720154 basi:ClassAWarrantMember us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2011-10-01 2012-09-30 0000720154 basi:ClassAWarrantMember 2011-10-01 2012-09-30 0000720154 basi:EquipmentMovingCostsAndMethodTransfersMember 2011-10-01 2012-09-30 0000720154 basi:ProductsSegmentMember 2011-10-01 2012-09-30 0000720154 basi:ServicesSegmentMember 2011-10-01 2012-09-30 0000720154 us-gaap:LeaseholdImprovementsMember 2011-10-01 2012-09-30 0000720154 us-gaap:GainsLossesOnSalesOfAssetsMember 2011-10-01 2012-09-30 0000720154 us-gaap:FurnitureAndFixturesMember 2011-10-01 2012-09-30 0000720154 us-gaap:ForeignCountryMember 2011-10-01 2012-09-30 0000720154 us-gaap:EquipmentMember 2011-10-01 2012-09-30 0000720154 us-gaap:EmployeeRelocationMember 2011-10-01 2012-09-30 0000720154 us-gaap:DomesticCountryMember 2011-10-01 2012-09-30 0000720154 us-gaap:CorporateMember 2011-10-01 2012-09-30 0000720154 us-gaap:CommonStockMember 2011-10-01 2012-09-30 0000720154 2011-10-01 2012-09-30 0000720154 2011-10-01 2012-03-31 0000720154 us-gaap:SeriesAPreferredStockMember 2011-05-01 2011-05-11 0000720154 basi:UnitMember 2011-05-01 2011-05-11 0000720154 us-gaap:CertificationMarksMember 2010-10-01 2011-09-30 0000720154 us-gaap:BuildingMember 2010-10-01 2011-09-30 0000720154 us-gaap:WarrantMember 2010-10-01 2011-09-30 0000720154 us-gaap:StockOptionsMember 2010-10-01 2011-09-30 0000720154 us-gaap:StateAndLocalJurisdictionMember 2010-10-01 2011-09-30 0000720154 us-gaap:SeriesAPreferredStockMember 2010-10-01 2011-09-30 0000720154 us-gaap:SegmentGeographicalGroupsOfCountriesGroupTwoMember 2010-10-01 2011-09-30 0000720154 us-gaap:SegmentGeographicalGroupsOfCountriesGroupOneMember 2010-10-01 2011-09-30 0000720154 us-gaap:AdditionalPaidInCapitalMember 2010-10-01 2011-09-30 0000720154 us-gaap:ScenarioAdjustmentMember 2010-10-01 2011-09-30 0000720154 us-gaap:ScenarioPreviouslyReportedMember 2010-10-01 2011-09-30 0000720154 us-gaap:RetainedEarningsMember 2010-10-01 2011-09-30 0000720154 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2010-10-01 2011-09-30 0000720154 us-gaap:PreferredStockMember 2010-10-01 2011-09-30 0000720154 basi:MajorCustomerTwoMember 2010-10-01 2011-09-30 0000720154 basi:MajorCustomerOneMember 2010-10-01 2011-09-30 0000720154 basi:SegmentGeographicalGroupsOfCountriesOtherGroupMember 2010-10-01 2011-09-30 0000720154 basi:SegmentGeographicalGroupsOfCountriesGroupThreeMember 2010-10-01 2011-09-30 0000720154 basi:ClassBWarrantMember us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2010-10-01 2011-09-30 0000720154 basi:ClassAWarrantMember us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2010-10-01 2011-09-30 0000720154 basi:ProductsSegmentMember 2010-10-01 2011-09-30 0000720154 basi:ServicesSegmentMember 2010-10-01 2011-09-30 0000720154 us-gaap:ForeignCountryMember 2010-10-01 2011-09-30 0000720154 us-gaap:EquipmentMember 2010-10-01 2011-09-30 0000720154 us-gaap:CorporateMember 2010-10-01 2011-09-30 0000720154 us-gaap:CommonStockMember 2010-10-01 2011-09-30 0000720154 2010-10-01 2011-09-30 0000720154 2012-12-28 0000720154 us-gaap:CertificationMarksMember 2012-09-30 0000720154 us-gaap:StateAndLocalJurisdictionMember 2012-09-30 0000720154 us-gaap:SeriesAPreferredStockMember 2012-09-30 0000720154 us-gaap:SegmentGeographicalGroupsOfCountriesGroupOneMember 2012-09-30 0000720154 us-gaap:AdditionalPaidInCapitalMember 2012-09-30 0000720154 us-gaap:ScenarioAdjustmentMember 2012-09-30 0000720154 us-gaap:ScenarioPreviouslyReportedMember 2012-09-30 0000720154 us-gaap:RetainedEarningsMember 2012-09-30 0000720154 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2012-09-30 0000720154 us-gaap:PreferredStockMember 2012-09-30 0000720154 us-gaap:OtherRestructuringMember 2012-09-30 0000720154 us-gaap:OneTimeTerminationBenefitsMember 2012-09-30 0000720154 basi:NotePayableSixMember 2012-09-30 0000720154 basi:ForeignTaxCreditCarryforwardMember 2012-09-30 0000720154 basi:LeaseRelatedCostsMember 2012-09-30 0000720154 basi:NotePayableToAlgoHoldingsMember 2012-09-30 0000720154 basi:SegmentGeographicalGroupsOfCountriesGroupThreeMember 2012-09-30 0000720154 basi:RangeThreeMember 2012-09-30 0000720154 basi:RangeTwoMember 2012-09-30 0000720154 basi:RangeOneMember 2012-09-30 0000720154 basi:AlternativeMinimumTaxCreditCarryforwardMember 2012-09-30 0000720154 us-gaap:LineOfCreditMember 2012-09-30 0000720154 basi:AmendedRevolvingLineOfCreditMember 2012-09-30 0000720154 basi:MortgageNotesPayableOneAndTwoMember 2012-09-30 0000720154 basi:NotesPayableToRegionsBankMember 2012-09-30 0000720154 basi:ReplacementNotePayableMember 2012-09-30 0000720154 basi:MortgageNotePayableTwoMember 2012-09-30 0000720154 basi:MortgageNotePayableOneMember 2012-09-30 0000720154 basi:LeasePaymentInterestMember 2012-09-30 0000720154 basi:LeasePaymentPrincipalMember 2012-09-30 0000720154 basi:ClassBWarrantMember 2012-09-30 0000720154 basi:ClassAWarrantMember 2012-09-30 0000720154 basi:EquipmentMovingCostsAndMethodTransfersMember 2012-09-30 0000720154 basi:ProductsSegmentMember 2012-09-30 0000720154 basi:ServicesSegmentMember 2012-09-30 0000720154 us-gaap:GainsLossesOnSalesOfAssetsMember 2012-09-30 0000720154 us-gaap:ForeignCountryMember 2012-09-30 0000720154 us-gaap:EquipmentMember 2012-09-30 0000720154 us-gaap:EmployeeRelocationMember 2012-09-30 0000720154 us-gaap:DomesticCountryMember 2012-09-30 0000720154 us-gaap:CorporateMember 2012-09-30 0000720154 us-gaap:CommonStockMember 2012-09-30 0000720154 2012-09-30 0000720154 2012-07-12 0000720154 basi:ClassBWarrantMember 2012-05-31 0000720154 2012-03-31 0000720154 us-gaap:CertificationMarksMember 2011-09-30 0000720154 us-gaap:SeriesAPreferredStockMember 2011-09-30 0000720154 us-gaap:SegmentGeographicalGroupsOfCountriesGroupOneMember 2011-09-30 0000720154 us-gaap:AdditionalPaidInCapitalMember 2011-09-30 0000720154 us-gaap:ScenarioAdjustmentMember 2011-09-30 0000720154 us-gaap:ScenarioPreviouslyReportedMember 2011-09-30 0000720154 us-gaap:RetainedEarningsMember 2011-09-30 0000720154 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2011-09-30 0000720154 us-gaap:PreferredStockMember 2011-09-30 0000720154 us-gaap:OtherRestructuringMember 2011-09-30 0000720154 us-gaap:OneTimeTerminationBenefitsMember 2011-09-30 0000720154 basi:LeaseRelatedCostsMember 2011-09-30 0000720154 basi:NotePayableToAlgoHoldingsMember 2011-09-30 0000720154 basi:SegmentGeographicalGroupsOfCountriesGroupThreeMember 2011-09-30 0000720154 basi:ReplacementNotePayableMember 2011-09-30 0000720154 basi:MortgageNotePayableTwoMember 2011-09-30 0000720154 basi:MortgageNotePayableOneMember 2011-09-30 0000720154 basi:EquipmentMovingCostsAndMethodTransfersMember 2011-09-30 0000720154 basi:ProductsSegmentMember 2011-09-30 0000720154 basi:ServicesSegmentMember 2011-09-30 0000720154 us-gaap:GainsLossesOnSalesOfAssetsMember 2011-09-30 0000720154 us-gaap:EquipmentMember 2011-09-30 0000720154 us-gaap:EmployeeRelocationMember 2011-09-30 0000720154 us-gaap:DomesticCountryMember 2011-09-30 0000720154 us-gaap:CorporateMember 2011-09-30 0000720154 us-gaap:CommonStockMember 2011-09-30 0000720154 2011-09-30 0000720154 us-gaap:SeriesAPreferredStockMember 2011-05-11 0000720154 basi:ClassBWarrantMember 2011-05-11 0000720154 basi:ClassAWarrantMember 2011-05-11 0000720154 2011-05-11 0000720154 basi:MortgageNotePayableThreeMember 2011-02-11 0000720154 basi:NotePayableOneMember 2010-12-17 0000720154 us-gaap:AdditionalPaidInCapitalMember 2010-09-30 0000720154 us-gaap:RetainedEarningsMember 2010-09-30 0000720154 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2010-09-30 0000720154 us-gaap:PreferredStockMember 2010-09-30 0000720154 us-gaap:CommonStockMember 2010-09-30 0000720154 2010-09-30 0000720154 basi:MortgageNotePayableTwoMember 2010-06-30 0000720154 basi:MortgageNotePayableOneMember 2010-06-30 EX-101.SCH 11 basi-20120930.xsd XBRL TAXONOMY EXTENSION SCHEMA 003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 002 - Statement - CONSOLIDATED BALANCE SHEETS link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 005 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 006 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (Parenthetical) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 001 - Document - Document and Entity Information link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 107 - Disclosure - DEBT ARRANGEMENTS link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 40703 - Disclosure - DEBT ARRANGEMENTS (Narrative) (Details) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 40701 - Disclosure - DEBT ARRANGEMENTS (Schedule of Long-Term Debt) (Details) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 40702 - Disclosure - DEBT ARRANGEMENTS (Summary of Principal Payment Obligations) (Details) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 307 - Disclosure - DEBT ARRANGEMENTS (Tables) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 101 - Disclosure - DESCRIPTION OF THE BUSINESS link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 108 - Disclosure - INCOME TAXES link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 40804 - Disclosure - INCOME TAXES (Narrative) (Details) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 40803 - Disclosure - INCOME TAXES (Reconciliation of Effective Income Tax Rate) (Details) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 40805 - Disclosure - INCOME TAXES (Reconciliation of Unrecognized Tax Benefits) (Details) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 40801 - Disclosure - INCOME TAXES (Schedule of Deferred Tax Assets and Liabilities) (Details) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 40802 - Disclosure - INCOME TAXES (Schedule of the Provision (Benefit) for Income Taxes) (Details) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 308 - Disclosure - INCOME TAXES (Tables) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 105 - Disclosure - INVENTORIES link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 40501 - Disclosure - INVENTORIES (Details) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 305 - Disclosure - INVENTORIES (Tables) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 106 - Disclosure - LEASE ARRANGEMENTS link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 40601 - Disclosure - LEASE ARRANGEMENTS (Narrative) (Details) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 40602 - Disclosure - LEASE ARRANGEMENTS (Schedule of Future Minimum Lease Payments for Capital Leases) (Details) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 40603 - Disclosure - LEASE ARRANGEMENTS (Schedule of Future Minimum Lease Payments for Operating Leases) (Details) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 306 - Disclosure - LEASE ARRANGEMENTS (Tables) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 104 - Disclosure - LOSS PER SHARE link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 40401 - Disclosure - LOSS PER SHARE (Narrative) (Details) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 40402 - Disclosure - LOSS PER SHARE (Reconciliation of Computation of Basic Income or Loss Per Share to Diluted Income or Loss Per Share) (Details) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 304 - Disclosure - LOSS PER SHARE (Tables) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 115 - Disclosure - MANAGEMENT'S PLAN link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 41501 - Disclosure - MANAGEMENT'S PLAN (Details) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 110 - Disclosure - RETIREMENT PLAN link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 41001 - Disclosure - RETIREMENT PLAN (Details) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 113 - Disclosure - RESTRUCTURING link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 41301 - Disclosure - RESTRUCTURING (Narrative) (Details) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 41303 - Disclosure - RESTRUCTURING (Summary of Restructuring Activity) (Details) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 41302 - Disclosure - RESTRUCTURING (Summary of Restructuring Costs) (Details) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 313 - Disclosure - RESTRUCTURING (Tables) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 1021 - Disclosure - RESTATEMENT OF PREVIOUSLY ISSUED CONSOLIDATED FINANCIAL STATEMENTS link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 402103 - Disclosure - RESTATEMENT OF PREVIOUSLY ISSUED CONSOLIDATED FINANCIAL STATEMENTS (Balance Sheet) (Details) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 402101 - Disclosure - RESTATEMENT OF PREVIOUSLY ISSUED CONSOLIDATED FINANCIAL STATEMENTS (Narrative) (Details) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 402102 - Disclosure - RESTATEMENT OF PREVIOUSLY ISSUED CONSOLIDATED FINANCIAL STATEMENTS (Statements of Operations) (Details) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 3021 - Disclosure - RESTATEMENT OF PREVIOUSLY ISSUED CONSOLIDATED FINANCIAL STATEMENTS (Tables) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 114 - Disclosure - SELF-INSURANCE link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 109 - Disclosure - STOCK-BASED COMPENSATION link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 40902 - Disclosure - STOCK-BASED COMPENSATION (Fair Value Assumptions) (Details) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 40901 - Disclosure - STOCK-BASED COMPENSATION (Narrative) (Details) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 40904 - Disclosure - STOCK-BASED COMPENSATION (Summary of Non-Vested Options) (Details) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 40905 - Disclosure - STOCK-BASED COMPENSATION (Summary of Outstanding and Exercisable Options) (Details) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 40903 - Disclosure - STOCK-BASED COMPENSATION (Summary of Stock Option Activity) (Details) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 309 - Disclosure - STOCK-BASED COMPENSATION (Tables) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 41401 - Disclosure - SELF-INSURANCE (Details) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 111 - Disclosure - SEGMENT INFORMATION link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 41102 - Disclosure - SEGMENT INFORMATION (Geographical Information) (Details) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 41103 - Disclosure - SEGMENT INFORMATION (Narrative) (Details) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 41101 - Disclosure - SEGMENT INFORMATION (Operating Segments) (Details) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 311 - Disclosure - SEGMENT INFORMATION (Tables) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 112 - Disclosure - SETTLEMENT OF CONTINGENT LIABILITY link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 41201 - Disclosure - SETTLEMENT OF CONTINGENT LIABILITY (Details) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 103 - Disclosure - SALE OF PREFERRED SHARES AND WARRANTS link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 40302 - Disclosure - SALE OF PREFERRED SHARES AND WARRANTS (Fair Value Assumptions) (Details) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 40301 - Disclosure - SALE OF PREFERRED SHARES AND WARRANTS (Narrative) (Details) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 303 - Disclosure - SALE OF PREFERRED SHARES AND WARRANTS (Tables) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 102 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 40204 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Components of Amortizable Intangible Assets) (Details) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 40201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 40202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Summary of Activity in Allowance for Doubtful Accounts) (Details) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 40206 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Schedule of Assumptions Used to Compute Fair Value of Warrants) (Details) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 40205 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Schedule of Future Estimated Amortization Expense) (Details) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 40203 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Schedule of Property and Equipment) (Details) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink EX-101.CAL 12 basi-20120930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 13 basi-20120930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 14 basi-20120930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Amendment Description Amendment Flag Current Fiscal Year End Date Document And Entity Information [Abstract] Document Fiscal Period Focus Document Fiscal Year Focus Document Period End Date Document Type Entity Central Index Key Entity Common Stock, Shares Outstanding Entity Current Reporting Status Entity Filer Category Entity Public Float Entity Registrant Name Entity Voluntary Filers Entity Well-known Seasoned Issuer Trading Symbol Accounts Payable, Current Accounts payable Accounts Receivable, Net, Current Trade Accounts Receivable, Net, Current [Abstract] Accounts receivable Accrued Income Taxes, Current Income tax accruals Accrued Liabilities, Current Accrued expenses Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive income Additional Paid in Capital Additional paid-in capital Assets Total assets Assets [Abstract] Assets Assets, Current Total current assets Assets, Current [Abstract] Current assets: Capital Lease Obligations, Current Current portion of capital lease obligation Capital Lease Obligations, Noncurrent Capital lease obligation, less current portion Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Common Stock, Value, Issued Common shares, no par value: Authorized 19,000,000 shares; 7,638,738 issued and outstanding at September 30, 2012 and 6,945,631 at September 30, 2011 Customer Advances, Current Customer advances Derivative Liabilities, Current Fair value of warrant liability Goodwill Goodwill Income Taxes Receivable, Current Refundable income taxes Intangible Assets, Net (Excluding Goodwill) Intangible assets, net Inventory, Net Inventories Liabilities and Equity Total liabilities and shareholders' equity Liabilities and Equity [Abstract] Liabilities and shareholders' equity Liabilities, Current Total current liabilities Liabilities, Current [Abstract] Current liabilities: Line of Credit, Current Revolving line of credit Long-term Debt, Current Maturities Current portion of long-term debt Long-term Debt, Excluding Current Maturities Long-term debt, less current portion Other Assets, Noncurrent Other assets Preferred Stock, Value, Issued Preferred shares, authorized 1,000,000 shares, no par value: 1,335 Series A shares at $1,000 stated value issued and outstanding at September 30, 2012 and 2,135 at September 30, 2011 Prepaid Expense, Current Prepaid expenses Property, Plant and Equipment, Net Property and equipment, net Retained Earnings (Accumulated Deficit) Accumulated deficit Stockholders' Equity Attributable to Parent Total shareholders' equity Stockholders' Equity Attributable to Parent [Abstract] Stockholders' equity: Unamortized Debt Issuance Expense Debt issue costs, net Unbilled Revenue And Other Current Unbilled revenues and other Unbilled Revenue and Other, Current Class of Stock [Domain] Common Stock, No Par Value Common stock, no par value Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding Preferred Stock, No Par Value Preferred stock, no par value Preferred Stock, Par or Stated Value Per Share Preferred stock, stated value per share Preferred Stock, Shares Authorized Preferred stock, shares authorized Preferred Stock, Shares Issued Preferred stock, shares issued Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Series A Preferred Stock [Member] Class of Stock [Axis] Statement [Line Items] CONDENSED CONSOLIDATED BALANCE SHEETS [Abstract] Statement [Table] Accumulated other comprehensive income (loss) [Member] Accumulated Other Comprehensive Income (Loss) [Member] Additional Paid-in Capital [Member] Additional paid-in capital [Member] Adjustments to Additional Paid in Capital, Share-based Compensation, Stock Options, Requisite Service Period Recognition Stock based compensation expense Adjustments to Additional Paid in Capital, Warrant Issued Fair value attributable to warrants Common Stock Dividends, Shares Common stock issued for dividends/make-whole payment, shares Common Stock [Member] Common Shares [Member] Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Comprehensive Income (loss): Director Stock Issued During Period Shares New Issues Director Stock Issued During Period Shares New Issues Direct common share purchase from Directors, shares Director Stock Issued During Period Value New Issues Director Stock Issued During Period Value New Issues Direct common share purchase from Directors Dividends, Preferred Stock Preferred stock - recognition of full dividend/make-whole Equity Component [Domain] Foreign currency translation adjustments Preferred Stock, Beneficial Conversion Feature Preferred stock - beneficial conversion feature This element represents the difference between the proceeds from issuances of convertible preferred stock and the fair value of the common stock into which the shares convert, as of the issuance date. Preferred Stock, Deemed Dividend Preferred stock - deemed dividend This element represents a tax instrument used to shift a tax liability from shareholder's incurred from the beneficial conversion feature of preferred stock. Preferred Stock [Member] Preferred Shares [Member] Retained Earnings [Member] Accumulated deficit [Member] Shares, Outstanding Balance, shares Balance, shares Equity Components [Axis] CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY AND COMPREHENSIVE INCOME [Abstract] Balance Balance Stock Issued During Period, Shares, Conversion of Convertible Securities Conversion of preferred shares to common shares, shares Stock Issued During Period, Shares, New Issues Issuance of preferred shares, net of issuance costs of $900,281, shares Stock Issued During Period, Value, Conversion of Convertible Securities Conversion of preferred shares to common shares Stock Issued During Period, Value, New Issues Issuance of preferred shares, net of issuance costs of $900,281 Stock Issued During Period, Value, Stock Dividend Common shares issued for dividends/make whole payment Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive income (loss) Cost of Goods and Services Sold Total cost of revenue Cost of Goods Sold Cost of product revenue Cost of Services Cost of service revenue Earnings Per Share, Basic Basic net loss per share Earnings Per Share, Diluted Diluted net loss per share Change in fair value of warrant liability - decrease General and Administrative Expense General and administrative Gross Profit Gross profit Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest Income (loss) before income taxes CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) [Abstract] Income Tax Expense (Benefit) Income tax expense Interest Expense Interest expense Net income (loss) Operating Expenses Total operating expenses Operating Expenses [Abstract] Operating expenses: Operating Income (Loss) Operating income (loss) Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Foreign currency translation adjustment Other Comprehensive Income (Loss), Net of Tax [Abstract] Other Nonoperating Income Other income Research and Development Expense Research and development Restructuring Charges Restructuring charges Sales Revenue, Goods, Net Product revenue Revenue, Net Total revenue Sales Revenue, Services, Net Service revenue Selling Expense Selling Weighted Average Number of Shares Outstanding, Diluted Diluted Weighted Average Number of Shares Outstanding, Diluted [Abstract] Weighted common shares outstanding: Weighted Average Number of Shares Outstanding, Basic Basic Other comprehensive income (loss): Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net income (loss) to net cash (used) provided by operating activities: Capital Lease Obligations Incurred Equipment financed under capital leases Cash and cash equivalents at beginning of year Cash and cash equivalents at end of year Cash and Cash Equivalents, Period Increase (Decrease) Net (decrease) increase in cash and cash equivalents Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Supplemental disclosure of non-cash financing activities Deferred Income Tax Expense (Benefit) Deferred income taxes Depreciation, Depletion and Amortization, Nonproduction Depreciation and amortization Direct Common Shares Purchased Direct Common Shares Purchased Direct common shares purchased by interim CEO and Board of Directors Dividends Accrued Put Unpaid During Period Preferreed stock dividends accrued, but not paid The cumulative amount of dividends that have been accrued during the reporting period, but have yet to be paid. Effect of Exchange Rate on Cash and Cash Equivalents Effect of exchange rate changes Fair Value Adjustment Of Warrants Change in fair value of warrant liability - decrease Amount of expense (income) related to adjustment to fair value of warrant liability. Gain (Loss) on Contract Termination Termination of capital lease obligation Gain (Loss) on Sale of Property Plant Equipment (Gain) loss on sale of property and equipment Increase (Decrease) in Accounts Payable Accounts payable Increase (Decrease) in Accounts Receivable Accounts receivable Increase (Decrease) in Accrued Liabilities Accrued expenses Increase (Decrease) in Customer Advances Customer advances Increase (Decrease) in Income Taxes Receivable Refundable income taxes Increase (Decrease) in Inventories Inventories Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other assets Net Cash Provided by (Used in) Financing Activities Net cash (used) provided by financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Financing activities: Net Cash Provided by (Used in) Investing Activities Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Investing activities: Net Cash Provided by (Used in) Operating Activities Net cash (used) provided by operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] Operating activities: Net Income (Loss) Attributable to Parent Net income (loss) Payments for (Proceeds from) Productive Assets Capital expenditures Proceeds From Issuance Of Registered Direct Public Offering Net proceeds from registered direct offering Proceeds form entity's registered direct public offering. Proceeds from Lines of Credit Borrowings on revolving line of credit Proceeds from Other Equity Net proceeds from registered direct offering Proceeds from Sale of Machinery and Equipment Proceeds from sale of equipment Provision for Doubtful Accounts Provision for doubtful accounts Repayments of Lines of Credit Payments on revolving line of credit Repayments of Long-term Capital Lease Obligations Payments on capital lease obligations Repayments of Long-term Debt Payments of long-term debt Share-based Compensation Employee stock compensation expense CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS [Abstract] Stock Issued Preferred stock dividends pain in common shares Unrealized Gain (Loss) on Derivatives Gain on interest rate swaps LOSS PER SHARE [Abstract] Earnings Per Share [Text Block] LOSS PER SHARE Schedule of Earnings Per Share Reconciliation [Table Text Block] Reconciliation of Computation of Basic Loss Per Share to Diluted Net Loss Per Share Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Antidilutive shares not considered in computing diluted earnings per share Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Warrant [Member] Basic net loss per share Earnings Per Share, Basic [Abstract] Basic net loss per share: Earnings Per Share, Diluted [Abstract] Diluted net loss per share: Net Income (Loss) Available to Common Stockholders, Basic Net loss applicable to common shareholders Net Income (Loss) Available to Common Stockholders, Diluted Net loss applicable to common shareholders Preferred Stock Dividends, Income Statement Impact Less: Preferred dividend Redeemable Preferred Stock Dividends Less: Deemed dividend for Series A Preferred Shares Weighted average common shares outstanding INVENTORIES [Abstract] Inventory Disclosure [Text Block] INVENTORIES Schedule of Inventory, Current [Table Text Block] Summary of Inventories Inventory, Finished Goods, Gross Finished goods Inventory, Gross Gross inventories Inventories Inventory, Raw Materials, Gross Raw materials Inventory Valuation Reserves Obsolescence reserve Inventory, Work in Process, Gross Work in process INCOME TAXES [Abstract] Income Tax Disclosure [Text Block] INCOME TAXES STOCK-BASED COMPENSATION [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Text Block] STOCK-BASED COMPENSATON Schedule of Nonvested Share Activity [Table Text Block] Summary of Non-Vested Options Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Summary of Stock Option Activity Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Fair Value Assumptions Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block] Schedule of Outstanding and Exercisable Options Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition Unrecognized compensation cost, recognition period Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Stock Options Unrecognized compensation cost related to non-vested stock options Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Common stock authorized to issuance under employee compensation plan Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Common stock available for issuance under employee compensation plan Share-Based Compensation, Options Outstanding, Issued Outside Of Stock Option Plan Options outstanding that were granted outside of the plan The number of options outstanding, as of the balance sheet date, that were granted outside of the defined stock option plan. Share Based Compensation Arrangement By Share Based Payment Award, Options, Aggregate Intrinsic Value [Abstract] Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Exercisable - September 30, Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Exercisable - September 30, Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Exercisable - September 30, Share Based Compensation Arrangement By Share Based Payment Award, Options Exercisable, Weighted Average Grant Date Fair Value Exercisable - September 30, Share-Based Compensation Arrangement By Share-Based Payment Award, OptionsExercisable, Weighted-Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Exercisable - September 30, Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Terminated Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures Granted Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Granted Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Outstanding - September 30, Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Outstanding - October 1, Outstanding - September 30, Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Options (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Outstanding - October 1, Outstanding - September 30, Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward] Weighted-Average Exercise Price Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Grant Date Fair Value Outstanding - September 30, The weighted average grant-date fair value of options outstanding as calculated by applying the disclosed option pricing methodology. Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Outstanding - September 30, Share Based Compensation Arrangement By Share Based Payment Award, Options, Weighted Average Remaining Contractual Life [Abstract] Weighted-Average Remaining Contractual Life Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Exercised Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Terminated Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Granted Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Exercised SEGMENT INFORMATION [Abstract] Segment Reporting Disclosure [Text Block] SEGMENT INFORMATION Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block] Geographical Information Schedule of Segment Reporting Information, by Segment [Table Text Block] Operating Segments Segment Reporting Information, Expenditures for Additions to Long-Lived Assets Capital Expenditures: Identifiable assets: Depreciation and amortization: Goodwill, net: Intangible assets, net: Nonoperating Income (Expense) Interest Expense Operating income (loss): Segment Reporting Information, Significant Noncash Items Other than Depreciation, Depletion, and Amortization Expense Depreciation and amortization: Product [Member] Revenue: Schedule of Segment Reporting Information, by Segment [Table] Segment Reporting Information [Line Items] Service [Member] RESTRUCTURING [Abstract] Restructuring and Related Activities Disclosure [Text Block] RESTRUCTURING Schedule of Restructuring and Related Costs [Table Text Block] Summary of Restructuring Costs Schedule of Restructuring Reserve by Type of Cost [Table Text Block] Summary of Restructuring Activity Acres of headquarters facility Corporate [Member] Corporate Expenses [Member] Lease Related Costs [Member] Lease Related Costs [Member] Products Segment [Member] Products Segment [Member] Restructuring and Related Cost, Incurred Cost Restructuring costs Restructuring Type [Axis] Restructuring Cost and Reserve [Line Items] Schedule of Restructuring and Related Costs [Table] Segment [Domain] Services Segment [Member] Services Segment [Member] Business Segments [Axis] Type of Restructuring [Domain] DESCRIPTION OF THE BUSINESS [Abstract] Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] DESCRIPTION OF THE BUSINESS SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract] Significant Accounting Policies [Text Block] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Advertising Cost, Policy, Expensed Advertising Cost [Policy Text Block] Advertising Expense Cash and Cash Equivalents, Policy [Policy Text Block] Cash Equivalents Comprehensive Income, Policy [Policy Text Block] Comprehensive Income (Loss) Consolidation, Policy [Policy Text Block] Principles of Consolidation Fair Value Measurement, Policy [Policy Text Block] Fair Value Foreign Currency Transactions and Translations Policy [Policy Text Block] Foreign Currency Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block] Long-Lived Assets including Goodwill Income Tax, Policy [Policy Text Block] Income Taxes Inventory, Policy [Policy Text Block] Inventories New Accounting Pronouncements, Policy [Policy Text Block] New Accounting Pronouncements Property, Plant and Equipment, Policy [Policy Text Block] Property and Equipment Receivables, Policy [Policy Text Block] Accounts Receivable Research and Development Expense, Policy [Policy Text Block] Research and Development Revenue Recognition, Policy [Policy Text Block] Revenue Recognition Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] Stock-Based Compensation Use of Estimates, Policy [Policy Text Block] Use of Estimates Accounting Policies [Line Items] Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Accounting Policies [Table] Table containing information disclosed in the accounting policies footnote. Advertising Expense Advertising expense Allowance for Doubtful Accounts Receivable, Current Allowance for doubtful accounts Amortization of Intangible Assets Amortization expense for intangible assets Building and Building Improvements [Member] Buildings and Improvements [Member] Cash, FDIC Insured Amount FDIC Insured limits Depreciation Depreciation expense Difference Between Fair Value And Carrying Value Of Goodwill Difference between the fair value and carrying value of goodwill This element represents the difference between the fair value and carrying value of goodwill, determined during impairment testing, as of the balance sheet date. Fair Value Inputs, Discount Rate Discount rate Fair Value Inputs, Long-term Revenue Growth Rate Revenue growth rate Furniture and Fixtures [Member] Office Furniture and Fixtures [Member] Leasehold Improvements [Member] Leasehold Improvements [Member] Machinery and Equipment [Member] Machinery and Equipment [Member] Products and Services [Axis] Products and Services [Domain] Property, Plant and Equipment, Useful Life Property and equipment, estimated useful life Services One [Member] Bioanalytical Services [Member] Bioanalytical Services [Member] Services Three [Member] Vetronics Units [Member] Vetronics Units [Member] Services Two [Member] Preclinical Services [Member] Preclinical Services [Member] Allowance for Doubtful Accounts Receivable Opening balance Ending balance Allowance for Doubtful Accounts Receivable, Charge-offs Accounts written off Allowance for Doubtful Accounts Receivable, Recoveries Accounts recovered Provision Doubtful Accounts Provision Doubtful Accounts Charged to expense Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Less: accumulated depreciation Buildings and Improvements, Gross Buildings and improvements Construction in Progress, Gross Construction in progress Furniture and Fixtures, Gross Office furniture and fixtures Land and Land Improvements Land and improvements Machinery and Equipment, Gross Machinery and equipment Property, Plant and Equipment, Gross Property and equipment, gross Net property and equipment Certification Marks [Member] FDA compliant facility Finite-Lived Intangible Assets, Accumulated Amortization Accumulated Amortization Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Gross Gross Carrying Amount Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Asset, Useful Life Weighted average life Schedule of Finite-Lived Intangible Assets [Table] Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months 2013 Finite-Lived Intangible Assets, Amortization Expense, Year Five 2017 Finite-Lived Intangible Assets, Amortization Expense, Year Four 2016 Finite-Lived Intangible Assets, Amortization Expense, Year Three 2015 Finite-Lived Intangible Assets, Amortization Expense, Year Two 2014 SALE OF PREFERRED SHARES AND WARRANTS [Abstract] Stockholders' Equity Note Disclosure [Text Block] SALE OF PREFERRED SHARES AND WARRANTS Schedule Of Share Based Payment Award, Warrants, Valuation Assumptions [Table Text Block] Schedule of Fair Value Assumptions Used for Warrants Tabular disclosure of the significant assumptions used during the year to estimate the fair value of warrants, including, but not limited to: (a) expected term of warrants and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. Class A Warrant [Member] Class of Warrant or Right, Exercise Price of Warrants or Rights Exercise price of warrant Class of Warrant or Right, Number of Securities Called by Warrants or Rights Number of shares of common stock called by warrants Class of Warrant or Right, Outstanding Warrants outstanding Common stock, shares issued for dividends Contingent Payment Upon Conversion Of Stock "Make-whole" payment Element represents the contengent "make-whole" payment to holders of converted stock, based on the date of conversion and stated value of the shares. Conversion of Stock, Shares Converted Shares converted Conversion of Stock, Shares Issued Common stock, shares issued in conversion Convertible Preferred Stock, Shares Issued upon Conversion Shares issued upon conversion of securities Dividends Payable Accrued dividends payable Equity Issuance, Per Share Amount Equity issuance, price per share Gross Proceeds From Issuance Of Equity Gross proceeds from equity issuance The gross proceeds from an equity issuance. Warrant expiration date Beneficial conversion feature Deemed dividend Preferred Stock, Dividend Rate, Percentage Dividend rate Preferred Stock, Outstanding, Fair Value Fair value of outstanding preferred stock Element represents the aggregate fair value of outstanding shares of preferred stock. Preferred Stock, Total Possible Dividend Percentage Over Three Years Total possible dividend percentage over three years Element represents the total dividend percent that could be paid out over a three year period. Preferred Stock, Total Possible Dividends Over Three Year Period Total possible dividend for preferred shares over three years Element represents the total amount of potential dividends that could be expensed over a three year period. Proceeds from equity issuance Sale of Stock, Price Per Share Common stock, price per share Schedule Of Stock And Warrants By Class [Line Items] Schedule Of Stock And Warrants By Class [Line Items] Schedule Of Stock And Warrants By Class [Table] Schedule detailing information related to equity by class of stock and warrant. Issuance of common stock for stock dividends and stock purchase plan, shares Unit [Member] Unit [Member] Units Issued During Period, Shares, New Issues Units issued during period, new issues, shares Warrants and Rights Outstanding Fair value of warrants Investment Warrants Expiration Date Class A Warrant [Member] Warrant A [Member] Class A Warrant [Member] Class B Warrant [Member] Warrant B [Member] Class B Warrant [Member] Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Fair Value Assumptions, Exercise Price Fair value per unit Fair Value Assumptions, Expected Dividend Rate Dividend yield Fair Value Assumptions, Expected Term Expected life of the options Fair Value Assumptions, Expected Volatility Rate Volatility of the Company's common stock Fair Value Assumptions, Risk Free Interest Rate Risk-free interest rate Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, by Balance Sheet Grouping [Table] LEASE ARRANGEMENTS [Abstract] Leases of Lessee Disclosure [Text Block] LEASE ARRANGEMENTS Building [Member] Capital Leased Assets, Gross Capital leased assets Capital Leases, Lessee Balance Sheet, Assets by Major Class, Accumulated Depreciation Capital lease, accumulated amortization Equipment [Member] Lease Expiration Date Lease expiration Operating Lease Option To Cancel Lease Minimum Duration Of Lease Number of years before "opt out" provision in force Element represents the number of years into the lease before the option to cancel the lease becomes available. Operating Leases, Rent Expense, Net Rent expense Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Domain] Schedule Of Capital And Operating Leased Assets [Line Items] Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Schedule Of Capital And Operating Leased Assets [Table] Schedule of long-lived, depreciable assets that are subject to operating or capital lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software. Capital Leased Assets [Line Items] Capital Lease, Future Lease Payments By Catagory [Axis] Information pertaining to future minimum lease payments by catagory, including but not limited to principal and interest payments. Capital Lease Future Lease Payments By Catagory [Domain] Listing of the catagories for capital lease payment obligations. Capital Leases, Future Minimum Payments Due Total minimum lease payments due Capital Leases, Future Minimum Payments Due, Next Twelve Months 2013 Capital Leases, Future Minimum Payments Due in Five Years 2017 Capital Leases, Future Minimum Payments Due in Four Years 2016 Capital Leases, Future Minimum Payments Due in Three Years 2015 Capital Leases, Future Minimum Payments Due in Two Years 2014 Lease Payment, Interest [Member] Interest [Member] Lease Payment, Interest [Member] Lease Payment, Principal [Member] Principal [Member] Lease Payment, Principal [Member] Schedule of Capital Leased Assets [Table] Operating Leases, Future Minimum Payments Due Total minimum lease payments due Operating Leases, Future Minimum Payments Due, Next Twelve Months 2013 Operating Leases, Future Minimum Payments, Due in Five Years 2017 Operating Leases, Future Minimum Payments, Due in Four Years 2016 Operating Leases, Future Minimum Payments, Due in Three Years 2015 Operating Leases, Future Minimum Payments, Due in Two Years 2014 Operating Leases, Future Minimum Payments, Due Thereafter After 2017 Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block] Schedule of Future Minimum Lease Payments for Capital Leases Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] Schedule of Future Minimum Lease Payments for Operating Leases DEBT ARRANGEMENTS [Abstract] Debt Disclosure [Text Block] DEBT ARRANGEMENTS Schedule of Long-term Debt Instruments [Table Text Block] Schedule of Long-Term Debt Schedule Of Future Principal Payment Obligations [Table Text Block] Summary of Principal Payment Obligations Tabular disclosure pertaining to expected future principal payment obligations for outstanding debt. Debt Instrument, Periodic Payment Debt instrument, principal and interest payment Debt Instruments [Abstract] Long-term debt, parenthetical information Interest Paid Cash paid during the period for interest Long-tem debt Less current portion Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months Principal payment obligation Long-term debt, noncurrent portion Mortgage Note Payable One [Member] Mortgage Note Payable One [Member] Mortgage Note Payable Two [Member] Mortgage Note Payable Two [Member] Note Payable To Algo Holdings [Member] Note Payable To Algo Holdings [Member] Acres Of Land Owned Acres of land owned. Acres of land Amended Revolving Line Of Credit [Member] Amended Revolving Line of Credit [Member] Amended Revolving Line Of Credit [Member] Assets For Sale Asking Price Assets For Sale Asking Price Asking price Credit Facility [Axis] Credit Facility [Domain] Debt Instrument [Axis] Debt Instrument, Basis Spread on Variable Rate Debt instrument, basis spread on variable rate Debt Instrument, Description of Variable Rate Basis Debt instrument, variable interest reference rate Debt Instrument, Face Amount Debt instrument, face amount Debt Instrument, Frequency of Periodic Payment Debt instrument, frequency of periodic payments Debt Instrument, Interest Rate, Effective Percentage Debt instrument, effective interest rate Debt Instrument, Interest Rate, Effective Percentage Rate Range, Minimum Debt instrument, minimum interest rate Debt Instrument, Interest Rate, Stated Percentage Debt instrument, interest rate Debt Instrument [Line Items] Debt Instrument, Maturity Date Debt instrument, maturity date Debt Instrument, Name [Domain] Debt Instrument, Periodic Payment, Principal Debt instrument, principal payment Debt Instrument, Principal Payment Made Debt instrument, one-time principal payment The amount of cash paid at one time towards the outstanding balance of principal on a long-term debt instrument. Schedule of Long-term Debt Instruments [Table] Fixed Charge Coverage Ratio Fixed charge coverage ratio A ratio that indicates a firm's ability to satisfy fixed financing expenses, such as interest and leases. Line of Credit Facility, Amount Outstanding Line of credit, amount outstanding Line Of Credit Facility, Borrowing Limit, Ratio To Accounts Receivable Line of credit, borrowings, based on eligible accounts receivable, percentage Element represents the ratio of allowed advances to eligible accounts receivable. Line of Credit Facility, Collateral Line of credit, collateral Line Of Credit Facility, Collateral Monitoring Fee, Percentage Line of credit, collateral monitoring fee, percentage Fees associated with providing collateral for the credit facility, stated as a percentage of available credit. Line of Credit Facility, Commitment Fee Percentage Line of credit, facilities fee, percentage Line of Credit Facility, Current Borrowing Capacity Line of Credit Facility, Frequency of Commitment Fee Payment Line of credit, frequency of facilities fee payments Line of Credit Facility, Frequency of Payments Line of credit, frequency of periodic payments Line of Credit Facility, Maximum Borrowing Capacity Line of credit, maximum borrowing capacity Line of Credit Facility, Periodic Payment, Interest Line of credit, periodic interest payments Line of Credit [Member] Revolving Line of Credit [Member] Long-term Debt Long-term debt Minimum [Member] Minimum Net Worth Required for Compliance Minimum net worth convenant requirement Mortgage Note Payable Three [Member] Mortgage Payable, Maturing February 11, 2011 Mortgage Note Payable Three [Member] Mortgage Notes Payable One and Two [Member] Mortgage Notes Payable One And Two [Member] Note Payable One [Member] Note Payable, Maturing December 18, 2010 [Member] Note Payable One [Member] Note Payable Six [Member] Note Payable Six Member Mortgage Notes Payable, Maturing May 4, 2013 [Member] Notes Payable to Regions Bank [Member] Notes Payable To Regions Bank [Member] Original Covenant Terms [Member] Original Covenant Terms [Member] Range [Axis] Range [Domain] Replacement Note Payable [Member] Replacement Note Payable [Member] Sale Leaseback Transaction, Net Book Value Net book value of facility and land Scenario, Unspecified [Domain] Size Of Facility Size Of Facility Square foot of facility Scenario [Axis] Total Liabilities To Tangible Net Worth Ratio Total liabilities to tangible net worth ratio Ratio that indicates the amount of net worth that has been invested in tangible fixed assets. Line of credit, current borrowing capacity Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Schedule of the Provision (Benefit) for Income Taxes Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Schedule of Deferred Tax Assets and Liabilities Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Reconciliation of Effective Income Tax Rate Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block] Reconciliation of Unrecognized Tax Benefits Deferred Tax Liabilities, Gross Total noncurrent deferred tax liabilities Deferred Tax Assets, Gross, Current Total current deferred tax assets Deferred Tax Assets, Gross, Noncurrent Total noncurrent deferred tax assets Deferred Tax Assets, Inventory Inventory Deferred Tax Assets, Net Net deferred tax asset (liability) Deferred Tax Assets, Net, Current Total net current deferred tax assets Deferred Tax Assets, Net, Noncurrent Total net noncurrent deferred tax assets Deferred Tax Assets, Net of Valuation Allowance, Current Classification [Abstract] Deferred tax assets - Current: Deferred Tax Assets, Net of Valuation Allowance, Noncurrent Classification [Abstract] Deferred tax assets - Noncurrent: Deferred Tax Assets, Operating Loss Carryforwards, Domestic Domestic net operating loss carryforwards Deferred Tax Assets, Operating Loss Carryforwards, Foreign Foreign net operating loss Deferred Tax Assets, Tax Credit Carryforwards, Alternative Minimum Tax AMT credit carryover Deferred Tax Assets, Tax Credit Carryforwards, Foreign Foreign tax credit carryover Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation Accrued compensation and vacation Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost Stock compensation expense Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Other Accrued expenses and other Deferred Tax Assets, Valuation Allowance Valuation allowance for net deferred tax assets Deferred Tax Liabilities Current [Abstract] Deferred tax liabilities - Current: Deferred Tax Liabilities, Derivatives Unrealized gain/loss - warrant liability Deferred Tax Liabilities, Goodwill and Intangible Assets Basis difference for intangibles Deferred Tax Liabilities Noncurrent [Abstract] Deferred tax liabilities - Noncurrent: Deferred Tax Liabilities, Prepaid Expenses Prepaid expenses Deferred Tax Liabilities, Property, Plant and Equipment Basis difference for fixed assets Current Federal Tax Expense (Benefit) Federal Current Foreign Tax Expense (Benefit) Foreign Current State and Local Tax Expense (Benefit) State and local Deferred Federal Income Tax Expense (Benefit) Federal Deferred Foreign Income Tax Expense (Benefit) Foreign Deferred State and Local Income Tax Expense (Benefit) State and local Income Tax Expense (Benefit), Continuing Operations Income tax expense Income Tax Expense Benefit Continuing Operations Current [Abstract] Current: Income Tax Expense Benefit Continuing Operations Deferred [Abstract] Deferred: Effective Income Tax Rate, Continuing Operations Effective income tax rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate Statutory federal income tax rate: Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance Valuation allowance changes Effective Income Tax Rate Reconciliation, Nondeductible Expense Nondeductable expenses Effective Income Tax Rate Reconciliation, Other Adjustments Other Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings Nontaxable foreign (gains) losses Effective Income Tax Rate Reconciliation, State and Local Income Taxes State and local income taxes, net of Federal tax benefit, if applicable Effective Income Tax Rate Reconciliation, Tax Settlements Uncertain tax positions Income Tax Rate Reconciliation, Increases Decreases In Tax Rate [Abstract] Increases (decreases): Alternative Minimum Tax Credit Carryforward [Member] Alternative Minimum Tax Credit Carryforward [Member] Domestic Tax Authority [Member] Foreign Tax Authority [Member] Foreign Tax Credit Carryforward [Member] Foreign Tax Credit Carryforward [Member] Income (Loss) from Continuing Operations before Income Taxes, Foreign Losses before income taxes from foreign operations Income Tax Authority [Axis] Income Tax Authority [Domain] Income Taxes [Line Items] Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Income Taxes Paid Payments for income taxes Income Taxes [Table] Schedule discussing various components of income taxes. Income Tax Examination, Penalties from Examination Income tax examination, amount paid Internal Revenue Service (IRS) [Member] Operating Loss Carryforwards Net operating loss carry forwards Operating Loss Carryforwards, Expiration Dates Expirations of operating loss carry forwards Operating Loss Carryforwards, Valuation Allowance Valuation allowance State and Local Jurisdiction [Member] Tax Credit Carryforward, Amount Tax credit carryforwards Tax Credit Carryforward [Axis] Tax Credit Carryforward, Name [Domain] Unrecognized Tax Benefits Liability for other uncertain income tax positions Unrecognized Tax Benefits, Decreases Resulting from Prior Period Tax Positions Reduction in gross uncertain tax positions Unrecognized Tax Benefits, Period Increase (Decrease) Unrecognized tax benefits released in state tax litigation State [Member] Balance at beginning of the year Balance at end of the year Unrecognized Tax Benefits, Decreases Resulting from Settlements with Taxing Authorities Settlements Unrecognized Tax Benefits, Increases Resulting from Current Period Tax Positions Unrecognized Tax Benefits, Increases Resulting from Prior Period Tax Positions Reductions for tax positions of prior years Additions based on tax positions related to the current year Additions fror tax positions of prior years Award Type [Axis] Maximum [Member] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Expected life of the options (years) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Volatility of the expected market price of the Company's common stock, maximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Volatility of the expected market price of the Company's common stock, minimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Award Type [Domain] Stock Options [Member] Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instrument, Nonvested Options, Weighted-Average Grant Date Fair Value Non-vested options at October 1, 2011 The weighted average fair value of nonvested awards on equity-based plans for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units. Non-vested options at September 30, 2012 Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments, Nonvested Options, Vested In Period Vested Number of previously nonvested share options (or share units) vested during the current period. Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments, Nonvested Options, Vested In Period, Weighted-Average Grant Date Fair Value Vested The weighted average fair value as of grant date pertaining to an equity-based stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement. Share-Based Compensation Arrangement By Share-Based Payment Award, Nonvested Options Forfeitures And Expirations In Period Forfeited For presentations that combine terminations, the number of nonvested shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired. Share-Based Compensation Arrangement By Share-Based Payment Award, Nonvested Options, Forfeitures And Expirations In Period, Weighted Average Grant Date Fair Value Forfeited The combined weighted average grant-date fair value associated with nonvested stock options during the period that have either lapsed or been forfeited. Share-Based Compensation Arrangement By Share-Based Payment Award, Nonvested Options, Grants In Period Granted Net number of share nonvested options (or share units) granted during the period. Share-Based Compensation Arrangement By Share-Based Payment Award, Nonvested Options, Grants In Period, Weighted-Average Grant Date Fair Value Granted The weighted average grant-date fair value of nonvested options granted during the reporting period as calculated by applying the disclosed option pricing methodology. Share-Based Compensation Arrangement By Share-Based Payment Award, Nonvested Options Outstanding [Abstract] Number of Shares Share Based Compensation Arrangement By Share Based Payment Award, Nonvested Options, Outstanding [Abstract] Share-Based Compensation Arrangement By Share-Based Payment Award, Nonvested Options, Outstanding Number Non-vested options at October 1, 2011 The number of nonvested shares outstanding under stock option agreements awarded under the plan that validly exist and are outstanding as of the balance sheet date. Non-vested options at September 30, 2012 Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Weighted-Average Grant Date Fair Value Range One [Member] $0.79 - 1.01 [Member] Range One [Member] Range Three [Member] $4.60 - 8.79 [Member] Range Three [Member] Range Two [Member] $1.02 - 4.59 [Member] Range Two [Member] Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table] Exercise Price Range [Axis] Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain] Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price Weighted-Average Exercise Price, Exercisable Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit Range of Exercise Prices, minimum Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options Shares Exercisable Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options Shares Outstanding Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price Weighted-Average Exercise Price Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term Weighted-Average Remaining Contractual Life Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit Range of Exercise Prices, maximum RETIREMENT PLAN [Abstract] Pension and Other Postretirement Benefits Disclosure [Text Block] RETIREMENT PLAN Defined Contribution Plan, Cost Recognized Contribution expense Defined Contribution Plan, Employer Contribution Match, Maximum, Percent Of Employee Contribution Maximum percentage of participant's contribution eligible for employer matching contribution The maximum percentage of participant's contribution to the plan that the employer will contribute a matching contribution. Defined Contribution Plan, Employer Matching Contribution, Percent Employer's match percentage Defined Contribution Plan, Maximum Annual Contribution Per Employee, Percent Maximum annual contribution, percent of participant's annual wages Definied Contribution Plan, Employer Contribution Of Participants Total Wages, Percent Company's contribution to plan, as a percent of participant's total wages Percentage of participant's total wages that the company contributes to the defined contribution plan. Long-Lived Assets Long-lived assets Revenues Sales to External Customers: Revenues from External Customers and Long-Lived Assets [Line Items] Schedule of Revenues from External Customers and Long-Lived Assets [Table] Segment, Geographical [Domain] Segment, Geographical, Groups of Countries, Group One [Member] Segment, Geographical, Groups Of Countries, Group Three [Member] Europe [Member] A third specified group of foreign countries about which segment information is provided by the entity. Segment, Geographical, Groups of Countries, Group Two [Member] Pacific Rim [Member] Segment, Geographical, Groups Of Countries, Other Group [Member] Other [Member] The aggregate other geographical areas in which the entity does business about which segment information is provided by the entity. Geographical [Axis] North America [Member] Revenue, Major Customer [Line Items] Entity-Wide Revenue, Major Customer, Percentage Percentage of total revenues Entity-Wide Trade Accounts Receivable, Major Customer, Percentage Percentage of trade accounts receivable Percentage of trade accounts receivable pertaining to a single external customer. Major Customer One [Member] Gilead Sciences, Inc. [Member] Major Customer One [Member] Major Customers [Axis] Major Customer Two [Member] Pfizer, Inc. [Member] Major Customer Two [Member] Name of Major Customer [Domain] Schedule of Revenue by Major Customers, by Reporting Segments [Table] SETTLEMENT OF CONTINGENT LIABILITY [Abstract] Contingencies Disclosure [Text Block] SETTLEMENT OF CONTINGENT LIABILITY Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or prior to issuance of the financial statements) as to a probable or reasonably possible gain or loss incurred by an entity and typically discloses the amount of range of possible gain or loss recorded. Contingent Liability Annual Rent Payments This element represents the annual rent liability contingent upon the sublessor's ability to continue payments. Contingent Liability, Discounted Amount Of Liability Discounted liability The present value of the liability as of the balance sheet date. Contingent liability, annual rent payments Loss Contingency, Settlement Agreement, Consideration Settlement agreement for cancellation of obligations under lease, agreed contribution amount Loss Contingency, Settlement Agreement, Consideration, Monthly Payments Settlement consideration, monthly installments Element represents the monthly payments made on the settlement consideration. Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Issuance of preferred shares, issuance costs Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block] Summary of Assumptions Used to Compute Fair Value of Warrants Property, Plant and Equipment [Table Text Block] Schedule of Property and Equipment Schedule of Credit Losses for Financing Receivables, Current [Table Text Block] Summary of Activity in Allowance for Doubtful Accounts Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Schedule of Future Estimated Amortization Expense Schedule of Finite-Lived Intangible Assets [Table Text Block] Components of Amortizable Intangible Assets Employee Relocation [Member] Travel and Relocation Costs [Member] Equipment Moving Costs And Method Transfers [Member] Equipment Moving Costs And Method Transfers [Member] Equipment Moving Costs And Method Transfers [Member] Gains (Losses) on Sales of Assets [Member] Loss on Sale of Equipment [Member] One-time Termination Benefits [Member] Other Restructuring [Member] Other Costs [Member] Total Charges Restructuring Reserve Balance Balance Restructuring Reserve, Accrual Adjustment Other Restructuring Reserve, Settled with Cash Cash Payments SELF-INSURANCE [Abstract] Self Insurance [Abstract] Self Insurance [Text Block] SELF-INSURANCE Self Insurance [Text Block] Annual Aggregate Attachment Point, Minimum Minimum annual aggregate attachment point Represents the employer's minimum overall limit of claim liability, which is adjusted based on the size of the group insured, as of the balance sheet date. Self Insurance Exposure For Individual Claims Self insurance exposure for individual claims Self Insurance Exposure For Individual Claims Self Insurance Reserve Aggregate reserve under self-insured plan Self Insured Employee Health Plan Expenses Self-insured employee health plan expenses Self Insured Employee Health Plan Expenses MANAGEMENT'S PLAN [Abstract] Managements Plan [Abstract] Managements Plan [Text Block] MANAGEMENT'S PLAN Managements Plan [Text Block] Capital Expenditures Growth Decline Ratio Capital expenditures growth (decline), percent The overall growth (decline) in capital expenditures during the reporting period. Gross Margin Growth Decline Ratio Gross margin growth (decline), percent The percent change in gross margin during the reporting period. Long-term Debt and Capital Lease Obligations, Current Debt and lease obligations, current Operating Expenses Growth Decline Ratio Operating expenses growth (decline), percent The overall growth (decline) in operating expenses during the reporting period. Operating income (loss) Revenue Growth Decline Ratio Revenue growth (decline), percent The percentage change in revenues during the reporting period. RESTATEMENT OF PREVIOUSLY ISSUED CONSOLIDATED FINANCIAL STATEMENTS [Abstract] Accounting Changes and Error Corrections [Text Block] RESTATEMENT OF PREVIOUSLY ISSUED CONSOLIDATED FINANCIAL STATEMENTS Schedule of Error Corrections and Prior Period Adjustments [Table Text Block] Schedule of Effects of Restatement Adjustments Basic EPS Diluted EPS Total operating expenses Total revenue Total cost of revenue Total assets Common Shares Error Corrections and Prior Period Adjustments Restatement [Line Items] Liabilities Total liabilities Other Liabilities, Current Total other current liabilities Other Liabilities, Noncurrent Other long-term debt Preferred Shares Adjustment [Member] As Reported [Member] Schedule of Error Corrections and Prior Period Adjustment Restatement [Table] Derivative Financial Instruments, Liabilities [Member] Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items] Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table] Liability Class [Axis] Fair Value by Liability Class [Domain] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Fair value per unit EX-101.PRE 15 basi-20120930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 16 R17.htm IDEA: XBRL DOCUMENT v2.4.0.8
STOCK-BASED COMPENSATION
 12 Months Ended
Sep. 30, 2012
STOCK-BASED COMPENSATION [Abstract]  
STOCK-BASED COMPENSATON

10. STOCK-BASED COMPENSATION 

 

Summary of Stock Option Plans and Activity

 

In March 2008, our shareholders approved the 2008 Stock Option Plan (the "Plan") to replace the 1997 Outside Director Stock Option Plan and the 1997 Employee Stock Option Plan. Future common shares will be granted from the 2008 Stock Option Plan. The purpose of the Plan is to promote our long-term interests by providing a means of attracting and retaining officers, directors and key employees. The Compensation Committee shall administer the Plan and approve the particular officers, directors or employees eligible for grants. Under the Plan, employees are granted the option to purchase our common shares at fair market value on the date of the grant. Generally, options granted vest and become exercisable in four equal installments commencing one year from date of grant and expire upon the earlier of the employee's termination of employment with us, or ten years from the date of grant. This plan terminates in fiscal 2018. The Compensation Committee may also issue non-qualified stock option grants with vesting periods different from the 2008 Plan.

 

The maximum number of common shares that may be granted under the Plan is 500 shares. At September 30, 2012, 339 shares remain available for grants under the Plan.

 

The weighted-average assumptions used to compute the fair value of options granted for the fiscal years ended September 30 were as follows:

 

    2012   2011
Risk-free interest rate   1.39%   3.08%
Dividend yield   0.00%   0.00%
Volatility of the expected market price of the Company's common stock   93.00%- 97.00%   90.00%-91.00%
Expected life of the options (years)   7.0 - 8.0   8.0

 

A summary of our stock option activity for all options and related information for the years ended September 30, 2012 and 2011, respectively, is as follows (in thousands except for share prices):

 

    Options
(shares)		     Weighted-
Average
Exercise Price		     Weighted-
Average Grant
Date Fair Value		     Weighted-Average
Remaining
Contractual Life
(Years)		     Aggregate
Intrinsic
Value		  
                               
Outstanding - October 1, 2010     705     $ 2.66                          
Exercised     -     $ -                          
Granted     27     $ 2.24     $ 1.84                  
Terminated     (59 )   $ 2.54                          
Outstanding - September 30, 2011     673     $ 2.65     $ 1.83       7.2     $ 69  
                                         
                                         
Outstanding - October 1, 2011     673     $ 2.65                          
Exercised     -     $ -                          
Granted     200     $ 1.30     $ 1.05                  
Terminated     (519 )   $ 2.58                          
Outstanding - September 30, 2012     354     $ 1.99     $ 1.46       8.0     $ 42  
                                         
Exercisable at September 30, 2012     94     $ 3.83     $ 2.59       5.3     $ 7  

 

A summary of non-vested options for the year ended September 30, 2012 is as follows:

 

    Number of
Shares		     Weighted-
Average Grant
Date Fair Value		  
             
Non-vested options at October 1, 2011     385     $ 1.14  
Granted     200     $ 1.05  
Vested     (128 )   $ 1.25  
Forfeited     (197 )   $ 1.09  
Non-vested options at September 30, 2012     260     $ 1.06  

 

No options were exercised in fiscal years 2012 and 2011. As of September 30, 2012, our total unrecognized compensation cost related to non-vested stock options was $217 and is expected to be recognized over a weighted-average service period of 1.24 years. As of September 30, 2012, there are 125 shares outstanding that were granted outside of the Plan.

 

The following table summarizes outstanding and exercisable options as of September 30, 2012 (in thousands except per share amounts):

 

Range of Exercise Prices   Shares
Outstanding		     Weighted-
Average
Remaining
Contractual
Life (Years)		     Weighted-
Average
Exercise Price		     Shares
Exercisable		     Weighted-
Average
Exercise Price		  
                               
$0.79 - 1.01     128       8.32     $ 0.97       24     $ 1.01  
$1.02 - 4.59     155       9.40     $ 1.38       7     $ 1.35  
$4.60 - 8.79     71       4.24     $ 5.19       62     $ 5.21  
XML 17 R53.htm IDEA: XBRL DOCUMENT v2.4.0.8
INCOME TAXES (Schedule of Deferred Tax Assets and Liabilities) (Details) (USD $)
In Thousands, unless otherwise specified
Sep. 30, 2012
Sep. 30, 2011
Deferred tax assets - Current:    
Inventory $ 202 $ 236
Accrued compensation and vacation 255 271
Accrued expenses and other 252 118
Total current deferred tax assets 709 625
Deferred tax liabilities - Current:    
Prepaid expenses (74) (116)
Total net current deferred tax assets 635 509
Deferred tax assets - Noncurrent:    
Domestic net operating loss carryforwards 2,483 1,585
Stock compensation expense 14 29
Foreign net operating loss 2,334 1,326
Foreign tax credit carryover 119 119
AMT credit carryover 42 45
Total noncurrent deferred tax assets 4,992 3,104
Deferred tax liabilities - Noncurrent:    
Unrealized gain/loss - warrant liability (296) (685)
Basis difference for fixed assets (459) (562)
Basis difference for intangibles    (21)
Total noncurrent deferred tax liabilities (755) (1,268)
Total net noncurrent deferred tax assets 4,237 1,836
Valuation allowance for net deferred tax assets (4,872) (2,345)
Net deferred tax asset (liability)      
EXCEL 18 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0`!@`(````(0!E98!:8@(```) M&#N.Z2:@AVX[;I76_0`O^2`1B1W9;@?_?DYH454Q$!K2W@L1)/F^%Q^>TSN_ MW79M\D3.-]8L4IY-TX1,::O&K!?ISX>ODYLT\4&;2K?6T"+=D4]OE^_?S1]V M/?DDOFW\(JU#Z#\QYLN:.NTSVY.)=U;6=3K$KV[->EUN])J8F$X5*ZT)9,(D M##/2Y?PSK?1C&Y(OV_CS/HFCUJ?)W?[!8=G*UT2A:[/QFG6Z,2^Y3^P?'_9LO/`K!QG^WSCX MPAP")$<.DD."Y"A`]G,8XYTS/S M8=>2OW(W9#_TW.9:.ZI^!!<+D5ZXKVS MO8_%34>7!WAI9@YO3_HXB%QHZ-#-/-9Q/&R,I<_+%[XI6=)0*ZVH.K*;C376 MY1\```#__P,`4$L#!!0`!@`(````(0"U53`C]0```$P"```+``@"7W)E;',O M+G)E;',@H@0"**```@`````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M````````````````````````````````````````C)+/3L,P#,;O2+Q#Y/OJ M;D@(H:6[3$B[(50>P"3N'[6-HR1`]_:$`X)*8]O1]N?//UO>[N9I5!\<8B]. MP[HH0;$S8GO7:GBMGU8/H&(B9VD4QQJ.'&%7W=YL7WBDE)MBU_NHLHN+&KJ4 M_"-B-!U/%`OQ['*ED3!1RF%HT9,9J&74"T\U<%J"`=[!ZH^^CSY MLK$SO+=N5#9@NIS]NHFD++28,5\YS3$$X4UD^&'!Q0]47P`` M`/__`P!02P,$%``&``@````A`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`T;)D;*'/+EKF%,G?L[#B8'<>6A(.2\+-*(I>/A^+%5^?- M^OR+`TQ^.0/CRP8QY+"<=7K^IZ6`#I=LATOL"S$'R6 M#3Z+P3=K_]>&??O8A5U_@=^T"]U,L=LLV&5Y=EOC)RO4K[Y)7?T"``#__P,` M4$L#!!0`!@`(````(0#S/]Y&:`4``#\5```/````>&PO=V]R:V)O;VLN>&UL ME)A=I8-?HBB3/+M6M$^J,A#9*E\GV=.ULHQF_UPI M@[**LW6T_#X?E:BMVAN6^$/&ZW`I1[=*AKJKV2;3;(2TWSU MO!-9U4`*D<85I5]NDWVIW'S9)*EX;'8TB/=[/]Y1WK]399#&9>6NDTJLKQ6+ MPOQ%M-XHGO>WSTE*GXX-U5"&-\=-+HK!6FSBY[2*:'MO=*J7;NJZ7?]G78K' M1+R4IT5U./C]+MJ2Y^KJGI\[UXD3]OJ[4W" M#X%_J"!]S^%UD!VV]U813B?%W:Q*JE?N94WUDYR.L*ZZ1SL;&+!P@8*YF+VYM"GLW@'*B$I_+(OU,8P&'!LP!R_>N:>)TRHP4$;= M9*8NFX3>(O("OZY&=._RVR7S?)>U$)C)59?!E@\/3OB]7L^\.]^;>1/'C[@S MF01+/X+]C$:0RKB+"=UC36O4(G0?O6#)YM^YQ]@2,31%CN75U"Z'.7/W#V#F MAB&Y1Z=#<.[X4_X-.6/D2/K.`\;XP@V;Y;#NBGKO]/V2LI[_2'(%H>=B":_H M8$^+)$/GKL-<[H2AX]\U+ M?:!)ZK$HF/Q[2PE/.2U?N#YS:H$P8^P`3;(N=",O/&R3+V@LX$(T39-5<^_J MSN6>/PO"!^E;T2]-$HRY431OOI7\HND4>51LHLT]Y];#)%`PFK2=N5:+&BXG MT3*D];@,?=(EGY@[GWD^6](13W#FC%$G7=+IP?&=/TITBS5&IW3)J?Z^Q$$S M1L%T2;!^$*T]S*7Z@C!&W71)M_X6;V6$!C8711Q^_3W>`J&)NF1BN\EY%/]( MZ9X$-H0^ZI*/T.MGUJ*.NJ2CW/)G$&BB(9DH=?X9`DII2%+B`)`7TVT$3!Y# M6HYQTR]1IZW[+:>W1<@.EH.!#(!+[ M!$)##$G._HQ(["-(4[%?#,G3?A)MYT@R6KY(TO:#:#M'D%;?@!ZO>*;D;O\L MP*%BHCL4=,K=#\)STU0\.%/6N??.`5/25#PY4_:YEX0YF7AP%'0VUYE/?EP4 M]'CR2_"IJ.($RFVVJBW)W>&$8I5GJR1-#L\Z'#FM$DENX\`[I)"6L%A3<5Z9 MDM!G1A[L"$!FBR/I?(;#5ENQ?DX%SS?`T534V91T[@?A=42C&\V3SI:DLSR* M(2,LL*:ASI:DLPR"$@G@R!7T<+`YU1$M'"UVFH(\CY8.';V&W4]`!7;H,-KEA M@5!K2]+Z$F<6)P5_1`Y:;4E67^*PY]TNQI.WT6D*WKFOAH,%LM%I"CX$PL%J MH],4=$"=!X=F"K;.W$:7*>@`V)D;C6`OZJ&:/6&;VN@R!>_@W(G\J8CWVV0% M1V6CRQ2\@W-2&CGHLBVYW/]LTSHJ=-F67&[?1)U2:88])*1IK0I),K=!C3*O M-)UY2+^3M21$F6U)YGX.[FR$-E,@E1J>O\Z8,T*'*>@L[SZ'G2.@O*.#O,/# M_1#]OK:*TQ7]\%>_U`]*FFG9S2/B\.VWSYO_`0``__\#`%!+`P04``8`"``` M`"$`<]NQY7D%``"R%0``&````'AL+W=O@$V`$"49#53='6E'6JUV9YXI<1+4@".@3?OW>^UK,':2 M3GB9:7*/KX_/O3YVO/KR7AV=-]:T):_7+IGYKL/J@F_+>K]V__OWZ6'A.FV7 MU]O\R&NV=C]8ZW[9_/[;ZLR;E_;`6.=`AKI=NX>N.RT]KRT.K,K;&3^Q&B([ MWE1Y!Q^;O=>>&I9OY:#JZ%'?C[PJ+VL7,RR;>W+PW:XLV",O7BM6=YBD8<>\ M`_[MH3RU?;:JN"==E3'@E<>(D'F3:K;0DK$+([#=NMW:]DF07$]38K M*="/DIW;T=].>^#G/YIR^U=9,U`;ZB0J\,SYBX!^VXJO8+!W,?I)5N#OQMFR M7?YZ[/[AYS]9N3]T4.X05B06MMQ^/+*V`$4AS8R&(E/!CT``_G6J4K0&*)*_ MR__/Y;8[K-T@FH6Q'Q"`.\^L[9Y*D=)UBM>VX]5/!,D5#4FH2A(`>Q6G,[H( M21C].HN'C.0"'_,NWZP:?G:@:V#.]I2+'B1+R-RO#'D,:[VU5%BC2/)59)&Y M8!4MU.=MDX0K[PTD+10D59"YZPP8:D*R`2)J`?P&DK!TFV0`1;PN?\])#+(X M1>:$Z24D,!'9)6*^&"`&1Q#/YCB_V2(]1S$(FF&D21(/Z:6T*4+FLJN$UMGH M"X,`*#LF\+DX`KQV875#,1*]+IP8(;&L)B70JB:QS(B'$='2&;1`@_MI";!% M*S&G31$225K1(K%*FHW#<1B08;1!*II"2H!-4L3WA[PH%F*0%5U0WQ(S&\># M@,SGPWB#5SR%EP#;O/1ZD1=BD!=9S&.[B$8\B6*MML%+'&0CE_B\MP38YF7- MFR*FU\ONO:'4$H3``U,=EE*HF*$ZHWB,E,N.K]S-"#36:V M<9/>J,5Q&,ZM'9"9X4`7W.0UR=7)I:T3VXI2!4)%PI#JF54K89(^'NFXR6R2 ML8O;TL7VT]M:U7)LWDE`K7BFDB"SA!(=-YE-J[R+[<9"H. MR@WG::1SF.PF>3RY8O)$][#2;>SB#V&TT)M?E70,('2A6]6D-LGFR16?MR\) MJ0+-Y7']$!/=3(H9)NGCH^UM,K.L7EQ3?WT#)%<\?W1-4>(A"!G$%_8QMGP2 MWSJ)Z"3'EVC+\6UE4@5"7K:NV:VHH1J=9/82;;.RS5Z!<",\1`&Q`)D!H$&H M;<^D)FS[;K^E:/*&WQ*KR5,%0L'TM-AG1C"\L37II$-`HFV]],["[E(@K9<% MR`P`#7Q-W-1KTCE`T<)A.8,=$:(O*XH:@D;GMAIV>6Z+WY?C:MVW_>0H6R#M MV8H%>KXR`*J7K^IFA.=ZM*G.),>G5QR?ZI90O!"$/W^@T0,]M6(V!E`::N

WK%[D=7%D5-@0B:JC];6*7-^C0#(M:^:[*;Y/CTBN/;%4M[T##W)3N5 M9D#<9&>Y_N>758I6;30]U551VO5N+QYIY,]I->RRZ<7Y,F[ZSV>7:*O9[:M5 MJD#H!C$)[;H9\3"*M%D858.GKBG,\'YNF">U;#N5*=?N;6:8!.-7F.'3&;XL M5:S9LXP=CZU3\%?Q+"8J/7R+3W8I/-G)]RUO","+V2G?L^]YLR_KUCFR'0SU M9S%80(-O;OBAXR?YKO/,.W@KDW\>X&V4P>.(/P/PCO.N_R!>DH;7ULW_```` M__\#`%!+`P04``8`"````"$`Z`'&V9X)```5,P``&0```'AL+W=OZVW5V'#9=Y&))?GR[LT^UR%3&/?_S<;7L_BF.U*?=/?6,P MZO>*_:I<;_9O3_W__L?_-NOWJM-ROUYNRWWQU/]55/T_GG__[?&S/'ZOWHOB MU&,1]M53__UT.CP,A]7JO=@MJT%Y*/9LY+4\[I8G]NOQ;5@=CL5R74_:;8?F M:#0=[I:;?5]$>#A>$Z-\?=VL"K=R*_4D$.1;;Y8D=?_6^.51-M-WJFG"[ MY?'[Q^';JMP=6(B7S79S^E4'[?=VJX?H;5\>ER];=MX_#6NY:F+7OT#XW69U M+*OR]31@X8;B0/&NGA=?FQ/ M?Y>?8;%Y>S^QY9ZP,^(G]K#^Y1;5BCG*P@S,"8^T*K?L`-C_O=V&;PWFR/)G M_?JY69_>G_KCZ6!BC\8&D_=>BNKD;WC(?F_U49W*W?^%R)"A1!!3!F&O,HAA M#LS9Q)A,;X@REE'8:Q/%&%CFQ)[=FRAW'`L[]]H6]BJCW&'+5`9A MKTV0.P[%EE$,OC?N7B*C7>AND<:3V^TUFE4R.H.OMV8H=E^]F=WE:?G\>"P_ M>RQ#L*.K#DN>;XP''IEOXS$[X?/;F.U?/NE//JN>R]05N_9^/-LS\W'X@UTO M*ZEQ4#/6%0M4V#-+U[A2PXZL?2MKIFL\C$/>R;^H""XJPHN*Z*(BOJA(+BI2 M5%!#,I38<[(\^3E-9_Z0;8]VC["->\<>X;/T/6+9^L(Y*+%G9.D6YS03/8XK M-5:=&_D&]<[-FNJS_"LTP3D-V7[A. MD0T7-)KFG4,*(@IB"A(*4@HR"G(%:+:QK':#;5S-DK.2"6V;[`]':#J;%A2X M%'@4^!0$%(041!3$%"04I!1D%.0*T%QCI<$-KG'U4Y_MY?;^8<]))G"$QJYO M9).915+E0@QWIKJJ?CJQR2[SJ-ZG(*`@5"-.9B.2&B)MV)Z1XX_58D@25 MJ,/&R.ZR?'WUI=JP:767>#V'N[',%:.O"JJT;UH6KR;K8)),Y0M.]]8(" MEP)/@$F]E-9H0D_6IQ,";8(Q'I'3#^F$2)_`BF0]1!3X%`04A!5$#>!]%:^18'1R3ZS-1!PV:UYO!UED*<@5HSO*.]XX= M74^C'I-#=J1(,1F("\0#X@,)@(1`(B`QD`1("B1K"5^S";U?Y_\ZK-O,>S`U M<7R]@_DG";"%Z2U3BE1[Q;2.N*#Q@/A``B`AD`A(#"211*1R8VR1$C:%&1F0 M7"6ZI;QI42V]\O,,T>NH52(488XA1)V1"R`N$*\E73*=C<@Y^ZVHN58#("&0 MJ"5J:'(CC%M1$SIIB3J--']I*VJF94!RE>BKP!N>.U9!]$GZ*I"LYO#/P=A5 MH*X")2YH/$F:"F(TH'6>#W,"("&0"..2XXUA3H)SP'QZ1AE$R56BF\_[ICO, M%^V6;CZM1_@GA,1\2ES0>$!\(`&0$$@DB;*(M"B!.0F98]%"<(:%(`3)@.0J MT=WGW9'J_H6<+IHIW75R5@[_LP)QG1(7-!X0'T@`)`02`8F!)"WAMT.#_<%# M[WG2=KS+)O0,4JW))VEQ#4H\21I M+O$9VTI:IV?!Y>I#D`!(""0"$@-)@*1`,B"Y2G2W>2-SA]NB_]'=AK)/:9*D MVY2X!B6>)*(4&S.C]OEPYP`2`@D M`A(#28"D0#(@N4IT4WE[ZY],Z:L7+ZP=<_T;P;M)$S:K2V`N$"\EJ@I M@532?BOJ4@)]LQ`T$9`82`(D!9(!R56B&\P[#[I[KF= M&A`7B"=)LWM'`YM<%3[,"8"$0"(@,9`$2`HD`Y*K1#?WOEZ-_6$'\RZM<:5( M30VTU7%!XTDB:MP9?%3KPXQ`GP%5<0@S(B`QD`1("B0#DJM$-YJW3G077WYP MRQ0=E[:+35KQ2I%J-&W47-!XDLC/=>))(2RV+5"(^S`B`A$`B(#&0!$@*)`.2 MJT2WE/9G%RP]TY>9I%QR3"&2YK"GGVG[NI`*2SR@")]*N>UX<\OR@/A``B`A MD`A(#"0!D@+)@.0JT2SFU_X-N[:6DTK7)$63(T5*(I#DWTUW88X'Q`<2``F! M1$!B(`F0%$@&)%>);BIMS[[>M^,S;9E)+EI'BH2%\\F,W.L7YK"4_'M!/%`]ZXXOA6+8KNM>JOR@W_S MP&")KZ7B6Q&N\<">I63Y;M@.L"\E')9O1;8\OFWV56];O+*IO`;M]X[B:PWB MEU-YJ!_G?2E/[.L(]8_O[.LG!7N`R/#6_\#?X;+[0\OP/````__\# M`%!+`P04``8`"````"$`+?ZQ7[`$```($@``&0```'AL+W=O=-FW!ZI6+IK[KT#IGVZ+> MK]R__WJ=Q*[3=EF]S4I6TY7[25OWV_KGGY9GUKRU!TH[!SS4[>VQHMA63JM+#OA]Y55;4KO2P:)[QP7:[(JJOP9=U76O)V.DYQ51W"Q*;@N(@*?=:>AN MY7Y'BQ2'KK=>B@3]4]!SJ_UVV@,[_](4V]^*FD*VH4Z\`AO&WCCTQY8/P63O M:O:KJ,`?C;.EN^Q4=G^R\Z^TV!\Z*'<($?'`%MO/%]KFD%%P,Y4T"59. M`F"O['B*XQ"%T==>/,E(!/B2==EZV;"S`UT#:[;'C/<@6H!G'AFY&QFPX7.^ M\TEB*J!;*,?[.L;1TGN'%.8*DR@,<9T>%)B0]`:$Q#W&`X8]30C>IAE`&6\7 MX$*33S)IDEGO7D22*`@1F>:QI?J(00&RHU-XO#0'0Y6UX`D.K;4E1EM:&S!6 MAAP^OS('KUR(HD\[N:J-Q,Q$Y;"/35ZI80V&NAJ>Y\3!-B>[$A)#)*?0 MRE5J6&>H9VQPBL9PXF";T]!\LCLDYL+)SI-N16B8:W":C>'$P3:G>1^KY"0Q MDM/,MZRI;@59Z.<:G/BQI.WYQYW,P58G!W[O5W*2&*V3M0%CY?F8E3G8S(;= M%HF$R&1,9L2DE1I6A.YT,@(=>3X=`FVR(H$E;(D"25Y1,)1!I"LUS*%60R-7 MR)+FQV42:+M.5D(2!=(*I8^8JW,=U)J$'PQ?*RZ2ZFFHCQU^HD"1W.HDMK*7 M&G84QD/Z3(9<+C6&7^1'BJO);.@(V=9[(:)=;HAEH' MMC(JD,I7$%SQDDZD'06:VIO,1DDV?[VQ=A\)!HU3^=)E&:$A):K/[YE-7J-D M&]W0[WA_`!DYPZ.47*!M9O;.4R#8^?UK7F3U6]IC MN)I-\%!TD]S_$GI\+?0QMH5+@53Z9O;IG2J[;/@)PM$0I4G14OKGSB)\0_'# MH4*JPA*D]B2VM3=53J0=Q??>AK&E^D\RO*'^H74:)L+URE5)(O',"B$U`3C0 MNMC,XBC]YU=*2_]C/-1'9>\B\(^Z\"%&,I07;WDOK6BSIRDMR];)V8E?JC&\ M*/2C\L*?H$6"^9W-&D_YAP!QE>\-<`\_9GOZ>];LB[IU2KH#E_YT!K0:>9.7 M#QT[BKOBAG5P`Q<_#_#%A<*=T)\">,=8=WG@WPKZ;SCK_P```/__`P!02P,$ M%``&``@````A`!_]T;<>`P``U@D``!D```!X;"]W;W)K&ULE%9=;]HP%'V?M/]@^;T)@210!%2%JENE39JF?3R;Q"%6DSBR36G_ M_:YM"+'9,OH"L7U\?.ZY-[Y9W+W6%7JA0C+>+'$4C#"B3<9SUNR6^.>/QYL9 M1E*1)B<5;^@2OU&)[U8?/RP.7#S+DE*%@*&12UPJU<[#4&8EK8D,>$L;6"FX MJ(F"H=B%LA64Y&93787CT2@-:\(:;!GFXAH.7A0LHP\\V]>T499$T(HHT"]+ MULH36YU=0U<3\;QO;S)>MT"Q9153;X84HSJ;/^T:+LBV@KA?HYAD)VXSN*"O M62:XY(4*@"ZT0B]CO@UO0V!:+7(&$6C;D:#%$M]'\TT4X7"U,`;]8O0@>\]( MEOSP2;#\"VLHN`UYTAG8:*>,5"(!?5#-=&N`(>37_!Y:K5G-QK>+\`4\S8Z8 M]1$38]2!QBYDTT%T,D!@IQ)B]U5.((M_]_\D2F]R1<53]\#U)63B(C:7B'C6 M01R-X%Y?X[`V#88JZ'D1)V=>8^K:8F)33]KE36_".1DLO?YD#5YB"*O+0ISX MJ;*8J4GDC>](?W%R-M11!%5]O2(-]A2E4>>Q]<)B8J,H<=-'9F(X\78,01]WT/>HTV"N=]!RUMJ73FW!.UAVJ]_H/ M%ZT&>[YA=[L/IQ/)U#]8,=C$YOP]6E&VOMOO45.SH MAE:51!G?Z]89P;O=S=JVOM9MW33F;@&Z:DMV]"L1.]9(5-$"MHZ"*=P!PO9E M.U"\-5?_EBOHI^:QA.\G"M?H*`!PP;DZ#72SZ;[(5G\```#__P,`4$L#!!0` M!@`(````(0":J>+0.@,``+,)```9````>&PO=V]R:W-H965T4U7^)E*?+/^^&%YY.)!%I0J!`RU7.%"J6;ANC(M:$6DPQM:PYN!1[5S:"DJS=5)5NX'F)6Q%68\.P$-=P\#QG*;WCZ:&BM3(D@I9$@7Y9L$9V M;%5Z#5U%Q,.AF:2\:H!BQTJFGEM2C*IT\75?3]Y$[ZA,P5&@<8)8,Z6\!`'P%U5,MP8X0I[:_T>6J6*%P\2)IU[H`QSM MJ%3W3%-BE!ZDXM5?`_)/5(8D.)&$H/[T/G""6>S'R?]97*.H3?".*+)>"GY$ MT#404S9$]Z"_`.8N,Z.CS_6M5"%'37*K68`AP@C2D%"@Q_4L]);N(YB:GD"; M5T"!#=GV$%T-4-C+A.2',E\WOE.CP:T:70FM;W-:&<@+1Y'/$=&LAUA2P*7K MI6@P5'L0.`K\GM>(,YBH+;96NQTL6)'!WNLC:_`*0UJ#BHPC&XP?)&W%/">, M;&G;"P!+&73Q].1)DMB!-P8S\&2P8$5.[,BZ?T,XWY<;1&^RO8F2Z4B! MP73>3/Q/DW'+V(C(\>R/MUMP3. M_$S\2Q!+O)YI@POCLG@-ML5'TW$3&DPO'KHPC"TQ+T*,]/,-<3@??MXXN//W M*-?@L?+1Z=@8#)R1_H@EHSMO:R!= M00+'MXSWH(5?S#=ZS8PT(Z2B8D^WM"PE2OE!S[\`+I)^M9_-MX&^VT;K&SVS M];K;OX"1V9`]_4[$GM42E30'2L^9PMD79NB:!\6;=G#MN()AV7XMX,<1A;O3 M&ULG%A=C^HV$'VOU/\0Y?T2 MG`0("+BZ2;3ME5JIJGIOG[/!0+0D1DEVV?WW'7N<8$^VD-T7/F:.A^/Y.`Y> M?WTM3\X+KYM"5!N73::NPZM<[(KJL'%__//P)7*=ILVJ7782%=^X;[QQOVY_ M_65]$?53<^2\=2!"U6S<8]N>5Y[7Y$=>9LU$G'D%GKVHRZR%K_7!:\XUSW9J M47GR_.ET[I594;D8856/B2'V^R+GJC/%M%'H@0Z2MA'8?[$ MCV9L-K_/Q<-]J32E69MMU[6X.-![P+PY9[*3V0HB=_G!W?09^[^$0:9DD&\R MBHH%N6B@RB_;*`C6W@M4)M>86&/@1WJ0;T.2'B(+(0.G76!98V#U8RD4VRW!A,XB'$+*-9(@((SM(.H0LV+3'6/N`HIK[N,U?@J$!C01& M0=C'50F+$1.J_I,93*@A-0P6%2C,>"H2O'%AHWTMF;%%I(*8A6J'@"UG-M,$ MW?#:AYA?DX35[R"T^C!ZXZE*L$TU"@B7&#&AHLIH5YI.6NK.1QG.;89RK.[W MIUQ$F<[MK,6(T4R),[GE3$UG<,VTU0.+S]"6BRAM.E>(N57LI(-(]6"DK=/. M2?,LSVDB7_?S+!=1PJ2P,6*,.:*&U#!8.5S:E&Z/M`3?&VG$&%2H(34,%A4& MDFBFYS87A:9Y69+^TR!LP)".2N^%.FD!EQ0VKF)O).6.>^%M&PV.2D0H\GAWIND0L9;3!#]%4Y$T8MJ6FQ^4@]'L\' MU1LV9R2+*$\LGQ:[!M9\J"4U,38?*;H&GW'G`$.IMO-$1BW6H#D>K_.`G@7: MCX.Z",F)E_9NJJA,2JU!^4[_HS#;5,DC4ZQ";ERD&D4SDN)$^Z_SD9H6.Z%2 M=<>S0XVVV9%?CYDAY+K`U)*:&)N/E-[Q?%"H[S2::#[6DS+!8?/P/*;Y" M$\4/:?4T"*L7+NFS4Z+]1O5,B\WN4YKOOZ?YI)]C#9*R?AWFD`Z%1IE<,;BR MV%RA:\97UI=HFDGZ$*1!F$E_%I!GCL3RLZE/I#'5_G>X2GT>W84^JKD]%81+ MK$'73"4#2VI:[-Q]Z%CP4=]O3X4&F7P&QX*)L?E\Z%B0_Z8'M1Q,!8*PELMP M3@]1'>3*-S4M-KM/'1+^>X?$8"H0=&\J$&5R-2PV5W(ZC#O0X(9GD-%@,!T( MNK)(]#+\!SGX2Z"]"H\<\18(KS=*7A]XPD^GQLG%L[SA87!2]E:\?8K9"NX< MY`G8.^#RYYP=^)]9?2BJQCGQ/2R=3A90[AJOC_!+*\[J*N%1M'#MHSX>X9J/ MPU_NZ03`>R':[HO\@?[BI,`?OWZ^0[8 M;*X?ZPH]4"$9;V+L.QY&M$EYQIHBQK]^WETM,9**-!FI>$-C_$0EOMY^_+`Y MMV"Q M9Q533\84HSI=?RD:+LB^@K@?_9"D9V]S5YV"[#U<9]@)RF)\WNI`DQZD3!4))T$ET,`.PH(?8Q MY0RJ^._\GZ'TI"%4N!@NN+N4S(:*Y%(1+CO)@!&RUV><9M-BZ()>+L+`[WQ- M4G=6$YHFT%E.>@\&*T-*W[ZR%L<8PNJJ$"[#T=O2CUI2!DNQ\UO-9.49XE^HZ_\YS89`.I#KK>%3#>^%H_!QCN%U4R" M34H&=*O_H=/B$=UJ7%RK>>'E>&'0$MGSQ6Z_-14%36A5293R@SX[?'C=NJ?V M6-O!L68.`;<;@&.E)07]1D3!&HDJFL-4SUE`UPM[,-D;Q5NS]^VY@@/%7);P M_4!A'_$<$.>&ULG%7);MLP%+P7 MZ#\0O$?48GF#Y2!!D#9`"P1%ES--4181411(>LG?]Y%TE,1RT=@^6*(];][, M/(I:7.]E@[9<&Z':`B=1C!%OF2I%NR[PKY_W5U.,C*5M21O5\@(_V"3[")VD^FG373$E.Z!8 MB4;89T^*D63SAW6K-%TUX'N?C"A[X?:+`;T43"NC*AL!'0E"AYYG9$:`:;DH M!3APL2/-JP+?)//;*2;+A<_GM^`[\^8>F5KMOFA1?A,MA[!A3&X`*Z6>'/2A M=#]!,1E4W_L!/&I4\HIN&OM#[;YRL:XM3#L'0\[7O'R^XX9!H$`3I;EC8JH! M`?"-I'`[`P*A>W_=B=+6!<[&43Z)LP3@:,6-O1>.$B.V,5;)/P&4'*@"27H@ M@>N!)$VC9!2/_\]!@AYO[XY:NEQHM4.P9:"CZ:C;@,D<>)VO#-(Y[0L,N9H; M5^1+`6U@%MOE-$\69`L!L@/F=HA)>P2!YKT"Z'J^`E?T7L%Q_R$B.]T_NZ2_ M*X*D,.H3&,U&/;]/Z39@1GY?O34\NJ2A*RHPF.H;3O/70$/#@!G[@>2Q^_2* MWB4..^[\Q%W1L8#71(.`@`D"LFSV3P'C2P2XHF,!QY$'S,0GD":3T_8GEW1W M1 M-T5U7JO:9*8J^3FK=L7YL%;_^=O]LE25IDW/N_14G?.U^C-OU*]/O__V^%K5 MWYICGK<*.)R;M7ILV\MJ.FVR8UZFS:2ZY&W1=B7Q997375OIV` MW91WE#[SP_1A"DY/C[L"GH"%7:GS_5K]0ULEFJ%.GQZ[`/U;Y*_-Z+/2'*M7 MKRYV<7'.(=J0)Y:!YZKZQJ3!CB&H/"6UW2X#?];*+M^G+Z?VK^K5SXO#L85T MF_!$[,%6NY].WF004;"9Z"9SRJH3=`!^*V7!A@9$)/W1_7TM=NUQK1/!'T6CV1^PD<\E'9]JMM#,^5A[K+FI&WZ]%A7KPI,!>A4 MX/&O4'CO:5!H\N_01/!CX&`08A!A$&,08)",@!0GV]CN"Q-1K%2;7L)%8%MI*;*ZQNKW(7!JH>#,N M7I@66HB<:TOI6QQ5\J86DZ9,4-AL[G&Z%.&2C?C4FM^[11_ M3Q"E8B7<8N!BX&'@8Q!@$&(081!CD(R`%#[KKO`QM1P^"X\ZFVL6/'RZB9:^ MC51,)H3#BZ]C=HN!BX&'@8]!@$&(081!C$$R`E(`V8D1O[G^^J6)U<+K*YIO M-M=<0['!P,%@BX&+@8>!CT&`08A!A$&,03("4K#@#/.)8+%:>-2AB6=SS2A8 M&#@"7-<;R\(+JM"(Z>MBX`GP@8LO-,(EP"`4X`.72&B$2RS`!Y42H8%*4N#9 M\>\3D>^JX="C3`9ELTE`J'>""='O4Y&4I)J-GQ:KPB?/RFI?'3F/P6@=Y-[5XT#C&O=B5. MK]%TOO0:$VTF_>C;+VC#WQ);%YE8D]F#]&,0$P]5N:%=G[0;(),;V@U)%4/J MZ8-%NAJ1=F-"DC&1IQ`[1=V15W[HDO.*-D-;XZ)K%C>$.#TQNPW5T.#>1WXO MVY(J+B'>KTQ\4B4@)/R5242JQ*C*;$ZFT2@":.(3TA`2$A(1$A,2#(F>.^/$CD1P_?.*# M&UL6/WZ:L32T!V^DX@6^!7+ZXNM@WQ+B$N(1XA,2$!(2$A$2$\)NI/GX&-9T M?L',KRK+O#[DF_QT:I2L>F&7QW.8DP/E%]NVMH++0JB/N;Z"6Q'*-_H*[D98 M>T,%N(>^I(<\2>M#<6Z44[Z'IF83"TY#-;_)YE_:ZM+=NSU7+=Q`=Q^/\!^' M'.XK9Q,0[ZNJ%5]8`^P&O;MY??H?``#__P,`4$L#!!0`!@`(````(0!%)V>9 MM`(``/D&```9````>&PO=V]R:W-H965T%OE^-?/NZLY1MJ0MB"-;%F.GYG&U^N/ M'U9[J1YTS9A!P-#J'-?&=,LPU+1F@NA`=JR%G5(J00PL517J3C%2N"#1A$D4 MI:$@O,6>8:G>PB'+DE-V*^E.L-9X$L4:8B!_7?-.']@$?0N=(.IAUUU1*3J@ MV/*&FV='BI&@R_NJE8IL&_#]%$\)/7"[Q06]X%1)+4L3`%WH$[WTO`@7(3"M M5P4'![;L2+$RQS?Q_4>ZEOO/BA=?>E_85Q`<7D3?N09\5ZA@)=DUYH?P:&K*]E\7S+-(6"`DV0S"P3 ME0TD`+](<'LRH"#DR3WWO#!UCB=I,,NB20QPM&7:W'%+B1'=:2/%'P^*>RI/ MDO0D\.Q)XB1(YK-XEOZ?)?09.8.WQ)#U2LD]@D,#FKHC]@C&2V"VSJ;_=`:6 M;,R-#7*A@-;0C<=UEDY7X2.4D/:838^98C2`)@,D!/4A!9`]3V$"+7JYN(<4 M;-!I"M-LH'=9;GK(U+5V+#@Y%7Q=R(*A7V,;\W,EC[D4`O-C9Z\+67".$U?. M)(J/Q?)N_';FMB=9/'@]*25T[NV"%CP2/&^@WY[V@M'+@NE[!"UX)#@;*+U# MO^T%D^3H_\1A]AY!"QX)IF>"?ML+CNI]HF9<> MX_NXR(XGR:OZ$>1OJ&"J8I]8TVA$Y$3P^"&1P&`2RG-86&GX_#1 M6O\%``#__P,`4$L#!!0`!@`(````(0`:C`=>WP,``)0.```9````>&PO=V]R M:W-H965T[>1@H3:N<%J)BZ_"-J?#KYH\OJY.0S^K`F`[`0Z76 MX4'K>AE%*CNPDJJ1J%D%EIV0)=7P*/>1JB6CN5U4%E$2QVE44EZ%Z&$I/^-# M['8\8P\B.Y:LTNA$LH)JB%\=>*W.WLKL,^Y**I^/]5TFRAI<;'G!]9MU&@9E MMGS:5T+2;0%YOY()S@#N+TE^3Y=UXQJ#;TR71@*\2S@3[EYB]8 M'%VL?K0=^"F#G.WHL=#_B-/?C.\/&MH]A8Q,8LO\[8&I#"H*;D881B8*"``^ M@Y*;K0$5H:_V^\1S?5B'XW0TG<5C`O!@RY1^Y,9E&&1'I47Y'X*(":IQDC@G M\.V02:VM3[AN$MXF\B`H5]>&K,T[C$AYI((DO5, M8M(6"[-!\\R:Q_-Y$T&GE-"YSQ,:L$T0ID,(#=@CG/8( MT8R$R9PTU@[A;`BA`7N$:>,2,T2S(R1M_AU"H^'>@-SNH0%[A&W1D!#-2'B% M;C&$SH`-73MBL[2M&W(B)K5M)&1QA9;`P'T^38ON$R>]ZCK0Y520GN;<+JE% M?S2`#O0.5T]V9MD'8/V=WNS2],OAD MD-18M,?9GT1G=YR>M'?S'*0VYGWIST9_&)W=<<;7\APD.*2G./UY=';D;`O? MS7*0XI"SY-P:20=R,QFG[:NSRSQ(>LA9>WSF_DO$@=Z9DT&Z0U!4;K\4'>B2 M*QFD-1;M[=5^2LZ./9Q>V3;)(,FQ:(^RW1DXDLZ.E.,KW4L&*8]%>Y3]B71V M-QVMU'8V3#)(>"S:H^P/I+,C96OL,@Z2G:1WQ.F/H[,#JCDR>D>M+O$@[3'G MXP]?E`Z$)RPXF#>O,R3&RP&>G4LF]^Q/5A0JR,31'/P)O%^;?_%24"```RBH` M`!D```!X;"]W;W)K&ULG)I;<^*X%H7?IVK^`\5[ M`S(7`Y5D:HSOEZJI4^><>2;@)%0#IC#I=/_[D2S)2'N1`//2-)^7-O;2EKVW MHX<_?NZVG1_EL=Y4^\MC]W__#;]-NYWZM-ROE]MJ7SYV M?Y5U]X^GWW][^*B.W^NWLCQU>(1]_=A].YT.\WZ_7KV5NV7=JP[EGA]YJ8Z[ MY8E_/;[VZ\.Q7*Z;0;MMWQD,)OW=7S:KTJ]7[KMR?9)!C MN5V>^/G7;YM#K:/M5K>$VRV/W]\/WU;5[L!#/&^VF].O)FBWLUO-D]=]=5P^ M;_EU_V2CY4K';KY`^-UF=:SJZN74X^'Z\D3QFF?]69]'>GI8;_@5"-L[Q_+E ML?LGFQ?.M-M_>F@,^O^F_*B-_W?JM^HC.F[6^69?*ZJ[T*:K`7B M@_LP.FQFX*]C9UV^+-^WI_]4'W&Y>7T[\>D>\RL2%S9?__++>L4=Y6%ZSEA$ M6E5;?@+\W\YN(U*#.[+\V7Q^;-:GM\?N<-(;NX,AX_+.VLWNM3 MM?M;BI@*)8,X*LB0G[TZ[O2L\53504_JFCC.ZVQ55!^%I309Q1;SH>CR93]W9S9RH*$[DAW>5A7#:8 M#>^(PMJ)/D_2T+GUDOHR:YHD])>GY=/#L?KH\)7-H]:'I;A/L#GCD77ZR61I M$_*S?.2)**+\*<(TP7BJU7P1_7AR&7OH_^")OU(:3VEX=K0BQY8L6HG(-@^GZ9VKO@JA;D:\J2Z?*O04R-&V5-#)T8IS(D9DHFY(!E-;8VO-/QF*>9_ M-)BX(UL1:(7[F2)4"B-%R)E$5Q7QU5])KL9(K\;(KBKRJ[]2H,(PU9IZOC*M MJ?]ZRH5:3+G.2T^!44L60'Q%Y+.N67R!CF.F,YF/\`9-A)K);&+G1GR#)KFD M<>TXZ0V:##53DJKY=4GQI<2:/;ZRK-D3-]GK"U>,XCIC+;B,G*8G-<:\4N!3 M$%`04A!1$%.04)!2D%&04U`8P#*+/UC!K!&'7Z>\&/78Y0NJ?;:X;&RGAB4^)#`>!^$`"("&0"$CR:3]J#V)6W) M!7G6'M3R'$AA$MM(T6N82_F*D;(UL1ZS#FTG1*?*T]4TDA(?-`&0$$@$)`:2 M`$F!9$!R1=13:TIRHS`'V/Z)$OX._V3%;_HWHR4=DQK3/DI\T`1`0B`1D!A( M`B0%D@')%?GLH5]\?MQV4Y34=[@I*W#33=<@J=$YF/+:!_4RUQ*`A@5 M`HF`Q$`2("F03)%SO\-(]Y'#F,(DMI6BPC>MO%(XR8;`MI`VV\SH&E2J4N(K MC<.:IP[K34F0`(*$0"(@,9`$2`HD`Y(#*4QB.RB*>]/!&Y-1]@2FDVP$B]YH M')23FH@2^MML1HI6G^GCYR<2)2%H(B`QD`1("B131-X"^,D-:`6:PYC")):Q M#FV.;C.V&4:;)/IR0XF,50[$!Q(`"8%$0&(@"9`42*:(M'+"Z-^&E[;M?6I#Z,"H`$@*)@,1`$B`ID$P1]80? M3$IF6ZA;I*TNUIKUC0IP02`0D!I(`28%D MBGR>I?3L"C.&;>E]39)SH4D:DAGUE,BT5+=-VBX?-`&0$$@$)`:2`$F!9$!R M1:2E(^:2:RK,$;:!M`FZ\8%SH1D:D@;$$]M/K-9G`<0'$@`)@41`8B`)D!1( M!B171"_WZ80YY#E:F(-L+T4K7 M?2`!D!!(!"0&D@!)@61`,CF?+\2\,+?.',^?X.U/O.G._RX+S?_@#?27A8 MOI;%\OBZV=>=;?G"3VW0$_O2CG(OHOQRJ@[-'J+GZL3W$#;_?>-[1DN^16O0 MX^*7JCKI+^('VEVH3_\```#__P,`4$L#!!0`!@`(````(0"=\`/,=0,``#T+ M```9````>&PO=V]R:W-H965T MP)!PB9)4[;;=K;0KK59[>7;`!*N`D>TT[=_O&`/ADJ1)'I*0')\Y7*1)9C&J2,64++[KC]_6NX9 M?Q$9(=(`AE*LS$S*:F';(LY(@87%*E+"/RGC!9;PR+>VJ#C!2;VHR&W7<7R[ MP+0T-<."7\+!TI3&Y('%NX*44I-PDF,)^D5&*]&R%?$E=`7F+[OJ)F9%!10; MFE/Y7I.:1A$OGKQ% M09\3]1,LMB>KG^H=^,F-A*1XE\M?;/^-T&TF8;OGD)%*;)&\/Q`1@Z-`8[ES MQ12S'`3`NU%051K@"'ZK/_`KBQ(4(^445I&O%.2%;\TR#4 M4&D2MR&!SX8$^=;,G0?A!2RV5E0G^(`E7B\YVQM0-1!35%C5(%H`L\K,`W^T MCB[74ZE"CHKD3K$`P\PT8+V`#7I=!YZ_M%_!U+@!W3>@'L;M$#;(Z32!CKZF MXRZWH16X#JUL5V+NFU]Z<;SC<;QKXBCPR@3N7H9!QZLC:\RLKJ5^0N!+/R%E M\NQD^;2)J46P&8.`X2B@QDP#`GD_X'D'%7B8F1O.1X$T!KE^O;?("@.G_T*/ M-R?VTK]&B0*/E8P]UIA6B=/I'%10,(S:5O5Y']2B1[T=.U'L= MEZ/.@5Z3G9>AP$,9X'7'JPM-8_KMYH<'S,"*Z)K8"CR,[48'7AV[P:"F$F:> M-ZB$3NE`!8*9$OL7H0[X@?$N^D#P71LQVZH:B6+I?N]O3G5N?6=T? M<'FI\);\P'Q+2V'D)(6E$!KLXOKZHQ\DJQ2EL6$2KBWUUPRNJ02.8<<"<,J8 M;!_4!:N[^*[_`P``__\#`%!+`P04``8`"````"$`*44`[^4"``#K!P``&0`` M`'AL+W=O[E?TBBD M:E)UM])66JWV\NR``:N`D>TT[=_O,4Z0(;WD)0$S'L^9.1Q6-R]M@YZID(QW M&?8=#R/:Y;Q@797A/[_OKQ88246Z@C2\HQE^I1+?K+]^61VX>)(UI0H!0RE[@M81TV#$MQ"0%0PJT+8C0J>:4J,\KU4O/UG0/Z1RI`$1Y(0U!^?!TZP MB/TX^9S%-8J&`N^((NN5X`<$30-GRI[H%O27P'RJS.@8:WVO5*A1D]QJ%F"( M,((R).3SO$XC;^4^@ZGY$;1Y`Q1,(=L1HM,`A:-,*-Z6^;;Q)S4:/*C126A] MF^.*)2^^V2= M5?1N%Y[,T)N@WR8*9K9O#,928"U,%,!I-+4@C>;Q&(R)YSI,;.^''H;AJTD,X.UTS'`ULZ>E MHJ);VC02Y7RO!V<`R8^KXTR_#?1+,5O?P*P?)J,[/H!9VY.*/A)1L4ZBAI9` MZ3DI](PPT]K<*-X/$V_'%4S9X;*&CRJ%E\YS`%QRKDXW>@*-G^GU?P```/__ M`P!02P,$%``&``@````A`!&[DX&#`P``-@L``!D```!X;"]W;W)K&ULE%9=;YLP%'V?M/^`>`]@")!$2:HV5;=*FS1-^WAVP$FL M`D:VT[3_?M^;[(=J3$ MPF,UJ6!EPWB))3SRK2]J3G"N-Y6%'P9!XI>85JYAF/%;.-AF0S/RR+)]22II M2#@IL`3]8D=K<60KLUOH2LQ?]O4H8V4-%&M:4/FN25VGS&;/VXIQO"X@[CJ!LX4-58UB&;`?(S,Z&AC/1-)"+(V0O;[&R]H4&*J@EXLH25M>G=0'@QGK(E!97O5>6"=#2F\_ M68$7+H35NH#0\&2#2;61HR0:KJ_ZZV$4=#9:LJ"T^[)4:5TW36VRY:7C>)`8 M@P$1;0A)8$-6!I*8".(XZ(RW)":VQ,N>*?!06L=K/#.8B]*.$/65C*93U"JW ME*6VLMN2IS;9"J.T,\UU5WV58%M52CL7#%9:S#(%%3@38:ZAH"TB\M2 MAJ!M]1-W69I&#_I$VCEBM#6@7J/HO[%/_Z#=7[<-F;[<[QFG==6`SC<-&W"^ MLI!JN?]=6GJ7[6+4\Z#)E.GF9XNK(3'KYZL+1@U+X14/3=ON9P^%PZ]24X+\ M\P5V@NA%9SPVXXNYW4O"MV1%BD(X&=NKT40QMV_-V/2@QB8]^+0+,+74>$N^ M8[ZEE7`*LH&M@9="/^5F[C$/DM7Z:ETS"?.*_KF#^93`-15X`-XP)H\/ZC)O M)][E/P```/__`P!02P,$%``&``@````A`+AD12T'`P``E@@``!D```!X;"]W M;W)K&ULE)9=;]L@%(;O)^T_(.[K[X\D2E(UJ;I- MVJ1IVLE-8G->7IYS#H$LKQ_;!CU0(1GO5CCT M`HQH5_"2=?L5_O7S[FJ&D52D*TG#.[K"3U3BZ_7'#\LC%_>RIE0A<.CD"M=* M]0O?ET5-6R(]WM,.(A47+5'P*O:^[`4EI9G4-GX4!)G?$M9AZ[`0EWCPJF(% MO>7%H:6=LB:"-D0!OZQ9+Y_=VN(2NY:(^T-_5?"V!XL=:YAZ,J88M<7BR[[C M@NP:R/LQ3$CQ[&U>7MBWK!!<\DIY8.=;T)$D762\&/"#8-K"E[HK=@N`#GUS."5+3V1HO-%("5T(6'=9[D M2_\!2E<,FLV@23`:1;$KV;XB26:CQ@>R$0^2GN+IPL?0OK8SF5%KM4^:35ELIJ$D,5S+?NQ:[5/%Y?S968RMU%8>G96VIG'`2)&,E':KY>ZBT MV*5*3[:V5%8R;/0L/2^5&XY/80ME[P%[3+94[.F6-HU$!3_H,SZ"!HRC]OK9 MA(M-I(^2L_$M7$MFW!\#<"WT9$^_$;%GG40-K<`R\'+8YL)>+/9%\=X<83NN MX$(PCS7<_Q2.JL`#<<6Y>G[15]?XCV+]%P``__\#`%!+`P04``8`"````"$` M2WI4#*D#``#Z"P``&0```'AL+W=OTDL\O'IS9OA:-:?GMO&>\*,$]IM?#2;^Q[N*EJ3[K#Q?WQ_N,M\CXNRJ\N& M=GCCOV#N?]K^^1DL`V#:KFL"$4C;/8;W&_\S6A4H]H/M6AGTD^`S-WY[_$C/ M?S%2_TTZ#&Y#GF0&=I0^2NC76B[!X6!R^D%EX!_FU7A?GAKQ+SU_P>1P%)#N M&"*2@:WJEWO,*W`4:&:ADE'1!@3`7Z\ELC3`D?)9_3^36APW_B*9Q>E\@0#N M[3`7#T12^EYUXH*V_VD0DJ)&DG`@68#Z83^EZ+U`U\$[>E[(&T0J8+Y%I'6.LKX4*\B3)9\FBN"`*#OEYVJ;Q?!T\@:?5@,D' M3.1[(RBT(<4(DLH&SI*-"8 M5"5V$2?V;F'NHBQ[Q1XH=%/76N,4:^C`7KS:G]9GGWWJ]J>>B]BM$80X&Q8"F0'RCC]K^=%`EV M8W>N2ZXQB4I*G*;76E"E7)C;26@DS5*UM%7=YHL\Y*J+[$K--4:KB](TMK<+ M:WN>7>O<4H>@\9BFW29/G;+U3>_9`!IJ>G+1AFVM__6;AIR>_G96%=H6EL:. M,_D`,BK*7+'MD1W3J*D;[=%]]NU&B#3(5&&LV"IDCS14O..![JA`-C;!U'4_ M1QH4J]J.XG#I].EB`"AYMIC_U9C1M#.GL?L!&T``'94GF9.]8@2YGU4YPWS` MI6E73F/GAN>*@33$TJ+V0$7N&FX5]&3 M'*\0>#^NZM$OEZ.?&M[ B\^O*`OY7L0#KN-7@/1^>S%-[,].RF'P3MU7BP MHP)F+O7S"#,VAD_L?`;@/:7B\B"=&Z?V[2\```#__P,`4$L#!!0`!@`(```` M(0#6?X\-B@,``'8+```9````>&PO=V]R:W-H965TD&)\_K-<\YQ#F=Q_517WB-FG-!FZ<=!Y'NXR6E!FMW2__7S[BKS/2Y04Z"* M-GCI/V/N7Z\^?E@<*7O@>XR%!PX-7_I[(=IY&/)\CVO$`]KB!NZ4E-5(P"7; MA;QE&!5J4UV%212E88U(XVN'.;O$@Y8ER?$MS0\U;H0V8;A"`OCYGK2\=ZOS M2^QJQ!X.[55.ZQ8LMJ0BXEF9^EZ=S^]W#65H6T'<3_$8Y;VWNCBSKTG.**>E M",`NU*#G,<_"60A.JT5!(`*9=H_A'C\S M4GPE#89L0YUD!;:4/DCI?2&78'-XMOM.5>`[\PIP'EGD!$ M,K!Y\7R+>0X9!9L@F4BGG%8``)]>3>31@(R@)_7_2`JQ7_JC-)A,HU$,O3@ MU,`S>8OD&8SGX"PC&T%^-,<0ZVNA0HS2Y$:Z@,/8]V`_AP(]KK))M@@?(:EY M)UJ_($ILR6:0R&H`X8`)P9N8+R>^IY%B12,K(?G6W8J!-W*>?*X8G_@M%,B2 MB2(S-G[U+/1(;+6Q$FJ*A<'HVQF_7VZ<@ME[Q@%41:9?[&YPV*'3%W.+L4N^]1AUYJ>/;+O M;EZ[:S&E-M-E%96;;+8L=9Z^UIJ!+9BYI^Y,,.!;@-/_`92;7,!X\-?OA=88 M@$YV-V>"DX-%*'_IC#;R]I&48ILLR=R706N,EZ%?.)WC+#V=2@MF]B\P4FS# M3#,G"VNM,6",!>O),;1.,P^7'26UZ[WNT(D,"'/%IG":^MO5B'73M3N$6XY. M!*_]T$92MXUL!I';O6/972\^'DIMER1+G3=GW8G,=.@6KE;L=,@^:CS]PJ+H M[@N?0\3G+3LV6K3NV>:*32%;ID'Q3E%T@WVG*%ID%L5\)SJ@7C0418\Y>@JH M,=OA#:XJ[N7T($>8!'X#AM5AO+I)Y"SBK*_EV*4&I^$&3#TMVN%OB.U(P[T* MEV`9!5/HPTS/3?I"T%;-'ELJ8-Y17_4BOY"@@\3\^HO```` M__\#`%!+`P04``8`"````"$`;><1RJ0$``!?$@``&0```'AL+W=O83&;^?3_[X^++;`K[,!OP\?'Q=SE@-E_>J])Z(PTK:+VU?<>S+5+G M]%C4YZW]_9^7I\2V6)O5QZRD-=G:'X397W:__K*YT^:570AI+6"HV=:^M.UU M[;HLOY`J8PZ]DAI&3K2ILA8NF[/+K@W)CF)25;J!YT5NE16UC0SK9@H'/9V* MG#S3_%:1ND62AI19"_K9I;BRGJW*I]!56?-ZNS[EM+H"Q:$HB_9#D-I6E:^_ MG6O:9(<2]OWN+[.\YQ87!GU5Y`UE]-0Z0.>B4'//*W?E`M-N70;T=^"R:[ MQNP7D8&_&NM(3MFM;/^F]]])<;ZTD.X0=L0WMCY^/!.60T2!Q@E"SI33$@3` M7ZLJ>&E`1+)W\?^].+:7K;V(G##V%C[`K0-A[4O!*6TKO[&65O\BR.^HD"3H M2!:@'L<#^/EXLHM"Q+Z>LS;;;1IZMZ!88"EVS7CI^6M@Z3>$RP];_-D.86N< MY"MG$5P@GD%:WG9)M-RX;Q#*O,/L.\S2M@90H$+2`<)S``('E;!E7>4"DO=Y MV'M1?)(JRE?7VYN(A8I(3<0R&2"*1`B>+/&Q-`Z&W$NA2*)PX!4QW2-F*5+/ M@YQ*-Y25(:+35^;@K0W;&I*01)&V,F*6(H]1K(=$'HV]4;6B":IYNB8.5C6% M@9XJQ,#:@^[(4V6G#R&*NFB..@[6U6F%NT<,1@PL61.FC,;#H"(IGB.)@W5) M6IKVB$%)3Z&_&I85U96JP^.H(HH_MB1S>%S3'*R*2J)QLUC3B$%1BU!SB%0> ME>M.T;2:HXF#=4UC_Z(FQ*"FE2ZI']0-R0?WF1X:@=;[?8PYZNA`4L/+=Y08 M^)IK/TZ,0.M1T'N^!_FBZP-'MZ/4`(P,JC9NF9.+QD>#E?W([/T.]+#Y'V-4 MA=Q(IRM$VU45ZOWO=R",GN]HS9BJXX$3+#WYWTBG"N56.UTH&K,J5!.R]SM0 MG^90ZX;4`(P=H6J;Y?#\'E`?Q)76(:D*4&I4U3;+WWW3X)-("\N^ M!Z&VA9-H@4T[@.A>58SF[/P-Z__?77ST9RBKX7F7Q-IS9=^!9,?H;=WPJUE6 M[IM>'@9CD79^U8'Z=$FO`@*0]BP](/E9*IEW`+.4`LWVIY62F*4]?&+]]:H#2:4DWU%# MPBU[LBL%'*V'1$]7!Y(-/HFT>DL_`\4C2-4XR^+Y\!H M-!:XJFJ63<.QWE1E)`E!N*XFF7\8X`Q2-'2JSB,'F@+ M!WOQ\P(?<@B<[#P'P"=*V_Z"N_?P:6CW'P```/__`P!02P,$%``&``@````A M`!F#9E4Z`P``&PH``!D```!X;"]W;W)K&ULG%9= M;YLP%'V?M/]@^;V`(=]*4K6KNDW:I&G:Q[,#)E@%C&RG:?_]KFT@0)(V61Z2 M`,?GW'-]?2_+VY@!$K8Y'PQ#QKF"E=B22Y51#_"KCE6K8BO@2NH+* MIUUU$XNB`HH-S[E^M:08%?'BZ[84DFYR\/U"1C1NN.W%$7W!8RF42+4'=+X+ M]-CSW)_[P+1>)APS+"_GII$_2'L[WJ_$,D@ MV[!/9@)SE8XFGCC:1`1@*,-4_J1&TJ, MXIW2HOCK0*2F*-P/)U=P.*[B*S!!ZKI>BG%'D'5@*:JJ*E! ML@!FXRR"_+@X6J_GK()'0W)G6(!AA!&L5[!!S^O9=+STGR&I<0VZKT$=3-@B M?`BGC0GBZ,9T.LN-M`%;:9-V$\Q]?:>C$YW6B:[1,6#(38=U-IVTO$[986PA M]@Q!7BXW9,`K#";:5(ZC@P$GY#`CF^AH=DAT3Q5*ZW)5`QZHAH?M<:H.XU2A M`[7F>ZJ3:U0->*`:C5I>I^HP3O6&A+/V<4]V>HVL`0]EAWOI,(WL?'I:UG3X M$\?G[9(UBX;R!UO.MB>>]S.NUDT+;>B<-UGMZ1.BIN2PG!$GNH8)B?.57$M)?.EK\C M[9I13_JHPBUE1SH\)WU5PR*N&_6EAU7>@%K7\Z#[(6?2/VAHS=1X)Q>G.MNP M[LT,@?)LRB$X!.R.NYO1;H053&[9)Y;G"L5B9^:OL='>;=\-[D([W=L',)HK MNF7?J=SR4J&PA@,F<`#<"J$;B[, MZT/[6K?^!P``__\#`%!+`P04``8`"````"$`QF-]*;<"``#C!@``&0```'AL M+W=OYJCI$VI"U((UN6XV>F\?7Z_;O50:H'73-F$#"T.L>U M,=TR##6MF2`ZD!UK8:642A`#MZH*=:<8*5R1:,(DBK)0$-YBS[!4;^&09\TR;9D6(DZ/*^:J4B MNP9\/\430D_<[N:"7G"JI):E"8`N]$(O/2_"10A,ZU7!P8&-'2E6YO@F7FXS M'*Y7+I\?G!WTV372M3Q\4+SXQ%L&84.;;`-V4CY8Z'UA'T%Q>%%]YQKP1:&" ME63?F*_R\)'QJC;0[2D8LKZ6Q?,MTQ0"!9H@F5HF*AL0`+](<'LR(!#RY/X/ MO#!UCM,LF,ZB-`8XVC%M[KBEQ(CNM9'BIP?%1RI/DAQ)4E!_7$^"9#Z-I]GK M+*%7Y`S>$D/6*R4/"`X-[*D[8H]@O`3FDS.OH_?Z)ZO@T9+<6!;'!2XTM.=Q MO4AGJ_`1,J5'S.:(F6#4@Y(A9-M#;#-`8*\2O(]5IM#%W^=_$F6+AJ(F8TV7 MD'0DZ1(QF?>0@49([USCW[59,)R"LRRR>+3UQF,F[A#8E+=G#P8[0Z3G.]L> MOIZ.+0`V MDSDU230;'QZ_?*DG^Q\]MFBD9S(*8.,Q/ITX2>.A7)A'EN*X',U?W/BT_+#Q M[Z)@JF);UC0:4;FW@R0&E_U3/^,V,./<1`C[!9@Q':G89Z(JWFK4L!)*HV`& M42@_I?R-D9U[$7;2P'1QES5\3!@4#``"7#```&0```'AL+W=O:D4:KW=DS`2=!#1C9 M3J?[WV_9)H"=G9XDAR24GU_>JRI#9?WIK6VL5TQ93;J-C1S/MG!7DJKNCAO[ MG[^?GY:VQ7C1545#.KRQWS&S/VU__VU](?2%G3#F%C!T;&.?..]7KLO*$VX+ MYI`>=[!R(+0M.%S2H\MZBHM*;FH;U_>\V&V+NK,5PXK>PT$.A[K$&2G/+>ZX M(J&X*3CH9Z>Z9U>VMKR'KBWHR[E_*DG;`\6^;FK^+DEMJRU77XX=H<6^`=]O M*"S**[>\N*%OZY(21@[<`3I7";WUG+B)"TS;=56#`Y%VB^+#QOZ,5CE"MKM= MRP3]J/&%S;Y;[$0N?]"Z^EIW&+(-=1(5V!/R(J!?*A&"S>[-[F=9@>_4JO"A M.#?\+W+Y$]?'$X=R1^!(&%M5[QEF)604:!P_$DPE:4``O%MM+5H#,E*\R<]+ M7?'3Q@YB)UIX`0*XM<>,/]>"TK;*,^.D_5>!I*.1Q!](X',@0;[C+R,4Q0^P M!`,+?$XLCTH)!Q(0/Y'<*\55R9&YS@I>;->47"QH8+#/^D(%R)-%\0E_-?7[L3X#A+,S*$"/3H,*$\E2)*NS,0&8&\EE`TP;UOE^; M`&]L,#ZV2!(:U4X59J;-#&0J@/Q8=N*3YZ!PF6BO,8VRQ_(9@Z8=#L3]V@78 MU&Z4-%68JS+/B;U0TS755PK;*?SD-=,)P%I@6#,8\AF#9BU^Q)H`Z]80\O0< MI@HS2=V9@4P%%K(H`4J,`Y%?\5/MX^DW-.V+1[0+L*G=;'>%F6DW`YD*#`T5 M!^:!R>?K?N!-/:L)%Z.)<;/]]?U(;-(-)&%H)%]AKGTEVL*/O/G+N!GOU(;) M<68&\EE`\Y#H'CZ^UPBPKATA0TJJ,*%LBS":,J=.@%H=$N\GH7&B,FT]BI?& M`R6?KR-_.55>,X7@J?!X9>0NW5X2&FV=#J`IU;N;2#9$QOHM'*3=%I(H?S(2 MD\]9="_B<3CKLH\K!!.<6:(D-)*8#B!U=%'@3>=2%6E8GSQFO]@A!D?QLW*' M4J_F0#6;M)@>\0XW#;-*Z8U:##T#I.0NX.5(U6*H+3GKYY-\3#@.A_'J"/P`8GH">`^`#(?QZ M(6:-\2_%]C\```#__P,`4$L#!!0`!@`(````(0#[8J5ME`8``*<;```3```` M>&PO=&AE;64O=&AE;64Q+GAM;.Q93V_;-A2_#]AW('1O;2>V&P=UBMBQFZU- M&\1NAQYIF9984Z)`TDE]&]KC@`'#NF&7`;OM,&PKT`*[=)\F6X>M`_H5]DA* MLAC+2](&&];5AT0B?WS_W^,C=?7:@XBA0R(DY7';JUVN>HC$/A_3.&A[=X;] M2QL>D@K'8\QX3-K>G$COVM;[[UW%FRHD$4&P/I:;N.V%2B6;E8KT81C+RSPA M,S*A/D%#3=+;RHCW&+S& M2NH!GXF!)DV<%08[GM8T0LYEEPETB%G;`SYC?C0D#Y2'&)8*)MI>U?R\RM;5 M"MY,%S&U8FUA7=_\TG7I@O%TS?`4P2AG6NO76U=VJ^>?__J^5/TZOF3XX?/ MCA_^=/SHT?'#'RTM9^$NCH/BPI???O;GUQ^C/YY^\_+Q%^5X6<3_^L,GO_S\ M>3D0,F@AT8LOG_SV[,F+KS[]_;O')?!M@4=%^)!&1*);Y`@=\`AT,X9Q)2"M.69EN`YQC7=70/$H`UZ?W7=D'81BIF@)YQMA MY`#W.&<=+DH-<$/S*EAX.(N#UO5D"53,+2L?VW9`X M8NXS'"LY1ZMAUC_J"2SY1Z!Y%'4Q+33*D(R>0%HMV:01^ MF9?I#*YV;+-W%W4X*]-ZAQRZ2$@(S$J$'Q+FF/$ZGBD".S1P M1%H$B)Z9B1)?7B?-AOZ'&(KA\1JCX_M\+H> MSHX;.1DC56#.M!FC=4W@K,S6KZ1$0;?785;30IV96\V(9HJBPRU769O8G,O! MY+EJ,)A;$SH;!/T06+D)QW[-&LX[F)&QMKOU4>86XX6+=)$,\9BD/M)Z+_NH M9IR4Q>Q,O91&\\!)0.YF. M+"XF)XO14=MK-=8:'O)QTO8F<%2&QR@!KTO=3&(6P'V3KX0-^U.3V63YPINM M3#$W"6IP^V'MOJ2P4P<2(=4.EJ$-#3.5A@"+-2[\JIB4OR!5BF'\/U-%[R=P!;$^UA[PX7988*0SI>UQH4(.52@)J=\7T#B8 MV@'1`E>\,`U!!7?4YK\@A_J_S3E+PZ0UG"35`0V0H+`?J5`0L@]ER43?*<1J MZ=YE2;*4D(FH@K@RL6*/R"%A0UT#FWIO]U`(H6ZJ25H&#.YD_+GO:0:-`MWD M%//-J63YWFMSX)_N?&PR@U)N'38-36;_7,2\/5CLJG:]69[MO45%],2BS:IG M60',"EM!*TW[UQ3AG%NMK5A+&J\U,N'`B\L:PV#>$"5PD83T']C_J/"9_>"A M-]0A/X#:BN#[A28&80-1?F#R`Y+<E"VY%@.3CJS/>!Z#7(N6J`I"EJB;.;X4$CJSD[1_[VS?,Z* MKUURJ55BY"Q1VMEO7M_L#FGR]KL7UU&^6$%H^]Y2'5^.5,7R-O[6]IZ6ZM\? MC(NYJH21Z6U-Q_>LI?IJA>IW=[_]S6T8O3K6IV?+BA00X85+]3F*]C>:%FZ> M+=<,+_V]Y<$G.S]PS0C>!D]:N`\LQ/XH;^+ M+D&>UO M`<0??C[XT;>_2WZ]^=.;-Z/_?//MOWZPMO_^\8_ESW[\1M6R:9!,\$&SS,M1 MHUCX.)&LI1KY\#RDR`S,1:]U\]OROGD$^@V``] MQG?\0(G`RZ!??,0S72OYQMIT[,?`)E_;F:[MO":')^1`'!CI]UP;W$0.:LD, MIYWGD:#)=)H3&)1.4W($Z^2"2B8YV*R3^5.%3M1BZ52I!^G7L&-#[9KA>/&4^\6+ MSR,+B3HC MRTHX.E;&K,]=6]L;Z/YT7(6%'4"#6,]?4`0N]7B[5XI.O%0K30B0$_@H6^ MG9$?P4(-^&\MS*9I[NBB0.;RE,@F6\_1Y?5BL9B/K^;S^4*?CG4]-O)C&M&V MM[5>++(;%6:F,H(9(%A,YXNK"0`9Z?-XJI,BF`*`Z]EL/ALO)CK\'U>OX1&( MMBGLOB5[%2&0Y%6$0))7X]V/)H#YTTR!1I!DKR($DKR*$$CRZK5@!KZ6[E6$ M0))7$0))7HU[=@)S%1JLDG,5(9#D581`DE>%+3Y3!EY(]RI"(,FK",&IO9IM MJ];9PKJ\,A.V/D[G(HMX(^X6\OI9#>A7^NC:WTVN4HV;(*F=JVM?7#+VN5S5\8EF)'8 MMEUQ9$,OGR0-AZ)YJ!$OI.YC'!&[.O8TXP"(B2PD&$>(T+%HI+/JB$:PZ8@& M,.J(1K#J"*E3E5R9);?^`4[J'CO8,.:C4=*S9)VG62`"7A$QU2#0F+(]6X=4 M6+1U#*^NP"^EW%A-R$^\.J[0M&5$6<^6`15:MHQ@U9&.F\R[E/"\=4'HN0+) MD;VIKW>#`1,E`S,\1R28\A-I0"=G4YCICE:W-,^1*J+F858#61>P\97%+I,P MCVGR8UJR806PL1SG$ZG)_]SERP#HK-W=ONS0Y1APC0RY7H%<[4%>0OLZ?9F4 M_.0-J%\W:%([2#'W>^?UX\%]M`(COG`FGB(^2MKDQ;M5O%8IWK]U["?/M>+> MH)J(^3[P(VL3Q1?VQ&W].CS3&CSC5!`+GC[SZS7S@YV8[=%G?N@]53H1[")U M?@@NYOE%Q@.YA"D-:G`!#NHF/"(10(!-@PD,J+IB2MZXCO.E&021+F`H+`(TT&01 M<5&).!?F+``T6V0E[-4):09#NCFP, M)"UD8R#^3C&,H12P)4&/-&UU#`8$]9$/4,/I'+(?X1/6@82&U:X%$-?DHGW- M-;EH5_3@.^'<>XZUJ=4Y9T')*//[5Z$^(2$Z-ZI"HM4ER!K"J8MKL[VE"E*6?,$%5&\TW<(.F,X\#RJXG@-LE#NH606UAVRFOLBYC5YZ"S"_.-I#K!9IX@!EA M*QK4Y:+"D+)-"V5I"G1;:-)K,N8PP`5+ MY!KM!'!98Z+.O%0@GX"H&,U;%\(MM;1.4+#S;I"Y#/6'JU-H/EEQ"]E0XL)J\"FR4+_BY&8LCN+N= M(:@S4RV'#HT([OK%>8:@@4WXA;6H)V8C74X,EAP6L.EC7=#7;4M:-JF_2BU* M/;8STP+Q1VTXEP-*'--R7:%6CW!`VN5"6-]T::$\.OV8=H/E)D#>%FZ_TI`" M2O4#S@RH%)]7+J!PJI#7Z5_\TDUU\=;K5'GQV>,M2;5 MX(7##-O(EK+>92U7MW*2NC>K`]42]!W9K"T)<6=B.@"%<<4X6GL/@06'4)GW M95L*H^N0<)BLA"0=4WG MK''-'P(H5WR@'>,06/JY=&A+870=,ILJ_=3VKJ5DB%T.;78RMT"X5JV<.VBX=N4K#&(>J(@O$*#FX)PXZY MS-,"I>`,4A+*7-.&3W@/%!>#3J>0,.-1%AO&@3D9)P],*Y$QS%K)Q5V2FR,! MRY[,@2;/`&,&VH6+90"E?#T&U$V5M\^"B>O$^@3\O!/5IL>AW5+,>S-X0P`Q M+#M(U#-I75UN:\FT=55&72W(?..D:A2T#6LQ8<9*BTR7VRG]JI#'=\."^U^A MIPG0SQ+([Y:ED,&7EG#$A=[=#N&!IRBL+ID_X9PK:(EGPH`5N M67#'P506N?=@@4N'^.;%!4-26;3M9XRVUZO\2!8!"!=1F047EE7XD13&0D=X MDC*WK,*/X#@L"U3FQ57X$1`B63I,PBNK\"-X`(1N1I0:+C1(IA=?H*)\R1GDBI?`7 M'=\Z8WPG4@I/@3RDD0X?L&N4^VA*6U=GM.[*W&:L2P<,J3,L,-:FLSDX)GG* M32:(7(*&%"(W"&:2]&QM/BMK>`)0+HC.!U)&603=O^P=TS,C/WA5R%TB,XO[L^[F-:`D3>,L"Z"^6N;6])P7LDA0X.H;)C1PR, M3M#0\4<6\CQB8'0BAB95LGYB$?/>VQ]R#]%<2DHWBX@/MO?9VM*10UN8['18 M)'VT#E%@YO%'I]2$T3`?R7.C,WZ$QT1E1B0K;90[I)/"`OQO MAPB9D8Q"0DB7G$7(@QW!$_Y2;](Y3&`QB?#ASJVYB"-&893Q#S/P2+90J7L4 MHS4:%3?"A=7_]J5XAEAL]\B$)QC&3Q?+]P-@J*VU,P].])!_N%2+UW^-GYT) MP91^ZWO[BQ_%(I9J\?H#>2@I9#$TI(!N/H3PH$OXK1P">ZG^]WYUO7AW;TPN MYJ/5_$*?6K.+Q6SU[F*FKU?OWAF+T62T_A^8S'6\\.9EK"_5YRC:WVA:N'FV M7#.\=.U-X(?^+KK&PO:Y^\W8M^A@B%'4Q$4S8..;ML3$`]NSDBBFJ3M<$SL11$HDFB! M`!H%B&)?S:,H]B7V7H^R3[*___=E9IT`DFIW]^[%SKAM"965^>5W/F76]__V MZ7J4?2QFY7`R_F%M>W-K+2O&_WGL\,G+]>R\>ZX_&'M:CZ??O?MMV7_JKC.R\W)M!CSY&(RN\[G_'5V M^6TYG17YH+PJBOGUZ-N=K:WGWU[GP_%:UI\LQO,?UG9WGFVO98OQ\*^+8L]_ M>O7TQ=J/WY?#'[^?_[@_Z2^NB_$\`X[L8#P?SF^SH[$O`-S9^L^G^]FCQ]]_ M.__Q^V_UBK]V-,[.KB:+DK?*C:SXU"^F\^ST*I\5V2"?YQLL."K*,IO,KXK9 MS;`LLG):](<7PV+0GFI[)WL[&<^O2I8?=!^?%M/-;'=K(]O9VMYIO[M?]#>S MG9?+'[[-9[RYO?QAVG=O^;[_LW=>SF=Y?_X_.FM&C)W=3HOVP^VM)__1_JT' M?@>&X\-1?ME^F@!Y7\R&$]%@D.WG\\[,:=SAL.SGH^RW(I]EA\!2KIPQC`P3 M+QU[^%O[[;-9+@[-3F^OSR>C]M/7O=.C]F^!:TZ*RZ%0!B^]RZ\[\+\^.NZ] MZ[WY[>QHK_. MCU7("R`>#D?%+-L#NY>366?"T^M\I.Y/K:3[N#`RS\?0:"3F= M3_H?-ISYR^QX,3>9YO4VP.&U]XOST;"?'8XF^7S%D%\FH\5XGL]NV1P0=2C\ M;K+BQ5^+T>C)A_'D!K"*O$2M#+*CLEP4LQ4O1"16>SZ=Y_,N3_U6=("HV'J_ M*/NSX72.ON@L\VDZRL?Y''1G[R9MKIZA@:3IOBNG>1\-B"HKB]G'8NW'U\,) MKXUNYT/Q^NEM.2^N2W@!<5]?NRG6-K*U1:E_3Q8S_C.992B:;"T0;.UQ-BRS MB^%(1)Q?\><*6"AVB/K,)*G?]K)U>[R6GO/J?)+!OX@A]\7@!!(Z?K/YR MAI*T52]<(&\ED+P&RM%9P'L.+T7%)1"'ET.V-+H58`RZ&?# MHG0E_*E_E8\O"W'?];"4]1"4[.[T8`_P^"MJ+TP?M%L8;ERZ[8IE/>V@&F0(A^5`=5EUB]F<\R6&XSLR,C-7[7OUJXVLKS,1J@:H&;$ MFH\U`OHO38*O9>?%:')C;^49T"]&\VQR83,'=-AF-\$J$(S`C3\<(OO].!0# M5A^*0O& M4AMR/"UFN1X$95';P#\)^,V$J9IS`D3BYWW/US.\'LZ?L?1..LM+A?X M6C#G[D9V`['&8T;VH6B>#>#[6S%84".2F*@X_IPD8'XU*_3>(!L/QT6&/9`C MXUK@WQ?\$A3`+@[1?#C*($9`MOAI,OIH:XE%1E@Y,8O&P2H(_D(\Y\)78Z;P M?([7-[<=2@T)N$EE>;*;?"9#7&ZB,HT-2S2:0]?:Z/PJG[/+CZ!L,BNS$J=N MQ&8F&3[I)0H,"&ZSQ11::XWIK/@XQ.WC-P-P\$"6EB3$O0Q1D;BQ`U$G7\!( MK/L'GLKH_KVJ)5F`OR[RV;R8F9)=HM`JE3V#[O.;219>,/8-BMS9`:QB^C.4 M.I2]+`4^%A6ILGV(1$X4-`-`^]6 M3G4/CY529O9KX6HW!\M9-J,7T3.R&*1$=@IH\9%WQ2#&3=;T+V= MR<4%2!)?C[.WR)7L`1)'N#`D),*1Z\^A6>!_EA&A4//%7Q<*2"1?6O,B'\ZD MP9`,]C._FH#K!$=@70$FF'0R$\Q,E&,Q\G.LXOQV,ZOAN4(A>)?2<*L/ M_B*?.V/R^[V82DI!GD!4`EU7P':C_9M)NL%C$X#:'BM`;AF4AZ]5*:!R^*FI M?[I>@O!(5`0_AK!HM\.#1V/$!ZV/]X'_/;'_EG"AZW77MA7''J,3:BKMBHT, M"B:X1AE6O`*5;XP&;,OF'!1P])!@V!2LV&08EXU#)@3.-:EQ*IC426$)/X2J M"[DR.1"PI%R7FR+_,";L-,P.DGF&Y]ZC%K*CH^R)N1;9JYXS4-T=@2^Z,\F/ ME$2UX3:%@Z"=8Q2-X>''SB@\N@TQ_(,WM^'2'65,TN$J0:Y\?CY"U4QP")V/ M711KNY>SF.R>R8=9-+FO2),!,;P6E`]FLILAS#F>S%%LIOK111*0F1&Y;W^6 MPIGC;2"]YSF>PJ:,)+\%[,M)`)2*1_`Q@*#BJ*B8--[=RXA'=@Z[3F<3[+&\ M3J$R\&;$]$HFB0JCPQE95*C%`&1CNKN,@4)R50?EFJYD5UC,3:VYGDT'MRTM MPDR0\X_%6/P?])BT=(Z,;;06!$(WB2%2Z'C"8BY&R$;,BOFM\?TU&2;E60Q] MY0+CA$;AKS=D8HH,!8V`*+3$?,V*BQ&:UX`*^D\NA4<-%Y,1?K/I[#N\\:S2 MMQ8T:5WGV6#&@$G:.RVF/6J_B56_:Z/IR_]J_^)$BL*[W=O,3H;EA^P0_QPC M^\?EPY.PO]A$Z46WZQ_HX]ZW[DMD(?G,IU$RG:U/%U,\/B%;I-@G9?9'X>F> MG;QBYWNNBWR:]TDZNKR)9.).S@:$=>A?!9LY:^))2(\02F:S!2FZ#LL%]B_A ME!N+RI+W(=<'>SR#Q.>WV0EO9]N[^9/MI^Y^&%U7Q;(]N`P]L/UJ]ZDQ:>25 M];6#&.XR9.WQAM*'SD-!@P7W6S\OT=EMA.&K&$..45J+J<\UK-BWKN]K/)D5 MR"-R-.D3B9N;DE^@:FQ'+9DS^-#^,+&>Y](1F^ M.V/N#AWWCM^='K\YVN^='>QGKWMO>N_V#K+3/QT1-_?/[R MN?WF?G%.O&;!87]2SI'?)&W#Y; M0*95&-XCXIY<(SSYX*-44P>])/EXGLUSBX=GN"^=(2?%1T)GF2;27*86^FBE M80?]AXUX(40*5230QFWM=CM.Y[O[CXC2RH)Q>OV M&3+\^D?VIJ<@!R'2"XD&D_9:BH/1JV*KC6UF7_:\J]0\A1^WT(2R5]O0J]:. M_IB]V'B^^W+CQ>[+&``_',#G&Z^>/N/U[8.+<:FEJ,T0;!1];XV=3T0]Y,[%"QEG%B M]I]O+=G=*<3=:1EQ&5'*5X45$!ZOLI1[@?Y>PJF3O[VOYLC(L8E#'C3<.?E! M0VO)O/;X"CTH4E6>[@6F\\9=&^T,#M,O!W[5Z*^"?VYND^=UL*R^H?:V&]0^ M/<,=>GOP#A_H^#`[?G]PTCL[PE'*>N_VL[WCM^]/#OYT\.[TZ)<#51B/WQYD MZV^.3T]7\L'1>$DY^SV@G/Y=)>U_#*RK2]"(RL?<2<1CA^?U+R5'1G"N6_&E&4D.!_D77@H>*`I8^^A,=2W1* M!@U7H(V$$TJ)ENJ27A[@,XXFYJ>UQ_U4C$ENC4Q-Y0,25U;$GI,Z;8]TO,GW MPP6H0=0>Q\KS&?A?6"31AX,NNUY.M3'7N-DZV8_R<7LN'$6B=M`7MM]^ON>E M0DQ",S?:\74(G@<%7A(I[/8<[BTN5_S!&7/@2`.1E_64K7MHW7V%%^2]K0#Y M7:&"@ZS,BCT[/`R85EGLQ@L=%B"Q4@PO,8OFMY-55!M"B1VT&M7@+[B<GKUJB/?0UN:V^7&WJ(F+655IJ?S@B*4D!Y=Z1OP+QE8:R4;41!#5;4YR= M;1H0;MN9>I(VFKC)HRK MK+*YJ:O'-WFP(6X=^C^0S3OADKM1I&>=VQ3YNFBLD-`CPDO;+#H;`6GY^6)M M'L@?L$$6ANJ71Z]P^G=>=ISLWSE=1&4;T[7@+I_/9\/SQ=Q26Z0:8TVH_4K% MN.8ZH1//T?ZJ16``2,U0<[!VBPMJJZ2<[W]]4)##P[P,/RJO/+C_!=6D+L=> M/`=E%PL2[/%M^O8^%$]N<+`[*Y/TB[`MH8DR60TMTH;C*U]?A7%XM::IW"&T MHE?<06E;(-/,%HA5;E'`>X2R,WZ? M)"?^4QVGV71!W0P1RBYFDVOZ)#2"Y',;U5_QZE?NJM/\>,^N.N._VB0\,(:J M)RB;COE22[/215_M[]ZM09J:J$V0.W:]USO]4W;XYOC7E9G4RDNCU("0JTFK MHY9[R<&@C*LZ!YJD3XN7.0$-QT6/I3XM1[I.I\#@L?Q>*0_+J5>^Y1W+[1?H M9*6:S;G!NP&&,"?:N=3VSO9CW8H M8!0/L^M][ID[;&T7-5Q:%M<<_%I>HD/&D^*"-@HS(7^/*9E/L)N"X@RGV0I;0+#KI(A5,VQ-!V'Y1#.BQD0:+V$\)[/;P!+?X M%(^=?[J`M%\*!:^[@=7,$+T&S,QZAXET9$M-]\:&D?8"2_0K[GC0S29$L="] M=W!LM'D]R6<4"BY6Z^SW;JFL!^CNK&TU4NTE#TM"OZ:]Q>JHS/_PM^HKK4I" M=RB<2+9$MUQX*;)!F39R#^C2P>Z!*SKZ/;(T:?8_+UUN/4:5M-R./;X4KYB& M4^1]7SEH;U7=2)[V.6PQ5ON50%)731O@.]_&(5OU7JW\*O\KM1ZPS'@R?F)` M/P1A*`/SCN%;5[#)$Y*^5!V$IK#%W'HHI#7:\,?WNZ\S6A+7\$$Z!#B(Q:?0 M*0,8U@D6\\->MNB\=F8-.FY`V/$J]FH#NW]PNG=R]%Z)-F7=SOYTD+W^^?3H MW<'IZ5<,S5:;>3J$OV*-I2WB&S0\TB,NSE-C1+DXI]5DF%NAP9NH<6*G-/:M MJ8UEC>,,0_\3/>6/Z:.XI#M3:$=]>O8HY,%JU<:8&@N=@.`_?3NZ)##(^_.LM[>WO'/[\Z.WOV4O:=BF M%D8#HR=94%1&EQ9G0Z2M:H)!XQML59)`LU8/ZMYF0I_(650+;)I84F69-3DB M`%_K_2E&0U*G(FR'ANOG'3R<>`D_.ZFBX67[O\[_`GOB&**DQ)5-B1?6Y[QQ((5V M:J.BI*XE^HXUR8$`O/3L,GAG.OGYWMF*OOX$%2YPS#5%D2/?/F=<%D2"'NMT M($I&'UG>0,55U_"",!RIZRL=R30()`DJWX;MK>HF-\KQ1E0;PLU]#G<4PIHUXE])")B]:#8$EG82BO-KE;.O6!`=F<<_H M]?0*JEJGK:%1ZLS8@6HUQ_/XFZMCZ\,&ZK#,.00BHVUGK[Q_CN4()H;EE;2O MZ!%1`P(IW@1&\WZ3@#2&T-(1^96^O@BQE+^R0W**!`QRSQ$C!8#,JQ_BW+8T M9J!Z$Z5`0W_PY@9>D]`;UIG0>MM8-IQ[T9A(%+&/@Y:ZH0-61-J[^YG$Q0%' MV,D*+FO3JGAD;%VF<%YLV10-FS8X;5)R$_N')!`ZG8"2`B.>HH6H)(6].P&- MR+$+;#E:#WIK(R.:7[Q#4J:4C40#E5I2-K-NMQ$[EXJ!E`$KD,=FC2Y78GQF M#+TMHHZZEM`A940L<(C/GC=X]X5,*BEZT M&1ZCC6AJ"R&GO/(>)4L4+H(U1ICIG4$VS.H'2R+F@S/\G%K0E:`XN1E"8.@" MU-!EL)BN"P^&7NC([1W\VCM]5F-;R'3*M]SOFRZ(.^=XK6MQ^-7FT'N<,6F575'JP M`"..8--ZYF&T^WO>EHD4QX-[<#\BZB;/6_O#D2(H;/T^MJDJWD6DSEFMU7/7 MV80HS0PDBD(3)6A/K:E"I7KIW:33]R,NDOCON0.@EFV+TJ*#(:TYI:&>O/D4 M1C2NM!<.]X_V&'VFZIO["%G/7\I^6N0ZD:2.Z]GD+V:J5\9 MO,K5_RJXJXBW@X&5N-D!-_0J@A[MC/8@+2O8*K)V&.(0;EC!`1,,BU0*CGDP M#U]#5K%9AT0-]JF0!:L8L*:UY4!B^^Q,$/8=9P;20#\4DU6M<3TGV:.=9]97 MQI4#EJJ0E?[W!:-V_"#L%K[LLKXP7S/P,P&_3KC-W7V5A]N`#SR#3EUI8&WS M%_Q[!G(%B2/6(>V@='W0412!^4MTW?)>5PY(KC@`C0X)7H[^B^=!R.9-CC0K MR>2EUVJ'-V>?[#VN$AS7_\W^\XE@H"`A`NJP96!4TI[PPN%\2(LU0&YK9V6J3:I^3D]K7B]#V3J0I`C MFT*`N-VL/YSAPF*8U5OK'D_PLC(5)B:*_2O.`#F!N\3B&_6E<7,X.`CO1+5? M;=!O] M^U-4@XCJ@UURZ7C!D`;>_LVNX?;6^]E+Y> MU;QJ!P/Q-+DNA8H3YZJJ#=:..-,TN[B^UMD1>$^FEMI4.DQW'SPP'!#Y^9YN M.8N:E_F1Y][QT`[,'[5_H.9"@Y.IYQ7]!+T:!RD?U;WD9?UYIP:[6IG>X"#- M80[XIPW+^LNGG9]>M7\Y0"UBX%;L;[WHK*P*3#A/8!$CPB7C#Q&E>A!NW!C( MH`C)O*Q\]H$*AU)H[D==##EMC%W>0#GK3S*MZX='A\>/_9UE(;MIG:#II7`J M"-!X.B5\29\OB3J=N9-DJ/^`?*)XP(?"&6/D!'_=[-DUAV[/EF MVJR<;ND!^""N>N%B83E*0H._P(3L%$;3CD@<\MA/^%7+A!X(8*C-C^-OL86E M/.Q0,SZX)SOL3%UZ72?4(\`&*-O!JY+Y[0)6062I3L4)!"\`R'DD3N)4?`\P MG/A5TY_OGI-/L\DGC_Z-:#$.U=;#=L/NVMRR?M'A!SQ8;'(H6*8/Z%0LS%JY^M6>V(&+R+#(<@.;Q.(E M553,$YHK)2+C"9>4QD[(-Y[YCFSST((.]U/(/Y`JL[-Q@+#[5-S]=,O*/^4? M8<4^(7N!XA.G)F1N9,\T;CN,<[N'@E"7[,6"(_S&T<;PC(\3^A!V-5"J!3YK@GDWIC@O)E2]\$UL0'9.3I13^6=2$7Y3 MB#D;(JV42H"`IW[R1(9%OR<00[Z=.+K1#Q`TL)VW?K2SL;/]0M)476RPXS9H M9V/KY;/F$XHO!SH4%8K'YG3I(C$TK6=5+/*G+!7R^&$EU*`$UM1'M,75^?"& MI-2(-2Y@>UYDMW?80?!DB4,$/*#%;19(ZU3OWXBV^E^=+FV1?+V2T=HCWRYG ML_:PX[LXK#UXC]TDD84JL/DE;-`IS[WAM^^^?);C53O-44EP>][UG=V-%Z^> M=W]^MK'[O&,/0_%]B4+J3'#9T7QVG.@-PLW5,-Y54>FN56?=[!TI!+&*SM/A MM>I*#,B_7#&Z\%8Y#G@P'):S@IYLDF2FKKQX!7?>/5;6D;0HC3F<6>Y5KB2V M@#R[+`U<1\!4-8HT'52*9SC8Z$PS1A*Y/G>IW$I.0XX`5I2MT5;01K<62F'Y MI.M90_TCRFV%O]B-$^)>W[K@9NQ5@0(1LZ(NX=B2I'WNL:4,&6P/[+-AB48. M?'\7#$P9%2H3`GYI=2"AP>VX1;<7N"ED+)%PL^@.AP<&LO"LJ[T:E.C#D%2^ M8^<>'R/ZX+-:OK.B:%DG!7C'66RE^,(F`WX!Q2W%"N0G.$.,[A%(L_T]C6E% MZ8JW?\0P&SXICOKI3'ERLL1D1'G1\A?-TYE>8+F_)D. MXN?`FN#5G+6F\727S0P"JW&A286^NO7TJES%^Y&#\CY91.5WC$$%Q.1<-V?9 M+YX\0VUBKBDTYW;S`XDK_D"&\0JE"^_K'2R]=3J!^O-"S%W2U:1>#_(<>(BD MRIEA7%Y8$IUC@]A174RR`9MC$?@O\\0>$?ZF*24`E!!5HD*TDXBP$%=O6,M1 MQ/=F%G6%&&%,*B(AS'70/<%<2#%XDN%WI!B61E9UT)1>UW;L#C@PT]0KKJP,.DERBTFL'Y^IIS,LGT(8=:-(0ED5$4?7.#V!3E.AAQ@HX`?;HA#"G#M- M:Z$7`EM,':NF8Z7FA=ZPLQV4[PB(=)D:JFH*N!`^G%5- MJA94C?HZB:FD.L)$@`;^SB>3#Q42[*^685 M];>_25:AAJUH!+1$XHVP+#K5Z0]F@NB09/*^9:#M58T.B$DGK M-2=>H?1!,3!$!$9L-*DH$*9/$"DBJ>8AF'QS:8-:4%0I91[KNII:F&Q\ MM2-/65=)X8-/HJVV!5L[,&;S5QP@GD,^+''%80#A]IV?`\>G'58>1GTW"1-+ M9H/L:=/,7!%,$Z1YG6%J8TT$?+]);;N6.+L9I9YHGNI#AS\4KTV*QSFI8M.PZ)J-/[:%"J+(FJI(F4.UQD MH]DW6CT6RK6C!0E2*]]1Q1N9"1;'+O!S:VHH2L4*E56Z-PJ>HT/R()*%3"WQ M!-:1'B`GM)O,&F]6WKB,JC>2-&G/1+JD)K$S^FY9;,C.?RFX18S^$Q2K>XK@ MW@GO+*.-$WFJKDW$4%S*\M"'V>S@235AZ`A&4D=+['R)H M5B`WD"H2HBIW,LGPQ(L(A[5[M?./*%USP=(64OB"W)!H"_=$6B(GD%6Q@2JQ M=%500<7M4R3=+*Z!DU"9[JLD`PNIL)Z1Y=IG%`HNO.F_X-TUG;HH)$UNB?V0,>=+ MFD0#Q6BD,TGQA0P+ZE+73[+_2(H*,XE>J#CBL)'[['1A?C0D2G]`1@B@B[.< MD9LV,F`K"8BTNCD8YIUX_A:S)K5GUQZR5VDD.1W=[A,\#&M*#7(KOF4S06Q1 M8C%V-IB$(BG?ML!*L%`[8A%M8WE9@T*_8B/UZU5FU:6YP]K)]$U-/.$.;1[N:+C$MX1Z"LP\-*#I'#M_Q! M3?JSORP&IK\L4J(6F^YN2[4!K2V"D1412WKJ$C4L.2);.IO`#Z'L%Y(>>E)7 M\YVHG=BS;E,L2>'VI,89M3)TE=&!4[@#%9O=DN%@MB0VL%E;D#1W@`64J M)6J'YY*-2FD&3[BF4;D9K:'6 M.N=P*U-O9Z/0)1PKD91#_AI6($$24.&Y[G"Z:&O5',\B'#.HO>M.L)X&BD!+ M*O^N8MM:4-,(IMK[DE5!Y'"?(X\#/'R:QN%$:Y=@ZW!EG]H%RH>,0(EBT`WA ML'-UC1]*I]X+'()91)A4NBA!$Z46$:]UEY<3A.%VU]+FI!']DHN$)3O5/39= MH#L"T5MN_D&IWYTZHQCE#6])X27$>\%U8_?EKL?H`IN4S\MC33@W9^ MM&7"\^C94^4[:I58NTU=WCLZ+W1:=SQ+M58O2U&:S\;DJ\JNOP9KV\["1N,[ M&EYTC@6OVTVSG2RM7ZBQ%[)W[0E[UNK4^;5*-G<>W7&^\'"_![LIRE&75"Q* MW#6#;)]R29Y,:?OE]FLPIDNOT?WR.5ZI;S3R>X1%LV=/G6AZW"1:;T6=`=[` MIG4)6(F"]W&EY%2'1]>O.KCO2>3F-+PB(@>^TS8V,+T1!R:@8;24H@(;(`K5 ME*P^67S%>'MG:]=WN[/S*EG(I?B*%Y#O)'2UT-.&;GW8V=.ISFH_>6W>K3() M\?Z`YJMW]C(93G,_)/7$%3M-'7XT5?P3I\STN0@#=<5@Z53=D:%6>N]B1[=W M9J@[[Y7Q]E2==06B_M[IGOYM=8PIK`SQ$UV(RF^&GEYT!(PJD,)9!V`K/A6S MOCYH8UW">#8(O9"M[U3\(B-X.CCT0 M56Z*U!>-0!R?CU#'9#)?&W(+X(8C^3,V-ZK>"?:P[.KO;N`ZQCI,Z0W7)<^8 M!3\8;0GBQ/[F5W)\:=`H[`#M@`W'O52^=#./'B]]P)L*AQXV'K0_T/H[/YFP MHA4H-B-H5S6Z3687A1_(M0,Z40_\?>L$Z M?<1NK)"F\:Q,[*+65:1Q;90)PB)Q2@?4/0L74VP>S6"N=8%S4&XP1ZW-"%5% M*(=#LG]9=#+V\]P/1IFJ*DLYS^N_Z6C9X_\5J2S92?;PS,[]>ZNA#=5 M23,`J&D9`Q?F(\C$[13;!CC:I58`$GM6.=+GF\CQ6JY03L1`\4MWKA!]= M&FL2C%S>"PMWQ&R9OK5")$U4 MX2HC&,ZT;0)MAK409./(3Y^&[&+&7T.(W!=Q>>-)*2XN(A@BG#1,;'IP;C07:&VVK/T@5 MF`,''&X6X`@JCF`^LE/$A@8FAO_LU*+,/!)542YP99V`R`O_F#MH$9K071L6 ME#X>GWK^&]F"FK)T=;J,/\A06T9`T:NR+9B\ZAB"X/"$*%L;>/'.6=BYT`[Z M5;1IE"=J+&K&L!9_PY`U&87,X^(3YI#/AD`]/QO4$8/U#QW3HD]!A39<*5>R MX_ZE(]&JTX!T5'VCQ5-DA[W3U[`<7R02H27==7_TR^>@'(WPHJ*2.>A>^/7+ MYU3B-87!X;N9SM[A3T]NOGR&H.'=FG_[Y;/F",5"Z%FE#:IYI:)B`N8-*8I1 MMEN;(4YJN[/B;?S,BBH^L;.A,E`^`]?QLJ[_>6?5;"ZQ$0DP:?Q@4]HG`E-Q MA9BI$-X/L41O?3SZIH+U1E)UB`1&&O_R-N7S]O/[!N6VRZ]B&Q,2;C( M.DA[1%':73[`18,^UF9;`>66IU0N$-I!'S1,S%9;W86T3ZHH108?0R%83@;_ M[D.>;>F&@^SK5YZJT1S&0O'6?_U`A8,V3HFW6T$I.57O4TG=M=K+>$)^C='*"NU\^4SJW)K%2'TE\^NE22S MN&;&5D&&8H-,2I"V\J]?/I,6!CI.X+GOG601WO/&&3F1_T]V(!UYFB7HCN3J M:.=R4/G'R_C+G1B- MOWSN&!-.5N;Z?)Z9$],/!$N;GZ85P+*I&% M;',"BL:-$)7;1&(4PK?NT,6X.QA%6:6N;!5QW+4=_>K,3+3.JO;I+>*NCZ'C M@^:7SDC%^4/?5P#=.OUDO^V4O:I-'GQH&^PZ)N"TN@7X\CVJC$]U=4.*1T-R M>L"WIJJ68;\*$"E1+H=VPO1E3C/#J7%0A_6[N&@#'7I'3`:#DN"(=ZI@5YD\ M`$X=2P&LOWNG:7_"Q+GBR%I1N$*Z<*81C89<5P`5=\&#Y[.)OJ(YT">T\=/5 MH*(OO-I9LEK.0E,%>N%(K*KI_>__^I]M&8ZAQA,3<4MJU*;]ZX*BA/J1[((8 M29V?ZY.W'M(X-3*'R[:(1:6Z')'![@F^J*?EZNCO,@L7H%L+LK@*T+DT!KR+(DO@Z/D1E82*O)3UNNI3H`$.=;66M/%\KP&1O- M^CK[-7QZ-V;DB^I[IYQ'(PN$`C41%U1!"6+1T+95^R%F5RZ(RH`:#HOKPXHI M90*'0$_T`#E,U:M"VJ,N_9Y/\[7DO";O1CX1R:_@:WN@KT^1RMGDMC.N!0M5 MAQ`<0H;:VW6E73\>^'K$9Y:ST[XN?E:^2#U@J:_-+,K`,I;Q4.9.W+F,`P$Z MJ(B=BE*7Z@.LK1I3-?PWGC06/R=_V]0Z3DI@6-%A60`0KGBG4<0(5B,5>1H[ M4@%/AX_3>KE4JU185>4UUGC@F+\5LTEPV&KJS/0]3P6`CEYJBMI6@EJM"'=G MEP,M>&#F#@43F"WKM24Y/GC=?J`/)S[AN(+45\B[*6O5'O9-^X?]<,5Y=COD M\%+[Z2^3$^3H MNKDV"9>?FXNAM<(071V!;U-O"A-W()D5?R@EE3XA[0])*Y-'L[7P2<.M`'3P M.[<[`U831!P2'H0R2[=DSC M(XD\VV(`T#F;=QI\A=HZ)DU:+>07WXGE\$7YE)V$2J>J_-.)".!A<0Z>*(-( M(X5M\RE*U`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`"_M6!,F^+]$2#H[:."#?@Z"J ME7_"1\ONAZ66JA?E[MA81]V<'*0OGNB2ZO^V-SX M_,CAT3L^WWS4>Y.EMSH75__^&>^XT'J7JPG^X1`?C;/>XG)!Y@7[LFM:GMH> M==$^DJKFCA$]&5`A?,E;JA,UCG\BDEU/AX)^XH&:F! MEQ)#V^\N#K]N=*T.2&7H3EWOK+5$NE%!RTM5E[6R"6.2XM!JM>=SG>.0]C%0 M!)P4FHHJ4@HQ4+.3G7J36YH#=*V-FM>E>`%?`$547IFMIZHJWQ<#``3H2K<< M4CY#*HK\$JHZ#8EK,NY/4BK_H&GLE[*2'GS6G!V']C#AM7W MUVK!?[=OJSX[A]2MW!E>,!U;.=@P`Q/:*4NNR@6?"J#M0AO[`_H-%+M?AZ;' M9G+:H>2D7A4#T:X6#KG;G2'+,-.1R1ZJ@G64OY?*%](\B\9M0*Y2I7]T!8G/ M;H2T3(Y%"W.\:ZG5IAH0Q>BAX$WW0Q(!X6I8[U[Z6?J&44&I&K<(LLA@D1&0 M$T91$3(=:&&"+;@@0]]G^9!!8EC(5&Q[DD"6D]8^94I]+@7 M3XES'\BRV`P3BF1=&O;2N0!XP!<4K:[VEIG@%!"R#^/!@?YMSV5&22CBL]0[ MV[N&/_WQY7,AE=]Q@W'Z%(]V#B6TW6GIP6JY5>@16-:TN$1^@S)=H.RV@["70I*K@QP5!;3\%^ M6S3[S3ZLE;Q9\1X2K2RFRKHW"$OD^L2I`@@V5UX`&>8KH\&5?"RJB?]]23-) M52X)7`0IJ%9Z8@?*;2>/TX9U3U8?PAL/:)T;G0909L8N%;<8E+FA(/D".3(0 M0PM0^:SV?$T=J-,ME^T5#F01CJ<.Q$" MTR325$VCAIJZ9YADRI@]G61U_5_CE%*&WR-)19A=-&OFAQ`6FM9/QB%;'>5^ MIJGL[@^S'9:!HIA$*2(5^GQ'!K,6#CK)3'S-E]ZH"X>JE@N<3#KQ(=@]B'BX MNQB"ERC,JU1:YS*SGFX,EB'OWI392\1LAV8G0?>V?W_2_F&=;\^_[%X7]F*[ M?+?OU5><3J>L:^Z(]]LMG___#AT6S[=?7=SK? M.UQ_^JHSZOG&T^WN0`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`O"V7HD5JJTUC# MQ(?#;W:OAZC?['B3VR8D6^>;K^('E[I9CY9/Q5+*9>DK4SA^RLL\VMY\138O M7!1EJVO!N^>K"=*2^;9>T'#G%T_Y!L-L,8"RKBVNI]IZ^BR.\TW4VTJ<\;^F ML\W`QLR+::HMWM/2)F9;36J3R0XQ&MQ2Z_DUXEVZW%F$79`XU6D0[Y*^\I- M-&M&"CWO"!,3;;_\QC\:X(4Q2QV9<7GTZA7Z_67XYIAS1:UWLLMPG=F-R9YO M;O\?WLY]*:XCV].O4N&0IW$$<(#BIIZ9CB@!4/?$>)3$EV,G85E#J(9JIDG&U%K M*^&0HC7MF$2KII:'X4>=8%4`TH>:,YD.Y,/-$B!8P@*[0FAJ2DY$M,,?I(N) M:#Q4B/VLT-7\C7K*E_/"J@G=VO+ZYFH\L.71JQ!KTWR#2XSUS%V5%,.2G@7F MXJ:H0!Q7#>?LFAF'DTQ4ZB4T=-"2V)BT#&W,U5\Y7KTE8.XX$#X)$)0''41+ M@`TG,W__2GD_5^N)#X4J0IJ2"[-/R-S_J/] M.-=A@DBGM)U1%=05AL!Y<=J92.-&^80R'\*?2[HK&K[DRJ4K>%$%C^<7U"VM M*7)*UENH_<0!'(W+PLZ(">:4T>9"EPD-HVY;WD=[<92YG)U(%E3E+H/4SN:! M,#">%C2WP]O,UO.\L8D6+'L`#LC0OM1X;NW!5[_13.2[ M71QO;>)16\E3^II96;%DAI;<`#O[P/]B;6UK\>76EIB.L#)BHL@J;Z_$#J4T M0B-V-:!17X.7@EYLZ9ATCS1$(]X.CDY/1\=[)^Z/K3&G^W2.JW5C>=1]MQX) M,8KF9&4**C&Y\-"SO`IV>H6VV[0"QNF@L#'3"?`;X<%O9\3ZY'D7`M MOXI\U:#DG0DLC`@+TP%HA'`6^C,$=?6RGDHQBFW/Y?<)+%0%B3"#^-8PK[8" M.`T43--5T#QY;+WV*#%2N96"7@(R',JZ63?$,_M%@Z0SC7=#PQ+U>P&682G; MX,$97^YXI!A]1]!0W89NIWG/-9!NRUXJ1F2=7%@.MI M>\470?LWU0?"!\^BYHIR9N[SQ]?O*MT-%C.+BI:K05Y;DO%@)POGZME41.M. M#-YSY5J69@LT@BJD?U`I5?F\%%$(D,8CU`0PVL!-M<-L'Y6DZ[M_.=Y,EM/0 M>T(*LU=4Z\^]"P\L;+C M)$F=YKI;I\&>!=?J7^/0^>O(L^LW%S"TZ]\.$4"6GQ6J%X:E6?WE`FK=RR9! M(C;]38GJ7>(JQ$8]WFY@>4^`YO[ACWN'9T1P*%1O%BO)-[? M*8%4ZE3JU.O,+<8J)442]30H?C+]@O%!.`89-JLG^WN#9M6L_+(,U^7K][LA;4D??&T/B@`;4 M[2PDS#N$U;"U;;^]V%Q<6UOK,D\4Z,)T9DF$O6)_/H5!/M%-@SM`E5O918DV M31+)B<=SG>DV?#H2*+!F=$BAU)'*[]&D,P5.O%"@D:]""Q>?=:=&@2S-Q;*2 M2^$&Q0,:G6O7BT$*"6*F*DW(0*X7XXU-J2Q0J;1FVK\E=WLT,2E5[$*`4"'% M'.\MUH`]M%]697DQ5AA[=7%[>UNC%X-BC.)M?+M\NFS0>;O\PW)UCTGR_8O\ MGKJ(<&$&0"YNVK+"?4*")L?N=<^K&3.'4G-)5D%AL5BI0H(\(9NV!+9IVFDM M91R"#8GNW[)RH7&815TT/YVN\QM!X=#Q\=L;)S M@C<[2QE"N:@T60.]=U*9/1]/D0N0T!E3>QWVL9=A3J]KEK0?ZJ?KW[&J`MWY MY:"S3VH=)1TJ'ZR3*7<`<+G;!:4)DB,AK1#-+U".>QU#T0TCZ)(QPI0/E.%R M!/FTT>W@T`+NVQ_27;IA#1Y5L^K3M15N(#]_,`O*FW82(D&;EG$BOOK9VLH$ MMTZZJA9%D!/,Y(!1N1-"R&Z4S<)V+?;J]PK@@_T"`TB:^IGU<%/>%[\&PL-M M<`D!@1IY`.,%2E5RJ^K%^OIJ=_(A;QTUL&NNO@? M\:,%8B0KX7$$F(Z@81[S$35.D$1@!*OCH0.DP8)2I!;\`44N2TJEP$:FJMMLFEZQWU$1V$^C!KQ!FKQ7S=Z-&$_T.J(M MX]R?WOR24QTXP%CF1VQ&I=*%0$WLOUNGV'LE6:.'%Z$!X M?9D+[E`X=U1&R#;4'FT M?N$TEG9?@*BZ6SL\BTQS3 M^O+&M["=YFQ^0GZ-#J;OIE_I@NPL=N\SA9-VWY-8FHX+>0;^ML?UVS\6IM_U M'=IAA7>3Z_>WH[]2AXM1/NM%OW9G*V$O4"GKQZ><]F0.(?N-%=-JV#I*J,P' M=!;]J"ODZ(P_0#]SIAMZK>G74YP_MKC5<<-Y9-90W^+)M9SZU*R^`2]9ENGACK"V]V-@&Y7>4$Y2VEL(%"(87 M6ZL;KM!MKF^YK^,C7?UYN5LK4&EZ]9(C`2'3(>R;XF3J-Y&ZYE[6.SD@`-LX MP9V'AV7T"N8Q6O@F_/,;BD'>ZVQ)#2@%/AD\M,U`3UCP)`[F?#LUHK,,'#=0M9RU/MP+7>+LB MY/IP1&E'Y5)>&E83PT:IQ+E':U2IE##JR\"L(0:@>'VKFS>L""X`G_K5<)Y3 M3H^/)!BL>0;RX85<_ST8[AJHCBW)$X./3IXCB8UVB;G[L@P"\X932F<$NX,Z M#)6:E^262CJB9DTAN?N);W$]7'Z3%6;@"94J`BX>U MF,`%V1,Q)FR&+S@3KVR71XRD-])R;6AGDL[A M^H>,V3.R.3,W3^N&,K1$P1`6@EV%I,4TNQFM+J]M"%M7R3"W<,142KFGI.`7 M$([P-#<\R>,(49ZUB3AYY]+!M>75E3P_>:XP4])_C(+DH4`,&.L$DV`+Z2@] M6F/':^4?C7UY8T>NAQO3XC*7!Y%$OJXHR*KM<-\G\5L\<)09 MBVF*)DJV67#$]7D<<7-YY7=Q1/2UKEK^W\T1:^UATA^H![52G$C\1!B/IG2A M7`ZP3`?03_7&0GCZ+`HT54UC=K#)M)5%HW&HK>B.%MWRKN+Y6M0KH6QN`4,I MW!0FW`MWG/,J0QVI]>:+BPI^^,ST]+0;A)'WL6!<$7&,2(NL\S_)X(X<-Y^BHX0G#/JLXZ&)#8\S6S( MP@.Z>]$4?DFL#-]QX"3R*HMI(K>>A32)?9J55(QKG(BASH$_^CE0U6D_:P.) M-R<+S'NN2T4+,Y7]-3@;=@.W4=%S%^UR,Y/Y2&#GG4P[.K'8B3-J=3;"(SGL M+L1E?8>X8Y$Q,BZ`8E?,Z!JC#"=@$G)>TN*]@S&@5X[=NZD:=#Q$-V":6JQW M)FJ0#!7SPT7`5#_EG&YS7WJ7&T6G MF^J#FFMIS#GPC!"U/D?Z@"Q:7J8RJD9_TGNDN)A21>C7^M+X&7A0S#@T=Q8] MZ%.R&(4Z:,C7M^(+,9,QJ['Q]M@LM8,ZC0JD>[7(1=2BSA\^F.='W**KVR?3 MW(CI;P]0HGBF(*T'1FT`:4DKY(E1=``F/< M3@TC#QC(GX7.7%P\D5KMZ-!=A#QHV)Q)"4B:SCQZ<18SF<`&*IIAE/XHC=383Z_M36GN")89H*9. MSU1\9V'%S)QJI`<[')U>QQU/W0"_Y<@"Z`?K=13,'94X?J\(!!'4IE)LNKD_ MNH'&26(J!X&I[!A3J94X5(&_@4-J["KI!94$[X]%T$PJ3AT/$X61K4IO6=7E$=T;2]J,. M"$-[@3]59%`J&>;H4">MR,L>(&"+L(6U-:?UBFXYMU_`$ET[&AC++[`? M1!1N8/<$`R!(&[C&V)**<:,C)'I(N!7JO14.H7JH5D(GCL_/[K#0^]ZBFI:M M6KZ`=7V-PJ;3BJ,"<8J59[PA[Y5N`(O2.BZD*]ILI"*4`@?*?B[!".&(Z@=@ M8B64FQR6J)!:@SK`+T>;'#GP%3_L^X@H^%*WF6<:`;ND`+8@>U4D>CTK_E MX\\#D^JOA]#=_2$[19YM=A2(`.06$2>4:6F::%H>&USD.&GHS'/GG0W=V1\4KJ&(\SU>+$`'"4J:T[%WV\7J\<.=*@9-SC=R MIJ;GX/"I=3[.8A&QC MM.E^6H1RJ(_+&DAD=I`7BCBD?7DW;97'HR&W3Q2FKCEDKY&Q8!RQ]3Z#+B(' MD40!5$(F"1\+0'/@&RT6WC>OG7UK:>$.;;%\_J(T<+&XV*\`4_`%.?T%HU84 M(L0V`\F\$D$Y)]"G3`EWJ[(T3UQ*(8@`\K6&][@\$\ZF.J?-9Z>?UC+H'B@!B"CI=7#_ M$SZ!RI!OWWT8!+HW!Q#LX;*$V#ZB-869(IX M'>A]1]F%5W&4L)#30KPE)$V,W$,\GH=K%N3X'"Y-0FL/JHOX*?HZ+`@0$_=X M2>43`QMA2?:C:*`G6["4I^OKZV:1%`'9AK;V#W>.WNR-SB;_IR]#-C^;DR/S M$JUDSBAEPWQA``'$D),B^'5ZS\?<1H!91C@JGM".2*5T=%A9\GGIT:^@#DX26',K+ MY@BIWSRS$$_T=_8`J/Z@LZ42<,/[6F@[KBVLMDV]?"DR''_O/OA-`F';?A_'UN',.=`X8W]Y(5[7DK?<(Q7\S^"W! M`>RBI$11#2HOK/6T;=O<;A+V\30C?OP&!W42,AY8AL;J;2RL;[QL?MO8;'H0 M]@Z,*A7$3W-$"VM-<<+"UD:SW@72*3>;;H,9I=%1GH'5/\9[,60!^#WN!@!A MU!-HE!J([:UFYPMKI!8T"S^LAOR-]I!&1]SB%)L0-WQMF,U*"B8_*5E?J+KO M/MQ_9ZM7<$Z%]M-?I=!V>*K8*])$7\>D*"1P:;DVW')G@,!?4RU/7F&#"^/Z MEU/%-,UPL)L2ZL>!BNN?([DTZSEC[?D^ZKQ7-^41G-(?6';MYTG(%3STYK3P;VH+E7'IBNE(MVS6X"4ZUZ=5KWR[[ZM?]DO ML[[+Q&MI+"B?)DJR(SCT%)*"*IX+)9U?Z:UB8GZ3QC9>W!QO&GZ_V%K?J'.: M?@IY?'&&5EBA_]W=?>4Y3/W2A]Q>W-Y8ATJQDRT)$#>/K'!\F]P>`M/G;C%W M=T5>1XZW\.$:FP-Y%_R]ZP%Z\M^R"X!(=7G-HJY'$\UFM[IW"(B:6TRK>`0:[FXH!':`DJ7`IZL]K0+36T"9CC%[4*$" M7BG<"=-?+386L*5T>7*S%V@?'8N6$Z`^/#6\L#BRV9/1QJ,"!`7&H:R(?"69 M>[A"4IV/,6/3AZ,NE-%K>70<0S@QC[1W&C;X MN_W8$3KF/Q?"N_>`R@[LCPF91Q;D#M@<\5&(7BIQ$2=`NVIQJZM89>7,LW96 M*DU2-Q'\`9']1P$5:3?0!/G5C74"5#CX.B/-R:*WK=3X149F%*Z3XS M1XKCNHKCH7G<5'+&<=@EBPCW2C2'#-TK^J+R76M"8E*^D!(.=ALV>F+UE#9. MUC<1FQ-_/B$9O'^HA#A4Q6E^4<\[RPZ[(9;'5LX5!^!0,4QI'X;AQX3O'V`< M$J57O]+QTMM49G>FZ/S^ZN+G&[GE1A^IAU16EBLA%9$&Z&7'Z( MK!T,NITI6'_U*^%(0J2LU,K:60U`TUS0$(VRN^SP)-S3/,X\<,V.!XB2/-W5 MS:S8`UZY55FRB,R#[+J)YLZBYQF%TCG&EG>9-T\,)U32#?=5H"8!F.QJ]1

4`;@6^#LP0J/YO)H23,#Z0."=DP_M MJPK+E*):"W/U(_.LF.0U+W%9$86.+(MRA`]9S+%USFT,YJ9<4$6=7 MW/2RY)2W1\O8U=W095-)FFF<.(QI^>47,%:)A=P`)3!S")7C*8LB5]=_YPI6 M\PKLWHP9_(@^*2"2:1C%J@RU'XA4PWW:JY=AG;*3`$BXW*@(=5H,*+)L[:]@ MAS12!X9=L2+@P>$H9^/YQPJWZ1Y'A;9^3RW)KF%QDC#@QV0=6/ MS2P]\*$U3.^]I18JJ$2#63:N0&+^I&#W?\"H084H5L4>":,I20A*K%AYSP(SX)E%;-8LHL6&")G/W!@Z"7& M]!QL27<#PEN-\#L].]KY8>G5Y-2N*'MSO'=X.CG;/SILB&S@O3FNT-ZAZY%I M#''_EU421'K?3@M1IXK0K.)?U*CBMW_XEKN=*D[M1A'S,+M_[7++2Z]O5?+F-$NV0L4(=YQV^(M>3[%(@U)-8R]OT=J[.U7PMS- M>T)$JQ3"EK=P;FC`0K-0*!0.1Y!1LE0:J(8SPBN]7ZI06P`2CG MHZIOQ#1S:DJ,ZV,J?G7GC$M4:2A`&8H1V:I@/(C.$4[(M M*[[TX0*5#76B9UJ@GV8`VD'7/!IE/EK\:]=TIG4!&&*]YH">R&@UF`R^/OL?G@=_)KG0-'8OBE+JK MSL!VCN*"!ZS3PQD[3L?E-3F="DH=B-(TBUL2K M:(<"I($V0H+\$8X@J<(\]2>F"!K+?^"H`2GY?T/<-6S7S()/0KTX(CP?>9WE M:BB;`Q5RT()_!+R026`I(];%RF*XA+%P(4AFS(S,PBG9A"&J*T@*'OC/=(5= M/]#88ZJMFVG5(%HO'YRX-@362FNK?C-N`=0/J M,A?=A%=@*]*4"\LK(VUPE\2Q>Y<<>\(MQ4M6<5@\>#]0LHNL2_:\9L$.Q5EF M,3I>]A(.RH48VAM@+_VMGO,_1YW^L;F*'B3TR&F@&"0C&D]`0:$!07`P4&@- M&=D9UUS]);V15[Y=&KW*I,R M(K4.=J4^&3H4L:H(+[&GJ*V7MXSI/<%O"'">F6I422RVI;I%H9=TO'1A%J'[)$SF!H^"XZ3C;L^=C]JW)9DNZKDJQYG[U?R MR739VK'FKY^&C\A=1F;5#W>E@Y&X?C>2/[;Y-JUD8.:3F&)7C[N#\UPB"A8Q M.L#/6#]?^+L,H6;GDU![W+R_SW`PVP\7]4"]RY8>$&\J74JA=<]':?`M0N^R M'MH`UO85.XN9C\T'"VU(J[N2DF`-[QI_>O?]F!3@*V]>7MA8?5DONCM`,V$3 M90J[=_.NS[U73]`A3\)D2^+Q,*-(AR6]T?6^YE.!W#IDU9CQA[&+9CWYJ:EA M]:\$(>I5H`P\`KP?;=GU4`NK:TU4\/7MW3M2O%I,6%AM[Z_J7\MCYR"U?_3K MQ^L_6U.<__W-)_R_:L;US5\.\?H%]<2JNH(N`L"S\';6I@3[Q,:61[ZS1PR% M/^I&GXFII>TN7=&_MZ2%CA<'H9*UC(M;]*W(NU&+"ZPJ>3\Z!:SXQ=KJEFT3 M%$H2S!V*A9=($7G\`XTL%E0EY5PAD;"C6G7]MW\8"%$.!O>!",&TE36Z2JF" M,VZ4T,QG@I^/%Z(>HJ>R1H)$+72Y]"\&YV2.R3A2)TZ"1/;IP:5Q*!;^I::F0`?4CB831@`PH.%+] MV8N5Y:V7:`TH%`TSY(:!E36>4?#>,$5=5N+:QE;S[&3O;/_$&M:-C@\FC:%? M/9YCWZ]R`6SU=KU^_$,>&/CM'^LKJPN_?# M$VT"3EJX??^%N-37)75<>3+,ZW>N)Y M@*LKZ8>X%XNQVU2XD]TL-2BXH>%M0TADC#VXW$T6FWVE95I5HWOV@R4@LXQ\ M8HDE!(&6H'[ZF,F%U_K5+6%2K3`Z"X)=7`Z+^0']8H5KB`(`%B"Y(9`A#9!) MQGEKQ5N`*50'&)PLHFH#XA_,ZY&B6\Y95B!\,E=!U1H&WQ#1')G=<+ULOJ$C M?+&8"GQ50E>:LY]$.(5>H$NYU9(%"'T16''TJI(@0<<`(+,3<4(0%-NE1Z"S MX\"-58>1)5)'%E5!1?,^Q-(TL>P[+7?@VR`6M%5YACU9H@LN*1Q:^MZ#&AMA MX,8>$HUU=KKWO1I3DI'X^NCD3;]?KWUE'LG3A.\)@T+V'K%5U-_[D$#6WIAK M=O5>U#^#<]FVT)G9\PSM&!H*).L^G/0K]*#SX52.V/:I2S3UW["1@L<(NDP? M2&I<$GNZOO4KD&8/GSYQK"%X%31UN<`1J>XW4K`.]Q3:UD>:].&@5JQ3V#U3H%'9;:\%V>\,6::]JXZ&W.(:39=OZ6=I*>148B% M&'U>>>S>%`00B_(^E`5]"@M6:Q)5G;%-K M0YS\,_I,L!W[0WG][%?HA\,PYKYFQ[I@2@4=_A1;8O>!5>VY,TA,PW'T(NZ< MO:!_>5,,99)<2JO#J1:A:*7%Z-2(G[!P;.>:)'"_37&8"#`XGP+X^(%0Q.TH MG11/,5]SO5X5"_;:('-"W5XKG2,*O.+(;'#&H2`5=Q\LT4L1$65:6,,!92H7P_84?^W-X=]SB5`_WTDA7//,BK9@ MA;T7RL=TMGJ($X:_@]MYT-`QC1'4=PF53JC,GRS-CI`M"\U3U-*YKLXEY%Y) M5F21N6:N&QUL@+&-EV`0*[3ZA0]UNZ#6TXWQSB][1?UE4JEG[7 M/`6.L9S"::;_M5W5H2OU24+8F)+*U4+HK!DT%JG;V83RJN:E[Z^C[0M[:"V&)LK/N)C6`QU3H$"$8G3R MX6/]R,5W_:OUS[R&R5]BFZE6K]G!F^E_<*AI/?4`9YSN,4SLZHY8L5BJ;L"X MRX6QM+X[/I[$\MACDWB:2%7L%\M<$0J=9X2:4XJ/_H5>A#)/.HL%-BP]Y0N, M0TJV0JZW#^^M_8IR:]S#/+(<$^X)LB0ST%JX&#RO9'8UB[FY_3+ZA?_C]&>C M[VFM3];5J3+4$$>^X-'"G_SW/WTW^OQA"FN"QWMB#G58S@M9H>B@F^2TM3S^ MUG!J51W#HCKH:CX5Q^),5;P@.QNZ"I[7>VTMK_MXFQI86S.+`:<@8JBG8%.* M>K)?BWZN$'CKE@4V[\AEI\6H#BF`$PG4@6?:K^B_W?`X+G!#9:TL4#KD[]EO MM9@ND+?C+.MAEC\4##6RG^Z=G1VX+7OT>K1S='BV?_C]'AKOP?[DU?[!_MG? MG__%//5W+/7W>5/*T_67?6HI'[S5A@5."R-$#29T8#H-TE7(?U(VQ`Z_F>;F M-$$1\NW[KR-D@^O)"O8'\X0&I4GF-X6:$S;\3I-T,]^[=`C//TB[-'N833K9LO>_4N=7K7!CV)E^82Y[G]6\F+='YE^ M`49T$ILT6:]:?;RRCVVG2@S!!X>E-<=W(`O"QF?U;7')6W1_1ML: M*'@J\K5+^A"05_D3283AK>"-*YR\Y_^ZJTN"WE-,]J])/>GW@XLBWA"#EF?! M2-T\*8*[-']*^L.%SR(!VMA!K\@]77QAB!4K8_(>BNM73O9.ST[>[IR]/8%; MU@RR\W`>+Z0S1N?=>B!;OR?`A!W@'"*S5)78=/R4I\=H-JJ[*,H0ROD'NCY- MK[^Z!7Y-`AX8H!39S`(,$T'Z&>:-,@V/SG!0%YZ^MEXOJI.0*Q()>=QT;#W M;#*RWZN;]YR2YP[&Y%D^^GA%&H?K1K,_D>)_10(!OCB&EA8GI3Z#HY-#!J@- M,=A<4T`LBDPXA-&!-F@K5$F$B@KLTD8E!O.>@)/V+L0:/`T!9GKWYX2;&DX MD:>6XQG`QK:K&EU8868!0&O6I$T`,/,8C=Y?DYZL/LCP:4DQ`>A*7K^(/0+K M)=DZ.%)2_'WGY(BA+&XB>1.P)O1?3MXVUC#)OD3!7]X8)JNVJ_6N,<*0MF-_3[I,$4<%.5$2BA8I M28F5\>',(6DA(#?6JZ3$^:OBNS, M_.5(ZYOJD*V#BRBVKG#"8."V6=RN7?UG$IHP[,#\Z_6D3!%Z##O4ZED. M<)?(,SJSWF0$/^*L]8M6:]8_!L1H<1[`K2BNVUNFF$8YA;%R[R=G^Y:7R[+$ MQ&7L4Y&D+%5]K-L-I6ABC4ICE)*D?X+@1@9"@)P?17-H*(CF=9:_>\^MM5&N M2)$VW/ZDBU<@8[-00V]T\0#/A5<6B[1;%P[.;2U"!853C(IP863_.#< ME;O",/8L^,K2,P-;\!OQRD7RF4:]JEGK$VCP#A)EZZJ^$\L0I'O)C4K18#P\ MC])0\R45%FL\Q,FF0I7F9UR]]6^Q5JS^'>_>RLIF^VM[R]?">N,S7-@8-T'5 MA9?M:^.M=H+%M8TFD%O0E=#`_-;7=+-T\D64O4-RP$KX@;933@)>S_($+B@& M814?$G1)J%DR(K\SVOF5GNCF9C`,%OY%#0_Y;S4VU(%]B(0+ZH@3"*1S]5DW M$2%A73]UKSYEE5&/('8"9N!]050I3UHH&E!%K&)48A&$2!Z<6IFB-ZAW%9OE MS]CCRO`HFS41Z6);)2?!,/S;'QJ4/MT[>+VT?WCZ]F1RN+-7GTWWZ3S%=T-. M@'E#B7:"4TOI=&@E[Y8PL5"RG#%>A*"!@SCR`3&G%+)$';U&U$E+YL:/W_ZQ M8Q$'R$L54IR7'2!I(W'8X.Y%WTKW7HO?>66V]5&,#,:&*U>HLI9H<$N2LDY3 MQMRRM1(+\5=+/O$2,I$S9;4N+-;K8XV_KX6E7O%4`@\@S_'&-;CT9G(X\5O__L0-S3UI%,T+\S"*6LKF_1H_ MCV#Y.64^:\6WY];H6(1I'FM+(,97:!`(6`B(4&/1]72WLP M4:YT[[=0@5MN2@["R;2-/*)15HZC9+VUP8$0OR*$?(71)J=Y%_]Q++]TE[#7 MA\':J-#+;X_MN*IO_[S9RT3$;"Z?7FM(BLWRD6<^]LQ4=,VYD*$E7&^N:5\TE>)ENAQ-4[,;,1HDU\7*C#")EJ!."@OOK#>*>L:*/BB*%WEE:X="& M8AR'Q$95Q:B?2J/.KMIR1@PGR61$UH+UP0[4$-1MFD.N*`P3X%6- M7>P?=8)#QRF($(S*:T%2:^4@BFV;/<875&.T@%<1?R;U`HSK&VNQ+K$+&-RT MTCT?7R?Z$\DCX9#@?'F:=+QKBR_7QW$D#[3)_#84&SGC>!'S%>-KGZ0-76KS M,PPBBX/Y(Q@CT^$4)O7$0L,T-^<:%;"JQU42?#\X/4QDP%WN4<."RB?R":<2 M_2BNN'&8"&JKZ>Y*A<1:,9C.+.H553([H1"*S:=$\VL[Z>)8Y:*.U57FD#:R M*=!@T753/,U>V$]XVNNN6945X*?&SXX68=(&]^$B*4@`P2%WT#R\322"1?OR MGHCF^3\IK@Q3M!.`&^R%ZR3ZX#U!GS4SEE7$]&N<;6-/&))0$"&'I@LVY!Z@ M'NJN?G"P$Z(/]-^$O*5G36^W":_5FO^1R8V.+C7M/L2I8HZ`OYZC#)_=;E3H-#ALN*]Y#/AG,4N+] MOT0P2K+FX\QH@@6`J=LMW,/*"VY*81>'T'`"B$\3VF&/J*>'OW2.H=`O7WV`5+ M%0B%9[9#.SIWM#YUC]&UFE?IBAQPE+K.V-@V7X(+VV"AV3R/4$PEM*`U$6]A M`6TL#S8NL4X`-$@6\&OXWNG;-V\F)W\?$28_W?_^6/?U43ZG$'.%#9N"YZ*@NI)X1&8=/HL[=X^G-\K<#`) MC:Z;A9!3>?D`-G-,Q^$V5J/-Y#*MOY`EE)MM3D(>D2+;^SD7R3-NZD_+)1>5 MC6_E,($Z-;)2QW-1F59%=`0S^K[Q4IUQS/"QAZ?71PHQ\+'9:/T6L>T=)_,;8S>12C17T9P.6T\G!GG"3%;W> M.SEA\M._3ECM:'*X._IIO/%'W MHN#1-C$T<"('1Z-YM1.-HYZEQ3`@'Q+8_D.EP?'4W.D5/ M-?M]ERMZ9%H<8B=TG]9HOG_XX][AV=&)L8"A0\[YH+$9+$9//=+!WN1T;V2' MYCZ2)YZ<-R`@<&L5T`?F]X\>7).M,YW`8N\^V) M!21Z7#["$9WD,V^'/RW0/RQDSD:R#=._E>::[4'$*.>UW,$S8D^T<#YO*E_+ MML1/&FXW)A&>T3C%6:-QFH.07-!S\N5J!$1X\V>_37[AE;=<_,X.4[B;"2K$HQX@KP7;45N9[QU]O3W=&+1OT) MVHCL@Z@BC?[]0#KDOA+[_V^]\->[^SL`RQW_[DBO7^GJ/9=1[XGYHO7KG83H M8)4T[U#Y90W+E?4CG MKL>+BI1E:(<%&85C3W8SO)LO=:70/6]6W_&/=)S*Q\=+P?K_"*D(4YL^26V6AHWE?A9C"/S.U;MDX(C\5/ M1O]O%*5!_*F&1T>-33%XO`XS=`I.DBSKF273J(MI_?%XW2,9]>]/7%KH.3*T MM/65_M'?R!V$R]ZORTJJ=P+4$W:]\?M'?F319!U:<*<&R9&U[E'O2JQX0G+& M+5]S;RQ_#Y^QB6FU;AKUGF\]R5;_W,^QGPH>&?FX:/Z,G_'BX:.:8X+VET412/WV<_;R#`NPLZG7 MNQ/<`/@VN+WE/H6UR7CKE1&OY5N]6CI`HH`KF0D&_6F>N(B]1VC$8UU/<`>T ME/Z].<]WD%I?Q3GAOP]MDQ,$50)?R:'_&?"5JEUC6#UJ!G<@V@^YG>LIQLLD M&FB)B]2+]O=>/?K>+D[_SYX]S*%@C,GMAS1&W3`3=)$^+9Y\J;C-$.\KU+PW M&"0PB?`QNB;A$)V!)";*&J+%?UBTUC)NF9U9_];_5"W)O*/?BYV)=.31]Q1Z M'=3[7S7>4O\:FPUNR3UY__-LM(EC^FNC,@8Y,7KDM4<>_Q%NA-/H%C`W03"( M<*(^`5,V1V]\CWLJ_*XA,9F-3F)`;>A4LR=B\.#_B#V&#":L<3)[G[`QS-'E M6`K4M.UYHHOD.0KMREQ`*J5W$#R)'1S1AL,LFPED$)TKHU=?*6$1/<_#^OWH M)$'!A,."N*'UE6QP;X1B229$75RW\M]BLHKE=Y`B*%='@^@24$HV"E,07U*K M*"M4L0]JK-E5-@L3]:J-YDTAZ,=@TL-P),H-#Y=66I;(E4"5@D$]%G'J[!/6 MJ;<[>Z4\6_%B\KRCDZ]>6FI(XEM@@/!F_>(W;TA^7/J"FG+U3%#ZAX:.$=@',^F7CDQ5,PA2(\8Z+ MV!$8]?B[NJ$4O29@7/TX()N/@P)4/^\"P;$_HB8*8I[_.1^*XN*"&EH*.`.C MSNU_ZL%1.>Y$'&D0(:"\#_6+3V1CA=PMM(TG\-"(X)-!UI6'7E0IF;EIC4/3 M,8[F`HCTQ5'6&)*%&QF`.D8KD,MZ;8@(I/)@=QO-V-BGG"&AW0PD?"!<3MPW]-(?4 M(EL/&$'*BT\#H3L3K'=70Z1UXU4K=V=W<`:"N5W'MH(RT>T]],X3$,DMD8I8 MS;>!YT`JXZ2HLW:B;39FQ@Q.!WPN2@6)Q%&_UW&]/^:%^NGV[A=9@L:@VBN[ MG'O%RV![)%*?=[X/!X>\8*7DCPYYR?[*IQWKU^=J`,F,'*26.(/Y[$G84*EZ MPZ`Z+Q&D+\R?:=$QH`9[](X,3FY6?R$JZP&R<#=Q%5.&OD%S%Z]$""?_-P<& MCVV;59X@^H;\7WTGE:"/&O!XG"$"QJ,,3T#ZS@=/.D(7ZP-!%_($:I@=I[8G M0\P,J_D*C6Y8]_SGX5+AZE.,CIZ03'D6W=C+$R#]AI2_]U)Z#M40FS"7N^IQ M)@_!A0KR8>N@?[BS+[>#PV$D*;O6(K.=-0S-WWGI[!97U/O;T5_QB9D0&?I* MH:C"[)[+#@R(N-(MG:%&G/"0Z):2'6@8DF^L4_HDFOAC7R@?#]OXRA."BYZY M]8>V9K*E@ZM@44E$V/`W%U8BB!PCFY!H:XPMUI^;!7[]M?ZY&15]/G0`D@L! MC[FC?1CVT<_3!WV>[F:R3KY:/78FRC!Y4;!>O[NCY&N[;?T2FP=!KP""PR1Z M_FT?]7<]!/0>UI^V+-YYX]\"%4C^85R!Z-IU%9PZ-LNZZB1HB&53)=/)44RB[SR\_F?DJ4)W'O= MN,W"U`G2Q$0F?:F6%L[K8P([N"3.IS>_4$T.A9,8>-)CZA_LOSHZJ6$R]LO< M>Y\URSJWNHP99K7RJ6^(&H9E]JVI^3JJ#GE//8LD0(/^?&'9UU@J*F_3K(IK3:@<*,SUU]VY@VIPP(>)8>#@LYKN5I)UXR="TL8 MSHK@@\OG,6C0^$91(,KJR[3;WSU(/=VK>)=XV80TB(3)>S*'33M";7`/'RB( MGVXZ.L=IH"LWU,9*"*_D3"`_LQI-='[^OJ?_(]*=8DZQY5CQEZX%P411X$8] M*V-UH]Y7IQR:77B>L8X0WZ#WE(^C!@O(WU#?&LQOI20'93(LIION[0DAGZD$ MM888S`DX4;`!K#W"`]GU22(7M26[P8D*;,S[#Y`TR"`]97/CVQBAN"C\),K'#".W]436B)'*9+>9ND_.!!JP'<"G*[DSRYALC%'0/"'!I M>BRGQHEZ38KJR$A+:U/NN-T[_]B7SM5E"0)KJQRHOYC`+RS^`4(UCKY3E=.I M$P).%H`;T_GK,939ITSOG*P1W[3CZAMY,E->N+O$Z^&Z:6*EB?.$?+`GV#W. MG@OE/?7AU/UNZ&DQ>*\:NMRK" MF7M-"K=P?P(I<'\I*&[V>LH702&ZC`.$-161Y`R!0;HS9PF.1.,BDOAZU% M8\"BZWAKOJBSP9!=J_==VGNZ5'B_F>LU72AHJ3AZ[OCE=Y-X`=_@:N0!A9.< M]URU[`6F81423>8`;M8I\@I/80W72B2V-#`=I`#1?+`;;[_5SAY?(2'N$'`R MAO>LJ9HTW76,SMAH;JUIQO!C>QUQC3LFF@:AV:63EJ8'LTH+FAYRG^8;.#D8 M4HU+/!6;QX+@Y][PUW".ZG-(&5]Z"J*-IHY9_X5F@Y8'L2RI7)0RJAD(8\0#V1.S!]1 MU5_6H?`_OA'W,*%/>5)_?5Y_%&CN[56C[[=3X9O'LD\'#ZT(J>O/!S*G+`P MB;!WCJ\_2RJBUM!56D=9V:3#?JQ)76V:Z'3?ZS#8&@S%_20,.??5F,*V%._@ M2KD+^!_:X$?S^O>J<:G`D?1K'XY-P`B6NROA_`D+D&%1_#/)) M,Y?8(!NO//*`<4]82GE;S:!L+=E(R6X6G<$05LTBZ<'Z2G=(Y1CI@W'8Q2O\ M6KJ\9U[TVM]`OG:_9*@!UC+G@WYNX>"W*UD'K+W`3S)6K?4GZ861BD-XE`2Z MNTKPD12NORWO#1H\I9?.^D;KD0#6UGL)H+QH:'"PF'3XF-BL+A-ZO"!#^!/O M;!3]41^MA"Q4`@E3?"1X+&)^D>E6UF.@YTJ?&D9[I/MR3^X=C7.(FU!(/L?+ M$*1!?J.=";]#7EUR9T@["BI6N+G&7$7%N_6RHN0)/93*89-3K9T]O&UW\M0C M&L.,<`MF8_U.;YW0D1L2F`KQ>H\// MP>?YCH,A>ZYWET-E3T_8:ZA&"1ET[3T"YIRQP(3GBJ/%D=DP%PCVMM\-T)\' MT;F*8!`6Q_E.@L%W_'*"PTNU9H'R.B1)@IQ!/>=?!7.`$#)E%?!Q<>_\U M`D-[.4[N11'6O74WN0O7`]2$4KT[U/F_^:QL[3^TCL?;SC^%7:IUA/JZ)S^; MN9IOU,7-?)Q#P8+3W![=^HZ;6US\RQN?8XF%1-BB!4$P(BUQ!U8L;SH1G(*[ M#42]BKEX^_]3=O8X#,(P%+Y*QW:H>H-*_5E94(]0U(6-WE]]>;:3X#0)S"C$ M&&)LQ_["TC+>'G_JX(N1#H-\ZCPSS^25^=3N-\QEN<1B(]XU*>[[,GV[(M?Q M."V$&;8\D)CK_0MI\<\AI4?C)$$N^R*K7S1FSWHH0W1<)&O4/O971S*42-B$ M0\]2Y.A%=&K,@INU0!1^@\6,^-Q7AL^]2]MP78I40C8()%=T=8,7.TQ`V+\/ M8.$*)+>JP(R6"XT;+;>M=-8%;^(FL\+)7K+Z[AEWVS`ZPU@`B1*PDOHX&1])/9)HXZ,75LI!\89CUS M5IB"F,G"VC.NIE7=%6NE0#'V'U%_6-9Z>E0BX"EZ95XZJ=)4!MI'&E;[HY+3 MI:Y:.#6=S:[]L5;9QY&&Y-H\FOOB(3*D.<^J@Q!`Z099>L3+LGRO/P```/__ M`P!02P,$%``&``@````A`+9O1HH%`P``M0D``!@```!X;"]W;W)K/$"")0JHF5;=*JS1-^[AVP`2K M@)'M-.V_W[%-*3@=2W-!`G[\\I[C8Y^LKY_KRGDB7%#6I"AP?>20)F,Y;0XI M^O7S[FJ!'"%QD^.*-21%+T2@Z\WG3^L3XX^B)$0ZH-"(%)52MBO/$UE):BQ< MUI(&1@K&:RSAEA\\T7*"C6F#C,**7Z+!BH)FY)9EQYHTTHAP M4F$)_D5)6_&J5F>7R-68/Q[;JXS5+4CL:47EBQ9%3IVM[@\-XWA?0=S/P1QG MK]KZYDR^IAEG@A72!3G/&#V/>>DM/5#:K',*$:BT.YP4*;H)5KL@0-YFK1/T MFY*3&/QV1,E.7SC-O]&&0+9AG=0*[!E[5.A]KA[!9.]L]IU>@>_426)G.PH)*O_&$A'U(O,.I$0W'?C,W>VB((H_K^*9QSI M`&^QQ)LU9R<'J@;>*5JL:C!8@;**+(3\O!\9A*3FW*A)>BK0`I;C:;.(UMX3 M9##KD.TY$HZ)W3DQ7_2(!_9ZCQ#YT..T-P6G"*YOWN)>5MO?&F0^0&)_C.PF MD9$Y2-KEYA1LF4O&;]X:)-99#9:^_HR1W20R,@K.#QBY=6%6\-TM72NZ4T18RLJ58V.">F]Z""+6MO M56"6RR!0+?TV/=N#D\C(W/(CYA1LF9M9"V:0+F]A:)UMN^'P+!@,CTP%<(Q> MGC)-6[:L$W/;,?_T-1J?,&:=^=-K"7WU+%]V@7=,8@XM*+1Q/E5O5AKOC)N, MF<9K^E*+#^0!\P-MA%.1`LK#=Q/8NMRT77,C6:O[SYY):)?Z9PE_CPAL+M\% MN&!,OMZHQM[_X=K\!0``__\#`%!+`P04``8`"````"$`XQR:FA\&```N&@`` M&````'AL+W=O`=M< MHTZ/!D:S.]*NM%KMY9DF)$$=0@3T9?Y^?:D$5]'I@7V9Z5#'Y>.J\BEC[C^] M-4?GI>KZNCUM7+;R7:VV/NTW[M]_?;U+7*3OW&/0S#>>UY?7FHFJ)?M>?J)"V[MFN*0?[L]EY_[JIB MJPVS5FZ>*R/]?!=.W6=IEQ_VY_:KG@\RG6_L:`H+[[UCXG[IBZ[ MMF]WPTJZ\PS1Z9I3+_6DIX?[;2U7H,+N=-5NXWYFZURDKO=PKP/T3UV]]M;? M3G]H7W_IZNUO]:F2T99Y4AEX;-LG!?VV58_D8&\R^JO.P!^=LZUVQ?-Q^+-] M_;6J]X=!ICN4*U(+6V^_?ZGZ4D94NEGQ4'DJVZ,D(/]UFEJ5AHQ(\:;_?ZVW MPV'CBF@5QKY@$NX\5OWPM58N7:=\[H>V^=>`&+@R3C@X$9(]V/F*)R$+HQ][ M\0PCO<`OQ5`\W'?MJR.K1L[9GPM5@VPM/:N5"1F?]U[V0#""! M#K1:6FX_011D<&P*'P=(@64@K<4'*9G:0*R9K0=H8AG"^1,K\,:5B[A&/?3) MQ`82Z[3%G&%K;EMY&HTY0YQDU<[GI,`X&"&9-3,0*QC6`S1QM&1B!2;!X'BY MF8%$.AA"1*2*<]L<^/&-:,1+2"DP(36Z-55I(($FE4XR9*R&,F-LI(P"I5J/ MM:\_+E<%)IP"$B@#@5FC<)Q54\ZQ68QF1"I=0DJ!":F0D#(0$RC.1^TPG&QK MF(QC$24FQ6Y^H#2:D!K7:K('&!.J*$E)R>7(SGQQJZH8D>:/4ZC1A!E5.\!` M$I-H$C$$X+Y(1]'"05,J.;NZF-%4)$HD5QE@@)I(R);(;]LQ,26B\XD9R47$ MQA5#-B^R/"IJ1!0U9Q>,ZH3AN',PM44ZSJ9"'E'1!(PI?T8BFB-K?*OZ%PFY M.O*0+1F1ZLX`8TA9L3!;$EFML3A2BT2>357>ZEJ01%O'>91:X0!>-D!P81UG M,+5%4L^,5,OJN';C:*P.H'81>W5JU"<0&*6;(9Y\D::SJ:A'8Q7`Y+9LBU00 M*NT5A"Z<098`PQ MX3-2_CFVA_&X9U'$^")MUVA"C&SW##`@!C1>R&HU;TQJD:KSJ:I'5#P!`_43 M!+2^L/WFKN-*7V>KND;C:,5$L3/``#'.:+LA]F3L\3AB1-/GO3WQJ;9;=6)V M)F!,.H4@_'-DCBSZF-XB=5&6!`W2==&IEC,L#\%K4`/FT!M/-E@#$3ASR<$+-;1)@$8T5@8HM:`#1^)D%S M08+*BLJ^]KQQ@6!BU0T0-#[`'J7C>)0^L4CZ-9I$CM1-!AB86%XDC*$!9J9_ M7)B'UGL2IK9(_(5"8VH)$8,,,&;F.Q8$Z:@&P,UX`40B#QC7%T_,[7_IOYCJ M?S*>$S2###!&:#D);HZLUF4*)K=(_<54_9-QKP,I@S%A241,=DL./B"E@;!D M&#,C#6">RHII(Z`-*`.,8?#>01\!/CCH"]((?B`ETP:0T`:@/6Y<2\_L)S@^ MBU1>&(7^4$P!8T]N1KTCID3)9VJ546ND5:0\,GE#K_:FN7F4+7BB"+;]'3$U MU_/F]KJINGV55\=C[Y3ML[IZY_*Z[/K4?!;(V#KCZFJ7/,_EYP+]W+L:Y&W] MN=A7OQ?=OC[USK':29?^2G61SMSWFQ]#>]97RH_M(._I]9\'^5VFDE?'_DJ" M=VT[7'ZH+PK7+ST/_P$``/__`P!02P,$%``&``@````A`$T2O4(]!@``K!X` M`!D```!X;"]W;W)K&ULE%G;;N)($'U?:?_!\CL8 M7R`Q`D9C1]D=:4=:K?;R[)@&K&",;"9A+7<7&ZJL[I#KWY M]E&>G7=2-T5UV;K^?.$ZY))7^^)RW+K__/T\>W2=ILTN^^Q<7G8$`_.N4!1T-J$CVP?Z_%?OVM'7# MU7SYL`A]@#LOI&F?"YK2=?*WIJW*_SC(%ZEXDD`D"8&]B`?SX''I+U?#63S. MB"WP*6NSW::N;@Y,#7QF<\WH#/IKR"Q7QGFHM=Y;*JR1)OE.L[!=(7X)IT&H2![[*SXJ;<$S$AH%6.]4>&`R@M#J#_NI0 M\-:%Y:ENQ&&$/IEC](ZM%B8DE1#<,9CK\5PH&'-9FA^4<,R*#5?HQRB<\O`= MJD:55E.843!FMD+,.(8SFX&B4?]2'F?],X@\3"%"P2:1Z`&WBV,B5J+9,HQ- MGJD,XU;174JS@/ZQH6"3ASTV',,+XD<+W"H>'M.JV&1&S6E8]O0EQ##XDBR7 M%,=HDM(>&#WRP67TXHRCP-X:DK4`:23T)R8+Y-+]+?*YC?9+6X#N=(%5*548 M/#$^=<71(\/0J",A&HI$@.30+-%LIR)NJ\BG;CB>"_=.LS98T"SEUI6*AK,6 M4I(`=)"A=CB>#$6;A;%%[7-0?Z,DQFK4)!NF1QK$QQ:W`'&7B;3-4,R,-&*+ MRB3?]3N,-T![:V/S':DCKEEPLQ\;9+6]LQ2;UV=Q3VG]2=9+4.; MX]'1CEXW%3V1&*LGR&`'?*7#66T=2R>EA\#'%=X+?1G&5`)DM/U4&!J7!JDT M$2"Q'UI45-BB,LEM`]MM;1$+4*^(%<;B,\EM`XK&I4%NF@@0+\WC`A_J5-BB M@LQVG(R"#M,-T.DD$2!-1OH38SL,J-UI+CN2!3?)?C&SU(:8]22O]$ M&VZ+-,\OO[$.W"*1O?<$DPR6H?&8X$U9@/B8^$ODOZD*6V."W'9`S-PN^_?D M0'HJ]969OT`3G:JXQ662YP;<*G4N'6J6?MK7)HFQ^$SRW*#+<]':$P$26S(2 M5JJBF`D]2NLRZN\20^.!0<:1")`F8OV)(9\0N>PX$;.WAD[6`J2SX"9MBR:< MY*T,C6N`NR%`O5ZO,%9/D,$.]*3#6*T=.>0@,1WH&Y!412TFR&0'F'!SU743 MAWA##CF(,YE%V$Y4V*(RR6E#VVEM"0M0?Y.D&UM\)CEMV'&4M;YI$2#1)/3G MA@I:1";Y;-CEL^B`E@B0KAWIO-:G(V<=J6!NC/W;<*BY)S_#ZD],'YGDI^$8 M/Q6@_N'@B6Q'B2:Y*D-C1\';L`")X8B0K%(5Q@V*D,7V2YBA,17T68D`]99& M82P^D\PVHFB3CZUC`1*68G_GI>(6ETE&&W49+39^`1)<8FQO*FQ1H;:H'6<' MVD319EGB$'V1GD0(S M@0I;59GDM9'MM1T"EC[:S2P)W?!.4P]-#4"-`#^Q+=CW%I1%BCPB\- M^9U:2>HC2,V.Y&=6'XM+XYS) M`5Y=S!]`+36_;>2_M-6576B]5"W<$K(?3W`K3.!2:#$'\*&J6OD+[9VZ9][] M#P``__\#`%!+`P04``8`"````"$`Q\GBH!$$```@#P``&0```'AL+W=OW7W4I7>,V&\H/7:1Y.I M[Y$ZHWE1'];^__\]WMSZ'A>XSG%):[+V7PGW[S9__K$Z4_;$CX0(#R+4?.T? MA6B60<"S(ZDPG]"&U#"SIZS"`A[9(>`-(SA7BZHR"*?3>5#AHO9UA"6[)@;= M[XN,/-#L5)%:Z"",E%@`?WXL&MY%J[)KPE68/9V:FXQ6#838%64A7E50WZNR MY?=#31G>E9#W"XIQUL56#X/P59$QRNE>3"!0`:R[!XC M^[5_CY9I&/K!9J4*]+,@9V[\[_$C/?_%BOSOHB90;=!)*K"C]$E"O^=R"!8' M@]6/2H%_F)>3/3Z5XE]Z_D:*PU&`W#/(2":VS%\?",^@HA!F$LYDI(R60`!^ MO:J0K0$5P2_J[[G(Q7'M1_/);#&-$,"]'>'BL9`A?2\[<4&K7QJ$VE`Z2-@& MB8!].Q].PML9FLW'HP2:D4KP`0N\63%Z]J!KX)V\P;('T1(B=YEI'GVN'Z4* M.9.$BU7P##7-6LRVQ<2^UX-"&Y+V$"D&$.Q90NXNRPA4 M?+_^'2FYR"85NYR&D,BA-$3$MSW$X@C5^SQ'N0BZP:A)$J(^OBKN5F-BU0RR MVJDQ8#&`TIH,+E='@M<^I->K@=#4>;/&+)2@$4IF]G2JI^&W#S%_BV`Q@RXW MFZ0%F7)\Y)7(,&[[1XJZ M:7=SA)^R3X5VO"IRCGS;%F3(88Y8A0B_Y)AJU=@'I`69+/19=-B2<,_XA$$H MM%V#X>9H0?J<%4;NA[R=-JCHBXH^QU>$'4A*RI)[&3W)2PB"3U$_JB](6[@@ MJ=M$T$_`_:3!!_(#LT-1U@ZG2S`%)B^X>@'01MUB-Y1`3<3]>\1;J($ M#J+3"8#WE(KN0?9+?[?=_`8``/__`P!02P,$%``&``@````A``Z7KY9L!``` M"1```!D```!X;"]W;W)K&ULE%?;CN(X$'U?:?\A MROL0'*Y!P&B(U;LC[4BKU5Z>0S`0=1*C.#3=?[]5=A+*3@^7EZ8I'Q].77P2 M+[^^%[GW)BJ5R7+EL\'0]T29REU6'E;^/W^_?)G[GJJ3[##+`LGN5V*_\;VS!PZ$?K)>Z0/]FXJ+(_YXZRLMO5;;[ M(RL%5!OZA!W82OF*T.\[#,'FH+?[17?@S\K;B7URSNN_Y.5WD1V.-;1[`AEA M8HO=!QKCRA]-!Y/9<,0`[FV% MJE\RI/2]]*QJ6?QG0*RA,B1A0S("]%(GZV4E+Q[,'BA7IP0GF2V`N:V/R::KV,\*!I5"DF_(HKF@%@JZ M_+:.PN$R>(/.I`UFTV#@1SI0:$/B#H*-0&+>$F./07$G&TKJRA[!<'S>UE8E M;K)5CF>V@DT?,K(1<8.@:8SG-H;W66;S<8>Q$H&9H(G<3@#!F$!;GDT;N)9T M-G<%-YAQMXM_MFORN3Q(D\K#\;A?9]P$.-+H*&0=OV[LQF"NHF(WP$G`JAB< M.RKI=L40O/*A']W,1:$S=1N#F>JQ9>#/0V=R8P.X:N5M``=]!L;1Y68)G3XC M%,&V4,8<'1N#F6FA(Q9=?U:7-#;+4+8NUZG#P%N(>YQFSTA%L"TU"IVAVQC, MM62Q&^`D8%4-G[R.(=V?.-QT;^(,ADAR`YP$+$F1+>GVQ"'8KDZ_D08SUHV< M3YVC$;>K[2GG)&#I8N!XM%:WA6FTK2SJC5@#(E7J13B-V'K0K9_N'3,>?]LN M&A#59;9=(YQB;%WHQT37G3H9]Z:>T>\@,Z#&-$;N08N;=:K.[-`16QW:\>/J MC'E3=5%X?;88%UNWQL>,X^0Q:Q<[ MEZ`16QI:[>/2C#';TJ;=$ZX9,.+>30O="&8T^[QUG^K M8,3"&UUNA%.,K0M]ENBZTT+CRK1.G]B$`34'<3YRCD+,B+5KO9Q&+'5P2WI" MG48[9M^SB09D7BA87UVS?CT0>%7#X0KMX`+Q'``X+V4=?L%?Z"[Q*__!P``__\#`%!+`P04 M``8`"````"$`W\-DX5$$``!2$0``&0```'AL+W=OK@^7NVT>>6>^XHBDI]C9R/-O"14R2M#CO[7__>?T: MVA:MHR*),E+@O?V)J?WM\-N7W8U4;_2"<6T!0T'W]J6NRZWKTOB"\X@ZI,0% M?'(B51[5<%F=75I6.$KXHCQS?<];N7F4%K9@V%:/<)#3*8WQ"XFO.2YJ05+A M+*HA?GI)2]JPY?$C='E4O5W+KS')2Z`XIEE:?W)2V\KC[8]S0:KHF$'>'V@9 MQ0TWO^C1YVE<$4I.M0-TK@BTG_/&W;C`=-@E*63`RFY5^+2WG]#VV=_8[F'' M"_1?BF^T\]ZB%W+[HTJ3GVF!H=K0)]:!(R%O#/HC8;=@L=M;_;U$=7385>1FP;"`%"TC-GIH"X0LH0641A9@CH8OT6X$$X;$\31C6FXN(TT`W-I5FT6S+.\T]%9#.M` MU1[78>"]#=R=#,.65R@+S)*/4#M`M$ZMYJCR\"F+C)T)4;H@K&JSS7=]1Q=!C9U MU22*3@K,BJ>+_-#S5$$T86;L`]OG?L'9(B.`M4I,!"`PVH8*1\9XH\=P7YN! M#>V5:J;0EIBFV1NUD;7<$?A$-_G[PAQM*(=+H]T2).KN+T?+CD9L:R($X4#: M'@X#,P0)FAHYQ&RFT_H):6%*NO3*E!:@_G9&AE,]9B!\U92#2-"`IF%:$_D) M)]+S4WM&S!5[/K#A:TNK=IT^6+/LBSU_S9$.S>W4@(3TT@G4S.O2LQP,#5F8 M2DIF+4#22X)@?*@-%VN>Q1.5'["SGIL@`=+M9&Q;&YXV(3]@9CU#01+4-'ZA M'IQZ]6=9&1KPLKZC")"H_GJT]K[A98_5GJ\R/; MTJJL8O0DJ+^Y?>8T'?-ZS%#XJBE#D:`!35S[(30JXAI-A(DQQV-S[OA.;HR>.MN((F./JC'_'64:MF%S9L94M M:^^V1^HGGY]HV@_@1%M&9_QG5)W3@EH9/L%2.!3`@%;B3"PN:E(R2NM(:CC+ M\K<7^.T"PR'-&PO=V]R:W-H965TRY8+LJLA[]=P2K(3MUF,Z!N6"2YYH3R@\ZW0<J_SMGLH,#`4: M+XHU4\9K$`"_J&&Z,\`0\FK^#RQ758(G,R^>!Y,0X&A'I7I@FA*C;"\5;_Y8 M4'BDLB31D60"ZH_[D1O<_B6T4FP7NBR&8M^`%!T\"9LB.Z!<,5,)\R MLSKZ7/^7*N2H2>XTB^&"+"24YV6S6`9K_P4\S8Z8[1$SQ:@'14-(VD-T,4!@ MKQ)R=U5.H(K_]O\D2@<-14WGPP.W8\ADB$C'B.FBAPPT@GN7&J]KTV#H@@LO MXM@US&*FI@FTR^G%B\')8.GER;J&[[NC@Q(,Z?756"S#/C-3UJW%A-',E#3P M`@>06H"1.%`$77VIZ+H7&NPJ<3IC:S%G)9$#2"U@K&0V5**]F0+VNB(=Y"IR M&F-K,6=%KC5V?RQH/A;T?K%TD"MHZA3+8LZ"',&IW1\+TG?4Q02X[HP&NT)B M1XC%S$W/A,X7!U-:$QPWSY&V>^P`MO.IH:*D*:UKB3*^U\,U!,;^K9W[6YC[ M9DKZ_0;,W8Z4](F(DK42U;2`T,";0]&%G=QVH7AGAL..*YBXYK&""Y;"AQ9X M`"XX5Z>%'D?]E;WY"P``__\#`%!+`P04``8`"````"$`W`RA#?0&``#_'@`` M&0```'AL+W=OTQ"::("@)#T]\_=;=CFQ708Z>9D>JHZ+4Q?[A/CQ MT_?3 MFB[::3LDW"FOO[Y='K;5Z0(A7LICV?Y00:>3TW;]V^NYJO.7(^3]G2WS;1=; M??#"G\IM7375OIU!N#D2]7->S5=SB/3\N"LA`UGV25WLGZ:?V5J$\73^_*@* M]&]9O#?6_R?-H7K_I2YWOY?G`JH-?9(=>*FJKQ+ZVTZ:8/'<6_U%=>#/>K(K M]OG;L?VK>O^U*%\/+;0[@HQD8NO=#UXT6Z@HA)D%D8RTK8Y``/Z=G$HY&E"1 M_+OZ^U[NVL/3-(QG4;((&<`G+T73?BEER.ED^]:TU>D_!#$="H,$.@C\U4%8 M,`O2B$7QB"BAC@)_392Q5)8Z")`W0892F6-Q5*UYWN;/CW7U/H$!AO2;2RZW M`UM#Y*[(6)*^[+>J#N6603[+*"H6%+2!4?GVG*[BQ_DW:.]68S8:`VGTH&1! M0%D/DOV4H7EO,@:32Z$.;P^05TNG5A M6PQG+L&$>Y[!DC1=T@ MQF)/#;PS*/9DN4`G]HPET:ION%-S^61BG;7WMX`$4]:F*CA(B+%84P/O#)(U MHR6_X70XK\9PEF#*F\6("29C'<8\ M6W26VZM$OTINH M8B^%<#A[E$V7/3E:-@Q!9G8RS\*U14_+8D7Z)5P_2VZQEX(WG#W*H\T^79&Z M;>3/##C(;/;4PCV,L"WN=$AMLQ@.DRV&B@ACT(^T_X"F03;33DC-E%.+L%>Y M3*6064SO2Q1#V;-KZ3^F:9#-L)-2P]#6SX#!+S1W>PL=1`]Z%%OZ[?*7DC:< M/PJ@P]][6&.=2G9L,\_"M07I/81I3(Y2T2]13P]+HQLN>ZELP]FC#KKLO4FV MQ9)%:6PVD3Y4$&#:P]D'2X0+2%E@CBXGG6"4`BLT56`J61K4'1D+XL^TW\KF M@Q7BMM_-993\!E?DUY,L#;HK63VF&S[>6\RI0(5.])A[DA7`X`P?-H4FW4E, MW_&!0H-,]3//PK5%[^1%:!YW5`SA^%FZ,AUV^S%*<(-K@DO.F(T&V>RI!/,> M(ROK;2:AW=UX6KKBDA^EMX&OMW99=.D]O=7+3#K0;,9#- M^XJE0897YEFX9Q&VQ65*M/6^8@4HAW/4:.L2>VCC=:FGWB4A\EM<$UJ:5BI4%8U"2( MS3>C5FF_28U_L$*X_OC6(V0@)6^P\"HT.0N]'U<:A"]Y0NN+=2J>[-Y?(&ZZ MG:;(ER'#$U%HDH@G4QIT5Z9Z3"]3O>6.3-W'N'F-DM_PFOR:'8@GI@:98%*D0I=83*.^HUR&:(RXR%:PR>J0\LM:94#W&WY.I.=5,8I;5P-TC? M!OJOU#0(W]&'Z=(\[N$YJ?UV0ACVU@IY)2F_%OUQ%)E]C[G@?2/>@9V*^K7( MBN.QF6RK-WF7&,!K]]Z*]YP;ML[4I2"Q<[C_5/9Y[X#KQTO^6OR1UZ_EN9D< MBSV$7,P2*'&-%YCXH:TNZH;II6KAXE']]P`7S07IY[0,````.```9````>&PO=V]R M:W-H965TRL-YHPW-6K6PR M<6V+5BG+\FJ_LO__[^5A;EM<)%66%*RB*_N#N$X/#W0,N$35M,*=G:L*1,!C\W>X75#DTP=*@O'<]VI4R9Y92/#HAG# MP7:[/*7/+#V6M!)(TM`B$:"?'_*:G]G*=`Q=F32OQ_HA964-%-N\R,6'(K6M M,EU\WU>L2;8%Q/U.@B0]@T&',D1,YP+1>9CE$(--N M-72WLI_((B:1[:R7*D$_+']CIKR;/_LXK"MF&.LD*;!E[E=#OF5R" MP\[@](NJP#^-E=%=;[@X!RAQ"1#&R1?3Q3GD)&@6;BA9(I904( M@+]6FR!\D"F,^1H8XNUJ]" MA1@ER9-D45P0!8?ZO*TCERR=-\AIVF(V+2:PK0[DF9"X@\AB@,!.)<3>5^E# M%3_/_UF4/&2*"F;F"S=#B&\BXB$BF'<00R-D[WZ-\A!T@Y:3R.UE98.80#6# MS':L+1@*(+6Z@NO9D>"5#>%UU0AG01>9*NL&,3-54&_NN9?(U7ZL[_L^"2[G M#5W0X^-U2;"I*W)[1=D@9HJZ7'?>VX^-?1+-+ON&KND]NB2XK^L2+^8+,5JE MM`7CS3/SS?+6W>YG>>A6KR!&4Z`M&`KD5Y-V[Z_WB@2;L0][!3%M34(WZ'5Q M;.Q'07BQ!T-7=(\N"39U#7L%,5_WBKD_GUUT&[H(V,WXA"ET7UG8NUTM2"N6 MOF*^_1.;OMTP!/WTNKNT(%T%'E,KI@IIAJ.;AJ!U7G>8%A3@=\;TTA1H,.8V M^:HVTA#'ZT+[U'5%[K1?&\UC6RG:BIF5GNV.N\P$O1-(._\=.G\+TFN#QSZI MS5TF*X>7WLT9WN@6A%>'S,.^^QO[7JC=>#,_=]DL^'P2KU9"X M90(F;_7Q`+^T*`Q:[@3`.\;$^4&.I=UOM_5O````__\#`%!+`P04``8`"``` M`"$`Q3()2N(#``"U#0``&0```'AL+W=O*Y*YXDP7M!ZY2(OA&@6OL^S`ZDP]VA#:MC9459A`8]L M[_.&$9PKHZKTPR"8^A4N:E$99!1HO'`BF3):@@#XZU2%;`W("'Y6_T]%+@XK-YIZDUD0(8`[ M6\+%0R$I72<[5$'M?9015O)[_3I0TLD7%,]MA.H1$-F(S1,27P"R- MD#U3X^O:)!BZP,A%$B2VZU1C8M4$,LL;8\'R#"D=[UF"5RZ$=:X"0D'/L\;, M5"$CE$SL[8W>AK]GBNF%P5(&W3U>F03;RI*!,HTQJH3&& M9V/!\CR[Q;,$VS$/JZ$Q4U4-%!FI5F=OH[>5,$N'?/D8)_OU?I1@6T<27&JJ M'*4:8V3`6+`\)[=XEN"W=0_#.W^ M,/^H-UI?+X!"VUH2A.R#E[8@(Q'FBIT).;A&EQ_I,??Z/&I!IG=M=B5V.:K& M>]>#S9Q)">J]&U*D02C4!V'FA8GUF7RZZYEL>B:!A^+8LKE,7#MWW7#=)CT8ZB]SI)6]`EBL@6-+T2A>;M3*9>9&)LX3?-6WF#Z1]Z%/=;SABP M>MZT9E>*?M/,16.&;@LR6^Y_8Q?=-'<5NG_<>OV3MJ`N\Y$7!]8G-`O1)D=/ MX\YDXB&[OG/3Q*Y=;UZ/;+HK@QL-FDZ#.E'S?AS7CHYM$GOPB\/\7.E!?7O6 ME\N*L#W9D++D3D:/\F:,X/5U7M6W]E3>VM6]^[P!E^8&[\EWS/9%S9V2[,`T M\&;0A$Q?N_6#H(VZV6VI@.NR^GJ`GT<$;DF!!^`=I:)[D'?)4_>#:_T/``#_ M_P,`4$L#!!0`!@`(````(0`H[][8?P(``(L&```9````>&PO=V]R:W-H965T M?<<^Z-F=_N98NV7!NANA(G48P1[YBJ1+DU,KSFM?)%L21K'8R*IZ'!@F.G7<*BZ%HP_*+:1O+.!1/.6 M6NC?-*(W)S;)7D,GJ7[:]#=,R1XH5J(5]N!),9)L]KCNE*:K%GSODXRR$[>_ MN:*7@FEE5&TCH".AT6O/4S(EP+285P(T^Q*,$ MX&C%C5T*1XD1VQBKY,\`2HY4@20]DL#U2)*,HRS-B\DK6$CHR!M\H)8NYEKM M$"P-:)J>NA5,9L#LG(T@GS\[`TNNYLX5^5)`&YC&=C%-\CG90H3LB+F_QJ0# M@H#XT`&H_G\'KNB\@ZP8Z'V3]]>0T8`X:V#TE@9<$42%T1!!/OEM,'00,)E? MK>>.L[<(NJ(2@ZE!<)J,!T-!,&`*/Y%)'`]/S^S"QEWFG;VXRZ>)NZ)+]O*">'$N_OF%:,"$P--G MXPB!A_,DO&X]7?//5*]%9U#+:QAB'!60F`ZG2;BQJO=+O5(63@'_M8%#G\,[ M%T<`KI6RIQMW7@U_(XM?````__\#`%!+`P04``8`"````"$`X+A2_3X)``#N M*@``&````'AL+W=OGSO0)&B`1G1G,O/OMVR7[7+90,C)RS#Y_%5U?>7J M*M/TPV\_][O>C_K4;IO#8S\9C/J]^K!JUMO#RV/_/_]>WLWZO;:K#NMJUQSJ MQ_ZONNW_]O3G/SV\-Z?O[6M==SWP<&@?^Z]==YP/A^WJM=Y7[:`YU@=8V32G M?=7!GZ>787L\U=5:&>UWPW0TF@SWU?;0UQ[FIX_X:#:;[:HNF]7;OCYTVLFI MWE4=Q-^^;H^M\;9??<3=OCI]?SO>K9K]$5P\;W?;[I=RVN_M5_/?7P[-J7K> M@>Z?25ZMC&_U1^!^OUV=FK;9=`-P-]2!AIKOA_=#\/3TL-Z"`IGVWJG>//:_ M)?-EGO>'3P\J0?_=UN\M^7^O?6W>_W+:KO^V/=20;=BGKGK^5[VK5UV]AIWK M]^2./#?-=VGZ.T`CZ6P8>%NJ'?G'J;>N-]7;KOMG\_[7>OORVH&3,2B40N?K M7V7=KB##X&:0CJ6G5;.#@.#?WGXK2P4R5/W4%]ZNN]?'?C89C*>C+`%Z[[EN MN^56NNSW5F]MU^S_ITD)NM).4G0"G^^X/AY,D]%]-@4G%PPS-(1/-$P'>3J> MSM35+QCF:`B?:/B)L"$VI1T^3=CI()V-D_'D!O$3]`*?SLL',SC4NZ$VMZRZ MZNGAU+SWX`Z"?+?'2MZ/R1PZ;8,$&$N9"A+`@Q!DM4%%<)U97`/Q*O5R)!& MOHS$CW&!#"HC\RF%I9@8RP`1X85RW\LR9(PMPQ,*%7V[4&D$-R#9C(GUKE*_ MT`RXP8V*(D#*`!$:45U)N5D2P(L:$LBCELWDQK*37A[[D"I;4U,F0S.D:TN9 M^93"4HS2,D"$1H@N`GBZX$)4U^5RDV0__'L_MH5F8/C/ZL9B%5E8B@T_0(1& M2/@$\,*'#D##_V0WD%Y\70EO!YJ23)2D/$EFO!E8@I45($(C1!8!/%G3+Y$E MO3!9;#,6F@+[)5M@.DJX*KMN506(T`A110!/E3QI_?'6+;TP52SJA:9X-U'" MNY[E6&4!(C1"E!'`4W;_),H2 MF$%?L&G*#=/&.SAR?'&L/Q:.9-6%D$"(Z*.(+U`.Y#]>E8F>Z[2U)ZQQ+Y"# M=]L4;K5IDD)\>7(N$WF7&WRBI[BG@K=XY"@5FZ>[ MN_N[#)KE1C:0NY3UE\*1G1Y]#;`WD$`6U:-)$3UR0!,]G^SXB9[S5&C*6SYR MO'H,!6I'1$WI[)Q`WIX5T0.";4(H3*$!$)Z M]DTGV6R:L=)>(B4B1TYN(N=*_>DY[\E@C7LA]P/:I"\)9`-J MD6B.+Y#=+H4C.8'6SD`"652@)D4$ROE-!%ZYS?!``.ERFQ#T>23!)2U)=GKZ M+;E(+,E$78:0,)!K^4L/\NZVE)TX+DM1;.@&4SM-%@::6:@(H3*$A(%(F![D MAQD[-TS@X0Y4]HW?"E.<\%0#0I!>EWP^7(W=O15:AI`P$%6%WA7DJX+:_G@= MI9+-DH^0BZDP+`>5(20,1,-$7Y$PV2G@2HW@C*;YU9#<7I=?U_[U03JU)%O< M(200@AO>L)8>Y.>73?NI[A4W#GKU[!/##*`R#2"!D!9R:5@)"7>W8(*5)+,A5=AI`P$!6%AA%14W@`2R MO!L6+Q@&+K\A?#QPQ?8#-Q#);PB5(20,1/+K05[[RV)#,U<_P-PZ-)4KIB$V M--D!M#!V3F@90L)`5-79H9G=-#05FP4>#DW#HF$&+&%8-,RS0S.[:6@J-@O3 MSD,R--GYMT`[N`-L<8>0,-YIX-J[KG>_:N2<^O!=F>%4(\W#0"Z910B5(20, M1,,\.S0S.7E(F')HCJ%H;CP-*C7;.YFS.?K+!*C=L*^QH=7G/^;'8V#F190@)`U%%9T=R?M-(5FP6.`Y- M%U-A6`XJ0T@8B(9Y=@##:SO!_8M=Z<;AICPQ"3A0X4:SG3;G1V9C1T59.W/0 M$(9%187C6K\QI%\JV=>GE[JH=[NVMVK>Y-M`D)BG!POK5Y<6>3XOP3E\91`;G%YC*Q`; M'`_#E6^0T6_17"]@13YW#&W@82!$'8TMA=C@V5C,!F*#QU&Q%8@-'N[$5F!/ MX1%+;`7V%.9W;`7V%!X-Q%:FL*+Z*\]H`A'`H21BDT`$\#-,;`4BT,?JP!M$ M`+\3Q&P@`OW<*;"!"H$GTQ$;,(G&#`91/FQ:=,\2V#/XO39RA03V#'[\C*W` MGL'/B+$56(CA&PO M=V]R:W-H965T$C.&5F^__#M'^OJT6_[]UZ>[=+GH^O)Z*,_-M=HMOU?=\L/#SS_= MOS3ME^Y45?U"9KAVN^6I[V_;];K;GZI+V:V:6W65D6/37LI>?FR?UMVMKTA25N=RU[R[T[UK7O-=ME/ M27Z_ZZ3+Q66__?QT;=KR\2SG_8U%Y?XUM_Y`TE_J M?=MTS;%?R71K($KGG*VSM?FGKPV_UM9)JRW52*_#8-%\4]/-!#/5)@DXD_#%8]7UGVJ5KL)T MPS;Q^UG6P$A/4)1]^7#?-B\+N6OD/;M;J?8@V\K,:F:QU,<_,SDE=IBA`>3L&``K>4TAKE(A?!< M^+MS41>Y;FX@D5X.)4!!1H0]XI#B+JEQ815XMY2Y!LUB)%H.D$2K M'L99LG')%G:.$\%=GER'KDWR@$3:Z*,\12I6MCQ M+,6B"PA3GO+`3.>IP"[/Y&WOP.("Q-`,&9*[<,,I5A/"E&4\AZ4"(Y:(1@Z0 M5Y9Q@&91.'&I-KI>0)SR3.;P5&"7)^=H^^6``:*;+$/'N;##<8;5%A"F-)61 M6E5J?',J,*:)UBT'C-$SW1">;CP@IPCBE&@VAZ@"2RNP3GN">0)$WT=OUP(/ M"&O`.<],5K[IFFDT%@TM7FY`1C6R]H43ET<)[0UAXE0UIJK\Y/75:,R5V`\8 MQ^L*)\RM3H5)8N(QW@#"Q#U<5:6?SA5\P:[H":$*&$,EB[%N!7,`&[F2$ M`7C(JFH_G2QX@TTV184F9X`!LG-BJFF^Q5%72:'?7IF@= M8,MTXBSBV`:$"PCB^"V#2UWYP7REP44+:'<@>+ M]#MZ@Y?89)/@30XP?V89#M17,B+L$5=$90+3^8!EV'Q(;\=LV_&*9P.\X@'` M(Y[RB>EDP55LLK3!8P`R=QL_$/5QG.5A('8QSW%,9D!$VX2GJ4PH7$"QE/2`;ISV@";NX3K+B4*/$Q&J@`%9PR#"74AA MDAC=LRA`"R,,P$-66<+DRA^"@=B;@/2`!@-<9`\89.B(%2XB20($$`;@88M\ M:EH/&%*_2E$?EQO,#WI`)XK5%T,4EWW5GDX75Z/=4DIZ0(,!<;--AFI/X<39 M9D.^DC``*BU'%C5-6GT5XHRMRF#,[O5]*64_C?GZ%I/!0WJ65W'J50D^*;D! MZ7M!224CPAYQ2BJ?Y4<:[8I'FCZ#&6U-)F#$@"%[=)8I<3`ENP#0UL^`QCE# MHC&,&/(0SK.GATZR[@X-:Z$'"?'MSQ4W3BE M"G$/U5F^Q:EO$;_/#6ALE8L)&#%@R$Z895^AL1-L:I5=$L<])HMU9QCKJ,W(!&EWL"1@P8O-P1 M,JEQ"34:<\:]E0&-+I`O]&_E4_5[V3[5UVYQKH[R5L$JD:O7PD\" MX$/?W/3[Y,>FEZ_R]9\G^=.-2KXW#E82?&R:_O6#FM#P8Y"'_P```/__`P!0 M2P,$%``&``@````A`&4HUR%_!```D1```!D```!X;"]W;W)K&ULE%C;;NHX%'T?:?XARGMS(^2"@*,#N4IGI-%H+L]I,!`UB5&2 MEO;O9SM.P-ZAE/)0R/+RLKVV]X[=Y8_WJE3>2-,6M%ZIIF:H"JESNBOJPTK] MY^_HR5.5MLOJ75;2FJS4#]*J/]:__[8\T^:E/1+2*:!0MROUV'6GA:ZW^9%4 M6:O1$ZFA94^;*NO@L3GH[:DAV:[O5)6Z91B.7F5%K7*%1?.(!MWOBYP$-'^M M2-UQD8:460?S;X_%J1W5JOP1N2IK7EY/3SFM3B#Q7)1%]]&+JDJ5+])#39OL MN81UOYMVEH_:_<-$OBKRAK9TWVD@I_.)3M?LZ[X.2NOEKH`5,-N5ANQ7ZD]S MD9J&JJ^7O4'_%N3<"K^5]DC/<5/L?A4U`;]HSX" M?S;*CNRSU[+[BYX34AR.'81[#BMB"UOL/@+2YN`HR&C6G"GEM(0)P%^E*MC6 M`$>R]_[[7.RZXTJ=.=K<-68FT)5GTG91P215)7]M.UK]QTGF(,5%K$%D!K,? MVBW-\N;FW/F&BCVHP/>@8MF:-Y_;CN<^/A=@]@MR1!77-/S9-T3<0<2_B#SN MBLX=[@,69%VV7C;TK$`6@(?M*6,Y92Y`F$7*@7C?CA2$B/7YR3KU78'=PO9Z M6SO^?*F_P9;(!\YFX(!O%]),IFQO4&Q/Y@33H9!*^"4C&AB6VT_5-@W'D$>) MO]1(I@P\U?0N10>_+Z;#UL2FS[XTG7623?<=>1F;@6+W><`BM9T@P53&P3KA M+8XKCQ4]P(EO<5"`DP/,!);W&N<9%\@+P3?6!Y;7]:@<>\9IV@U@HIZ_B^'/<-YP@. M82#`0(B!"`,Q!A(,I`(@K1/6)*[S?KP9>:7";KJ4)'@?H/5QCK`^#`0<,"VG M+R>FYKF&^#'#)TO6#"<]PB=4Q2(\2BSWL353',,P9A.)1.[A:9D;'-UVW*,XUS!)LQ$'!@M!E5[/!N:X3%XKOTY&YK^EFK M9!"\G$6#6+Y]7=)9)VP4JH\;SA&,PD#`@=$H.%8[ON$+GTM$>^=#3#<=XPX] MPL/%D_XNVLO)A&':MK#33'E"J4PW-->V+6'ZPMM)1X;SA&O!W>D;YO5LV3T7FS=P^`G5M$P4V"UJ]]#)+QC:K^Z' M$R22--`$X@D]F2#LRLBV03\(]X/?`/F%HB+-@6Q)6;9*3E_9[)*$ZP#NLX5=*_M#14W\L M?J8=7`7[GT>X^A,XSQD:D/>4=N,##*Q?_IFP_A\``/__`P!02P,$%``&``@` M```A`+5XJ%`T"0``5RL``!D```!X;"]W;W)K&UL MK)K;;N,X$H;O!YAW,'P_L27'1R09M*WS"8/%[.ZUXRB)T;856$JG^^VG*+)$ M4;\F:\_V3;OSL>JG5"Q2+$IWOW\_'@;?\G.Y+T[W0^MF/!SDIUWQM#^]W`__ M_:?WVV(X**OMZ6E[*$[Y_?!'7@Y_?_CUE[N/XORU?,WS:D`*I_)^^%I5;ZO1 MJ-R]YL=M>5.\Y2=J>2[.QVU%?YY?1N7;.=\^U4['P\@>CV>CXW9_&DJ%U?D2 MC>+Y>;_+G6+W?LQ/E10YYX=M1==?ON[?2E8[[BZ1.V[/7]_??ML5QS>2>-P? M]M6/6G0X..Y6X*YN2&XD+Q3O>3E: MCDCIX>YI3W<@PCXXY\_WPR_6*K,7P]'#71V@_^SSC[+U_T'Y6GSXY_U3LC_E M%&T:)S$"CT7Q59B&3P*1\PB\O7H$_C@/GO+G[?NA^E?Q$>3[E]>*AGM*=R1N M;/7TP\G+'4649&[LJ5#:%0>Z`/IW<-R+U*"(;+_7OQ_[I^KU?CBQ;F[MZ7QA MD?W@,2\K;R\TAX/=>UD5Q_]**TMI215;J="O4K&F+95//"?*DWYU_XOI]':V MF%/_GWC>*D_Z59ZSR[HDV?J6Z9( M!\0'$@`)@41`8B`)D!1(UB9&6.D!>D58A74=5@[&6I&ESD,@#A`7B`?$!Q(` M"8%$0&(@"9`42-8F1L!H_W!%P(2U&3!)9C0@K:1;=I*N,>(X.T!<(!X0'T@` M)`02`8F!)$!2(%F;&#&D:7E%#(6U&4-)*(8^' MT];S!)&CT(PZT(OHTC*3UM56G+4>:OF(`NW8EN]4`Z&V8OD(M6)$B7;4\I;= MV>"EVHKE,T/+'`^QJ6\O$#UQIZ.`)O"J!I@W"^C:DFA1GU34P[-1B'[X"AR% M)GIX7$0>.OJ(`G0,$47H&"-*T#%%E!F.9OS$SOV*^*F-?CM^$MGSNKRTQ];$ MS,:-J,(IV>4YDJH>&Q^="+8U-1U==ES*PG7269L];M<7XS.JSZSJO@)&](AI MI@ST%;*5[&O:V0M'W*R[BAGIKA)&GW:5LI6ZK46GKXS;Z[[,P1(UPA6#I4H* M?=%K<:Q!8S$9\V#=FC'?L$$[]1L?G@TN6]E29M:Y!8_;]9SR&6GA@)&V"AE) MX4EG=QAQL_:(&6G=A)&V2ADIW7%GS1EG$9R;2QIYW8>-RN77Q&6CA@I*U"1DJXL]I'W*P]8D9: M-V&DK5)&2G?1>4IEW%Z[F#$7-<@5,58'B.MY3/26@$CK14RTEH1(ZT5,]):"2.M ME3+26AFCGFP6!<__'U99-E$W',.U)1$E.:,-(YT@CD(32O@FV6#+X2JKF6*BN^,6O9F<49 M*_?,!U%X?39P?Q9O?U=>M;?YLGXS1JY=TJEM/B#'`N0B\A#YB`)$(:((48PH M090BR@QDK#/BJ!?B^H_.46HELW15J'.2TBT#M!5/'0>1B\A#Y",*$(6((D0Q MH@11BB@SD!GMZXI2&XM2A=H'*X@<1"XB#Y&/*$`4(HH0Q8@21"FBS$!F_$1Y MV%X%/B_J;5E-MF<[(YK.S0H\Z:Y#&VVE4U)IM>I\M/(0^8@"1"&B"%&,*$&4 M(LH,9(;TNM+1QM*1D8[,!I&#R$7D(?(1!8A"1!&B&%&"*$64&T"7D:K/Y]VC'F['K9XMJHHKU@I9A!AKA41Z8#I[HTW=A7F`Q4AO MEUQ&^4K1X+M\9- M?L\F/]@YYN>7?),?#N5@5[R+;]5H$7ZX:[#\D&Z]7-$[!7K*=+E%#;1MZVFQ MQ_3M71W3KH\MOLJKYQ.TV-1B]ZI-J*4>TXX/?>+WI=>#.NGO@X3Z>J`.>O5O M2;]>TCH=KV]7]'*^Y\:G*WH'W<-G*WJOVL/G*WI]V,,7*WKOA9S>H:S$&Q)L MH=U*K6T9-4.BSQK?M2YYN MSR_[4SDXY,^42N/ZO=)9?A@I_ZA4`?185/0]8UT+O=('K#E]E#46KT6?BZ+B M/^AR1\TGL0]_`0``__\#`%!+`P04``8`"````"$`99);'@(,``#"/@``&0`` M`'AL+W=OA%U@L9C=O78[3F)T'`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`[H::4[&2]?9$36Q%=@=7K\_KN]GCX,:)52W-^ M>EV;/2"[,6Y]:=D$]<7V1[5&16:\?#9NR`5EENKH1"OD^UUQ/;N=?*>JWCBC MU8!1SDVJWL04L?%<`VF`""`2B`*B@;0QF5""^BQ1S?\_LF3<=%GRT:UZ$N4M M24EOXCO50!H@`H@$HH!H(&U,6$IH!;.4#.]%OCZ,->TZK#SF/-"5M:%]S0=: M`:F!-$`$$`E$`=%`VIBPT*G*+PC=6-.DTW;RQM*P1CDMP,AHP1-4]48^0360 M!H@`(H$H(!I(&Q.6#MI9+TB'L>[2X8-8.7(=YAU(#:0!(H!((`J(!M+&A`5* M=X8+`C76/%!':)N/)GF93')OY/-3`VF`""`2B`*B@;0Q8;%3^5X0N['FL3L2 M33*0&D@#1`"10!00#:2-"0O4:.;XAOCVOF:L>:".=(*NNX-5EBS[\JZ=R;*[ M3>;3++D)-GV[+P&1NI`I4'T?<^LEGQDO*]VW>Y]MY((E@,KS@@08:YX`1ZQX M-+?PRI$\9,`2VN[\U31`!/220!3TTD#:N!<+U,@=%JG1/O/RBM;_VY/>=>1! M.Y13645K^YI/0N6MHEKP*.Z89XER:IQ5F5EEE1?)O5,$-SZCTJ,PF/+HS<%T M,MAL4?`PVN"&!N,I-0KJXZLGE_"HV`E M/0J^E$?!2GL4?+4>=58\9B.1XI@_7$9.6\716\3*J)Q.>?ZKS%F%F:T]"KX: MAUS-9+,BV68$]I$>!<_*H^!9)Y[GBY)?8,OZ\&09414GZYV5YC18&'R56<0* MQ")6(`Z%26UQ04"OK2W"KY:CP8*Q"BG.&93((N%>51_;Z.Q MFHNTHU_5*_.(11MN4B');E]YJS"/M4?!5^.0KY!I.H\"^TB/@F?E4?"L$\]Y MF6QH+>O#*\3(KSA;[U2(4VMA\)4Y&:$4L0JQB%6(0V'N&]>150A826\55PA8 M:6\55TALQ6,VLBN.V53(+#=WHO/3;O-U=:!_TUXYD(J"[@CN$=QIMS@3%B7% MDNP#5>:LPI36#I5Q^V1B>?[W1+JI8\$ M;CE&R<6Y&T@2K;0^2\8\N7=;Q.H%4&T>X$Q5Q8]H`S=J:U5.NS!FRS))M@AN M_)*6'L4%]9'!M.OH!IO/%LD#8^L]V]/%^$`C,^HOSIJIN&QV9:M0$[5#K.2L>RHY4Q.S9>)%>"]A>.E1<*S0L?;(.EX44&UV M8%HW4&U&3?[YO#E-&BY\E5E$Y>7KHO(HU$7M4$DW@7X1#A2A]56:JJ>\Y;-$ MAPKO.0PF/0J#J0\-IKV5&PPJOO6>L0C-<<>;R?SU\/I'^UZTI#LW?$E[%#UN M(JH1-8@$(HE((=*(6H;8+2"_3#EWYDG,3DS3Y/>U44X3:5;YCB$S-:(&D4`D M$2E$&E'+$$]#*J;?WLUSE-`.+)I,,KV@C18(D!U#JA!)!!)1`J11M0RQ&,VDO""F*V"9#%;-*>@HE6?'`]4YE&#Q`M9 MA:D'U*"50"01*40:4DP8I!E@:+H@"K'%"-J$$D$$E$"I%&U#+$ M8S82+X[9*+!\9C3_A>_>C+Q/)*U#254D\K`*5J$JK*\HCPU:"402D4*D$;4, M\0RE&O6=?1'%:&Y1%$V%J$;4(!*()"*%2"-J&>(Q&^F65@7]M.#BFK`2D"T1 MBY*:2%\_Y+U5J`E`#5H)1!*10J01M0RQ_)C'+Y:?MVNB,^,RI;/P398&2LK"( MET66GD0'JU`6?4>/&K02B"0BA4@C:AGB*3)2+]Y-W]DMK#*,-\W"HJ@&*D0U MH@:10"01*40:40PBI$E@Z+DJI(3Y]=QRAI-:(& MD4`D$2E$&E'+$,_096JS0+7I4!1@A:A&U"`2B"0BA4@C:AGB,:=J\YV5@)*R M<(C$0'C02%]=5\'*K_X:48-(()*(%"*-J&6(I^$R25F@I/0HG)]4B&I$#2*! M2")2B#2BEB$>LY%OZ8;P$Y*RL#*0;0>],HQK(CFFK5S':+74B!I$`I%$I!!I M1"U#+#]T?,[S\_;2Z,RYI'0H"K!"5"-J$`E$$I%"I!&U#/&8AR3E3SU\TLO# M5%%ZQ'>*]"`R6/4[!:(&D4`D$2E$&E'+$,_098J27EM`&AR*=@IO%5"-J$$D M$$E$"I%&U#+$8TX5Y3LK`56C>3M(1Q%T`A=O".E!9+`*4]]W]*A!*X%((E*( M-**6(9Z&RU2C>1F3'+]X%.:Y0E0C:A`)1!*10J01M0SQF(=4X\]M"*@:Z454 MER&^(:1GE,'*ET"-J$$D$$E$"I%&U#+$,W29:BQ1-7H45X6S"JA&JP:10"01 M*40:4998EYT;XDO/'DH45%ZQ,LB/:0,5J$L>BGJ48-6`I%$I!!I M1"U#/$67* M$GGE4)R@,DL/+LO>*F0(4(-6`I%$I!!I1"U#+$.SRU1F9\[3X%'8*RI$-:(& MD4`D$2E$&E'+$(]Y2&7^Q).'Z9+4A$>\)M)3RV#5UP2B!I%`)!$I1!J1^3#0 MW?WH(FQ^[(=^]CNL_?;XN*VVS\^GT>;PS7S$1_>@N]L>VR\,5^7BQNQ"Y`): MEM32_=X%6JZII2N7M&4VI0\6NQ]D0$O_*6/:4E(+Z>6A*\BII?NI&/0IJ*7[ M"1RTE-32O8Z$EAFU=!\!0*B% M@;),O[L9&"&G+--/489:*,OT@PULJ9?.9 M-B0<>&76H^&3?M71%\2OZ\?M/];'Q]W+:?2\?:#-B;X;)C5_M-\@VW^^TXG<08VQW8 MGLG,OU^JI+0IBBJQ*.J5^O3AGW_>WYW]<7A\NCT^?#R?7\S. MSPX/-\>OMP_?/Y[_S[^:?VS/SYZ>KQ^^7M\='PX?S_\Z/)W_\].__]N'7\?' MWYY^'`[/9^3AX>GC^8_GYY]7EY=/-S\.]]=/%\>?AP>Z\NWX>'_]3/]\_'[Y M]//QW#^?1P]7C6WP+N_>8N[^^O'WW[_^8^;X_U/Z?G9_7-_`=_\/X_[^]N;Q^'3\]GQ![B[CC=HQ[RYWE^3ITX>OMS2" M$/:SQ\.WC^>?YU=^NSV__/2A#]#_WAY^/67_?_;TX_BK?;S]^A^W#P>*-CVG M\`2^'(^_!5/W-2!J?&E:-_T3^*_'LZ^';]>_WSW_]_%7=[C]_N.9'O>*1A0& M=O7UK^KP=$,1)3<7BU7P='.\HQN@_Y[=WX;4H(A<_]G__77[]?G'Q_/%\F*[ M6A7K[8;WP>?YVZVB3VM'?:4.C:=K?(?V=-K1=:DA_WS:T.8T\9D+(P?B0MQ>; M^6RW#(E@@W(9,ZE/S.KZ^?K3A\?CKS.:[90J3S^O0^V87P6O2,GH8DC2EW*4 MDC-X^1SLSE0/?1ANHA!EH:4AE2&](8TAK2&>(, M\3D10Z(,\3D1 MX:"",R$(SXD8*"TD$P8:K.5`$Z$J MGSUD/=T'(\2G,J0VI#&D-:0SQ!GBS!6HX]D>PA&U(94AO2&-(: MTAGB#/$Y$0,-6MLNB!=A67W^<7OSV_Y(#X\6BI%ZMZ1U+RZ'P8DQ'AH>05X1D) M`^DXQ"%8RSA$DL4A@G46A]1H1O>0S9-"KA8U6^&F&^.J-:3C9B><.[:";0N4A^DM?3G5UU(-PL-QWY<,8Q!<$\*8]%D> MQHAV=*-#-(K%1H1)W>=PB4NFWU7%+5IP25?*U*[*X1:M=J(0A M;B;7DI<\UXSCSCIV0-'Q?*YNSZ?KVY'$"OHMC]LK\S/*/9*M2(9]V-U1M5%E M:J<#%*UV_/PK;@A?=4(IL38SY:6Q35HT8<>=M7*PBHE%6WUY>UXTD8D5=-^$ M`"69F`B#&LS#\+Z:DC0EW\4^[/K"E,F7-%U$2QCQ@*J$1$F)KJBD M9&5]J>IF`U]R*52SJX45]]C9'AV0[%&5,@]?+_4H`QUT91[H5XI04J9Y1"/: M4:KPZK;4FZAYLN*&%5"^NB6K;5^EUTM5*QK;I`5BQQT0.W9`T?%*5S>/ZWT3 M&:`@,R<$*)@K,1E15G'*N4$5$!>.&H@+1P/$5BU07H22>[9RL&)?'L@6H7#J M,6',O;D<IKT+55$DDS-"T^A$[Q,#7,M#<2W7">TVT4Q4VS5;&ML MFQ8HC\^@G*$"G/0\7VW5#/1PT]^-C%80JWFT7@E1U+94K-#Y?I$4L-#)6JF7 ML.),KA+*=3*LHNJ8J\QK;(L6+=AO9ZTAV<\`[. M`26_IC`E)R-I%41L'K57"E/4O&+F1217LT)+ZD6TRO=9"8FT2NYG\=2CV.U, MA(;>4!E;Z[JSKEU"\^1Z.9^I6>U%(YE:04RA[82>J\%Q-*D M!N+IV`"Q50N4R1P@MG)`[,L#C&X[W*$,Z)L;GJXFGC%2=]-J7D$I>K1E@Q:E4)92O?4"T%@V17LYU\L(7 MYV`+Q.X[^,J60*#$-47//XRH7PE3$BD99+[ M(DE6:E5MN"&'="0MDZ\\+2/*>G2X+]FC*M?^M1YE_,C7A.*Y#.9JID=$3XWC M9U"5&M*4@54-Q&-N@-BJ!6+W'1!;.2#VY8'LNKFS3TB*K)4JJF6R$C4G^9KQS=?P/Z,IEJ6>6NV;L3Y' MJD[L(.NS&_QSGVY@LD^UF/O7^I3I%:2U#O7TY3`*=)%U"VKOH,9!6\P&UDD4P?Y(FGZ[`9G)_MT@]G)/GTR&WFM;AGT M^JEP_^OXDTK<:^>"O1M5"N-.@`YC4=A+6#&J+*HM:BQJ+>HL&%%>%`O!B50%Q(JX0H-=/[IM31 M2(L7*P.NG>PVHD9X+^G)`S2:[R`/=%1*JHF)(;K41128B? MG,U MYJC!PWO*AK0HUNI8K43#/`Q#0YZ3!C6V86M19Y&SR`LDPS!-4:^B7,TE`1`/ ML+2HLJBVJ+&HM:BSR%GD!9)C#FHR?_3OJ])1DXI01,3UL5PE(ZZ/54(O[^C9 M`.G16#>M11TW?&%'SP;P[(4;&:4@-O,HG59)JZA-13@2XL&7L&)4`H1 MUH!QT]:B#BCSYD:8!^N]R7%/$\DK*Y(3DB<9:[4_+&'%V5(!\9I;`\7-H'G/ M&B[330PU:+%5:UH+*^ZJ`^*N'-!X5QZ77^I*!C$(T0G)$W6K2)Z(Q&I=K-7( MRE6RXC6T`N*5M@;BU&F`V*H%8E\=$%LY(/;E@486W"`Q\S#TKPZ]Y>VTJRA. M140BHOTF/^MBK8^04T.A`6/#[(RAAA5=&?*&OL!#BY:A(5O9EX3@*\^NH2$* MC8-5S*[9A5HG/:Y;0;C6HOIT(>K-Y4J=T(86V6RTZCBK3%:Y\@/BYU\#B:>P MT0=HL,KWR39RL,HR#HA[=$#QM&QQH>[;X[I-O[66TJ]$+@KD/.=Z#Q_/9<[I M#\J5R2K/.2"N+S60R+F-.EQJ8"7*C'F;$ZRRG`/B'AV0[%&=5GA8O=2C*&SK M('3UC)[\(F3O1>5H5-`R1S=JEI2IHNX"Y5L,JW[`4&[4`-;#B5&N! M\H0T[AVLBO[XEKXF2)8-C^LC"1ED;AZ]5Q(RJ6)^I/MU1%FJE1950-RP!F*5 MT0"Q50N4YU7JD:TYI\YI72+T>P%=>U8J-6H%:6'&/G>W1)83M\H4Z#_+PDO>5*QL9X]<4_=LV MMO0%`'IC"\2/NK2HLJBVJ+&HM:BSR%GD!9*QT+J]UQRK"QK;Q.]36EM)#R0K MJLJ3DJV08)5%M46-1:U%G47.(B^0C!!E^90J%,Q5L4XHSPJ#JK5!M46-1:U% MG47.(B^0'+,6Y._/"JO5UPG)K%`ZI60KSHJA(5!MK1J+6HLZBYQ%7B`9(;K[ M*5D1S%56))1GA4'5VJ#:HL:BUJ+.(F>1%TB,>:.E=1L\@+),<\)G+?F191/N9[BK"9"#-'IH5:_TNVXK08&@+5UJJQJ+6HL\A9 MY`62(9JF9(.L5]4"*$^+9,6HLE:U18U%K46=10L\@+),&BQ^4H8K*@,W^,59P`&6%I4651; MU%C46M19Y"SR`LDQ:U'YRIBM9F:(337"ZA'6C+!VA'4C MS(TP+YF,1Y!V;]_(AGV5GOX)\7>.E;!B5%E46]18U%K46>0L\@+),8])R,E' M'QLK'Q/BJECUBA?>")G:D`':--9-:U''#5]XV80-X-D+-S)* M0=Y-R(RD!OET8;^)2+Y\L-4G0;#BDXH*B#)KF&'V=6I8I;>7J?."!I?YAEH@ M[JH#.MF5@U5Z14$I/X_+]LQD.Z9+W_0U%'U+*4,3DN2ECQJ44%Q`=D M-1`ID2'$]LTZL.*&+1"[[X#8R@&==.]A9<_7MM/$:F^N@A7UJTH^E21E:IB= MPE5`G#=.E=`K;W9*5B06PIJIWT35 MP"\G8`O$775OZLJ=[LK#;]^5S$^MTW5LWW8H3-^.J[4;4*98+*HLJBUJ+&HM MZBQR%GF!9"RT?@^Q6+SG4#A\)E%)6:"\$!<[O:%G*]3YRJ+:HL:BUJ+.(F>1 M%TA&*.CQ":M!DN]<,?;A#:YJ5V=195%M46-1:U%GD;/("R3'/*;HWY<55M73 MYR13.+CR%OJ;7TJVXJP8&@+5UJJQJ+6HL\A9%'YNA9]Z-7@:Q M5^AW=3Z/WAG]WDZ_*.G(T%!&[6D@8^/X7%Q]ID2R'>]I?*/#H]&-#XY&,.8G M1'V,+RE5Z.V$MF=ZK^%5'3?$:G#T7L$K-WJ%WH]';<;ZI_?649NQ*]5F>U73 MEMC>`6VNK]SHE?V:[II>C;%M]NL=7>G75G77^\V,0M"O].8*/44ZT+;>*KJU ML5XZNK$Q7NVNZK&^N]T5?2/[B/]B?A4^A&FOT"$X?R/YR M?*:?72)-3;^D0[^S=:#O`)Z%EW^_'8_/^$?H8/CEKD__+P````#__P,`4$L# M!!0`!@`(````(0!EIE._,AH``%Z+```9````>&PO=V]R:W-H965TV;KZHDDRU)5XE2I1$<9[=CI*X.HY2 MMOOT.?]^-D@N;0`+HU@]_CQ^>'[_L?NX_F_=Z_G__7I/__C MPU_[ES]>O^UV;V?BX7KX_?=L\/KQ?[G[L?4O)E__+\\";_ M^?+U\O7GR^[AWY\C[OGAY<__OSYC\?]\T]Q\?O3]Z>W?S=.S\^> M'\?9UQ_[EX??O\MU_ZLW?'B$[^8_R/WST^/+_G7_Y>U"W%VV#>5KOKN\NQ1/ MGSY\?I(K,-U^]K+[\O'\M]ZXOKX^O_STH>F@^FGWUZOU][/7;_N_DI>GS_.G M'SOI;8F3B<#O^_T?1II]-DB,+\DZ;B)0OIQ]WGUY^//[VWK_5[I[^OKM3<(] MDBLR%S;^_._I[O51>E3<7/1'QM/C_KLT0/[_[/G)#`WID8=_?3SO2\5/G]^^ M?3P?7%^,;JX&/9&?_;Y[?8N?C,OSL\<_7]_VS__=BGJ=J];)H',B?W9.^G<7 MMZ/1\/KV1KPSAX";_YR:DL1^IX&XKVCIH=0F+^@WIX.VR-=VT,L>MJY[ZVVC\XU?^FJ M/=Y!_0@,>N1\3PE$A&)B21$4B(9D9S(C,B<2$%D061)I"2R(K(FLB%2$=D2 MJ6UR*8$_1%\"_O\1?>.FB3ZB=G\@.AZ\T3`Y2&`T)1(1B8DD1%(B&9&?PK3>' M#Z+#%"82$8F))$12(AF1G,B,R)Q(061!9$FD)+(BLB:R(5(1V1*I;>*$6Q94 M)]S'-U!&[<:T)?9\)3(E$A&)B21$4B(9D9S(C,B<2$%D061)I"2R(K(FLB%2 M$=D2J6WB!-`DMTZ(8"-W0P@D55CWUCMO7JKJ,#$918QB1@FCE%'&*&YH3;)#'MM/CY93;;3FZU`UD:8T911Q"AF ME#!*&66,PJ/KJ[\*7Q0Z10F%*DOJ&)&":.44<8H9S1C-&=4,%HP6C(J&:T8 MK1EM&%6,MHQJ![FA-IF,$T+=)3[L4'?(GL*$IN;90SL@$,2(4N)G5AQ[5]F'!AGO2]?7MZ_.-^ M+_=669`#2_9`GAETCQ+:!(@DJ!"U>_-^?\+_H'72A,M'?BSG.OWC+FS+5[:WET M*-:3;H9U^3&:K]:_,D/#0Z[="VAT9G>+;(">WH2D=2,]0F)N/J MA[;S96)SZ)C1%843,CN<8*ZI/F1Q+]<S+_<7P;4]*SC6VR`LA[8\[E1W" MSI>)BW6-WD.$R#Q];::X'4JPZR;Z>DAVK\V<"DZXMO80X5Q;A^R[":&IV5>8 M%JHJ8A0S2ABEC#)&.:,9HSFC@M&"T9)1R6C%:,UHPZABM&54.\B)JWGX<$)< M&[F$QUIV@"1PULCSEUQ5X7XS910QBADEC%)&&:.TIW*+1X+`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`6N,<2-M5`&EN<@&DJB60^BJ!5+4"4E]K(%5M@-17!:2J+9#Z MJH$:E3M&3&[OA#'2I0+M,=*B&[N71WUOIS7IMRII"'IY"J2^(J!N0GL'DAC% M:I$`J=\4Z!=K1]<@K!W]H?U,P,]$Y^H4[9\!:=5SH*-5%U"U5?&T=_:739>W#1( MA[P5R#O#3SJ5O0(!:?XD`I*#S6$%&O6]SH^A<0Z(R>`6EE=B:HPS:<=&NBSTPCHIHGA]8TW M'&-XT=F4`.F<2X&.+A895%BGKKTFYQ!H93,@K6P.=+2R`JK#RN1=V0("K6P) MI)650*I:`;6>;RZ\^\,:Y6JR`5+'%=#1J]A"U=9U[4W=&L5-5>[@,SE7^V;H M#[YJ_U.6IU\]*#4;#N^0W"&I&N-JPF@*I),G`M+)$P.I*@%2]RF0JC(@]94# MJ6H&I+[F0*HJ@-37`DA52R#U50*I:@6DOM9`JMH`J:\*2%5;(/55`S4J-]XF M,VK'^_B)>-`F4NT3<8>L;@KTB]U%YPN[ M"[Y;4&4S>-;*YD#:I`)()]8"2%5+(/55`JEJ!:2^UD"JV@"IKPI(55L@]54# M-2IW8/A)T%],>,YV#EKDG7;\$W&GLI:%*9".Z0A(3B*'0<8G8JC4,`'2*9," M';TS9E`=K3&'2FN<`6F-Y>MHJ!K(FWXYET*FM+,`72X1T!=1/:?ZDW M1KF:)$`Z;U*@7RP>;;OE?MF];G=X([#)X.3J!0O5#$CKF@,=K:N`"G7Y><(% M!'IA2R"MK`12U0I(%X0UD*HV0.JK`E+5%DA]U4"-RATX,O><@>/O'M_U$NC` M>/'.P"WRUAQO:S[I#)TUIS4<:O.C3C5T,WI^H@6^Q/ZP,O5[WD8Z@4HG7PKD M&GI'E@PJG&E&WM//'`*=5#,@K6P.I*H"2&?Z`DA52R#U50*I:@6DOM9`JMH` MJ:\*2%5;(/55`S4J=R#Y>=N_-Y`XG3OH$J+NKL;K_(FJ,,VG'1KJ*XI1AV[: M,_#`3V/$\**S*0'2.9<"'5TL,JBP6-QY(S&'0"N;`6EEO80M56]/0N_74*&ZJ>R8K: M-S]_Z+WS!-PF5YV34HNLY6DR(#0%TJD3`>G4B8%4E0#I-$R!5)4!J:\<2%4S M(/4U!U)5`:2^%D"J6@*IKQ)(52L@];4&4M4&2'U50*K:`JFO&JA1.?$>RC@Z M&N]WW;,:+^X]JT/>`ZI>;.2YC&<*(3)P'2B9,"'9TX M&53MQ!E,*Z.A5;*%JZ_)V$C5*FYK.BY2%29_S+X21JD:6@O.E;=SSU0% M][GCR^V9TU*00TY!=LCIF59EH6FG\GK&.PE$JD+38W:?,$K5T.H9_QWL3%5P MGSN^W)[Q$V_^V>-]>U'.QPU;9/7.A-&T0_8;JHQB-DP8I6IH]X[7^9FJM'?L MIKJ]8W(Y)\RH-O7CS*@.Z0YO,B0T[9`<&="HB%',A@FCE`TS1KECZ%ZSGPCY MQ2K"&0]YX]2L(G+JM`(Q\+;#$U7AFJ=`>K"*@-JLU<#_%\PQRM4D`=(36PHD M/7_8P_";C5"U=?4N>@/G'SY[!X4<\L`!SS_0_Z(+^>`^;)'W!HXWEB>=RLYF M`^DV+`+J3CR4S4:YFB1`.FI3('L;&.C"MMV';+:?8<[5C43=&7?R#^E/F6N- MW#V"=,A-V0Z\D^ND4UDYD2F0#J((2*[G,&)&`R^G&D/ECBMOH"1060,2R#7T MW&=084#V/4$.`0_!T:\.>N]:UQLO7B>WYSQW9`Z\=-VD,[1')I#U;AB0[#JL M3O9.LS%4[LBC3F[;9=68A@V]/LR@:J>'_$+!G?-.HK>MR2'GL_7(/VO]K5MI MX\7K\O8-B>-&ID`#9P[=K MT2^&;Z?"\+WR1DD.SX'AZY];_+Y\7TI4=A_^>0;(.KM,`FP:8%&`Q0&6!%@: M8%F`Y0$V"[!Y@!4!M@BP98"5`;8*L'6`;0*L"K!M@-4N<^\(IYUG1GR>`7)7 M<6_IF*@*TV3**&(4,TH8I8PR1CFC&:,YHX+1@M&24/J=#&K$)5(JFC")& M,:.$4E@\8<3X`2/(B MUCY_Z.VL)YW,VIA-8>EF$KQC<*0J3/Z8?26,4C6TVD691E7!?=S!DW_AL9$?SKP29F7PFC5`WMKO&VE9FJT#4Y^YHQ MFJOA$?>%JN!^P;Z6C$HUM-P/O6/Q2E5POV9?&T:5&EKN_>^0;%4%][7CRQDW MUZ>EAAJY.VZ`[''3,7O<0*8C(F(4LV'"*%5#JQ]Z7C8J4Q7Z(6=?,T9S-;3= M>_NB0E5POV!?2T8E&ZX8K=EPPZA2PR--W:H*3:T=7^Z(\--;Q_>5\GS!7TF` MG!'1RIP1T5G:(X)0W#FS#!-&*:IT5R4O+YZI"OV0LZ\9HSD;%HP6;+AD5++A MBM&:#3>,*C;<,JH=0S?6)HUDWS7\7-"[4IG7;3+*"O<]D'P,$ET]Z9@5R6F' MY/T]J")&,1LFC%(UM*;"D!:%MJU6C3G[FC&:JWLTM6"T8,,EHY(-5XS6;+AA M5+'AEE'M&+I#P$\'_F*Z<]KOND/Z5O:$T13H2L\;48#%8.HM890"6=ZR`,O! MU-N,T1S(\E8$V`),O2T9E4"6MU6`K<'4VX91!61YVP98#=9X]7'N,:N4UXN3SM!^E@>D.'/[QP"M9D!J>K[W$ MR!K%:K$!4K\5T-&+V$*%B_"_UF1^>=V,!/ELE"P1[9!J?TF]_77DY]W+U]UD M]_W[Z]GC_D_S*^D]^8#YIP\'WOZ&^_UH.#8/4<0'E8RDI/E-5"JYEI+F"3"5 MW$A)TR*_I'\U-M]/#M33EY^1ER_P!DJ&4B(O(H=*^E+2W/+]>H8#*6E>"/!+ M1E(BCP8#WN[&\L-,`=Z3-LOO^(1*I&7MCSGXM?2D9?+#(2$;J5]^!B!4(@V0 MSXASR6^]\6]A7V(0T-]+Y4&]5!VJ^;?A^#<91USQO8R*\*"0/@SI940$_42 MV7B.S4:32R3).3:'$RZ17.?8G%&X1%*>8Y/0#)7<24DHZ)+Z4D M%'@Y#DE)J`62^1V;XQFW0!+`8W-*XQ+)`X]-EC=4D=Z--1J.?E+ M2:C5GXQ-^H)+Y#'*V#PD"97<24FHU5-IM]R=O>8_,N=ZAD)"6A]4O>])62D#=Y!7R< M!TOD%=NQ>:`N5W(NW^Z`W>2M^;%YG9F_R>3E<2D+7(V]! M2TG(F[PQ/S9O/W,]\CUSN7L$O?7%FWRXE&WDPZYC\R57+I'/M([-=UFY1#ZZ M.C9?6>42^83JV'PSE4OD4^YC\WE=+I$ONH_-5W:Y1#[L+MY"8T>^W2TEH35> MOM@L):&^EL_V2DFH'OF*_=A\69A;(!^S'YL/#'.)?-->^B#4-OELN92$VB8? MJY:24-ODB\52$JI'/N`_-E]0YA;(=_S'YD/*7"*?\Y?(A=HF7VR7DE#;Y#O= M4A)JFWR964I"]R\,>\_73AY\/7W?%P\O7IQ^O9]]W7V1??]7\/-G+TU>3Q&[_XZW[ MOMGO^[>W_;-L_<_/ONT>/N_D=\>NS&\`?]GOW_`?&ULE%1=;]L@%'V?M/^`>*^QG8\V5IPJ796MTBI- MTSZ>"<8VBC$6D*3]][N`XR1-M64OML'GGG//Y5[F]R^R03NNC5!MCI,HQHBW M3!6BK7+\\\?JY@XC8VE;T$:U/,>OW.#[Q<P*&G*^L>'WDAD%!@29*)XZ)J082@">2PG4&%(2^^/=>%+;.<7J+ MT9H;NQ*."B.V-5;)W^%GTE.$X+0/AGJ26+N9: M[1'T"DB:CKK.2S(@?M\(.'#8I0,#<(P1)&N@^KO%9#R;DQV4C/6@AQYT@DD' M!`'501KDKI=V8"_MBNJ2>>AW3G1&[^N,_D?'@7,,SZ/#23SP!N6`&?M..34$ M=;G>D`.#(3C^H])%+7L06#V")LF0SEDYH0>N5W=@KSZ4L]])+UQ-SWE=RZ?3 MNPCP?V\6%WI*M`8UO`3*.+H%+SH,&PO=V]R:W-H965T[Y]V+YOWUW]O]M?__/"?__'N^^[UC_V7S>9P11Y>]N^OOQP.7U>W MM_N'+YOG^_W-[NOFA:Y\VKT^WQ_H/U\_W^Z_OF[N'X=&ST^WT\ED?OM\OWVY M=AY6K^?XV'WZM'W85+N';\^;EX-S\KIYNC_0_>^_;+_NX>WYX1QWS_>O?WS[ M^H^'W?-7-Y_>7_^6K?IE=GW[X=T0H/_; M;K[OO?]_M?^R^]Z^;A__M7W94+3I.=DG\'&W^\.:FD>+J/&M:MT,3^"_7Z\> M-Y_NOST=_F?WO=ML/W\YT.,N:$1V8*O'OZO-_H$B2FYNIH7U]+![HAN@_[UZ MWEII4$3N_QK^?M\^'KZ\O\[SFVPVF9/UU4?=!?^)C?%(M)GEW@)&=9-.;V;18+`+;'*7+P@=:3CGAO27&\[.:K?@=O27VTV7YXV1INMPJ_276Q9G]7C' M[>CO94/,2(E.&%:2[JD?'>2M$]:@T^K^ON^Q5-?M+._NN]3279RGJ% M0EU\1\W^2+*D5>OE-^N&7-!#)CWN::+]^:$H\G>W?]+D>&"C=<)H&IJ4HXF= M"]9SI4BM2*-(JTBGB%&D]\DM!6B,$LV=7Q$EZV:($D:W'HG$+8I:.9J@4:5( MK4BC2*M(IXA1I/=)$!+*!$%(TBD-^K#6E+P">,=!2D4J16I%& MD5:13A&C2.^38.BD\@N&;JWIH5-6.3(UG-&4)J!G5(0!*D,+PF&MAW!@$&M':.P@I2*5(K4BC2*M(ITB1I'>)\%`:4$) M!FISY3R_D>7H['1I/85!8$(K@2>`>22`T0B1JA2I%6D4:17I%#&*]#X)XD+2 M#N)R/!58ZW#L3.Y$`(I4BM2*-(JTBG2*&$5ZGP0#M66YOU@>'ZBU#@?*))>! M.C*EN34^]NQN&3[V*F%4%(O1*+A%$M`%MVBMPUMDXCT+12I%:D4:15I%.D6, M(KU/@H':8N6"D0[FX5"!O+%J5#&:D2C&1Y3/H[6K%BM,S4:C5J-.(Z-1SR@; M;C4,@ZU9?$VZ`FY(2H'D=MJV4*US!2J M@*8VTG]^F$ZRJ-ZM/0O$H0$3WZU&'9#XSL:,,#Q4XUG`=P\V^`Z%9,L=/U0) MP="&<50,5T=^3!C)?9>90A6C&26U43&SJ9I/KB%9X=8;[:O5J#O+O1$KN.\# M7V%D;.5S061 M9BK-N(:SB9MM&9UPA*X;\8,0MT#26P=TM#?#5NBMF&?1SJT7/]1;&$M;2_FQ M?%O6YHI,GN@Z8S2E9"0AGD_".)1L1H)$'"I&L^F(:D;SY1#/^?(NJD<;N)$; M:('$XMENQ4%^E1A7041'4;`41 M+*>3:%8WX@>A;H%\R?$]'>W-A+WE>3:+\F8/U^Y8TC_"R&P5>4'<7-%)_G#; MZ\'#D,6`2HTJ(&E8`TF::8#$J@7RE>-N8BI6!E;BJP<:K,)I9JO'"\;,Q:9T MMZ::8M"*_UQHIL?3B:WD@5;2$,&J@62&-4"R]VV!Q%<')%8&2'SU0/K1VV.% M"\(PF(>E,E"85E3F9C,_K0"1OL=\I#,WK"B.HU4QC[,WK$)?T?+1PLK3$5#8 M,%H^#*SNAG2WF$77>US7.K,+VB4!YCK:T]G@@6(>+HTJ;[.9OS0"B3AJH.DP M$+4(XK*T:($\T0&)E0%R?HM9]'QZ7$\HT-;&_D1\TWIGU1=M5X%"8JH#\-)B8Q>R+AC[&C]:H,%DV:5\J?NJ^NG3# M:)8:MN(5.9LNY:!DV!;UXD9%\[)"WY[:Q'(<"WUD_9*M/"%40#+_:R!9UAH@ ML6J!_-3&/8J5@97XZH$&JU!!MF;V9^8)!7$)+]VM[:>(MISRM5',H\=2PDHR M3`4D&:8&"A44^6I@Y?E[O$HNC<+T@DHU6>Q;M$N/=O(I'2^%;E)KJS;L+`RJ8:.H?,"U6Z MC4&(%T4[@X[&_??=5YIZIU+;X":#1*U3E"M4:-1JU&G4:&8WZ`(5COJS2SEWYZN<9('FHI485 MHQ,?-XD5IDZC4:M1IY'1J&=$)PHJ&]ARTW_T;\K"N2M:@^@P\J.C4,4-3WS< M)%82'>?+_[A)6W4:&8UZ1JGHV)+SYZ/C"M<@.HPD\9>Y0A40[7!^\'&39R&A M48Y:F$EW'9#XC@[!C&TV:K9"OOI8AE_]MV('[AN@:2W#NAH;R;JC;Y=&LFL%S_4 M6QC+RZKB7%?%0/;`16*I3N'8C&I5#+@"$AW4C'A7M)BJXTS=I@42SQV0>#:1 MY_DB.F+I@S9AC&R=Y^OM;?G;58N!#!F%,E0'<;DS"V3(2#9&-5O-%T,>RY>S M:&_?P(T<';1`ON249Q-ZGA>%DA>WT9LNF@&_('2#E[`88N3)J=2H8F13R2A- MO=M@J[G;XD_G=XMH/C=P+7IJ@3S5G=6;"7O+I_DL.ICHX5IG/IH7Q\-YWKYB M7P7H MS#HNJ!E%BV$T;4I8R8.N@$0.-9`L8`V06+5`XJL#$BL#)+YZH(0D+JNQ[3E] MM*\`"K.06@S9+)"#FE[,B5=L"*YM,H@@W\"Q*:(%\O9S3F>&&/^RL MA^>$H&RYZPOJ36G>GFS$`69T8H7DEEY*JQC1T\>B60.YY M\.RK4/7?G=69@=6/.NN#SH)BPV[3C@;SS!2O:__!<_A5!(TJ('D,-9#DHP9( MK%H@7V7C;@/R-;`27SU00EB7%?IV_Q]//:[@_0Q%/^,*/UTKN:&GLPI(U%`# MR9QI@,2J!?(SUW@3$@9&XJM'PT1BNJQ&M]\2C,/`*,Q`.L4[LR`#,:+[/3:Y MV(KJP-%*?23;\(W1>HLXM$"^:,[IT:"AJ]F*N)C'Y82F;*WZ\\G*5;Q^,3]C M%"ZC:A_$9H'67$LZ0$)<:ECY.2T14&[HRX^1+S_EWISEOH>55F3Q2\KZP4M8 MAC+R%%AJ5#$Z4=;#RI>NCB'<>Z($\D0)7TD9A7;^(-JTE MK.0I5T"BA1I(UJL&2*Q:(/'5`8F5`1)?/5!"$K;<]?/4\>U-X:IC/R$!A0E) M)7TV"^1P3JE=3/-K'-O`L2FB!?+VM' M\DUU?>$JYB#`C,)5565\;NGEM(J17]<#\3%T_#VQ!EY$3RV0KSIW2YYC$SG. MH[.-'EX2$K3E[\\'SA710>!475T6"E6,3M3UL.)/::>+Z#"[@6=?A:JS#FXH M?F,%HTZ*#*RXLRR/ZXZ@LZ"N+WY-73^XB5(\5]DB@Y*M`LFI6KR&E>2C!LA7 MF7+?:2L#)+YZH(2P;/7K"^M$;G/%&YPA9M5`4CKZ8'!'Y[7%9 M"W#^2\KXP4N8DAAY^:?4J&)THHQG*SZ=IU>91+OW!IX]$0*)X+NS.C-19UE\ MO-;#LTYJ\U]3PP]NHFBZ&IX."+`_+-G*0Y5&M4:-1JU&G49&HSY`P82<7U;# M#^;1F+FL%YF7;&6_EBLI:Q*5]57*JEC(85]XGY<5V7-=9#/R'D2I4:51K5&C M4:M1IY'1J`]0.&9;(OK)\OCB.W<5I9\5@62M+S6J&-ECK?%QZ=^`BQ6TW6C4 M:M1I9#3J&26^=C*W-:`?AC>M&8.72+FNN'1=#M^>+V$E`:L8V;-/+SI1;5Z+ ME43'N:>&0*VVZC0R&O6,4M&Q1=_/1\>5CH%V&,F*5LX5JH#DBS-1:5=[%HA# M`R:^6XTZ(/$=I1#C63+3+]4)V83ZXF#6+B4'1>$6TM2OI@WQ[K M>FMJ!20+0PTD4FN`Q*H%\M?'\28P9@,K\=4#)98_6_==$`97)@9A8!066_%G M\27]LM;&P3^O`/)/^=7FK68KG%<4$[7'%C^(00LDFNJ`CO9FHM[N9NI;$^*' M>@LE92O!"V+I"L<@EHS"C4%<&I945"E-,1*UU+!RNX"[^)><#:Y+DQ;(%YAR M;&#%CN,?W?6XKM6VB"O7XY-N,`_3-%"DMOA;Q6SFJPU(ZO2:$3YU7L:O*6AT MFQ;(4Q:0>#:AYZG^_6#0)E#1XE1!>M9;3@8O4>A9-]M@/A`+8\/#.$E(:ZX>GU3:;#0!].,/#&5 M&E6,3IQ[P8J/HA(_HH=K45,+Y&O.W>;QWDS86^I']'"M=YF+N,B.PWG>)]J# MFTB(KA[W%%:RE8VC(\R>[A.2.J7E.H+7:H#G5HA74LOJ573H<'F;QL4`/-PDMVL+7+[;B]'3>,NG*9[\&L[]>"POV M4J.*T8E#,+:B@LB.+RE'5;^WNK?NK-Y,U%MVYYV?N-^#PW5"CO$^(`[GF=E> M[P\6#M&6'DFGU*C2J-:HT:C5J-/(:-0'**S`;,GK2^M$FG,55DT/YN%*S,A_-AI5&M4:-1JU&G4:&8WZ`(5C M3E7']EL)%[[$F=Z$/BQ$L@RL&=FSIS'7%7K:7SWLOMEWK@\+XHC="^'7B^7*S@(: M1WQE.:%WQ0\Y5UT9WR(?7UF0LY2ONQ6]V#+11TY]N$HD]I13'VY=4E>F=&4H M5>(K>4)_KAW*JFGZII7_2SMY7] M89N^LI[/5FLZ=-17Z`!Y98])]14Z1Z;@)N]@3OTDV]"Q+PTGY6T]I_'0V7BB MGRQ?U?0^0WV%7H^XLB\_U%?6%)UU,CKT*]55F;Q"/U:EZ*2\T0\UZ4IJI.ML MLK+O%M5W4-*5,GF%WL%*=YV:>O3^4;J2\D:O3"5=IJ[06SDI.BEITCLUR=MP MY7:<2_3/,7R]_[SYK_O7S]N7_=73YA.ECLGP?M57]P\ZN/\X\,_@/^X.]"\Q MT))"[]*G?WAC0Z\&G=Q0Y?QIMSO@/VCPM^,_Y?'AWP(```#__P,`4$L#!!0` M!@`(````(0#54>T*=@(``.$%```9````>&PO=V]R:W-H965T":U:I%C+6KK70$J)$NECV6C#US7Z?HDG7!RXP^&,7DEAM-6%BY". M=86>>[YA-PR9EHM^IC[$":SL^R',(!OAN10\&WMONO=%Y!EY7#:4S3D?:7YZSU8 M@0U%FBB9>B:A:RP`GT1)?S.P(?PEHPD*R]Q5&1W/HNGU:!PCG*S!N@?I*2D1 M6^NT^MV!XE!4QQ5*N^>.+Q=&[PB.&]&VY?[RQ"D2OUT+%N&Q*P]&X(02U+'8 MP.?E=!XOV#.Z%GO0W1XTP"0]@J%J+XURETM[<)#V??'%W.TC`YWQVSKC8QW? M]C$.[WVK/@EQ`_;I_*^/KH(.,PG]'1K#_@R-><%DYF?Z'TV?AQZOCT1/V[L' MH?O!#/[A'!6'A;SOV(.#>M_A?20Y,S@[Y@T&Y_$%#GWBL<8^@I=F8&=R,LAN MI;I[J\"4\`GJVA*AMWY=$KR(?;3?Y%4H^S0^25=APUG_`3>LY24\<5/*QI(: M"J0<1==HWG0[VAV<;K%RW#/M<+?":X6_4L"K.(H07&CM#@?_%^A_SLL_```` M__\#`%!+`P04``8`"````"$`&\C;<)H%``"=%0``&0```'AL+W=O5Z8QLTR"7 MG.Z+RW%E_OE'^&UN&G637?;9F5[(ROPDM?E]_?-/RW=:O=0G0AH#%"[URCPU MS=6WK#H_D3*K1_1*+O#F0*LR:^!G=;3J:T6R?=NH/%NN;4^M,BLN)E?PJWLT MZ.%0Y"2@^6M)+@T7J<@Y:V#\]:FXUE*MS.^1*[/JY?7Z+:?E%22>BW/1?+:B MIE'F?G*\T"I[/H/?'XZ7Y5*[_8'DRR*O:$T/S0CD+#Y0[//"6EB@M%[N"_"` MA=VHR&%E/CE^ZGBFM5ZV`?JK(.^U\K]1G^A[5!7[7XH+@6C#/+$9>*;TA9DF M>X:@L85:A^T,_%89>W+(7L_-[_0])L7QU,!T3\`CYIB__PQ(G4-$06;D3IA2 M3L\P`/AKE`5+#8A(]M$^WXM]Z(Q/&7CT7PR\:;SV?TC`,O6#W@*$>]QD:D0@6;3JBQ&T0DLY$-@H0V2$2(A(A$B.2()*J1`O)>!"2VSN4S`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`<+KV>VHUJH+-AEV$W[#>N#]^-6&?#9\<-/O&A2K_!ISY4L,"M;J1P.7;-CN37K#H6E]HX MDP,$RVX7><6OU_B/AEXAB'#)11NX%6O_/<$U*($K"'L$M=^!TD;^8!UT%ZOK M?P```/__`P!02P,$%``&``@````A`.I&A#/$"```=B8``!D```!X;"]W;W)K M&ULK)I=;^.Z$8;O"_0_&+X_MB794B(D.5A;WVB! MHCAMKQ5;B86U+<-2-KO_OD.1(W(XBH^-]F:U>31\Q1D.R1&MI]]_'@^3']6E MK9O3\]29+::3ZK1M=O7I_7GZKS^2WQZFD[8K3[ORT)RJY^FOJIW^_O+7OSQ] M-I?O[;ZJN@DHG-KGZ;[KSN%\WF[WU;%L9\VY.L&=M^9R+#OX\_(^;\^7JMSU MC8Z'N;M8^/-C69^F4B&\W*+1O+W5VRIJMA_'ZM1)D4MU*#OH?[NOSRVJ';>W MR!W+R_>/\V_;YG@&B=?Z4'>_>M'IY+@-\_=3[SX_QQ#DHO3[L:/!!AGURJM^?I-RND'X%_7":[ZJW\.'3_ M;#ZSJG[?=S#<*_!(.!;N?D55NX6(@LS,70FE;7.`#L"_DV,M4@,B4O[LKY_U MKML_3]WE+'`6CUX`*J]5VR6UD)Q.MA]MUQS_(XT<)25%7"4"5R7B^;-5L/`< M>.:M(IX2@2N*N+HG5YZ^5`WAJAKZLZ6["A[ZIU]I"'WK?8>K:N@\WM;25RWA MJEJN;FL8J(9PO<])F*]]7^%ZGY./JB%<[W32@624N2&R4H[[=3?G,KGZ7(W* MKGQYNC2?$U@`('W:0O:(`V@Q$&*&(D9B1A)&4D8R1GI#`)"0$0UCWX4`GUI+X M2SWNC$2,Q(PDC*2,9(SDC!0F(8["GD(<%6NENYJ!_9VKI1"B,5`$M@)C_!UK M_`?D8B1F)&$D921 MC)&_-1#EV9P(()1H$16@"V+OC8#0D`",Q(PDC*2,9(SDC MA4E(7*#3)"[7$T!84]\5,1*`D8B1F)&$D921C)&OM]_7#70;!GPD)3QX+5!O M"ZJT,J,C$8D.0Y$CD0\/,**SLJ,S6.GH,)1J+;3*.,HY*A0:BXZHD?[WZ,A* M"RI&[-A:O%C!HFE.%YM$RL9W^[L#5`W8;HI(YEN)M[J0-,D2XPZ3?0B#X[`P M2"M/GI3)0P:%8'\?&KH.6U>4%:S:@Y7G6F]IB>J$1[6LE]T4K70G,D2TH=6) M7%DM%W*:>PMKFA=:!C*/!EA4<&:`^Q<87QP_CJW7YCQ4M9\9:XD"$@S?>J_= M.-**I)Q"6BM&*S)?':LJ2M!*-TP1F5G(Y'.T(O*^-2(%6L$@#Z/K.MJ*AA*T M6"B=U;W[H%"Q"D2)2`I[@95C&T=:D1162)<7,5K!5C%XY/&PJH;]:7:_/Z?8 MT$Q.)I^C%9$/K-VA0"N:U5^$U04K%E;WE@SM6])0*N2113&PILM&69D9BHAF M@C418[2"P.CHLM4`K:B6=E\&'*V,/$9$&UJ=R-&*="*P9DZ!5E1+=X*DMFM7 M]_TJ(9K>7-_U$M9@R)<`*Z^MNG:C&IIYC7ESO7A%<^48`:SB6#6N%R$+KN-8TVR@K MDL92RX-=?TA0OJFIAIZ9&YYKK>,)RIM6YN*HTE@^T>A$AO)7.Y&CE2GO>9:/ MQ9]U@J:QJ/BOC<M$-M[0ZD2.5J03?'<9 M=4AW@HZ!>`=A8W#?[B(DK-U%(K)&>@';7:0524^)EGH:Q:Y$_L.7NXN2,9.5 M*6=*QE#.J?+8[F(JT[!!A%C8[M]=A(H5.8E(&CLN2V-I1=)8HB7,R2%!1W87 M)0^7P6ID=U'R?Y+&RLI<&"6ZWHD<%@SA=@`7W0F^NRCYKSHAQT-^[B%_0C]6 ME_=J4QT.[63;?(A/.6"'>GD:L/S.9!V$\),";._`24@8P[D#OP/'&*$XI.!WX+N8;_UTL/LK'C)BOW;A.YHQ M[H7P$^J(_A+T1P.R#.%'1MY@O0KA-[D1[H?PH]0(=]QP#8=T_,X&[FQ&[\"Y M*X1CS`TXWNM3 M.SE4;Y!*B_Y=\B*_&Y)_=*IB>6TZ^-ZG+U[V\'U7!9])+,2OD&]-T^$?X/Q\ M^&+LY;\```#__P,`4$L#!!0`!@`(````(0`#:K=@F@<``%(B```9````>&PO M=V]R:W-H965TBHNV>/P6U8-?WGZ^:>' MMZ+\7!VSK!Z0A4OU.#S6]74S'E?[8W9.JU%QS2YTY[DHSVE-OY8OX^I:9NFA M43J?QNYDLAB?T_PRE!8VY??8*)Z?\WWF%?O7*K9WW MWV/NG):?7Z\?]L7Y2B8^Y:>\_M88'0[.^TW\SDX9,_IZZG^ MHWB+LOSE6%.ZY^21<&QS^.9EU9XB2F9&C^7(R=4A\\"FKZB`7)H>#_6M5%^=_I)`C)M4:<941NO88N:$X58IT M945GM)K/9XO5DH:_H3E3FG15FHO1S)TO5\V\;RB2V<9ANBI%U_D^S872I*O2 M7'W?7)=*D:YW>DFKM)DL7>_S9K. MU@_C+[0L]DIHVR/DFB*[5D24KK#L`?&!!$!"(!&0&$C2)6,*4!LE6C3_1Y2$ MF29*[-VV)9VX62%I15C)`^(#"8"$0"(@,9"D2XR0T'8`(9E2`?5O:EPG0HNV MKVZ9S">FPULI0QLD.[P#X@'Q@01`0B`1D!A(TB5&"*C:C1#<=EU(4_)I@[FQ M1*30@H;40G/'#-"N%>(`>4!\(`&0$$@$)`:2=(D1#MJM[PB'D&["P4YL)5G, M=-Z!>$!\(`&0$$@$)`:2=(GA*#U<#$?%GNG.1R1_YZXI#)DQ4(0>"9W\VYMD M*\2A\X#X0`(@(9`(2`PDZ1(C+%391EAN+PDDW\@'A`?2``D!!(!B8$D76(X*OHDPU.Q`4Q7HGF_=P=H M3)EA4(CVP>X>,+-J0$NU18#(1Q0@"A%%B&)$B8',$(E6JKM&;A>#HSJO9;OV MMPIU'P>(/$0^H@!1B"A"%"-*#&3Z+'JEKL^REQZ)MZ3ZF.\_;PNJ$_*T)Q93 M:IE5)ZTZKFXH).HL#$<2=]'&RU-H+@;C%MQ=65N'KZ6X;`*T%2**M&+7O%65 ML99B\XEARXR7:*RZ\>J)"RVI-C"J#^L&1B'YIBM>%W8.($^AV:H-EH\H0,40 M482*,:+$4#1]%MW3'3[+9HN:1H[G5KQCT<;ITM.ID^>YO3TH*>VSIQ79EL]H MW;RPT5O]TC03L(`YV,*4"EE*#Q8QTA./&2&8(12=W1RVJQD^G=.M(9-6BE=<=2^GR\!AI6SXC58N3Q6AM MO?<$+/)>@32Y"%E*#QDRCQAIJ9B1-`OQZL[##([H&>^H M--5BZG1M'8E.65%M8J/E3*QNI:$Y9NQC2B[--`=46[$S67'2"=UA\A# MY",*$(6((D0QHL1`IL]V;_WCKQ\N]MV,*)'M8W$ZMXIGIZ7:JD/D(PH0A8@B M1#&BQ$!FB.Q6_'9KZ6+/S:A;%DI*(P^E?$0!HA!1A"A&E!C(]-ENIT59_-"Q MA(N=-B.S*JP69J>E=%4H6SIH/DH%B$)$$:(846(@,T+W-=\N-M^,M#<[1!XB M'U&`*$04(8H1)08R?19=9?@C,IT-D''[CCLAG>;1!7?$A^=^'9?NN+W6IG1GVGMG1G>:TW-[ M')IT\S7%YHL-G>;VS'BYH_C%/1>^S.RWQM: MRD63BG$;<_JB?TU?LM_2\B6_5(-3]DQ%-FE.ATKY-P'RE[JXTHJB[_I%3=_R MFQ^/]+<;&9UN3,09\W-1U/P+16G<_C7(T[\```#__P,`4$L#!!0`!@`(```` M(0"L5&3X$P@``&,C```8````>&PO=V]R:W-H965T&ULG%K; M;N,V$'TOT'\P_!Y;U,T7)"FJ"]4"+5`4O3PKMI((:UN&I&QV_[Y##4F10\=6 MN@_K^,SAB&=F2(XLW?_T[7B8?:W:KFY.#W.V\.:SZK1K]O7IY6'^]U_\;CV? M=7UYVI>'YE0]S+]7W?RGQQ]_N']OVB_=:U7U,_!PZA[FKWU_WBZ7W>ZU.I;= MHCE7)[`\-^VQ[.%K^[+LSFU5[H=!Q\/2][QX>2SKTQP];-LI/IKGYWI79G325H>RA_EWK_6Y4]Z.NRGNCF7[Y>U\MVN.9W#Q5!_J_OO@=#X[[K:_ MOIR:MGPZ@.YO+"QWRO?PQ7%_K'=MTS7/_0+<+7&BKN;-NWCOC[UGWVKP7;;W_K3Y5$&W(D\C`4]-\$=1? M]P*"P4MG-!\R\$<[VU?/Y=NA_[-Y_Z6J7UY[2'<$BH2P[?Y[5G4[B"BX6?B1 M\+1K#C`!^']VK$5I0$3*;\/G>[WO7Q_F0;R(5E[`@#Y[JKJ>U\+E?+9[Z_KF M^"^2F'2%3GSI!#ZE$RBOB6,#.18^Y5@_GCPXE(/A4PV.%OXZ8E'\B>F#T"$& M\"F]!,&G8P"3'IS`IYK*>K&.HC!>KZ9':RN1T+#&U0Z5D95\^WK?- M^PR6'R2O.Y=B,;,M.%8E@@G51?-1S4"Q""<_"R^#+RB'#@K]ZR/SX_OE5RC. MG>0DD@/I,$@KFY1>)*UM4G:1M+%)^252X-DD?I'$;%)QD>1KTA(BJ<,)54[# M&<"ZO;SB5/3$(!(][7V(;R(9X;"R1,13!\D<)'<0[B"%B5A*8,V92JXK$.2' M.?@:4QL$1`-R5E@=7AS3U*/=+(^8I"NS7+`-251NF8,@(E?@IOTNV*S)^,*T M,V^\N!47F.#TN`@RC4M(XH(<([4*&(/I!`(I\1#+<,.B@)$UDBLG8E<7!<,I M4!B`)1`VI.D"!1F.!2OQ$1&('$,@!3(*Y!3@%"@,P)H];+'39R_()#V,%$V" M'`RU'WCCNA_"FJ)Y%)=1(*<`O^ZQ,/B6,MB=365BI[Z]M8A!1&%`-V;DA$,Q MW85D'TV551521H&<`IP"A0+$P6!>P=(GND[C)+J^X0@RU44SAQS4!4O$KLI4 M6;4N"N0*&(XS.IXKJQI?&("E:V/KFI8W,8CJ(TL\08[[)*&"N\`+R?:9WB)DDC!&)=?(QT<( MUQR=4!.Q58LFP5`],:/86MCJR9&;,"3!6:0[!WK8I9(C(^2',7&2:2=*2FX- M<4=P9T1A(K9XT148XJ_O2PQ["%LT.3,22;HN&AU]7-AH-Y-.$2ZO(P/GKHY" M3P0"9XL6S8$A>F+&L:6PQ9-]-V%(DL?-AC9QJ;:K9&8.DCL(UPCN7M1KH>V. M4M%(?%XIMA^V4MK8B5MMV,2OIQDY:O4'*Z>VE1,A+/2).9?7P/'^)B*["]=S M4-$L3,3.N6@\/A\);%?L2)`M+&%&3X-MDT2NZ,8A2&`QW"S3$REWO'('*4S$ M5BMZDL^KQ4[&5DL.WH29[4Y,[T)2;?YXR\LT1V1]32Z06]:(E@S7YC'G:D9. M]8NFA40AA(J[LBDD`;?<:-Q"K-#XI&V['IJ!3=HU>NN02-)X1J42P6!=B(5ECS=A%`?C M=(YW)4EV(#Y93JDVJ^TS8JOD%QSAN.'>.#:JOB%B=CJ1/?R^2QBSV-E,:3=E?@-_U9W MI3E#"M9T:\XLN_F+G]QJU"7$\!4=S?7H,0YJ`"!V'/Y7;R4>=M"52V\/$TD: MEV&JD8]4FZU5Z(E_]F\CN?:@E'$'*4S$UOJ_.BM_2F(WUUZ47^X@A8G8>DEG-7&_OM!AT7N8Q$<29IWY)&>I M-E\3;[KP2=WDVH.H">8Y^YT:K.)2Z`&`6%$0/\C2K-_^D78814YHHTT;-J-$ MDHQUKI$KPB5'=J<><^^BM!>ECCM(82*VWD_U4P$V1E9U1^3X320)GQ.M@Q6I MTM2R,WC*8^]=F6U?T[NCW+9O8NJ`6X0[%H8;4A"%Q?#''RGMT(!,LQ2N'^SP M&H"SU=.?G!-),DL`A\GT7@B&:5_%P7H5D.63.TZY@XB7%/"LU?6.[QS@D^1C MU;Y4:74X=+-=\R;>)Q#ST2B^ZY"P;3*\ZD#PE&W32WC&MO!$$ZY'^#G;PG-- M%^=L"T\W7;R`=RP&?*D=P2L.Y_*E^KUL7^I3-SM4SS!E;R&>Q+?XD@1^Z9OS M\%3VJ>GAY8;ASU=XF:6"IVG>`LC/3=.K+R(P^O68Q_\```#__P,`4$L#!!0` M!@`(````(0!W>I)!:0(``%(%```8````>&PO=V]R:W-H965T&ULC)1O;YLP$,;?3]IWL/R^&`@D:112I:NZ5=JD:=J?UXXYP`K&R'::]MOO MC!-$EW;JFQ##W>_N>>Y@??.D6O((QDK=%32)8DJ@$[J475W07S_OKY:46,>[ MDK>Z@X(^@Z4WFX\?UD=M]K8!<`0)G2UHXUR_8LR*!A2WD>ZAPR>5-HH[/)J: MV=X`+X`]. M<;,_]%="JQX1.]E*]SQ`*5%B]5!WVO!=B[J?DHR+,WLX7."5%$9;7;D(<2PT M>JGYFETS)&W6I40%WG9BH"KH-EG=9I1MUH,_OR4<[>0_L8T^?C:R_"H[0+-Q M3'X`.ZWW/O2A]+28DX6*?5 MGQ"4G%`!DIX@>#U!DGF4I?EB^0X*"QT-`N^XXYNUT4>"2X,U;<_]"B8K)'ME M,_0G]#%J?4LJ:O20K:<@(:,$\RW.YW&3Y-F:/:*IXA1T>PJ:Q*1C!,-VQIZP MCVE/K[M\+NV#A]+>=M_,[>G.I$ZV?+W0[&4A+SY[BO$!KG3/:_C&32T[2UJH,#6.%FB9"2]%.#C= M>R39:8?+//QM\-L%.)PXPN!*:W<^^-=N_!IN_@(``/__`P!02P,$%``&``@` M```A`+!OM+NJ!@``;QP``!@```!X;"]W;W)K&1N/46QC`9-)_GZKNQJZ MJ[#'."^3V'4H3I^J/M68QP_?C@?O:]FT57U:^V(>^%YYVM3;ZO2R]O_Y^_-L MZ7MM5YRVQ:$^E6O_>]GZ'YY^_NGQK6Z^M/NR[#S(<&K7_K[KS@^+1;O9E\>B MG=?G\@217=TB.OF8X:&9DJ/>[:I-^:G> MO![+4X=)FO)0=,"_W5?GML]VW$Q)=RR:+Z_GV:8^GB'%\=-P^_ MO9SJIG@^P+J_B:C8]+GUAU'Z8[5IZK;>=7-(MT"BXS6O%JL%9'IZW%:P`B6[ MUY2[M?]1/.11Z"^>'K5`_U;E6^O\WVOW]=LO3;7]O3J5H#;4257@N:Z_*.AO M6_457+P87?U95^#/QMN6N^+UT/U5O_U:5B_[#LH=PXK4PAZVWS^5[084A33S M,%:9-O4!",!?[UBIU@!%BF_ZW[=JV^W7ODSF<1I(`7#ON6R[SY5*Z7N;U[:K MC_\A2)A4F"0T222P-_%P'BYC$2>WLRR0D5[@IZ(KGAZ;^LV#KH%[MN="]:!X M@,S]RI#'L-9K2X4UJB0?51:="U;10GV^/HDX?5Q\!4TW!I,93.1[`RBDD'R` MJ&(`P8$EK)VSE%#%R_KWI-1%E%3$.8TADE$:(Z+E`"$<03V7X_O<%!BZP-%" MQ#:O%C5#3*2;0*F<.U^0.X.DT^^LP&L?EC5400@N"V)276:JWHZJ;IBZ8NXL*L!L%1&,0XPCA?$`8)9?!^2128"9,$[,Z(2;0P M89BRBN4D+&0T7$U8I925TN5V,ZN+.#LQY$==$!-I=DO>R&Y0Q#9*J*F!Q=S@ M-C5U$:,F;'ZDAABD-DM9-,C(AF"A)(`%W(5>Y^31G-23(S,@&"/#3N4]V$^8)35SJ1M!$KN@KG?+J=` M%R8.D=A61N4,"*6+8DM`AW,2GETIIU#>ZG3;#>W0B2DM5K),IP2;>5<[3-17 MW:Z,:J?,UB$W;9<*M&CX.]1.)+9UC':.CQNYG&\H"^6T#HL;$J$ONQ+QRF0" M,;CZUKCLZ9,:;J],6;&>D+>V\HJSN M\GMQR?!M9D,+0:99I.UD4S@W'%\3BQG^C2)>RI3%:6, MX5U6K]'4ZA/>7`9C](B=L8?=9>+]7`R$W15$L/"'?%Y?11F*A#5X9D"&(CQV M#F/04,1A@11%L+2-2ADJSYWL%R$Z-''1E-TY,R#G%.A^0^^N['7ZW=&,7;<2 M*1MP68B@H30K1B]G`)':/4JYW>7PX=CA16JW$7J6`6'-X'C.2]9/@-%#UEVF MKIXY^0&+'^PR`S+MLQR=8TR\E_&Z2GXBN3/O'ZF]4ZJU;/:[KQRMSF>XH M6B-FX-/.`N$%(^>6F!D0E&0X,(Q%PD0H4I0$U_R)^?E$EF-?%ZF]@]'*-6X1 MVDUNA.O#%Q=!I;S+V\.QMXMTY*+$O5/)W=TDZ7LLO3:FU1G`"D"!);>,KM M+G>7Z.[$7Y?,I#(#,L:1Q"/=,$E?5!E9@Z;4F/5/VQ3RP@A8VCO@IC"@GH+@ MST@Y`HO7AVEARX;[U>0PXDI;=LJ+C8.)TET8 M"_RWB$PBJ-\78<1&6$X`(KY:7386)E)$YZ<-R,>#1)#9'*O$BF0T=.,B"NT* MJ(@_-#KDA=&Q9%L@,R"L8AJR]LQ-^,("*,$?FAH2'9],6.?<;+JP'PO#A#67 MC2>L9&-A8B$OC(Z8R.F/R@G1D0_E@MG7UHB&&.*P]YR+E_*/HGFI3JUW*'=P:3!/P>D:?&&$'[KZ MK-])/-<=O.C1_]W#B[T2?M\/Y@#>U777?U`'].%5X=/_````__\#`%!+`P04 M``8`"````"$`P:GM0VL"``#3!0``&````'AL+W=OT9*/U(+EP&G@-D`#%$6/9YI:281%42#I(W_? M)66K/M+`+X)(#6=V9KF:/>Q53;9@K-1-1N-H0`DT0N>R*3/ZZ^?R[A,EUO$F MY[5N(*.O8.G#_..'V4Z;M:T`'$&&QF:T(.EZ9D MMC7`\W!(U2P9#"9,<=G0CB$UMW#HHI`"GK38*&A<1V*@Y@[KMY5L[9%-B5OH M%#?K37LGM&J18B5KZ5X#*25*I,]EHPU?U>A['X^X.'*'Q16]DL)HJPL7(1WK M"KWV/&53ADSS62[1@8^=&"@RNHC3QPEE\UG(Y[>$G3UY)[;2NR]&YM]D`Q@V MMLDW8*7UVD.?<[^%A]G5Z65HP'=#2>@:"\`G4=+?#`R$[S.:H+#,7971X20:WP^&,<+)"JQ;2D])B=A8 MI]6?#A2'HCJN4-H3=WP^,WI'L-V(MBWWER=.D?CM6K`(CUUX,`)'E*".Q0"W M\W@:S]@678L#Z/$`.L$D/8*A:B^-W"0]KGX8AX/.R1A>MZX:HNZD*3`F?H:XM M$7KC!R3!J]?O]K.["#5?[H_219AIUG_`F6IY"2__P4``/__`P!02P,$%``& M``@````A`%A`$F:C)0``1=P``!@```!X;"]W;W)K/=?__SV]=5?-W?W7VZ___)Z\^;H M]:N;[Q]N/W[Y_OLOK__/?U?_.'_]ZO[A^OO'ZZ^WWV]^>?VOF_O7__7^?_Z/ M=W_?WOUQ__GFYN&51OA^_\OKSP\//R[?OKW_\/GFV_7]F]L?-]_5\NGV[MOU M@_[S[O>W]S_N;JX_'CI]^_IV>W1T^O;;]9?OK^<1+N^>,\;MIT]?/MP4MQ_^ M_';S_6$>Y.[FZ_6#CO_^\Y,]RWZ[L__OSQCP^WWWYHB-^^?/WR M\*_#H*]???MPV?[^_?;N^K>O.N]_;G;7']S8A__`\-^^?+B[O;_]]/!&P[V= M#Y3G?/'VXJU&>O_NXQ>=@9']U=W-IU]>_[JYG#8G9Z_?OG]W4.C_?KGY^S[X M]ZO[S[=_UW=?/@Y?OM](;CG*N."WV]L_C&G[T2!U?HO>U<$%_^ONU<>;3]=_ M?GWXW[=_-S=??O_\('^?Z)3,F5U^_%=Q<_]!DFJ8-]L3,]*'VZ\Z`/W_5]^^ MF-B0)-?_//S]^\O'A\^_O#X^?7-R=G2\D?FKWV[N'ZHO9LC7KS[\>?]P^^W_ MS48;.]0\R-8.HK^901[I>&P[ZJ_MN-F\.3\YV9V>GVGZ1WKN;$_]73>EACV< ML/YF.C[SA$_M(/IK!SE[]&C5>IA4?ZW]5ET?.3U=GX<.^FL[/"['A;777VN_ M.7MSMCFZ.'Y"QXTB;@X`$WJSM4@)0@%4@-TH"T(!U(#S*`C"!32")I=4K9#76!UF= M&%0,^P7(W>E%"`E2`52@S0@ M+4@'TH,,("/(%))(0R6\*S0TUK&&,PF##J0`*4$JD!JD`6E!.I`>9``90::0 M1(*9A'^%8@?S6#*'@K7$HF@QV1YMXE`LG%6XFFR/?-H;'Z=)')]_=9BJ)'&M M0Q=^02$JB$JBBJ@F:HA:HHZH)QJ(1J(I0K%^)CL,]3/5S.GQ&U\//K^@L8GF M81OCL*IO-%:L;;\GI-.)>$NZ*Y,+*XYS M3E6C2R?,7N>,TI2W\G.0,Q5$)5%%5!,U1"U11]03#40CT12A6#^3=Z[0;TY3 M-9Z[`JXV2^8:NBNM]KV5ZU@0E40544W4$+5$'5%/-!"-1%.$8DE-9KI"TCF1 MC20-RD?K4KTX M5-*J(JJ)&J*6J"/JB0:BD6B*4*SVNB)DRR+$H3!:6830JB2JB&JBAJ@EZHAZ MHH%H))HB%.N7%B&/I\5FNR-)BQT*TCJ+XKV13;)-5SBK**W;^!V4^#A-8OK\ M>ZCY)#\]SAD%.=S>6@6H("J)*J*:J"%JB3JBGF@@&HFF",7ZF1PZU,_<0X_/ MS1,2:ZM-\SE^JNV,)&1P$]WX;2Z[+"U6;@TJ[%B!!TJBBJ@F:HA:HHZH)QJ( M1J(I0K'J(>J*!:"2:(A1+:JJ#<`5X8J6?BXFP M"MG.*`I)H()6)5%%5!,U1"U11]03#40CT12A2#_S-$&DGUE!-R>'W>6'SU\^ M_'%U:T#VD8-C/1)S6`-_/8P25R`.S0^8F:=>]@YMEZJZL.CX_/!TC3YI2%;7 MTANXN*TX3$W4^([FN1V-[&_!AV-NO8$;N8N&B65:5SX5MY=K]+D[MD)^K<2@^R&2NUEG9N4Z3]LZU'^:*95R7RQ\S ME[?(1&<@H]\IG/,09Q5&TSR6.KH0+YW5]J#9>>*+RC7['K5#?MS&(6_5.C2/ MNTGN2)UKGI^!#9\>.UZ7JA_,DY5FSMZ38$EWYFQ'W4F<%H5#/CY*AZR;$R]7 MKMGWJ!WRXS8.>:O6(=U8`AU0&,W/F:M-YDK7XLX-?)@K5M=4"6$&E\;Q?]_^^%D&HCIO24',,,G",*,P MLSL&*HA*HHJH)FJ(6J*.J"<:B$:B*4*QKNN*#:5@T,\B?W7MK56\![)-[B*% MLPKC^L0;Q8=IV^UW%J)2J**J"9JB%JBCJ@G&HA& MHBE"L=KKZH`=ZP"+PF@E*HA*HHJH)FJ(6J*.J"<:B$:B*4*Q?NMJBAUK"H>" M1E]N.);E"Q+23:]]U9^69K'"CQ0TJHBJHD:HI:H M(^J)!J*1:(I0++=)V9]_$]T9\V2EGU&@S-Y:!:@@*HDJHIJH(6J).J*>:"`: MB:8(Q?J9''>%?G-*'(7DC)*03$J8_6ZQ\B$)5-*J(JJ)&J*6J"/JB0:BD6B* M4"QIFM8_GM?MF+Y;I#].K#U10502540U44/4$G5$/=%`-!)-$8KU2]/WM"QZ MUL;LCEF]0[Z,WA,5%LF_=OLTJ:!+;^"\4W&8FJCQ'7^R,>L-W,A=-$PLT[KR M8.L_#D7#NEJ?63CP5G-NV@7Z8YOY=K]E5T[Y.=J''ITKM99S7.=!`G= M8=>H<^W<>#A9E\L?S!,9Y_0^WBD[3G:W]K:C-MI=Z!0.^0W4TB*5'H?+8K,] M2_*9BIUJA_S0C4-^Z#8=>G><;#%U4:WR:^+&+.L4BK:L63E@M6)1$ M4N*FO;/R[BX<\NXN'9JWXL_2;^]4KMUWJ1WR`S<.>:O6H7E@B1\_=]^Y]D.7 M6*!<.;!Z!_6$E8!%27#YK:;YHQ%GY2.@L$A%H;LH2X?,QYI_O3].=CDJ-XB/ MF=HA/V[C!O'CM@[-X^XN$J]V;I3,"K4NK3]A6F]1L/;LB0J'O*]+B^QRM-OJ M_V)O5^Q4.Q2&T7Q,P4=0;3+TR=DI%`D[Q8%DLN7G)^HG\_TN'E"[XN^$QEJ3Y(.(9-\G%4[NQ_(R-0W[&UJ%X1K^)8>]Y3\P8 M2YHFZB]*-/73.&E):5&RIB5WM;VS\C%36&3*72\K/MUP5N8C`-T+SD^WR="5 M&]J'=>V0GZUQXSPZ6^NLYMGT#;F+Q(&=&SJS^CV5RC_O$XX3YO(6J8IPJ]B> MJ"`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`K%6`2H<\I^6EP[YAUDJA[Q5 M[9!?XQN'O%7KD!^K<\A;]0[YL0:'O-7HD!]K(7[=JA_RXC1LD6E_3YR9: M9S5/=1S\;//\\(@;V,_5.^3G&MPHC\XU.JN?S#6Y@0]SQ5[+%7YAVO*\9R;. M6?0Y%"0N1`512501U40-44O4$?5$`]%(-$4HUC6M\%YV-;#P.Y]1J&I*"FNC M)SI\X,]&`:HP4FU)D%@V;BB;#!Z=;Y(+K_46;K*.J"<:B$:BR:),,GB^K@@\ MF"<+]ES+1?=`B_R]IK`=S;.[?OU)'\HLO963H7+(CU43-0Y%5SB206_EAN\< M"A<0>_0>#3'ZHD&A_Q8(]'D M4$;I=87F.0M-BX+,;T]4..23KM(AGW15#GFKVB&?P#4.>:O6(3]6YY"WZAWR M8PT.>:O1(3_6Y-#!*K[]I?7BRVY_+"//9_14,FBM_`VPL!VC9'"VTD\[')YL M13*X3.4NS=K-[L=M_+C!1<%D,)HJDPQBKIYS#<^::W16\VEM=\FFYN0&9C)X M\52Q^;QD\#!,O.`[%*0M1`512501U40-44O4$?5$`]%(-$4HNAHN=`]8<<,\ MF"?ZF1&$%";!TIM^@N(Z>I4+HI*H(JJ)&J*6J"/JB0:BD6B*4"QI6FT^OB%U MP;+2(2_6GJ@@*HDJHIJH(6J).J*>:"`:B:8(Q?JE==\3^K&^N[`HV$FU*'ZF M^R19?XJ\E=]J(>J*! M:"2:(A1+:LJ2%9+.54PDJ44^_O870`512501U40-44O4$?5$`]%(-$4HUB^M M8IY8>EBN7%@4+CTSBI>>]*NEA>V86/D/7N+C7%<#7+`&<"CTL[7RJ*!52501 MU40-44O4$?5$`]%(-$4HUL_DM.%U8FJ`ESU3 M.KJ5JJ151503-40M44?4$PU$(]$4H4CNS5&:O3]^78Y`23G&"2$TQR@DE.,,D))CG!)">8Y`23G"%+Y%R7 M[6^.F.XO++CI.I;<3Y,]3BD\#V?>%N&KUU/_04)RL.M2_LT1<_Z%>3_K4F+6 MGV'R/>SD>S#Y'DR^!Y/OP>1[,/D>3+X'D^_!Y/N0)7*:S/P_'-DL/UK( MELP_=&ZZ-;%T]1Y17"Q=W>(F]<&D/IC4!Y/Z8%(?3.J#27TPJ0\F]<&D?L@2 M]=<5"YLC5@L+\](IF%DO9)CDA)WD!).<8)(33'*"24XPR0DF.<$D)YCD#%DB M9UH[_!LW9=85FR/+XIMRLH$A\1*93")#R;QP20^F,0'D_A@$A],XH-) M?#")#R;Q0Y:(OZX@VARQ(EI8%,NLB3)VDA-VDA-,ZAPHZ%L4RF%Z9GBB4R MO3(==GIG.IA>F@ZFMZ:#Z;7I8'IO.IA>G`ZF-Z>#Z=7I(4OD-*G\&CEMZA_) M:5F88-K7M<<)YEFR^2B%YZYQ@GGF/YE.#M8DRFL.UB;6T<&&R;:]E**7G1^8 MC@QV98;)]["3[\'D>S#Y'DR^!Y/OP>1[,/D>3+X/62)G6ER\_)[L7G<>*3T7 M#_$W-<[\GIT3?S'SZY@=+O@.M\2'G<0'D_A@$A],XH-)?#")#R;QP20^F,0/ M62*^2?S7Q+(M%"*%9Q;(M-_85Z$'3+$,.\D))CG!)">8Y`23G&"2$TQR@DE. M,,D))CE#ELAI,OE0SI?O66[=*(0GF=-?2=8W57[JZ`)?Z8%(?3.J# M27TPJ0\F]<&D/IC4!Y/Z8%(_9(GZ)O$/U7_JIFP+A4CAF072*9C!%,Q@DA-, MC!) M#R;IP21]R!+I3=H?2O^4PK9,B!2>62"=(AE,7,DO02^Y?VY?*)V<_V+P\O1U]Q ML.YEZN'!.A:6%F3%AJS,L"K#Z@QK,JS-L"[#^@P;,FS,L"EFL>\/[TH/Y7SI M*N9>NA[I;&L.Q8'?F3[#YJ7KZMTAZ9>N_GY,)NEA)^G!)#V8I`>3]&"2'DS2 M@TEZ,$D?LD1ZD_2'TC^QBKD7K4<*AX6#S=6=720G[!3)8)(33'*"24XPR0DF M.<$D)YCD!).<8)(S9(F<)HT/Y721_)2L<_JOVXV+M*N->R>[?V9WOS"9!\&< M[%XJ<.UP?B&4T@L+N_K-HN1$3`(=GLA3)S`GW/$)6.9C0"<`IJ,%T]&"*2[` M%!=@B@LPQ068X@),<0&FN`!37(`I+D*6R&DRXE#.Y\;%G$G'LEH6Q85E3\7% M8N;"3$HO+(B+<[__DIR(R47#$WDJ+N;<-3X!RZ*X`%-<@.EHP1078(H+,,4% MF.("3'$!IK@`4UR`*2[`%!+!Z>RU,G,">#\0E8%H4&F$(#3*$!IM``4VB`*33`%!I@ M"@TPA0:80@-,H0&FT`A9$AHF<0WE#$)C;75G7UH>2STGQG%UE_X.A!;LQCB3%4R3!EYZ'P3/? MH`U,W.#2?^GFF/0'D_Y@TA],^L_L<-J)_"9C_0_(;Q/?,$NU;VOW6N\W0))_ M[FE^Z=GGK>?)IJA2"F?D)Y((4R05+ST!_!*,EOC%Y.2A7YY:96P.'SG`LO">;]\1K\_,W%'(!;-= M^-JM#)/>&$^"@TEQC"=YP20O^DI?,`F,OE(33&J&?1,Y30*^1DZ;L$=RSBS^ M]N%YLE^D&+=F_FN"4GCIZE171%LVOU/KZ$WZ:_C2>^D5!I;?>3H4U'(!)I0+ MEJYN0KD@F?`\&4D.67H],J%\A`GEHZ6KFU`^2B9,WU71]=)DM7=XIRHF7S+R3XTNC@&GEPZ1+.EN@N#UHS M/YL\N'1UL\F#C\TF]RU='IE-[L-L@-8LNP*6K.S_YSK+Y`M2&_IODKB/_+=WRY^BN0,PH_RU= MW8SR7S+CYLTNN4W(B4N_1Z:4$S&EG+AT=5/*B=&49[LWN^.CX'])X,NKRQCY MZ1.OFC)PC5=MV1AY=6;)%>EWG^RVH;ZH;1(\93+NY+2L+ET=DU0YSR7.PD^>BN8[2$Y&KPDZ) M7TSQN,8OMMB,_#(SU:%.7%U:8'*"9;ZOG&"93\VD.^RD.\:3[K"3[AA/VL). MVF(\:0L[:8OQ)&=HE\AIJL$U03SRR.+77#HZ?QR4CK_3N_O M"OZ7K#7RX#*NFU\>Q/SRX&+WR/QR:C3_Q9NC8&[]\[S\1U+8R>?+R#J"V.=Z M*=\JGQ_LDS+?,7\9[#=D18:5&59E6)UA38:U&=9E6)]A0X:-&3;%+)'35*#A M)63VK%[VO*M>3(I2W[)XR^HBB7B)/W<-/E67^&`2'TSB@TE\,(D/)O'!)#Z8 MQ`>3^&`2'TSBARP1WY29H?A/%)-Z82<5MBR*93#)"28YP20GF.0$DYQ@DA-, MY=Y263\'(\.%DQ'!B;?@\GW8/(]F'P/)M^# MR?=@\CV8?`\FWX/)]R%+Y#153RCGO[&.S054K/3,DG4L*1(D_F+F[IP2'TSB M@TE\,(D/)O'!)#Z8Q`>3^&`2'TSB@TG\D"7BF^(D%/^I=6PN9F*%9Q;<`B0G MF.0$DYQ@DA-,3[\'D M>S#Y'DR^!Y/OP>1[,/D>3+X/62*GR7S7R#EGRK&<,TL6JR3-U]6UF`6+%9@4 M!I/"8%(83`J#26$P*0PFA<&D,)@4!I/"(8L5/EE90!SLDP+"LBA@R8H-69EA M58;5&=9D6)MA78;U&39DV)AA4\P2.4UZNR)@S:/.YD_!=&1@\CV8?`\FWX/)]V#R/9A\ M#R;?@\GW8/(]F'P?LD1.D_&ND=,FUY&<,XL6*VV%OGO[ERK_#^_?V6U&_0IJ MDNI*83`I#":%P:0PF!0&D\)@4AA,"H-)83`I#":%0Y8H;#+>-0K/&7)\=859 MLY,33'*"24XPR0DF.<$D)YCD!).<8)(33'*"24XPR1FR1$Z3PZZ1<\YY8SDM MBQ:KF46+U?%1LLTAA:V9_BR95?BSH\G!F@QQS<'.&65\L&&6Z7P/IB,#D^_! MY'LP^1Y,O@>3[\'D>S#Y'DR^!Y/OP>3[D"5RFK0VE//?>#KKQ&;7T4(VLV0A M\^6_4W\Q\UF7'2ZXI4A]V$E],*D/)O7!I#Z8U`>3^F!2'TSJ@TG]D,WJO[W_ M?'/S4%P_7+]_]^WF[O>;_O/MS^^5V7@+E6`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`^2Y%AV??D>;+7H/TJ5Y!0Q; M]#JDRS:KD-[7HY:<0GISC%IRH^D=29?FC3&+>7$,6Z[48J26W%'K=3IJR1V!7AQU:=Z9P]'T:L]+\^+.7,N%6G+7AEZ, MJ/C)K?UZWZ?B)]>B-XCIV'(^U0O!-%JN12\ZE4]SH^E]IY=M]JCU0DZUY(Y: MKX:43W.CZ26H\FFN1>]"E4]S+<7NXK+,5BR-6MIL2W$F_^A5M-1:;\B5UKF6 M*QW!5?8(])99Q4[VV-1B7B7+>?0V5+7DU-%[.>6?W&AZ`ZUB)]=2J(PJLU54 MHY8VVU*8922[4C1J:;,MQ4[GDZT<&[6TV9:K8RWL>A*+&ER9`B]?W^VT5N6K MNYUN7'I$0J.]71*A^_?O?ES_?C->W_W^Y?O]JZ\WG[0IL9?SI]O;!_8>9X._;NS\.&P_O_[\` M````__\#`%!+`P04``8`"````"$`7(K*BD(?``#RJ0``&0```'AL+W=O_WSZ.7NV^W3V\>?MQ] M5U<^/SQ^NWU6__OXQ\G3C\>[VT]=T+>O)]/3TXN3;[?WWX][AYO'UW@\?/Y\ M__%N\?#QKV]WWY][D\>[K[?/JOY/7^Y_/,'MV\?7V'V[??SSKQ__^/CP[8>R M^/W^Z_WS?SK3XZ-O'V_=WQ[]-;IJ+L^.3]V^[#MK>W_W] M-/C]Z.G+P]_KQ_M/_OWW.]7;ZG-J/X'?'Q[^;*7NIQ:IX!,1O>H^@?CQZ-/= MY]N_OCZG#W\[=_=_?'E6'_>Y:E';L)M/_UG/#U]5!=1_ MC[[=MZFA>N3VW^^.IZK@^T_/7]X=SR[>G%^>SB9*?O3[W=/SZKZU/#[Z^-?3 M\\.WLA=-M%5O,M,FZN<>DY'`,QVH?NK`2Q8^$J>JUM5:_=1QTXLWD[/3B[;2 M(W$7.D[]U'$7;\ZFYY=776M'`B]UH/IY6`O5..MJJGX>U,)K':=^HH73UU5U MHG*H*[+]Y;!63I`-[2^'M7.B$J@OE9GTNL]R@NQI?T%;7_5I3I`^[2\'MA09 MU(Z5`UN*))HPBU[94F31A&DTG;VYG)Q>SR['$W>"/&I_.;"I2*4)R M?HI4:G_1I;ZNJ5-D4ON+CIR^,H&G2*7VE\/:.D4NM;_HT->V%W@\7M\^W[MX\/?Q^I>ZSJYZW+3 MNN%&T'^\NUO#2W<&=4MH77YK;92%Z@,UZS^I^]F_WL].S]Z>_$O=@SYJT8<] MHJDIF>\D[2VG=5X(LA1D)+^&UG4VG19A$__PXX,\LI*F9T$00M!EH*L M!%D+X@CB"K(1Q!/$%R00)!0D$B06)!$D%203)!>D$&0K2"E()4@M2#,D1LJH MF5:DS)F:"?>O0#'/M%%JK6E,,^=F0GSH->H.C828"[(09"G(2I"U((X@KB`; M03Q!?$$"04)!(D%B01)!4D$R07)!"D&V@I2"5(+4@C1#8J2(NIL8*3*>&JU: M31YJC31R"^I%%ZK(@>C"3*#Y3H0$6@BR%&0ER%H01Q!7D(T@GB"^(($@H2"1 M(+$@B2"I()D@N2"%(%M!2D$J06I!FB$QTD5-'@>D2ZONT@4?\@=-KCEO"+(0 M9"G(2I"U((X@KB`;03Q!?$$"04)!(D%B01)!4D$R07)!"D&V@I2"5(+4@C1# M8B2"6L8:B="N::?G;Y3^P%5M:V3FB";JD6@P?UQ:\\=.A-1:"+(49"7(6A!' M$%>0C2">(+X@@2"A()$@L2")(*D@F2"Y((4@6T%*02I!:D&:(3'21MTYC+09 MO]VT:C,W-!G,'X(L!%D*LA)D+8@CB"O(1A!/$%^00)!0D$B06)!$D%203)!< MD$*0K2"E()4@M2#-D!B)H/9*C$1HYX_95;L1>N@$TCJ92=(3M;4[G$"NK`ED M)]I-(((L!5D)LA;$$<059".()X@O2"!(*$@D2"Q((D@J2"9(+D@AR%:04I!* MD%J09DB,O%%W!2-OQB>05FWF1D_Z;?]N\V,NR$*0I2`K0=:".(*X@FP$\03Q M!0D$"06)!(D%201)!1+Y$@42A1)%$L42)1*E$F42Y1(5$FTE M*B6J)*HE:@QDIDV[OS;OYR__'/#P]JM:(R8T_NS-2^O-ZNU]MRE[MGW0_M25R;3?T1;;OU/M?HXF*G M6FAT>=IM\4]/)]8&_I("3$DKB=82.1*Y$FTD\B3R)0HD"C4:-"^2*&9@>ZBA M6CPQ)^&$`K0XE2B3*)>HD&@K42E1)5$M4:-1WV(SK=I-N/]_6NFMO&%::31, MJQX-^GW1GN&JY+M4>ZIR$*MBGTBN3*&?@T-[JG((JV&^E5RE1Q<"A MO=4Y-56P;PPO,UG;+BN M,;/)S!P\&ZC8"QX02_2!1DL,M.KE]H7T0?LB()86`XV6EIBES6:3,^M@.:4/ M2LN`6%H.Q!XH@+AGLP6BJ@2B5P4T6O-:JW0_[:EY0Q]5+7HT4\\HNW29G%KI,F^_X*("9YRW%T"SW7!8:G1QV2?Z9'9IC:$5@KJO MHW6+CS40K1T@6KM`QDZ)S.I=8_#)>PBDO0]$^T"CEVL>(H@UCX!H'0/1.K&L MIQ&R"J M/"!Z^4!4!4#T"H&HBH#H%0-1E0#1*P6B*@.B5PY$50%$KRT05240O2H@JFH@ M>C5`GP MX3A:`W$<.4!4N4#J^6DWG^ZY_8HJ>0BDO0]$^T"C%RL>RI@(B,XQ$)T3TWER M>GYJ'82G,B@#HG4.1.L":+1/ME`QL`2B?05$5:V1[I,]-6^,(#,MV^W;`Z:N M?K=7^2&5/K3?I;2G+H$64#%P"<3ALP*B:@W$H>@`4>4"T6L#1)4'1"\?B*H` MB%XA$%41$+UB(*H2('JE0%1E0/3*@:@J@.BU!:*J!*)7!415#42O!JA3F3G2 M[NP>D"/]1K"1(SVRIBZQ?ZM5S/9%^VW;=C9CMB\UTME^/9M:-BL9LP:BLP-$ M9Q=H=)ANH&*@!T1['XBJ0*,7*Q[*F`B(SC$0G1/+>3JQNB25,1D0G7,@.A=` MT]UXWP)150+1JP*BJM8([1>U;(P8(P/;;TX;&?A+J__.Q;RG:F0^^=H[+7.H M.*86&IVQ8Y8:75QUJ__9Y-IZ#E[!AN-P#41G1SJ[0&I;:.2>"B_:>T"T]^'% MB@<:O5CQ$#9TCH#H'$OG!&BTXBF\:)\!T3Z'%RM>`'$9OT4@O4H@>E4(I%<- M-%K5!EZ=O9FBAYU63.5IA4:#9\RY1`L@#JPE$%NS`J)J#<1!Z@!1Y0+1:P-$ ME0=$+Q^(J@"(7B$051$0O6(@JA(@>J5`5&5`],J!J"J`Z+4%HJH$HE<%1%4- M1*\&J%.9.=(>*KS^1MJ^N6$]`VADS5?6[N0<*F;\`HCC8@FD;K<5ZGEA! MI1;L.Y68NM=0L40'B"6Z0&:)UE[+!BH&>D"T]X&H"H!,>ZM!(52C#8J@8HDQ M$$M,--([6I/IE?7=MU3&9$!TSH'H7`"9;;&Z:@L5`TL@VE=`5-4:O5CQQH@Q MD[@]G#@@B5NY==/MD3'1";1H7SZREGY`'&PK(`[)-1`'K@-$E0M$KPT051X0 MO7P@J@(@>H5`5$5`](J!J$J`Z)4"494!T2L'HJH`HM<6B*H2B%X5$%4U$+T: MH$YEYLAA1Q+MRV)VCNP[DK"/5^Y;H`IDE6J-W`Q4#/2#:^T!4!4"FO=6@$*J?3'2B03$#\9"?`)DEVALD4(V6 MF$'%-N9`;&,!Q"?4+1!5)1"]*B"J:J#1VC=0O51[,\/;G?;A+-@^D:C7I]MO M18[O_K8*.]EWV_:\QT[LS?VY#AQ,FPL@CM,ET.A#[`HJ!JZ!.`TX0%2Y0-/N M(>=2I/2N)4@=#Q'T]8'H&P#M]PUQF1$1$'UC(*H2H-'N2*%B8`9$^QR(JD(C M;+U=GEM/WEL94P+1N0*B<_TSY\:(,7/3/H[XM:=E>4K1OA&K4M=:?5H+K#E4 M'),+C8RGY=[KK/T6SK_>VS/["B8E7N/\.+]AX0[7UX M\9X7`.VO=@@3^D9`](UA0M\$:+]O"A/Z9D#TS6%"WP)HM#NV\*)]"43["EZT MKX'V5[N!2>=KYJB:98WY\R>39BNW5I$]&DR'\S8QE6J`%D`<64L@-F,%1-4: MB*/4`:+*!:+7!H@J#XA>/A!5`1"]0B"J(B!ZQ4!4)4#T2H&HRH#HE0-150#1 M:PM$50E$KPJ(JAJ(7@U0IS)SY+"S";4*%#FB#R)47NPF@XG]_92Y#C16D;M` MW,>64)F+".N!;P75L,0]JTAMS\'E,!`END#7+]QK11T]1-#7!^+0#H#,EEBG M\B%4HRV)H&*),1!+3(#ZEIQ?6\N&%-<9D@'1.`>BJM`(S[%[[K^BDTK8T+D" MHG-M.D]GY]9WM!HCQLQ;U;&'S&VMW)K;>C28R.93@19`'%]+((ZO%1!5:R". M50>(*A>(7AL@JCP@>OE`5`5`]`J!J(J`Z!4#494`T2L%HBH#HE<.1%4!1*\M M$%4E$+TJ(*IJ('HU0)W*R)'V*,S(D5]:HW4N9NIHU,ZJ@RG/>E*;0\4QL-!H MN$8#ZN_NU@!8P8.#9@U$6P<>[!47:'1-LH$7[3T@VOOPHGT`M+?6(3QH&P'1 M-H8';1.@WO;<^F97"A/Z9D#TS6%"WP)H<(B!0'J50/2J$$BO&FA_'1N8=+YF M.AYV>J$F)GO*TF@X94FT`.*P60*Q&2L@JM9`'((.$%4N$+TV0%1Y0/3R@:@* M@.@5`E$5`=$K!J(J`:)7"D15!D2O'(BJ`HA>6R"J2B!Z54!4U4#T:H`ZE9DC MAYU>S.3IA4;6W&0MH>90,=470!P02R!U6]S-<^K,U?R:[PJJX6PHEV-0L40' MB"6Z0"\LQW"9$1X0?7T@J@(@HR53:WX)H1IM20052XR!6&("I)=C9_9R#-<9 MD@'1.`>BJM#HY>68C"F!Z%P!T;DVG:>S4^MNU!@Q9MZV!PG#K;KQ1\U9*[?N MJ3U20P-K\[E6#=`"B.-K"<3QM0*B:@U$>P>(*A>(7AL@JCP@>OE`5`5`]`J! MJ(J`Z!4#494`T2L%HBH#HE<.1%4!1*\M$%4E$+TJ(*IJ('HU0)W*S)%V%_R` M'.DWS8=?<9KI??3A^)Q,K(>J.51,]@40DWT)Q+WO%1!5:R!Z.4!4N4#TV@!1 MY0'1RP>B*@"B5PA$501$KQB(J@2(7BD051D0O7(@J@H@>FV!J"J!Z%4!454# MT:L!ZE1FVK3;W<.T^;55O#P1F.WVT0=WMZE]S@\5!\("B*O))9!*4-XII];\ MN8)J^![$GCNEKA=+=!#($ET@HT3[/&,#%<>L!T1['XCV`9!A;S5P&2VKT*J+?K4[D7N$<&9A)1`+ MJUY56&T6-IV>BS&E*JN6ERJ;U5K2'$"JKT=O)OG##[4N_=GY\JRUL=:O/1HL M5N=:-4`+($XF2R"NH59`5*V!..4X0%2Y0/3:`%'E`='+!Z(J`*)7"$15!$2O M&(BJ!(A>*1!5&1"]*X6,SV!.Z99;7*?,BU'OU7^[VLA_HU5*R$`V1. M5]:DYD+5SP2G;TZM!=4&`LX$'A`+\X%&"PN@,EML/1"$4)E>5HLCJ%B)&,@, MM%J<0&56PK)/H3*]+%4&%2N1`YF!5B4*J(Q*S*P-CBU4II=5B1(J5J(",@.M M2M10F96P$J"!RO1B)]3NR^Y6*+.9M32?S[2*\\4":!BX M9]#I0./++U,QZ/940MSJURB1E7"`1BOA0M5_LV??H-N5C]T5#S$LS`<:+2R` MRFRQ&'2[$MGMHL41O%B)&&BT$@E49B681-V;RBE4II>ERJ!B)7(@,]#*]P(J MHQ)RT+VF)TIXL1(5T&@E:JC,2HA!]Y-*&(-.?=7JD$'7RT:H`6 M$BTE6DFTELB1R)5H(Y$GD2]1(%$H4211+%$B42I1)E$N42'15J)2HDJB6J+& M0&:.V(=)O[3CJ[[U*E)'(]YCYUHU^&M>"XU>_H-S%&!*6DFTELB1R)5H(Y$G MD2]1(%&HT:!YD40Q`U_X@W,4H,6I1)E$N42%1%N)2HDJB6J)&HWZ%IMII39B MC:GGU]*J=;$6.ST:KG5Z:XD>H@*J()]*+TBB6(&#NVMI]>$*MBGTBN3*&?@T-[J MG((JV&^E5RE1Q<"AO=4Y-56P;PPO,U?;8X[7[S6U_XJ-G90:#>[;;/F<\78EVN1=PD6NBX=GM^-\7) M#1.MTD<%TXOK2^NQ>L7RD91K();FO*HT%ZKA9I-\507V@SU)();HPVNT?8%6 MO=R^$-8L+0)B:?&K2DO,TF;3V9FUG9S"FJ5E0"PM9VGH\P*(@5L$$I5`]*H0 M.-I/M5;I?MI3\P;676EFZJN/,<];:6/?R'@W.;.9:-4`+(!XE+(%X ME+`"HFH-Q)G4`:+*!:+7!H@J#XA>/A!5`1"]0B"J(B!ZQ4!4)4#T2H&HRH#H ME0-150#1:PM$50E$KPJ(JAJ(7@U0IS)SISTE&4Z;X\KGFH0R*@&@=`]$Z,:VOK\ZL[?14QF1`=,Z!Z%P`<;VS M!:*J!*)7!415K9'N`%G+QH@Q<[#=C1WFX*_=NOL]72,U]VSSVG\@=7ZF11Q4 M"R!^?64)9#ZP6,N`%50S00R=/2`Z^T!T#G[F M'"*&SA$0G6,@.B=`HUV20D7[#(CV.1#M"XUV77)EW44E,J8#(C..1"="]-9 M_=4=.Q=E3`E$YPJ(SK7EK/X&@S6G-$:0F8R''3J4#T\H&H"H#H%0)1%0'1*P:B*@&B5PI$509$ MKQR(J@*(7EL@JDH@>E5`5-5`]&J`.I69(_8)PR_=6\_EP8-&QG<`SZ^OK>/S%6PX<-9`=':DLPNDMKI'5GWPHKT'1'L? M7JQXH-&+%0]A0^<(B,ZQ=$Y,YXMK>T&0PH;.&1"=<^E<`/&&N$4@O4H@>E4( M9/MKC73[92T;V'3.9F+:QQKC#Q[G\OQ"(V/RZE4#M("*`V@)Q(:L@*A:`W$P M.D!4N4#TV@!1Y0'1RP>B*@"B5PA$501$KQB(J@2(7BD051D0O7(@J@H@>FV! MJ"J!Z%4!454#T:L!ZE1FCK2G!,,'@Y_D2"NW5EL],E9;LYEU]YZ?]RICN:41 MA\12J[#L]X2_5'"ALX5$)UKR_GJU-XA M;(P@,QT/.X8XE\<0&@WFI[E$"R`.FR40A\T*B*HU$(>@`T25"T2O#1!5'A"] M?""J`B!ZA4!414#TBH&H2H#HE0)1E0'1*P>BJ@"BUQ:(JA*(7A405340O1J@ M3F7F2'L0<,"4UFL M;M#6O3^5,1D0G7,@.A=`HUVRA8J!)1#M*R"J:HUTE\B*-T:,F92'G0V*AC(F`Z!P#T3FQG"_LM5TJ8S(@.N=`="Z`1KMD"Q4#2R#: M5T!4U1JA2T3%&R/&3,IVN_Z`&VR_NS\\%3COD3%37HJ<[$7&1*D1!]=26V%P MG9Z=BZ0406L=-+!V@&CM`AG3PIFUPMY`97XIWFJ,!Q5G"A^()08:8?*\OK#G MN%`&14"TCH%HG=C69_:_QYC*H`R(UCD0K0N@T7[:0C7:3R54++$"8HFU1N@G M]4AE?;FI,8*,[+TX[/R@DYO+0XV,*?7*2HNY%@UG5"".PB602E'.>V=V!D.E MUA<[E7AU90T5Q[T#Q!)=(+-$J_LV4(V6Z$'%$GT@EA@`F25:>^PA5*,E1E"Q MQ!B()29`9HG6>7@*U6B)&50L,0=BB0606:*U0-E"-5IB"15+K(!88@UDEFAM MJS10O52B.3+LPXQ?VJB^D&<<&AG3_965Y',M&LS)"R#NDRZ!SKIUL?AGH'"9 M<\4:B#.*`T1?%TAM:NR&F%P50T5[#XCV/A#M`Z#]U0YQF;X1$'UC(/HF0+VO M?>M+<9F^&1!]9$S@/1J>FVB5WGZ_/K^V[@,KV'#HKH$XP!V- M!LXND/$T:7_Q9`.OEP9X]]JA!Q5+]&'/+95`(]V6J]FEM>,1PH9MB8#H'$OG MQ'2>G)_;I[0.?KC%F2K>G(Z]?.E^TS28)N=:-4`+(`[6)1!;L@*B:@W$(>T`4>4" MT6L#1)4'1"\?B*H`B%XA$%41$+UB(*H2('JE0%1E0/3*@:@J@.BU!:*J!*)7 M!415#42O!JA3F3G2;JP/<^37IKU^>W[XU-6^V*BRR9SVK'787(N,:4_'J?W. MW70IOT:M`U_^FO$*UASC:R"..$>C\2]MNU`-!_2>^W5?\_[OKNBI4".6Z,-K MM'V!5KWK+5JY,O6L!Y,HB=/7^[NGA>WS[?OWWZ[>_SC;G[W]>O3T<>'O[ZK MQ%1_QF&`CQ[O/K\[_G!]TW2[OSNYYI/3FV;2C3UQ9:*N=,/9OG*F8M0CI_K. MA+BB8M1.RKXK4W6E&_96S&^3F]_V\0]M\?N_>RFZ19;MO_9S6^J"_=5 M2=5H'S^_:;K7PRRC#Q5-TWTVMO[JING2P>+JU9Z;]ET>62/UHLY- M^V:.O*)>N[EIW[.15]1+-#?M6S/RBGHEYJ9]!T9>42^XW+1OM,@KZA5+5N-,M6??%?6RF&K/OBOJ M/2]5MWU7%I/I33#9ERZQNE+OO;*8S&Z6DWTM==05=^\57UT)]EZ)U95D[Y5< M72GV7JG4E;J_CKW6'Y^^*;63,='7^YN/]T]M@(E_OSP\(S_40EP\O?#XY_==/+^ M_P0```#__P,`4$L#!!0`!@`(````(0"&UU:W#0D``!TM```9````>&PO=V]R M:W-H965TJNLV4ATOS.'^[W=[OE\MF_U:==\VB?J\N:N2EOIYW-_7O]779O%^K MW<%,.I^6<12MEN?=\3('#_?7,3[JEY?COI+U_N-<76[@Y%J==C?%OWD[OC>M MM_-^C+OS[OKUX_UN7Y_?E8OGX^EX^V&CBD"G?7:M7A[GOXG[,LOFRZ<' MDZ#_':O/QOM[UKS5G_^\'@]_'"^5RK9:)[T"SW7]54-_/VB3FKP,9G\Q*_#7 M=7:H7G8?I]N_Z\]_5K!;9.DJ$@L^>J^;VY:A=SF?[C^96G_\/(*%)622=D[%4EI`'J[UYTP5 ML`J_>=_I[2#NE>_:2_&ETIHHTKEV],ZRAZ6W]3R[A&3 M(T:%X8%6%%18D%X$[5I:BYL6TTFEA>AR4G'9X-2J\>`258?=%=3&HB?16+:, M91Y"$DJI"!$L'3)$,!]EB$@W]C$D3E57?IS#\6GPXUPYM\L@HLCZ-4G/`9.: MK:!7H>`&"8:U6>MX$T>.F?%0^N-)(M+4/H$P5]4PGKD&<^8L:3E@/.;<(,&P M`N8B6;/82S(>KQ(7&6&N-LMXYAK,F;N,0,X!XS'G!@D&8+[:>,0@Y?ZPB++( M52TAOII"7(,Y\:U=2B`.&(\X-T@P`/%M$C,')1F.A1LFO-=3>&LPXRW80N>` M\7AS@P0#\$[$EFWALL6[G;1RSR#<]9W$.V6'-Z@&<^Z"Y1PPJ2GB-&,'8@&C MP/LNWJ9LDT@RGJTVKE*@DOQQ$6_6]N$DJ.V4H#28!\5HYX#Q%H0;9&O0"G.W M%FP+E72X;P,()0'^:FC-^[DLF%D\`I;8'$%>"(%%6HN12>:AQ%%8.['.>C:# MT)HWNJ(,FG-GR-9!!:)%MP3JX0[*0D@3KP]1>EK81M/'V20TF>[+1<`\NESB[08G?@@[RU< M#V8]1Y#0NC:>.*@@)>[.`3CXC4N:=YCF0I&(<7EG3DH"B)/(!4?SKM5M/'W0 M0I47=\D13LB1/H`N_)#[JU*MC?Z`J>Y:"1: M;)$DCAZR!R<`B./,G9J4OA:N\?1!YGSZ21QL3@`YLH7@%HF66!@YOHL6&U9J M98!8N].71J`E;'P$('@D@H2M?"Y:570+P"T2,4,1X*-LC'T1Q$Q=ATO(H*DR MK2-V1.0(\M8@L,C`4OH6DF,5Y80<&S1E&/9+"/(9!MJ)&*SACI:)``9ZIEBM M]_@:,6C.W^T?V*0(\OGKAY"C$#'(OZ-QHH#^SBG6[!_FW"FAK M'*>YB"1:@']'^T3&!_JG>)*0&C2GSXZW'$&.;!%8)%J`?D<31<=[NRC]J=6$ MY(,@^@>,"/HHX](OE2*P2+0`^XY6RLYP@MW72\5,9W]RP'3I*^^FC$L:0:"O MB($([CJ:)@+H[YKB21)KT*Q\^+T[1Y!?/EQTI<68ZT'8.K'QOMXI9@H[[I)C M9O$H@C.(ZVJ!TUQ?YY%X4@E^TBL$BTX"90GXWQBXZ=8EJ1K5MCRGZ2`B<@ MI?00XO@>=KYY09!/O%`>A%CT[YEE^S2 M.C%I]S[OH6F?)+P):*KZ.=!#(M$!Y=NW<%%5V"2 MNB:ANH8M%()\]H&ZMHYL>[%AZU<&B)4[`F@$DP0V`:7T#Y/G_2+O7E'1:" M_"@"];683H:X%NVL3@R-8I(.IUV=+KLCY@CRHPATV&(Z&6(4[:Q.#(V"Z?&X M&U$:ZK(0P5G%5;C`:2X^:2WZTK!F'DHIUVZ+5P MMRV3N1Q!/G>NX-)B.K.+*]#.ZL20%<@FZ;5!\SKBW1>"O"@"B[26SA7`T9^M M0#9)I0U:?2L]V'LAR.?>ZFW[,:@,,*5OH=EE"CSNI,DZE-A[@P-J!4$^4YCF M+-)B.NL`:F480Z/1J^MK552G4S/;UQ_Z3=-89<9:X2W8 M7-P7YI519I?J[5AC7]H!]7+J^^ZU^G-W?3U>FMFI>E$NH\5:D;K"ZZWPSZU^ M-^\?/MM#@``Y4L``!D```!X;"]W;W)K&ULK)Q=<^(Z$H;OMVK_0RKWFV"^DE"3.36`C0T8#-CL-4/(A)HDI("9 M.>??;\M6NR6]#A/.V9L)\ZCUZJ,E66J!/_WQY\OSQ<_-_K#=O=Y?>E>URXO- MZWKWL'W]=G^9I<%_;B\O#L?5Z\/J>?>ZN;_\:W.X_./SO__UZ==N__WPM-D< M+TCA]7!_^70\OG6NKP_KI\W+ZG"U>]N\4LKC;O^R.M)_]]^N#V_[S>HAS_3R M?%VOU=K7+ZOMZV6AT-E_1&/W^+A=;_J[]8^7S>NQ$-EOGE='JO_A:?MV8+67 M]4?D7E;[[S_>_K/>O;R1Q-?M\_;X5RYZ>?&R[D3?7G?[U==G:O>?7G.U9NW\ M/R#_LEWO=X?=X_&*Y*Z+BF*;[Z[OKDGI\Z>'+;5`=?O%?O-X?_G%ZRP;[+P]/NUV"_?1AO7S?4V^0GY8&ON]UW91H]*$29KR%WD'L@ MV5\\;!Y7/YZ/\]VO<+/]]G0D=[>H1:IAG8>_^IO#FGJ49*[J+:6TWCU3!>C? MBY>M&AK4(ZL_\[^_M@_'I_O+>NNJ=5-K>&1^\75S.`9;)7EYL?YQ..Y>_EL8 M>5JJ$*EK$?JK11KMLT4:6H3^5HB<*+VI,])?G?'VJG[;\EIMU803&2DU;SO] MU1GKU((3&=HZPTV9P6SGB8PTV_*2Z.]Y5;S3&>GOQZKHT0@J'$HNTUD^6$F/ MW:@^G%=-CYVG/G!%FS($3G2-Q^Y3'W16ZM]3.=AO:IR?V43VH$&\)M9Y,5`?=-;? MS`B5G/>*^J"S5#;MNEAW\F6LOSJN/G_:[WY=T+.!BCJ\K=23QNLH$5[`BOXL ME[3W5C1:RI3*%R5#$C2&:+4ZT#K\\W/KMO7I^B>MG6MMU*TPJMLFO=)$+95* MN0_$!Q(`&0`)@41`AD!&0,9`8B`3(%,@"9`9D#F0!9`42`9D:9)K#XKZ_M+^M>8SFW;@=W"AIX"[,`>D#X0 M'T@`9``D!!(!&0(9`1D#B8%,@$R!)$!F0.9`%D!2(!F0I4DLE])J>X9+E35- M4GH\&#YUE^C"J$U%&D8WMN-[I1$[O@_$!Q(`&0`)@41`AD!&0,9`8B`3(%,@ M"9`9D#F0!9`42`9D:1++S;2[.D#X0'T@`9``D!!(! M&0(9`1D#B8%,@$R!)$!F0.9`%D!2(!F0I4DL!])FUW*@VF.I8Q[O6C^\RU)" MMF\UH6VJ,5]OG?E:&O$`Z`/Q@01`!D!"(!&0(9`1D#&0&,@$R!1(`F0&9`YD M`20%D@%9FL1R-ZVPEKM//VF5M>U33>YDO@+I`_&!!$`&0$(@$9`AD!&0,9`8 MR`3(%$@"9`9D#F0!)`62`5F:Q'(@'1//<*"RMAVHB3TI[YQ)61J5DQ*(#R0` M,@`2`HF`#(&,@(R!Q$`F0*9`$B`S(',@"R`ID`S(TB263\D99_A46=L^U<28 ME$#Z0'P@`9`!D!!(!&0(9`1D#"0&,@$R!9(`F0&9`UD`28%D0)8FL1RH(FN6 M!XM(Q94*_AR?MNOOW1T]`NFD6['<-B@@H>,42L7V;"Y,J$X;,'F(WM6<^:K- M9`#T-6E[>;BC7O.<8(8O!CS'`U/%;IXZHYN!F(IF4#RU;(<^TM^4#XFN5Z`Z M+6M&,SRW&=KJMLS8K\I8]YR3@:^MFD5KO6:K:2L'(D.MM=NF#J5GM$V?81(_*C.P"GZWJN=MNVTX/!9Q>!/[-:(F*KEKM MR#=R;179KQIUIKOT&"GZX[BL0W1%*QHK%K[!J%QYM>'?.P`A8N<*E:DMRJLWI[NV] MYY:Y@NB=C=EH<[.3/]YZZH9##6SS*07(1ZL`T0!1B"A"-$0T0C1&%".:()HB M2A#-$,T1+1"EB#)$2PO9*ZK:P9C^_LV#7&]X3+^6>R`9DJT[&,NE%:\[?75; M97O?1Q0@&B`*$46(AHA&B,:(8D031%-$":(9HCFB!:(4489H:2'+U>J*[PQ7 MY^;V4X>1S-<>HCXB'U&`:(`H1!0A&B(:(1HCBA%-$$T1)8AFB.:(%HA21!FB MI85LOYZW%Z_C7IP13#CZ_6ZH9 MPFX4KUY:R10&Y*-5@&B`*$04(1HB&B$:(XH131!-$26(9HCFB!:(4D09HJ6% M;%>?=X1581YW"FLD\[7'5H+ZB'Q$`:(!HA!1A&B(:(1HC"A&-$$T190@FB&: M(UH@2A%EB)86LOVJ3M%G3.'BT&U-X0*UY.S:4P=$\GZK608P^HSH*5X^J]LU M)_SGBQ5/]("1:`T0A8Q,>3B91F+%\D-&(C]"-&9DRK=K3F0L%BN6GS`2^2FB MA)$IW[QQ3OPSL6+Y.2.17R!*&9GRT/>96+'\DE$N;P\;%;`X8]@4\0UKV!3( M&C8:26OZ=8W,JC?:3ES`%RNN>L!(M`:(0D:F?+OFQ"HCL6+Y(2.1'R$:,[+E MG;AA+%8L/V$D\E-$"2,)]\T0S1F)U@)1RLBL*G1T)E9(RJ<8XZ1 MOQ5F4[%"]TE2(&OH:"2-[.N,+17.__F9+@X,Y,#=A*#B8# M1G)U$#(Z66*DK=Z]Z1F*#'?PB)$4-F9TLK"8KEV4/6*KD.0-6 MF3LGU@(Y=P'.+.K5M94LX7U&>6`_#SC[C.C$6PY^Z+F`K23C@)'(AXS$*F+T MSEW=D-,ERXB1"(\9B57,R*QWW7.\,&$K\VZK[L&P@YY*)"//D!DCLT3HJ3E; M2547C*1!*2.QRACIGG+WKTM.S[-8`TJ-`VM`??A6,\]ICRV-G,706:UZ;"73 MIL]()I?/B+KWQ-AB*\DX8"3R(2.QBAB],Q"IF9%:[77.N;B=L9784+E5L)24FC*3$&2.SQ(KA M5'B+7,-KW((SBGS*2*PR1KJC[*^1+#DUSV"/)JK/.:-)F3NK4X&0TT5XQ$B$QXQ$.&9DUKM=LIS;^J7G%ZQHJG`\S\?9TK%6>@T4F&R M=.JXI$+?9RP_,D6S]C*E*]82;6\ M:0656'!5I2=2EC]9B4Q;Z6[WFNXV=LG*>;?;BZ@*M9\:W!_[XE.CB-B;`5I& MY&QSMJ:5)913O]Q'YB`)$`T0AH@C1$-$(T1A1C&B" M:(HH031#-$>T0)0BRA"I]Z9(1Q>N+MZ#4KQ`X&6S_[;I;9Z?#Q?KW0_UCI.F M"LF6N'@!2[?1HC>PY'%?2&GSNUGD6.+DE5*77K)%1E MWZ`NJ>!?FITOY`ZL4K?9H1^.5G"J:66G4Y]7ZMQTZ/=0J$,7@!T5JL<4NN'K MJ(@]IM!%7T<%[C&%[OLZZC:O*J5-*54UHW@_I52IT75H1UU[/ M.^IV'-7HBI12JFI--V"44E6W;EW-C,JI4:>Y0=\"P7*Z=9H$]#T"2KDNYR6] M9.EM]6T3K_;?MJ^'B^?-(RU0M?S70OOB-4W%?X[ZV]=?=T=ZO1(]5N@5*/0Z MK0V]>J2F?J'[N-L=^3^J@/(%79__!P``__\#`%!+`P04``8`"````"$`6UG>O90%>1;:2%6M`A9&`1%5HE)9[5;![U^/-[3"V$),%1F%>36U@M*39*+DIM0U:*"-YG2);?PJ'?4U%KPU"TJ M"QI'T9267%9!P[#0UW"H+).)>%#)OA25;4BT*+B%_9M-N<7- MW+>1GL[HO,[H/3H(AL/IL4[9K.-ME!N,JS;/$.3E>D,(!D,S3VF8RQ8$5GL) MO^VVXZE#(5VOCF"GWJ6SC;B2\WBG/J^K?#8)`?]VL>`Z7Z*-0('TW,S/NX&\ M7.\&P;Y4&SEU@PVY5^_H)H[&X>RB'5SH:[01STX^ M<[V3E2&%R(`S'T"9=A]& MZW\```#__P,`4$L#!!0`!@`(````(0#G+6G3>P(``!`&```9````>&PO=V]R M:W-H965TF]JSBT"AM;DN+:VRP@Q MK.:2FDAUO(4_I=*26ECJBIA. MVD"B>4,MY&]JT9EG-LENH9-4[P_='5.R`XJ=:(1]\J08298]5*W2=->`[\=D M3-DSMU]8K)<^/K\ M$OQDSKZ1J=7IDQ;%%]%R*#8$D/C?VN M3I^YJ&H+IST!0\Y75CQMN&%04*")THEC8JJ!!.")I'"=`06AC_Y]$H6MVE77)?,NH^9PQ?>H!PP M8]\QYX:@+K<;JE44`J@]#*=\=LVH0=N5W=@KSZ4,T32],K5])+7 MM_X8#OGOK>)V70KT$=AY5MK)*R]A`D.'2JXK_I$WC4%,'=QTI=!R0W08_)7/ M^75\G*W\A4"&'S"0':WX5ZHKT1K4\!(HX\A-H`XC'196=9`Y3)2R,(K^LX:; MET/3Q1&`2Z7L\\)=&L-=OOP#``#__P,`4$L#!!0`!@`(````(0!(HJKW1!(` M`)-:```9````>&PO=V]R:W-H965T11[NZ^KQ]O=Q?;Y_437?FZ?7F\W=,_7[Y=[IY?UK?W0Z/'A\OLZFI^^7B[ M>3KW'I8OQ_C8?OVZN5N7V[L?C^NGO7?RLGZXW=/][[YOGG?P]GAWC+O'VY?? M?CS_Y6[[^$PNOFP>-OL_!Z?G9X]WR^[;T_;E]LL#C?N/R>SV#KZ'?QCWCYN[ ME^UN^W5_0>XN_8W:,=][[]N?SP)?MMO?G&EW[Q`UOC2MZ^$)_./E M['[]]?;'P_Z?VY_M>O/M^YX>=TXC<@-;WO]9KG=W%%%R'YV]V.WWS[^O[>9 ML"?O(V,?]!<^YA?YXFHZ.<')E)W07W:2C_=QH.\9-Z._W"Q;'-..1C>,F_YR MN\7%+,L7U\,]'^APS@WI+SH\&)P%V]-?MI]0G`YT0#-SN#/ZBPZ.N[,;;DA_ M3QO2A%3G1>#DYY]P\AXOO7@&+9:W^]M/'UZV/\]H@I,^=L^W+EU,ELX;5.B' M.>KR-5F2'IV7S\X-N:!G29K;T63Z_=,\GW^X_)TFP!T;K1)&66A2C"9.[\YS M:4AE2&U(8TAK2&=(K\DE!6B,$L7T/:+DW`Q1PNA6(Y&X3:.0C"9H5!I2&5(; MTAC2&M(9TFL2A(1F>Q"2=-J"/IPU)2@ECSR?A0-=>1M*@1AH84AI2&5(;4AC M2&M(9TBO23!T4OD)0W?6]-`IBXQ3(\\7T=C9:"IC]R2C/V.SRLJM5(4A)9/,A?;W3]G5)%KN*C$8XV&\-(:T MTHS]3L(P=V(`O[WV$DB&BHX@/@EI4#$(;3CK,!!,5"`,*3V9T3V,VIAE\709 MC7#/M7'4&-*.K0ZX[D8CN.ZUHR`1@01ID>;9Y'J;L0*]Q3";08 M4VP%)#.O!A*K!NAZ;-@"B54')+YZH,$J#(.KA?2T.2R+"9=.TMT***-+XU// M\YM0J@6;344_)1`]B;%A-HE3"5O-KOSDFM">)71=BQ^$N`&2WEJ@@[UU46_Y M?!+5:;WXH=["6+HB2L?RE[*RVWQ$4P\HHTMCI/+Y51B'@LU(D(A#R6@V[&^' MK%\QFE\/\9Q?WT3E>PTW\HP;(/'<6L]=Z'F13Z-TU<--0H:N"-.A>T.&7+/) M+:XF'BE]%1:50`=%4+$5)'>=746SNA8_"'4#I"7']W2PMR[L;3J=S**,V<.U M/VC0&Q:W$SLE;KZ0I"(5M[T:/'P\5Z(I+"J!I&$%)&FF!A*K!D@KAZM9L>I@ M);YZH,$JG&:N(CQ!*UQ`2G%8UQ/Z,R5FB<$F"M3 M'6!&X=)H\[8W4ZFK=-M(KU`1&J-L&(A=!$V+!DZTZ(Q5!ROO-Y]%SZ?']80" M7:VI`_1KZQU7K#INC$)ASJ.5N)AXLT"8'@7K'2/*Q4J%48JMX8OB,UIE$Z-" MTV/+#56/'9#N<6KK"/:5$)XK6G5]`:%2;+.NW+Q,_<1)MN&,W2CJUX19YDU]'!2B]N:,($RT5&PSLAFH-Y M6.@S4CHK+"J!Y#%40+*LU4!BU0"IU`8D5AV0^.J!!JMPS*=5]2X_124GHVB) MC!Y+`2LE*B!9UBJ@4$&1KQI6H1IC!<%*>FR!I,<.*.PQ*G1[6+W68QA2\A7( MR"6[;.[>V;SR*@=;:9?%XNAZE.ELD\^C^RNXH=)="23"J(!X@8N29(W+TJ(! MTH(;;PCK3<=6LXE?;Q9Q7=##34)^KN[5">R7%@8Z3C%Q\RA0Y23.104W5-FO M!)*#UPIHEEY/<5E4U0!I[?$-B=\.5FF_/2[;Y=2=`0=1.YSV!_,H47%E+0^V M8*M`0Z;^KF`ER:4&TKHQ[EMKU0&)KQXHH1178__W2O&5.E4J4._*3HF.EBY4SLZ M=ISF<>D&SPFMN=KY4-S_M7TF;;V9VGP)'@3>(SHRQ[,H,H-*BRJ+:HL:BUJ+ M.HOZ`(69W=7$<2RR_((4=.+;49?/XTS/B`J?44[Y/*I>"C24.5-:5%E46]18 MU%K46=0'*(R0*U5UA-[(3+ZR#53A4:`*@TK*4BY^RJJRJ+:HL:BUJ+.H#U`X M9E>JGC!F7]D&8V8D#[7(#"H9T9A%(/85DUAA5M46-1:U%G46]8RHB";W01C< M4AN$X9>6\L%+N%8!J>A85#)ZXVV36(W1L:BQJ+6HLZAGE(I.7&?_6G1L^4VU MRY!)9$TH+"J!J*9XY<63LI#0&-\-S*2[%DA\1^=CG;*`[QYL0 MJ2V:&;DTI5)IM.86L)(:J`22):D"$O750&+5`(FO%DBL.B#QU0,-5F$8XM+X MC3#8&GC*R.U>)`YQ=5ZP&3T0/)P2*"Q'XM*&K;#5SJ_C]]VU^('K!DAZ:X$. M]M9%O=&'NR*9]>*'>@MCZ>K1XU/TU)>O.D4#N:V,Q-(S:-M?PXW:C0%IR1G/7>AYGN=&7MS&ULC3MVKDHSYD,7B) MECY?#RLY%6RE4,G(_1FE:4_GV&KN=__9_&81S><:KD5/#9!6G;^GP[UU86_3 M;#J+SBQZN$YD/E<)Z]D:KY7';3FF7%#+<%:,E,8*BTH@D5`%).];:B"Q:H"T MT/Q-4&&`A-#!2GSU0`EIN4)7Q^*-5<#7Q4'F\BA:#*-I4TS92AYT"23QJX!D M`:N!Q*H!$E\MD%AU0.*K!QJLPN1T6HT]M34V4)B%[&+H6RJ%E-S2U7:'II=O MB,7PZBJ*<"UNH(0&2.N%^S_86<<-7^VLAV7$?EJL%+F*N`WE@A MV4SG+T;JQ4@%Y,O5:;R,U?`B>FJ`E.K@169:!_2*XQY>K`1IM7Z/P'%)+3>^ M&AS3.V9106%1R>B-TR98^8.>R?0Z/N2%9\E'#9#TW\+-P:.M#E:O==;#2VV6F%_F`>33U?Z`<9BKZS$;YX*[BATED))&JH@&3.U$!BU0!IS8PW(6%@ M)+YZ-$Q(XK0:W4V$Z`0-*,Q`)L6SF5)(":0WC+:"@A6EZ'$A,&]K:UB)'!H@ M+1I_^\&J;'KLT-#7;/'GXWM<3FC*U:JZ;(CGUW%9WE>\NIJ8,0J74;,/8K-` M:UP^JV(>5CK-)`+*#;7\&&GY&??=4>Y[6"44^2YEO3N1BH7JD5)@P58*E8P. M%]H5K+1T$S'D'K4HS4VT\$571H$G1.D;4LWJCI*L*'578:)SM?`A41Z9]'U) M':C2(R6WPAV34M@5*H%$2!609*@:2*P:("TW=B]6':S$5P^4T-9I=;W[H'0L MHE1=OX@VK04W#'0U-D2BKF`EZU4-I!7##74:,[XZ-!1?/5`B3[ER5TOB\/9F MYJOCX-$S"A.23?K>+)`#HX.E=L5=4EWH#TZGT3ZV9@.UPVN`M%Z.Z:P+.YM< MWT2;B!Z>K:#R=ZGK!R]A<0$4KJHFX[.9%AHCJGQ&H0'Q,73\$;(:7I3J@)3J MX$4<=T#L>!J=;?3P8B68OTM=/WB)`N=+?26Y@JT4*AFYI?SUG%O!BE_@9HOH M,+N&9\E'#9!2(=P<[*R#%7L9*7T5%I5`HI\*2/)1 M#216#9!6F:WK826^>J"$L$ZKZW-?+.O+G$=9%3`R2.6R!QW`%YQXO(;X_+ M"0&Z@O2_CYLO:X.X<:4K(BAR@TI&;Y3Q;,6G\Z2+:/=>P[/.6::S]JC.NJBS M27R\U@>=!35\[NK>0\$\KH8?W`RS7";FW'P'&E:B@H*1^YR8S.BKJ.HM4U;Y M0L["PB&Y&E8/Z7`-FON2-Q""1U3M8QH4;*50:5%E46U18U%K46=1'Z!PS*X< M/6',OGH-QLQ(EL(B-ZADY/9!X^.RGUD1*\2OMJBQJ+6HLZAGE/A4QOQ=BN;! M2[AD`:GH6%0RI3*>VQ-O($GXA44E MD'RN)*I\*F4AH>'NQ'<#,T$MD/B.4DBG+."[!QL]AW/(8!XI9JPV M10MYG)@+;JAK'"!)/A60J*\&$JL&2):O%DBL.B#QU0,-5F$83BMYY[;D!0IK MD?A5=<%F>B,%='@[SU;8SN=79@LJ?O#<&R`M('_K06ENC\JBWFYFYD,%<&W+ MEKFK)X]/T8-Y)"E?D4["NCFNG`IN&6AJK&41@PI6ODB^B;\#6>.Z2*/XZVH]KB?4%A?$;TPZ6_G.DY7O(O[0+9L%:N-B6,K8BJU86I/K^`O^ M-=Q(FP9(*\MX[D+/F?WF'=PD5.1J1*VB7]HTS'VEJ==_H$!<,YNP3(U:/S-'A)B.NM0O>H-RCT.:5X-\M( MB:FPJ&3TQK$0K/BD)O'U<[C6FO/WI&Z@A1^:G6,ADLAFOB&],'%[U]37SX/> MPI4A+K)C'1ZW;Z#?(C#Q]$BEKX*M%"J!)#U50+*RU4!BU0!IG7&/8M7!2GSU M0`EIG59\TY[0C-DC>H3RO.CW[J(7OMQ0/>@22.10`GH[(]_3AH/%,9 M*>T5%I6,WC@C8BN:46Y\23F.FPB1(R,M1X\.]]9%O4UNU/G)\'4T]UNH;KA^ M5?9R]+]MZG]/\G']\FU=K!\>=F=WVQ_N=TOIP\>?/HR8?U0U7RP_DR>ZX>C* M*K]>NB,,>X6VADNW^;-7:&.W=%LW>X5^O/5SLA?Z4=>4_2I;TD\=6C^KZ9)^ M!]#RS[/E9SHVLQ=6.8TBQ;,Y]9!LD2WHRK!N1"&AK]]0[X-\HROT#8]EY:=? M=(6^G[%TW\!(W=G-@LW1F+;4.G&13ZE#U-)]DRG1^Y3N.-EFE9'T_)R-HKF: M+U>I)U/,ET6*EW,*2JKOQ9)^LL[>4T^B2/'R>EFEID)[O:3?=B,_E^.-TD\" M/]]^6__]]N7;YFEW]K#^2E/O:OAYNQ?_H\+^'WO^XN:7[9Y^#9A65OJM5_KQ MYS7]&PO=V]R:W-H965TXDGPU',R9<-YKAC@)-2%.`3.9^??;LO6Z);5#DF_W M9L(\ZGYUZ)8L2W#]]^_]<^%7=#CNXI>;HG=1+A:BEVU\OWMYO"FNEN%?5\7" M\;1YN=\\QR_13?%/="S^??OO?UV_Q85X4WPZG5Z#4NFX?8KV MF^-%_!J]4,E#?-AO3O3?PV/I^'J(-O>)T_ZY5"F7_=)^LWLII@K!X3,:\CU#;;S\CM]\7?Z MDX@6"_MMT']\B0^;[\_4[]]>;;.%=O(?(;_?;0_Q,7XX79!<*6VH['.CU"B1 MTNWU_8YZH(:]<(@>;HK?O&!=J1=+M]?)`*UWT=O1^%PX/L5OW"O?1P^;G\VD>O_6BW>/3B<)=IQZIC@7W M?]K1<4LC2C(7:3.V\3,U@/XM['O/V#>T/?W5]O6+6J5^>97T\8RC MA]%1'U#59WKF5765ZH-V]#_EB*'T>"R]+\?#\U$]?=#5>Q=7]7K-O_I";GB7 MD*$/6J:6]>*3">8A6NI#UI:O9EB%9E<2<_5!JU2SIIP)806S1'W0CI_+L@J" MKSY\M>&E=*XF4[^].6UNKP_Q6X'64VK%\76C5FJZ](O6FZTV:N8856R35F:BU@2EW!:D(T@H2%>0 MGB!]00:"#`49"3(69"+(G2!306:"S`59"+(49"7(VB0E"GP6?0KX_R/Z2B:) M/J+6S`CG0]4)=68"I[8@'4%"0;J"]`3I"S(09"C(2)"Q(!-![@29"C(39"[( M0I"E("M!UB:Q0DT+OQ7J_*W,9WK5[X=P&9J0SL$!+`E2%N0CB"A M(%U!>H+T!1D(,A1D),A8D(D@=X),!9D),A=D(G1:2S1#2>FVHAV)IE1_"3`69"3(79"'(4I"5(&N36&&F[>@7PJRLDS`C.$U-&CQ/!6D+TA$D%*0K M2$^0OB`#08:"C`09"S(1Y$Z0J2`S0>:"+`19"K(29&T2*X"TZ;4"F.ZQ+M3. M]_2TV_YHQNEK4-6 M\>JV6R9B+42ZM3]%;PA4XI:[M3*:G2:X$1%&>,6]HH??5- MMKF9&T:]HTDEB=.5[XQ+:#I8':"UV^J`RK:*KU[9WWF31X"4H]V7E#@!/AM'JS/D42\SM+FCDQ,/)AA:LC(``)6BG$:UZ#21F_4LL_6CO4FW\:4VZG[SO/ MHB:L:+YGO:DWW.TE6V']:$O4D2B4J"M13Z*^1`.)AA*-)!I+-)'H3J*I1#.) MYA(M)%I*M))H;2%[HJN]C)D5'RQ8RMQ9=S7BC4=+G24K*T9MB3H2A1)U)>I) MU)=H(-%0HI%$8XDF$MU)-)5H)M%6^$-=TYT?OC)B) M37642T&L\X+;`JIE5FT@6C>RB>Z7G>6@PU:0#X%8JRM1#\B4%\MIGZT@/P!B M^:%$(R!3WB\[>[@Q6T%^`L3R=Q)-@4SYVJ7SF)JQ%>3G0"R_D&@)9,J+L5^Q M%>370(F\G39JM_R%M$DWUU;:I,A*&XVX-VUU.*&2RVQZU7<>9AVV0M-#(-;J M2M0#,N7]LK.Q[K,5Y`=`+#^4:`1DRSM[W3%;07X"Q/)W$DV!>/JUUPMIA`RB'0"S3E:@'Q.>Q6[$!1F\-E"C;J:#>Y\Q4^&#WD+[^63'/W@CY^2&/!F@G MH3+#VB_G..;LE[45_3U7/F:DAY#D7NT"\0^\!T=*5:8D:^]KJW?.(`FW:PXAJG0%SC#,BL48S4'%;LN`!B^2406ZV`]$BY^] M.>@;H)Q=AD`L/`)BJS&0V6Z_[*PY$UC9ZX3(+3V>7..4';'ZSH#,&G-R*XL- M'!=P9/DE$'=H!:07*Z>-:Q0G'G9JJ1.OSS]0R#6'0&QU1C(;+9?=LX;)[#Z M8*G2P\DU3MD163$#,FO,22>MQ4U=P)'EET!LM0+2`V6?3*]1FCC8V>0>>9[? MJE7DV:9&SNKDS,P6K'A2M(%X4G2`SLZY$%;LV`5B^1X06_6!L$%PXCU`.;L, M@5AX!,168Z"S[9[`BAWO@%A^"L16,R!3WB\[I\=S6)U=_!:PXAJ70%SC"LBN MT7F4KV'U7HUVIGUTT/RI6U!UV>DN9REREC,GMBWM:"UGVI&/LCJPHI)S6Z^L M1DSO+AQYEO:`6+X/],[5Q`#E/+&'0"P\`F+A,9#9;K_L/%0FL/I@/=.]XQJG M<.0:9T!FC3GKF1BI!1Q9?@G$\BN@=*2\AI/L:Y3GK&CNT?4_.H=0-S5NGFGT MP26.]K3V8:GG!Y;)V@7A*]Z!U]MJHKZW>O38:0)DK&P)Q M9:-/53:&E=D]WW..A">0-ZURW@[2`37&>`KYLSV>PENI+_BKYZ)%*ZTNZB*9?VD^_N;N/#H]1*WI^/A:V M\4_UA?RJ.K?)0G4@:@LH0N80)V+ MRA*ZAPG4+4M>R265Y+6:CE.I)$^-+F<"=8PJU=I^0-]*DIPNHP)U/"Q+Z$XJ M:.66T-54H"Z>I`_=/E!)7IOI<)E*\NII>I2Z=-U&:J4L#>@W,:^;QVB\.3SN M7HZ%Y^B!IF@Y^;K7(?U53?J?D[Y9_QZ?Z-&ULG)E=;Z,X%(;O5]K_@+B?@"&! M-$HRFE!U=Z1=:;7:CVM*G`0UA`AHT_GW>^QCP#Y.`MFYZ#3VR_'K<^P'QUU^ M_2R.S@>OZKP\K5PV\5V'G[)RFY_V*_?OOUZ^S%VG;M+3-CV6)[YR?_#:_;K^ M^:?EI:S>Z@/GC0,13O7*/33->>%Y=7;@15I/RC,_0<^NK(JT@8_5WJO/%4^W M\J'BZ`6^'WE%FI]S]_R\V/>_)!!7:?(%M_WI[)*7X\P[T\V3;,VMOQ@A2_RK"KK M67*M_^EI\X9!OJ)"KP6I9O0OI]*YK@8<]Z^D56X(_*V?)=^GYL_BPOO_)\ M?VB@W#.8D9C88OOCF=<99!3"3(*9B)251S``/YTB%TL#,I)^RO\O^;8YK-PP MFLQB/V0@=UYYW;SD(J3K9.]U4Q;_HDC.J`L2J"`AN%?]P228S]@L&H[BH2,Y MP>>T2=?+JKPXL&I@S/J[490A5O)[_UI1XR#0UC[SO38AA%6BYB"*2C0UJIG(]B2PG6H,Q,J1T_,A"O')A M6ET5HHA,>H.:6!8RF/G=?&6Q$^R5O@P;L)3'VQ!B:F-J#K1!S53:8`$QF1B] M_HVB1(]X$F+J:48\H2;"U`2,+*C$Z/;G_=-&IN)'7`DQ=1415ZAA`?KR)VSJ M&__(7DQ0;Y=0O+`(#8;WF7B(&B1YV:`&[86Q3Y<4=MM^GDP_]_>4$)L^9OVJ MD$MW@Q*TP<(Y75(WNXWJ,2"/GJ7[KJ2:V'HBY5,:V%C]IJ0IZC2"KK-^JYC6 MKN!\N(`,N6LR@:9.B7`W:N,C$XS>L/=NNA,PU9;70.(0O:8K*W,H0E>!3PO* MC.Z@?]KT)<`ZWA=B6/?%0KK>6G)/(MHSB?H'@OE0B[5VGMYA9>0CI#($,U>AWEO6B M52)]='S,!A)["-U2;>[]*"8LWBA1#V^_?VNHS74+UXSP>F!#70%U3);`1H9< MN7HN;L&9/41GJ1XZ\BB1/CHRV:Y$\!"%I7JH$DK45<*D=**ZKU@AU+U?AN`* M;>,>`;@AE$A+A-YB;(A`,&XT)J1ZJ`Q*I(_>@M0ZF3_$SL!FI[TAE.AF&5JT M6E8(+\5WF>&77V!S,XI[\JERH$A/B-9BEN,A.HIO;D#'^WQ2(GUT?$RVF*,3 M.H[,`>).?W=$,:'0!@Z7PBK,NT=I3`ZB22>RBD/`.=(8DL\T1E]J@89'!*;> M8J;G(6`&2+Z!XFAX5*-K+>;H!)@CVCE*I(^.]+5W3B@(IV%T9`[$4S0' MM#@R--DY-(26-53.G1X\017IZM!:S.()WFHO[[[@0Z0C! M>E98QRXETD>_!=600'5D<9"21@XLK,G0M#CD5)1T(JLX_XNWX17>TB\)&R72 MT],2V')!X#I0'.3E0'$LJ(9:B[DT"%1'%@Z#KA4 M/Z=[_GM:[?-3[1SY#A[U)S%L]`JOY?%#4Y[ES>]KVC.D"```/"``` M&0```'AL+W=O#:.0ZPF<62;TO[[7=L02-)U[0O@W'-/SCWW:I* M],B5%K).,0DBC'C-9";J?8I__;P?S3'2AM89+67-4_S,-;Y9?_RP.DKUH`O. M#0*&6J>X,*99AJ%F!:^H#F3#:XCD4E74P%'M0]TH3C.75)5A'$5)6%%18\^P M5&_AD'DN&+^3[%#QVG@2Q4MJ0+\N1*//;!5["UU%U<.A&3%9-4"Q$Z4PSXX4 MHXHMO^QKJ>BNA+J?R(2R,[<[#.@KP934,CZ+#F1;@(@6F]R@148&U' MBNSH4VV`3LI'RST2V8?07(X MR+YW#?BN4,9S>BC-#WG\S,6^,-#M*11DZUIFSW=<,S`4:()X:IF8+$$`?*)* MV,D`0^B3^SZ*S!0I'B?!=!:-"<#1CFMS+RPE1NR@C:S^>!`Y47F2^$0R!O6G M>!S$\RF9)O]G";TB5^`=-72]4O*(8&C@G;JA=@3)$IC/E7D=;:W_*A5JM"2W MEL5Q014:VO.X3N;)*GP$3]D)LSEA)ABUH+@+V;80VPP0V*J$VOLJQ]#%E_T_ MB[))75&36?>%FR%DW$5LAXC)O(5T-()[[]=HDV`:KCPAB[YQ'C-QPV#=WEX] MZ"@`:Z\5O.Z.!:<8RKMT@TS:REQ;-QXSUH@OE^NR8+ M[FOJN^$Q$Z=IWA.\O0Z22RL[BI+W*++@GJ(X:BOU+GF,5T0N-GB3KH.CA+2I M'4FS]TBRX)XDTI]KC_&21@.7.M'%RY+LS76U%UZ?)0ON28HO[GN7/.8T2_TH M+&_+,)PT;Y-?S'YO55SM^9:7I49,'NS2)3`+[5-_'VS@/G#;,VP#L(\;NN?? MJ-J+6J.2YY`:!3,8&>4WNC\8V;BEL9,&-K'[6<#%R^&/%P4`SJ4TYX-=4^U5 MOOX+``#__P,`4$L#!!0`!@`(````(0#?,(T.4@,``.4)```9````>&PO=V]R M:W-H965TZ M`C^X4Y(*'VKYDQV_$KK;2RAW#!&IP!;E\RT1!604;&8H5DX%JP$`/IV&JM:` MC.`G_?](2[G/W3"9Q:D?!B!WMD3(.ZHL7:1S$R<3LR"$F=N5&']%%0 M"RC'XRJ9ITOO$5)8G#3KDR9RG5X43B6;-R31O-=X0-AC0O`V9O@AICHTQ8QL MRI,DTD53L6W&*Q,$R,[E".H05'N4A"!+^A!U-M=&,T(8+4P(()=C@O=KI,2Y M"]'TZ4>A;[W9:%)=P2R(IKN;\6Z,ALQ-F*!_SV=28ILIF+YU;32)9D(!2H>& MT-G:3/>C<&BJ"5=R"9<2VUS(XC(:PQ5DD5W%S7@?H3`9XIIPI9=P*;'--<1K MNL=H(IVOU!_>:K(UW@7H/J8)DQI3HSO@_;Y28IO)ZIRUT1BF,.Y?:I#&FU$V MA#-!RBY!4N(I4C*WVF9M-*9\$8(_BVJR'Z?)?[@"N'3.SY56VV1#$4P!3R*# M=H7"]%5K68HX3`;Z2=9@!EY"9^[?Z15AYTU;YJZY(X)Y@BR!FKLJ^T:`_#`; MXC-L9JJ:H=,0OB,;4M?"*=A!34P$C=NOFFF^#A9KI"YD:WT#4UZO>_T&#-D. M[\AWS'>T%4Y-*K#T9RE<$MR,:?,@6:<'P99)&*_ZZQY^3A&X\/T9B"O&Y,N# M^B'0_T!;_0,``/__`P!02P,$%``&``@````A`))MI+R^`@``<0<``!D```!X M;"]W;W)K&ULE%7);MLP%+P7Z#\0O$>;;7F!Y2!V MD+9`"Q1%ES--41(1411(.D[^OH^DK4IRLUUL4QP.9^8]/ZVO'T6-'IC27#89 MCH,((]90F?.FS/"OGW=7"XRT(4U.:MFP##\QC:\W'S^LCU+=ZXHQ@X"AT1FN MC&E78:AIQ031@6Q9`SN%5((86*HRU*UB)'>'1!TF492&@O`&>X:5>@N'+`I. MV:VD!\$:XTD4JXD!_;KBK3ZS"?H6.D'4_:&]HE*T0+'G-3=/CA0C05=?RD8J MLJ_!]V,\)?3,[187]()3);4L3`!TH1=ZZ7D9+D-@VJQS#@YL[$BQ(L,W\6HW MQ^%F[?+YS=E1]WXC7?S,>%D9J/8,#%E?J_SIEFD*@0)-D,PL$Y4U"(!/)+CM#`B$/+KO M(\]-E>%)&LSFT20&.-HS;>ZXI<2('K21XH\'Q2+0D-Y;%<8$+#>5Y MV*3+:!T^0*;TA-F>,%.,.E`RA.PZB"T&".Q4@O>QR@E4\?_YGT790T-1T_GP MPNTE9#)$["X1TT4'&6B$]/H:7]9FP1D&\G]9S-*.UX6Z]9BI:P*;\J[W8'`S M1-J_V=;P]73L(<#U%*3+>*3`8WH*>@\&"J"+^PI>]F[!0^_I?!8_UC=IBZS%SU^J3:*SLN=V!IOE[-%GP6--T5"V/>4Y3 M?S>YZ&$_^OQD$$R5;,?J6B,J#W:LQ>"S>^HG[A8FKIM/8;VE@UKF?%;S:&+1X%`"XD-*<%W80="_+S5\` M``#__P,`4$L#!!0`!@`(````(0!ZZV+CIA$``/A6```9````>&PO=V]R:W-H M965TSW M[?/^?O?T\7QZ,3D_VS[=[N[NG[Y]//_7/ZN_79V?[0\W3WS@CA:?]Q_/OA\./S>7E_O;[]O%F?['[L7VB*U]W MSX\W!_K/YV^7^Q_/VYN[/NCQX7(VF2PO'V_NG\ZCPN;Y+1J[KU_O;[?%[O;G MX_;I$$6>MP\W![K__??['WNH/=Z^1>[QYOFWGS_^=KM[_$$27^X?[@]_]J+G M9X^WF_;;T^[YYLL#S?N/:79S"^W^/YS\X_WM\VZ_^WJX(+G+>*-^SNO+]24I M??IP=T\S"&D_>]Y^_7C^>;KIENOSRT\?^@3][_WVUS[Y_V?[[[M?]?/]W7_= M/VTIV_2+U60^)?K9E^W^4-T'R?.SVY_[P^[Q_R)IRE)19,XB])=%IJ1W)"#C M`/K+`;.+V=5BNEB&48\$TM7^=NDO!ZXNIMGDM;`EA]%?#J.1CPRS8C[]?=N$ M:#GU]T5_3YO0F@/I[RD3FE*A]`.&_\.!\R.9N(R/O:^BXN9P\^G#\^[7&2U- M>K#['S=AH4\W00OU$Y,S5-1+!465%%0^!QF2H*Q2L>QI&?S^:9DM/US^3J5[ MRZ3K$=),4_*!$BHU*!<.*1U2.:1V2..0UB%=BEQ2@H8L437_%5D*,GV6,+OK M`9&\S4U*!@J""H>4#JD<4CND<4CKD"Y%5$IHK:N4C#<5 MX]1.IW&1,RF9.R/T9PB;34W*RDA: M3W@UF<54#1IXPC4C,DXS<(Z,T^IQYN;NNT&#QE&Y"T;LA.3U=)T]AM;D:(8\ M9#.SZ^1@S89**1BBFL/D2[!"#Z,FL3#9K'Q(C1`1;CRK!8N%5Z;Y="I$)R@X MM71EO:L53]GOR4*Y9LB4W959R)LM,ZC(JJP!B7#C MA5M`47@Z-;?70:47UGD+=B[-V_&.%$YQ9EDR9'K2VB8H!J[E^1<2*(7%K/C\ M5Q.C4OF0FJ%$N/&L%JPH3(=#?7N="M$)"J;OA`2Q1TPK*$+S>$(.1YA\ZJ`" M4'^X[XU!"4AR5@$25@U(Y!M`PFH!B58'*+Y.2`\WX=1VRIS9"*9SCI`NBOE$ M9SWOQZ$W#5+P> MY2ZNP^L86D6JI]@FFH,D$RH84BTE2E%+2=KZW/3-"EJTOPS-?S8UJZL&2T9L M_(@M(#VB:64=M%X:42JU]*,/GC!-0VA"LV5X=_O" M*UV,Z!5S*+`I#<AW-3'9E5EOE8VI`HMP`$N56 M*T\75V8%=BI&96MVFD_NZ=HG,Z1]LC7J.5A2R05#J4\&*[J.J:F\RD?4B!#= MQK-:L-@FFS[>J0B='NN2CS?:F;?##)D*LL<(L.0Y%X#D.9<,H8+F@./Z5 MQ-20$>4&D+!:K3R=S^Q!2\7H%)UFB&?>$#-D*LA8\APL>=(%0ZJ"E"&>VBV[ M\B&U%VX\JP6+2],*=RI$)\@:XG>YHIGWR0R9TC+%G8,E!5`PE-HB0/%`E!EW M4D%$2J8&)+H-1.0$UP)B7=N8(-+KZJR=9JEGWE(SI'>SS%IJ9B7'H4("L3.6 MD)_$%Q[9>NTR-!AX!-5>NO'2K9&>3R=F57E-!I5E=((Z9TL,TTO[\?Y>*Y:3@Q4.QEK4=]/JM3LRQ5KJ5H> M22EKR0)K)!#]JL5]Z1&-5>DD4.XK'5$WJ#$S/EV<^('/S!MSADSQ.L_`]EU* MJ>!`M?=%EGHE,)^ZXF4MJ<$:-R'RC9=O`5%;31ZDV:8[:-$H`^O%M,Y/<^T] M7?=]ANAAXO'G#*5ER5!:EF"I(EF87;62P/'9]&?$&EI)64H@[JL%2X]HVG4G M@>,CJK*D[>Z4E=[33?ZBTT[W368E4`%(]KH2D,RY`B2L&E"R;P(25@M(M#I` M?M^[J9,WMKM6_:=_(Y!ZYE8RL`R:N=$O*3:7\:ID_J39^I?%`-2*0; M0"+=&NGIE3V,=BI(%P85V0GF8A[H)DD1HN>``LZ9E4`%('F8)2!YF!4@8=6` M1+X!)*P6D&AU@$8*PSKM_H4);9QO_T1^[MTW0VICRA:FJ>;,4CV'M29R\R7T M)[H'F-V^&ALS[:'<=>(`R9C-H"]CM@.FQS2;>??:F+J\@K5.O>N[CH+S:-!3 MXP%H0G,;MH]L8=Q"SK34S`V1Z?;D/^\=:.GB]YLD!D@V24"RTS2#V-$QVX%V M=,P.`_1CZG0'CVW3/5M=!ME_UDNME9KS'-5CI MAIXM3)?+A85V47BH]%#EH=I#C8=:#W4*TAD,_CG-X/$#YCS:;569#$E%Y&`) M5'BH]%#EH=I#C8=:#W4*TG,.9CF=\_L6:;3<*A4,2>_.YPQ)WRD8HC_\A2+S MIJ$4`DJF\C*UAQH)?.&K2D*`I991_F< M6=(_"D#B`TI`4E,5(&'5@$2K`22L%I!H=8!ZEDI#=IH5[^G:,3"DCS(+;]$:GKL_D2W-\R#DP.0\5@*0R2D#Q(QPSR0I7):`&E!0<(&&U@**L M/7EVN#Q2?*=Y^BP:^'0-,J2+;VE:3LXL57Q1BXY=Z!4E6&FE>8L`E@36@-*R M96L"*VD6^?,4G436=36)#,,24>I$"BL&E!: M+$ZK!4NT.D`C!1*\[@ES9N\M-W6=12@=_,D"XXWYACH"JX"%$?Q/,H62NT MB6,Y9"VIU)H#$_D&6B+?`CHJWT%KI.#^$L.=>-U#*+1[)O6SOHCI1G,,]IX^O?[?S; M)^`L>G+:&R4_R\RXQ6NPTD:4+<>*CQ4>JCR4.VAQD.MASH%Z3E;T_VNIK:(QCLU4`S) M_I6#).VD8(A.GB\<@(6`BJF\3.VA1@)?.``+`P9.>,.]H85491$@?_)?F M.)4OF"754@"2+:H$%,].[AM1N)QVJMF5V0)JL&2H!I`,U0(:'ZK#Y9>&TDD\ MS9@OO#%G2&UNV=+,+`=+MIP"D&Q,)2`IG0J0L&I`HM4`$E8+2+0Z0'Y_6@3[ MFM92OS^]Y&Z]T^+8&O3)+[2B*(+5@LR0BM:<8/?R99F/\_[ M<=17H@M`\OQ+0.HIK.S[)K#28Z7_J`:LM.*\AP8^84W\PSI&EV959(S*SU4`IK+@0A0ZN^SE=F`*K"DN&M` M:4'&6Z7/5R6M#&6]@Z&?#=%'@PXJ(P5)3^*4@@QT4Y`12DHM7SBH`)16'[/$ M952>50-*>QD'BE8+EFAU@'S[6EJ'_2ZWV:OH5#"D=\B5W2'!DD=:,$3'/SS2 MDB$Z@ZA2DYQRL=SKG]RW) M:.!3H[&,D/2%G!'ZHJL40221X7GA`,@Q1$!,Y65J#S42^,(!4`A0[I2,SM)I M'G[I/3Q#^B!T9?9OI[NMD>HY,VQ6>*).?`Q$\4@*1N2D!D!8:./Y*L842L MKAJ!:<$Y5@O64?D.K)$BH^)5_>SX"6D9Z"99$3*597;VG`-3]PE('GT)Z.BC MK\"2P!I06EG#?2&E+5BI?'9EK$H'5KI'I\<(W>G^$E._]*:>(:HNJ9OLRAS@ MAWK_S(]'6_3?A&G[]"7]?;M/'*Y5`- M]+NC/VZ^;?_[YOG;_=/^[&'[E!_NED2B6E5%*Z*'_XSU\//\[^V#\]WQ\>/YZW&LWSL_WCW>'+_>.W MC^?;3?;+U?G9\\OMXY?;'X?'_'/P]-OS]_W^Y'VQ?YY].WB^>?3_O;+Y71PX^+ M=K/9OWBXO7\\KSTD3V_Q?HJ+7^]_W+_\73D]/WNX2T;?'@]/M[_^D.O^J]6] MO8/OZA_D_N'^[NGP?/CZTA!W%W5#^9JO+ZXOQ-.G#U_NY0I,MY\][;]^//_< M2G:]SOG%IP]5!^WN]W\^.[^?/7\__)D_W7^9W#_NI;=EG,P(_'HX_&:DHR\& MB?$%66?5""R>SK[LO][^_N-E=?BSV-]_^_XBP]V3*S(7EGSY>[A_OI,>%3>- M=L]XNCO\D`;(_\\>[DUH2(_<_O7QO"T5WW]Y^?[QO--O]"Z;G9;(SW[=/[]D M]\;E^=G=[\\OAX?_J44MZZIVTK5.Y*=UTFHWKGJ];O_J\NU>1%DU17Y:+]U& MJ]OLOZ,A?>M"?FI#NNW>Y=5[+D?F1M40^6F]=!KJY$0_7%M#^6D-KYQN.&'8 MDNZOJC2_'.L\#L,IRPXLY9=CI9>MYG7'=/TI2W16R^FM5J-]U6OUJCX_97N) M6N476VOW;:9M"?$ZXDRLVY![6_>VC\$JO[SE6B_J8*_FSO#VY?;3AZ?#GV>R M((G]\\];L[RUDK9T.69-??1_32.9/\;+9^-&7$C8RQ1YELG_QZ=^K_7A MX@^9L'=6=!,1M7W)X"@Q\]-X'A))B61$[(PA._/6)> M&RNY$3K3NGO=]0?RIM;(K18#.2`R))(2R8CD1`HB(R(ED3&1"9$ID1F1.9$% MD261%9$UD0V1+9&=2[RAE577&]K30VK4,EGE=N4LU<$Z?&-%`-9[K8;9G;Y\O[_[[>90GR\B\[T+F_WCQ99:*&;.>^:9!GQKBG2=CFU MH/%&[3>^)FUW-9)]=[#06-'5L75#ZZC5JBZHU>A<77O_I;^$5P@+[90,J';2 M:32OFNY_+=>)=]$F9>!NFD]?M%'[%UT3<_<]KJ[MJ\O@HJU(AW5H';5,,/SQ M*5B-4Y1VC[V4`84&WL7(&N]=C(G*=M^T8+1DM&*T9K1AM&6T\Y`_KF;'_XYQM0<$=UQK5*==Z^57[AYFJ!TTM.A2 M;A?.1.\?EYK*,%45)GK&OG)&A1JZ[G4EJ]R/5`7W)?L:,YJHX0GW4U7!_8Q] MS1DMU-!QWPK6RJ6JX'[%OM:,-FKHN@_V`EM5P?W.\^6'C3E!O"-L[('##9L: M.3$R,*F],&QJ%(1-T/34&HH*3<_85\ZH4$.G9YK!W7:D*K@OV=>8T40-'?>M M8+,R517`.32[$?#**L=V;"X[= MQQO"P"0C34#HN`XMZNIM(V64L6'.J&##$:.2#<>,)FPX931CPSFC!1LN&:W8 M<,UHPX9;1CO/T!]7DRMXQ[C:U(([KC5J>[O(=K`6#UI'%0)W"*2^4J#KZM![ MV0S6Q`SE:I(#:<`40!)=QWUMNQ7X&D%5U]5N](.Y5D*@E8V!M+()D*JF0'JJ MF@&I:@ZDOA9`JEH"J:\5D*K60.IK`Z2J+9#ZV@%5*C\P3)+E'8%A';<3)&DOUA::.@;3&"9"V:PJD6:T9D*KF0.IK`:2J)9#Z6@&I:@VDOC9` MJMH"J:\=4*7R8L0\R?".&*GD_M;1HDNWEWOM8*.Z#"VM'NN@GD,(590JY5CX&TZ@G0R:JG4-55MQI7P=EB M!H%6-@?2RA9`JEH"Z?*P`E+5&DA];8!4M0527SN@2N6'49C%_$>[2_-L3+"[ MM.C27X&",_S`JMP5"$BWI2F0''Z/*U"O'71^!I6_M@1[[QPJG8H%D&\8WK.@ M:E?WQW:C%]1?0J`S>@RDE4V`5#4%TGD_`U+5'$A]+8!4M0127RL@5:V!U-<& M2%5;(/6U`ZI4?B"9=*9[S_IG@62\!,M4C8(]3C`Z`_,H'32XAT,K&0%K9!.AD95.HCBM3 M<&4S"+2R.9!6M@!2U1*H]GS9".X/*Y2KR1I('6^`3E[%%JJZKGXP=75G;LN-?=6.0L4`-&0R"=/"F03IX,2%4YD$[$ M`DA5(R#U50*I:@RDOB9`JIH"J:\9D*KF0.IK`:2J)9#Z6@&I:@VDOC9`JMH" MJ:\=4*7RQ]ND0=WQ/GTB;M=94V]<:^2L%P.K#DP'[3+W<*9U4,@#V`*I4?(]*%[XD1(P^VFC4*SBS!CF=@ MGK4)%P^+-+Q3J.R$#A_DS%"N)CF0SIL"Z)7%PU9?UR5/9OD?(Y?J!?N:,9#6 M-0$Z6=<4*M05Y@EG$.B%S8&TL@60JI9`NB"L@%2U!E)?&R!5;8'4UPZH4OF! M8_*C[N+RSXXN=9;56W-J%*PYP>@,S,DF/+K4J*O-3ZVJZY^G*=%B?4E`'%>F M=BO82.=<8P'D&P9'EA%4.-/T@D\_2PAT#H^!=*9/@%0U!=*9/@-2U1Q(?2V` M5+4$4E\K(%6M@=37!DA56R#UM0.J5'X@F;SE_S^0ZNRG%T@U"G8U0>PZZ?852-5@#J=L-T,EKV$)5U]0- M;CT[%%=5>:%G'I`\&7IO.P%7;OR;HD42]8BJ`:,AD$Z=%$BG3@:DJAQ(W1=` MJAH!J:\22%5C(/4U`5+5%$A]S8!4-0=27PL@52V!U-<*2%5K(/6U`5+5%DA] M[8`JE3_>_TK>UBPHP1[(HF"I">;M0%4(BJ%%[E)CD5UJPC]BRN!$)TX.I!.G M`#HY<490U1.GT[@*[K(E!%K9&$@KFP"=K&P*55V9I(*#[IE!H)7-@;2R!9"J MED"UYUZXDUNA7$W60.IX`W3R*K90U74%.XD=2JN:_-`S>=53=[DW+C5U>E9N M<[I5Z8=WHYN.59E/,(X[FEXG_(C;D6E`JBE8&M%E$99'6!%AHP@K(VP<89,( MFT;8+,+F$;:(L&6$K2)L'6&;"-M&V,YG?JB$>=G3>;H.YU^!9/PQB(,(&T98 M&F%9A.415D38*,+*"!M'V"3"IA$VB[!YA"TB;!EAJPA;1]@FPK81MO.9/]CO M2\IV."EKD?,4V8#1T"+_&=A.D,E)586XR=A7SJA00V?!:0:;OI&JX+[T?/D] M8W)W[HKYRC2H4WWN`:!3(Z]G"`VM*NB98!.9J@I-S]A]SJA00Z=GPL=W1ZJ" M^]+SY?>,2:ZY/?./CM[R$1]M8VKD=1BAH35T'VYDE%GD^,H9%6KH]D[0^2-5 M:>^X[?)[Q^1UW-YY)6Z,/-B\6Z2;@X%\^%FI%`TMZNC.,V64L6'.J&##$:/2 M,_2OV60PWG'-=<+#FRLV!R(_G!U#L!\<=(XJ#,002/?D*5"=\.B$?R69H5Q- M3'$@=%T#N-C#2A;;ZNBYY\520P"K5C339 MB[NN>'Y'W%5R?ZY9Y&?[.L%3(@.K"$@(.P>Z_@35T(Q/(>:P( M2#8B3B<'!Z$,*C_RJ)/K=CDU%G'#H`]'4!U#]MI[G"W8UI20\[%,DL5^`/^C M6VGE)>CR^AQETIY.-P4;HH$U].*Z-I1;'M:'U*ID^3=_3MWN!^>X#%YT*N1` M;OC:%KT2OE:%\&T&45+"Z_>""+B!RIOKW:!G M!JI"9PX9I8PR1CFC@M&(4MU@\1Y8F9/+&,+27UR#4T.J*DS^C'WEC`HU MU!6H1X=95<%]R;[&C"9J>,+]5%5P/V-?: MT48-'??A7TEO507W.\^7'S>RE7E/W!AYL$NSR(N;FGEQ8V4:$6F74&:18Y@S M*M30Z8=6<.`9J0K]4+*O,:.)&KKN@WW15%5P/V-?>E:4;$80RJW(,,-FRX9;3S#/VQ-FD+=ZS# MX\:;WE+6K9,?SG#?`,F?&J*K!Y8Y(SFT2#)*4*6,,C;,&15JZ(8`+0IU6YT: M2_8U9C11]VCJE-&,#>>,%FRX9+1BPS6C#1MN&>T\0R\$Y#5Q?@B1X M6T;8"DR]K1EM@!QOVPC;@57>_!$.4V*OC'"=4')GZ03<.>D>5QI1%FK9/H;*I MS##1E:%<37(@)],/I*H14.WXNA'<34J4J\D82!U/@/Q$;G`JF$*%?&PGF!DS M"+2R.9!6M@!2U1*H]AQT\0JE:K`&4K<;H)/7L(7J>`W!1>X@J"KS(RK,?+X2 M4<<,)P+C1CXF-?O)8)4*>G&@*A@.@71.I4#UU+@,\BD9BM4B!])96`"I:@14 M^Y7O#J"(LA>A-F/8J.<)T,GY/86JKJS7"!_'GD&@E,]^:Z8")=LEQA4V\6@0V0S MF9C-(],2V7PE9K/%)9+H2\P&G4LDWY>8 M?3J72-HO,4F]6$E?2JI/JX(KE0.^E%2A32574E)-)RJYEI)8"R3[F9@C"K=` MDJ").:EPB>1"$Y/IC)7TI236:DEQ2$FLU7+ZE9)8J^50)"6Q%DA*.#&'-&Z! M9(836).KMP" M295$IBK99DF)3$6BU)$2F)M5K.RE(2:\&-M,`2JM-_B]FY.'ZA+SR%RL1/I:G@^+E4A?1[W)DW9)&2V1)YD2\^A2S)N,3[3D1KS=1+W) MPX?)(%HBSR!*/;'KD6?PI"1V/?*PF93$>D<>3$S,0V;<:GGCJ-P-8B7RLK;$ MO)V-;>35:XEYUQJ7R(O4$O/F-"Z1UZ(EYCUH7"(O.4O,6\VX1%ZVFI@7X'&) MO',U,>_!XQ)Y]:IXB]VNY.V:4A+K47FGHI3$>E1>K"? M-YN85P!RB;QU5OH@UC9YL:B4Q-HFKY.4DEC;Y)V"4A*K1UZQFYAW''(+Y$V[ MB7G5(9?("W=EY&)MDW>J2DFL;?(F32F)M4W>G2@EL7KD[<*)>9,ISD MT1)YU[#$6ZQMA;1M%&V;O$142F)MDW=$2DFL!3=2STVT9"`E@VB)O&999DFL M;4-IFWE/+E^IO"Q52F)MDW=A2DG5MHOCS5Z^SN[G[;?]]/;IV_WC\]F/_5?9 MVS:K+YAXJK\0K_['BWT#R:^'%_DB.]G^RO=^R1<7[N6[(YH-^43YZ^'P@G]( MHRZ.7X7XZ7\%````__\#`%!+`P04``8`"````"$`NJ@KN-X'``"#(0``&0`` M`'AL+W=O79`2>X!C!E.Y.9;[\M2VU9:I8A<\Y+@)^Z_Y):K9N=AU^_ MG8Z#KWE5%^7Y<6B,)L-!?MZ5^^+\]CC\\P__E\5P4#?9>9\=RW/^./R>U\-? MG_[[GX>/LOI2'_*\&8#"N7X<'IKFXHS']>Z0G[)Z5%[R,Y2\EM4I:^!G]3:N M+U6>[5NGTW%L3B;V^)05YR%7<*I[-,K7UV*7N^7N_92?&RY2Y<>L@?;7A^)2 MH]II=X_<*:N^O%]^V96G"TB\%,>B^=Z*#@>GG1.]GSE"O[\9TVR'VNT/ M(G\J=E59EZ_-".3&O*&TS\OQ<@Q*3P_[`GK`PCZH\M?'X;/AI*8Q'#\]M`'Z MJ\@_ZM[W07TH/X*JV,?%.8=HPSBQ$7@IRR_,--HS!,YCXNVW(_!;-=CGK]G[ ML?F]_`CSXNW0P'#/H$>L8\[^NYO7.X@HR(S,&5/:E4=H`/P=G`J6&A"1[%O[ M^5'LF\/CT+)'L_G$,L!\\)+7C5\PR>%@]UXWY>EO;M3VJ!,QA0A\"I'9R%S, MC)G-1&XX6L(1/H6C88R,Z>1'?E/A!Y_"S[S'#1K3=A8^NW8N9K.IO9C?;J=XWWMA%G65@B?GVGG4KC!IW";CJ;F;+YH!^5&/`W('SZ<,&#"];Z6&CB& M[,MGVFK@&+(OPG$VNBNJ!@XC^W)/:\<\>=NYX&9-]O10E1\#6&"@M_4E8\N5 MX3`QG`4\5-V\^+=I`?.!J3PS&9```4CY&B;SUR=[.GD8?X4)N!-&JRM&IFJR M[DS8?&/*+B$>(3XA`2$A(1$A&T*VA,2$)(2D?3*&0'?1A@SY?T2;R;31QBBM M.B+C;VFA[4S0R27$(\0G)"`D)"0B9$/(EI"8D(20M$^4T,(<4D)[?1G'?&76 ML&#WTM5:S-6`K;@-;`D8L#4A+B$>(3XA`2$A(1$A&T*VA,2$)(2D?:*$$&;O M)T+(K"$)86'O37E#BR$WLM5U09_TG1$&VB7$(\0G)"`D)"0B9$/(EI"8D(20 MM$^4L,(&^8FP,NLVK!B,%2<00R1K0EQ"/$)\0@)"0D(B0C:$;`F)"4D(2?M$ M"1B<&92`\3UIQ$X:S:'8?5F5_%QU98I;L/7P'8F)J''D9+:4<23$Y<2&!;Q+ M:FNI);77&>&`^$0H("3LO/K2VE2(.B.4WA"A+2%QYR6E#5-;SI+."*73OI`R M`#"GE0&X$F@XGF*DF;4::4X6[?F['8VUL.&'WW9?Y\22H^$1XA.O@)"0>$6$ M;(C7EI"8>"6$I'TO)6#L3M@_1=T.&+-6`\:).6\/3N;$T/=N4;[H4M?M/.20 MF\9,77T]8;1L92U+.X_YG09F1$#J"3N;&_5$2CVSA=J*32>!U6Q)-7%G(I[UYDP+BX_ETB5`)(5#1-(J0B2$M:5[@\728XM(ZL:( MI%6"2.@NM.TFQ?+618TYNVC6"Y=`D12.$0DK2)$7%AKW`9+I<,6D92-$4FK!)%HKZ'-Z!3+6Q`%,BDC(>(IXU6@=\+)4.`2(I&R*25A$B MF.?R!*3O1QNTDHY;1%(^1B2M$D176YUB:>N@AIU=6OIA_ZDS(7O0HJWM`L$$ MP*5ZC4BFD(O(ZJP\1/)8[B.26@$BJ14BDEH1(JFU022UMHBD5HQ(:B6(I%:* MZ$HVLTO+_QY6?O6!JR#&<,6>!+$@I1EC9/&>,B4U6 M=%)90"L+[ZHL0BM^%(.GANIZN$%AV;$M(MFQ&%5N=BP15M@Q8ZG-XA25K\P' M=GFZ-7!_E!?877_XV([?P;1+O';Z7+&GXFS:*&N"WMBUM,(L<"GR*/(I"B@* M*8HHVE"TI2BF**$H59"Z&K&;4S_ZM\_[!K]H*?-#('G]6:.51"Y%'D4^10%% M(44111N*MA3%%"44I0I2X\N77+*K5C"\N6%/6F^FNQ$!7`:4'',FCC;9ZKMD2PL:M/RR=#P;" M0RL^!J:IK4<^EM-ET>Q?0B"Q?NJ4T(JH5Q.!Y-!H)]$U&O2&!I'[\IV]=X7UX^FAP_A2>.8\@Q+DBE8"NY3#ENQK)3:4V%=* MX!7SLWF%K^#5\]4Z3'@E?>H\PQY."U93!YX77^'0AVM=<&T' MGCI2^]!VX)$AY;'MP/,^RMVY`X_9*`_G#CPVHSR>._`8#/BXBS:\`K]D;WF2 M56_%N1X<\U<8JDG[<+;B+]'YCT8<0%[*!EY^MV>1`_RS0P[O]"8C.%"\EF6# M/U@%W;]///T#``#__P,`4$L#!!0`!@`(````(0`?O&FWTB(``.7&```9```` M>&PO=V]R:W-H965T/;__C_;__V[L_[Q]^?_Q\>_OT!AZ^/?[R]O/3T_>K MT]/'#Y]OO]X\GMQ_O_V&ED_W#U]OGO"?#[^=/GY_N+WY.';Z^N5T?79VO'W[& MW=>;A]__^/ZW#_=?O\/%KW=?[I[^.3I]^^;KAZOZMV_W#S>_?L%Y_V.UO?D@ MOL?_(/=?[SX\W#_>?WHZ@;O3Z4#YG/>G^U-X>O_NXQW.P,G^YN'VTR]OKU=7 MPVI[]O;T_;M1H?^]N_WS,?KW-X^?[_\L'^X^=G??;B$W)LI-P:_W][\[T_JC M0^A\2KV+<0K^\^'-Q]M/-W]\>?JO^S^KV[O?/C]AOL]Q2N[,KC[^,[M]_`!) MX>9D?>X\?;C_@@/`_[_Y>N=B`Y+<_&/\^^?=QZ?/O[S=7)R<7YYM5C!_\^OM MXU-QYUR^??/AC\>G^Z__-QFMO*O)R=H[P=^$DV&?Z;GU/?%WV9!P.YXP_B8Z_N0)7W@G^.N=7#Y[M&@=!\5?;[]&UV=.#^MS M[("_OL/S7J;+]Y0<<5(FX*`!=ZT^0^?RZK.63P+S]W-BL) M$/77]:'%A53DOU\X-7,`!%LXC]H2_O[]8;]^=_AW+^(,W M.B2,UMKD.)NX5>L\9T1R(@61DDA%I";2$&F)=$1Z(D-,3B'TK#9"X:]0V[D9 MU1:5#C,)^F^,M+.)=,J(Y$0*(B61BDA-I"'2$NF(]$2&F"AIL69(V@W6=_JB M(''K>F'[C\)VM;_0PATF&UQ@1+@CD8Q(3J0@4A*IB-1$&B(MD8Y(3V2(B9(2 MJUA)^;R$SAK!B`UT7OJK_=YHZ(TV0<.)K/$GZK;3W3)OA$TP,@J^U5'#:,%1 M.^OQJ&52#Q.YV(9#))(1R8D41$HB%9&:2$.D)=(1Z8D,,5&"X6J\0#!GK06; M"`0+DX-,6,_@<382G3,B.9&"2$FD(E(3:8BT1#HB/9$A)DI#1/T"#9VU62KK M,W,)/'BC:*E,1"V5]=E*"YUY(\SVO%1BW^JH72447_2?7^#.6L^\)_NP5(AD M1'(B!9&22$6D)M(0:8ET1'HB0TR48$@QE6`N2[K8G(0\\Z<3)>=)B^D)_D03 M9R_>L]&\C(CD1`HB)9&*2$VD(=(2Z8CT1(:8*'U=1JX$?CXB1W.MHJ`H)AEE MC')&!:.24<6H9M0P:AEUC'I&@T):/Y=QQBO:!>CZ_`2[P=)$WN>NE_/:/KCB MQ\4L9B^*4)/<'X/5'**,D:#0EIMEX3&:K\0K3YG MQ0X=Z6>S3%H9#0II_5Q&ND"_*8%%@Y5TS!CEC`I&):.*4T7$GJ49RI M$,IW"/%CEC`I&):.*4WVT^FP]WEOG!#[> M6\/]@O&.XG$U6X5H)92S5<&H9%0QJADUC%I&':.>T:"05MMEW+':+T2K3]`1 M>R%369E*\^`201>:<:8R(9VIK,R]@,QW=!^R)-VK0U\O*PE&K"&5LE3,J M&)6,*D8UHX91RZACU#,:%-+Z+2M,UER8>&1"TMY("58B?,8H9U0P*AE5C&I& M#:.64<>H9S0HI"5U*??/;_YN\S:)M4=1_!T998QR1@6CDE'%J&;4,&H9=8QZ M1H-"6C]7,,3ZN51E=3[>]7OZ?/?A]\.]`\F/F#;X"'3Z9-3MMU96CZ8'"MRG MG$>Q6L^%8N;19C=^FHH;OF9WS8.!A'+!;DI&5>CH/J>%9W.%KX.!>&Z4&RV3 MR_1CF9[/,=Q#`%8/CV(]"&6^XR;*B!D5XC[X*AE5W+%FU*B.^IQ==K[@G'TR M'Z6JZPFY/U$N9&^JB=4N"HMD1W-3*)>.^S%X5F>F8BND/1Q1*2B,50G2!VG& MJL7*CW5AVAMI'\?2,KJT>X&,/DL/!WU83\A]T!O)&&Y^31F_6(6@R`2-3QJ- M5KF@]:C9SLQ%(_K.7N757OP MR,U`)(^]V2168>8S04'J7)"?9C/+A32''J6@X+<2%*QJ03CZZ!A-P#9BI<\D ME'8JKEPXJ+AZUM$EA4FZVX$"L=X.&\ MQ]`MQ2J,6`D*(]:"](CFLM*(U8]&U$JGJHS%U\@-%Q@>;7"I#%&Q-FOGZ*VP MA"3D,^F("TCHN#+1FHO5Y;0_6L>%.`YQ6@H*8U7BY=FQ:K'R8]F]N!''XUA: M75M4V#C^[_OO/\I`<,&6%&0S%QM!DG.SO1W$*,3+T2.7(04I[5-=F5C%,Q5Y MUR>T+,O?<);O49R2,LH8Y8P*1B6CBE'-J&'4,NH8]8P&A;1^+D>/+YBOOGNV M<9[,YC8A74"MSD:#0EIMEZ?':C^? MV;J]:I(T7B[F8GL0JWB=31W-.C-)3.8[ND0\6HW!O3YTES\O.'2?;H?M[K"9 M4#3/1T89HYQ1P:AD5#&J&36,6D8=HY[1H)#6SV79L7YNH;WN[MG&N3(K;4)F MI9F4Y^@[1C.0,H9#0IIN9<5`JB)2=()16(=O56$ M,D8YHX)1R:AB5#-J&+6,.D8]HT$AK=^R2@$U-.DW(1.2)L\\^HY*TKFCI&`Y M6Q6,2D85HYI1PZAEU#'J&0T**4GQ!1:]`SR_^8_F>I5[M`V;ZI%1QBAG5#`J M&56,:D8-HY91QZAG-"BD]?M+*H,M5P:"0JUS9)1YM+T8$_S$W;-@('%;L)N2 M414Z_N#N63`0SXURHV6R*?X+83:G\N+[L/4HUH-0YJVVH7K)&17LJV14<<>: M4:,ZZG->5@5LN0KP2-_7V-@Z7*S".6>"]&T$D^/F8C7=ZMBO3*U42'M8V:6@ M,%8EZ-FQ:K&:QCI?AX1N+.T;:>?J<&N+@1="AS/^T0/R&E7J;\PMB*-8A0#+ M!(6[7+E'V!#&9;%:7YI\IN!.I:#@NA(47-?6]79C[@,TJI..M64Y_';.X[8([E8+":)6@X+HVKL\O+T@1?]2)0%J6J&\Y M4??(1(R9[*-8A9G-!(7YSP5AE'!+86-N/!1BA<@(5BNS>$JQ"B-6@L*(M2`] M(EWSIM/6YQB-J-;FN4W4[4W2G_J8=O2B\W>/S)YFKFI'L0HQDWGD+DJ18&:* MH9#0IIN9>E^N>&2BU18(P4HZ9HQR1@6C MDE'%J&;4,&H9=8QZ1H-"6NUEY<0YEQ,>1:%Y9)0QRAD5C$I&%:.:4<.H9=0Q MZAD-"FG]7`YNH_42/U&S^,G=\RF;5]$Z(1.M)H,]^H[1!&2,D:#0EKM947*.1LVVA]W4=EYU/>K\)U0B9<32UW]!VC&<@8Y8P*1B6CBE'-J&'4,NH8]8P& MA93<%[;<>?ZNWVBNZQI!X4'*(Z.,4^.P6J^WC/*&16,2D85HYI1PZAEU#'J&0T*:4F7%5,7 M7$P)BD/26P64L57.J&!4,JH8U8P:1BVCCE'/:%!(ZYH9#0IIM9?54N[*8Q[?$!24.3+* M&.6,"D8EHXI1S:AAU#+J&/6,!H6T?JE:ZG77^PLNI@3I<#4W"(_!*H2K]Q4F M)6>K@E')J&)4,VH8M8PZ1CVC02$M][)BZH*+*4%!F2.CC%'.J&!4,JH8U8P: M1BVCCE'/:%!(ZV>+J1>N]UPQ720K)G.S]ABL0DC.'07E;%4P*AE5C&I&#:.6 M4<>H9S0HI"5=5C%=<,4D*`Y);Q50QE8YHX)1R:AB5#-J&+6,.D8]HT$AK9^K M:6S%M/C3Q`OGQ63V$PH2'KT1OLDD(9AYA-OE@G)&!7W.?K`Y6XKX1 M%-RWC#I!VKTI(OM@)>X'00GA;1GVJ@]"+[DZ\TC-QV2EYL,CY&%1I)H/;7+Q M%7Y-M1`4!"L958)"QYI1(RCX:AEU@H*OGM$@**&T+=B>SRDNN2KS*'J(X<@H M$Q0^`,X%A><^"D'!JA04]OA*4+"J!05?C:!@U0H*OCI!P:H7%'P-@D8KO478 M$NQUD6$](,#Y[;8%:OPJ$+F$;X0(`LM%R1?VS*/CXB3L+^6@H+?2IRH M_=5^&ZT6JVFHC?U)T$8(BA*7!AEC')&!:.24<6H9M0P:AEUC'I&@T):5TS8OYX.7CHO)H&9 M4*RJ)9GOAMO[(?`GHP@5WBIX*CV)$LM*7/ED\&RW,@NO#A8R6,.H9=0QZAD- M'J62P65%X"47@1ZI:^!DI:Z!'JFKNGW.,!=?84(^UAXGH.\;/5GL4)X."?I`,BI.PF9:" MPH6U$B=J?Z5D4*Q^D*`UXCB,U0H*8W7BY=FQ>K&:QEIOS4W-01R/8^E9>ZG8 M_+ED<,?5IJ"0;!P998QR1@6CDE'%J&;4,&H9=8QZ1H-"6M=EI>6.2TM!V$BC ML+>?H`0KV7HS1CFC@E')J&)4,VH8M8PZ1CVC02$MJ:TVGZ_6=W-9&>MG;N@= MQ"JZ.>B1?DSYW"RI+&T5W.M#MR77"X?.I=7.HW@U$G59+_3EOF. MQBJXUX?N$N@%AS[EV_'3:#N/XM5$*&.KG%'!J&14,:H9-8Q:1AVCGM&@D-;/ MY>:Q?J]_Z'\WI?E*6X_T2C,UUE$ZAAG(&.6,"D8EHXI1S:AAU#+J&/6,!H64 MW/MEA<5HKC%_9SX MQ]<%4YP=Q"JZ+GAD=GQSKR03*Z0ZT64GN->'OBSGWG/.+2A>:-XJH(RMD:#0EH_FV"__KJPGY-O63`'07JEV7HF6$G'C%'.J&!4 M,JH8U8P:1BVCCE'/:%!(R^WR]_@R_,)*\^E^N%]PV%,%<&24,H9#0II_5QF'NOGPO5UUP6?X\?2SFE_O/&8(O"XGZU"M!+*V:I@ M5#*J&-6,&D8MHXY1SVA02*OM\OA8[1>BU5<"L:0>A9WTN">4,H9#0II_6S1\OIHY7IF/Q#GMO%6%PPSB]9:@N$]BFXL]`UV>)$B,;Q)D1A>I4@,[U(D MAII&9+#2(/[E#5V$0GQC$)P;QB4%\8A"?&,0G!O&)07QB$)\8Q(^9$7]9-;$Z MF\L)D>0@+)+IF&"0<^H;V4%.8I"3&.0D!CF)04YBD),8Y"0&.8E!3F*0,V9& M3EOAO#Y#7YUQ^2/,!+.]=Q.9R2Q!_F*0GABD)P;IB4%Z8I`^9D;Z987*ZFRN M5$02+#O/0A*/2":&2"8&.8E!3F*0DQCD)`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`KY$3I^P*SDGIK_M ML3/WBXXK_P;W^.L>,PONH+!W-[V6X^S$_OHP]$X.&.X\C1<.3($W"].'*9B[ MRE1A"LR`.^,)$S+WBB/9F&&.:$#,T=Q5!L0RDQ8W.O](!F$ET]LF02 M??T25,>:F)C^R?4=W?,1LQ#J6"9S5SE%3*)GTS=20VDT3@UF<.Z2/C^906\6 M1L,,SEUE-,S@^ M,E)S-S&S`,TM#BQ`;Q;6`^9N[BKGA[GSS+]N>'5Y8JXZF+^Y6_H<9?YH1,S? MW%5&Q/R9$5'-K+HR<,FL^K)1S>K$S(H,=Y]&C3&KWBRL$0<$TAVF$#E?'MROE?_F+$PF>0#,T=C8>;(#C.GQCJS)X*IBCN9>7'% MXY)Y\<6FFI>)1=S-_+3K9[?#P2?1/N#LC5Z?9KXR%&:'Q,2.SW3/C8Y+L^%N\`B3ZQ^PU MF,'9KXR/&:3Q,8.SW3/C8U+5^/N3LVAL_.LN_YMY]@5S/GO&$9@Y=R7KDCGW M)6Y8!D@VXK)7]C%BF&!BF$UB6$+$,&'$,&'$,#O$,`'$,`'$,`'$H#8QR!DS M(Z>K0&,Y79G_JD=B5]B1J-3W3-^RVIN(Q^KRM7%XK@GB$X/XQ"`^,8A/#.(3 M@_C$(#XQB$\,XA.#^,0@?LR,^*[,C,5_J9B7,WG;SS*Q%D^A"_*EK-"$0GQC$ M)P;QB4%\8A"?&,0G!O&)07QB$)\8Q"<&\6-FQ'=E4RS^"VMQ,Y599BV:3/.P M$K-X+7IFUJ*Y80'1IQ',6@PCF.-W!<*2XY\*"I4+;28633W"@1B.C!C"@1C" M@1C"@1C"@1C"@1C"@1C"@1C"@1C"@1C"(69&3I?$+Y%S2OJUG!,S"\ZD6U!X M-I-T"PH3@\+$H#`Q*$P,"A.#PL2@,#$H3`P*$X/"Q*!PS(S"+J]?HO!4!Y@% M9^I1+#AOIA;$E>UX.@7*K'@O)E:+L/9F\8*+1S#'OS!;WLS9LDPS#G9B M>L$1PY$10S@00S@00S@00S@00S@00S@00S@00S@00S@00SC$3,N)%^3JON8":SE*V8Y0E6)%B98%6"U0G6)%B;8%V"]0DV:#:I M?_KX^?;V*;MYNGG_[NOMPV^WQ]LO7Q[??+C_XQNN.2N\=S/B;QYN/_WR]AH7 MIBO\W[C3S7VF-D3TQ=6XKT(];KMT;:E^<+>#3PB=[+=W_<:;A.1S>X:V'_1; M[]"&>I=]7J.R=.0X'/!"-?G@J.G6<9^[<\=ANLLWIB6=04VTK=W[31Z-TG"MW M#G@6+=GOW+6-/UW(_5Q,X%&99#]W#E,20OW6K@TWB[C?]=Y-'[X?P$V0Q4T? MOD^7;'.GAZ][)=O6KFW\J4`ZE#-WZOAF3;*?FSY\3239YF1)'N?U[O+J&K]B MD>BUP]SAQV]2+9@Y_$Y+HF6/D\8OD*1:<,K)<:[WB%=\`S75!Z>+GUE(M>!D M\8L`J1:<*K[KGFK!_.-[V8F6"\PP7N^1:H$&>'%%HN42X^`WC!,M.TP@?M`N MU8+SP>^R<<" M:P'/:7'+M=NADQOM88,S36_/&YQILL^UNP[B9>4\SL%=!5%F51TA7'PH!>/<[W"IIJ\M!W6&`>/!'&?PQH1 MC\4L<<0' MIWV*NRA/\&OL@LEP=6LY87]PNTR"N^?TKL:G\%A?]XC=U?@`';>YI^.NQF?? MN`V?`IS!9S+\\#'*&7PFV_"1R!E\IMLN+Z]Z_%@XCX:?P$9+:J[Q^\QH2<44 M?G8>^G3GG&H[[.$1/\7!QW?8(^"3%VW\3ON5^XEJ[H.? M:[^JDV>+WQ-'2^H(\,O6:$EYPV^X7[E?M.9Q6K2X'[;FE@-:#LF6(UJ.R98, M+>X7ZME;AJ/.DT>=X:CSI#?\L/U5D6S!JX_&04MJ?>'%+6A)K3"\ MCPBQD&K!&PYP;*E5@Q<6P%NJ!2]BPIRFO.%]3)B?U%'CA4%H21TU7EV#EI0W MO*0)IEFR[OLJWJ98*+76R!>_\NG(O^>(YQ1N\KMQ[M;CE@",X M)(\`;\%"[*2.`"_#@M8I=?"V)K2DU,F@CGLK$!\!WI"%V$FU9.OSJQR?B'"? M"BUULB5;(P[P1$&JSP7ZI%JR+8YZFSKJ"BWUU'(Z9TB/[]]]O_GMMK]Y^.WN MV^.;+[>?4,R?G;@W?SS<_>9NK$S_\73_'47^VS>_WC\]W7\=__7S[&ULK)S;;N,X M$H;O%]AW"'(_B27+CF-T9Q'K?,1B,;M[[4Z[EZWJ^5]W^GYZ3(%C?K9+-W;?GUBVQ73\L]'?_N7XEB2_KI_7^KU[T_.SY;EY^?=ELEU^>:-Q_!M'R#MK]'T+^>7VWW>PV M#_L+DKO4!RK'?'UY?4E*-Y_NUS0"%?:S[>KA\_EM,.\FH_/+FT]]@/ZS7OW8 M#7X_VSUN?N3;]7VS?EE1M&F>U`Q\V6S^4*;EO4+4^5+TSOH9^.?V['[UL/SV MM/_7YD>Q6G]]W--T3VA$:F#S^[^2U>Z.(DHR%^%$*=UMGN@`Z/]GSVNU-"@B MRS_[GS_6]_O'S^?CZ<7D:C0.R/SLRVJWS]9*\OSL[MMNOWG^KS8*C)06"8T( M_?2('.DX-AWII^D87%U$X>1JUKL_TC,R/>DG7'ZL(XVJ'S#]A$LZ[".>IJ8# M_30=HHO99!)-9U>D<:3CE>E(/^'I@X.CD[,_1OIYVN"N34?Z"9?'!Q?0@M/S MKU:>GML/#B\X+!WZ!=X^.,``*T;]?-IN_EQ1CL9#77WNE3[8C!7:CC=M/?#"?C6^43-`I$205)!,D%Z00I!2D M$J06I!&D%:0;$BNT=/*(T([I-/)?-[!N52^Z0@R6;7`]M0.WT#9T#4+@8D$2 M05)!,D%R00I!2D$J06I!&D%:0;HAL4))9[$5RN,A5-:T&.FB,#CUW1AJH^EP M?P@#=X4>C!#H1)!4D$R07)!"D%*02I!:D$:05I!N2*RPTL7UA+`JZSZL",9" M$XHA2"Q((D@J2"9(+D@A2"E()4@M2"-(*T@W)%;`*$&Q`J:O31&%"^BR`H:SL(A@R"($BBR?CZ M$)94D$STR@4I1*]2D&K8RQJHJNN&"Z":A*1_V)["(+(#'QNCV6&D MB;>;D]"DQNBZ7R7!:&:K9@<-3& MBHDJ$$X(2F]N1\4@9TE=V9,?PVJPIH"N#LLL!3)+R)G9#,W<(P=BW0*(K4H@ M"L-@ZIP%6L'*/CFN#R.Q`Z>RVN&9^%/;L2JRG%5FD+W,PM'A*/I]/(;58)T! MC0?QU/)CN@CSN$-GG\W0T5[8/.[>8PXK]E@`L<<2R/;H7"\J6+WET8ZT2G+_ M_TB;5)E7Q4(5IQ3\L;J`HDP+0S<-,U8AK[`$'>ERQ!T#9[6FL+K2^Z$KG$&8 MCR@'8E\%5([Z*F%E?+E[;P7AWI<=797W'HON[YM7.N'?JQQ4M:X7,H=D&CJ[ MP,)8V8EOZ*RTF*VP8R82I1)E$N42%1*5$E42U1(U$K42=1:RHZ_2XV'TCU_/ MU1T%=[O0*.)5%!NK`4HD2B7*),HE*B0J):HDJB5J)&HEZBQDQT]ER\/X_=PN MK'-N*MJPX!;J'JN*-.]VL42)0=&T/\4]B3$;0#F3,KE$!7=\(SEF`RA7EHP= M)I4X#\/TSC(S>?8P'@8-XR%0$F@4\?Z52I09-(AM+E$A.Y82559'>\PJASYA MS";E'HY9(SNS&8LKL;'B,2>J^J?%8W>4UP=CI9.=:S<+SU@%,YP#L:\"B,3> MOA:5L-*^)N[&7*&]'[T=1I5.GQ!&G7V3'@YZ$6AD)S1C)PF)8<4++`'JGY#T M24AJ4#32)UP07CE)7"8[Y4`L70"Q=.E*1V,G$ZBL3G:05'Y]0I!T.FX%22-[ MR8R=O"D.C!7/?P+$`4\-B@*=>%Q'[CV\3';*@5BZ`&+ITI:F9&GJS&-E=;*" M%)Y6:O3F=JEAD+.2G&F*8<73G0#Q=*=`N@B[&CGCR-#.77(@%BZ`V*H$TL(4 M?#MSK]#>=[$#]$M*BE"6%`8YB\NI.V-8\0I(#(KX5E`*I&XI?;\9.TEO!A%> M,SD0ZQ808=T22.M&U\ZL5E#IA>VPN?7!\8M;*`L!@\8\L;%$"1#/=6J0V8ZB MD/ZS9SN3G7(@]E8`L73I2$^NIB(BIGSQ+"0WIW\G(H?<_;!GAQHY*\:9[!A6 M/+,)$,]_"D1[%U^AQLY]DPQ6]G7,.7ER6+''`H@]ED"V1Z<8J6#UED=[D;F) M^D\EFJ',WPUR]C3GJA;#BM=,8E!$DAQ6D63`2MW\_'X3S*:A(YU!FM=>#L3> M"N@<]5;"2GL+1^-K9P(K2'L6K2^5#R<7A,73U_Y^]\<*4_6:@RQ,G2`LC)5= MF$:.5M=9?(?SVA"4POP2;@` MXOOEL42)1*E$F42Y1(5$I4251+5$C42M1)V%[/BIY'X8OY_;+Y2*DP-I-(RJ M)G0LO"HUFO`)G*JMG*0&*#-HT#&7J$!'G<]$03!SLM*2+7``E42U1(U$K42= M0?HP[2"?5IO0+3P138TF?`#KRJ0X:K^YT$0YLA4./0-BK5RB`LB6=_*LDJT@7P&Q?"U1`V3+.TE4 MRU:0[X!DX%6:8`7^I[:57L7>5@P:S@<0#S(!HFOJ8*4ZI5/*5AA1!L1:N40% M$+];4DI4`;%6+5$#Q%JM1!V0)](T:U:DCR]QJAWP5A M]E4#L:\&*D=]M;!ZPU<'X=Z7/6MNY>C.VL>2[K&L*($&B8M$B42I1)E$N42% M1*5$E42U1(U$K42=A>RX_I+R43W'==)!@X91U49,$F,SX7642I0)I=R007Y8 MH)])!D>SP#GQ2K;`YE])5$O42-1*U!GD20;58]Q3-NQ#78CC7/0*E"(/DD$@ MOM8D0-95722#;`7Y#(BUD&%9\`4P,HI,+\Y$"O94,'ERA1RYU M"XC07L4'))-!K44+KG^((I-!X:N6OIH/^6IAI7V%[DW-#L(R&:3'&L?WEX\E M@[U,O^%S2*;N2S\+8V7=@9V*A^ULA4E()$HERB3*)2HD*B6J)*HE:B1J)>HL M9)TS]/C6CO[Q`K0WMR^K0)P*QA(E$J4291+E$A42E1)5$M42-1*U$G46LN/W M2PI0>O3I;N4&#:.JC9@DQF:JWU/PW#1-V0(K.1/"N2`%=U,[1^1)P-D"PI5$ MM42-1*U$G4']6.UXOU M.K2^Y+)K24R9+F3NYC4;.*>8^L*=7H%5'>I"%>"5`O!!3(+T0`_J*`N?" MD<&"Y`9+0TR8\%9P1QQ`"01OP47D[/853(ZZJV'%@VN`>'`MD'9W%5U$X]'@ MG[.\.YB_Y=J>QM/*8KI2B&DT9;&]:IR71F+3<5@I`_'Z3('T^AQ?.-.3H9V[ MY$"\\`L@MBJ!M'!T,;FV_CE^*IBS0@W$?AH@MFJ!S`GF#J!#>]_%G@A5+YZP M^>GRTMK\3,7)BRF.!$J`>'VE0)R>94!LE0.Q?`'$5B40:U5`;%4#L58#Q%8M M$&MU0+V5%3_Z!I=3XM>;V_N10>IY&.\0U\[&'[,5MH,$R#H#W!L&*:RP-&:S M8'`2C\3;J[#GU94#\1HL@([Z+F%U\!W1:UV#?\X64L&>?==`[+L!.NJ[A97V M?7TQ&OBE7V?I;\YS-/5E/.8J3B'6DZR_7$=_S\?S:OMU%:^>GG9G=YMOZHMS MIFIG/&#SK3[1:'Y+2B3AM-!]BKDJVGTM]%5`5([*EMM@/+^E%]]D"WT@:JX^ M'>1KB:C%U^Z?"U3:NGO=;GC&=,1T',KV8>^V>BVO[GG M]J!A^D:Y",F%1V>A''CX;32_I8^E2<<+&KEOX`L:G6]P5/S-56DGE:ARFZNZ M3+90V35OO2U4UI":SS\5*:3F:Z&2@]2\+>/)O*5')YXC&$^IQ3:6OI- MR@D]/82A6/I:Z(8#';4OFG3'@([-UT)/G^;JQKL\-GH(-2^]1TU/2:C%=]1T MOYY:?&KT9&JN[M-+/S6UJ-OULH6>QHZ9'1]3B.VIZ MB$$MOB.@QW5S]:1"'AN]4#57KTOY6JZIQ7=JTNLH-*>^;8/>LJ(Y];70PI.9KH=?+:$Y]:O26V;ST'C6]!D4MOJ.F%W)H3GUJ].H9S:FOA=Y` MHSGUM="GP^;JXV`R;O19K[GZ<)=L24*:'TKR90N]ETBQ]K4LZ`@6WB.@=_MH M[7B/C5K4"WS2#[V#1BV^Z-#;4#0_/C5Z[X_6CJ\EH1#XQEE0`'P\H>'[QEC0 MR>;C](E$BK%OOZ%/%%*,^Y;+P[9"WQ3WNORZ:I?;K^N7W=G3ZH$NB*/^*T6V M^KOF]!][\QG@+YL]?4<<93[TS5CTG8`K^K:0D7I!^V&SV>,/"N'EX5L&;_XG M`````/__`P!02P,$%``&``@````A`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`Y-H/IK`OOO^A>CWNA,EWX@4+U;5UO]-8$7[WK# MTY?"SDR8^HN*OCOOG5X.S@\7=V[BU%_$O:Z!:IC5]51_VP8.^Z/SB[I[#S3P MT@2JOR;P_'4]TU,I5!>I7Z"RKVID#[F@7R#R=]5_S@?20.OK% M&QN*Y.DQ>WJO:RBR1P^4-S84&=1C"O5?E>H]Y)!^T;;T8C0:GEV\D'T]9)%^ M@?J^KJ5(HQ[SZ)5#LX\\TB],H?UWK\K=/A))OVB;^JIQW4_W"!'9FSP/#NX\\TB]0VT,?Z4DS;]>7@?U_I*W;O29OH",%`?65-X>TEX[HJ@+@7:Y3=MHRQ4 M!ZCX1W4=^^OCV:#W_N0O=>VY,:)/>T1]6S)N)?I2HYTG@DP%F0DR%\03Q!=D M(:GG4N00YUY=/C>BL>YT: MG%[:"31N14B@B2!306:"S`7Q!/$%60BR%"00)!1D)&J-P`&0LR$60JR$R0N2">(+X@ M"T&6@@2"A(*L!%D+$@D2"[(1)!$D%2039"M(+D@A2"E(U256(JAEK)4(S:;& M.WV;]/3M]N:/3_?-EL2>^62@EJ[-BE:;V/EA2+-WH=>FXX:T%;-`[M:]-TU:$KIT)H[D@7AO5M78^-;\5P7HAC):"!&U4U]I)^[`5 MP7HEC-:"1&U4U]KID+@5P7HCC!)!TC:J:^UT2-:*8+T51KD@11O5M78ZI&Q% ML*ZZ1E9&JDT;*R/WS%IJ_P#3EE;;J=>0OO)OTZIWZO3BV(CJG>;FOGM/6+_G M++6GC6C8:Z:[B_[IA9VNL]8%[9R+DKQ6PPJ*DGPC4OM0;2L&/>=6<-$ZH;2E M*"UH-302I86-Z/EVK5H7E+06)46MYD!)L5728-`;#NT>W+0N*"D1):5"DQER MV5Z9MD*3"Y^BU1RH<=F(3-_LJ7'5NJ@:6YFL/CPKDW_INJQ-[`1OB-ZT:E.C M=^JDQMB(.`%/#!FT731MR-EYD\V]P;DS2F9M2?@LYL+6$[:^(6K=VM9/IJZP M7@KK0%B'#7F^QBMANQ:VD;"-;=O^V<`9UAMAFPC;5-AFAG"!O14^N?`IA$_9 M$+1:5J_JVEH9J`\UK!0\/)G6`Z+* M!Z+7`HBJ)1"]`B"J0B!ZK8"H6@/1*P*B*@:BUP:(J@2(7BD051D0O;9`5.5` M]"J`J"J!Z%4!U2H[1_0N9W=+_(4<,9NB+.Z3/@!3BLP=$9Q]([=`=F)>@8N`2B/8!$%6A0<]6?"5C MUD!TCH#H'-O.O=/1Z9ESS91!"1"M4R!:9T`'^V0+%0-S(-H70%25!ID^V5/S MR@JRTU+OI+XA+`1!5(1"]5D!4K8'H%0%1%0/1:P-$50)$KQ2(J@R(7EL@JG(@ M>A5`5)5`]*J`:I6=(WHK]0TY8G9>6=PG?8XNIRYW@Q0J9OL$B-D^-$)U]()6JAZ:NMBW(Y"4":1\`T3XTZ-F*KV3,&HC.$1"=8\>Y MWW.Z9"-C$B`ZIT!TSH#Z[;#=`E&5`]&K`**J-`CM%[6LK!@[`_7N;#<#?VF- MK\^1G46^0?9MK+L[,H:*8VIBT)`=,S7H[*)>Z`]ZE\YM[0PV'!AS(#I[TMD' M4IEW*#&;YG6FV*6T#^#%BH<&/5OQ%6Q8\340*QY)YQCH8,4W\*)]`D3[%%ZL M>`;$FZTM`NF5`]&K0""]2J"#5:W@5=O;*:KWC;LI^L+ZKMEF5N=*F$4^Z9-M M/4ER%(TEF@!Q8$V!V)H9$%5S(-I[0%3Y0/1:`%&U!*)7`$15"$2O%1!5:R!Z M14!4Q4#TV@!1E0#1*P6B*@.BUQ:(JAR(7@405240O2J@6F7GB-X??D..--O) M5HXTR)FOG!W&L?X:F%YL,>,G0,RW*9"ZK>W,*L[]Q`RJ[D:?F+KG4+%$#X@E M^D!VBR@(J!BZ!:!\`414"V?9.@U90'6S0&BJ6&`&QQ-@@LVO5ZU^>%89[`ALXI$)TS(+LM3E=MH6)@#D3[`HBJTJ!G*UY9,782ZRWE-R2QECN; M'0VR)CJ!)OK(74^''&Q3(`ZV&1!5!1!5)=#!VE=0/==?=H8K+RO#]1U)_TP_ MSO#"=\WTEY[=";%!]LZ>>PPU-H&=:7,"Q'$Z!3IX$SN#BH%S($X#'A!5/E"_ MOLDY%RG=M@0C>8D(^@9`]`V!]ONN\#8CUD#TC8"HBH$.=L<&*@8F0+1/@:C* M#,+6V_G(N?/>RI@)&;O=$;OZE2N]@7;H.<2=E9 M8(VAXIB<&-2]6P;27XWYZZ,[L\]@PE$\!Z*O!Q->E'R@@_=Q"WC1?@E$^P!> MM`^!]E=[!1/ZKH'H&\&$OC'0?M\-3.B;`-$WA0E],Z"#W;&%%^US(-H7\*)] M";2_VA5,:E\[1]]V'**?V7`F38,ZT^%8H@D01]84B,V8`5$U!^(H]8"H\H'H MM0"B:@E$KP"(JA"(7BL@JM9`](J`J(J!Z+4!HBH!HE<*1%4&1*\M$%4Y$+T* M(*I*('I50+7*SA%]9O#Z5:1^.,?-D08Y$Y:S4!J;P.[M,A`'Q!1(7>':%>F@ MY]SPS:!Z;A%1'[_-H>+@\H!8H@]TN?]:B[<9L02B;P!$50ADM\0YC%]!=;`E M:ZA88@3$$F.@IB6C2V?9L,'[#$F`:)P"4949A/M8>?V5,3D0G0L@.I>V:OESH6V0=;<)M!$/U.F`KMWR$`<7S,@CL(Y$,>J!T25 M#T2O!1!52R!Z!4!4A4#T6@%1M0:B5P1$50Q$KPT050D0O5(@JC(@>FV!J,J! MZ%4`454"T:L"JE5VCOQ73C3THX%NZK2G`)RF>CWG3FUL`JTIKPFTUF@&-5=W M9P#,X,%!,P?BT/(,ZMCZ0"I].S.I,RP8.V:R#: M1O"@;0S4V(Z<+W%M8$+?!(B^*4SHFP%U#C$02*\=7NB[7#?OY.F%475FL0D0A\T4B,V8`5$U!^(0]("H\H'HM0"B:@E$KP"( MJA"(7BL@JM9`](J`J(J!Z+4!HBH!HE<*1%4&1*\M$%4Y$+T*(*I*('I50+7* MSA&]E_V&Y5BS]=W=U--/`JNT<99CSA)J#!53?0+$`3$%LAW6!R+H&P#1-P2R6M)WYI<55`=;LH:*)49`+#$&,LNQ MH3/U;O`^0Q(@&J=`5&4&'5B.B4[*84/G`HC.I>W<'YPZ5Z/*BK'S5G796_)6 MRYWE6(,Z$]E8Y[!2==`$B.-K"L3Q-0.B:@[$L>H!4>4#T6L!1-42B%X!$%4A M$+U60%2M@>@5`5$5`]%K`T15`D2O%(BJ#(A>6R"JN?Z#7-;L]%MS6U[]KY[/>>F:JP67/4,R&2?`#'9IT#<^YX!434'HI<'1)4/ M1*\%$%5+('H%0%2%0/1:`5&U!J)7!$15#$2O#1!5"1"]4B"J,B!Z;8&HRH'H M50!150+1JP*J57;:J#G;2IM?^EY27[LX,TZ#K!.!0=\]YS>!UB1D`KF:G$*E M%O-<;O>=^7,&5?=Y!W%:-(>*0\\#8HD^D%6B>YZQ@(IC=@E$^P"(]B&09>\V M:`75P0:MH6*)$1!+C('L$L5E<\^')KHP@1=+3(%88@9DE>AVX18J=F$.1/L" MB/8ED&7?=QI40?5<%UIC0>?J/Q\+M8L]%@S2DW>;OSUW?32&BJ-[8M!`K3G: M0/%0UA2JKOV@[QQJS&#?58G/=@X5*^'!_F`E?*B:AX3$L1I\.4\M@5A4`).# M1850=5LRZ#M[HBO8=U6BO6NH6(D(]@E)YSHQ-JH.F@!Q,ID"<0TU`Z)J#L0IQP.BR@>BUP*(JB40O0(@JD(@ M>JV`J%H#T2L"HBH&HM<&B*H$B%XI$%49$+VV0%3E0/0J@*@J@>A5`=4J>_)] MVU')0!Z5&&3-LH.^NV\(%*9SY9`J5ND2V<_&@[]SZSZ"RO9R;^CE4 MK(0'9`GSH)J`0%G@B40"PN`#A860F6WV+DA6$%E>SDM7D/% M2D1`=J#3XA@JNQ*._08JV\M1)5"Q$BF0'>A4(H/*JL3`V>#80F5[.97(H6(E M"B`[T*E$"95="2]-HD+XF<%0,G*7Y&"K. M%Q.@;N">I8TY(%*CG?9RT!F5[<4V-T>6*)&5\(#L0*?C?:B:;_;L&W1M^>W& M&6)86`!TL+`0*KO%8M"U);)?]BQNC(J5B&!_L!(Q5'8EG`[=0&5[.:H$*E8B M!;(#G6[/H+(J(0?=:WHBAQA>J(0]Z-0MRUL&G98[JR&# M>(<_'@@TD6@JT4RBN42>1+Y$"XF6$@42A1*M)%I+%$D42[21*)$HE2B3:"M1 M+E$A42E192$[1]YVFC60IUD&V;_H-G#6\F.J,'--))I*-)-H+I$GD2_10J*E M1(%$H40KB=8211+%$FTD2B1*)1+M)!H*5$@42C12J*U1)%$L40;B1*)4HDR MB;82Y1(5$I4251:R:XDB!G;MG;O7F"K8 M;Z17(E'*P*Z]TSD95;#?2J]HD(&E1)45:.6(>B#&SI%?FL]J%SMU#+*V*<_<=3E$W"2: M&*0O[.T4)S=,C,H<%?3/+L^=V^H9K+E#.`=B:=ZK2O.AZFXVR9]P@SU+7`*Q MQ`!>!]L7&M7S[5O!FJ6M@5A:]*K28KNT07\P=+:3-[!F:0D02TM9&B:"#(B! M6P02Y4#T*A!XL)]*HS+]M*?F%:SKTNS4_^\`1!5(1"]5D!4K8'H%0%1%0/1:P-$ M50)$KQ2(J@R(7EL@JG(@>A5`5)5`]*J`:I6=.VJC[`V75O6E:I$C#;+FQ\'` M.5X=FT#UQ19DT@2(PV=JD*IN_8A>;^#^O,%,!LV!:.T!T=H'4E?]=CK>,_6U MC4$UEPBD?0!$^]"@YVN^DD%K(%I'0+2.;>O+BZ%SAK61,0D0G5,@.F=`7.]L M@:C*@>A5`%%5&F0Z0-:RLF+L'-2[L=U3C5^[=#=[NMW#CN&>;5[WMU#'$'%0 M38#X]94ID'W#XBP#9E!Q-,Z!:.\!T=XWR/P4:*_O?N]F@1@Z+X'H'`#1.7S) M>848.J^!Z!P!T3D&.M@E&ZAHGP#1/@6B?690VR47SJ5\BQ@ZYT!T+H#H7+[D M7"&F=K9356_;=U/U\)W(4,N=Y62#SM5$T\Y#[K=OQB;.FBV;.#7-8F::&M7S M<\X,/@R:`W$T>T!4^8[UGGP4U5G"ALX!$)U#U_G,_0GOE0Q:`]$Z`J)U;%O+ M*6@C8Q(@.J=`=,YL9_6K.R(717?DL*%S`43GTG'N]=PM_\H*LI/Q;8<.^A\E M*A0<]6?`4;5GP-Q(I'TCFVG<\NW07! M!C9T3H#HG$KG#(@7Q"T"Z94#T:M`(-M?&F3:+VM9P:9VMA/3/=9XX4HJSR^& M#;(F+X$F4'$`38'8D!D057,@#D8/B"H?B%X+(*J60/0*@*@*@>BU`J)J#42O M"(BJ&(A>&R"J$B!ZI4!494#TV@)1E0/1JP"BJ@2B5P54J^P<<<\H7L@1>1@Q M;)"UVAH,G*OWV*BLY583:"VW&H3EUOG@PIGM9O#A.)H#<1QY0%3Y!L%ZSW)+ M5&<)&SH'0'0.'>>+D3NWKF30&HC6$1"M8\?Z[/S,.:+8R*`$B-8I$*TSQWK/ M>DOT1PX;.A=`="X=YXM3=X>PLH+L=-0G!MUKZ0OI:`X86/JG88.L*4N@"50< M-E,@#IL9$%5S(`Y!#X@J'XA>"R"JED#T"H"H"H'HM0*B:@U$KPB(JAB(7AL@ MJA(@>J5`5&5`]-H"494#T:L`HJH$HE<%5*NL'!FYQQ"'&7%V$FI-\-??[T;:;DSES7(67XYWS@>F\#N\@N(XVEJ M$-9(%^?.-Q9F,F8.Q)'J`='9!U)7X@,WB5`Q<`E$^P"(JM"@9RN^DC%K(#I' M0'2.'>[9`L5`W,@VA=`5)4&H4M$Q2LKQDY*O:?_ MAJ1LC@"ZIP*C!EDSY;G(R49D390&<7!-C14&U^EP)))2!,U-4,?:`Z*U#V1- M"T-GA;V`ROY2O-.8)52<*0(@EA@:A,GS\LR=XU8R:`U$ZPB(UK%K/73_?<6- M#$J`:)T"T3H#.MA/6Z@.]E,.%4LL@%AB:1#Z2=U2.5]NJJP@.WOU/O$;LK?9 M5K:RMT'6E'KAI,5X9+:C.0HG0!R%4R!KD`]%!ALOM;72SH[BT94YO%BB!\02 M?2"[1*?[%E`=+'$)%4L,@%AB"&27Z)S;K:`Z6.(:*I88`;'$&,@NT3D/WT!U ML,0$*I:8`K'$#,@NT5F@;*$Z6&(.%4LL@%AB"627Z&RK5%`]5Z(],O2)0G=D M_-)&]:@YE[`&3(.LZ?["2?*QB>O,R1,@[I-.@8;UNEC\,U!XFW/%'(@SB@=$ M7Q](C;1VB.U9%9LS%]HO$4C[`(CV(=#^:J_P-GW70/2-@.@;`S6^[J5O@[?I MFP#1-P6B;P;4^?B5`]&K`*)7";2_CA7>KGWM?-1G`O\\'YN3!2L?&Z0? M"FD_[`MG"AR/S(D$A^'$H.ZYB4%F^_UR=.E/\>YA(HE!K#GEDIHD&G+Q>#W<&XW< MT]L-?&B=`-$ZE=89D-U-SNG5%EX'NRF'BB46L&06?NC%V M2JL*6"G]PB:#ECOWT!4>4#T6L!1-42 MB%X!$%4A$+U60%2M@>@5`5$5`]%K`T15`D2O%(BJ#(A>6R"JF/]GT][S?:\->TUR)[VG'78>&2V]3D&)@:]\#5JHWK^:\8S6'., MSX%8FO>JTGRH5.IS=G1/:!>P9XE+()88P$M-^*V7^)IX:%3/MV\%:Y:V!F)I MT:M*B^W2]GP9>0-KEI8`L;3T5:5E4!WLS2WL66(.Q!(+>!WLS=*H#GS9&M9U M:>-3\.KJEX\ MN7QT5=4/8;E\H`+4P\U[G`8J1(W9?>^<;G2S[3(=]0#*U?Z"17YCGK\Y$H_;R+?40^37.FG1^0[D\&Y*J?^5)T^ M4(_]J9A][ZB'U51[]O6S>LY,M6??.^H1,57.OG?4TUVJ/?O>40]FJ?;L>T<] M4Z7JMN^=R=E5N.\SB,ZNRGU\'1^%>_CZ?E5MH\7 MJG-K?M)V^^/']S^OO^["ZX>OMS\>C[[OOJAA=%K_DS$/MU_UW5_S/T_F-ZA^ MOW]ZNK]3ZY'CHV^[Z\^[!RU0B^@O]_=/^!_U@9_\??_P1SU4/_Z_`````/__ M`P!02P,$%``&``@````A`!["?@-#!@``ZA<``!D```!X;"]W;W)K&ULK)C;;N)($(;O5]IW0-P/QB<,%F$4X[-VI=5J#]>.,<$* MQLAV)C-O/]7N;O>AV$Q8S4T(']5_NZI_]VG[^6MSGGVINKYN+P]S<[&7ZF'^K>KGGW>__K)]:[N7_E15PPP4+OW# M_#0,5]\P^O)4-46_:*_5!7XYMEU3#/"U>S;Z:U<5A[%1KY_*MKF"Q%-] MKH=OH^A\UI1^]GQIN^+I#'E_-9VBY-KC%R3?U&77]NUQ6("<01\4Y[PQ-@8H M[;:'&C(@99]UU?%A_FCZN>G-C=UV+-`_=?762__/^E/[EG3UX;?Z4D&U89S( M"#RU[0L)S0X$06,#M8['$?BCFQVJ8_%Z'OYLW]*J?CX-,-PN9$02\P_?PJHO MH:(@L[!>N=S8'J@\5?T0UT1R M/BM?^Z%M_J5!)I.B(A83@4\NLEJXWM(VH<^/BCA,!#Z9B+E8NZZS6M_Q)-#= MF`Y\,A'G?A%X-T81^/S_3[)A(O!Y]Y,8=)#&,0^+H=AMN_9M!B\2#$-_+(6/-AV;:?S_:_AAW(G*(Y$!":@T#&T/IOVR6SG.UO@"1BM94'`CR%)# M]E,(\151#A&)$(D121!)$]B;E9IH0&-@JN&)[A$) M$8D0B1%)$$D1R1#)9:*D#BY7W/!^ZB0:!MV3WI_[,U:#=I/ M0;Q`(2(1(C$B"2(I(ADBN4R4$,@]9R'J<0:VEJ^_ZZ2=FC(E%O0DO=@;=03V+$CRP8UF MEJE-&A$-MD3EDPATI-01YC.E MCN]7CT2KU:/$E@Q#R5J0D!%AH8@1>S)5C&(2I).BF`SIY'*,DBC9.BF9DGW4 M1QPS-E239DCQC+-<:I[A49)I.!H/!^,$$S'$/&*ZMC:AQ+A-PI%03CD2RIFF MO/*TW5ZNM%&+1?99\NOUOBU,MBT3G0<,R<9@2'8&1Y(U.)*\P9&(2C@2+DLY M$E$91T(KYVB,4G,F&RDY9V(0SR-'J!_,*2;;@LGI4Z0Y1)O7]ZRA)<8QY$AH M10QQARSU<8QQFX0CH9QR))0S3=G2-SVYTD:M%ME[R=7Z@4/85DUT'I@4*0ZA M2'$(0V)4(]9P+48UYDA$)1S)#D%:&8\26CE'-QQ"-EARSL0AKD46G>%4ER]! M"]_A5;A1"AM6`'8.8[LTN1(4:6;1YH$].;K!Y*N8A2)'I!VQ*`=2A8>AYSS; MU):#F&N)AT@XDAV#Y#,A3[8J:VV]R[G(J*OZA>S9Y-K=*!*\:5.52+@VZ5*D M^`6AD-R#0$,;9OLI?[1<1BS*68X+L[MVM&+'0F9:F3F2#?61SC*ULY7K>>I" MD7-E>NLCGVI-LL^3JT8/_PMR.W*'Y=C^48QV,`J#F>1=C[/4;++G4<(3(4.* MY:@\6(YXPEUK*C%7$=TG'`GA%`MG'%%AST9NHQU#$OJNAISE?D+=V.Y3/'@P M"H_VXK[8')AR5Z1C55]USMJ_.YGY7M*[E>KY<$C`'&Y<'\=)4.LW(#>Q-^(#RX=[$ZP3V#Y< M*F#^Z/B/4"#\0^#X<.P&;DP]PTWKM7BN?B^ZY_K2S\[5$8H%]ZOPRG;TKI9^ M&=KKN%H\M0/V'?@7TL%T2[_[#@``__\#`%!+`P04 M``8`"````"$`8;2&%SP%``!P$P``&0```'AL+W=O^=4;6=>0EAL+[.7E[>-%]]?R[/Q0NJFH-72=$:V:9`JI_NB.B[-O_^* MOLU,HVFS:I^=:466YAMIS.^K7W]97&G]U)P(:0U@J)JE>6K;2V!937XB9=:, MZ(54\.1`ZS)KX;8^6LVE)MF>-RK/EFO;$ZO,BLH4#$']$0YZ.!0Y"6G^7)*J M%20U.64T;>FA'0&>)%\4YSZVY!4RKQ;Z`#)CL1DT.2_/!"7:. M:UJK!1?HGX)])J0XGEH8[C%DQ!(+]F\A:7)0%&A&[I@QY?0,+P"_1EDP:X`B MV2N_7HM]>UJ:KCL:3VW/@7#CD31M5#!*T\B?FY:6_XH@IZ,2)&Y'`M>.Q`%_ M?;"QWS6&JVP\FHW'_F0V_?@;0"1/`ZX=B?]YDDE'`M?^33XK!>3-7P2N/<>G MLYEW)'#]>C8.>$D,+3-5-VP?'5I+V(2[+LS:;+6HZ=6`J0Q&:"X9*PQ.P'J0 M?A/NZ!WX,P."\QC+`Z,!"AAS,%<#T^9E-?%F"^L%K)YW0>L[0:X:LNE#F+,9 MFO#;V\.;3M5$UR(&BIU,=(.0$"%; MA$0(B1&2("1%R&Z(**F#RQ4WO)\ZBX9!GPYRGWAS+?65U;4>KF]O^N50U0APQ0I*^%:O7P.JHKDS[YY)U-^10M`%[*]KA*99HPZ M2OJ8VP1%':5J1]Y8&Z5=3P(=*>JQW?MP%7Y?/1:MJB<0#];O6_F8::.YZ8+$ M5H^OK7TSF?BV0USALYFV%D6H08Q($Q23*J3>5"MKNV$#116HAHHJ7YIOC$05 M2R":U;2AVG1!`ZL)Q.=[?SZ5MQW"YC9,G^E$M5W4]R/5C1%I@DA3A=2S=;&& MI(I8;/.FJ/6^AWBXJDL'>3>#;#`42FCH-303MEV4;XLY-Y_HXMQH>G4D=.L_ MD="[G:5J9Z[M:W5C=Z/1)Y[#MGS#F?MKNXDU\]Z5/W)=I+_ M7>EN/SKMEX`U?(VS&:[8%D%A%^7#+F:@CI;15D:)==:9C)%M.V;^$<^K0(S[ M3R3-NYVE,DIVYFF=L7,&GIDX,>#?(^+<0'S!E:0^D@TYGQLCI\_L3&`.LZU' MQ7E%.`E@&D@_\]PP2;M@.EK;QA'?1G9:L?````__\#`%!+`P04 M``8`"````"$`<-J<8WL%``"%%```&0```'AL+W=O]`>!^NBDK420LBD-UDL]G+,XVEDA;+`'V9;[^G MJ"J@.([19.=A:'^>"^=?IR[6\OM7>=8^2%47]++2;C@4.0EI_EZ2 M2\.#5.2<-?#^]:FXUC):F3\2KLRJM_?KMYR65PCQ6IR+YD<;5-?*W$^.%UIE MKV>H^\N>9+F,W7Y`X!OK3[1SUU5['\K+@34AG%B(_!*Z1LS3?8,@;.)O*-V M!/ZHM#TY9._GYD_Z&9/B>&I@N*=0$2O,W_\(29V#HA#&<*8L4D[/\`+POU86 MK#5`D>RK?7X6^^:TTEW/F,XLUP9S[974352PD+J6O]<-+?_E1K8(Q8,X(@@\ M;P2YX^@*1W@*1]LR[(GEL>1W_";"#Y["SWG$#8*VQ<)3N,T>3`YV_>$9Y?P`546P@V>SY1G0]/Q'F#=Q\?7,>X5:/(F M:GLRS)ILO:SHIP83'=JDOF9LV;!]%E9V(Q_*KC]_UI[0ERS*"PL#(6!TH?5J MF%0?:\]UE^8'3(1<&&UN&#FJ2="9L+YGD4-$MHA$B.P0B1%)$$F'Q`2!.I5@ MFOP?*K$PK4JRNDU'>MU&J@6=B70*$=DB$B&R0R1&)$$D'1)%$E@`D"0N--#M M94SV"?."!6O0)N[44GM@PVU@290%!XB$B&P1B1#9(1(CDB"2#HDB`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`8BC7CH^7#>P3SV?#BL8![.?#@C8![/?-CS,8?+ MH!?G!M^P2Z);W/'A)Q..LW%]^!V!^;B0\G;>!F5S%<`EVS(_D] MJX[%I=;.Y`!B6>VQL^+72/Q#0Z\@(EP%T0:N?]H_3W#=1^`,91EP=#Q0VL@/ M+$%W@;C^#P``__\#`%!+`P04``8`"````"$`RS`2W:<'``!X'P``&0```'AL M+W=OQW[.K9O2NEJ7R;#Z;D'^_K8]^+5OMRO/S_?BO;]&7Y7C4M/EYEQ^K2[ M+NATG-JSF3L]Y>5YS!7\^A:-:K\OMT50;5]/Q;GE(G5QS%L8?W,H+PVJG;:W MR)WR^N7U\F5;G2X@\50>R_9G)SH>G;9^^GRNZOSI"//^8V-9X^W'4)^KLLWAKE M_Z/F4+W%=;G[K3P7D&U8)[8"3U7UPJCICD$0/"714;<"?]2C7;'/7X_MG]5; M4I3/AQ:6>P$S8A/S=S^#HME"1D%F8B^8TK8ZP@#@W]&I9-:`C.0_[L=++R98P%]]%0T;50RR?%H^]JTU>D?3NIF)$4<(0)/(6+-)M9\YC*- M*W%S$0=/$6=/[.7"6GP4"++=J.$I`MW)Z(A">.-*)9\U6S@=Q MGHB#)\;=-$/89MU`X?FY&:Y$(#P_-T,++-1])?L/CO7:'*?<$9W!@KS-'^[J MZFT$NQ;6O+GD[`RP?":&UN(+*LWVGM?`9$SEDZ64)(PAQ%!8H(D!$D)DG&$#U&;.]A7FSLO(1-6;-M#N7U95S!> M.%H'%M^!2L$+"!/14\(1-24$"3CB@KB2DH61$DF2*2%(3)"$("E!,HX,I(0U MWK2J?C(E3$1/"4>4W6`"`0=!@`,>/!1#&'U(*$DXX,C4B4T@ MD3%7A%-)0N%,T=$RP5JM3Z2BH^NY$%"WR[#E&P$RU[*@R5`R)-0B%"? MV0BAGA4CU&LE"/6L%*%>*T.H8^EI8!V7NE&N.\(2#5K_=6L!>5"LY8I;%DD# M#W3X+QK>5PH(%D(&VI9Y=@AY!]H@R7+LF;X#(F3I6D9_$R.K'T2"D!YH#"(5 MK/F,[VIG9NSJK)L'S51:BT\>ZI;H*OL9K06D6=CQ#(]M!$NS,-=R^JXA1!9T9')&#DVK".QN M';KZ&V.@:DXBGR)+D_>,@I`A2W?U>VEES:.95OLFAXJV4TTEAQS6>LA#T3.V MRX;]3(7*HCE40+H3C(T88J#F*GH:#&KUTQ<))X-(4/[J(%)D:8/PC)V3(4O7 MZ@>A6YOUM60-6.C-_1N[CC*JM8`,7QL-ZT:P-%]S+-M<1FVCY_(O#&&GX%8M>PMD3WK1ZTEFUL MLXU@:3;F@0X\I/\'BII@J=YP;))1SH)#6]7J'21L+%CJ<2SDX?'^(%(Q>D>5 M=QQCCAG.466]?T(#Z^IZ?*LNT$1]6/F8C-%L<4@QZ8;]:@>6`@4(]1X,$;+E MXD8(]:P8(=6I0KYGI MLS03"JC7"BT!]4UAA%#/BA%2O42T4F3U6AE"G9:>!C@EM33^4&%>KA3L+\?6"P\N&2`4Y2`T]6/MP14!S>'SYV=C3X:WBOV$W=Q&UXWSB@ MLW9\N+4>T)^#_J#0W(?+6QJP7OAPUSF`N_ZZ++TX?H)\*D<$+SWO.3/Q>]Y_5R>F]&QV,,BS;I? M:35_<\H_M*(7>*I:>.,)ZPCOON`-=P'OG&;L*G]?52U^8%\@WYD__`L``/__ M`P!02P,$%``&``@````A`$OY$^N7````JP```!````!X;"]C86QC0VAA:6XN M>&UL/(Y!"L(P$$7W@G<(L[=I*ZA(DD(%3Z`'".G8!)))R031VYN5R\>']Y^: M/BF*-Q8.F30,70\"R>4ET*KA^;@?+B"X6EILS(0:OL@PF?U..1O=S=M`HAF( M-?A:MZN4[#PFRUW>D-KRRB79VK"LDK>"=F&/6%.48]^?9&H",,J)HF$>1A!! MP_D((K86D$;)_XWY`0``__\#`%!+`P04``8`"````"$`8*1L'/L#``!2$``` M$``(`61O8U!R;W!S+V%P<"YX;6P@H@0!**```0`````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````"<6%UOHS@4?5]I_T/$^S1IISM=5801`:=!2P!AD]EY MLCS$2=`0B,"-VOWU>PEM`\F%*GD#?,[]/->QHW]_V::#O2S*),_&VNW-2!O( M+,Z72;8>:Q&;?OE;&Y1*9$N1YID<:Z^RU+X;?_ZA!T6^DX5*9#D`$UDYUC9* M[1Z'PS+>R*TH;V`Y@Y557FR%@M=B/CT;>A?%$R6\KE ME]V'0:VV^+A7UQI=YG$57[E@KSL(V-#-W2Y-8J$@2V.>Q$5>YBLU("^Q3/5A MQ MRHM!F?P'9;O3!K]$*:MPQMI>%(G(%(15P>J7PW.Z*U5A_,B+W^5&2E7J0P#4 M'P^/36SS.;DW'NX."'AJ(RL+=22PT(Z1)2J5I;\*1*&0D!]:,1^BJ".N`WKO M(@=M<)(IJ!=WLKK;2=Z,_",'R_>H[SJVR8C-)Z9K>A;A=$8(HY?B>2`^IU`& MGN;$8Y3[4^X'Y%(*G9E74&XOY5@FGK]-J!4Z`7-\KTJ`S0B?1-3Q",7Q-)K/ MS?!GA:7.D^=,'S7^@%->GE`FTM,2K@9AJ;W5/<4-6.3 M"23\&$A)!Z`I%$,)4^5 M#KGC3?UPWFV+$L;C:!T M%CX"<],SWZK:DT.ONG#1]RNRWK+>]K>/7:)?DAU^>C6)<]JBY$S\@MT0+6!# MFWVP4`Y_5*^1OX==>N5/^ZG?QO'_9R,C">*`HY4>\EMJ42"EN"$$LHXS^(D30Y' M,8Y2FN-V,)SB8XG,6R,BU#1"H7!<73ZGDN>K*RCXUG(^VPTO>-+GE$8N$HVL MM2DT'=AR)8O+*&HC>?`YY:1]'25K!=9,`T32TPH\#("83[<(&#.E[\B#%ZO](W1T4.\6J)LVI:[J*\P\#R7.;/CS^&6#\#P``__\#`%!+ M`P04``8`"````"$`Z?Q[:C(!``!``@``$0`(`61O8U!R;W!S+V-O&UL M(*($`2B@``$````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M````````````````````````````````````````````````````G)%12\,P M%(7?!?]#R7N;IA49I*;S&YVX)-&G*CW?Z]6=?5B3X)>0GGW"_G MGM3SG6F33_"H.]L0EN4D`2L[I>VF(4^K13HC"09AE6@["PW9`Y(YO[RHI:MD MY^'!=PY\T(!))%FLI&O(-@1748IR"T9@%ATVBNO.&Q'BU6^H$_)=;(`6>7Y- M#02A1!#T`$S=1"0C4LD)Z3Y\.P"4I-""`1N0LHS1;V\`;_#/@4$YK1:$%SDK4Y:GC*W8K+J* MIWBMZ`'S(_?//^1<```#__P,`4$L!`BT`%``&``@````A M`&5E@%IB`@``!RL``!,``````````````````````%M#;VYT96YT7U1Y<&5S M72YX;6Q02P$"+0`4``8`"````"$`M54P(_4```!,`@``"P`````````````` M``";!```7W)E;',O+G)E;'-02P$"+0`4``8`"````"$`\FO=RL8"``#<*@`` M&@````````````````#!!P``>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-0 M2P$"+0`4``8`"````"$`\S_>1F@%```_%0``#P````````````````#'"P`` M>&PO=V]R:V)O;VLN>&UL4$L!`BT`%``&``@````A`'/;L>5Y!0``LA4``!@` M````````````````7!$``'AL+W=O&UL4$L!`BT`%``&``@````A`"W^L5^P!``` M"!(``!D`````````````````X"```'AL+W=O&PO=V]R:W-H965T+0.@,``+,)```9`````````````````!PI``!X;"]W;W)K&UL4$L!`BT`%``&``@````A`$\Z.OD4!0``?10``!D````````` M````````C2P``'AL+W=O&PO=V]R:W-H M965T&UL4$L! M`BT`%``&``@````A`+!U!=/1!0``"!D``!D`````````````````QC<``'AL M+W=O&PO=V]R:W-H965TWP,``)0.```9```````````````` M`+E```!X;"]W;W)K&UL4$L!`BT`%``&``@````A M`(E`BJ>4"```RBH``!D`````````````````ST0``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`!&[DX&#`P``-@L` M`!D`````````````````8E0``'AL+W=O&PO=V]R:W-H965TE0, MJ0,``/H+```9`````````````````%I;``!X;"]W;W)K&UL4$L!`BT`%``&``@````A`-9_CPV*`P``=@L``!D````````````` M````.E\``'AL+W=O<1RJ0$``!?$@``&0````````````````#[8@``>&PO=V]R:W-H965T M&UL4$L!`BT` M%``&``@````A`,9C?2FW`@``XP8``!D`````````````````1VL``'AL+W=O M4#``"7 M#```&0`````````````````U;@``>&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`(5.,#)##@`` MJ9````T`````````````````%GD``'AL+W-T>6QE&PO&PO=V]R:W-H965T&UL4$L!`BT`%``& M``@````A`.,OEFP$ M```)$```&0`````````````````?%0$`>&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A M`#L^!C#H`@``]P<``!D`````````````````2AX!`'AL+W=O&PO=V]R:W-H965TIY[0,````.```9`````````````````)0H`0!X;"]W;W)K M&UL4$L!`BT`%``&``@````A`,4R"4KB`P``M0T` M`!D`````````````````N"P!`'AL+W=OV'\"``"+!@``&0````````````````#1,`$` M>&PO=V]R:W-H965T&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`+5XJ%`T"0``5RL``!D````` M````````````!DD!`'AL+W=O&PO=V]R M:W-H965T`0!X;"]W;W)K&UL M4$L!`BT`%``&``@````A`&6F4[\R&@``7HL``!D`````````````````Q',! M`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@` M```A`-51[0IV`@``X04``!D`````````````````S*0!`'AL+W=O&UL4$L!`BT`%``&``@````A``-JMV":!P`` M4B(``!D`````````````````1;8!`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`'=Z MDD%I`@``4@4``!@`````````````````7\8!`'AL+W=OSP$`>&PO=V]R:W-H965T M&UL4$L!`BT`%``&``@````A`%A`$F:C)0``1=P``!@````` M````````````?](!`'AL+W=O&UL4$L!`BT`%``&``@````A`(;75K<-"0``'2T` M`!D`````````````````T1<"`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`.&PO=V]R:W-H965T M&UL4$L!`BT` M%``&``@````A`+X9\K/%!0``U1D``!D`````````````````450"`'AL+W=O MC.D"```/ M"```&0````````````````!-6@(`>&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`))M MI+R^`@``<0<``!D`````````````````]F`"`'AL+W=ONMBXZ81``#X5@``&0`````````` M``````#K8P(`>&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`+JH*[C>!P``@R$``!D` M````````````````ZHP"`'AL+W=O&PO M=V]R:W-H965T&UL4$L!`BT`%``&``@````A`&N&PO=V]R:W-H965T&UL4$L!`BT`%``& M``@````A`'#:G&-[!0``A10``!D`````````````````G/("`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`&"D;!S[`P``4A```!`` M````````````````\0`#`&1O8U!R;W!S+V%P<"YX;6Q02P$"+0`4``8`"``` M`"$`Z?Q[:C(!``!``@``$0`````````````````B!@,`9&]C4')O<',O8V]R ;92YX;6Q02P4&`````%(`4@!G%@``BP@#```` ` end XML 19 R4.htm IDEA: XBRL DOCUMENT v2.4.0.8
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (USD $)
In Thousands, except Per Share data, unless otherwise specified
 12 Months Ended
Sep. 30, 2012
Sep. 30, 2011
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) [Abstract]    
Service revenue $ 21,312 $ 25,613
Product revenue 6,896 7,531
Total revenue 28,208 33,144
Cost of service revenue 18,472 19,679
Cost of product revenue 2,898 2,959
Total cost of revenue 21,370 22,638
Gross profit 6,838 10,506
Operating expenses:    
Selling 3,263 3,121
Research and development 542 534
General and administrative 5,524 5,564
Total operating expenses 9,329 9,219
Restructuring charges 3,195   
Operating income (loss) (5,686) 1,287
Interest expense (714) (706)
Change in fair value of warrant liability - decrease 73 1,759
Other income 12 12
Income (loss) before income taxes (6,315) 2,352
Income tax expense 2 50
Net income (loss) (6,317) 2,302
Other comprehensive income (loss):    
Foreign currency translation adjustment (22) (49)
Comprehensive income (loss) $ (6,339) $ 2,253
Basic net loss per share $ (0.88) $ (0.74)
Diluted net loss per share $ (0.88) $ (0.74)
Weighted common shares outstanding:    
Basic 7,158 5,667
Diluted 7,158 5,667

XML 20 R10.htm IDEA: XBRL DOCUMENT v2.4.0.8
RESTATEMENT OF PREVIOUSLY ISSUED CONSOLIDATED FINANCIAL STATEMENTS
 12 Months Ended
Sep. 30, 2012
RESTATEMENT OF PREVIOUSLY ISSUED CONSOLIDATED FINANCIAL STATEMENTS [Abstract]  
RESTATEMENT OF PREVIOUSLY ISSUED CONSOLIDATED FINANCIAL STATEMENTS

3. RESTATEMENT OF PREVIOUSLY ISSUED CONSOLIDATED FINANCIAL STATEMENTS

 

In August 2013, we announced a delay in filing our Form 10-Q for the three and nine months ended June 30, 2013 until management resolved a complex accounting issue related to the accounting treatment for our outstanding warrants. In the same month, we announced that investors should no longer rely on our previously issued consolidated financial statements and the related independent auditors' reports for the fiscal years ended September 30, 2012 and 2011, or the quarterly financial statements for the first two quarters of fiscal 2013, or any earnings releases relating to these periods, because of errors in such financial statements.

 

As a result of the identification of such errors, we have undertaken a comprehensive review of our previously filed consolidated financial statements. We concluded that the warrants issued in connection with our public offering in May 2011 were incorrectly accounted for as equity and the fair value of the warrants should have been recorded as a liability. As a result, we have restated our previously reported consolidated financial statements for the years ended September 30, 2012 and 2011. The restatement adjustments resulted in a cumulative net decrease to Total shareholders' equity of $1,213 and $1,286 as of September 30, 2012 and 2011, respectively, a decrease to our previously reported net loss for the fiscal year ended September 30, 2012 of $73 and an increase in previously reported net income of $1,759 for the fiscal year ended September 30, 2011. The decrease in our net loss and increase in net income was a result of the changes in the fair value of the warrant liability that is now correctly recorded in other income (expense) as the change in fair value of warrant liability- (increase) decrease. Except as otherwise specified, all information presented in the accompanying consolidated financial statements and the related notes are presented after inclusion of all such adjustments. There was no net effect on the consolidated statements of cash flows for fiscal years 2012 and 2011 as the change in the fair value of the warrant liability is a non-cash item.

 

The following table summarizes the effects of the restatement adjustments, previously discussed, on the consolidated statements of operations and comprehensive income (loss) items for the years ended September 30:

 

    2012     2011  
    As Reported     Adjustment     Restated     As Reported     Adjustment     Restated  
Total revenue   $ 28,208     $ -     $ 28,208     $ 33,144             $ 33,144  
Total cost of revenue     21,370       -       21,370       22,638               22,638  
                                                 
Gross profit     6,838       -       6,838       10,506       -       10,506  
                                                 
Total operating expenses     9,329       -       9,329       9,219               9,219  
Restructuring charges     3,195       -       3,195       -               -  
                                                 
Operating income (loss)     (5,686 )     -       (5,686 )     1,287       -       1,287  
                                                 
Interest expense     (714 )     -       (714 )     (706 )             (706 )
Change in fair value of warrant liability - decrease     -       73       73       -       1,759       1,759  
Other income     12       -       12       12       -       12  
                                                 
Income (loss) before income taxes     (6,388 )     73       (6,315 )     593       1,759       2,352  
                                                 
Income tax expense     2       -       2       50               50  
                                                 
Net income (loss)     (6,390 )     73       (6,317 )     543       1,759       2,302  
                                                 
Other comprehensive income (loss):                                                
    Foreign currency translation adjustment     (22 )     -       (22 )     (49 )     -       (49 )
Comprehensive income (loss)   $ (6,412 )   $ 73     $ (6,339 )   $ 494     $ 1,759     $ 2,253  
                                                 
Basic EPS   $ (0.89 )   $ 0.01     $ (0.88 )   $ (0.66 )   $ (0.08 )   $ (0.74 )
Diluted EPS   $ (0.89 )   $ 0.01     $ (0.88 )   $ (0.66 )   $ (0.08 )   $ (0.74 )

 

The following table summarizes the effects of the restatement adjustments, previously discussed, on the consolidated balance sheet items as of September 30:

 

    2012     2011  
    As Reported     Adjustment     Restated     As Reported     Adjustment     Restated  
                                     
Total assets   $ 26,975     $ -     $ 26,975     $ 32,346             $ 32,346  
                                                 
Total other current liabilities     11,387       -       11,387       9,847               9,847  
Fair value of warrant liability     -       1,213       1,213       -       1,286       1,286  
Total current liabilities     11,387       1,213       12,600       9,847       1,286       11,133  
                                                 
Other long-term debt     5,998       -       5,998       6,913               6,913  
                                                 
Total liabilities     17,385       1,213       18,598       16,760       1,286       18,046  
                                                 
Shareholders' equity:                                                
Preferred Shares     1,335       -       1,335       2,135       -       2,135  
Common Shares     1,871       -       1,871       1,698       -       1,698  
Additional paid-in capital     20,451       (816 )     19,635       19,408       (816 )     18,592  
Accumulated deficit     (14,096 )     (397 )     (14,493 )     (7,706 )     (470 )     (8,176 )
Accumulated other comprehensive income     29       -       29       51               51  
Total shareholders' equity     9,590       (1,213 )     8,377       15,586       (1,286 )     14,300  
                                                 
Total liabilities and shareholders' equity   $ 26,975     $ -     $ 26,975     $ 32,346     $ -     $ 32,346  
XML 21 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 22 R24.htm IDEA: XBRL DOCUMENT v2.4.0.8
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
 12 Months Ended
Sep. 30, 2012
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]  
Principles of Consolidation
  (a) Principles of Consolidation

 

The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant inter-company accounts and transactions have been eliminated.
Revenue Recognition
  (b) Revenue Recognition

 

The majority of our Bioanalytical and analytical research service contracts involve the development of analytical methods and the processing of bioanalytical samples for pharmaceutical companies and generally provide for a fixed fee for each sample processed. Revenue is recognized under the specific performance method of accounting and the related direct costs are recognized when services are performed. Our preclinical research service contracts generally consist of preclinical studies, and revenue is recognized under the proportional performance method of accounting. Revisions in profit estimates, if any, are reflected on a cumulative basis in the period in which such revisions become known. The establishment of contract prices and total contract costs involves estimates we make at the inception of the contract. These estimates could change during the term of the contract and impact the revenue and costs reported in the consolidated financial statements. Revisions to estimates have generally not been material. Research service contract fees received upon acceptance are deferred until earned, and classified within customer advances. Unbilled revenues represent revenues earned under contracts in advance of billings.

 

Product revenue from sales of equipment not requiring installation, testing or training is recognized upon shipment to customers. One product includes internally developed software and requires installation, testing and training, which occur concurrently. Revenue from these sales is recognized upon completion of the installation, testing and training when the services are bundled with the equipment sale.
Cash Equivalents
  (c) Cash Equivalents

 

We consider all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents.

 

One or more of the financial institutions holding the Company's cash accounts are participating in the FDIC's Transaction Account Guarantee Program. Under that program, through December 31, 2010, all noninterest-bearing transaction accounts are fully guaranteed by the FDIC for the entire amount in the account. Pursuant to legislation enacted in 2010, the FDIC will fully insure all noninterest-bearing transaction accounts beginning December 31, 2010 through December 31, 2012, at all FDIC-insured institutions.

 

For financial institutions opting out of the FDIC's Transaction Account Guarantee Program or interest-bearing cash accounts, the FDIC's insurance limits were permanently increased to $250,000, effective July 21, 2010. At September 30, 2012, the Company did not have any cash accounts that exceeded federally insured limits.
Accounts Receivable
  (d) Accounts Receivable

 

We perform periodic credit evaluations of our customers' financial conditions and generally do not require collateral on trade accounts receivable. We account for trade receivables based on the amounts billed to customers. Past due receivables are determined based on contractual terms. We do not accrue interest on any of our trade receivables. The allowance for doubtful accounts is determined by management based on our historical losses, specific customer circumstances, and general economic conditions. Periodically, management reviews accounts receivable and adjusts the allowance based on current circumstances and charges off uncollectible receivables when all attempts to collect have failed. Our allowance for doubtful accounts was $123 and $108 at September 30, 2012 and 2011, respectively.

 

A summary of activity in our allowance for doubtful accounts is as follows:

 

    2012     2011  
             
Opening balance   $ 108     $ 165  
Charged to expense     84       13  
Accounts recovered     15       (61 )
Accounts written off     (84 )     (9 )
Ending balance   $ 123     $ 108  
Inventories
  (e) Inventories

 

Inventories are stated at the lower of cost or market using the first-in, first-out (FIFO) cost method of accounting. We evaluate inventories on a regular basis to identify inventory on hand that may be obsolete or in excess of current and future projected market demand. For inventory deemed to be obsolete, we provide a reserve for this inventory. Inventory that is in excess of current and projected use is reduced by an allowance to a level that approximates the estimate of future demand.
Property and Equipment
  (f) Property and Equipment

 

We record property and equipment at cost, including interest capitalized during the period of construction of major facilities. We compute depreciation, including amortization on capital leases, using the straight-line method over the estimated useful lives of the assets, which we estimate to be: buildings and improvements, 34 to 40 years; machinery and equipment, 5 to 10 years, and office furniture and fixtures, 10 years. In our European operations, we depreciate leasehold improvements, using the straight-line method, over 7 years, corresponding to the terms of the operating lease for the European facility. Depreciation expense was $2,217 in fiscal 2012 and $2,085 in fiscal 2011. Expenditures for maintenance and repairs are expensed as incurred.

 

Property and equipment, net, as of September 30, 2012 and 2011 consisted of the following:

 

    2012     2011  
             
Land and improvements   $ 914     $ 527  
Buildings and improvements     21,278       21,433  
Machinery and equipment     19,496       22,361  
Office furniture and fixtures     701       949  
Construction in progress     35       493  
      42,424       45,763  
Less:  accumulated depreciation     (23,796 )     (25,364 )
Net property and equipment   $ 18,628     $ 20,399  
Long-Lived Assets including Goodwill
  (g) Long-Lived Assets including Goodwill

 

Long-lived assets, such as property and equipment, and purchased intangibles subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized of the amount by which the carrying amount of the asset exceeds the fair value of the asset.

 

We carry goodwill at cost. Other intangible assets with definite lives are stated at cost and are amortized on a straight-line basis over their estimated useful lives. All intangible assets acquired that are obtained through contractual or legal right, or are capable of being separately sold, transferred, licensed, rented, or exchanged, are recognized as an asset apart from goodwill. Goodwill is not amortized.

 

Goodwill is tested annually for impairment, and more frequently if events and circumstances indicate that the asset might be impaired. First, we can assess qualitative factors in determining whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. We elected to bypass the qualitative assessment aspect of this guidance due to the restructuring circumstances. Then, we followed a two-step quantitative process. In the first step, we compare the fair value of each reporting unit, as computed primarily by present value cash flow calculations, to its book carrying value, including goodwill. We do not believe that market value is indicative of the true fair value of the Company mainly due to average daily trading volumes of less than 1%. If the fair value exceeds the carrying value, no further work is required and no impairment loss is recognized. If the carrying value exceeds the fair value, the goodwill of the reporting unit is potentially impaired and we would then complete step 2 in order to measure the impairment loss. In step 2, the implied fair value is compared to the carrying amount of the goodwill. If the implied fair value of goodwill is less than the carrying value of goodwill, we would recognize an impairment loss equal to the difference. The implied fair value is calculated by allocating the fair value of the reporting unit (as determined in step 1) to all of its assets and liabilities (including unrecognized intangible assets) and any excess in fair value that is not assigned to the assets and liabilities is the implied fair value of goodwill.

 

The discount rate, gross margin and sales growth rates are material assumptions utilized in our calculations of the present value cash flows used to estimate the fair value of the reporting units when performing the annual goodwill impairment test. Our reporting units with goodwill at September 30, 2012 are Vetronics, which is included in our Products segment, bioanalytical services and preclinical services, which are both included in our Services segment, based on the discrete financial information available which is reviewed by management. We utilize a cash flow approach in estimating the fair value of the reporting units, where the discount rate reflects a weighted average cost of capital rate. The cash flow model used to derive fair value is sensitive to the discount rate and sales growth assumptions used.

 

Due to the closure of the McMinnville, Oregon site, we tested for impairment of the bioanalytical business at the end of our third fiscal quarter using the cash flow approach as explained above. This test resulted in no impairment to the goodwill valuation as currently recorded on the books.

 

We also performed our annual impairment test for all reporting units mentioned above at September 30, 2012. Using a discount rate of 14% and a revenue growth rate of 5% for the Bioanalytical services and 0% for both the preclinical services and Vetronics units, the fair values of the reporting units described above are greater than the carrying values by approximately $3.7 million.

 

Considerable management judgment is necessary to evaluate the impact of operating and macroeconomic changes and to estimate future cash flows. Assumptions used in our impairment evaluations, such as forecasted sales growth rates and our cost of capital or discount rate, are based on the best available market information. Changes in these estimates or a continued decline in general economic conditions could change our conclusion regarding an impairment of goodwill and potentially result in a non-cash impairment loss in a future period. The assumptions used in our impairment testing could be adversely affected by certain risks. There have been no significant events since the timing of our impairment tests that would have triggered additional impairment testing.

 

At September 30, 2012 and 2011, remaining recorded goodwill was $1,383, and the net balance of other intangible assets was $0 and $54, respectively. The components of intangible assets subject to amortization are as follows:

 

          September 30, 2012  
    Weighted
average life
(years)		     Gross Carrying
Amount		     Accumulated
Amortization		  
                         
FDA compliant facility     10     $ 302     $ 302  

 

          September 30, 2011  
    Weighted
average life
(years)		     Gross Carrying
Amount		     Accumulated
Amortization		  
                         
FDA compliant facility     10     $ 302     $ 248  

 

Amortization expense for intangible assets for fiscal years ended September 30, 2012 and 2011 was $54 and $30, respectively. As of September 30, 2012, all intangible assets have been fully amortized.
Advertising Expense
  (h) Advertising Expense

 

We expense advertising costs as incurred. Advertising expense was $203 and $229 for the years ended September 30, 2012 and 2011, respectively.
Stock-Based Compensation
  (i) Stock-Based Compensation

 

We have a stock-based employee compensation plan and a stock-based employee and outside director compensation plan, which are described more fully in Note 10. All options granted under these plans have an exercise price equal to the market value of the underlying common shares on the date of grant. We expense the estimated fair value of stock options over the vesting periods of the grants. Our policy is to recognize expense for awards subject to graded vesting using the straight-line attribution method, reduced for estimated forfeitures. Forfeitures are revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates and an adjustment is recognized at that time.

 

We use a binomial option-pricing model as our method of valuation for share-based awards, requiring us to make certain assumptions about the future, which are more fully described in Note 10. Stock-based compensation expense for employee stock options for the years ended September 30, 2012 and 2011 was $83 and $153, respectively.
Income Taxes
  (j) Income Taxes

 

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. We record valuation allowances based on a determination of the expected realization of tax assets.

 

We may recognize the tax benefit from an uncertain tax position only if it is more likely than not to be sustained upon examination based on the technical merits of the position. The amount of the accrual for which an exposure exists is measured as the largest amount of benefit determined on a cumulative probability basis that we believe is more likely than not to be realized upon settlement of the position.

 

We record interest and penalties accrued in relation to uncertain income tax positions as a component of income tax expense. Any changes in the liability for uncertain tax positions would impact our effective tax rate. We do not expect the total amount of unrecognized tax benefits to significantly change in the next twelve months.
New Accounting Pronouncements
  (k) New Accounting Pronouncements

 

In May 2011, the FASB issued updated fair value measurement and disclosure guidance that clarifies how to measure fair value and requires additional disclosures regarding Level 3 fair value measurements, as well as any transfers between Level 1 and Level 2 fair value measurements. The updated accounting guidance is effective for fiscal years and interim periods beginning on or after December 15, 2011 on a prospective basis. The Company adopted this guidance in the second fiscal quarter with no material impact on the consolidated financial statements.

 

In June 2011, the FASB amended the manner in which an entity presents the total of comprehensive income, the components of net income and the components of other comprehensive income either in a single, continuous statement of comprehensive income or in two separate but consecutive statements. The amendment eliminates the option to present the components of other comprehensive income as part of the statement of equity. The amendment is effective for fiscal years and interim periods beginning on or after December 15, 2011 on a retrospective basis. The adoption of this guidance will not change the previously reported amounts of comprehensive income. The Company has presented other comprehensive income on the face of the condensed consolidated statements of operations for all periods presented.

 

In September 2011, the FASB issued an accounting standards update that amends the two-step goodwill impairment test by permitting an entity to first assess qualitative factors in determining whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the entity determines that it is not more likely than not that the fair value of a reporting unit is less than its carrying amount, then performing the two-step goodwill impairment test is unnecessary. The amendment is effective for fiscal years and interim periods beginning on or after December 15, 2011 on a prospective basis, early adoption is permitted. The Company elected to bypass the qualitative assessment aspect of this guidance due to the restructuring circumstances and performed a quantitative analysis in the third and fourth fiscal quarters of 2012. The quantitative analysis resulted in no impairment to the goodwill valuation as currently recorded on the books.
Fair Value
  (l) Fair Value

 

The provisions of the Fair Value Measurements and Disclosure Topic defines fair value, establishes a consistent framework for measuring fair value and provides the disclosure requirements about fair value measurements. This Topic also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company's judgment about the assumptions market participants would use in pricing the asset or liability based on the best information available in the circumstances. The hierarchy is broken down into three levels based on the inputs as follows:

 

  •   Level 1 - Valuations based on quoted prices for identical assets or liabilities in active markets that the Company has the ability to access.

 

  •   Level 2 - Valuations based on quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.

 

  •   Level 3 - Valuations based on inputs that are unobservable and significant to the overall fair value measurement.

 

We have Class A and B Warrants from the May 2011 offering that are measured at fair value on a recurring basis. We recorded these warrants as a liability determining the fair value at inception on May 11, 2011. Subsequent quarterly fair value measurements, using the Black Scholes model which is considered a level 2 measurement, are calculated with fair value changes charged to the statement of operations and comprehensive income (loss). Class B Warrants expired in May 2012 and the liability was reduced to zero. The assumptions used to compute the fair value of the warrants at September 30, 2012 and 2011 were as follows:

 

    September 30, 2012     September 30, 2011  
    Warrant A     Warrant A     Warrant B  
                   
Risk-free interest rate     0.41 %     0.86 %     0.08 %
Dividend yield     0.00 %     0.00 %     0.00 %
Volatility of the Company's common stock     117.30 %     111.44 %     74.43 %
Expected life of the options (years)     3.6       4.6       0.6  
                         
Fair value per unit   $ 0.881     $ 0.844     $ 0.091  

 

The carrying amounts for cash and cash equivalents, accounts receivable, inventories, prepaid expenses and other assets, accounts payable and other accruals approximate their fair values because of their nature and respective duration. The fair value of the revolving credit facility and certain long-term debt is equal to their carrying values due to the variable nature of their interest rates. Our long-term fixed rate debt was initiated in February 2011 and renewed on November 1, 2012. Our interest rate swap expired under its terms in fiscal 2011.
Use of Estimates
  (m) Use of Estimates

 

The preparation of financial statements in conformity with generally accepted accounting principles requires us to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Significant estimates as part of the issuance of these consolidated financial statements include but are not limited to the determination of fair values, allowance for doubtful accounts, inventory obsolescence, deferred tax valuations, depreciation, impairment charges and stock compensation. Our actual results could differ from those estimates.
Research and Development
  (n) Research and Development

 

In fiscal 2012 and 2011, we spent $542 and $534, respectively, on research and development. Separate from our contract research services business, we maintain applications research and development to enhance our products business.
Comprehensive Income (Loss)
  (o) Comprehensive Income (Loss)

 

We report comprehensive income (loss) on our Consolidated Statements of Operations. Other comprehensive income (loss) represents changes in shareholders' equity and is comprised of foreign currency translation adjustments.
Foreign Currency
  (p) Foreign Currency

 

For our subsidiary outside of the United States that operates in a local currency environment, income and expense items are translated to United States dollars at the monthly average rates of exchange prevailing during the year, assets and liabilities are translated at year-end exchange rates and equity accounts are translated at historical exchange rates. Translation adjustments are accumulated in a separate component of shareholders' equity in the consolidated balance sheets and are included in the determination of comprehensive income (loss) in the consolidated statements of shareholders' equity. Transaction gains and losses are included in the determination of net income (loss) in the consolidated statements of operations and comprehensive income (loss).
XML 23 R67.htm IDEA: XBRL DOCUMENT v2.4.0.8
SETTLEMENT OF CONTINGENT LIABILITY (Details) (USD $)
In Thousands, unless otherwise specified
 12 Months Ended
Sep. 30, 2012
SETTLEMENT OF CONTINGENT LIABILITY [Abstract]  
Contingent liability, annual rent payments $ 800
Settlement agreement for cancellation of obligations under lease, agreed contribution amount 250
Settlement consideration, monthly installments 10
Discounted liability $ 216
XML 24 R56.htm IDEA: XBRL DOCUMENT v2.4.0.8
INCOME TAXES (Narrative) (Details) (USD $)
In Thousands, unless otherwise specified
 12 Months Ended
Sep. 30, 2012
Sep. 30, 2011
Sep. 30, 2010
Income Taxes [Line Items]      
Restructuring charges $ 3,195     
Payments for income taxes 12 8  
Liability for other uncertain income tax positions 16 16 30
Reduction in gross uncertain tax positions    14  
Alternative Minimum Tax Credit Carryforward [Member]
      
Income Taxes [Line Items]      
Tax credit carryforwards 42    
Foreign Tax Credit Carryforward [Member]
      
Income Taxes [Line Items]      
Tax credit carryforwards 119    
Foreign Tax Authority [Member]
      
Income Taxes [Line Items]      
Losses before income taxes from foreign operations 3,636 745  
Net operating loss carry forwards 8,854    
Domestic Tax Authority [Member]
      
Income Taxes [Line Items]      
Net operating loss carry forwards 4,935    
Expirations of operating loss carry forwards

September 30, 2014 through 2029

   
Valuation allowance 2,538 1,021  
State [Member]
      
Income Taxes [Line Items]      
Net operating loss carry forwards 9,469    
Expirations of operating loss carry forwards

September 30, 2014 through 2029

   
Reduction in gross uncertain tax positions   $ 14  
XML 25 R18.htm IDEA: XBRL DOCUMENT v2.4.0.8
RETIREMENT PLAN
 12 Months Ended
Sep. 30, 2012
RETIREMENT PLAN [Abstract]  
RETIREMENT PLAN

11. RETIREMENT PLAN

 

We have a 401(k) Retirement Plan (the "Plan") covering all employees over twenty-one years of age with at least one year of service. Under the terms of the Plan, we contribute 1% of each participant's total wages to the Plan and match 22% of the first 10% of the employee contribution. The Plan also includes provisions for various contributions which may be instituted at the discretion of the Board of Directors. The contribution made by the participant may not exceed 30% of the participant's annual wages. We made no discretionary contributions under the plan in 2012 and 2011. Similar to fiscal 2011, we suspended our match of the employee contribution as part of our cost reduction efforts. Contribution expense was $17 and $15 in fiscal 2012 and 2011, respectively. The amounts recorded in fiscal 2012 and 2011 relate to statutory contributions for our European location.
XML 26 R48.htm IDEA: XBRL DOCUMENT v2.4.0.8
LEASE ARRANGEMENTS (Narrative) (Details) (USD $)
In Thousands, unless otherwise specified
 12 Months Ended
Sep. 30, 2012
Sep. 30, 2011
Schedule Of Capital And Operating Leased Assets [Line Items]    
Equipment financed under capital leases $ 356 $ 1,888
Termination of capital lease obligation 322   
Equipment [Member]
    
Schedule Of Capital And Operating Leased Assets [Line Items]    
Capital leased assets 5,778 6,222
Capital lease, accumulated amortization 4,775 4,086
Equipment financed under capital leases 356 1,888
Building [Member]
    
Schedule Of Capital And Operating Leased Assets [Line Items]    
Lease expiration Dec. 31, 2023  
Number of years before "opt out" provision in force 7 years  
Rent expense $ 1,284 $ 441
ZIP 27 0001144204-13-054919-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001144204-13-054919-xbrl.zip M4$L#!!0````(`.)U2T-THIRW+T8!`#:[$@`1`!P`8F%S:2TR,#$R,#DS,"YX M;6Q55`D``ZA'6%*H1UA2=7@+``$$)0X```0Y`0``[#UK=^+&DM_WG/T/O>Q, M3G(.8`EL8SR9N8L!.][8QL=F9I+]OG?SV/7/)$?<&X][Y@EHT"H9[-'>8-WA<^/I8:C\WKZP(1 M@>4YELL]^K[@\<*_/OSG?_S\7Z52TZ=60!W2FY)/S`NL`267S(6^@OQ8^'19 M^*E4TBW'/G="&YIRCU0,LUHR#?B7_`\Y.X<_C5O5\+GGNP0@\L1YSQ+L?6$8 M!./SHZ/)9%+&'SR[;//1$0Q0,>I5@%6UA1F_I-KB.&7N#Z"E43W"Q]";1LW# MP*>#I>WK1_`\:HH/V(JAF8>4L>.AGX?!R$VUGU1E:[->KQ_)IW'3!:A33?%I MU-2A,QCD_(+:Y0%_.H('DA@EPRQ5S:@Y\YZH"+)[J&<9G4)1&EC6..[5MT1/ M@J,?9'4)_,VHR`0_KIBU5714+72'30@.XD+(STBE3,<@ MIH*-QBXR1OXV]&G_?0%EJ!1)3_E9.`5RI`;")^<-VZ>BT[\!6>],/!!6YKPO MS/]8-L].ZM6R,?M?@=C<"^AS\(!S6*+$^R5%K5K)K"RVQQZAQW1S&+Y`'&JS MD>4"YM=WEX4/M7+EY.>C3)A>!.[Q9N#62T"5A?8I<,6?_6`!7*`G_+,!P)X7 M6FYC,`#]`[O1"`++'HZH%]QSL!ZWS&.C<*2PV*1ESJA]?&PE,2M5"Q\J1JV2 MP&P3H)+H"D$#<(H8E.`BQ. MP.>96%^*[SA,JQ/@6X(6M8K&=B,`DZ@#7$`1\(F,BA83MLL%=.H"K!^-4`-41UDJS$$$U,7#/1EYZY[3DQC')`N&U%![NB$ M//"1Y175#T7R2'W6?T=N&P]7UW?G!)L:X^="/)8(?.X-\*M9+9/'=K=[T[YM MWW5)YY(T8?CKNRO\=G/=N+B^N>[^CGV.9IWDU_&.(?O!&HW?>3TQ?K?KV=^1 M;ONW;NGZKM7&$8SR"?,41-<>^=_0HX3W(?@RSH@ER!BX@]\%=3%@(SSTR87E M!FS$?4J:\!NS+9"IH>6/+)N[?#`E#U10R[>'Y".H6Y%,*!%ASZ406CDD&%+2 M"YF+D2,18PO-'$Q@V^&8X6,N6X!ZVD-H[^/4^(,EK4^9?*;$!R?.T(W9D3H% M[I2XS((I2)_[LKT/OP+L4Q0J@8.\.3,,,H8!IP`:-/%Y.!ABB'E"F">[T"?L M@Y\DM$+`4`YSB,<#[`@CC\I((8Q:BG-0V@HY#NW0,'@"!YV1"7P<$3AA@`@" M;'3``P:^00X34'\D860`:D0I.=6MI*+DAFD4B05<"`*7(E)D`LR!L!IB&H=, M6#"40[DPD\M])R);3.G)D,%(-H9$KN9"C*64O/^NUM\)"2ARF/=<-M"8A)Y# M%5$E8(@9?0:\@?*2W!8,*X81L0D:J?3XDFL6>$/%7V2;SWHA8/\&7$S$\AEJ M11Q+Z)D!#V'P&L9W+GNC+>P-$`2\#"`9T!."%VUJ-A`#(VO M`P:7AQZN0U!88/T13&7OBGF*,REB(Z4E&;#OP&-_Z=X^=>42AJ)'4%0`R0-V MN[*UY8Q`$T!I@6@`J6XETBI>GM-LQ>(ISEF1:C*R'"42?08V-"8I3@`^`/@8 M,C'4`,4XE.<,!-C4MN>D+:ILDK3!T9?(W:WQ3%F>+KB)(%`!SP-&.)'&I=S= MJI:[=/(908TL9`RR,LP]RY2(5=`F*-&B MO>`:S)$?R@#?9Z!!8\O5O6]1GY$*ZYLA^&=GY:IAG)R6SSE"N2\AKFZ!LE@Q`V=3=C,R.NT*YCQ%',_)<(`KWX&K; MH['+I]1/_GYK!?;PUGK&-=X]]6V*.J0;TF1#3:3\!][GLLDL?(`N,4GS1V:> M"6RS\3O]>XA;&;(43'B70[CPV1I0H>>:T3Z?\?9)\@J2W$C1/!\DDJ1F_3Y$ M41`L7E`(P*AW:3'_D^6&M.$Y3H!^>AG@:!(L?2XA/TW#_0Q#>LQ]7P!+1+.EQDA) MC9F@PNEJ*N@-Y+D-?3;[E3[\6(J1.*_1Q7PN6S=Q1'6%1+1^)!+Z;=M%8F$:U"@')R1+_MADA,@:9 M;;;*:9,4,8`@L+2=(\BF16-L+6##]#*AU?5B<`G*X/2,>J$W9$VZ6WEI_<+\9BH"/J*]#>DRT M0)J\M+-FCCP?_KX,^37KP[\'\LCY$V,.T)>P>F&0KU:;-T1X'7NW0_A%FLV>J=,< M6OZ`-OD3]<%^SY*^ECV,792!T"X]!]K412V.LFHOW9RE4"Z#+X'?E<^%N(46 MS%N2V;:RQ?XSVJK'=8W=2L!R1?'4,-:C"$@=9Z$XUWE]A'%JG+P$PWN?VY0Z MXA+@P84VVJI.O_UG&)WT7\6B1Z7,;/Z ME8'H_""K#\QJD9"\`H$U9&QR%U.$?,N]Y0`+Q]V&2TKGXO@7]3P4Z50(;U16 MT&XM[$FJ@9S.,HVFCW'&5P.3P_`#/!6P0E!)=+4%7^B@>]Z0SC90^_9Q;O/K/XM`S-[AI7,K,XSJE\)/W]06R9(,H%YGR/,`&%_J9S')A^-+6^: MR$9EF+L`C+?)$\:>,GU7'MR5$UAE?/J%3RC$;T5,TO2I&'-,V(3I,+,5,RL] MFV%VIQV[F.PL\X'I:#P$7198Y2:39_LNG^A\4IG"0[K# M$.B.`(LA]P-%R,`"XB$D2^G8!UN2&%'FXNJD9&]`L/L3J!$5\SFCN:G$(:3M M`3.W\1#(4?&>0ZSQV.=`$N"-.R7@[^IO91+M`",EH!:&B+/65?E!UJ#$Z12>I7(#:GE:&F2TO&9BH#< M6'UK"DZ`%F$>A\$@18)9M\BGOO*M:A!R:]\RSWMBK@MM.SX=@-`@,BAT'W]5 M">58,YE@M,U%H)*Y0?>H-X"FG@0E2DU%F:$T@!D9^HI8YXB',236:;(1D/`) M!XN1FI(P@.Y_:1'%I&Y7<"+KY]#$`DD``L%!\ET%DTH@ETGE`((OX2)V&$@@ M1]3"'&.)XZ.J+BB2!PD*_M>2_:X2.=:-=(YU/_34!*@M5&"*-J;SV8$\YTD( M.V`;6)CU_J9:-.MQOK\=^K)*``L"RJ0!<.((H:LJ%GPZ!KU#60*:!&#-A$HU M/RU6S1H.D1`-K).PT7KY2M.Q`_/@%ZKRRXM5HY+N8N:O@%^9"P"6@*+]`:J@ MLNQ5#GTV@[":`LUO4=:!^$A%S2-MBX>6VX\&T4147&N%5-2@H('0>XXL3>'*K[C@!84J0WJ`2`^M_H7E?2EBV4I$0VD0 M4,2!S8Z,FCCIV`'O@6/`4O^R"AN9JC^SY2I3#=D&T:%C+)N"!FIKA^@"37)S MT]2E4!Z=`'2R(LE3[D;9B,O0QV]%Q5D1Z$8"7,*B>]:N=[K"3\^JK;#6R),E M7;(RJF?!*NS,>*LLE140@<-BD117RW]/EV%I=9!J(JDW\["H&,"J$.#0UF!6 M4_;-RUDJX*I*AJ5M"EH'(3#(1O)CK*+X[3AZ<:@C#&5KL)@.J`W"@6'Q7TA, MCWLEZ`Y<8TLL2%%%+HN-(T=05#R*-SM4O=RL\`\!HOT^LYFJID*@^TH$XT`- M`T>?6E]*&+F2,9:%@YQR?P%]G-26$B8@L!<8T_?"("9(;$2E+FJ#]L3=4+D8 MT`C2X_R+O&A#2BV(=H`[>>E>8Y\APK.03D\;^TWE3>%+'U12.54PM8HA:8HG M@T%519?M\N5<0PO,O$-[JL)-51#MM!EZ#-O4_[%*-X MF=]X`8X9K:'ESNKH+BD&`HH:&[>.4H$64T]?D`FT+G]U[BRTWQ\#!L_[;:_1)TOX8<@Q?QMA,&\D)`/!*.$H@R M4,YJ)J'.A'E9:7B,J[$]KJ>F65F&:Q9T2S&6.U/WL%AB/9=&])F=A7?`WG6' ML!C]G5J^R"#%5OWW)1R9"17F62:UMD(@14;^Q-`5M'C8"_JA&Z5?:"(M>;KW ME-YJ4DR6`)436GM,XCT[W@XM?>*V9*&W].G^T]_,./UM*5`)M-"..Z%+.WU9 MI"HW%'0&1F-B^4Z4\(@V0*Y]&D*$([E"$EW,$$HG8^0WW/?TC:ST#;F-V+BY MOKH[)YB5ROK3=V1'1UG6C#4D%-%%5J-QJ$__^^`:=):"WC6:1$F^EKI43!X2 MX25?.CF/3"C>#(8;AJ[+)^)\V4;KOM!OB/7#R)F%#?1_CCJ[^;KELX+TOH`.A M_BSQ)O`CB#ZU'[K7S<9-1*,>#P(^2K1TDEO6ICQ7CN%@Y.2G"WY\V MD)$TJB[M![&_J%7>R@$>F/A2DJENT6V/!-/PMJ"F'E"/]VJ&I*`TW[Z8&^E1 M?388)H8U]+AF^:R6(YQO_R%DPSAXEV1[K:I,ABR@+](/V2G>4IHRZCI[-D@Q M%/DP3PX%JQ3CM>!L+MO_,#I\%79==OK$72N([^+-S@.WY45>,"XLA;\!CIK& M:;EN?I=MH(1Y6C;RI\2!37$[RCUQ63_>#N!Z\^!'3$H3/WT#S#LIO]HN'2R" MWHDP[Y(>!S#8WQZ'#@K4X2$X)%GV99)ED\O99BR6C.$9P:'8]"8'LW)\XZ\O29S,[_`G>4!%W?ZU)T(?#Q`@S)`O:;CD/F:F MP_(OM-RF:[&1.EW9NES4W?%HC.9<8ZUK![WHFFP'`QPP6(455PF MSR]U+=H$BT/ALRR\RQP^B<$0WPDUNP,\TCU=V2(KIX0"7NNVQ)'%VDUL9:&P ME".=VW^JWKN#$UADI%_R9\GWL1`K>ID>L>*WZ:FZ"5WE9M0J>-#Z2,1054ER5&;\QBI6JJFCFS:)S5X[=-R34=H1Z^ M:F@1!-DCJ^CS17XET^)E64OJ1"]4^$6*CWPM0%3-F#*>JUKN.$5PU7X%['&:@9,-3%55@E*$*."ZFV9&(NB-H]BZ4.R[?_4H=E?LO M/E,,P:C34%=B76'8T@(%2:?T'6YZ26AS.9>228(Q8\REC%F\3%_>$F9&]U@> M#M'OS-;,SO$UM=G,-DZ_26:+>2@^R2_77N+Z['U-MDO;FOT^C,I9WDQ=@^(! M6+AG]7TM-#MVL/\>4__?4AB67_KXU=`B#VF9!P'6U7VJZIH;G@-!`]/UHOFH M_-;3[5_IZ[77\GEK)`_"R!TK?O[P'$[UC?K>1>(@RB]GV9&FI\?>NUI79JND MW6"T>W[L66&WG/R`VOEJQ_Q*U'?!^D0-V5TH]X9R9>["\#M?$H,.5L]RY]0" M'M\,+W:Y8D5[>)J[/=P)+_38[6?JVTS@*=>.S>`+)LS_.&RIM:N43UX=B[P` MPQPYF9"2_7!RFPESMH*K_=99-2=.;H/A/XJ3^]%)LWS\ZLV_77!R<4SUXD#\ M@3E4OYE>M<(3@A4\VG:HG7LP=?B1>*%F/G`G:7\>5^2)O43Q+FZF8X MUDIF9;']RFIDN?^8S()(39X`5-;/WS!U1QFCHLN[(&U83']'@\_<#X:S.NL- MVQ[T]2I`J`CG#<%-$..CU\-;CQU=NPUKZPY>H]?4%_Z8[31IIUXQMT/,H>R\$5T,VJ+"]IE418E-UH/O:3KKTG14H5_.63KM M9\QH4->-WG%=-K==CLY.X)I+SCG(VQ(N4M>Y/TYA0302Y-JSR^3'PH06BJ00 M"OQ_'OKP1Z=_%'0N2>$G3/#I,U?==PN?8[''VR8ON3\"<$N_'C7(C_+Q3"V@ M*V;$X%=YS6-#Y;T\R%O(4YWCI)/$1=A+4T\01#9@@)([1<"@47Q[[2.U\3)> MO*@2$U3:S_80`QM,C!DQ@3>`()2`W6.[">#!UQ:U]?"FSFQ1#3IZ#G(I42_\ MI*Z7GB&/)9H0[?P_>]?ZW"B2Y+]?Q/T/G&\FHB<"R2#TPC,]$6[9GM%MM^VS M/#O;'[$HV>P@T/'P8_[ZJY<0((1``H10QDYL6Q)49?XR*RNK*BO3I:Q% MU1A7-#DTSQ^,GSACS])6E_G*P[V<"4_(M-_H6\M\X.$\Z$MFVQA53('I+G^, MY!YUHP_3""X=<^^[)/J*]L!R:5MT*`O*,FA)FTZ93K)R`%D0QVV0X87F9"2L M\GZ&`J2N6,\&+T!P248*K6(QPQ@M6QW9%LO&2Y]YH(S31^Z";*5T0+-^CK`0 M19+M>E@)2?BB3?]Z=FS?TLNV8W6UHF-+N/2??==;)3+6+`LC,J7U%'0\M#]8 M^EYSF4!Y:=[^-QCD'DD3177((AEZYZ0@TG*T_X^/O^$#7<%>C&>8)&LVUU@R M9&SSE?9%1H&)WNEX\"V6@I\L&N)!?J'?/0=IM,(A)85F=UZM.(*T+K0\2%`! M@%(78Y2F]S7HKIJ-[93[8OLF9L:FE7%H,FALD_T%3T.\<-"K8?LN24Q/5S49 M1RVS)SQF%(-#,EE3(T<2\^-^5Z4]6$6+7:UH,-GQ5.ET/DF@:=4ZJ37@O=E" MD%L]4KQ`H0V2B%+%&ES\+86"(<.K3[R2,@TZF>;^0A8? M$0YZP8MJ4D2%:!VF#+\94T+F+&S509K'&S\U-7U]J?.1[$=LM*Q:XW(8 MQ',PV6Z(#C[\*!Y/")'"4+AE0C.=H$V^+OU(*N#Q&LS">ARFH$S,]M&:,UB8 M%Z,P3?(O2T-.1K:;JZ^5$76-]Z@-77?FR&/?-`#R$5(?-Z1Z;!BP98]&RP&XGN'YQ.4GM=#PR^2I-Z3]14JD4=5>N;&XCWL\ M10CCL="B+KB@7K(1'':H\\QA9Y+,0]650%3B(WX/QZ@\T1-N:Y1CDM' M'C9HU"8A:AQMAPJ9WD`G7CC-/(=-%=G(<5F9"6V)/H=FGN3M3\.#9#E#D/?8 M4[8.0YZ%Q MD49W!EA=F55G8KRWC0DBRQ)Q).\C>S5()1>DG,O3<>OQ[IZ^NCWKXYNA>R^? MSV1IF;XI_>*X9R^2+H?SE$V];EO)>Z'YYO+;^.OW"V'R,7^RS57VIV&XH;FA MZ[:7T!3YDYFLI<62+]L"R5LFW&A3LB[+<_\8!%&`(`))#-I"J;M;(-E#27;8 M#DEJ$MTGF?@+7K6)V/0KS=-^)M^#K`XD*Q7;PU'8@[P//,AV#J$ MAJ.S&]1D4T3#6FI,J:9-KD>"XYNL/&K$V^&NKTL+O)$3C&`+R%T5#7OZ$![P MVX*L:"VYR_:`4L]]+MFI@ZPJ779JP=V43V?A1\Y^$@6V)-&"(PN^CTN+.JZO MVRH$]%#5,:EO1Q9B_D+GM_<#3S`BN9`O29=K+J]X2Q=#,X]+*.XZDC9%?D2% M5Y46W]O27->>LIJR%]<+MFV[^'M=RU]T[E_0E3`C:D]1\,!R#3@MQ(()K\GD1STN4XPXR:L&8F_ ME$1L6#,2^UTG^/%C$:63?%$">20.(4H8Z6A%SS5>9WL?(_R]HYEC/(N\_P.Q MJ+O$7TJ@D,3:#?!#O2ZC,['?-8)IGE$:14@C$,.AAF'J4QZCU/0RQ67A_SK# M]>>W1_L/^LIPH`PCC*60M,8ELS(/RUTXXBCST9CV0`E"^H[<"!.)_<;)QW,B M+@ES\V[)(?>*YN@/)8#]97QW M>7OY]3M=U0B3[Y/'ZV\387P["E,>I2)._#]MTZ>+/2J3L'['?BF!_%L[3&>L MOSBA?^*UWC\L^\V:T',$I-.H9B=$\(8G2B=\0[\K!AX=C5@8MBAD,0=/KC9`) MOD]*L"GR+^<9R2Z5QV$1/`[7>.SLQ*/OMIXU;7%Q&03EC.CZD]ZN)K$-(Q83 M0',E1O(!YGH#XH^K3!,XL\DY34JJT1?#J M7;B[$>X?KO\YOOMC\O6[,)Y,_KB^$D9WMY.[K^,K_-"5<#.^O;P=CB1QJBQV ML+GE&4T[PS[?U$^U&Y@&4M\"]VJ20(I(MYM@(N21)+2Y+J]0"@>,/(VFJ&7] M8-XW]<%3VC+6!CTU3W\<^H`='OH6D,[N2*Q^#/7WEG#)@QV9!.$@&W5TI8-\ M?G%)B3YAI?V!Q@;75'BOGWC"VI^""%%V2D/FX4AO:SVUA$]+3GX*&&Z3HR`, M"M4!TL^;@1DELN9Q6)J)UW@61G3.K`X6@LM"SCB/.UPZ"4]WENWQ),6KEMFA M"#WP6@:K$3*HM0L-#"HZ'L>(YV,B&H1-RY1>G>*A1"MJ0C20N$#-Q;,-*<%* MM24RC494?QWFK(*E88*6;;5H7^1P:.-,5I]4V%66UUW%4/%3=G\^UQSC;\00 M9[)T5T%@B=91#)N%(+Q4S*`"=A"\084=G2F7HXT8@9_XR=XVHWZ"Q7QI;,*V M0(8,L0O%%Q/E)41HK=;$HJC9NHG!;H=@H4?MTN6QYVQOT6&IH-+CQO.M('-4@"^`GV5W*94) M$\K*Y^YFR+OI#+%P4BK0%\A1UJA^D$X@G18(IIZ"@6%39^DHBBAWN[623J0& M;+2-0JK9%D-8@A!BT!Z66-#Q>NEX:?6S$SW;W5D*>XBDH"DY7=GJ*=9DO;$O MUT73D%-Q^7PIB\I`RHEU%9R#D(L3 M90(EN_O3>66[!]VY15@L1OOP`@.ML0.MBNW>70_M"WIO@^87LU(^/%&'IP!@ M`5@`%H"E:;"4MLVU[W3^FT.N`"P<>V:DG-WG:K/?3_&33%\UY3O.F(&"GN(`=19357DZH(?KQN&0,(;+N(YC&(*7(7@9QE@=/?F-6Y]P%@C[]0`+P`*P`"S'!$N]\S:QUNZ"`\%( M&F/8'HUV\JDG]H'C00=CDL(;N=XR4AF\J=AB;2"7DG02EFJP8J@+Z*#C%<-= MYH72+7##Y`Q:>`@MK.V-K5'6:JU"*ZC1"KH$L_;!01\H@#J@?AJH@X$YR$'" MH%>#RW,`_-&BE[%[!-<9H^,\`"L``L``O`TJAMBE*.(L;!-L7VBVEPYE1@D?:<,,.9XG') M%\Z,FRU?&+_-EF]/JJ&`U[P42/:\$T:0[!D&&>QH'='R"F`!6``6@`5@:=2. MUK[3^2WR(,_SM@@$-<7)@@B$@@&'0)N#!=J4F(H5U#R^<.N"GD.@S>D`WQ$5 M"0)MP$<&6``6@`5@`5A@6V);DIRI/5\XZ`59KO&*HML4%R!L&`,`"\`"L``L M]8*EM`5GV>?YJ7_=V`XRGBUAZCL.LJ8?@N=HEFMJGF%;@J;_VW>].;*\S;!" MU$=Q41^?.E4'SZ7LWX)@(>85Y`L#][0%VTTY50#!'J]@P2(W6[XU&+B'N/G6 M:?>*X&6T>8XR^X"$]XJZ4G+,/S!\CTBX736E4B&,WR:(>$LT&0BY"4+N8,>Z3C,Q M!+3E:PD.Q0`6@`5@`5@:"LLQ!+1]T5QC*ES?3])AR-Q@%?<"4ORN_5>^4GM8 MXCV,8[IN5";,4EN2RZ/\*&^[E*W5D)2]"IC[51:$/UV8)=#F*F`>I.P4UNZX M<>/^P;Z47AFF[R$=O"3PDL!+:C#W5-6E!:O<,BU'R M^(*$F6V:]IMA/0N46\'UYW/-,?[&'7CX9S2;H:GG"O:,?G20ZVD>(E<^0K<_ M<-<+![T:MN^:'X)NN%/?=9$N"K9%WYK:%HW;TXB;]Z29FC7%';T@DH0*-^8* M&NU@@A;XTQ-R!$6ZJ`:;+1+AD$0.';$[_/7R?G)]@=DR36WAHCS]_SF^>OR= M/"K]>"9,D6FZ"VV*T?]\)K'/"TW7^>?,[GK8*\\ZZ+E73X].]TN'NRU6,]I3 M6'Y3K#O(.2-`8ABLSV?J3.! MSG'7%S`&9:XWT$I'5+HIYS\G`W0)_20CO@>I=>-S,-G%D%=?.,=R[ MAVSG[A)X`5Z`EU/DY1"W,^@S;"5ILTS"-&NA)YB&]F28AF>@A,7E@3"795$9 MYBB]4E?=25D]'0L+31&%*@Z[#6"C29:U6)$<-L$4BI>4D&LN]9;09RK*WHFN'FBQVY!PI%0`Y0`Y&ZJ'T;9AC MEP60JQ*YPUQ\7U+^]?KF\4)0%^'5%JRS*N`C?0HX&C8Z8E_*45BWKGPT9*VU MQ5P=#1NR*"O%C0[8\S\^%0!>@!?@I?%[_MD=:%9,T+2MYY:'G+F@HZ=\=8J. M=Q'2$U4UY7(J+-]@NP#TK1;(]445-O9V0FY'A@&^RA0/5E'@%0(OP`OP4KM5 M5+[M_5INZP]$99ARH>!8%*@IV_I#L9>V!#@:/OKBH-^`XXFF[.L/12DMW!\\ M4IAA@1?@!7AIFD=*GYF\:`YZL4T=.2XE[[\5]6!\7348<>`%>@)?3 MY*7T(/_H$O_>03/D.$@7J+6MT0I?5)0&+/";<#^J&9+HB'(3V&B`0A4KB2K# M3J*V;B,4JDA)5%@2*-E^7NJZ MX1FVI9G"0C/TEF$)4VUA>)I9&\0[DMCM-6`,?QK*>??1$VI0'$KM5;'?!-<- M\]'-4S6DKGP](,LU7I%@6/@SVLQ\HV*".RE%)R&4&NZ,@+(='K:TM2C` M!K=%CE/K:G-S-.XH2.W.JEPB#89V4V)23D0;5+R`3O%G81QM1.Y388F\4@K$ M-@JQH:@,4M;=H&N;,U'UQ!XD\=IYF!8#W:D,4[DK*FEIG>K@)$#T/O`"O``O M)\9+K>J^;5M=A:Z:"IJE%[3:HN3L-[FFU\%A+!1<_(;ODQ53.6MG1^Z8L=N_ MLMM)P@8JMSMV!16H.DGL8+C66.7";L2YIV&"@H__U6I=6_J-HSV3RN&M%FV( M/*8;KZMW^(=?SGVW]:QIBXO+Z=3V+<^PGDMCB3++4EM*=+Z\^0-WS+8XW],KLX$'4V-N6:ZG\]:RMFO M\J#?E21IC;T8(47PTR4*B)Y ML`<[7U?KH01VUG^MQ,YUDAA:IZ4XADJ53T?J)THH`T/+T*$KM,`3EJ&1*0O_ M;2+R!Y[-+N>VXQE_T^_O'7N!'._CWM0LC\QT>`V[F(?X+Z2Q\N7?Z2GK$UTA MM!\+O.5JHS)0U^Q?N?#21,FC<-@;,TY?;=?%D\?=#%NI.(I9WJE@II`W(96% MOL,`4J[VJ,<'B-SN]KIJNZOVY)QZDO!>\[0E*SAQG6 M87X^\_`DGEF1UIJ)8O4^-RWW`C?]^>S%\Q87Y^=O;V_M-Z5M.\_GV!V2S__U M[>MD^H+F6LNP7$^SIKCO\\/IS$ZPK*M0);`$EP#O-0/[Q2-V`Y"QG_Q;!5XN M?B'FYB:34@POY2Y`U+[2JXZ7RNRYK':E894RJLH42]WX5%6VO-;&>3%F,\I7 M:RCWJQ57-K9RF[TBV7(?[5O;X@7T+ET7>6Z$M83?*:']S19CYMASPI?4PO]) M2QO`@V2Q5).`L_&X7 M/;TK[L%[>6!1*6X MAH.8:M/Z"I_6S1%CEXE?3%E:;;EPF`@WW4;KV-5+O2BYVT5,/O M:0A4S2C0]'&53Z!#D&>)`[0R)PZ&99G#LBH_]6@&(VE^[+KDH!/_/]GW&=EN MX#_LWD"%PT8Z^Q4O"CI#.2?>&RC/#^*?FN-HEL?:RHQK&=YUR4G](R-8GR90=U&(D6.AZV>]4Q&Y[UM M&M./ZW=B'Y$>^Y$CE/V%XB>%7WF8W=7=Z/'[_;7PXLU-X?Z/+U_'(^&L=7[^ MIS(Z/[]ZO!+^]?OCMZ^"W):$1\RZRU$Y/[^^/1,2M.KQX?R=M"63E_F?+2_T M9EOW]#-A%=(7CNCC?W/2)I[F>-$80!:'2&*0EJ&(WRX??AO?!I&($HE#O+F[ M?;P09/RW\&C,D2O@?#L19;+#=+B?761@1/SOG:U(?S5 MP_BWWY??_3F^>OQ]>?6!1V&.;Z^N;]D#NZD/"!-,<5D*63]/%H MX:'Y$W($11(%8M#H\\3.B8*#W`4)Z7U%YD<[QOBNX<,Y+/)&X\^?CYMX_G7% MLUPG?@B_1M`^?%2W2L&JDH\/T[3?B#=S8SM7MO_DS7QS/8Z5\9;I44+R<+"9 MW^#H1UJQ&'U^ZWJZ'W-',M%5`=LE'XO'#UQKPW:Y)^@=I2*V1WBU_HSN9C,W M!P"KEZIVR_OR#KBLR#T40A4>+.YB)O8$*!Q6G>>-NIJ/Y.CK"K"HH4W9`PNR MH8?G87*S.CLJ-BWJ#NBLJ#T40-59EM:P6R1"H0CRN]G8\C3KV<#/AX]] M4Q^I6#V46+A&*FUEL%J=H'O=W5FU/$,W3)^LNR8(+_'H;9;K]ZGIXQ7;#::3 MG`GX'F_L6G,L[*.[]\BAIP:X*W]I/(MHB8NYIW0[[:[:[^RC*0F-!"#2I!%N M;"^_,X@?@17!4OWQ5K/BG:ZNN?&6E0%9(YT^MW0B.@W\GZG1'O M+4$1>?%6E7[I<(=FI-7,4ZJ'KG24;HROI'DED;!R;S;UU4%O1\+DK1&'&X'+ M'58YE#ORSOAE)C,.8VXR>VO1D#G13`OO2T4S7P1C//0X)YB9J$P",Q>5G?B- MZ!Q8RO)N4":\ET9COQ>_4I`#R:PTQH',2:,R[*H[XUC1G9/][&-5%TCVLI7' M=:=N(]+'=`..4A[9JPI_4\6^G!)/D!(F(#^UI;H"_6'\:MYF8K_XAOG_['UK M<]LXTN[W4W7^`XY/4B>IDF11U#7[3JH!P`,17WIFM5!K]?J M@@%*:U:WGXL5Q4XG*(I19&7%63/-C+.2-4.VOVKL3ID#C^W#9%GVL?#J/%-(2\?/@M+A@L;R3' M*H7=_BXEE&R04VJDJ@QU0M[C!SPE[WD,^_I.7!SSZU9%N*$#*0F;:YKR8S17 M'3V01UGQ:7UU;,>DWU5=73B+.V7%O*D+AV[Q&MG2BY<,!C+[?]KE:>B3\0/= MCP8@DLZB0.CN#<+6D_$'`'K5Q"!'P9*'XNQ/EKNZ@M!YB" MYDO3V6/WZ2R\:IH!D6$URO/$QYSK)A=)@D1UQ> MC/2HB&=*F&+]O2R82W"9"!4TN6)B4!4&*,^%5GN0$R+7U+(H_:)HZ%8_S"D5 M:W3=@>#F#!B M=C!;\S-]@C^PGL"SHJ'XG]GGBFFN5'WVIZ)Y@<8$+0NXG]O=\AT2T)4[TSF? M)1GU-[>V*\%TOGLIG4UG*".>>1JL*WULXE2ZH/QG#.OA#Q2](=[K)L$CG-:B M82GPMERGTTVB$`[`A>6?\.K5Q0$2;)D]$G6VH#I;4*6R!8T/R!;D+U.)*;_4 MZ2K'%$(X58EOKAZ8/RB4^%*2"A5%R0^*RLM2)]0DBJ:1N3J;:RNBJ8#IA*CZ M,Q59VV"ZV7.BZ,0PU9D*RH,L%!MO3:V(,24VQBK(`M3@W((61`-'EKS,J4Z6 MCCF>XQE$F(#D"=Z&(T;7([:97:B"8Y'#2V]UBC`M#)-R^"B9`JCZ6,52"3IP M:SOL3`G!8NJ8W`F;X(TT15]YA=4MCJ8BKHT3!7I;@J)6Q^I2P4*MT!5[\.O% MU;GO*68]%%:QE8@[Y^2;HV#R/1C%.].8FIH(&HS]\43\K3RJ/52 M5H&,J-!6$7<1.3^BFQ:Y<7I\5X)#ORD@F-[;/'\3 M0L8&#Q@VN9V*]**WYCW6XKY\I>98M>B=J8ZI]Z4EOA4ASST>9!RQ\&YOT!KU M$T3M>DU)$D^%/N='XY\@K?]\$:_T0W-U\Q6P:060V8/Z:@`WW!.X8:6!NW%0 M3=Q.U[?-SV&JT\F757(,D_>1HQR&YS/H[4(P.>U5!C-KV:P"F+>.C4>(F)\9 MB9:O4<9:/ED^DEU$;?!I+!8B;?Z%^@S+&WUBL<0-0AXBOQ8AO)#LZ0DMBP?G'P_I)-X<9>[W:$D^Z0]DLQLASHA MMSMNQZ3E5AI)_?:@>&[+23TCR;W!Z+"QO3'N%-.WEQ/V3=B&U3Z9`")=<>9# M,0ZSGZJ)&>RF9S#Q6B-/!OD`GSGVW##5_[@WV**_SWC[,6(:MML;JZEH@K+E M+&_O(4/.?'4W(KXK8JSZHVZO+TLQ#(75S=B7F9R'9]"7AP-Y>"@S6WYK3(-J MC%$2?W5/WDH?LB2\A6KX@HY;2/V-$JJ;).Q+=;Y7\(:;EVPSHKJXNM_YX5Y0 M@J9E&YHCRNB$P7J3SJENJ<_T2A\;"WI#[=OIH_+J\ACU?<'GA3J= MC;2A,:1ERV.!AW_Z\N9AYZ*8[.]2*0FSP:;3+]W-6];%C6E"=G>LB-.QV^QW MI4YYX[NE4/89WQU::<-^##8O$!4YP(GXW37`J?@=9*>B^.9DZ&&]A(WK\WKU M>;TW?E[/.)[S>OY)2_BL)1^N#0*C%KFUY]2,[<_$.R<6>W8\5_09 MAMYUPD(&>%2-FI9WXH8=\[-7K*R@:O%>53Q<`R^=&B959SKA"9/&*W[:2IS> M4M;%8K,Z^9+06&S:(QN-U1CL;NW)F@Q=2E1IG&"TS; MVNZDI.1QSL^,>^9D?=;36AL6P!LK:?B/ZUKNF4_W;"0S#'@.$RR'MB+&BPZ] M6;J[1(8K+E*M]+X;V] MF7H&WX75>O'M:?"/078DE[7X5J6>,^A*@\#>TPY:$P'`]^%BN1=-2F6]TQWV MI"UC#6;:S*=F?2*<64K%O/_+$T]'6G/CQ2/2>.!.X`*?(@86I<>AN3 M(2V]FT!9]NWTFV%,,!T\V(UG=4RM!W#[!1Y17Q<>)._+FUM.4:1ER6&!);LE M>;!YOJ$(#LN)CY=:UV!,C9C_X"=>MPZ[S"3OI=D?*1[WY4=$*)47\0!K]+SC[4%UA_?=@=;&X- MQE#/L^9^Y;?F'I77R]ITJHIK:O%M"AX=>2-E53QQ^7!;X$:^?#BW M/$XQ3"?C3[/B.]1:K[W'O0L^69;$V"CKXWQ#AF/;UFTU@V5 M]'@2\^>_P*+GA[-OV<:"FF>39Q2/8(FF\._R#Y')O'UBH>MWD+:63N`:>FC8U%R#23S9/5V/9?!N9)4XQ-,UXP7/R M2C`=PZ<"B8Q$)K#S^>7V_N+ROGE^>WU]=O=P^0F8T31E:=$T&S5BDV[4?K][ M[U/1P$'X[61,<=LDR>[GDV@C;`$4"FP]7_W/)J0SNX/$79+^!EV`'=(LN M]L&/2][Y$RS8PDC-O7\<6A@9`+_#WH5*[NB8*`$DJ6@F_)N\F/F`FW+[?TG8LZ>/G3:W4:GUVO`SX^I M-;I&IX?(LC!2@\[[*+G^;ICV3)E1S(Z$:M MR)(?XU`T?G1`I(!B*:843?-.M+WKMEODROO6(E/U%?P%<`^Z+>E]:XTZ.4?[ M:V,X@MU(6V\@%X/;H=KB M9:[:M#9N6QX$#D-^3A"3F_RZSYKX&N5]B3]V8UZ\`9<&%37@V5F?;'I:2[?4 MZ,EI5IA9T5-E1/J#;G[TU$:W-@>UT:TLRF_3Z-[3I::,V1G[_>SNMJGMDJ7F M6)XQ]AM+/.KO&6D3["S:XFZK][X58GA_8*-K9:JLJ&U39N`OGQ7=>E8U($;8 M8G:H/\0&KU_Z0?GX9BQR.T_[5BA%GK;+K0BA!T]Y\?8G?<[>L)')V?V"-AU^TR MG2QI7N6;.'QV*3JX3_ZWCG\[KR0C_ M)'EN\-V%I[3)X:6WCNF+AL-"G(72C2=-G?'D8V[AR1553$)Y`G;O5/F:9%'M M3\8U^3LPEBW":M%Z:W/1,U_+#Z0>BX>_ZW<'O.K@0IE049VRP[["HZ\-`H\N M>:E!;95;34C-S8JT,0"^)$AYOM4]-\"S]O@W,8JD(A7O!:;T8XF+$!3+'S^Z MIS.6UNB+HO\D'T[$GRC]LW1 MW+^3&G)7"O#JC:87*T=)1%%(+!>(3>1KL6KQ>L:Q^M!8B1B@T9T%G]7TWPY@ M"M0C0W*[.5%6Y/H*G$L^6V48OR?%`O=C::@(^H>%JJL+>!K`PCWZCURV4JF" MK<,`))8+>+F%!2CY`0"30N>4Y0!$AE!5)E..,%1C-P-M3$GE2#+FRH0=?M!8 M<6>V>8);[\$Q*UV55$:IG5FL2KQ[?]+33.OYI&B6X==!V(*UQ3E%QC`W="PQ MZOG*)M78U&,7-.&!)\I+VT^59YB4PH=Q?/K-Q-3`6+8/9`V^6B@@_I%95DU5GESCC%-'T6>8[XSHU"8O MH-3F_`DNUW%=CA5M[(A\Q&L?P:-;$'828-C7#\Z75$RX+X=QPI,X_/V=%E:B=]]_-44C-%54ID@P;28P MP=0"5Z?>4#;6P\O&G4TRU`"F.D9-`;1QFE;8T=(Q`37+\SPLBVZG:OZ%9]B' MIZ!+,'+56,`C();ZBNZ<._\V?(%;G^D4)>]#YP^S7"1LN-@WC^]WV,>BK M[4YP=L^:BP%S(X4;P#[A]A$D`-.^,LD4A[B(++GGN'!:.3K;B%X;')^/`KZ! MLF&O$UGH7F,P[#.KR0JB^>RFSR1VXTQBO]7>RR3"BKUZCAL^C9GS MJ??<5#5!`G25N=D@B$SHIJH%%D**>:31JT0Q/&H]C&$H^Q6)7' M#9H#[LQSH^*6O0<]#?/,99,?.:$*RZ,`W_!D_:V`WNJ[$+N\OBC@G4]20"RL M;;@N2]!K2JO^16'U!70\;OHO*G)!HP)9XRL+'8I+#>&KI!*:H/?CZU=<:2%/ M@#^L](5WEE)) M(JJY-3;8!<<,%1OCL$6^@E^!88HMU\+PNQ:(R=1A\0R/^!?#T28(O0(^XU1Q M-)O?VPE,++:`:PB_"6<"=Q9U.C-L%36JWZX1#(.9S%?DQLJ8L)SA7`0,DS-B M6JY/A&Z9H[N^J?'$O#'+&<\CGUQC,F;4X\IP#1<1R[7ZDM,^Z"=Z[+5$7I5 M;/$&W?,Z`J)DP((G]H=^-)4Z^.A"^8FC"A@UHQ.5IPLZVKCO3P6&P+,4$&W7&S-VV[^=Y6$^&\9,\LYJD;E8H M#W-@56.:`9D8-7K#WJ^I97^@C5JAT75T,'0([M3!"T$$U2"WJ3A6[C+0*]?! MHCILDJ%=YU]Y/6V%>+[RZ6CAA%0L`RVXZK.XOC22 M"2U@CH$%X/-L770$9'RB\CB-YU5,T&#C\DV93IG/4BTEGMDNYKUGY*Z%D3MG M1JZ`G=12-N]!*8/68ML&LG^7A:W-O5""#B]Z)S,U'.D%K*-<'TXX9N3,_>A$ MQ`DNOYUS9<@DTBU>L]$8W6(6$C36Q(EX2-=U-O%Y5H,&]2G.#^ZDLR=YB-%= M+4!#%HK3W1EC.4__$BL5T+6PS@.A=KMCQQ7HQDZ!&_+P8B3N^I'%Q7M,\?H7 M*&(-NK:>8'=5S4?;&YDZT2_]8I@F2R!H^18A6\.,L:?@AHW.=FL`^>!VS3DH M([R(Z=7!L\@=+-'`Q64"@+&D*=;5`[4V9O+7>_^Q@?IU")[$>UR?A=JZAHA= MB>%=WQMQ+X.PX0VF36!Q.-&22_+F+,#`]!B6ABIS7UR&?#O<*%^XU'PO]@W; M+?AU[%W^Q-Y5<"E0<*!I*R&83++783(%#TGI/S%4HE+=W6<'@"S,P^GE<6CX M-@3CQ-+R$$YH&T\GQ]2K"UPT,R%(T)NNP MIR`D_F9K(,:'&&EHD[`H.L@L9DL5*_`_6@^M0'4KUKK?>^_.Q+"'=$-O_@$( MNU4;K74/JP#8B*B[9X&@NH&0`>\_#J86^2-RI!J!@EUSQ1\V=K<'T-QR+QL^ M]#/8(%A["[^?B)2J,`)HV.E$QPT3OCCFBRX,+J`==UQ'VK=%XLI\2-@$8UL*U] M#+4&S`KQD(^U(]RS%2#D.A>4DX@Q@M/&OX@\2Y!@OR"EW$0%N)&6R."V7R"4 MB"WY`R+:&V'H&$:P-W:NC<>:YS`L@3!SX$VX6@^"IHI3=RW$\%?L5**V/<7W&-]6`)ZDUO]3S#UR!GS;MW$\`G:BASV M=\[PT'*U/=A#WH9\)?`BC\%?N?D,S20@UPG(+(X%&"Q*'7:H]0@;#VW M`X->=3'HM8?27I(0\N`.%+J9HG#!-@R6-JLVZ7^(]18"1?P#H@K"KIF1K))" M2"^?_8<)HX"()[$,-&)G2%(P-COY[*[6K?_G6Z4?#2@[IDQ"5+9[^9R3;'Q5 MQO2,;>V$L+S^,E?;$%J^IQLL]!)%6"QOZ!!2?;RZG=Z!5VQ,U/&=.%4=PFMD MX_7L[PRRF/V;O7P6\:!(9B,I*Y;Y82;,#X^2^9ST_G$PWY.S8'ZSE^-@OM/I M9<#\5B]'P7QNMBP7YMTP.YJ]2S<\=,=#^FP7?@N!'4\4N!+H,A]XV(E<"^P@ M]0!<\.-[19_1[^XV55J<-GO(6VM&PRCSI<2^*&XR4DE4\YJ4NQ9H_8)!99LK MD\3S=[,YLCKL[W3:O-D+8/4%0L-^N)^V2^X&4A*(-@DM$`_NP"?#(\2!3XM' MM^IX"/F(\VMCY6/SP3ZO\Z]T4_;E+@0W(DEWYRLNGT].7EI?4BMPQS=MIIMZ73?WR_?AC/Z4)ILE(3 M^AA(."T"A5%J%.+%HS`4#).J,ST1"K%-CUL6,D7A6&4A"?LI1C_3X0XJP^:6 M>8BE+A]VCWZ8KWWY.D*9]C5@5$K1`^P%*?UC*J494ZG3WW2"HLG)FK-N`LXV MPZ^).1OT>@+3D7N9/\ M$(2VR']B]SOAXA]*3O:\Y3NUVZ-L>;LQ]/%.]M:-\A\]66J'V]HHDO+B,M=Q M[(Y&G2RYO'*OY(;SYWV=__AUY'X\8QXM6;*4ZV!UVCO&*BE+/KM[0R-$,=@F M;+QB+,0^PY>/4=B3U6YZ5E,,:Q&LQAJ+T*;YS\G>+JL12E<1;.<,>$2D+RTZXK$"9$?N[-`H M.XDL$YM\!4>6=ZQ:#L4&?N$7\P//GFDV-3%IU;-[-AO:A:.4HH/\9:F[0PNE M(+9JN.5LU,K%+78>QCY2@'Z2=GBYL?25`4>NHI(W'.YG(J2)V:S@)TMN=Z9/ M1(33NEPL-6-%`U]'PK5_EP7$-0:;EYFSI/\8X<[7H$;L850+[H>Y8E*63,C? MX-RP(E9#&71<@*3OUAN',G'L^.>KN'=XDF7@?T\M:CY3"WH_&X]-!XB]99GY M$L(<]7P17D'X+N\>Q%8+M9S5[VY',QO4_E0TAPNNIADO//=9&#K;[8K8R]BU M3MFF*E]V\UU<#`<[1CT%N[[@V@4UU6>V^K`VF0UO5<`><708+)RD_/C,=QZ/ M(D,V^_/YS3`FF,P59OJ5[N9`Y`(2PW?,4P7,Y$CG/1F%Y<%R7#MB/L;N3(J9 MLH5UB(-@HV41/D&26;%!5OX\YWMR)-*K/)1EGO#[3E-T&X3X\M^.NER$[`::`K=!^I(E+0F`YB.1K]7N1Z[V]$%%U7&_HMJD^.>@JX!.XYKBG8V.FJ__! MBA(2(4FT^ET=@*5@.Q$Z'U77C%F?\;*2&QTXD:W$J"8HILBT90037DG MF"FHWP1U:<++_*'0]0<%*YA.>VO=L:8E+=G%Z85.9TLS)"$;(P%8]4/]3S@7 M&]\7/1;2UI9M)&G9\ECDP`TVHU\%\=AO=4:]P:#5'?7ZAPQG6"_QQYY&F^Y, M8:.:E./XP4W+<:>]=="KT#$>9C+&F[W$A^6BE6@!0YR$X=U#G(KAK6W_Q`R[ M@1V?*Q\\JAG=H(@K6,--T8TF)VO.\MW#`>M2&F=2J]OKCE"^I#6U^YP:#^DF ME_#1X4.Y)\.;XWLL#.,(]]H;E"8O%X0?[Q^^/W:P)2 M1!Y-1;=$O;W3T\N;$Q*B`![O3U^Q+PD?%K\V;=^3K8D].2'K*D+^(D+B=T': M@ZV8=K#L4.;5;BW;-/09_BFU6^3A\?;\[\TO9P^7%^3\]OO=Y/5[0TK M<+1NFG\=WH*KM6]6_WUP%@NL1(?U0EG1R%M6DX-@$(+713O#],BJO4I0#S@7 M4BM3SOY*)]\5&HT&Y-:Q+75"R84*/J]MF"%]\.)BHKT;#-INUR)?>34[MR8H MTFKQNI1/E,Q@HK)"]%BN,)IB7AEQZ9A++-PM*L$Q,E16JQ-87A@VW:B\[5:4 MM;`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`L7_]OX3,6=/'SKM;J/3 MZS7@Y\<$0A>D5Z-3VYL.@\Y[UL&]:OUL3K'XK^L!$A/,BO[T&8AM5 MKUL)^@U#6&K)H_=[49F9^.Q!M=QJ#[>H/E0P7N:J3?>2!O;0!:P5)V`>R$JE MVB0Q_UGB%HH5V(MV._D0YSFN*>@K8I9O3^JDUI#W]J>A@8>MB2K4S/=WBV.+ M=]X8!,3E62DPB9$#>%(QB%LDM&@XJ(V M8K+6Q`AY]B)WH/ZX=&4'UF.>S+@^Z0?F?7ZLCE:!D29-,FRU*SS:(=3YQ_B4 M^!C!70Y%K8/X M^I0]CFY;`SJQEKS"',9I8'&[7B.1#RK&3@S'@N;0V>L8.F)O8"M;KC>MCP4L MI4I<24GM!$NI3-=.F?!\=JC_<@$L`US,>?0E\=LFCL!3+Q(_3K(IJQ),C3KYAY"KP#:NR M\Q7#7'BEKP;^<.##I/N>Q6%!8P<^98>7PN'I`-0LYF M,Y/.1(C%@_4*SXOKECH.?%J"[*=93.08]LS6R?8-R;ZR4#-2,U(S'V"Q_+V::/I] MRS;>[Z#=*YW*`N![EREHI-/J]W\%V/*2NL/[K6&L83Q:&(N+T;MK@.O+KRQ0 M*'F'+MQ81M%[?-Y.03:#R;IJED!+QF@<9*#>"@@9BD2I1)5/00U+Y6`I9<$3 MK?^_\?.!;V#P.H/CE^7#U7^GU>G6..!1L.$;P.'(=%L-2T7\?%^L/T[YDT?W MYD5R`Q!]T#CWS10/ZOSW;=8"0C[T1H>!$\7$H?ME>V.>@L8TBGAGMSY0.ZU> M&O6<@N+,-@R+@#>?_GTX'PL#-=HUVL>#=JEK.)=R4*%B)(/[5UO'&+SU MDNQ,+NN33`SG2:/Y&_CHM_E$J3^0#P4IUVEPX#"D(O@0DQ_2<<#H]]/L,M8P M[PX$B\!ZTT]QG?-MSY277_D%78GB`7M7"OPRIUM*F&I8:EAJ4J ML)2PPJL'JI;?&I8:EAJ6JL!2J/L?=P@]>02ON@.6+L1640'.XGQ&JAA817$X MLHE%PT$WCBN!P9!JMAJ5ZCGY]1/O`5P6.:$OU&>ULN@V>T1[F0W%]CK4:YUAK MM*O+0(UVN6>T][]TE?A@]L''!C.VZ14\F"T?=$VH/EN9],3PJ(33E;\@S-TT MZ:+>-LP%',Q.D]#]K<.=GU1W2SC]7A_/.Y(02PU+#4L-2PU+%<.W6:SP+GT% M696P$I?U$F_7$F]4K_#R=]+D^DYH,3><#TH6\[9@+F"%UVO54IV_5*=)K)?# M`B_STF:A+\^R,!?_&5&\#`N58Q5R.O&JE/FKD447(PL4'9?MZ+8C5OG'5_M59IY8"7%*L/WT:%Z5/6MCKS&SU:MDB+?75V:RRRO MXE83O]DV>+!4WO>&VU&7&)"'=9F5U*`1J24=DLOWR"HRU$>_*Q44K?J1YXK= M5ON3*?HW(+P?I$Z:TX^AY!1=XCQ3H>U46&CSRXC]U3"G5*U/6\>=MI9&AT2$ MZM/6$8>#VCF=8:^H[=B.D88O%.H]M?1[:IU^??*IB/-\[1+.\^4:&D\_'^A)B74S8!`5)U,56NL:"Q4;O&XN*)/6`BAQ0B; M&KKMTB;4%)LXK.LS"R/PVQJE00S')+9A0\^.;M*Q,=/5_\`+Q\9B275+06K@ M#\LF)M7P,A8T]D?R+=N`N>E1K5CD74<:,-)4"QA8TK%XZ(D27__&,U"A`)LB M4JB(X*!%S6=U3,D2H#,F2+2$A7V\T6#LMT@T/_8+LX'D&%[;C@6=(&2,8:V.,Q\C(BR,!S=MCYF MO[^S!]BY[?1([01;/8E=DT1NQRYGESWPX_+JV^^/V*\6Z6K?*_J,31(W,0NY M,V&JIMDG"7E7E#N;CV>_@]F(\M_K_2!OR\)WPZ5*_!\IP+$;1H'/[NE"476! MNO?I.2AJ4QG;CJ(%/K]6IY1\^`MM1IHE5CU,APY34$54"9DCA3Y$!?F.8%:) M_R,%^&AD.^/]ZA"R]E^?YMK5YHAE))XUMQ7HJN:V8B0>/;=E'@"1Q0;^NW9K M,")-C)?](N<\#ML[/)IS'GG!1X8M.4V4_V@!S/B@3+N5:F?N:&'+2^X.*IU^ M-.AE?CHKE58_@M-9'"7@JP-&JYOF2D]UC[-(O3KMHA^/4:M;'TZ;L;RD!Q]S M*A^'#`7C$`-:$30RD8H*G_[:-WO'NVZKWP:5/H3ER%N0U$/,;D5$-4,XNJV# MW+>*`'+XW.VU4B5#K2@.&0I&_Y"E9$7@R$(L.CGJBYA#2?^GV;S4)U]-9;:@ MNMULLHZPV41]7C\C_OBO4\=JSA1E^>E"M<::83DFO9V>^T[AW//S-^>&95ML M-^B+8M')G;+"WJU'^FI_T8SQS\__^W\1\E_KSI[5"=4G%K1#XLX=TX3F9_KD MQM#'_`^B3GX[2=*P)0U[HVZK.Y3:K>ZHWVFU^3\8X=-M(.">3G\[4:RF,6WB MD8]F>]24V^*I=MASCJ[RA_YXN#@A$SI6%XIF_7;2E$\^=SJ#T6#0;K?]T.PF M,HI_DTXI-)@\L`-+098#WS%Z^ZUNMS<$:GN#<"ZGIK%`)MM-^+1Y>U.XEANCD92!,,!$K/BL;W^9Q_N`H]7AZ_!+@EUN0-^>@'N>DU)$EVD M%E=D<=A.S^6E8N)Q!NN.FNZL5L>,Q]!O&L-T:=->L MA=)V.&.CW8Q)`<;\.F:T+V/#8>Z,@3[I=4>H"J2#],EV)TF9[/<+&+V$3,:/ MX0%,#D>%C&2OG<%(;G62E,EV_N(Z2LKDKI'O6^SUT:? MQ0K[XO;\\:^[2S*W%QJY^^/+]=4Y.6F>GOZ0ST]/+QXOR#]^?_Q^C7MUY-%4 M=$O%I;2BG9Y>WIR0D[EM+S^=GKZ\O+1>Y)9ASDX?[T]?L2\)'Q:_-FW?DZV) M/3DAZ]6\?S$O?A>D/=B*:0>7_\$;#?Y0P[\\$++-LT]!F/ M?9#KVX<'%THY7I&S1@[A\A+^J.CQ+@\G1-&KQMA-*%T#E1*PMO5:(#%!W M1I;N8M,E&"<7:_)=6?'7FG2F6C8U63\F'>/;X1F$8D*ML:D^\2MG-P;@UF5W M?M;O=Q>U!,C2\?:4SC[W7Q**I*55X-"7=I,*@W:*OB)S!1$S*8B@8M.9P3"! M89Z@8E6?*5D"O+JM@C`$).S3CO%4+`7.WV58-Y:RH&L)\;VWP43#1Q:3?6<)#[M7%Y%A<4>LY9^-$V$B MJ3`9H7-2G3:!'IB/V')![;G!Y=T'"8L((178WC:I8CGF2GSL>R)X31';OPC> M6R+;VV[Z^:5!W;`1)+PP:+J0(4ML\D0SY4[3P"W.R(R'[LU.\D3'B@-4P*,K M_GZ@66VZ(M1:#R&^0&K(@WZCUV[S#AJ#GMQHPU]!!8;?C>0^^R:N71`0/A`6 M"@9`LB64AV*SUHIK[AL@P!9>(`5.M54C#`S-,C80^14TS.9=3;Q7JX]5C5DG M4X#.K^["6''#YUFI->Y@I-Q1V?[V;=_#'-89-Y/T?E!NR'XH(>PR'KE$S8PJK()%%BR[P$W[QF/_.?@UDE2@2CAK60^`HY4(1_^#QKVOX1+7!(1D' MP1?!&=[7EPA'[],;.,M4#%%)W[0WM_LS5]E$@]OW&D*S#&YE1X;Y[H6Z/J#` MILG0<'RW13[T&[*4Y26EMPU7IR&W"[H)5XIB3SAK>%_7U+(^K1D@%R$Q8"]> MZ!TV2EO&H+K*OUD"+=5%XT.OT4N5?R]9BMZ24],>-"'6,N_.B0/747L/6?6S MV*:93)DD6ZVA]Q((CT8'+O`3)Q"NJ%'SIO!-XDW3LC3VX3':B59)22'#2D7IJ;N;6-RA3^7J/?SRG+?<66 M8!%IJ6.F=U2`[0"XRLK+GD:Y[Y^._0.>!CX4G3R*)KQYV`>Y%9UVOW>NW^ MQN$_RK7[_M&XW0OV:,^J7CO62_:*P5[2DCV;K$615S\W[H].I_P^QQ4[^/.H MO-XK-L7R+:KNP/.W,$$5?MN&72A-W#S/Z_Q+)WAU5F979SO^N[.)Z2P2CIRN M_X?`@9>FV[GA<2^NMZCLD3/[*X5EAJ(]V(KMV(:Y"C2.`2I5/T4*%+N++7=W MX9>*_FH#6Y!H5@/8\SE63KO2+\0A%6AT9EG4MOY4-(>_$N]S*?HX.<@I^BQ8 M-8(ND'LI(4_!S7'"7Z@JEN5>A>"_,?"NEP/-P,VX?,5\ALEQ#GNX!%,_2H=G M&-55`:Y@IR"E)&:#W"T6@3V;X.4(EAPS,6J;#Q8O:NU..L`V*2X;K`WQ>K74 M3[JJ_79BFP[-6MI>%YIN?8)7_!:2R*4##NGI/[Y?/XSG=*$T51VC=V-XZC0] M1.@(T#-]N8&63LYU8_ M5ZPY/(H_+O_MJ,^*MC%+DSU0=,I760[D0DU#:M&HY)#UTM<)H?TIHV\P9P>6:3][4@WY^I[M#ORK\,\QP\(-#H)@PZ7H;&O4,& M>\+&0KG*;6DT;,G2<$?6ZG@%'=9+O$L@=?T^>D*:BX)EE!B6>#V0'I;V0*XN M+%Q:1IE(RV8O.V#I=:H+RR@Q++NE)24L@2#C?K"`J;=75YAT"]8I[C[*V<)P M1(F&N`8B:WUG-.B-6J/^CJ(%\8GO0SK9G4X4S&LPQ7\\LHQN=W.J@GQT3,]#Q<@^F^R<>REX'JA[I>*ZK_W:H]8C; M6L'\I(6\J=,X2"=BL.D=:ECG2DN8S2K+]GV5?.61ZVI:Q8EBI#"SAN>&V8(FY M+7LX*WLGOSIV\,-E4F02)6>_F"C6:"1'XTL5YV,>5P-"<#GT-349Q1X(C\P( MU.WSE$#WJO6S.<7\W"JR1RV;F(H=^/D>%A3/Z;-\EP.^9,;FJ&'Q?^71WRSOYA#N(U0&=4D: MM.3C%1I)DEK=F!/R%2=_T&UUY;*%/IW>QN-78[P]HZE3+U+FUL+XP"I8A-SG M*`E?N97"(ZCJ;>+N6V"BG2$3>6KYBL*7RRMK7JK(2^;J''_]NM[O`_W MX+W=&@Q&&?/.?5PW1N%==$O:6&S8[Y""9'O^<2*Q>>JD#6CL0F*;VF(!B1&- MY(!$R]OY*QB;3DRUX.:A./OI?/7B%*\/-=]Z_!]_Y%^>P6 MHM8^W\D58;<01?7Y+B]FUW']_\_>FS8WCB,)P]^?B.<_<+W=$>X(627J5L]6 M1[AL5X_?J2H[;-?4S/-E`R8A"=,4J09)'_WK7R3`2Q)%D>(A4D+,;I M`#(3>:3:IUAR;3@17&/C?3^_V2Z`1!.Y\IQK=>R$XBE>(>/N!6S1Y0 MQZ-DNL2!7"U5JMZD(1I`'=>7*H??GH%"XV%]*73@C=FC4'_'07]X&3KLGMQA M0E08A6[-I>O8U\36()]KDRB;OU=>]DN-4V@VX4I$\(MESL",\/+X?J?6JS/? MANW6A_W#C(N@Q426S,.+I[M[ M_NKN5+]7HCOSCV=JQ^_1FQRWX%C+-%E^/.G1_](#YFVCJ'/TJX?;W__N?^<% M.HO&@NO)D\NW]"6X2P(K"2K#;V5_;FPTLZ\`QEU0\4`2OD(CP"D9(@(.D@U; MYJ206[RDU@NQ>0BD%Q$9TDF);&4V3QH&1<.PX#OER5H2C>VX4V(R8,(4Y);" M-"U&-V+/V?<(MC:;V`X;0IE2M,"O%OV#-WA>\,'98HSF+\,D'"2=O0S0Z.&, M%/_ID@":9\MUHF\N(K"V&6K$]D!DYX&U!M.<8(JH-G_G@!!^*(C,:F+&P^7, MD:,LT!M9D+\\R-CS0#+KV<;TA6]CWD"`PX*8FX^ZYN;#S^\>7C`AGP5>6%BV M$S/R,Q90OLZQJ:`71`SXM:W<;<)`@S\]T.D?V%&6;!DF))D#@^>;L6489PPM=>6=\?L&&M61S/T-%&L4R_2%UY"`&JH.8'.@*'%Z* M;;E4@T)HIHZ7F/V'\7XUMKRM?(^AQ3K0%$\-K#E;@M+_X^K\-/%$P5E+E,^+ M<8`G_/X,R53$9-*RX($Y(?%A)'A"(U1S%Z(F'Y<_')$R)HO/U/J#,4VW7DU( MS[+82Y"I90!=[=7)?&J4F)9_J!1\?M;N.I@C9W%5!]O@YSQG;8RFL%G0OA`X MN\EP/KN&40LXU;K3,QZX+[`:%56Y4((0O,C:_-.U('L`]@TX\>#D@*V-:,@0 M&X@=W4$(WP`5Q$LI>KN1'>[PWGZFS)$X(OQMA^T,2&/CV^U*-1.Y(<@-06X( M6S:$;JH-@9BKJQRT&=-R_!V`;0VP9;S.B39G.JFAV&1FDBG;/:`<5J@`A6H1 MTZ0)E"1F.C!E:I#QKG!EU?\D-PBY0<@-HA8;1&_+!A$U9F!MKQB`8"9&]P!N M$[#U#]WZV/80;]K6:M%77@SM!S.J$-M+KPRF;RF7G(2?E!]^L3-N?`(-OZ)W M4=_,FDYQ:%D#"SQ:ZE`9+5HWC6EJ2I"%`1PDS(K[`4X'S:(ZU%R;8SM:6`W\ M"%'[V,$4C'[/H(RZ-&![US`W2V$>`$Y513FHMO+H,HGXTP4[]D^7V:J8LGU^ MBUNCQ4Q7?X)/O`K.HS:W#$;:A:4S,11G"[&%ST7''$UA8K(S+#)2BY."Z:V: M:R`XPE[901.=551OMN%?.A,%YV!2&\I^+SQSW@I[.0$?H"`=Q7/,9GX!&Q9J M@BOGT*3NE[;'L`BK\-N24.%O\9@EJM+!+"%57QF5*;1/$"#\A:G5EA7Q9$6\ M!E28DA7Q9$6\NLFDK`$GJ2$KXAUY*;J:@"$KXLF*>+D0EA7Q9$6\&M1ED\#+ MBGBR(IZLB+<;?%D1KUSZRHIX=4%"5L3+13Y91>YD<)$5\9I14TY6Q(N3V%K% MOU=UQPS7BQJB]!UN6A%O[R:"_31DS\5-)_R!PT:V+8C8$\]1K&'B!>\0\X7] M:E$"4"PI7B*BP[TGM(`75Z86C^X1H8.109;H/0@0\![1-.HB@[VU7%+KC2R0 MN.=D^T!XTPGAX1KR0LW%CR9R('`>!J+87HJVSHKNBGM;<96Z>55*\8MEO`#Z M&L4Z@7MR39A#''M,(=9;,2QS=@&7WHJ.GQVX=68D089W54QH2$0/.AW"Z,4] M\@NBA*/H`1@`O.*FL]O*G4LC$TW)&]-5X29,\+(Z96[U+Q<6=IUL5D7ZGEFWO(@E_J$HIR4``#EM9Z-:/WYG0_6[CJ6M\`<,_&>7P M02]C/QGM=#G_&V/\=J]V_IT&RQ"\KYOR[QEF;=\Y'G+RQQYR['V27G)S&(5*_XR3H`[ MC457LG'5K:&=QRBH6,P`L-UGF^@$K`;+=2!LUK>#OL/&K"N/$/3J!7&+F%IB+IY:[L5L"^#81`DAS+'S!.'0]BXP/3J(^DS>8._HNKYME\#BV*+BK+5`HDO MPQ2CC4_ZDU5M?!LHQ>'33X'/NHF1&I\14]3WP.=W)L%?V+=WYA4#AS(./T6$ M%7!*?"(P`R)0OMGD5Y,8'\\ MM3E>H`NV-'D2_YGRH7B<2ZH7%F!&(5%*B.^1?]@9J?"-B$3#2V$5SJD-ED M.W"4O.`;7YT![).?J9CQ@\&POXIV,GCEX%L=FP>#;AY\+4M_)88A$/,^E'^" MJKUQ;Q5H;^JTT)5Z'N:&3FUW)X/1J-V?#(8921CW8B*LGV_"GQSJSP<\4[M-H9=(:K$(>P M9`.ZNFUV..Z-BX%YV.X/^A/@;R[G><2, M68;]D8(W^^"VBU55X':[6")"00>]H]?$7EHV,NZF4*>57XR(ZZU;[B$AYFS] MWFM[4=82QI77(/(:Y,BO06:-N0:!E7S!E[(BEJSG1@4ON*\+U?MJI(8W(YRH M!B>J'YMFNU"TRH;2K-QO$-P+++UR(E"VU:7:'(DBJOX^:L/URG]X#4\+@NF" M&!11@83B%\+#LW@QO6"OYO5-\0NF"A3H%F7U_(HDQ%PMM#^0P>7A<#S`<`KE1_C=D>;=$S$X M9MS`=\2\0>'2MG*[>U;\IF&LVSR>+9Q^8T;@9905H@(,H`STFIGD+XBF$]-Y MLS!01.69+2"$!59]&.)+M`A<#BW]]5F'/SQJ*C/?U&0"KEDVX_<=#PL-UYDO MK;R.#Z_)3!PHI//B72[Q6R'=?S^X$?-6I(B/1`JXBR"LF"U^$XL:2+P< M&1%:'IDBQF\KEV`$;X""-%ZM60]++P5%@ITYM=S9G*M-X(F&L%&HG(EG[`\> MV-R"SZ)&T9*K&$Q$GC&(E7]%:+Q#L0.])6XBIYBRJ5H,(@T<7>PO"@GM.A_' MOY+4_4TGD&,HXN2O#P25@D4)*9_>;24T\FU1R\\G&`C$E('ORX2?C8)USCLA MQ?!`<.Q(D6:31NGI,'D"'I@FX[_QOG8&B#.%D9OM%%04R&+/D*E_)/#KS!T' M@;?E@T#!YBD&QWI;^4RHS69X!?D2_+=M*+_%]G[N+X6(9\>B_+2)5O9BYQ(L MO)">A`<^?E.D%O&:M$U3FYV-<:2Z, MV+FQ2A&(6O"+>?'BF@MVM#+*LF-FR<`%Q+PB9?ZA%50R@WOE%J`&='RVK#_6 M@M!;$?4P7.2,K+KE:04&8?*U4C)=S$4"^>*U/,6!!39US#GFE_9=L-V.P>U1 MVP_@T!$@PW8M#L6+9;@+$=`12H'Z7J6J(N^B@$7-O%*R_^=L4^/THS8ONP% M->RV*"BA.'B4B!F-/3J+;&`APV(H%WFV%>(;4'Q-R^(9/*#J!TH68+421 MIK$%N;"$'RBB!D0D.3$U".-9=,X6FK^]B<`33D[U%RZO@K.$USJ,C2(Z#Q>3 M:T9.U0U=X!>A<+`E`?)DBTR*M=X*_@%K0TG,D%M;IB9V"AY)57(EJ*CVRJM# MB\8F6&.J]-Q+.T&PY'#WNZ](GY^:P\HHOJ* M04&#D\$[(;F)`N%X:,GT"X._T/;R\GRH1,%37Y+882&TMNC>:&/NZ'S!X98: MA6!#Y-=KBF[=/DHOIUO"!G`=JGQ^.QV/95^UK\0T7]A28)O"'<4S*&M"8(=@ MIY:GHZ^Y9[PW5R7]&6K3PN;NJ;T03`H1B"Z8CX3J?NZ<5^4V4LHV1M80]WP8 MPEQ$S\P(]5KZ.#Q5#]NNX06-KFHV'HK!XG[QBS)SG9(')8(9$13U]=N[,%71 M+I[?-6OWQ!8X[X7D[:&`/F..MX6N[9R\`2CI\^6^.VSK7SGW$5K M:X[)@]K_66@#L`]!][WHB0,/#'[F<_,:Q]NWTHYXBN^8WF&SL;7R!X--W-^1 M5C]MIHV.VKY+G$$\*D&(X#+?I?+R94R1#EPG:3[WVB!F@A@$!@, MU6E^W(0G2]BH"70\#`H@!-N#`B"69ZC=:]'"TB`_X`)`&K78>C6M!=$"-S"O M%1U1(3;\F&WE@1B0=!_M#Q,?-Y`JS<7@P=8Q*9(IELWY(671=P>(G M^D83J?!`]NS+R&G=5JY"+[>H-^XCR'W@O)D:(XS+QM2YO//V4\(I;"@AD2QF MJ@K$-6YV>"'Y`F[0+Z#A&Q/Y&:*ZH//:]AYJ1Z"V1,PXL?6*:'W3,B\XP3=, M2_C5XPCC);'T+56[-SD">P_W1'"XG]D[.M,*;%A+B!E$FF?I^$GHE-A_"$<% M]4K#/V/,#X5H97W/961#&79AN!.N07K'T]KT7JJ',-CXF`XELYFHIJ[KWMUI M#-#U6N!5F1:7B?74P1$+?A`@=W#J!M(%"?P_J:W>N-<*JK]#FH.?P`$,VN;I MAE<[_*V?!OU6I+Z!\>XIBWX."=_C-T?8`#PXO'V_]T( M*(N\&=ZWEO(&2/R+'S=BKF?+T#<[B>2IW9QFOCWJ-S<5U5+GVU4G.ROI4]:T M3RCU7PU)]JY[+Y=I9;*TI0R[YPP!8)ZI\H%#YCM&H$KCR@];2S36AFK'R261 MNG?E67\K++GDMPHUIM!Q_*&6JX%KM0.J\D]>.IW^TG M-'8^1M=AF2&2*\UZ_,+J/#UE([X3OO5R3KBM"QDI4&;==[F$\&]$K8KHTD%? MA)?"SZOAI9<\I'0S[JO%4R8V00DCDZY)_W_DJ+L[9[0VZ>5FT+ZJGQ=,**X$/>VKN74PR M-=U"/41QU\&D)]E;S9H]1.E;MG['8\G@JM;O1JW;$HH!KQ5G'@TFDK]5+>!4 M_,U9$'FMP4ZMMFKU][>_0YWE18;*;!'8,`J,'N$":3(ZZP*_5.@]:Y`N'+1 MWSL*;D\B1^'?FU.YR7[^@$6AX(2PL,(A/5ITJ[@7WTZ#X)+H.N9`O?#Z!CN_ M;F*>EORQDV5],;PF*V7*X\$EKS"E#PS;'D(A`B9ZPT@4V,B+D%'`[C`=BR:$ M0JS*:O8(FV197P]82;C;W3Y0?$1--^GZ/!M4V?%L$IUZP_+I=)!HHS1KPKN? MUC0*Y;G`L,&F[5448O;+"])V1)*N'#7%,+N`8<)=C5&L4CAJ28-1@EZ:"XYZ M;?"KPNS%67C%[W@%_)1$B-/$BS(\4I`[57C2_O-$@WP&J<^(&)KD`?]$":ZJ M"5%5)1"\)MK\DP7%)KU*MG'.LN;NK:/.Y.3/EV&WK#.VM/-EBYOW-,RR8\*E M)COXB4BH4XK%:LUQ>I\U"]!L4KI8CTE.JMJ:G=) M'D)7YC!)>P>TILM"O>>]]-D=DQ9WFY8S\R7MT!'9&/82U,##P=MDD@Z2K(O" MX2W\Y#L=I>&8<*FC2AU<`7ZS3$TJU(W"I8X*];6U@/87&C_(P]8MO!$([X\S MM>@KHGJ#/5/=5G_T M=]2U9*@J;\+*HT$=-^?+KT][RN\)>4S[,L2B6GJGUO:/+\+"#)PCQQ5DT6]- M)GM'LQ[-X=)KJ9VR]$;I^I6NNOKL9@G1%-+_VSA+1]A/G#\AF]B* M3J9LW\30@UJ4$7R#YM\-U_W.^X-\-G63Y7@PS*?V%B['9>S%L<(;EJ.4P6[K M)NZ%]"A42>[S;NKTJ;J&O!V+"7P^RIG.U^3#0&UUAZG3APYT')R.57-,N#0A MVG9?W^811X40@H M4(=\(PWVY;TOFD[)@NBWQJ,R[H%E@M*FL=;JE7(%7+$K)4NEN,1N*]_6UFB$ M$\%??-DJYX'7>V^QRM83)T5WFC2RE5`,*-<,17A<]5: M9XZ5);5>B`W'^ODS-O&4.+]XOEA/=%Z=R*EUSF> MXK7CP_9\SV9$[=',-9LI56Z+6Y@U1:W:2K%L+AE+Z,=>LA5;ROUHL'=L+\%1 M^-K;V]+=Z>;U4P_8QU39&0@0`4-@[-TJ]Q@[4:QSO.$ MA,;,H"58.KQL9I[?MJG@VA4?N] MM\>+U+$CX%R"B7^"*\UP:=*G*A.#LR7P1)YIN/G&%_^TZ5 M[@9Z/U[D0$&2OES25W<>I0Q7V&I2W`8W\[M+N:6;O&!!6HWUR!P_DG>2:&^; MO)0I=0D?-^T'G>J)?ZPA/$]SK.#I%&L.><&1T!R%@L)JF;REN6C'[E?(LTQ; M>4&48%V!'N<\6@=ZAKK0ZE"9"H-M8Z@R^T]O1^_DPGK21ES$Q7J$#S[=W?\J M"+MQ4H1?/8@I8NB?P_O:Y+@8&5YT`N%%>==@K996@4&`&YRL(8B-Q[9FSMK, MLAS&%&V3Z\==BD0&ZE805;,?VW?'URB]?CN+EKL+SI\EV0HA6QU\RP6=(,S8 MIQA!!]MS'7M__B(O$X_617V"EXE;5TI;[3(3,K.5!Q*T6;R<8(`5L,N2-FCV$Q=-N[.LG)4R5F7<15/M#FR)P=Q^+H]>3J M$(08Y#\L#EAL,=9_7,)RN'/F22T>3O[F^D*R,^)UVGBO?VC9_V`KYX?S4 M]=W'I6>AL9Z%$H-H"EHI-]MNX7-L.X>*`ZEBMFA5IFPNB4PA(;]D<9V?*/V[ MY9$_T0-?>"#.'H$D94YZ:RI38H.[$:(+N/<1[L=;BN52**7#V_Q%HG)FV(2_ ML1E@?>4*X MI`38R?E%*/@"B1#?-H]%B^,_B5\&RBNRE9^ZK4%O+$19;76ZZJHP<]F!U:+[ M';G#Y=)6[M'[@E>L6B!]^S2;-:L6EFMZ4O>3]R23_]55=.S2=NFLU.5J<:*U ME%=8R7I([C1[!UHNJ?5&%DPN&<=^ZK+=IW`"3UK]X81_#<&&N`4J MG387`H1%).(&0+`A4JD]69[0OS#>[R,V<$!E.$@U3!Q$A!DO+)F(+-1G9R51A3S(J+N`<-<@?P`MVR+$C MQG*`#<^8[74VO,U(RG=!BF*?<;_+0";K0`A@(AW7+=L$`#\1FPV#D"*$7P#K7GX>P:B,[86 M(Z/Y(^F8">2"0P[[+3N9%P`YR"<3O6>O6B=`3FQQLK\"&`;!8*0DTB1H?\5) MXAH.EV.%2:QC8-AS-S'>LJ$@MN:&8<Y8@XUV0=,/]F4N^J3&J!2J!$*,9,4W8C&%79< M72UB7\+C+^,=S\7-E_QL$I%JO!FHUKAZ=NJNGASE1[=J_:+OBBK+P]][#/QJ MZ87WY"*X9/#\EDF/GJT7W((O*.9WM,\8PT6:EP8"#T/XPHS"S7G\3:6MZ"X% M7UTT>B'P52!Q7;[R1AL*]$4>5X-[>Z107T_F43UJ?T\(U!`"S:(0&0$I8+#W M\<"3"%3\_LEUYA8ESO&'3?S`O.498[!A,?ZRH\E]_@_6^+WI]_9C.[C)%T78 M@OMC8;5P\\2/ZNIV.F/%#X>(I*;&/3AJ";K[E__X3<-++PKF0GW+>_#_WQP[8L9 M0LM?16F])_1VS9:(P>_LG_";\XFQ[(_?_N__493_V7@2V_>(L.U"_WBV]EU; M'0\FPW8G_-\9K]/%!GS`TX]G0+\+M@@[%^S_.NJ%8\$G]:(SN>AU-E^&UUU& M#/[N]\?K,T7'&ED@P_YX=M$[^VW3Z> MS1UG^>N'#Z^OK^W77MNBLP\,??7#O[Y^>=3F>($NB,D.9:;LG"D?BF/J/CCO MXO$!<;X*"DO>A1'L"72(>[Z6NV\OKW_8TR=Q:&L7A2T; MY8DB4QA!R/CPX>;;F1*S4IX>/KS!6"J\[/UYX43>;.N.?J:$RF14E_3^]D![ M=!!U5K7/S4BR0F+D@G"XG=5,7XGNS#^>J1V_"E>RU\VQEG&>M77WP4KZW+Z5 MYD1$9)[DU)+`2H**S8\7_-[B/^+:07S*"&-LI&G1V;T!J%[I<*Y8)\!\6ME; MZWW.- M:@!/,6`[+O[3!?^+'5CT?B:!3J9L#O';,W9>P0'%WV<&LZD19`@/`X_:YDD# M8<0POSGEH>?\NRW@F;J7[!,FR(@X6EY]#GY>RQ#A;\1G1MCI21($PKLVC(Q- MI#G>6Y`D9_,Z1)H7N0,ENMYY",]JNI+G*Q".`?9!1-XSWM@0Q;]86A31]Q42 M(HI71GX6S'G!``JX:_A=G=Z.E-X&+UELNM8:5I`5$G$,AI@0.RH`82"\![W( M[A`A_.P7P]6QR`W@-.&,!4\+S\.#<:@>EX=E1YV*?N[`2FQY@#9=344+49(9 M)@5DF!2:5L(V)>IZ7L.&I94D9),QZ+ M"'+!Z)6<%@-\9+RQV!9F>A1<\9=R!;ZM7)KO?D4J?S<)#REQC,7?"+QRYS!9 M,+W1X1<(895`SE^*E!2&I$W8#U,F\Z9CO$?W1I[9 M^L9&?,4&)-PQPV"^L?WD=>:N620;1@VOJGKM55>]-2^%`F#?HW=QQ@CK)OFI MBFWAN6]%?>[#JY3Y.P?PU$,O&OCKF]SHI5GU&[*^8LL9.!WJI MOPBM.1[W]<>JYKO*AMJ!^SJ(96)>X8(?#"8%(QZY5-RYX<4^6S7S![L6?2R4 MU9"APM6_2P[VI,(+TR4MNGW;BSQ1->-[N\ZZ"&S%(UKMO411>-Y3O$1$]]U. MWMW&I:GS\2@31`UX%F%1X9?;5?`M$<9JQ"073QZS?L MW+R!;XZ8L]\M2W\EAN&1:/>#'"=U.T&0?6%-U^5&S4*#P3H%=@-5-K[]5>@3 MKL,#]*,BT$]&OZ"[[^*9W)T,1B.XMA]FY'71P2^W!^-S%J+0#C/4@0 M)P_KXS2"!/V]21`G!=60@#MNO6/!QS;Z7<5JP*BS;@*L0+,?^-6=R*.-`[D` M\`\3&U@2)PX1!%@:5YH;[I>>7[A]N; M1WYY&/YX[*E-47\0BA1S#('I=7@D$N&Y0MZ5O2@HR#2\XVX+/ZIA6_BXZFFR M>)RLV%<_HLN*?;$5^Q[0JP)U=2EAND0&$C6NU)RBMOJ=48'@G4B)/D:WWB#+ MCM7<,GT_+/H'!'XMJ35CRO,Q%''JCGL'@*:^].B-CJW):(9:-Y^)2>PYTYMG MEJ7+*D_;>Q&-\M0LD76>.&'RAWSVPM8UOC17F8QH3I2YY6@T>^LYWWU"RRDH$/Z1MR(.!!Z=^K5TW`O5.XME^4;;ES\RTP"$6Q5V_; M5GXJ/Q:/J=EK%X9Q$LEL\KT_>SP?L/.*K3LB_)IJPXWDM'"Z;-"6BY5AQM)%#LAC:]N M$_^CO*V7U6V.O+H-;E!UFR"T(0'D-,5M2N[_6)].E/%A(5#[U>'=DI!(]C>L M5TPA%D2S;`?*HRP0_8-MZ*)FBRA#0VWG@C``Q%^6ZRCGGV\_W_TBWA&51-?F13;\GD_P@E=V9TFM_XAB*!Y&.F94U$6YW7`:'>-% M4"?&'Y^7M64#O#"X.+C<.>,5]B%V^'H[H.Z[5]W%W@Y8")%K8U$R1G8+UT0@P<^9$H5Z_I=]9C*-,C\4^_:M"#$-DU3#9^+I\G M_PUXOV/1R/+;]5D.3775W[6P`I!I-263)92T5(APGD M;R\<;Y?+AX?+;[S=?F=9<>KQXW2R# MIYAB7_A/ERR]4I-+XOCEWGBM3.\;IIHR`6;*LD%F**AEQMX-(LZ57JK3JP3Q86=8(:AN;JY*L! M[MNFZ[/I!F*Z?JLS'FY,MS+%-*CZJ#$:T$@WC;6IN8[/BSCRDF\Z7E*V]8E1 M_+IMAV9M?83L>J,WCF@:H@/Y?NH-AD!#*(/G,M4V(GX^\4T&P:K@(4JARIPX MR)@!MM%(QQM;;8W'8VZ.A8-:O!0>;_0"&&MI@7BVN56&R0-45=S!,H(!,TK'.HZ!B_(R*#Y9C'#3>US2/T:GB#O:Q.` ML1G`\A[!P>^>\@^OFJ28!MTN='#A-B.;FBSUCH/,3:(D'QSE+C-">"3Y% MWV!4%Z:YPL.*0T0ES(7.79-DM[S7D(/QS]O6!=,?LZ36-"[OJ]?+$]A\HLER M@[&D669!&U=$M,-E%Q9^*+/-)WU491\<90+S4A?:9%C=G=D6I"E!Y' MD'I;I'1D4(6EEN#O"^DUJ_IROD2^-Y`:%Y(:U-14K]XZ5>K<%%]4HSY!DI5#\@/[\>73*=&P`C&4F`?KAB&P(AS=M$P-\B4-'L=I+3'D M99@S/VB5ITX&`;80P_J"*+%<6]&]1$H1VPM^/A%*^_T?RK-+##T8!,*Y"16= MMR$CA/WL^+'?-N1L6DOHK>V(7%$;8FS1%,*81R(4MN4EJH8!RH.VB+U1GFNF1D2F^'P\AFB2WNC82G%NX]917/%W2ZQ,7C,7[1ZWL2?G M2Q88=O1NWUGG( MV*Y1'?("C-$J"2$HV6#NIX9YO:)#5IA'O?&@&)C5N`:)*>F\H['B&LS=\;`X M,J<#>9/,&4%6>T51N<1Z)>JXTR^,M"56(X$7QIGAO#3U1X=M'W/+8*:X??.G M"_G4:\#'/E1!Y9YN;SOE8V$J"\UR*_L,)Z.MVTVE:%9V*M2)LQ4=*O7B]HE@GSF>D\2(\ ME[R^UIWKP';&K\8$:BF>].#N==1^6^UV)AFQC7DON?IH?ZUN7QH8=Q/@"JY[ M'$SAYG`+YN$C7@F['2BGJX*W.\*N84$?8()@7)(-"4DMVB$*9.[@`9G\[[RWO>AA8K'D7O=@@,P)W85Y] M9"C\JV'R`JZ/5EA+N,5O9PE#T#"PYKB14;W*9.()!&!9[`^H7C9#,^P#\P/; MCO(%3=$[=AQQ97[S@DS[A;`!V9QP>\R+/XMA#`/*;BW8RS:H!'`?'=3&LMUG MF^@$B:+1[.GAX&>_87C<2Z9E7GQG8L5H]>CPV_5@A/=VLC"%;$\C18L%<8`] MGS&^QQ1N]X``VT4J]OERY2M<7TLF/-$%UCW[C3W0W46/6)A3$$=L1H%T7R&X M'@UTP/0O5+SC3-9KGF8`=3=5/E/\IXM-[9W]L$)9<0N_E3@[WBMYBT*FR=:_ M\9Y,E1TP9B+.O1^5D((@_K,;1.AU^^-V7QV/\I-B=:C?V([CS#/0PP=Q-PV^ MHC<(SDB_;+:]4.VRZ74V]/;TH.ZF"MMXB*43S:.C7V=K*U&V/%^=A"3O,>O. MA=0(;%+*]M]<55(W?ZBBWOV&HV@3C+P8E%SL/D;=W(&!9,%U@,P>]%[X\5DX[<_*);>Z>".H7_AP,!H52.$2]^K!N%^<#'-9&*A[RL+&B\EPKVM*N>'N[0OW^HN) MG5-&PW&A>T:W.]AOS]A\,0GN]?"`G-3>G'R?6XG=2!1S+9$&I4%GO)_@Q[R8 M*/BC=0]L*E9L?&"OX)[P-[` M,_,(AZ5(9G"WT^Z;96I;F!_^5$$_HR2=(02D"#S*Y5IW,-D##]N^LG@_1'!* M/6+',?C=0G#)P'ZUB8Y%/R&OTU'&ERH(P1FL[ZS9(%PERE>DS9F-3]_9IGSC M)_2%O9FW_UQ!7VEF%*LKJ&Z'IDBD2FX^W9\,]T-*9*U]P\X/BSKS!RRZXGRV MZ)6U6!J$MZKDZ*5XL%KG*%=!5W!.`6(5V'>&H_W0WWPQ$?]UYW!V_-FC5\B> MWXLFJ/JG]^\VUF_-S\1DS[*E?QDVMP$JI'^<(S7<+O*^&[BSX@:.+NIA)OD? MKH58IX>T2H(4VNTMD2`7JCKLETD1:+YH.ZDI$O-XQ2+"*#)*19$84*ND2(4R M,DZW:/8ER)V?U)R.(#&/5[V+=,;C-`2)@;1*@E0H(=U.*@E)0Y!;4[,6^(NO M+:U\4S&?N[U.=QVM$)CLD%?(D&%/'14)^K#=[P_&$"BWH[5J,NEC!JF6`2FQ M2&9#1BS*8$9R^&E*9F2+11WT>P7S(AT2.WB1#0G&B\G&5I67%XF1IVEYD2T, M=;3F@2B`&:FPV,6,3%B,]A.HRQ=$>)6?)^N*1Q]&DQ@^(9MHFUCN?J=J-;.O M3@;;T=\-[V$(5)LCK#P"71/#Y8U3,Y'(>ZM!4N1!?#@R-4.6MI#I]5*$;S-E MEFFY)OM3$^U_[RV#:._BOZN=WK.^5#R1&MSX?:5^E"A'%90>X/4(LA:S\NN) M.KNK1[T2W9E_/%,[G9_3U(YRK&5<_8KU@@DK=4OW[:K7:7<'Q,Q3Z[0DL)*@ M8O/C!?QY_L+A+G;<[GR)"E1=DN#@$?($1E.T0Z3>FKNA!)8_P MF9E+=.Y[Y^4=-0,QV,!;,K=>PX<<2_'&BIT'QJ;"!6Y#LWAORXK,!RDZ,T1Y M&L\7_((-I1<928D`"DDYMO+*]@_X%YGO"M\%I^P<49ZQ\XJQZ8V@ M2U#R(/O391L\F_&5.'/%9*R!=!\"F6!L*,UATT4XQQ.,3%[M2,B)\$*SIWGJ MDB#2H26\5FOM_W--O+[8$*.3SKG#Q`N9)N9E2%_G1)M#V5)&1,AP6#)!YSD? M\)C#JXQ:4\CO8C_,,3O*7WA54*8SM?S,KZ5E\C?8B;-BQC8#!Y/@):3&RSY$YPQQ91HT7*+)KO+,YEA;E MV]A"I#UN8>;JQC('Z@FJLU<3J&R)O68*Y8&#U$0F]4P"]-4]))0$SKBE%YD@ M*K!"'J1/RV!>N<-$=YBPWFS\F8XB&WAX9(7?\31A=IK:X5?BA(ON^^PTY^O! MVXU>K0O;P4ME9EDZES,X+`CERX@MT\B2>7X'_BV(P\_)<'=CJW=*J.WPY%G; MAF/(($P2^,IBYXY%>5UG'8L:T?#RZQR#O$66HP/G[<)BBH1!_L!,J!F@)I=Y M45YZ'M4P0+J0)_8P'!BH\+X!T_,7"1-!#5'ZSD'ERR*R[&Z%%'OP^X#YI:S% M6#!UJ?!P]II`4K8Z%O!]1GX02*LVV?YCVY#]>^"=+OQZ0Z%I*6PJXSWC5;172V=KA&KN0H04 M"]0]ZL/:@EE`(+QIF)[ZSF#W-2TV`]7Y*U/+I4R_6M6Y^(8'+@*!3OQ0#!C7 MX(X=D*05Q@IH`YZ#5/&M$XXX+^:-;_2:14'=\+;D9\OZ8T-)V[.V7U87RIK7 M)@C-N^09],(KL_:E7Q=C-&#_F0PSU\78?"_QAJLS'JU=<:W!LR\*_=0H;)3$ MR(I"9RV*M2@4($U!A1N6[&R(>S&YT$I'+8D-<:#LE[2P"Z5"DA:RL&>K:[*` M\$MULGX]5!A'=H.]?WAL]L40U/07#ND;KZ6#!W_\KU5?,PPG_76DX@$K#KL* M;P=&ZU$&Z;`+HEF\7X7,;7Q;,:\F;.6L8+,!T/Y85,>32:];&A:'"9\HER^' MB*4HFT=9"A`6%&51R`F:E7/[X)DS#J-8/-?"2V*^KSI`L[M6-2\&I'RXC/?8 M"7L7/77SY=VQE9.UP*O"D:GPJ!T,U[)0"T:&#;X;&09^/PZ9M9=WIF0/NN7R M9=CN3@:C$:SD83)&R>LF;I3$N*RU,@\E"%Q:Q)+E+BMB%[WQL.2U)'@V+H1G MZZ,D1V>6+(R3U(CMYED6Q-32%YFJ;@"46].(&;,&)_`D#J[L+-R)W'I&S;A7 M\H9R&)6^?#7C0$'299_21Z+?9V!BXW5\T55'M+#T\D?]JHK7+E[%/_G9\IUP MD]&699D,V%Z81XMJ9'NE?#KT1NH^=(@MQ9'RW5OSL^72?_-;NPPDB;Q64768 MS%2)@+@G99[F%.,]2!.^5X'_NKLG<4(@]Z7.J[4/;;RWJEA,G3TIXX&82)<' M]KCG&/J&8W>3U2>\(V_480_G"+*WYO_&Z@V3T/[[CF MD9#)Z*X][5N;R=Q-:6UN#%+G-):8L+R5,+J86+NT87IGT>B9F#R9C4;P?<69 M4\N=S=F'[B0Y[F:Y$76S)00GM0Q4*6@[EEE*BVIC$"EHQR1H__3CU2X-PWH- M2C9E><&+8TE[:JU'OV0\M=1.=YNRM1O4JJE2V5G>'?3&15&%SI!)_N*/7`4Q MXO"\J=^+Z&_^\6[ZV4\\>0RBQV,Z"PO*%3RH3`.-I('FSYD+-S?;H98Y@X]J M6[F^>;QZN+U_NKW[IMQ]5I[^?J-\^OYX^^WF\9%O3^'#VT+P"X5H+>)_]^Q5 M)0!\(A8/%78(!!8_OMM,<-DPMZ;6%F':CKW:+^H<8H#/O-#I,XC4/OMT^4C$ M7Z_X[!<%F[QO%3$A]IA9RMI]/5RCN@":=@5T.B0 M36?Q"H9MY0=6V)8!^66F"P'^D/YG:P3"Z:=0`,&$F&N1!@+QY@NL\S%\$%I> M?M0KY*\9ADA7\Z>VK:GS"BW!X$W7YK`34V=DATRVEC*S7C`U87`V(F^OI2$= M+]BT!GJVV&9E`6DXC)"DXD)\N$N59]>&`'^;Q_B+\Q2^#J@"(X7H0*SX5/0K MX06B3,8$1G03M94[]I;&H+$6$/0-@+*-1!!-C&NY(CO@U:+&1GK+GK'91>][ M:ULU"(&(H%RK`AO[2_D!JL.U>\DX*/*C4&X=V_Y>*%Q%\Z_"NX[/%L5D9@KO ML?;.3PPFJ$(`^"=#B(,.^Q-P_1MV[J9/Z"VD0>%#5UZ/8[))TL*1.@:>5%F< M+F:E2I[$KI-^OU]`C;?U,>2**6;%I./.KMIUF;@CUT[ZM7.`"!2Y>C*LGD-$ MTLCUDV']-#8@J)$4;W18$I!E2XOX+;_Y>;W)NT!"O_MLN3'C_FASY>]J%K\O M6OW4:&W<,V:,>%1[ZR&/9>*E9A31!.[562K[^Z*YRB6Z:@ M11;G8XK]N=J=<3A9C[_;"EB1^%6V1;)C<'P`_!J^569G9H,WS*R<+7';/-AJ M+''_S+<"-Y/_0X0V?ZL\L743L4V@BL&J.@]ME5@=*E.H2KX=PM-1-0\;[2O8 MDZM-M=;]J;O.!(R9Z4SU:][Z[W!$L)9C5TJ'"G M[JQU3]F/#N#)XEXJ+O'WENU0[!!1]/@3-O&4;`^OVO=E&495?AB5VE8>;IYN M'VZ^WGQ[4NZ_7'Z3L5.1V*D?6)DCJ+480MCOJ.=__*(\!!*LW!O(](*FX,^S M7YB4OF`>[0/%:?%B:5COF,$#WRK.*WOG_<(RL5V7S47)FU!V!,L#DJ>70^6B7]G,ME\FDN,A(I8<]EZW^[,_@ZC#JG:"+WRB!C@$E`F.)!$_6K0:WM#8+JM0S/=T]BN>,LI#>?JKZ#O8 MJ^WVRE[^21UQR'Y2!P!I"$\(<`L"V[P2K$90&5;4A@YJB&YYUXO$`U2AG+/+ M^+5.+I`-`/W&I4R?8@3C(7`@6,6$N^U[#JT=A11/,3-%==YRYII`NT13?V"X MW6.J0Q#W_T':2;(KV7@S1A93!$_Y<9;_]KSQ$LD0.CW-\7Y0TWZ4%19CC= M42Z\.L>-[2&/,%D,`;8]NET"BF9YN!5TP%S:O@]L`[4*2L0*1M&24"HE^`/V MI>O,+4K^\MK0)3]2H@QPC.T8E!.P7@>O#&S+X7,UV-Z*;A+;,!4_5\W3KMH; M)*,HX"H2O2J9V"L*O3O7X7T^P&S=AF/D&0YR+,#;^#BX4%7OK7WX.!KT=DIK M!+YR$*Z5X):.;:WD."6VVQ2MJ%JYU:PHH@C^6MF*&"CR@5]RH:6RP2]-I3L$ M)TK2R0["E6IBB2KA2D61E95PI4$10OMPJD$Q00R-)2*Z5S&SYM6*78D_M#-=1VP)9<>A5 M=ZW<'8TFZ_IX9O2X&_Z&-]3<0"[RFP===S(:3-J38:YDNIA!$JN0#3=LY%@0 MB\&Q.NED>`VKPZMY+NL0ET=DX+OI5Z3-F4S3]TM3!\1XQ8H-O!.>K7IY]K:+ M;0*4&V188NJ\PXVN$WWL=^H74$Y^I/PCL#\8#3>VH02(RD"PU/.QWV7_*QY! MOWQGT@,5&,N=WF22#KF-,IWY42O7D!X/-S2;W*BMM2G3Q='?/7V5$Q89A+Y%&S!EXMOCG)=)U__,K MT9WYQS.UT_DY#(5RJ`_-/V\>GFZO+K_XT4V.M8P\ION/W5]>7]]^^ST"]=O? M%/]+#YC(-U]N/C^M??5P^_O?_>]^W%X__1T"G[J\#.%J-%00LK4:I.7HU8&5 M!!6;'R_@S_/I+QPP\2DCC+$!97L#O@M4?]'RZ)A@Q29`_\&AD;]!>F5K*QGW?T)0:V^P'M"0.,OCEG"YJ<_%(+=ZL6K2Z M-T639R_F;('^`UVN@_I=7C&PQ1+B[72\9*`0'JX4G0XMH'>W*+$%[96]67F4 M'Z`,]8^X%1.2),EXMI=>'I_H=$8[X-X:GIQFN$K.E M#.`YU7NN)0J]3:=$P\K4I>PL="D6G:S)&_S-'O$?;D,7^I70+B]@GI&81[L% MY,.",G/+6`$3L$`FGR(I[P'G=_>!7@ MO)ET".TC(O]IH_+;":_^^]@UWU),S/Z#.)\WRMY&XA%A>1,;5I0?Y&I!R5$F M$+^FP0QBXC#-@=@._K\;`>593+QW[#&]]EYXT/KG MMIIG,(^B_EC/!F+Z-!M1X4405_4!CPI`=$8S$Z(G80H0IT.!7T-:J*6"'U6` M#BB%^Q,Y!1%3:=@GBD@6_C.)OKSZQ^\/=]^_7<.>>??PJT)GS^?=3K_5'0Q: M[-]?4LC(*JH&GCK!'CKJ"MOM"Z\4NZ919:"E-YPW6FYVK,"HBD%_VG,L"AI6 M.)AGK$[4?H&P[2,G#23:H#NJAFAY%PDS'QR\U\K@+WW::F14O"T%$.4>B3-4 MG'!JJSL:'P"@6I.DW^N5!U`M]GS^TM=XD_@(>*A.6OW)4(IU5*R[K=XPBS9; ML5CGW*7ODEPV1\"^4:=$WC60'I/^I+ZRO-<6'6,];@$ M14<_F*D=8E'Z5*&T*+U!/MH4BL.)T;X_R:)-%4+\J@ZCX]M7^]U6OYO'&CY" MD@Q:H^%)&`1?V!GR:PBH@C3-7;BBU5#T*O`(F'K>[;5&^4V$7XZ"%`-F&N1> M\QNDJ,XB6#\SNNW!]E,#(JGB+]9SG%)\QH(/<3ZFHEONLX&W(9/%I9=QDL@) MKHY;PVX6+U$FAA2B0QTW`[J=5F^2Q>`IB`$)`3K[5JM)&=B7,G8P9=2@C!=, M++XF8QMD;(.,;9"Q#3*VX?`A`4>#2"W,6AG;(&,;9&R#C&V0KDP9VR!C&XY6 MK&5L0Y/9)V,;9&R#C&V0L0T-I+V,;6C0OBIC&V1L@XQMD+$-,K9!7JW+V(:Z M,.`$8ANR1C5\Y\4POI`I3@YK")_S0A-&G4&[KZJC=J_;'[._QJ-]0QRVC/3; M?:__[Q08AY!5B;):&,IJ%.5^IUXH]]1QIR`V;QOJM_M!C7'.Q^=M0_UVK]:, MT=WNR!/)/+5!-P:I(:*33@&(;@SRV_TH)YZBP=]GBUZS0\QA3UUJFN@,YR&X M]8&J&\-N%#[="EG12%97__-"72\-G1;+!ZQA\@*'O!U7;G#[SS)@4!88//(" M@WIC"@P&^U*X7A-`E]4%MU079*?@U*(+KR@@T11-5&+'+\AP1?FZH-\J@\1: M8&H'36.5*8&Z;@09L`_J1#P.OH89-C%%AO'.+#[>A9:"]X%B$?KJP&]0*Y!M M23H&]UO08=5C99L39,HV5Y\FGK.$&Y,<^A_!BZ*P'1\J',%6GA%4EH-9(DU< MGXEAL&\=*T2GK=Q#/V+=77T=ZM/I&`KJ$9.]$8S&.[HBS8%FN;S<'J^2Z*') M(*+0$\(OP0A=:\UWGX(;,'H-9B%RF=?'`T1T[_`*R4+L%4#>%<9S-!.=F0.P M8/PY82A1`L7X#,OFU1>AF2V9`E\]=!6-4,U=B+K@7HU#CUL*9KA9"W@XX"8C MCB<9P,U6=&J*7PA^M>/8QT=%.LBN+<@?H!C2T6O-L`(/?U&;(SKCI1^G3`4` MB8&&O#!LE#^OT,0`4GQ%0.I;-)6.6$)YB ML&QX@L$&$1N02U`!S+6X,=Y(&[A;8A.**C\C`TZO#++>N-AWIOH4"-N))`RH MPRQ!6,U-&+CB:CJWI;PZWD<0)#"6,4$K`>8G$0]T&;%@H<@^UH^!=7EVH>.3 MY//\20$UBOQ)B!8-A/F5$L?!T-ACF@'S$PO:/<^TX6=@0_J(N=.C>9X(GRPD MKT5^@Q>2M';MP:^)Q'@WHH-+=G/BM&+#U&Z>\'H9F9>3^IDLP=J&Y6V_W%^/ M$=`Q7L!SJZV]K\D+T;&IVUZHP(ZG*@[\&`S6>M[N!+`\K)O6$?_ MFVXVI=[Z:]4]MSL3=;3&XBV0%8=>E3VWAY-!;O0L<_:$Z>)*-*+[`KW/[IX- M,O.NLS<03GZ^ZN"M7E_=3H%D4*NE275B,1PD"$5>DESCYYA%$/FQ:@$8#=8W M\7BXBD*M.CZ.>KOY&(>9C1'5YI>F?HU?L&'Q0,T;KTFA0"_AB:K/X%Y_#<<$ MV(I'M#IF#OK=4A`5>MEN=,5S,B93QF0>>4RFV9B83'^]\L"HR(I-@%\&9L9! M4GMOV*\#1VX*S&G[4@NHY&6:&'K&A#'!NBT(88MD81 MV.E%-(8OV9B^$`C'>X:>Q-@6+8QY)U_V_PI:+MG>ZZF.VV;B]X+FG`=XP2Q+ M:NFNYH1CKL?)[6W2[SPD-DX?7E2$=\1F;SU@GOE]*<+3"+:O&>D-RW8I7L\, MR/ZB/)_*+S(<;D.,/TR-Y+=?_;;RSPN,@6]ME M=H-4SO[RE:]9D#6^MI%I6BY;JKJ"E*6!3%B]-)!WL8*?B868'+P[(L(8/5ML M'[$@N#-H=>YUC#?Y!0"OIP`O1AYEN\=7[2LQS1<(Q&XI=Q3/>'$?-A\\JG8[ M+:96*O:?+@1@3RW+4>88Z?#1P=0.>I;#2#\@Q/H+FJ)W[#ALL%M3)PQ"B*HF MMD`#0GG)8FGPD&41K$`QVX>BW=$U"\*48?MB^&)SYD!D,8]0?193L9<6&#N* M9A!>#S&(?SNG@<)K][,?3P]Z6^8*SC5"$0A\X6EACD%4/%-L.V5F02 M.7`'-?W(49?5^;(F,+S$2U!B)CE(*.EC/H*9A-8[QA[DXKT M`;XBT2I%:/14\X.TV6'&?B2V/\$[.V*WQK4?1!4K8=*G:!EYQ3.F,*P$"]8L M$$ML%<3DR0LZ"(4&DB(JE+T2\92=0-0(*X&F3$."M;Z96U`+8A]K:'O\C;MB M6J\4+3^>B7_#<5SXZQK;&B7+H"R0FVR-Y9CQ`$7@XP`IH$!^1OQJ$1`6=EKH M>^&^)KYPF!`'6R@L]6>VVT_)D58+]T!4U%9_4%'!\`.'LO);`[9IBQ)@?),_ M@I"W<9WKX!87O1G4;E`60@4/]?D%=N:6KG`K=@J9J\UGJCJH<4ANSF7X1-$+ M%BHT6XN>^GLTR[&?IX]`8U;C%\NVP0%I(X/;J\=4;KW?+['6>BV#B>\\4SS+ M"CRY>-9NKZ08XIJM]Y11?9NQKJ/0Q`;_1`YB'7>09:^E3O(4\"X^S/+H?#P_ ML*@-`;=6](4I^U![P.#JOQ^+`OXX[NOAW[KL_\&3S;42_BIO/:A#EI`RI1B& M@KZ%-G!66!$FDW&A?\(PILL=.^PHU-&[K1!'>;5<@_V&_L"^E]T"#QUX]Y9( MXU^"_]5BDL'LS4AM%65)"90Z$<[.:(N>MO(IK'9"Q'7=*IX_,6L@@NR*K5,+ M9U.9DZ[&JK-^SXA2L>?;^SC6>B:>5/P6_WOE?; M^\TK(=(:]P;"6TB7%K]]]5(FCY_V*;RJE/W,/KTBJB=ZI=]%I9_3]IWR")M= MSM,BO:6Q;KPR*UH4-E_Q!2[B0/LD$G=:`,PS53YPR%:D>VE5CRAPG)[AM7V,J'"?5LY\6)12ERD:S M6C@7`_VGUSG5>SD/\8L"(3N1DCQ57F4>%=W.U5:GD\?IO0Y?EK((C2.77)F9 M2=;O5U1A3$88E'`AED?@]X6EOM0H-=ZB@?0HH^12`\D@%\G*(NETRH.F%I;* M"08E21&O+$2K@?0X5SO%=]UL(!WD*ED)IJIQ8WL9QRC%N`91G0TDQWD_]]DG MM_IC$XH2:VK71^,_YL!G*T0A&1*2]`=,3Y'$#VK=][+8A[*_@-QK&DUZ=5*2N-?,`I2I<&5, M4M`:EKT>\M'^0&F(DOZ^SJ"RS2A+Z$0F!N11'(Z<[MDL=TGU0JBNMOH=F?1< MZJ01#P6DNQJNCAF-9EZUPB6UIMBV>8U790H5`^%;:_6=[?7N@@JQ$.42E&3D MQ879]U!#&//X%\.R1?'!5Z@`R?Y=&YNG0B^L%[R2V,R@PR_$"BFD/J]DERXI62!*V&`43PT,B;H(NCYZ38%X?JF- M'4?49O2343716\)+G?:&__Z/X@H89RXKG*JB\14C\*U'7O@[J8CQ^K->Z>'N M9#`:M?N3P3!/^>*X49)[H$`'C,Y.$JT#7255QH5097V4)*K4EQZJ6@`Y8@9) ME)'Q1C.1O#3Q4D(W">#]$-=))$5?J[T;BQ34URHKAM6U$.FI&]V>-F'*CTYO MT.VV^_WN)`]2,8,DBF=_L-$'I@34V!XR5G/C%C=*(G*#7@6XJ:-N)S=J,8,D M8=9?;ZY6"M-ZO7Y^GFT.DHA8?[VI5"DK;:CFQRQFD,2><9L-E\K`K#_I#_*C M%C-*$F[CX7HON)(VD=HI><7M(K7330I";=AF1\P$H%(+5$=BQJR)4A(#679& M[D3O``H*,'+0*9Z1&V/6AI'[8+N+KY5C^^"Y%S:P]7[@L*EQ>F,"MLB^L*;K M[%33J)\'0K"_2[L.,(JRK)]=H>[WQ]M7H@=1?F[%:<+[L&NW1GTP?NTR&;8R M+*N5T)]4P+`8_7X??NTT$P[&KAU6T%9N935\JEA,=GA&MJ^CK,Z03H*_ M(#7'+C6-NLBXU*&[([_DVX;?QI/;G5RY[9?#[9+YZ7$(=^;%H+=;N]P`N`IJ M9%-("W)BUUDZLEE415U8U)@BV3P"!=U.U9@>6T_Y@F\;Z[MG9-02BKIK*$TF M'GD$C?Z#.',H][N5'FO/'?*ZMM-)N!^+![=L.ASH;K>SVQ50,2$.4\*TKKJND4X@X1KZ,+@?YCX^Z3H^'1T<1$RL MWR`*X;(V4PCPUS'N16&[S[J?'>Y'@VO'L;GOBL>+]@T\4/6+-F)D]YN+<,HKT'4?D> MVCN>*O[T_LW+/KB^NWKZ]_V-,G<6AG+__=.7VROE[.+#AQ^]JP\?KI^NE7_] M_>GK%X712WD*TC:0\>'#S;WKX\`9CJ?"R]^>%$WFSK3OZF1)F.D03 M';R_/=`>'42=U=0(D>@3;9,E$EJ"S!Z>[I,U'>;BZ>Z>O[JS1Y;R2G1G_O&, M-]1*D4+L6,NXW.#U?"2>B>-_Z0'SMI$('/WJ0;3KX-]Y]^N59I+N)3QEAC"9R@9^$3-]S`+X+5&^U*I'EF@#Z*26- M0=^^!?J/12&ERIKR[H:?B(78LG]WB.8ECT4^4J8`(ZK-_20POJE1I/$DKQ?+ M>!$]+G5&<<-:^OE5D0%$8>2P<^:26AHDIIDS>/!Y96Z;D<3`O(F@LIPCND`: M=L5/FK58(I-X>6PS;&**#.,=AGLANLCQ0LJ4O$$#3RP^8P1P\S']:;'>5GSI M(#8DB8&`_,5>H\Y:E-J=W]%W;<74" MLB$JE2;CRLBRM*C8]W?BRTE'(*<0F,]3#)E6P,PE=AX[,",!SK^W/-1Y*IYH M7XH4[Q`F3%Z>$0/;3[AC;2RZ9C M2Y38H".K9ZS6$)PWS)LR#]'$%O M!#ZUC2-O:KS=JS9'Y@S[34;A#>A;M/XV!XDP^=4<3UP$4^!K`1K%P`61B^F] MR4MR<*F:$I.QA'#6LB^\UK`A*QPK`A?O#QO*B&DYC(9,\N!7RL:`%[?(ED@3 M%7F3("1+8)P&%.$2`4S5\13SO$X0"(,M,,HT+2%IFH'8JIX2$'5F)D-2*=OG M&?/8NM1?8`0&]'?SF1C0>]4C`<<ST:QK:GS"G(BMAX`AC\: M!PM?IAXP+6_Q6TQ7YRSGF7VF8[R'NS7'V^&K4&`?@P`<$@:.+N#=_[ MT#=9@ZCR:9O%GS:+J#H;KNNLI*Y<-D`'75GMHM@.9I\GMV MTSQ+@L]HT%OW!.]#\NISR(?C#9]75HKW1P.5S3CS(SME'_$.9R7WAN#),$]R;DN)VFAWD7M;%!O7,]DI76O MHP+%!>[>1GYZ'-R/3.OD_0:?D?8'=_0B7K#G&W8^6=8?_T2&*Z)ZTSQ8_N7; M9#!>#<5.`]8FQG?31X>IP?=@VM]C^C@'W=S',NY'#FDG!69,V@87JKKY_#IF M_[O$]']M&#N*8Y@W^W+-UFZ`?XK/]0L6:_H?_$P907 MG>J4_PVM*!LZ<9A4SY--:VL-GOT0.*0)5@@"L7GR)23&5\2-0Z3!E\B9IB:^ M9V%84]/=H_@\>AZO.%PCOU6\YVWZ/K;`50QB%>Z%&ZZ1=(@QCNHN:!=7UF)I MF>#_OYO>FG`S\H3>;MZ6V+3Q)VSB*7&>X/YR-78AQ_LRJB$2U5"FE_^1S$RX M/*\U@KM3P[!>;?C3>_L= M(ZI@4\-G'KH&4IL]\X2F5J);4+M*9M_+`^/`480IMX M8`:TUDZ_-NJ[TV5I?W#\^[Z:NV]D4_9[;X^W*&8&QQ%P3C:"K8@:M=RA)UG2 M$QK#1:F<2^4\M#JOO:AF:79*R3ZV_3NBD62T.NO+3*F1-$0C*4.Q/CY#48IS M0\2YD*;"L>V0B[,C3ZXYM>P+?CJDK^X\VK<5N+]L;X.;>06+^(HV91Y@APVAII1;%.G"^6;6.;'<&?10HVU`/SN\K: MWEUU]4 MYB^)MI4ZKYJ4T3*OK]-TW)<^Y(8$&Q6RN_.7+GV3`\H@O6!F:AX#ZV387)0< MY\,L6FDL-!O1LX?SHB8X?0-A?J7$<3`4\)KF\$T=N>?]/-.&GX$-64*M3XWF MDXI(7HMK2L^YNW:]P0L8B_%N3'T_<^*T/.QJ-XLN(N\W"J9^)DNP"1<<>UXH M;+OGN,;/SJT)#4]X6=EM]QC;'I/W%!7EAW^QS-D%KRVL,U;XI9^Q[N=XB_L& M7MO4*3G+NTZ7#9/#7C;$>9:++VM?D!<^Q@E>]OC%WU4<`(D#$"GG341V)`J^ MB*CI&BCP;G"#:S4$L?'8UL+5EK^_RJC[\S:Y_FI19X9F&*JW8V6)WOE!Z5@* M8H:5^4\8(PE6_IM>K@==BQ[?B5SA=^W9B?^IVV1LP[ABDD'[.SN-\> M_-R..7A_P$-?T!2]8\=+4[YY0:;]`FWO_+.80"N\F#,XG/0<_7(T)W*GS/.G MD13I]DL,$C#%KC_A%XL_(3 M8M@:C/*42:[C/?-ASN0OV+85K[NV`CWGB25K"VTOCS'.$[PK#[ME?S:MIP%1^]O"Y[='Y8N"Q$_H[=*VL6-? MFOH7@IZ)0B7^S;:VK_D!/$^#[7;S*MN]D>]2]605F1^QY M'%PI`O:K0O\4:+TK[K]<]/=.`MB3R%'X]^94;K*?/V`;2DKK";>MA4-ZM.A6 MX4K93H-`S[N..5`O$KH+IB7_WAZV>%VWE"F/!Y=ZE9_?[.-W:[XP<;+H>]KU MFCU^/UG6,P3O;Q\H/G*_VTDX^+-!E1W/)M$I*2VD*#K5+(QKO4;]I:91EVVV M8-A@TT9@D''[Y05I*-G#O'+4%,/L`H8)=S5&L4KAJ"4-1@EZ:2XXZK7!KPJS M5QQ.&.*6,V?+%C?O:9AEQX1+37:X M%7]%U.LOG19-PZ6..NT]Q3PLUM=II6*UIEB=)^6H[*U8I72QGA*=536UNZ01 M)333W@&MZ;(F=O;39W=,6MQM6L[PE;1#1V1CN#/>ZR#P-IFD@R3KHG!X"S_Y M3D=I."9`WRQ3DPIUHW"IHT)];2VP[1"-'^20TXTJY%N]1P>"2U?N]'8VS*D].U.; M>4][NDQVW2#&=CJ]:08JZU>=^_(BV9OS+Y0@V*K\7X`0N>` M'E`-9J@J;\+*HT$=-^?+KT][RN\)>4R34J%DB$4)]$ZM[1]?A(49.$>.*\BB MWYI,]HYF/9K#I==2.V7IC=+U*UUU]=G-$J(II/^W<;C4477];E+L%?V<(6)^ MX([?"^65J;&0X>O+7,K$D#J>%N?=23[S.FU^61UQ'^;T^=:CI6=Z1R['@V$^M?>`K:-S"B\Q'63."/3#E";N MFHF;4,!1>A2*)_=Y-W7Z5%U#WH[%!#X?Y4SG:_)AH+:ZP]3I0PU\TG9(%T6^-1V7<`\L$I4UCK=4KY0JX8E=*EDIQB053 MOZVMT0@G@K_XLE7.`Z_WWF*5K;!MBA*S:60KH1A0KAF*\+CDKB4LZ5T%O<>T\8D/P8SFQGG"65V4YX8K*"4-/0E'M M%^*91?U=ZC&&30`UA2%PWW6$VF5-E6=D>^DJ_*YRB=F1`^R$QDPZ,5R';>^; MOQ9?2G@[3FO+JX+RPN.JR@O'7W+D*X6[JS-$W.#E]V_8J$(ZC`7DWQA16V$; M(]9A\F>J?."0!.6ME5ZG52T!]JY^>\+,W;MH='7X-9%ZN\I`GX;D%[>"]N#" M.0PY9:I+U@./O^W76(9!\`*^$2:1^)O_"6,''ZHDAR1K'G(<))!'?/'T[R_L M&^(PA41;)?Y_7-LAT_FJ>3X3I\ MQTVN;JN75(8\,WAUZ\N<FSF]4X*QDA^@E M5'SS?+;<:;/K@KL)FW^6OL-%P5)?:IP/6H/.KHOFG0`=,,`S8__3%`LBE'E_ M3>2TH_9F6?V;:\HFW@0?M(;#+'M68VHAI.T>G+"\ MMSG8]%9*UFR1K8FK4RG6'/("[[E\4%/Z.T!.9E25S(/ M(!-8*DQ@P3Y[_``P2`&FC$,*4[B`ZL1T(;W%*]QOF;;R@BAA.SFP07'FD!2" M'->QZ+LRQ_']A01U[U^ MNU,@G#]+LA5"MCIG[_(*RYYC]NT>]P]5HJ?!)5^ MM<"YQ(Q84U<,2ULYE<`$Y&WMILIG[\B"L^H9FWA*G)9"II%+NB.0HW-&O;S@ M'.Q2KD`Z=-I9/(0-O'8N*:(TEX*.PL7-B]4!&.^\R*P&%QT*X5?MP9J5474 MZJ.WU$Z*\*W4BD@*?2/UX9"BX4%:;-.?$?NWGTO4E1TI&6F-C;='2[6;!9D MA@C7`O#QITO(BXP)F\T\S=@O!#UFS$E(2"T0H[0^3,F=@#L)U\.2,7+92.[$ MVB5^RAKVV71=H2%JELUC M^W=JBC6Q-_)B730,&077.R_55F^4D,A5"K_38"Z97!R3$[15R=\CX*]"TC">79)%DD6219*DU64IS M<^4]SG^GO.HNM:8DX>X^TYCE>DOW\\CNI5\-6^,D]:HJD^7T"%_*I:4DNI3V M6A)>[22W"Y:4E_O,$1']<.(N'10-T98E6219)%DD6219I(-"A-QXBAX)[49Z41<41$E])^,,)WU1H07I[;4AX/*X]5.!-*">"`%$'J M:HY+09W2YH@FEI:5`3O%!>STDIOWRNC'(^"Q#&$^;O[*-7S\/*[C&I;!RS)X M6:ZQ.FKR:>L(2\>T]-=+LDBR2+)(LM2:+/6NVR1&NPLN!%?*&$OWZ.HDYX/6 M<%QBL)4DN+P-/#S1I917'.J1=;LYUP M,B"ZN(#HI-;6,JOD"!A2 M+)(LDBR2+$=*EF:$=D52S91G/+4H]O//'/0FBU)N7(D/6[UQB4T%9"2,O$RK M`=5!S-6$HD!2S`LF^&`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`$&TV[%!F"DG2Q4#R(HU;*G%RO>(IGH,RQT?UXQ/OPN-F=K$C+;OVCN'>/V0[\Y02%XF+ MQ.44<3E$=@9_1EB2EJ@DS*L6.HI!T#,QB$-PC'%Y()JK:JLWSM!ZI:ZRDV`] M-06%8V'%I#7N'P$:Q[2S%LN2P]:8Y2]^1H0J+\AP,83LO")*462#?4^OF1<9 M7A$+:3F%QC*[C+:3LFQ7=.VHIK:Z:H:2"I)RDG)RI1Y*WL89O"R22(@<9&X2%R.WN>?7H$6S00-RYQ=.)@N%!T_9^M3U%PC9-":3!*2 M4Z7Y)MT%4MYJ0;EA:R(=>WM1;D^$)?DJ$SQI14FM4.(B<9&XU,Z*RN;>KZ5; M?]3JC1,2"IHB0,?BUA^W!DDF0&/P&+9&PR.XGC@6O_ZXU4D*]Y<:J3QA)2X2 M%XG+L6FD_)G'.:)X;ADZIC8'[[][D[\I^$^7..^_'C/%)2X2%XG+:>)2>I#_ MJHE_3_$44XIUA>^V-;+P6[W>$1CXQY`?=1R M68N%9=9OXQR/,C0VJ*N0'(&<'PDGU-;P&'R[1R%017*BPI9`\?OGI:X3AU@F M,I0E(OH%,14-+8F#C-I0O-MI]0='L(;/QVI6/WI,#XI#B?VD-3P&U8WAT<_2 M-:2N>#1;F."J,J&_0`VUS]3[J::Y"]?@?39T/"4:B8EX/I3,J/U69])]4(>$;\_B1KG$&-X!^U1IT&RTY_E#6FH$;`CUOJ*#?M#UNZ9-N&J41W M3*]FE+584CS'IDU>L$),]AEO1_ZH8H*["4TG92BUS!F1PG9XLB79HI)L,END MF5)7F\S1=46AT^Z&[1)Y,+2=$)-R(M(P809T@CXKU]%6RIT75L@KH4'L45%L MW.J-$NQN*6O;*U$-6@-9Q&OO95H,Z4YEF:K]5B^IK%,=E`09O2]QD;A(7$X, MEUKU?=ME7452315DZ@596QR?PBPL^$#RF MDY?P'>_#_WQP[8L90LM?'[4YUET#WTUO*+7HE44IUB`LWYH.,F>$`7K)V\H^`.!9^Z M%YW)1:^S^3)[_3>/A-=W5T__OK]1YL["4.Z_?_IR>Z6<77SX\*-W]>'#]=.U M\J^_/WW]HJCMCO)$D6E[D9,?/MQ\.U/.YHZS_/7#A]?7U_9KKVW1V8>GAP]O M,)8*+WM_7CB1-]NZHY\I(;NBW/+^]D![=!!U5OG+GUK&J:3`+#)]_YOR^>X; MT_'4#I/@)[)@"MTW_*H\6`MDML07+>61,7CZ-^7KY+2S?/-D\_;; M]B[_AS+%B8D=Y1@8R-=[.1$0`D$``O(;$XM4.?^NG01^F ML9<@JB_8>&\K3VP@B!JP3!!1&&=S!-M]_@][0W$L!2TLZI"_$#!!8=HM>T29 M6H9AO=HBIW6Y2=\22+FVTL-)^=I>VY68*?#E\O[QYE=H56V@I8VSL-?KM3CI M_,S6"C:@U[7&>/3QK",^+Y&N^Y^106;FQS.-D1+3B*F1H;U]E&@7C[?_[T9` M&1H?3W?WOPKBK)DCT:\>;G__N__=*@V7;V>*:;U2M/QX)OY-?7!L@,2_^'$C MYGIF=DX(0-0O6.9\T;7KD3W:D/R84"UUOEV>TZRD'\:"MKG]'9HD6?P+ M1I;BE_$/#$HDU@&89ZI\X)"A%\P.>JP89(I7?CA_QXC:"1<:!Z?:<7+I=VK9 MMG*%*'UGA^0*2RX7EFLF%+4^.(6.DR.1H-%U=@2:W:&)%+\K9XBK+6Y;]M2_ MP?CGF"TZ3A=-1S9OV&[Z!N<;0VSZI_?HOYXXZFH7<[53U+C%02O)*,E8,;15 MW$AMW;Y27U'E5S\Y6)^O+[EWP"#0*'7*+-_D/JGI`"_XB$SCNZQBMFA$24(T MR;[,S8%(7;B0X$$ND/B]3A:S4E+_"*B?X-_/[X:4+L?Z^#+2VA8%J1OE.!/+ M1:+I9FM*UV%"4H=T'4H7B'0=-IU+TG58-XY(UZ%T'3;+62/)*,E8'S)*UZ%T M'4K7H71>2>IO"=WO)Y07/(#K,'=H<.K`W*T1P:[C4OR5#;-P%U\PLO$]>N?! MQ)\M>B6JC?*O=P0([SF,C!<^9+RPX)JR$&QCPLP8I"P]QBE64&Y6_&(K*#:^ M>&I1+UKXC1W#4!:,^S/2!N]6A6SU[O517=SK6]/*Q:RU=`RFA+TZ#\<>[HQ[ M2DR-+./J-=<'[V,@]"T\A>TL#CM)YSWHS+.0#XYSX?_!O7[ZO\'#? M,:I^3\)<&V].@6MAMWN:Z8\)Y;X.X0K,8H?N=@#V>EE\+8WUGQ9+M$$6&UW2 M3`C:N"*BE5:HNOI#F6T^_=*/B1Q)^"F"A^"M[C`/ZZL^-LNG1R^ATQQV M)W76.D'Q3\_34Z!&-X,J++4$?U](KUG5E_,E\KV!U$BHL7:"U*CQGI`]NC9E M8XO#>?SC@Y/W9FEY1=!S396QZ\Q^[)0\D#R0/,@6FG;T\<(R/G)W:'"K,\SB M-)+QJ073OYO>\2BI7[STJY,L*F\3XH/WC,M-%2[\P,9!1F3`NR6FR"'F+&O$ M<+:19-!P7-!PY?'!?MRO"/"%JL)38FO(\,)_75/'5+%\1B;'$)]2H=]!B6'! M);K//.C'_9\]?_*1ANYX(/9&>:Y'&A%1X?/Q&*(@>DDMY`_MK"ID!?K<.HJK MZ6Z6O:/9KL4];A%/S@.2Z2@Y>L^'--A2&FR3I-ZWC3?7LAE%VRRV6_.%O6[1 M]RN74O97HE&6_+"TNRJRNWPVD#5[*13*7@I(UGI*2F3K`ZM.6HT7V5$;U11P_*]&2//VG]`K\H",1H29-A'Z=;P2Q*I MK7ZNB/`33;!A=.L-\@00-\;2#_@(:FLR/((T@OR$Z+8Z_6.[?LFPI.Z>V5K&-C/"-`S-;S%]P7)GV[:S MG?=R%:!,X$.6"NJG1O1^)T]D4Q:B'^[Z+>=EQVG=G:BMX2"/?B?OKG+3OW<` M^I=Y>Y5\>[3M@NJ;Q5Z#>XS'.:+X$OK&$^<]\9HJS2ORLJK0RRKQ;WCO2$8HEA+@#D,#H180`6;.OLI)NR/V*5&_:T#?7*754WI*%5" MJ<)O+ACW]FFY:S\XZ:N7U<@WN< M],994I;D;:*G_;=S%=RHY67B6G)F6^WZBA<_%T1+KX9?G'4[)?HYF^/P9;9- MGE5?QQU^N_3^DV_T1R"\YVHW=PVH]#[6&@IMINS:9F4=;!=?Y;-%IYAD$>'3 MB>($SYS<4&G!&(:8&EU8Z!+XR3IA8`_245R*>LGE@ M1\A8!0E!@@P=77RS\[:CS455IN54U^QLB\.8C>/"7]?8UBA9!DW%W6!S.5+O M?4Y-HV07?'6U*^Y,?.$P(588T1;$Y&WEE6=LXBEQCC/[HQMF?PR.SO$8JV[P M'%FV:?/35VSR1^#"&0]K7+2]N#(7-W^Z9`EJ@K*P7N!P%8@Q,50='40TC%C"F9+Y@@W..K45+$WOML2S'_K'W5A%;J67S;L`V8JJC M-56POSJ/@8/]$B/X:UF)YHX9*C3C"CPYAW"W5U*X=,W6>^9:O/[]PB@TL7/V MA#WN,-]>2YTD4T*%(3ZT5[3QYU0O9SS$\_2>.]DX^NKNLXZ*;N=JJY,ITF<7 M?%GB'!M'+KDR,Y.LW\\3:BZOF?<`I4CI63L!!+[=F>PQ'X/FD>$U` M!LKO%[IP^$#Y+'N$;!%2*.D/D*,@B1]V,3BV@D'UI[G<:PY&^M+J8]7,`I3Y M4&5,4M`:KGT1IYK3_D"Y:)+^OLZ@LLTH2^A$)@;D41R.G.[9+'=)]4*H#HV& MCSGS-2D)=7OVZPLV76Q_IM;BYLW!U$3&E6LS#093^]+4OUCF[`MYP?JE#:F4 MG]Y_Q]:,HN6<:,BXI!C9B7UQBAY>YM)&A`)*/P[ M+T*WTX9*P^N)M,NW]%I!26`E0<7FQPONS'P6&[CX5!6,NZ`*EZ5R:TXMND!! MC;IX0!,VO2!)>C.G*;O(!HG3L=RM($EZ?.!^2GL?U@?S%VRDKPWYO/_&B-K* M#63:PV3;,]9*PZ\FW7GJQ!K1,J>`*HW'1(L\!E.Q4EANG,$C,M@&Z%B*K[DI M@>KV:VH2U/?:\*!`'1Z"0Y+E<%&3FW[2H=`6U_II*=]XS9A+)NS,%,E`B<;E MQ2G=0:O3S[*_RX1"CW"35C^3]^R`284%9<;'+AXQUCU3?Z?,/G@@BR/8!2!]OE]\:EUC)].]#ZYFVH=E>QV6X-T MGW.V8`+F[__<[;0ZXR.HX%$()<:C&MOH!??"CHAR1K_3R1F',L7B<"D6+;63 M\ZZ[$9J_--+S&>E93S%II!?,`+4U&1V``>4&-A<;.+PM_OD1-EC8Q:KG74,+`<.0-R,/F?:V@O1LKB%&Q@^K;9ZN:)*3S;N?-`:JGFNC>H>=Y[U M#N6>6KJKI2]_>G*>_&%K/,E2251>I!1*_E%KT&O<14JF$)3#:QP%W$%G#3:L MJ>Z5GQ*9H_[J'V!2$]XT3"^69*E9^BI_*71I$U.S%E@Y-RS;_D7:P%*HF[4I M)RGU62W@VAVBY[W6>-C<%B7Y"3#J9RFV5MLM>+N(9C4[Z[N_E)GKH/;F%D`AL.\K-VQ*;]C&4?#D?J;+M,:=#I_ASIQ;9D.%+ M01QJ7/W;JSDR9U@AIC)%A"HOR'!YA\A71"DR'<4@Z)D8Q'F_4'2L092\$/]E M!-M&2\!N$GF)$ADQ/H6]7VV-!D?1*3MS1SWA1I92WT;M:Y1E/+8K]"UP'O>$\+5V/.[_U?-CJJ:4U[I']DK;F M%;=Z@SRG3_%IQ0=I'5)FYM]*_R;1V1GLM9_45F_849"IPY_CWD!!8K,P7!WK M8-\QO56Q@C@0V%,8/&Q+4:;$UI"A0/(3_PP/>G?I?+S@9D>QO7S(ED*QO<2: M0UZP\=[>AGV5))=YC[71>F7>8W-8(_,>:YWW6*YW\%9G)"!3PK=.).L`2D.J M>8:4S(I3U$%K/,QSFW.J67'JN*5VC[D;RRD$(HY:W:&,15RER'!4XU2<\@IC MRA#$W5TK6N-^Y:T3)/G#K-I!IO9?3;V=D?4QLT\2=:,.6Y/1`?K.2P;XVV2W MU>OG27\_4!.+AD4.-\RZE62IS_D2"^/OEJ6_$L-H*29VI"M+2G6CS)PCS&A5 M6YU.B0&"DA!U4O%ES:6\QGDFMXTTS9M.?-E2LA'&H-KJR685IT=_&=3<$$U= MDJ6F29/(G)$PM$0:Y5*F#RW3LN+4*L^RE,:HJ03G)\+@)"_+I35>M[(QDO2- MK=@CK\BK-@KSB(@TR//1/M.!61-K7-Z,2W/E-,R56!BO\9)BC?!.HSRI#RV@ M`^E?_`MIE$LI;Y2-+?5Z>6N1'5XT2WBIGP\D3?ETC9/-!"[F,-,KW*O_1'65IAR0-\Z+IK_8::)O+F_)#`W5X"$[#@(D%[`HM MB8,,45U8)XY+L:S#("6ZL5;.$5KG^>HKU$2&"XEBGY38[E)>EC?7)NS*9L$' M(_ZH:Y@>DOYHKP:3XRJC_=7%Q8^J?*>(U/2\N..7A M,9V\A.]X'_[G@VM?S!!:_OJHS;'N&OAN^BBJ@3[@)5PEFK-;BH M%XX%G[H7GGAP]O,)8*+WM_7CB1-]NZHY\I(1^C;/3^]D![=!!U5AG/GRJS;.VE8KN+ M!:+O4*S6IS_PT'CS%M%XI6GX\$_\6=Y"K6P8O7R>+ M*2D:!XBW(\'$017<LBPSE"YFNOG+.:W/+O6=OAES.9A3/O,J#`5EO&C#]S2]WN?61!(B(1D8CD`N@@GD#/9NEYA9SO7,=VF.T&?4TNE#O- ML<`(5+D-F,7G54$%Z_U.K`V?TD8MZU$G2TQ6.5`VKP!XMSW,$W/;&+*5)77Y MQY5DE&1L+!D/E_B@!E?3OB]#KUC#*",R1E8C.`XB-"Q82I)%DJ5AH77A_L^] MK$>Q^W='S9?E`O(`VUT9:LC>4MOC(Z!#P_8V29::Z/F)<:GAYJ\\8;H@)LIR M`)Q<=.3YH*2&1WGOR_:F>088LVS$.X>-QONVIC'"I-%(X_0K2+)(LDBR2+)4D>7K2Q) M=&B@#@^!)(LDBR1+@\E2J?J?%(2>WH-77X9E<['55("+B,_(Y`.K*1T:MI`E M6219:JW[RPCMQ@BSC-!NWHJ69)%DJ9_:?R)AV9TL*;0UE>`BXI%[D@Z<#KDR MC6M"AX;M:)(L]5/T98AVSJE60K15&:-=S+"K,=IYFK'(.-;:Q[%*:M<7`4GM MYK?\VA&8G3MLL.`SO8:!V;U#](JNC@TUB:U4VYE:9DHR[TOF?IY."\=%Y@H" ML\?MH^Y84!.ISM5*578,/&X7BR2+)(LDBR1+'=VW15AX7G`&[ZJ!'&GB[6'B M3:2%5[Z2UI,YH=5D.._=K>@NT?O M`-/E*Z)Z=#QHV<$GN;1M=R&^2]F.;O\A96NZBEK3/]R(4LD5Q M&1\5QV+47RQ=!_/&*S!]2]=F>\`75U MKHA81>J::2LZ.QZ4=X*-JH.&$]80.R\ZG?0L+I.O&>"K8I5O+NJTIZ$8[9^6 MP;0_`UK>,O4!5`7\!OUIF8*P0/0/[(BNL_Z/H.@B\YW3\K][D[_9H(LL+%/A M7723"9L:J#2)8^&D!RR\4":CFHO:A,O:Q40M0^1R[A\WONP89!K( MC*^3GK]G:^Y8.BD9IY6+3)>[U7,[!KIJ3-K][<5MYNUWDV+-FIGD+ZP_H;=/ MV,13XM@/3(__;%&8)]&4S?JZ-%OCS%9AE@5Z;J!K9S'J@NCR$;/A@B^?[N[Y M>$)NK^;(G($BJ;@1OBD.>E.>/UO,G9"!3X[>WSWA&3.A\[:M`H/D`;>4 M!I;J272O+)9FN=(X:]D<,-8DN&1GH]#_GT&M5)BM"$K`TK*]KRDV("D-_-JP M5#274K8595LR]8U?D34:*J)&+0Z%-8GGMR\KPL[.@R4E[&MN"TN.2OFN7Y!: M+&`/S`K7I%2?I%2?J[D[X&UX_>J2,L_?>\2.8V!PF:07WI/+C<^R)AJ5YBI) M7[>(Z&T`1TQLN*3@6S=A.$^;P/ M>&E1AYBS:V)KAF6[=/W*9_=S\FZGT)#$<*>V'6J9,^[2Z[:5QYO?O]Y\>U)N MOWV^>_AZ^71[]XV+2/@4_UADG&`<*&O"7N+LVV,S?\`]-H9P*+C3SP!7A;QR_8L);\"=M=PO(`=QH*9WU&-K$5G;!EZACOX%);SA%= M(`V[#H$`4(W';Q#L37SO@;$YL4'^=(FN:'.VDI!CS2A:SM];"C;8R-1B.\*" MCP=@L1]L8AG6C'^SL$SB6!2[B:H+] M"+,ML,Y'"'XEINT0Q^66:!OXA%_X%356&+^8K;H0*@-[%1EL[X`?V+N62X'@ MH4]RSL8+.-E6KC!U$.,TQ-0R0B';Q@P11+%B6DY(8>0XE#R[XB+2\V`&W+0V M":CR>T`^/XXYX!3[E5!E2DS&*\)>]UT+ MG%H*TC3+-1TN4DQ/U@BV/=TOPC(^.`!AHP4/97;F%ON9R;+&.,1I(GYV%PM$ M>;233=A1-F72!!3>G*-=X?:2[HJ[D,O[X)Y^9P3T*]&=^<@;'1PI=LB2PDJ!B M\^,%=Z@@X0\1GZJ"<1=4=_Q\@Q7@:6!V`I`):N;AUXG,%3BDCV0CDF#(Y_TW MSSVY@=P3F.R9*A_XS"NISJ7BE\6K<2*LZ>X325-VD;E#TR)/G^O&2&&QH:MK M1%3.'[#MP+5^^>&^34/D4"6''ICU:+KXUXH)V]2B()(L-;D9\&-QA]UH,*X? M=>=;VQDP;ERDF-)56[U,)[0,L?,(-V@-U3SMXBJ,LRNO"/PPS+7V_%%-T,\. M<]4Z;(TG>6YMY$UW+O*/6H->3O6[OK?=-=$X"N@].68[5):2_C75O?)3HM=K MJ?W3R1(?@KZ)'EWZ7R\C31LGDIM0X5[\H*- M]ZWYP5627.8]UD;KE7F/S6&-S'NL==YCN=[!6YV1@$R):+;,"US(B$!I2#7* MD))9<8HZ:(V'>6YS3C4K3AVWU&Z6S;ZI67'''(@X:G6',A9QE2+#48U3<7+> MRL@0Q#QW`[W6N)_EQDY>S11*_F%K,&A<6F-W* MQDC2-[9BC[PBK]HHS",BTB#/1_M,!V9-K'%Y,R[-E=,P5V)AO,9+BC6"H)FH MZ`&[@*;2?_$OI%$NI;Q1-LX16N+=5J>7NQ+5X46WB)OR\43>E$O;/-%`[&8J MMRRM\V*)7U8-XSH=,=(HWZO\1W>4I1V2-,R+IK_::Z!M+F_*#PW4X2$X#0,F M%K`KM"0.,D1U89TX+L6R#H.4Z,9:.4=HG>>KKU`3&2XDBGU28KM+>5G>7)NP M*YL%'XSXH\II7PLOFC3-,P51=R8=:9H?D/YJK@23(ZF,NE*F4[P:H,CQSCKQ MQ=/=/7]U=Y'.5Z([\X]G:L>O_Y2\>SG6,FY;6F<,+];J?^D!\[:A3$2_>KC] M_>_^=U[]J$Y;E"_CK`B*OFZA9JP`E016$E1L?KR`/\^?145D\:DJ&'=!]3NV M9A0MYT13;LVI11?\KCL!T%JO%5G2]I!ZG2QIVQS6R)*V)US2]A$9;`-T+.7F MC5'"1(9RY=IL5DRE2[5F[JB&D>5PEP2IB]U^LZ@S5RZ9L!,-9:!$\RJW=@>M M3JZ.VZ=:\K8[:?4S52#,0;A:G`K);EVF_DZ9??!`%D>P"TZ&>1A[?*?")),& M6-OC8+O\WKC46AY#-UJU-1Z4>*_40(IT6X-15O&P#;BHJ<[9CNB#((]'`-ZO9;:EU&PS=1[I(/KZ!U< M_)$OECF[,,@+UI5+V7A,"N^AA;=\7]-^SMG:A8!V.ZU.IFJ,-97O0B@Q'M78 M1B\O&C:CW^GDC$-9.>I@I%=;:DLI)HWT@AF@MB:C`Q=U3A/C M]Q_7=LCT/4>0WWJ@8CLX1F60[$D%R6IU#)+]BOYCT3!&*@'"1JR76U-HM MQ28SD[U(3,5A(TT)M1WE3Q=1APUB3=D7MH8,!0+X6@I^6Q*8Q35A"N+8BO7* MWL-TP0!WYI8[F\,H[PK%"\1&1(J!Z`PKFD$`$C8UD#TL`SRCDG_7_W)G\3OP"%*0]J=+;`*!UBWV M0;-626F]D@1QLO"NC=N]G7H=,[;<'/P-LEDO9;@)YT!2_8--E M[&$XA`3H\L<%)2BVEUASR`L;JL6_'[7[8KPA#`RH\J$VP:.GD)MPKOP_]\<.V+&4++7Q\Q?_X!+Z$" MG3F[9B@;ENU2_(3?G$^&I?WQV__]/XKR/^$+AL&>X^GQ-E:(_O%L]:NV.AY, MANU.^#\(@65$>6.S3#^>3:FUN&#X="[8_W74"\>"3^I%9W+1ZVR^#*^[)A'O M?G^\/E-TK#$^&O;'LXO>V6\]M*.:$.UG")!:H(G*ICT+@HE"XI1>:,GT*? MWL-'[M$[?'7YBJA^PW9KY_W6M!WJPI_N,"/TG,ER<0,4#0./)4W-LISWN]W=Q]@!TDL*45I@FV80I>4?(+4QC M50I3@X5)[$SCXG:FV*%2"E-G_U^'D5I/EW"0EYY(W_T9Q[GGW M=,]9IGO"=*&&+"ME^#)7V6_WXW^O<:04'(Z)%9%ET^OVQ^V^.MY;<]HRTF_W M(\F67&Q1"V.+&F7+P59+T?OD/RV##6,P'0=VRJ_HC2S<17EG3^QTAU$?NJ`D M%J(C9D;XE/A:N7(A^#HZ#;X2LU*^BND.LUY5SM=JV2KP/26V'FBY]HZ,KP_$ M_N,SQ?@6JI=@VRG'HHN;Y3"+L\\]+KW.N"0^QF%ZO.RK?!$*]JF]LK;7$MGW MS86+WKLI_]6^=)VY1Q;*@/7!J^!#KS;;*C%$P*6A^;\PA!R+%Z%19\.OM'UL;=(' M'JQ&S-D5(QY%FN,BHP#OXO[S%A].\]O]X-^]K^KXNI3M+BU>Q:Y(=MQ-L6@% MX]^6%K+Z8L8M,V8K7F4K0G'>CD^S&5%2H%D\(]0F<6(U=J`0)JP.6?E"Z!;A M=XU%I8F4KU+RNX68*I63ON0PIUS!3*4LFR2U36V/"]2P#Q.9U#`NEQ<%G<#E MSN!(N'SG.K:#3$BU6[6A"^'GUM$Y\=44EE1T2:I)S%IW-0P+X"842_;AJ$`W MSA&1O6S/_Z!`-:PZLI?NZ$PY5\$;4I(NU6T/AZ6P*J.C\_@86*Q^E<3`+>0JX8]YBW>,P$AYMVO:K?`JX8]\#IM MAA9\=U1(<'JAO,RQ(_P3VS"GJ0>1\19\%8&+_Q9<;CWQ__AE%PK9=/.!4`*' MO5(5UW=73_^^OU'FSL)0[K]_^G)[I9Q=?/CPHW?UX6*XBB(FR/CPX>;;F7(V=YSEKQ\^O+Z^ME][;8O./CP]?'B#L51XV?OSPHF\ MV=8=_4P)RV)$JV)X?WN@/3J(.JMU-%:KV914N&9J&8;U"O5*O(I3[F*!(.C) M5JR07;P:"`X9IEB"T5`DQIHJ0?F0L"A/4$?DG->UL5R;#6&S,33VK,+.1H6? MC0I:\'HDO_RZK8K/P8IN%=EMDY?2VE5W*W7]P%2U`7<53^0O_+@1=:*>+6-K MZ<8'6/3`95^A4+A&86B7R/XW@&73TC6UB=\&\H M@?T#\F*%QMYQN?)=<':N?!LY2%>^_T*F6#GGG5E_J1,5CYY-JUM$G2C34-+' M;$$1O:E.^#>4P(V1[8*[/,>`M7^AV5*'6N=80>(IL:W!4!+;FH'8>&P/4H?= ML_)Z7KWDGSKMT42Y`#]"ECKT%702WH\'NWL*J]T\K3L;TXBY+/(IXW9/=K+. M3C8H6W`*9"M+[KI96N0UEGH%"UW&7?V`S=,S=6/[B>'598=6OSU(W]:TO@W' MU,'@`-#4EQZ3=K_3?(+D[]BEMGNRRWB4('D.T)I0HQ"I*'&[.%17V)_Z[6&' M;>EC9HX<@Z3F.79K(JH%DJ/?SJ6^U80@^=?NH*UFZ<->4SH4*!C#$AM2-DDL MNB7N%PF=D/9MB7+0F)N,(4AVN@((>%N:U1YQGH5.&1<5^&:37TUB?#QSJ(M+ M2U]\6QBF_2N;ZV-,/%&WTU$__.OKET=MCA?H@IC`.HV]]>$4^3/)S)\"$@_K MP9^81/KR.91QTD/E_';;F9)-"L;Z5!E]@+1?QN@LU1'KS>C$K.,2>)Q^OL.M MXVZ1ZS@]PJ?%V8/DZ_>RY!Y7RUDQ*-.%;TT("2(O^-Y`IGUO&41[3^!0XGLR M9#T2LBY;%Q]CZV)2Q];%CPZS72_X6E6BBS4!U#0]C+,*:"'MBDN8]`=6YN@% M*XC-`83B.4L*7BP-ZQUCMD.%%%.6;#?C:1Y;'H:?(".$Z%C1"<6:8]'-$5IP MZ:C-%4CMT+&M4?+,!EE8[./4-8QWZ&_[S7(PP[.M7!I&D$@R@TT^:&SLS+&- M^8"VAX'IIY^PK_E9BO]TH:NMQ1L:+Q#]`SO*"R_=X34YYB,9[Y"]PL!<,`!% MZKIBB4;+.I2H9L_RF=M`*^PU:(5?L>WPMKVZ,D6$AB-SV@106R\"6.4%GF6LNG.ILO2.(!NP8@2V9B;Y*X2*]Q.& M8]%6;/?Y/XP!\-P,VOKJP?RNS5-YYK#_4@0GY85!3.CQZS!6N)Q/"^S,+;W% MY1"`XJ)"L>YJ7@?A".ZASMQ6(@HTYR_%+XP=>DLA4\7$&K9M1-];P&$&G\WX MPXZ%@"#L&1&H'QV3"=)TRB@(QR,D"=DAW6TABTPD=>C=#4<,4"8@BPYMBYTY M_(>MC?6VQ,>XDET;%O(S,:T%0?["N8#%`"Q?6#HV>#H6DR3!81!"D%NQ.H&Q M?`%X"UN($G1W_M,E5,@."-0"_<%V!DP=WCX\K$BNH&>V_$6+X%UWJD04> MKOKH4G^,;"DKFT94NH.]9G61P4\P[3OD] MTIRD)B?5?:T&`"]] MOM=1)VJ[/QYES;J/>S%M*;'U!D8'(H&4ACAIZ.XK#>LOIC54UVMI2&FHD33T M]I6&]1=320/<&-96&C:.FCTA^6*]8BK^(@N2U'.BF`D\Y\:NG3Z=@V3O;1\" M\G>=W<7@>YRL2]J6T[-NSSVZTY6LVY]U27MH>M;MM:%"^%GC6>?WHMG2XWEXS!-2=\F M,C(2HE8Z(S?GJGYG5;OC\CFYB>@I<;*BK54=#"0GR^5D19OK2*T)(XOR.&Q. MEN1Q^(1GQ(3R2I^0`1&-)7B!<@)T,(]Q3&OTFI!$2L\^TE.YAWD]AK$F))'2 MLX_T5.V1WNC.5A.2'%)Z]BE)7#DL9?N]H6AQ[VMWN+,*=>682]%(+QJE^-5_ MNY_\N_^UVY>BT631*,5O_]M]_]_=K]U1(T2C*/OK^W)9[N7+V@3UN/*,B70I M"=_C9-T!KSRA!(]DW?ZL.^"5Y[B\0(/=K(OVG@CI'?W6:QS5F_0F[?YD,`JQ M2\BNW=I]*F:8#2];^7@P`1$[?1Z:7!8%ZN8]Y)QZ$_404]=][,4PPHU-1KKXI09C>&D/QCV MU@_MHB0J+1KK$I49C=&P-QYM>+T2T"`SDTR)ADSG4M.@&PA[A$=,$VRO]:5) M]:A,QHOK'Q,M<`(9%63ZGCT3+\A4"!.Q;(=:Y@P^=MO*X_>O[,%_*W>?E4>51]^.ZV5(KRH5Y+Y]@*DLQJ M/,:L1I0CJS%6-DM+=62*H*F1I8%Y8/X`\,(_&M'VGBOIWG/3YC;"K88`J_ M"8!NS7,[.`_E]GB,V^-S8[;'!_R"31L846VNV)B^0*JUYOEJ84M\L8P7L27JC.*& MM>29N6S8R``B_=3;TN:0L&U!=C!8*.S!YY6Y;482.-,@R7/)#(4%TK`K?A); M)/%2@6?8Q!3!)LN&>X$L=)X0S;;N-]C`L9="B@!N/J8_+=LU%5\Z5C.(@UQS M!=)#87^&=&4VS`*\$)$L6A08&P%.%!O\Y!"I\`Q6V_&SHH/Q7^=L\_:(*'[T MA@>0>,8W>]@@YBZJAZC#H45L3N_HN[;CZ@1D`Z"C.W!E9%E:5-@7._'EI".V M"``SX=TI<<(D;9[[S8ZQEH?ZU."E!R'%'BF:NW`9D0@<8XB!K1"1>"]2PN&3 M2""V7?8?&DSSS(!>8.4/DQVF;2Z];#JV1(D]]V7-)XTH!>`)FN5PF?%^$0SQ MY-6.I)6_8I'BC$0N,SOD,?>Z^2>[/P*?>B4AG='$T!5MSOLAZB[U,^W9<;Y8 M?ULH!DQ^-<<3%\$4^%J`1C%P0:1).VGTD2@K'"L"%U<40ADQ+4>H#?`K96/` MBUMD"]8-%Q/,N,2$9`F,TX`B7"(0K^(PQ91R"7*(P188-2'GGR-B(+:JIP1$ MG3ASAHC&]GG&/+8N]1<8@0']W7PFAH$#N>28@[`S5@9?B5$](8UN-_Y`8N,P MF,#/[*-/]K^GENYJ`7E$>00;>:H_Y.N+71$)2^)X8W%),IG'F/:GV(MBA M)%T/V0NY<"4.#CJV2RES,INS#=4@C*:@"T`A'^%^X-L08ML:)3,"NAH[SUU? MB7?F%$/9%=.9V[#'L]W1%MO:TF4'/:^SPK;T9S8;<`R''*NO"Z',#14.-$8F M7J?&.R="'0M.#.*XGMO%,G1?L_.\/!SB_^Y-_F8+:H8^&U#I$=.E-;)$CCB$ M^8N?KV^O(F\]A7X=Y?]O[VN;&\>1-+]?Q/X'7EUW1$^$K!+UKM[ICO!K3\U5 MM2ML]]3>?=F@1$A&%T5J2,JV^MUNFJT30,U(O=JW^+.EMPK(#M#5)778U'ME,U?HZ#:.I M0_:"QT8\\B2-C^\,I#%+G4O:?1966\+]%4VAZ2+][JO(TT4)+)5-O0+6/;P& M>G!&KW4ST[S[S?R(X+X14[<$S<"A!%;@-%:PWP2:L'06IBNS%"IY;:/@T7H' M!R:H-$9G8#%8-/7`M@R94E8_U%NU2JTFP,.&0Z)KLOXY%4_5Y817K?,XA_FI MDO'(ND*-@F$L:>-F;='OQ@254G@M.M(2;+U)NV>0$GBA13:\+L]'E]'C6 M'^H&FB<`S$LX_,)WR'0)_)"I^@N3J5R#E/);\D.R#K"IM(7((CX_R:=)%D-D M27=/UJ'PU8EBRYUF?T[N)7"?AT M]8(H`D@DON/$^37@X6`ZIE@VZ925LV4Q,;9@#`\GLRF$(Y$!LUG17PU.4?8< MY4T?.>V1&S,B\2=#3.5(+I5L?\AS]^B$(W0G#:VI#XB!_1::U><'SQ-@1CFQ MV'(G,?H=Y<.TOPX=[JE;R81*%#S;KPD<.1KMNB)IK'7!8EM!ZKB:P_$=*YAS M*YJ.QTXX([^]D`^<$#FA=0W8.W#U`H]%/Q][*.L90A>W=U?7=U`:[_/YU_OK MGTG?32)6I$]RS^X(Z^954\CQ^,C_Y0/P>;)P'6.("OFM6Z1O-U71TQU>&0RV M;'^SLKQ2RJHQW!.@20OO*'([H,-$"FN^!#PLZ5,:97G%6*2TV6Y&6:2(Y1ZQ MO_'OYH5XR'>?;I^/4)IT14GLCBP#?CMAZ/+I4[9Q`:R7KIRX,'UVV+=W4H/= M;F]3K?<$*[`OJ3]YB68ZGJ4D3_K>=<[^RY-VWT#5VET6JF_LKS,GH=T_9'Q) M<'__)$[N[EN8NCW6#"^A.'YJ;UUP]V_'4\`Y)O&23EH)F)]#'L<,(D^&!4:^ MS/C>RPDC?P1[?U6*"NNG0@J_P#0L@,7(/)%YD8KHVXC\*#O,?(?KU9;^L;SV MP&LB:N^:TB.+'R=RW[1CX&";Z)SSV#*Y%S&?"[Y$0XU=+V*++)F%'8+_G4F_ MT$EP1](OQ:V=N0A_BQ?AK#07X9_\)^;#M1\S\8Y%>Z+)#N][,9_!5=D7'I1Q MH(P.N,H-52''M(SAD(=1?,9%!^A?$,GTT\VGF]N_T6_RDU:@F"-=KS.,J50] MP+R4D(VFGA/*I)0XL+@+06_#6?+H#!Y\I%0?T=.Q,X-(RJ`OC"X6,XJ&PB"B M"*_NU3TK_(!JXT'\WI^4"B-'Y#(A11>+*&JO<1D;)Y&:JOT*Y*BH)"<'$X/" M)R8#]#"-1OZ\FDAW1AVE')O\CJ4]@D*"&$E/%1_[,RRSF%P5BLXX8N]X8AXU MZDS$3U]DKHE>&A/>((?6$(_X$01@Z!;RJ%ZUG0R;B7BW#'E&,8>J41$ ML9U0&F'%:C3AJ6:-"JK^IQCGX%%T(9P39L5JP7.V?([BF(+A$/('A]/0QQ*^ MM.?Q%RSG6TD>AIT)(U"NIS!1D,4@Y$S!;KB])>)C)!F(NI_KYFI)54A4'=4Y M@0J($`KHI"_+0F/PF)*9[('X%M^8!+PG790S+;;5*VURDPJU&+)4K]3M#FRR M0QY!$%@2I"2^J75;V6_LJG4-/W9EM>,A&C@`2)_2*S%E;N((PP9M(_DF%X)R M."7$G?">>O">?,U=\Q7+9^+_.3C/J\H"R]QIYB8)(!CW)`"Q5N03Q6)L3SYT M\""G;EF#G([FL]U-]-).NW^"LBARV5.\^R4/-UI+B)MX1=_+0$[BZGHA,.DS M4:5D394"LBQ=I$W/WB9:XYV&)[7JG<,([U#ETY62]^NGK MU/8X=R641Z]9)/BG#"JZ0(#2I>[#)<*ZD8!Y$1O]G86*-8H$L1:8B7*Y.8XC M^V9OFX"KC81_J,WH[>G59KW2K)O3GM*,0;$+LIG"9 MJ-T6O8%)_:G>J'2V/R*L'YU]RJ)HB:/!UFO^A+(:5H:)_L[B)1?K6^Q2;SQH MMUMIUX\0MVLF0+ZE7JLT>MMD.QPH?D47\ M'(.3M)BHWX+`!1K(%6,Q\6YY/4&A>BA4%?&%9/E.M&2?IB"ME`*6^['CCSBR M.473/@0`8WRO%J2FJ/N!:0H8$2$^>0PQ21A0!Q10#`*M@)([1JI9(L#'2.,L ML13W@<,*8M`>97CWP`G#F8R*FZHR$304#*KVD:I>Y003*]F=^@-CL?`GA"<* MDGYD'MW`3G%\D35F#C$W0APSU8P(>:3Q^:_H@T:CC^3S/,(0L7W@ASJ4\%<7;-<:"K>$!Z MB^@*100NZ4+2SZ0/&`W"BE2E,[(1CY2HH$)#Q63E!X=2J:G% MKC@#)`:4R0SPMJ`?.\ATIQAT=<8]9),>0442Z$$%_G80F!,T,:`0`P-814RL M--$);P9>+K="_+U4+*(B>C3`6$8@;H,5A>T(U*'R<"OSI5*<*%T?#E`J$_F_ MDG0U(,1P0,Y_U%D_5MT@\=4 M.68H4!F$N-LHAD99P0$67BI/CMDOV$N/?P=0BI?[")6D%UE%Y\@2+-`<5#2% MWR.-.OX0E/.=1D-QZ@- MN57`"!H$WU-AXD_TD/ETD:!P0!C*'8K\*9CBK!/46#_F.SH6NOZYCD_+#^`FU;< M%)Z#\#MMUU+_PDH1WVM[.G"(9G?T10MB\9UI5XCZ.MF5Y+`7<3T)8DAQ(Z9K MN?BP.P(2SUC6*`:N3UE,A2%>K#K22(;(21\H.XM*K&1'@&"CGU34]QY4!=)D MQB.%/5&J%BE`THVR+>PYJ;H)R=#0,NE..V_(5YI9F$EJ1W= M!Z)R,I$AK?&G=#%-?6U77;`%_B9KO)[]0;6,IJ$!T;/X-]ZJ%]`TZ_S7,:@C*4R_%@,7UJ*+%D]ANT().AI`< MNC.$T[@-RFF%$VVRMV(B+NS2D.-+,[:N@L'!,:F],_!31?N$7(1R!`,-=@:Y M0U)6]C!)8H,?D!),>S4.7.8E2!*;!5EMNFX4X(."YD\L5:EZ#Q8@G\%WM"(' M:E_.U'V6>[A*3;Z!V&RF:4&:+X,OW/>?@#Z]8MV&;`3UV;C,!YK)NB]9RT8.,5G<"=D]VI2JUIM,YTP7$9B*IU%]8Y\O!6)]+PK2:EGSU6;7^P-EUYM:-BT4#XQP"]=.+)%54>LM5C`UGSTIM"/5=@)'%"2A_WY]1[:AV!V:(= MXTCU8HE4J*9UA@)?.%K"MXJ2!!/=93V,UV=$%.H-+J- M2E+BVF>QHLS#"5KFZ8:?UB@)OM6<*]1!QJ(X^`<^W1\--F:>_R9E@L^N?0F?SR@?Z[>>@)?O!ZX8)]ON^5Y->W--2]OF_7 MA3#:N5U;5'_'%LF.T]C-,MT#EO*7\3?I#('.]$/K(_9,.48\/F29+WY"&IHB MC,1FQ>]BEGY#W^FE//UEIN0<;Q5.6$)OE(++MC"RE?*^\BSGK3 M@,!6]\=M@A2/P9FP6<=>9T_8OMU244\8,1HQ'CWG:9N-]!E/W8NJ;K<`\5=HWK\*UAR;@.RSM+QG5X:C-B7(?&=5@N M9XT1HQ'CZ8C1N`Z-Z]"X#HWSRDA_"5=0\T0KK)8QCT4WRI,:29B>LA#?"9_* MG!,\ZT)&"G/38-6T_XM5>S"ZM-6D\%+X.AM>>KZD[$\%4R86NY)&)@^G$$6= MT`B<1,BP(7%ZBR1.CUN0..V-K^D(=94ZO8SNNF;S*T"AB@0%&6U,7$*#F:,$FV4Q*R)Y_@RP3/W M8*;Z[J>CQ;4#6;+(^R27J=U%]]DNEOE#67)*=BVU$5)SJ'=0H/(SA50'

?9"=U,!I1X`^P0ZOW+JJ`Z<2RF8HKS)"NB(@X5TU52 MWAO>HHT]"(>,RI%B+7+U1T("B)1=?)BFAU:0C63:CXCZ*1$(AXKK2!BFM2G) M4HB\2W0JDS=)U"-B4X4D.)6&JG.`*:HFL39.8M_;\TJ&.NR.U>>0*NJHA7,& MBP&FG'@5H*RI0%):Y3[-HX>)Q04@%S9!J2+IA@@[2-SC?&=)FJ:>^.GTQ?*G M+&S,$-67NK;`TU6O+_5[3:5DE(:.[D379!=908N(;*JN-*GL5L.82,9$.HB) M]&=IZ'<_^6(1,NO!>9$UG8RM)$42@T@HE7B0L+L*!938)8IU4B.VFDF%"Y7` MB=`2FEE&@35'9:FTFTR[AQ]"Z6G^%D*BSK'J5S\U#3FM@K4-Z21B$MC0XQ$?@+Z+88.) M%BP+(9-)$`*#A2Y"54A=X^J5_,+`_R"T(HMCCTD>!(9,!F!`NFN,"DDC)8,# M="P92=:.X?Y<[\EDDNQJ1"H5268>(1.<6!>9E;XQF9JOT^5`\COQ:B8<%DY" M%D?/2.,T&7;('$^Y9N&[9$AOBDGI&T,2Z=2P1D()`#;SV9!+"EEA<4Y]9?[` MMY,@XB09GWA,5U&'(GXBH;Z)`&DZ00O'222?H16)V>"1B&_&8BAQRK\FWRBY M-[)TS(-!*(UH97ZA#47,4+BVHPS-M4/0\8`,.HJUUM2H-1Y!A(J,J9'DH'VE MX8A4F`@V6,*WN5H0A"LE!UI).@]5,M`W!C.Y*#E$,3')VBRL7,3G2B1$'H2G909@X@QDL>D$2U.U/Y,)US'F4\V*=K&\K`=2=(4 M1>4CCA"DZI3N#Y6^D7RKI#H(Q0&PZ*2XRC!*:LL+#Q<:N8LWTW4C\H>\B!:? MF?<$YPD_?CR\^C%F^5LTR[^7QBP'-)V3V0DVT-NS$?>1.PH,I]!RAD"_=\4&X.ZIFBY'3>8H)6> MX427NT<$)&H+7)7(&.L'*1>NVN%\;>:0)):OE6]/XHB<5:^^?4 M9_.+S1F39X[<\;Z/Y%^:C0J<\PD1?*29#L#%)V8X9(_`^_JDSG+4=)8+S$?: M/31[%.M8]@$B':+C'@A'*R,EWPL+&@\%LBS'3D[P492],N%1@\Y*;E2"O.%#]+'D'T.+%!I.TH*T2A_*V\!ZD-I( M%_A0J6L"A.99DITJ[B=5+!31*4YE$UDR0_4]\`?*DSQ-Z_[WVIT+E M).8HX@O,!P>2X.0*\MB:+OUXP:"I6.)5WBS5=%!L@Y"D?(Q**1VP8(QT4"AR M:2=;(@:9G".>.!2(%!Q^,@R@=,FHF/! M.\60J!O0Q?_"TV?:.:LT'H,]O/0!;<3@B4=ZE9-43M87[32,BNTJ.95;#\&$ M#Z@RG^B,7DI)Z%,A-QX],G+-"DLQ`KYM:QB*O0>K.<$>0T=MT+G:+DE%1427 MU-5.Z@=0;@+9&PRZ6'%R%\J4NH@5`K)]>N3"[`P'C[)$FS^9QBE_=VZ_9/VL M%W$T^4OV#,).P(3M`SN_O&O#AI#C71@Q"X]._<6'^S,MT"2Q&\;(Q;[X,*-> M8N&8A'>]:MTN]B%,_JF7_H*C$!_P"01?2=Y4+\P<9&[X"H1 MUKJ;WM3()H7MZ*2%$/&J*!+;GZQ?QR9P^$UO-N0F7K7^R)'%?*=E217]A[A. M_D^C]Y]12L*?QM_H43G;CGB1Z#Z_"HW<_!<+S6DH$UCLA\%W,6EN\`SW&+B9 MATQ8CB#7*/LR)8T],G8?BRH']]K7-F9M+S[4QM;:*O4[QU)83'O:23_KJ_O9 MGWK>2?33/G5YYG=..8?/5#+Q"@$HQ",0EBB$.IK*03N9U)PC\:J^LLH"*,@C((X"0716*(@ M],,,K.W,`1#+-6HZ0#KX(,(2U$/^T?:D%OW!W8@J;>O2`[?O.8KPPOKFA)A- MI+)E6!+R($Z=0Y:>K#/1M$[&>R`OXL"/"H_+2_8D9(VN;S$M5;X+P\[T\W%Z M`VYNH(-5ZS[-"))^8B@)E@[FR?Q*?7DYCJ5*B2LJ/PKT86_6!@LJ;LFOI4%UI?4 M<4TG;F5U+^N9O:-B6=T#,]?NDEMOEVV]1LNW`0=?D1)*;U(LV]/#[HMD<`V\ MEEWX2_A420=:Y^\,BD8:ZTOCXA37XVMR65=NK\AEV]>8;AR60W$IQ6.S33?Z M=SSZ?C:$>Y8DY03"$Y>+)$L1652(>3231=N8H\!L42NU:G/%1OE:'WXLXX"[ M[7\+VQVGU/M:;W>R/]GX]T/=,=$)X^,"1H>;TI>\@=1;EV"<)5^Z4[FWI*G7QJC1D3X'WA,E0 M1%REBH+0Z"5-BA?XHS.X]+9I$&7OM)2K)R?D.$39P:3#&3== M5+6`_3-]T9"_`"D3#![?^8PLTCSFCLR8NF%](:=07O[3L'WV3,$8OP=/=/-$ M=^]U:CWS1BMZ=B;)W30QFR%!BW@[!GC)C"Z\NE\&5,/!8E*EUD^5&I>&@^4/ MTBS7BH=V1;_7V42.GGIXE)T%]X$P893+8]0`/3,(,-<$8V`@-&8@[70&8J*(NZ^.*%4BU*V`)7<\AH+"+4\ M&)"?#/KD!ZC`[[4`-ZT?65(&2%W'K%SZ.UKGA9+_#YDF5*0M$$?$:;32`K>? MME=64CY`W-RAXDT\G'K)+ISNWS,(R84HJP$0(U:R#(=)%FX$7XC9%?V$/RMZ MZBY%49&0B,%79_JE?4AR0%/^+_@7(5-I!0NT2>DU^]0A]RF_-/O4G5`@D'9' M":N4MXAT!V:_*LPVDMJ[>F&59[&\)Z#8?F@UZ?,?6HUFEDV\`B9WJ$^%FTY% M%4(PB2D(=1OP*@+E4`@45,F/(%(:,ROZ$/;*H@C?/':@&A5D5DTFGMA8:"=; M]B;8"YC_2+L+E!((`WO20>C0HC1Z]S`1T2Q;PGSY#0+=1I9MP MWX)-O2I,'JETA(ZZU(W?^PQ?UFT2`P\EX51 MB5CEFL0S!/F;"C)M,J)$:5&E5Z4%4Z*8TJO9$K MZ%*NH-/6G_435*!"@J@;H8`2=SGX>%7-+>E$^,/GB;Z4G@W*4))Y^)87@"F; M*#'F/_$P\"D=2N/.5'5W1&MCRLA5ZHX\"]GWN)!\$T96PMOBQX_@I8$DOA&3 M90VPN(3D901.1H=[X")QIZ'*YH)0B\JJ(A!:'\2KX/$SAIV5S8:)?T_D).R?6;8UU=N+WG^I+[CH7D>/3(U M>B*"00=/XH-:\.:LVOGRWI-EGES532D'2-P6KQJ)PX:[S1&UK7[ M5""C;FX]_N^SLVO?O1&8@\;.SA+-XO*G5)W(/_[^<1J=C1QG\K/FG4O9M;]" MM36!NP?V$E^(1?/]U__X7Y;U]^0WX,"2@KN6L^K^\F'QXZK=;74[U5KZOP]X MR!/-WK'A+Q^VLUCMKU!:?AU_`[38^_L?]U0S MQH=?[5J[W:G5:MJ`%GJQ1>=[]AJ=M]/.9Y]_M?/-1JVVQ\XWU^A\7>M\LTCG MNXW.'@4O4-#H-7K59J_52?OS$O&??>[]\B$.IVQ-*.4TDQW6R]CSHY]%T[]\ M>(SCR<\?/SX_/U>?&]4@''VLUVKVQ__Z\OE^\,C&SIE0`TCO],'ZN!VJ'4UVDNIVH[57@*T[CGF8%1R'W=CG.`1.[%JCL]V]XFK=<>\_*JMEL=3="U>+O5@WDK-'K[E=;K3N0!5P5 M'$C7[K3W"ZPU![*`K((#L9O-7F//V&IN!JWYGZVVVO=I]MKK#F(15D4&T=KG MVFBN.X9%1!490[VWWWEH-='*LXM.Q.+O5L*IU>KN>7VO.9"%V2@VD%ZKM^>% MT6K5-IN0A=^MUE/UO4_(>@-9G)"B`[&WU;=0YSLES4Y<*DO&M^1I'$!/=7IQ MP'"'3A,'JMD^BX/YT6=^+'[^JW0:7=U>/OR_K]?68SSVK*]_7'S^=&E]./OX M\5OC\N/'JX4OP]\"]-@*6>(BK MFTS['A^DW&W!T&I56K4V+E9TM3O$N0G?_&!7Q!)-$F&JUK4S>*3J*HIY'B\Q M`Y]9[1]Q7`RHX\273RR,.5P,3D(5TH=>X0R/6O(0DG8+TSY)_85'HPHVK/CH M%(D*%*N:AH-')V)6O37W$YP5D`8*#D8#A6I9..`1T\95K\IAX:]>E6"%T@62 MSEP97@HYN]08DA:$V M*Z^\`ND7';JW@/A4R?L0RM;%"@.4.+X_'5>21):4V!!"FR%[)@@K<)7W)P8> M!TE."=0,XS*:%O_4D(I5AN"COGX'E.3D9!>E(VOU0OD`'.DYUB]SD_U@<(33][!OK* M#]`GQ2KY@]TE32,5NUZWS\WF*2T(`VMIS<\1U\1"`XX0$7,Z6Q6\1]5'A1W& M8^9":I$W4Q?#'&_^%&-E>SU>2TJS@OM`L98'C+D:46GD>,EP<'>KR$I:+K!> MQ@F;*%.7NRI]3(E`J%Q9HW6D*K62!DF>1$++'YK5MC46B,:A?Y-E1*"%5W5Y MVFF0(;Q3;2:B#Y[3#\3:AR!YN#J=).5BD>HZ"+]C%IDSX5@*6WPN$QG$3(23 M`+6&:&X21"S*V3-.<@,Y9+:(/!PL!;Q*?,`J=1[%)SP%D!L8C+!Z'F6/Z(M/ M-3GU<;6DNH,85--%2K!=O=EH/+-4V!ZL!W73#U75*-CW0>=?Q1VD#Z5X98@" M([3,$>H"6'"UNTM);U4!%R2_I;=0X=3%E,;%Q1ZG62>01OB#7>UU&FJ))%2T MJ]N[6-E>K5-/VL,!RM;2,8*Z:U1KS5:Z-+E>8S1O(??/Y6H-/_>,FLY%M=8Z44L6JV]5N9X?]7,'+^:;$!D[W?8IM;RQQKW9M+;K/O2JD M0D1/KT_>&G25ZW5G?6R_,SFU>$D=6 MQ9LQ>)9N\EK5K?72T2SHO8!YG_(X@L)^>S-TU$X=OP?'%,NA5#(^LA89YV&F M:05SY-IJI=E806%=%KQN+XA:M=/I'0:A)T6RN:=[K!6W['`QL7#/D[U8=B!A M-KUI3R]QP=Z!4ID+K8K/ZY5.JX$WR.HN!Z+J\+H(B_2FP2V85HRL7'/%&>DZ MNMIM5ZUSO"-0(15TCS,)H@@C@Y(HB.2&-*<_=O='+.TI'@!G$EIF>,W^0Z]G M5VK=6D5K6JO,N'C9LRA#N&]J5VT[N6_"*U[QK(\L9P-*718_'86BS^DUM#(7 MM4"K'UI5B+12]U8R4&#Q\B_ODGKYM93+HD'(^Y!^W!="V#UUYHEA7M4IQ8`+ MJ"`Z\OE?6(RSSWPVY$AFI^%XR(@'-61)FOG*X)2*>H*]Q$ARI*K*+[992:O1 MTDS*N=>`\>K+B&?U3#QU)I8EFV6N&<4_9K2,X;:1N5#2=/#XRD"):)!>KG': M>C,(-6NV[13(%Y+3=G6PCAO@/7@V.DE\S^@>U8)L:U0$8[&^^WK(3'^&32@0KQ;EZ_(].1'?@>I!)4FSU,0RFH\=, MPKV+C<5T2^XR-M:CK^0KYZ(%EDM+JC&:A,55#[?07`9`]4GR@>_-TM=&L5C, M4QQY4AY7Z;Y5;]53YGF4Z)VJ=3,-(5JADC`89Y5.&LXC7I+&#:FP(8I%2%F3 M:?ZDCM(U_[Q^ES`.)FH24REBT)0VYZC@ID(@J.`JFM:>BUO01YG+Z*QF69_Y M%3..(0$0DRIGPP]D@$\JE)W,P5M7R>>X+A:KLE:L9L7NV$LB'7&-ILH"8X#K ME6:W7;'KG7DS14RNW6A5.KW&W#=I4Z0B<:+2H,@\H,,3(0.N.P3N-(;4<[!! M*N*(H0?\97M=M7X/\D)M5$@OT+_FRT'8.'F%D2N676DT6CD6`(RVTNBT*Q`3 MG;R2^@S[3=IET33L@[F%E\5*JM<[E5ZGH]:?6ED`T3S)T!LBXD1?LLY`>L,I M:MJ<)G9%GK%N^D9.CL@GQ(&=IH'(#S!9H_UZIDXM/-2 MAV5?BG9[IPDJKR3FU'(2C%[K]A72[7P5>B-P[Q'$E\G&?#N\3$/][Z$,/%'O MS`UT@R;DI+Q"E;#>O*[B3:!EJ4NJ!DF\C8Z=*Z8-1G**@NVM*]C5R"LNV.X2 M^+T1N;9?XV!8#["K"!ERY6JWNZW6VQ9M;UW1KH9L8=$V\]*N#R%98;OA5VM( M,'GTJ%I3(+"]IIR2#A]"'IUJO==I]:J]]JO(J;4R\FB=V;9LHI;7R%'E@5_> MTI7E=6*GOBJ;W)_EV4\K>*.V,:>4J';'('4P`?4*"V@3P^T0`OH7G,:W4MWK MM7`H?91+Q-+(HRG:="2G)]8#V'"YM##K[8=EE>H!++@[?=UB7, M>3M";;_"S+4>4(O1=-5[K3G187@(0_,P M,EOKV)9]\HA6(YS9UEZ-Q4YM6TKC\,K^K%=`,QU4%AD\[]'/WVSO%PWX79(5 M\IH4,D\O7R-;:]@#DC_O22ZY1Z.MM6CYY7*J]TZ73XD7HYQ/FGFL$&? MEER.L>NT"GAMC@:7PY\2[.4WSJ[U:_7JK$'-;D%`7+#U=[RS(#7M&SG0^Q M5>OT-AIBS@]?J7FPV1C_\)UQ(`Z5?XG99_WXDV2RN5;5F<0P5S^R_PHNG2Q> M5W=G'Z/;:XD7N[O%Z$+F>/#H;P[WH6+DK7\E%N^3`[5A(SF\E<\<6!$W[+G! MKNSW(B5\!78'N6H"S6D3A"]9K=: M;]5;6QTA%AM972-L'=D5&LWI"_I0.O\="O>-;#'Y`[]G<>Q1,<5O/'X4SXLO MSJ?Q8Z#=:>RTQ5+>"Y5!IF\$IY_\/`E0$>"XV%HOV-1;0N:1I?BFL;C!KE.H MH;>/PX-(L'08C-CM\#J*,:E7RB+SD:EHHU6TR7`>4T*C5JP^+D[`K`K8QZ\S M'C]S-W[\Y8-=4]2%JTE3XF"21XPR3_Z*F9CJ0]D9[9//USB?>S,?SSIS'Q;M%?!?N82\.]<<=?Z^H?Q.6? M+,X5_5Z'N.3H'.)'H>J?A&SBA`D=P)#[0C-"]K]6XITJ:`R#<`R9XDC-+^LA M0(F)P0"R8UV5S0IYOY.0BT8F0'8?`J\^)-Y.D6(`LN`MEFA8R,;5:>.1$,(9 M#K%^1Y+J#ZU,`IG)O%B,/K?/V/)@0#R)T"<_`/UM::7C]7Y$6#)%Y?(F_//T M=[3."V6*NM6?QDE]`X\+B:54%2Z#^CA:F9&4>@0*:`#%/;X5TH#=8-J/AU,O M21*&RB5/XDU0LR+H1U!)8`#E=RJ0<4^9PK'S@JTYLM2)R\3LBGY2Y1XN1,%# MK'1!N?PD)**0`4$Q/Y+U=6ZGH7AO/!4C#'&O!W[)J0>YR)!WK^J`!)$VESO* M3L[NM]GM654M./?=.RQ#=)LF:^-FO>H!W'TIBZBS/!5)=X`FV4?P7,[O5L<^ M=[*79*NZMI]1=C<<97?]439JS=:FHV3P/7//GX0>&;'?IY!>?SN\XMY4?$J9 M0`L#+_:;??KE%A/.,':BWC!?L\7%$M*>K\GP1=>Q6=^\B6OC5A1/QP2H! MY?_B=!&4W]_#"^WW>C?PWA%N_#U1NV"$LYOED=!LVYW?A9/;-3R9+I4$O07 M/+"9+&@R5[5-CVPJD?^>L/"_L8FYEQ!UBOPL\U,!%88%P)(OBPH4?_%Q58O: MZZZ8'Z#AM^J%KXEB_HV+C:IOM7&O+3]%A5-J$4*9PI_52/8N0ZGM4(Q*VPG] MULS3=NU:;4[;9>6,I=!F\P.'.#&H@@D53,%WQ3+>K8@-JJ/@Z>/EI__[X5<( M(!`VI]UJJNZF/YX;6N9=\DT3].#-OS\"U\^5L,1_38>F6DF_F_L1\UWM)S#^ M],6N]@/UJ?9J]9&4[&O"7KVU0+AXW4[#%XX@\520#(]!\\AU13=>)AX0IGTA M@BE7'.5]R$_ZY8/:Y6ZXP!W[S)^8^\D7.]H(,I;.HXC%T<7LB_-G$&)9M_,7 MGF:M8]M)U^%/Y0AM?Z0O/_RJVD\KK8K7?G'"[Q'UY>\?<[NXL(ZR8]L29')* M2P.R3JU=;=IVI^P@^QH&0D3Q[*LG5*;";`PDZ6DV M0%H;2,U>IUYM-)MOPZPXAP2N7R`/E"# MJ[5QU;5KYG2R""T&E4S.OZHB#MB:@=7ZL.ITN@"KTM_=)+#ZC06CT)D\[G_Q+9\)CQS/86A];K1:88ZVWH\GN!\QW MA+`VUV*J`1=2*:!)@Z<">&KV#)YR\21L^R<>3"-O=B>34PRNUL=5L]4UFV`N MONY8C)4(KYT0:B@:)U<15#4-J/(MJ[1`ZRU4884F0_8(+WYBY%(S.%L;9XM$ MQ`9H29B+\7AMAJFV+917L]XK.Z;N6!2'TT&,U*>7003!3N(S%CYM?NF#.BO3 ML$'6^LAJ-1L"6K5VZ=75US!P!0!NPWN!)CXHCB=,#Y$_CAX>0V9VO6(X:A@< M+>+(^-H+HJAN4+2`(N-#+X:B>MU82\NL)9\!(*/A'@$FPQIHH@B@;2G;:W=)'<1,;RC2*@S$+B]]B(:(R;1CG M7E$@=0V0\H!D_'M%@=0Q(=GSKN+7X['QIA0_-6@KA+:V05MQM%&NB;E'+8RV M1K79[1R3"G`W:`.JR@LG`O]=2A].[*LR/?,OYO[ANRS4TG;AF!M=S*Y?6#C@ M$?L:\@';[`R).,6?&@P6QV#=8'"W'A8((M`T"=XI`<\8HB,!FU:[7>F_C M#H7*D]\X`^YM0XKPF?M,6'C8V,GYBLU-R<88+[F2/1JZ#8P01A"O9W!$>^VY M:-5E[AU["KPG[H\,J#8%5:MA[K&4LS@(XQ'4,($R9?)"2]ASY[YKSA4%405_ M&531L8!-/&>`'D'MHM3`J0B.@=-R.!D71A$X0;G& M7J9<8TG1)$GW)*GW;8C%(S<#U1^^L<(+0JAK()2!$#9U81CF-\$2UPZ MW>TC]1+.3)CE)LO#J-HM%H;!$F*IU;5-7ED>I-)4A^!)-@GUR+^P^#%P'P3. MHB$+C=XJA#5D8VZURXZU)#SN8AIQGT61#'+;,,!7,@"H5@RD"D&J8R"UG`[" M0*HXI%2]P)(C:E_I@)AO_1AX;O'Z@`9@`+!&PS"T+0/7;P[WH\]!%`&3S;WC MB?\,J42U0=CZ"*MWC`I;A;*;:>AS@5NX%K_A+_`O@Z\B^!+0,D6@LI`*0L9' M/J6TS`R8U@:3W6D99;4*604I%PRH$%3UFK&QE@%J//&"&0/.I&#@F$)UQ9#5 MKM?-WC=WR2,:BF(^,)M?8339QB.Z!%2703@)0M&J@=/Z<*H!L[(I*)`+I_$X M\$TU@6*`TOYW!"B]?6$WSAHV"KO[/H4-X]^?L&NM5-CXETW"!O5H"@Z7I.`P M3F(16,F9/@ZL3"3M"4;2GAJ$:IEMP-;V7#@'0%&H.I`:E!Q!-US,._O,GYC[ MR8\=?\3['J.[G(L9<9IM%5IXR4+HM/1@..'W8[KP:\6W/WN_ML9JD'5J;>-T M70&NBRGWW./6ARH;I%J-9MU85`M(.GY,:MF`U.QUZM5&LUEV')T_.Z&[E1;2 M>'[,YE8$0,VN\='/0TG(7VR0GX.!X_US&O+(Y8,CW_V4#E?&9U`>'I8-7! M2R##&CL/JW6)8X]*'5`^M+5L@[;-T79<9H'2H:UMFPO)7,"=NRX'^\OQOCK< M_>1?.A,>.Y[!UOK8:K7`'&N]'4UV/V"^(X2UN193#;A_3J/XR$&#Y<-3LV?P ME(LG8=L_\6`:>;,[-@G"F+D&5^OCJMGJFDTP%U]W+':XS]QK)_2/7&RK?*AJ M&E#E6U:#P70\Q7JP6,8&F@S9([SXB9%+S>!L;9PUX#[:`"T/:,;CM2FF3*%` M+3[FA`H%EA%(IE#@"18*+".03*'`LA8*+"/:3*'`LA8*+!O:4FI60Z>9A=P& M!*U%>OH^Z33+N#P,VZQAFS7+8\GR,*R-)\[:6$9(&=;&DV9M+!VD#"75PFYX M,I1490.3H:1Z!5FG0$E5.E`9JI=3IGHI'9P,U/RFQV**H5BTS`@E(8!(0.1S&K:.T1, MBN?)IG@>$Q4F0?-$$S2/"0J3\%:NA+=C8L6DJYURNMHQD6&2S18TR)&3S8Z* M!I,JM@0-QTX5.R8J3*+7:29Z'143)DVK)&E:1T2)2;(ZR22K8R*B;9LJ@X6(8+GSV(-SVP<,Q]](I?,)\-^:&K1QX5'[6N7;7KW=)O M)5>L'Z?1NYL%U/T>Q.RK,W/Z'KOG+^\)!)U>%9%0\V6V3_R\(%UK>\8'DB@O7>T9]3J]9;9,Q;WC(?@ MW!L%_P@\]UWY+$QZ:LG24X^,E4:UV>T<,[II-UAY=$)V(?8`%[P6XEL\0."G MD0S.^(NY?_@N"S5>=@BMCBYFUR\L'/"(?0WY@-TY_FC#30A_^OX05#<(VBV" M#LTBXKY$/AIM9,'RQL7<$@AJP1!@4D(H0K;K,O6-/@?]KIZAW#!B6@^$] M^2'JO4ZGB?^_M(X(8HVCS!"\3KV9QM.0X3_%C")+Q,7LTHF=41!N>.S0&_LD MQ!JRZ/T<-P`=#8.1(ACY&G)_P"?O*%4IY7LM*41.@^GUC2"A8Y"PB(1BI*9O M`@FMKFWBOO(`D9*9!4^RR4BT^87%CX'[(%`2#5GX?H)_#-_K*?*]'AD0AJWU MU-A:CPF(1L.D)BV[&/W-$?+_'$01BV[]>\<3_QD2Y=/[P8?AXEV`Q3&Y>(\( M!<.D^PHNCL2D>U1(U&MF]U@&A_'$"V8,TE`"2>OW;G#1KM?-KI&%PY5H*(KY MX-UM&X8K^\2XLH\)!L-T?7),UT>$@_:_\O$H[UU4G3.[CJ)JE%Y4,)1]BJIU MUK"%J-JMFKDS.^T[,YBI?2*A04AH]>JE7S2-?8I*+QD`\0>&I[UT/.WVGK>@ M>8@81NX2,'(?'!2&D;NTC-P'QXIAY"X)(_?!D6$8N1#8:1>PD: M3HB1^^"H,(S<)\_(?7A,&$;N\C%R'QHEAI'[U!FY#XX(P\A="D;N@^/",'*7 MBI'[X/@PE+NG3[E[<%`8RMTYCI#3HMP]/!X,Y6Y9*7A\6'R?%_!R/'S?`\/"9/G6X8\WX/CPN3Y+L#A5/)\#XX%D^=[NGF^ M!P>#R?,]Y3S?0\.AQ'EX!Q!5Z\RFE,6:2;(J39(53-K!0&$RFD\UH_D82#`L MP#E(.#H+\*&14.X]==^BJDM1=7MTE=HR5ZFK[M6/'7-3WR<<:F>V:+^#<.A* M.+0-'!;C]8YYHRXG:8\@2(XD..\F%[DLN8;E MRS,\-$I,GN&IYQD>&A'&#W[2?O!#PZ'$9_8#B*JM1-4VL?"G'0LO)^N@8#`. MG!.-A=\>#/2)^,?_`%!+`P04````"`#B=4M#]V7@1?$:``"O90$`%0`<`&)A M`L``00E#@``!#D! M``#<75MSXDBR?C\1YS_H>%]Z'HP15WMB^NS!@'N(L,$!=,_.TPE9*DSM"A5; MDGR97[]9NB%`EY)0@:HW=K=M+)1?7BHK,ZLJZ[>_?VQ,Y0U1&Q/KZY7::%XI MR-*)@:W7KU??%]>#Q7`RN5)L1[,,S206^GIED:N__^]__]=O_W-]/:1(<`F?-=6OES]>+CZY?HZ>')+B>'J\"BQE%93;5^K3?BO\G_* M[:_PS^#)?Q"^^J]?V?^]:#92`)IE_PH_XJ]7:\?9_GIS\_[^WF`?6'I#)YL; M>%.K>=<&T/ZS'R_4-)SH:?9K@]!7>*[9O?'_&#W*R.R]][WM/:O>W=W=>'^- M'CT`$#P(+U5O_O'TN-#7:*-=8XL)24?P+1O_:GL?/A)=1]6^B;A- M?8+]=AT^=LT^NE9;UVVU\6$;(<0C9I*)7(&0%<47,R4FFJ.5PO[]/I^DB9C] M^69$='>#+&=@&6/+P<[GQ%H1NO%X`PC>^]84K;Y>L6]>AVIA"/_F?6)H"(77^QSX3G6:,@N35R ML*Z9?.!>[*TX<`L'_I\ITYZM%FL`MR:F`0Y@_&\7%,L'T"8V.@_"V191S\QL ML+TAV6P!+[)L_(8FX*8VZ)'8G!JW"=%T;)X']E"SUP\F>>?&IJ^J!<;D\HRH MIV`N#.:VX@$11[#47DS$)PO`X8@#,M4H,Z MG8/M@)6[3O#+/7Q1]TU]1O=$2D;8=,'LDOY8D#M*=/*""1.]X?U3,;<3ZPV& M!:&8TP:P]28,0`%3!!@5FV(,1Q$5`9#*-<*,9JE]<(M"=[2/:C$L'*+_"^P; M>7X=G#I_.&&_Z.?`4L!6`%'%MI(,J90#`W!5.[!D=`MWL]'H)P06[,^S+?ML MH`-<[!0T>8`,00;1JH:-7MD,731\M=$KMBJ>H8^A%#$W#U#5%G>$*(B^K-?@ M3\54Z&$D54\FQ@*J(TA$0FEE'=@H*IV#WNH(J_` M/J5N\.F0V,7LB>&T"=4KACI"MD[QU@^WEFMT[\+?$6=681#GI>)!&+E0_&KA M%22-D';K.G$M-@Z?(=G0><,H<*!:Q8DD'[KB*"\"L]Q"J;4 MSXDU,"')9+6&!T)'Q'UQ5JX9?+&8KV9D/-N(MSAHAF)"MO9\76)$0T(-7=0B8@Z^DRV1(*_>9.5`?-$Q_:*;+QIN[ M\>;W@H..H5Z]53WF'A%D30.&\=6O%O)5:9!&!>,H5QL#7)47QPZ1'3J@)VSA MC;LQV7//VJ?W#$R`0VV+')[%#A+-3I+0+ MN"KV5R/TX@P*#B6C\J%T@**`2`SA(MF9VR.!7!71#7N@B#D9GCF9CE%YXK4/ M-(Q%GB$[U/%6,X/1,'LQ\:M6V'_[L+=;(A9V*:]I"/":L9)NH1HW*^Q67N:. MH.S,;Q1,U/"Q'P'#7/V(M1=L%BX.^J!M8CB:5K6#2\2^7"/(2MXPVR5QCRRT MP@ZXZ-BC9=`[VQ=XCSCXA^M*X]4*L<011<_,(8@OCIP2A!TJ#G>I$>5#$SBF M#J7YW:+P"61-?WDF'5A%"4.@Q'5>SE*=/SDB?M&K#X=S%A*FQ/J!;,@U9Z7P MVL1ZJWH"R$$\J;==LVT[LX^(K(*]8.-9R:;F'KO*T'#F. MZ6F5[63PZDCPL:WEH"I6%Z@\1^3?GE5B,QG;J[55+U$W+%3, MLK6MR)6QY#6HL)!>8AFJ^I5IW;: M5+R`=("AB#@V6P%KJ8%/\.J=;YBXMODY@2".A2`[U_&`+=`=ULR=#^&S:++% M^JIB4Y2.^-[L$ M*R]5>[NB2W"QW.T[I"!+XF\715%R-UN%*R!E%H!=!W(\\L[!)`0@NFMZUOT( MOX?/8XBSOEXUFRWE6HFD#C\/9]/%['$R&BS'(^5^\#B8#L?*XO?Q>+D(:3%Y MG+;GWT>+/AQD&$VB!T^9V@LROU[!!__O5Z*&+F5A5:-[V^\TU$ZC MMR^R^&F2%:1RWKD*U[Y^U;2M=P3E!IF.'7[B"?>ZJ08G-/X6?+Q/:A^PR8Z) M$!K*-Q,QVUG.ML+#/RPD?--,9M4#9PA*_P2+\6R@T>MV>\(XX8+`Q6',A@8T M9'9%R89+.PXI*1)"(:+V3CNQ_UPI[PB_KAW_@RME2S&A$!2"%5\IK@WHB3?> M=@&W1O4C6]T_R&93/J%]>`01J;06)'0[Y:=]W>78)FD_UW MSMO.J*P";`7Z:LNAKW#O_B<87T-5.VI?V+B+DSJCZE(Y#!35D451\:)]X#$: M:K/?%JFQ!)IG55T>SX$.NW+H$(+ZK8:-8%-9R+[::77$A36)-,^HPWR>`QWV MY-"ASS;P>]L4'%17IZ1CM%$0DJ9$N8+)<',MJVHY\1VVGL_O].[$^<@LTN?0 M(#?KV!A9++#T,Q]JMEK@I,I'F.;28SZQTRP?(DW MK'<]:Y\LC=M5N@3B3Z99A>EQJ>*PU)?.NESA-O!#760DR*`+_Q&IS62REU!H MO@#D"NV&KNV0#;A+XXW-=!%#_=:=N/`[A>C9]V0'^V6I(D8&CA2*UU6R)"\232)Y=E;E\RQ7$Q<_SQ0X! MA8SU.@(+^MFTS^]VN441J+@OAXKC9])V!MNZ%1BH'U,\_SC-X3K0X:T<.APA MBM^\K6$)0KAM"MR(DD7Y[$KE%8-48+P/+\(Z^[&U(!X'TV^+"WCSR%6N9 ME\7=A)MI('+EJBES3*P>!-.,.,><2_["NBXD'LD&>6P^BI?_8$I*VH)4_41< M&R5S2$*N8D42][U>3US@7#L?G2,!N:H5NW8WC"M_8ZO:45OB"A4)%*M0*)== MQG;&9'(MV3Q+-AMBQ5CIB=QV?DCM[,K+8E>N:7)@&-BG_ZQA8V(%$4&CVQ-8 M6$HA>G8U,&7]+>O)M$E/DS%9+[0,LN]D26?\O`N;\P[V\L&JW5O#;S:%X M'N%W_J-LG:RC;(LE_/,TGBX7RNQ!F3V/YX/E!!Y0!M,1//GT/!__/IXN)C_& MRF0*OX^5+X^SQ>*7$&VA0V]E;T8I?"XNX7V1JGMWJKAP,X-P^0T5\(:=3""9 MZ_?%5:SV:%4Q;`NI(AR^Z1S+%2MG^9X'0@&[Y1?>],\EU2Q;TSTQ6H;W6R!4 MXY^N[00;?7VYJ>UV4]SN"S&@+V9+9]"!7'D`ZUP_6[&MJUXQ`M$WK"-[`3-K MHZ\*+(:GTRWO&OUWAN\"_"+WL.S1JL:>^36QRT?3.);+-<9X#QANB0M7#XA= M5G>)/,OE0KY1=EL7)2N6437;77'+*C%*Y;T$Z[5M!R=ZO=,RW5Y/7,GJ@%H5 MQI8M[ZA4G,%F;9U#)9SS#<:T,79]<2$D6FTL3`%Q^&W?7&R][C*G>[2"`":V M]>T)6QX+$\M!K-$7"&/_+7[B_(2<-3'8>6D_J($0N]GKBELK.R,GY9U$U+$\ MGGFTFP)/?R90K,)97-9NHK`[1YRU=4@I8]$73'0N2%7[0H^^Q:G]/$:1)<:T M\GM-O;.75DZ)1?;M'&R\TQ87R*90_7DLA$>L,"2%S?VSA"&A_1.*#0@T]R]J*'V1#9(V"=6A='Q2#XJ M-J2S*I?KF",;P;.L!>,(O2&3>$U5(KZZK3MQRX69M,^M47Y!2%:L!)=(-1/8 M&A@;;&';\3L!1YPU6[?BJH$YU,^MY"+"J.V&*%YY9%9R(HFD5!AKZ\4JY3[; M=B2+'/8OZ%YK])7QTVTG=B*MS(,?D:QT3'-I,9=QR8HK\96,L)H?K&CTQ6U\ M2*%:R>:UW!6HI$6<--9KZYIRE>DMT80"$!=7)9&\G!H3F:Y=#'7J-L,^_S;# MX6#QN_+P./NC7._\^#9"UC7]P23O)^P53&R__HQ``ZQL0MF!N1'R_VWTN@*/ ME!5!YAF%C1A!-<*H217W80E[_R`ZEDO\9):HYM3"PC M/+D<=@J3?J7PB$F!.\;X@=3>0O*$5[OIH(R%!/?5'#+9$5>[XP=2>PO)$UYM ML_%$"_%OZYVMQA_ZFETVS>[JG5G)`FS<]E5Q!9@B2.IC)&7E)]?::'!%.MN' M#<-!1\CPUJ?@9\/U[GH.&G^J[7Y'8&=O/A05+>N4GUJC\\0EI)86@=2T`!#G MBZ52L]63IJ^QA>AGO/4Y,-=MBHM0.5'4QS!*2$VNP"/.8=BKF5V*^HIMMM9M MC#`%M_GLOIA8GX$+9?4P=FE/D3T696@(-`&^H"K)!$H)2*Y498ZV@3.E5;Y,)="MW:&`*?9-(.NTHP+1PPU>D(;$B<2KM.&F1[&?K8C%"6W!&6`OZ(@S\"Y.\7QNWS8ZXTFT& MX=HHF5,XM>LJE+UE@\TX]VRR88TSD&7[_*B]ED!M)Q.MC:(Y9")7>O5-PQ;S M3#/+KQ7N73`9*Q8VU3MQ/=#Y0-3&"$K(3+)\:A3T*DT[6-+OM<3-XSG$:V,& M!80DUV4(APN4$RN\TFSO7N[;KKC2*@^$VAA"87D%YG`GB3+FQHR:=?8`M(D%`;]38EU'YTQW3/O.U5<[LZ)HM;VD">UT#)D69T_YO&9 MHJV&C7!>#*9#R(=B-[-Z@^&VLJXZXG+ M0O,!U-@6,F456H(D94A/-C:\XX'0$7%?G)5KAHX/..JWA2[PII*NC?:YY2/7 M*N%W"VS9Q'\A8U=NVUU/")SUU9ZX.#*'>FV47T1*:4O]-0T,Y6J958DV3^]X M)>G!T4ZSTVPIU\H(V[I);)8-O_= M%NP-\`+O^_L09ZL8P-G*@^=3GM'XMY8DP)7TQP#/ON`+G&S=6W\>O,&[6*JP M)+$KK8+[5#Q\S#I;XDZW%D3#-3)_RHT')^KL9]M],$<&0ALFA?U[]$:8N5O+ M8+L7FP+7(W+IUTOMQ<0EV9ZB%)9\T45M`2:;K::SC<^JP&8A1:#4RT)*"[%^ M361.#3VZ3?4P])A,?XRGR]E\,EZ4B`AB:S^GSM[AJSZ]!E4-56WWQ1V!W"=6 M?NZ-WC/7WI_`DBC63(:]TQ*Y3IA`LXHAEZN!714FCVNYIMR(GS\(_1=;B"`Z MLGV&SF"">T0OH\=TOFN7??$I\H&U^ELCPVM%Q!@2NJR21/0RBDSG6ZZ26,20 MUT:*3(75Z=P(;>V20+A_CIKXU\%S`DM"6%!G$ MJQCH!?456XOBE8I<_GSO$O'=60_XV40)ASY2Y<#NF!:W7ED5R@M:D`A!UV^> MR;2U1_#XP`K[9[+94O*&@HLYU*[`,Q@I5(6:0IJO#(V!1Q)R^9%[%YL&S+KL MAL(X2[XD>JHJ+C+,)'U1-7,+1:Z\.['M4B"+ELC<.YWP1=7,*0^Y*UW%'"SHW*BE`E:,;C_\DNM?^$?7/`]@B]^M/F+I/WR0?43?9M4>R_;(QM2'+FHT6L+O$B7"T+YA)_K]4.74I9\]#I-<06-(DBJ!D%%(9"N)(I0KN^!D]8&X-.14X$T,1='(8RN)`I0L3>'D%+^%@Z*=N('^O*82 MHI'(5)($^!/F.D<+F:?G.M%AB`MD.Q'M:O*=@]>E6IO:5M4S7%HL*NGA)!!& M[^QN0G%G!XJ!J<*CE-?RT\BDN2"^.1REY2Q"A7*L3/ MZRZ29]R*"W!+()+-;))%*5=6Q,WM+JP'9N_$9='%`4EF-LF"E"M!XF4@RD9(5]RB8&$\4ME,BAAKUU+WU/2Z M?WSD;#2^7V9DUZPA_#7K"*^PEO!E,F?VO4%2WASO-7]J7KS?M[[5$EBZ+MS# M/Q?PE%AZF(BU6@(SV62B58S4'/E'&^ORN98K_8PS-(QQ(VX/=@+%"RDPB=_: M98*G>LS;I$.ZP]G36%D._G%X=B+LEJ@LM0_%[Y'H':.(]48KXT%C/3QWWC.D M!1_[E-B&U1V=4QWJ49/I>'^W?D]@<3&+'4S40X)2=7 M_2>9U7C;,V!-_/T$J>3K9@0IDJE=C,"K=-]^8PRRYFM!$-3O"6PRP8>A^LG1 M:P$=M'X&%795<6$M%X0J#;RH/O.FQ%1927;Y^9%\O`W6.['TSF(#QZ1KIOML MV?Q4+@X8:XO;,YI#_`QJ/^8O5=^Y]B)MU)O$7ZQ"`[8M;D&"&T:=C2%96)([ M@JB/QL`TR3MKZ0V!G,!K-#@`U,L&L@54OYYU):;^/<,6>,UY'O5*PEO_S;M5 M(39]:Y1^K@A]UZAACR#IL1VL`ZO]LZ3WO("$F'VN?E/MOI@$)9\5X8>#>W#B MEW`.+".X><].OJ5S2&Q6&1-X*%<$XIH97,4ZD'Q>3A]^#X0"*Q;P>H:;,OGQ MU,R:"LE/VB)E-'*&\#MV4OA4Q9W&*(:E9C;"+3>YMJ-Q\CDP'40MKW@;;)>! MYQC79_0J!9!)83NY,JWM%K73\JFL.D)V:2U9^+4-)\\GIKSE&\U.*8KSJ&DEM)3AT*B,&H[""K.J<:;K4D^T=Z?621_WGFH/-8Z&5)E M0I<\?3J60]@GF+5Y9/=9:J;M770+PKT[8QV('UB]S8I'G+5+JT[?*GC4IRE] MJR!(0XEN4%2^!`/O%^^\I,VINP"\EN0*:@#'OQB*V\Q9DG,R>P,9C/!!J9PK\$I,KR`@MW:\/)3(F M;MTTAWCMC(!'2K6+#[ABS,#3I4BKT>_VQ6>SV1CJ8PS%929GJ77/Y:5RV>N* M3S1XD-3//HK*K[9EU&S/X?O$=/X$GFGDPU`_R^"7V4]WE/?VN%/6?K9Y?&WU M>+5"[#IP%,LPE3F,K1.3S,/;IR,ZT3.,R*GY9?);$PWGMM\6-U;X<91/+I-I M[,MY$&95S#VZK#R\]S`(H2-NUVX%`*OP)J?81.A+*I:U7&DL#_/)TR]B(A5X M\_4IR&0R+1[IRI4)\W`])03@XUJC%KO4!UGN7-:A,>#)9%K>5B'#Q?(@:C;OP,,Q"CN M)$QQ/#(94;HDY7@=KEG'HXG%-+P#BY#UY+.*3)K'Q`TNO!$)@T`YIT2Y$<.7S05<( MX^S>0"5`!+#GD`H4`0!02P,$%`````@`XG5+0P;9YC511```V%0$`!4`'`!B M87-I+3(P,3(P.3,P7V1E9BYX;6Q55`D``ZA'6%*H1UA2=7@+``$$)0X```0Y M`0``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`,Y3)&PP=D4(WSD41%AA+M&J-$LY`]F42BV M_,&7A[F-E;\3^T;NNDX6=79WPEHJ9?"2PU8(1YQM)9ZE0@L888[W`A;/W=S9 M;F7SDS@6],_3'?ULJ!!V-3NGR1.6B9.!9=YLHS7=H?.ZKQ9::P;G'?J,>_-9(8LVS$5\C_"%Q,C)N+M4ASQD$-ME!-( M5@JM#I0IWLO#$5?AJD`_-1W_TQ&V\MD3Y=/"IL*9U0=D*::V\]RMQ0;=.^3O MB/%4H6)[R7D2ADNHMC:T%3DTDF.WHF#'H//PE1PV%%8WBBR@,N>#)!MW^;FL MA,UB>REEE_MNRL1O^)2_I7Y.C*%.#IDTUO"(S0?L+.V5H_M?S+=64U1DN]7D ME>DHURO]KSGW!,BIZ8AY7'M10O9HC1( M-H'Y*!8;(WQQ#XZ=4^E4ZXR"$2%5PD!W-[ MPN2LBLPM?2"/.:FN.>FVROW@=7_`W:O*QYP&3O?I)DY>:GCLXZ#%M M8=669=X+7"SOBPTBIY*]1JLD[I&!5II-ENC(HT6XMW=+,@X<^Z=YI?%JA>C! M$87/S(@3GY]S$R/--N'X+C2C/-8`Y]2I--\,DWQ"3DU_N";M6T4!0S"Q8R]+ MB M;6C93N3C_!F0M0;.:[%CNEXU`RB.TW6#VL(FT7CG::L.)O3)5SGR:A[O`,L'469CZ]>S;7" M>)B(YR>0)14K+?"00%07%,41K[7+FX*+G-W>R!%D@;UR410>[J:K M(`-2)`'LV.2,A]\90,JF$N#T?XQ"#?L/-,.^4[7MG?_,G:R?^"T)30M!OP9M M>.BX?$:^R9TK`]O#PHP=?YD[;QLRH*DX2W1+/J6U[Z=%:\R,IHS$G>N0PJV* MM[)6E.6D8?CSZPY_NT7;)3*+,ALW!J1DT4IV=/MRT1Z/D\PQ>5`S-+KX/)%? M@\D M!ZOADAP.9,6NMP:=>J_>C96L*]65;"U=T3K6[5J6=VXKVAW2;2OXQ%UD;QN2 MWZGU)_]C)OK'X'3:18;-0!6%T=4[[8Y4!2PF.`?;&IH!L)6)M\6U9N-<,L$F M.6>[/9#T/S>UG:EADQP.B6G?U!R+<([=??=P\/9G9,'%Q9,&>81)L6_&4M-U MI,[0'AD.&AKJU-X@,X#1''2Z@W/=QN_V&8-5K"YVI+[&FF)JS,MRG8+N#)I@ M4S".8/&EA/:PT:8[\@\-/NUEG?K/0WM$W,M/XINZWF:]V^ETH0`Q<<##6EDT M%9AG7K$(LZQPE$&^Z2WV-`UZLCX)A+HDM:4>E#E'*95MM4DH?=VT1-5--/_J MFUI=:O1:@$J*(5F^MC)P^VIKBZFV5Q/M9$WU2X*#C5MJ-]M@6T4LR;+5EHG; M5UM'3+4=8:UW^KUV*9Y*V5I*@NDKIRNR)]5BUG.M0&#E9HLLB.-JZXVVV[.P#;K](HEZ8[5OAB>X(_,%;?R=&3;+0M"2Q0$E`I M33EQL$1W^XY[I8@5C3\4W:$U50:ZE)/DAI0:DVG79I"V44@ML/HQN5\F\2&$OB[K683;+N+)5F: MXC(!?P4?DKB\?;`9YI$HV6F,(/(5T!-3`2-=MBS_=I0'=[CZ`.Z4=4ZM>#!X MCNBE1<-#NR4=]-D51;W=AUNQ4^AR,+)L?02&QH9?[$-*I-OF])C5'+3`SI/) M9"]/<[[*GS0T=DCF=<%TGK**0^QC=O2BA8-)-OM@KFD,P8IF8SIRL0_G,9Z8 M)'7A#A2B.*+IN'V=]<74V0,YEN_=MI08%/T&7&E:&N%JU,@HBG!#[(BHSPCK M0\,+LASUOT:DT`;T;MB8X*OG?'B3)V^,H8@=#4C8]2,!=K+Q@ZW"F=1%T'(> M$8D=,XAZ"-$4"G$28LK7^;M'8NDU6QIB!Q!2(+<'?;#-5^PEF4DHHD<4TF5` M',1>"RS&ET5=!"7GD9#8,8BP8\_MNBU54MMJ0E6F!!#D(O:F&,DD3["-.2"AW/Q=HN-".==P$;"4V+5Z"L% MLC#N57P!D*IJ'O5765,GAA]GKG>Z<+4C"32KT5RV`,1V#6?TBC<#J6/9-#1C M;0T5Q=DZ.KTMZ8'(2M'LNM1I=\"J2++I5Z/7?'(1.Q@;X=V[""?^+>@OR)ZN M%O('L=T&W!4S^7BI:%(7%ICHD=KS*'.WVP6;W""1]P+Z3,==>2W8G^].8#^1 M7YDOS6NQ7YI7^^7H^N]?`XZ*7Z(7>YUX[AOUKEU-UZXF`:)CU_S5-7]US5]= M\U?7_)7H-GB\W_AO;G7L#9'I'TAU0UU@[D,Z[7)S.QBQY#BK-![E0+%`!<[2J9;_2P\QR]VC"@.0^1%=!0(W)T? M&<2KUV:"),2.]AP#(;+ M(KM'MP]W$4(LQ7*5F`5:[$[!"/=G3ENWWP-K9$BA6YGZ4@0@=NO@&09_SR?\ MES'SJO-WLH'[BAM\$<5%M_=NOUM&L4'%3@ZC"()81T-,15[K&K],<=FUKO%K MF=ZUKK'2NL;+4L*=M)3P?$'^>1Z_+.:UZ6-M_MMP-OYM^O0PGLW_LS;^G[?) MXF^%TL+IKYTNGAH^+[T(RB["M+_4`/68L^@7GWMDI$,U25UJ]GI@+9%'I'BD MB`OH)9A]B;#%SA.GE0(]8A-I:\.[04'Y7)BR81$14.$9JON;[G;<#]7_=RS; MO]C>*QZ26JT&V'D!AN>*[0=>$6)G2[PEE0H`&P2`OX%)O1Y887LL15[I.[]< MI#5H@:WB0'4R;(J(CSN>H19[\8L<&'W.I48+S-[.J)6NK#2\8J\."17I05%6 M%^X%KFF$2U<@HQC$SJR>5J$'W+<[8-<9Q9,L77V9R,5.IS)4D(>(X%Z2QLI$ M^9,SOWC$SK5^Y1K2$]59?N2DTP-'$$>Y@EK2#`%M*?NI[T)VF, M8D[_,35$"7J^B:G(ZK;A>OHK3M2FHA7[\'((L5D+G'`<<^'=RV2EH]LOV0'= MX)QKGE.7=6N&B'U:FHWFR-QK"JW/TK`Z0PI>>P*N=[IP)<(E82C7ILI7C.C. M.T'EU;`\.":98QX4MZ3L!;V[?['H`MF`6V586*A@C\@C%;&K)!/@>.OK$9XF M6&R%C0G]!/V<:NL:6>$ M*W:5YC&D!T0DH3YH>TU%ANJBB&E:8%+:\5!5ZBD9E."%EP'+UC&>>K_;`EM* M$VB6J[]LX('F!,WCIGEUA\5BNO)^MND[X^=((4_2VU"I%P!XI\4EK`GA-.67 M8F`MHL9:TIQ#)J!P;P6^C#>HWQ2[6.-! M,Y%"C(0MXM5J-SLQ/E#"T2/7V&7[L@5A!^;<%?,5@!FX3B-;%%A,35PQ?58: MRBL./-!H3TR-,E1J0/?Z%2Y5R5O!#02D>`4WHWDRJ2:PU"S\7Z?]+QDV=`M@ M:18)!*1"BXSI",S"_^6[`MN-=D.JW=8>-(N6%CDF(K\\3>?SVNMXYK4!UGYY MH;%^^@;@7VN_/-`*7-UBOR26MM\$MZ>$`_FC'$/*T?\W-&Q-U72'CG4X$8\_ M%-TA`SP2K5.=.;:;GIZN@G+A@(_#IMGI]*'*RGCQ>$']DK)!JJ.CZ>I"7OSB MM,Z@"U:#QY55#NL%E(6%AWXHW?PTA8-<-0"5R*U\CE_(P7"+'<.N=_H2V&5? M7#@4;4;'9LNO>SF[7[G@=Y)TR'D7BNLC2APLF/T"]B2,8G>37J_- MSW%MOJ#K`H1?`]5P5+[/F1XU^'FN[8]<*R MKQN:E*3ST.1\_(->4E:;O#Q.9\_#Q63Z4OME2M9ALH$8Z]K<"V!810*5_GP-X#XB9'PYNSKU# M!(\L*Y!J$(&'<_32*'-U=XJK]UT)+*K,P`"/\'I. MM8/'T/G.Y@SC+Z+D\RAX$1'^-*%N=AF"14`@)TJXCT;O=VPUX-X<$D.P5$N/ MNYTP709B]VS/T!X9;K]?IP-WBWU`I6I5Q:$5.^@VM"QD6_5.'VY*>22J5LT9 M4+&[BW]@K+YKNDYO"93`%N^`2M7*B4,K=E?PQ+!E8TW;*CS#>D&V%YHDT`]H M)*D%ED!FX:!JO>:5DM@MP.[-39#K:*;@MN3TRF6[56V40B>C\QVIE(T;R;N0UUN*6" M^,/]M=YOP-V0F4*W:KVRB>2@5R$+]XE%XN/CT/B#7B:$ZE*S/P#;:Q/)5JU4 M)GF$S5)"JO11UKR7[1WN#IFN_"H4JS[H-^-NH4]HIDD=JVI=,0,-+[=J=@34 ME[OKG]L=V?/;<'( MR,-OR%S('\AZU@P7`/'MD8DLF^PEQZ-XG0_/R-Y@\I<]\N\#(F>[;@>L?;=$ M(%4;744Z"^,E0NXBOD3]5':[!Q?..J)T00K(N^0P2-+YM7K-0:<7XD8GW0,6,49H",A&('7H>89,L?[(= MW,PO27&2YW6[PQ&MTE24C%'LM`U#+0%T;6'AB@O6_0$*0.[]@;&VBTD5A\4Y M'N_7*2M,A@M=6@AN>5``RK>\F,K")+P_055AZ[RJ<#:>+V9OH\7;;/+RX\)^ MYQEQNQU3L=TK-K@U/--13<:-6LRD:!X%1NHS%;`HLDA-@> MBAII)&C3AKN@DH6!XN8Z5.A[059/LJ%.WPVDN@?)F'A=PE'X].NPYI8L\,,; MX9+AB!V8.(+M0G;?:T<%,/'RL>[/=:G3ZH,E,AF9J%K+!60E=E"$71I`I>"P MB\RA:CM%6NB>1V2GX:4O6^!^++N-;*[=\MI6%RR5 M%$=1J'4N1@KACB9F9KCOF:8[[FF*\YYFN.^9IC%M/RKCEF(9,(&:D0 MH*WILJ10+)`G)%LH>A+P=Y]6>Q#W]NP$YR9A%`Z&Q2[HP*@8$%7N;5Y:O]#, MJ%^8.]NM;'[6\*IV)+J:*Y"+BQK\X4_TXHY]+7.XECE"4AEQP2J3STDJI:VC^]!]$-,BD M\QJJ%Z9L6"MD6H?L69S=)H3(\@Q=B1*+8A=[2QUO=SK^1#0@2,5(^`C2:[TF M6-X_B6@U>LV6@-@)1O=VCB/$P:K2E<`*IY.(5K.^9DM`[#>I_R`#6/22"F1- MC;FLTY)^[RZR8#UIM%C2I]#I]FHPFX_F%W;%A[FBNK0UM MI2FR80\5A;[ZD*CF%>N:HB&+6]ML4/A$/)F@",U7?ZO7!JLA2J1Z>1$@\;5# MISKVIJZ,`L#P^QSF%KMP3PL!8U&(?38(6%^\XPCK[)?:G7V_4@7$HA#;E0]9 M)V*.6D^,XY"E@L,(U2HA'HG8[K@/=VKZ*+Q05*/;@\ICQQ$LOHYF:`L60\$- M@AU8BKY$^]GC1T%P)T]=?2`2O%Y^>KI9L4L_$P?-E8L7Z'^_F2WA.JL MR.6,<%9:'$3`18&;:I+39W"3KE@^D_\L2P,.&(GEIKMSS$]AEQK%'=-?R[RT M/_&X#CQ-)<59X]71FDM\ATO!,T']-&VKV0)BO]H=P+Y&LK5Y?)B,)@8M)*6O M(R8DZMVN!'<_6QS%4BPQ[M*V#/B"NZ2ZCM]E0T&/V'S`SM)>.;HO!FN&%*3M MZ;0:>>\.KW=ZS2[8B]3S<%*5LHN*2^R$8J*G^V8A`O!)6Z&ZU.YVP5H:&1BH M2N,Y92-VCC'ZYGCZJGBPTJ0HH:HTEP`V?(VSD!H*7RT^,7:.;=$I\)MNH M/I!:,;?]V0XZ(>)W^V-!ZC9!0O0 ML3(AB*)9A.1K_9_M75M[XCJR_2L\SLOP8>X\`B$].2>!?$#O?>;1;0OB:;`S MMDEW]J\_DB_8@&S+MLHN9_,REW2BJEJK)$M5I=(()^L/QFY'Z`Y`(S/B_B+$ M/%M(/R!SU;8_*4#>_U_MOEF6_LLX'#QX.)NKA)U\$1&U+<0EX0C('N,D^ZRQ MTNDI8'.X;@YY5@:\3'#R\F2ZJKDWZ';-F^J36:JP^YA'YE]WG9^XUK: MSY6G.CUVTQ.98[@D"""_$FJD3@_CUM['F@+"NX8NRQ,JL:$^]ZJ:HM!GD89* M6/,M^KMO=.?R0/>G!\N+!8133QETX1:=5-%U.8@P'B&O2",CTZ-%E]&_/-== M[:Z_CNW!:`BV34@77=O,%P4D)+:AK=0[W4Z_3"<,MN99)EL@6:OU$#4*5"O" MK.6#!MF#ATR29$A:#LAR>TUZ9L."NCTO!(;8Z MLO(SH+;1(@H4]]JH^6B*G*#W*'L!#+PW=I8:L*Z=3.EM:^P<@%WG=AM;8B`. M7?7+N839D#+Z-]MRG/9DT@%+;F8)K]3S>>%W<7!PI[&3#8GE:B?C,=AG6T0! MO&QS06KL1YQNDD_'D]?!+WZ4HH!\X))W]=4;7/AD5G@*9%(M,!,R$$1_%SLW/$!W1O'.A.H-QC(3 M.%=MBR.(_QYWWE,>^.LJ4H[%/"[6Z\5#:_.OZ7JQ:4V7#ZT_I^OU=+DMW1!:982]4J@/^R08U77FMH#WB5KM@W)6]-O9OX=O#DR%8^_D4L<7G]W=*X[G%T6C` M.=0FE(Y%?RAAON5`-)Q??,5Q'S3]&1]8&5.>4X^;@#IGA'K@SS`%]W453_G9 MK?*Z%!P'[NCENMM]A83+L0GW=$J66 M7A.O:8/]/.>=1AF1"6$NKI9`KM'HO\89Y@)]Q*IS/=BO<*6NE_SUY1J-_Z,; M!0%]2Z-(TNS3L^S<*V3("7LFO1PD-&B)[VTZ25"1Z%(31C06FX^&\Q=8`!$D M8=<2!Q,@8LL=3&")%0"D"3V[,F%XCI?94X\5[;4D/K",`E$!#J4I+JO4LPST MMQ6?H@A\F8Y2N>$3?EZO`L]E^0/GR7%.1'_P'G/UKY/Y6:,E^>7]DZ\XYY": MDA3)'K0.STW(H.1#`'=4G_74<3^9UJRU$C7&LR3HI#6>\!J<27JE/44P$JX% ML<&=+K@,HCP8'X9.3)WU]*`&:7195/>LBY+2`RO-%-$`">-YP<)=ACFW3.^& M.OV47AKFKU;^*O;]W3+]7V2[L?:H,P%KI%%`'R1^40Y)W&VON">"Y8D-2"$C M&OW*N>R>(]WQ$'WV&8(7_*+3'HZ&8!^)DKIA\1YI"./NN,6U<_&;KIR&0^>- MH9'S/UX85VWQ3X9"F'U&'$O<3;KH*LFN4-/OZ:OZZ35TO%@Z`]P\<,1?>!<; M%`N]N1'`W8GK\JOXJMHKVPLAZEYOL7#KS+9.PXKVF4DZ('&`_(!A;_GU0?QN M-2$6B]_OANW=6WI@#02[6?T('**U]]8'58Z-Y-/N_^]KPOV?9HI$PK0X,L@; M?;W:ED:([CQ2>%;N&[']\S'UT?X(K"0A02@2;@4@J;]'2XZ%VS_.K$ZNXZHF MZT?'%B"XYZ+4Q#:TV,9C,!R`M65(DHJ$>A%0D/=4$_!> MY\)I_32&APGG.%Y\EO.D(*%9`D:A%R`-[5U:&/MFG;M`>\:(M[[.'A`EMUF6 MAS0BC:MYK6#B6\TP);7:!?M-9HOX?:C,\9"0F,OND$.D(:]+AYP1DZ*G&>HA MBOD\$M4]V-Z4]!&Q`ERP6#;\"N(3<(@U@<;.B\5C< MD-L7`#";C"]Q\,N&.,B"B!A/2=6 M(?-(PU<>#ME5MLIPV`5KBRNF`Q+Z\P-V+J@?8'2`R)TO3AO4@WM@4>D$F4@8 MSD8D"DFCI#0TF5KOERM=Y-!&O0'8ZRUIDI&P*PI.5")0%\=ENYQU"W8Y8X'; MEA>Y94]ZG([^\T80+<^B)Q(C.??N9W_CAEQ8#[I_MX9<33J4WAMR-:'YT;TA M5\-]\MZ0JT$-NZ]H^ZQ, M>#?Y);_47E"YXCX>2?[DR?:OPBN321_>]&0%)+B]=/IO'K$7`_#+M!*0`RC4 M@RSUSZ?8^6UM.#\?;<*>923TM.>R*[WM2;<#%G,050+-O.*]4),?2-P[=9Y! M[+U/TKX#R#IT33/",#2-Q=$M(,^L,ZJ*YQH+KZ)@'>D!=7HZG> MD0@F[E8*:29MB7VDCJ[`O6V7(;RIOG`%'.XV"7Q#8O>QJ25]L$QTIO3F^0`? M.MP=#L1/&E`O^L@ZJA6(&C6P6V(AOO*W2JR[!6:YG-SP]N6AY\5TLVAYN;=O MBY=%^6>&GHGJD"D#%7JU+0J4^_E*Z67E+NQFP#L3L:4C!3&R?F<" M]G$6D%]\0IX'"W(BR@BV(5M,EH395X2:>.\UON6XDW*SDW%@2?M`[1&O]E\. M7Y>2:J8KR6S<\8!$BV>?S&:_W[&B@"7Q!.077SN$Z:S:N)P+8T&G3:$PUKTA M!T+H/-G"1A/H3P9PNCLCIZTC1<]4!M6E$+5=8XR]M/ MZM/8DZ*LM&Y2X$4!D<$!W/::4*##E:PY*5H!68RJ3!?FHH7D\"7'B9_C-:*C M3H&V[Z("BCMS(9JE&R*_CWUQ:F[[V>=%YLLDHPO#F;^_/;RG!Q+BHWK-"-K# MW@2NV6V"T#I]G5>KF8T-[E-?W`#GF5`++B+>T]OGQC7M=#P=6'?&!_)N$\WK MW4?M'3JS`^X^ M<>N+#Z0?V.^%LA_I#CN^&R]]P?7V5!AYSECAQ('`#LT0D:[S^%$0IS\8<\)T MDGI/9,N7L`;DX2PQTI6*S)>);F5"55U,2')XR[E8(\+EX>$4=I!I#_L=N)9* M.12IPN&S8A;B6#4H!)9DU).Y_67Y#P,,,=^A+U##C(_3R'MR) M.*\RR)V!@QGNT)>082Q0#W9S4D@#S+3'T,$=^!(^Y0&5+BFX+F)7BO=B%J]EM?"J3@L^$NUBQDG MW*40@//DXHU@V%?;,#7C73U$W0AY1YL$E5-&JM(ED^"^*,S(-ACWC;NX$6%7 MFI@-XD\I)0^$E;-DT3$Q*=*I7N""Q%FB"S^#IY.6!PB;X+EPWE MR),P(T6I.#=@3[7ZRV0Z4V&!ZKPOVT/C4Y9JWH7+6,0E03LE[VN08&CMZ[\P M/6'JE"H_!GO+@R.P9K(X9N-.%,:5CSTIP_0'6Q?X,FMFCF\\[JS>I;W.](?C ME>E1`^`:HR3(K(&];.MQI^'";?ZK:NAM1>GUP6J,XY)J("K)4-R)L?CB\,+> MKJ5XL)KG]^!LQ]X:"<[63^:2;ORVO\CA@[S07>";XZTA8'R64JWF=;84E.?E M&.532(E'":!T6M$#E(#R7M23Z@[6P>!6G'2_Y!/`_WIK14YWG56)`)9['254) MF(X_)95N1"5'GIS\<ODU(;Z0-)=W! M4@`/W4S4--S9)XX5VU]6S`KQ*\!I0R$AB&L:[E@C/3P<5,V+M,<,B:SHB7>@ M21NJ#H)$3<,=6(R[ES4][*U_65XK4>=L2+?+N7R2P%'&:'70E,-`W'&H2\L? M;?+?$S&U3WHH]QZ;-K0@+=T>]>!"&J)*2&&E%_`DG[U4'G=JET7^@WWQJ$MPK-^)JU,ZT($9-6K>#N.HG M:\-#3>B#-2A/%EL[K0D8U)YG*%LUU1.HFBKUCL-5D92T5QSF-M$-]U'5O*>A MSANJ#EA%`$]@B7H3PV17,+PQS[LZ!:[HY$:I)MWDIF4IGN_EX/=R\'LY.$`Y M>&S_9YJ=?3E1SZ1KH<4E(9G6!7`)V4<:%.`N7M:!/11AJP=V!.C` M-=Q/E8V$*UX?4$@&.E(%L`BY[C2) MZR-=G[S<^855=/R`E:X64`A M),Z0`[;0*<;-<8JK0HLP&^]]T\":4N=0!(D3",`4DH^TX6"&:X=M4KQ`1"5I MU10ED)">`4](.-9+DQR+7M3?[(C*#3\,P/J/Y]$$"?4B0(7\(XW3)9=9+78[ MHK&:DHM*JSX8_[DTJ<$!BB(5.@#20-W68NVP#/4'\VB#.%MKJYI[X\>!G$-4 M+%#A'6G$>W@)CEH#C07L#1E$&H)[-'X3??ZFVGLRMS[HL71/(A/$>^4E#5,# M1R(6A:0@C8SE6BW8C]>LF"\(#M/5`^[]NE*:85]W4Y`,'09IT.W2S!F=D<[F MW2:JOC+_4&V#!8;7?I4L7#VCH`ZU.X$(.B'=2.-NEP8]$$>SC7?_*&*>`?:1QMZL+2JI&_%0_=5_>16*0"UMGH;63RK4_(!!I MC.SJ&E+8"R8$*>D9XG M-\9?9+4+TXKMWD`9BY\=+_^X#C(2M0]A1WHH]-^4?+1LYDY3YZ=A[NEQ1R.> M"3DN'B<,4\=:)V!12$HC@F/WIKSWIKR@[U,FW'(%(JS@16-YA*7:"[@3E4:8 ME]WS].XKGC6`9["I;'B!1&8>1N-F"I5T+=A,N`\V2MI8\J36#%; M658#=K^_=R6_=R6_=R7'Z7GWKN3-ZO?1V*[DK*.M][SW+D*<"D-PL&XFT%L#S#D&4*[A0\[XT""GO0(?_VH9N$R76@!)BO.H#=6(?[!!N&N+^;SCO1C)U!].`+W1_PCJV2HOQ)4HL[ MU\HV]@8%D=TL-%739259T1-`'5Y#NH2M4,I($EQ)'/#0L00M0^YGR3D5H*U' M\4Q2D8D"942IB9+AB4*4G)-B`O:CWV>EF`RTD:G6"Z&,J,<+.?LT$?M1[-K* M/34S[O2OGYIY6LY7+XO6=OI_B[*OS#R9]'^2K?J;R'MAYCSF].2^>7![/'8' MW0'4VL@767QNW8X7N%9WT*O0"&DS2Y"2<&H)F(]^?4\S&6AMK-8+*S.B$B_D M+/`"YJ-8WTMP"'2F*L4AUXQ'RR;&WIRS.]SV9W#BZ'85L+OL/($@+IA`Q[E1 M3;KAN$]:U#;BN(9VJ;TR[,)=BN5)K(.W+--Q)P^\VYM4]IK0<_Z);(C]86CD M:;T)'7`$UU4_0W8=9(K#@;O:P#O@3$W]F:)V^)^3;3BZX5UJ"N.)$[@X:(;L M.F@5AP-WC0(UV2^ZG],CU.?.LG^IMAY+<`XZ([#O9(;LXE_\Z<&;<^Q`&(2S MN:*B)RES]$+)-;8$S\Q+T/FN55$,<&\+@CU-JBT4$O$KP-D#UDAB/FMQ[PNX M1GB'**\L`B@PD2BU^.HB1&:5YD@MMA:GZ=RS5!@/](&7#..!PA9U^6B5YE3I MHYQXC#@>#0K+$&<;O,BD#'JW-]D2/GC7?RXSQA?%Q(#NU94(4PH>`!)!30[M M75G=A(O%&3,(B+UR"YTL`D5L!UP%I'$8L_CYW'J!6=V_?5,W>RTX#R%A/;BD MH(`RLI[K%8/H9F9S]/\R3_6F0")Z9(+PFF?+<1XI;W.*G6&>#'._HM.$M54W MG1FADY3$I`;'HK;2&?;`^G$5UPO6<;DQ1AD0XCX^!K:8>V9F?.5VVDJO,P0+ M4B7+K9QF,0APAY&3;6!=L3QGG1X.UB__H=E>9P16O)E'$T14I\.$^QX6?^?E M-]=6AF/>A47(C:>L!N/YJ!4$`7?#ZN^F331K;QI_$9T:-",F18@]+3921F"E M`0E"*V=0P'C<#>(3#'@@FLVZ%CIKXIP.;/5AVXE7IKK??)G^[JOE>"AZUH[! M-E\R-,3B%X5AQ?U,Q!F;Q6_U:)C>-^F54&78NU7,PMC/Z39SI("UMLZC24U[ M\_PP(7\A)L'7?8>F-GL>'WJ^MS)R4G*@:P5?%2R+0C90R%^$2MZA+GZ_&_ZQ MDW7Z]LXF<`]S"ZN!:`N?`A#N8I$8`*^JH;/E"H[9*V'U+=RWQB)_W8_N,US[ MI+%N^^;>?ZB0.MF@-P1;@GD2*R7:3;;U?Q_ M_SF;;A8/K?GJY76QW$RW3ZMEZQ^/JF&WO#[CK:GCG(Z>84Z16S8;U])^SNBW M29];QW=B.M["Q<;WAH^-7O;NS90MCEOZ5UXNIM?O0Q517`@J'KC>4!VIY]1K\3/%OCR8X4,/77@VK&$M']\0C,;@B%)^,9S(UG@%=5B8YS[W2%JM,5\(I3 MMM/5O6'1O6%1X9:4ZN]+K<&BXQ>2JN(DP3K<)28;[8WHIP-9[8IOJ/S"L?X0 M[D4@:5H67U!N-Z5`MN8_C&1UK8)B^'SMB@]-$VJ"F_=V#3R=*2_>0,01Y;UX MDX5'$AQ1G+4_'DQN:WH6_EU3N*BLGF)B[7A_'RT"8F_.]Y6ACVX#C'@ZB.:];SF"56RA_S,(1.* MQ>]WHKE$?S`^#)V8>@A%%ZQ.#US]OY$C9[&'N[`?!(H_K`,=AKT%RL`((CVL M$Q+OMA)BC^;:\3=T[4P^<=<_58&)'SGS,`$+"59GQ]W';_G$?4?',_A'-B8_ M\F#">KTK;64P[,"NVR!Z-\"'P?G"_7`47/U#70LP5+$)'SY6XK?R/>#2N=C&IE#Y?)G7,`UG)J4G-BD]Z/W6"3C!_$?T[ M'=>.N0=S*.IY`1CDU38TXN44PJ#E:%A7GK"@CW44(7I*^8'L=N2XH8<(+,(:^ M[!X,ZDJKV+_:;,<'7A-GN_!%`EF,X;]'(-7^>.QFI%1;2E-69;CR&AD;TYIJ M;BHX,8$M!7G<4[0X1QJ57[QB1PY!E88B:UP_I.IC_2)VH-G18/VU>D.P]E20 MFB-?/(1S:_)Y;&)Y3T$4OK^_7Z,P@GMS!U#SO[DWI_#8Q!J?@B@L3TR1BQ!^ M$+3WIG?%N3?I1OS-?5R,W0:4^]RDU@L"<@O$G\38O[E$GWX06]V3-6$*L]8U M=(=KJYI[4@\L#]]E>7@%+AN+P\B&3I?Z@8M[1Q,KBZ``N_B3&=D;)D-OIAY8 MRV16VS*8P-Z,0&+I?6+)\I,FUD"5_'K'BCAB7V_`ASZK,:*AZ M2-P"D;9(^(61L`&YFBQKZ,1`X`>X&[Z#Y?6:\!TH6Q[K[R/,L.=)KZ-,.)/_ M!_^MI,L_QC:_$JB\Z'[`M;SV(M=LQK:_K)C>'%=-8^S\QTUDC&LY[CBYKS?E M)>YKG*=_4CF+_KR1K/&MKSTB7*J<7%$X78L7WUX6RVWK:?FX6K\$E>3?B+6W MU?-^2C@V2GSTV(_+5H>OR0(NIE2)#V0@D1V6X5[_":5(F-O2 M>(M:C]\B@/L3N;1,[63;[!*,9V-;Z0XG8#YY+0TCAVF((/]XEH("J)BJ^F4H M*E?**3LH1QK0K1)X95D1U6J?+:FU827!OM[?-+?V2P(BX%?!P-POX6*IZGI4 MQ?=??@'R9`CVRGBB5*G7KJ20'%THS0:J$9>C_`D9MR(\^HS&<-VTDJ26\-S; M(;_9UNG=6>WF[*5.VR".]X,H.M(?`3;LR*V.#%\7)O/LQF50P[U?%C8M"K[T M1X#5>;G5P>T0/-1P;[K%3;N*ZW`.60E1K2(BD-/,QZ+V&%=IIE?N&[&]G\:L MXWSP2C!]+0(MTVE8("_X2]^&05TR+K5?+;(/@S*DU#XLPU6%J4EQU1L,\-\_ M3C<;ZB)LY1X)94A]'LF[72N``8H[LF53/CVAE,]2M=DKN!]$3H[G/%S9K,[" MI*9\_FGH)#CCOZC_L>SP;!^%QI11#VQ_+ZA#\?F8+N"5V!I%5]V3]G@,E](1 M54+";"U*:CAW"^"%^T";"Q"@L#BXET?ANAM1L\\+8<[L+9L]V!VL+6', M;MBKX)6'POI5/3=2R$Y*R)1HP/9G32$M+K='D= MVQ/.CD7%H%I4BR.$.TKT99YB+TNUX./L2`,#EXN8_[27,@9K.W8KKO@GD+4S M7>TN1@P.';U>?PAE0:)4":XH0,:YID/`>/0Q@"1[@<[,%3H?D`5U.!_GN"]B M/(KC?AD*H0K&2E&8/8TNB]HYQ_B$S19_$`E^)0YS],9JECVX#Z`7^E^6K',V M1R)\R,QUEN2#:P_NK:JT4QQX$1/L63G7-QC(UH+?8-':)7D$AD1#S MX'O3G0Q&>0H/.&/(JRQ(`#-*B&58@'L',[=L.EO8(T^^XHH"5_!U):LRBI)M M1+Z;R5Z9H)/GA==ST>4)-FDN/U$N1,55LOS&WFK"-:6:2&?;"UU)!.YZL!5$ M5;I>Q@I//;31?CA\.7OY(;SS-8CCLU=?HSNM$(.M_WNQ,H[\V077P" MLM?)KO`*G'.@C,'J$A.E2IB8>6D*IZ8($N@#^D+&`WWZ:="9Q'/T8]ROXF9PAAZP+IU, M*N_*KSAD7^9M!W'L*JGLD#TAODRE2B&>1O/-(0:D(V/>,(#+2,E0L&<`U9F61+H6`O+1BF=\UL1DSJ#*X3EO<,NF!= M<+.$2W!=<:)"1\V!".[L[>*_)^/=2SM;'\&<8WU[7HC[9NE;6S6=';&=*"?- M\]ND*QDYAJZ%Q**VXS[^+([O!^N3$+KJ,ABI'F'2>M0%*^9($EH/K]D(X#[] M>+TC+BP.5Y6A`O8B6)+0>M;7;`1PGV>^T0&<9\MQB+,R-^J!_M?.[X$6KB>] M'AB56<)KH30'(N?9*;]03@*UST1U2'Q/&[IF?]+GA#T3OHX)H]1"C8!%@+6+ M%33@[G0Y';A9SG^Z77@M&5:/K=?UXH^GU??-\[];3YO-]\5#:[Y:;E;/3P_T MEQY:CT_+Z7+^-'UNG?]JT_K'N;3"8;4"*WIP\+XW3M'Z@&"TU>[5)A^&=7(. MGT^.G+Y-MAF!5,Q"--[IS]\LFDFUS"SG[,,^&N%'$$HJ4V`QS6KW9^LD2"%H#T9=WEE%@EAC=2Q MT%(GC`#N!RZ]J.G2,JW+M86N*_T>7'Z.+Q0MUP(@!2Q/<+(BT%*:"$A()-+@F@0TH)KKUI0HB-J-""H0DQ_6R'7!6@Z75P_' M%$IOPUL>^7#:#1M_;\?;];(WG&WRQFH:/TBTT-!59[6CWQ$?&/ISF^6#'XC_ MW],?CFNKFMON#?M@W][RZN%PR*3SABSD0X=$&DG@F!F:V!Y.%+#;&BERT?J% M&%8AX4@C#@O5-NEIQ:%0A$_%&UI[/.2]^B3I@\Z3B);D+'Q">I&&&J[5?S`. M)Y?HU`"XRW0),AM#\2U&86(%&*"+SS&J;T>AVP6\`P.DOP,8!]ELA&0@Y/N,MU-AHQ5:K1=]-Y)YJQ,X@> M-B<:#,"V%HE2RQP._2&C&C^_X231P]<_!WVPY35+N(0Y($Y4=&@31J09/AK- ML[,!`[A.F@E":Z4R!0'3@7[&/2Y3BU])) MOND&G`!2$VZNIM@`W;0Q-]%%]@I01I3:*P@V<4REY'H53K,??8>X%).AN]96 MXH501M3CA;SNM0+VH^@!5_IR$;>A:-G+13/UH)H::6W>"'&KOE$4"/=D([A' M=$\/WM.#:-.#C<\.WB_Z\6*BSX;ZPSA0!R6.'UASO2)!V!OXMT)QS*6D@&0Z M2+B/^@_4_`_OM72.%>/.`.QAMS3!:.D61`OW)3*>NRK#(5AA0X/X38<&]SVR MZZ5H:9E:M!H!UZUPY:*E60PJW#?+8NJSMWC@MA\Q06@)30`#]PVRC6MI/]^L M`]71\>O5S_G/_F0,]N%-%HN67B&D<%\PBWDH:Q]P8Q!S6[A^"UG2T3*?!S;< M%]/\/D_MP1CN[J\O`BV7-PC4WE#I7FMQK[6XUUK<:RWNM19UQ\'OM1;W6HM[ MK44SLMSW6HMF>N&]U@)+K44JBW13NB/T^^"?=KV6+&VEKW3!CAP<@5*H$XYN MA?QE6(Y[*SZWCD?+C&D^'(_`TJ37PNKA*\5DW'ONJ:X;OO17U="?S+GZ;KCJ MH3T8PCT/D""S'N:R`<"=PERS:BR3Z.'%LZFFG8XGKWGW`\5*8RU`!OT!X#M9 M6?+KX34?+KCSF3'=16Z44=^%RX'EU*6F25T8,-R93E[4?S@<@DUND/1(`3[3 M[:X]MUFR8+@SO*X7WGQ_>9FN_\UJA3=/WY9/CT_SZ7+;FL[GJ^_+[=/R6^MU M]?PT?UJP1P>"@`I[C9ZO3^NX0O>5:+>;[)Y>T6%?#EKU?K0-=78D3!7IB6C&EME:@TKG/ M8M1=L6QM\?R@.LYYN)6]-O9O;G#RF<`UYT\16_P,ZPTZ#<8\OSLUXGW*$]IO M'J>;@OPXPY2?W2K/*2-*XV&&A8=D4W`?5;CV>E&0"?T2``46 M$X66G-*!>PJD^X$'!0H[25,E7PN<],HO0)> MT'\*!"`$6D6;/>N@06GVK.-\I:KDI4$?.[^FJ2]J3;`4O'BBHA MZ)]X\/:BSCU5:&74JW)`Z!$"*`+&YZ0Y0T7I)^@P3:UIP8Q=SKD!;^P0>:&O5[BG].$: MU>741>:4K,RM;C=#>7&O/1&35'@>_)S]QP_5(?0G_P]02P,$%`````@`XG5+ M0RKM67=W\```&_X.`!4`'`!B87-I+3(P,3(P.3,P7VQA8BYX;6Q55`D``ZA' M6%*H1UA2=7@+``$$)0X```0Y`0``[/UI<^0XFBX*?A^S^0^X-6U6F68*E>]+ MS6G>42@4V9H3(6DD9=5M"QL;H]SA$CO=22^2K@C5KQ\`W)T@B9UP1=H]MRM# MCN5YP>==L+WX7__GC]T6O,(P\@+_/_\R/!_\!4!_%:P]__D___+[PX>+A\OK MZ[^`*';]M;L-?/B??_&#O_R?SO_]__:__H\/'RY#Z,9P#9[>P#\\/W:?(?CL M;5'="/SREW]\_LNO'SZD)?=AL#ZL4-'`!Z/!/]W__V-_S/\R!\_MMH,)C^+?GQ M+UE17#4O^?W[]_/O8U)VN%PN_T9^S8M&'JT@:G3XM__KZY>'U0O77?_-US@;UOW"6[_ MYO[PHD]PXQZV>!Q),R\AW%0'O-8`^H:CO\%M'.&_X-:B#_A/'P;#5(K_!Z7= M^&V/^!-YN_T6#>G?)(&O7ES_&7[!_XV[5@J^H6VU`FQ"]WD'_?A3L#K@_R6T M4BI&:P]ZA"%CID6(2LO\X(\U:)F@7\-]"%?8BC4CKU3=AN%Q3:S`2ZS`PQE! MW-"F!LR?T/_1@;O6KC+L/GP6&>RTVC%B6FNJH=[!T`O65[YBS/1F]8!_B-VP M13/%X=<;5BW`8Q"[6[70ZTVJ!GT#%8_V<8/*1QE%@-R&I&.4:TTJ!"TPO'$= M)^N8$@_W!?U76A*WV!*9)5XQ"39++<,?,?37<)T$;'G;P2HM17KYS[^@/_S_ M+I"_6Q/'#:-5Z.VQVSX?3L;GP^'YK-FY1G!U_AR\(@OO)7X5_<>Q-T5_HC9? MQ;K%06X09L-0&8B+,$.\"8,=!^`X0(7=)WKA^5]`$*YAB"8A?P%[9%M"+W[[ MS[^@^<@A0H`"4LK-/Y8;KCJ^0EKB;ZL`!?#[^,.V_JU1$:J$1Q^D!3(''^K= MAS`*#B&97>RVJ#<\Y8+^A]\?_@*\=6N_3OYW4/KA?_VM@,W!L<];]QE]JXEJ MYJZD",2,_",4XT51@.K^=6*6S?7VCIWTA]!\BO`/P/T.\`%^%B8 M368O?!0]QVCTK_U-$.[(W/;B*8I#=Q6?CY;3V8+"R2@DHK-L.E$+,H/1Z,3HN$1;K,DK'9>HR#Q\!($S-?'DD!M M-E1,OTK[:LC7#OF8>M728[L#RV;0IDA7Z[E@7&KMY,+)1P3H?#0<*:89;E8- MNZ@`CTE%"HU/PX;E6$U1*.NP8`[^"Q]=DLCO$E4.W>VUOX8__C=\.Q\N5(5J MU/;E",0&.6-20^G!T&I.M:#6S:[FKIUTFI#^!LB/`/TJ1+E@MPO\ASA8_?'P MXB)8',OP_&W>_NC$ M;HBOC0!RHJ:KC'D1D)01(>AG;PO#2Q1//@JEK@IK:N@8SO<*@NK99=V M+QDV03;#N5J_&=7(#R#[181@=X>GK;?ZO`W<&'VOF5)ZE=I60:XVJ%5JE4LN MER=`K&/`9FAUU&M&JN3/@/Q=A%+W\-G#J]!^?./N(/I4JA;M:,VK(%8'X"JW MC@L/[%XS:09MAF.4GC.>%3\!_)L(U?X1;`]^[(:)A<1QCZKC*=3V59"M"W*5 M;<>EE[,38!L-M!FV47K.V);_E#A-H6CLGW"[_=]^\-U_@&X4^'!]'44'&*)O MJ';FV]"/"OJQBE"E85.MY2G,=-O`FZ%E"X*,GKC(AS]P&9`5`DDI/J(^ABZ> M##^\[9Z"[?EPKLKW5MJ5(V([Q(QXU5(SN[UL':QN8M5Z=-*_@.1/G.?P5JL` M63R?4\ROL=RGP7X[9E/ZYH4_)PWJ,1H\;09ORGPV M(BB(6A0Y`ZB0I#%M_V;WBS2Y$G[:X@J3;)@N?O.;A@W$K;9[R7$:[ MAP>XOO97P0X^NC]@E/OK:>>=4BEVT[N5 MIC2K-"4B-U49V[V*VH'<@)5NZ=Y)?P;)[X`4$`^5.[ZJ+@O<#T=IQK:A"IE% MVWTYIAN\*;/:#L-)F1J[/X"+"[M;SLVHM(LOGOOD;;W8*W_9SDNPTCRM=ZN$ MIRS2'/&46L7Z!8@VY(9L:4/WN2TM_2YG2EL^JDY3:IZB3::44H68`>OW%SK` MFS2ES3!RPL(?>^A'D-^.'G:'+4X48GF7`W-++\6)"2/`:O-#,WF;PK-UI-1CN_L@9=T6-U0@-L#RT*4#NAG;V@ZB3-$] M*O`!470E1-$H@G%T/ETL-)I)THRB1U(>4:6GTVH(N6P-0UY<#EHDO3ID(RZP!6F2[[G-=5YP*#2E0KV M-,*NDJC8T;/]>CH5KQF34^TT-3WB6_O4[Z,G>-).JWJD=#1B>*/8\L"=CMA, M7$3M6\*YY0O0BWE7K@)96JE90F]'7655OLQK>T(^&EPSIJK29\HCT;T:ZJ?1 MI)%1#"%7>-[#];@<5L,&`ZJCK-*Y:I>?69R-H@VW4KE7[/K9ODB%9PT?4&)F98V)#G$8]UW<*2PY-P`U&;0T0 M\FSBB4G\.V<:^V35ZPMT(WC[M/6>20+GW/C.)N.NF[OBG&SO6XZ[; MZPV7EM\L8L*OVX2R@'#20H"4`J5B@N$CXQ?78ETM8'+-X'9^A,'(\@._C!(8 M,<%L6');3#*N!3X^RI#N*X`MX7F0UU7"[ALTS@41]%V2[^Q>"\?;I.N@>:DJ M,C=V3[581>C);!_C:+/<15E=]#9IO\W3F]6*5[X),CUV9RUD%Z)/6UZ'DS/] MV':?H;]$4;X8D5I[7LI'+Q?^&O_/U;\.WJN[14U%%_&E&X9OGO_\#W=[@.>S MZ;0K&:(,[1D@R%)?2,J"_BS51\.%W=N2/&+HM_+,6!Q<"+C^&I#_*!4_`VX, MLAJ`5-')?DU&WS+V4XP_2W6R#F![),\CB"$GP`&I4(05_@]85.!D?9%D//WT M.K?-CGN3Y'(G]IRVQR5'<\OS!C4@UFZ*J=TZU0SSY)>S)`G?6A'=]-A3,W2K M6\GCDN20G^53OB;,9FQ?0^\9\R+RJ,$9\`.P=T/PBLO\'5PZ>8`C&@S.`:41* MS9+R]>ECI#J M-H_5[ISLG[)LT6+@=+&E9KF*(OB@I]U6JH;5B$4Z[E60.*544$6N/?1AYAJ/ M>%'[E*,4JQ@9O^CE%[.AW4N2;;!UVZF6OIUR?KM*&E*A`*[C8VJQ;.8Y6;-Y M#>7Q9H/=*S7MP(U8PU8(SCW<'/PU_E.:!P/GM^.=$5_[,>K90XTD)V]O8'SU M8[4]X'7,PA@/AQH/7+%`D.6LD)`%A1FJ+T9!5^%4G\3599[N(3['=+-5QI&;WO08N.0Q9=G9$91UP4QWP(7?T\8HB MEB!\0SVA;ST9Z@R$BZYDZ=L*NJ!IJ=AR-K5[(DY!J]_>'G?IY'\B]E0%ES29 M2+UCGL"PF5\[*XZ&%K^0BVK"+JM(",.IU2.G-E(?M5%9RV7_FVA M59.7E%Z=N^'^%IL//"B0ZXN:$E8+94#VIQ-OO' MPI-@NV-P;EF,Q.>\J&KZH-0U%,F39AH?N%9]0(5)``JE\\*#P=+NI;%FT`;- M=;7G,A$%]]K:OION@%L[\=J"ZLIY2;LO"K:@-ATX'_5_E'^K%#++LK#D%\?Z M,IXV]ZN:E,WR-'.S'(9-3HVBQ^#-&\DC!%1CJ2*&;?K"NJ-6TXQMBTQI::A& M=I]:8$!O.OILP)$GD"G95\Z,7E\\'T:WF\L0KKWB,>S10.-#'K0N93G*)$1! M3UKQP71I]^V2-MCZC6ACWP[^#9]K3GX4#C?;/J$FBVF6AQ0S22N.`RC;)SPM MN`V9QF8$SCU\#;:O^%S+-F7FBI3C)&3@/S_"9=[U&2CDPB MY&RDE1X.+#]CW8):NTUL[-K!/WU`_-X!_&,15'YUXT,H,@UJ^Y)ZC*-1,M9- M(ZTTUF_+][5:8)LQC,T`:-D&MSE/UZB"."?+R;#0-UT:L9&J\JTQ"T(C9[D" MTGV[STVU`S=I+VN]UTQF<3I5I?&D?5_M]M,445NMZ'&^.LOGX.W(C=O2.H82 M8=>$L/(Y_LB[GNEAUE)_X]%(WTE3:I]R-&45(V-I0_G1;&#WTF8K;MW&M*US M)WDY.3_L+YAEM>,[:C&;YNE8,YH-Y?&*F]W!9SMP(R:S%4)*2Y&W6.X0Q2!J M;%W.0C49CL;:["*E1SD:LHF0D9!>>F#Y_:@6U+KM87/73OZ3@AQYK5]1BT4T M2\2:-:26QLH\MY0L[RA7WG%>O>'9>#P%#Q#?#P`7 M:2&<"N\_ADFMF#SUGF0;X4ZN-SH;HM85)-9#,N*GDJ]^[*$?P7PI8C*:Z$L0 M1>U36EF8Q"BI"[V\Y2_AMN(V8+L;.W?2'T'ZJ^#V4L=WU&6Y#=.19KUIY7$\ M9KW];@%NRH(W0\AI"9.?N>/98`_#^.T.]1Q?^&M\G'2_0^V3BV"3V5+?A+^M M:UER<@E5<+2UVM+R]WE9X.LWH)T8G*S,&2"E\N/ZI)S`#5:VKZW)L/9+88J9 M;:N&+8;=)TN8\!LRNMU(#&P_&!U,VC=MK>Q9Z?\RU^S^ZL7<1QZ3X>8)(:+`W#G M\J\XM'U.+?>G3/*Q=G^JZ=*\W>=A6E!SV$?Q^U/-_:?WI^3OC[9<6ITL%_K6 M8G5=F^:1IYF#FW^\4)!O1&HM)N'$>$3NPNY\6JWWUWAP^!_1O'ND\QWFS&KZVDR\GGP_EP MJ.^*57OGK`]YJ=;%86E@ZI%A3-[.FHF^I M;MTHNMV0.=VG8.=Z_OE2YSOJM>[D&,P`/W\ZM5YT-+4\AU4C9MW.O:ECA_R` M;\>2G\"WY$?.Y:K2H]DWP9T;9J^23_7EK*)V*M;HMJGK1MUO6XTCPQ%':?E&+";]K6-B(Y,KG9G2]5%$XN M0N*/;20X+7>JF+I-DC32-JTPFEN>S^&]`@%W8AZ*FAZ6]RM15]XIG%MJ:5GQ81ME:F1M>5:H_GP MQ'A;1V_C4F5@^0)7%W3=-K>C_WJ^&/&5U^X/:R!G MC#F6=F2/.5I+G-C])%4G=B.FM0M%.9F,[()LM2_4TVWX0++)D![O8$B,._[< M,ZU)7!A`J&0RAZ!T7K^C!9#=AH9AJN5T]6K?II@/Z\AISV#1WK)[.C0*U43FO-)C;G:NF&WP? M%KF"H-$:RR?3I7]A8U;8%&69K&]6"=L*N\].,J#OS>I6<31:7)$M0%IWE47O MR7"A[WIO1^_J2=PN6AN3CVH.3B\NIDC0AQFNPVBTQ<)[@\R?WIA5-L]J)OM< MV]^R^ZX:JPB]66H*F$9S+;QEF.1,OZCV_Y4D.3^?+#1F8VCI6([47!+E241: M*@WGHZG=,3(#>MW6N1N"DZ?G/S+1X%M2CCOWC1M#?/&N?&?IXH<7G4^6LY'& M'$X-W4JREEV:(O%-4Y7A?+&P>UFY$[MVOG8`J%UXP[^),O2+Y\-K])_X8TX- M4#/O3Q$G6_#7R%B410,YLWN>U@S:&/V.>W;R7\`W_!L@/XH2[W;SV?-=?^6Y MV[L@\O!@EQ)J3?4]V\R"0!$YN62LT;6M-KE\;?>Q(2XYC)&:`8QS>7OSZ>KF MX>H30/_U75^#AOZZN'A\D$N.E4!YQICW,`XV1;*4O M1:QNP%WC;U(.VPZ[-R/H@(TQLMQKV<22OW-RJY25.Q@-MV8Z-LT8T8A1TAQ83.JLK:`+.+C&JLUU[RB>Y<;WWM7[I[+W:W&4-F0WWJT-:SI`IP"973OK76S/)5#`;T MVNG="<$IB@!L+Z'J^#9)RV>3V<:KV`9$D)6Q7H:Z4);S0"86Y[DV.@XZ/>`YH1Q M2IWAYQN.7"LH7&MZ[N##$^X4E'L]2W<4TH[/0-XU2/L&2>>@U+O=)DV3K__3 MI#6/M&F3AMVOY4]IF!X*0T&14:&21SY`8K56I=:R-YW5&Z)_NF'H^G%Z+G$Z MT[AWSPU'OW'HD)Y'S:M-S2T_(RLHD0W11!T63UR0UA8Z'"[.J-YSZZ5W]X%[](#:]Z1"))SOYY/WZJVAOXZ20Y?G ML\7"2)+5HW[E-(-''DJFG^,ZH_GI9/FA8]?M)KH`5!)4@;Q(=AI=.5MUYZ8R MS=:VO%1'=4@NN]GI9%5KA&_$"#,`J22E2B\"@4T0@G56X6\[]P_XX?L+P@+V M[ALVZ=E)=&%F9\N\@_'8A/E5L67`@)Y"W[3H:+8\&5^JQ95;*F_ M^8/IMI]ZZ=9F+W1_%T134)):<,37T)Q\+G$C"#`O0-9R)+9\V`&,I`.M$HIV"U!,-:J-:]6,3CD8%>.H M'>+J[9Y1BPG483JR_(!7.W#]84]+[T[IC,M1?B^UO-2R&=`++RD&F5X! MG\L8V'V-L`NZ(1/;"N(X>2+X`,+B!#S>Z-H M!#X*HSX%.]?SSX?SN;Z#+=0NY=C+*$7&77KQZ<+RIX/W=ST$(O6?_\H`TPE^]/8:N'[DKDJO)7Y-_;V;JM#?PMEG:G!^071K?3XT943^A>5`)%+9!6TTYXMN4@>PG? MD,F@;V\KV\.<'X4NY<^^84Q MM2'`C/K>Z/](JUU^3ZIOB@B&J@?^RJMR!\?%-PQ=O]4)^ M2]]<2!L^`VZ4U6$F-:RVI5+S.E'2=>VH M&OGN=A]D9<)O-G:B@ZB'2TFY_`ZB#E**Q$3F2=D1^=#&T^Y#0TSX>XAOZ$@H M(9:(S6%XA;SW.R*3NI#.AO8O5?%A+^?&(0.IC'L<$'L_D`Q0!2'!`(> MWC6^`A.]>)LX_7GKN4_>%J_9D@B$A`@OP19]GK]&.)_R@1"?_(8#A=9@'D<3 M1Y&*5"R17F<;+\?ZKI>I?\>)30:ZNF07^"9#R\]]ML$V&TY4^CZ.(@0O/;9^ M0@//Y6FG84=(4;I'.CI%'J:X>P@AJ@C*=)2YA'L/8]?SX?K*#7W/?X[RG.P: M7\*A]RG'258Y,E8VE!_.AE.[MV?;@>LVD*V].]FO(/M9#RFUF,D>2%DSE4VC MBR_=GR8K4^1&S&4[ALHS!FL2:<:BSRS6WR*=34;ZCK(H?N*6!7[^J%*]['PV MM7N:U8A9MW%LZMA)?C@3?W"YY9,-!Z=-N0)_"^?P]7.[MY6;0;.S;I_<'8O= M,!:S@(T@G(_N%B_"B]TI:_MZPQ-GWY")?;/1";*/@.9EWY6_5L@]#$&2>]G# M=$='`Z/T(>#I7/\CAK2N)1G))U7MB4-JM>%\,;<[1R43?NU>F@%$[;!I)/?: M7P`MY_!PW]=W%_]U^V73U?W#W\%5_^?WZ\?_QMH5^N M;AZN_W$%KF_0OZ\D7J<]QHB<]&PVUQCBUGJ450,6"0K6UTOC6,WN]R1:4)L, MXE+';S8Z1>X1U.:"W$8,$LQK2A]2G`:[W5P6)[8> MX`H5C3T8X6\\UO>`FAPX!816.3`5[DLT/%\N;(]"5`BH/SI1@-)ISHN0994_ M*Y^'#S:@U!PHVNM':;5L8[P'I:WMB\@VC).XVYWH69&$1O99U&!UJHI9.MR3 M;&?'027#@V`Z+,;$:HAZ(WW[W28RR0D+RJ1CI0;FR[G=Q_[Y!.G5T1VC87)H MHKE^>!EBWCWUI`I\[J;4`'X?T.XS^IR2].\^:IB>7S)9 M!5%,KI[\QW(P.!LMADK=!LE(Q!3(#&E9%;6J$!LV+9HE/"P="L?:[GQY"LMF MLO+UY*FX0+8Z,-*2P0D9+RU-.KP3TE96]\C:+KY:<))>DU/`/ITI'U3>J9@Z M[:Q$8P.-)^A8,.C3MC8Q6;2J,D\8VWULGDN./GW:,1@6WZ5X[M5$#N.>J!\= MX/(L1S.#DUR#:!"D=T]1@R0[ZU*G'XFRZZ,=+5'#HTY(N<5DTY:B- M^7)H=X(:;EGZ]!HT0"R>(RDBEG%`@##&/4B_^L'E28[:P-L1I[M\0!>F=X]" MA96_HIQ,*[Q$7^K/*(/*,\K*'E$\GRV'6A]2;NI83AVX)&)X+!&_OCM2+WE(C4S,:&GW'C\+?`[#'<3N5LQP,P`YXK=7?NF3 ME[L1:OJW(%A'%_[Z`8:OW@I&#\%V?3X?CFEO>JJB;E._LLQEEZ<@;F.=\7!F M]VW*3NSZ;7$[``<7P.:6%"'YZ[)"`)=23E=-EK8WNE+L;&,=;![F=E]%9T!O MR,IVX7`><>MD]03S-X2OT#]PGB`N]9)^U)&^MVJ..E/&3#IR"AU3K;=\NY<. MV*"=+'H],HY2]K#RE30]0&^`7Y2'Y:L%B7:>C%.N0#8R[V_H/*?:/@S6AU4L M8\\R:XD^VE)WB)CUI8)MS;BK9,O+C4<3NZ\34/&:,6753G-Z97]6PBN-9DPK MKQJ,6%Z.Z*3=.0L:$!LT8<=]YQ2+DA_$+%B6?N@.AN1,XTW`35O*2N]46YF64$M,(_;2"#$[;696@6C^:5(S M@]Z+W3P"X:3_EK:=GUTO)/OKQ3MXMYM_NF'H^G%TOER,DJ=()VP9_EM;DV,@ M-]",B:T5)Z/SZ6PZF=I]GHE5!`9F+A-F^O`9IRT5XR8C'.?R!=7&6WU'3_]\ M3XJ6TOGC5RI6(70C3O;^!GT8NML+?WVQWGF^AQ,%Q=XKO/JQAWX$SX>#T4)? M)JR.WN7XSB]:1OBNFO/%W.YM;38!=,<(3"BA: M,-%9$Z^VV'V)@54$(\$%(Y@*N=U*24Y2ARA"N0N#C1>CKSS6^!!`J2=)LK9" MSHE9*C5?+NQ>#:B#U6Y"CWMTR%]`\B<%'-)R<$(OAVIG(RJEL.+9O7U#@\MA MM,1//U`Z3NFT%Z!3Z:%P]+TN`S_V_`.:<-VB>11Y_BKZ"#=!F!YF>W1_P.BK MYY-/<>TCTPNC&)G/:BM)_K:O,'X)T"^O,'T>''W[V53?0I1!2>34H=\AS]3- M)(K%9&'W;H7YP=#M/SQ7=@J)?\$0Z!FDBZ*0Y4&KO+#OT35"= MH?D#"K80>3S?#=_`=0QW.%V[&,XC,1*/0B6VT%RHC\S=NDQ_QCW(&*C\ISC>7[QT72H.Y:J=:I"]1DD MJ6IIO0(>Z=DI!!3-T,VX_\;^V[+2W]Y=W5\\7J,"S;GH?_ER^_#PJW!*^ES= MTH66C^2!6CPYG"WTK8DT]*J"U"RB5%E=K[&8CNW>?6D';H;1#;UG1A?]G"TW M@U_2$IRWJCH_J)8%YWZX65M@;JR!?=MILC.#;F1!N0-$1E/\AC<4V17)@I)\ M@7HXG.LTF)7>9,G8!;T@8;7DY^.#EB_0:3TZF1_%=MU:_Q(Q^<>3HE@ M]:,0M:)8/>V^E]($V=!1AX;N"[H)F;,;&!=SJ_/A:#[7=PVTTI<'S.[D6G3`1F;JU*X=G.Y!XH9\.LWWGU/:HH;'@YF^!,*U_N1XQ@(_XQJE M[&@\LCMD:\2LVW4V=>SD/V3NDW.QIN6+:3%JY@A7,VZ4LEAI[8[4FD$;,7*- MW:?WU8.`6P^]MJ66;IC:FUE9:6P<9G.D[,<=?`&UEMZ8118FQF4/\NR--R<#H>+`S$ MD*IF*VPBU'A9F>&,9W9GIFE!;./Q0-]3JWI`2^J#J8',54I3AZ/YV.Z#+7H%U^Y:=*)W2.N@ M-=MJV@G(>@&E;LAEB%)'H.BIG*;5+A.C9U+Q$YJ8^GQ&4X?8@=E]HTFSY&9F M4EIE<#([LLKL2%RR&VY>3YVMR!`D>=/1W\F=VD_IW=IB=CZ;Z-L]E\>GSP2( MC@^+MC.V/1PMAI9/*I4)V6>@P(64)2@H?+OXZA_NY2;P@^J4!;F7R5A?CM6& M7A5H&9,H%=VAU1@M1Y9/<=N1&V%Y8_X#?8X8LJ/XTQ'2WT/L+3V+4=1 M7K$RHG;56UB>9I@)OVZ#R@+"R0J1^7ZIF-@!0\;OK<7&]D_CFKWMJ(=WL>R^ MY\(F@!';RP2E2N=U48Z;QG%X6,7D<:[+%S=\QF5O(+;!-F!@F_IV*K^!]$>5+-1E0XVRD&8Q:\7G27QE=]:9=N"F+&0S MA"-"KD0(^>!N872?I/8FKQC)K7X;#*U>R[? M!ENW66SIVR&_@?3'L^1Q%;+FI)*)>MYP-SKZ4O$>=2;.O;1H=.(EZFRW><"&A";-'Q%MTYN[:3,7.4;:3D8 M9H9>M0-AM9)8,>T.]IH@;ZSFXU]*J.=^VB MT/A7J3&;G!`-*A7E9"T@Q2OZGV@,\'W1,,;S?I:ROD)9;H]A!'L>NO4>.(S^.%OD4^3C1R[)07/:,O=TO+ MD>4W]@4ETFU95G>PIY-'0[K..0O+8XHS*H'@] MD<#[Z(([,'CUUG#]\>WW""*<>8:=BU7LO7JQ5\I&-M&8+DP'8#D=-C*$F:/4 MTMG<\E5X?4+KCE:U(7=*+8,X`'G;Y+IZ]6DZ]#/N`F1]@*DX?LD)PX MN\[Z?#9>Z+N%V-&YG*IS2Y:I;5?%X=+R,TEL`NCVSDPHG+04(,5`J1S("NKA MLQ9_9P6?:VZH^T,,9I;'J*PB&'$.C&`<_+1GDMQ@X_DN&H4U./AK/,%,.;_% M+7!>BL1.Y\)?X__![;^Z6^Q'+N)+-PS?D"?XA[L]P//9=#K#7!@.]-"<`8,L MV<7$+#C/4A][Y+'=V]9\@K#S?T]61!YB-XQ%M8`#F$.F2#A)`@EE8%$!N#%X M@L^>[^,P)MB`-^B&6E5B^'.HQ%!")>R^;,PG"*]*7/F"CYIQP6I7"(C^KE`5 MZ*N?B"I:0WMV)#KT@E7F=NUH:&4TFMA]'E!`&OW3`5Y(A8Z0_RC5.@-)/9!5 M!+]D53FST`N11\MU6,L5IG:/EJL58O7LSAL@)`_'?$/\!JX(,O+6X2_K3"GP MLE*B*)Z?>!R:Z^%7G<_;X/L-&GWTG]?^*XS(RI>__DSF.Y55L$]>M-H&T2$L M=MT6&I,,RH*3US"E0U-6.JF&1[8_&JI(0A/>3!YFXN%P.V<@;0GD31$5S1LK M[Q\5S0EO):EBJ*9EM/>@O)1U.,F&R<*2[4O/BF0TM)*G!JWS<-COMQ"O];E; ML"[4$TWB_,#_0!1[DZMRL5G#I[2?X`;B%<9D$^K1_9%>SOP(?;CQXO/Y;*3O M6Z*HX7EM_<8A-`MSMC0N%DI;(3$#AI?UH0_)(6Y9Q_L7YX M+7[&"DK7W$1711SA#^U>H6,5P8B19P13L#O=@H_='_P&>A_"E>>FS]E<[((P M]OY-_GF^&$STI6IKZ5B6Q1P2%0QNKC29+.W><.D&K]\8=R!PRB7.`/K7%N:/ MJ)6+DUG%/LDXB/ZIGLR:S'*/9*:8X^9*Y$2/W?-I%OB&S'`GD`JO"9G=4BE. M]GJHI?B2W-U+KE[<(8`O;@37Y^/)8D`[0_WD1AXAY6`Y'A!*XK^T-27)1RZ, M.2%;:HU&@_G$WFL%K/"U6]AN#$Y2!B2%LHML>3$-9"P"(HO96(!DH.-PE(RF MW6GCV`1@I^0Z6!W(2D#=8#EQ>W1('_S%P0W+6(:D:A+PS+@\?AO;7 MT<5J%1[@^NX0_^[O76_]B3P\D&R2G8^6\PDML6PCC1D:E26T&.Z"VBSUATL4 M65D^W>(21']@P('&R4N#M#@RP3%(*H"D1GI002NIYR=*ZOI4BWWT+5__XA+$ MS/2+!Y)S%R:+88C241RL_@#KG.IN4O\,/"&N^T$,<"-:^_0KS6,7-P8O+OKU"4(_XSY8 M)[8]?L%YG/=XB0+]*SD^FN@%J?(&8WR!ZPD2%3GGTY&KS0;%0[>;JQ\H>/*? MX;T;PUN??A3H?#$?ZEM;YD$BIUYR,F76M3%U0JVG".[UW.$Y#$2@XD@*ZD.S%0GQ*J3 M_#>GEGQVO9#<0RCN(-]N_NF&H8N[7"Y&<]J1S(:`J[4Q.6;SXLRXW%YO.IM. MIG;'56P"Z+;P3"@<7`J08J`H!VXW("NIA9MLL]W^N5FSL]V#.K-[YX9-`".6 ME`F*#KCBP8,#BX3)9="T\0TX*@5%(+C;7,!ONG<2T0::\W&@VG<[N#9#8! MC`0B3%"/[X=?^Q6J%IQ71G?OF/FTA(LMBH._1Y<[^Y11"1+Q,%;KK+N:6 MW[-A%4&W+V#$X5#2=>#5F:PP2$MKH[B6"-\>BMS(+H21B)\9 MCI/3>J^6UO=P!;W7[--/]2W!L$#01>Y6(;OY7:J^F"_LWN+GD*(_0WX,I=.6 M%Q5T\EY/+&\;\>MQ/$O]+,*T>W6>4Q)#,3P?JL+4ARI9C\^:?4F7[CT883Z, M]+W]P0)!`^F[A6SE_''UQ7QB]^(EAQ2]6'LJE!9K3PY$EBKHY+VY^+U'WK-% M\;7JV!+9?3"+2X[^8OD&1$[&]70S5IKHEXS"W/Y,,L@WFS3@?29-2STB`KKH_IA@QZ?TQG,.;UROCDI]T[ M41Q2]&3(F_`X.;M=1>S.\PK!ZMQM.1P9-.94%*IYSBIJ,]GI+2P6EI\XX!/$ MO(%O0=-DY8L<;E#E8DT'14RMU]B@#BRK-M0FLH4%N]_DX1>FM[6;#F#./=P< M_#7^HT3R-UJWK]!'%$NF=\NQOF,XK7VKIWV;6&U<+^HM;+_@R@*_#SM_A*'9 MNN<%M;#8G!TW2V,VFYU7S&S(J*6Q;PA;P?49-6+UZ2S9S-%\_\+4,;06HTU*L*P M=-/8!C%AIQ;@=$K3TU).%Z[TGE^$-:3T(G(40?R:FK_.KS_QOXY:2OO#7M_$+#"](IR2<,+GXPP)*M?X(#D2S,C$UN%@L[3_$ M#J[))Z4MY`\!8(4CE4%2VZS"F9J7V*]Q+#,9EA:S@/P]JEU)MM[F/GPXG4S= MLEUHHF\!T3=70-]N8(P3C]R%`4YYM?[X]GN$7TJ@O'YS/AS-)_I.'[$#D5,K M*8$S3>)I9#A?VKV.RR^,;C?%C8B\=DCR1V5U<*[97W`U@&_6T%Y1TZ\G6IX) MM5E/:F^$\C2"MV?MOH@@(`W'C$G\?5!^7$1?R*-DOZ"!7?^*KYKE:B/_3AD[ MH'PJ-Q[/]%U"X\=C2G>:Y>=7H6):/)S/[%Y[$!?*'M=SA$S$!0FOWDD03,LJ MW@DI6&U53^2+X^=J[+Y5(2&5D54^<7S.9XI_XES6:^B]>/^S$MR,]1W*90>B M16'8!.[0%&HCP_G\)&<]+<+TY'J:$76YG.(E:<6SGE;:F)SU6*$GK+,>:B,X M'C_)6*U-FCYG/2VXBEG/(5$1]/_RM]:U:T@I$ED8G^JTX#&E,,WR\^M-*?9> M3.P^BR`NE#W^Y@B9B-]1/=5A(9C)J8Z-"L8ZU6G]XCCH?B\.JB95GU,=!GS. M-<4_J9GJY&9D1=+J];`0S.2LQT8%8YWUM+0U3P+P M]Z9BA5A]SGM8`#JW%!?%/_%)KGWB5+PDA-&ZC5/T)D^'F%P`C@-PYX;(0HZ3XJ)F;&5O83*W^QP'IR2Z#2H?'";#<2/EI^/ MEE.>1UY%^I`DNQJI^T6AI]VET*;FT^PD)<$[N)W!MD%7'#\L6#8"D M!9`T`;(V3.H/VT.TIZ8_M=*$_0 M@]8P/H5[:FI3?SA7].N-!W8OY$C)Q:XWP`PH"&_Z\117_V MB?/)U(CS<=TRQB^>#Z/;S25JW(O/AY/)5-\1P<9^U>E/ES@T'3FN,[7\5>E. M["9C+!J`$H^Q^2=%\+-R22'E7-6RTMD?5UOCH*,Z>$)G]VV';O#&(QHJ#.=C M$(;!=V1,R4N((7P-MJ]X&PCU0]Y$7$F2ER15P&\PQF_X6\_U)31HZ%4=<=M% MH=&V6F,ZMSNE1P=RD^:UWOV1<4T2WB0E%)-S\7[(N6`DY^)\-%P,QJ?C_ZG8 MV0GZ"L.G0(5-I>$P-!-,GKK]ZJY>D*4.WR[\=>D]XLETH.]@,2,*==SF$Y7& M]?869F.[#]QS2F+24'?#.3+1623TGP(7)NDFBW[?;H0ZOM;VD!V;'1 M8#X^G?":298>?`,+KB/ER!XB%WQ[G)S\BM!W^1R$GX+#4[PY;+.'$A$QYF.M MP7=CU]+$YQ&JQ/:V:LN%]8M^G?`-V/DN#$Y>AIPXR$KEC]+JX*^N=8]>^4M; M_6BIAA=.K=_MZ<9O:@VD$\D1C]<9CUTA'M_#?7HTX79SM.HR'8WU/1_>V*\< M@WG$R>C;5F>^M#O<[L2NV_!V`7"*`CA:D%IH9OBX>LYQ]4?6^EFMEDIXF=3N M@[?=X!GXJN(\5B>0XGBBLJ7F2I^!__P(PUUZSNL+3O=[^[3UGLF69H0),-&W M*L*!1"'#N46F4KZSE87E;RL(2&/4B#-!.C;KJ-('%/?L\K='2#U0JFA`5PP8 M?^N4I<-!=#6#C9W=.STBXO3A1-B@5=S**M65+=&50*6N?()/)(J8Z'MII*E; M]4K0($P;X=,J"\LS<79![\/PE_IOM/*XC&J2FK/>)EC*9I=QG?3]AM%I,K6$ MOD>K6T52,K(;L,U)N^8F[<.+&\*/R#BO+X,=?E*#F.?SX6PTF6BSJ_1.Y?C* M+$A&UJ8*\XGE-]_;@>NVIZV].^37#T_X9U#^72TIM:PY]T'*VCHSO4*:&,#N M"SE=T(VL+G>`<*YV^VWP!B&(XF#U!UB5"F5/"G%2-49F'EOBVPW.]O!Y&WPO M`_NOA M]LOUIXM'](^'1_0_7Z]N'A_`[6=P>?'P7^#SE]M_/@AGX7G`.H*O#\#U$-FL MV5#?,W_9+'_U*OO/9PQB1_'8&]2[*48S^]0QXZPMZ=<^GH M=S^$[M;[-US_AAK#*4EN_4\P]%Y=?"<]0L1&T9@VN];1NQP[^47+"-M9<[&8 MV'WDC%$"W3:2#893%`.X7)9X"5&Z5%@3K_4L.ME![/H25&=5_(ZHW8?-6$4P MM!C%",],XWVEIE[E MF,PN2T;@YAIHG"T_&=^)7;`!W5_?@X;\N[J^$9T;'_3S"'_%' M],,?YXOY0-^)LL9NU9*T19HFEA95IA/+[X)V03?-T:/^G>QW@`H`4@)\PV4` M*:27F$7(+H;YW1Y1`E%-:3:.4J;": MYH<#R[.%JQ13MV]5B-4IMP6*QD#66G(/^$CQZR[Y#"2M]JG@6MSPNU/PFH]6 MQ";L-.P^9*Y64",>7"GDJJXG.XG`#V*`1C?RUB0;3++3B%K$]Z#6J1^'F;KO MD;I'QOWX%\^'US'<1>?3J;[S%ZI`]JKKS4.E2-N+#I#[L#M"5RRIY4[]"*XJ MOPZ^X88!:5EX5BTI&IF>G$^F2WUAO%JLJB;A>L:M/C=7TL]P-K/\)14]`IM; M2%.(NK+`ILQ4D!XXK<0_W3!T_?@KW#W!\'PZUGB7K=*5G(YVH,Y4K%ILN!S. M[=Z]IN+537!:IT[Z1_`M^;/DGA]9J#I?S)9S;3G7J%VJW>MKD*)IGX\47Y#@ M?V*W8>Y`SDY`J51I[2B<9+'3AS'`;[>)3H6HG92.Q&A\N:VU:PU,;9:JE;%Y MM>EX8?=Z`@M\TT!CSM+MZU*7WQJ[B#;4>=JF=PI61.7CRM.;;\9S":`::M, M14&UR]G6J2K+W/3EC=CF7CC=:9]K%;%5L3MW):L(O=CH!C!.1F5I.UUY3?GB MU?6VY+Q"<$FN1)'[5"_!%GV\*)DA#4=SC8?B.-'(D5Y>=.KSW2PM#>=SNV\K M"TJDV_:+P:*]29_5Q4=JDMJ@7#T-X@WITO+GU:6EM"[A)02[XR91D3@\3H`S MIIE1J00=S]?NNM,ETJ7Z5-Z^E2HM0'8BY-;'!)*1Y3BM0L/K\JY6T- M;<_]*2R3/:ZI"DS(.:5-&-,L+3.:T]&LVK1'H"UL-NT^I2DNE)&ID3`\;:XJ M3RQ!.O^4I95(4.:I=JYW>S)SFPSG.E^=98O-99YJ/RBB"I:4)E].28L%UGZMDG>-I)DWE.[%YG$)2(0754 MY*800^=\@5'T=U"H4I9PB#??[QK"'796#3#.A].!QDV4SO[E=$)$O"(1<'?= MJ>6;*HV84P9-*9`:56 M_!,J73+AY,&P!QCB(YP793402!WW3^@]O^#-G5<8NL_PYH`/X]UNDJ9N#W$4 MN_[:\Y_3=;?Y>*[OA!T7%LGCG9)BY^<_>=I)CYK9O;8E*!&[@Y`ZPB>&SLFJ M`3>I5TVV"(*B(I_V7/NO*/8*PK=/7K1"L_M#*1W3:+[0MR#P^'L4"7W<`Q(#!N;[YQ]7-X^W]]95XOF-*/Z6\`,/QTBAG%66UX!2J MA;9%M>7,\AQ?#.A[(.T1!"[FIC-+,]T MRRN*;IO-B:=RCS"O<0;2.@HS<[&217,N+KLTHR7?5GL3B=&:O@_=*(0QX@RX M83D/A]W.13%.24<\WI68O*_/GN]%",%O08!7@H:3@;XM6WJGBL*9+D%J@4RU MPG)F>>;25MS&8F]*YT[)4&<_`_+[&?@M#"+%S-0;;AMD9G.(?50!J[W=RW@= MR,T&U50,3L[,9_QG04H2.N-)TES?O=IJ9XHHV`2\1KVDX'*ZM'LKD8K7F!$L M=5HV?C+&[N@#:3D>;X)9MZ%>0_RSG3.G?4N_$P1@E MFZ<-U?)8P>T^"=D.W.RD@0;!P93<97\5Y.(_W.V!9#F[AQ$,R?->P_%LJ-]& MUCI6Q$H6@6K4K%=:3D_%9#9A-V8W&P"4=COS$B`KHIZM>HXC]DG7^@'$MEK8 M)MA]FXD!/0-G51PY[$;BW#Y%J)MH!9'@($Q^%23M/X/PCVO_+@Q6,$HA1!:SU)[*D2$=N-ARE8G`R:NZ3O_-R$E_A>71_T,Y:3D?Z;M6T="Q+3@Z) M"H(V5R+C;'>22!;X^BUI)P;G^N;R]NL5>+SXOZ2.C]8Z*IU:&,PF^AXO;NM: M.6O;A&KA;>FQSLGDY&A[C+X'UAY!<-+[OJB,JO.C+)]:4S#0+W\I@4%;-6PU M;#^VSX#?4)#0C:1B?_E(6[1ZN\%)^J$?I3.X+9X07@91')$;,$]N!-=W[AN^ M$!P5#F`ZU;JQR53#-EVT0>?V7WP3I&$NAV$&IC.P^/MY?_^\/'B MX>H30#IX=W7S#H8VAV/ MJ1'0&HUL0^F40KGTS=FL'9`V!$A+9\F5Y@]$O4'6FD3XIXJ>6@+$=Z&XM2A3 MLN'DC/7,[E5493(:B595H:7[U=L;T0L@-X'_"B.$('G9$JG)]*J^7/J>6U51XB8J/2IJO4MFK M0RW7JM@:6F+AWY42I1(9\4!BV,JWK%"]#_](=.F6C#/GUDN!H/!T95](TO&D M+;>02=^NMCQ`59JE<(#JVB;>.#*O=I]64B>D.<\FB;3B[>:%]_= M<%T&EI]9NXBBPR[Y6YV7TX51;RP.5KT2*QVX-H66Z6@V79Z>;LL+W(?WED;= MZ,G3E@%INN;*BU//I0ZT^'45C#?FX]^;J6#R_3(=H0G?X%36J)1*W%M,((_= M^>QZ(;$`L*S]G*I.#5(N\%/QSR3/^<4G\<$]AVU8!G@N'126P)RU98L3*ZZA(A\;ZTC@;$<%2D]4^RMHM5:7[ MZ6QD]Z$DD\-PLN%9719S45EE0]5F.W9:,=BIVC%S$5>E>^QZQW]:LF(@3CN^ MHHG4$5:AJ"JYB!<'P`_\#ZE)BXAY"HQN[58?>;PXQ"^(B0CT^7`V'FL\@:T: M;T^+_QS#)[V>W]S7?#JR_/"7+IFMW?GL`*YB,S/I(C]#%H&B%VN,AUW;C"=G M/-1M!C;WA1<"[$ZHH4]HN[?LNN`[E^E#RR1N/LQ%:^NM\4;A)^#\#=4-R:4U[<+IPNV'8:#83!5VX]ZE_/IT/)# MI9I%/Y50I`&_GH@DZXSLA)'N;+,W5DH>[C&?_#6^#Q_L=!SA_H\'T\GU%TG9!H]8A@& MR_&`F`7\%T6]ZK``"B1OUW?N#D:CZ=#V.RIJ)>TG>A"%FP8+'RD[-&F3Y5.! M9R!I%:3-@MNC2ZYWO:OP_*=584:7+<84NWQDVAJ4SO#&+VX, MOL,0@F?LJ)'>!JG>HL`^?H$6>-PBF9;KVX]#S(V]%;L#F.8C'@^&2]B8"ESE0!J??^T?\8Z7J M@E%7SWBUVO)7:DT-@;5KA'QR).$_J(?_E;7"C^E:85JNZ2IFWB?(.TTONHMF M$#>F2C*SAI_-["B_U\C$5;O3DIL:`KL7"OF$<1KMA8"1>.J&^]0`MW3+L0H8 MA>C3V6"D=R]3"W`%EL34@%:,B*9.9V/;DV!J%]Y(O*)3`J5)(TJ]G=EO?(;# M/ZV/KA$U87ZPN_MY[4\J/;L!2BZG7?F"3SCKE\4IYT7X`![0\$.RB#,>G)F= MWY2`))NT9`-?<\2B$F^_4QZ6X5,UR:'T-9]:_MB2-IEM7SUI`JXO"$FZL<9Z M:`PY?@KST1!@J.T,GQW^Z0Q(*K39<$*'"%9&$?^$WO,+OC7W"D/W&::_P+O0 M6T',[M%)Q!9M4EAC,CB'6H,=:4]U8/YTB<4,S"((Z^2";K'*2]9[]" M0/JWW+19'_B\(]NF-4AJAX!=\"F>2M4W%*<84+$(=@IA%CE&_\F-(S/ M[-B=VK:7\>CW`H1>X1JO*%(CJ@]M$14UH/J@.J!2<_C@:'SNX<[U?,]_O@Q\ M:CV(R0X'!QI_6LRF83G%HYN\0MHSO?TT]>4!#W.[5E&T)5$UAJ;_/I^'U/4UNDMGU9OQFZTA"J MU`WP_/0A*8MLR63TIS%1-X8:K0GN:CD8+]YI9G`FP1ELRC*Q*3ZY4MK3X816 M(1P<<7@^1F?6#)"%K0I[QTMKHXDJV'YUOW/@5&G]<4?SZ>A]'[ZD"VQ[Y$!% MK31H2'HHXH4S<`-CG,VG9%GL,!YVI=L](>.A?./^N"/L;48_E?5()3Z)S7G4KD8/GVN_S0ZS$?#$CFT^'[GHH(CLAI12^L8FD.;VP\ MUBBLFR<0$[U7LZ@YJF(YK3(8+]_WB4C1(3G!N(Q9N'X"MW*NV4J2$I(MR<+7 M'KMP]VMU>(93E7UIZ7,^?>?I#CMEMSV4ZA)`:=!4?8!!.EN97CVQ\P+MZ=H= M]9=D&SL=IJVLA;Z%T^`_&D^Y,9/H_W`^QSO>WFD66C> M>.(A=L.X]XBB*L11''&[B@,<10SM"2*LGWK8;@9T3C7*9)K\C&9@&C5._[S$J[X"56[PD:&.7[MO3^YL2#_3PK&%313V(?MD.(_*'; M7R+<2O1K;U:A*\GE]"0"$7OSB8H/M093TI52=_K3S&E81N*$HAD&H3C%)646P:Q<:&X#CN>JFWQM8SH]];E?29Z3L$^MXV_84)6Q M#.>3\4^S[ZN'!9JL]8AI%_::(GG/\)SKGS#X>IQNJ M-0LE_U1/_E)/>;9JXXUV,54\7E7[TZ))#F-_)NUGC:M:QN,=+)TU2W<*ZV>M M.F/FN9YW;WJ4YR?E)^//NF#?,A[LIJ??YWI$A',>7R#XGL5`;AH#/>/R']8X M!MK@&.@55\%Y#8,T@@I*]LJ-P,K=K@Y;G"H5+Y.Y^_WV#?\2H[;77K3:!C@6 M2^IB3JWPCSL8OP3K8!L\OYV;?8>B>9R:$L^/\!L()#:P\]D>`8D4V,?>/X&J M5RB$T,S&LQ,(T_H9%2/SSUY$,[A78,NS/5*Z:N>S/3^7O53_;(\`G"S%Q0F< MO.UM8,S./W.>.7'4M67[OLTH.B2V[R,(RB6_E5`*XACC-HP#?,N0&#[K(:R<\S\-G?JQ[-70O>]< MX*)#3NDJ%T6S#=`\\LPE3 M#&0^69SX<0\M`])[G*9#*J:EMHCSB6S8_IR!UF-LFI2RG].X?UI#@8!.,1!\ M^>;$'Y[3,R)VA'-:9,N>OE;^AD$76LICF1UJ,IHL[(W6.,7IV4+)#[XR&\4- M93X9G/BA$DU#8GW4)B:7VKB-^BZW;9&;L'K:&;O])+91??S[]!,X1=+' MF)Q&#""RTUQA-1`OM#,_>M>%3'Y3QH,#>^9UO,`@,QVF$8OR"";X&&@>K M/ZZCZ`#7GPZAYS\G'1)L$?GQ:'UOC=@]&T_T15+<@"3M@HH!R-5;H+'YTO9' M*82%TAYEB")3>O"=LAEG3@X;0_W01BC+O,S0Y/Y7&,B](9>)36!69:<[4TUR"OA MEA\%[L*NW8-T`'`>KG[[>G7S"*YO/M_>?[UXO+Z]$3_X>M39I^0VZ2&$C_!' M_!$5^0.9M>%P9(RS%`1JZ5BAW!DAOR,7B_H"XHS6@+GK\ M\T]L?^K1@+9.L:M#7\#RG5`#XIN)/?0+XE2,R+6_"<(=6<,4M1O'\5*IR8]O MZ8]E#B_G&B>J8JA4:;SL4-35F;/%V7)D^2173C)S@8`(O(J7KT^,2TT0;YZ5 M4.?"!?FGV3^?DBJV>%:N%M,9XKM4QD(VPSY1#*5SNX>A2S0P+1/QZ=?%>NV1 MO8?'X`8-^R$,\:8[<;OGT]EXH,V;M70LIR9<$F6:T%9IMK3["E8G=MV.I0L` M91VUXBZN?NRAOTZO`*"_@[Q!$`?UV:)Z@B_>'<$7/`3':00LM^8L\-EI_@K# MIT#49#-`<2[=O1>C&4B9V7_GY&WZ01<+C115P<8&G#GQR.^+9&CL?GGK&*HI M0E6[=:[7B%#>QB.!LTM^Y.3.)[@/X.R>Y#4WR"&*(S%RBG M*)TZ?1'2HX@TR%8$KOU5L(,D!(W@^7"TT'C7K[%?.7KSB)-QNJW.8&;W;G,G M=MU3^2X`3KD`2$J`7](RORKGZD3+ZFU_9)W4EF";*XU&P^EP>J)TS<`S\+5Z MPOI1?"VU$PTVL1`U%(/T!SZ^WE8;_Q)$:,(_'B3S7BU$I?0H1U$V$3)N4DLO M!Y.!W6M%;;"-+.JW`"BMUWNI\=RBGW_E=/.W\0L,OR)]"3UWBU>AW.CE.H8[ M_#5'X[DV-]_8KR0M.<3)R=E<9S0;V6TW.['K=O-=`+I6[!^\9]_;>"O\D&9: M'9#Z@+0,XA?7!^75@#/\KRU,_A.O#)07$`3-<3=IM$SJ^M.!VO2MI0Z>5-@= MZW:#-S1-ZP2B=%WK+@S6AU4TA`0-^=BIC3QB"[N-;SMP(P%"*P0G_15\2_[.>6`F.UMW/IQ.Y_K2QV;=R)&N!6S&LZ(( M'AZ[=^)K6(VPZ;A7)_T#IV'B/(J"=Z?.)[,Y[;F<7@Y984!&#UC11T#P;!5I M;#A;V)Z<1%PJW3&M.#2IHXV2=_]*C7_Q?)C$'9/Y3.-3I`P()/5(2,:FRW_4 MVL/Y<&!Y6D4.,;2K!CN6]ID?^(;+)U,];N*'K]X*4N++.<<[1+1&9,G*AJN@ M)ZT\<;V6F^Y6X$8BE58(3OJK<-P;Q2$*FTF"C0M_?0_)<]47J]A[]6(/1D76 MB,E8GW5EAB$;.`M+6P36K$W@MXM?TJ0@N@RB. M*A?:IB:6G9C0J%IR$A6==DN>J:795'I$6!.(>@0XG:6T,&T^Y]/@FI>O).#-!:/%1:&V]^ MX/JX`&Y!EY]BXYI)7V6INK'ZK+;6DMPY([OG3E)R]>F]F!`VN[!TZO7&>75X MA0#?;KZ@P/+VNP_79#>#%M\U[+(3B>4)S9H@ M&S%L#9V7J)8>&X\$.4?,97ENF3%ZLIQ,*<:MP5LV-"/'*G9L&;V::HQ&^/RX MU33K@J[;I'7T[Y#?CY?H]%"N6.NWD',%.";2V6W;NJ"SDVX=K`[X.`LES8DL M^28JR==QPI_-VIF_>5"S=$VGYP?CI=V9?-N!Z[9RK;UGEPZBXG2K#HXQFC?S M)*N;ML;AF@SLSF+5#MR466M%H8IM+1L%UTEF-O+?^+#!POCQIF,46@Y9,(C: M<:ZBWL)L,+%[-9!3$MV&E0].R^DD7.H,9'7(/S7K@\D32#WK`^LYHWH+>-YI M]Y5&7E&,S-\Y01WIQ8I_\[;2`&Z:=$K6WR]^>-$YZD;?J:&.SA62G44R*L`TJNW&H-Z#B!&#JS1 M)>8\JY;>>5T.[+;Y`M+H5@Y^2`('/L6N$G\*=J[GGT_F"WV/-52ZDN1[.^JC M6\!I,?P>J]UK>U2\VEE)Z32_P/LM^;/::[ILB\3FK^E2^$._:CH8+^T^3M(. M7#^C6GK/;NC*+MMU?$O&16+S)*LO$K<,E]U7_]J!FUHD;D6AC&T(',3U/QXB M%)9&66]1,G5>3F?ZW&9;UY)4Y9,J)VQKM>%\,;=[UY8)OW8CR0#"R7[+W^42 M6@E(CHU6PL?4VT^'"WVW#AJ[E2,MAS0989NK#!?S@=TQ82=VW43M`N!DI_FK M\Q.QR/$V?';]-"?B9>!'P=9;9\^%W"&PF9>XW7SV?-=?>>XV5Z0B&<)XJC$1 M@1*(^'@XTG=$7#7<'I6:;?"4*#BUJ]'$\D5R72); MK?3-N)URNV>@TC)96BRWC9U[WCHHFE>3_D0?[_4\I_"3&(WZ0P[*N\*>R.Y- M!&TR&SD\H0M]6^S`>\EP%1Q\G"#R#H%;E1.:C1?Z-J:;NY731@YQBMN*C57( M:-M]AYT!O6X'V0W!>?C]Z]>+^__&5'VX_NWF^O/UY<7-([BXO+S]_>81Y\F[ MN_UR?7E])1[YEMZRJ`,J7Y*?S,;Z5@J90$@N&8H*FB\>,C8PGP_M/B+-)XCV MY40>-$[YZ96B.,C*2T1SO/S0DX#!0D6HIUE@;``;,%K!9G!J]UJ] MD#Q&7(T(LHHV";U<=^E&+V@>C__GZE\'[]7=XEE[TGGAWV;3N;X-7B8(+H.I^FAD>=9?'C%T.PX.+`XN1%:3R7^4BF>^0]Y!\!%$3R88V]2@GC6& MJ3HV31.[XR@^08Q8?RY(SK$B\"8XVNU#^(*!DXYJ3%@.]1U(8T4A M27EA68M<28PMC!:6IQGAE$2["^""XU2*@Z2\0@?`RQ--V<"LU`E*_C#&%K#! MFED>%?'*8L8?<**BJ@?X!;_W_BNO)I2V^.J,F.GT",T]RS*>1Z:"Y2VU1LN! M[;SN1*_?PG=!<"I%5)ISA@^NR83W2F**J6ZI1>))N\].,.$W9)*[D3AWH>>O MO/TVR79;J<+'X,^N%_[#W1[@5^CBXQ/X-`7=`RQUGKYGAB'';0EI,Z*S-S$; M6?XV!J\HNNTX)QX'EP>D`BC54&?=^=FBQ=1;JQLU)\#>!%E8MON^(+\P1MP# M-ZR2FG#2/PBA]^Q?XKQ%/FHX=/W(7>%O$EWX:_+/+?$X]?6CP6"H[V:^,"Y) M_5`X'+G""+[9'7Q+[U-OSD1?L@WFR^!__S% M>X7KBRB"<73MK[:'M><_7_LQ$L)[VL+DAP9_/)@N]9T2UX!83C7-#&&FM#IZ M6XQG=D_@]`FMV_MJ0^X4+:,O![*V\2H);OT#:1XDS9#$LTD/H.@B_U&5R]:J M"%J<^<]E2VH!@);>\&3,[M!`I]A&@@:-`C@UXP&\W';\%@3K[]YVRVD6R-[9 MH_NC3LSY5-]*:U.WD@K*+DRN94U5%K.QW>=Z.I!K]YVMW3OIGBSZ7:$+Z_R\ M>OQ03URM>X3&*M@\V'WKL1.[&=O<@:)$6\AYSNS:?T4F/PCKMGLXGNE;AFSJ M5I:.')<5B!\QG'^ MIH:+A=TS0U&1=!MP05P.JE>Y2%ZIJ<[:BY-*BQ0W^IK`MM'L.*2R3 M$2\CBJY=L[C?5=S#,'Z[V^);\?X:WT/9%Z<=2GU/9AKW55AAR&F+A+"EUQM9 MFU@.[)X7\(JBV\]PXG&R\LB5X!KD-$!>1YU_X2>-%K]BJX;4_`A[$]B:V7WL MGEL6(WZ#%U6N*545X7TZ;`6]5_R:3/TPP&2YT/D`7E/'MXGO1."42J@SX2R?6M.+I?UQE_(N:7,E;"CL3JW&@-Z(\>W&X:2A M>02*LMS/-$(T,O@.^2?X"K:/X\8 MAFP\,Z!&=>"E^BOT#Q`YC.#9]ZAW$J?3H3OZEZ4YOW@%R3OKSD9CVQG. M*(-^.\\&Q$D+@E))E8:=F0Z:S+HM;*>8],ZZ^'*RW8=AV(4P9,X9X=!8SYGJ M^,4-X4X5XZ2;*/,EL/->8`)P?D1S[U0Q! MGA%9I+7Y=&%WY"\AE6X/(0[-(54_/.&ZH%SY#"3528B4-T!6[=5=V9.BG9Z, MXR>E>?58J0X'S[6-)!/E7Z/X.WF*HJ]G1M# M_.[H:*SOZ<1J9W(*T`D\X_9QP87MMT;H@'7[`FJO#OHKONB5_UW=O*#I^VDQ MSR:(5S.JQP7Q(H+=Z^X-B(V80GK?-0+*OB_UQ?/A=0QWT?EH.9_2%ED:7HIO M:4J.3WP8F]^-*FH-EZ/!V.Y[MBSP=5L\!@P.]7$<7`R0UU-/3!3]$0YZ^$\@A/OD,3^PR1_I3,HA1Z>]>_`+6Y)5OL(.[)V3[P1HB#$EO`0(8A&#G^F\`7T'"K<6*S@<\B]L56-D$3$#RW8SLZO$-&(SZ!9,W6=,W01! M[`LJ@FR=EM)[U?^Z:&6 M[Z7[Z2W=?&M[1BLKB_5]NCPURF6HC4SFF_NOL`\*L6^[#;ZC,!=^#L)/P>$I MWARVV2F\XA!>DJ0L/I_.1_I.SG%!D>2LG-0YG;F:65B^OB\@C7:CRPW)R:L@ M_Q^"K%)VZ:M\LO0LS;W'>>!(C#MZ3+GM&E-W`%S-D%C0[OUH,8',N`T1:$?Z ML\[T)PVP>5>,=P'R3O].]N$VQQFM$$UF&I_H;>U;4ALXY$VNQ7\EJ]'G\X&^0]1,".3(+B9D M1GFVVL/IP&[:\XBAVY!S8'&R`N0<7/Z/L/>-W M&B]&EK]PR">($MM_-X8^)/^!@(/IJ!AOE\,9CHR])1[DF. M?>V8,])52DTFEM_TIJ#5;>WJ73KE/RG@D19SIIE'->-5*87U;F+W81LJ7B.F MBM9SA5)B6W>?O,T&XK>#X$<8?X?0SY_>0^'DI1N&;RA6)/^^W61/`)!#+;0M MO(8#-R)]2))/C50Y2T6:([NK=D]FI.32;D$EP#E%99#6!J6'5%$#(&LA_=/M M1O"%"SFJS=^E`M7-O/"WM'LO0THN,VY#`F%9BYY2+<+GY#98DUZ)VN`UA%6F M2]S2ZWL;N;EC.57EDJCV'CBETFPXL?M4 M8C=XW6%>)X+2T]X@*7,&LE(`%U//6KTOW/?!VN97["F5R.S2[L"+!;Z1^(H! MB).S-91E*WZ@[Q%9^311SF]A\#U^23[T:*;O.3U6%$IYS"%K`ZF;6YB-QR=E ME[LD,6RD.^#0+#9Y6A('*"!+\I34DK?@W3PQ8=V'7;L\[`#AY`3+MS(H(GA!A^+QZ3'1_=*V;X>8ZQ"S8G4"5`;T9 M4]N)P[G=;+P5!$H)_`6Z$7P)MFO*N:K14N.1UI:.Y2C,)5'&X;9*P\%@:'=( MS8!>M]GMAN#D150UF''9L/N75H6^$:L+P,0M?S]ZJY> M/!^&;^57EM(.Q\.%OF>O6SJ6XR^71!E_VRH-\0:7U?1E0*_;[G9#Z M-!)7B^'ME;@UP]LZ[MA@V)TEA`6^$_"8'U8Q;?A`PQ?43Q]\<.+ MSB>#F;Y-/5J/)M('ZY=38R_Y!S@4":OP(B=CY.6ZF]L/Q9\U)!8!K:"2]V;>9>R$]^XO,Y=KXRI'=\S@>,8Q$Q1R`JD\PPX+U,$UBOL9# MC/F_Y>9_YC-N?9C-AZ:3,2.J37YB]M@FW*"E+X+-TA^U,$J/E=HAE6-[K`V1':?\FB#;=0E M4@`X_X!Q&/C>*@*_^Y[PCF+K=^3TAV;(U>P3:Z-D]S9V&VS3?I&"037!O@>E M+TE+_-_%KJP!1=QJP5,C5EZ61`UV+\8U@S;F"(][+KG![X%Z'G&Z0.T\:G9_ MU8&Q>Z>B&;19UW?-6T&;=SG'2-0 MR2RV-.'GTSG5%9I,9"]'6%$Y^5+7GR]F=K.:1PS=;I@#"\>[#EKI/QS\)/PO M!.54`+QO,[,[8."4A%T-]A")NGZ(W3`6BR7XD#FW>TC>1DL30NAE_O!G8?Y0 M@OESNS=.."7A9?Z5O];.>X3+0?UHIOWEBQL^P]O-!K^#,*&MBAM]PB='8T(3 MVF3G?,BG:&EA^0JJF$!V1$A'J/C>P")U/P2HLB$]ZO,IK+[U2/1!K**ET6@X M'MF]KBDYQ(5B5R=4 M\RG0ZWTH``OW$R8_PC7W8>]7+T(?Y[C;\_%TN*"];]"PD=#8D!RS>?"5SF#*'=83`+?`8V+A,V^O`97PYYE+JDTH7' M2::):Q`'8F]XH"8/N\,6(RT_"(+^>POQ?USXZ_*KGXWW9LZGLX&^G!JJ4$J& MOMK&*@^)5?4PLWV%1JF@VF>B*M$ZI=9`N;DSD#=(KIJ5FSP#1U/!M.K#:<#NP^(L,#7[?48,+2\"'P&2#D= M%-;Z#'9O%&Y\][IA_/%)!+OO,K()8&3/C0G*$9N]4CG.MX0#/XK#PPJ/_C7V M`L\(8O:YEW/:\X>*7A1N[EB.PEP2Y:\+MU0:+2U?'.T&K]O^=B)PRB6`YX.L MC)#M9?G$>I[![I.T]2>Q6RJ1J,WN%546^$8L+@.0&G_W:2GY%/%I/X/A0)^Q M;>Q7CK4\XK1EB$_JS*>6)SSH@J[;RG;TW_":@9"%9?BRQMXR,$-4IJ<,2C;! M[LP)W>"-6-9.&-D[!IL*=3=I4=+O69UH9>Y?C*+DJ> M_+VAQG)I>9JK=N"Z36IK[P[^,R'DE^,E`\7,U/,Z02_,K#]+T%0#SV3M/B'5 M!=V(#>T`49!4?!&`FG@[M=.CB<:'7YH[EF,IET"M:=S32D,TUE93M1N\;E/: MB:`I=[M0@,KRA.6!`;\3"=N,XHBX4V\MNW&-+^YK, MEEH3O;=T+GT"BT^PSIS!644T_%93F$T`W::7"4579FP!(\SZW9?OE=!+7D+C M6:_=\S%&"3@,OULT)&W\"8?/:Y>3ZCKC6QF2Y4)Y=)-3SV M=L_>F/#WR^,2$@?]-]Y5H#"9!MO!4YEO/5#?_(WJY;CFD75Q1MC#5T M*KDKQBI*OB/65&$TL7RIH0.Y]@WMO`BBF`O^73TJKXYS=\6,9%VYUN4D,K,=K8P M/D>["GU\^^K^3Q!>;MTH(B]4CH9+?:?H.8!H4YINB1FTI=8(LHAV'YOC%Z9' MOT-'U.%PP-,;(-4`J2?TG&H+IF3Q:+D#Z]CN,,.?J%O@Y0%@39ZM\C(0/&B]GPTM_NN"H<4 M/=KP(RA=\4!N:CZ8G MJR(M`O6H+3 M4UT@JDG1GSX<0VE7`HDGZ;D8H26?IV6LK^7M9*F](&&LY2^A\@G"SGVI_)Q< MH)Q_0N_Y!2]_NJA3]QF*O$&_>H'KPQ;>;EJ\T2-Y_6`RG>N;*K#CD"._C+SY M06IJ&Y*4=YXN$I2\-W`'_'C=[A] MA5\#/W[!2RRC>2];V=W8]&V_B8P+RU8<0[OS\>!DIR/L\O6Y]$='#)-)-6L>!S'URMN;CV;O2:F.Y+++_57!";H]W`C`K1A5 M.PN\G!5J)^G5\O:(_;1[SB[!@C]EYS[6J$9$!!T5A?YG,Q3,;5B#H. M$FJ$VT/S![M3&4O)9:'WRL%)>2_4BE&UL\5[]:UV*KP7;H_8SW>I>)EDMGJO M$D;LO6:ZU>@1:0S$Q[]L69O,09E6I(:1$->DI,'Y:'ZRQYX9!+//A970R?@P MTHQ9[;/$BUF@?0K\6-(@,:5VYX60%VDE&(9:$#R[!)N:_O@4E]L\5U]:MO*MP6:HX8S7<7-)8$ ML]5E%1"QPYIPGJ&*@]4?+\$6?;,(YZ&)WVZ"&%X\17'HKN+SR5+C%8OVOB7/ M2G'*E9^/:J\W7*+_S^XE!D8)M)^$8H+A/%Q\N0*WG\'=_=7GJ_O[JT_@X;\N M[J\>P,7-)_#/B_O[BYO'!_`MJ\=Y^(D.XI,7K;9!=`CA(_P1?T0%_\"GL>9C MPTRGX-!!>C9QVQ6`VL9B,+;[?#BW+/TH13,@IUSAKR"I`G`=4%0"WW`U0.KI MUP\M,9.]^E$+CCC:P";.[BD(OS!&@B!N6&QN1/1T^<.+&\*/;@37=^X;SL!W M\=T-U_]TP]#UX^@?[O9`8C(4I1UVY'LF)WP+E*/E?$K;:&UX&%U=SZK.FVL8 M@?J!=.E.,!EF=N=-TR"M=I^E'')QYOUV`TBC@+0*TF8!:?<,9"V?@;QM4&H\ M/0\/Q+V?!G[/?WH-KWM,Q02R^^4%#=*:\;G*<5>OMKA>2-085E3X=ZSVFR#, M=;U_#1Z.?GH5+H9`EP[;G7E%@[3L.KP.5@?<$R7%8`]JO/B+@_Y\V+HA6!&U_3@`,(J]G8LFK_B/&VP1 M7HE%0,U]SWV]YZ^V!_R6\1EX.L3`#V*P]78>OBH:!W\'O[B_`OAC#U?D#S#< ME6N31-D1*HWQ>N2)SO1)[U^>2M5>@RV2':>"S21!A="__AJ!"(\:+K\JE5][ MK]X:^FO\]_6O(/2B/SYL0@A!B(3Y)?KUC/3["_R5C!'.=D-LVCZ(X@^O6&@T M#JC5./3(@Z'1.6>29)(N+?UR62)FI*MSRD7N!FM%:4+.[+!ARE,=UTLOSD>C MT6QL]X9!*VYVE9:Z5MV&P4E295QD[E,T"S=NY7:3-G(;WN.KV5<_8+CR(GB' M6`OS'Z/TU^A\-I]-]"60%T"D@-#28U`A/&]KH^G8[MFKA%2Z9ZGBT%(=0HX@ M4R)DNDF!,Y`U`$@+I3)17HCWK7(9FNG)AG]:JE9/HR_2VG`Y&@[M/F$E)9>1 M*:,,0B=7K7VF6FD0IT"?;@[8":(0&*Y0$!I[,+ITMUNX_OA&HY6^]RPEP6G0 M,IF1:54XCH:1U;5[^J=&P%X\'B_*-N>7M(5_*UH#27,X);,63RC`3W-.\=0T ME\U5LC<\3XSW"4S95,C8GPL50.L4RIJL8.#_6@6[7>"#".^F@E6NN-EBB0)U MO3W$4>SZ>+4&L6ZJ[S9.5^\:%*Y5ME:-*M<<32T_`L`H02_>K`:CS5V5"FMB MMCE/8Y[9;+ZB7!-;GE,,Y&@R]&?K*6B<(K(2IC2Q_.08S:=L[9KL!Z#@0&<" MT.9^)6G,(4].X.8Z9*#MWD9F0&]J_;D3B7-9"C3.L@#$BZ)#NKF;[Y_PLMC' M6R?0C],=K-_W@8_^B,2)T+=!`5*<;EO.:$=WF[9"F%J5Y:L@\H*\3`V0Z,_N MX^BT;9\;X]/$E/G6?A@.5=; M2(QT"/>H<7ST@QSO0",4P\2,_V57)SP^FY(>-T_637#S^.!'&M$\D=.IR-;C MMM;X`$M>BK@`J<$FP=9F!0A9U,-/X='M7]](J MQRM=2=>I9;;*$W+2SJ MJ$JF6]9'1(Q"F`J&V.`X*:E72DE]3:;`^)O/]>7W:.];"YT;Y>K@A7@^OA:XRL@YS"'%A,+(-.2@A@-HWP M2MI46B?"IW/R,SU\NI5OO=VY;_B:UN4!P?+C"W]]@SY*\H_SQ4SC8UTL".2T M1TS&3%V8:D]'<[OW?3FDT.UPV*$X>5&0EM5(;BV>PC)RUWP!4VT2/ML=7G') M8<3:\R!R+E:K\%"^$(IW$/CYGN2TP8[$16-Z!T/B-BYV^.;H^6(YU7SF5D\MC>T1HLDK$Q^3?PB"*[L)@!>$Z^HS( MD'5_NTDZ(CO_M(BZXXY'=?&470K?994;BD)(@*PIP MV=P4X[-C27%MQ&4[-V8/<6M&EFVDQX-W0%PLA!%CRPPG9>\^8R_^I`!6C;`V MZC(>%+.'N_7C88P#;?>"';L0[.25.Q3&C,AY?('@F<)AUS^F,>'Y:#'K"(0CN#I_#E[_YI&FDC`X^>_C`#CY:V>?6=%LCAJ]TR.608C]ID53793"&>J2G\FQQ/YJ%Q=Y/X(?;CQ5IZ[+9:W M/T,W/H2(`=(JY83GBRN#/.,S>!K$L=E^!YA>&G=525XFX@3E%F?(^ MRB8I)4/S3Q#NX#I;_"/,F(DRN]J62C)WHJ3S]Z@:&4R[;PDQX>^%I70L3O+G M?"%8BHII&_?(34[+%[6+H M7K3@P.+4SHEDQ0$N3]:0TQHZJ:]E&=DVZM<":K;J.`2T>]6#2PXC@34/HGQ3 MFV1YE6%YZ8X_3H--LF"350.:>6>*.&@MJJ0L(V(Z8:F5R7*HW0=E.:0P:ZG; MH-0-=:GT62GMNCX"LRTQVT3@#HO;/-YV+V)P2-&#M6W#XWRN)`,OY3U!HYSQ M.^*_9<]#"L;E9IMX7%]P9AURN_/V<$AA:LF9'5+3'63W^3F$S_CR\*:1[$7N MMB/:NKE0J MBJR,=`7B:Y40P.Z+;2K$,QO\"&&L1T6D&9"U4\QFBY8`;@J0MLACU)P'M)70 M4224.C65ZPB^!+[W*2UMBHG70[@F!-1)U&R?J5FV/(I/:&5J%F`UBXF:O?6D M9D*AWJGI65=P*/"![,%MIK\B(:R2M&^W:R"@;AR)26R0KDW8? MT905S8+@L@T?3(&G(L%HI"R@M5"N10++QVX[L/H,G*YHM`60;R,;@ MD;RE5ZR'I&LDNL/(=O*I"R$MU"RAT+'YTY[2#CV_:!:%C&TXV\-%EURT(0N/ M08P?PRR%D-%1[(B?Q?1)0D15L6-QD/<600JS,[R3R9SVIK:J4P#47F4UCU64 M0K$::N!XP_95^G;HAGQ.*PCG3MW5A0>7/*N+M8\\;I9=4CL?3F?3D;:36DW= MRC&50YC\#>C&*K.)Y3FPNJ#KGG5T]._@WTOYVY+7)O-KNJIIJL6>]D73FD5M MKH(=H=TGICJQ&[&I72B.\K-)W<$MO5>.6[OP\Q?*/[Z1!U.^>#Z\CN$N6=FD MF=F&T)N]94F*RDB0DY:]$7(7VG)SRR^-=@O,#HP3CQM9G]]>LG[=>P^AR4@C:E))#\T&]3@$:?8(?RAY>(4 MU0#2JF;V-R%G)G[2`/D6=F]S!,)_VR,8+VZ$ M)L@(19;,G$]K?O>]^"O$[SMC0SNEO?W3X"**FG)T;D604;94B!@;NUE)0:L[ M)JEWZ>`_@6_)'SFC"MHW88P<=-*B'@$[S^IR2F+!@['`(>_.G!9(*Z3&H[-V!,X!J)24$ MG"(/2=A.0ME([]H.!\]7L'L+F5,2([L??)A2CJ<)_]<)Q_Q#%.7`)^ZD-&0Q^")M MJS1MYTAP3FE"CI!LF/(7L2BE41PV6-J]']P&6[?/;^G;2;:T+C)Z":XSM'Y" MMEF765K5'UJCC]%P8G=(V0;;B"-N`9!GIKW0P2K&94ZSM*HO?#;JGM6.LA6V MJ:70%@PJS=;'^K=<<'K#CZKYU8FI0J^/E#&R^X9H&VPCWI#>=TJKCSIIQ>$- MC=&*[@WK8S2Z1QMLH]Z0 MCD&EV;K=I(W*'%YTOJ0]@*7J?N:E7!<1D$J;"36J-T=3RI(]=T(VX MU.;^4WX&FYR@09BL*X-ON)0*GGX*=J[GHX]+RR2BD:E)OQJXVB!0*UO3.FC0 M[=[1[@;?"V/+"-HXFY3C9&V>(_(BB@X[,O[1U0\8KKP(DAM6Y\O11)^9[>Q> MCL("TF5,[JXZ&UM^98]5!-VL9L3A%!FA0:GD&-A>2D MYFPTM_O(/Z,$?9KY`D:W><=E-1';N#4W2&PNZTUJ$IMB]VH+LPR]6^LR&B?G M\M;;D`-\.%-=,I2<9_C:NOQ'L'5C;XN^5^+&!TM:>@'])*_BT$?W+GE9B'_4 MQFRPL'M;D%N6/JT\#5"WO2]J*0[H&_ABW`GTK!]VY57DWHO^^!Q">.TC"6$4I_/`@;X+.:PHU*L' MFZQMRD%M83::V'T.CE.2/AQ',YQ&MX&K`%P'9)44>8U6FACS&1:H!)._H+9` M[-CI;7>URM*;KVA#Y>`?/VRP%GB9%O"_\IOW^M'=XLP@#R\0QK^%P6&/WP7T M?/0WS]T^Q*AA?/;GTDV`?2FE6*,FM%2L'8+H%&F-LK&I:9-HR[.QY0>P%4EH MS"%)P2PYJC.0M@1(4R!KZPSDK8&\.9"U)Y%XL)#@C29#ECAKJ>]<$0L"58K( M(V-=V5IJSR:6'SGGD,*W3P^ M@&]9(2&JW6Z^P"B"\),7K;9!=`CA(_P1?]SBIXV'P]E(7QC4V;\*1O*)5V5I M:]W!P/+CG,PRF&%R-Q`G*8@7B)*BH"B+C"DJ#4AQ?337,A>VA^:UZ6]GW7EB M=^P.RCFD,#+E9<=#L>9\W/YX\+8XN49Z\V0^Z,IZ(4[C:E=RG.V`G='SJ-AP M:GEV>2I>W=:5UJF3_5'TSI&[]V)W2XB\OD`LCB,4U49D7CC5=Y.CH527\&R>\@*7`&2!'%_-3BR'OB9_T:<-LP3RW/ MC-&%W8B'[D*14W6;4-4E1<0Y&B6A0'E9(>GUX]M7]W^",,FIL%H==@>2X_T3 M?@AR16ZD(AHL])U]4012G08H'2F:PLAT,%S:?B-:J:`FW84TVJIW06XEG4)6 MUN;.4J>#%^U(L\G;(>C/1K\MJ]V+M1^58?*<'!>< MHH)6LYT.6+>KHO;JY'\5G&83]E<33&)K-AOJ"_AH72I8?^P6HK+D6"L^&%B^ MM-,&V\CZ.;WO9,E<+OEH^P?4MR1ND(7TA>]:<7P"Z11IF.(VM[C=@"!E(\Q_ MY2/B[1[B:OXS:>:6C/1C<(F#@B10^.KYWNZP^W1(6L#N;X#;*U]JU3$;K'HVE:K-QJ?5.C7 M@-]L?$<'<1S$X?M;6$?2@OCU/,Z45HR?7,N$O'\F=P1BM7K8--E]&(--@!Z" MJ@8H#N$O3/[.1]V[,$`]Q&]WJ/?XPE_G"Z,?WQX11I)S=C(&7U#YHHP;0OS%UGA]:)W:"22\)X-906^,EJKX([Y]*2<"MM=HT=\<;N;%N"$EGC MXRJP^/V;R&5U43:I=FL]*H:$.RM],+MO$@M*9)T;J\`K-"38@&W@/W_8>J]P M?89\2'+^&[N>Y.('\AMN3-Q4='CZ'[B*L2\)C/C(]0&UA;I_.D3(;47$1^W#`/T9@N<@6"?U(QB^>BL8G8.K M'^YNOT6^;.>^9:X5H#%!J)_2&W_1&?IQ]8*:"]](;5C,_/`_`X0@!'ALR47K MS2'TO1A?L*Z431LG&5Z>#C&"'(.MM_-BXJ7/4,T-0E1NN]K0QON!_SM*^EP% MN_TA1MT6[1.Y@DW\'0T.IS.F7-XIXI.%QC3?;1VK.P[?*5++-;!RG#:W^S`" M`WK=GK4;`OW*HL17I#L6+2WED19%%B+/P9_96W1_J'8Z4\%V;6DD30U"IE]MHBXB?M MX(RLGBEYF%-:%FY5RS98\->W^TR:J$C6N*`JKJH38O%!0AM;PI12[8=ZU0\) M7U3^:G8O\XF*9)T_JN)SOGA1LAJ1I-=/O8R'IOF;V@)%ZD1`\+3UG@E,&7\2 M)3#30Z09T$\'_.K=0M_CBTP0U&D2AY342^B-U8<+RY,>\XAATHUT8*EEA$B= M1W:M)GJ4PL22,XC[JAI0K+6 M0O[+0QBB_SR?332F+^9!8D`5&F7FTHBL%?3Q3F>EBU$:*YQ#!1*/C\!'^G_$ MX/$[W+ZB$H$?O\BD!&.ED?XD0/:I3GLZG^XO.QI.WT%(=2P/AVM1E)B'$9F# M6#;6H`K7_F?O%?XWOER&XHRYOA>\>-$84(E6V;G4HMS2<&'YHY""$EGA66JP M>+P+/AR`JP-2WY`R]>=;^EE0$04YI M,AD;2KO*@,:,BC3+SJLB>4O#Y?QT\A%S2&2+OZG"XO8WJ+I.?U,C5*_^IF=E M$O8WI6^,K-_I;/5SR625OSE&A_W-3(N*/")%R.*2R4#?8W;<<(PH29OTG%I2 M:FJX'+^#!66*2)8XG6-6,+3.?G"*95- MWH>"#_N?J1Y=^1YDL^*9F8=]&,"8T9-&R7FU)&MHN)B_#[]3%<@6KU-!Q>US MO@IT>3T[3 MX^,3A;3)3,/IR.:6Y$C,A;"2&IQ>B8R5W>M9#.AU&_1N"$[E_.X9R$K)/*/0 M\9G9B/VL!N'8X!^C,?$^^1?_?!WU]#9?<2"`3T[ M`>6.='=#T6@1[[)[1*4/3CM)P4#)HZ;4<;(;(XV3Q[7(6-J=28$%ODG_W(#A MF(YY,9U\Y'?1YOG8ZJ2I@VGWD@`+?.-NN@&(8X2%`I[:/`W;?35U_.P^]L4" MOP]OW8!%M7VL9;`A[:\OHE+:FLE4XUTJ!@!RM!:2L#&C$J4RFE>.[?;]'%+H M#@'8H52R)#5D0Q')'':4D;SY#LMX.-1'>T845X.;`[`.<5A2,8%[]>R`E*\05# MQM[S.RCCP4)?SC<^,$84HUEP3OW(&QJ-YW:OY8D)9(GWJ*+BR1^ER0L_$?5/E/BLRD^\D_*.( M99=WJ@,4N.?(WEM^X04QQH(5/#77M%2(SZ\P>5NC\7L)Y8YELL:&CN`)W(1D[.OQ!8;0W<3X'.EX,)WU M[80*/$94I55\3E4IMS4:#]_%Z86Z3)8XH1HP7B=4-&!,K_IT01;HE:@+*K>% M#W?9G=U27"B;7%`=GG.!_P7XMX^*<]V5SLHW&J+/05C)$4!.;S_"'_%'U,(? MY\,I_>URU?<,1`&JNH:@<(#JUQ3$&Y_-!G9OUZH34K=W4X:T<@?BR-%5+@(E M3RU54].DUR,`;A205H7O!LE35HM7?$\Z7?.;*AI?#I>6IXE6**41SZH.KY1N M*U'D>WQ1<5M"?10VU*FZU+=\J02C%G66'J8.C>9M?S:;G*1.B\G9DZ\6`MNF MTDF#59T^GLSJ\MBB##;IM$]8T5E=-V_[V$_8?9I?K:!].G`QR)P^_%C?^93[ M$WR*/WG1:AM$J)^+IR@.W16^W+/0]SP1O4\Y[6.5(].FIO+H$XSMOG/<@5RW M:VOOWOET]?$17-S?7]S\=O7UZN;Q`7S+RG"ZG6I'A9;,QPM]YX,;.E7)S19) MZ.0L*HRGTU/BYC%PL]0\ZMW!OX+B9Q06B09$7=]32X33"S-K04A#A7FB_W8_ MYM&)W4BHT(6B;D%%HW7/FV]9Y(N[GB..5K.IR/V=*G"':E= M2Y&1KVG]A+U-_/4LOT4G+YSI)5%NA(7RW.;+(D6BPK054&I&^<*G``O9DL"> MKI9UKE+R?>;E:>U!\`O7RVHD-TSGX;#;N>$;=E.M*F9P1E'D.?]"5A&OWD'$CK6W2@4ZGT^F^D[. MM78MOZC%(55Y::NYVG@VMCL"9(%O8@&V`X-S-.4_`UFQS+_HH+"V%=E>*4Q= MG6VN-ERB+V#W:4PV`8RMTW9"2=CLE=AWEN1Z5-S:4IPQRI MVYUEDH3.Y*+">#:W^S&]=N!F#?!1[\>F-Y+:FFW[G`;,K2%B=IC84@5L$.R> MO79![\&LUD`XQ=X`CF>1/75Q5LP7&'LK9%,]'T6].Q(`\S$V>X#JSO76Z+N. M)[0U4#4\+7)\(FT[DF$:#B;8'$\I=R1&N`W3^SE.E&/(!([L3<%#Q%;G(I28G.)@*-:GEI/(YV3RC:8+,3[Q6&3X'P8W;-$)PO M,(K`*ODCV`1+K=<^?CX@>3T@>3R`?&]] ML9P4-G7D5C$L-#40:'MK_456N7:1F;;\.)<:`8T$_4J@EMY]K6_KB:OB#?H6I1AH:22, M*SI5ISRM@M"THJBP2):1[+XCT06]AZ".`J.V$.?G9<3"O*^HTK/[#&^"&-]I MQUODMSY,WZ$=#P8CVBWPAN,=;6W)$9$394;'UFIX1*=V;QXSX=<=%+&`<+)" M`)<":3&`R@D^5XQM7NUF`D_.S'EC@"Q@#%!T,?O0>G+ M+Z3L9MZ6MT(H$HE3@XA9J_A^AZ^ M!MM7G*3-\^'MYC*$:R\NIHPSCH7J[A8E>2:".&=>=V4T.9LO[5ZZYI!"NZ-D MAN*D14%>%N#"V)CZ=# MZL.-301N:$>2MNSH=V+6'"!T`G*0`0"4`+@*2,H`44DT\ M5M/9$_,H9K*ASG"4C)_="]T,Z(V9Q4XH1HG(.$7OB8?U*7M#E602:OEQRV[P MIJ;P74"G]RI&3!G[&14G8\LCQ2 M;,2LV_\V=>RD,5[V"_B&?^,,]:J-?PIVKN?C[T8[H:.#=TF/*IG7)`.=>VEI M-*!V.^(6U&;Y5^ZZSL#D5ZG4#*GET/A`?+T_.?ZQX*?G8DB4>;JPV_(U8M;- MO*:.C[.""%F^:N,?4;06/>Q#Z*YO_7^XH8?WG._=&)[/)T.];S;,A8"\GP^ MG@T,^8EV)"H5A%=FNI9TM#*>CNP^F2P@C5G?P0*I[D!*M?#V5\5_)-[%@+H8 M<"76J4N'4^EHA5B^4TK;QBA/#^Z%#5G=Q^0^)4^6B+$+ M#B1I*O6&J0X=*7I5J0]MLM"Y7ZHQGB[M3G/3@=RL"SCNOF[N<0F0%%',3P,V MW!@_.VQSJ0:V#M,396B&O0>;6T=1MZ\;3%57GJHA_-6WVTTM'_588PHF M5A1*JZ`0S'560V2"4EALGD&EI@PYK9H1)>Q M;VZ!I!PYI>4=!EGZ<`:=J"C.H:P<^TPYLGQ&,MJ1)4C%,X"KS0:N8N\5(EPK M?&CE&2\*3O2]0<$M-5Y:N9L:SX2D%2VSBF'4D3)CJWB1/'(WKG8&\ M)BBJFM`:`X[%0JWI<#%=S>`0>7%*JZ.L`O7@;!BAU3T.S#6F6.^17.7IP(+_ M?(\D@E\]W]L==HA.U2$E*S6['@V>4>NJD$\JUP7':.0*TNV M+TAC9R!MK@]-[=_=V:BIUSETU0Z^YSEQ30XSP?8O1_ MUI7`:SGLP5,>X]"E;-WR=FM6K8WQ;'Y*![<89.G/N]$!=;JRI)J&*5DC80P[ MJ-X5A,/UU-H@BU&G&A,V2M.S4VG"5?<@RCS'%\^'US'CDYI-^<8N%G3?M1[_>@Y+@!(":D#Z&EN_K=/R>G3RL`ZC%'5@9\DK2CU*]K(*`PRM:.@*%2A^0L MMOL6+0/Z'@("&@[*%#(C[EJ2N#?N#N8W!)>F#FP7O:HD;9LL=,J6:B`+87?> MBP[D9HWK+0/GK^\@Y?0]-W*9<.@DKWLBQV?4OC<*4D/H4D7IGJ8 MLC]^)DU*";+&TOZ_NFN($[)-.9X`Z&Y1*9W9$#=PF589C_3DE):F6Z4P;,M; MH%`L>4[=M#C`Y?7QERV5ITW\[;+%C<-]4M%(FQ1]V.`6/'7[&_CP0^RA0-R@ M(6;,2&<3D^M9ZA@'W?(G`3FD8*>R7-8Z=DC.XTMVYP4?;%ZYT0LBK[<&;HQY M#0BOX^"[&ZXC$*.RP2&.8M?'CV&`)Q?UOB)9;`OJ!SYPP;;R)F9)6SB3U5<% M><2W'W&6&U,K**1#E1K2(`%=(9+"X^GHE+8`RZ#-1AZEGIV'U0M<'[:$FM77 MOTOA1P2^D3J<"R>?O1]P??GBAL_P,GB%87(JQ0M(VN(Q>Y3OL\R2D)@V^+`!?Q9JGQO`X3!CF]$!4STQ'& M^H/IQ.YDDEQRZ`X9>,`X7ZK/A&3ES]*<&J!41:L&:-G[L$\#:D$*8_WE>#&P M.SL2GR!&PA3'Q9(_!Q6J%>XKNX0IZ MK\DL$X45M+-R#4&/1%?JV2\N8YM.L+9*'I$Y/4WA%:\/'\*),5&H6XIKR1L" MI*6S9+9*WL)-6P-%GM7DM5(9ZI M=0<%6)VK+21'#D*X1SV2#0&\PY6L5R#M=+?;X#O217?]BK>Y(KQ&T::4"I8@ M+H/MUD7&"1_W04.E[TII>^?JM:]5L#;]*E<]`USSU+YH`11L`-7(FG"1`DG#B MDWV[%8G36[1^4;L/",D)9H%OZ8#8XG+`KE"B#50\;><@F\2$W6XM8INDLWW* MI=U7$^4$ZW-BSHS207^-@!M%P_$+^A+!JT<.G)84:Q.$9+:>Z!S. MW9YZL"A):>/B,P:%MI'Y_*OK;:!H M4!=VH5OUI;&9P=3RUS%%Q.G%O;1C:O$O2<72&8.LJKS.E-YUJ*IR]K@#(KV^ MJT,"B-1K$/\0M"E29VN#Z>+TSO(P2M6'6K%!:]:NRA,^QZ&HOW&`'6X[ZREE6#0,$7@3K0I8`BM3BA:P/3N],VAM MHMC@.XY!M?L+R;?C:%B^NC_P4P?4:3,U;Y,^[6B"HEY%.(1NTY/F9@93RW-5 MBHC3APOIP-3L1]**6M8*NNECS*/8I#-,OJ6IF7EB`4\OYNH6J#<_TPFMYFUV MJ=;DEPK`2IG6'"4GS-Y5(&<@YT8=30,2]3K#+G*;RC2V,IC.3^_T3H2S:K:D!;C+D8>[2%R<$TMH)-WNEMX'2)TYMSZ0!67+:3?&FIG7:EFSH<2*;7=FK1;4QNUDM7_G'KX&V]?D7KP*+@;^\R,,=S@M M(7*0HX%&`UCJ2I*`[:!S[E6*#1:V+SM2X&JW=/4^G6JN2A5TTF/5--.I;LHJ MQ9;CV>B4^)3B-6.^*#V7:+7FIE7ZT&[F;$83?>>:*UW)\:H#=<:K:K'A<#*U M>\F7BE>WH:)UZJ1_%'1]:>T;&/\S"..7>_BO@X=<@O`QV^ZV'[]LC7NVZOC*D-TWB+GD,!(=\"#*-!I'4;RS"V=NUV>!H M-K!1VN"M#R_\]>/WH$0$CN=4&)I4QUMVS#3N-M4F+SS:?1J`1PR3X4$'EBJ% MHYS#J#AY0P!5,,%D`>O;/Y7;[7#;P$].)X#H$J,/B]R!J8W3%U*<+KD#U%B) M#QPISVEMR)&6$55&4FIQ,G1VWZ1JQ:W;I+9U[E2\/V:9#G:Q3:E,LZLV?6H> M*+N7I%IQ&YDJM2&H4*PT.?H$5Z0<&"[(Y&B@A7J,WMDT]^K^MWD([0X>6W&; M\K!M(#28N`?O1_9!IX,%+:%S-\WR-I31K`T5A65%\=%HN+1\[[T5MT$'6NN\ MRB[TLQ9V\5LQ(_1JM6)Y^>$H&2R[CZAU(._!DE%@U-F6E%#)->Y@S0C5VH*U MO/@\&:>3B=8HP$V':W4(#5/04N3VU7T#$Q*SC26L7383?@SNX3/Z(-%'U_^C M%"=QNM66YN1YR8>U3-&VFF0=R^XSXZPBF'#!##BUMZ#U[Z%/@)WSQ\0Y\@#0J6$`]A=?` MV):FY-C*AS$C:ELMV7CW7+V3&: MBX'=)X-8X)NRF`Q8%!/S'L&`%S^\Z'PR7.B[[YYW(\?0%K09&XLBP^G0\M.4 M-:RZ#=]QAP[Y`_B&_R1"G)2:Z&/H.]5>ZD@!>9H05^B3:1P:([N=*06M$0I5 MNLQ(]"G8N9[/2R.XW[HK"3N_KC,73]R%UA\#2P0Y-@M*&1&,72;8@XL#BX+\L*@5/J,7$##%0"IH9/ZBY^!^@LAZH]&HZGE=IY+ M#G;RO\+P*1#=/>+!Y&"B/V&BO^(_EW)KOY$SNJB#-2?[5VC*CS[3[WZTARMO MX\%U$G:?3Z;4H^6*&-_4K23-V:7)J=U893B;#NP^QM&)7;O][@#@9`7.0*F( MX,SNP?LWO-UD>;G.Q]/A@N,9X6IM29IU(IQ8?SQ1@EM+'R&,3N]HOG/J5O\#P&CPB` M][2%>8X+;'7)CBPMO5Z#>6-L5HYYXM@S,K*V@+?IYW;/7GE%T4U93CP.*0]* M%?#1G*Q*.8D0KJ69XVS'.WP+M>'L-L&\XK"SG&)`[ZL$MYMK?Q7LX*/[X^K''OH1_`A]N/'B1W+:&OZ(/Z*J?YP/I_.AQLFK.#+9 MG0.50U)L+DBT.IN.[4Y;JD`Z_1L4LA"=K(GTN>BT$?ROI!DT@_D!TH;`+VE3 MOX)OC\GE`]0<(.WQ[G:H(*06SW;:.EJ;/$FUND0$M3O*5"&>D4F6`J`57<41 MZ%T8O'H1&OZ28N+,Q(7F0LYG>0J4G^`&(G>\1HU+LYGE20TE)3/G)D7@5=0N:X"XQ:0)5>;#5S%WBO,/?2]&\-[B#\4 M:IHL/=5CL#DM/9YJ]>.'IDH'E0Q*71%%FIW-AK8?7I,7SYQ?%,98T<>\E?+< M$3<$JBTI])`RE-3L)D]33UL.9R*K&KA'R&7:Y52)3Z9,5UIKC1>6OV?( M@%ZW'^J&X%061TH_GX'?PB#20=W)]!URMQ"*A;R3*3(CD^'2[I.VC!(PD'B9 MD-B'SVB^L$Z.5BDG=`$I/7KHHT%(SXJL,Y;'B.5;T76_VE(D49'T``NB@L9' M:%N[5L-O1JF.^4VO-EZ>B'5N@V_*/+=@<"B+UZEI/@-I21TD7KY+$B_Y2(S, MR6!J]UR830".F%K>-K="24TSU2XGAUU5L/DFM_SHTVM\A[ZK=QV<;I.MG=:E MFN/E^#1BCPX)^K'0QS!:C7116!.S#9IJX\QF--BEFMC.S.T^C,8L0X]FNXZF M(ZA68KRO\:OAB$AOB`!3_>L<]7X5T[I%GD9"%W7&:.!/B\C'V(V;YR,`=,.< M%U+.5BW+WSVRM;9ZW5*'!'CV7HAA1&]D];D;AZ.*HZ7UD1N(_>I87^["CLX5 ML[5+LD;*'E4<+X%IN)?/M@<7?<>U01KWQ:_HX* MJPC]1+UT,"358#W.!;]D:\AOORJE=K%@-=)W1I0-@U:B-\K)R/=BC71P8NMS M;7+T;,,K8!I-N:IEYW9"]&':^R`^KZ$O+Z=:GM&,4Q(;S/X1IFS)`QE\?6L> M5025-;"9OM..S#"T:D.;M(P*45F+G9^T,ZB)TK,_.,;3XA*4+7)W\J,/Q]"? M-O"ZA^JR[=#R5VOYA;'!2=1AE?R$UN7QPD-=;E&#W@:G&4(?\.(IBD-WA?", MYP8W.[O@*%86?ND;E::SJ_3>M"T3JI_]!%9XA=H5 M/@I\R'3K[_(J5/C*9A[I2P@B@DB](O&/09LN=;8V&0Q.+.ICEZH/[\4&C=^! M%>WJ]&',Y#/FQBQ60"9GUMT:LJV3$UN(X)&K-Y?&BK#!JQ7591W;[1[BI,7^ M\Q=\P-4-P[=-VU^M8L&9^5M47LYHD=W627RC9_=83/2?]-<5:2 M2H3^(WD@H-+]Q1:)Z;LX_]17S_=VAQTJA^BD,0N_##+%BB4U)HTJQM/J9#`> MGY:J\4MGW*%Q0Z2[-OS?23O';JW4%$C;PJ5[T%`S#N^T-+3;"?*T2@SSB:W\ MB\C7CV,40.IE?YD$MGDG53.6YMZBC1SV0P M.K'L`BKD[<,9RH)N=I;Y#VG39Z!%'-X+K;U:`N"_]YQE#>2O0TAOR1">VCZE.:GN#AB[HBD('TLV')]Q/M1CNR2)S M8ED@<9+F1&%0T=(;F;[^A`8ED]OR`*-;`N"&W<;W<8O,#R?SY8&3]FR`].NWNPCPJ'%C8U.!L/36]?C$\X"%]^.D,>3 M9RT1+YZU=09(:^:5LR^G;*]RBKC8QD;)M._$#NX*B&>+P^P"FD^_4V>8*&&@ M0/7R6V3Y)3(4LXU'YOQ?'8!B56*1L%%E*)71!SFQ`Q&-0ACW3TU(Z'Z(PWL`E"<@IVG2E& M+)_OI91Q)KV,GU]R'"/ZTD[Y/+F11[@]6(X'A-GX+VR-*B,V%VX*M5OJ8_]Z M.AE.&00Q:-*[T32^`Y3Y9]!$--Q>C>DZG7P MTN-O*C*=E+K_!$/OE9P%C9`?GQ@Y_$+O7@?Q6Z5KYWRYZBD]SM(J0C_6NX:C MY?W.4EE=]-8>B??+[]8HG%YW,CJ?SJ;3XD/X#O;ABZ*%+)<[.KH/UO0;#^[FVW%_[ZVH\1T' M-C@ZM()+^G8E:6MJ,EB?4[KDF7+HG:ZTF-*HTPZ%@M5 MBM7QM+5%EBQ.9E^`4ZA>G1(#0.9\)[,$RB9+/TZD&5#S6E$IIZ':Y:(VLLBL&/5/ M=<9UHX:O,3W%R72++#VN'C6C:EM`4I%4L`3B+H1[U\OVFE%`,!T:2>C>#$&' M/G1*V:X+Q]7'\^')G"3L%*,?8T_%TC)+2,MG1XZ4A#--K#`Y%^B1_*PQ_W%] M)D^*W.X0O1I.)JW\=O/V.//\RGTR,F_T& M,'IT@%GR+F5H:F@RF)_BY+=+H+[<0RNJ5D>1U$3_A>N25:6\MADE,NL_K-(B M=I_2T-)DE*QHG,Q+@YQ"]>QK.@'2UY$VW@^D:R)'C-+][L\0?4MWB^"DCBZ] M]W$^'RWT91#JZ%Q.1;@ERS2BJ^(8!0!6LY]-`-V.@PF%DQTF2HL1?Y$6!+^D M13E?5&;]\%JN(5A!Z=H24E=%;%PF=M_H817!R((1(Q@G+2#&WR2/#_4KZSOC MW]&Y&OXR2W;,WZ:*R);8O>##)H`ID]R*HC#):2(IA2:YZ\-K-Q8LXHB=%C M.6R8Q!9;\CZ2:4$C`V8#_?NO[1@4,9U3SAK3V^N/%R?R`!.3',;,/0.8DKE/ MUV4TF'LV3^9C[3*V,ES.[ERX%I#'E#-@A%2[A>,U'O6O@(H]6!V&IPC0Z"Z96 MB%$[C3.;7/(8=1P\R.06B1H:OPS\V/,/GO^6JT1_,+H]B'_A%)<<_1)R2\UH=T`:[CE*-Z3,1WHEE!`)2BI MGX83NP,L!=)9Y%\:(-(<3MH*W=M(IYM3P42V&\6GK&NUZ8OLI[9[_4N!=$:F M-O(XLW,AG+>1.3K.IE\54M$6SN35YK@K8WK#(*.`XM1:)=_LW<1QC>)9Y*:: M,/+[J7PQSH"C:J:C+9YJR:@^9HVI[^ZVFS@"J<% MS#'3D%4%`&B/K;_RX2JKB%0MQJ!#G*AR]YWN( MA]O;>LF+#]DE/[Q?=$`,?*L41N293`T[$RZ`.K1(ED:?=T29V0 M_3@L`:3-G@Q46SL#;G'Q.V_QN%)_.JWE&,.[TNG:3$Q%XV23Q>X9F4HQC^BSBBK2C9-VJ"O`F\-=P?4#%GK8P77K&(2HM[[TYY::A MTJ_%;&/!HZ[4%M%$[_0C]!;);/#4S?`X7'*ED6PGT[`*]N9?+51!(8]);1&; MVIG=EXJE9;/&![:A=/(?7:QCZ8%0#7Z./"M_L?Z?0Q3CI*!XYV*N[S$`$43Z ME:M[#'@4J];:=#H^Q5T<)JEL\&ET:!S^C#0`2BT85+/>_)A%:B;DOVJMD6F" MW3=$I>2RQF\U(73(#^IUYQ[NW3A,^]ZD5[2OW-#W_&=,HEF_<[)6>/JUBG-T M>%2LO>GI='3ZVL8BH@T^C@$GA\,KMP:"39[](VNP+QWNS1F>A`X+NJ$M,:!,L'%,\#8_4&F?YM4/W_!#U%'OP+\%+6.R2#]LCO$%)SJ>[%! M!IE^W60?$QZU;&QU.K4\Z[@"Z6QPJ.T0.7QI<1/[8/(PX5% MTR/5NT4_A=!%D\=/,/V/:S\M6+X3.QT*7+47ZDU.5Y1+6KO]*]8P.=9L]VE4 M11+J]E9J8#I='BMO"^2-H;\5Y:7OWTL2E/,*_@FKXK$/4T$`JZ\9*Q+0A&=3 M`]4IE.V7=5;Z5\X+'A=;)(;O8B_[U?.]W6&'>KL,X=J++]TP?-L$X7J`)R/$G)M0C(D)Q?B$ M'%84>ZO+X.#'X5O6_VRD[[E;:I=R6L$H19XFG%I\.A[8S?`VV+H->TO?3O9; MOL M@1*53&SUK]/!G"/K8G>+2GC'A_B(AFV5$8670[N/PW!(88BF#%`JM%7GVWGH MP!CIVL3@>DS+..*6G\ODD,)4],H.21.5DY65+T$4?49(`LS7\7W`3OP),E8:L MN4^DG&:[&= M:WFDSA=R-CG3P?)1K$1EL[/,@>S;/_GTY^*'%YV/IB-]"9KH?2K:+^N0H[8C M72V_F$Q/@?P-N(WM'E,Z+^\)EZ;2N(#H)F_>S*=@YWH^^IACDZ1,>E5-RR99 MFHF9UEA,+-]BZD!NGISE[AOHF101)2B,OG@^O([A+B)[)[1Y0]?9@E(;BJC6 MCJK&LW)Q+[KKSQW"])1B'"PN#VLX1HG^W,!R7QR M#AY?4/FBC(N"2C3J:Q`'8.U%JVV`?D6M!F&2*<7S48"Y2].$15&`>D#1,/CN MQ2]@36PGV)$%F@BL(<*0]!8@@$$(=J[_!H@VH-;C%YAB$%:'.]=;HVG/?*HO MH\I1;\I4I@$Z15E(R<7L5-X[J0`V:'Z+7JMV%_]=$<&T''\W0[#FYW?2DJ/1 M:&;Y]G439':2J7@FI]JY<^>^D1/F>-Y=F8T+<^Z1V$3L2&E7@KO=.ZFOC$9- M:"@\2HH2IV3WU:%&S`;-5:7CHTB1_"8>)!Y],OX`42N#6@/#TJB> M3T2X@^ASQ!XD2YNEOV,G-*3==U'^0G@G%$6<%A.:\O!==S.+Z?Q$G#*[-,:L M+#.DZL.1^8]G(*^6K*V7?C.A+WKC34OUI>VA2(9F\,'7$UFOXI'';(S+@2Q3 M'>1%`"RKCKO#Q^O`7F#Z1?#\6"F[W!R<\=R7.82*.-Q6Z71>&SU-4(&\+KYVXG`R4L`7*1R<(YS08+E M^VJ)3_HD;"WV:*N$YUNGR]@4O9&XHAN'_5C[R7G M8CZY,23?7N/N`3,.7=SN%K>;ZK4V1N.1W9-2;EGZL]QT0*V&_`P4E0"II5TY M#%OZOI6#PP_4VEA.$%G>BW:DPO3L)1I@.<7?R7JF$?]!>S]K/)CKR][*`T67 MHC`)W:TKM&9&XZG=Y_Y%Q.G/G31BZO`HTN\\BI''L%^Q0V,XO$O#:WV+4W4P M+?+T[&.:D='>1>33C4J"U?_W(?2BM;?"#:;K3I/E1-\4I*-S.07@EBRC?%?% MX7PQL_L0`:,$NET!&PSG.(MVN:3@DB;U,N<%6?4_'\X6XX$V2K?T+$=G/I$R M+K?66HR6=O.8`;UN#G=#NIH.%OD,VC=WJ8"U5FG;*XBK#Q7AH=USH_8_)4Q=(@^;#N;[+J`V]RO&8792,P(TU M%HN9W5M"'Z?\,SF%F!50S$TM06T_W*P%LXTU\#*.W7.P+NA&@M@. M$,X7SWWRMOB2-+[J$I`WG0_YK)AW9R:HWJXOD;![[`[MO9RF5LT_G*X38N8?K0[*R MCQSSPM'K=Y#)TBR1R874\>7U02_9'5_-:([)OV<1;K#ZKF:VL&&T.Z]"S&!^O1%[="J M.A07C\#BG#1;7)(D@HG(/C3^&!JY2L1PZT:(X5ARDJRM&Y_X^WG^Q= M4V:%KYWXC$#2@Q1B)R8ZU[2*/:#37Y\K9&%9H%O:_2)J%W1V>NZ)%44L"F/U MRW0(BO/1W>(3:L"-D05^]GP?S^2##4FW]0;=4#5EA^^(LD,NRIYD=)Y#YZ7L ME2^8\[@#2)FPT%\KIRI]"EUZ&_B?7OR"RJ,?LC2@'DP64?2=8%.*U>"2D\"P M":T]=?>#)FYV)[_5(J]5B\V,H(56G4MM)[DED]9!J7DKK(.>QP?>OWFH/U&@ MN"/L7$YRTU=28`8+H>(A`RW@G5)!)=J=/X1<@7-Y"$/4!7WG9*[OW4HU(+6H ML_Q`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`++Z M$8S.S5S@W_ M@#'^^JL\5L.X7/_MKQ%8!;M=@//J!*L_SE!92TV9Y^>:=6);<51![#=EC0-N MTI1E()!S_].250?C/<1N%8EZBMT2#/8;O).-W4[5X/42NV4@L%>W]^Y33Z/Q M;F*WJES*8K?>3=F]%_WQ.83PVD)EU"#Z]CN(O.)XNIOE<+Y/'U9!Y:QD=: M_8NVA_.)Y5?YU`EI;<1QC%0^I`#?<)N`-*KZ=DCC19?B!J2_OD,C5'H=R56\="[ZT^X-61VR2`R!]" MT)BEL=Z?I/8QX,]UIUYV.%^.+7>)C:"U\[:I9X?\`M*?1.\FBSK0JW\=T/>Y M]J,X/.`_W@3^*PIGX3K%\T_H/;^@?UZ\PM!]AK^A!N-/*-3-0^;S\6`TI-UF M1K[5([P=("D):_%?>D3:4S2J8X2EPUAY4&@J-)F]T^FMNM'IW1MJ%S&-N#^V M1]P?LXC[(VT1+P$#"C1G(,>3&<8SD$'ZD&("!!3`J$K+@*=G-X\?TOG3<&H< M8ELLI]UO#ELP.NR64_J5HOZE=5#-#ZF]RZXVN#&X7<4!B@7!\`P@>S`\0=,V M^M.T&1MB2TS;_,^@L&-TV$W;.EB1O@C&4[-K2%3G\06"[VEIX*9QVP8':Z]D MSS;8`#^/]%S<=X23@T("(%V>W2/ADMR_WU^\U4MR:&6WWP9OR#1Z^&2*C],7 M(IS;-Q`\;;WG+)6H%T6HCZ0QX.7BH"Y"$"/0T0:UX$811']"Q5T_:Q>!?@G` MBQLA=#@+:0SPV$4;#[4;P?"5G)`)`?(\"-:.O`BV0BQ'CL@%/ES!*'+#-]SD M,WG%VHNW$/]K'P8K"-=1DH,CP1K?"#QKV+VM#;/N`/B-9Z03C`0EO1SW9 MMNA8LG^0?US[21I@RL_Q)'/1OA:A.J1G6S"AG<7JV8J=R@J5 MAO$W;089%Z[?Z?U_;8/U7F:3S!+W.-VT_!R,.B,Q_]-(VS'^EAKI$S]B;WRP M[+Z"ITMLJR?6'-IHV0/@U75@@QW:.3NV0)B$DIV+P"1WT MIQ##**\UA'`?A/@\3[K:<(9O:R:G;Y(3,>GQ&]=?5\[?A!A3"--`&L$,X0IZ MK^2<3@@Q_./#-&<@0!V&Y8-!9_C'E1N]H#\"=[5""D4:_^[%B03(->ZB_,!. M\0U-K8D<4^!S$&Z@%Q^07!?^^NK'W@M)4U%E\9%V1URU`^%&UI.'4#&"TAZ` M'P19VGNG^6_$1\/:A0=AD52L+-16$4"I>X#Z!R4`QC>R)110]U;V3V##%&YG M"W+\G<:IXJ-A^Y:VL&1.6M+8]%M"+W3/KW\"TZ)PABQ(N7=Z5D9\-*R?XPJ+ MAFT+WMV.,LP1FI*Y,4Y3^H3S]^")FN>[Z28*GJWY^:;XT4YXE%RXR#?$23O? M80C13!!]]NVVNAE^/$'%TV47_34Z;&/<>K!*MLN3)*IN@035@*\X3(OV<.61 MNR1HEHEOKX3N*CZX6^`^AS"9P1Y-NN<1KZ!>3/.N(;U3J^7:!RN]S-19I99RTSZC&TJ76S2`QLVZ75: M"\W;]']:;)YO8*O%7ORYTCGVN2S#2?ORG M>>0WLL$L.]F_3]GR!EEB>$&M`P0?[Y=OW3T.E8,0/$%(MO@3>]W7^@,9J>IZ).T-&-VVMPK# M$CO:.3;*3>)1C^1^VSM]78I1]).9>]/Q:YI')YWUOOO.$Z.!:_K5IJ9HC-KRDZQOBX[-*4_RF*6T:A;( MH4K]3A/?O:4R-M%D).I/N5;-/C8G/E5E%I1^29:^MU8Y4IS-9N8C2O\XP[&+\$ZV`;/;WW-D&\/<12[ M_AK!N7B*R`%FLG8T[6$63,%BB5%D&R7E=H_6+:;U^"<)P]KD/YE9:8L0>NZ( MECH$W[(N33U#R:4YAJ>.)VI?]$T!&ZGYDZSBM\E_6E.Y%DE*241)6Y&-EL#T MW.Q$38'&.58C@WZ2:]YM\I_<7*E%F"3F`(PQ!V!=[;8UZ$B,']&@6;]3F@2) M?5:F<81TFIBT4\+)G^028+/TISB5J8J@:0NM;%22#NTS*+H??7X'%D7AH\UL MC)S\)#OZS=*SFY3^'EUFEL:J1Y5Y>-_?I.9D3(.1"4V93C_?TNF1]*<\F:F* M0K9V6K+!!*7P(6VW3R1Z).[)6E&HQ<(DY2K%NSKU'1.\T.^[\$LJ7N(EY'-[_2M=7;I M>2,6\P_I,LMBVT.Y*=Z+]=I+6/0IV9`F5UBSY:')8D;;\TT_!?D,&S=Z(M_B M$'UX=MW]W[`,?X/;.,K^0LS(A\'PPWA(#$GZ9[W0>S(G8J,J;4^8NAW.I\-W MNH?#([^U"RL<0J1+*T_M2RM/V=+*$VUI)5]0*3H$I1[-+]ARZ<[\3XND(< M%41!X'AF]Z9I`V+=[I+>K4/^#-#?P;?D%TXOU/2AV$X7F:!,S=;21L+N;;`& MQ$:L&;UOYS\&Y_,E^`"&YX.A8NHPKMR:X$Y]A90V''9[U@;$IE8BZ=VKL3N/ MB"#E;\:1_/BXO@+^M*.I$*A<%(^(Y5>[&C$;<5J4CE/ZD%^4$XC#=1D@$-U] MU<;$[@LWC9C-N3!*[\Y_3,YG`^3$%MB7J:81CQLSP*,&5U8;%KL3!35B-NK. M*`"46:3O0>G+C7@=6E9;!8M:D%0IE!X/JPA;<;^F)G,#G/Y(U MSCL$-OKX=O4#ABLO@G>AMX()5/=I"\\GLSGMO+BBS0>MV"5W'PR/:[[]H+?? MX6RQL%M-S0R`]BU1$U(X62_YI3;*_NA9>MT-%)VEY[M(=^FF*"`=DK>ILSX! MZ10D!NH;Z5?)OJBPZ!<_O.A\LI@/#)_/D`*L8P]4\0BV[WS*=3:<3T_R3)<2 MJ?LY=Z$"ND,W`KB$.1M01_@IV+F>CQE,FX[W;@.:`/=F`]A'4($-:.P,46IJ M]ZJZ1JDMM@$=T!M/7/%%%'1+DO0D8DN>%,F:_@6'->EICZ-<2I4J:`H\G0UH M1S`46IV>1%-@GNSY*!5#UANLV7AJ]SD&&X;'B&GL5T:--C3_*X94'&VMO=-9 MK7N*!E??P=<_#:[\1['#X.*S+"=PTK_O\3&R4V*#I/5#N54[6+&>/XQ>ZQP7=P9(;WVN MF7T)OL,P%7[GQ3@P-7[#40UTF\Q-YZ#JL3K'WS],\5"30-@;IJE6Y3T?%*P.;(MR-CL M/-_;'78]&I,DW<3MICY'Q"HP69Q&E-,LA44FAFNHM5B;-@3SZ?@G"H.Z1^*D M(J).<;0&1T56<,IRNN6VS?Z8Z=W8-KV15!L"[(?MO@ED>BA.+[KJ%LI)+9D= MJ](9WE)JKY)&S":G%5C5I;#0^#`-M5;C0T,PGY["KIJYD3C)P*I1'$.!53E] MN3V!59O"G4Y@=?*VS4Q@14.`'>^[/9HN-!2G&U@U"Y4%5J42/9Z!JN-L.\WP M$3Y[OH_*?DSR*>/C-]/E\C0.H4J*:M$9*?4?3<>K],[)*M(\JY#LS;; MV7N(+Y2AGR\#GZ3G/;C;1QCN1OC(^E#S=='^I3PEZ\KSJ?HQK"T(9[8G&;5L MI-Y7?-PEK@6A<0X1E#`"#/+$S?<[B)!_%O/=0B\"BH7J'T7"G MT/5`F&Y5OWB;/K?I?]_OC\_]SD_DT.,1=(LVK;H'5*? MU'X[70:M(2'ITI*K'8V*8_]N^@E:([W[YK5NL5^T.S>P$?E/;X>\09*V>QWN M#_Y['97WM?SU/8R]D+RP53R<5;R;-9CJRRG+`41.S:4DSI26JY'E<#FV^\"* MB#BZ7;P`)N?^ZO'Z_NKKU%=@%K)^_\(?;CQ MXJC`\0A_Q!]1O3_.A^/%G/:$CAH=$84EIS`*!R-3'XDF9Y9?5)053;=:2>)S MTOKD(7G2`J@V`;(V2B^T@F^X&4#:,:Z)6J+84]7$6O0IWB0VN79/=*5E,Q(U MRJ(\=GI\^O4)->_C@-6/0^_ID`6DEPC%/5P%SSX.6<_GJ"-M7HT)@ISB"$J9 M*0E;]L]>S@SRB8(`TI$XAG,<7F&T)LIN+.``QJK='*-!_ MN#'Y5VXVOGO;;5$>`I=N2,Z56I*O:1>5WQ-YSN>+^=STNA0#+JTFA&L\&,U$ M6YN3D>6W2Z5EZWGRT`F0:8*0M5(IE$\-C&NDR=6R4]!(W@"_IIDA9$W)0ZQY&^5*%[J]R]\_^!NCY!D,4!!N(&^`PCR^+0HHM3X M="@D3]N3X=3NK%O*9.S)97(#;7.=V5PZ:>VH!/*H68-JG:@(5TTZTU/495;G MRM,VF4;9?>-(H91]NEH!O/DZF)OH;GGV>99YW_I4-RW]'?EESDQV!+K'-E6_ MW=P5O4:/0>QN_XE[S&3`JSFTTQ1M:UQJNE:@L-K&H**ZBGHA\=D)>&3%XAIQ MSFHQ.UF;[)M@MQM0;AJ0M@%I7,9CJR8XQW[7NU5RNG]6R:#YSZ7D6RUP M!Y_K=_TWRLKSGFB[B_QTLPN/B9;;XL%YMJG>K78W;$JII(W=;W+K$-?H%I1: M[,Y=RVY327^+#:958A)*6TM1MA.U3N?O%5N!#07G)M,-^M"',$2P+J((QA%B M[6RI[S;;<7=R:LL`/E.]>M'A?&#W_DT39-UA;$._SI?`?_[PQ7O%N7G(#ZJ8 MIF49QQ33:C'<<='Y^7`\&2WLCL2:01N)IQJ[3TBW):1S!4AW#U^A?X`13G$Y MU_=*;-:-',E:P&;D*HK,Q@.[*74,5;?9.NK/R?XM2YC)XI084Z"M4V8YF0SL M7KFM864@S3(AC0]C,=MSW*?SX&Z3..OJ!S)I/MX".41QL$/F[>]B9/J,/EC6 M6-[6A;_&QHTXU,3J?2G>?)\L],5@HJC44%5^+(Z)S=TB-A!VKW[*BF;*U@KB MRVTSP/R@Z!FY15V+-V5>H%^]P/5A"V\WG-`?\ESR MY#UR[0YG,]O?"%0BH&X]58+2R5K!JQ:BFDL:Y%5:^(P7<'Z#P7/H[E^\E;O] M%."TA>>3^4+?^=;&;B55C5V:7(L:JPSGPZ7E"M*%73OW.P`X:8$S4"X"OB6% MY*GZ6Q@<]M'MYC(XX"4Z&)$_W/KP*\1O/*&O/AV:Y'`''N7DYI:_A?5=;0WG M`\MO68L+U8.>L"&C*Q#Z%ZF-G45>/_TC0$V`;TDCNA3L$:E1AA-OQ=#F40W; M42)]&%*;=JFX-:?<'-Z=6-J]E"0EES7Z0P'7H4*W%!4BK?2B1&PG-DY-B>IY M1X6_I]V[L5)R&=D%D$'H7!W"8-^/8C">=C@US:B?7Q#_0'9?RI&2R]2)!!F0 MS@6(7[QP#:(]7'D;?)[PF7@3%*1M@A!ZSSY898T`]RDXQ.`[ZN(%1$FOP/-1 MN1U!#KP(?<+@U5NC9I[>DJNP?HP^*.?9`W:)O@?YI$'G@P#<>$RI9[/\_*J9 MMX6FP=/WXK*.A;(GZ#M")C!I0DUH=VLU@NG)<7\Z"B81%A9?'!M?NS>:)*2R M+"0\QN?A7"@:I>/2BUAS9:K<[ M+9N47#:XGR9P7&L.22;KQ`_UH43JUAQL4B(AYT+_GG9G+9.2RQH'TX302;2C M#[U0N.1@DV*(+3G0OX_=>;JDY+)IR:$)),FSY3X_A_#9C2$(B*H\EW=:W1"Z M$?#\=*6A6$8`ZP!&X.D0>3Z,#"Y'H%&"Q_)>_/"B\\ERIG&KMJE;245DER;7 MM<8JP_G"\BRZG=BUAV0=`)SJ*0/\B[DS!OW.YOL_8U`)N$0VO/&7/OJ_D\09L?5OA0'4^=C?0O+ MC"#DU$-8TLS\LS8PG5FL"OR"Z'8,7&BRD]$X"Q,JE9^KE#CZW-Y_<2?U?+'0 M>$.*%85.'6B3E4T)2BU,9XM3UH*:)/VJP3$<)RG^`9<'#3J19S/A3B?(31,M M\9.E*E%;G&)M89Y,_=Z'5A3"&%F&XH9UE$P@21\0"EUY+/I^#-TUO%B1DP#1 M/5Q![Q4?VV]BS'@P&G$D[!+M1Q7_I:6K*P1GD^C;32V?1TO+9LZ/B`&L>!;2 M!,C:`$4C.GR-*/_8]D!.5;M:W(W(![9[/T1:-L/.2`SEL6\B2N9F2A;FS9A6 M),9-DU/5I/KFB=R'M'L#15HV4YLHLD!9M0GGAHM=S\=O'<0!<$&$_@O]&69W M-%=I%YS;(A5XQ2(=WK.CK9@U*!6]%3F584:6Z4-#!1)2VWT#I@.Y[J"KO7OG M:*U*_)97UQ=E"X7ZX%HMC&D;,KM/W78@-Q*"M&-P?O.VT%V#AY4'D<#1&;CV M5^>:.,<8-?1!NKK';QLWN^]@="`WY:W;86BR=!'9)QX/%_J2C-3[4TC-!OQ4 M4B9EA\/1T.X+V\V@C3K;(,<:TCBCL:+KM793J0]Q+%U6"H,W`W[@[>;BJ]I3F&QN.) MQBS:3=W*$95#FCS9<6.5X7!N.5<[L>MVPUT`'%P`K_D=GP422U&5YX*K;39_ M?*O&G!_?[N$^"&//?TZ/[V7Y_F;(6.K/@R@,4/*`J8X1JF=$%&]\.)O/[$[@ MJU!*W=JG#BHM02*^B7`T73O#?\L;`EE+8KD1+X/=SHM)`Q<^>:4"M0G]E0>C M3UZTV@;1(8073U$KF$=Q^!I>W-X_7-[_A?WVYOOAX_>7Z\;_!MZP2M])0(3S" M'_%']/L?YZ/E?,*Q"M+5GBS9N=$6!.^H2@;;[@5A9AGTTY@-B%,I"(J2R,*C MLH`4UL98MK446QA;6U]A&N2)W2LMS#(867-A1<-@<'5QEG%1QA;2UA=JV,;8 M[I"=6093BS>L@)Q/,%J%WA/.6.:_`?C#BTA@C49E[24O'D=>?'"3_T21>`3) MPXDK+T3PHMC%6\?`\U^#[2NN=T#_)B=HXC?\V"(^:_."XGAWBPN"Z`6BZFM\ ME_D7U!;YC/BP#Z+(PW]^1MWCWY#(&!IY%(G<:G;]['(T3K".QA)?I$,UU\GXD%?C M('!W^%00AA*BD4V>F:,V'<(5IN2:\RQ0_FGB+Y[[Y&T1GN1YZGOTISOWC4B+ M3Z0-:,L$7>K=UJ@B'>?$7=/SUOID>?%$E)U)$&.1%0N:(KR*05X<).4!K@"R M&EHYS>NSK"%UB_?J'GZ[+_7P"6+)*B!PCV6;?2.H(=,W8V M<'U!G,[M)O^)<(YVE(5=5UI:5ZXT?)*T*$];0_@SC^P^E"`H40].@@$6U5N< M@:(F2*KB?&?Y[V:4@G.F;K%2-,_B.;[5B*ICJ_AMT;Y((2]1A?,<`C>&;.P;^AYL_D7Q$X^*@AL(5N!,^2:FNRP!5Z3P=2 M/MD%T:I\J;>M!$*T%+$-`9Q<;T8UK5M20;T[;IAPPNYC5HHDM,S'-<`4<8E_?>@]+5E_]4?&>[#V0JDM#4\J`:N,X5?4LVT[ILX03L<%J>;!>V05DY MUPXOUO]SB)+STX_!Q3HYU.1N[UQO?>U?NGL/Z?M#'*S^N(ZB`UQ?IR>1+H,H MQNF$I_JR"<@@DU-@M6.2*:]4J_.QW:#S#D4;`#>"'QE) MFT%!+&X()"V=@:PM0!KK03^UK-VN$_\+[>183\,+YYE.V1>##Z"EU\ MEGA]Z]]#?+@6!0>HP$W@A]D_/Z(0-<+UB<=^A*L7W_O7`287_HHSR,O10-^- M.B,BR.EY3Z.<&00SW<]&4[N/;)DRV"W/\00E.P;*OE/-PQ=[E7!NS#`&87? M[I#8,4)]]:^#M\=FLG01:S*C)HU38U>Z`<@9!2$!,Y5FJKP$$F]\-K4\-8TZ(77[(&5(*VJ:M`62QLC9IKRYTGM#:.J9MBCMPE12 M5L^[P>](IVLN4D7CR-B/[;X9HE!*(RY6'=[*#&P5>Z_XOHCG@XOM-OA.EJRQ MBG\*#D_QYK#-GQ834^%@@_!Y,?SBO<+UM1\CT7`JAV2F^?D0X_19.YQ.[M]D M]GCU8P_]"-:X.AN.M3MH%5#5J+6F03M6<#7=S,9SN^\_ZA#7E"-7B+GBTI-6 M/Y!F0=$N2!H^`TG3H-PV2!M7YMW5LERKGW^OIJ'1]ZOI!D_Y[-ZTUB*OT7A` M)?*JB4A,P%44>SLWS390,P:B<7T+YAI7%V/:M035@3PS(E61N\P0U$-UCM9F M,\LOWDE(96Z"S0N-P_TJG#\+D$SSA/D4]*QE2LSRLB4@E^%I+S]" M!^\E!CXY48GGNJG_PJI5TSG.AWQW^VWP!N$])+S$9Z_3YSGF(WVO"S3U*J6DR!G,TPSY)G9']$+R:+?&`J"&#W3496$70;<$8<#BKW(48%0:DDR(J* MDCM^@>$]C.+PL(H/^'90]N%G0WTQ25.ODF1FEB4G<5.-X6@VM?L@1!=T[:1M M[]\AOX-*`5T4U1)8]$316B#15&-.L@6-[3[)UPW>2.C0"2-EJ\QR>*7YRQ(L'6#[$;Q@J,XA$.YV/R,HI2 M'@[?!0^'S#P=&G70-@WJ: MLHC91EM*_=E@""E*P(R',\20&]_J<7OURZT0O^]'-]-V,9$*CG=[>(;>RNU9X- M+'^BD$.*/BP['4J374]+@^^H.,#E-5)^8LRJ]\?Y"9-)/ZX^&@W'EF\&\XC! M0/ME0GL?/N.KBH]JK7H#+@?_0_"-F`>XW5S[T2'$H?_%$^K37<7GX\ER,F,_ MUDQM1(Z?C]_N+F\@I\RPKP MW@)L_Y:,9R3-DZQ^ZK%YN"Q??F@'SLXRN7.,K2@<_"O(?U;#MN).)?ZJ"T&3 MINHJ*"LR*MV*"F3`[#Y.VX':#^XODY)#.9 MBSAV5R\8]EW@^?%7S_=VA]WY>#J9T*Z9-W"0J5$Y2HKBSE_'8:H_&DV'EA]1 MXA-$MT/F0N,DI4%>'!3E`:EP!M(J6DG-YKWM(W7]R2?VT;=[B9)/$".>GPN2 MD_X;N`G#W9SA;L'P/:ZHE=B,(8-]S*X'%!S#;W=\P2>(J7"#"Y5S7WW7$R;) M&\*_1F"7\CYXA:&[W8*MM_-B?(EEM76]'?IG\LS'VQGX_N*M7H`7`9?L7<$U M0%Q$_S=[#M3[-[G\@O_[.0P.>_Q6+WX6Y`RX4?;#4W*2`40O$,9@C8!SOA9: MB;*N?NP#W,7G(+SVU]ZKMT9#ON[1]3%F=C\)Q2V+^;41 M!E0)W;V<[C"C.\X&[A5T7QFAN\CRBD5\[UB"Z?P<=J?SX9:EEV4:!F#&3'QQ M'A[-1_1ELZ5TJ9#YS4)029X7GP^7)[09?`3;:%12[?N8G4+W)MJ_H)YDKX9I MV!Y<9,6QREM^S+<5M_F@X0B!4RP,ALDOX."CL001JO0AG0^"/6I7D*%PG>4= M_"_H;N,7_)I8FF<\<:TTR]D5&+0UJHB4G+AK+&VM3P;_1,(!)D&,&506-"43 MB[B;)V!-*I#G&;-,]Z+>GXTS8,LHVU<"CN+#[+%L7=-UQ1$?_SM>+FXO?KKY>W3S^ M]0'&#M%W*N<)IO1 M[@ZS<4_123<.=`WDJY[56M@]_^_$;MCFU0!0>"=\U*W[V[)-BOIB7FWJTSYX M=D>$G=B-3'"Z4-1]KFK*B7E:8YSK]+5'0V;W"8%.[#UYVQH0E6;OTMU[L;LE MDY.UAY]8C'X+@^_QRR>X0F7A/1:!'+V:LGM?ID;ER"F*.R,J6WU\I&EB-VOY M!-'ML;G0.&EI4"X.DO(@K0!(#:V<9O/K]G&ZYO$Y!M]N]\\GB)%8@`M23FQ8 M)O9S0NQ?UDF-7\_`'J).>4_Y%Y%/$%-A!QWT`B6AZ: M!O*W-B9'>EZ<^0L+K?6(G;&;XVP"Z(Y'F%`XI!1(BBF(/QB_.5O#D\P;;H0 M,"?7G"W1F*"L,2L1C;E%/LK%SBH[RM,0CM!>EFH(FQB:E&.[&.;\>1Z&VL3Q MVWTBF$<,W>Z``XN3E\T/CRF8G7(Q@FV.:A>+ZX],L0ZYW2?0>,0P,G?E`%2B M?$5>\Z8Z),V-W83K!J\[RNU$X*0E%`2T M#)^7+8SMCWZ4M/JMXV?W,EPW>"/A:2>,G(.*(E&&#\T8?_;'Q'JLV3&,=I\D MZ@9O*J[L1%+>.7&?86GS)$RJJ@P>+U:KX.#'R=.LJ)OHPE]?A6$07@9A"%=D ME:RX6Z/Q:54>('+DEQ(Y3S3(T\AT-IU8?A))2![=P8,(*.?^ZN'QXI$W MG\'=_=4_KF]_?_CRW^#ZX>'WJT_@\O;FX?;+]2=4Z!/X?'US<7-Y??$%Y+4> MA"\ML>`M#G%/)Z-AK^JDZ'J`I-0\&E6Z>C"T._(6D,8&;:I"VFYBO]]1W^X'@RQ1;3A=S&@I_!5EX)*`)J=PB@QL;OFL M285XNMV:`HQ.U@;.&%UW;MCED89`TE+I=6#L^=PG5%'\S2`EQ-23+^_$M;6> M!$JF63*_L/OFTX*DLYWY.\<24='8C_?."[)`:L7OS+MK56FF"$- M5:.TD-;RJP7N\M7"[&!S'_3AO'Y/LC`/3Q.IW8/#(_\'7QY'SNHNF[T-HV,. M`_1;%A$J)?N\'*%R.[,-I>8+I+IGJ/3!>&(V M\B3PQKW"64E#GN0$G!;XW&P;,A0Y9D=V^:"UC/1<\=YS@K/8FZDQ(^?/?@0S MNJ?R'>9H]N"%-<);;"[V:N%Z6=!?VPO"/3W`@:_)W'/&4='0C;>1Y M^R3+'_[^EB0!GJ0^P?04[F'VE$3!?&W=6,HXQY>.3AV,=W^&0Q$\Y6GO_Z4='.'?*]X`(U\S66J'= M,9+$K*@;ERVU,/W>OQ:TJBG;%.DQCR2PR+T^%KE=+"+#HMF'"MO@CIBF MXLGEM#E$BV`Z5XVFMU=M M(&ASK'4A^8Q53J:7PG[B?754K9$KRFZU8^$J+ND*X&XD91\1 M"R%J-&"B:)9M+6^4<;5%HAA)AZE0LK.M-!F^S*9E%VQ-?.R`X%7O)L5=MMD,0"_XB370;3$S:/N_C]B);P MN+]1+6)#ETAODX,?QMBKJXOH*H(3^=*Z+//IG_&C[CY\&7WX> MD6PF.$&VYY_?_/B!L"K[AIK(L[NXB`/^!@I&[$U1H^7GJB+_YF!H>NYL(T4_3\WSGTYE5NQF`D&5AFWW=@7F<-=^DBE\R9IG8Q6SZ1V?([\L7' M.&QFB[(/[M%?Z&'Y"/V#G3UZ\A]02P,$%`````@`XG5+0P5@"T8S<@``$(,' M`!4`'`!B87-I+3(P,3(P.3,P7W!R92YX;6Q55`D``ZA'6%*H1UA2=7@+``$$ M)0X```0Y`0``[%U;=^)(DG[?<_8_,)Z'[7DP1EP$].G:60KL:I]Q&=:XNG>> M]@@IP;DCE(PNE-V_?B-U`0ET28E,26BJ3W?;QK(BXHO(R(Q+9O[RU_>MWMHC MT\+$^'0CM3LW+62H1,/&YM/-M^7M9#E]?+QI6;9B:(I.#/3IQB`W?_W/?_^W M7_YT>SLUD6(CK;7Z:/VO9H-8#UN%OK=9/-[\]W/SE]M9_`:>_9]Y6I:_;A:?ICFY@;>*XSN/-^>7B4DHF\ M]WO/?58:C\=W[F\/CYXPX#\(+Y7N_N?KTU)]0UOE%AL4)!7!7UGX9\O]\(FH MBNTB&_KS,%>]NX.TB4_0GVZ#QV[I1[=2][8GM=\M+6#Q3)AX(C<`[G0`ZZX@2U-B6$3'&K6_SXI.D5^^(61; M3/RHZLHJB9^%8@)R;\C&JJ*S,;>R=N*86]KP?ZI,:[Y>O@%S;T37P`'<_],! MQ;(Q:!$+EZ`7V18>(\>P4UMT1.QN$:*H6"^'[:EB MO3WHY#LS;^J:+V,4EP4R704S\:#O.`^(,`>ORDI';%@`'[8X1IX5DYK3'LV0 MK6"=F25#$\?3"U*)`9:)73L'VP$K=VS_A\_PAZIGZG,S`BF98=T!LXO[94[I M3**2%284>LW]PEG:1V,/PX*8F-$&L+$7QD`.4P0V.)MBB(\\*@)&N&N$&LVK M\LX,A6HK[WQY6-I$_0?8-W+].CAU]N6$M5++X"6'K0!'G&TEGJ5"#@R8X^W` MXKE;.MNM8G[`PH+^>KZCGTU48!?;.4T>6(9%!E%XLXTV=(;.NWRUT`8;G&?H MTD1X2&' MVB@G(EDIY!TH4[S=0X2K@U>@GYJ._^F46/GLB?)I$5/ES.H,6:J)=]YRZ_4- M?7;@]X@QJM"(O>(\"`\N%&\,O(:@$<)N526.0GO*GU(]'8Z)#D$ES#0_$G!%G9:\=W?_#?+Z:2@73 M+5;6&O?].UT% MYA]*%EDC_II2/$-":V2:2'-C8II`^IV.>(,Q1P@F9"G?RV4LSQ+098_W$C"# MOX(NDW+*W6=FL/J@8/,W17?H>'.V[OR><]!1KM=[WF/N"4'4-*$\;KQL(5N6 M!BFF8#Z*Y<:`+^[)L5/.3AW05VS@K;/5Z7,+Y<-]!B;`J;+#MJ*[?YY+U50( M\$-;?;=6]9H(>$49#=8B"X@.5;Q3='\TS%U6%CNVK;M:I9T,;AX)O@\F>K;^(HNHG&TM@ZM\ M>0'N,2)[>U:!9C+:J[63JL@;YDIF6$\?2/QYA M$4>7($?7\8`-T!U6]*,/8;-HLL/JFK,Y7<)UGHJZQ[L`UU&4^?CNU5P>QI,) M5GXULJ1BK06>)"*Z"XK*$>[-+B#*BK>WRUN""\5NWR`$>25>NR@Z!'?S=5`! M*5(`=FR(\"N"QS1ZMY&A(D/V=AK"[ M:89^X_)\VY'\K21_AH\BKV5B+FP%$S-@=&V2[47(VB153&+"DMC=KD3_N6GM M3$Q,>#G8W4W+L8!=X@Z1XQI9,=4STXKND?&?N-NY2^Q;]0V?+O/A"2;=3(!C MC7+]H"N;MM3O7\= MU)4EN*^V7KW5]H`MB'W_CA3S`3ZQVMW.D+/B3BC4277)POO*ZU^#\CP##"2( MFU,O5U^(1OT4&`^`K\)!/57X:BHTI[W\V*Z(WI:&O$9=Y+UU4%62H+YZY'JJ MQY/T!6TP%="PGY4M^/81+RW%O;X.RLH0V]?9L,XZF\);3%ICT-#[W]`'<,_+ M(\:^OSY:2Q;<5]NHGFJ;.J89F8L/2ZG!@)/FDDC407D,XOOZ&]=3?Y[0#UA' MYA3XWA"3VAXOU<6\O0Y:2Q71_EQ0LVNQ%[2C.[$@:`78'&J5O'+.:63JH\U,&`)EUC2W MVV;EN'XC-\/YT_ M+^=/C[/)Z_VL]7GR-'F>WK>6O][?ORZ92Z"91Y_EKG\&6X9?D(KPGG9?/"/; M'U0'/?;&;K0P3+;'M6*M7*0=ZW:C*#O/*)%N6\$GI];I?\S$0/%B:=K;VX/^ M0*I$+BXCL)#F#N./$9<*RZV[8'_GDZ?.Q/>Y+[-A28;<)YGLXINQPKJ.M!>T M1X:#P(O-[3>(CWT$J.,:QYA&0L$__6W5:SN'M!46<(4JW-MX=`K8P(N3Q3B` M.(K%/1D]5Y`>A`A?:$/P7M'AM=;$GBJF^0$+'[<#J"T/!K(PB9A8X&/M3-HZ MI"7S0M,`K\87P9S>I:E.(CBD[P.D;TM27QH*&TMA4A4,F41)*^P$$:S:\'X^ MW\C;4F?8$ZGC&)J5*#M+]@I;2(1J?6&BG8(U_X2:8+TC];M]<;-D+,T*M)XM M>X5=)]6M]<97L-:+O*X]&`W[Y7`NWDK'9RN/)%$K[+G):9R$GCR3TSA#N`A, MK41(<51N(O>Q6HWQ5`U8@"?,-]X!=G3GF!T^QEH21UA%E%.O$R[2$'#$V- M-=Q$NC\:B*$&45:OVQ4WU! M)I@0-X:EJK#A7VC`.-45R_+OU9B1K8*-]GB8U>1S09'GC%QQTULB>M_-Y'A2 M+WWI5[1=(;/='WES@Q`A4@AS,5(&G02&RHA!O?N`Q&,MW+ M6T(6R@?-@Q^;'F1Q"_EXFEQ,,8]J3LM]R1`T-4$#DIL.TLY!:P\&`Z%-3O%D MJS2!;"":FJ*9.I9-MK"$U?8T7CF(/NR.Q25L$HA69@$,(#0UM>,;?Z@N>C1^ MKP=5I!]9.C!#]@I/E1":&YPA$^_=LSEC`!AU M!/:"IU&NS(NQPG%8V`SJ;@Z%O=G$\#*-D3/$0PCV12YRV;C@;28Y14YV'7&& MUM2$6,+"+U36@[6?N#50)OF:&$DNF)J:-@LO$L-U7U@GQFV6X[]*KIU9,"#2 MU!Q:"ES]\4CU)E`E8S%M+"LFR4 MKB?=F"](.QP"X5YN`4Y@(+#Q(4+K@LZ-X#WA3H?).[:`?3GKP"`.[)^2Y6+/ M68HX>G`&X>O=L'$0@2;Y'^%;RON@!,4=Z%6CL5AQZWTH?0KO@A908E65(D:T M>2^FS;0!439/G(HL1IL:?!YPFZ\/=_LLB(4C!TX!DEDG*',8."D<\!U*N40] M\X5G/K,V4Q8S`-FKCT.")JTCLS:"QUIVM#74.ZQ$ZDM=<8TH,10Y&2Y[3B"T M33U5^@9,"?&)U^/YO?[Y-/[>9S%YUA-JE:D[3>RF3ET33<,>WPL%:X^>QN M#V2!K48)1"M3/`,(34V5OM#;^`RDW2NF@8V--5%59^OH]!#'&5IC%=MM:=`? MB&LZRF:@,K/(B4U3TZ8AL;VC^<@6Z+TAP\)[Y+5G/A&+;KB=KU^5=Q@U'8$G MU^5CICJ74ARTZ\DUEBA$6:9]ECC/D/UZFC#/4N67 M'ZS<8S]8N?73PI7F#=E85?2_!/(4/V@Y\KXH/#E.7?ZQI_/'GLZJTPX_RE(_ MRE(UJG7\*$M=C:KJ5)9BR*AZUV--'/L-X/T#:6YZ45RJ+9UXZ;6V'%@T-=4: MA>"9P!KND&?NB]OTG42V8A-(D+^IR=%),+,G2;2!3\.M)0!;6^-E261X-Q6US22%RKBO=*G((/SU;*:^4._A59$\DDOISJE^?<@*@V\&XZ:9 MP8]&TQ^-IE?;:'IY=7605EU=OL*7K_?/K\O6_*&U_'7R3](T`MRL&ZI(W91E\5`\20WO.G8XP(B M#(?BSBZ,T.)3;2VBFV`,)HO>U!1V'KA&5V?*:=U;#\1$>&-X1W.H'Z^F8EA` MC)J5H;D_Z9Z1:?_G6+9_T8S7[R7U>IV!,$3$,%WZX!J=#JX2E'$UM88],E2-WAN M"0(^7VBITQ-GKV?DJM!UJLQ7XY[X[$,)&M=D<>O'5,I5Z)\5BJ:61$^W702" M]P?BSOJ*IUF%]K.E;VKADV'+Q`$,X1/]&[Y>3VO MW46L"'&DJ^D\S0*A\HSECW[AG/W"5:Q%+E.5U*F1KA*83]YN)8I[07O-&+3` MLLF,/GTU`>\.`6>TBF#:.>:V\\XWN>\=.R%(Y667=F,TGB[SU02^Q11^'3L: M.-?R\U19FAKM'M/1UBM)"/W=H?%9L9!&00/$7`6X+G+N"FV](/"1%K;1$IE[ MK-)62##"%Z22C>&^L3V0!6XG*$F(TFVT`N4T-;IW`?$:MF:.">[=0\'MWGQ& MW]W?6'2.[XA+[S+Q4+J1Y4>FN2%]+!+>RB`"15=<*I"-B;I821HV36V$9O'* MORNFJ1BVWR$ZD&6!1]+D9:>6TU@B8$UMI8Z65#\CPSW22=&GQ-C#FT"B!Z38 MCHG:W;':\C0 M7`#BMEZ+#<+(!D86_TS=SRC%2:,>N(R M,I$D>C*K)HD3XJ(L592`4&$SC4FZA1L+# MHL`;46UY)/!:O&2Z5109&"`(+*"!";7D`IQ4H[I2_L*W(.Y++WQ+L3XL1>K` M5NL?CGN%T'M#XU/W%J/QTNO>YPI/ESG0=_V#]`+ZGF$3J0`P6PFDU^\.XN*S MA)Q,KI=7$*87%3VP"+EI5X1G0'):ZJ"8Q&T+*&8.5==W+A`^,(AATPPB=`9` MZD'E`W''4S.QP-=8\@E[12<>Q.HXO0->B$Z+[TIDUB%;?W>@NTP,*E?AY6[G^]?UX^_G;?>GR&G^];/SW-E\MB9^:' M3W28PZ+%99E>8IBPL3@*2HXS'KQ7',@=;T0<2.*"[P2B%X1ABHZL%[1'AA,T M,-%K2]K20!9XYE0"52ZCE%DO!]_*`,'5-"3GG8-#LG\A1`L$EP4F&&-(5J_X M6.&OIBLYI]:SD!)RQXU0UQ5HKB^,_1-JI5CL^>4\*2)?3PMUODOLI\2BBV;? M,;>'TEC<;O$HK6J\4K*\36T>]B1V/?`2PB(0N2NND>.$6)4ZCI6XJ=V_(9'I MC>*^>?O2]R1A?CN9;C4NG`V'ZVGNS>?,OY@0HE2- MHI-$O9Z.VWRJ]8-M8W/_3O?)(.L`46_0$S=E)Y*MQK,SH=#4GML7!+(ZJNUF MMJ=OBKFAW3N#GBPN(1)'LAK-9PK?U'[<@\F'3\;L=;RK/(3X]AB*U?CX+-&# MM%&G_CK/Y^RSD.IWKR*%\&B`K<.X]9UU6Y*DX4@D_Q%RI=CL49+`:%.%OH+F M\;%GL0;:T'Q_#C]%SU1Z)@:)#EH8L'V!&P<2J%:T.F&`H+$=W:'#9`'!*3$` M`` MB$ZEEB))-?-J5:JZHN[R(O,U`.4[?6]W(`U,Y9&XS=8)5*OQ?2P0-+99/.'< M>B'>B?^1_;G]1[*X5]0,GC/]DG)X>G#RCM=L!I^;2+'0#'E?CQD*N2_.%US. M7X5+)FZX'KL[:V]^W*Z):,MCJ22K,9=9$I_/3L\C[I>V_1I@C9A6TCJVRK*O^:0\)B-K>W> MCZ+9V"72]6.9M"W)4D_@J6\18ESTGJ/C>2Q:YJ?W%+P`B4'F;&-H,[9%. M=N[^B0"!07AI]"_81),(FMIF@4`,1FR2T*4`NH1\BH%>2&2?W0\0*?CW] MR_Q2KSSNK2P]'UOQ):(B4MEEW3':X+4<:[CJI;RD86]8?8#/+Q-X>8(C;]A_ MCN._F&7Y^;.8(U2&/8$GH.7DYCJLBPG+*PXY+M_"/F3?PCZ=+']M/3S-?U\& MDA3>HCY5K+<'G7POO@\]'\VW84&SJ!!9_2TQ;DKL"#2B>Z/79#@-X5SPQ91Q2#_"Y)_,3^*\3<."#0TE[\X4,6!DD*_]@#RO.>(N?6?MM21QK(X\V+CX@JMK`B\]3]AH:BQS?RW)[6Z#^6NN(W8 M&<1K;UPQ,0TSFM=S7$/N+5.1_'H(2/]BL6._BRS%W:C$;2,)(Q_79V;%,+Z> M4R2$M'^Q'0HLOONK5$MAQ^80+]>V;:S@+@,_6_H,.,.WWC8^"J*A/6!#`?## M@,ZPI>K$1^4K'&V^G+'@B6M#6VG)/Y*TPZ<3K;2HYD&MJ_NAP?\Y$54T8,@O' M_F;L%!PYIK[='0]C[YE//)2?X:7U-HW\N#2UQG$,M>E^?`K:*S*W`*Z7K>]( ML2LSWOF+&-KU-B!VV.J?!"LMB!1V?!#/*))1V*`,`=$!PGOW^@:I,QK$[F(1 M)>.1;4$1F@&O<>3)A=2QT>(>)UMI=$C.J_ MTN=I*(>C<"+C9BP)+%LQLE%OX\G$K?X3,S\S6IC(7=WZ9/V4-ZR"W,;IB64A MVQMDI5H5"U=U-K+\J#:W2)4\WR^4CV"R%[CQ(9-^58;$4!E(0^I?IP;EA^)/ M6%EAW;\BO#/JBNN58F&AWE:3AE=32TGG0$P=RX;)WIQH>XCH/1AD<17Q;`9J M;#2I6#7U`/-G9,<5ZV(R0,>=9CU9W%R5GY_BF0L@HB*DN6=ETK()U?I\_8(V MV*(G:FK>%:8+9Z5C=;X&'=#=(]WQ($]!M@@-+F.$AV)#O::7`57__$7IHT=, M(%'F\'F!%?Z'OZGGB1@;FN6=H16]HZO;%Q@L)=&M>MB9JI3*4OK6Q\-.^-?2TR3;P/-\J'?2-5ZQ1MZ'H>#.L3M^2;"E0`VG'=U2EZ M1CLI#O?Q#7)"CSI@%":L6K6BC-,\F"1T@AB![!7<'\C\8?!5&I+PR,PXGPW= M'4?R>C%W;Z3_N]WKCSLT^4BL+TS\E'1,9R4[8/QHT##&)Z`9EMK1T!R7'QY* MV5`!B^AYFT^&&55__.?]A2R#_"1P;]0?P9',N`U([>'C=V`S\^`G?Z!5L*_. M@FV9;BN(*K&O1?Q,P,FA[!NI6I]8??4L#.4/S@KUU5F@+=-7ASF9(N;4;:)_ M43$3=&1^3O5]I(>^/^B,2_'=4W91M2*E^O*LZ#77MT]`-JW9%2,+US?.OY]" MQQ+MS3DHN@0_L2>"`@+Q56QKJ3^AATSITPT#.?^_>5/V(UAC:E4Z` MPE=6\G_DVOJ!+[-DK-!XI,"-,.;9287:F1>PIA8A,:$(XE46]@BH]-`Y27]B MICT4H0$IFN!6D@U:;6Z=U198R+:8O6`J6Q6@!"F6Q:H!34`J5&#:>N%LQU M>F(>QM<4.(BJQEV:19]S4CK]UC]:(3KX/YY7FTWK=;YN;?XY7<_]/6<^W$2" M[-BQ<4JVK@GE>*-IKIHZYEOPH8!9RG`$U[:>M&I^@WC[Q2W&X`'_Q4]\Z^G` MC7]+7%:(W6-G3G`?9(&AQG&^HMK7R]*^UA];,K_"^N]<:NC^VR^OC)O=&]I? M2,G![;?]5*'['I<#5RBBRF#FQ``2_L);W._V.DJ7G2S*>G-1G M_G?KCT=DJ]HII](''_*^DEO]I[JM[OOO0ZI'I$],=*!XQ9*0N7 MS3I&#"K,1^>XQ,;\1!`N0OK_!4\'Q[UM]P?N$VDP,BQTK^5<%^+2#P:XY);/ M#V1&+<7TMV:U^Y,AW"&5N*R8:#>P]H3/T#"`)S?_17NW(-)2ZHU)%N$"X(PT M9S=S>B7;*@6YE31/IW(=%!&/Z6;%8ZX#6RWCT(I("/G/!]72=BVWP0!CTB(Q MF!86F)8C,2W;P-_'`H?VB;]3--)SO<75X4J$G>VY*Z_,JZ"PX>V+]I=%8T:W MBN/L(N(PN"W'I<2-KY;^JMU*G/SX$HU)!0079M8`D.2NT1ZA,SD7KZ^AP4M= M;670@7Q>)W,#)8HX;;`9%SSREX[GGZ1()=\U`('SL#B_.WCVE1'@I!&>O50J M/?E!D[]8/J\@L6$)4@YNYIES M-R7J!ZTS,#=P]6D&X*M]9H,29&@$D'K\A;3C&S81TP]DJD>TO)#X-KXV.E.[ M5A?;LE5]C]?U>#SJC>!(Y-I+B:H1&X21'[3:-`5PC\.@0MD>#R;-X&"!M]7B5,D MP5F*S(%>6`JF\"%NP8J'E,?Q&_!L]3)O;:?_RQ53)IGTK?J[4-C*^P:-J8,N7(5& MRL)%[&WLHY$(3&?8ATN-I2TM2/TX.!6J'R,@-;X&%U?'R:TZ;K:KV?_\XV&Z MF3^VL&*^SI>;Z7:Q6C*KIE/)\D">-R7]6TBWG+5S:VFX.;_E+-?12FX&X^M:S+V?U9'#+`Z7]B-UL[\17$EQH? MK8RBO#2!H[]:[)6LWW+'#MYF:B"(WKDU-H="/E"F9WW=T.H$?/NEJZVNL M@R)Y"/GW.]KA/VX-\J-(V;KS=\C<:9:#[@W$P^X8T,I62IS?Y.^R6&O!QA6$+U?J<4PG+Y46 MJ96A.K;6V!DNQ?C[[?08PF]DQKQC9>!T`FK;4DM_*;QJ;!B:"I[GYD6NQPO+ MNJ`]^8&V1][$6O>W7D^JWNX-^E2OGMSJ'&'M3'H=1U3)3P2M6D.I+`2L_#5X MH)&''GOD87,YGU7SDXP/=@!MN8BV_,BIN("$M](5XR*O8=ZC%.+SNP5#@1'= M6QNG$[;VY"_;_?$0,"D!LN<:VC^1;&KJ)4T@S>KP`-WHU\2V!H'H(4!W` MQ>3*I^>K*$8.]GXM/Y8=U>E^K[ETAWR//(X]'LJK'ZE;;[0J,#/M'J.F`WAC M0-:(/$&"#V]CD+MN.>ZYH%MK]&R7H15]RA=@OTX'DVG M76R!,=1T2]N1BJXK#">T]A0@<<_83J/%FX<5-8Z#R.KX*QT9/1L@S[]*\$E0 MV56A6D,NQ!9)(>\E7\NN^5^;$,:[DPC8NNL7OW\`)PM?-N21!:F3Y63%LSNIL/!9'"5WQ1(D!5\VI)*%YY-A'I!F MDU`4*ZA]B56+DYR[?HF4AWO@1KSGK]3XVE73FVZ=(:^[00O!K^ZFJ]0H9N?> M=.:9R_?%1M]*1JII-D M<("%&R1>,C52Z!=G.84H32K"^"][HK&2KY54&>VZXS5O(08R-#R;JY&A*?-RF,7%^PTQ=S&\]*4$ MO$T+T""ZG7_$_1M.:@&@NV$I+`NS+`*8%!K?OG@-13%NP;QT()WE(+UY;J/E MX\7$7W7OA\X>K.A<$S_>0J9!#'M]0(2X=U0'W8\_+U$4>?EK-_(^.R$VU.'T MJM8O,,\9P,%048.M2+DE2V!\!,GUEF:J4"OG#-P5M M5P%PDW/R2>`J!-S.6%Z5RT'27>4$2T5M@DD5N`O,0P9*<@]$#'R`OCU?;\TI MZA[)>Z5(W+@4=B:'_`'.1!42C/2]*.KQ5V'$IP,9$-%ZF[QIRHH@7A`; MIWRIS<)!_A+/?#ZY[_^1:=@CN(FC_C(2<)I*<6.O7#Q0C>MGOMQ;27LP=A45 MA`)WC?(E=WPKN7%B/;$=22^V'\C\8?`([C?#V/_23J>VTNDI<-+I+R,!=ZD4 M>PP>-X_!"PRD?M2P*^F*]1+9\]^[TX5D=4,H%*4W!F,^RQ8D$`QNI#RAF31/ M:%;V&S)?\/72U-33TM!WJO7FHJ?TNNZ+YR"2DKBN!.+!AHGOX'2:)Q3^>!!K M:Q#R+R;9C']6#GN`CD'RPA+(!2,LOF#([_IR"\8CP@OL-!=??3\]$QC_=OZS M/>[T^V""D;*P!(+!"$MH,09-$PPN_/HUC.I@A3>N`QKSWZ2B"&&"QN[8>QBR M$A$OU72& M%K0GX^ZH1R,MH2XZ]6L52'6LNYV#W*#CM#NHA61S7@SB^HU=X'X/KC0E854) M@IPL>`32,"3B(*,TE!#SG-3/OH49"E*T03IH-/V"5_%2&-CC?T!X/>3^WE;] MC:P737=8N]`QELBRL=MW_97Y?R[XKU^0_6;@O_E`KAW!5\C.<#`!PZE$2LK7 MRZ(NV["3EK#>\3=W7H@3CT2#= M@A@#P*STU5)%2M_-#VV'_)*7%^3,0.A.!J,1QR1QVD=$RE<2H&$)1Q853/*S!P6`_(@*&HQ9H:)#3:^[7A<4A2722![ MOED,4"9C!U4*G16V>7.2RE<#>E,1%T>H\M.W>"]=[[;&>3W?;-??9]OOZ\7R M&W/Y\AI[KA=S9SMS57-7*).OF!?O*]A77J,3"2-,=[;VH=E:=&A\OP=7L<>\ MC?Q6(W,):E_9H#>$:Y+(LR4A!J@`U\.:L()PUM@?*MZFEVX#^!OTKHQ!P=Z\ MKV,2HCT]U,5FAF5;5QUG`\`IRWR[D<40%`&QQC8@CV#A_\#71/3PN<7[6!T( M,%>X0);$\^](<@%C!K/&%[?B+76]>$O=S5&S)'DOS`V4IX?NZMP)OE2T;>Z* MSX2QCN`X[':O#?TN7(MD]1U""47.7E$TJ:$@$YD/Z M>@G.>_S7F&"1PZEKV.0*+OTH^]K)Y\^4PG9>O"J7XN#P+-]R-K(V M(*,.9\CDO9==341)?V=1(;-"V35!,2YD4U&+03PUJ@5,JG@!V7-Y ME3TQASJ%SMH\X)#L2G^YFJ!4F7Y&JH6BSH/'\UY_TJ>YDPG6,.$S0J26(S/A M,X.%JLKY(B)]ULU(GVTNY[-J?K:,0^L*P):#2N&Y9MGN6 M[9YENV?9[EFV>F;9[A%V_@A[@Z\%U83>FJ#[]XATWHBTI*&;E8ZVVAF1!QXU MW6U(13HZ:.$]:]#M@G$^:_6J+IT\J,BMW=G$@YQ^Q6XI5$I(._V[$QXU/OR; M*58]M[]^:ZJZA0\/*XR=4JE+B'GP?+LDF8R=W+GI;VK9Q/S\?C(^$0D.$29@ M"OP@YZ@+%X!.6K4RL6!`H0&A7OKA12;I7*'EF^>A`E=DE;1J51+`@D)31^1_ MP\A89.`*LE;Z1CV1PD-WCJ9O"'L].$G(6KTJB>!!);`-#:NHNF=#*JOT*-RY M'F\E>IQO9NO%J_,JU^JIM?WGO/7P?;-8SC<;YG3'([)VIN:0OCILWY"?%,R= MUUB91U7WIK/.#-TR3MK>G]SZ&J%P=7C"MPA]IZFG(",91AI[`\#&;R%;S.^S M%UJ>VM?=4[IPB7K1VQ5B)8"D+/`>(%E4XV!B<2,62^ANOK^\3-?_(@9LL_BV M7#PM9M/EMC6=S5;?EUN2Y'U=/2]FBSF[30NRMAOMJ&L';:?J]G2W,RYD@-WQ M%3-SIQ7HT(]_*A2H,5PR('G9`CFO-("B[SOWASVXZB6F30@Q&QRL"U);_!!] M807O%E'PUA\^KAS/B#+I^EWGHU5^D?/,^>QG*,;#R1#N`?"TE:M2;U8T:JS3 M+,_IK='.P/I#`T$9#!3P=_:2UZ]*,/B`:6HX>:9:;]CG)?]'0NT?ZHEXN#$] M&8S@LB9,6ZC,?/#BT]2H,]83A,DGHZ]B>M*?C"%+2I(6KLYR,$'1U.@SF>JM M8Z0_8\0KO2%<"BIIV:JD@`F&X$6#ALG`JTG><;`_7T_$'=?W09HVKA##"9QS MP;J-JF0D%TS!=/R&R. MY.T;DRYB,=PZ`T#Q`MAQ9=8*&/S:O/O+*;33_0=68,WR:D]<"+Q'NO8W?]D> M#"=P87J>G50E97G1JLVCPKP#+M[PX@^J1=*69X*"FU1X]S(-6-_PUK#^D?/! M4[*V,NR-`&.Q_#NJ+#!;$+S:/#K,[7][K_'$[?%H`'=-3UJV.O^;`8;Z/#+, M*01+]"N"F6GH^(\[-SV9<%AW1X!Q;-[M5"4TA6"KS\/$G,(4/-CX@E22U`EO M*+=P3"#+IYFW497TY,+)EYK&A8Z_6VAUF%NV=E9MTDXUZ@(6'5XO5I4`I)#L ML[F!@5\+X55(%/P1?:"3X00P/*?>=[L&O0Y<6I%A!]6%@OG`\:6D<4%AXJ*; MZ`V3C3URUS6C6\;A1(%,0+/MHKID-#]*OL@T+H;\9)A(.^HS,O94Q\239AX, M'J:$=/@X_WER7R&->_@=!2[1D'M?E;DE0H#TY:R.<>?"DV@ZW7CU-4]=4Z%7 M'MA*G(0]_Y`M82!=KQ"E3I2"/:>-N3L9#6CS.Q+'B5,_4Y(^Q]H=6*B2N__6 M'^V'S8\_:]'K\>B-^G`A\L1E"Q30>M]9Z2AH@@X?K&>0K=@'A$@5!\"W0R_I ME#2U_,VG>OO+B%!-BZ]G\"_X0-7\HU/2U/JT@&K,I*C M";T:A[2D^G-/.Q.X4D:&#>27T8<+!L:=Z^/_<7%^-XT/-[WA69M1!RX)Q+0# M4:++STE?DGF!:JIK]*+B975D?D8!]`\E!7":=>+J:NV1<3 M8?*?M-_D3\'XA.X(SG8DKUN]2+!ATE3?S1F^\&:<]A0CV9T`'B#M:H? M?7K'<&(;+)-?.)U/>)8&[Q7N]AE92(BPI4`2,GB9QP[] MS&HP$E2#*K=*QHE\#J9'$T(Y9M2E?`HH<9O%#U;B:O-:8R[E3(TI5WA)%B6= MK"^4%Y-.>I&=:KT]/2YF"YV4J.RG9[)$>SA4`%]QHRT)I%]I8$?G,:1"T-1H M[?1T,GZI^@X]&>:CXF MND[?+82Q>=8.B'2B#VGE+<"!C7`'%0H,+SY-#?D^(OSYG>:@VQYW^G`9T>A* M%3(^B>"FAF^#1J:%_GYQ!YH2U-:JC=H3I3>";_&*+UPA^QGA:.HPEQORR5`( M\@:,-R#MFVG\LM]<++K#$KK_,G8ACYPP`=74:2Z/V@%_'&'OZ@'9OQ#2`W"< M<6FF^8G!=?Y[=?AF&/M?VNGD0$OS2Q,N47G6J/(4*0I)4X>H!,0JG9X"9T$D M$`$JI4V=;A(9Z.)U/)*9+G"S2^+K57FY3"6^J;-'IOM_7RS;*7;8&M/]7G.) M>%6U_4*?J>^:K9[HSY;V].6FCN%:4'%X1EV4*%TL:-4'`@-NSUI=1I M`&UET`4\'%/7KE`XV#%I['B=Z=G`GL+?WH,RM]K2'HR&@%,#4]>N\HAB!B6P M%J-!W<1"1%]ZH?V]H%A:VEZ*\B,M`Z&V?)S(RT_.0+7Q![\ MEK^;A9Z6I8%O=5O.E,W"BN/VA`(1QK0)(+.2S#N^C-\51K7)%[\[ MWO?&5DV;X^AISK,VC-E7/@5-2:FMYDL"Q* ML[0BM'@PA$EU*BA%3P6E1HE?]U28ZWN1XC]NEO23B-4'Q@D1Z]93X"CDW$U) M"C'.IP]TU&KS<#;>^@]#[*G0KXVO]&H:'YJ%V7#+WG9OH+@/%-T2DY""3?Q2 M2<+;CWDTC+0%-7S2"NK$%50='I2UZ?8!!S8D M+UR5+#!"T=1`!VUPB4=]1P$&J)($1BZ:6>F`L?RU_5OPIG_5=(MLQ-*/R;2]>6CK+>PM'?7H!8G971#RR7R0>2>J4 M#9WQ/ M#.PJ8\#`!-]F\LO\C/0&$1-"@']1S9_^;-!)#ZZ9/FE1(>)X)2/E=GJ M00?*4XB.O,5">:O:4G!\^`P=-V=.8U>9P(TNYM@(B`.2ZJ2637'NRT8!ML-WQE:L0Q0X:I\/+.(*.Y`5%7I MTX648K3FEJV=BW/N;^?94'^&Z1;"I M=;TYD,&_VYZ,)Y4DF%+V5"/9ND&PQH7"16^""J6[SQ]; MFW].U_C6-UT^MOZ:KM?X5KAAO\2I;O^?1Z8SL)!T]?REFJ8:ZS;CN(LY0P[) MXYT8$U*I97\N#1L%TM*?`&9@T]]# M3`B'DY-!I4TNM&I\N2JJ[+V_=Y=]ZD5=N%0UU?UD]2? M3G^I9@`=F3WNJI)E7<[ND%<'SE#9,!Y`W,K5F@,8`+^PO>AW>ATE MI\58$K1M[&CEBOQFF(_@XT4#NDYN9W7POKLRU]KQS?8R8I-A'RP]DK)N?@OR M'?O!P>OEHP'M9>L$"Q#^2R$:S(.JK[T)FY<[S\9`*$@%!XCXN'E.[YL15HPH M9"3($>4390E4K'PDBYS:Q$*YRT4,BE:8K'F;RO1;&WG%/_:V/P%V$R'(%[A;."+AIZ%"1C_KO MDH^5#ER[3O+"(B4QC2?!]8`-`[EE<(.A<";A1`EWWV>>N"]:PK`Q:5E!%SYF MHF[L"9WOLK.0Z7H+Q$?PV(7#N_"F]O#IL"IXT?[R8)('LOK7@Q`Z7Z)?S5^[..6+C;%\M1RC3 MX(^&T3A1J'&`.U4@W'.<$$S&9&,<'!"F9U)?T!Y/!G#UNFDKRR,JK/C4)E#& M*1_7-\%'[4/;(WU/GG[&6.P(_$?45OI*#ZYME64+\@@,-V!-K0><&;KS;BSV M$:XQ<CH9P)US!S4DD?.)0KG$5(;\@SG]CDZ]96&.U M'0K^\@H7N'>[\NQ(9'TDSD!E@=.&D>;^*3;+F6D4E(BN/D"U'C M[NZT.,;J8ENVJI-7C9SK<@/2$<';:>IIS!$^H14,@<.;W[8 MH;5@,5FSE`]7)M"Q%J=\6/B"+7^\F+OSZ:9"`:$SVONGOX/!,*\\7']+5A%( MH=CGNOQ17OY^M]OLB'N3].H*T%YICSI#P!<[LI:7YP3D0LJ7F,:%?1-0<`M- M"`0CZ$J=I+6EEQ0*1GYY8.,BP3/C?#;TJUHWRT6A/80AK*1/JL`A! MCQ44W%U^*:=Y%VO-^OED(K30L>XCRR;=T>U)MP/G5+/N0H@"B!>%X!6''&`V M]3BG84&>K]C987+7PX(ZRP1.L&B[J*%@98'95`8%'8-(9SP&H0_X8E_6 M\K44H03XFCJN(H3WDP:P.]E/F4S@;J$L.Q!PZR@J/L"T`][&V#6,1P1B6B0` M8&EFT\-"QC':5-(81\VG,D/--^85B\J97/P]Q.%M5NMY/MW,6T[VZMO\9<[S M^.$S4BTT)4IQ=&Q%_JR3\Z7P+IOE^](P*(?G06V;LOZH:#L3F>%^/[.J16I@SRYB:\\K,N:[8-)L/^ M?,6G-JF<)*?^.Q'T+?Z,EX#J=R8T+@H;:2G4U]2,/'P2NMW7/!0% M[H1CV``L>],(C4S,XI$-:5C.7D^9TRW(!(B.KC0`%7.6GJ/5IB/:*VM%'2:Q M<3-A["Z(D-PG61'B>)]+$1'A=Q$%;CL+VW)#?R?G1BZ9KY\OY\>(B0T(:^*>..>`H.,VYC'R"(@*OIDY8 MO<;&6N.-D)RV;J$ELMM*KS.""_^EKBV[&*5!U=C9JQZ*4>2-A\\7]=^&Z;:![':7\^5$1I\_(KRUG<,C M#-48<+J'F$W*+7F"T`]JF.K7/,:"8N(_&FL-9>6/_59TS(.K:<+F1/8\JXJ+8\%&JMU,,R6QS[WKW)U MZ\92KJ%LN,M[JY_([_EK/^$#)7KX%&[?C?M0H>2-`(DU9'AP.M+N-5)>"ST[2_#'94][$&^*LBW&.7BW8W\LD3#K:G=12Q`3AIV?2!!F$XIA"5NH30EF.12 M@BA"]7F>E[R1PR[YC2AK#G@?5K'T!V-:98Z@UI[L#51;[IP.B-QU6%$27,U\ MCD:.'CYGJJT>#?/3*2\C446%O02+Z^,PD5(68:69*3XLZL/C))L-,TJJZ'E; M&KM38)&[D(Y99KT*6B*UM,[EHAHLPEF%U`MDPIY3/E6N4"9"?E43R4!T4Z/E4?K]H601\CG>?T[^ MDL0L3R&YQF%M$?G6GOA\:Y`DKR#C>E.+"-01*W7S^@T$6:E"I=$HR01/*#!!4XE>#>CXP"E(!6C<\=03(4I@4)+G`YL!P[DE2. MZ(@U-9/*C$N8$\2P3.!2\_P;DE..Z'@U-8G*#DN0#E1Z"J"CQ[\A2<6(BE=3 M\Z>,L&S?\$53/=AD5$*O,QA6+47A?F04H@2TZI.)S!&%B:,'DITN^3I);(`" MEVMGW`6DC,<2['F0":K[I9?L6(Z]:+2IQS*@L/6'DS\J$BER/_"E0CX)P;&K MR.EM.X(#4V2$WV`$^-)\\0V6>GH)QK.IX:($F$@#N'I*#LK&D9K`J9B0/K$P)WG+.!J#&=K^XLY>M=_R^WHT"%O3TFJ"&X6%! MOKS0\?UO7@.WT;ICN!Z9!(6+5#D%T$$[[KKMEW"!!HC2PG39B8.!)5>2<36 MQZSS=;1D(32NG8P&53;=KON@"P@)E!5+D=AQFL322*_-T?*!S!\&5PHD0OG2 M<(<3#B2Y]T>I9GP!`;0HZN+F?A1;8G4NHX;JY4D3\S4E95/`E#8H*,37X MD8%`4\M)_%+R5U7;MQ6EUX>;`QM=JAH^)Q+;U"J/J'5^4?'=4+,U,M+VW8N[ MKP[!77&A+_&U8OL+G3[0BZ';;Y9CQ`%?!2NRMVKD1QR<31VZ>0VI]RQA%["Q MF[*@J)/0:0W$FX=KKX^O!R#7"4R@GWVW-,O=PYBEP"4PC<__`N0%.NL7BG&#!?C-EU4KVE>O:?5\(^X`&O@&PHS@5$9GZN(5SQ$5ACUX/8PGDSTGPO2 M=Y_XCHWP/O?:SLMNDQ(EN"@%ZRX`V)T2B:6[(6P8U2>+6"3T$`.@/R@KF"VA M9*2@49O<7"%Q\"._:]5&&YN\AH,AV1'$CPBC,8%KUV;?APR"PHI34P/FUVAX M,=Y/\N8DIKX/U_Z8O*X,4I&$0XT;&T64C,6%*QI:J2=H:/I"`"K'@6X7? M7L&X:?:3NM-.A*N^2]FAO1HJ:(HC9<4"I3::3L8U.M\,_%H%KE`_OIX0K61C M0Y!\2B6ZJ5[=].P(]1I]&*" M[0`.EXVME]\HI3*\A-V+G)[*P(9@0FH&V7+'5YM1P46O&`:OVJB^"..*V*8> M@5_B3L+`>*X[2>..QGL\(X^4<,8SY*]1%AD4#8K5,!(CN+L?VQYDD!86?+Y& MY.L+IENXI84KW=*XPO$;S;EI.7U1]XC<6*FMV@D7\^PORL#U3$IK'!3E,1#J M#DW/QL5))G7A!MXDK2J#*-`QJ,],M"+\?T36SM0<0E:'/U53(Q4'Q,MZP*IL M80,X[)0D$^D[D4%.V+'R9&?<;-EQR-[@!=7]2H_B@=4(,(K/N`D9)(8)(4]8 M)LT6EN@-;GXXH!U)@(67./+C-7/%B*M>EGO*N349!*L`FGYXK=,T>7O2 M?J/][$TUCVAF?"#3Q4$SG(P+Q_-12=^IAN],5/D\;5S,=.M,H,!FDV0E-&1M MC2T6:PU;T26R_S),^RT$@^.U*,;/5L/Q/#3[`O"%PJ44LT?BQW`SQ;BV4H-# M(HJ6+S^-"YP^1Q+P?G+S1?U-#L4'PS2-7YI^G*GO^&_LS[:B3`!GTO%LI:*4 M7%ZP?/%I7'2,ALA-D-#7,I(LAQS*S;X3>82'!2I?=AH7:*,!$HTU>\,&B")1 M7[J$DQO*+N21F2R(?'EI7.8F`XR9<3YKMA.O1/ZX=Z)("ER`+L>.I)2C3.A\ MF6IZ-2X>2\,@ MN$8^:]BP.G&LK3'=[4CRU5JC'=(^G/DI1&MH%9$<5H1Q*7GD(P\VOO`T+O#K M)2Z"B"?VY32\%'G>R#B_GS15WY$I.X,AG,?"LH5JI(<;'%],&A<>IMI9=W8M M-6(U`9R#R+$5>8P.$UB^^'R)Z+!;";2ZV):MZF3DAA-]@.LB8=J#/`*3#H\O M*8T+!#=CMOUTAT5D=7C&G%O]TM&^W9T,J/M/ZKF\^?>EB&5L5GDJ%;X$RA\> MY!Y3OM'^)F_#>(K8[@V4\8"==]?_NAK.I5#@\TW^-``_W]03,'Q!47^6"VWH$PM"SF/ M:!)0IM9/?+J^FAKVY8FBC#C,=,)W*C+7+%3Y7)4_-%;P=8G[+.W[+.W[+.WJ M9VE7X6<`$IX^ZD'N@9Y.I;*SY;X":%F"9 M*L%,BT+`,8(T_6L5\9:#Q*:..(F0OM%^^X0/.F-:$6*VM@;?J%Y;Z>0T=5:> MV\+NTMM7QG`36",+">%Q2D3K*B04ITUR?]DM//-%L-N'8\G54N*8DB1--Z5U M<0KE9HP?JOJN6^]HIQTTM/>L2G]`O;T(BM@E+9O?TUJ9VE'#*))A![JJVV1$ MK!49G-M&5BP!8F#F*K+)!53GS11R5ZG?'MDQ*+ MY6SU,F]MI_\[W[3^<,*2'`](+'3\1[15?R/+_:?76^=X,B+X$B6FVAUT:6-2 MQ)B*E(7S&XO-[@WM+_@2T)'S/GP`\_SW.](M](!T=-#L !:[O MJ<#.9!"U8G`V]#/.7:NXI\,!-/,F_,1FDK1"8-1XV7?Q! MMG%'2?>>?9!;QJ'E.RPMC''+=5E:JKYO19R6/"^V11QN9N>HZ&MNL<\OD;W$ MMLGMT)J=5,O"%Z:=*[!!'41O!.?(YME1D4K3F]56[XB\DZ*/%0\?^[ M..M[WX1OWO"V'U0+[:._,#,LNST:=2#?\1&_XSK(JV#&-/7FP*'GV`%!VE'' MJ'0A'QCBW4\=A)$+U*9>&6@JZA:@)R"BE.BCI.ZE#B+&#&:-;PDBQ&MZPM_5 MG8>4O:P=_CV"3XDVC6-G]16]3*";6BU4".U)`V]DWTQ\ZH7KX7N"FQ\OA]:; MU:M7J$FF0J4`5I_B*V<>?2&EF67!"?EJ(>=V!*K+0O_`RQCF)^;[`++<-6E= M,!7A9&BB?E`1NH<<;F^V\_/[R?A$5W]-[K3E>CKY]RJ]'`KCQ)>)+L016V/V MF1^(1,6GNYUY44_6RGY#)E;M28E!6O:-U5`J63#^,E$'9J1+<\7+;@E-](B=\OG=MJ_M`DO&%3/,7<$(CN6L/E@"('F8S MQY-Y3!^50A`8:6Z`&U>:2O'$'[^`;Q*1L!"9*R'CZ!EE_:YLNI5!>7W.7SXQ M8$&PWY7Q`&;S.\DT1E=\3B?CES-F?#3J=>'(8MA!::(?4IAH#3/PD3]/,G'% M7D='U?9^5YC@@]Q/RI'[J&5#Y";1&Y1WX[I>O#1QS[Y=):/R!7(;+([DK4T$ M]YXY-OUJHG=5\^-*5GLT4,:EV/'D/8@.)_"Q*-VA28-+_JMB7K/.">9$,G&G MF:DP&N1ZHU78<*#P&1>+&*TZ!:[ZW(U%&/>TFTPA^Y[S$L=EXHUW9-J?KR<5 M+Z+OY_^Y:._.VY>C4;]?OK%/V`V@&K`Q+\ORLZ#XU[8B4L#=LBC@:0W:4=GE>%7\-15>X& M7,D<+[L8G0XZ;O6)'8/['0/)Y#^()T36P:QSW]>^W:U8F:28^ M@7$O?Z1X+N.^%2'BC\C4/IRRD4\KV&2+K2^XC)"'EB0T6HWJ(C?!.\2Y[ MI[C]AEK8E__0+/RUUA]>0=]_MPZ&V7+UD_20"VP7W[ZA8#UOM2?#C/QJT8;Q MVE9[I%-S/0-F9NBVIE\T_>BUWADZ+;K1IU60)YR+^5>J+LTJ"!WYKZD%$Z_9 M\/@6]@H?6GUJ<>FY7:H6XI.*C_R74+C$?7WREQS]DZJ2VSF MA:NI%U+O`'E"F#SU%,.E/?+>W@'Q+3(6%RLE(ER-X`4V=M2:>@I[$#@S8B-@1;.J![&N3._6`"D$7W`8E+"Z]^+"@5I_#*U\EKF>' M$V!NCP8C^(;<]#V4+48,%Y_;*!0[B$T]TGPDKBQR(A[#`7RC(\M.:B!:O(`V M]:`+5,VUV'(F5M\C\ MY(+A\NN5DH8TWR/E46I8!EE/_8LHL;,7,F'CZI?;XU%_`$:U@`U6%RH5C&Y3 M':,4=/!?F4BU2(++^\-"]WXQ:LL''*^Q%5M-@KA[<92:Z@`U*_1.MQ[44/)X MU.N#$<>^C^KB[OFPJH_GQA=U9SEWZ)`[920^0%Z&AZUK M]5XB=J2<1D-6%-G[]Z6%OF+OH*=24OG[YVQ,F%[L-V=?SI/OF-0!O#1=K2E` MD(+O>:_0=P>],JEP5Q4KAAELB4E@"@1R"Z)WR9P9%]TV/U_0^00_JM$8? M2+^@#3(_M!U:K#>^&([<0=M`1C1U\8HXR@%)A0$P$27]:I[_/%E_+83&X:-!\WX<[$]7$ADLW-)%_`\^,@M[<4MG,D$X-!F;`S M-?N+U7*2DV*YW24J%<[E;-`9*^6:&^9KMXZF8W2`QPKG7]G M)7[I2<25"\K0S'/;@&_925J["+K$`TM>3GNVZBG7'4 MM;^=ZB?_K>6V,E)&<$'GA%6K$``6`)I:O)A`>U#;M$;6Y42YE:JD*G<4'FR,VZ:["0HF:M)?JFFKW*.18>;$<.U%XDL M$@-8GOA,FB8^R7?B^>]WS;TI/&*_V@FF#.!RULS[D"MPD`:2_$/U"T<-7E5M M3ZPLH&#%#UUG<%-_KDK>'A3XGT#OHE!Z=2FBR'SL@]#2RGA#B8. M,4<]R#^1/_SIZ?J[X\-N;-6TQ0Z_J<]@L@2&!OUJ5_$&;U8M/>(P@AON*V:3 MI:D-ZQ6J",A-3YC8?221+/%-.6\BF0NK2&/[7YK]AG\?_X5?DTG>922@=221RZS-UD5` M^4"7/\^=5U*9+DI*W<^!R`T.A);*K[(*_U56J5$&W[W*SG71[W5.XN]U;K:K MV?_\XV&ZF3^V9JN7U_ER,]TN5LO6'T^J9K9(72!J32WKGU8:+T8%KE;*K\";-RPW M,6BFIDE&$CGF^N$S_)U7]9/\S%D[W("^?SVI>J21HS\>P1$.L6,AAB.=]T$3 M)C#@0A*J_.D3I7Z,3.4=GAF5;#O4_(M1;@?U5!H,AW("`0GLKH(+!@\'Y M9<-M_^@/71<*1N]$;5.(LHD6I$`](9@AMTZN"4&.S>HK8[CNYV"9_)KB?,)O M5E?&<#,F(@L)D=84B(.<)YTVN47'Z[+V.W*[?3B67"TECBE)TN2S)9%"R1F# M[]=7VX9K,[Y:JD3&)%$H31-C%IF`YWXP$"'!)95;>#/A2$+C.:@MZ8\'M&D( M)=U`,ORE_85$!%?F3#^8,'SBTRSQBX M`>1[\G`;KX<*P/-,_@JIG")/2C56+O7!6.(1W%3X^'KE2)B0LHIPL',::)4' M>T74#<7>W4FN&]I?^/Z-]JV5Z/(A;YG5`2_BKK$24T,D M*+4-8M@KJY'(:[$QY%IMH(<=X= M+Q/NT;$;`#W3<9XU4",Y; M+<+;^YF>89ZL6[3=JS0?VK19$=#'4=&-?TG5`N7^/5&68#/.`--OAL;X/ M!^=QVC;:3!KHXW5O'"*]6-5:E1 M9I3>9"]!&@0ZLB,J#U(:1,N+]V!HMS.L&"!W*]4:BIS"!)E&HG'H'KK*$=YP M(*3U&90;F:J1@)<5>+KBS#VN5(1EC.^J->R`XPR^.'"-RX"+>6KEA48<1"=5F(_,K7U-C2C(0?F#5Y7K1+IC#QQ-D?,0Y;F#5`=0 M_6Z)XL))G!RJ>;A(1&UU[#D1IMKJ"*XM_'^M^6]D[C2+C#T`++:.2A$Q\F1- MU<)KRE5\_:4&U#D_M;QAOG^C_7>,M1GI22!M#-;#IR<@Z-74=LB9?^'/R!C! M80:[=YD*5[E'V8EC6^4=)CG.^MS4NT-;QB/`28OB-US*P"'1=B#=%1#&P,9* M;YSTYTC_X@AN)!S,GK^J##.R49JY=_!B'/9#`C:&BM\PX'U,\&D&(K5QKGUI MRUMBFU8IEK<$#(U?R/1V=M9L,DBH](XW,5NOVA)PR2?,$9;"R]HD[H4D-W," M^/W]_1;`$=P;T)!;ORM#&B^_5J8_)X!N8/]W0G2#C13V1$41=,H*(VFT%.3:J="KKJVW5 M8WBI25VB2^97`L M(\GMB-O1K\F%*YF*^JI4R1RNS=.=51YE<0S3S),[T!(X%EH1:?75*QEDP5.V M42.5#2B=(O\IQ)$$HZ+G>D"Z_S)8KZ-,.$;H7/]K^?0SB9U7#P;1J6]JO-S- MJ_\R(B1S3'JY_MC4LXQ;N3VW]>5Z0D(U#BX6;1,65$Z MMT7*Z_EVL9Z_S)?;UNOS=,E<8+Q&MF8Z%>2$1[D+A:^JTO5]^-5PDV&)9@=P M)#/'1O*?O:]X!??[*_L-F:\&_F"PT`/2T4&SK7#!+0;R`?^[GVVE-Q[1-%@, M[7FW)<0P%)(`7^&%`%MC!Z!P_X+2Z2@9IB%'%\*UD2C:5/"U;,4CEEE=(\>E M;IO:CXM_',[/[R?C$YG1GZ\.KZII:SOMG;2Z;PU;/?V%[X;6*SXX\;:+*/J+CLIRO$X!L8?:R%]QA&M\Q\HCFAX^4UV_ MJ*<;K?6Q"A6X`^?)%]^?]$*:$^NF%E$DH$3:'==H9QQU$E9ICR8]N.H]IBU( M+U?)B-4XQ5_\7JATNK&^]ODWYU*X6#ZMUB]>2_LW9!Q-]?U-VZFGUD(_&.;9 M^6:NYG5T)$R-?"7Z]SBZ6;9PQDEC`G@W] M^*Q]H/W4LI!M19)__;$C7/TQA$+EW5:!I)"W(BEM&0W@*1-B#01R+P@<4W&0 M_XH7S+CA&'U8&#Z0PZ1\V5\:^NYB$BZXG\2D#2=P!-XN)XO,, MVYHY`?7:E@<3P$[:0GLKT'N(I<[QL:)GL-OO.AD"-K\G+2NX?UT,H\,G9!G` MDKM?M[`I`1$'T&.A*FD1`;7D\PI<3WZ-W@W3CHXLZX\@IQ4EK"I&&)A)BD\0 M*BH^KLBQALR"DHI'4]-(V5A" M>NHY?;=,`6$/7:0(2!R'RMUP$6F='E-:9ZF:9/S[!Q*3QPD^5S1S,]U'\;IG^7"F_*RJ@'YT8Q;B+_/21]`2_+K1Y1>SP>P8WP8MV%$)W- MS5A?@_-@UM1[1XC%UE3W:+K;D4/.6J,=TCY(<"$)FUZGV^4H&,V[CFP24P"E MIEXUUH@\E;.S+R8I2'Q3S:.3'>T-X89ET):40U(RP6CJ/>(**,MQH7K*&"[9 M%5^O0'Y7/:/5X>J+GDO7Z_7A@M")RPH191:&!*E<%@`J]VD+\A`F5U^(A]F: M=-V(3'-4$PY<^E>$2!8'U+Z`,=#45`_KBO3K-F/:`ZZ?KQOV`!^U*+Y!P2EQ@4!1!3!VN,E]4O'ZF"!2 M(C(P4:DDY$!3\H((/R3Y<+'P[BW+!\(+2P*^>Y6ZM/RBP(Q<8!\&4@K`O2)& MN*#(?2)XVP[3"(#>072I(N4OYH>V0[Z&>?Y?=S(8T3)!B6E!RD=$REL2H&$J M)XL*N>5F9IA8\+'1\W:N*",XC^%FL3+YE$*G-&+5`-SX<*%N;#R_3R;DR?^O#L%?.9!PC#GF^[I,HE,`EQH7,Q?U:3N=(7%B_6L[_C-V M83>KY\7C=#M_;&VV^/^(<[LAWNWFG]/U_)^KY\?Y>O-?K?G_^^YXMZ\.A6_( M)D7"[#XN463CI.WQROM@?L/)]?!9GQ/'F8S%MXA\'=C42_6NU?XY,INPY!S;0]/#L'>07 M^/3F[A(($MCIGH]7;&WNXQK%^CZ0^#N>E$21MV;Y M8A[21I5S*A:UN5V_([PSDD\VN5X`X("O7\*LCS*$W:VMV?^EV6\SU7HC_'9? M`"V!0/H6RE>%?NPZSXV4_)'YX$V,(_&XMD7&WF3`V1#-F.YVYD4]A4E_QQ;" M#6YFVD/YRL&D&^E8-34MP'?>*LU0BXA'`$]1==Z1PND=*34*R;K>T5S?4T6= MY_D'[D@(_4Z5&C1K4!B@[&@MGPFHFO%4O*3I>:5R?Z6CK79&V)LZ:[H#W`/2 MT4&S+7]*T*`+-Q8N:W4A7.>(V?L\YD%%;NW.)A[$%2R6L*!2$I2KO1@?GN:1 M+.4+LM^,_=94=0L?(%8X%8!*7=*\4XYOER23\:FF>>FO37"/=QBN]S@PMMV$ M":2-QALX,.K2NA\%C6)*6+4RL6!`0?Z[?3X)<";[7Z'EF^>A`M?]D+1J51+` M@D)3+[#?,#*66W&UTC?J"?_?P2U@\0UA#_"A[*S5JY(('E0"VU#^="W8SE6D M6BCJUOM*T9_T:5>9I)94^F>J7*!\I4,T1_5Q87T0=1,=BGC6R)*D6N\2P1]2A:\">]E@0ASZ'2`RQDIRQ9 MO4+1:*^Q.K$Q'>W]R]$_D7JRWTCCF]<"8A'@J(W"68*9]M%J^R"D?>43/EN]6K.2K0G`9VF.?WN%*CI\6@Z M10)3VU9W;R1F]FIHNOVBZ=KYIDNI]^3[D<)L2/I/?<;KY MX)4_/N1X2S3I.T+4A1V\\"$"!K)J[!<5OV8,XM>,F);DN&G<`%_TKB&KVG@S MS[^9QB_[[1'M\-^C-<':,<(<[F;BARI2'#;":JPYZ5%FT["L%]4\:GH"`K1V M_036IGZL(O:R$]C4NT-ZBT2]GD7,H]Y?]!W$);(7.CZE$,F68%I'([B:B*NU M*F)T,KU-S1"NWIT9F_K1#X4D&#B.UW$9/ED1>WF)K4W!)_8,5'9W<:V0H M49)>TKI/D@;G`F$LNIT1G"7@VDQ5-J(`8IX0C>45H@3K43BTV>G&HC9DG(PW\Y@,)GU= MS_]/U_.1GQ;+Z7*VF#Y')B4S!W?([2$82_MJH@_-N%BG M3W>&;'0\LC<1B\R8]>?17S)N^PO;Q&*_J01+B+HFFS/`(,TO(7VEH!32,])EZ.>(G( M[(SAL`]&Y,UJ0I1`,$\#M4@!IC;W"NZA:Z0S977X9AA[@F/P;K=QVK='BCMB M$40PDM>564;8T*J-N\S4JT:3Z','3$SR@*4+R7R MQT;%]!N`6#KQ_09`MB@9%%\.Y(]Z2YE,^., MEWG#*J!]H-!"8G.Y.N#STP4:_]PDQ=&/R/W_,%,_I$X"$WA]*[0_B620?M,3 MAKY_B-4@O,9GL2@(^>BTAQ/W36T0SR9E88G$*N;G,.+ERXO$L:8JP[$#D"?- M*@K'SE53QXZ.A9?9O&'6D&>4=^WQ<#("))6VID1Z$U(=S+C.1,G7&8E=`?_I M$L/2;*S_'&IS0_VC=KI@9P+3/X9[R3)A48G$)%9'PX"3+R;RQV>YJVC2?)8G MPT3:47>;YG:?SF,!JH,]AM[YKY/+K`#ZX%Q2>KT.W)MH,)L6(J00'CB+?RF( M5[4I+N2=\;A#NHII^:Y;[VBG'32T]V9F]P>#'F"I=L*R1:K3W4^&G0%K]&Z8 MV&)Y,[W[@SY3I]0&?-$U852)IH6=3,H"J M3?<\IY%YQ-!]J$X^.0[`N#.`.Y+25I996E@1JT]K.>>KZ??A-1F&=FGHN]"$ MN"E\W)O>9$%C[>:T[N-2?WFI-[ MS\W=^:NJ[1>Z]_95 M>S#L`@8:Z(N6Q?IX6"$;A*:&YM>D/%!'>[^1;;K;7&Y`SZ M@Q&8+&1OH#*QX,2F/B4Y?"(2(9NE00UK#6`1#N=FJC,I^4&K31:#-Z29#2-( M1@/"-Z;5APR'PU&)1)0EVK'42P;M-<[`"&@GZ`QONPDVWU]>INM_D4Z"S>+; M@O/`#>0AJ:EF7LX.4U?INH7W+ M-EK$BEQLU"+SBEJ.ETI^TQ]4E*?-8',YGU7SK<<+' M'++"L$AD5V136\/;4C!!*9R;)*[SP-]&I*)\4$*?P>VR^H:G92+2O0UI6YUHYOMA=OF[@/!H%(5,JZ^17, M^>C4^Z:7>>E.1JYO?D-&TN/F\4\($5`>G(-81`8Y-9"LA_CN:5U1:1($XYG5W,G#C\9TK0#4,F%9??8:;KB82;?Y5:KX-AZ^/3/JT_74!#*E?$$ MCIVI2PMPB]+/7^?`_:X;/RQD?I!#=J%CEQ/_M:'O\+]RQ.1V8QYO\6D,5UL" MOGTARL(I-C$GJ0S>U$3QQ/J+SV%N=Z+`S;N"WKV86Y%_J5QKUL\G$R%_X/]: MM5%[TNWT2L$G;1=BE;$T4:)=>EC!KDV.,_?8ZQ`+,O=[1R+[VH>V1_K>PP)P M/CKK+AHH>%E@UR;?*E#P_C3(D#UR2+IH="9*):)WO8\&"U\RX$U-]J:AL47F M&:N@`O>V9=;J#1:U6W";FBKV)R63"45G\HZ&QR>3S(@AA8`/G^&OO*J?Y$?3 M7ZJY=_-("YV\)NK40#I)T^V;JJ]<)+\Y*86%[A9+_H7(_1WMIQ_(5(_(^G:);)V`KO?EQ'>##V,^($7:'B MY"F5_A!N%B7G9L0*8'DIH_A)SXU]Y4=/VE]))J5)5U)3K9/'8B$)&PI@`5`V>Y??P]`4J)$B*8D.H*SG&EJBCP` MSP%^Q/G``?#+/QZ6@;/"7!!&/UXT7KV^<##UF$_H_./%W?C*'3>[W0M'2$1] M%#"*/UY0=O&/7__[OW[YGZNK)L=(8M^9/CI?")5HCIT.":"L<"XOOG0N?KBZ M2BA#SOS(`U)&G3>O&V^O&J_A/^=_G9\_P!_W-B9\$/X'X2WP$CD2\3F6?;3$ M(D0>O'8A9?CA^OK^_O[5%`E"O5<>6UY#76]>OW^KV`[P$E/987S9PC,4!?+C MQ9\1"LB,8/_"`3FI^*!*/EU53/LPY<$VL;KSBO$YD+Y^>TVH:A4/9^E]N2Z0 M)7YW'3],22FC-%J:Z_8EOY:/(;X&HBN@PIQXZW)/%]HN``VZ5>#^;#4-"9RRY!3>AB__XH/X'S8='>.8\Z#N< M!;B@P=3C:P\%7A3H5_0V%5PD-2PXGGV\4)URE7;'[U#B%4B3DB@Q/UX(L@P# MG-Y#W,N].Q&U\?[]^VM-=0T8##&7!(OKE/=U.ZD;Q<53TASEMI";FJ\K:2\? MSP@E!S07%/@/;JX`37%0LJ6`]C^XI4*.!8R7AWR)4.2[:##%X028=]3%W:B[ M3R/H=FHR*EA`?*7H;E"@1OSQ`F,IAHA#^RVP)#!"73C$3YK+FXKP4!;7#*8L M;C[[7X'0N7+&T%-:P<%U<]`?#WK=ECMIMYP;M^?VFVUG_+G=GHR=RRVV?OCE M>K>ZW3=%`OL#^JN^WAFGT!E]KM%B'E@&H4"VO<*G?9$MH@@6F@JQP%SRX)>XQ ML0,DACP25(NE'\MC:3!LC]Q)%P@JWV:/PWI_U_ M=]W);S6`[`?07O-9H2EL5(NGGT[#4VU5VX*O%O,BU8>@\MI4`HRZ=,;X4HN: M`9&/,*D600U`3?KR["6BOA-SXF18J0%R-H#@J70YHO-XY,EB`B->)28:VI!N M$>$%3$0HH3FM,68BI:+E$_'$P&W(@(R$*ANA1/1E,`S*/G?E]"`M# M5CG"WI1!6,RS`MB::R=AV\GP7>/-/KQ-T#3`NU"25:+H;0DCR+F,^:AQ<49< M"(^34$DVF$T6^":"YW@K/N@S.:W6/#;HKW%SU!VJ&*#RM">?V\[-W;C;;X]K M0_ELT(B#Q1/TL#50`(E$#]7BX>==/"1!WXG[KW8-`!L`4.`EQ8"HVD_Z64\@ M[`5%[2)9"Y41]A@8@P%!L5)ISV;8D^O))Z`9(;D71YQA(GGE8,HYW=M@VN99 M6;1KKIV8;0?X=A3C-=SLAML=Y7!G3LE?V`>"&TRA^:3!>4KQ%LEIY7![=RC< MLEQKJ*5\UW"S"VZ;X$]+L<`UR%PAL%23[3V"IM"M*G]M'^`$\R5"0>60R]G4 MVY#+AH-2SC708M[U;$6&^QIVML(.?+0A9RNB\O*30:+#>(9T/_!D.`7JRI&7 MBQ7M1YY<8&?-O7.9\/^#,V,\HV=K^-D&OURX*(94Q0&C0C>PCA59`(@52,8X MV8'"JMIH@,%X^M+N3P:C;AT,L*+S31IF5;%:>6VQVWZ_P:.Z%0$#L.GB'#YJ>\YLC# MHXX?6PZ:C?\HZO"6=9]S<6Q4ED<337:<:$T$YP(D_\J':#7S(TDU4X=%X"G*QZ<.9F M/$X'YUJB&IX6PS-GC`?5I_:4,,!JH_S\T&!"##'7*VRR>`@K75KZ&R.Z6NEA!',OEQ`P6]>&I@ MP+.E)JQ%@DABW_30"#K./#8E#*ZDK_]4#L*\A;X#POQ,?$98]5.+F\Y-@0VD MA')`*D>+Y4CF)%+OI:GA;1F\\P82`+!:^^@)C5C;1F<'Q"VB*#&8AP'*KA!= M5KI'3Z.1BUS?NGTW-I+_!ICHN?T:!9:@(*^EEF&U.JEAF-?*X:%6&.='Q@A+ MPC4R=H8'CL-*=TII-%[O`F+4GG1'&A#U\&`1"/*C@\)"Q>/#Z_SXL`.'>G2P M`1A"1MR#?X3.MP!1K279:.3"N*/V>#*Z:TZ`Q?ZG&@%6(*`@MJ(047%PI?'6 M-$9D4%''5BS&RGJEM[K+H^2NJ]::$/EH!I!@'%6.H>*196MY]Q:K3LIKC:V7 M@:TF$Z;U+PFPO,J!E0NZE0669K1&E6VHRL7+%'*J#9@]8>;4\3(K$)'LDJ'S7;FUO\]?I]MU^L^OV,AO^U4A[B4C+;J=MT'@Q^*95SS.] M:9B-J=,0Z%PFTCA:G%HOOG!L%CF),3"KGH1_8]AII0IP$J M6-4[C0%$C>["J1#="*;YRJ;2E<)>1(#Z41:$_7#+Q9<`3Q7'EDJ[A'7`Z/P@R0:, M#(--QN"P`1-S%8HVGR\G\)S02H_E;30,F/BDX]#=?F63RFC2`6-7VC"$!Q8B@SNTU,$L@?!"^95O&C68.%,)KUU>D9S MT)]T^Y_4KU[7O>GVZK/?[06*01VQJK=K;+PQJ:*G(%,K(0O`@]16BT.>'%JB MMW!19ZU\55;G]NH"P4*![JM-X,B;P&ZOG62`==JC4;L5[^DR=MQ^R_FJM\"K MEP_8"Y>2>1T:2=6G=AA6QY7"4YWG\8(A5^2X:YQ5G?1A6"!>$F6U*_^2@)7W MQC2<*IZO.DX#UO[9^>&SGCHG.2 M_*6^^"ZT"9T3N(J/%C0I/8"9QQ"IVKIZ8\A,*PTWYW(CD,K.+@6FA]05`K'S5I<'X.@"$M07V\B"V3Y56JDO?G*)+G@U[$@@SB9&I=`ZASEH^?KJ@/3+]8/P M/X#SJQ(*];WD#J4LYCV^J>Z190CJQJ%HB46(/%P``T+5(CZU:X>`L6&)>LS3 ME1444;^NTG)7ZM95X\W5V\:K!Y7G>'T4&VLT'LA&6NXH-G1]`GNOYFQU[6," M]4(-KQM0R5X^C&74Q=6F\($<)!*]T[]\6;H)T@)*]G='-KXO^;4$D%U31J]H MM,2<>.48R);LQP45(^]5)S1^.IF=XU@Y@8^MCB5TA84\&`^98LGU4:B8(3'5 M@D7B:HY06)H/8\%K'$B1WCF9']7.HB*&=%W'?S=IJVN]R!\/[JULN?3'Z=S@ M!V]Q,"OK0OJJ@B:)N%(R1[1)MN#ZU^D,440\#9O&(=QL2L675YL*CN1#$.]@ M+M(RZJ("#F3(#VAT;9U'X\2(F)U#WA2,U>7P'*H7WJW>J M2@X22=O;A>(D%,\@BB\_+("2>]%4-]C10H$U/ICUP"D=W%,%S(PTNX]VQ>/,\;O$?=O\7**>5:2 MP\H]._#`A`/3Z8//EHC0,G+#M8_]$5ZQ8*6.8H>/9#"+!<@+6X+8/@F!'`7N M?,[U2.=*B;R%/K&*$2J33LL*68[>#-AIO"$U"(6G1%8%XR6#`1+QQS+2ZN2+ M#N,J,\X5?Z@!`^SHK:%D+XFE,C512"0*=*P5D!;!V`&5W\M%"WO@->*1@D]& MP)+T3P\YAR(38*F&3;4@K+14^G3Z.,BL+X?H,=ZH_;&)))HS_N@^$)&7KFRY MY]$//H&7";A]@GXH+4A+?^K'-$%:TKI!J1D@(=QDQBLWSAJ?VBG#3:$,NT_M MDR%=:Z4LJDUP=((?Y$W`O#^R`CU)6OV`$DLCTU<<(M!F\5BLT$9*@R4?B$FJ M8OIC-<-19O,AJL&P5@ZZ1IG*>A(R4@OJ#.LM37(7%GRB`3QM`YU#-Z[E2#KK M+F04;JXP5\-SLBF84?#B`K;V>`M/99>J0[&T30:ZQB,A"A)A;I&?-77*$%MJ M]+22)0W@3J0P5!G%.HPCW63[+)EE`F7@TVC+BW4)L8;LE<0&6MYM-,@]NN M%'1\%$A+'S\XU$S$ M$1]37[B>!YSYPTC>T1"1+6FVY"Y%;Z^\S-/VF4K$`N-4Y7.OM],QZ?]2Y+;I M_IC5K]!1$PYV9YJY/<(>)BO%Z"WZ-^/-2$BVQ#S1+:!F,H(?7\69-=0Z)>V6 MK=+C=J'W;K%

R+#F=+I;T5\L%=@>%A*Z93@M;6CZE+/1BS`6#FR6SS M8]M47(;+W>GK_"-[YZW7O";)_3>8@K0`RY"!X-4Z"G5F1M7&4K'#"@./>1[R.P M[AO?8G1RSXHER1!8*`F%CT*NDMFZ]3$-M>9HX+7\Y9[1303 MVYHZM,V[SO,:,B'4GJ9I+VW"'P,`I[:6?\.(B[TM<&`M9QZ02_`NMEC.I:(< M78.]Z#=-)RI[0:BXM1_G'`VC:4"\@4JD`ZQOM<7HY#,0JG`6(YPH7]40'-F);S9H"Y9YNA2?]O/\>,5O*9$D6,* MVQ97+BW#;I+)H07M34'9W5=S=^72`.R%>9PKH64QQ=Y/J,.&X/R&?9V??J-Z M+^'<57EW:8*D8KX@'0X+! MF38\LW"V4P!`@,S^SC?VTIJV,;X,.-#6-E1,6I M/3>/9F,Z7G.QV7ZAS_0^JMB/Y^G$5TSF"[7;1KPRZ).RREHH<_Y%MJ'.R,3S M;$U7>C5L9:*+7=F_Z!]=FHOB?[M7GGNI\;>2]"Q8/YVGYPJ%:?Z?LWMV)0=+ M<8;CK>#4LN&'D"1+3:I$_Q$O?;'X/UC6;_(%/`=7W\TWH(5[5L#OON&[0?>V M8&>!\L$L?#>XS621F$(>S_H:ZR(GSR!M/]KU2I[Q)2_5F$XD6F\+W%4Q0RJ( M%^_<4"$NR[[INX%F(G#[`7./""72-QE@CWIMU?#]5F-J_H/\EFU\V&M?>!OO M2#C"*LZBMZ^A^ON,4-`CL^<8,@Y^\\L80O(@BO?V4C>(G\[LQ50JO/QDBQY> MX;FU%OE+3>,G2W.S\NT\./`Q0````(`.)U2T-THIRW+T8!`#:[$@`1`!@` M``````$```"D@0````!B87-I+3(P,3(P.3,P+GAM;%54!0`#J$=84G5X"P`! M!"4.```$.0$``%!+`0(>`Q0````(`.)U2T/W9>!%\1H``*]E`0`5`!@````` M``$```"D@7I&`0!B87-I+3(P,3(P.3,P7V-A;"YX;6Q55`4``ZA'6%)U>`L` M`00E#@``!#D!``!02P$"'@,4````"`#B=4M#!MGF-5%$``#85`0`%0`8```` M```!````I(&Z80$`8F%S:2TR,#$R,#DS,%]D968N>&UL550%``.H1UA2=7@+ M``$$)0X```0Y`0``4$L!`AX#%`````@`XG5+0RKM67=W\```&_X.`!4`&``` M`````0```*2!6J8!`&)A`Q0````(`.)U2T,%8`M&,W(``!"#!P`5`!@` M``````$```"D@2"7`@!B87-I+3(P,3(P.3,P7W!R92YX;6Q55`4``ZA'6%)U M>`L``00E#@``!#D!``!02P$"'@,4````"`#B=4M#$$>X[:(6``!5(@$`$0`8 M```````!````I(&B"0,`8F%S:2TR,#$R,#DS,"YX`L` A`00E#@``!#D!``!02P4&``````8`!@`:`@``CR`#```` ` end XML 28 R57.htm IDEA: XBRL DOCUMENT v2.4.0.8
INCOME TAXES (Reconciliation of Unrecognized Tax Benefits) (Details) (USD $)
In Thousands, unless otherwise specified
 12 Months Ended
Sep. 30, 2012
Sep. 30, 2011
INCOME TAXES [Abstract]    
Balance at beginning of the year $ 16 $ 30
Additions based on tax positions related to the current year      
Additions fror tax positions of prior years      
Reductions for tax positions of prior years    (14)
Settlements      
Balance at end of the year $ 16 $ 16

XML 29 R38.htm IDEA: XBRL DOCUMENT v2.4.0.8
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Schedule of Property and Equipment) (Details) (USD $)
In Thousands, unless otherwise specified
Sep. 30, 2012
Sep. 30, 2011
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]    
Land and improvements $ 914 $ 527
Buildings and improvements 21,278 21,433
Machinery and equipment 19,496 22,361
Office furniture and fixtures 701 949
Construction in progress 35 493
Property and equipment, gross 42,424 45,763
Less: accumulated depreciation (23,796) (25,364)
Net property and equipment $ 18,628 $ 20,399
XML 30 R27.htm IDEA: XBRL DOCUMENT v2.4.0.8
SALE OF PREFERRED SHARES AND WARRANTS (Tables)
 12 Months Ended
Sep. 30, 2012
SALE OF PREFERRED SHARES AND WARRANTS [Abstract]  
Schedule of Fair Value Assumptions Used for Warrants

The assumptions used to compute the fair value of the warrants at the time of issuance were as follows:

 

    Warrant A     Warrant B  
             
Risk-free interest rate     1.87 %     0.18 %
Dividend yield     0.00 %     0.00 %
Volatility of the Company's common stock     106.91 %     116.01 %
Expected life of the options (years)     5.0       1.0  
                 
Fair value per unit   $ 1.433     $ 0.779  
XML 31 R26.htm IDEA: XBRL DOCUMENT v2.4.0.8
RESTATEMENT OF PREVIOUSLY ISSUED CONSOLIDATED FINANCIAL STATEMENTS (Tables)
 12 Months Ended
Sep. 30, 2012
RESTATEMENT OF PREVIOUSLY ISSUED CONSOLIDATED FINANCIAL STATEMENTS [Abstract]  
Schedule of Effects of Restatement Adjustments

The following table summarizes the effects of the restatement adjustments, previously discussed, on the consolidated statements of operations and comprehensive income (loss) items for the years ended September 30:

 

    2012     2011  
    As Reported     Adjustment     Restated     As Reported     Adjustment     Restated  
Total revenue   $ 28,208     $ -     $ 28,208     $ 33,144             $ 33,144  
Total cost of revenue     21,370       -       21,370       22,638               22,638  
                                                 
Gross profit     6,838       -       6,838       10,506       -       10,506  
                                                 
Total operating expenses     9,329       -       9,329       9,219               9,219  
Restructuring charges     3,195       -       3,195       -               -  
                                                 
Operating income (loss)     (5,686 )     -       (5,686 )     1,287       -       1,287  
                                                 
Interest expense     (714 )     -       (714 )     (706 )             (706 )
Change in fair value of warrant liability - decrease     -       73       73       -       1,759       1,759  
Other income     12       -       12       12       -       12  
                                                 
Income (loss) before income taxes     (6,388 )     73       (6,315 )     593       1,759       2,352  
                                                 
Income tax expense     2       -       2       50               50  
                                                 
Net income (loss)     (6,390 )     73       (6,317 )     543       1,759       2,302  
                                                 
Other comprehensive income (loss):                                                
    Foreign currency translation adjustment     (22 )     -       (22 )     (49 )     -       (49 )
Comprehensive income (loss)   $ (6,412 )   $ 73     $ (6,339 )   $ 494     $ 1,759     $ 2,253  
                                                 
Basic EPS   $ (0.89 )   $ 0.01     $ (0.88 )   $ (0.66 )   $ (0.08 )   $ (0.74 )
Diluted EPS   $ (0.89 )   $ 0.01     $ (0.88 )   $ (0.66 )   $ (0.08 )   $ (0.74 )

 

The following table summarizes the effects of the restatement adjustments, previously discussed, on the consolidated balance sheet items as of September 30:

 

    2012     2011  
    As Reported     Adjustment     Restated     As Reported     Adjustment     Restated  
                                     
Total assets   $ 26,975     $ -     $ 26,975     $ 32,346             $ 32,346  
                                                 
Total other current liabilities     11,387       -       11,387       9,847               9,847  
Fair value of warrant liability     -       1,213       1,213       -       1,286       1,286  
Total current liabilities     11,387       1,213       12,600       9,847       1,286       11,133  
                                                 
Other long-term debt     5,998       -       5,998       6,913               6,913  
                                                 
Total liabilities     17,385       1,213       18,598       16,760       1,286       18,046  
                                                 
Shareholders' equity:                                                
Preferred Shares     1,335       -       1,335       2,135       -       2,135  
Common Shares     1,871       -       1,871       1,698       -       1,698  
Additional paid-in capital     20,451       (816 )     19,635       19,408       (816 )     18,592  
Accumulated deficit     (14,096 )     (397 )     (14,493 )     (7,706 )     (470 )     (8,176 )
Accumulated other comprehensive income     29       -       29       51               51  
Total shareholders' equity     9,590       (1,213 )     8,377       15,586       (1,286 )     14,300  
                                                 
Total liabilities and shareholders' equity   $ 26,975     $ -     $ 26,975     $ 32,346     $ -     $ 32,346  
XML 32 R46.htm IDEA: XBRL DOCUMENT v2.4.0.8
LOSS PER SHARE (Reconciliation of Computation of Basic Income or Loss Per Share to Diluted Income or Loss Per Share) (Details) (USD $)
In Thousands, except Per Share data, unless otherwise specified
 12 Months Ended
Sep. 30, 2012
Sep. 30, 2011
Basic net loss per share:    
Net income (loss) $ (6,317) $ 2,302
Less: Deemed dividend for Series A Preferred Shares    (5,506)
Less: Preferred dividend    (991)
Net loss applicable to common shareholders (6,317) (4,195)
Weighted average common shares outstanding 7,158 5,667
Basic net loss per share $ (0.88) $ (0.74)
Diluted net loss per share:    
Net loss applicable to common shareholders $ (6,317) $ (4,195)
Weighted average common shares outstanding 7,158 5,667
Diluted net loss per share $ (0.88) $ (0.74)
XML 33 R34.htm IDEA: XBRL DOCUMENT v2.4.0.8
SEGMENT INFORMATION (Tables)
 12 Months Ended
Sep. 30, 2012
SEGMENT INFORMATION [Abstract]  
Operating Segments
  (a) Operating Segments

 

    Years Ended
September 30,		  
    2012     2011  
    (Restated)     (Restated)  
Revenue:                
Service   $ 21,312     $ 25,613  
Product     6,896       7,531  
    $ 28,208     $ 33,144  
                 
Operating income (loss):                
Service   $ (3,863 )   $ 745  
Product     12       542  
Corporate     (1,835 )     -  
    $ (5,686 )   $ 1,287  
                 
Interest Expense     (714 )     (706 )

Change in fair value of warrant liability- decrease

    

73

       1,759  
Other income     12       12  
                 
Income (loss) before income taxes   $ (6,315 )   $ 2,352  

 

Restructuring costs of $1,360 and $1,835 are included in the operating losses for fiscal 2012 for the Service and Corporate segments, respectively.

 

    Years Ended
September 30,		  
    2012     2011  
Identifiable assets:                
Service   $ 15,864     $ 18,121  
Product     7,262       7,674  
Corporate     3,849       6,551  
    $ 26,975     $ 32,346  
                 
Goodwill, net:                
Service   $ 1,009     $ 1,009  
Product     374       374  
    $ 1,383     $ 1,383  
                 
Intangible assets, net:                
Service   $ -     $ 54  
Product     -       -  
    $ -     $ 54  
                 
Depreciation and amortization:                
Service   $ 2,036     $ 1,899  
Product     242       235  
    $ 2,278     $ 2,134  
                 
Capital Expenditures:                
Service   $ 864     $ 1,098  
Product     226       76  
    $ 1,090     $ 1,174  
Geographical Information
  (b) Geographic Information

 

    Years Ended
September 30,		  
    2012     2011  
Sales to External Customers:                
North America   $ 25,042     $ 29,451  
Pacific Rim     961       912  
Europe     1,858       2,542  
Other     347       239  
    $ 28,208     $ 33,144  
                 
Long-lived Assets:                
North America   $ 20,083     $ 20,872  
Europe     -       1,101  
    $ 20,083     $ 21,973  
XML 34 R40.htm IDEA: XBRL DOCUMENT v2.4.0.8
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Schedule of Assumptions Used to Compute Fair Value of Warrants) (Details) (USD $)
In Thousands, except Per Share data, unless otherwise specified
 12 Months Ended 12 Months Ended
Sep. 30, 2012
Sep. 30, 2011
Sep. 30, 2012
Class A Warrant [Member]
Sep. 30, 2012
Class B Warrant [Member]
May 31, 2012
Class B Warrant [Member]
Sep. 30, 2012
Derivative Financial Instruments, Liabilities [Member]
Class A Warrant [Member]
Sep. 30, 2011
Derivative Financial Instruments, Liabilities [Member]
Class A Warrant [Member]
Sep. 30, 2011
Derivative Financial Instruments, Liabilities [Member]
Class B Warrant [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]                
Risk-free interest rate     1.87% 0.18%   0.41% 0.86% 0.08%
Dividend yield     0.00% 0.00%   0.00% 0.00% 0.00%
Volatility of the Company's common stock     106.91% 116.01%   117.30% 111.44% 74.43%
Expected life of the options     5 years 1 year   3 years 7 months 6 days 4 years 7 months 6 days 7 months 6 days
Fair value per unit           $ 0.881 $ 0.844 $ 0.091
Fair value of warrant liability $ 1,213 $ 1,286     $ 0      
XML 35 R49.htm IDEA: XBRL DOCUMENT v2.4.0.8
LEASE ARRANGEMENTS (Schedule of Future Minimum Lease Payments for Capital Leases) (Details) (USD $)
In Thousands, unless otherwise specified
Sep. 30, 2012
Capital Leased Assets [Line Items]  
2013 $ 388
2014 307
2015 281
2016 214
2017 4
Total minimum lease payments due 1,194
Principal [Member]
  
Capital Leased Assets [Line Items]  
2013 330
2014 268
2015 259
2016 208
2017 4
Total minimum lease payments due 1,069
Interest [Member]
  
Capital Leased Assets [Line Items]  
2013 58
2014 39
2015 22
2016 6
2017   
Total minimum lease payments due $ 125
XML 36 R31.htm IDEA: XBRL DOCUMENT v2.4.0.8
DEBT ARRANGEMENTS (Tables)
 12 Months Ended
Sep. 30, 2012
DEBT ARRANGEMENTS [Abstract]  
Schedule of Long-Term Debt

Long-term debt consisted of the following at September 30:

 

    2012     2011  
             
Mortgage note payable to a bank, payable in monthly principal and interest installments of $40. Interest is fixed at 4.1%.  Collateralized by underlying property.  Due October, 2013. (b)   $ 3,236     $ 3,573  
                 
Mortgage note payable to a bank, payable in monthly principal and interest installments of $17. Interest is fixed at 4.1%.  Collateralized by underlying property.  Due October, 2013. (b)     1,532       1,674  
                 
Replacement note payable to a bank, payable in monthly principal installments of $14 plus interest.  The interest rate is 4.5%. Collateralized by West Lafayette and Evansville properties. Due October, 2013.  (a) (b)     1,074       1,245  
                 
Note payable to Algo Holdings, payable in monthly installments of $10.  There is no interest on this note if paid within terms.  Termed May 1, 2012.  See Note 13.     -       85  
    $ 5,842     $ 6,577  
Less current portion     583       735  
    $ 5,259     $ 5,842  
XML 37 R64.htm IDEA: XBRL DOCUMENT v2.4.0.8
SEGMENT INFORMATION (Operating Segments) (Details) (USD $)
In Thousands, unless otherwise specified
 6 Months Ended 12 Months Ended
Sep. 30, 2012
Mar. 31, 2012
Sep. 30, 2012
Sep. 30, 2011
Segment Reporting Information [Line Items]        
Revenue:     $ 28,208 $ 33,144
Operating income (loss): 452 (2,943) (5,686) 1,287
Interest Expense     702 694
Change in fair value of warrant liability - decrease     73 1,759
Other income     12 12
Income (loss) before income taxes     (6,315) 2,352
Identifiable assets: 26,975   26,975 32,346
Goodwill, net: 1,383   1,383 1,383
Intangible assets, net:         54
Depreciation and amortization:     2,278 2,134
Capital Expenditures:     1,090 1,174
Service [Member]
        
Segment Reporting Information [Line Items]        
Revenue:     21,312 25,613
Operating income (loss):     (3,863) 745
Identifiable assets: 15,864   15,864 18,121
Goodwill, net: 1,009   1,009 1,009
Intangible assets, net:         54
Depreciation and amortization:     2,036 1,899
Capital Expenditures:     864 1,098
Product [Member]
        
Segment Reporting Information [Line Items]        
Revenue:     6,896 7,531
Operating income (loss):     12 542
Identifiable assets: 7,262   7,262 7,674
Goodwill, net: 374   374 374
Intangible assets, net:           
Depreciation and amortization:     242 235
Capital Expenditures:     226 76
Corporate [Member]
        
Segment Reporting Information [Line Items]        
Operating income (loss):     (1,835)   
Identifiable assets: $ 3,849   $ 3,849 $ 6,551
XML 38 R72.htm IDEA: XBRL DOCUMENT v2.4.0.8
MANAGEMENT'S PLAN (Details) (USD $)
In Thousands, unless otherwise specified
 6 Months Ended 12 Months Ended
Sep. 30, 2012
Mar. 31, 2012
Sep. 30, 2012
Sep. 30, 2011
MANAGEMENT'S PLAN [Abstract]        
Revenue growth (decline), percent     (14.90%)  
Gross margin growth (decline), percent 60.50%   (34.90%)  
Restructuring charges     $ 3,195   
Net income (loss)     (6,317) 2,302
Operating expenses growth (decline), percent (32.50%)      
Operating income (loss) 452 (2,943) (5,686) 1,287
Capital expenditures growth (decline), percent     (7.20%)  
Debt and lease obligations, current $ 1,300   $ 1,300  
XML 39 R63.htm IDEA: XBRL DOCUMENT v2.4.0.8
RETIREMENT PLAN (Details) (USD $)
In Thousands, unless otherwise specified
 12 Months Ended
Sep. 30, 2012
Sep. 30, 2011
RETIREMENT PLAN [Abstract]    
Company's contribution to plan, as a percent of participant's total wages 1.00%  
Employer's match percentage 22.00%  
Maximum percentage of participant's contribution eligible for employer matching contribution 10.00%  
Maximum annual contribution, percent of participant's annual wages 30.00%  
Contribution expense $ 17 $ 15
XML 40 R43.htm IDEA: XBRL DOCUMENT v2.4.0.8
SALE OF PREFERRED SHARES AND WARRANTS (Narrative) (Details) (USD $)
In Thousands, except Share data, unless otherwise specified
 12 Months Ended 0 Months Ended 12 Months Ended 12 Months Ended 0 Months Ended 12 Months Ended
Sep. 30, 2012
Sep. 30, 2011
May 11, 2011
May 11, 2011
Unit [Member]
Sep. 30, 2012
Unit [Member]
Sep. 30, 2012
Class A Warrant [Member]
May 11, 2011
Class A Warrant [Member]
Sep. 30, 2012
Class B Warrant [Member]
May 11, 2011
Class B Warrant [Member]
May 11, 2011
Series A Preferred Stock [Member]
Sep. 30, 2012
Series A Preferred Stock [Member]
Sep. 30, 2011
Series A Preferred Stock [Member]
Schedule Of Stock And Warrants By Class [Line Items]                        
Issuance of common stock for stock dividends and stock purchase plan, shares       5,506                
Equity issuance, price per share       $ 1,000                
Dividend rate                     6.00%  
Shares issued upon conversion of securities                   500    
Number of shares of common stock called by warrants             250   250      
Exercise price of warrant             2.00   2.00      
"Make-whole" payment                     $ 180  
Preferred stock, stated value per share                     $ 1,000 $ 1,000
Warrant expiration date           May 31, 2016   May 31, 2012        
Proceeds from equity issuance    4,606     4,600              
Fair value of warrants             1,072   3,045      
Preferred stock, shares outstanding                   2,753,000 1,335 2,135
Total possible dividend percentage over three years                   18.00%    
Common stock, price per share     $ 1.86                  
Preferred stock - recognition of full dividend/make-whole   (991)               991,080    
Fair value of outstanding preferred stock                   6,112    
Gross proceeds from equity issuance                   5,506    
Beneficial conversion feature                    2,461    
Deemed dividend                    5,506    
Shares converted                     4,171  
Common stock, shares issued in conversion                     2,486,127  
Common stock, shares issued for dividends                     135,793  
Warrants outstanding 1,376,500                      
Accrued dividends payable                     $ 227,977  
XML 41 R69.htm IDEA: XBRL DOCUMENT v2.4.0.8
RESTRUCTURING (Summary of Restructuring Costs) (Details) (USD $)
In Thousands, unless otherwise specified
 12 Months Ended
Sep. 30, 2012
Sep. 30, 2011
Restructuring Cost and Reserve [Line Items]    
Restructuring charges $ 3,195   
One-time Termination Benefits [Member]
    
Restructuring Cost and Reserve [Line Items]    
Restructuring charges 1,454  
Lease Related Costs [Member]
    
Restructuring Cost and Reserve [Line Items]    
Restructuring charges 861  
Equipment Moving Costs And Method Transfers [Member]
    
Restructuring Cost and Reserve [Line Items]    
Restructuring charges 153  
Travel and Relocation Costs [Member]
    
Restructuring Cost and Reserve [Line Items]    
Restructuring charges 47  
Loss on Sale of Equipment [Member]
    
Restructuring Cost and Reserve [Line Items]    
Restructuring charges 446  
Other Costs [Member]
    
Restructuring Cost and Reserve [Line Items]    
Restructuring charges $ 234  
XML 42 R25.htm IDEA: XBRL DOCUMENT v2.4.0.8
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
 12 Months Ended
Sep. 30, 2012
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]  
Summary of Activity in Allowance for Doubtful Accounts

A summary of activity in our allowance for doubtful accounts is as follows:

 

    2012     2011  
             
Opening balance   $ 108     $ 165  
Charged to expense     84       13  
Accounts recovered     15       (61 )
Accounts written off     (84 )     (9 )
Ending balance   $ 123     $ 108  
Schedule of Property and Equipment

Property and equipment, net, as of September 30, 2012 and 2011 consisted of the following:

 

    2012     2011  
             
Land and improvements   $ 914     $ 527  
Buildings and improvements     21,278       21,433  
Machinery and equipment     19,496       22,361  
Office furniture and fixtures     701       949  
Construction in progress     35       493  
      42,424       45,763  
Less:  accumulated depreciation     (23,796 )     (25,364 )
Net property and equipment   $ 18,628     $ 20,399  
Components of Amortizable Intangible Assets

At September 30, 2012 and 2011, remaining recorded goodwill was $1,383, and the net balance of other intangible assets was $0 and $54, respectively. The components of intangible assets subject to amortization are as follows:

 

          September 30, 2012  
    Weighted
average life
(years)		     Gross Carrying
Amount		     Accumulated
Amortization		  
                         
FDA compliant facility     10     $ 302     $ 302  

 

          September 30, 2011  
    Weighted
average life
(years)		     Gross Carrying
Amount		     Accumulated
Amortization		  
                         
FDA compliant facility     10     $ 302     $ 248  
Summary of Assumptions Used to Compute Fair Value of Warrants

The assumptions used to compute the fair value of the warrants at September 30, 2012 and 2011 were as follows:

 

    September 30, 2012     September 30, 2011  
    Warrant A     Warrant A     Warrant B  
                   
Risk-free interest rate     0.41 %     0.86 %     0.08 %
Dividend yield     0.00 %     0.00 %     0.00 %
Volatility of the Company's common stock     117.30 %     111.44 %     74.43 %
Expected life of the options (years)     3.6       4.6       0.6  
                         
Fair value per unit   $ 0.881     $ 0.844     $ 0.091  
XML 43 R6.htm IDEA: XBRL DOCUMENT v2.4.0.8
CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (Parenthetical) (USD $)
 12 Months Ended
Sep. 30, 2011
CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY AND COMPREHENSIVE INCOME [Abstract]  
Issuance of preferred shares, issuance costs $ 900,281
XML 44 R8.htm IDEA: XBRL DOCUMENT v2.4.0.8
DESCRIPTION OF THE BUSINESS
 12 Months Ended
Sep. 30, 2012
DESCRIPTION OF THE BUSINESS [Abstract]  
DESCRIPTION OF THE BUSINESS

1. DESCRIPTION OF THE BUSINESS

 

Bioanalytical Systems, Inc. and its subsidiaries (the "Company" or "BASi" or "we") engage in research services and other services related to pharmaceutical development. We also manufacture scientific instruments for medical research, which we sell with related software for use in industrial, governmental and academic laboratories. We conduct our businesses through our research and manufacturing facilities in Indiana. Our customers are located throughout the world.
XML 45 R11.htm IDEA: XBRL DOCUMENT v2.4.0.8
SALE OF PREFERRED SHARES AND WARRANTS
 12 Months Ended
Sep. 30, 2012
SALE OF PREFERRED SHARES AND WARRANTS [Abstract]  
SALE OF PREFERRED SHARES AND WARRANTS

4. SALE OF PREFERRED SHARES AND WARRANTS (not in thousands)

 

On May 11, 2011, we completed a registered public offering of 5,506 units at a price of $1,000 per unit. Each unit consisted of one 6% Series A convertible preferred share which is convertible into 500 common shares, one Class A Warrant to purchase 250 common shares at an exercise price of $2.00 per share, and one Class B Warrant to purchase 250 common shares at an exercise price of $2.00 per share.

 

The designation, rights, preferences and other terms and provisions of the Series A preferred shares are set forth in the Certificate of Designation. Until May 11, 2014, the Series A preferred shares have a stated dividend rate of 6% per annum, payable quarterly in cash or, subject to certain conditions, in common shares or a combination of cash and common shares, at our election. After May 11, 2014, the Series A preferred shares will participate in any dividends payable upon our common shares on an "as converted" basis. If the preferred shares are converted prior to May 11, 2014, we must also pay to the converting holder in cash, or subject to certain conditions, in common shares or a combination of cash and common shares, a "make-whole" payment of $180 per $1,000 of the stated value of the preferred shares less any dividends paid prior to conversion. Class A Warrants are exercisable immediately and expire in May 2016. Class B Warrants expired in May 2012. The net proceeds from the sale of the units, after deducting the fees and expenses of the placement agent and other expenses were $4.6 million. We used the proceeds for the purchase of laboratory equipment and for working capital and general corporate purposes.

 

The holders of the preferred shares are not entitled to vote together with common shareholders unless converted to common shares. The Series A preferred shares are considered to be an equity instrument. The warrants have been accounted for as a liability and valued using the Black Scholes pricing model. The total fair value of the Class A Warrants at issuance was $1.973 million and the total fair value of the Class B Warrants at issuance was $1.072 million for a total liability of $3.045 million. The assumptions used to compute the fair value of the warrants at the time of issuance were as follows:

 

    Warrant A     Warrant B  
             
Risk-free interest rate     1.87 %     0.18 %
Dividend yield     0.00 %     0.00 %
Volatility of the Company's common stock     106.91 %     116.01 %
Expected life of the options (years)     5.0       1.0  
                 
Fair value per unit   $ 1.433     $ 0.779  

 

The Series A preferred shares were valued using the common shares available upon conversion of all preferred shares of 2,753,000 and the closing market price of our stock on May 11, 2011 of $1.86. Adding in the total possible dividend for the preferred shares of 18% over three years, or $991,080, the total calculated fair value of the preferred shares was $6.112 million. We then allocated the gross proceeds of the offering of $5.506 million to the preferred shares after deducting the fair value of the warrants described above.

 

We have also recognized a beneficial conversion feature related to the Series A preferred shares, to the extent that the conversion feature, based on the proceeds allocated to the Series A preferred shares, was in-the-money at the time they were issued. Such beneficial conversion feature amounted to approximately $2.461 million. Because the Series A preferred shares do not have a stated redemption date and may be converted by the holder at any time, the discount recognized by the allocation of proceeds to the beneficial conversion feature has been immediately charged through accumulated deficit as a deemed dividend to the holders of the Series A preferred shares in the amount of $5.506 million. This will be the only deemed distribution recorded for the Series A preferred shares included in this offering. Further, because the preferred dividends or make-whole payments are payable any time after the closing on May 11, 2011 at the option of the holder, we recognized the full value, $991,080, as a liability included in accounts payable and charged immediately through accumulated deficit. There will be no other dividends recorded for the Series A preferred shares included in this offering.

 

As of September 30, 2012, 4,171 preferred shares have been converted into 2,486,127 common shares and 135,793 common shares have been issued for quarterly preferred dividends for remaining outstanding, unconverted preferred shares. No warrants have been exercised as of September 30, 2012. At September 30, 2012, 1,335 preferred shares and 1,376,500 warrants remained outstanding. Also at September 30, 2012, $227,977 of the $991,080 in preferred dividends remains accrued in accounts payable for future preferred dividends.
XML 46 R9.htm IDEA: XBRL DOCUMENT v2.4.0.8
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 12 Months Ended
Sep. 30, 2012
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

  (a) Principles of Consolidation

 

The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant inter-company accounts and transactions have been eliminated.

 

  (b) Revenue Recognition

 

The majority of our Bioanalytical and analytical research service contracts involve the development of analytical methods and the processing of bioanalytical samples for pharmaceutical companies and generally provide for a fixed fee for each sample processed. Revenue is recognized under the specific performance method of accounting and the related direct costs are recognized when services are performed. Our preclinical research service contracts generally consist of preclinical studies, and revenue is recognized under the proportional performance method of accounting. Revisions in profit estimates, if any, are reflected on a cumulative basis in the period in which such revisions become known. The establishment of contract prices and total contract costs involves estimates we make at the inception of the contract. These estimates could change during the term of the contract and impact the revenue and costs reported in the consolidated financial statements. Revisions to estimates have generally not been material. Research service contract fees received upon acceptance are deferred until earned, and classified within customer advances. Unbilled revenues represent revenues earned under contracts in advance of billings.

 

Product revenue from sales of equipment not requiring installation, testing or training is recognized upon shipment to customers. One product includes internally developed software and requires installation, testing and training, which occur concurrently. Revenue from these sales is recognized upon completion of the installation, testing and training when the services are bundled with the equipment sale.

 

  (c) Cash Equivalents

 

We consider all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents.

 

One or more of the financial institutions holding the Company's cash accounts are participating in the FDIC's Transaction Account Guarantee Program. Under that program, through December 31, 2010, all noninterest-bearing transaction accounts are fully guaranteed by the FDIC for the entire amount in the account. Pursuant to legislation enacted in 2010, the FDIC will fully insure all noninterest-bearing transaction accounts beginning December 31, 2010 through December 31, 2012, at all FDIC-insured institutions.

 

For financial institutions opting out of the FDIC's Transaction Account Guarantee Program or interest-bearing cash accounts, the FDIC's insurance limits were permanently increased to $250,000, effective July 21, 2010. At September 30, 2012, the Company did not have any cash accounts that exceeded federally insured limits.

 

  (d) Accounts Receivable

 

We perform periodic credit evaluations of our customers' financial conditions and generally do not require collateral on trade accounts receivable. We account for trade receivables based on the amounts billed to customers. Past due receivables are determined based on contractual terms. We do not accrue interest on any of our trade receivables. The allowance for doubtful accounts is determined by management based on our historical losses, specific customer circumstances, and general economic conditions. Periodically, management reviews accounts receivable and adjusts the allowance based on current circumstances and charges off uncollectible receivables when all attempts to collect have failed. Our allowance for doubtful accounts was $123 and $108 at September 30, 2012 and 2011, respectively.

 

A summary of activity in our allowance for doubtful accounts is as follows:

 

    2012     2011  
             
Opening balance   $ 108     $ 165  
Charged to expense     84       13  
Accounts recovered     15       (61 )
Accounts written off     (84 )     (9 )
Ending balance   $ 123     $ 108  

 

  (e) Inventories

 

Inventories are stated at the lower of cost or market using the first-in, first-out (FIFO) cost method of accounting. We evaluate inventories on a regular basis to identify inventory on hand that may be obsolete or in excess of current and future projected market demand. For inventory deemed to be obsolete, we provide a reserve for this inventory. Inventory that is in excess of current and projected use is reduced by an allowance to a level that approximates the estimate of future demand.

 

  (f) Property and Equipment

 

We record property and equipment at cost, including interest capitalized during the period of construction of major facilities. We compute depreciation, including amortization on capital leases, using the straight-line method over the estimated useful lives of the assets, which we estimate to be: buildings and improvements, 34 to 40 years; machinery and equipment, 5 to 10 years, and office furniture and fixtures, 10 years. In our European operations, we depreciate leasehold improvements, using the straight-line method, over 7 years, corresponding to the terms of the operating lease for the European facility. Depreciation expense was $2,217 in fiscal 2012 and $2,085 in fiscal 2011. Expenditures for maintenance and repairs are expensed as incurred.

 

Property and equipment, net, as of September 30, 2012 and 2011 consisted of the following:

 

    2012     2011  
             
Land and improvements   $ 914     $ 527  
Buildings and improvements     21,278       21,433  
Machinery and equipment     19,496       22,361  
Office furniture and fixtures     701       949  
Construction in progress     35       493  
      42,424       45,763  
Less:  accumulated depreciation     (23,796 )     (25,364 )
Net property and equipment   $ 18,628     $ 20,399  

 

  (g) Long-Lived Assets including Goodwill

 

Long-lived assets, such as property and equipment, and purchased intangibles subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized of the amount by which the carrying amount of the asset exceeds the fair value of the asset.

 

We carry goodwill at cost. Other intangible assets with definite lives are stated at cost and are amortized on a straight-line basis over their estimated useful lives. All intangible assets acquired that are obtained through contractual or legal right, or are capable of being separately sold, transferred, licensed, rented, or exchanged, are recognized as an asset apart from goodwill. Goodwill is not amortized.

 

Goodwill is tested annually for impairment, and more frequently if events and circumstances indicate that the asset might be impaired. First, we can assess qualitative factors in determining whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. We elected to bypass the qualitative assessment aspect of this guidance due to the restructuring circumstances. Then, we followed a two-step quantitative process. In the first step, we compare the fair value of each reporting unit, as computed primarily by present value cash flow calculations, to its book carrying value, including goodwill. We do not believe that market value is indicative of the true fair value of the Company mainly due to average daily trading volumes of less than 1%. If the fair value exceeds the carrying value, no further work is required and no impairment loss is recognized. If the carrying value exceeds the fair value, the goodwill of the reporting unit is potentially impaired and we would then complete step 2 in order to measure the impairment loss. In step 2, the implied fair value is compared to the carrying amount of the goodwill. If the implied fair value of goodwill is less than the carrying value of goodwill, we would recognize an impairment loss equal to the difference. The implied fair value is calculated by allocating the fair value of the reporting unit (as determined in step 1) to all of its assets and liabilities (including unrecognized intangible assets) and any excess in fair value that is not assigned to the assets and liabilities is the implied fair value of goodwill.

 

The discount rate, gross margin and sales growth rates are material assumptions utilized in our calculations of the present value cash flows used to estimate the fair value of the reporting units when performing the annual goodwill impairment test. Our reporting units with goodwill at September 30, 2012 are Vetronics, which is included in our Products segment, bioanalytical services and preclinical services, which are both included in our Services segment, based on the discrete financial information available which is reviewed by management. We utilize a cash flow approach in estimating the fair value of the reporting units, where the discount rate reflects a weighted average cost of capital rate. The cash flow model used to derive fair value is sensitive to the discount rate and sales growth assumptions used.

 

Due to the closure of the McMinnville, Oregon site, we tested for impairment of the bioanalytical business at the end of our third fiscal quarter using the cash flow approach as explained above. This test resulted in no impairment to the goodwill valuation as currently recorded on the books.

 

We also performed our annual impairment test for all reporting units mentioned above at September 30, 2012. Using a discount rate of 14% and a revenue growth rate of 5% for the Bioanalytical services and 0% for both the preclinical services and Vetronics units, the fair values of the reporting units described above are greater than the carrying values by approximately $3.7 million.

 

Considerable management judgment is necessary to evaluate the impact of operating and macroeconomic changes and to estimate future cash flows. Assumptions used in our impairment evaluations, such as forecasted sales growth rates and our cost of capital or discount rate, are based on the best available market information. Changes in these estimates or a continued decline in general economic conditions could change our conclusion regarding an impairment of goodwill and potentially result in a non-cash impairment loss in a future period. The assumptions used in our impairment testing could be adversely affected by certain risks. There have been no significant events since the timing of our impairment tests that would have triggered additional impairment testing.

 

At September 30, 2012 and 2011, remaining recorded goodwill was $1,383, and the net balance of other intangible assets was $0 and $54, respectively. The components of intangible assets subject to amortization are as follows:

 

          September 30, 2012  
    Weighted
average life
(years)		     Gross Carrying
Amount		     Accumulated
Amortization		  
                         
FDA compliant facility     10     $ 302     $ 302  

 

          September 30, 2011  
    Weighted
average life
(years)		     Gross Carrying
Amount		     Accumulated
Amortization		  
                         
FDA compliant facility     10     $ 302     $ 248  

 

Amortization expense for intangible assets for fiscal years ended September 30, 2012 and 2011 was $54 and $30, respectively. As of September 30, 2012, all intangible assets have been fully amortized.

 

  (h) Advertising Expense

 

We expense advertising costs as incurred. Advertising expense was $203 and $229 for the years ended September 30, 2012 and 2011, respectively.

 

  (i) Stock-Based Compensation

 

We have a stock-based employee compensation plan and a stock-based employee and outside director compensation plan, which are described more fully in Note 10. All options granted under these plans have an exercise price equal to the market value of the underlying common shares on the date of grant. We expense the estimated fair value of stock options over the vesting periods of the grants. Our policy is to recognize expense for awards subject to graded vesting using the straight-line attribution method, reduced for estimated forfeitures. Forfeitures are revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates and an adjustment is recognized at that time.

 

We use a binomial option-pricing model as our method of valuation for share-based awards, requiring us to make certain assumptions about the future, which are more fully described in Note 10. Stock-based compensation expense for employee stock options for the years ended September 30, 2012 and 2011 was $83 and $153, respectively.

 

  (j) Income Taxes

 

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. We record valuation allowances based on a determination of the expected realization of tax assets.

 

We may recognize the tax benefit from an uncertain tax position only if it is more likely than not to be sustained upon examination based on the technical merits of the position. The amount of the accrual for which an exposure exists is measured as the largest amount of benefit determined on a cumulative probability basis that we believe is more likely than not to be realized upon settlement of the position.

 

We record interest and penalties accrued in relation to uncertain income tax positions as a component of income tax expense. Any changes in the liability for uncertain tax positions would impact our effective tax rate. We do not expect the total amount of unrecognized tax benefits to significantly change in the next twelve months.

 

  (k) New Accounting Pronouncements

 

In May 2011, the FASB issued updated fair value measurement and disclosure guidance that clarifies how to measure fair value and requires additional disclosures regarding Level 3 fair value measurements, as well as any transfers between Level 1 and Level 2 fair value measurements. The updated accounting guidance is effective for fiscal years and interim periods beginning on or after December 15, 2011 on a prospective basis. The Company adopted this guidance in the second fiscal quarter with no material impact on the consolidated financial statements.

 

In June 2011, the FASB amended the manner in which an entity presents the total of comprehensive income, the components of net income and the components of other comprehensive income either in a single, continuous statement of comprehensive income or in two separate but consecutive statements. The amendment eliminates the option to present the components of other comprehensive income as part of the statement of equity. The amendment is effective for fiscal years and interim periods beginning on or after December 15, 2011 on a retrospective basis. The adoption of this guidance will not change the previously reported amounts of comprehensive income. The Company has presented other comprehensive income on the face of the condensed consolidated statements of operations for all periods presented.

 

In September 2011, the FASB issued an accounting standards update that amends the two-step goodwill impairment test by permitting an entity to first assess qualitative factors in determining whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the entity determines that it is not more likely than not that the fair value of a reporting unit is less than its carrying amount, then performing the two-step goodwill impairment test is unnecessary. The amendment is effective for fiscal years and interim periods beginning on or after December 15, 2011 on a prospective basis, early adoption is permitted. The Company elected to bypass the qualitative assessment aspect of this guidance due to the restructuring circumstances and performed a quantitative analysis in the third and fourth fiscal quarters of 2012. The quantitative analysis resulted in no impairment to the goodwill valuation as currently recorded on the books.

 

  (l) Fair Value

 

The provisions of the Fair Value Measurements and Disclosure Topic defines fair value, establishes a consistent framework for measuring fair value and provides the disclosure requirements about fair value measurements. This Topic also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company's judgment about the assumptions market participants would use in pricing the asset or liability based on the best information available in the circumstances. The hierarchy is broken down into three levels based on the inputs as follows:

 

  •   Level 1 - Valuations based on quoted prices for identical assets or liabilities in active markets that the Company has the ability to access.

 

  •   Level 2 - Valuations based on quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.

 

  •   Level 3 - Valuations based on inputs that are unobservable and significant to the overall fair value measurement.

 

We have Class A and B Warrants from the May 2011 offering that are measured at fair value on a recurring basis. We recorded these warrants as a liability determining the fair value at inception on May 11, 2011. Subsequent quarterly fair value measurements, using the Black Scholes model which is considered a level 2 measurement, are calculated with fair value changes charged to the statement of operations and comprehensive income (loss). Class B Warrants expired in May 2012 and the liability was reduced to zero. The assumptions used to compute the fair value of the warrants at September 30, 2012 and 2011 were as follows:

 

    September 30, 2012     September 30, 2011  
    Warrant A     Warrant A     Warrant B  
                   
Risk-free interest rate     0.41 %     0.86 %     0.08 %
Dividend yield     0.00 %     0.00 %     0.00 %
Volatility of the Company's common stock     117.30 %     111.44 %     74.43 %
Expected life of the options (years)     3.6       4.6       0.6  
                         
Fair value per unit   $ 0.881     $ 0.844     $ 0.091  

 

The carrying amounts for cash and cash equivalents, accounts receivable, inventories, prepaid expenses and other assets, accounts payable and other accruals approximate their fair values because of their nature and respective duration. The fair value of the revolving credit facility and certain long-term debt is equal to their carrying values due to the variable nature of their interest rates. Our long-term fixed rate debt was initiated in February 2011 and renewed on November 1, 2012. Our interest rate swap expired under its terms in fiscal 2011.

 

  (m) Use of Estimates

 

The preparation of financial statements in conformity with generally accepted accounting principles requires us to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Significant estimates as part of the issuance of these consolidated financial statements include but are not limited to the determination of fair values, allowance for doubtful accounts, inventory obsolescence, deferred tax valuations, depreciation, impairment charges and stock compensation. Our actual results could differ from those estimates.

 

  (n) Research and Development

 

In fiscal 2012 and 2011, we spent $542 and $534, respectively, on research and development. Separate from our contract research services business, we maintain applications research and development to enhance our products business.

 

  (o) Comprehensive Income (Loss)

 

We report comprehensive income (loss) on our Consolidated Statements of Operations. Other comprehensive income (loss) represents changes in shareholders' equity and is comprised of foreign currency translation adjustments.

 

  (p) Foreign Currency

 

For our subsidiary outside of the United States that operates in a local currency environment, income and expense items are translated to United States dollars at the monthly average rates of exchange prevailing during the year, assets and liabilities are translated at year-end exchange rates and equity accounts are translated at historical exchange rates. Translation adjustments are accumulated in a separate component of shareholders' equity in the consolidated balance sheets and are included in the determination of comprehensive income (loss) in the consolidated statements of shareholders' equity. Transaction gains and losses are included in the determination of net income (loss) in the consolidated statements of operations and comprehensive income (loss).
XML 47 R41.htm IDEA: XBRL DOCUMENT v2.4.0.8
RESTATEMENT OF PREVIOUSLY ISSUED CONSOLIDATED FINANCIAL STATEMENTS (Statements of Operations) (Details) (USD $)
In Thousands, except Per Share data, unless otherwise specified
 6 Months Ended 12 Months Ended
Sep. 30, 2012
Mar. 31, 2012
Sep. 30, 2012
Sep. 30, 2011
Total revenue     $ 28,208 $ 33,144
Total cost of revenue     21,370 22,638
Gross profit     6,838 10,506
Total operating expenses     9,329 9,219
Restructuring charges     3,195   
Operating income (loss) 452 (2,943) (5,686) 1,287
Interest expense     (714) (706)
Change in fair value of warrant liability - decrease     73 1,759
Other income     12 12
Income (loss) before income taxes     (6,315) 2,352
Income tax expense     2 50
Net income (loss)     (6,317) 2,302
Other comprehensive income (loss):        
Foreign currency translation adjustment     (22) (49)
Comprehensive income (loss)     (6,339) 2,253
Basic EPS     $ (0.88) $ (0.74)
Diluted EPS     $ (0.88) $ (0.74)
As Reported [Member]
        
Total revenue     28,208 33,144
Total cost of revenue     21,370 22,638
Gross profit     6,838 10,506
Total operating expenses     9,329 9,219
Restructuring charges     3,195   
Operating income (loss)     (5,686) 1,287
Interest expense     (714) (706)
Change in fair value of warrant liability - decrease          
Other income     12 12
Income (loss) before income taxes     (6,388) 593
Income tax expense     2 50
Net income (loss)     (6,390) 543
Other comprehensive income (loss):        
Foreign currency translation adjustment     (22) (49)
Comprehensive income (loss)     (6,412) 494
Basic EPS     $ (0.89) $ (0.66)
Diluted EPS     $ (0.89) $ (0.66)
Adjustment [Member]
        
Total revenue          
Total cost of revenue          
Gross profit          
Total operating expenses          
Restructuring charges          
Operating income (loss)          
Interest expense          
Change in fair value of warrant liability - decrease     73 1,759
Other income          
Income (loss) before income taxes     73 1,759
Income tax expense          
Net income (loss)     73 1,759
Other comprehensive income (loss):        
Foreign currency translation adjustment          
Comprehensive income (loss)     $ 73 $ 1,759
Basic EPS     $ 0.01 $ (0.08)
Diluted EPS     $ 0.01 $ (0.08)
XML 48 R28.htm IDEA: XBRL DOCUMENT v2.4.0.8
LOSS PER SHARE (Tables)
 12 Months Ended
Sep. 30, 2012
LOSS PER SHARE [Abstract]  
Reconciliation of Computation of Basic Loss Per Share to Diluted Net Loss Per Share

The following table reconciles our computation of basic net loss per share to diluted net loss per share:

 

    Years Ended
September 30,		  
    2012     2011  
    (Restated)     (Restated)  
Basic net loss per share:                
Net income (loss)   $ (6,317 )   $ 2,302  
Less:  Deemed dividend for Series A Preferred Shares     -       (5,506 )
Less:  Preferred dividend     -       (991 )
Net loss applicable to common shareholders   $ (6,317 )   $ (4,195 )
Weighted average common shares outstanding     7,158       5,667  
Basic net loss per share   $ (0.88 )   $ (0.74 )
                 
Diluted net loss per share:                
Net loss applicable to common shareholders   $ (6,317 )   $ (4,195 )
Weighted average common shares outstanding     7,158       5,667  
Diluted net loss per share   $ (0.88 )   $ (0.74 )
XML 49 R32.htm IDEA: XBRL DOCUMENT v2.4.0.8
INCOME TAXES (Tables)
 12 Months Ended
Sep. 30, 2012
INCOME TAXES [Abstract]  
Schedule of Deferred Tax Assets and Liabilities

Significant components of our deferred tax assets and liabilities as of September 30 are as follows:

 

    2012     2011  
    (Restated)     (Restated)  
Deferred tax assets - Current:                
Inventory   $ 202     $ 236  
Accrued compensation and vacation     255       271  
Accrued expenses and other     252       118  
Total current deferred tax assets     709       625  
                 
Deferred tax liabilities - Current:                
Prepaid expenses     (74 )     (116 )
Total net current deferred tax assets     635       509  
                 
Deferred tax assets - Noncurrent:                
Domestic net operating loss carryforwards     2,483       1,585  
Stock compensation expense     14       29  
Foreign net operating loss     2,334       1,326  
Foreign tax credit carryover     119       119  
AMT credit carryover     42       45  
Total noncurrent deferred tax assets     4,992       3,104  
                 
Deferred tax liabilities - Noncurrent:                
Unrealized gain/loss - warrant liability     (296 )     (685 )
Basis difference for fixed assets     (459 )     (562 )
Basis difference for intangibles     -       (21 )
      (755 )     (1,268 )
                 
Total net noncurrent deferred tax assets     4,237       1,836  
                 
Valuation allowance for net deferred tax assets     (4,872 )     (2,345 )
Net deferred tax  asset (liability)   $ -     $ -  
Schedule of the Provision (Benefit) for Income Taxes

Significant components of the provision (benefit) for income taxes are as follows as of the year ended September 30:

 

    2012     2011  
Current:                
Federal   $ (3 )   $ 37  
State and local     5       13  
Foreign     -       -  
                 
Deferred:                
Federal     -       -  
State and local     -       -  
Foreign     -       -  
Income tax expense   $ 2     $ 50  
Reconciliation of Effective Income Tax Rate

The effective income tax rate on continuing operations varied from the statutory federal income tax rate as follows:

 

    2012     2011  
             
Statutory federal income tax rate     34.0 %     34.0 %
Increases (decreases):                
State and local income taxes, net of Federal tax benefit, if applicable     (0.1 )     0.4  
Nondeductible expenses     (0.5 )     2.9  
Valuation allowance changes     (33.5 )     (35.4 )
Other     ---       0.2  
                 
Effective income tax rate     (0.1 )%     2.1 %
Reconciliation of Unrecognized Tax Benefits

Change in unrecognized tax benefits:

 

    2012     2011  
Balance at beginning of the year   $ 16     $ 30  
Additions based on tax positions related to the current year     -       -  
Additions for tax positions of prior years     -       -  
Reductions for tax positions of prior years     -       (14 )
Settlements     -       -  
Balance at end of the year   $ 16     $ 16  
XML 50 R71.htm IDEA: XBRL DOCUMENT v2.4.0.8
SELF-INSURANCE (Details) (USD $)
In Thousands, unless otherwise specified
 12 Months Ended
Sep. 30, 2012
Sep. 30, 2011
SELF-INSURANCE [Abstract]    
Self insurance exposure for individual claims $ 60  
Minimum annual aggregate attachment point 2,072  
Self-insured employee health plan expenses $ 1,231 $ 1,089
XML 51 R37.htm IDEA: XBRL DOCUMENT v2.4.0.8
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Summary of Activity in Allowance for Doubtful Accounts) (Details) (USD $)
In Thousands, unless otherwise specified
 12 Months Ended
Sep. 30, 2012
Sep. 30, 2011
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]    
Opening balance $ 108 $ 165
Charged to expense 84 13
Accounts written off 15 (61)
Accounts recovered (84) (9)
Ending balance $ 123 $ 108
XML 52 R70.htm IDEA: XBRL DOCUMENT v2.4.0.8
RESTRUCTURING (Summary of Restructuring Activity) (Details) (USD $)
In Thousands, unless otherwise specified
 12 Months Ended
Sep. 30, 2012
Sep. 30, 2011
Restructuring Cost and Reserve [Line Items]    
Balance     
Total Charges 3,195   
Cash Payments (1,251)  
Other (539)  
Balance 1,405   
One-time Termination Benefits [Member]
    
Restructuring Cost and Reserve [Line Items]    
Balance     
Total Charges 1,454  
Cash Payments (1,006)  
Other     
Balance 448  
Lease Related Costs [Member]
    
Restructuring Cost and Reserve [Line Items]    
Balance     
Total Charges 861  
Cash Payments (61)  
Other     
Balance 800  
Equipment Moving Costs And Method Transfers [Member]
    
Restructuring Cost and Reserve [Line Items]    
Balance     
Total Charges 153  
Cash Payments (104)  
Other     
Balance 49  
Travel and Relocation Costs [Member]
    
Restructuring Cost and Reserve [Line Items]    
Balance     
Total Charges 47  
Cash Payments (43)  
Other     
Balance 4  
Loss on Sale of Equipment [Member]
    
Restructuring Cost and Reserve [Line Items]    
Balance     
Total Charges 446  
Cash Payments     
Other (539)  
Balance (93)  
Other Costs [Member]
    
Restructuring Cost and Reserve [Line Items]    
Balance     
Total Charges 234  
Cash Payments (37)  
Other     
Balance $ 197  
XML 53 R55.htm IDEA: XBRL DOCUMENT v2.4.0.8
INCOME TAXES (Reconciliation of Effective Income Tax Rate) (Details)
 12 Months Ended
Sep. 30, 2012
Sep. 30, 2011
INCOME TAXES [Abstract]    
Statutory federal income tax rate: 34.00% 34.00%
Increases (decreases):    
State and local income taxes, net of Federal tax benefit, if applicable (0.10%) 0.40%
Nondeductable expenses (0.50%) 2.90%
Valuation allowance changes (33.50%) (35.40%)
Other    0.20%
Effective income tax rate (0.10%) 2.10%
EXCEL 54 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\X-F4R9&1B9%]F,V0T7S0X,C-?8C0P,U]A,&(Q M.&-E9F0U,&(B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-/3E-/3$E$051%1%]35$%414U%3E137T]&7T-! M4SPO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-534U!4EE?3T9?4TE'3DE&24-!3E1?04-#3U5. M5#PO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-!3$5?3T9?4%)%1D524D5$7U-(05)%4U]! M3D1?5SPO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DQ/ M4U-?4$527U-(05)%/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I% M>&-E;%=O#I7;W)K#I7;W)K#I. M86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-43T-+ M0D%3141?0T]-4$5.4T%424]./"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T M4V]U#I%>&-E;%=O#I%>&-E;%=O#I. M86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E)%4U1254-455))3D<\+W@Z3F%M93X-"B`@("`\>#I7 M;W)K#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I7;W)K M#I%>&-E;%=O#I.86UE/@T*("`@(#QX M.E=O#I%>&-E;%=O M#I.86UE/E-!3$5?3T9?4%)%1D524D5$7U-(05)% M4U]!3D1?5S$\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I7;W)K M#I7;W)K#I%>&-E M;%=O#I%>&-E;%=O#I. M86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-%1TU%3E1?24Y&3U)-051)3TY?5&%B;&5S/"]X.DYA M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I7;W)K#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-534U!4EE?3T9?4TE'3DE&24-!3E1?04-#3U5.5#4\+W@Z3F%M M93X-"B`@("`\>#I7;W)K#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX M.E=O#I%>&-E;%=O M#I.86UE/E-!3$5?3T9?4%)%1D524D5$7U-(05)% M4U]!3D1?5S,\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I7;W)K#I7;W)K#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE M/D1%0E1?05)204Y'14U%3E137U-C:&5D=6QE7V]F7SPO>#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/D1%0E1?05)204Y'14U%3E137TYA M#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I. M86UE/DE.0T]-15]405A%4U]38VAE9'5L95]O9E]$969E#I.86UE/@T* M("`@(#QX.E=O#I% M>&-E;%=O#I.86UE/DE.0T]-15]405A%4U]38VAE M9'5L95]O9E]T:&5?4#PO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DE.0T]-15]405A%4U]296-O;F-I;&EA=&EO;E]O9CPO>#I.86UE M/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DE.0T]-15]405A%4U]. M87)R871I=F5?1&5T86EL#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DE.0T]-15]405A%4U]296-O;F-I;&EA=&EO;E]O9C$\+W@Z M3F%M93X-"B`@("`\>#I7;W)K#I7;W)K#I7;W)K#I7;W)K M#I%>&-E;%=O#I.86UE/@T*("`@(#QX M.E=O#I%>&-E;%=O M#I.86UE/E)%5$E214U%3E1?4$Q!3E]$971A:6QS M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE M/E)%4U1254-455))3D=?3F%R#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/E)%4U1254-455))3D=?4W5M;6%R M>5]O9E]297-T#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I. M86UE/E)%4U1254-455))3D=?4W5M;6%R>5]O9E]297-T#I7;W)K#I7;W)K#I7;W)K M#I3='EL97-H965T($A2968],T0B5V]R:W-H965T3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X M-F4R9&1B9%]F,V0T7S0X,C-?8C0P,U]A,&(Q.&-E9F0U,&(-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.#9E,F1D8F1?9C-D-%\T.#(S7V(T,#-? M83!B,3AC969D-3!B+U=O'0O:'1M;#L@8VAA2!);F9O'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^=')U M93QS<&%N/CPO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$6UB;VP\+W1D/@T* M("`@("`@("`\=&0@8VQA2!296=I2!#96YT3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^,#`P,#'0^+2TP.2TS,#QS<&%N/CPO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S2!&:6QE'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^ M/"$M+41/0U194$4@:'1M;"!054),24,@(BTO+U&AT M;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@+2T^/&1I=CX@/&1I M=CX\(2TM4W1A"<^(#QS=')O;F<^17AP;&%N871O71I8V%L(%-Y2(I(&ES(&9I;&EN9R!T:&ES($%M96YD M;65N="!O;B!&;W)M(#$P+4LO02`H=&AI6EN9R!C;VYS;VQI9&%T960@9FEN86YC:6%L('-T871E;65N=',@ M86YD(&EN(#QE;3Y-86YA9V5M96YT)B,S.3MS($1I6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE"<^(#QS=')O;F<^)FYB2!I M;B!F:6QI;F<@;W5R($9O2!I6QE/3-$)T9/3E0Z M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE"<^("9N8G-P.SPO<#X@/'`@2!R97!O"<^ M(#QS=')O;F<^26YT97)N86P@0V]N=')O;"!#;VYS:61E#L@5$585"U)3D1%3E0Z(#`N-6EN M)SX@3W5R(&UA;F%G96UE;G0@:&%S(&1E=&5R;6EN960@=&AA="!T:&5R92!W M87,@82!C;VYT6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE"<^("9N8G-P.SPO<#X@/'`@#L@ M5$585"U)3D1%3E0Z(#`N-6EN)SX@1F]R('1H92!C;VYV96YI96YC92!O9B!T M:&4@2P@87,@;6]D:69I960@86YD M('-U<&5R6QE/3-$)U=)1%1(.B`U M-"XS<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=W:61T:#H@,3AP=#LG M/B9M:61D;W0[/"]T9#X@/'1D/E!A2!$871A.R!A;F0\+W1D/B`\+W1R/B`\+W1A8FQE/B`\ M=&%B;&4@&-H86YG92!!8W0@;V8@,3DS-"P@87,@86UE;F1E9"`H(D5X8VAA;F=E M($%C="(I+"!D871E9"!A7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA'!E;G-E2!A;F0@97%U:7!M96YT+"!N970\+W1D M/@T*("`@("`@("`\=&0@8VQA6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA3PO=&0^#0H@("`@("`@(#QT9"!C;&%S M7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA'!E;G-E'0^)FYB&5S/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M/B@V+#,Q-2D\"!E>'!E;G-E/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA'0^)FYB'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-3,\ M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^)FYB6UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M<#XX,SQS<&%N/CPO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^)FYB'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%\X-F4R9&1B9%]F,V0T7S0X,C-?8C0P,U]A,&(Q.&-E9F0U,&(-"D-O M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.#9E,F1D8F1?9C-D-%\T.#(S M7V(T,#-?83!B,3AC969D-3!B+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!O<&5R871I;F<@86-T:79I=&EE65E('-T;V-K(&-O;7!E;G-A M=&EO;B!E>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX M,SQS<&%N/CPO'0^)FYB'!E;F1I='5R97,\+W1D/@T*("`@("`@("`\=&0@8VQA'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^)FYB2!F:6YA;F-I M;F<@86-T:79I=&EE&-H86YG92!R871E(&-H86YG97,\ M+W1D/@T*("`@("`@("`\=&0@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^)FYB3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%\X-F4R9&1B9%]F,V0T7S0X,C-?8C0P,U]A,&(Q.&-E9F0U,&(-"D-O;G1E M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.#9E,F1D8F1?9C-D-%\T.#(S7V(T M,#-?83!B,3AC969D-3!B+U=O'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$6QE/3-$ M)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE"<^(#QS=')O;F<^)FYB7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA6QE/3-$)U1%6%0M04Q) M1TXZ(&IU"<^(#QS=')O;F<^,BX@4U5-34%2 M62!/1B!324=.249)0T%.5"!!0T-/54Y424Y'(%!/3$E#2453/"]S=')O;F<^ M/"]P/B`\<"!S='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y.R!&3TY4.B`Q M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G/B`\=&0@#L@4$%$1$E.1RU43U`Z(#!P>#L@4$%$1$E. M1RU,1494.B`P<'@[(%!!1$1)3D#L@5TE$5$@Z(#`N,C5I M;CL@5$585"U)3D1%3E0Z(#!P>"<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS M1"=0041$24Y'+4)/5%1/33H@,'!X.R!0041$24Y'+51/4#H@,'!X.R!0041$ M24Y'+4Q%1E0Z(#!P>#L@4$%$1$E.1RU224=(5#H@,'!X.R!724142#H@,"XU M:6X[(%1%6%0M24Y$14Y4.B`P<'@G/B`\96T^*&$I/"]E;3X\+W1D/B`\=&0@ M#L@5$585"U!3$E'3CH@:G5S M=&EF>3L@4$%$1$E.1RU43U`Z(#!P>#L@4$%$1$E.1RU,1494.B`P<'@[(%!! M1$1)3D#L@5$585"U)3D1%3E0Z(#!P>"<^(#QE;3Y06QE/3-$)U1%6%0M04Q)1TXZ(&IU#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@)FYB2!A8V-O=6YT3L@1D].5#H@,3!P="!4:6UE6QE/3-$)U!!1$1)3D#L@4$%$1$E.1RU43U`Z(#!P>#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1) M3D#L@5TE$5$@Z(#`N-6EN.R!415A4+4E.1$5.5#H@,'!X M)SX@/&5M/BAB*3PO96T^/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$ M)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@5&AE(&UA:F]R M:71Y(&]F(&]U71I8V%L(&%N9"!A;F%L>71I8V%L(')E2!P&5D(&9E92!F M;W(@96%C:"!S86UP;&4@<')O8V5S6QE/3-$)T9/3E0Z M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@4')O9'5C="!R979E;G5E M(&9R;VT@F5D('5P;VX@8V]M<&QE=&EO;B!O9B!T:&4@:6YS=&%L;&%T:6]N M+"!T97-T:6YG(&%N9"!T6QE M/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@)FYB#L@4$%$1$E.1RU224=(5#H@,'!X M.R!724142#H@,"XR-6EN.R!415A4+4E.1$5.5#H@,'!X)SX@)FYB6QE/3-$)U!!1$1)3D"<^(#QE;3XH8RD\ M+V5M/CPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,'!X.R!4 M15A4+4%,24=..B!J=7-T:69Y.R!0041$24Y'+51/4#H@,'!X.R!0041$24Y' M+4Q%1E0Z(#!P>#L@4$%$1$E.1RU224=(5#H@,'!X.R!415A4+4E.1$5.5#H@ M,'!X)SX@/&5M/D-A6QE/3-$)U1%6%0M04Q)1TXZ(&IU#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@)FYB6QE/3-$)U1%6%0M04Q)1TXZ(&IU M#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@)FYB M#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@1F]R(&9I;F%N M8VEA;"!I;G-T:71U=&EO;G,@;W!T:6YG(&]U="!O9B!T:&4@1D1)0R8C,SD[ M2!C M87-H(&%C8V]U;G1S('1H870@97AC965D960@9F5D97)A;&QY(&EN6QE/3-$)U!!1$1)3D#L@4$%$1$E.1RU43U`Z(#!P>#L@4$%$1$E.1RU,1494.B`P M<'@[(%!!1$1)3D#L@5TE$5$@Z(#`N-6EN.R!415A4+4E. M1$5.5#H@,'!X)SX@/&5M/BAD*3PO96T^/"]T9#X@/'1D('-T>6QE/3-$)U!! M1$1)3D3L@1D].5#H@,3!P="!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&IU M#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@5V4@ M<&5R9F]R;2!P97)I;V1I8R!C2!O9B!O=7(@=')A M9&4@2P@;6%N86=E;65N="!R979I97=S(&%C8V]U;G1S(')E8V5I M=F%B;&4@86YD(&%D:G5S=',@=&AE(&%L;&]W86YC92!B87-E9"!O;B!C=7)R M96YT(&-I3L@1D].5#H@,3!P="!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ M(&IU#L@5$585"U)3D1%3E0Z(#`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`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U! M3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SX@)FYB6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@5TE$5$@Z(#(E)SXF;F)S<#L\+W1D/B`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`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$58 M5"U!3$E'3CH@;&5F="<^*3PO=&0^(#PO='(^(#QT6QE/3-$)U9% M4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z(')G8B@R M,#0L,C4U+#(P-"DG/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ M(#(N-7!T.R!415A4+4%,24=..B!L969T)SX@)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T M)SXF;F)S<#L\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=. M.B!R:6=H="<^(#$P.#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P M<'0[(%!!1$1)3D6QE/3-$)U1%6%0M M04Q)1TXZ(&IU#L@5$585"U)3D1%3E0Z(#`N M-6EN)SX@)FYB#L@4$%$1$E. M1RU224=(5#H@,'!X.R!724142#H@,"XR-6EN.R!415A4+4E.1$5.5#H@,'!X M)SX@)FYB6QE/3-$)U!!1$1)3D"<^(#QE;3XH92D\+V5M/CPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/ M5%1/33H@,'!X.R!415A4+4%,24=..B!J=7-T:69Y.R!0041$24Y'+51/4#H@ M,'!X.R!0041$24Y'+4Q%1E0Z(#!P>#L@4$%$1$E.1RU224=(5#H@,'!X.R!4 M15A4+4E.1$5.5#H@,'!X)SX@/&5M/DEN=F5N=&]R:65S/"]E;3X\+W1D/B`\ M+W1R/B`\+W1A8FQE/B`\<"!S='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E3L@1D].5#H@,3!P M="!4:6UE2!O;B!H86YD('1H870@;6%Y M(&)E(&]B2!T:&%T(&ES(&EN(&5X8V5S6QE/3-$)TU!4D=)3BU"3U14 M3TTZ(#!P=#L@1D].5#H@,3!P="!4:6UE6QE/3-$)U9%4E1)0T%, M+4%,24=..B!T;W`G/B`\=&0@#L@4$%$1$E.1RU43U`Z(#!P>#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1) M3D#L@5TE$5$@Z(#`N,C5I;CL@5$585"U)3D1%3E0Z(#!P M>"<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@ M,'!X.R!0041$24Y'+51/4#H@,'!X.R!0041$24Y'+4Q%1E0Z(#!P>#L@4$%$ M1$E.1RU224=(5#H@,'!X.R!724142#H@,"XU:6X[(%1%6%0M24Y$14Y4.B`P M<'@G/B`\96T^*&8I/"]E;3X\+W1D/B`\=&0@#L@5$585"U!3$E'3CH@:G5S=&EF>3L@4$%$1$E.1RU43U`Z M(#!P>#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D#L@ M5$585"U)3D1%3E0Z(#!P>"<^(#QE;3Y02!A;F0@17%U:7!M96YT M/"]E;3X\+W1D/B`\+W1R/B`\+W1A8FQE/B`\<"!S='EL93TS1"=415A4+4%, M24=..B!J=7-T:69Y.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E3L@1D].5#H@,3!P="!4:6UEF%T:6]N(&]N(&-A<&ET86P@ M;&5A'1U M65A2X@1&5P'!E;F1I='5R97,@9F]R(&UA:6YT96YA;F-E(&%N9"!R97!A M:7)S(&%R92!E>'!E;G-E9"!A6QE/3-$ M)U1%6%0M04Q)1TXZ(&IU#L@5$585"U)3D1% M3E0Z(#`N-6EN)SX@)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU" M3U143TTZ(#%P="<^)FYB6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#%P="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA M8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!C96YT97(G(&-O;'-P86X],T0R M/C(P,3$\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M5TE$5$@Z(#(E)SXF;F)S<#L\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SX@)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5TE$5$@Z(#(E M)SXF;F)S<#L\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SX@)FYB6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM' M4D]53D0M0T],3U(Z('=H:71E)SX@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@5$585"U!3$E'3CH@;&5F="<^0G5I;&1I;F=S(&%N9"!I;7!R;W9E M;65N=',\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB M6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E' M3CH@;&5F="<^)FYB6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@5$585"U!3$E'3CH@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^ M36%C:&EN97)Y(&%N9"!E<75I<&UE;G0\+W1D/B`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`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`N-6EN)SX@3&]N9RUL:79E9"!A2!N;W0@8F4@2!W:&EC M:"!T:&4@8V%R&-E961S('1H M92!F86ER('9A;'5E(&]F('1H92!A6QE/3-$)U1% M6%0M04Q)1TXZ(&IU#L@5$585"U)3D1%3E0Z M(#`N-6EN)SX@)FYBF5D(&]N(&$@&-H86YG960L(&%R92!R96-O9VYI>F5D(&%S(&%N(&%S M3L@1D].5#H@,3!P="!4 M:6UE6QE/3-$ M)U1%6%0M04Q)1TXZ(&IU#L@5$585"U)3D1% M3E0Z(#`N-6EN)SX@1V]O9'=I;&P@:7,@=&5S=&5D(&%N;G5A;&QY(&9OF5D+B!)9B!T:&4@8V%R2!I;7!A:7)E9"!A;F0@ M=V4@=V]U;&0@=&AE;B!C;VUP;&5T92!S=&5P(#(@:6X@;W)D97(@=&\@;65A MF5D(&EN=&%N9VEB;&4@87-S971S M*2!A;F0@86YY(&5X8V5S3L@1D].5#H@,3!P="!4:6UEF5D M(&EN(&]U71I8V%L('-EF4@82!C87-H(&9L;W<@87!P'!L86EN960@86)O=F4N(%1H:7,@=&5S="!R97-U;'1E M9"!I;B!N;R!I;7!A:7)M96YT('1O('1H92!G;V]D=VEL;"!V86QU871I;VX@ M87,@8W5R6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@)FYB M&EM871E;'D@)#,N-R!M:6QL:6]N+CPO<#X@/'`@6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE#L@5$585"U)3D1%3E0Z M(#`N-6EN)SX@0V]N6QE/3-$)U1% M6%0M04Q)1TXZ(&IU#L@5$585"U)3D1%3E0Z M(#`N-6EN)SX@070@4V5P=&5M8F5R(#,P+"`R,#$R(&%N9"`R,#$Q+"!R96UA M:6YI;F<@6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE#L@5$585"U) M3D1%3E0Z(#`N-6EN)SX@)FYB6QE M/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`\=&0@#L@4$%$1$E.1RU224=(5#H@,'!X.R!415A4+4E.1$5.5#H@,'!X)R!N M;W=R87`],T1N;W=R87`^)FYB6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U7 M14E'2%0Z(&)O;&0[(%!!1$1)3D6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T M;VTG/B`\=&0@#L@4$%$1$E.1RU224=(5#H@,'!X M.R!415A4+4E.1$5.5#H@,'!X)R!N;W=R87`],T1N;W=R87`^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z M(&)O;&0[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U714E'2%0Z(&)O;&0[(%!!1$1)3D6EN9SQB6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!&3TY4+5=% M24=(5#H@8F]L9#L@5$585"U!3$E'3CH@8V5N=&5R)R!C;VQS<&%N/3-$,B!N M;W=R87`],T1N;W=R87`^06-C=6UU;&%T960\8G(@+SX@06UOF%T:6]N M/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U714E' M2%0Z(&)O;&0[(%!!1$1)3D#L@4$%$1$E.1RU2 M24=(5#H@,'!X.R!724142#H@-3@E.R!415A4+4E.1$5.5#H@,'!X)SX@)FYB M6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5TE$5$@Z M(#(E)SXF;F)S<#L\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SX@)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SX@ M)FYB6QE/3-$)U9%4E1)0T%,+4%,24=. M.B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"DG M/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#(N M-7!T)SXF;F)S<#L\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ M(#(N-7!T.R!415A4+4%,24=..B!L969T)SX@)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T M)SXF;F)S<#L\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=. M.B!R:6=H="<^(#,P,CPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P M<'0[(%!!1$1)3D6QE/3-$)T9/3E0Z M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE"<^("9N8G-P.SPO<#X@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU# M3TQ,05!313H@8V]L;&%P6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@4$%$1$E.1RU43U`Z(#!P>#L@4$%$1$E.1RU,1494.B`P<'@[ M(%!!1$1)3D#L@5$585"U)3D1%3E0Z(#!P>"<@;F]W6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$58 M5"U!3$E'3CH@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52 M+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!&3TY4+5=%24=(5#H@8F]L9#L@ M5$585"U!3$E'3CH@8V5N=&5R)R!C;VQS<&%N/3-$-B!N;W=R87`],T1N;W=R M87`^4V5P=&5M8F5R(#,P+"`R,#$Q/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0[(%!!1$1)3D65A6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0[(%!!1$1) M3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0[ M(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$58 M5"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SX@)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5TE$5$@Z(#(E)SXF;F)S<#L\+W1D M/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@ M;&5F=#L@5TE$5$@Z(#$E)SX@)FYB6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@#L@4$%$1$E.1RU,1494.B`P M<'@[(%!!1$1)3D#L@5$585"U)3D1%3E0Z(#!P>"<^($9$ M02!C;VUP;&EA;G0@9F%C:6QI='D\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!4 M15A4+4%,24=..B!L969T)SX@)#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-) M6D4Z(#$P<'0[($)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@ M5$585"U!3$E'3CH@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U14 M3TTZ(#(N-7!T.R!415A4+4%,24=..B!L969T)SX@)FYBF5D+CPO<#X@/'`@6QE/3-$)U!!1$1)3D#L@4$%$1$E.1RU4 M3U`Z(#!P>#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D#L@5TE$5$@Z(#`N-6EN.R!415A4+4E.1$5.5#H@,'!X)SX@/&5M/BAH*3PO M96T^/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M#L@5$585"U)3D1%3E0Z(#`N-6EN M)SX@5V4@97AP96YS92!A9'9E6QE/3-$)U!!1$1)3D#L@4$%$1$E.1RU43U`Z(#!P>#L@4$%$1$E.1RU,1494 M.B`P<'@[(%!!1$1)3D#L@5TE$5$@Z(#`N-6EN.R!415A4 M+4E.1$5.5#H@,'!X)SX@/&5M/BAI*3PO96T^/"]T9#X@/'1D('-T>6QE/3-$ M)U!!1$1)3D2!I M;B!.;W1E(#$P+B!!;&P@;W!T:6]N2P@:6X@6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P M=#L@1D].5#H@,3!P="!4:6UE6QE/3-$)U9%4E1)0T%,+4%,24=. M.B!T;W`G/B`\=&0@#L@4$%$ M1$E.1RU43U`Z(#!P>#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D#L@5TE$5$@Z(#`N,C5I;CL@5$585"U)3D1%3E0Z(#!P>"<^("9N M8G-P.SPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,'!X.R!0 M041$24Y'+51/4#H@,'!X.R!0041$24Y'+4Q%1E0Z(#!P>#L@4$%$1$E.1RU2 M24=(5#H@,'!X.R!724142#H@,"XU:6X[(%1%6%0M24Y$14Y4.B`P<'@G/B`\ M96T^*&HI/"]E;3X\+W1D/B`\=&0@#L@5$585"U!3$E'3CH@:G5S=&EF>3L@4$%$1$E.1RU43U`Z(#!P>#L@ M4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D#L@5$585"U) M3D1%3E0Z(#!P>"<^(#QE;3Y);F-O;64@5&%X97,\+V5M/CPO=&0^(#PO='(^ M(#PO=&%B;&4^(#QP('-T>6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE#L@5$585"U)3D1% M3E0Z(#`N-6EN)SX@)FYB2!M971H M;V0N($1E9F5R"!AF5D(&9O"!C;VYS97%U96YC97,@871T M&ES=&EN9R!A"!B M87-E"!C&%B;&4@:6YC;VUE(&EN('1H92!Y96%R"!A"!R871EF5D(&EN(&EN8V]M92!I;B!T:&4@ M<&5R:6]D('1H870@:6YC;'5D97,@=&AE(&5N86-T;65N="!D871E+B!792!R M96-O'!E8W1E9"!R96%L:7IA=&EO;B!O9B!T87@@87-S M971S+CPO<#X@/'`@"!P;W-I=&EO;B!O;FQY(&EF(&ET(&ES(&UO'!E8W0@=&AE('1O=&%L(&%M;W5N="!O9B!U;G)E M8V]G;FEZ960@=&%X(&)E;F5F:71S('1O('-I9VYI9FEC86YT;'D@8VAA;F=E M(&EN('1H92!N97AT('1W96QV92!M;VYT:',N/"]P/B`\<"!S='EL93TS1"=& M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)U!!1$1)3D#L@4$%$1$E.1RU43U`Z(#!P>#L@4$%$1$E.1RU,1494.B`P M<'@[(%!!1$1)3D#L@5TE$5$@Z(#`N-6EN.R!415A4+4E. M1$5.5#H@,'!X)SX@/&5M/BAK*3PO96T^/"]T9#X@/'1D('-T>6QE/3-$)U!! M1$1)3D6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@)FYB M6QE M/3-$)U1%6%0M04Q)1TXZ(&IU#L@5$585"U) M3D1%3E0Z(#`N-6EN)SX@)FYB2!P65A6QE/3-$)U1% M6%0M04Q)1TXZ(&IU#L@5$585"U)3D1%3E0Z M(#`N-6EN)SX@)FYB6EN9R!A;6]U;G0N)FYB2!D971E2X@5&AE(&%M96YD;65N="9N8G-P.VES(&5F9F5C=&EV92!F;W(@9FES8V%L M('EE87)S(&%N9"!I;G1E2!A9&]P=&EO;B!I2!R96-O6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5#H@,3!P="!4:6UE M6QE/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G/B`\=&0@#L@4$%$1$E.1RU43U`Z(#!P>#L@4$%$ M1$E.1RU,1494.B`P<'@[(%!!1$1)3D#L@5TE$5$@Z(#`N M,C5I;CL@5$585"U)3D1%3E0Z(#!P>"<^("9N8G-P.SPO=&0^(#QT9"!S='EL M93TS1"=0041$24Y'+4)/5%1/33H@,'!X.R!0041$24Y'+51/4#H@,'!X.R!0 M041$24Y'+4Q%1E0Z(#!P>#L@4$%$1$E.1RU224=(5#H@,'!X.R!724142#H@ M,"XU:6X[(%1%6%0M24Y$14Y4.B`P<'@G/B`\96T^*&PI/"]E;3X\+W1D/B`\ M=&0@#L@4$%$1$E.1RU43U`Z M(#!P>#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D#L@ M5$585"U)3D1%3E0Z(#!P>"<^(#QE;3Y&86ER(%9A;'5E/"]E;3X@/"]T9#X@ M/"]T6QE/3-$)T9/3E0Z M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@5&AE('!R;W9I2X@56YO8G-E28C,SD[2!I M#L@4$%$1$E.1RU43U`Z(#!P>#L@4$%$1$E.1RU,1494.B`P<'@[(%!! M1$1)3D#L@5TE$5$@Z(#4E.R!415A4+4E.1$5.5#H@,'!X M)SX@)FYB6QE/3-$)U9%4E1)0T%,+4%,24=..B!T M;W`[(%!!1$1)3D"<^("9B=6QL.SPO=&0^(#QT9"!S='EL93TS M1"=615)424-!3"U!3$E'3CH@=&]P.R!0041$24Y'+4)/5%1/33H@,'!X.R!0 M041$24Y'+51/4#H@,'!X.R!0041$24Y'+4Q%1E0Z(#!P>#L@4$%$1$E.1RU2 M24=(5#H@,'!X.R!724142#H@,24[(%1%6%0M24Y$14Y4.B`P<'@G/B`F;F)S M<#L\+W1D/B`\=&0@#L@4$%$1$E.1RU43U`Z(#!P>#L@4$%$1$E.1RU, M1494.B`P<'@[(%!!1$1)3D#L@5$585"U)3D1%3E0Z(#!P M>"<^($QE=F5L(#$@+2!686QU871I;VYS(&)A2!H87,@=&AE(&%B:6QI='D@ M=&\@86-C97-S+CPO=&0^(#PO='(^(#PO=&%B;&4^(#QP('-T>6QE/3-$)T9/ M3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE"<^("9N8G-P.SPO<#X@/'1A8FQE('-T>6QE/3-$)T)/4D1% M4BU#3TQ,05!313H@8V]L;&%P#L@4$%$1$E.1RU224=(5#H@,'!X.R!724142#H@-24[(%1%6%0M24Y$ M14Y4.B`P<'@G/B`F;F)S<#L\+W1D/B`\=&0@#L@4$%$1$E.1RU43U`Z M(#!P>#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D#L@ M5TE$5$@Z(#(E.R!415A4+4E.1$5.5#H@,'!X)SX@)F)U;&P[/"]T9#X@/'1D M('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!T;W`[(%!!1$1)3D"<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=615)424-!3"U!3$E'3CH@ M=&]P.R!0041$24Y'+4)/5%1/33H@,'!X.R!0041$24Y'+51/4#H@,'!X.R!0 M041$24Y'+4Q%1E0Z(#!P>#L@4$%$1$E.1RU224=(5#H@,'!X.R!415A4+4E. M1$5.5#H@,'!X)SX@3&5V96P@,B`M(%9A;'5A=&EO;G,@8F%S960@;VX@<75O M=&5D('!R:6-E2!O6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE"<^("9N8G-P.SPO M<#X@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P#L@4$%$1$E.1RU224=(5#H@ M,'!X.R!724142#H@-24[(%1%6%0M24Y$14Y4.B`P<'@G/B`F;F)S<#L\+W1D M/B`\=&0@#L@4$%$1$E.1RU43U`Z(#!P>#L@4$%$1$E.1RU,1494.B`P M<'@[(%!!1$1)3D#L@5TE$5$@Z(#(E.R!415A4+4E.1$5. M5#H@,'!X)SX@)F)U;&P[/"]T9#X@/'1D('-T>6QE/3-$)U9%4E1)0T%,+4%, M24=..B!T;W`[(%!!1$1)3D"<^("9N8G-P.SPO=&0^(#QT9"!S M='EL93TS1"=615)424-!3"U!3$E'3CH@=&]P.R!0041$24Y'+4)/5%1/33H@ M,'!X.R!0041$24Y'+51/4#H@,'!X.R!0041$24Y'+4Q%1E0Z(#!P>#L@4$%$ M1$E.1RU224=(5#H@,'!X.R!415A4+4E.1$5.5#H@,'!X)SX@3&5V96P@,R`M M(%9A;'5A=&EO;G,@8F%S960@;VX@:6YP=71S('1H870@87)E('5N;V)S97)V M86)L92!A;F0@#L@5$585"U)3D1%3E0Z(#`N M-6EN)SX@5V4@:&%V92!#;&%S2`R,#$Q(&]F9F5R:6YG('1H870@87)E(&UE87-U'!I2`R,#$R(&%N9"!T:&4@;&EA M8FEL:71Y('=A6QE/3-$)T)/4D1%4BU# M3TQ,05!313H@8V]L;&%P6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@ M5$585"U!3$E'3CH@8V5N=&5R)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R M87`^5V%R6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ M(&-E;G1E6QE/3-$)U=)1%1(.B`Q)2<^)FYB6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^)FYB6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!724142#H@,34E)SXP M+C`X/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1( M.B`Q)2<^)3PO=&0^(#PO='(^(#QT6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXP M+C`P/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B4\+W1D M/B`\=&0^)FYB6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H M="<^,"XP,#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXE M/"]T9#X@/'1D/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=. M.B!L969T)SXF;F)S<#L\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/E9O;&%T:6QI='D@;V8@ M=&AE($-O;7!A;GDF(S,Y.W,@8V]M;6]N('-T;V-K/"]T9#X@/'1D/B9N8G-P M.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\ M+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G M/B4\+W1D/B`\+W1R/B`\='(@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL M93TS1"=415A4+4%,24=..B!R:6=H="<^-"XV/"]T9#X@/'1D('-T>6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D M/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXP+C8\+W1D/B`\=&0@ M6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]5 M3D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"DG/B`\=&0^)FYB6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%, M24=..B!R:6=H="<^)FYB6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@6QE M/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXF;F)S<#L\+W1D/B`\=&0@6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T], M3U(Z('=H:71E)SX@/'1D/D9A:7(@=F%L=64@<&5R('5N:70\+W1D/B`\=&0^ M)FYB6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B0\ M+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^ M(#QT9#XF;F)S<#L\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M)SXP+C`Y,3PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF M;F)S<#L\+W1D/B`\+W1R/B`\+W1A8FQE/B`\<"!S='EL93TS1"=&3TY4.B`Q M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E3L@1D].5#H@,3!P="!4:6UE2`R,#$Q(&%N9"!R96YE=V5D(&]N($YO=F5M M8F5R(#$L(#(P,3(N($]U6QE/3-$)U!!1$1)3D#L@4$%$1$E.1RU43U`Z(#!P>#L@4$%$1$E.1RU,1494 M.B`P<'@[(%!!1$1)3D#L@5TE$5$@Z(#`N-6EN.R!415A4 M+4E.1$5.5#H@,'!X)SX@/&5M/BAM*3PO96T^/"]T9#X@/'1D('-T>6QE/3-$ M)U!!1$1)3D3L@1D].5#H@,3!P="!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&IU M#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@5&AE M('!R97!A6QE/3-$)U1%6%0M04Q)1TXZ(&IU#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@)FYB#L@4$%$1$E.1RU224=(5#H@,'!X.R!724142#H@ M,"XR-6EN.R!415A4+4E.1$5.5#H@,'!X)SX@)FYB6QE/3-$)U!!1$1)3D"<^(#QE;3XH;BD\+V5M/CPO=&0^ M(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,'!X.R!415A4+4%,24=. M.B!J=7-T:69Y.R!0041$24Y'+51/4#H@,'!X.R!0041$24Y'+4Q%1E0Z(#!P M>#L@4$%$1$E.1RU224=(5#H@,'!X.R!415A4+4E.1$5.5#H@,'!X)SX@/&5M M/E)E3L@1D].5#H@ M,3!P="!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&IU#L@5$58 M5"U)3D1%3E0Z(#`N-6EN)SX@26X@9FES8V%L(#(P,3(@86YD(#(P,3$L('=E M('-P96YT("0U-#(@86YD("0U,S0L(')E2P@;VX@#L@5$585"U)3D1%3E0Z(#`N M-6EN)SX@)FYB#L@4$%$1$E. M1RU224=(5#H@,'!X.R!724142#H@,"XR-6EN.R!415A4+4E.1$5.5#H@,'!X M)SX@)FYB6QE/3-$)U!!1$1)3D"<^(#QE;3XH;RD\+V5M/CPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/ M5%1/33H@,'!X.R!415A4+4%,24=..B!J=7-T:69Y.R!0041$24Y'+51/4#H@ M,'!X.R!0041$24Y'+4Q%1E0Z(#!P>#L@4$%$1$E.1RU224=(5#H@,'!X.R!4 M15A4+4E.1$5.5#H@,'!X)SX@/&5M/D-O;7!R96AE;G-I=F4@26YC;VUE("A, M;W-S*3PO96T^/"]T9#X@/"]T3L@1D].5#H@,3!P="!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&IU M#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@5V4@ M3L@1D].5#H@,3!P M="!4:6UE6QE/3-$ M)U!!1$1)3D#L@4$%$1$E.1RU43U`Z(#!P>#L@4$%$ M1$E.1RU,1494.B`P<'@[(%!!1$1)3D#L@5TE$5$@Z(#`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`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$&AT;6PQ+71R86YS:71I;VYA;"YD=&0B("TM/CQD M:78^(#QD:78^/"$M+5-T87)T1G)A9VUE;G0M+3X@/'`@3L@1D].5#H@,3!P="!4:6UE6QE/3-$)T9/3E0M4TE:13H@,3!P="<^4D53 M5$%414U%3E0@3T8@4%)%5DE/55-,62!)4U-5140@0T].4T],241!5$5$($9) M3D%.0TE!3"!35$%414U%3E13/"]F;VYT/CPO6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE#L@5$585"U)3D1%3E0Z M(#`N-6EN)SX@26X@075G=7-T(#(P,3,L('=E(&%N;F]U;F-E9"!A(&1E;&%Y M(&EN(&9I;&EN9R!O=7(@1F]R;2`Q,"U1(&9O2!O;B!O=7(@ M<')E=FEO=7-L>2!I6QE/3-$)T9/3E0Z M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@)FYB2`R,#$Q('=E2!R97!O2!O9B`D,2PR,3,@86YD("0Q M+#(X-B!A2P@82!D96-R96%S92!T;R!O=7(@<')E=FEO=7-L>2!R97!O65A2!T:&%T(&ES(&YO=R!C;W)R96-T M;'D@'!E;G-E*2!A6QE/3-$)U1%6%0M M04Q)1TXZ(&IU#L@5$585"U)3D1%3E0Z(#`N M-6EN)SX@)FYB65A3L@1D].5#H@,3!P="!4:6UE6QE/3-$)U9%4E1)0T%,+4%,24=. M.B!B;W1T;VTG/B`\=&0@6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(&)L86-K(#%P="!S;VQI9#L@0T],3U(Z(&)L86-K.R!415A4+4%,24=. M.B!C96YT97([($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)T-/ M3$]2.B!B;&%C:SL@4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].5#H@,3!P="!4 M:6UE6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`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`\=&0@6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0Z(#$P<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4.B`Q,'!T(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4.B`Q M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@5TE$5$@Z(#$E)SXF;F)S<#L\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F=#L@5TE$ M5$@Z(#$E)SX@)FYB6QE/3-$)T9/3E0Z(#$P<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!& M3TY4.B`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`Q,'!T(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)T9/3E0Z M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4.B`Q,'!T(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE6QE/3-$)U1%6%0M04Q)1TXZ M(')I9VAT.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E M6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE6QE/3-$)U1%6%0M M04Q)1TXZ(')I9VAT.R!&3TY4.B`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`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`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4.B`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`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`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE6QE/3-$ M)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z(')G M8B@R,#0L,C4U+#(P-"DG/B`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`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE6QE/3-$)T9/ M3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4.B`Q,'!T M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT.R!&3TY4.B`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`Q,'!T(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0Z(#$P<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE6QE/3-$ M)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4.B`Q M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0Z(#$P<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT.R!&3TY4.B`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`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E M6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE6QE/3-$)U1%6%0M04Q)1TXZ M(')I9VAT.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E M6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)U9%4E1)0T%,+4%,24=. M.B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z('=H:71E)SX@/'1D('-T>6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0Z(#$P<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4 M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4 M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4 M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4 M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@5&AE(&9O;&QO=VEN9R!T86)L M92!S=6UM87)I>F5S('1H92!E9F9E8W1S(&]F('1H92!R97-T871E;65N="!A M9&IU2!D:7-C=7-S960L(&]N('1H92!C;VYS M;VQI9&%T960@8F%L86YC92!S:&5E="!I=&5M6QE/3-$)U9%4E1)0T%,+4%,24=. M.B!B;W1T;VTG/B`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`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`R+C5P="!D;W5B M;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!724142#H@."4G/B`S,BPS-#8\+W1D M/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N M8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^)FYB M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P M.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ M(')I9VAT)SXF;F)S<#L\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT M9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^)FYB6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9#XF M;F)S<#L\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXF;F)S M<#L\+W1D/B`\=&0@6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T M;VT[($)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"DG/B`\=&0@ M6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT)SXQ,2PS.#<\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H M="<^.2PX-#<\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL M93TS1"=415A4+4%,24=..B!R:6=H="<^.2PX-#<\+W1D/B`\=&0@6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T], M3U(Z('=H:71E)SX@/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K M(#%P="!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<^("9N8G-P.SPO=&0^(#QT M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@ M5$585"U!3$E'3CH@;&5F="<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=" M3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@6QE M/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L M86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI M9#L@5$585"U!3$E'3CH@6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P M="!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<^("9N8G-P.SPO=&0^(#QT9"!S M='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)! M0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"DG/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S M='EL93TS1"=415A4+4%,24=..B!R:6=H="<^,3$L,S@W/"]T9#X@/'1D('-T M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S M<#L\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXQ+#(Q,SPO M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D M/B`\=&0^)FYB6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H M="<^,3(L-C`P/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G M/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@6QE/3-$)U1%6%0M M04Q)1TXZ(')I9VAT)SXY+#@T-SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%, M24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0^)FYB6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL M93TS1"=415A4+4%,24=..B!R:6=H="<^,2PR.#8\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R M:6=H="<^)FYB6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT)SXF;F)S<#L\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P M.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^)FYB6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO M=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT)SXF;F)S<#L\+W1D/B`\=&0@6QE/3-$)U9%4E1)0T%,+4%, M24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P M-"DG/B`\=&0@6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U! M3$E'3CH@;&5F="<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M M0D]45$]-.B!B;&%C:R`Q<'0@6QE/3-$)U!! M1$1)3D6QE/3-$)U!!1$1)3D6QE M/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$58 M5"U!3$E'3CH@6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI M9#L@5$585"U!3$E'3CH@;&5F="<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS M1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1% M4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P M.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^)FYB6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO M=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT)SXF;F)S<#L\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S M='EL93TS1"=415A4+4%,24=..B!R:6=H="<^)FYB6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S M<#L\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXF;F)S<#L\ M+W1D/B`\=&0@6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[ M($)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"DG/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^ M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^,2PR,3,\+W1D/B`\ M=&0@6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=. M.B!R:6=H="<^,38L-S8P/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT)SXQ+#(X-CPO=&0^(#QT9"!S='EL93TS1"=4 M15A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0^)FYB6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT M9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^,3@L,#0V/"]T9#X@/'1D M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#PO='(^ M(#QT6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^)FYB6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^ M(#QT9#XF;F)S<#L\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M)SXF;F)S<#L\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL M93TS1"=415A4+4%,24=..B!R:6=H="<^)FYB6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\ M+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXF;F)S<#L\+W1D M/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT M9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^)FYB6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9#XF M;F)S<#L\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXF;F)S M<#L\+W1D/B`\=&0@6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=4 M15A4+4%,24=..B!R:6=H="<^)FYB6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\ M=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXF;F)S<#L\+W1D/B`\=&0@ M6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]5 M3D0M0T],3U(Z('=H:71E)SX@/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S M<#L\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXM/"]T9#X@ M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT M9#XF;F)S<#L\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXQ M+#,S-3PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF;F)S M<#L\+W1D/B`\=&0^)FYB6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=. M.B!R:6=H="<^,BPQ,S4\+W1D/B`\=&0@6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#PO='(^(#QT6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9#XF M;F)S<#L\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXM/"]T M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^ M(#QT9#XF;F)S<#L\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M)SXQ+#@W,3PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF M;F)S<#L\+W1D/B`\=&0^)FYB6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%, M24=..B!R:6=H="<^,2PV.3@\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#PO='(^(#QT M6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=. M.B!R:6=H="<^,C`L-#4Q/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT)SXH.#$V/"]T9#X@/'1D('-T>6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0G/BD\+W1D/B`\=&0^)FYB6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL M93TS1"=415A4+4%,24=..B!R:6=H="<^,3DL-C,U/"]T9#X@/'1D('-T>6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\ M+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXQ.2PT,#@\+W1D M/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT)SXQ."PU.3(\+W1D/B`\=&0@6QE/3-$)U9%4E1)0T%,+4%, M24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P M-"DG/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^*#$T+#`Y-CPO M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXI/"]T9#X@/'1D M/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF M;F)S<#L\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M)SXH,30L-#DS/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G M/BD\+W1D/B`\=&0^)FYB6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=. M.B!R:6=H="<^*#6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0G/BD\+W1D/B`\=&0^)FYB6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4 M+4%,24=..B!R:6=H="<^*#0W,#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%, M24=..B!L969T)SXI/"]T9#X@/'1D/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS M1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0@6QE/3-$)U9% M4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z('=H:71E M)SX@/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)T)/ M4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@;&5F M="<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B M;&%C:R`Q<'0@6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1% M4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)T)/ M4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@;&5F M="<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B M;&%C:R`Q<'0@6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P M="!S;VQI9#L@5$585"U!3$E'3CH@3PO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/ M5%1/33H@,7!T)SXF;F)S<#L\+W1D/B`\=&0@6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P M="!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L M86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<^("9N8G-P.SPO=&0^ M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@6QE/3-$ M)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI M9#L@5$585"U!3$E'3CH@;&5F="<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS M1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@6QE/3-$)U!!1$1)3D6QE/3-$ M)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@ M;&5F="<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]- M.B!B;&%C:R`Q<'0@6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<^("9N8G-P M.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@ M6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=. M.B!R:6=H="<^)FYB6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT)SXF;F)S<#L\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N M8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^)FYB M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P M.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ M(')I9VAT)SXF;F)S<#L\+W1D/B`\=&0@3PO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,BXU M<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B M;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0G/B`D/"]T9#X@ M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L M93L@5$585"U!3$E'3CH@6QE M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U! M3$E'3CH@6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O M=6)L93L@5$585"U!3$E'3CH@;&5F="<^("0\+W1D/B`\=&0@6QE/3-$)U!!1$1)3D7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$6QE/3-$)U1%6%0M04Q)1TXZ(&IU"<^(#QS=')O;F<^-"X@4T%,12!/1B!04D5&15)2 M140@4TA!4D53($%.1"!705)204Y44R`H;F]T(&EN('1H;W5S86YD6QE/3-$)U1%6%0M04Q)1TXZ(&IU"<^("9N8G-P.SPO<#X@/'`@6QE/3-$)T-/3$]2.B!B;&%C:R<^+CPO9F]N=#X\+W`^ M(#QP('-T>6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M#L@5$585"U)3D1%3E0Z(#`N-6EN M)SX@)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P M="<^5&AE(&1E2!I;B!C M87-H(&]R+"!S=6)J96-T('1O(&-E2!D:79I9&5N9',@<&%Y86)L92!U<&]N(&]U2`Q,2P@,C`Q-"P@ M=V4@;75S="!A;'-O('!A>2!T;R!T:&4@8V]N=F5R=&EN9R!H;VQD97(@:6X@ M8V%S:"P@;W(@'!E;G-E'!E;G-E6QE/3-$)U1% M6%0M04Q)1TXZ(&IU#L@5$585"U)3D1%3E0Z M(#`N-6EN)SX@5&AE(&AO;&1E2!I;G-T6QE/3-$ M)U1%6%0M04Q)1TXZ(&IU#L@5$585"U)3D1% M3E0Z(#`N-6EN)SX@)FYB6QE/3-$ M)U9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0[(%!! M1$1)3D6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!& M3TY4+5=%24=(5#H@8F]L9#L@5$585"U!3$E'3CH@8V5N=&5R)R!C;VQS<&%N M/3-$,B!N;W=R87`],T1N;W=R87`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`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^ M)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$58 M5"U!3$E'3CH@6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)3PO=&0^(#PO='(^(#QT6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)! M0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"DG/B`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`N-6EN)SX@)FYB2`Q,2P@,C`Q,2!O9B`D,2XX M-BX@061D:6YG(&EN('1H92!T;W1A;"!P;W-S:6)L92!D:79I9&5N9"!F;W(@ M=&AE('!R969E65A6QE/3-$)T9/3E0Z M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@)FYB2!W97)E(&ES2!T:&4@:&]L9&5R(&%T(&%N>2!T:6UE M+"!T:&4@9&ES8V]U;G0@2!T:&4@86QL;V-A=&EO;B!O M9B!PF5D('1H92!F=6QL('9A;'5E M+"`D.3DQ+#`X,"P@87,@82!L:6%B:6QI='D@:6YC;'5D960@:6X@86-C;W5N M=',@<&%Y86)L92!A;F0@8VAA2!T:')O=6=H(&%C M8W5M=6QA=&5D(&1E9FEC:70N(%1H97)E('=I;&P@8F4@;F\@;W1H97(@9&EV M:61E;F1S(')E8V]R9&5D(&9O6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE#L@5$585"U)3D1%3E0Z(#`N M-6EN)SX@07,@;V8@4V5P=&5M8F5R(#,P+"`R,#$R+"`T+#$W,2!P2!P&5R8VES960@ M87,@;V8@4V5P=&5M8F5R(#,P+"`R,#$R+B!!="!397!T96UB97(@,S`L(#(P M,3(L(#$L,S,U('!R969E'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/"$M+41/0U194$4@:'1M;"!054),24,@(BTO+U&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@+2T^/&1I=CX@ M/&1I=CX\(2TM4W1A#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@5V4@8V]M M<'5T92!B87-I8R!L;W-S('!E6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE#L@5$585"U)3D1%3E0Z M(#`N-6EN)SX@5&AE($-O;7!A;GD@:&%S('1H65A2!W97)E(&%N=&DM9&EL=71I M=F4N(%=A6QE/3-$)T9/3E0Z(#$P M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@5$585"U)3D1%3E0Z(#`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`],T1N;W=R87`^*#QF;VYT('-T M>6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[ M($)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"DG/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@ M;&5F="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@5$585"U!3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT)SXF;F)S<#L\+W1D/B`\=&0@6QE/3-$)U9%4E1)0T%,+4%, M24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z('=H:71E)SX@/'1D('-T M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F=#L@4$%$ M1$E.1RU,1494.B`P+C$R-6EN.R!724142#H@-S(E)SX@3F5T(&EN8V]M92`H M;&]S6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SXI/"]T9#X@ M/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5TE$5$@Z(#(E)SXF;F)S M<#L\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$58 M5"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SX@)FYB6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]5 M3D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"DG/B`\=&0@6QE/3-$)U9%4E1)0T%,+4%, M24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z('=H:71E)SX@/'1D('-T M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#%P=#L@ M5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU,1494.B`P+C$R-6EN)SX@3&5S M6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#%P="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/ M5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!L969T)SX@)FYB M6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52 M+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!R:6=H="<^ M("T\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ M(#%P="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=. M.B!L969T)SX@)FYB6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%, M24=..B!R:6=H="<^("@Y.3$\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F M=#L@4$%$1$E.1RU,1494.B`P+C(U:6XG/DYE="!L;W-S(&%P<&QI8V%B;&4@ M=&\@8V]M;6]N('-H87)E:&]L9&5R6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E' M3CH@;&5F="<^*3PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G M/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1% M6%0M04Q)1TXZ(&QE9G0G/B0\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^*3PO M=&0^(#PO='(^(#QT6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[ M($)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"DG/B`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`\=&0@6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T M;VT[($)!0TM'4D]53D0M0T],3U(Z('=H:71E)SX@/'1D('-T>6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU,1494 M.B`P+C$R-6EN)SX@3F5T(&QO6QE/3-$)T9/3E0M4TE:13H@,3!P="<^ M)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$58 M5"U!3$E'3CH@;&5F="<^)#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z M(#$P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)SXH-BPS,3<\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F M="<^)#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M M04Q)1TXZ(')I9VAT)SXH-"PQ.34\+W1D/B`\=&0@6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"DG/B`\=&0@6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#%P="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/ M33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!L969T)SX@)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/ M5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!R:6=H="<^(#4L M-C8W/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E. M1RU"3U143TTZ(#%P=#L@5$585"U!3$E'3CH@;&5F="<^("9N8G-P.SPO=&0^ M(#PO='(^(#QT6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,BXU M<'0@9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<^("@P+C6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#(N M-7!T.R!415A4+4%,24=..B!L969T)SX@*3PO=&0^(#PO='(^(#PO=&%B;&4^ M(#PA+2U%;F1&'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^ M/"$M+41/0U194$4@:'1M;"!054),24,@(BTO+U&AT M;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@+2T^/&1I=CX@/&1I M=CX\(2TM4W1A6QE/3-$)T9/ M3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@)FYB6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VTG M/B`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`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#%P="<^ M)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]2 M1$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!L969T M)SX@)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!R M:6=H="<^("@T,#0\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U14 M3TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!4 M15A4+4%,24=..B!R:6=H="<^(#$L-C4V/"]T9#X@/'1D('-T>6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T.R!415A4+4%, M24=..B!L969T)SX@)FYB6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\ M=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@ M8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<^(#$L-C,V M/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU" M3U143TTZ(#(N-7!T.R!415A4+4%,24=..B!L969T)SX@)FYB7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X- M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE"<^(#QS=')O M;F<^-RX@3$5!4T4@05)204Y'14U%3E13/"]S=')O;F<^/"]P/B`\<"!S='EL M93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E#L@5$585"U)3D1%3E0Z M(#`N-6EN)SX@5&AE('1O=&%L(&%M;W5N="!O9B!E<75I<&UE;G0@8V%P:71A M;&EZ960@=6YD97(@8V%P:71A;"!L96%S92!O8FQI9V%T:6]N6QE/3-$)U1%6%0M04Q)1TXZ(&IU#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@)FYB2!R97-U;'1E9"!I;B!A(&QI86)I;&ET>2!R961U8W1I M;VX@;V8@)#,R,BX@1G5T=7)E(&UI;FEM=6T@;&5A3L@1D].5#H@,3!P="!4:6UE#L@4$%$1$E.1RU,1494.B`P<'@[ M(%!!1$1)3D#L@5$585"U)3D1%3E0Z(#!P>"<@;F]W6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@4$%$1$E.1RU"3U143TTZ(#%P=#L@5$585"U!3$E'3CH@8V5N=&5R M)R!N;W=R87`],T1N;W=R87`^)FYB6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#%P=#L@5$585"U!3$E' M3CH@8V5N=&5R)R!N;W=R87`],T1N;W=R87`^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@ M,7!T('-O;&ED.R!415A4+4%,24=..B!C96YT97(G(&-O;'-P86X],T0R(&YO M=W)A<#TS1&YO=W)A<#Y);G1E6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5TE$5$@Z(#(E M)SXF;F)S<#L\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SX@)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5TE$5$@Z(#(E)SXF;F)S<#L\ M+W1D/B`\=&0@#L@4$%$ M1$E.1RU224=(5#H@,'!X.R!415A4+4E.1$5.5#H@,'!X)SX@,C`Q-#PO=&0^ M(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B9N8G-P.SPO=&0^(#QT M9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(&QE9G0G M/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1% M6%0M04Q)1TXZ(')I9VAT)SXR-C@\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M5$585"U!3$E'3CH@;&5F="<^)FYB6QE M/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z M(')G8B@R,#0L,C4U+#(P-"DG/B`\=&0@#L@4$%$1$E.1RU224=(5#H@,'!X.R!415A4+4E.1$5. M5#H@,'!X)SX@,C`Q-3PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P M<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[ M(%1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=& M3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)SXR-3D\+W1D/B`\ M=&0@6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[ M($)!0TM'4D]53D0M0T],3U(Z('=H:71E)SX@/'1D('-T>6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU43U`Z(#!P M>#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D#L@5$58 M5"U)3D1%3E0Z(#!P>"<^(#(P,38\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E' M3CH@;&5F="<^)FYB6QE/3-$)T9/3E0M4TE:13H@ M,3!P="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB M6QE/3-$)U9%4E1)0T%,+4%,24=..B!B M;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"DG/B`\ M=&0@#L@4$%$1$E. M1RU224=(5#H@,'!X.R!415A4+4E.1$5.5#H@,'!X)SX@,C`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`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`N M-6EN)SX@)FYB6QE/3-$)U9%4E1) M0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L M,C4U+#(P-"DG/B`\=&0@6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@5TE$5$@Z(#(E)SXF;F)S<#L\+W1D/B`\ M=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F M=#L@5TE$5$@Z(#$E)SX@)FYB6QE/3-$ M)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z('=H M:71E)SX@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E' M3CH@;&5F="<^,C`Q-#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P M<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[ M(%1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=& M3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)SXS-S`\+W1D/B`\ M=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^ M)FYB6QE/3-$)U9%4E1)0T%,+4%,24=. M.B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z('=H:71E)SX@/'1D('-T>6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#%P=#L@5$58 M5"U!3$E'3CH@;&5F="<^(#(P,38\+W1D/B`\=&0@6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]5 M3D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"DG/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U14 M3TTZ(#(N-7!T.R!415A4+4%,24=..B!L969T)SX@)FYB7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE"<^(#QS=')O;F<^."X@ M1$5"5"!!4E)!3D=%345.5%,\+W-T6QE/3-$)T9/ M3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE"<^("9N8G-P.SPO<#X@/'`@6QE/3-$)T)/4D1%4BU#3TQ,05!313H@ M8V]L;&%P6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M5$585"U!3$E'3CH@8V5N=&5R.R!0041$24Y'+51/4#H@,'!X.R!0041$24Y' M+4Q%1E0Z(#!P>#L@4$%$1$E.1RU224=(5#H@,'!X.R!415A4+4E.1$5.5#H@ M,'!X)SX@)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U714E'2%0Z(&)O;&0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z M(&)O;&0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`\=&0@#L@4$%$1$E.1RU224=(5#H@,'!X.R!415A4+4E.1$5.5#H@,'!X M)SX@)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U714E'2%0Z(&)O;&0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=& M3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)R!C;VQS<&%N/3-$ M,CX@)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U714E'2%0Z(&)O;&0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=& M3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)SXF;F)S<#L\+W1D M/B`\=&0@6%B;&4@=&\@82!B86YK+"!P87EA8FQE(&EN(&UO;G1H;'D@ M<')I;F-I<&%L(&%N9"!I;G1E2!U;F1E6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M5TE$5$@Z(#(E)SXF;F)S<#L\+W1D/B`\=&0@6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SX@)FYB M6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5TE$5$@Z M(#(E)SXF;F)S<#L\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SX@)FYB6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[ M($)!0TM'4D]53D0M0T],3U(Z('=H:71E)SX@/'1D('-T>6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@4$%$1$E.1RU43U`Z(#!P>#L@4$%$1$E.1RU,1494.B`P M<'@[(%!!1$1)3D#L@5$585"U)3D1%3E0Z(#!P>"<^("9N M8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M M5T5)1TA4.B!B;VQD)SXF;F)S<#L\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G M/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/ M3E0M5T5)1TA4.B!B;VQD.R!415A4+4%,24=..B!L969T)SX@)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z M(&)O;&0[(%1%6%0M04Q)1TXZ(')I9VAT)SX@)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0[(%1% M6%0M04Q)1TXZ(&QE9G0G/B`F;F)S<#L\+W1D/B`\+W1R/B`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`Z M(#!P>#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D#L@ M5$585"U)3D1%3E0Z(#!P>"<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=& M3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)SXF;F)S<#L\+W1D M/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U714E'2%0Z(&)O;&0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD.R!415A4+4%, M24=..B!L969T)SX@)FYB6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0[(%1%6%0M04Q)1TXZ(')I9VAT M)SX@)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U714E'2%0Z(&)O;&0[(%1%6%0M04Q)1TXZ(&QE9G0G/B`F;F)S<#L\ M+W1D/B`\+W1R/B`\='(@#L@4$%$1$E.1RU224=(5#H@ M,'!X.R!415A4+4E.1$5.5#H@,'!X)SX@)FYB6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/B9N8G-P M.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5) M1TA4.B!B;VQD.R!415A4+4%,24=..B!L969T)SX@)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0[ M(%1%6%0M04Q)1TXZ(')I9VAT)SX@)FYB6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0[(%1%6%0M04Q) M1TXZ(&QE9G0G/B`F;F)S<#L\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0[(%1% M6%0M04Q)1TXZ(&QE9G0G/B`F;F)S<#L\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ M(#%P=#L@5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU43U`Z(#!P>#L@4$%$ M1$E.1RU,1494.B`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`\ M=&0@6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#%P="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA M8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!L969T)SX@)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@ M8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!R:6=H="<^(#6UE;G0@ M;V)L:6=A=&EO;B!F;W(@=&AE('EE87(@96YD:6YG(%-E<'1E;6)E6%B;&4\+V5M/CPO<#X@/'`@2`D-2PX,#`N/"]P/B`\<"!S='EL93TS1"=415A4+4%,24=..B!J=7-T M:69Y.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E3L@1D].5#H@ M,3!P="!4:6UE6%B;&4@8W5R&5D(&%T(#0N,24@86YD(&UO;G1H M;'D@<')I;F-I<&%L('!A>6UE;G1S(&]F(&%P<')O>&EM871E;'D@)#,X('!L M=7,@:6YT97)E3L@1D].5#H@ M,3!P="!4:6UE6%B;&4@;6%T=7)I;F<@;VX@1&5C96UB M97(@,3@L(#(P,3`@86YD(&$@)#4P,"!P6UE;G1S+"!296=I;VYS(&EN M8V]R<&]R871E9"!T:&4@='=O(&QO86YS(&EN=&\@82!R97!L86-E;65N="!N M;W1E('!A>6%B;&4@9F]R("0Q+#,T,2!M871U2!,24)/ M4B!P;'5S(#,P,"!B87-I6QE/3-$)U1%6%0M04Q)1TXZ(&IU#L@5$58 M5"U)3D1%3E0Z(#`N-6EN)SX@)FYB3L@1D].5#H@,3!P="!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&IU#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@*&(I($]N M($YO=F5M8F5R(#DL(#(P,3(L('=E(&5X96-U=&5D(&$@'1H(&%M96YD;65N M="!W:71H(%)E9VEO;G,N(%)E9VEO;G,@86=R965D('1O(&5X=&5N9"!T:&4@ M=&5R;2!L;V%N(&%N9"!M;W)T9V%G92!L;V%N(&UA='5R:71Y(&1A=&5S('1O M($]C=&]B97(@,S$L(#(P,3,N(%1H92!U;G!A:60@<')I;F-I<&%L(&]N('1H M92!N;W1E6%B;&4@9F]R("0U+#6UE;G1S(&]F(&%P<')O>&EM871E M;'D@)#0W('!L=7,@:6YT97)E6%B;&4@:7,@2!R96%L(&5S=&%T92!A="!O=7(@5V5S="!, M869A>65T=&4@86YD($5V86YS=FEL;&4L($EN9&EA;F$@;&]C871I;VYS+CPO M<#X@/'`@3L@1D].5#H@,3!P M="!4:6UE6QE M/3-$)U1%6%0M04Q)1TXZ(&IU#L@5$585"U) M3D1%3E0Z(#`N-6EN)SX@070@4V5P=&5M8F5R(#,P+"`R,#$R+"!W92!W97)E M(&YO="!I;B!C;VUP;&EA;F-E('=I=&@@=&AE(&9I>&5D(&-H87)G92!C;W9E M2!I;G-T96%D(&]F M(&%S(&5Q=6ET>2X@3VX@3F]V96UB97(@-BP@,C`Q,BP@4F5G:6]N'!E8W0@=&\@8F4@:6X@8V]M<&QI86YC92!W M:71H('1H92!F:7AE9"!C:&%R9V4@8V]V97)A9V4@8V]V96YA;G1S(&9O2!O9B!T:&4@;&]A M;G,@86YD(&-A=7-E(&$@8W)O6QE/3-$)T9/ M3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@)FYB2!A;F0@;6%N=69A8W1U2X@ M07,@;V8@4V5P=&5M8F5R(#,P+"`R,#$R('1H92!N970@8F]O:R!V86QU92!O M9B!T:&4@9F%C:6QI='D@86YD(&QA;F0@=V%S("0Y+#4X-2X\+W`^(#QP('-T M>6QE/3-$)U1%6%0M04Q)1TXZ(&IU#L@5$58 M5"U)3D1%3E0Z(#`N-6EN)SX@)FYB#L@5$585"U)3D1%3E0Z(#`N-6EN M)SX@3VX@2F%N=6%R>2`Q,RP@,C`Q,"P@=V4@96YT97)E9"!I;G1O(&$@;F5W M("0S+#`P,"!R979O;'9I;F<@;&EN92!O9B!C'!I2!T97)M M:6YA=&EO;B!F964@97%U86P@=&\@=&AE(&UI;FEM=6T@:6YT97)E6QE/3-$)T9/3E0Z(#$P<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@)FYB2!A(&)L86YK970@;&EE;B!O;B!O=7(@<&5R2P@86YD(&EN=&5L;&5C='5A;"!P2!A6QE/3-$ M)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@5&AE($-R961I M="!!9W)E96UE;G0@86QS;R!C;VYT86EN'!E8W1E9"!B2!O9B`D,2PY,C<@;VX@=&AI7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE"<^(#QS=')O;F<^ M.2X@24Y#3TU%(%1!6$53/"]S=')O;F<^/"]P/B`\<"!S='EL93TS1"=&3TY4 M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@4VEG;FEF:6-A;G0@8V]M<&]N96YT M6QE/3-$)T9/3E0M M5T5)1TA4.B!B;VQD.R!#3TQ/4CH@8FQA8VL[(%!!1$1)3D6QE/3-$ M)T9/3E0M5T5)1TA4.B!B;VQD.R!#3TQ/4CH@8FQA8VL[(%!!1$1)3D6QE/3-$)T-/3$]2.B!B;&%C:SL@5$585"U!3$E'3CH@8V5N=&5R M)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^*%)E6QE/3-$)T-/3$]2.B!B;&%C M:SL@5$585"U!3$E'3CH@8V5N=&5R)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N M;W=R87`^*%)E"!A6QE/3-$)U1%6%0M M04Q)1TXZ(')I9VAT)SXF;F)S<#L\+W1D/B`\=&0@6QE/3-$)T-/3$]2.B!B;&%C:SL@5$585"U!3$E'3CH@;&5F M=#L@5TE$5$@Z(#$E)SXD/"]T9#X@/'1D('-T>6QE/3-$)T-/3$]2.B!B;&%C M:SL@5$585"U!3$E'3CH@6QE/3-$)U9%4E1) M0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L M,C4U+#(P-"DG/B`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`\=&0@6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT)SXF;F)S<#L\+W1D/B`\=&0@6QE M/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z M(')G8B@R,#0L,C4U+#(P-"DG/B`\=&0@6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT)SXF;F)S<#L\+W1D/B`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`\=&0@6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!#3TQ/4CH@8FQA M8VL[(%1%6%0M04Q)1TXZ(&QE9G0G/E1O=&%L(&YE="!C=7)R96YT(&1E9F5R M"!A6QE/3-$ M)T9/3E0M5T5)1TA4.B!B;VQD.R!#3TQ/4CH@8FQA8VL[(%1%6%0M04Q)1TXZ M(&QE9G0G/B`F;F)S<#L\+W1D/B`\=&0@6QE/3-$)U9%4E1)0T%,+4%,24=..B!B M;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z('=H:71E)SX@/'1D/B9N8G-P.SPO M=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT)SXF;F)S<#L\+W1D/B`\=&0@"!A6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT)SXF;F)S<#L\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F=#L@ M4$%$1$E.1RU,1494.B`S-G!X)SX@4W1O8VL@8V]M<&5N6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$58 M5"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU,1494.B`S-G!X)SX@1F]R96EG;B!T M87@@8W)E9&ET(&-A6QE/3-$)T-/3$]2.B!B M;&%C:SL@5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M M0T],3U(Z('=H:71E)SX@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU,1494.B`S-G!X)SX@04U4(&-R M961I="!C87)R>6]V97(\+W1D/B`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`\=&0@6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT)SXF;F)S<#L\+W1D/B`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`\=&0@6QE/3-$)T-/3$]2.B!B;&%C M:SL@4$%$1$E.1RU"3U143TTZ(#%P="<^)FYB6QE M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@0T],3U(Z(&)L M86-K.R!415A4+4%,24=..B!L969T)SX@)FYB6QE M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@0T],3U(Z(&)L M86-K.R!415A4+4%,24=..B!R:6=H="<^("@R,3PO=&0^(#QT9"!S='EL93TS M1"=#3TQ/4CH@8FQA8VL[(%!!1$1)3D6QE/3-$)U9%4E1)0T%, M+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U M+#(P-"DG/B`\=&0^)FYB6QE/3-$)T-/3$]2.B!B M;&%C:R<^)FYB6QE/3-$)T-/3$]2.B!B;&%C:SL@ M5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)T-/ M3$]2.B!B;&%C:SL@5$585"U!3$E'3CH@6QE/3-$)T-/3$]2.B!B;&%C:R<^)FYB6QE/3-$)T-/3$]2.B!B;&%C:SL@5$585"U!3$E'3CH@;&5F="<^)FYB M6QE/3-$)T-/3$]2.B!B;&%C:SL@5$585"U!3$E' M3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^)FYB6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^ M(#PO='(^(#QT6QE M/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!#3TQ/4CH@8FQA8VL[(%1%6%0M04Q) M1TXZ(&QE9G0G/E1O=&%L(&YE="!N;VYC=7)R96YT(&1E9F5R"!A M6QE/3-$)T9/3E0M5T5) M1TA4.B!B;VQD.R!#3TQ/4CH@8FQA8VL[(%1%6%0M04Q)1TXZ(&QE9G0G/B`F M;F)S<#L\+W1D/B`\=&0@6QE/3-$)T9/ M3E0M5T5)1TA4.B!B;VQD.R!#3TQ/4CH@8FQA8VLG/B9N8G-P.SPO=&0^(#QT M9"!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9#L@0T],3U(Z(&)L86-K.R!4 M15A4+4%,24=..B!L969T)SX@)FYB6QE/3-$)T9/ M3E0M5T5)1TA4.B!B;VQD.R!#3TQ/4CH@8FQA8VL[(%1%6%0M04Q)1TXZ(')I M9VAT)SX@,2PX,S8\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G M/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^ M)FYB6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N M8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT)SXF;F)S<#L\+W1D/B`\=&0@6QE/3-$)U9%4E1) M0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L M,C4U+#(P-"DG/B`\=&0@"!A6QE/3-$)T-/3$]2.B!B;&%C:SL@4$%$1$E. M1RU"3U143TTZ(#%P=#L@5$585"U!3$E'3CH@;&5F="<^("D\+W1D/B`\=&0@ M6QE/3-$)T-/3$]2.B!B;&%C:SL@4$%$1$E. M1RU"3U143TTZ(#%P=#L@5$585"U!3$E'3CH@;&5F="<^("D\+W1D/B`\+W1R M/B`\='(@"9N8G-P.R9N8G-P M.V%S6QE/3-$)T-/3$]2.B!B M;&%C:SL@4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@ M6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@0T], M3U(Z(&)L86-K.R!415A4+4%,24=..B!R:6=H="<^("T\+W1D/B`\=&0@6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE"<^("9N8G-P.SPO<#X@/'`@ M6QE/3-$ M)U9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0[ M(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E' M3CH@;&5F=#L@4$%$1$E.1RU,1494.B`P<'@G/B!#=7)R96YT.CPO=&0^(#QT M9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B9N8G-P.SPO=&0^(#QT9"!S M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(&QE9G0G/B9N M8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M M04Q)1TXZ(')I9VAT)SXF;F)S<#L\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]5 M3D0M0T],3U(Z('=H:71E)SX@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU,1494.B`S-G!X.R!72414 M2#H@-S(E)SX@1F5D97)A;#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z M(#$P<'0[(%=)1%1(.B`R)2<^)FYB6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SXD M/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E' M3CH@6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SXI M/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5TE$5$@Z(#(E M)SXF;F)S<#L\+W1D/B`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`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`\ M=&0@6QE M/3-$)T9/3E0M4TE:13H@,3!P="<^)FYB6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@ M"<^(%-T871E(&%N9"!L;V-A;#PO=&0^ M(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B9N8G-P.SPO=&0^(#QT M9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(&QE9G0G M/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1% M6%0M04Q)1TXZ(')I9VAT)SXM/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)FYB6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E' M3CH@"<^($9O"!E>'!E;G-E/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@ M,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<^(#(\+W1D/B`\=&0@ M6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE#L@5$58 M5"U)3D1%3E0Z(#`N-6EN)SX@5&AE(&5F9F5C=&EV92!I;F-O;64@=&%X(')A M=&4@;VX@8V]N=&EN=6EN9R!O<&5R871I;VYS('9A6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE#L@5$585"U)3D1%3E0Z(#`N M-6EN)SX@)FYB6QE/3-$)U9%4E1) M0T%,+4%,24=..B!B;W1T;VTG/B`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`\ M=&0@6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SX@ M)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$58 M5"U!3$E'3CH@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F=#L@5TE$ M5$@Z(#$E)SXE/"]T9#X@/"]T6QE/3-$)U9%4E1)0T%,+4%, M24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z('=H:71E)SX@/'1D('-T M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F=#L@4$%$ M1$E.1RU43U`Z(#!P>#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D#L@5$585"U)3D1%3E0Z(#!P>"<^($EN8W)E87-E6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB M6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E' M3CH@;&5F="<^)FYB6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@5$585"U!3$E'3CH@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F=#L@ M4$%$1$E.1RU43U`Z(#!P>#L@4$%$1$E.1RU,1494.B`P+C$R-6EN.R!0041$ M24Y'+5))1TA4.B`P<'@[(%1%6%0M24Y$14Y4.B`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`\=&0@#L@5$585"U)3D1%3E0Z(#!P>"<^($YO;F1E9'5C=&EB;&4@97AP96YS M97,\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]5 M3D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"DG/B`\=&0@#L@5$585"U)3D1%3E0Z(#!P>"<^(%9A;'5A=&EO;B!A;&QO=V%N8V4@8VAA M;F=E6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]5 M3D0M0T],3U(Z('=H:71E)SX@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@4$%$1$E.1RU"3U143TTZ(#%P=#L@4$%$1$E.1RU43U`Z(#!P>#L@4$%$ M1$E.1RU,1494.B`P+C$R-6EN.R!0041$24Y'+5))1TA4.B`P<'@[(%1%6%0M M24Y$14Y4.B`P<'@G/B!/=&AE6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#%P="<^ M)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]2 M1$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!L969T M)SX@)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!R M:6=H="<^(#`N,CPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[ M(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U! M3$E'3CH@;&5F="<^)FYB6QE/3-$)T9/3E0M4TE: M13H@,3!P="<^)FYB6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@#L@ M4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D#L@5$585"U) M3D1%3E0Z(#!P>"<^($5F9F5C=&EV92!I;F-O;64@=&%X(')A=&4\+W1D/B`\ M=&0@6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T.R!415A4+4%, M24=..B!L969T)SX@*24\+W1D/B`\=&0@6QE/3-$)T9/3E0Z(#$P<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@26X@9FES8V%L(#(P,3(@86YD(#(P M,3$L(&]U&5S(&]F("0S+#8S-B!A;F0@)#"!A6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE#L@5$58 M5"U)3D1%3E0Z(#`N-6EN)SX@4F5A;&EZ871I;VX@;V8@9&5F97)R960@=&%X M(&%S69O69O&%B;&4@:6YC M;VUE('!R:6]R('1O('1H96ER(&5X<&ER871I;VXN(%1H92!V86QU871I;VX@ M86QL;W=A;F-E(&EN(&9I&5S(&%M;W5N=&5D('1O("0Q,B!A;F0@)#@L(')E M2X\+W`^(#QP('-T>6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE#L@5$58 M5"U)3D1%3E0Z(#`N-6EN)SX@)FYB69O&EM871E;'D@)#0L.3,U(&9O'!I6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE"<^("9N8G-P.SPO M<#X@/'`@2!I9B!I="!I2!T:&%N(&YO="!T;R!B92!S=7-T86EN960@=7!O;B!R96=U;&%T;W)Y M(&5X86UI;F%T:6]N(&)A6QE/3-$)U1%6%0M04Q)1TXZ(&IU#L@5$585"U)3D1%3E0Z(#`N,C5I;B<^($$@"<^)FYB6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T M;VTG/B`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`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E. M1RU"3U143TTZ(#%P=#L@5$585"U!3$E'3CH@;&5F="<^("9N8G-P.SPO=&0^ M(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@4$%$1$E.1RU"3U143TTZ(#%P=#L@5$585"U!3$E'3CH@;&5F="<^ M("9N8G-P.SPO=&0^(#PO='(^(#QT6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU" M3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE M.R!415A4+4%,24=..B!R:6=H="<^(#$V/"]T9#X@/'1D('-T>6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T.R!415A4+4%, M24=..B!L969T)SX@)FYB6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\ M=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@ M8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<^(#$V/"]T M9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U14 M3TTZ(#(N-7!T.R!415A4+4%,24=..B!L969T)SX@)FYB"!P;W-I=&EO M;G,@9'5R:6YG(&9I6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE#L@5$585"U)3D1%3E0Z(#`N M-6EN)SX@5V4@87)E(&YO(&QO;F=EF%T:6]N+B!&=7)T:&5R;6]R92P@=V4@87)E(&YO(&QO;F=E65A'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE"<^(#QS=')O;F<^ M,3`N(%-43T-++4)!4T5$($-/35!%3E-!5$E/3CPO2!O9B!3=&]C:R!/<'1I;VX@4&QA;G,@86YD($%C=&EV:71Y M/"]E;3X\+W`^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU"<^("9N8G-P.SPO<#X@/'`@3L@1D].5#H@,3!P="!4:6UE65E(%-T;V-K($]P=&EO;B!0;&%N+B!& M=71U2!P M65E65E2!B92!G6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@ M8FQA8VL@,7!T('-O;&ED.R!&3TY4+5=%24=(5#H@8F]L9#L@5$585"U!3$E' M3CH@8V5N=&5R)R!N;W=R87`],T1N;W=R87`^,C`Q,CPO=&0^(#QT9"!S='EL M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD.R!0041$ M24Y'+4)/5%1/33H@,7!T)R!N;W=R87`],T1N;W=R87`^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@ M8FQA8VL@,7!T('-O;&ED.R!&3TY4+5=%24=(5#H@8F]L9#L@5$585"U!3$E' M3CH@8V5N=&5R)R!N;W=R87`],T1N;W=R87`^,C`Q,3PO=&0^(#PO='(^(#QT M6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@5TE$5$@Z(#(E)R!N;W=R87`],T1N;W=R87`^ M)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$58 M5"U!3$E'3CH@8V5N=&5R.R!724142#H@,3(E)R!N;W=R87`],T1N;W=R87`^ M,RXP."4\+W1D/B`\+W1R/B`\='(@2!O9B!T:&4@97AP96-T960@ M;6%R:V5T('!R:6-E(&]F('1H92!#;VUP86YY)B,S.3MS(&-O;6UO;B!S=&]C M:SPO=&0^(#QT9"!S='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA M;BP@5&EM97,L(%-E6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@5$585"U!3$E'3CH@8V5N=&5R)R!N;W=R87`],T1N;W=R87`^(#DP+C`P M)2TY,2XP,"4\+W1D/B`\+W1R/B`\='(@'!E M8W1E9"!L:69E(&]F('1H92!O<'1I;VYS("AY96%R6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@8V5N=&5R)R!N M;W=R87`],T1N;W=R87`^(#@N,#PO=&0^(#PO='(^(#PO=&%B;&4^(#QP('-T M>6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@)FYB M6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`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`\ M=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F=#L@5TE$ M5$@Z(#$E)SX@)FYB6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@5$585"U!3$E'3CH@6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z M(#$E)SXD/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$58 M5"U!3$E'3CH@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F=#L@5TE$ M5$@Z(#$E)SX@)FYB6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@5TE$5$@Z(#(E)SXF;F)S<#L\+W1D/B`\=&0@6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SX@ M)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$58 M5"U!3$E'3CH@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F=#L@ M5TE$5$@Z(#$E)SX@)FYB6QE/3-$)U9% M4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z('=H:71E M)SX@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU,1494 M.B`P+C$R-6EN)SY%>&5R8VES960\+W1D/B`\=&0@6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F M="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M5$585"U!3$E'3CH@6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU,1494.B`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`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`\=&0@6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D M/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$ M1$E.1RU"3U143TTZ(#(N-7!T.R!415A4+4%,24=..B!L969T)SX@)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU" M3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M4$%$1$E.1RU"3U143TTZ(#(N-7!T.R!415A4+4%,24=..B!R:6=H="<^(#(N M-C4\+W1D/B`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`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$ M)T9/3E0M4TE:13H@,3!P="<^)FYB6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$58 M5"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)T9/3E0M M4TE:13H@,3!P="<^)FYB6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@6QE/3-$)T9/3E0M4TE: M13H@,3!P="<^)FYB6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@ M;&5F="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@5$585"U!3$E'3CH@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU,1494.B`P+C$R-6EN M)SY%>&5R8VES960\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)FYB6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E' M3CH@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^ M)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)FYB M6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U! M3$E'3CH@;&5F="<^)FYB6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@5$585"U!3$E'3CH@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ M(#%P=#L@4$%$1$E.1RU,1494.B`P+C$R-6EN)SX@5&5R;6EN871E9#PO=&0^ M(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#%P=#L@5$585"U!3$E'3CH@;&5F M="<^("D\+W1D/B`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`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T M.R!415A4+4%,24=..B!L969T)SX@)FYB6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S M<#L\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#(N M-7!T.R!415A4+4%,24=..B!R:6=H="<^(#$N.3D\+W1D/B`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`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E. M1RU"3U143TTZ(#(N-7!T.R!415A4+4%,24=..B!R:6=H="<^(#,N.#,\+W1D M/B`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`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`\=&0@6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@5TE$5$@Z(#(E)SXF;F)S<#L\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F M=#L@5TE$5$@Z(#$E)SX@)FYB6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@5TE$5$@Z(#(E)SXF;F)S<#L\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F M="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P="<^ M)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$58 M5"U!3$E'3CH@;&5F="<^)#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z M(#$P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)SXQ+C`U/"]T9#X@/'1D('-T>6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T M;VT[($)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"DG/B`\=&0@ M6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^ M*3PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B9N8G-P.SPO M=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ M(&QE9G0G/B0\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ M(#%P=#L@5$585"U!3$E'3CH@;&5F="<^("D\+W1D/B`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`@6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`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`F;F)S<#L\+W1D/B`\=&0@6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/B9N8G-P.SPO=&0^ M(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B M;VQD)R!C;VQS<&%N/3-$,CX@)FYB6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/B9N8G-P.SPO=&0^ M(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B M;VQD)SXF;F)S<#L\+W1D/B`\=&0@6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G(&-O;'-P86X] M,T0R/B`F;F)S<#L\+W1D/B`\=&0@6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/B9N8G-P.SPO M=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4 M.B!B;VQD)R!C;VQS<&%N/3-$,CX@)FYB6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/B9N8G-P.SPO M=&0^(#PO='(^(#QT6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5TE$5$@Z(#,P)2<^)#`N-SD@+2`Q M+C`Q/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5TE$5$@Z M(#(E)SXF;F)S<#L\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SX@)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5TE$5$@Z(#(E M)SXF;F)S<#L\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E' M3CH@;&5F=#L@5TE$5$@Z(#$E)SX@)FYB6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$58 M5"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SX@)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5TE$5$@Z(#(E)SXF;F)S<#L\+W1D M/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB M6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E' M3CH@;&5F="<^)FYB6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@5$585"U!3$E'3CH@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$58 M5"U!3$E'3CH@6QE/3-$)T9/3E0M4TE:13H@,3!P="<^ M)#0N-C`@+2`X+C6QE/3-$)T9/3E0M4TE:13H@,3!P M="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^ M)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)FYB M6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U! M3$E'3CH@;&5F="<^)FYB6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@5$585"U!3$E'3CH@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M5$585"U!3$E'3CH@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@3X-"CPO M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X-F4R9&1B9%]F,V0T7S0X,C-? M8C0P,U]A,&(Q.&-E9F0U,&(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O M0SHO.#9E,F1D8F1?9C-D-%\T.#(S7V(T,#-?83!B,3AC969D-3!B+U=O'0O:'1M;#L@ M8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$&AT;6PQ+71R86YS:71I;VYA;"YD=&0B("TM M/CQD:78^(#QD:78^/"$M+5-T87)T1G)A9VUE;G0M+3X@/'`@3L@1D].5#H@,3!P="!4:6UE65E(&-O;G1R:6)U=&EO;BX@5&AE(%!L86X@86QS;R!I;F-L=61E M'!E;G-E('=A'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA'0^/"$M+41/0U194$4@:'1M;"!054),24,@(BTO M+U&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO;F%L M+F1T9"(@+2T^/&1I=CX@/&1I=CX\(2TM4W1A2!A6QE/3-$ M)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5#H@,3!P="!4:6UE6QE M/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G/B`\=&0@#L@4$%$1$E.1RU43U`Z(#!P>#L@4$%$1$E.1RU,1494 M.B`P<'@[(%!!1$1)3D#L@5TE$5$@Z(#`N,C5I;CL@5$58 M5"U)3D1%3E0Z(#!P>"<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=0041$ M24Y'+4)/5%1/33H@,'!X.R!0041$24Y'+51/4#H@,'!X.R!0041$24Y'+4Q% M1E0Z(#!P>#L@4$%$1$E.1RU224=(5#H@,'!X.R!724142#H@,"XU:6X[(%1% M6%0M24Y$14Y4.B`P<'@G/B`\96T^*&$I/"]E;3X\+W1D/B`\=&0@#L@4$%$1$E.1RU43U`Z(#!P>#L@4$%$ M1$E.1RU,1494.B`P<'@[(%!!1$1)3D#L@5$585"U)3D1% M3E0Z(#!P>"<^(#QE;3Y/<&5R871I;F<@4V5G;65N=',\+V5M/CPO=&0^(#PO M='(^(#PO=&%B;&4^(#QP('-T>6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE#L@5$585"U) M3D1%3E0Z(#`N-6EN)SX@)FYB6QE M/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)FYB M6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E. M1RU"3U143TTZ(#%P="<^)FYB6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!4 M15A4+4%,24=..B!C96YT97(G(&-O;'-P86X],T0R/C(P,3(\+W1D/B`\=&0@ M6QE/3-$)T9/3E0M4TE:13H@,3!P M="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P="<^ M)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$58 M5"U!3$E'3CH@8V5N=&5R)R!C;VQS<&%N/3-$,CX@*%)E6QE/3-$)T9/3E0M4TE:13H@,3!P="<^ M)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$58 M5"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@5TE$5$@Z(#(E)SXF;F)S<#L\+W1D/B`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`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`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E' M3CH@;&5F="<^)FYB6QE/3-$)U9%4E1) M0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z('=H:71E)SX@ M/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU,1494.B`P M+C8R-6EN)SY06QE/3-$)T9/3E0M4TE:13H@ M,3!P="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F M="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P="<^ M)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$58 M5"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ M(#%P=#L@4$%$1$E.1RU,1494.B`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`\=&0@6QE/3-$)U9% M4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z('=H:71E M)SX@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^ M)#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q) M1TXZ(')I9VAT)SXH-2PV.#8\+W1D/B`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`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`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`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@ M,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<^(#(L,S4R/"]T9#X@ M/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ M(#(N-7!T.R!415A4+4%,24=..B!L969T)SX@)FYB#L@5$585"U)3D1%3E0Z(#`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`\=&0@6QE/3-$)T9/3E0M4TE:13H@ M,3!P="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@5TE$5$@Z(#(E)SXF;F)S<#L\+W1D/B`\=&0@6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E M)SXD/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U! M3$E'3CH@6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"DG/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4 M+4%,24=..B!L969T)SX@)#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z M(#$P<'0[($)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$58 M5"U!3$E'3CH@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU" M3U143TTZ(#(N-7!T.R!415A4+4%,24=..B!L969T)SX@)FYB6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)! M0TM'4D]53D0M0T],3U(Z('=H:71E)SX@/'1D('-T>6QE/3-$)T9/3E0M4TE: M13H@,3!P="<^)FYB6QE/3-$)T9/3E0M4TE:13H@ M,3!P="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@6QE/3-$)T9/ M3E0M4TE:13H@,3!P="<^)FYB6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@ M;&5F="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P M="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M5$585"U!3$E'3CH@;&5F="<^)#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-) M6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)SXQ+#`P.3PO=&0^(#QT9"!S M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(&QE9G0G/B9N M8G-P.SPO=&0^(#PO='(^(#QT6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ M(#%P=#L@4$%$1$E.1RU,1494.B`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`\=&0@6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@5$585"U!3$E'3CH@6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)! M0TM'4D]53D0M0T],3U(Z('=H:71E)SX@/'1D('-T>6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#%P=#L@4$%$1$E.1RU,1494.B`P M+C8R-6EN)SX@4')O9'5C=#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z M(#$P<'0[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#%P M=#L@5$585"U!3$E'3CH@;&5F="<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS M1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E. M1RU"3U143TTZ(#%P=#L@5$585"U!3$E'3CH@;&5F="<^("9N8G-P.SPO=&0^ M(#PO='(^(#QT6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF M;F)S<#L\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/ M33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!L969T)SX@)#PO M=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($)/4D1%4BU"3U14 M3TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@ M;&5F="<^)FYB6QE/3-$)U9%4E1)0T%, M+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U M+#(P-"DG/B`\=&0@6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^ M)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$58 M5"U!3$E'3CH@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$58 M5"U!3$E'3CH@;&5F="<^)FYB6QE/3-$ M)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z(')G M8B@R,#0L,C4U+#(P-"DG/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M4$%$1$E.1RU"3U143TTZ(#%P="<^)FYB6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O M;&ED.R!415A4+4%,24=..B!L969T)SX@)FYB6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,7!T M('-O;&ED.R!415A4+4%,24=..B!R:6=H="<^(#(T,CPO=&0^(#QT9"!S='EL M93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU" M3U143TTZ(#%P=#L@5$585"U!3$E'3CH@;&5F="<^("9N8G-P.SPO=&0^(#PO M='(^(#QT6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#(N M-7!T)SXF;F)S<#L\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%, M24=..B!R:6=H="<^(#(L,C6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T.R!415A4+4%,24=..B!L M969T)SX@)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@ M,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<^(#(L,3,T/"]T9#X@ M/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ M(#(N-7!T.R!415A4+4%,24=..B!L969T)SX@)FYB6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]5 M3D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"DG/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U! M3$E'3CH@;&5F="<^)FYB6QE/3-$)T9/3E0M4TE: M13H@,3!P="<^)FYB6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$58 M5"U!3$E'3CH@;&5F="<^)FYB6QE/3-$ M)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z(')G M8B@R,#0L,C4U+#(P-"DG/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#%P M="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!L M969T)SX@)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=. M.B!R:6=H="<^(#(R-CPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P M<'0[(%!!1$1)3D6QE/3-$)U9% M4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z(')G8B@R M,#0L,C4U+#(P-"DG/B`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`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#%P M="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!C M96YT97(G(&-O;'-P86X],T0R/C(P,3(\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^ M4V%L97,@=&\@17AT97)N86P@0W5S=&]M97)S.CPO=&0^(#QT9"!S='EL93TS M1"=&3TY4+5-)6D4Z(#$P<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=& M3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^ M(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(')I M9VAT)SXF;F)S<#L\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M5$585"U!3$E'3CH@;&5F="<^)FYB6QE M/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z M('=H:71E)SX@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U! M3$E'3CH@;&5F=#L@4$%$1$E.1RU,1494.B`P+C8R-6EN.R!724142#H@-S(E M)SX@3F]R=&@@06UE6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SXD M/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E' M3CH@6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SX@ M)FYB6QE/3-$)U9%4E1)0T%,+4%,24=. M.B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"DG M/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M M0T],3U(Z('=H:71E)SX@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M4$%$1$E.1RU,1494.B`P+C8R-6EN)SY%=7)O<&4\+W1D/B`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`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`P+C8R-6EN)SX@175R;W!E M/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU" M3U143TTZ(#%P="<^)FYB6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4 M+4%,24=..B!L969T)SX@)FYB6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!4 M15A4+4%,24=..B!R:6=H="<^("T\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@4$%$1$E.1RU"3U143TTZ(#%P="<^)FYB6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,7!T M('-O;&ED.R!415A4+4%,24=..B!L969T)SX@)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@ M,7!T('-O;&ED.R!415A4+4%,24=..B!R:6=H="<^(#$L,3`Q/"]T9#X@/'1D M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#%P M=#L@5$585"U!3$E'3CH@;&5F="<^("9N8G-P.SPO=&0^(#PO='(^(#QT6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\ M=&0@6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T.R!415A4+4%,24=. M.B!L969T)SX@)FYB6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@ M6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA M8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<^(#(Q+#DW,SPO M=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(&IU#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@)FYB#L@4$%$1$E.1RU224=(5#H@,'!X.R!7 M24142#H@,"XR-6EN.R!415A4+4E.1$5.5#H@,'!X)SX@)FYB6QE/3-$)U!!1$1)3D"<^(#QE;3XH8RD\+V5M M/CPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,'!X.R!0041$ M24Y'+51/4#H@,'!X.R!0041$24Y'+4Q%1E0Z(#!P>#L@4$%$1$E.1RU224=( M5#H@,'!X.R!415A4+4E.1$5.5#H@,'!X)SX@/&5M/DUA:F]R($-U3L@1D].5#H@,3!P="!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&IU#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@5&AE(%!R M969E2!R96UA:6X@82!L87)G92!C;&EE;G0@;V8@=&AE($-O;7!A;GDN M(%!H87)M87-S970L($EN8RXL(&YO=R!K;F]W;B!A2`S M+C0E(&%N9"`U+C(E(&]F(&]U3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%\X-F4R9&1B9%]F,V0T7S0X,C-?8C0P,U]A,&(Q.&-E9F0U,&(-"D-O;G1E M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.#9E,F1D8F1?9C-D-%\T.#(S7V(T M,#-?83!B,3AC969D-3!B+U=O'0O:'1M;#L@8VAA&AT;6PQ+71R86YS:71I;VYA;"YD=&0B("TM/CQD:78^(#QD:78^ M/"$M+5-T87)T1G)A9VUE;G0M+3X@/'`@6QE/3-$)T9/3E0Z M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@26X@2G5N92!O9B`R,#`X M(&%S('!A2!297-E87)C:"!5;FET+"!W92!S=6)L96%S960@=&AE(&)U M:6QD:6YG('-P86-E(&ET(&]C8W5P:65D('1O('1H92!P=7)C:&%S97(@;V8@ M=&AE(&%S65A&-H86YG M92!F;W(@82!C87-H('!A>6UE;G0@9G)O;2!T:&4@2UF:79E(&UO;G1H;'D@:6YS=&%L;&UE;G1S(&]F M("0Q,"!W:71H;W5T(&EN=&5R97-T+B!792!R96-O6UE;G0@86YD(&5X=&EN9W5I M7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6QE/3-$)U1%6%0M04Q)1TXZ(&IU"<^(#QS=')O;F<^,30N(%)%4U1254-455))3D<\+W-T6QE/3-$)U1%6%0M04Q)1TXZ(&IU"<^(#QS=')O;F<^)FYB2!O<&5R871I;VYS+B!792!C;VYS M;VQI9&%T960@;W5R(&QA8F]R871O2!I;B!797-T($QA9F%Y971T92P@26YD:6%N82X@5&AIF%T:6]N+B!) M;B!T:&4@9F]U2!I;B!787)W:6-K7-I2!W:&EL92!F=7)T:&5R(&-O;G-O;&ED871I M;F<@9&5L:79E65E6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE#L@5$585"U) M3D1%3E0Z(#`N-6EN)SX@)FYB6QE M/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%, M24=..B!C96YT97(G(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<#XR,#$R M/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU" M3U143TTZ(#%P="<@;F]W6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@5TE$5$@Z(#(E)SXF;F)S<#L\+W1D/B`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`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)FYB M6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U! M3$E'3CH@;&5F="<^)FYB6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@5$585"U!3$E'3CH@6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM' M4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"DG/B`\=&0@6QE/3-$ M)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@4F5S=')U8W1U M6QE/3-$ M)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0[ M(%!!1$1)3D6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0[(%!!1$1)3D6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED M.R!&3TY4+5=%24=(5#H@8F]L9#L@5$585"U!3$E'3CH@8V5N=&5R)R!C;VQS M<&%N/3-$,B!N;W=R87`],T1N;W=R87`^3W1H97(\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/ M5%1/33H@8FQA8VL@,7!T('-O;&ED.R!&3TY4+5=%24=(5#H@8F]L9#L@5$58 M5"U!3$E'3CH@8V5N=&5R)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^ M0F%L86YC92P\8G(@+SX@4V5P=&5M8F5R(#,P+#QB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O M;&0[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5TE$5$@Z(#(E)SXF M;F)S<#L\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F M=#L@5TE$5$@Z(#$E)SXD/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@5$585"U!3$E'3CH@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F=#L@5TE$ M5$@Z(#$E)SXD/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M5$585"U!3$E'3CH@6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SX@)FYB M6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5TE$5$@Z M(#(E)SXF;F)S<#L\+W1D/B`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`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P="<^ M)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$58 M5"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F M="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M5$585"U!3$E'3CH@6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)FYB6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E' M3CH@6QE/3-$)T9/3E0M4TE:13H@,3!P M="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^3&]S M6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E' M3CH@;&5F="<^)FYB6QE/3-$)T9/3E0M4TE:13H@ M,3!P="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB M6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E' M3CH@;&5F="<^)FYB6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@5$585"U!3$E'3CH@6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^ M)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$58 M5"U!3$E'3CH@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ M(#%P=#L@5$585"U!3$E'3CH@;&5F="<^("9N8G-P.SPO=&0^(#QT9"!S='EL M93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@4$%$1$E.1RU"3U143TTZ(#%P=#L@5$585"U!3$E'3CH@;&5F="<^ M("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!! M1$1)3D6QE/3-$ M)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z(')G M8B@R,#0L,C4U+#(P-"DG/B`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`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%, M24=..B!R:6=H="<^("@U,SD\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$ M1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@ M9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<^(#$L-#`U/"]T9#X@/'1D('-T M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T M.R!415A4+4%,24=..B!L969T)SX@)FYB6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE#L@5$58 M5"U)3D1%3E0Z(#`N-6EN)SX@3W1H97(@8V]S=',@:6YC;'5D92!L96=A;"!A M;F0@<')O9F5S2!I;B!T:&4@'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/"$M+41/0U194$4@:'1M;"!054),24,@(BTO+U&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T M9"(@+2T^/&1I=CX@/&1I=CX\(2TM4W1A3L@1D].5#H@,3!P="!4:6UE6QE/3-$)T9/3E0Z(#$P M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@5&AE($-O;7!A;GD@:7,@65E(&AE86QT:"!P;&%N+B9N8G-P.R9N8G-P.T-O&EM871E;'D@)#8P(&%N9"!H M87,@82!M:6YI;75M(&%N;G5A;"!A9V=R96=A=&4@871T86-H;65N="!P;VEN M="!O9B`D,BPP-S(@870@4V5P=&5M8F5R(#,P+"`R,#$R+B9N8G-P.R9N8G-P M.U1H92!#;VUP86YY)B,S.3MS(&5X<&5N3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%\X-F4R9&1B9%]F,V0T7S0X,C-?8C0P,U]A,&(Q.&-E M9F0U,&(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.#9E,F1D8F1? M9C-D-%\T.#(S7V(T,#-?83!B,3AC969D-3!B+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M&AT;6PQ+71R86YS:71I;VYA;"YD=&0B("TM/CQD:78^ M(#QD:78^/"$M+5-T87)T1G)A9VUE;G0M+3X@/'`@F4@=&AE($-O;7!A;GDF(S,Y M.W,@:6YTF4@9G)E92!C87-H(&9L;W<@9G)O M;2!O<&5R871I;F<@86-T:79I=&EE6QE/3-$)T9/3E0Z M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE"<^("9N8G-P.SPO<#X@/'`@2!T;R!A8VAI979E M(&]U'!E M;F1I='5R97,@9&5C;&EN960@-RXR)2!I;B!F:7-C86P@,C`Q,BP@<&%R=&EC M=6QA2!E>'!E;F1I='5R97,N/"]P/B`\<"!S M='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E M65A2!A;F0@;6%N=69A8W1U6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE#L@5$58 M5"U)3D1%3E0Z(#`N-6EN)SX@26X@9FES8V%L(#(P,3,L('=E('=I;&P@8V]N M=&EN=64@=&\@87-S97-S('1H92!N965D(&9OFEN9R!N;VXM97-S96YT:6%L(&-A<&ET M86P@97AP96YD:71U2`D,2XS(&UI;&QI;VX@:6X@9FES8V%L M(#(P,3,N($)A'!E8W1E9"!R979E;G5E+"!T:&4@879A M:6QA8FEL:71Y(&]N(&]U'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$&AT;6PQ+71R86YS:71I;VYA;"YD M=&0B("TM/CQD:78^(#QD:78^/"$M+5-T87)T1G)A9VUE;G0M+3X@/'1A8FQE M('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5#H@,3!P="!4:6UE M6QE/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G/B`\=&0@#L@4$%$1$E.1RU43U`Z(#!P>#L@4$%$ M1$E.1RU,1494.B`P<'@[(%!!1$1)3D#L@5TE$5$@Z(#`N M,C5I;CL@5$585"U)3D1%3E0Z(#!P>"<^("9N8G-P.SPO=&0^(#QT9"!S='EL M93TS1"=0041$24Y'+4)/5%1/33H@,'!X.R!0041$24Y'+51/4#H@,'!X.R!0 M041$24Y'+4Q%1E0Z(#!P>#L@4$%$1$E.1RU224=(5#H@,'!X.R!724142#H@ M,"XU:6X[(%1%6%0M24Y$14Y4.B`P<'@G/B`\96T^*&$I/"]E;3X\+W1D/B`\ M=&0@#L@5$585"U!3$E'3CH@ M:G5S=&EF>3L@4$%$1$E.1RU43U`Z(#!P>#L@4$%$1$E.1RU,1494.B`P<'@[ M(%!!1$1)3D#L@5$585"U)3D1%3E0Z(#!P>"<^(#QE;3Y0 M6QE/3-$)U1%6%0M04Q)1TXZ(&IU#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@)FYB2!A8V-O=6YT'0^/"$M+41/0U194$4@:'1M;"!054), M24,@(BTO+U&AT;6PQ+T141"]X:'1M;#$M=')A;G-I M=&EO;F%L+F1T9"(@+2T^/&1I=CX@/&1I=CX\(2TM4W1A#L@4$%$1$E.1RU224=(5#H@,'!X.R!7 M24142#H@,"XR-6EN.R!415A4+4E.1$5.5#H@,'!X)SX@)FYB6QE/3-$)U!!1$1)3D"<^(#QE;3XH8BD\+V5M M/CPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,'!X.R!415A4 M+4%,24=..B!J=7-T:69Y.R!0041$24Y'+51/4#H@,'!X.R!0041$24Y'+4Q% M1E0Z(#!P>#L@4$%$1$E.1RU224=(5#H@,'!X.R!415A4+4E.1$5.5#H@,'!X M)SX@/&5M/E)E=F5N=64@4F5C;V=N:71I;VX\+V5M/CPO=&0^(#PO='(^(#PO M=&%B;&4^(#QP('-T>6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE#L@5$585"U)3D1%3E0Z M(#`N-6EN)SX@)FYB2!O9B!O=7(@0FEO M86YA;'ET:6-A;"!A;F0@86YA;'ET:6-A;"!R97-E87)C:"!S97)V:6-E(&-O M;G1R86-T71I8V%L M(&UE=&AO9',@86YD('1H92!PF5D('5N9&5R('1H92!S M<&5C:69I8R!P97)F;W)M86YC92!M971H;V0@;V8@86-C;W5N=&EN9R!A;F0@ M=&AE(')E;&%T960@9&ER96-T(&-OF5D('=H96X@ M2P@87)E(')E9FQE8W1E9"!O;B!A(&-U;75L871I=F4@8F%S:7,@:6X@ M=&AE('!E6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M#L@5$585"U)3D1%3E0Z(#`N-6EN M)SX@)FYBF5D('5P;VX@6QE/3-$ M)U!!1$1)3D#L@4$%$1$E.1RU43U`Z(#!P>#L@4$%$ M1$E.1RU,1494.B`P<'@[(%!!1$1)3D#L@5TE$5$@Z(#`N M-6EN.R!415A4+4E.1$5.5#H@,'!X)SX@/&5M/BAC*3PO96T^/"]T9#X@/'1D M('-T>6QE/3-$)U!!1$1)3D3L@1D].5#H@,3!P="!4:6UE6QE/3-$)U1%6%0M M04Q)1TXZ(&IU#L@5$585"U)3D1%3E0Z(#`N M-6EN)SX@5V4@8V]N2!L:7%U:60@:6YV97-T;65N M=',@=VET:"!A;B!O2!O9B!T:')E92!M;VYT:',@ M;W(@;&5S3L@1D].5#H@ M,3!P="!4:6UE6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@3VYE M(&]R(&UO28C,SD[6QE/3-$)T9/3E0Z M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE"<^("9N8G-P.SPO<#X@/'`@2`R,2P@,C`Q,"X@070@4V5P=&5M8F5R(#,P+"`R,#$R M+"!T:&4@0V]M<&%N>2!D:60@;F]T(&AA=F4@86YY(&-A&-E961E9"!F961E6QE/3-$)U!!1$1)3D#L@4$%$1$E.1RU43U`Z(#!P>#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1) M3D#L@5TE$5$@Z(#`N-6EN.R!415A4+4E.1$5.5#H@,'!X M)SX@/&5M/BAD*3PO96T^/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D3L@1D].5#H@,3!P="!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&IU#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@5V4@<&5R9F]R;2!P M97)I;V1I8R!C2!O9B!O=7(@=')A9&4@2P@;6%N86=E;65N="!R979I97=S(&%C8V]U;G1S(')E8V5I=F%B;&4@86YD M(&%D:G5S=',@=&AE(&%L;&]W86YC92!B87-E9"!O;B!C=7)R96YT(&-I3L@1D].5#H@,3!P="!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&IU#L@5$585"U)3D1%3E0Z(#`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`\ M=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F M=#L@5TE$5$@Z(#$E)SX@)FYB6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@5TE$5$@Z(#(E)SXF;F)S<#L\+W1D/B`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`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@ M;&5F="<^*3PO=&0^(#PO='(^(#QT6QE/3-$)U9%4E1)0T%,+4%, M24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P M-"DG/B`\=&0@6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T.R!4 M15A4+4%,24=..B!L969T)SX@)FYB6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\ M+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/ M5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<^ M(#$P.#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1) M3D6QE/3-$)U!!1$1)3D#L@4$%$1$E.1RU43U`Z(#!P>#L@4$%$1$E.1RU,1494 M.B`P<'@[(%!!1$1)3D#L@5TE$5$@Z(#`N-6EN.R!415A4 M+4E.1$5.5#H@,'!X)SX@/&5M/BAE*3PO96T^/"]T9#X@/'1D('-T>6QE/3-$ M)U!!1$1)3D6QE/3-$)U1%6%0M04Q) M1TXZ(&IU#L@5$585"U)3D1%3E0Z(#`N-6EN M)SX@)FYB2X@26YV96YT;W)Y('1H870@:7,@ M:6X@97AC97-S(&]F(&-U2!A;B!A;&QO=V%N8V4@=&\@82!L979E;"!T:&%T(&%P<')O>&EM M871E&AT;6PQ+71R86YS:71I;VYA;"YD=&0B("TM/CQD:78^(#QD:78^/"$M+5-T M87)T1G)A9VUE;G0M+3X@/'1A8FQE('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ M(#!P=#L@1D].5#H@,3!P="!4:6UE6QE/3-$)U9%4E1)0T%,+4%, M24=..B!T;W`G/B`\=&0@#L@ M4$%$1$E.1RU43U`Z(#!P>#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D#L@5TE$5$@Z(#`N,C5I;CL@5$585"U)3D1%3E0Z(#!P>"<^ M("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,'!X M.R!0041$24Y'+51/4#H@,'!X.R!0041$24Y'+4Q%1E0Z(#!P>#L@4$%$1$E. M1RU224=(5#H@,'!X.R!724142#H@,"XU:6X[(%1%6%0M24Y$14Y4.B`P<'@G M/B`\96T^*&8I/"]E;3X\+W1D/B`\=&0@#L@5$585"U!3$E'3CH@:G5S=&EF>3L@4$%$1$E.1RU43U`Z(#!P M>#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D#L@5$58 M5"U)3D1%3E0Z(#!P>"<^(#QE;3Y02!A;F0@17%U:7!M96YT/"]E M;3X\+W1D/B`\+W1R/B`\+W1A8FQE/B`\<"!S='EL93TS1"=415A4+4%,24=. M.B!J=7-T:69Y.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E3L@ M1D].5#H@,3!P="!4:6UEF%T:6]N(&]N(&-A<&ET86P@;&5A M'1U65A2X@1&5P'!E;F1I='5R97,@9F]R(&UA:6YT96YA;F-E(&%N9"!R97!A:7)S M(&%R92!E>'!E;G-E9"!A6QE/3-$)U1% M6%0M04Q)1TXZ(&IU#L@5$585"U)3D1%3E0Z M(#`N-6EN)SX@)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U14 M3TTZ(#%P="<^)FYB6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@4$%$1$E.1RU"3U143TTZ(#%P="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@ M,7!T('-O;&ED.R!415A4+4%,24=..B!C96YT97(G(&-O;'-P86X],T0R/C(P M,3$\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5TE$ M5$@Z(#(E)SXF;F)S<#L\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SX@)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5TE$5$@Z(#(E)SXF M;F)S<#L\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$58 M5"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SX@)FYB6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]5 M3D0M0T],3U(Z('=H:71E)SX@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@5$585"U!3$E'3CH@;&5F="<^0G5I;&1I;F=S(&%N9"!I;7!R;W9E;65N M=',\+W1D/B`\=&0@6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@ M;&5F="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@5$585"U!3$E'3CH@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^36%C M:&EN97)Y(&%N9"!E<75I<&UE;G0\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U! M3$E'3CH@;&5F="<^)FYB6QE/3-$)T9/3E0M4TE: M13H@,3!P="<^)FYB6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@'1U6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)FYB6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E' M3CH@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#%P M="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!L M969T)SX@)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=. M.B!R:6=H="<^(#0Y,SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P M<'0[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)T9/ M3E0M4TE:13H@,3!P="<^)FYB6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@5$585"U!3$E'3CH@;&5F="<^3&5S6QE/3-$)T9/3E0M4TE:13H@,3!P M="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)FYB M6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U! M3$E'3CH@;&5F="<^)FYB6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@5$585"U!3$E'3CH@6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T M;VT[($)!0TM'4D]53D0M0T],3U(Z('=H:71E)SX@/'1D('-T>6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T.R!415A4+4%, M24=..B!L969T)SX@3F5T('!R;W!E6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T.R!415A4+4%,24=. M.B!L969T)SX@)FYB6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`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`N-6EN)SX@3&]N9RUL:79E M9"!A2!N;W0@8F4@2!W:&EC:"!T:&4@8V%R6QE/3-$)U1%6%0M04Q)1TXZ(&IU#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@)FYBF5D(&]N(&$@&-H86YG960L(&%R92!R M96-O9VYI>F5D(&%S(&%N(&%S3L@1D].5#H@,3!P="!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&IU#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@1V]O9'=I;&P@:7,@=&5S M=&5D(&%N;G5A;&QY(&9OF5D+B!) M9B!T:&4@8V%R2!I;7!A:7)E9"!A;F0@=V4@=V]U;&0@=&AE;B!C;VUP;&5T92!S=&5P M(#(@:6X@;W)D97(@=&\@;65A6EN9R!V86QU92!O9B!G;V]D=VEL;"P@=V4@=V]U;&0@3L@1D].5#H@,3!P="!4:6UE MF5D(&EN(&]U71I8V%L('-EF4@82!C87-H M(&9L;W<@87!P'!L86EN960@86)O=F4N M(%1H:7,@=&5S="!R97-U;'1E9"!I;B!N;R!I;7!A:7)M96YT('1O('1H92!G M;V]D=VEL;"!V86QU871I;VX@87,@8W5R6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE#L@5$585"U) M3D1%3E0Z(#`N-6EN)SX@)FYB&EM871E;'D@)#,N-R!M M:6QL:6]N+CPO<#X@/'`@6QE/3-$)T9/3E0Z(#$P M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@0V]N6QE/3-$)U1%6%0M04Q)1TXZ(&IU#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@070@4V5P=&5M8F5R(#,P+"`R M,#$R(&%N9"`R,#$Q+"!R96UA:6YI;F<@6QE/3-$)T9/ M3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@)FYB6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VTG M/B`\=&0@#L@4$%$1$E.1RU224=(5#H@,'!X.R!4 M15A4+4E.1$5.5#H@,'!X)R!N;W=R87`],T1N;W=R87`^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O M;&0[(%!!1$1)3D6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0[(%!!1$1)3D6QE/3-$)U9% M4E1)0T%,+4%,24=..B!B;W1T;VTG/B`\=&0@#L@ M4$%$1$E.1RU224=(5#H@,'!X.R!415A4+4E.1$5.5#H@,'!X)R!N;W=R87`] M,T1N;W=R87`^)FYB6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U714E'2%0Z(&)O;&0[(%!!1$1)3D6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0[(%!!1$1)3D6EN9SQB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@ M,7!T('-O;&ED.R!&3TY4+5=%24=(5#H@8F]L9#L@5$585"U!3$E'3CH@8V5N M=&5R)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^06-C=6UU;&%T960\ M8G(@+SX@06UOF%T:6]N/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0[(%!!1$1)3D#L@4$%$1$E.1RU224=(5#H@,'!X.R!724142#H@-3@E.R!415A4 M+4E.1$5.5#H@,'!X)SX@)FYB6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@5TE$5$@Z(#(E)SXF;F)S<#L\+W1D/B`\=&0@6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z M(#$E)SX@)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@5$585"U!3$E'3CH@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@ M;&5F=#L@5TE$5$@Z(#$E)SX@)FYB6QE M/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z M(')G8B@R,#0L,C4U+#(P-"DG/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T.R!415A4+4%,24=..B!L969T)SX@ M)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$ M1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@ M9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<^(#,P,CPO=&0^(#QT9"!S='EL M93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M"<^("9N8G-P.SPO<#X@/'1A8FQE M('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU43U`Z(#!P>#L@ M4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D#L@5$585"U) M3D1%3E0Z(#!P>"<@;F]W6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!& M3TY4+5=%24=(5#H@8F]L9#L@5$585"U!3$E'3CH@8V5N=&5R)R!C;VQS<&%N M/3-$-B!N;W=R87`],T1N;W=R87`^4V5P=&5M8F5R(#,P+"`R,#$Q/"]T9#X@ M/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O M;&0[(%!!1$1)3D65A M6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U7 M14E'2%0Z(&)O;&0[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U714E'2%0Z(&)O;&0[(%!!1$1)3D6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SX@ M)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5TE$ M5$@Z(#(E)SXF;F)S<#L\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SX@)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@ M#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D#L@5$58 M5"U)3D1%3E0Z(#!P>"<^($9$02!C;VUP;&EA;G0@9F%C:6QI='D\+W1D/B`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`N-6EN)SX@)FYB2X\+W`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`N-6EN)SX@5V4@:&%V92!A('-T;V-K+6)A65E(&-O;7!E;G-A=&EO;B!P;&%N(&%N9"!A('-T;V-K+6)A65E(&%N9"!O=71S:61E(&1I6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE#L@5$585"U)3D1%3E0Z M(#`N-6EN)SX@5V4@=7-E(&$@8FEN;VUI86P@;W!T:6]N+7!R:6-I;F<@;6]D M96P@87,@;W5R(&UE=&AO9"!O9B!V86QU871I;VX@9F]R('-H87)E+6)A2!D M97-C65E('-T;V-K(&]P=&EO;G,@9F]R('1H92!Y M96%R&5S/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\(2TM1$]#5%E012!H=&UL(%!50DQ)0R`B+2\O M5S-#+R]$5$0@6$A434P@,2XP(%1R86YS:71I;VYA;"\O14XB(")H='1P.B\O M=W=W+G6QE M/3-$)U!!1$1)3D#L@4$%$1$E.1RU43U`Z(#!P>#L@ M4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D#L@5TE$5$@Z M(#`N-6EN.R!415A4+4E.1$5.5#H@,'!X)SX@/&5M/BAJ*3PO96T^/"]T9#X@ M/'1D('-T>6QE/3-$)U!!1$1)3D&5S/"]E;3X\+W1D/B`\+W1R/B`\+W1A8FQE/B`\<"!S='EL M93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E"!A"!R871E'!E8W1E9"!T;R!A<'!L>2!T;R!T87AA M8FQE(&EN8V]M92!I;B!T:&4@>65A'!E8W1E9"!T;R!B92!R96-O=F5R960@ M;W(@6QE M/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE"<^("9N8G-P.SPO<#X@/'`@2!T:&%N(&YO="!T;R!B M92!S=7-T86EN960@=7!O;B!E>&%M:6YA=&EO;B!B87-E9"!O;B!T:&4@=&5C M:&YI8V%L(&UE2!B87-I6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE"<^("9N8G-P.SPO<#X@/'`@"!R871E+B!792!D;R!N;W0@97AP M96-T('1H92!T;W1A;"!A;6]U;G0@;V8@=6YR96-O9VYI>F5D('1A>"!B96YE M9FET&AT;6PQ+71R86YS:71I;VYA M;"YD=&0B("TM/CQD:78^(#QD:78^/"$M+5-T87)T1G)A9VUE;G0M+3X@/'1A M8FQE('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5#H@,3!P="!4 M:6UE6QE/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G/B`\=&0@#L@4$%$1$E.1RU43U`Z(#!P>#L@ M4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D#L@5TE$5$@Z M(#`N,C5I;CL@5$585"U)3D1%3E0Z(#!P>"<^("9N8G-P.SPO=&0^(#QT9"!S M='EL93TS1"=0041$24Y'+4)/5%1/33H@,'!X.R!0041$24Y'+51/4#H@,'!X M.R!0041$24Y'+4Q%1E0Z(#!P>#L@4$%$1$E.1RU224=(5#H@,'!X.R!72414 M2#H@,"XU:6X[(%1%6%0M24Y$14Y4.B`P<'@G/B`\96T^*&LI/"]E;3X\+W1D M/B`\=&0@#L@5$585"U!3$E' M3CH@:G5S=&EF>3L@4$%$1$E.1RU43U`Z(#!P>#L@4$%$1$E.1RU,1494.B`P M<'@[(%!!1$1)3D#L@5$585"U)3D1%3E0Z(#!P>"<^(#QE M;3Y.97<@06-C;W5N=&EN9R!06QE/3-$)U1%6%0M04Q) M1TXZ(&IU#L@5$585"U)3D1%3E0Z(#`N-6EN M)SX@26X@36%Y(#(P,3$L('1H92!&05-"(&ES2!T3L@1D]. M5#H@,3!P="!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&IU#L@ M5$585"U)3D1%3E0Z(#`N-6EN)SX@26X@2G5N92`R,#$Q+"!T:&4@1D%30B!A M;65N9&5D('1H92!M86YN97(@:6X@=VAI8V@@86X@96YT:71Y('!R97-E;G1S M('1H92!T;W1A;"!O9B!C;VUP2!R97!O2!H M87,@<')E3L@1D].5#H@,3!P M="!4:6UE6QE M/3-$)U1%6%0M04Q)1TXZ(&IU#L@5$585"U) M3D1%3E0Z(#`N-6EN)SX@26X@4V5P=&5M8F5R(#(P,3$L('1H92!&05-"(&ES M65A7-I7-I&AT;6PQ+71R86YS:71I;VYA;"YD=&0B("TM/CQD M:78^(#QD:78^/"$M+5-T87)T1G)A9VUE;G0M+3X@/'1A8FQE('-T>6QE/3-$ M)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5#H@,3!P="!4:6UE6QE M/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G/B`\=&0@#L@4$%$1$E.1RU43U`Z(#!P>#L@4$%$1$E.1RU,1494 M.B`P<'@[(%!!1$1)3D#L@5TE$5$@Z(#`N,C5I;CL@5$58 M5"U)3D1%3E0Z(#!P>"<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=0041$ M24Y'+4)/5%1/33H@,'!X.R!0041$24Y'+51/4#H@,'!X.R!0041$24Y'+4Q% M1E0Z(#!P>#L@4$%$1$E.1RU224=(5#H@,'!X.R!724142#H@,"XU:6X[(%1% M6%0M24Y$14Y4.B`P<'@G/B`\96T^*&PI/"]E;3X\+W1D/B`\=&0@#L@4$%$1$E.1RU43U`Z(#!P>#L@4$%$ M1$E.1RU,1494.B`P<'@[(%!!1$1)3D#L@5$585"U)3D1% M3E0Z(#!P>"<^(#QE;3Y&86ER(%9A;'5E/"]E;3X@/"]T9#X@/"]T6QE/3-$)T9/3E0Z(#$P<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UE#L@ M5$585"U)3D1%3E0Z(#`N-6EN)SX@5&AE('!R;W9I28C,SD[2!I#L@4$%$ M1$E.1RU43U`Z(#!P>#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D#L@5TE$5$@Z(#4E.R!415A4+4E.1$5.5#H@,'!X)SX@)FYB6QE/3-$)U9%4E1)0T%,+4%,24=..B!T;W`[(%!!1$1) M3D"<^("9B=6QL.SPO=&0^(#QT9"!S='EL93TS1"=615)424-! M3"U!3$E'3CH@=&]P.R!0041$24Y'+4)/5%1/33H@,'!X.R!0041$24Y'+51/ M4#H@,'!X.R!0041$24Y'+4Q%1E0Z(#!P>#L@4$%$1$E.1RU224=(5#H@,'!X M.R!724142#H@,24[(%1%6%0M24Y$14Y4.B`P<'@G/B`F;F)S<#L\+W1D/B`\ M=&0@#L@4$%$1$E.1RU43U`Z(#!P>#L@4$%$1$E.1RU,1494.B`P<'@[ M(%!!1$1)3D#L@5$585"U)3D1%3E0Z(#!P>"<^($QE=F5L M(#$@+2!686QU871I;VYS(&)A2!H87,@=&AE(&%B:6QI='D@=&\@86-C97-S M+CPO=&0^(#PO='(^(#PO=&%B;&4^(#QP('-T>6QE/3-$)T9/3E0Z(#$P<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE"<^("9N8G-P.SPO<#X@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!3 M13H@8V]L;&%P#L@4$%$ M1$E.1RU224=(5#H@,'!X.R!724142#H@-24[(%1%6%0M24Y$14Y4.B`P<'@G M/B`F;F)S<#L\+W1D/B`\=&0@#L@4$%$1$E.1RU43U`Z(#!P>#L@4$%$ M1$E.1RU,1494.B`P<'@[(%!!1$1)3D#L@5TE$5$@Z(#(E M.R!415A4+4E.1$5.5#H@,'!X)SX@)F)U;&P[/"]T9#X@/'1D('-T>6QE/3-$ M)U9%4E1)0T%,+4%,24=..B!T;W`[(%!!1$1)3D"<^("9N8G-P M.SPO=&0^(#QT9"!S='EL93TS1"=615)424-!3"U!3$E'3CH@=&]P.R!0041$ M24Y'+4)/5%1/33H@,'!X.R!0041$24Y'+51/4#H@,'!X.R!0041$24Y'+4Q% M1E0Z(#!P>#L@4$%$1$E.1RU224=(5#H@,'!X.R!415A4+4E.1$5.5#H@,'!X M)SX@3&5V96P@,B`M(%9A;'5A=&EO;G,@8F%S960@;VX@<75O=&5D('!R:6-E M2!O6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M"<^("9N8G-P.SPO<#X@/'1A8FQE M('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P#L@4$%$1$E.1RU224=(5#H@,'!X.R!72414 M2#H@-24[(%1%6%0M24Y$14Y4.B`P<'@G/B`F;F)S<#L\+W1D/B`\=&0@#L@4$%$1$E.1RU43U`Z(#!P>#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1) M3D#L@5TE$5$@Z(#(E.R!415A4+4E.1$5.5#H@,'!X)SX@ M)F)U;&P[/"]T9#X@/'1D('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!T;W`[ M(%!!1$1)3D"<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=6 M15)424-!3"U!3$E'3CH@=&]P.R!0041$24Y'+4)/5%1/33H@,'!X.R!0041$ M24Y'+51/4#H@,'!X.R!0041$24Y'+4Q%1E0Z(#!P>#L@4$%$1$E.1RU224=( M5#H@,'!X.R!415A4+4E.1$5.5#H@,'!X)SX@3&5V96P@,R`M(%9A;'5A=&EO M;G,@8F%S960@;VX@:6YP=71S('1H870@87)E('5N;V)S97)V86)L92!A;F0@ M#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@5V4@ M:&%V92!#;&%S2`R,#$Q M(&]F9F5R:6YG('1H870@87)E(&UE87-U'!I2`R,#$R(&%N9"!T:&4@;&EA8FEL:71Y('=A M6QE/3-$)T)/4D1%4BU#3TQ,05!313H@ M8V]L;&%P6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E' M3CH@8V5N=&5R)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^5V%R6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE M/3-$)U=)1%1(.B`Q)2<^)FYB6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^)FYB6QE M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!724142#H@,34E)SXP+C`X/"]T9#X@ M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^)3PO M=&0^(#PO='(^(#QT6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXP+C`P/"]T9#X@ M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B4\+W1D/B`\=&0^)FYB M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P M.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^,"XP,#PO M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXE/"]T9#X@/'1D M/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF M;F)S<#L\+W1D/B`\=&0@6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/E9O;&%T:6QI='D@;V8@=&AE($-O;7!A M;GDF(S,Y.W,@8V]M;6]N('-T;V-K/"]T9#X@/'1D/B9N8G-P.SPO=&0^(#QT M9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0@ M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B4\+W1D/B`\ M+W1R/B`\='(@6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4 M+4%,24=..B!R:6=H="<^-"XV/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@6QE M/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXP+C8\+W1D/B`\=&0@6QE M/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z M(')G8B@R,#0L,C4U+#(P-"DG/B`\=&0^)FYB6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H M="<^)FYB6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G M/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@6QE/3-$)U1%6%0M M04Q)1TXZ(')I9VAT)SXF;F)S<#L\+W1D/B`\=&0@6QE/3-$)U9% M4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z('=H:71E M)SX@/'1D/D9A:7(@=F%L=64@<&5R('5N:70\+W1D/B`\=&0^)FYB6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B0\+W1D/B`\=&0@ M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S M<#L\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXP+C`Y,3PO M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D M/B`\+W1R/B`\+W1A8FQE/B`\<"!S='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E3L@1D].5#H@,3!P="!4:6UE2`R,#$Q(&%N9"!R96YE=V5D(&]N($YO=F5M8F5R(#$L(#(P M,3(N($]U6QE M/3-$)U!!1$1)3D#L@4$%$1$E.1RU43U`Z(#!P>#L@ M4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D#L@5TE$5$@Z M(#`N-6EN.R!415A4+4E.1$5.5#H@,'!X)SX@/&5M/BAM*3PO96T^/"]T9#X@ M/'1D('-T>6QE/3-$)U!!1$1)3D3L@1D].5#H@,3!P="!4:6UE M6QE/3-$)U1% M6%0M04Q)1TXZ(&IU#L@5$585"U)3D1%3E0Z M(#`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`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`N-6EN)SX@5V4@3PO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/"$M+41/0U194$4@:'1M M;"!054),24,@(BTO+U&AT;6PQ+T141"]X:'1M;#$M M=')A;G-I=&EO;F%L+F1T9"(@+2T^/&1I=CX@/&1I=CX\(2TM4W1A#L@4$%$1$E.1RU224=(5#H@ M,'!X.R!724142#H@,"XR-6EN.R!415A4+4E.1$5.5#H@,'!X)SX@)FYB6QE/3-$)U!!1$1)3D"<^(#QE;3XH M<"D\+V5M/CPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,'!X M.R!415A4+4%,24=..B!J=7-T:69Y.R!0041$24Y'+51/4#H@,'!X.R!0041$ M24Y'+4Q%1E0Z(#!P>#L@4$%$1$E.1RU224=(5#H@,'!X.R!415A4+4E.1$5. M5#H@,'!X)SX@/&5M/D9O6QE/3-$)U1%6%0M04Q)1TXZ(&IU#L@5$585"U)3D1%3E0Z(#`N,C5I;B<^("9N8G-P.SPO<#X@ M/'`@3L@1D].5#H@,3!P="!4 M:6UE&-H86YG92!P M65A&-H86YG92!R871E M7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&AT;6PQ+71R86YS:71I;VYA M;"YD=&0B("TM/CQD:78^(#QD:78^/"$M+5-T87)T1G)A9VUE;G0M+3X@/'`@ M3L@1D].5#H@,3!P="!4:6UE M6QE/3-$)U1%6%0M04Q)1TXZ(&IU#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@)FYB6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VTG M/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U714E'2%0Z(&)O;&0[(%!!1$1)3D6QE M/3-$)T9/3E0M4TE:13H@,3!P="<^)FYB6QE/3-$ M)T9/3E0M4TE:13H@,3!P="<^)FYB6QE/3-$)T9/ M3E0M4TE:13H@,3!P="<@8V]L6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)FYB6QE M/3-$)T9/3E0M4TE:13H@,3!P="<^)FYB6QE/3-$ M)T9/3E0M4TE:13H@,3!P="<@8V]L6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)FYB6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]5 M3D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"DG/B`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`\ M+W1R/B`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`\=&0@6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@5TE$5$@Z(#(E)SXF;F)S<#L\+W1D/B`\=&0@6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z M(#$E)SX@)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@5TE$5$@Z(#(E)SXF;F)S<#L\+W1D/B`\=&0@6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SX@)FYB M6QE/3-$)U9%4E1)0T%,+4%,24=..B!B M;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z('=H:71E)SX@/'1D('-T>6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^0G5I;&1I;F=S M(&%N9"!I;7!R;W9E;65N=',\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E' M3CH@;&5F="<^)FYB6QE/3-$)T9/3E0M4TE:13H@ M,3!P="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U! M3$E'3CH@;&5F="<^36%C:&EN97)Y(&%N9"!E<75I<&UE;G0\+W1D/B`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`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]2 M1$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!R M:6=H="<^(#(P+#,Y.3PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P M<'0[(%!!1$1)3DF%B;&4@26YT M86YG:6)L92!!&AT;6PQ+71R86YS:71I;VYA;"YD=&0B("TM/CQD:78^(#QD M:78^/"$M+5-T87)T1G)A9VUE;G0M+3X@/'`@3L@1D].5#H@,3!P="!4:6UEF%T:6]N(&%R92!A6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!&3TY4+5=%24=( M5#H@8F]L9#L@5$585"U!3$E'3CH@8V5N=&5R)R!C;VQS<&%N/3-$-B!N;W=R M87`],T1N;W=R87`^4V5P=&5M8F5R(#,P+"`R,#$R/"]T9#X@/'1D('-T>6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0[(%!!1$1) M3D65A6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O M;&0[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U714E' M2%0Z(&)O;&0[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SX@)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5TE$5$@Z(#(E)SXF M;F)S<#L\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$58 M5"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SX@)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@#L@4$%$1$E. M1RU,1494.B`P<'@[(%!!1$1)3D#L@5$585"U)3D1%3E0Z M(#!P>"<^($9$02!C;VUP;&EA;G0@9F%C:6QI='D\+W1D/B`\=&0@6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@ M9&]U8FQE.R!415A4+4%,24=..B!L969T)SX@)#PO=&0^(#QT9"!S='EL93TS M1"=&3TY4+5-)6D4Z(#$P<'0[($)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T M(&1O=6)L93L@5$585"U!3$E'3CH@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$ M1$E.1RU"3U143TTZ(#(N-7!T.R!415A4+4%,24=..B!L969T)SX@)FYB6QE/3-$)U9%4E1)0T%, M+4%,24=..B!B;W1T;VTG/B`\=&0@#L@4$%$1$E. M1RU224=(5#H@,'!X.R!415A4+4E.1$5.5#H@,'!X)R!N;W=R87`],T1N;W=R M87`^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M4$%$1$E.1RU"3U143TTZ(#%P="<@;F]W6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0[(%!! M1$1)3D6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@4$%$1$E.1RU43U`Z(#!P>#L@4$%$1$E.1RU,1494.B`P M<'@[(%!!1$1)3D#L@5$585"U)3D1%3E0Z(#!P>"<@;F]W M6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O M;&ED.R!&3TY4+5=%24=(5#H@8F]L9#L@5$585"U!3$E'3CH@8V5N=&5R)R!C M;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^5V5I9VAT960\8G(@+SX@879E M6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@ M8FQA8VL@,7!T('-O;&ED.R!&3TY4+5=%24=(5#H@8F]L9#L@5$585"U!3$E' M3CH@8V5N=&5R)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^1W)O6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0[(%!!1$1)3D6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z('=H:71E)SX@/'1D('-T>6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU43U`Z(#!P>#L@4$%$1$E. M1RU,1494.B`P<'@[(%!!1$1)3D#L@5TE$5$@Z(#4X)3L@ M5$585"U)3D1%3E0Z(#!P>"<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=& M3TY4+5-)6D4Z(#$P<'0[(%=)1%1(.B`R)2<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F=#L@5TE$ M5$@Z(#$E)SX@)FYB6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@5$585"U!3$E'3CH@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E' M3CH@;&5F=#L@5TE$5$@Z(#$E)SX@)FYB6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@5TE$5$@Z(#(E)SXF;F)S<#L\+W1D/B`\=&0@ M6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T.R!415A4+4%,24=..B!L M969T.R!0041$24Y'+51/4#H@,'!X.R!0041$24Y'+4Q%1E0Z(#!P>#L@4$%$ M1$E.1RU224=(5#H@,'!X.R!415A4+4E.1$5.5#H@,'!X)SX@1D1!(&-O;7!L M:6%N="!F86-I;&ET>3PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P M<'0[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@ M,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!L969T)SX@)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@ M8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<^(#$P/"]T M9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U14 M3TTZ(#(N-7!T.R!415A4+4%,24=..B!L969T)SX@)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#(N M-7!T)SXF;F)S<#L\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%, M24=..B!R:6=H="<^(#,P,CPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z M(#$P<'0[(%!!1$1)3D6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,BXU M<'0@9&]U8FQE.R!415A4+4%,24=..B!L969T)SX@)#PO=&0^(#QT9"!S='EL M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($)/4D1%4BU"3U143TTZ(&)L86-K(#(N M-7!T(&1O=6)L93L@5$585"U!3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&IU M#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@5&AE M(&%S6QE/3-$)T9/3E0Z(#$P<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@)FYB6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`\=&0@6QE/3-$)T)/4D1% M4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R M)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^4V5P=&5M8F5R(#,P+"`R M,#$R/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`\=&0@ M;F]W6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@ M5$585"U!3$E'3CH@8V5N=&5R)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R M87`^5V%R6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$ M)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`T M-B4G/E)I6QE/3-$ M)U=)1%1(.B`Q)2<^)FYB6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^)FYB6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT.R!724142#H@,34E)SXP+C0Q/"]T9#X@/'1D M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^)3PO=&0^ M(#QT9"!S='EL93TS1"=724142#H@,24G/B9N8G-P.SPO=&0^(#QT9"!S='EL M93TS1"=415A4+4%,24=..B!L969T.R!724142#H@,24G/B9N8G-P.SPO=&0^ M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@5TE$5$@Z(#$U)2<^ M,"XX-CPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!72414 M2#H@,24G/B4\+W1D/B`\=&0@6QE/3-$ M)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z('=H M:71E)SX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/D1I=FED96YD M('EI96QD/"]T9#X@/'1D/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4 M+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0@6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT)SXP+C`P/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0G/B4\+W1D/B`\=&0^)FYB6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS M1"=415A4+4%,24=..B!R:6=H="<^,"XP,#PO=&0^(#QT9"!S='EL93TS1"=4 M15A4+4%,24=..B!L969T)SXE/"]T9#X@/"]T6QE/3-$)U9% M4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z(')G8B@R M,#0L,C4U+#(P-"DG/B`\=&0@2!O9B!T:&4@0V]M<&%N>28C,SD[6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R M:6=H="<^,3$W+C,P/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0G/B4\+W1D/B`\=&0^)FYB6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%, M24=..B!R:6=H="<^,3$Q+C0T/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0G/B4\+W1D/B`\=&0^)FYB6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=4 M15A4+4%,24=..B!R:6=H="<^-S0N-#,\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT M9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^,RXV/"]T9#X@/'1D('-T M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S M<#L\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXT+C8\+W1D M/B`\=&0@6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4 M+4%,24=..B!R:6=H="<^)FYB6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@ M6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXF;F)S<#L\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT)SXP+C@T-#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=. M.B!L969T)SXF;F)S<#L\+W1D/B`\=&0^)FYB6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B0\+W1D/B`\=&0@6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#PO='(^(#PO=&%B;&4^(#PA+2U% M;F1&'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA&AT;6PQ+71R86YS:71I;VYA;"YD=&0B M("TM/CQD:78^(#QD:78^/"$M+5-T87)T1G)A9VUE;G0M+3X@/'`@3L@1D].5#H@,3!P="!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&IU#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@)FYB6QE/3-$)T9/ M3E0M4TE:13H@,3!P="<^)FYB6QE/3-$)T-/3$]2 M.B!B;&%C:SL@4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].5#H@,3!P="!4:6UE M6QE/3-$)T)/ M4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@0T],3U(Z(&)L86-K.R!4 M15A4+4%,24=..B!C96YT97([($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE6QE/3-$)T-/3$]2.B!B;&%C:SL@4$%$1$E.1RU"3U143TTZ(#%P=#L@1D]. M5#H@,3!P="!4:6UE6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)FYB6QE/3-$)T-/3$]2.B!B;&%C:SL@4$%$1$E.1RU"3U143TTZ M(#%P=#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K M(#%P="!S;VQI9#L@0T],3U(Z(&)L86-K.R!415A4+4%,24=..B!C96YT97([ M($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)T-/3$]2.B!B;&%C:SL@4$%$1$E.1RU"3U143TTZ(#%P=#L@1D]. M5#H@,3!P="!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@ M0T],3U(Z(&)L86-K.R!415A4+4%,24=..B!C96YT97([($9/3E0Z(#$P<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)T-/3$]2.B!B;&%C:SL@4$%$ M1$E.1RU"3U143TTZ(#%P=#L@1D].5#H@,3!P="!4:6UE6QE M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@0T],3U(Z(&)L M86-K.R!415A4+4%,24=..B!C96YT97([($9/3E0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE6QE/3-$)T-/3$]2.B!B;&%C:SL@4$%$1$E.1RU"3U143TTZ M(#%P=#L@1D].5#H@,3!P="!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0Z(#$P M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)T9/3E0Z(#$P<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!& M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)T9/3E0Z M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT.R!&3TY4.B`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`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`Q,'!T M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]5 M3D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"DG/B`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`Q M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T M;VT[($)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"DG/B`\=&0@ M6QE/3-$)T)/4D1% M4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@ M1D].5#H@,3!P="!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P M="!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5#H@,3!P="!4:6UE6QE/3-$ M)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L M86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$58 M5"U!3$E'3CH@6QE/3-$)U!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@4$%$1$E.1RU"3U143TTZ(#%P=#L@5$585"U!3$E'3CH@;&5F="<^("9N M8G-P.SPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!& M3TY4.B`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`\=&0@6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@ M5&EM97,L(%-E6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M6QE/3-$)T9/3E0Z(#$P<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UE6QE M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4.B`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`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0Z(#$P<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE6QE/3-$)U9% M4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z('=H:71E M)SX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0Z(#$P<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE2`M(&1E8W)E87-E/"]T9#X@ M/'1D('-T>6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0Z(#$P<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0Z(#$P<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE M/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4 M.B`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`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`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`\=&0@6QE/3-$ M)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4.B`Q M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0Z(#$P<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!& M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4.B`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`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`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT.R!&3TY4.B`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`\=&0^)FYB6QE M/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE M/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"DG/B`\=&0@6QE/3-$)U!!1$1)3D6QE/3-$)T)/ M4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@ M6QE/3-$ M)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E' M3CH@;&5F=#L@5TE$5$@Z(#$E)SX@)#PO=&0^(#QT9"!S='EL93TS1"="3U)$ M15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I M9VAT.R!724142#H@."4G/B`M/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@6QE/3-$)T)/4D1%4BU" M3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@ M5TE$5$@Z(#$E)SX@)#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]- M.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!72414 M2#H@."4G/B`S,BPS-#8\+W1D/B`\=&0@6QE/3-$)U!!1$1)3D6QE/3-$)U9%4E1)0T%,+4%,24=..B!B M;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z('=H:71E)SX@/'1D/B9N8G-P.SPO M=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT)SXF;F)S<#L\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S M='EL93TS1"=415A4+4%,24=..B!R:6=H="<^)FYB6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S M<#L\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXF;F)S<#L\ M+W1D/B`\=&0@6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4 M+4%,24=..B!R:6=H="<^)FYB6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#PO='(^(#QT6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G M/E1O=&%L(&]T:&5R(&-U6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P M.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^,3$L,S@W M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO M=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT)SXM/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N M8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT)SXQ,2PS.#<\+W1D/B`\=&0@6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D M/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXF;F)S<#L\+W1D/B`\ M=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P M.SPO=&0^(#PO='(^(#QT6QE/3-$)U!! M1$1)3D6QE/3-$)U!!1$1)3D6QE M/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$58 M5"U!3$E'3CH@6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI M9#L@5$585"U!3$E'3CH@;&5F="<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS M1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@6QE M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E' M3CH@;&5F="<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]4 M5$]-.B!B;&%C:R`Q<'0@6QE/3-$)U!!1$1) M3D6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1) M3D6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%, M24=..B!R:6=H="<^,2PR,3,\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^ M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^.2PX-#<\+W1D/B`\ M=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P M.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ M(')I9VAT)SXQ,2PQ,S,\+W1D/B`\=&0@6QE/3-$)U9%4E1)0T%, M+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z('=H:71E)SX@/'1D M/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@6QE/3-$)U1%6%0M M04Q)1TXZ(')I9VAT)SXF;F)S<#L\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^)FYB6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^ M(#QT9#XF;F)S<#L\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M)SXF;F)S<#L\+W1D/B`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`Q<'0@6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L M86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<^("9N8G-P.SPO=&0^ M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T M;VT[($)!0TM'4D]53D0M0T],3U(Z('=H:71E)SX@/'1D/B9N8G-P.SPO=&0^ M(#QT9#XF;F)S<#L\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M)SXF;F)S<#L\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL M93TS1"=415A4+4%,24=..B!R:6=H="<^)FYB6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\ M+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXF;F)S<#L\+W1D M/B`\=&0@6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%, M24=..B!R:6=H="<^)FYB6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#PO='(^(#QT6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!! M1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXQ-RPS M.#4\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT)SXQ."PU.3@\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P M.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^,2PR.#8\ M+W1D/B`\=&0@6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS M1"=415A4+4%,24=..B!R:6=H="<^)FYB6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D M/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXF;F)S<#L\+W1D/B`\ M=&0@6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=. M.B!R:6=H="<^)FYB6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT)SXF;F)S<#L\+W1D/B`\=&0@6QE M/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z M(')G8B@R,#0L,C4U+#(P-"DG/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXF;F)S<#L\ M+W1D/B`\=&0@6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4 M+4%,24=..B!R:6=H="<^)FYB6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@ M6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXF;F)S<#L\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H M="<^)FYB6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G M/B9N8G-P.SPO=&0^(#PO='(^(#QT6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M)SXQ+#,S-3PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF M;F)S<#L\+W1D/B`\=&0^)FYB6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%, M24=..B!R:6=H="<^+3PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L M969T)SXF;F)S<#L\+W1D/B`\=&0^)FYB6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=4 M15A4+4%,24=..B!R:6=H="<^,2PS,S4\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S M<#L\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXM/"]T9#X@ M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT M9#XF;F)S<#L\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXR M+#$S-3PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF;F)S M<#L\+W1D/B`\+W1R/B`\='(@6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT)SXQ+#@W,3PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T M)SXF;F)S<#L\+W1D/B`\=&0^)FYB6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4 M+4%,24=..B!R:6=H="<^+3PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=. M.B!L969T)SXF;F)S<#L\+W1D/B`\=&0^)FYB6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS M1"=415A4+4%,24=..B!R:6=H="<^,2PX-S$\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9#XF M;F)S<#L\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXM/"]T M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^ M(#QT9#XF;F)S<#L\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M)SXQ+#8Y.#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF M;F)S<#L\+W1D/B`\+W1R/B`\='(@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P M.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^*#@Q-CPO M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXI/"]T9#X@/'1D M/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF M;F)S<#L\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=. M.B!R:6=H="<^,3DL-#`X/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT)SXH.#$V/"]T9#X@/'1D('-T>6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0G/BD\+W1D/B`\=&0^)FYB6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL M93TS1"=415A4+4%,24=..B!R:6=H="<^,3@L-3DR/"]T9#X@/'1D('-T>6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#PO='(^(#QT6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[(%!!1$1)3D6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT)SXH,SDW/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0G/BD\+W1D/B`\=&0^)FYB6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS M1"=415A4+4%,24=..B!R:6=H="<^*#$T+#0Y,SPO=&0^(#QT9"!S='EL93TS M1"=415A4+4%,24=..B!L969T)SXI/"]T9#X@/'1D/B9N8G-P.SPO=&0^(#QT M9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0@ M6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXH."PQ-S8\ M+W1D/B`\=&0@6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU" M3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K M(#%P="!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L M86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<^("9N8G-P.SPO=&0^ M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$58 M5"U!3$E'3CH@;&5F="<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$ M15(M0D]45$]-.B!B;&%C:R`Q<'0@6QE M/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z M(')G8B@R,#0L,C4U+#(P-"DG/B`\=&0@6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$58 M5"U!3$E'3CH@;&5F="<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$ M15(M0D]45$]-.B!B;&%C:R`Q<'0@6QE/3-$ M)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@ M5$585"U!3$E'3CH@6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P M.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^)FYB6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO M=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT)SXF;F)S<#L\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S M='EL93TS1"=415A4+4%,24=..B!R:6=H="<^)FYB6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S M<#L\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXF;F)S<#L\ M+W1D/B`\=&0@6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[ M($)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"DG/B`\=&0@6QE/3-$)U!!1$1)3D6QE/3-$)U!! M1$1)3D6QE/3-$ M)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E' M3CH@;&5F="<^("0\+W1D/B`\=&0@6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU" M3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@;&5F="<^ M("0\+W1D/B`\=&0@6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T M(&1O=6)L93L@5$585"U!3$E'3CH@6QE M/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L M86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@;&5F="<^("0\+W1D/B`\ M=&0@'1087)T7S@V93)D9&)D7V8S9#1?-#@R,U]B-#`S7V$P8C$X8V5F9#4P8@T* M0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\X-F4R9&1B9%]F,V0T7S0X M,C-?8C0P,U]A,&(Q.&-E9F0U,&(O5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/"$M+41/0U19 M4$4@:'1M;"!054),24,@(BTO+U&AT;6PQ+T141"]X M:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@+2T^/&1I=CX@/&1I=CX\(2TM4W1A M#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@)FYB6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VTG M/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U714E'2%0Z(&)O;&0[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/ M33H@8FQA8VL@,7!T('-O;&ED.R!&3TY4+5=%24=(5#H@8F]L9#L@5$585"U! M3$E'3CH@8V5N=&5R)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`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`\=&0@ M6QE/3-$)T9/3E0M4TE:13H@ M,3!P="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^ M)3PO=&0^(#PO='(^(#QT6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E' M3CH@;&5F="<^)FYB6QE/3-$)U9%4E1) M0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L M,C4U+#(P-"DG/B`\=&0@6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@ M;&5F="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@5$585"U!3$E'3CH@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)T9/ M3E0M4TE:13H@,3!P="<^)FYB6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)#PO=&0^(#QT9"!S='EL M93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)SXP+C'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/"$M+41/0U194$4@ M:'1M;"!054),24,@(BTO+U&AT;6PQ+T141"]X:'1M M;#$M=')A;G-I=&EO;F%L+F1T9"(@+2T^/&1I=CX@/&1I=CX\(2TM4W1A6QE/3-$)U9%4E1)0T%,+4%,24=..B!B M;W1T;VTG/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@4$%$1$E.1RU"3U143TTZ(#%P="<@;F]W6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%, M24=..B!C96YT97(G(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<#XR,#$Q M/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU" M3U143TTZ(#%P="<@;F]W6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@5$585"U!3$E'3CH@8V5N=&5R)R!C;VQS<&%N/3-$,B!N;W=R87`] M,T1N;W=R87`^*#QF;VYT('-T>6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE6QE/3-$)T9/3E0M4TE:13H@ M,3!P="<@;F]W6QE/3-$)T9/3E0M4TE:13H@ M,3!P="<@;F]W6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U35%E,13H@:71A;&EC.R!415A4+4%,24=..B!J=7-T M:69Y)SX@0F%S:6,@;F5T(&QO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^)FYB6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^ M(#PO='(^(#QT6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5TE$5$@Z(#(E)SXF;F)S<#L\ M+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F=#L@5TE$ M5$@Z(#$E)SXD/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M5$585"U!3$E'3CH@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU,1494.B`P+C$R-6EN)SX@3&5S M6QE/3-$)T9/3E0M4TE:13H@,3!P="<^ M)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$58 M5"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^*3PO=&0^ M(#PO='(^(#QT6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#%P=#L@ M5$585"U!3$E'3CH@;&5F="<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=& M3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E. M1RU"3U143TTZ(#%P=#L@5$585"U!3$E'3CH@;&5F="<^("D\+W1D/B`\+W1R M/B`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`N,3(U:6XG/B!"87-I8R!N970@;&]S6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$ M1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@ M9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<^("@P+C6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T M.R!415A4+4%,24=..B!L969T)SX@*3PO=&0^(#PO='(^(#QT6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)! M0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"DG/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S M='EL93TS1"=415A4+4%,24=..B!R:6=H="<^)FYB6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#PO='(^(#QT M6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^*3PO=&0^(#QT9"!S='EL93TS M1"=&3TY4+5-)6D4Z(#$P<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=& M3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(&QE9G0G/B0\+W1D/B`\=&0@ M6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$58 M5"U!3$E'3CH@;&5F="<^*3PO=&0^(#PO='(^(#QT6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$ M1$E.1RU"3U143TTZ(#%P=#L@4$%$1$E.1RU,1494.B`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`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`],T1N M;W=R87`^,C`Q,3PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[ M($9/3E0M5T5)1TA4.B!B;VQD.R!0041$24Y'+4)/5%1/33H@,7!T)R!N;W=R M87`],T1N;W=R87`^)FYB6QE/3-$)U9% M4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z(')G8B@R M,#0L,C4U+#(P-"DG/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5TE$5$@Z(#(E)SXF M;F)S<#L\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SX@)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5TE$5$@Z(#(E)SXF;F)S<#L\ M+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U! M3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SX@)FYB6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M M0T],3U(Z('=H:71E)SX@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M5$585"U!3$E'3CH@;&5F="<^5V]R:R!I;B!P6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M5$585"U!3$E'3CH@;&5F="<^)FYB6QE M/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z M(')G8B@R,#0L,C4U+#(P-"DG/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#%P M=#L@5$585"U!3$E'3CH@;&5F="<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS M1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[ M($)!0TM'4D]53D0M0T],3U(Z('=H:71E)SX@/'1D('-T>6QE/3-$)T9/3E0M M4TE:13H@,3!P="<^)FYB6QE/3-$)T9/3E0M4TE: M13H@,3!P="<^)FYB6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)#PO=&0^(#QT9"!S='EL93TS1"=& M3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)SXQ+#DV-CPO=&0^ M(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(&QE M9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G M/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1% M6%0M04Q)1TXZ(&QE9G0G/B0\+W1D/B`\=&0@6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#%P=#L@5$585"U!3$E'3CH@ M;&5F="<^("D\+W1D/B`\=&0@6QE/3-$)U9% M4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z('=H:71E M)SX@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U14 M3TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%\X-F4R9&1B9%]F,V0T7S0X,C-?8C0P,U]A,&(Q M.&-E9F0U,&(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.#9E,F1D M8F1?9C-D-%\T.#(S7V(T,#-?83!B,3AC969D-3!B+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$&AT;6PQ+71R86YS:71I;VYA;"YD M=&0B("TM/CQD:78^(#QD:78^/"$M+5-T87)T1G)A9VUE;G0M+3X@/'`@3L@1D].5#H@,3!P="!4:6UE65A6QE/3-$ M)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#%P=#L@5$585"U! M3$E'3CH@8V5N=&5R.R!0041$24Y'+51/4#H@,'!X.R!0041$24Y'+4Q%1E0Z M(#!P>#L@4$%$1$E.1RU224=(5#H@,'!X.R!415A4+4E.1$5.5#H@,'!X)R!N M;W=R87`],T1N;W=R87`^)FYB6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#%P=#L@5$585"U!3$E'3CH@ M8V5N=&5R)R!N;W=R87`],T1N;W=R87`^)FYB6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,7!T M('-O;&ED.R!415A4+4%,24=..B!C96YT97(G(&-O;'-P86X],T0R(&YO=W)A M<#TS1&YO=W)A<#Y06QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#%P=#L@5$585"U! M3$E'3CH@8V5N=&5R)R!N;W=R87`],T1N;W=R87`^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#%P M=#L@5$585"U!3$E'3CH@8V5N=&5R)R!N;W=R87`],T1N;W=R87`^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/ M5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!C96YT97(G(&-O M;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<#Y4;W1A;#PO=&0^(#QT9"!S='EL M93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F M=#L@4$%$1$E.1RU43U`Z(#!P>#L@4$%$1$E.1RU,1494.B`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`Z(#!P>#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1) M3D#L@5TE$5$@Z(#4X)3L@5$585"U)3D1%3E0Z(#!P>"<^ M(#(P,3,\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F M=#L@5TE$5$@Z(#$E)SXD/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@5$585"U!3$E'3CH@6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@ M;&5F="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@5$585"U!3$E'3CH@6QE/3-$)T9/3E0M4TE: M13H@,3!P="<^)FYB6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@#L@4$%$1$E.1RU224=(5#H@,'!X M.R!415A4+4E.1$5.5#H@,'!X)SX@,C`Q-CPO=&0^(#QT9"!S='EL93TS1"=& M3TY4+5-)6D4Z(#$P<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4 M+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT M9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(')I9VAT M)SXR,#@\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F M="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M5$585"U!3$E'3CH@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$58 M5"U!3$E'3CH@;&5F="<^)FYB6QE/3-$ M)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z('=H M:71E)SX@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU" M3U143TTZ(#%P=#L@5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU43U`Z(#!P M>#L@4$%$1$E.1RU,1494.B`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`\=&0@6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!4 M15A4+4%,24=..B!R:6=H="<^(#$L,#8Y/"]T9#X@/'1D('-T>6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T.R!415A4+4%, M24=..B!L969T)SX@)FYB6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\ M=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@ M8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<^(#$R-3PO M=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%, M24=..B!L969T)SX@)#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P M<'0[($)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U! M3$E'3CH@6UE;G1S(&9O6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE#L@5$585"U)3D1%3E0Z(#`N M-6EN)SX@1G5T=7)E(&UI;FEM=6T@;&5A6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)FYB M6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U! M3$E'3CH@;&5F="<^)FYB6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@5$585"U!3$E'3CH@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^ M,C`Q-3PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B9N8G-P M.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q) M1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z M(#$P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)SXR,C,\+W1D/B`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`@6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P M6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U! M3$E'3CH@8V5N=&5R.R!0041$24Y'+51/4#H@,'!X.R!0041$24Y'+4Q%1E0Z M(#!P>#L@4$%$1$E.1RU224=(5#H@,'!X.R!415A4+4E.1$5.5#H@,'!X)SX@ M)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U714E'2%0Z(&)O;&0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0[ M(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$ M)U9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`\=&0@#L@4$%$1$E.1RU224=(5#H@,'!X.R!415A4+4E.1$5.5#H@,'!X)SX@)FYB M6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U7 M14E'2%0Z(&)O;&0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-) M6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)R!C;VQS<&%N/3-$,CX@)FYB M6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U7 M14E'2%0Z(&)O;&0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-) M6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)SXF;F)S<#L\+W1D/B`\=&0@ M6%B;&4@=&\@82!B86YK+"!P87EA8FQE(&EN(&UO;G1H;'D@<')I;F-I M<&%L(&%N9"!I;G1E2!U M;F1E6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5TE$5$@Z M(#(E)SXF;F)S<#L\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SX@)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5TE$5$@Z(#(E)SXF M;F)S<#L\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SX@)FYB6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM' M4D]53D0M0T],3U(Z('=H:71E)SX@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@4$%$1$E.1RU43U`Z(#!P>#L@4$%$1$E.1RU,1494.B`P<'@[(%!! M1$1)3D#L@5$585"U)3D1%3E0Z(#!P>"<^("9N8G-P.SPO M=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4 M.B!B;VQD)SXF;F)S<#L\+W1D/B`\=&0@6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/B9N8G-P M.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5) M1TA4.B!B;VQD.R!415A4+4%,24=..B!L969T)SX@)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0[ M(%1%6%0M04Q)1TXZ(')I9VAT)SX@)FYB6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0[(%1%6%0M04Q) M1TXZ(&QE9G0G/B`F;F)S<#L\+W1D/B`\+W1R/B`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`Z(#!P>#L@ M4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D#L@5$585"U) M3D1%3E0Z(#!P>"<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-) M6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)SXF;F)S<#L\+W1D/B`\=&0@ M6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U714E'2%0Z(&)O;&0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4 M+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD.R!415A4+4%,24=..B!L M969T)SX@)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U714E'2%0Z(&)O;&0[(%1%6%0M04Q)1TXZ(')I9VAT)SX@)FYB M6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U7 M14E'2%0Z(&)O;&0[(%1%6%0M04Q)1TXZ(&QE9G0G/B`F;F)S<#L\+W1D/B`\ M+W1R/B`\='(@#L@4$%$1$E.1RU224=(5#H@,'!X.R!4 M15A4+4E.1$5.5#H@,'!X)SX@)FYB6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/B9N8G-P.SPO=&0^ M(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B M;VQD.R!415A4+4%,24=..B!L969T)SX@)FYB6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0[(%1%6%0M M04Q)1TXZ(')I9VAT)SX@)FYB6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0[(%1%6%0M04Q)1TXZ(&QE M9G0G/B`F;F)S<#L\+W1D/B`\=&0@6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0[(%1%6%0M04Q) M1TXZ(&QE9G0G/B`F;F)S<#L\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#%P=#L@ M5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU43U`Z(#!P>#L@4$%$1$E.1RU, M1494.B`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`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`N-6EN)SX@4VEG;FEF:6-A;G0@8V]M M<&]N96YT6QE/3-$ M)T9/3E0M5T5)1TA4.B!B;VQD.R!#3TQ/4CH@8FQA8VL[(%!!1$1)3D6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!#3TQ/4CH@8FQA8VL[(%!!1$1) M3D6QE/3-$)T-/3$]2.B!B;&%C:SL@5$585"U!3$E'3CH@ M8V5N=&5R)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^*%)E6QE/3-$)T-/3$]2 M.B!B;&%C:SL@5$585"U!3$E'3CH@8V5N=&5R)R!C;VQS<&%N/3-$,B!N;W=R M87`],T1N;W=R87`^*%)E"!A6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT)SXF;F)S<#L\+W1D/B`\=&0@6QE/3-$)T-/3$]2.B!B;&%C:SL@5$585"U!3$E' M3CH@;&5F=#L@5TE$5$@Z(#$E)SXD/"]T9#X@/'1D('-T>6QE/3-$)T-/3$]2 M.B!B;&%C:SL@5$585"U!3$E'3CH@6QE/3-$ M)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z(')G M8B@R,#0L,C4U+#(P-"DG/B`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`\=&0@ M6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXF;F)S<#L\+W1D/B`\=&0@6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"DG/B`\=&0@6QE M/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXF;F)S<#L\+W1D/B`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`\=&0@6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!#3TQ/ M4CH@8FQA8VL[(%1%6%0M04Q)1TXZ(&QE9G0G/E1O=&%L(&YE="!C=7)R96YT M(&1E9F5R"!A6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!#3TQ/4CH@8FQA8VL[(%1%6%0M M04Q)1TXZ(&QE9G0G/B`F;F)S<#L\+W1D/B`\=&0@6QE/3-$)U9%4E1)0T%,+4%, M24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z('=H:71E)SX@/'1D/B9N M8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT)SXF;F)S<#L\+W1D/B`\=&0@"!A6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT)SXF;F)S<#L\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@ M;&5F=#L@4$%$1$E.1RU,1494.B`S-G!X)SX@4W1O8VL@8V]M<&5N6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU,1494.B`S-G!X)SX@1F]R M96EG;B!T87@@8W)E9&ET(&-A6QE/3-$)T-/ M3$]2.B!B;&%C:SL@5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM' M4D]53D0M0T],3U(Z('=H:71E)SX@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU,1494.B`S-G!X)SX@ M04U4(&-R961I="!C87)R>6]V97(\+W1D/B`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`\=&0@ M6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXF;F)S<#L\+W1D/B`\=&0@"!L:6%B:6QI=&EE6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H M="<^)FYB6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G M/B9N8G-P.SPO=&0^(#PO='(^(#QT"<^(%5N"<^($)A&5D(&%S6QE/3-$)T-/3$]2.B!B;&%C:SL@5$585"U!3$E'3CH@;&5F="<^ M*3PO=&0^(#QT9"!S='EL93TS1"=#3TQ/4CH@8FQA8VLG/B9N8G-P.SPO=&0^ M(#QT9"!S='EL93TS1"=#3TQ/4CH@8FQA8VL[(%1%6%0M04Q)1TXZ(&QE9G0G M/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=#3TQ/4CH@8FQA8VL[(%1%6%0M M04Q)1TXZ(')I9VAT)SXH-38R/"]T9#X@/'1D('-T>6QE/3-$)T-/3$]2.B!B M;&%C:SL@5$585"U!3$E'3CH@;&5F="<^*3PO=&0^(#PO='(^(#QT"<^($)A6QE/3-$)T-/3$]2 M.B!B;&%C:SL@4$%$1$E.1RU"3U143TTZ(#%P="<^)FYB6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@0T], M3U(Z(&)L86-K.R!415A4+4%,24=..B!L969T)SX@)FYB6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@0T], M3U(Z(&)L86-K.R!415A4+4%,24=..B!R:6=H="<^("T\+W1D/B`\=&0@6QE/3-$)T-/3$]2 M.B!B;&%C:SL@4$%$1$E.1RU"3U143TTZ(#%P="<^)FYB6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@0T], M3U(Z(&)L86-K.R!415A4+4%,24=..B!L969T)SX@)FYB6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@0T], M3U(Z(&)L86-K.R!415A4+4%,24=..B!R:6=H="<^("@R,3PO=&0^(#QT9"!S M='EL93TS1"=#3TQ/4CH@8FQA8VL[(%!!1$1)3D6QE/3-$)U9% M4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z(')G8B@R M,#0L,C4U+#(P-"DG/B`\=&0^)FYB6QE/3-$)T-/ M3$]2.B!B;&%C:R<^)FYB6QE/3-$)T-/3$]2.B!B M;&%C:SL@5$585"U!3$E'3CH@;&5F="<^)FYB6QE M/3-$)T-/3$]2.B!B;&%C:SL@5$585"U!3$E'3CH@6QE/3-$)T-/3$]2.B!B;&%C:R<^)FYB6QE/3-$)T-/3$]2.B!B;&%C:SL@5$585"U!3$E'3CH@;&5F M="<^)FYB6QE/3-$)T-/3$]2.B!B;&%C:SL@5$58 M5"U!3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N M8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^)FYB M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P M.SPO=&0^(#PO='(^(#QT6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!#3TQ/4CH@8FQA8VL[(%1% M6%0M04Q)1TXZ(&QE9G0G/E1O=&%L(&YE="!N;VYC=7)R96YT(&1E9F5R"!A6QE/3-$)T9/ M3E0M5T5)1TA4.B!B;VQD.R!#3TQ/4CH@8FQA8VL[(%1%6%0M04Q)1TXZ(&QE M9G0G/B`F;F)S<#L\+W1D/B`\=&0@6QE M/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!#3TQ/4CH@8FQA8VLG/B9N8G-P.SPO M=&0^(#QT9"!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9#L@0T],3U(Z(&)L M86-K.R!415A4+4%,24=..B!L969T)SX@)FYB6QE M/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!#3TQ/4CH@8FQA8VL[(%1%6%0M04Q) M1TXZ(')I9VAT)SX@,2PX,S8\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R M:6=H="<^)FYB6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT)SXF;F)S<#L\+W1D/B`\=&0@6QE/3-$ M)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z(')G M8B@R,#0L,C4U+#(P-"DG/B`\=&0@"!A6QE/3-$)T-/3$]2.B!B;&%C:SL@ M4$%$1$E.1RU"3U143TTZ(#%P=#L@5$585"U!3$E'3CH@;&5F="<^("D\+W1D M/B`\=&0@6QE/3-$)T-/3$]2.B!B;&%C:SL@ M4$%$1$E.1RU"3U143TTZ(#%P=#L@5$585"U!3$E'3CH@;&5F="<^("D\+W1D M/B`\+W1R/B`\='(@"9N8G-P M.R9N8G-P.V%S6QE/3-$)T-/ M3$]2.B!B;&%C:SL@4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D M/B`\=&0@6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L M93L@0T],3U(Z(&)L86-K.R!415A4+4%,24=..B!R:6=H="<^("T\+W1D/B`\ M=&0@&AT;6PQ+71R86YS:71I;VYA;"YD=&0B("TM/CQD:78^(#QD:78^/"$M+5-T M87)T1G)A9VUE;G0M+3X@/'`@6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`\ M=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U714E'2%0Z(&)O;&0[(%!!1$1)3D6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU,1494.B`P<'@G M/B!#=7)R96YT.CPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G M/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1% M6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4 M+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)SXF;F)S<#L\+W1D/B`\ M=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^ M)FYB6QE/3-$)U9%4E1)0T%,+4%,24=. M.B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z('=H:71E)SX@/'1D('-T>6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F=#L@4$%$1$E. M1RU,1494.B`S-G!X.R!724142#H@-S(E)SX@1F5D97)A;#PO=&0^(#QT9"!S M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%=)1%1(.B`R)2<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@ M;&5F=#L@5TE$5$@Z(#$E)SXD/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@5$585"U!3$E'3CH@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@ M;&5F=#L@5TE$5$@Z(#$E)SXI/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@5TE$5$@Z(#(E)SXF;F)S<#L\+W1D/B`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`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`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`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]2 M1$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!R M:6=H="<^(#(\+W1D/B`\=&0@"!2871E/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\(2TM1$]#5%E012!H=&UL(%!50DQ)0R`B+2\O5S-# M+R]$5$0@6$A434P@,2XP(%1R86YS:71I;VYA;"\O14XB(")H='1P.B\O=W=W M+G6QE M/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@5&AE(&5F M9F5C=&EV92!I;F-O;64@=&%X(')A=&4@;VX@8V]N=&EN=6EN9R!O<&5R871I M;VYS('9A6QE/3-$)T9/3E0Z(#$P M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@)FYB6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`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`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E' M3CH@;&5F=#L@5TE$5$@Z(#$E)SX@)FYB6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SXE/"]T9#X@/"]T6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M M0T],3U(Z('=H:71E)SX@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU43U`Z(#!P>#L@4$%$1$E.1RU, M1494.B`P<'@[(%!!1$1)3D#L@5$585"U)3D1%3E0Z(#!P M>"<^($EN8W)E87-E6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)T9/ M3E0M4TE:13H@,3!P="<^)FYB6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU43U`Z(#!P>#L@4$%$1$E. M1RU,1494.B`P+C$R-6EN.R!0041$24Y'+5))1TA4.B`P<'@[(%1%6%0M24Y$ M14Y4.B`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`\=&0@#L@5$585"U)3D1%3E0Z(#!P>"<^ M($YO;F1E9'5C=&EB;&4@97AP96YS97,\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F M="<^)FYB6QE/3-$)U9%4E1)0T%,+4%, M24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P M-"DG/B`\=&0@#L@5$585"U)3D1%3E0Z(#!P>"<^(%9A M;'5A=&EO;B!A;&QO=V%N8V4@8VAA;F=E6QE/3-$)U9%4E1)0T%,+4%, M24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z('=H:71E)SX@/'1D('-T M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#%P=#L@ M4$%$1$E.1RU43U`Z(#!P>#L@4$%$1$E.1RU,1494.B`P+C$R-6EN.R!0041$ M24Y'+5))1TA4.B`P<'@[(%1%6%0M24Y$14Y4.B`P<'@G/B!/=&AE6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M4$%$1$E.1RU"3U143TTZ(#%P="<^)FYB6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O M;&ED.R!415A4+4%,24=..B!L969T)SX@)FYB6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,7!T M('-O;&ED.R!415A4+4%,24=..B!R:6=H="<^(#`N,CPO=&0^(#QT9"!S='EL M93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^ M)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$58 M5"U!3$E'3CH@#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1) M3D#L@5$585"U)3D1%3E0Z(#!P>"<^($5F9F5C=&EV92!I M;F-O;64@=&%X(')A=&4\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU" M3U143TTZ(#(N-7!T.R!415A4+4%,24=..B!L969T)SX@*24\+W1D/B`\=&0@ MF5D(%1A>"!"96YE9FET'0^/"$M+41/0U194$4@:'1M;"!054),24,@(BTO+U&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@+2T^/&1I=CX@ M/&1I=CX\(2TM4W1A6QE/3-$)T9/3E0M4TE:13H@,3!P="<@;F]W6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!&3TY4+5=% M24=(5#H@8F]L9#L@5$585"U!3$E'3CH@8V5N=&5R)R!C;VQS<&%N/3-$,B!N M;W=R87`],T1N;W=R87`^,C`Q,CPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-) M6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD.R!0041$24Y'+4)/5%1/33H@ M,7!T)R!N;W=R87`],T1N;W=R87`^)FYB6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O M;&0[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5TE$5$@Z(#(E M)SXF;F)S<#L\+W1D/B`\=&0@65A6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$58 M5"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)T9/3E0M M4TE:13H@,3!P="<^)FYB6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB M6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E' M3CH@;&5F="<^)FYB6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@5$585"U!3$E'3CH@6QE/3-$ M)T9/3E0M4TE:13H@,3!P="<^)FYB6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E' M3CH@;&5F="<^*3PO=&0^(#PO='(^(#QT6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU" M3U143TTZ(#%P="<^4V5T=&QE;65N=',\+W1D/B`\=&0@65A6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4 M+4%,24=..B!L969T)SX@)#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z M(#$P<'0[($)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$58 M5"U!3$E'3CH@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@ M,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!L969T)SX@)#PO=&0^(#QT9"!S M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($)/4D1%4BU"3U143TTZ(&)L86-K M(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA'0^/"$M+41/0U194$4@:'1M;"!054),24,@(BTO+U&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@+2T^ M/&1I=CX@/&1I=CX\(2TM4W1A65A M6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@5$585"U)3D1%3E0Z(#`N,C5I;B<^ M("9N8G-P.SPO<#X@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@ M8V]L;&%P6QE/3-$)T9/3E0M4TE:13H@,3!P="<^ M)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U714E'2%0Z(&)O;&0[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0[ M(%!!1$1)3D6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM' M4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"DG/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@8V5N=&5R.R!7 M24142#H@,3(E)R!N;W=R87`],T1N;W=R87`^,2XS.24\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P M="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M5$585"U!3$E'3CH@8V5N=&5R)R!N;W=R87`],T1N;W=R87`^(#`N,#`E/"]T M9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<@;F]W6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE'!E M8W1E9"!M87)K970@<')I8V4@;V8@=&AE($-O;7!A;GDF(S,Y.W,@8V]M;6]N M('-T;V-K/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE2!O9B!3 M=&]C:R!/<'1I;VX@06-T:79I='D\+W1D/@T*("`@("`@("`\=&0@8VQA&AT;6PQ+71R86YS:71I;VYA;"YD=&0B("TM/CQD M:78^(#QD:78^/"$M+5-T87)T1G)A9VUE;G0M+3X@/'`@2!F;W(@86QL(&]P=&EO;G,@86YD M(')E;&%T960@:6YF;W)M871I;VX@9F]R('1H92!Y96%R2P@:7,@87,@ M9F]L;&]W6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE#L@5$585"U)3D1%3E0Z M(#`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`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F M="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M5$585"U!3$E'3CH@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@ M6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$58 M5"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)T9/3E0M M4TE:13H@,3!P="<^)FYB6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T M;VT[($)!0TM'4D]53D0M0T],3U(Z('=H:71E)SX@/'1D('-T>6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#%P=#L@4$%$1$E.1RU, M1494.B`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`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`\ M=&0@6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T.R!415A4 M+4%,24=..B!R:6=H="<^(#$N.#,\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$ M)T9/3E0M4TE:13H@,3!P="<^)FYB6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$58 M5"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)T9/3E0M M4TE:13H@,3!P="<^)FYB6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@6QE/3-$)T9/3E0M4TE:13H@,3!P="<^ M)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)FYB M6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U! M3$E'3CH@;&5F="<^)FYB6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@5$585"U!3$E'3CH@6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@ M;&5F="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@5$585"U!3$E'3CH@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@ M6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)T9/ M3E0M4TE:13H@,3!P="<^)FYB6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)FYB6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E' M3CH@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@ M;&5F="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P M="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB M6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E' M3CH@;&5F="<^)#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[ M(%1%6%0M04Q)1TXZ(')I9VAT)SXQ+C,P/"]T9#X@/'1D('-T>6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^ M)#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q) M1TXZ(')I9VAT)SXQ+C`U/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE M/3-$)T9/3E0M4TE:13H@,3!P="<^)FYB6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@ M6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#%P="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU" M3U143TTZ(#%P=#L@5$585"U!3$E'3CH@;&5F="<^("0\+W1D/B`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`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`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M4$%$1$E.1RU"3U143TTZ(#(N-7!T.R!415A4+4%,24=..B!R:6=H="<^(#$N M-#8\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U! M3$E'3CH@;&5F="<^)FYB6QE/3-$)T9/3E0M4TE: M13H@,3!P="<^)FYB6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@ M;&5F="<^)FYB6QE/3-$)U9%4E1)0T%, M+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z('=H:71E)SX@/'1D M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#(N M-7!T)SY%>&5R8VES86)L92!A="!397!T96UB97(@,S`L(#(P,3(\+W1D/B`\ M=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#(N M-7!T.R!415A4+4%,24=..B!L969T)SX@)#PO=&0^(#QT9"!S='EL93TS1"=& M3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T.R!415A4+4%,24=..B!L M969T)SX@)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T.R!415A4+4%,24=. M.B!R:6=H="<^(#(N-3D\+W1D/B`\=&0@6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE"`P<'0@,"XU:6XG/B!!('-U M;6UA65A6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE"`P<'0@,"XU:6XG/B`F;F)S<#L\+W`^(#QT M86)L92!S='EL93TS1"="3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!&3TY4 M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#%P M="<@;F]W6QE/3-$)U9%4E1)0T%,+4%,24=..B!B M;W1T;VTG/B`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`P+C$R-6EN)SX@1F]R9F5I=&5D/"]T9#X@/'1D('-T>6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#%P="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/ M5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!L969T)SX@)FYB M6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52 M+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!R:6=H="<^ M("@Q.3<\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U14 M3TTZ(#%P=#L@5$585"U!3$E'3CH@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#%P=#L@ M5$585"U!3$E'3CH@;&5F="<^("9N8G-P.SPO=&0^(#PO='(^(#QT6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T)SY.;VXM=F5S=&5D(&]P=&EO M;G,@870@4V5P=&5M8F5R(#,P+"`R,#$R/"]T9#X@/'1D('-T>6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\ M+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M4$%$1$E.1RU"3U143TTZ(#(N-7!T.R!415A4+4%,24=..B!L969T)SX@)FYB M6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E. M1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T.R!415A4+4%,24=..B!R:6=H="<^ M(#$N,#8\+W1D/B`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`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O M;&0G(&-O;'-P86X],T0R/B`F;F)S<#L\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O M;&0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[ M($9/3E0M5T5)1TA4.B!B;VQD)R!C;VQS<&%N/3-$,CX@)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O M;&0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[ M($9/3E0M5T5)1TA4.B!B;VQD)SXF;F)S<#L\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z M(&)O;&0G(&-O;'-P86X],T0R/B`F;F)S<#L\+W1D/B`\=&0@6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[ M($)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"DG/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$58 M5"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SXD/"]T9#X@/'1D('-T>6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SX@)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5TE$5$@Z(#(E)SXF;F)S<#L\ M+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$ M)T9/3E0M4TE:13H@,3!P="<^)FYB6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)#PO=&0^(#QT9"!S M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)SXQ M+C,U/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U! M3$E'3CH@;&5F="<^)FYB6QE/3-$)U9% M4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z(')G8B@R M,#0L,C4U+#(P-"DG/B`\=&0@'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA6QE/3-$)U!!1$1)3D#L@4$%$1$E. M1RU43U`Z(#!P>#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D#L@5TE$5$@Z(#`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`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)FYB6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[ M($)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"DG/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T], M3U(Z('=H:71E)SX@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$ M1$E.1RU,1494.B`P+C8R-6EN.R!724142#H@-S(E)SX@4V5R=FEC93PO=&0^ M(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%=)1%1(.B`R)2<^)FYB M6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U! M3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SXD/"]T9#X@/'1D('-T>6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U! M3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SX@)FYB6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"DG/B`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`\=&0@6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F M="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M5$585"U!3$E'3CH@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB M6QE/3-$)U9%4E1)0T%,+4%,24=..B!B M;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"DG/B`\ M=&0@6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M5$585"U!3$E'3CH@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E. M1RU"3U143TTZ(#%P=#L@5$585"U!3$E'3CH@;&5F="<^("9N8G-P.SPO=&0^ M(#PO='(^(#QT6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F M="<^*3PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B9N8G-P M.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q) M1TXZ(&QE9G0G/B0\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M5$585"U!3$E'3CH@;&5F="<^)FYB6QE M/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z M('=H:71E)SX@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U! M3$E'3CH@;&5F="<^26YT97)E6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M5$585"U!3$E'3CH@;&5F="<^*3PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-) M6D4Z(#$P<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z M(#$P<'0[(%1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL M93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)SXH-S`V M/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E' M3CH@;&5F="<^*3PO=&0^(#PO='(^(#QT6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E' M3CH@;&5F="<^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"<^0VAA;F=E M(&EN(&9A:7(@=F%L=64@;V8@=V%R6QE/3-$)TU!4D=) M3CH@,'!T(#!P>"<^-S,\+W`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`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU" M3U143TTZ(#%P="<^)FYB6QE/3-$)U9% M4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z(')G8B@R M,#0L,C4U+#(P-"DG/B`\=&0@6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]5 M3D0M0T],3U(Z('=H:71E)SX@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@4$%$1$E.1RU,1494.B`P+C8R-6EN.R!724142#H@-S(E)SX@4V5R=FEC M93PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%=)1%1(.B`R M)2<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SXD/"]T9#X@/'1D('-T>6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SX@)FYB6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM' M4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"DG/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#%P M="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!L M969T)SX@)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=. M.B!R:6=H="<^(#8L-34Q/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@4$%$1$E.1RU"3U143TTZ(#%P=#L@5$585"U!3$E'3CH@;&5F="<^ M("9N8G-P.SPO=&0^(#PO='(^(#QT6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U14 M3TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU" M3U143TTZ(#(N-7!T.R!415A4+4%,24=..B!L969T)SX@)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ M(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4 M+4%,24=..B!R:6=H="<^(#,R+#,T-CPO=&0^(#QT9"!S='EL93TS1"=&3TY4 M+5-)6D4Z(#$P<'0[(%!!1$1)3D6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]5 M3D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"DG/B`\=&0@6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[ M($)!0TM'4D]53D0M0T],3U(Z('=H:71E)SX@/'1D('-T>6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@4$%$1$E.1RU,1494.B`P+C8R-6EN)SY397)V:6-E/"]T M9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F M="<^)#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M M04Q)1TXZ(')I9VAT)SXQ+#`P.3PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-) M6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL M93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(&QE9G0G/B0\+W1D M/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#%P M=#L@5$585"U!3$E'3CH@;&5F="<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS M1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[ M($)!0TM'4D]53D0M0T],3U(Z('=H:71E)SX@/'1D('-T>6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D M/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$58 M5"U!3$E'3CH@;&5F="<^)FYB6QE/3-$ M)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z('=H M:71E)SX@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E' M3CH@;&5F="<^26YT86YG:6)L92!A6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE M/3-$)T9/3E0M4TE:13H@,3!P="<^)FYB6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@ M6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@4$%$1$E.1RU,1494.B`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`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52 M+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!R:6=H M="<^("T\+W1D/B`\=&0@6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB M6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U! M3$E'3CH@6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^1&5P6QE/3-$)T9/3E0M4TE: M13H@,3!P="<^)FYB6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^ M)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)FYB M6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U! M3$E'3CH@;&5F="<^)#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P M<'0[(%1%6%0M04Q)1TXZ(')I9VAT)SXQ+#@Y.3PO=&0^(#QT9"!S='EL93TS M1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO M=&0^(#PO='(^(#QT6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#%P=#L@ M4$%$1$E.1RU,1494.B`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`P+C8R-6EN M)SY397)V:6-E/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^ M)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$58 M5"U!3$E'3CH@;&5F="<^)#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z M(#$P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)SXX-C0\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$58 M5"U!3$E'3CH@6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM' M4D]53D0M0T],3U(Z('=H:71E)SX@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@4$%$1$E.1RU"3U143TTZ(#%P=#L@4$%$1$E.1RU,1494.B`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`\=&0@6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5#H@,3!P M="!4:6UE6QE/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G/B`\=&0@ M#L@4$%$1$E.1RU43U`Z(#!P M>#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D#L@5TE$ M5$@Z(#`N,C5I;CL@5$585"U)3D1%3E0Z(#!P>"<^("9N8G-P.SPO=&0^(#QT M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,'!X.R!0041$24Y'+51/4#H@ M,'!X.R!0041$24Y'+4Q%1E0Z(#!P>#L@4$%$1$E.1RU224=(5#H@,'!X.R!7 M24142#H@,"XU:6X[(%1%6%0M24Y$14Y4.B`P<'@G/B`\96T^*&(I/"]E;3X\ M+W1D/B`\=&0@#L@4$%$1$E. M1RU43U`Z(#!P>#L@4$%$1$E.1RU,1494.B`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`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@ M;&5F="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P M="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SX@)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5TE$5$@Z(#(E)SXF M;F)S<#L\+W1D/B`\=&0@6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU, M1494.B`P+C8R-6EN)SX@4&%C:69I8R!2:6T\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$58 M5"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)T9/3E0M M4TE:13H@,3!P="<^)FYB6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@6QE/3-$)T9/3E0M4TE:13H@ M,3!P="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@ M;&5F="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P M="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F M="<^)FYB6QE/3-$)U9%4E1)0T%,+4%, M24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P M-"DG/B`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`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^ M)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)FYB M6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U! M3$E'3CH@;&5F="<^)FYB6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@5$585"U!3$E'3CH@6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]5 M3D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"DG/B`\=&0@6QE/3-$)T9/ M3E0M4TE:13H@,3!P="<^)FYB6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)#PO=&0^(#QT9"!S='EL M93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)SXR,"PP M.#,\+W1D/B`\=&0@6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$ M1$E.1RU"3U143TTZ(#%P=#L@5$585"U!3$E'3CH@;&5F="<^("9N8G-P.SPO M=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\ M+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/ M5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<^ M(#(P+#`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`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`N-6EN)SX@)FYB6QE/3-$)T9/3E0M4TE:13H@ M,3!P="<@;F]W6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA M8VL@,7!T('-O;&ED.R!&3TY4+5=%24=(5#H@8F]L9#L@5$585"U!3$E'3CH@ M8V5N=&5R)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^0F%L86YC92P\ M8G(@+SX@4V5P=&5M8F5R(#,P+#QB6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0[(%!!1$1) M3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA M8VL@,7!T('-O;&ED.R!&3TY4+5=%24=(5#H@8F]L9#L@5$585"U!3$E'3CH@ M8V5N=&5R)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^0V%S:#QB6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O M;&0[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F M=#L@5TE$5$@Z(#,P)2<^3VYE+71I;64@=&5R;6EN871I;VX@8F5N969I=',\ M+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$58 M5"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SX@)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5TE$5$@Z(#(E)SXF;F)S<#L\+W1D M/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E' M3CH@;&5F=#L@5TE$5$@Z(#$E)SX@)FYB6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@5TE$5$@Z(#(E)SXF;F)S<#L\+W1D/B`\=&0@ M6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SXD M/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E' M3CH@6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E' M3CH@;&5F="<^)FYB6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@5$585"U!3$E'3CH@6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB M6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U! M3$E'3CH@6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE M/3-$)T9/3E0M4TE:13H@,3!P="<^)FYB6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@ M6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)T9/ M3E0M4TE:13H@,3!P="<^)FYB6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T M;VT[($)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"DG/B`\=&0@ M6QE/3-$)T9/ M3E0M4TE:13H@,3!P="<^)FYB6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@ M;&5F="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P M="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^*3PO=&0^(#PO='(^(#QT M6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#%P=#L@5$585"U! M3$E'3CH@;&5F="<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-) M6D4Z(#$P<'0[(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#%P="<^ M)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]2 M1$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!L969T M)SX@)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!R M:6=H="<^("@S-SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[ M(%!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U14 M3TTZ(#%P="<^)FYB6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%, M24=..B!L969T)SX@)FYB6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4 M+4%,24=..B!R:6=H="<^("T\+W1D/B`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`\=&0@6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE M.R!415A4+4%,24=..B!R:6=H="<^(#,L,3DU/"]T9#X@/'1D('-T>6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T.R!415A4 M+4%,24=..B!L969T)SX@)FYB6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D M/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/ M33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<^("@Q M+#(U,3PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1) M3D3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X-F4R9&1B9%]F,V0T M7S0X,C-?8C0P,U]A,&(Q.&-E9F0U,&(-"D-O;G1E;G0M3&]C871I;VXZ(&9I M;&4Z+R\O0SHO.#9E,F1D8F1?9C-D-%\T.#(S7V(T,#-?83!B,3AC969D-3!B M+U=O'0O M:'1M;#L@8VAA'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'!E;G-E M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#(Q-SQS<&%N/CPO M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^)FYB'!E;G-E(&9O'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$&EM=6T@6TUE M;6)E'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!A;F0@ M97%U:7!M96YT+"!E'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^,3`@>65A'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$2!A;F0@97%U:7!M96YT+"!E65A'10 M87)T7S@V93)D9&)D7V8S9#1?-#@R,U]B-#`S7V$P8C$X8V5F9#4P8@T*0V]N M=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\X-F4R9&1B9%]F,V0T7S0X,C-? M8C0P,U]A,&(Q.&-E9F0U,&(O5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA3X-"CPO:'1M M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X-F4R9&1B9%]F,V0T7S0X,C-?8C0P M,U]A,&(Q.&-E9F0U,&(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO M.#9E,F1D8F1?9C-D-%\T.#(S7V(T,#-?83!B,3AC969D-3!B+U=O'0O:'1M;#L@8VAA M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$6EN9R!!;6]U;G0\+W1D/@T*("`@("`@("`\=&0@8VQA7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S2!O9B!T:&4@0V]M<&%N>2=S(&-O;6UO;B!S=&]C:SPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^-2!Y96%R65A M65A'0^-"!Y96%R7,\7,\3PO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA&-E<'0@4&5R(%-H87)E(&1A=&$L('5N;&5S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S2`M(&1E8W)E M87-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)FYB'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^)FYB'0^)FYB"!E>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S2!T'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^)FYB'0^)FYB'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)FYB'0^ M)FYB2`M(&1E8W)E87-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S"!E>'!E;G-E M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)FYB'0^)FYB'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)FYB'0^)FYB'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$3H\+W-T3PO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^)FYB'0^ M)FYB'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A&-E<'0@4VAA M2`Q,2P@,C`Q,3QB2!#;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S2!I'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'!I M2`S,2P-"@D),C`Q-CQS<&%N/CPO2`S,2P-"@D),C`Q,CQS<&%N/CPO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S65A'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!I'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'1087)T7S@V93)D9&)D7V8S9#1?-#@R,U]B-#`S7V$P8C$X8V5F9#4P8@T* M0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\X-F4R9&1B9%]F,V0T7S0X M,C-?8C0P,U]A,&(Q.&-E9F0U,&(O5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA65A'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M6EE;&0\+W1D/@T*("`@("`@("`\=&0@8VQA'!E8W1E9"!L:69E(&]F('1H92!O<'1I;VYS/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#XQ('EE87(\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$&-L=61E9"!F'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^ M)FYB'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)FYB'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA6UE;G1S(&1U93PO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0O:F%V87-C3X-"B`@ M("`\=&%B;&4@8VQA6%B;&4@3VYE(%M-96UB97)=/&)R/CPO M=&@^#0H@("`@("`@(#QT:"!C;&%S6%B;&4@5'=O(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT M:"!C;&%S6%B;&4@5&\@06QG;R!(;VQD:6YG M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^;6]N=&AL>3QS<&%N/CPO M'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$2`Q+`T*"0DR,#$R/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6%B;&4@=&\@4F5G M:6]N6%B;&4L($UA='5R:6YG($9E8G)U87)Y(#$Q+"`R,#$Q/&)R/CPO M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M2F%N(#,Q+`T*"0DR,#$Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^2F%N(#,Q+`T*"0DR,#$S/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^3V-T(#,Q+`T*"0DR,#$S M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M36%Y(#,Q+`T*"0DR,#$S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^3V-T(#,Q+`T*"0DR,#$S/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6UE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\'0^;6]N=&AL>3QS<&%N/CPO6UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^0VET:6)A;FMS)R!0'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^3$E"3U(\ M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S&5D(&-H87)G92!C;W9E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$3QS<&%N/CPO'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^0F]R M2!A(&)L86YK970@;&EE;B!O;B!O=7(@<&5R2P@86YD(&EN=&5L;&5C='5A;"!P2!A65T M=&4@86YD($5V86YS=FEL;&4@2X\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%\X-F4R9&1B9%]F,V0T7S0X,C-?8C0P,U]A M,&(Q.&-E9F0U,&(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.#9E M,F1D8F1?9C-D-%\T.#(S7V(T,#-?83!B,3AC969D-3!B+U=O'0O:'1M;#L@8VAA'!E;G-E"!L:6%B:6QI=&EE69O6]V97(\+W1D M/@T*("`@("`@("`\=&0@8VQA"!A3PO=&0^#0H@("`@ M("`@(#QT9"!C;&%S&5D(&%S"!L:6%B:6QI M=&EE"!A'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)FYB'0^)FYB'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^)FYB'0^)FYB'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M2!F961E"!B96YE9FET+"!I9B!A M<'!L:6-A8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@P+C$P M)2D\'!E;G-E3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%\X-F4R9&1B9%]F,V0T7S0X,C-?8C0P,U]A,&(Q.&-E9F0U,&(-"D-O;G1E M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.#9E,F1D8F1?9C-D-%\T.#(S7V(T M,#-?83!B,3AC969D-3!B+U=O'0O:'1M;#L@8VAA&5S(%M, M:6YE($ET96US73PO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$6UE;G1S M(&9O"!P;W-I=&EO;G,\+W1D/@T*("`@("`@("`\=&0@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'!I2!F;W)W87)D'0^ M/"$M+41/0U194$4@:'1M;"!054),24,@(BTO+U&AT M;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@+2T^/&1I=CX@/&1I M=CX@/'`@'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6QE/3-$)U1%6%0M M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%\X-F4R9&1B9%]F,V0T7S0X,C-?8C0P,U]A,&(Q.&-E M9F0U,&(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.#9E,F1D8F1? M9C-D-%\T.#(S7V(T,#-?83!B,3AC969D-3!B+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$65A65A'0^)FYB'0^)FYB"!P;W-I=&EO;G,@;V8@<')I;W(@>65A3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X-F4R9&1B9%]F,V0T7S0X M,C-?8C0P,U]A,&(Q.&-E9F0U,&(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z M+R\O0SHO.#9E,F1D8F1?9C-D-%\T.#(S7V(T,#-?83!B,3AC969D-3!B+U=O M'0O:'1M M;#L@8VAA65E(&-O;7!E;G-A=&EO;B!P;&%N/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$;G5M<#XS,SDL,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^,2!Y96%R(#(@;6]N=&AS M(#(W(&1A>7,\7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A2!3:&%R92UB M87-E9"!087EM96YT($%W87)D(%M,:6YE($ET96US73PO'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6EE;&0\+W1D/@T*("`@("`@("`\=&0@8VQA'!E8W1E9"!M87)K970@<')I M8V4@;V8@=&AE($-O;7!A;GDG&EM=6T\+W1D M/@T*("`@("`@("`\=&0@8VQA65A6UE;G0@07=A'0^-R!Y96%R'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!3:&%R92UB87-E9"!087EM96YT($%W M87)D(%M,:6YE($ET96US73PO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'!E8W1E9"!L:69E(&]F('1H92!O<'1I;VYS("AY M96%R65A'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$&5R8VES960\+W1D/@T*("`@("`@("`\=&0@ M8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^-R!Y96%R&5R8VES86)L M92`M(%-E<'1E;6)E65A'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%\X-F4R9&1B9%]F,V0T7S0X,C-?8C0P,U]A,&(Q.&-E9F0U,&(- M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.#9E,F1D8F1?9C-D-%\T M.#(S7V(T,#-?83!B,3AC969D-3!B+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA2!O9B!/=71S=&%N9&EN9R!A;F0@17AE'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&5R8VES92!065A&5R8VES92!0&5R8VES92!0'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$&5R8VES92!0'0^.2!Y96%R&5R8VES86)L93PO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&5R8VES92!07,\ M'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA2=S(&-O;G1R:6)U M=&EO;B!T;R!P;&%N+"!A65R)W,@;6%T8V@@<&5R8V5N=&%G93PO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$65R(&UA=&-H:6YG(&-O;G1R:6)U=&EO;CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%\X-F4R9&1B9%]F,V0T7S0X,C-?8C0P,U]A,&(Q.&-E9F0U,&(-"D-O M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.#9E,F1D8F1?9C-D-%\T.#(S M7V(T,#-?83!B,3AC969D-3!B+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S&5S/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%SF%T:6]N.CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'1087)T7S@V93)D9&)D7V8S9#1?-#@R,U]B-#`S7V$P8C$X8V5F9#4P8@T* M0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\X-F4R9&1B9%]F,V0T7S0X M,C-?8C0P,U]A,&(Q.&-E9F0U,&(O5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA6UE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M M<#XD(#@P,#QS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X-F4R9&1B9%]F,V0T7S0X M,C-?8C0P,U]A,&(Q.&-E9F0U,&(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z M+R\O0SHO.#9E,F1D8F1?9C-D-%\T.#(S7V(T,#-?83!B,3AC969D-3!B+U=O M'0O:'1M M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0O:F%V87-C3X-"B`@ M("`\=&%B;&4@8VQA'0^)FYB'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6UE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q+#`P-BD\ M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^)FYB'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^)FYB'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^)FYB'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^)FYB'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^ M)FYB'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X M-F4R9&1B9%]F,V0T7S0X,C-?8C0P,U]A,&(Q.&-E9F0U,&(-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.#9E,F1D8F1?9C-D-%\T.#(S7V(T,#-? M83!B,3AC969D-3!B+U=O'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'!E;F1I='5R97,@ M9W)O=W1H("AD96-L:6YE*2P@<&5R8V5N=#PO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'1087)T7S@V93)D9&)D7V8S9#1?-#@R,U]B-#`S7V$P8C$X8V5F9#4P8@T* M0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\X-F4R9&1B9%]F,V0T7S0X M,C-?8C0P,U]A,&(Q.&-E9F0U,&(O5V]R:W-H965T XML 55 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.8 Html 178 397 1 false 62 0 false 7 false false R1.htm 001 - Document - Document and Entity Information Sheet http://www.basinc.com/role/DocumentAndEntityInformation Document and Entity Information true false R2.htm 002 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.basinc.com/role/ConsolidatedBalanceSheets CONSOLIDATED BALANCE SHEETS false false R3.htm 003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.basinc.com/role/ConsolidatedBalanceSheetsParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) false false R4.htm 004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) Sheet http://www.basinc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) false false R5.htm 005 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY Sheet http://www.basinc.com/role/ConsolidatedStatementsOfShareholdersEquity CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY false false R6.htm 006 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (Parenthetical) Sheet http://www.basinc.com/role/ConsolidatedStatementsOfShareholdersEquityParenthetical CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (Parenthetical) false false R7.htm 007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.basinc.com/role/ConsolidatedStatementsOfCashFlows CONSOLIDATED STATEMENTS OF CASH FLOWS false false R8.htm 101 - Disclosure - DESCRIPTION OF THE BUSINESS Sheet http://www.basinc.com/role/DescriptionOfTheBusiness DESCRIPTION OF THE BUSINESS false false R9.htm 102 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.basinc.com/role/SummaryOfSignificantAccountingPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES false false R10.htm 1021 - Disclosure - RESTATEMENT OF PREVIOUSLY ISSUED CONSOLIDATED FINANCIAL STATEMENTS Sheet http://www.basinc.com/role/RestatementOfPreviouslyIssuedConsolidatedFinancialStatements RESTATEMENT OF PREVIOUSLY ISSUED CONSOLIDATED FINANCIAL STATEMENTS false false R11.htm 103 - Disclosure - SALE OF PREFERRED SHARES AND WARRANTS Sheet http://www.basinc.com/role/SaleOfPreferredSharesAndWarrants SALE OF PREFERRED SHARES AND WARRANTS false false R12.htm 104 - Disclosure - LOSS PER SHARE Sheet http://www.basinc.com/role/LossPerShare LOSS PER SHARE false false R13.htm 105 - Disclosure - INVENTORIES Sheet http://www.basinc.com/role/Inventories INVENTORIES false false R14.htm 106 - Disclosure - LEASE ARRANGEMENTS Sheet http://www.basinc.com/role/LeaseArrangements LEASE ARRANGEMENTS false false R15.htm 107 - Disclosure - DEBT ARRANGEMENTS Sheet http://www.basinc.com/role/DebtArangements DEBT ARRANGEMENTS false false R16.htm 108 - Disclosure - INCOME TAXES Sheet http://www.basinc.com/role/IncomeTaxes INCOME TAXES false false R17.htm 109 - Disclosure - STOCK-BASED COMPENSATION Sheet http://www.basinc.com/role/StockBasedCompensation STOCK-BASED COMPENSATION false false R18.htm 110 - Disclosure - RETIREMENT PLAN Sheet http://www.basinc.com/role/RetirementPlan RETIREMENT PLAN false false R19.htm 111 - Disclosure - SEGMENT INFORMATION Sheet http://www.basinc.com/role/SegmentInformation SEGMENT INFORMATION false false R20.htm 112 - Disclosure - SETTLEMENT OF CONTINGENT LIABILITY Sheet http://www.basinc.com/role/SettlementOfContingentLiability SETTLEMENT OF CONTINGENT LIABILITY false false R21.htm 113 - Disclosure - RESTRUCTURING Sheet http://www.basinc.com/role/Resturcturing RESTRUCTURING false false R22.htm 114 - Disclosure - SELF-INSURANCE Sheet http://www.basinc.com/role/Selfinsurance SELF-INSURANCE false false R23.htm 115 - Disclosure - MANAGEMENT'S PLAN Sheet http://www.basinc.com/role/ManagementsPlan MANAGEMENT'S PLAN false false R24.htm 202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://www.basinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) false false R25.htm 302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://www.basinc.com/role/SummaryOfSignificantAccountingPoliciesTables SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) false false R26.htm 3021 - Disclosure - RESTATEMENT OF PREVIOUSLY ISSUED CONSOLIDATED FINANCIAL STATEMENTS (Tables) Sheet http://www.basinc.com/role/RestatementOfPreviouslyIssuedConsolidatedFinancialStatementsTables RESTATEMENT OF PREVIOUSLY ISSUED CONSOLIDATED FINANCIAL STATEMENTS (Tables) false false R27.htm 303 - Disclosure - SALE OF PREFERRED SHARES AND WARRANTS (Tables) Sheet http://www.basinc.com/role/SaleOfPreferredSharesAndWarrantsTables SALE OF PREFERRED SHARES AND WARRANTS (Tables) false false R28.htm 304 - Disclosure - LOSS PER SHARE (Tables) Sheet http://www.basinc.com/role/LossPerShareTables LOSS PER SHARE (Tables) false false R29.htm 305 - Disclosure - INVENTORIES (Tables) Sheet http://www.basinc.com/role/InventoriesTables INVENTORIES (Tables) false false R30.htm 306 - Disclosure - LEASE ARRANGEMENTS (Tables) Sheet http://www.basinc.com/role/LeaseArrangementsTables LEASE ARRANGEMENTS (Tables) false false R31.htm 307 - Disclosure - DEBT ARRANGEMENTS (Tables) Sheet http://www.basinc.com/role/DebtArangementsTables DEBT ARRANGEMENTS (Tables) false false R32.htm 308 - Disclosure - INCOME TAXES (Tables) Sheet http://www.basinc.com/role/IncomeTaxesTables INCOME TAXES (Tables) false false R33.htm 309 - Disclosure - STOCK-BASED COMPENSATION (Tables) Sheet http://www.basinc.com/role/StockBasedCompensationTables STOCK-BASED COMPENSATION (Tables) false false R34.htm 311 - Disclosure - SEGMENT INFORMATION (Tables) Sheet http://www.basinc.com/role/SegmentInformationTables SEGMENT INFORMATION (Tables) false false R35.htm 313 - Disclosure - RESTRUCTURING (Tables) Sheet http://www.basinc.com/role/ResturcturingTables RESTRUCTURING (Tables) false false R36.htm 40201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) Sheet http://www.basinc.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) false false R37.htm 40202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Summary of Activity in Allowance for Doubtful Accounts) (Details) Sheet http://www.basinc.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfActivityInAllowanceForDoubtfulAccountsDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Summary of Activity in Allowance for Doubtful Accounts) (Details) false false R38.htm 40203 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Schedule of Property and Equipment) (Details) Sheet http://www.basinc.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Schedule of Property and Equipment) (Details) false false R39.htm 40204 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Components of Amortizable Intangible Assets) (Details) Sheet http://www.basinc.com/role/SummaryOfSignificantAccountingPoliciesComponentsOfAmortizableIntangibleAssetsDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Components of Amortizable Intangible Assets) (Details) false false R40.htm 40206 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Schedule of Assumptions Used to Compute Fair Value of Warrants) (Details) Sheet http://www.basinc.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAssumptionsUsedToComputeFairValueOfWarrantsDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Schedule of Assumptions Used to Compute Fair Value of Warrants) (Details) false false R41.htm 402102 - Disclosure - RESTATEMENT OF PREVIOUSLY ISSUED CONSOLIDATED FINANCIAL STATEMENTS (Statements of Operations) (Details) Sheet http://www.basinc.com/role/RestatementOfPreviouslyIssuedConsolidatedFinancialStatementsStatementsOfOperationsDetails RESTATEMENT OF PREVIOUSLY ISSUED CONSOLIDATED FINANCIAL STATEMENTS (Statements of Operations) (Details) false false R42.htm 402103 - Disclosure - RESTATEMENT OF PREVIOUSLY ISSUED CONSOLIDATED FINANCIAL STATEMENTS (Balance Sheet) (Details) Sheet http://www.basinc.com/role/RestatementOfPreviouslyIssuedConsolidatedFinancialStatementsBalanceSheetDetails RESTATEMENT OF PREVIOUSLY ISSUED CONSOLIDATED FINANCIAL STATEMENTS (Balance Sheet) (Details) false false R43.htm 40301 - Disclosure - SALE OF PREFERRED SHARES AND WARRANTS (Narrative) (Details) Sheet http://www.basinc.com/role/SaleOfPreferredSharesAndWarrantsNarrativeDetails SALE OF PREFERRED SHARES AND WARRANTS (Narrative) (Details) false false R44.htm 40302 - Disclosure - SALE OF PREFERRED SHARES AND WARRANTS (Fair Value Assumptions) (Details) Sheet http://www.basinc.com/role/SaleOfPreferredSharesAndWarrantsFairValueAssumptionsDetails SALE OF PREFERRED SHARES AND WARRANTS (Fair Value Assumptions) (Details) false false R45.htm 40401 - Disclosure - LOSS PER SHARE (Narrative) (Details) Sheet http://www.basinc.com/role/LossPerShareNarrativeDetails LOSS PER SHARE (Narrative) (Details) false false R46.htm 40402 - Disclosure - LOSS PER SHARE (Reconciliation of Computation of Basic Income or Loss Per Share to Diluted Income or Loss Per Share) (Details) Sheet http://www.basinc.com/role/LossPerShareReconciliationOfComputationOfBasicIncomeOrLossPerShareToDilutedIncomeOrLossPerShareDetails LOSS PER SHARE (Reconciliation of Computation of Basic Income or Loss Per Share to Diluted Income or Loss Per Share) (Details) false false R47.htm 40501 - Disclosure - INVENTORIES (Details) Sheet http://www.basinc.com/role/InventoriesDetails INVENTORIES (Details) false false R48.htm 40601 - Disclosure - LEASE ARRANGEMENTS (Narrative) (Details) Sheet http://www.basinc.com/role/LeaseArrangementsNarrativeDetails LEASE ARRANGEMENTS (Narrative) (Details) false false R49.htm 40602 - Disclosure - LEASE ARRANGEMENTS (Schedule of Future Minimum Lease Payments for Capital Leases) (Details) Sheet http://www.basinc.com/role/LeaseArrangementsScheduleOfFutureMinimumleasePaymentsForCapitalLeasesDetails LEASE ARRANGEMENTS (Schedule of Future Minimum Lease Payments for Capital Leases) (Details) false false R50.htm 40603 - Disclosure - LEASE ARRANGEMENTS (Schedule of Future Minimum Lease Payments for Operating Leases) (Details) Sheet http://www.basinc.com/role/LeaseArrangementsScheduleOfFutureMinimumleasePaymentsForOperatingLeasesDetails LEASE ARRANGEMENTS (Schedule of Future Minimum Lease Payments for Operating Leases) (Details) false false R51.htm 40701 - Disclosure - DEBT ARRANGEMENTS (Schedule of Long-Term Debt) (Details) Sheet http://www.basinc.com/role/DebtArangementsScheduleOfLongTermDebtDetails DEBT ARRANGEMENTS (Schedule of Long-Term Debt) (Details) false false R52.htm 40703 - Disclosure - DEBT ARRANGEMENTS (Narrative) (Details) Sheet http://www.basinc.com/role/DebtArangementsNarrativeDetails DEBT ARRANGEMENTS (Narrative) (Details) false false R53.htm 40801 - Disclosure - INCOME TAXES (Schedule of Deferred Tax Assets and Liabilities) (Details) Sheet http://www.basinc.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails INCOME TAXES (Schedule of Deferred Tax Assets and Liabilities) (Details) false false R54.htm 40802 - Disclosure - INCOME TAXES (Schedule of the Provision (Benefit) for Income Taxes) (Details) Sheet http://www.basinc.com/role/IncomeTaxesScheduleOfTheProvisionBenefitForIncomeTaxesDetails INCOME TAXES (Schedule of the Provision (Benefit) for Income Taxes) (Details) false false R55.htm 40803 - Disclosure - INCOME TAXES (Reconciliation of Effective Income Tax Rate) (Details) Sheet http://www.basinc.com/role/IncomeTaxesReconciliationOfEffectiveIncomeTaxRateDetails INCOME TAXES (Reconciliation of Effective Income Tax Rate) (Details) false false R56.htm 40804 - Disclosure - INCOME TAXES (Narrative) (Details) Sheet http://www.basinc.com/role/IncomeTaxesNarrativeDetails INCOME TAXES (Narrative) (Details) false false R57.htm 40805 - Disclosure - INCOME TAXES (Reconciliation of Unrecognized Tax Benefits) (Details) Sheet http://www.basinc.com/role/IncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails INCOME TAXES (Reconciliation of Unrecognized Tax Benefits) (Details) false false R58.htm 40901 - Disclosure - STOCK-BASED COMPENSATION (Narrative) (Details) Sheet http://www.basinc.com/role/StockBasedCompensationNarrativeDetails STOCK-BASED COMPENSATION (Narrative) (Details) false false R59.htm 40902 - Disclosure - STOCK-BASED COMPENSATION (Fair Value Assumptions) (Details) Sheet http://www.basinc.com/role/StockBasedCompensationFairValueAssumptionsDetails STOCK-BASED COMPENSATION (Fair Value Assumptions) (Details) false false R60.htm 40903 - Disclosure - STOCK-BASED COMPENSATION (Summary of Stock Option Activity) (Details) Sheet http://www.basinc.com/role/StockBasedCompensationSummaryOfStockOptionActivitiesDetails STOCK-BASED COMPENSATION (Summary of Stock Option Activity) (Details) false false R61.htm 40904 - Disclosure - STOCK-BASED COMPENSATION (Summary of Non-Vested Options) (Details) Sheet http://www.basinc.com/role/StockBasedCompensationSummaryOfNonVestedOptionsDetails STOCK-BASED COMPENSATION (Summary of Non-Vested Options) (Details) false false R62.htm 40905 - Disclosure - STOCK-BASED COMPENSATION (Summary of Outstanding and Exercisable Options) (Details) Sheet http://www.basinc.com/role/StockBasedCompensationSummaryOfOutstandingAndExerciasbleOptionsDetails STOCK-BASED COMPENSATION (Summary of Outstanding and Exercisable Options) (Details) false false R63.htm 41001 - Disclosure - RETIREMENT PLAN (Details) Sheet http://www.basinc.com/role/RetirementPlanDetails RETIREMENT PLAN (Details) false false R64.htm 41101 - Disclosure - SEGMENT INFORMATION (Operating Segments) (Details) Sheet http://www.basinc.com/role/SegmentInformationOperatingSegmentsDetails SEGMENT INFORMATION (Operating Segments) (Details) false false R65.htm 41102 - Disclosure - SEGMENT INFORMATION (Geographical Information) (Details) Sheet http://www.basinc.com/role/SegmentInformationGeographicalInformationDetails SEGMENT INFORMATION (Geographical Information) (Details) false false R66.htm 41103 - Disclosure - SEGMENT INFORMATION (Narrative) (Details) Sheet http://www.basinc.com/role/SegmentInformationNarrativeDetails SEGMENT INFORMATION (Narrative) (Details) false false R67.htm 41201 - Disclosure - SETTLEMENT OF CONTINGENT LIABILITY (Details) Sheet http://www.basinc.com/role/SettlementOfContingentLiabilityDetails SETTLEMENT OF CONTINGENT LIABILITY (Details) false false R68.htm 41301 - Disclosure - RESTRUCTURING (Narrative) (Details) Sheet http://www.basinc.com/role/ResturcturingNarrativeDetails RESTRUCTURING (Narrative) (Details) false false R69.htm 41302 - Disclosure - RESTRUCTURING (Summary of Restructuring Costs) (Details) Sheet http://www.basinc.com/role/ResturcturingSummaryOfRestructuringCostsDetails RESTRUCTURING (Summary of Restructuring Costs) (Details) false false R70.htm 41303 - Disclosure - RESTRUCTURING (Summary of Restructuring Activity) (Details) Sheet http://www.basinc.com/role/ResturcturingSummaryOfRestructuringActivityDetails RESTRUCTURING (Summary of Restructuring Activity) (Details) false false R71.htm 41401 - Disclosure - SELF-INSURANCE (Details) Sheet http://www.basinc.com/role/SelfinsuranceDetails SELF-INSURANCE (Details) false false R72.htm 41501 - Disclosure - MANAGEMENT'S PLAN (Details) Sheet http://www.basinc.com/role/ManagementsPlanDetails MANAGEMENT'S PLAN (Details) false false All Reports Book All Reports Element us-gaap_DebtInstrumentInterestRateEffectivePercentageRateRangeMinimum had a mix of decimals attribute values: 2 3. Element us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum had a mix of decimals attribute values: 1 2. Process Flow-Through: 002 - Statement - CONSOLIDATED BALANCE SHEETS Process Flow-Through: Removing column 'Sep. 30, 2010' Process Flow-Through: 003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Process Flow-Through: Removing column 'May 11, 2011' Process Flow-Through: 004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) Process Flow-Through: Removing column '6 Months Ended Sep. 30, 2012' Process Flow-Through: Removing column '6 Months Ended Mar. 31, 2012' Process Flow-Through: 006 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (Parenthetical) Process Flow-Through: 007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS basi-20120930.xml basi-20120930.xsd basi-20120930_cal.xml basi-20120930_def.xml basi-20120930_lab.xml basi-20120930_pre.xml true true XML 56 R50.htm IDEA: XBRL DOCUMENT v2.4.0.8
LEASE ARRANGEMENTS (Schedule of Future Minimum Lease Payments for Operating Leases) (Details) (USD $)
In Thousands, unless otherwise specified
Sep. 30, 2012
LEASE ARRANGEMENTS [Abstract]  
2013 $ 371
2014 370
2015 223
2016 13
Total minimum lease payments due $ 977
XML 57 R45.htm IDEA: XBRL DOCUMENT v2.4.0.8
LOSS PER SHARE (Narrative) (Details)
 12 Months Ended
Sep. 30, 2012
Sep. 30, 2011
Warrant [Member]
    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive shares not considered in computing diluted earnings per share 1,376,500 2,753,000
Series A Preferred Stock [Member]
    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive shares not considered in computing diluted earnings per share 936,000 2,753,000
XML 58 R3.htm IDEA: XBRL DOCUMENT v2.4.0.8
CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)
Sep. 30, 2012
Sep. 30, 2011
Common stock, no par value      
Common stock, shares authorized 19,000,000 19,000,000
Common stock, shares issued 7,638,738 6,945,631
Common stock, shares outstanding 7,638,738 6,945,631
Series A Preferred Stock [Member]
    
Preferred stock, shares authorized 1,000,000 1,000,000
Preferred stock, no par value      
Preferred stock, shares issued 1,335 2,135
Preferred stock, shares outstanding 1,335 2,135
Preferred stock, stated value per share $ 1,000 $ 1,000
XML 59 R14.htm IDEA: XBRL DOCUMENT v2.4.0.8
LEASE ARRANGEMENTS
 12 Months Ended
Sep. 30, 2012
LEASE ARRANGEMENTS [Abstract]  
LEASE ARRANGEMENTS

7. LEASE ARRANGEMENTS

 

The total amount of equipment capitalized under capital lease obligations as of September 30, 2012 and 2011 was $5,778 and $6,222, respectively. Accumulated amortization on capital leases at September 30, 2012 and 2011 was $4,775 and $4,086, respectively. Amortization of assets acquired through capital leases is included in depreciation expense.

 

During fiscal 2012, we added $356 in computer equipment through new capital lease arrangements. In fiscal 2011, we added $1,888 in equipment to our U.S. and U.K. bioanalytical laboratories through new capital lease arrangements. Due to restructuring activities outlined in Note 14, we terminated a capital lease for laboratory equipment in the UK. The activity resulted in a liability reduction of $322. Future minimum lease payments on capital leases at September 30, 2012 for the next five years are as follows:

 

    Principal     Interest     Total  
                   
2013   $ 330     $ 58     $ 388  
2014     268       39       307  
2015     259       22       281  
2016     208       6       214  
2017     4       -       4  
                         
    $ 1,069     $ 125     $ 1,194  

 

We lease office space and equipment under noncancelable operating leases that terminate at various dates through 2016. The UK building lease expires in 2023 but includes an opt out provision after 7 years, or in fiscal 2015. Certain of these leases contain renewal options. Total rental expense under these leases was $1,284 and $441 in fiscal 2012 and 2011, respectively. The increase in fiscal 2012 is due to the accrual in restructuring for the UK building lease through the opt out date.

 

Future minimum lease payments for the following fiscal years under operating leases at September 30, 2012 are as follows:

 

2013   $ 371  
2014     370  
2015     223  
2016     13  
    $ 977  
XML 60 R5.htm IDEA: XBRL DOCUMENT v2.4.0.8
CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (USD $)
In Thousands, except Share data, unless otherwise specified
Total
Preferred Shares [Member]
Common Shares [Member]
Additional paid-in capital [Member]
Accumulated deficit [Member]
Accumulated other comprehensive income (loss) [Member]
Balance at Sep. 30, 2010 $ 10,667    $ 1,191 $ 13,357 $ (3,981) $ 100
Balance, shares at Sep. 30, 2010      4,915,318      
Comprehensive Income (loss):            
Net income (loss) 2,302       2,302  
Foreign currency translation adjustments (49)         (49)
Stock based compensation expense 153     153    
Issuance of preferred shares, net of issuance costs of $900,281 4,606 5,506   (900)    
Issuance of preferred shares, net of issuance costs of $900,281, shares   5,506        
Fair value attributable to warrants (3,045) (3,045)         
Preferred stock - beneficial conversion feature    (2,461)   2,461    
Preferred stock - deemed dividend    5,506     (5,506)  
Preferred stock - recognition of full dividend/make-whole (991)       (991)  
Conversion of preferred shares to common shares    (3,371) 421 2,950    
Conversion of preferred shares to common shares, shares   (3,371) 1,685,500      
Common shares issued for dividends/make whole payment 657    86 571    
Common stock issued for dividends/make-whole payment, shares      344,813      
Balance at Sep. 30, 2011 14,300 2,135 1,698 18,592 (8,176) 51
Balance, shares at Sep. 30, 2011   2,135 6,945,631      
Comprehensive Income (loss):            
Net income (loss) (6,317)       (6,317)  
Foreign currency translation adjustments (22)         (22)
Stock based compensation expense 83     83    
Conversion of preferred shares to common shares    (800) 100 700    
Conversion of preferred shares to common shares, shares   (800) 400,000      
Common shares issued for dividends/make whole payment 205    48 157    
Common stock issued for dividends/make-whole payment, shares      191,607      
Direct common share purchase from Directors 128    25 103    
Direct common share purchase from Directors, shares      101,500      
Balance at Sep. 30, 2012 $ 8,377 $ 1,335 $ 1,871 $ 19,635 $ (14,493) $ 29
Balance, shares at Sep. 30, 2012   1,335 7,638,738      
XML 61 R58.htm IDEA: XBRL DOCUMENT v2.4.0.8
STOCK-BASED COMPENSATION (Narrative) (Details) (USD $)
In Thousands, except Share data, unless otherwise specified
 12 Months Ended
Sep. 30, 2012
STOCK-BASED COMPENSATION [Abstract]  
Common stock authorized to issuance under employee compensation plan 500,000
Common stock available for issuance under employee compensation plan 339,000
Unrecognized compensation cost related to non-vested stock options $ 217
Unrecognized compensation cost, recognition period 1 year 2 months 27 days
Options outstanding that were granted outside of the plan 125,000
XML 62 R2.htm IDEA: XBRL DOCUMENT v2.4.0.8
CONSOLIDATED BALANCE SHEETS (USD $)
In Thousands, unless otherwise specified
Sep. 30, 2012
Sep. 30, 2011
Current assets:    
Cash and cash equivalents $ 721 $ 2,963
Accounts receivable    
Trade 3,366 4,073
Unbilled revenues and other 921 1,116
Inventories 1,656 1,636
Prepaid expenses 228 585
Total current assets 6,892 10,373
Property and equipment, net 18,628 20,399
Goodwill 1,383 1,383
Intangible assets, net    54
Debt issue costs, net 18 75
Other assets 54 62
Total assets 26,975 32,346
Current liabilities:    
Accounts payable 3,934 1,764
Accrued expenses 2,067 1,762
Customer advances 3,012 3,571
Income tax accruals 17 56
Revolving line of credit 1,444 1,346
Fair value of warrant liability 1,213 1,286
Current portion of capital lease obligation 330 613
Current portion of long-term debt 583 735
Total current liabilities 12,600 11,133
Capital lease obligation, less current portion 739 1,071
Long-term debt, less current portion 5,259 5,842
Stockholders' equity:    
Preferred shares, authorized 1,000,000 shares, no par value: 1,335 Series A shares at $1,000 stated value issued and outstanding at September 30, 2012 and 2,135 at September 30, 2011 1,335 2,135
Common shares, no par value: Authorized 19,000,000 shares; 7,638,738 issued and outstanding at September 30, 2012 and 6,945,631 at September 30, 2011 1,871 1,698
Additional paid-in capital 19,635 18,592
Accumulated deficit (14,493) (8,176)
Accumulated other comprehensive income 29 51
Total shareholders' equity 8,377 14,300
Total liabilities and shareholders' equity 26,975 32,346
Series A Preferred Stock [Member]
    
Stockholders' equity:    
Preferred shares, authorized 1,000,000 shares, no par value: 1,335 Series A shares at $1,000 stated value issued and outstanding at September 30, 2012 and 2,135 at September 30, 2011 $ 1,335 $ 2,135
XML 63 R51.htm IDEA: XBRL DOCUMENT v2.4.0.8
DEBT ARRANGEMENTS (Schedule of Long-Term Debt) (Details) (USD $)
In Thousands, unless otherwise specified
 12 Months Ended 12 Months Ended 12 Months Ended 12 Months Ended
Sep. 30, 2012
Sep. 30, 2011
Sep. 30, 2012
Mortgage Note Payable One [Member]
Sep. 30, 2011
Mortgage Note Payable One [Member]
Jun. 30, 2010
Mortgage Note Payable One [Member]
Sep. 30, 2012
Mortgage Note Payable Two [Member]
Sep. 30, 2011
Mortgage Note Payable Two [Member]
Jun. 30, 2010
Mortgage Note Payable Two [Member]
Sep. 30, 2012
Replacement Note Payable [Member]
Sep. 30, 2011
Replacement Note Payable [Member]
Sep. 30, 2012
Note Payable To Algo Holdings [Member]
Sep. 30, 2011
Note Payable To Algo Holdings [Member]
Debt Instrument [Line Items]                        
Long-tem debt $ 5,842 $ 6,577 $ 3,236 $ 3,573   $ 1,532 $ 1,674   $ 1,074 $ 1,245    $ 85
Less current portion 583 735                    
Long-term debt, noncurrent portion 5,259 5,842                    
Long-term debt, parenthetical information                        
Debt instrument, frequency of periodic payments     monthly     monthly     monthly   monthly  
Debt instrument, principal and interest payment     40     17     14   10  
Debt instrument, interest rate     4.10%   7.10% 4.10%   7.10% 7.50%      
Debt instrument, maturity date     Oct. 31, 2013     Oct. 31, 2013     Oct. 31, 2013   May 01, 2012  
Principal payment obligation 583                      
Cash paid during the period for interest $ 715 $ 647                    
XML 64 R29.htm IDEA: XBRL DOCUMENT v2.4.0.8
INVENTORIES (Tables)
 12 Months Ended
Sep. 30, 2012
INVENTORIES [Abstract]  
Summary of Inventories

Inventories at September 30 consisted of the following:

 

    2012     2011  
Raw materials   $ 1,407     $ 1,352  
Work in progress     283       379  
Finished goods     276       309  
    $ 1,966     $ 2,040  
Obsolescence reserve     (310 )     (404 )
    $ 1,656     $ 1,636  
XML 65 R23.htm IDEA: XBRL DOCUMENT v2.4.0.8
MANAGEMENT'S PLAN
 12 Months Ended
Sep. 30, 2012
MANAGEMENT'S PLAN [Abstract]  
MANAGEMENT'S PLAN

16. MANAGEMENT'S PLAN

 

Our long-term strategic objective is to maximize the Company's intrinsic value per share.   However, in response to our financial performance through the second quarter of fiscal 2012, we began to operate the business in a manner designed to place more emphasis on cash flow generation. Thus, our short-term tactical objective is to maximize free cash flow from operating activities.

 

Revenues declined approximately 14.9% and gross margin declined 34.9% from fiscal 2011. In fiscal 2012, we consolidated our bioanalytical laboratories into our headquarters in West Lafayette, Indiana, closing facilities in McMinnville, Oregon and the UK to reduce operating costs and strengthen our ability to meet clients' needs by improving laboratory utilization. We also implemented personnel reductions and other cost cutting measures in Selling, R&D and General and Administrative functions. These restructuring activities totaled $3,195 in the current year. As a result, we reported a net loss of $6,317 in fiscal 2012 as compared to net income of $2,302 in fiscal 2011.

 

The majority of the restructuring activities, though, occurred in the second half of the fiscal year. Due to these activities, gross margin improved 60.5% in the second half of fiscal 2012. Operating expenses declined 32.5% in the same time period. As a result, we had operating income of $452 before restructuring charges in the second half of fiscal 2012 compared to an operating loss of $2,943 in the first half. The % and $ amounts in the preceding sentences in this paragraph are unaudited. We will continue initiatives to control costs and improve productivity to achieve our financial objectives. Total capital expenditures declined 7.2% in fiscal 2012, particularly in the second half, as we limited spending to only necessary expenditures.

 

We negotiated an amendment on our loans with Regions Bank, extending the maturity date to October 2013. Our line of credit with Entrepreneur Growth Capital LLC was renewed for another year. Further, we listed for sale our headquarters facility in West Lafayette, Indiana with the intent to leaseback 80% of that square footage in which to continue our laboratory and manufacturing operations.

 

In fiscal 2013, we will continue to assess the need for additional cost controls such as freezing non-essential capital expenditures, reducing non-essential expenses, and monitoring our operations for efficiencies to further reduce our break-even point. For fiscal 2013, we expect to see slow but continued improvement in the volume of new bookings with little improvement in pricing. We also expect improved gross profit margins due to cost controls implemented and restructuring activities. We have debt and lease obligations of approximately $1.3 million in fiscal 2013. Based on our expected revenue, the availability on our line of credit, the impact of the cost reductions implemented and restructuring activities during fiscal 2012, we project that we will have the liquidity required to meet our fiscal 2013 operations and debt obligations.
XML 66 R44.htm IDEA: XBRL DOCUMENT v2.4.0.8
SALE OF PREFERRED SHARES AND WARRANTS (Fair Value Assumptions) (Details) (USD $)
 12 Months Ended
Sep. 30, 2012
Warrant A [Member]
  
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]  
Risk-free interest rate 1.87%
Dividend yield 0.00%
Volatility of the Company's common stock 106.91%
Expected life of the options 5 years
Fair value per unit $ 1.433
Warrant B [Member]
  
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]  
Risk-free interest rate 0.18%
Dividend yield 0.00%
Volatility of the Company's common stock 116.01%
Expected life of the options 1 year
Fair value per unit $ 0.779
XML 67 R54.htm IDEA: XBRL DOCUMENT v2.4.0.8
INCOME TAXES (Schedule of the Provision (Benefit) for Income Taxes) (Details) (USD $)
In Thousands, unless otherwise specified
 12 Months Ended
Sep. 30, 2012
Sep. 30, 2011
Current:    
Federal $ (3) $ 37
State and local 5 13
Foreign      
Deferred:    
Federal      
State and local      
Foreign      
Income tax expense $ 2 $ 50
XML 68 R65.htm IDEA: XBRL DOCUMENT v2.4.0.8
SEGMENT INFORMATION (Geographical Information) (Details) (USD $)
In Thousands, unless otherwise specified
 12 Months Ended
Sep. 30, 2012
Sep. 30, 2011
Revenues from External Customers and Long-Lived Assets [Line Items]    
Sales to External Customers: $ 28,208 $ 33,144
Long-lived assets 20,083 21,973
North America [Member]
    
Revenues from External Customers and Long-Lived Assets [Line Items]    
Sales to External Customers: 25,042 29,451
Long-lived assets 20,083 20,872
Pacific Rim [Member]
    
Revenues from External Customers and Long-Lived Assets [Line Items]    
Sales to External Customers: 961 912
Europe [Member]
    
Revenues from External Customers and Long-Lived Assets [Line Items]    
Sales to External Customers: 1,858 2,542
Long-lived assets    1,101
Other [Member]
    
Revenues from External Customers and Long-Lived Assets [Line Items]    
Sales to External Customers: $ 347 $ 239
XML 69 R39.htm IDEA: XBRL DOCUMENT v2.4.0.8
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Components of Amortizable Intangible Assets) (Details) (FDA compliant facility, USD $)
In Thousands, unless otherwise specified
 12 Months Ended
Sep. 30, 2012
Sep. 30, 2011
FDA compliant facility
    
Finite-Lived Intangible Assets [Line Items]    
Weighted average life 10 years 10 years
Gross Carrying Amount $ 302 $ 302
Accumulated Amortization $ 302 $ 248
XML 70 R35.htm IDEA: XBRL DOCUMENT v2.4.0.8
RESTRUCTURING (Tables)
 12 Months Ended
Sep. 30, 2012
RESTRUCTURING [Abstract]  
Summary of Restructuring Costs

The following table sets forth the costs incurred in connection with these restructuring activities during the year ended September 30, 2012.

 

Description   2012  
One-time termination benefits   $ 1,454  
Lease related costs     861  
Equipment moving costs and method transfers     153  
Travel and relocation costs     47  
Loss on sale of equipment     446  
Other costs     234  
Total   $ 3,195  
Summary of Restructuring Activity

The following table sets forth the rollforward of the restructuring activity for the year ended September 30, 2012.

 

    Balance,
September 30,
2011		     Total
Charges		     Cash
Payments		     Other     Balance,
September 30,
2012		  
One-time termination benefits   $ -     $ 1,454     $ (1,006 )   $ -     $ 448  
Lease related costs     -       861       (61 )     -       800  
Equipment moving costs and method transfers     -       153       (104 )     -       49  
Travel and relocation costs     -       47       (43 )     -       4  
Loss on sale of equipment     -       446       -       (539 )     (93 )
Other costs     -       234       (37 )     -       197  
Total   $ -     $ 3,195     $ (1,251 )   $ (539 )   $ 1,405  
XML 71 R36.htm IDEA: XBRL DOCUMENT v2.4.0.8
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) (USD $)
In Thousands, unless otherwise specified
 12 Months Ended
Sep. 30, 2012
Sep. 30, 2011
Accounting Policies [Line Items]    
FDIC Insured limits $ 250  
Allowance for doubtful accounts 123 108
Depreciation expense 2,217 2,085
Discount rate 14.00%  
Difference between the fair value and carrying value of goodwill 3,700  
Goodwill 1,383 1,383
Intangible assets, net    54
Amortization expense for intangible assets 54 30
Advertising expense 203 229
Stock based compensation expense 83 153
Research and development $ 542 $ 534
Bioanalytical Services [Member]
    
Accounting Policies [Line Items]    
Revenue growth rate 5.00%  
Preclinical Services [Member]
    
Accounting Policies [Line Items]    
Revenue growth rate 0.00%  
Vetronics Units [Member]
    
Accounting Policies [Line Items]    
Revenue growth rate 0.00%  
Buildings and Improvements [Member] | Minimum [Member]
    
Accounting Policies [Line Items]    
Property and equipment, estimated useful life 34 years  
Buildings and Improvements [Member] | Maximum [Member]
    
Accounting Policies [Line Items]    
Property and equipment, estimated useful life 40 years  
Machinery and Equipment [Member] | Minimum [Member]
    
Accounting Policies [Line Items]    
Property and equipment, estimated useful life 5 years  
Machinery and Equipment [Member] | Maximum [Member]
    
Accounting Policies [Line Items]    
Property and equipment, estimated useful life 10 years  
Office Furniture and Fixtures [Member]
    
Accounting Policies [Line Items]    
Property and equipment, estimated useful life 10 years  
Leasehold Improvements [Member]
    
Accounting Policies [Line Items]    
Property and equipment, estimated useful life 7 years  
XML 72 R13.htm IDEA: XBRL DOCUMENT v2.4.0.8
INVENTORIES
 12 Months Ended
Sep. 30, 2012
INVENTORIES [Abstract]  
INVENTORIES

6. INVENTORIES

 

Inventories at September 30 consisted of the following:

 

    2012     2011  
Raw materials   $ 1,407     $ 1,352  
Work in progress     283       379  
Finished goods     276       309  
    $ 1,966     $ 2,040  
Obsolescence reserve     (310 )     (404 )
    $ 1,656     $ 1,636  
XML 73 R62.htm IDEA: XBRL DOCUMENT v2.4.0.8
STOCK-BASED COMPENSATION (Summary of Outstanding and Exercisable Options) (Details) (USD $)
 12 Months Ended
Sep. 30, 2012
$0.79 - 1.01 [Member]
  
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]  
Range of Exercise Prices, minimum $ 0.79
Range of Exercise Prices, maximum $ 1.01
Shares Outstanding 128,000
Weighted-Average Remaining Contractual Life 8 years 3 months 26 days
Weighted-Average Exercise Price $ 0.97
Shares Exercisable 24,000
Weighted-Average Exercise Price, Exercisable $ 1.01
$1.02 - 4.59 [Member]
  
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]  
Range of Exercise Prices, minimum $ 1.02
Range of Exercise Prices, maximum $ 4.59
Shares Outstanding 155,000
Weighted-Average Remaining Contractual Life 9 years 4 months 24 days
Weighted-Average Exercise Price $ 1.38
Shares Exercisable 7,000
Weighted-Average Exercise Price, Exercisable $ 1.35
$4.60 - 8.79 [Member]
  
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]  
Range of Exercise Prices, minimum $ 4.60
Range of Exercise Prices, maximum $ 8.79
Shares Outstanding 71,000
Weighted-Average Remaining Contractual Life 4 years 2 months 27 days
Weighted-Average Exercise Price $ 5.19
Shares Exercisable 62,000
Weighted-Average Exercise Price, Exercisable $ 5.21
XML 74 R30.htm IDEA: XBRL DOCUMENT v2.4.0.8
LEASE ARRANGEMENTS (Tables)
 12 Months Ended
Sep. 30, 2012
LEASE ARRANGEMENTS [Abstract]  
Schedule of Future Minimum Lease Payments for Capital Leases

Future minimum lease payments on capital leases at September 30, 2012 for the next five years are as follows:

 

    Principal     Interest     Total  
                   
2013   $ 330     $ 58     $ 388  
2014     268       39       307  
2015     259       22       281  
2016     208       6       214  
2017     4       -       4  
                         
    $ 1,069     $ 125     $ 1,194  
Schedule of Future Minimum Lease Payments for Operating Leases

Future minimum lease payments for the following fiscal years under operating leases at September 30, 2012 are as follows:

 

2013   $ 371  
2014     370  
2015     223  
2016     13  
    $ 977  
XML 75 R42.htm IDEA: XBRL DOCUMENT v2.4.0.8
RESTATEMENT OF PREVIOUSLY ISSUED CONSOLIDATED FINANCIAL STATEMENTS (Balance Sheet) (Details) (USD $)
In Thousands, unless otherwise specified
Sep. 30, 2012
Sep. 30, 2011
Sep. 30, 2010
Total assets $ 26,975 $ 32,346  
Total other current liabilities 11,387 9,847  
Fair value of warrant liability 1,213 1,286  
Total current liabilities 12,600 11,133  
Other long-term debt 5,998 6,913  
Total liabilities 18,598 18,046  
Stockholders' equity:      
Preferred Shares 1,335 2,135  
Common Shares 1,871 1,698  
Additional paid-in capital 19,635 18,592  
Accumulated deficit (14,493) (8,176)  
Accumulated other comprehensive income 29 51  
Total shareholders' equity 8,377 14,300 10,667
Total liabilities and shareholders' equity 26,975 32,346  
As Reported [Member]
      
Total assets 26,975 32,346  
Total other current liabilities 11,387 9,847  
Fair value of warrant liability        
Total current liabilities 11,387 9,847  
Other long-term debt 5,998 6,913  
Total liabilities 17,385 16,760  
Stockholders' equity:      
Preferred Shares 1,335 2,135  
Common Shares 1,871 1,698  
Additional paid-in capital 20,451 19,408  
Accumulated deficit (14,096) (7,706)  
Accumulated other comprehensive income 29 51  
Total shareholders' equity 9,590 15,586  
Total liabilities and shareholders' equity 26,975 32,346  
Adjustment [Member]
      
Total assets        
Total other current liabilities        
Fair value of warrant liability 1,213 1,286  
Total current liabilities 1,213 1,286  
Other long-term debt        
Total liabilities 1,213 1,286  
Stockholders' equity:      
Preferred Shares        
Common Shares        
Additional paid-in capital (816) (816)  
Accumulated deficit (397) (470)  
Accumulated other comprehensive income        
Total shareholders' equity (1,213) (1,286)  
Total liabilities and shareholders' equity        
XML 76 R16.htm IDEA: XBRL DOCUMENT v2.4.0.8
INCOME TAXES
 12 Months Ended
Sep. 30, 2012
INCOME TAXES [Abstract]  
INCOME TAXES

9. INCOME TAXES

 

Significant components of our deferred tax assets and liabilities as of September 30 are as follows:

 

    2012     2011  
    (Restated)     (Restated)  
Deferred tax assets - Current:                
Inventory   $ 202     $ 236  
Accrued compensation and vacation     255       271  
Accrued expenses and other     252       118  
Total current deferred tax assets     709       625  
                 
Deferred tax liabilities - Current:                
Prepaid expenses     (74 )     (116 )
Total net current deferred tax assets     635       509  
                 
Deferred tax assets - Noncurrent:                
Domestic net operating loss carryforwards     2,483       1,585  
Stock compensation expense     14       29  
Foreign net operating loss     2,334       1,326  
Foreign tax credit carryover     119       119  
AMT credit carryover     42       45  
Total noncurrent deferred tax assets     4,992       3,104  
                 
Deferred tax liabilities - Noncurrent:                
Unrealized gain/loss - warrant liability     (296 )     (685 )
Basis difference for fixed assets     (459 )     (562 )
Basis difference for intangibles     -       (21 )
      (755 )     (1,268 )
                 
Total net noncurrent deferred tax assets     4,237       1,836  
                 
Valuation allowance for net deferred tax assets     (4,872 )     (2,345 )
Net deferred tax  asset (liability)   $ -     $ -  

 

Significant components of the provision (benefit) for income taxes are as follows as of the year ended September 30:

 

    2012     2011  
Current:                
Federal   $ (3 )   $ 37  
State and local     5       13  
Foreign     -       -  
                 
Deferred:                
Federal     -       -  
State and local     -       -  
Foreign     -       -  
Income tax expense   $ 2     $ 50  

 

The effective income tax rate on continuing operations varied from the statutory federal income tax rate as follows:

 

    2012     2011  
             
Statutory federal income tax rate     34.0 %     34.0 %
Increases (decreases):                
State and local income taxes, net of Federal tax benefit, if applicable     (0.1 )     0.4  
Nondeductible expenses     (0.5 )     2.9  
Valuation allowance changes     (33.5 )     (35.4 )
Other     ---       0.2  
                 
Effective income tax rate     (0.1 )%     2.1 %

 

In fiscal 2012 and 2011, our foreign operations generated losses before income taxes of $3,636 and $745, respectively. We have foreign net operating loss carryforwards of $8,854 that have an indefinite life under current UK tax law. We have a valuation allowance for the deferred tax asset related to the foreign net operating losses.

 

Realization of deferred tax assets associated with the net operating loss carryforward and credit carryforward is dependent upon generating sufficient taxable income prior to their expiration. The valuation allowance in fiscal 2012 and 2011 was $2,538 and $1,021, respectively for our domestic operations. Payments made in fiscal 2012 and 2011 for income taxes amounted to $12 and $8, respectively.

 

At September 30, 2012, we had domestic net operating loss carryforwards of approximately $4,935 for federal and $9,469 for state, which expire from September 30, 2014 through 2029. Also, we have a foreign tax credit carryforward of approximately $119, which expires September 30, 2016. Further, we have an alternative minimum tax credit carryforward of approximately $42 available to offset future federal income taxes. This credit has an unlimited carryforward period.

 

We may recognize the tax benefit from an uncertain tax position only if it is more likely than not to be sustained upon regulatory examination based on the technical merits of the position. The amount of the benefit for which an exposure exists is measured as the largest amount of benefit determined on a cumulative probability basis that we believe is more likely than not to be realized upon ultimate settlement of the position. At September 30, 2012, a $16 liability remained for other uncertain income tax positions.

 

A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:

 

Change in unrecognized tax benefits:

 

    2012     2011  
Balance at beginning of the year   $ 16     $ 30  
Additions based on tax positions related to the current year     -       -  
Additions for tax positions of prior years     -       -  
Reductions for tax positions of prior years     -       (14 )
Settlements     -       -  
Balance at end of the year   $ 16     $ 16  

 

As noted in the table above, there has been no change in our gross uncertain tax positions during fiscal 2012 based on a state tax position. For fiscal 2011, we had a reduction of $14 in our gross uncertain tax positions during fiscal 2011 based on correspondence with a state taxing authority.

 

We are no longer subject to U.S. federal tax examinations for years before 2008 or state and local for years before 2007, with limited exceptions. For federal purposes, the tax attributes carried forward could be adjusted through the examination process and are subject to examination 3 years from the date of utilization. Furthermore, we are no longer subject to income tax examinations in the United Kingdom for years prior to 2007.
XML 77 R12.htm IDEA: XBRL DOCUMENT v2.4.0.8
LOSS PER SHARE
 12 Months Ended
Sep. 30, 2012
LOSS PER SHARE [Abstract]  
LOSS PER SHARE

5. LOSS PER SHARE

 

We compute basic loss per share using the weighted average number of common shares outstanding. The net loss applicable to common shareholders for fiscal 2011 is the net of the net income for the year less the deemed dividend for the Series A preferred shares from the May 2011 registered direct offering described in Note 4 and less the dividends earned on the outstanding Series A preferred shares.

 

The Company has three categories of dilutive potential common shares: the Series A preferred shares issued in May 2011 in connection with the registered direct offering, the Warrants issued in connection with the same offering in May 2011, and shares issuable upon exercise of options. We compute diluted earnings per share using the if-converted method for preferred stock and the treasury stock method for stock options and warrants. Shares issuable upon exercise of options were not considered in computing diluted earnings per share for the fiscal years ended September 30, 2012 and 2011 because they were anti-dilutive. Warrants for 1,376,500 and 2,753,000 common shares and 936,000 and 2,753,000 common shares issuable upon conversion of preferred shares were not considered in computing diluted earnings per share for fiscal 2012 and 2011, respectively, because they were also anti-dilutive.

 

The following table reconciles our computation of basic net loss per share to diluted net loss per share:

 

    Years Ended
September 30,		  
    2012     2011  
    (Restated)     (Restated)  
Basic net loss per share:                
Net income (loss)   $ (6,317 )   $ 2,302  
Less:  Deemed dividend for Series A Preferred Shares     -       (5,506 )
Less:  Preferred dividend     -       (991 )
Net loss applicable to common shareholders   $ (6,317 )   $ (4,195 )
Weighted average common shares outstanding     7,158       5,667  
Basic net loss per share   $ (0.88 )   $ (0.74 )
                 
Diluted net loss per share:                
Net loss applicable to common shareholders   $ (6,317 )   $ (4,195 )
Weighted average common shares outstanding     7,158       5,667  
Diluted net loss per share   $ (0.88 )   $ (0.74 )
XML 78 R7.htm IDEA: XBRL DOCUMENT v2.4.0.8
CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)
In Thousands, unless otherwise specified
 12 Months Ended
Sep. 30, 2012
Sep. 30, 2011
Operating activities:    
Net income (loss) $ (6,317) $ 2,302
Adjustments to reconcile net income (loss) to net cash (used) provided by operating activities:    
Depreciation and amortization 2,278 2,134
Employee stock compensation expense 83 153
Change in fair value of warrant liability - decrease (73) (1,759)
Provision for doubtful accounts (15) 16
Gain on interest rate swaps    (31)
(Gain) loss on sale of property and equipment 451 (9)
Deferred income taxes    (14)
Changes in operating assets and liabilities:    
Accounts receivable 917 (236)
Inventories (20) 37
Refundable income taxes (39) 56
Prepaid expenses and other assets 414 17
Accounts payable 2,375 (482)
Accrued expenses 305 (86)
Customer advances (559) (1,010)
Net cash (used) provided by operating activities (200) 1,088
Investing activities:    
Capital expenditures (1,090) (1,174)
Proceeds from sale of equipment 230  
Net cash used in investing activities (860) (1,174)
Financing activities:    
Net proceeds from registered direct offering    4,606
Direct common shares purchased by interim CEO and Board of Directors 128   
Payments of long-term debt (735) (1,756)
Payments on revolving line of credit (27,695) (30,917)
Borrowings on revolving line of credit 27,793 31,068
Payments on capital lease obligations (655) (1,341)
Net cash (used) provided by financing activities (1,164) 1,660
Effect of exchange rate changes (18) (33)
Net (decrease) increase in cash and cash equivalents (2,242) 1,541
Cash and cash equivalents at beginning of year 2,963 1,422
Cash and cash equivalents at end of year 721 2,963
Supplemental disclosure of non-cash financing activities    
Preferreed stock dividends accrued, but not paid    991
Preferred stock dividends pain in common shares (106) (657)
Equipment financed under capital leases 356 1,888
Termination of capital lease obligation $ 322   
XML 79 R52.htm IDEA: XBRL DOCUMENT v2.4.0.8
DEBT ARRANGEMENTS (Narrative) (Details) (USD $)
In Thousands, unless otherwise specified
 12 Months Ended 12 Months Ended
Sep. 30, 2012
sqft
Jul. 12, 2012
acre
Sep. 30, 2011
Sep. 30, 2012
Revolving Line of Credit [Member]
Sep. 30, 2012
Revolving Line of Credit [Member]
Minimum [Member]
Sep. 30, 2012
Amended Revolving Line of Credit [Member]
Sep. 30, 2012
Notes Payable to Regions Bank [Member]
Sep. 30, 2012
Mortgage Notes Payable, Maturing May 4, 2013 [Member]
Sep. 30, 2012
Mortgage Notes Payable One and Two [Member]
Sep. 30, 2012
Replacement Note Payable [Member]
Sep. 30, 2011
Replacement Note Payable [Member]
Dec. 17, 2010
Note Payable, Maturing December 18, 2010 [Member]
Feb. 11, 2011
Mortgage Payable, Maturing February 11, 2011
Debt Instrument [Line Items]                          
Long-term debt $ 5,842   $ 6,577       $ 5,800 $ 5,786 $ 4,768 $ 1,074 $ 1,245    
Debt instrument, maturity date       Jan. 31, 2011   Jan. 31, 2013   Oct. 31, 2013 May 31, 2013 Oct. 31, 2013      
Debt instrument, interest rate                 4.10% 7.50%      
Debt instrument, frequency of periodic payments               monthly monthly monthly      
Debt instrument, principal payment               47 38 14      
Debt instrument, one-time principal payment                       500 500
Debt instrument, face amount                   1,341      
Debt instrument, variable interest reference rate       Citibanks' Prime Rate       LIBOR   30-day LIBOR      
Debt instrument, basis spread on variable rate       5.00%       4.00%   3.00%      
Debt instrument, minimum interest rate               6.00%   4.50%      
Fixed charge coverage ratio                   1.25      
Total liabilities to tangible net worth ratio                   2.10      
Debt instrument, effective interest rate       8.25%                  
Line of credit, maximum borrowing capacity       3,000                  
Line of credit, frequency of periodic payments         monthly                
Line of credit, periodic interest payments         15                
Line of credit, frequency of facilities fee payments       annually                  
Line of credit, facilities fee, percentage       2.00%                  
Line of credit, collateral monitoring fee, percentage       0.20%                  
Line of credit, collateral       Borrowings under the Credit Agreement are secured by a blanket lien on our personal property, including certain eligible accounts receivable, inventory, and intellectual property assets, and a second mortgage on our West Lafayette and Evansville real estate and all common stock of our U.S. subsidiaries and 65% of the common stock of our non-United States subsidiary.                  
Line of credit, borrowings, based on eligible accounts receivable, percentage       75.00%                  
Minimum net worth convenant requirement       8,500   8,000              
Line of credit, current borrowing capacity       1,927                  
Line of credit, amount outstanding       1,444                  
Acres of land 120,000 7.25                      
Square foot of facility   120,000                      
Net book value of facility and land 9,585                        
Asking price   $ 12,500                      
XML 80 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 81 R47.htm IDEA: XBRL DOCUMENT v2.4.0.8
INVENTORIES (Details) (USD $)
In Thousands, unless otherwise specified
Sep. 30, 2012
Sep. 30, 2011
INVENTORIES [Abstract]    
Raw materials $ 1,407 $ 1,352
Work in process 283 379
Finished goods 276 309
Gross inventories 1,966 2,040
Obsolescence reserve (310) (404)
Inventories $ 1,656 $ 1,636
XML 82 R33.htm IDEA: XBRL DOCUMENT v2.4.0.8
STOCK-BASED COMPENSATION (Tables)
 12 Months Ended
Sep. 30, 2012
STOCK-BASED COMPENSATION [Abstract]  
Fair Value Assumptions

The weighted-average assumptions used to compute the fair value of options granted for the fiscal years ended September 30 were as follows:

 

    2012   2011
Risk-free interest rate   1.39%   3.08%
Dividend yield   0.00%   0.00%
Volatility of the expected market price of the Company's common stock   93.00%- 97.00%   90.00%-91.00%
Expected life of the options (years)   7.0 - 8.0   8.0
Summary of Stock Option Activity

A summary of our stock option activity for all options and related information for the years ended September 30, 2012 and 2011, respectively, is as follows (in thousands except for share prices):

 

    Options
(shares)		     Weighted-
Average
Exercise Price		     Weighted-
Average Grant
Date Fair Value		     Weighted-Average
Remaining
Contractual Life
(Years)		     Aggregate
Intrinsic
Value		  
                               
Outstanding - October 1, 2010     705     $ 2.66                          
Exercised     -     $ -                          
Granted     27     $ 2.24     $ 1.84                  
Terminated     (59 )   $ 2.54                          
Outstanding - September 30, 2011     673     $ 2.65     $ 1.83       7.2     $ 69  
                                         
                                         
Outstanding - October 1, 2011     673     $ 2.65                          
Exercised     -     $ -                          
Granted     200     $ 1.30     $ 1.05                  
Terminated     (519 )   $ 2.58                          
Outstanding - September 30, 2012     354     $ 1.99     $ 1.46       8.0     $ 42  
                                         
Exercisable at September 30, 2012     94     $ 3.83     $ 2.59       5.3     $ 7  
Summary of Non-Vested Options

A summary of non-vested options for the year ended September 30, 2012 is as follows:

 

    Number of
Shares		     Weighted-
Average Grant
Date Fair Value		  
             
Non-vested options at October 1, 2011     385     $ 1.14  
Granted     200     $ 1.05  
Vested     (128 )   $ 1.25  
Forfeited     (197 )   $ 1.09  
Non-vested options at September 30, 2012     260     $ 1.06  
Schedule of Outstanding and Exercisable Options

The following table summarizes outstanding and exercisable options as of September 30, 2012 (in thousands except per share amounts):

 

Range of Exercise Prices   Shares
Outstanding		     Weighted-
Average
Remaining
Contractual
Life (Years)		     Weighted-
Average
Exercise Price		     Shares
Exercisable		     Weighted-
Average
Exercise Price		  
                               
$0.79 - 1.01     128       8.32     $ 0.97       24     $ 1.01  
$1.02 - 4.59     155       9.40     $ 1.38       7     $ 1.35  
$4.60 - 8.79     71       4.24     $ 5.19       62     $ 5.21  
XML 83 R66.htm IDEA: XBRL DOCUMENT v2.4.0.8
SEGMENT INFORMATION (Narrative) (Details) (USD $)
In Thousands, unless otherwise specified
 12 Months Ended
Sep. 30, 2012
Sep. 30, 2011
Revenue, Major Customer [Line Items]    
Restructuring charges $ 3,195   
Services Segment [Member]
    
Revenue, Major Customer [Line Items]    
Restructuring charges 1,360  
Corporate [Member]
    
Revenue, Major Customer [Line Items]    
Restructuring charges $ 1,835  
Gilead Sciences, Inc. [Member]
    
Revenue, Major Customer [Line Items]    
Percentage of total revenues 7.30% 14.50%
Percentage of trade accounts receivable 7.40% 6.30%
Pfizer, Inc. [Member]
    
Revenue, Major Customer [Line Items]    
Percentage of total revenues 3.40% 5.20%
Percentage of trade accounts receivable 8.40% 4.20%
XML 84 R59.htm IDEA: XBRL DOCUMENT v2.4.0.8
STOCK-BASED COMPENSATION (Fair Value Assumptions) (Details) (Stock Options [Member])
 12 Months Ended
Sep. 30, 2012
Sep. 30, 2011
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Risk-free interest rate 1.39% 3.08%
Dividend yield 0.00% 0.00%
Volatility of the expected market price of the Company's common stock, minimum 93.00% 90.00%
Volatility of the expected market price of the Company's common stock, maximum 97.00% 91.00%
Expected life of the options (years)   8 years
Minimum [Member]
    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Expected life of the options (years) 7 years  
Maximum [Member]
    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Expected life of the options (years) 8 years  
XML 85 R19.htm IDEA: XBRL DOCUMENT v2.4.0.8
SEGMENT INFORMATION
 12 Months Ended
Sep. 30, 2012
SEGMENT INFORMATION [Abstract]  
SEGMENT INFORMATION

12. SEGMENT INFORMATION

 

We operate in two principal segments - contract research services and research products. Our Services segment provides research and development support on a contract basis directly to pharmaceutical companies. Our Products segment provides liquid chromatography, electrochemical and physiological monitoring products to pharmaceutical companies, universities, government research centers, and medical research institutions. We evaluate performance and allocate resources based on these segments. Certain of our assets are not directly attributable to the Services or Products segments. These assets are grouped into the Corporate segment and include cash and cash equivalents, deferred income taxes, refundable income taxes, debt issue costs and certain other assets. We do not allocate such items to the principal segments because they are not used to evaluate their financial position. The accounting policies of these segments are the same as those described in the summary of significant accounting policies.

 

  (a) Operating Segments

 

    Years Ended
September 30,		  
    2012     2011  
    (Restated)     (Restated)  
Revenue:                
Service   $ 21,312     $ 25,613  
Product     6,896       7,531  
    $ 28,208     $ 33,144  
                 
Operating income (loss):                
Service   $ (3,863 )   $ 745  
Product     12       542  
Corporate     (1,835 )     -  
    $ (5,686 )   $ 1,287  
                 
Interest Expense     (714 )     (706 )

Change in fair value of warrant liability- decrease

    

73

       1,759  
Other income     12       12  
                 
Income (loss) before income taxes   $ (6,315 )   $ 2,352  

 

Restructuring costs of $1,360 and $1,835 are included in the operating losses for fiscal 2012 for the Service and Corporate segments, respectively.

 

    Years Ended
September 30,		  
    2012     2011  
Identifiable assets:                
Service   $ 15,864     $ 18,121  
Product     7,262       7,674  
Corporate     3,849       6,551  
    $ 26,975     $ 32,346  
                 
Goodwill, net:                
Service   $ 1,009     $ 1,009  
Product     374       374  
    $ 1,383     $ 1,383  
                 
Intangible assets, net:                
Service   $ -     $ 54  
Product     -       -  
    $ -     $ 54  
                 
Depreciation and amortization:                
Service   $ 2,036     $ 1,899  
Product     242       235  
    $ 2,278     $ 2,134  
                 
Capital Expenditures:                
Service   $ 864     $ 1,098  
Product     226       76  
    $ 1,090     $ 1,174  

 

  (b) Geographic Information

 

    Years Ended
September 30,		  
    2012     2011  
Sales to External Customers:                
North America   $ 25,042     $ 29,451  
Pacific Rim     961       912  
Europe     1,858       2,542  
Other     347       239  
    $ 28,208     $ 33,144  
                 
Long-lived Assets:                
North America   $ 20,083     $ 20,872  
Europe     -       1,101  
    $ 20,083     $ 21,973  

 

  (c) Major Customers

 

The Preferred Provider Agreement ("PPA") with Pharmasset, Inc., signed in the first quarter of fiscal 2011, expired under its own terms, though they remain a large client of the Company. Pharmasset, Inc., now known as Gilead Sciences, Inc. ('Gilead') via acquisition, accounted for approximately 7.3% and 14.5% of our total revenues in fiscal 2012 and 2011, respectively, and 7.4% and 6.3% of total trade accounts receivable at September 30, 2012 and 2011, respectively. Pfizer, Inc. remains a large client, accounting for approximately 3.4% and 5.2% of our total revenues in fiscal 2012 and 2011, respectively. Pfizer, Inc. accounted for 8.4% and 4.2% of total trade accounts receivable at September 30, 2012 and 2011, respectively.
XML 86 R15.htm IDEA: XBRL DOCUMENT v2.4.0.8
DEBT ARRANGEMENTS
 12 Months Ended
Sep. 30, 2012
DEBT ARRANGEMENTS [Abstract]  
DEBT ARRANGEMENTS

8. DEBT ARRANGEMENTS

 

Long-term debt consisted of the following at September 30:

 

    2012     2011  
             
Mortgage note payable to a bank, payable in monthly principal and interest installments of $40. Interest is fixed at 4.1%.  Collateralized by underlying property.  Due October, 2013. (b)   $ 3,236     $ 3,573  
                 
Mortgage note payable to a bank, payable in monthly principal and interest installments of $17. Interest is fixed at 4.1%.  Collateralized by underlying property.  Due October, 2013. (b)     1,532       1,674  
                 
Replacement note payable to a bank, payable in monthly principal installments of $14 plus interest.  The interest rate is 4.5%. Collateralized by West Lafayette and Evansville properties. Due October, 2013.  (a) (b)     1,074       1,245  
                 
Note payable to Algo Holdings, payable in monthly installments of $10.  There is no interest on this note if paid within terms.  Termed May 1, 2012.  See Note 13.     -       85  
    $ 5,842     $ 6,577  
Less current portion     583       735  
    $ 5,259     $ 5,842  

 

Our principal payment obligation for the year ending September 30, 2013 is $583. Cash interest payments of $715 and $647 were made in 2012 and 2011, respectively.

 

Mortgages and note payable

 

We have notes payable to Regions Bank ("Regions") aggregating approximately $5,800.

 

Regions notes payable currently include two outstanding mortgages on our facilities in West Lafayette and Evansville, Indiana, which total $4,768. The mortgages originally mature in November 2012 with an interest rate fixed at 4.1% and monthly principal payments of approximately $38 plus interest.

 

(a) On November 29, 2010, we executed amendments on two loans with Regions. Regions agreed to accept a $500 principal payment on the note payable maturing on December 18, 2010 and a $500 principal payment on one mortgage maturing on February 11, 2011. The principal payments were made on December 17, 2010 and February 11, 2011, respectively. Upon receipt of these two payments, Regions incorporated the two loans into a replacement note payable for $1,341 maturing on November 1, 2012. The replacement note payable bears interest at a per annum rate equal to the 30-day LIBOR plus 300 basis points (minimum of 4.5%) with monthly principal payments of approximately $14 plus interest. The replacement note payable is secured by real estate at our West Lafayette and Evansville, Indiana locations. At September 30, 2012, the replacement note payable had a balance of $1,074.

 

As part of the amendment, Regions also agreed to amend the loan covenants for the related debt to be more favorable to us. Regions requires us to maintain certain ratios including a fixed charge coverage ratio and total liabilities to tangible net worth ratio. The fixed charge coverage ratio calculation currently requires a ratio of not less than 1.25 to 1.00. We are also required to maintain a ratio of our total liabilities to tangible net worth ratio of not greater than 2.10 to 1.00. If we fail to comply with these covenants, the loan agreement restricts our ability to purchase fixed assets.

 

(b) On November 9, 2012, we executed a sixth amendment with Regions. On December 21, 2012, we executed an amended and restated sixth amendment with Regions. Regions agreed to extend the term loan and mortgage loan maturity dates to October 31, 2013. The unpaid principal on the notes was incorporated into a replacement note payable for $5,786 bearing interest at LIBOR plus 400 basis points (minimum of 6.0%) with monthly principal payments of approximately $47 plus interest. The replacement note payable is secured by real estate at our West Lafayette and Evansville, Indiana locations.

 

At September 30, 2012, we were not in compliance with the fixed charge coverage and the total liabilities to tangible net worth ratios in the Regions agreements, mainly due to the net losses in the first nine months of fiscal 2012, restructuring charges incurred in current fiscal year and the treatment of our warrants as a liability instead of as equity. On November 6, 2012, Regions waived compliance with the fixed charge coverage ratio. On December 21, 2012, Regions waived compliance with the total liabilities to tangible net worth ratio. Based on projections for fiscal 2013, we expect to be in compliance with the fixed charge coverage covenants for fiscal 2013 and in breach of the total liabilities to tangible net worth ratio covenant for the first two fiscal quarters of 2013, primarily due to the treatment of our warrants as a liability. On September 10, 2013, Regions waived our expected breach. Failure to comply with those covenants in future quarters would be a default under the Regions loans, requiring us to negotiate with Regions regarding loan modifications or waivers. If we are unable to obtain such modifications or waivers, Regions could accelerate the maturity of the loans and cause a cross default with our other lender.

 

The Regions loans contain both cross-default provisions with each other and with the revolving line of credit with Entrepreneur Growth Capital described below.

 

The mortgages and replacement note payable with Regions mature in the first quarter of fiscal 2014. We intend to refinance the amounts in lieu of making balloon payments for the remaining principal balances or sell the building in West Lafayette, Indiana. On July 12, 2012, we listed for sale our 7.25 acres and 120,000 square foot facility at 2701 Kent Avenue, West Lafayette, Indiana with the intent to leaseback 80% of that square footage in which to continue our laboratory and manufacturing operations. The asking price was $12,500. We performed an impairment analysis on the building when we listed it for sale, but noted no impairment necessary. As of September 30, 2012 the net book value of the facility and land was $9,585.

 

We may be unsuccessful in renegotiating the terms of the debt or those terms may be unfavorable to us. For these reasons, if we are unsuccessful at refinancing our long-term debt, our operating results and financial condition could be adversely affected.

 

Revolving Line of Credit

 

On January 13, 2010, we entered into a new $3,000 revolving line of credit agreement ("Credit Agreement") with EGC. The term of the Credit Agreement expires on January 31, 2014. If we terminate prior to the expiration of the term, then we are subject to an early termination fee equal to the minimum interest charges of $15 for each of the months remaining until expiration.

 

Borrowings under the Credit Agreement bear interest at an annual rate equal to Citibank's Prime Rate plus five percent (5%), or 8.25% as of September 30, 2012, with minimum monthly interest of $15. Interest is paid monthly. The line of credit also carries an annual facilities fee of 2% and a 0.2% collateral monitoring fee. Borrowings under the Credit Agreement are secured by a blanket lien on our personal property, including certain eligible accounts receivable, inventory, and intellectual property assets, a second mortgage on our West Lafayette and Evansville real estate and all common stock of our U.S. subsidiaries and 65% of the common stock of our non-United States subsidiary. Borrowings are calculated based on 75% of eligible accounts receivable. Under the Credit Agreement, the Company has agreed to restrict advances to subsidiaries, limit additional indebtedness and capital expenditures and maintain a minimum tangible net worth of at least $8,500. Pursuant to the terms of the Credit Agreement, the line of credit will automatically renew on January 31, 2014 unless either party gives a 60-day notice of intent to terminate or withdraw.

  

On December 21, 2012, we negotiated an amendment to this Credit Agreement. The amendment reduced the minimum tangible net worth covenant requirement from $8,500 to $8,000, effective on January 1, 2013, and waived all non-compliances with this covenant through December 31, 2012.

 

The Credit Agreement also contains cross-default provisions with the Regions loans and any future EGC loans. At September 30, 2012, we were not in compliance with the minimum tangible net worth covenant requirement. On December 21, 2012, EGC waived compliance with this covenant as part of the amendment. Based on projections for fiscal 2013, we expect to be in breach of the tangible net worth covenant for our first three quarters of fiscal 2013, but in compliance in our fourth fiscal quarter. EGC waived our projected breach for our first fiscal quarter of 2013 in the amendment to the Credit Agreement on December 21, 2012. EGC waived our expected breach for our second and third fiscal quarters of 2013 on October 9, 2013. At September 30, 2012, we had available borrowing capacity of $1,927 on this line, of which $1,444 was outstanding.
XML 87 R68.htm IDEA: XBRL DOCUMENT v2.4.0.8
RESTRUCTURING (Narrative) (Details) (USD $)
In Thousands, unless otherwise specified
 12 Months Ended
Sep. 30, 2012
sqft
Sep. 30, 2011
Jul. 12, 2012
acre
Restructuring Cost and Reserve [Line Items]      
Acres of headquarters facility 120,000   7.25
Restructuring charges $ 3,195     
Lease Related Costs [Member]
      
Restructuring Cost and Reserve [Line Items]      
Restructuring charges 861    
Services Segment [Member]
      
Restructuring Cost and Reserve [Line Items]      
Restructuring charges 1,360    
Restructuring costs 1,360    
Products Segment [Member]
      
Restructuring Cost and Reserve [Line Items]      
Restructuring costs 0    
Corporate Expenses [Member]
      
Restructuring Cost and Reserve [Line Items]      
Restructuring charges 1,835    
Restructuring costs $ 1,835    
XML 88 R22.htm IDEA: XBRL DOCUMENT v2.4.0.8
SELF-INSURANCE
 12 Months Ended
Sep. 30, 2012
SELF-INSURANCE [Abstract]  
SELF-INSURANCE

15. SELF-INSURANCE

 

The Company is self-insured for certain costs related its employee health plan.  Costs resulting from noninsured losses are charged to income when incurred.  The Company has purchased insurance which limits its exposure for individual claims to approximately $60 and has a minimum annual aggregate attachment point of $2,072 at September 30, 2012.  The Company's expense related to the plan was $1,231 and $1,089 for the years ended September 30, 2012 and 2011.
XML 89 R20.htm IDEA: XBRL DOCUMENT v2.4.0.8
SETTLEMENT OF CONTINGENT LIABILITY
 12 Months Ended
Sep. 30, 2012
SETTLEMENT OF CONTINGENT LIABILITY [Abstract]  
SETTLEMENT OF CONTINGENT LIABILITY

13. SETTLEMENT OF CONTINGENT LIABILITY

 

In June of 2008 as part of selling our Baltimore Clinical Pharmacology Research Unit, we subleased the building space it occupied to the purchaser of the assets. We remained contingently liable for the rent payments of $800 per year through 2015 in the event the sublessor did not perform. In 2009, the purchaser ceased operations in Baltimore and sought to renegotiate the terms of its sublease. In March of 2010, a settlement was reached with the landlord of the building which canceled the sublessor's and our obligations under the lease in exchange for a cash payment from the sublessor. We agreed to contribute $250 to the settlement, payable in twenty-five monthly installments of $10 without interest. We recorded the discounted liability of $216 in March 2010 and recognized the related expense in general and administrative expenses. In May 2012, we made the final payment and extinguished the liability.
XML 90 R1.htm IDEA: XBRL DOCUMENT v2.4.0.8
Document and Entity Information (USD $)
In Thousands, except Share data, unless otherwise specified
 12 Months Ended
Sep. 30, 2012
Dec. 28, 2012
Mar. 31, 2012
Document And Entity Information [Abstract]      
Document Type 10-K    
Amendment Flag true    
Document Period End Date Sep. 30, 2012    
Document Fiscal Year Focus 2012    
Document Fiscal Period Focus FY    
Trading Symbol BASI    
Entity Registrant Name BIOANALYTICAL SYSTEMS INC    
Entity Central Index Key 0000720154    
Current Fiscal Year End Date --09-30    
Entity Filer Category Smaller Reporting Company    
Entity Common Stock, Shares Outstanding   7,638,738  
Entity Public Float     $ 7,402
Entity Voluntary Filers No    
Entity Well-known Seasoned Issuer No    
Entity Current Reporting Status Yes    
Amendment Description

Explanatory Note

 

Bioanalytical Systems Inc. ("we", "us", "our", or the "Company") is filing this Amendment on Form 10-K/A (this "Amendment") to amend our Annual Report on Form 10-K for the fiscal year ended September 30, 2012, originally filed with the Securities and Exchange Commission (the "SEC") on December 31, 2012 (the "Original Filing"). The Amendment restates our consolidated financial statements and related dosclosures for the fiscal years ended September 30, 2012 and 2011. This Amendment also amends certain other Items in the Original Filing, as listed in "Items Amended in this Amendment" below, as a result of the restatements. Details of the impact of these restatements are discussed below and in Note 3 to the accompanying consolidated financial statements and in Management's Discussion and Analysis of Financial Condition and Results of Operations.

 

Restatement Background

 

In August 2013, we announced a delay in filing our Form 10-Q for the three and nine months ended June 30, 2013 until management resolved a complex accounting issue related to the accounting treatment for our outstanding warrants. In the same month, we announced that investors should no longer rely upon our previously issued consolidated financial statements and the related independent auditors' reports for the fiscal years ended September 30, 2012 and 2011, or the quarterly financial statements for the first two quarters of fiscal 2013, or any earnings releases relating to these periods, because of errors in such financial statements.

 

As a result of the identification of such errors, we have undertaken a comprehensive review of our previously filed consolidated financial statements. We concluded that the warrants issued in connection with our public offering in May 2011 were incorrectly accounted for as equity and the fair value of those warrants should have been recorded as a liability. As a result, we have restated our previously reported consolidated financial statements for the years ended September 30, 2012 and 2011, as well as the condensed consolidated financial statements for the three and six months ended December 31, 2012 and March 31, 2013.

 

Internal Control Consideration

 

Our management has determined that there was a control deficiency in our internal control over financial reporting that constitutes a material weakness, as discussed in Part II - Item 9A of this Amendment. A material weakness is a control deficiency, or combination of control deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the annual or interim condensed consolidated financial statements will not be prevented or detected on a timely basis. For a discussion of management's consideration of our disclosure controls and procedures, internal control over financial reporting and the material weakness identified, see Part II - Item 9A included in this Amendment.

 

Items Amended in This Amendment

 

For the convenience of the reader, this Amendment sets forth the Original Filing, in its entirety, as modified and superseded where necessary to reflect the restatement. The following items in the Original Filing have been amended as a result of, and to reflect, the restatement:

 

  · Part I - Item 1A. Risk Factors;
  · Part II - Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations;
  · Part II - Item 8. Financial Statements and Supplementary Data; and
  · Part II - Item 9A. Controls and Procedures.

 

In accordance with applicable SEC rules, this Amendment includes new certifications required by Rule 13a-14 under the Securities and Exchange Act of 1934, as amended ("Exchange Act"), dated as of the filing date of this Amendment.

 

We have not updated items in this Amendment to reflect events occurring after the Original Filing date, other than those associated with the restatement of our consolidated financial statements.

    
XML 91 R21.htm IDEA: XBRL DOCUMENT v2.4.0.8
RESTRUCTURING
 12 Months Ended
Sep. 30, 2012
RESTRUCTURING [Abstract]  
RESTRUCTURING

14. RESTRUCTURING

 

In March 2012, we announced a plan to restructure our bioanalytical laboratory operations. We consolidated our laboratory in McMinnville, Oregon into our 120,000 square foot headquarters facility in West Lafayette, Indiana. This plan was implemented to reduce operating costs and strengthen our ability to meet clients' needs by improving laboratory utilization. In the fourth fiscal quarter of 2012, we decided to initiate closure of our facility and bioanalytical laboratory in Warwickshire, United Kingdom after careful evaluation of its financial performance and analysis of our strategic alternatives. We will continue to sell our products globally while further consolidating delivery of our CRO services into our Indiana locations. As part of the overall evaluation of our business, personnel reductions in the Selling, R&D and General and Administrative functions were also implemented at both of our Indiana locations during the second half of fiscal 2012. In total, 74 employees were terminated as part of the restructuring activities this fiscal year.

 

The following table sets forth the costs incurred in connection with these restructuring activities during the year ended September 30, 2012.

 

Description   2012  
One-time termination benefits   $ 1,454  
Lease related costs     861  
Equipment moving costs and method transfers     153  
Travel and relocation costs     47  
Loss on sale of equipment     446  
Other costs     234  
Total   $ 3,195  

 

We have reserved for lease payments at the cease use date and have considered free rent, sublease rentals and the number of days it would take to restore the space to its original condition prior to our improvements. Based on this, we have reserved $861 for lease related costs.

 

Restructuring related costs incurred during fiscal 2012 totaled $1,360 in our Services segment, $0 in our Products segment and $1,835 in corporate expenses.

 

The following table sets forth the rollforward of the restructuring activity for the year ended September 30, 2012.

 

    Balance,
September 30,
2011		     Total
Charges		     Cash
Payments		     Other     Balance,
September 30,
2012		  
One-time termination benefits   $ -     $ 1,454     $ (1,006 )   $ -     $ 448  
Lease related costs     -       861       (61 )     -       800  
Equipment moving costs and method transfers     -       153       (104 )     -       49  
Travel and relocation costs     -       47       (43 )     -       4  
Loss on sale of equipment     -       446       -       (539 )     (93 )
Other costs     -       234       (37 )     -       197  
Total   $ -     $ 3,195     $ (1,251 )   $ (539 )   $ 1,405  

 

Other costs include legal and professional fees and other costs incurred in connection with transitioning services from sites being closed as well as costs incurred to remove improvements previously made to the UK facility. Other activity in the reserve rollforward primarily reflects a receivable for settlement of the capital lease in the UK.
XML 92 R61.htm IDEA: XBRL DOCUMENT v2.4.0.8
STOCK-BASED COMPENSATION (Summary of Non-Vested Options) (Details) (USD $)
 12 Months Ended
Sep. 30, 2012
Number of Shares  
Non-vested options at October 1, 2011 385
Granted 200
Vested (128)
Forfeited (197)
Non-vested options at September 30, 2012 260
Weighted-Average Grant Date Fair Value  
Non-vested options at October 1, 2011 1.14
Granted $ 1.05
Vested $ 1.25
Forfeited $ 1.09
Non-vested options at September 30, 2012 1.06
XML 93 R60.htm IDEA: XBRL DOCUMENT v2.4.0.8
STOCK-BASED COMPENSATION (Summary of Stock Option Activity) (Details) (USD $)
In Thousands, except Share data, unless otherwise specified
 12 Months Ended
Sep. 30, 2012
Sep. 30, 2011
Options (shares)    
Outstanding - October 1, 673 705
Exercised      
Granted 200 27
Terminated (519) (59)
Outstanding - September 30, 354 673
Exercisable - September 30, 94  
Weighted-Average Exercise Price    
Outstanding - October 1, $ 2.65 $ 2.66
Exercised      
Granted $ 1.30 $ 2.24
Terminated $ 2.58 $ 2.54
Outstanding - September 30, $ 1.99 $ 2.65
Exercisable - September 30, $ 3.83  
Weighted-Average Grant Date Fair Value    
Granted $ 1.05 $ 1.84
Outstanding - September 30, $ 1.46 $ 1.83
Exercisable - September 30, $ 2.59  
Weighted-Average Remaining Contractual Life    
Outstanding - September 30, 8 years 7 years 2 months 12 days
Exercisable - September 30, 5 years 3 months 18 days  
Aggregate Intrinsic Value    
Outstanding - September 30, $ 42 $ 69
Exercisable - September 30, $ 7